# ESC Guidelines 2025

<!-- 2025_Dyslipidaemias_Update.md -->

# ESC Guidelines: Dyslipidaemias Update (2025)

**Source**: `2025_Dyslipidaemias_Update.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 20

---

## Table of Contents

- [2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias](#2025-focused-update-of-the-2019-esc/eas-guidelines) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 3)*
  - [2. Introduction](#2-introduction) *(p. 5)*
  - [3. Estimation of total cardiovascular risk and implications for dyslipidaemia management](#3-estimation-of-total-cardiovascular-risk-and-impl) *(p. 5)*
  - [4. New low-density lipoprotein cholesterol-lowering therapies](#4-new-low-density-lipoprotein-cholesterol-lowering) *(p. 9)*
  - [5. Combination of lipid-lowering therapies during index hospitalization for acute coronary syndromes](#5-combination-of-lipid-lowering-therapies-during-i) *(p. 11)*
  - [6. Lipoprotein(a)](#6-lipoprotein(a)) *(p. 12)*
  - [7. Hypertriglyceridaemia](#7-hypertriglyceridaemia) *(p. 13)*
  - [8. Primary prevention in people with human immunodeficiency virus infection](#8-primary-prevention-in-people-with-human-immunode) *(p. 14)*
  - [9. Patients with cancer at high or very high chemotherapy-related cardiovascular toxicity risk](#9-patients-with-cancer-at-high-or-very-high-chemot) *(p. 15)*
  - [10. Dietary supplements](#10-dietary-supplements) *(p. 15)*
  - [11. Evidence tables](#11-evidence-tables) *(p. 16)*
  - [12. Data availability statement](#12-data-availability-statement) *(p. 16)*
  - [13. Author information](#13-author-information) *(p. 16)*
  - [Appendix](#appendix) *(p. 16)*
  - [References](#references) *(p. 17)*
  - [References](#references) *(p. 17)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2025 Focused Update of the 2019 ESC/EAS 
Guidelines for the management of 
dyslipidaemias
Developed by the task force for the management of dyslipidaemias 
of the European Society of Cardiology (ESC) and the European 
Atherosclerosis Society (EAS)
Authors/Task Force Members: Fran√ßois Mach  *‚Ä†, (ESC Chairperson) 
(Switzerland), Konstantinos C. Koskinas*‚Ä†, (ESC Chairperson) (Switzerland), 
Jeanine E. Roeters van Lennep  *‚Ä†, (EAS Chairperson) (Netherlands), 
Lale Tokg√∂zoƒülu  , (Task Force Co-ordinator) (T√ºrkiye), Lina Badimon  
(Spain), 
Colin Baigent  
(United Kingdom), Marianne Benn  
(Denmark),  
Christoph J. Binder  
(Austria), Alberico L. Catapano  
(Italy),  
Guy G. De Backer  
(Belgium), Victoria Delgado  
(Spain), Natalia Fabin  
(Italy), 
Brian A. Ference (United Kingdom), Ian M. Graham  
(Ireland),  
Ulf Landmesser (Germany), Ulrich Laufs  
(Germany), Borislava Mihaylova  
(United Kingdom), B√∏rge Gr√∏nne Nordestgaard  
(Denmark),  
Dimitrios J. Richter  
(Greece), Marc S. Sabatine  
(United States of America), 
and ESC/EAS Scientific Document Group
* Corresponding authors: Fran√ßois Mach, Department of Cardiology, Geneva University Hospital, Geneva, Switzerland. Tel: +41 22 372 71 92, Email: francois.mach@hug.ch; Konstantinos 
C. Koskinas, Department of Cardiology, Bern University Hospital - INSELSPITAL, University of Bern, Bern, Switzerland. Tel: +41 31 632 50 00, Email: Konstantinos.Koskinas@insel.ch; and 
Jeanine Roeters van Lennep, Department of Internal Medicine, Erasmus MC Cardiovascular Institute, Erasmus MC University Medical Center, Rotterdam, Netherlands. Tel: +31 (010) 704 0 
704, Email: j.roetersvanlennep@erasmusmc.nl
‚Ä† The three Chairpersons contributed equally to the document and are joint corresponding authors.
Author/Task Force Member affiliations are listed in author information.
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), 
and Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council on Basic Cardiovascular Science.
Working Groups: Adult Congenital Heart Disease, Aorta and Peripheral Vascular Diseases, Atherosclerosis and Vascular Biology, Cardiovascular Pharmacotherapy, Cardiovascular 
Surgery, Cellular Biology of the Heart, Coronary Pathophysiology and Microcirculation, Development Anatomy and Pathology, Thrombosis.
Patient Forum
This article is co-published with permission in the European Heart Journal and Atherosclerosis. ¬© The European Society of Cardiology and the European Atherosclerosis Society 2025. All rights 
reserved. The articles are identical except for stylistic differences in keeping with each journal‚Äôs style. Either citation can be used when citing this article.
https://doi.org/10.1093/eurheartj/ehaf190
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Christian Eugen Mueller, (ESC Review Co-ordinator) (Switzerland), Heinz Drexel, 
(EAS Review Co-ordinator) (Austria), Ana Abreu (Portugal), Marianna Adamo (Italy), Suleman Aktaa 
(United Kingdom), Folkert W. Asselbergs (Netherlands), Antonio Baldini (Italy), Giuseppe Boriani (Italy), 
Margarita Brida (Croatia), Marianne Brodmann (Austria), Edina Cenko (Italy), Nikolaos Dagres (Germany), 
J√∂rn Dopheide (Switzerland), Christoph Ebenbichler (Austria), Estelle Gandjbakhch (France), Diana A. Gorog 
(United Kingdom), Ioanna Gouni-Berthold (Germany), Luigina Guasti (Italy), Bettina Heidecker (Germany), 
Borja Ibanez (Spain), Stefan James (Sweden), Peter Juni (United Kingdom), Marta Ka≈Çu≈ºna-Oleksy (Poland), 
Konstantin A. Krychtiuk (Austria), Gregory Y.H. Lip (United Kingdom), Roberto Lorusso (Netherlands), 
Felix Mahfoud (Switzerland), Marco Metra (Italy), Inge Moelgaard (Denmark), Jo√£o Morais (Portugal), Lis Neubeck 
(United Kingdom), Steven E. Nissen (United States of America), Elena Osto (Austria/Switzerland),  
Klaus G. Parhofer (Germany), Leopoldo Perez De Isla (Spain), Maurizio Pesce (Italy/Saudi Arabia), 
Zaneta Petrulioniene (Lithuania), Eva Prescott (Denmark), Ernst Rietzschel (Belgium), Bianca Rocca (Italy),  
Jose Fernando Rodriguez Palomares (Spain), Xavier Rossello (Spain), Anna Sannino (Germany), Anne Grete Semb 
(Norway), Jolanta Siller Matula (Germany), Thenral Socrates (Switzerland), Felix C. Tanner (Switzerland), 
Johann Wojta (Austria), Alberto Zambon (Italy), and Katja Zeppenfeld (Netherlands)
All experts involved in the development of this Focused Update have submitted declarations of interest which 
are reported in a supplementary document to the Focused Update. See the European Heart Journal online or 
https://www.escardio.org/Guidelines for supplementary documents as well as evidence tables.
Disclaimer: The European Society of Cardiology (ESC) / European Atherosclerosis Society (EAS) Focused Update represents the views of 
the ESC and the EAS and was produced after careful consideration of the scientific and medical knowledge and the evidence available at the 
time of their publication. The ESC and the EAS are not responsible in the event of any contradiction, discrepancy and/or ambiguity between 
the ESC/EAS Focused Update and any other official recommendations or guidelines issued by the relevant public health authorities, in 
particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC/EAS Focused 
Update fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive, 
diagnostic or therapeutic medical strategies; however, the ESC/EAS Focused Update does not override, in any way whatsoever, the individual 
responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient‚Äôs health condition and in 
consultation with that patient and, where appropriate and/or necessary, the patient‚Äôs caregiver. Nor does the ESC/EAS Focused Update 
exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued 
by the competent public health authorities, in order to manage each patient‚Äôs case in light of the scientifically accepted data pursuant to their 
respective ethical and professional obligations. It is also the health professional‚Äôs responsibility to verify the applicable rules and regulations 
relating to drugs and medical devices prior to making any clinical decision and to check whether a more recent version of this document exists. 
The ESC and the EAS warn readers that the technical language may be misinterpreted and decline any responsibility in this respect.
Permissions: The content of this ESC/EAS Focused Update has been published for personal and educational use only. No commercial 
use is authorized. No part of the ESC/EAS Focused Update may be translated or reproduced in any form without written permission 
from the ESC and the EAS. For permissions please email: journals.permissions@oup.com.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords 
Guidelines ‚Ä¢ Dyslipidaemia ‚Ä¢ Lipid-lowering drugs ‚Ä¢ Low-density lipoproteins ‚Ä¢ Lipoprotein(a) ‚Ä¢ 
Hypertriglyceridaemia ‚Ä¢ Cardiovascular risk ‚Ä¢ Familial hypercholesterolaemia ‚Ä¢ Acute coronary syndromes
Table of contents
1. Preamble ...................................................................................................................... 3
2. Introduction ............................................................................................................... 5
3. Estimation of total cardiovascular risk and implications for 
dyslipidaemia management ....................................................................................... 5
4. New low-density lipoprotein cholesterol-lowering therapies ............. 9
5. Combination of lipid-lowering therapies during index 
hospitalization for acute coronary syndromes .............................................. 11
6. Lipoprotein(a) ......................................................................................................... 12
7. Hypertriglyceridaemia ......................................................................................... 13
8. Primary prevention in people with human immunodeficiency virus 
infection .......................................................................................................................... 14
9. Patients with cancer at high or very high chemotherapy-related 
cardiovascular toxicity risk ..................................................................................... 15
10. Dietary supplements ......................................................................................... 15
11. Evidence tables .................................................................................................... 16
12. Data availability statement .............................................................................. 16
13. Author information ........................................................................................... 16
14. Appendix ................................................................................................................ 16
15. References ............................................................................................................. 17


<!-- PAGE 3 -->

### Page 3

Tables of Recommendations
Recommendation Table 1 ‚Äî Recommendations for cardiovascular 
risk estimation in persons without known cardiovascular disease 
(see also Supplementary data online, Evidence Table 1) ............................. 9
Recommendation Table 2 ‚Äî Recommendations for 
pharmacological low-density lipoprotein cholesterol lowering (see 
also Supplementary data online, Evidence Table 2) .................................... 11
Recommendation Table 3 ‚Äî Recommendations for lipid-lowering 
therapy in patients with acute coronary syndromes (see also 
Supplementary data online, Evidence Table 3) ............................................. 12
Recommendation Table 4 ‚Äî Recommendations for measurement of 
lipoprotein(a) (see also Supplementary data online, Evidence Table 4)
12
Recommendation Table 5 ‚Äî Recommendations for drug treatment 
of patients with hypertriglyceridaemia (see also Supplementary data 
online, Evidence Table 5) ........................................................................................ 14
Recommendation Table 6 ‚Äî Recommendations for statin therapy 
in primary prevention for people with human immunodeficiency 
virus infection (see also Supplementary data online, Evidence Table 6)
15
Recommendation Table 7 ‚Äî Recommendations for statin therapy 
in patients receiving cancer therapy (see also Supplementary data 
online, Evidence Table 7) ........................................................................................ 15
Recommendation Table 8 ‚Äî Recommendations for dietary 
supplements (see also Supplementary data online, Evidence Table 8)
16
List of tables
Table 1 Classes of recommendations .................................................................. 4
Table 2 Levels of evidence ........................................................................................ 4
Table 3 Cardiovascular risk categories ................................................................ 6
Table 4 Intervention strategies as a function of total cardiovascular 
risk and untreated low-density lipoprotein cholesterol levels .................. 7
List of figures
Figure 1 Treatment goals for low-density lipoprotein cholesterol 
across categories of total cardiovascular risk ................................................... 8
Figure 2 Average reduction in low-density lipoprotein cholesterol 
levels with different pharmacological therapies with proven 
cardiovascular benefits ............................................................................................. 10
Figure 3 Association between Lp(a) levels and lifetime risk of major 
cardiovascular events ............................................................................................... 13
Abbreviations and acronyms
ACS
Acute coronary syndromes
ALT
Alanine aminotransferase
ApoB
Apolipoprotein B
ApoC-III
Apolipoprotein C-III
ART
Antiretroviral therapy
ASCVD
Atherosclerotic cardiovascular disease
AST
Aspartate aminotransferase
AVS
Aortic valve stenosis
CAC
Coronary artery calcium
CI
Confidence interval
CT
Computed tomography
CV
Cardiovascular
CVD
Cardiovascular disease
DHA
Docosahexaenoic acid
EAS
European Atherosclerosis Society
EMA
European Medicines Agency
EPA
Eicosapentaenoic acid
ESC
European Society of Cardiology
FCS
Familial chylomicronaemia syndrome
FDA
US Food and Drug Administration
FH
Familial hypercholesterolaemia
HDL
High-density lipoprotein cholesterol
HIV
Human immunodeficiency virus
HR
Hazard ratio
LDL-C
Low-density lipoprotein cholesterol
Lp(a)
Lipoprotein(a)
LVEF
Left ventricular ejection fraction mAb
Monoclonal antibody
MACE
Major adverse cardiovascular event(s)
MI
Myocardial infarction
PCI
Percutaneous coronary intervention
PCSK9
Proprotein convertase subtilisin/kexin type 9
PPAR
Peroxisome proliferator-activated receptor
PUFA
n-3 polyunsaturated fatty acid
PWH
People with HIV
SCORE2
Systematic Coronary Risk Evaluation 2
SCORE2-OP
Systematic Coronary Risk Evaluation 2-Older 
Persons
TC
Total cholesterol
T1DM
Type 1 diabetes mellitus
T2DM
Type 2 diabetes mellitus
ULN
Upper limit of normal
1. Preamble
Guidelines evaluate and summarize available evidence with the aim of as¬≠
sisting health professionals in proposing the best diagnostic or therapeutic 
approach for an individual patient with a given condition. The European 
Society of Cardiology (ESC) Guidelines are intended for use by health 
professionals but do not override their individual responsibility to make 
appropriate and accurate decisions in consideration of each patient‚Äôs 
health condition and in consultation with the patient or the patient‚Äôs care¬≠
giver where appropriate and/or necessary aiming at shared care decisions. 
It is also the health professional‚Äôs responsibility to verify the rules and reg¬≠
ulations applicable in each country to drugs and devices at the time of pre¬≠
scription and to respect the ethical rules of their profession.
The ESC Guidelines represent the official position of the ESC on 
a given topic. Guideline topics are selected for updating after 
annual expert review of new evidence conducted by the ESC Clinical 
Practice Guidelines (CPG) Committee. ESC Policies and Procedures 
for formulating and issuing the ESC Guidelines can be found on the 
ESC website (https://www.escardio.org/Guidelines/Clinical-Practice- 
Guidelines/Guidelines-development/Writing-ESC-Guidelines).
Interim Focused Updates are created when the publication of new 
evidence could influence clinical practice before the next full update 
of a Guideline is published. This Focused Update provides new and re¬≠
vised recommendations for the 2019 ESC/European Atherosclerosis 
Society (EAS) Guidelines for the management of dyslipidaemias. View 
the full 2019 ESC/EAS Guidelines here: https://doi.org/10.1093/ 
eurheartj/ehz455. This Task Force was selected by the ESC and EAS 
to include professionals involved with the medical care of patients 
with this pathology as well as methodologists.
Guidelines Task Forces perform a critical review and evaluation of 
the published literature on diagnostic and therapeutic approaches 
ESC Guidelines                                                                                                                                                                                                 3


<!-- PAGE 4 -->

### Page 4

including assessment of the risk‚Äìbenefit ratio. Recommendations are 
based on major randomized trials and relevant systematic reviews 
and meta-analyses, when available. Systematic literature searches 
are conducted in cases of controversy or uncertainty to ensure that 
all key studies were considered. For recommendations related to 
diagnosis and prognosis, additional types of evidence are included, 
such as diagnostic accuracy studies and studies focused on the devel¬≠
opment and validation of prognostic models. The strength of each 
recommendation and the level of evidence supporting it are weighed 
and scored according to predefined criteria as outlined in Tables 1
and 2. Patient-Reported Outcome Measures (PROMs) and Patient- 
Reported Experience Measures (PREMs) are also evaluated when avail¬≠
able as the basis for recommendations and/or discussion in these 
Guidelines.
Evidence tables summarizing key information from relevant studies 
are generated to facilitate the formulation of recommendations, to 
Table 1 Classes of recommendations
¬©


	







¬Å
¬ç






¬è¬ê
¬Å
	



¬ù

¬†


			








¬ê¬Å
	
 		
¬≠¬è¬ê
¬Ä

¬ê


¬Å
¬Ç¬ê


		
¬ù






¬è¬ê¬Å


		
Table 2 Levels of evidence







	
		
	


		
							
					
¬©¬Å¬Å¬ç¬è¬ç¬ê


<!-- PAGE 5 -->

### Page 5

enhance comprehension of recommendations after publication, and to 
reinforce transparency in the Guidelines development process. The ta¬≠
bles are published in their own section of the Focused Update and ref¬≠
erence specific recommendation tables.
After an iterative process of deliberations, a first Task Force vote on all 
recommendations is conducted prior to the initiation of rounds of re¬≠
view. A second Task Force vote on all recommendations is conducted 
after the final round of review and revision. For each vote, the Task 
Force follows ESC voting procedures and all recommendations require 
at least 75% agreement among voting members to be approved. 
Voting restrictions may be applied based on declarations of interests.
The writing and reviewing panels provide declaration of interest forms 
for all relationships that might be perceived as real or potential sources of 
conflicts of interest. Their declarations of interest are reviewed according 
to the ESC declaration of interest rules which can be found on the ESC 
website (http://www.escardio.org/doi) and are compiled in a report pub¬≠
lished in a supplementary document with the Guidelines. Funding for the 
development of this ESC/EAS Focused Update was derived entirely from 
the ESC and EAS with no involvement of the healthcare industry.
The ESC CPG Committee supervises and co-ordinates the prepar¬≠
ation of new Guidelines and Focused Updates and approves their publi¬≠
cation. In addition to review by the ESC CPG Committee, this ESC/EAS 
Focused Update underwent multiple rounds of peer review on a dedi¬≠
cated online review platform. The review was conducted by topic ex¬≠
perts, including members from ESC National Cardiac Societies and 
from relevant ESC Subspecialty Communities. The Focused Update 
Task Force considered all review comments and was required to re¬≠
spond to all those classified as major. After appropriate revisions, the 
Task Force and the ESC CPG Committee members and the EAS 
Executive Committee approved the final document for publication in 
the European Heart Journal and in Atherosclerosis.
Unless otherwise stated, the Focused Update content refers to sex, 
understood as the biological condition of being male or female, defined 
by genes, hormones and sexual organs. Off-label use of medication may 
be presented in this Focused Update if a sufficient level of evidence 
shows that it can be considered medically appropriate for a given con¬≠
dition. However, decisions on off-label use must be made by the re¬≠
sponsible health professional giving special consideration to ethical 
rules concerning healthcare, the specific situation of the patient, patient 
consent, and country-specific health regulations.
2. Introduction
Since the publication of the 2019 ESC/EAS Guidelines for the 
management of dyslipidaemias: lipid modification to reduce cardio¬≠
vascular (CV) risk,1 there have been several randomized controlled 
trials that might change patient management ahead of the next sched¬≠
uled full dyslipidaemia Guidelines. This 2025 Focused Update ad¬≠
dresses changes in recommendations for the treatment of 
dyslipidaemias based on new evidence published up until 31 March 
2025. All major randomized controlled clinical trials and 
meta-analyses published after the publication of the 2019 ESC/EAS 
Guidelines were presented and discussed in detail before a consensus 
was reached about any possible classes of recommendations (see 
Table 1) and levels of evidence (see Table 2) to be assigned; these 
were then voted upon for inclusion by all Task Force members. 
Members with declared conflicts of interests in specific topics were 
asked to abstain from voting on those topics.
The Task Force considered and discussed the following new studies, trials, 
and any meta-analyses: Systematic Coronary Risk Evaluation 2 (SCORE2) 
and Systematic Coronary Risk Evaluation 2-Older Persons (SCORE2-OP) 
for estimation of 10 year CV risk;2,3 CLEAR Outcomes [Cholesterol 
Lowering via Bempedoic Acid, an ACL (adenosine triphosphate-citrate 
lyase)-Inhibiting Regimen];4 ELIPSE HoFH (Evinacumab Lipid Studies in 
Patients with Homozygous Familial Hypercholesterolemia);5 APPROACH 
(Reduction of Triglyceride Levels in Familial Chylomicronemia 
Syndrome);6 REPRIEVE (Pitavastatin to Prevent Cardiovascular Disease in 
HIV Infection);7 STRENGTH (Long-Term Outcomes Study to Assess 
Statin Residual Risk with Epanova in High Cardiovascular Risk Patients 
with Hypertriglyceridemia);8 STOP-CA (Atorvastatin for Anthracycline- 
Associated Cardiac Dysfunction);9 SPORT (Supplements, Placebo, or 
Rosuvastatin Study);10 and OMEMI (Omega-3 Fatty acids in Elderly with 
Myocardial Infarction).11 Beside these trials, the Task Force also considered 
and discussed: combination therapy with high-dose statin plus ezetimibe and 
intensification of lipid-lowering therapy during the index hospitalization for 
patients presenting with acute coronary syndromes (ACS), as well as new 
data on lipoprotein(a) [Lp(a)] as a risk modifier.
Only results that would lead to new or changed Class I/IIa or Class III 
recommendations were selected for inclusion in Recommendation 
Tables. All new recommendations included in this Focused Update are 
additive to the recommendations of the 2019 ESC/EAS Guidelines for 
the management of dyslipidaemias, and all changed recommendations 
substitute those of the 2019 ESC/EAS Guidelines for the management 
of dyslipidaemias.
After due deliberation, the Task Force decided to update recom¬≠
mendations for the following sections of the 2019 ESC/EAS 
Guidelines for the management of dyslipidaemias: 
‚Ä¢ Recommendations for CV risk estimation, with implementation of 
the new SCORE2 and SCORE2-OP risk prediction algorithms.
‚Ä¢ Recommendations 
on 
low-density 
lipoprotein 
cholesterol 
(LDL-C)-lowering therapies, including two new agents for LDL-C- 
lowering treatment (bempedoic acid and evinacumab specifically for 
patients with homozygous familial hypercholesterolaemia)(FH).
‚Ä¢ Recommendations for lipid-lowering therapy during index hospital¬≠
ization of ACS.
‚Ä¢ Recommendations on Lp(a).
‚Ä¢ Recommendations 
for drug 
treatment 
in 
patients 
with 
hypertriglyceridaemia.
‚Ä¢ Recommendations for statin therapy in primary CV disease (CVD) 
prevention for people with human immunodeficiency virus (HIV) 
infection.
‚Ä¢ Recommendations for statin therapy for patients with cancer at high 
or very high chemotherapy-related CV toxicity risk.
‚Ä¢ Recommendations for dietary supplements.
3. Estimation of total 
cardiovascular risk and implications 
for dyslipidaemia management
Atherosclerosis is caused by the progressive deposition of LDL-C and 
other apolipoprotein-B (ApoB)-containing lipoproteins within the ar¬≠
tery wall, which triggers a cascade of inflammatory reactions leading 
to the formation and progression of atherosclerotic plaque. As more 
atherogenic lipoproteins become accumulated within the arterial wall 
over time, the atherosclerotic plaque gradually enlarges and the risk 
of having an acute atherosclerotic CV event increases. LDL-C is not 
only a risk factor for atherosclerotic CV disease (ASCVD), but like 
other ApoB-containing lipoproteins is a direct cause of ASCVD;12
ESC Guidelines                                                                                                                                                                                                 5


<!-- PAGE 6 -->

### Page 6

therefore, lowering plasma LDL-C levels should be the main focus for 
preventing atherosclerotic CV events.
In clinical practice, the concentration of circulating LDL-C that can 
become trapped within the artery wall is estimated by measuring plas¬≠
ma levels of LDL-C, which represent the total amount of cholesterol 
carried by low-density lipoproteins. The objective of estimating a per¬≠
son‚Äôs risk of having an atherosclerotic CV event is to identify individuals 
at elevated risk who may benefit from interventions to lower LDL-C 
and other modifiable causes of ASCVD. The clinical benefit of lowering 
LDL-C depends on the achieved LDL-C reduction; therefore, indivi¬≠
duals with higher CV risk require more intense LDL-C lowering to 
achieve the same absolute level of residual CV risk while on treatment 
as compared with individuals with lower risk. For example, assuming an 
average 20% proportional (relative) reduction in risk per each mmol/L 
lower LDL-C,13 lowering LDL-C by 1 mmol/L (38.67 mg/dL) would re¬≠
duce the risk of a person with a 20% absolute risk of having an acute 
atherosclerotic CV event to 16% (i.e. a 20% relative but 4% absolute 
risk reduction), whereas it would reduce the risk of a person with a 
10% absolute risk to 8% (a 20% relative but 2% absolute risk reduction). 
This Focused Update continues to endorse the concept supported in 
the 2019 ESC/EAS Guidelines1 that a person‚Äôs estimated absolute 
risk of having an acute CV event should be used to guide the intensity 
of LDL-C lowering. We also acknowledge that the CV risk reduction 
achievable by a similar magnitude of lowering atherogenic lipid levels ap¬≠
pears to be greater at younger ages.14,15
Numerous randomized trials have demonstrated that lowering 
LDL-C reduces the risk of both fatal and non-fatal myocardial infarc¬≠
tions (MI) and ischaemic strokes13 as well as ischaemic events in 
peripheral arterial territories.16 Therefore, because CVD morbidity 
(non-fatal MI and non-fatal stroke) combined with CVD mortality bet¬≠
ter reflects the total burden of ASCVD, and in line with the current 
dorses the use of risk scores such as SCORE2 and SCORE2-OP (in¬≠
stead of the SCORE algorithm) for estimation of the risk of 
experiencing an MI, ischaemic stroke, or fatal atherosclerotic CV event 
over the next 10 years in persons without known CVD aged between 
40 and 89 years (Recommendation Table 1).
While calculation of the SCORE was based on each person‚Äôs total 
cholesterol level, non-high-density lipoprotein (HDL)-cholesterol 
(which is calculated as total cholesterol minus HDL-C) is used as an 
input in the SCORE2 and SCORE2-OP risk algorithms. Moreover, 
while the SCORE algorithm assessed the 10 year risk of fatal CVD 
in persons aged up to 70 years, the SCORE2/SCORE2-OP algorithms 
(accessible at http://www.heartscore.org) can estimate 10 year risk for 
both fatal and non-fatal CV events also for apparently healthy people 
aged ‚â•70 years (up to 89 years). SCORE2 and SCORE2-OP are cali¬≠
brated to four clusters of countries (low, moderate, high, and very 
high CVD risk) based on national CVD mortality rates;2,3 details and 
risk charts for these country clusters are in the 2021 ESC Guidelines 
on CVD prevention.17
Table 3 presents the updated definitions for very high, high, moder¬≠
ate, and low CVD risk, using the SCORE2/SCORE2-OP instead of the 
SCORE algorithm for apparently healthy persons (primary prevention). 
This table is intended to replace Table 4 of the 2019 ESC/EAS Guidelines.1
As a general concept, it is estimated that the risk of total CVD events is 
2‚Äì3 times higher than the risk of fatal CVD events, although this may 
Table 3 Cardiovascular risk categories
Very high risk
People with any of the following: 
‚Ä¢ Documented ASCVD, either clinical or unequivocal on imaging. Documented ASCVD includes previous ACS (MI or unstable angina), 
chronic coronary syndromes, coronary revascularization (PCI, CABG, and other arterial revascularization procedures), stroke and TIA, and 
peripheral arterial disease. Unequivocally documented ASCVD on imaging includes those findings that are known to be predictive of clinical 
events, such as significant plaquea on coronary angiography or CT scan or on carotid or femoral ultrasound or markedly elevated CAC score 
by CTb
‚Ä¢ DM with target organ damage,c or at least three major risk factors, or early onset of T1DM of long duration (>20 years)
‚Ä¢ Severe CKD (eGFR <30 mL/min/1.73 m2)
‚Ä¢ A calculated SCORE2 or SCORE2-OP ‚â•20% for 10 year risk of fatal or non-fatal CVD
‚Ä¢ FH with ASCVD or with another major risk factor
High risk
People with any of the following: 
‚Ä¢ Markedly elevated single risk factors, in particular TC >8 mmol/L (>310 mg/dL), LDL-C >4.9 mmol/L (>190 mg/dL), or  
BP ‚â•180/110 mmHg
‚Ä¢ Patients with FH without other major risk factors
‚Ä¢ Patients with DM without target organ damage,c with DM duration ‚â•10 years or another additional risk factor
‚Ä¢ Moderate CKD (eGFR 30‚Äì59 mL/min/1.73 m2)
‚Ä¢ A calculated SCORE2 or SCORE2-OP ‚â•10% and <20% for 10 year risk of fatal or non-fatal CVD
Moderate 
risk
People with any of the following: 
‚Ä¢ Young patients (T1DM <35 years; T2DM <50 years) with DM duration <10 years, without other risk factors
‚Ä¢ Calculated SCORE2 or SCORE2-OP ‚â•2% and <10% for 10 year risk of fatal or non-fatal CVD
Low risk
‚Ä¢ Calculated SCORE2 or SCORE2-OP <2% for 10 year risk of fatal or non-fatal CVD
¬© ESC/EAS 2025
ASCVD, atherosclerotic cardiovascular disease; ACS, acute coronary syndromes; BP, blood pressure; CABG, coronary artery bypass graft surgery; CAC, coronary artery calcium; CKD, 
chronic kidney disease; CT, computed tomography; CVD, cardiovascular disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FH, familial hypercholesterolaemia; 
LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; PCI, percutaneous coronary intervention; SCORE2, Systematic Coronary Risk Evaluation 2; SCORE2-OP, 
Systematic Coronary Risk Evaluation 2-Older Persons; T1DM, type 1 DM; T2DM, type 2 DM; TC, total cholesterol; TIA, transient ischaemic attack.
aTypically defined by >50% stenosis.
be.g. CAC score >300.
cTarget organ damage is defined as microalbuminuria, retinopathy, or neuropathy.


<!-- PAGE 7 -->

### Page 7

vary considerably according to age and sex. In this Focused Update, a 2√ó 
multiplier was used to convert previous SCORE-based thresholds17 into 
the SCORE2- or SCORE2-OP-based thresholds to define different cat¬≠
egories of total CVD risk. Notably, this Task Force continues to emphasize 
that risk is a continuum and cut-off points that are used in any CVD risk 
model to define different levels of risk are, in part, arbitrary and based on 
the risk levels at which benefit is evident in clinical trials. Therefore, the 
SCORE2- and SCORE2-OP-based thresholds presented in this document 
(Table 3) reflect this concept.
Because existing population-based CVD risk models are relatively 
crude tools for individual risk prediction,18 attention to additional char¬≠
acteristics that are known to increase CV risk is reasonable in order to 
refine risk assessment, as already discussed in the 2021 ESC Prevention 
Guidelines.17 This is particularly relevant for persons around treatment 
decision thresholds (Recommendation Table 1). Clinical conditions and 
selected biomarkers that can be considered as risk modifiers are sum¬≠
marized in Box 1. Their presence may support reclassifying an individual 
to a higher risk category than would be calculated by the SCORE2 
or SCORE2-OP algorithm, and may thereby guide decisions about 
LDL-C goals and lipid-lowering interventions.
This Focused Update endorses the Class IIa recommendation of the 
2019 ESC/EAS Guidelines1 that arterial (carotid and/or femoral) plaque 
burden should be considered as a risk modifier in individuals at low or 
Table 4 Intervention strategies as a function of total cardiovascular risk and untreated low-density lipoprotein chol¬≠
esterol levels
Total CV 
risk
Untreated LDL-C levels
<1.4 mmol/L 
(<55 mg/dL)
1.4 to 
<1.8 mmol/L (55 
to <70 mg/dL)
1.8 to 
<2.6 mmol/L (70 
to <100 mg/dL)
2.6 to 
<3.0 mmol/L 
(100 to <116 mg/ 
dL)
3.0 to 
<4.9 mmol/L 
(116 to <190 mg/ 
dL
‚â•4.9 mmol/L 
(‚â•190 mg/dL)a
Low
Lifestyle advice
Lifestyle advice
Lifestyle advice
Lifestyle advice
Lifestyle 
modification, 
consider adding 
drug if uncontrolled
N/Aa
Moderate
Lifestyle advice
Lifestyle advice
Lifestyle advice
Lifestyle 
modification, 
consider adding 
drug if uncontrolled
Lifestyle 
modification, 
consider adding 
drug if uncontrolled
N/Aa
High
Lifestyle advice
Lifestyle advice
Lifestyle 
modification, 
consider adding 
drug if uncontrolled
Lifestyle 
modification and 
concomitant drug 
intervention
Lifestyle 
modification and 
concomitant drug 
intervention
Lifestyle 
modification and 
concomitant drug 
intervention
Very high: 
primary 
prevention
Lifestyle 
modification, 
consider adding 
drug
Lifestyle 
modification, 
consider adding 
drug
Lifestyle 
modification and 
concomitant drug 
intervention
Lifestyle 
modification and 
concomitant drug 
intervention
Lifestyle 
modification and 
concomitant drug 
intervention
Lifestyle 
modification and 
concomitant drug 
intervention
Very high: 
secondary 
prevention
Lifestyle 
modification and 
concomitant drug 
intervention
Lifestyle 
modification and 
concomitant drug 
intervention
Lifestyle 
modification and 
concomitant drug 
intervention
Lifestyle 
modification and 
concomitant drug 
intervention
Lifestyle 
modification and 
concomitant drug 
intervention
Lifestyle 
modification and 
concomitant drug 
intervention
¬© ESC/EAS 2025
CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol; N/A, not applicable.
aIn individuals with untreated LDL-C levels ‚â•4.9 mmol/L, total CV risk is already at least high (Table 3).
Box 1 Risk modifiers for consideration 
beyond the risk estimation based on the 
SCORE2 and SCORE2-OP algorithms
Demographic/clinical conditions 
‚Ä¢ Family history of premature CVD (men: <55 years; women: 
<60 years)
‚Ä¢ High-risk ethnicity (e.g. Southern Asian)
‚Ä¢ Stress symptoms and psychosocial stressors
‚Ä¢ Social deprivation
‚Ä¢ Obesity
‚Ä¢ Physical inactivity
‚Ä¢ Chronic immune-mediated/inflammatory disorders
‚Ä¢ Major psychiatric disorders
‚Ä¢ History of premature menopause
‚Ä¢ Pre-eclampsia or other hypertensive disorders of pregnancy
‚Ä¢ Human immunodeficiency virus infection
‚Ä¢ Obstructive sleep apnoea syndrome
Biomarkers 
‚Ä¢ Persistently elevated hs-CRP (>2 mg/L)
‚Ä¢ Elevated Lp(a) [>50 mg/dL (>105 nmol/L)].
CVD, cardiovascular disease; hs-CRP, high sensitivity C-reactive protein; Lp(a), 
lipoprotein(a).
ESC Guidelines                                                                                                                                                                                                 7


<!-- PAGE 8 -->

### Page 8

moderate risk. Recent studies have provided important new evidence 
regarding the clinical risk associated with subclinical atherosclerosis 
documented on coronary or peripheral arterial imaging in persons 
without clinical ASCVD.19 While there are no randomized trials 
showing that the use of coronary artery calcium (CAC) to classify 
CV risk and guide therapeutic management improves CV outcomes, 
nevertheless consideration of CAC improves both discrimination 
and reclassification.20 An elevated CAC score has been associated 
in a graded fashion with a higher risk of adverse CV events in persons 
without clinical ASCVD (primary prevention);21‚Äì23 at markedly ele¬≠
vated CAC values (e.g. CAC score >300), the risk was similar or 
even higher than the risk of patients with known clinical ASCVD 
(secondary prevention).24,25 Conversely, a CAC score of zero has 
been associated with a lower risk of ASCVD events and mortality 
in persons at low to moderate estimated CV risk.26 Consideration 
of CAC improves the accuracy of predicted CVD risk by means of 
the SCORE2 algorithm.27 While the presence of significant (typical¬≠
ly, obstructive) plaque on invasive or computed tomography 
(CT)-based coronary angiography was defined as a feature of very 
high CV risk in the 2019 ESC/EAS Guidelines,1 the presence of 
less advanced coronary atherosclerosis with non-obstructive pla¬≠
ques was more recently shown to be associated with an increased 
risk of subsequent MI.28 Against this background, while coronary im¬≠
aging or CAC measurement are not indicated as broad screening 
tests for the purpose of CV risk estimation, this Focused Update includes 
a new recommendation that the presence of subclinical atherosclerosis 
by imaging or increased CAC score, if measured, should be considered 
as risk modifiers in individuals at moderate risk or individuals around 
treatment decision thresholds (Recommendation Table 1). It should be 
noted, however, that statin therapy may lead to a decrease in lipid-rich 
plaque and an increase in calcification, indicating plaque stabilization;29,30
therefore, CAC score should be interpreted with caution in statin- 
treated patients.
For patients with type 2 diabetes mellitus (T2DM) without ASCVD, 
the 2023 ESC Guidelines for CVD management in patients with dia¬≠
betes recommend the use of the SCORE2-Diabetes algorithm to esti¬≠
mate 10 year CVD risk.31,32
It is important to note that the LDL-C treatment goals (Figure 1) and 
therapeutic guidance (Table 4) for persons in each risk category have 
not changed from the 2019 ESC/EAS Guidelines.1 The intensity of 
the recommended LDL-C lowering continues to be determined by a 
person‚Äôs level of risk. Previous studies indicated potential underestima¬≠
tion of CV risk based on the SCORE2 and SCORE2-OP,18 and under¬≠
treatment with lipid-lowering therapy in primary prevention if statins 
were to be recommended only for persons at very high risk.33
Importantly, however, as outlined in the 2019 ESC/EAS Guidelines,1
the recommendation to initiate pharmacological LDL-C-lowering ther¬≠
apy in primary prevention is not restricted to persons at very high risk, 
but depends on both the estimated CV risk and the baseline (untreat¬≠
ed) LDL-C levels (Table 4). This concept was previously illustrated in 
‚Ä¢ Patients with ASCVD who experience
 recurrent vascular events while taking
 maximally tolerated statin-based therapy
‚Ä¢ Patients with polyvascular (e.g. coronary
 and peripheral) arterial disease
Treatment goal for LDL-C
Class IIb
Class IIa
Class I
Class Ia
Class IIb
& ‚â•50% reduction from baseline aClass IIa for individuals in primary prevention with FH at very high risk
CV Risk
SCORE2/SCORE2-OP <2%
‚Ä¢ SCORE2/SCORE2-OP ‚â•2% and <10%
‚Ä¢ Young patients (T1DM <35 years;
 T2DM <50 years) with DM duration
 <10 years without other risk factors 
‚Ä¢ SCORE2/SCORE2-OP ‚â•10% and <20%
‚Ä¢ Markedly elevated single risk factors, in particular
 TC >8 mmol/L (310 mg/dL) or LDL-C >4.9 mmol/L  (190 mg/dL)
 or BP ‚â•180/110 mmHg
‚Ä¢ FH without other major risk factors
‚Ä¢ Moderate CKD (eGFR 30‚Äì59 mL/min/1.73 m2)
‚Ä¢ DM w/o target organ damage, with DM duration ‚â•10 years
 or other additional risk factor 
‚Ä¢ ASCVD (clinical/imaging)
‚Ä¢ SCORE2/SCORE2-OP ‚â•20%
‚Ä¢ FH with ASCVD or with another major risk factor
‚Ä¢ Severe CKD (eGFR <30 mL/min/1.73 m2)
‚Ä¢ DM & target organ damage: ‚â•3 major risk factors;
 or early onset of T1DM of long duration (>20 years)






	









¬Å¬ç

¬è¬ê

Figure 1 Treatment goals for low-density lipoprotein cholesterol across categories of total cardiovascular risk. ASCVD, atherosclerotic cardiovas¬≠
cular disease; BP, blood pressure; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FH, familial hyper¬≠
cholesterolaemia; LDL-C, low-density lipoprotein cholesterol; SCORE2, Systematic Coronary Risk Evaluation 2; SCORE2-OP, Systematic Coronary 
Risk Evaluation 2-Older Persons; T1DM, type 1 DM; T2DM, type 2 DM; TC, total cholesterol.


<!-- PAGE 9 -->

### Page 9

Table 5 of the 2019 ESC/EAS Guidelines, and is now described (without 
changes vs the 2019 ESC/EAS Guidelines) in Recommendation Table 1.
We further emphasize that the SCORE2 and SCORE2-OP risk- 
estimating algorithms were derived from cohorts of participants 
without clinical ASCVD who were not receiving lipid-lowering ther¬≠
apy. As a result, these algorithms should not be used to estimate risk 
among persons with existing ASCVD or among persons currently on 
lipid-lowering therapy, and they should not be used to ‚Äòre-assess‚Äô 
risk using lipid measurements obtained after initiating Guideline- 
recommended lipid-lowering therapy.
Finally, this Task Force emphasizes that atherosclerosis is a chronic 
progressive disease that begins early in life and slowly progresses 
over time, and the cumulative exposure to higher LDL-C levels at 
younger ages is associated with a higher ASCVD risk later in life.34
Conversely, exposure to lower levels of atherogenic lipids at younger 
ages has the potential to reduce the lifetime risk of developing 
CVD35 and mitigate further progression of subclinical atherosclerosis.15
The discrepancy between our understanding of the biology of how ath¬≠
erosclerosis develops and the practical consequences of informing 
treatment decisions based on 10 year risk underscores the need to de¬≠
velop a new generation of risk- and benefit-estimating algorithms. 
These algorithms should: (i) accurately estimate the lifetime risk of hav¬≠
ing an acute CV event for all individuals regardless of age, and (ii) pro¬≠
vide personalized guidance on the optimal timing and intensity of 
LDL-C lowering needed by each person to reduce their remaining life¬≠
time risk of developing an atherosclerotic CV event.
4. New low-density lipoprotein 
cholesterol-lowering therapies
Bempedoic acid is an oral small molecule that inhibits cholesterol syn¬≠
thesis by inhibiting the action of ATP-citrate lyase, a cytosolic enzyme 
upstream of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
pathway.40 Bempedoic acid is a prodrug and the activating enzyme 
(very long-chain acyl-CoA synthetase-1) is not expressed in skeletal 
muscle.41 Treatment with bempedoic acid has muscle-related adverse 
events similar to placebo.40,42 Bempedoic acid (single dose available, 
180 mg/day) reduces LDL-C levels by approximately 23% as mono¬≠
therapy, approximately 18% when given on a background of statin ther¬≠
apy,40,42 and by 38% when given in a fixed-dose combination with 
ezetimibe.43,44 Treatment with bempedoic acid decreased C-reactive 
protein and did not result in increased haemoglobin A1c levels in pa¬≠
tients with normoglycaemia or pre-diabetes.45 Mendelian randomiza¬≠
tion studies have demonstrated that a genetic variant mimicking the 
effect of ATP-citrate lyase inhibition and lowering plasma LDL-C levels 
by the same mechanism of action is associated with similar reductions in 
the risk of CVD as statins and other non-statin lipid-lowering drugs with 
proven benefit per unit decrease in LDL-C levels.46
The CLEAR Outcomes study was a randomized, double-blind, 
placebo-controlled study that aimed to determine bempedoic acid‚Äôs 
potential for CV risk reduction in statin-intolerant patients at high 
risk of developing major adverse CV events (MACE) during a median 
Recommendation Table 1 ‚Äî Recommendations for cardiovascular risk estimation in persons without known cardio¬≠
vascular disease (see also Supplementary data online, Evidence Table 1)
Recommendations
Classa
Levelb
SCORE2 is recommended in apparently healthy people <70 years of age without established ASCVD, DM, CKD, genetic/rare lipid or BP 
disorders for estimation of 10-year fatal and non-fatal CVD risk.2 c
I
B
SCORE2-OP is recommended in apparently healthy people ‚â•70 years of age without established ASCVD, DM, CKD, genetic/rare lipid or 
BP disorders for estimation of 10-year fatal and non-fatal CVD risk.3 c
I
B
Presence of subclinical coronary atherosclerosis by imaging or increased CAC score by CT should be considered as risk modifiers in 
individuals at moderate risk or individuals around treatment decision thresholds to improve risk classification.24,27,28,36 d
IIa
B
Risk modifierse should be considered in individuals at moderate risk or individuals around treatment decision thresholds to improve risk 
classification.17,27,37 f
IIa
B
In primary prevention,g pharmacological LDL-C-lowering therapy is recommended in persons: 
‚Ä¢ at very high risk and LDL-C ‚â•1.8 mmol/L (70 mg/dL), or
‚Ä¢ at high risk and LDL-C ‚â•2.6 mmol/L (100 mg/dL)
despite optimization of non-pharmacological measures, to lower CVD risk.1,13,38,39
I
A
In primary prevention,g pharmacological LDL-C-lowering therapy should be considered in persons: 
‚Ä¢ at very high risk and LDL-C ‚â•1.4 mmol/L (55 mg/dL) but <1.8 mmol/L (70 mg/dL), or
‚Ä¢ at high risk and LDL-C ‚â•1.8 mmol/L (70 mg/dL) but <2.6 mmol/L (100 mg/dL), or
‚Ä¢ at moderate risk and LDL-C ‚â•2.6 mmol(L (100 mg/dL) but <4.9 mmol/L (190 mg/dL), or
‚Ä¢ at low risk and LDL-C ‚â•3.0 mmol/L (116 mg/dL) but <4.9 mmol/L (190 mg/dL)
despite optimization of non-pharmacological measures, to lower CVD risk.1,13,38,39
IIa
A
¬© ESC/EAS 2025
ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CAC, coronary artery calcium; CKD, chronic kidney disease; CT, computed tomography; CVD, cardiovascular disease; 
DM, diabetes mellitus; LDL-C, low-density lipoprotein cholesterol; SCORE2, Systematic Coronary Risk Evaluation 2; SCORE2-OP, Systematic Coronary Risk Evaluation 2-Older Persons aClass of recommendation.
bLevel of evidence.
cRevised recommendation replacing the respective recommendation based on SCORE in the 2019 ESC/EAS Guidelines.
dRevised recommendation replacing the recommendation on CAC score for CV risk assessment in the 2019 ESC/EAS Guidelines.
eListed in Box 1.
fNew recommendation.
gPersons without known clinical atherosclerotic cardiovascular disease.
ESC Guidelines                                                                                                                                                                                                 9


<!-- PAGE 10 -->

### Page 10

of 40.6 month follow-up.4 A total of 13 970 patients were randomized, 
with approximately 70% in secondary prevention and 30% in primary 
prevention. Patients taking a small dose of a statin (daily dose of ator¬≠
vastatin <10 mg or equivalent) were allowed and constituted 23% of 
the trial population. The time-averaged difference in LDL-C between 
the bempedoic acid and placebo arms was 0.57 mmol/L (22 mg/dL). 
Treatment with bempedoic acid reduced the rate of MACE, defined 
as a composite of death from CV causes, MI, stroke, or coronary revas¬≠
cularization, by 13% [hazard ratio (HR), 0.87; 95% confidence interval 
(CI), 0.79‚Äì0.96; P = .004). There was no apparent effect on CV death 
(HR, 1.04; 95% CI, 0.88‚Äì1.24). Cardiovascular risk reduction with bem¬≠
pedoic acid is similar to that achieved with statins for a given absolute 
magnitude of LDL-C lowering.47 The rate of myalgia was similar in 
the two arms. Treatment with bempedoic acid increased the risk of 
having elevations in hepatic enzymes [>2√ó upper limit of normal 
(ULN) for either alanine aminotransferase (ALT) or aspartate amino¬≠
transferase (AST), 4.5% vs 3.0%], renal impairment (11.5% vs 8.6%), hy¬≠
peruricaemia (10.9% vs 5.6%), gout (3.1% vs 2.1%), cholelithiasis (2.2% 
vs 1.2%), increased platelet count (7.2% vs 0.8%), and decreased haem¬≠
atocrit levels (2.3% vs 0.1%). Because bempedoic acid leads to a small 
and reversible increase in uric acid, caution is required in patients 
with a history of gout, even though gout does not constitute an abso¬≠
lute contraindication to bempedoic acid.
New recommendations for the use of bempedoic acid for LDL-C 
lowering [complementing the recommendations for pharmacological 
LDL-C lowering with statins, ezetimibe, and proprotein convertase 
subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) of the 
2019 ESC/EAS Guidelines1] are shown in Recommendation Table 2. 
Figure 2 summarizes the average percentage reduction in LDL-C levels 
with different pharmacological therapies, alone or in combination. It 
should be kept in mind that there is considerable inter-individual vari¬≠
ability in the LDL-C-lowering response to any given lipid-lowering 
drug or combination, which necessitates monitoring of the treatment 
effects after initiation or adaptation of any LDL-C-lowering therapy. 
As outlined in the 2019 ESC/EAS Guidelines,1 LDL-C levels should 
be measured 4 to 6 weeks after initiation or intensification of 
lipid-lowering therapy.
Inclisiran, a small interfering ribonucleic acid (RNA) molecule that in¬≠
hibits the synthesis of PCSK9, may represent an alternative approach to 
PCSK9 mAbs (alirocumab and evolocumab). Inclisiran has been shown 
in phase III trials to lower LDL-C levels by approximately 50%.48 Two 
CV outcome trials with inclisiran [>16 000 patients with CVD 
(NCT03705234) and 17 000 patients with established ASCVD 
(NCT05030428)] are currently ongoing and expected to report their 
primary outcomes in 2026 and 2027, respectively.
In patients with homozygous FH, in whom statins and PCSK9 inhibi¬≠
tors have little efficacy and may not suffice to adequately lower LDL-C 
levels,49 evinacumab, an mAb against ANGPTL3 (angiopoietin-like 3), 
has shown potential benefits with a reduction of LDL-C close to 
50%.5,50,51
Patients who are unable to take statins because of adverse effects re¬≠
present a challenge in clinical practice. In such cases, the addition of a 
non-statin lipid-modifying agent to a maximally tolerated statin is a valu¬≠
able therapeutic option.1 New evidence supporting the reduction in the 
risk of ASCVD events with ezetimibe in the absence of statin therapy 
(although not necessarily due to statin intolerance) in older persons 
0















	

	

+ 
	
-10
-20
-30
-40
-50
-60
-70
-80
-90
~30%
~50%
~20%~23%
~38%
~60%~58%
~68%
~60%
~70%~75%~75%~80%
~86%
Average LDL-C reduction (%)
Figure 2 Average reduction in low-density lipoprotein cholesterol levels with different pharmacological therapies with proven cardiovascular 
benefits. BA, bempedoic acid; EZE, ezetimibe; LDL-C, low-density lipoprotein cholesterol; PCSK9 mAb, proprotein convertase subtilisin/kexin type 9 
monoclonal antibody.


<!-- PAGE 11 -->

### Page 11

aged ‚â•75 years without history of coronary artery disease was pro¬≠
vided in the randomized, open-label EWTOPIA 75 (Ezetimibe 
Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular 
Disease in 75 or Older).52 As a general concept, this Task Force recom¬≠
mends to add non-statin therapies with proven cardiovascular benefit, 
such as ezetimibe, a PCSK9 mAb, or bempedoic acid, taken alone or in 
combination, to lower LDL-C if the LDL-C goals are not achieved with 
the maximum tolerated dose of a statin; the choice should be based on 
the magnitude of additional LDL-C lowering needed, patient prefer¬≠
ence, treatment availability, and cost.
5. Combination of lipid-lowering 
therapies during index 
hospitalization for acute coronary 
syndromes
A clear association between intensive lipid-lowering therapies and bet¬≠
ter outcomes in patients after ACS was demonstrated two decades 
ago,56,57 supporting ‚Äòthe lower the better‚Äô principle for LDL-C reduc¬≠
tion in this clinical setting. Lipid-lowering therapy is one of the pillars 
of the management of these patients, both in the early post-ACS set¬≠
ting58 and in the chronic, stabilized period after an ACS.59 Patients ex¬≠
periencing ACS are at particularly elevated risk of recurrent CV events, 
especially within the first year after hospital discharge.60 Observational 
data show a 10% cumulative incidence of a second MI, a stroke, or CV 
death within the first 100 days after experiencing an MI,61 reaching 33% 
at 5 years.62 Even in an ideal post-ACS scenario, it can take up to 12 
weeks for patients to receive optimal LDL-C-lowering therapy follow¬≠
ing the current stepwise approach that was recommended in the 2019 
ESC/EAS Guidelines.1 This early post-ACS period corresponds to the 
most vulnerable phase after a major coronary event. Observational 
data show that Guideline-directed, intensive lipid-lowering therapy is 
infrequently prescribed, with few dose adjustments performed after 
hospital discharge,63 and that the majority of patients do not achieve 
their goals.17,64,65 The reasons for this are multifactorial and may in¬≠
clude prescription inertia (prescription of lower-intensity statin), sub¬≠
optimal patient adherence related to side effects of lipid-lowering 
therapies or reluctance to being treated with statins,59 and delays or 
losses to follow-up after discharge from index hospitalization.
The IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy 
International Trial) study showed that the addition of ezetimibe to statin 
therapy (simvastatin 40 mg) within <10 days (median 5 days) after an ACS 
event resulted in incremental lowering of LDL-C levels and a modest but 
significant reduction of adverse CV events.66 Small studies have recently 
demonstrated that very intensive LDL-C-lowering treatment initiated in 
the acute phase after ACS is safe, feasible, and effective in getting more 
patients to recommended LDL-C goals.67‚Äì69 In addition, recent data 
from the HUYGENS70 (High-Resolution Assessment of Coronary 
Plaques 
in 
a 
Global 
Evolocumab 
Randomized 
Study) 
and 
PACMAN-AMI71
(Effects of the PCSK9 Antibody Alirocumab 
on Coronary Atherosclerosis in Patients With Acute Myocardial 
Infarction) trials reported improvements in coronary plaque size and 
composition in response to acute and very intensive LDL-C reduction 
in the vulnerable post-ACS population. A continuous reduction in CV ad¬≠
verse events has been described even when LDL-C reduction exceeded 
current Guideline-recommended treatment goals.72‚Äì74 Recent data from 
the SWEDEHEART (Swedish Web-system for Enhancement and 
Development of Evidence-based care in Heart disease Evaluated 
According to Recommended Therapies) Registry reported the lowest 
risk of CV events in those patients who achieved early and sustained 
LDL-C lowering to recommended goals after MI. A stepwise approach 
for LDL-C lowering after MI might therefore result in delayed goal attain¬≠
ment as compared with early intensification of treatment.75,76 These data 
support ‚Äòthe sooner, the lower, the better‚Äô as a therapeutic strategy for 
LDL-C lowering in patients with ACS.58
As the extent of LDL-C reduction in response to pharmacological in¬≠
terventions is predictable based on baseline LDL-C levels, it is reasonable 
to assume that a significant proportion of ACS patients will not achieve 
their target goal with high-intensity statin treatment alone, prescribed at 
discharge.77 Therefore, and in line with the current 2023 ESC Guidelines 
for the management of patients with ACS,58 this Task Force proposes a 
strategy of early, intensive LDL-C lowering to be considered in all pa¬≠
tients with ACS, with immediate initiation of statin therapy and combin¬≠
ation treatment with one or more classes of non-statin therapy with 
proven CV benefit as needed, depending on each patient‚Äôs lipid-lowering 
therapy prior to the ACS event. The choice of drug for combination 
therapy should be based on the magnitude of additional LDL-C lowering 
required. Several drugs and drug combinations with various efficacies and 
onsets of action are available to enable such a ‚Äòstrike early and strong‚Äô ap¬≠
proach (Figure 2). Recommendation Table 3 includes two new recommen¬≠
dations for this clinical setting, for patients who present either with or 
without pre-existing lipid-lowering therapy at the time of the ACS event. 
Beyond the treatment in the acute ACS phase, LDL-C should be checked 
4 to 6 weeks after initiation or intensification of lipid-lowering therapy, 
Recommendation Table 2 ‚Äî Recommendations for 
pharmacological low-density lipoprotein cholesterol 
lowering (see also Supplementary data online, Evidence 
Table 2)
Recommendations
Classa
Levelb
Non-statin therapies with proven cardiovascular 
benefit,c taken alone or in combination, are 
recommended for patients who are unable to take 
statin therapy to lower LDL-C levels and reduce the 
risk of CV events. The choice should be based on the 
magnitude of additional LDL-C lowering 
needed.4,53,54
I
A
Bempedoic acid is recommended in patients who are 
unable to take statin therapy to achieve the LDL-C 
goal.4
I
B
The addition of bempedoic acid to the maximally 
tolerated dose of statin with or without ezetimibe 
should be considered in patients at high or very high 
risk in order to achieve the LDL-C goal.42,55
IIa
C
Evinacumab should be considered in patients with 
homozygous familial hypercholesterolaemia aged 5 
years or older who are not at LDL-C goal despite 
receiving maximum doses of lipid-lowering therapy 
to lower LDL-C levels.5,50,51
IIa
B
¬© ESC/EAS 2025
CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein 
convertase subtilisin/kexin type 9.
This table complements the table of recommendations for pharmacological low-density 
lipoprotein cholesterol lowering in the 2019 ESC/EAS Guidelines and does not replace it.
aClass of recommendation.
bLevel of evidence.
cEzetimibe, PCSK9 monoclonal antibodies, bempedoic acid.
ESC Guidelines                                                                                                                                                                                               11


<!-- PAGE 12 -->

### Page 12

and lifelong treatment to lower LDL-C levels to recommended targets is 
strongly recommended.1
Several ongoing clinical trials, such as EVOLVE-MI (EVOLocumab 
Very Early After Myocardial Infarction; NCT05284747) and 
AMUNDSEN-real [Evolocumab or normal strategies to reach LDL 
objectives in acute myocardial infarction upbound to PCI (percutan¬≠
eous coronary intervention); EUDRACT:20210‚Äì005738‚Äì0], are in¬≠
vestigating the potential benefit of introducing evolocumab at the 
time of the ACS event. The results of these trials are expected in 
2026‚Äì2027.
6. Lipoprotein(a)
Epidemiologic and genetic studies strongly support a likely causal and dir¬≠
ect continuous association between high plasma levels of Lp(a) and high¬≠
er risk of ASCVD and aortic valve stenosis (AVS).78 Emerging data are 
suggesting that high Lp(a) may confer a higher risk of ASCVD and AVS 
per particle or cholesterol content than LDL-C.37,79‚Äì84 The mechanisms 
by which Lp(a) and LDL lead to these increased risks therefore likely dif¬≠
fer.78 Based on studies from the United Kingdom, Denmark, and the 
United States of America, the highest risks were for MI and AVS, less 
in peripheral artery disease and heart failure, and the lowest risks were 
for ischaemic stroke and CV and all-cause mortality.37,78,79,85‚Äì90 Risk 
from high Lp(a) increases slightly at levels of 30 mg/dL (62 nmol/L) to 
50 mg/dL (105 nmol/L) and becomes clinically relevant above 50 mg/dL 
(105 nmol/L), with higher levels associated with a greater increase in 
CV risk. Lp(a) concentration is predominantly determined by genetics 
(>90%), more than any other lipoprotein, and levels vary with ethnicity.83
There is an incremental increase in risk caused by higher Lp(a) levels, and 
if Lp(a) level is not considered, risk might be substantially underestimated 
(Figure 3).78 Lp(a) measurement should be considered at least once in 
every adult‚Äôs lifetime,1 either at the first lipid profile or at the next one 
if lipid profiles have previously been performed. Screening is particularly 
relevant in younger patients with FH or premature ASCVD and no other 
identifiable risk factors, or a family history of premature ASCVD or high 
Lp(a) levels, or in individuals at moderate risk or around treatment deci¬≠
sion thresholds to improve risk classification. Lp(a) levels may increase 
after menopause and a second measurement is reasonable, particularly 
if the pre-menopausal levels were borderline.78,91 For Lp(a) measure¬≠
ment, there is substantial variability among different assays, in part relat¬≠
ing to apo(a) structure and variability in Kringle-IV repeats, potentially 
under- or overestimating Lp(a) levels. Although measurement in molar 
units (nmol/L) is preferred, mass units (mg/dL) can be used for clinical 
purposes.
Although Lp(a) has not yet been shown to improve risk prediction 
on top of currently recommended scores (SCORE2, SCORE2-OP), 
another study testing whether elevated Lp(a) could improve MI risk 
prediction beyond conventional risk factors showed that Lp(a) con¬≠
centrations >47 mg/dL reclassified 23% of first MI events correctly, 
while no events were reclassified incorrectly, in a cohort of 8720 
individuals.84
Whether lowering Lp(a) reduces the risk of ASCVD and AVS pro¬≠
gression has yet to be shown; the extent of Lp(a) lowering required 
for clinical benefit is also not known. In the absence of specific 
Lp(a)-lowering therapies, early risk factor management and more in¬≠
tensive LDL-C lowering is reasonable, considering both absolute CV 
risk and Lp(a) levels.78 An online Lp(a) risk and benefit algorithm 
is available at http://www.eas-society.org/LPA_risk_and_benefit_ 
algorithm. Although small studies have suggested that statins may 
have a slight Lp(a) increasing effect, individual-level data on partici¬≠
pants in seven randomized, placebo-controlled, statin outcome 
trials found that statins had no effect on Lp(a) concentrations.92
Therefore, clinical decision-making should be influenced by the de¬≠
gree of Lp(a) elevation and the patient‚Äôs other risk factors, and pa¬≠
tients with high levels of Lp(a) should be strongly encouraged to 
take or continue to take high-intensity statins if their risk is sufficiently 
high.93
Currently, there are specific Lp(a)-lowering medications being tested 
in randomized clinical trials. The injectable RNA (either antisense oligo¬≠
nucleotide or small interfering RNA)-based therapies that target apoli¬≠
poprotein(a) production in the hepatocyte lower Lp(a) concentration 
by 80%‚Äì98%.94‚Äì97 An oral small molecule inhibitor and a small interfer¬≠
ing RNA that can lower Lp(a) significantly are currently under investi¬≠
gation.98‚Äì100
Recommendation Table 4 includes a new recommendation reflecting 
the increase in CV risk across the spectrum of elevated Lp(a) levels.1 It 
is reasonable to consider elevated Lp(a) levels >50 mg/dL (‚â•105 nmol/ 
L) (affecting at least 20% of the population)83 in order to refine CV 
risk estimation across the spectrum of CV risk; moreover, this cut-off le¬≠
vel should be considered as a risk modifier to potentially reclassify the CV 
risk category specifically in individuals at moderate risk or individuals close 
to treatment decision thresholds (see Box 1 and Recommendation 
Table 1).
Recommendation Table 3 ‚Äî Recommendations for 
lipid-lowering therapy in patients with acute coronary 
syndromes (see also Supplementary data online, 
Evidence Table 3)
Recommendations
Classa
Levelb
Intensification of lipid-lowering therapy during the 
index ACS hospitalization is recommended for 
patients who were on any lipid-lowering therapy 
before admission in order to further lower LDL-C 
levels.
I
C
Initiating combination therapy with high-intensity 
statin plus ezetimibe during index hospitalization for 
ACS should be considered in patients who were 
treatment-na√Øve and are not expected to achieve the 
LDL-C goal with statin therapy alone.66
IIa
B
¬© ESC/EAS 2025
This table complements the ESC 2019 ESC/EAS Guidelines table and does not replace it.
ACS, acute coronary syndromes; LDL-C, low-density lipoprotein cholesterol.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 4 ‚Äî Recommendations for 
measurement of lipoprotein(a) (see also Supplementary 
data online, Evidence Table 4)
Recommendations
Classa
Levelb
Lp(a) levels above 50 mg/dL (105 nmol/L) should be 
considered in all adults as a CV risk-enhancing factor, 
with higher Lp(a) levels associated with a greater 
increase in risk.37,101
IIa
B
¬© ESC/EAS 2025
CV, cardiovascular; Lp(a), lipoprotein(a).
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 13 -->

### Page 13

### 7 Hypertriglyceridaemia

Triglyceride levels are associated with CV risk independent of LDL-C 
levels.102‚Äì104
With 
respect 
to 
pharmacological 
treatment 
of hypertriglyceridaemia, this Task Force continues to recommend 
statins as the first drug of choice to reduce CVD risk in high-risk 
patients.1
Currently available fibrates (gemfibrozil, fenofibrate, bezafibrate) 
have moderate triglyceride-lowering effects.105‚Äì107 Fenofibrate and be¬≠
zafibrate lead to small decreases in LDL-C, but have not reduced MACE 
(MI, ischaemic stroke, CV mortality) or total mortality in patients trea¬≠
ted with statins. A reduction in non-fatal MI was only seen in subgroup 
analyses of patients with atherogenic dyslipidaemia (low HDL-C and 
high triglycerides) in these trials.105,106 In a pre-specified subgroup ana¬≠
lysis of the FIELD (Fenofibrate Intervention and Event Lowering 
in Diabetes) trial, fenofibrate was associated with a lower risk of 
lower-limb amputations, likely not mediated by lipid-related mechan¬≠
isms.108 The PROMINENT (Pemafibrate to Reduce Cardiovascular 
OutcoMes by Reducing Triglycerides IN PatiENts With DiabeTes) trial 
recently showed that the selective peroxisome proliferator-activated 
receptor (PPAR-a) modulator pemafibrate109 did not reduce the risk 
of MACE in 10 497 patients with T2DM, mild-to-moderate hypertrigly¬≠
ceridaemia and low HDL-C levels; notably, pemafibrate increased ApoB 
and LDL-C levels in that trial. Overall, in contrast to the robust evidence 
of ASCVD risk reduction with LDL-C lowering therapies, the efficacy of 
triglyceride lowering with fibrates in reducing ASCVD risk has not been 
established. This Focused Update supports the Class IIb recommenda¬≠
tions of the 2019 ESC/EAS Guidelines for the use of fenofibrate or be¬≠
zafibrate.1 Fibrates are not indicated to lower serum cholesterol or 
LDL-C levels.110
Regarding n-3 polyunsaturated fatty acids (PUFAs), the STRENGTH 
trial was published following the publication of the 2019 ESC/EAS 
Guidelines.1 The trial failed to demonstrate benefit of a combined 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) prepar¬≠
ation in 13 078 patients (70% with diabetes; 56% with established 
ASCVD) in lowering MACE (composite of cardiovascular death, non- 
fatal MI, non-fatal stroke, coronary revascularization, or unstable angina 
requiring hospitalization).8






1.0
0
Lifetime risk for major cardiovascular events mg/dL
nmol/L
Lipoprotein (a)
20
10
50
24
100
48
150
71
200
95
250
119
300
138
350
161
400
184
0
1.5
2.0
2.5
3.0
4.0
Hazard ratio (95% CI)
Percentage of individualsa

Figure 3 Association between Lp(a) levels and lifetime risk of major cardiovascular events. CI, confidence interval; Lp(a), lipoprotein (a). The risk of 
major CV events starts to slightly increase in individuals with Lp(a) levels >62 nmol/L (30 mg/dL), and the increase in risk becomes more pronounced in 
individuals with Lp(a) levels ‚â•105 nmol/L (50 mg/dL). The grey lines indicates the smoothed adjusted hazard ratio and 95% confidence interval (left 
y-axis) for lifetime risk for major CV events for a given Lp(a) concentration relative to the median Lp(a) in the population (data from the United 
Kingdom Biobank, sub-analysis including 415 274 white individuals).78 aThe blue line shows the frequency distribution of Lp(a) levels, with respective 
percentages indicated in the right y-axis (data from the United Kingdom Biobank including 443 180 individuals without prior atherosclerotic CVD).37
ESC Guidelines                                                                                                                                                                                               13


<!-- PAGE 14 -->

### Page 14

Reasons for the discordant results of the negative STRENGTH trial 
vs those of the positive REDUCE-IT (Reduction of Cardiovascular 
Events with Icosapent Ethyl‚ÄìIntervention Trial),111 which were pub¬≠
lished 2 years earlier, may be related to differences in the study popu¬≠
lations, active treatment compounds (mixture of EPA and DHA vs 
high-dose icosapent ethyl, i.e. a highly purified EPA ethyl ester, re¬≠
spectively), or placebo formulation (corn oil vs mineral oil-containing 
placebo, respectively).112‚Äì114 Proposed mechanisms of action of how 
EPA specifically reduces cardiovascular risk are the distinct effects on 
lipid oxidation, inflammation, membrane structure/organization, chol¬≠
esterol domain formation, and endothelial function.115,116 In view of 
the newer evidence from the STRENGTH trial, this Focused 
Update revised the respective recommendation for PUFAs by expli¬≠
citly stating that high-dose icosapent ethyl (as in the REDUCE-IT trial) 
should be considered for high-risk or very high-risk patients with ele¬≠
vated triglyceride levels (fasting triglyceride level 135-499 mg/dL 
[1.52-5.63 mmol/L]) despite statin therapy to lower CVD events 
(Recommendation Table 5).
Volanesorsen is an antisense oligonucleotide targeting hepatic apoli¬≠
poprotein C-III (ApoC-III) messenger RNA that lowers plasma levels of 
ApoC-III, triglycerides, and chylomicrons. In a phase III, double-blind, 
randomized 52 week trial including 66 patients with familial chylomicro¬≠
naemia syndrome (FCS) and markedly elevated triglyceride levels 
(mean baseline levels 2209 mg/dL [24.96 mmol/L]), volanesorsen was 
shown to lower triglyceride levels by 77% within 3 months; levels 
<750 mg/dL (<8.48 mmol/L) were achieved in 77% of volanesorsen- 
treated patients. Common adverse events include thrombocytopenia 
requiring frequent monitoring and injection-site reactions in 60% of 
the patients treated with volanesorsen.6 A meta-analysis of individual 
patient data from three randomized controlled trials including pa¬≠
tients with triglyceride levels >500 mg/dL (>5.65 mmol/L) (n = 207) 
showed a significant reduction in the risk of acute pancreatitis during 
a median follow-up of 8.1 months.117 Volanesorsen has been ap¬≠
proved by the European Medicines Agency (EMA) [but not by the 
US Food and Drug Administration (FDA)] as an adjunct to diet in adult 
patients with genetically confirmed FCS and at high risk for pancrea¬≠
titis in whom response to diet and triglyceride-lowering therapy has 
been inadequate. This drug should be considered for patients with 
severe hypertriglyceridaemia due to FCS (new recommendation in 
Recommendation Table 5).
Currently, new triglyceride-lowering medications are being 
tested in randomized clinical trials. Injectable RNA-based therapies 
(either antisense oligonucleotide or small interfering RNA) targeting 
ApoC-III can lower triglyceride concentrations by up to 80% 
depending on the dose, interval, specific agent, and patient popula¬≠
tion.118‚Äì121
8. Primary prevention in people 
with human immunodeficiency 
virus infection
People with HIV (PWH) have a two-fold increased risk of ASCVD com¬≠
pared with the general population.17,122 Underlying mechanisms in¬≠
clude chronic inflammation, immune activation, dyslipidaemia caused 
by antiretroviral therapy (ART), and traditional CV risk factors.123
Cardiovascular risk is often underestimated in PWH using conventional 
risk prediction tools.124 In the 2019 ESC/EAS Guidelines,1 the recom¬≠
mendation was that lipid-lowering therapy (mostly statins) should be 
considered in HIV patients with dyslipidaemia to achieve the LDL-C 
goal as defined for high-risk patients (Class IIa, Level C). The recently 
published REPRIEVE trial justifies an update in the recommendation 
for statins in PWH. REPRIEVE was a multicentre, randomized, double- 
blind, placebo-controlled trial that enrolled 7769 participants in pri¬≠
mary prevention with HIV, aged 40 to 75 years with low-to-moderate 
ASCVD risk receiving ART.7 Patients were randomized to pitavastatin 
4 mg once daily or placebo. The primary endpoint was MACE, a com¬≠
posite of CV death, MI, hospitalization for unstable angina, stroke, tran¬≠
sient ischaemic attack, peripheral arterial ischaemia, revascularization, 
or death from an undetermined cause. The trial was stopped prema¬≠
turely for efficacy after a median follow-up of 5.1 years, and showed 
a 35% lower incidence of MACE in the pitavastatin vs the placebo 
group (HR, 0.65; 95% CI, 0.48‚Äì0.90; P = .002). Efficacy was similar 
for men and women‚Äîan important finding as women have a higher 
risk of HIV-associated ASCVD.125 Of note, rates of muscle-related 
symptoms and new-onset diabetes were higher in PWH treated with 
pitavastatin (2.4% vs 1.3% and 5.3% vs 4.0%, respectively). The 5 year 
number needed to treat to prevent one MACE was 106. In the 
REPRIEVE trial, pitavastatin 4 mg daily did not interact with antiretro¬≠
viral drugs; as co-administration of certain statins and specific antiretro¬≠
viral drugs may result in significant drug interactions, the choice of statin 
should be based on potential drug interactions.126 The new recommen¬≠
dation in this Focused Update for statin therapy in PWH aged ‚â•40 
years in primary prevention is included in Recommendation Table 6.
Although outcome trials of other lipid-lowering therapies have not 
been performed in PWH, data on LDL-C reduction and tolerability 
are available for ezetimibe and PCSK9 mAbs.
Ezetimibe as monotherapy or in combination with statin therapy re¬≠
duces LDL-C levels in PWH receiving ART to a similar extent as in peo¬≠
ple without HIV and is well tolerated, although available studies are 
small.127‚Äì129 Regarding PCSK9 inhibitors, a randomized, double-blind 
trial including 464 PWH receiving ART (35.6% with documented 
ASCVD) showed that evolocumab reduced LDL-C levels by 56.9% 
Recommendation Table 5 ‚Äî Recommendations for drug treatment of patients with hypertriglyceridaemia (see also 
Supplementary data online, Evidence Table 5)
Recommendations
Classa
Levelb
High-dose icosapent ethyl (2 √ó 2 g/day) should be considered in combination with a statin in high-risk or very high-risk patients with 
elevated triglyceride levels (fasting triglyceride level 135‚Äì499 mg/dL or 1.52‚Äì5.63 mmol/L) to reduce the risk of cardiovascular events.8,111
IIa
B
Volanesorsen (300 mg/week) should be considered in patients with severe hypertriglyceridaemia (>750 mg/dL or >8.5 mmol/L) due to 
familial chylomicronaemia syndrome, to lower triglyceride levels and reduce the risk of pancreatitis.6,117
IIa
B
¬© ESC/EAS 2025
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 15 -->

### Page 15

compared with placebo and was well tolerated.130 As yet no data are 
available for the efficacy and safety of bempedoic acid or icosapent ethyl 
in PWH.
9. Patients with cancer at high or 
very high chemotherapy-related 
cardiovascular toxicity risk
Anthracycline-based chemotherapy is a key component of several 
chemotherapy regimens for many types of cancer (e.g. breast cancer 
or lymphoma). Its use is associated with the development of heart fail¬≠
ure in up to 20% of patients within 5 years, depending on the accumu¬≠
lated dose received.131
Recently, four randomized trials assessed the cardioprotective role 
of statins in patients with cancer receiving anthracycline-based ther¬≠
apy.9,132‚Äì134 The STOP-CA trial was a multicentre, double-blind, ran¬≠
domized controlled trial comparing atorvastatin 40 mg daily against 
placebo in 300 patients with lymphoma. The primary endpoint, defined 
as the proportion of patients with ‚â•10% absolute decline in left ven¬≠
tricular ejection fraction (LVEF) to a final LVEF value <55% at 12 
months, occurred more frequently in the placebo compared with the 
atorvastatin group (22% vs 9%, respectively; P = .002).9 Three smaller 
trials yielded mixed results132‚Äì134 (see supplementary data online), 
which may be explained by differences in patient populations, CV 
risk, sample sizes, outcomes, or follow-up duration. Although the evi¬≠
dence supporting the use of statins as cardioprotective treatment for 
anthracycline-induced cardiotoxicity is not unequivocal, this Focused 
Update supports the Class IIa recommendation introduced in the 
2022 ESC cardio-onocology Guidelines135 for statin treatment in pa¬≠
tients at high or very high risk of developing cancer therapy-related 
CV toxicity (new recommendation in Recommendation Table 7). This 
was based on the net positive results of the largest of these trials 
(STOP-CA) and two meta-analyses of available randomized trials (in¬≠
cluding unblinded trials),136,137 in combination with the overall safety 
of statins without reported increase in hepatotoxicity or myopathy in 
this setting.9,132‚Äì134
The effects of non-statin lipid-lowering therapies on LVEF or other 
cardiovascular outcomes in patients receiving cancer therapy have 
not been tested.
10. Dietary supplements
The role of healthy dietary habits in lowering atherogenic lipid levels 
and reducing CV risk is discussed in detail in the 2019 ESC/EAS 
Guidelines.1 A healthy diet is generally defined as a dietary pattern 
low in saturated fat, with a focus on wholegrain products, vegetables, 
fruit, and fish.1 With respect to dietary supplements, however, there 
has not been compelling evidence that these can reduce CV risk. For 
red yeast rice preparations, although a clinically relevant hypocholes¬≠
terolaemic effect has been reported with selected (purified, high- 
dose) preparations, convincing evidence of a clinical benefit resulting 
from this treatment is missing. Similarly, there has not been evidence 
that supplementation with PUFAs can lower LDL-C levels or reduce 
the risk of CV events‚Äîwith the exception of high-dose, purified ico¬≠
sapent ethyl used in the context of hypertriglyceridaemia. Along the 
same lines, the recently published OMEMI trial that tested PUFA 
(DHA + EPA) in elderly patients (age 70‚Äì82 years) without elevated 
triglycerides with recent (2‚Äì8 weeks) acute MI did not show a reduc¬≠
tion in clinical events compared with placebo.11 The recent SPORT 
trial was a single-centre, randomized, single-blind study in persons 
without history of ASCVD and an increased 10 year risk of ASCVD. 
Participants (n = 199) were randomized to rosuvastatin 5 mg daily, 
placebo, fish oil, cinnamon, garlic, turmeric, plant sterols, or red yeast 
rice. At 28 days, LDL-C reduction (the study‚Äôs primary endpoint) was 
greater with rosuvastatin than with all supplements or placebo, and 
none of the dietary supplements led to a significant LDL-C reduction 
compared with placebo.10 Phytosterols reduce cholesterol absorp¬≠
tion in the intestinal lumen and increase cholesterol excretion, and 
at doses of up to 2 grams per day they can reduce LDL-C levels by 
approximately 10% without reported adverse events. There are no 
studies showing benefit of phytosterols on CV outcomes.138 In June 
2022, the European Parliament and the Council prohibited the mar¬≠
keting of food supplements containing ‚â•3 mg/day of monacolins 
from red yeast rice. Concretely, this corresponds to a ban on mona¬≠
colins from red yeast rice at a daily dose of ‚â•3 mg/day, while lower 
doses of these supplements are under restrictions (warnings) and 
European Union scrutiny.139
Based on the totality of available evidence and in view of the new 
trials published after 2019,10,11 this Focused Update does not support 
the use of dietary supplements or vitamins without documented safety 
and significant LDL-C-lowering efficacy for lowering the risk of ASCVD 
(new recommendation in Recommendation Table 8).
Recommendation Table 6 ‚Äî Recommendations for 
statin therapy in primary prevention for people with hu¬≠
man immunodeficiency virus infection (see also 
Supplementary data online, Evidence Table 6)
Recommendation
Classa
Levelb
Statin therapy is recommended for people in primary 
prevention aged ‚â•40 years with HIV, irrespective of 
estimated cardiovascular risk and LDL-C levels, to 
reduce the risk of cardiovascular events; the choice 
of statin should be based on potential drug 
interactions.7
I
B
¬© ESC/EAS 2025
HIV, human immunodeficiency virus; LDL-C, low-density lipoprotein cholesterol.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 7 ‚Äî Recommendations for 
statin therapy in patients receiving cancer therapy (see 
also Supplementary data online, Evidence Table 7)
Recommendation
Classa
Levelb
Statins should be considered in adult patients at high 
or very high risk of developing chemotherapy-related 
cardiovascular toxicityc to reduce the risk of 
anthracycline-induced cardiac dysfunction.9,132‚Äì134
IIa
B
¬© ESC/EAS 2025
aClass of recommendation.
bLevel of evidence.
cBaseline cardiovascular toxicity risk stratification discussed in detail in the 2022 ESC 
Guidelines on cardio-onocology.135
ESC Guidelines                                                                                                                                                                                               15


<!-- PAGE 16 -->

### Page 16

### 11 Evidence tables

Evidence tables are available at European Heart Journal online.
12. Data availability statement
No new data were generated or analysed in support of this research.
13. Author information
Author/Task Force Member Affiliations: Lale Tokg√∂zoƒülu, 
Cardiology, Hacettepe University, Ankara, T√ºrkiye; Lina Badimon, 
Cardiovascular Health Sciences, UVIC-UCC, Barcelona, Spain, and 
Translational and Clinical Research, Foundation for Cardiovascular 
Prevention and Innovation, Barcelona, Spain; Colin Baigent, Nuffield 
Department of Population Health, University of Oxford, Oxford, 
United Kingdom; Marianne Benn, Department of Clinical 
Biochemistry, Copenhagen University Hospital - Rigshospitalet, 
Copenhagen, Denmark and Institute of Clinical Medicine, Copenhagen 
University, Copenhagen, Denmark; Christoph J. Binder, Laboratory 
Medicine, Medical University of Vienna, Vienna, Austria; Alberico 
L. Catapano, Center for the Study of Atherosclerosis, Multimedica 
IRCCS, Milan, Italy and Department of Pharmacological and 
Biomolecular Sciences, University of Milan, Milan, Italy; Guy G. De 
Backer, Public Health and Primary Care, Ghent University, Ghent, 
Belgium; Victoria Delgado, Cardiology, Hospital University Germans 
Trias i Pujol, Badalona, Spain; Natalia Fabin, Department of 
Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy 
and Department of Cardiovascular Diseases, IRCCS Humanitas 
Research Hospital, Rozzano, Milan, Italy; Brian A. Ference, 
Cardiovascular Medicine, Deep Causal AI Institute for Clinical 
Translation, Cambridge, United Kingdom; Ian M. Graham, 
Department of Cardiology, Trinity College, Dublin, Ireland; Ulf 
Landmesser, Department of Cardiology, Angiology and Intensive 
Care Medicine, Deutsches Herzzentrum der Charit√©, Campus 
Benjamin Franklin, Berlin, Germany and Friede Springer Cardiovascular 
Prevention Center@Charit√©, Charit√© Universit√§tsmedizin Berlin, Berlin, 
Germany; Ulrich Laufs, Department of Cardiology, Leipzig 
University, Leipzig, Germany; Borislava Mihaylova, Wolfson 
Institute of Population Health, Queen Mary University of London, 
London, United Kingdom, and Nuffield Department of Population 
Health, University of Oxford, Oxford, United Kingdom; B√∏rge 
Gr√∏nne 
Nordestgaard, 
Clinical 
Biochemistry, 
Copenhagen 
University Hospital - Herlev and Gentofte, Copenhagen, Denmark and 
Institute of Clinical Medicine, Faculty of Health and Medical Sciences, 
University of Copenhagen, Copenhagen, Denmark; Dimitrios 
J. Richter, Cardiac Department, Euroclinic Hospital, Athens, Greece; 
Marc S. Sabatine, TIMI Study Group, Division of Cardiovascular 
Medicine, Brigham and Women‚Äôs Hospital, Boston, MA, United States 
of America and Department of Medicine, Harvard Medical School, 
Boston, MA, United States of America.
14. Appendix
ESC/EAS Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Christian Eugen Mueller (ESC Review 
Co-ordinator) 
(Switzerland), 
Heinz 
Drexel 
(EAS 
Review 
Co-ordinator) (Austria), Ana Abreu (Portugal), Marianna Adamo 
(Italy), Suleman Aktaa (United Kingdom), Folkert W. Asselbergs 
(Netherlands), Antonio Baldini (Italy), Giuseppe Boriani (Italy), 
Margarita Brida (Croatia), Marianne Brodmann (Austria), Edina 
Cenko (Italy), Nikolaos Dagres (Germany), J√∂rn Dopheide 
(Switzerland), Christoph Ebenbichler (Austria), Estelle Gandjbakhch 
(France), Diana A. Gorog (United Kingdom), Ioanna Gouni-Berthold 
(Germany), Luigina Guasti (Italy), Bettina Heidecker (Germany), Borja 
Ibanez (Spain), Stefan James (Sweden), Peter Juni (United Kingdom), 
Marta Ka≈Çu≈ºna-Oleksy (Poland), Konstantin A. Krychtiuk (Austria), 
Gregory Y.H. Lip (United Kingdom), Roberto Lorusso (Netherlands), 
Felix Mahfoud (Switzerland), Marco Metra (Italy), Inge Moelgaard 
(Denmark), Jo√£o Morais (Portugal), Lis Neubeck (United Kingdom), 
Steven E. Nissen (United States of America), Elena Osto (Austria/ 
Switzerland), Klaus G. Parhofer (Germany), Leopoldo Perez De Isla 
(Spain), Maurizio Pesce (Italy/Saudi Arabia), Zaneta Petrulioniene 
(Lithuania), Eva Prescott (Denmark), Ernst Rietzschel (Belgium), 
Bianca Rocca (Italy), Jose Fernando Rodriguez Palomares (Spain), 
Xavier Rossello (Spain), Anna Sannino (Germany), Anne Grete Semb 
(Norway), Jolanta Siller Matula (Germany), Thenral Socrates 
(Switzerland), Felix C. Tanner (Switzerland), Johann Wojta (Austria), 
Alberto Zambon (Italy), and Katja Zeppenfeld (Netherlands).
Contributor either withdrew or was engaged in only a part of the re¬≠
view process: Winfried Maerz (Germany)
ESC National Cardiac Societies actively involved in the review 
process of the 2025 Focused Update of the 2019 ESC/EAS Guidelines 
for the management of dyslipidaemias:
Algeria: Algerian Society of Cardiology, Nadia Laredj; Armenia: 
Armenian Cardiologists Association, Hamlet Hayrapetyan; Austria: 
Austrian Society of Cardiology, Walter Stefan Speidl; Azerbaijan: 
Azerbaijan Society of Cardiology, Fuad Samadov; Belgium: Belgian 
Society of Cardiology, Philippe van de Borne; Bosnia and 
Herzegovina: Association of Cardiologists of Bosnia and 
Herzegovina, Zumreta Kusljugic; Bulgaria: Bulgarian Society of 
Cardiology, 
Arman 
Postadzhiyan; 
Cyprus: 
Cyprus 
Society 
of Cardiology, Hera Heracleous; Czechia: Czech Society of 
Cardiology, Petr Ostadal; Denmark: Danish Society of Cardiology, 
Finn Lund Henriksen; Egypt: Egyptian Society of Cardiology, 
Mohamed Seleem Mohamed; Estonia: Estonian Society of 
Cardiology, Margus Viigimaa; Finland: Finnish Cardiac Society, 
Markus Juonala; France: French Society of Cardiology, Franck 
Boccara; Georgia: Georgian Society of Cardiology, Archil 
Chukhrukidze; 
Germany: 
German 
Cardiac 
Society, 
Oliver 
Weing√§rtner; Greece: Hellenic Society of Cardiology, Maria 
Marketou; Hungary: Hungarian Society of Cardiology, Robert 
Gabor Kiss; Iceland: Icelandic Society of Cardiology, Axel 
F. Sigurdsson; Ireland: Irish Cardiac Society, Vincent Maher; 
Recommendation Table 8 ‚Äî Recommendations for 
dietary supplements (see also Supplementary data 
online, Evidence Table 8)
Recommendation
Classa
Levelb
Dietary supplements or vitamins without 
documented safety and significant LDL-C-lowering 
efficacy are not recommended to lower the risk of 
ASCVD.10,11
III
B
¬© ESC/EAS 2025
ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein 
cholesterol.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 17 -->

### Page 17

Israel: Israel Heart Society, Yaakov Henkin; Italy: Italian Federation of 
Cardiology, Savina Nodari; Kazakhstan: Association of Cardiologists 
of Kazakhstan, Makhabbat Bekbossynova; Kosovo (Republic of): 
Kosovo Society of Cardiology, Pranvera Ibrahimi; Kyrgyzstan: 
Kyrgyz Society of Cardiology, Erkin Mirrakhimov; Latvia: Latvian 
Society of Cardiology, Sanda Jegere; Lebanon: Lebanese Society of 
Cardiology, Samir Arnaout; Libya: Libyan Cardiac Society, Osama 
Bheleel; Lithuania: Lithuanian Society of Cardiology, Jurgita Plisiene; 
Luxembourg: Luxembourg Society of Cardiology, Laurent Visser; 
Malta: Maltese Cardiac Society, Mark Abela; Moldova (Republic 
of): Moldavian Society of Cardiology, Victoria Ivanov; Montenegro: 
Montenegro Society of Cardiology, Aneta Boskovic; Morocco: 
Moroccan Society of Cardiology, Nazzi Mbarek; Netherlands: 
Netherlands Society of Cardiology, Maarten J.G. Leening; North 
Macedonia: National Society of Cardiology of North Macedonia, 
Marijan Bosevski; Norway: Norwegian Society of Cardiology, 
Elisabeth K. Vesterbekkmo; Poland: Polish Cardiac Society, Jacek 
Kubica; Portugal: Portuguese Society of Cardiology, Jorge Ferreira; 
Romania: Romanian Society of Cardiology, Dana Pop; San Marino: 
San Marino Society of Cardiology, Umberto Maria Stefanelli; Serbia: 
Cardiology Society of Serbia, Vojislav Giga; Slovakia: Slovak Society 
of Cardiology, Daniel Pella; Slovenia: Slovenian Society of 
Cardiology, Zlatko Fras; Spain: Spanish Society of Cardiology, Rosa 
Fernandez-Olmo; Sweden: Swedish Society of Cardiology, Lennart 
Nilsson; Switzerland: Swiss Society of Cardiology, Isabella Sudano; 
Syrian Arab Republic: Syrian Cardiovascular Association, 
Mohamed Yassin Bani Marjeh; Tunisia: Tunisian Society of 
Cardiology and Cardiovascular Surgery, Faten Triki; T√ºrkiye: Turkish 
Society of Cardiology, Muzaffer M. Degertekin; Ukraine: Ukrainian 
Association of Cardiology, Olena Mitchenko; United Kingdom of 
Great Britain and Northern Ireland: British Cardiovascular 
Society, Amitava Banerjee; and Uzbekistan: Association of 
Cardiologists of Uzbekistan, Aleksandr Shek.
ESC Clinical Practice Guidelines (CPG) Committee: Ulf 
Landmesser 
(Chairperson) 
(Germany), 
Stefan 
James 
(Co-Chairperson) (Sweden), Marianna Adamo (Italy), Suleman Aktaa 
(United Kingdom), Folkert W. Asselbergs (Netherlands), Colin 
Baigent (United Kingdom), Michael A. Borger (Germany), Giuseppe 
Boriani (Italy), Margarita Brida (Croatia), Robert A. Byrne (Ireland), 
Estelle Gandjbakhch (France), Bettina Heidecker (Germany), Anja 
Hennemuth (Germany), Borja Ibanez (Spain), Peter J√ºni (United 
Kingdom), Gregory Y.H. Lip (United Kingdom), John William McEvoy 
(Ireland), Borislava Mihaylova (United Kingdom), Inge Moelgaard 
(Denmark), Lis Neubeck (United Kingdom), Eva Prescott (Denmark), 
Bianca Rocca (Italy), Xavier Rossello (Spain), Anna Sannino 
(Germany), Felix C. Tanner (Switzerland), Wojtek Wojakowski 
(Poland), and Katja Zeppenfeld (Netherlands).
EAS Executive Committee: B√∏rge Gr√∏nne Nordestgaard 
(President) (Denmark), Shoaib Afzal (Denmark), Marianne Benn 
(Denmark), Kirsten B. Holven (Norway), Meral Kayikcioglu (T√ºrkiye), 
Ulrich Laufs (Germany), Evangelos Liberopoulos (Greece), Katariina 
√ñ√∂rni (Finland), Kausik K. Ray (United Kingdom), and Jeanine 
Roeters van Lennep (Netherlands).
15. References
1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/ 
EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce 
cardiovascular risk. Eur Heart J 2020;41:111‚Äì88. https://doi.org/10.1093/eurheartj/ 
ehz455
2. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk 
prediction algorithms: new models to estimate 10-year risk of cardiovascular disease 
in Europe. Eur Heart J 2021;42:2439‚Äì54. https://doi.org/10.1093/eurheartj/ehab309
3. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk 
prediction algorithms: estimating incident cardiovascular event risk in older persons in 
four geographical risk regions. Eur Heart J 2021;42:2455‚Äì67. https://doi.org/10.1093/ 
eurheartj/ehab312
4. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic 
acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023; 
388:1353‚Äì64. https://doi.org/10.1056/NEJMoa2215024
5. Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. 
Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med 2020;383: 
711‚Äì20. https://doi.org/10.1056/NEJMoa2004215
6. Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. 
Volanesorsen and triglyceride levels in Familial Chylomicronemia syndrome. N Engl J 
Med 2019;381:531‚Äì42. https://doi.org/10.1056/NEJMoa1715944
7. Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, et al. 
Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med 2023; 
389:687‚Äì99. https://doi.org/10.1056/NEJMoa2304146
8. Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high- 
dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients 
at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 2020;324: 
2268‚Äì80. https://doi.org/10.1001/jama.2020.22258
9. Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, et al. 
Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA rando¬≠
mized clinical trial. JAMA 2023;330:528‚Äì36. https://doi.org/10.1001/jama.2023.11887
10. Laffin LJ, Bruemmer D, Garcia M, Brennan DM, McErlean E, Jacoby DS, et al. 
Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements on 
lipids and inflammatory biomarkers. J Am Coll Cardiol 2023;81:1‚Äì12. https://doi.org/ 
10.1016/j.jacc.2022.10.013
11. Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, et al. Effects of n-3 fatty 
acid supplements in elderly patients after myocardial infarction: a randomized, controlled 
trial. Circulation 2021;143:528‚Äì39. https://doi.org/10.1161/CIRCULATIONAHA.120. 
052209
12. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. 
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence 
from genetic, epidemiologic, and clinical studies. A consensus statement from the 
European Atherosclerosis Society Consensus panel. Eur Heart J 2017;38:2459‚Äì72. 
https://doi.org/10.1093/eurheartj/ehx144
13. Cholesterol Treatment Trialists Collaboration; Baigent C, Blackwell L, Emberson J, 
Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL chol¬≠
esterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. 
Lancet 2010;376:1670‚Äì81. https://doi.org/10.1016/S0140-6736(10)61350-5
14. Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, Sherliker P, 
Emberson J, et al. Blood cholesterol and vascular mortality by age, sex, and blood 
pressure: a meta-analysis of individual data from 61 prospective studies with 
55,000 vascular deaths. Lancet 2007;370:1829‚Äì39. https://doi.org/10.1016/S0140- 
6736(07)61778-4
15. Mendieta G, Pocock S, Mass V, Moreno A, Owen R, Garcia-Lunar I, et al. Determinants 
of progression and regression of subclinical atherosclerosis over 6 years. J Am Coll 
Cardiol 2023;82:2069‚Äì83. https://doi.org/10.1016/j.jacc.2023.09.814
16. Oyama K, Giugliano RP, Tang M, Bonaca MP, Saver JL, Murphy SA, et al. Effect of 
evolocumab on acute arterial events across all vascular territories: results from 
the FOURIER trial. Eur Heart J 2021;42:4821‚Äì9. https://doi.org/10.1093/eurheartj/ 
ehab604
17. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021 ESC 
Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 
42:3227‚Äì337. https://doi.org/10.1093/eurheartj/ehab484
18. van Trier TJ, Snaterse M, Boekholdt SM, Scholte Op Reimer WJM, Hageman SHJ, 
Visseren FLJ, et al. Validation of systematic coronary risk evaluation 2 (SCORE2) 
and SCORE2-older persons in the EPIC-Norfolk prospective population cohort. Eur 
J Prev Cardiol 2024;31:182‚Äì9. https://doi.org/10.1093/eurjpc/zwad318
19. Fernandez-Friera L, Garcia-Alvarez A, Oliva B, Garcia-Lunar I, Garcia I, 
Moreno-Arciniegas A, et al. Association between subclinical atherosclerosis burden 
and unrecognized myocardial infarction detected by cardiac magnetic resonance in 
middle-aged low-risk adults. Eur Heart J Cardiovasc Imaging 2024;25:968‚Äì75. https:// 
doi.org/10.1093/ehjci/jeae044
20. Lin JS, Evans CV, Johnson E, Redmond N, Coppola EL, Smith N. Nontraditional risk 
factors in cardiovascular disease risk assessment: updated evidence report and system¬≠
atic review for the US Preventive Services Task Force. JAMA 2018;320:281‚Äì97. https:// 
doi.org/10.1001/jama.2018.4242
21. Dzaye O, Razavi AC, Michos ED, Mortensen MB, Dardari ZA, Nasir K, et al. Coronary 
artery calcium scores indicating secondary prevention level risk: findings from the CAC 
consortium and FOURIER trial. Atherosclerosis 2022;347:70‚Äì6. https://doi.org/10. 
1016/j.atherosclerosis.2022.02.006
ESC Guidelines                                                                                                                                                                                               17


<!-- PAGE 18 -->

### Page 18

22. Budoff MJ, Young R, Burke G, Jeffrey Carr J, Detrano RC, Folsom AR, et al. Ten-year 
association of coronary artery calcium with atherosclerotic cardiovascular disease 
(ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). Eur Heart J 
2018;39:2401‚Äì8. https://doi.org/10.1093/eurheartj/ehy217
23. Mehta A, Pandey A, Ayers CR, Khera A, Sperling LS, Szklo MS, et al. Predictive value of 
coronary artery calcium score categories for coronary events versus strokes: impact of 
sex and race: MESA and DHS. Circ Cardiovasc Imaging 2020;13:e010153. https://doi. 
org/10.1161/CIRCIMAGING.119.010153
24. Peng AW, Dardari ZA, Blumenthal RS, Dzaye O, Obisesan OH, Iftekhar Uddin SM, 
et al. Very high coronary artery calcium (‚â•1000) and association with cardiovascular 
disease events, non-cardiovascular disease outcomes, and mortality: results from 
MESA. Circulation 2021;143:1571‚Äì83. https://doi.org/10.1161/CIRCULATIONAHA. 
120.050545
25. Peng AW, Mirbolouk M, Orimoloye OA, Osei AD, Dardari Z, Dzaye O, et al. 
Long-term all-cause and cause-specific mortality in asymptomatic patients with 
CAC ‚â•1,000: results from the CAC Consortium. JACC Cardiovasc Imaging 2020;13: 
83‚Äì93. https://doi.org/10.1016/j.jcmg.2019.02.005
26. Valenti V, √ì Hartaigh B, Heo R, Cho I, Schulman-Marcus J, Gransar H, et al. A 15-year 
warranty period for asymptomatic individuals without coronary artery calcium: a pro¬≠
spective follow-up of 9,715 individuals. JACC Cardiovasc Imaging 2015;8:900‚Äì9. https:// 
doi.org/10.1016/j.jcmg.2015.01.025
27. Hageman SHJ, Petitjaen C, Pennells L, Kaptoge S, Pajouheshnia R, Tillmann T, et al. 
Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible 
addition of risk modifiers on top of SCORE2. Eur J Prev Cardiol 2023;30:1705‚Äì14. 
https://doi.org/10.1093/eurjpc/zwad187
28. Fuchs A, Kuhl JT, Sigvardsen PE, Afzal S, Knudsen AD, Moller MB, et al. Subclinical cor¬≠
onary atherosclerosis and risk for myocardial infarction in a Danish cohort: a prospect¬≠
ive observational cohort study. Ann Intern Med 2023;176:433‚Äì42. https://doi.org/10. 
7326/M22-3027
29. Lee SE, Chang HJ, Sung JM, Park HB, Heo R, Rizvi A, et al. Effects of statins on coronary 
atherosclerotic plaques: the PARADIGM study. JACC Cardiovasc Imaging 2018;11: 
1475‚Äì84. https://doi.org/10.1016/j.jcmg.2018.04.015
30. van Rosendael AR, van den Hoogen IJ, Gianni U, Ma X, Tantawy SW, Bax AM, et al. 
Association of statin treatment with progression of coronary atherosclerotic plaque 
composition. JAMA Cardiol 2021;6:1257‚Äì66. https://doi.org/10.1001/jamacardio.2021. 
3055
31. Marx N, Federici M, Sch√ºtt K, Muller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC 
Guidelines for the management of cardiovascular disease in patients with diabetes. Eur 
Heart J 2023;44:4043‚Äì140. https://doi.org/10.1093/eurheartj/ehad192
32. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. 
SCORE2-diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in 
Europe. Eur Heart J 2023;44:2544‚Äì56. https://doi.org/10.1093/eurheartj/ehad260
33. Mortensen MB, Tybjaerg-Hansen A, Nordestgaard BG. Statin eligibility for primary 
prevention of cardiovascular disease according to 2021 European Prevention 
Guidelines compared with other international guidelines. JAMA Cardiol 2022;7: 
836‚Äì43. https://doi.org/10.1001/jamacardio.2022.1876
34. Domanski MJ, Wu CO, Tian X, Hasan AA, Ma X, Huang Y, et al. Association of incident 
cardiovascular disease with time course and cumulative exposure to multiple risk fac¬≠
tors. J Am Coll Cardiol 2023;81:1151‚Äì61. https://doi.org/10.1016/j.jacc.2023.01.024
35. Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, et al. 
Association of genetic variants related to combined exposure to lower low-density li¬≠
poproteins and lower systolic blood pressure with lifetime risk of cardiovascular dis¬≠
ease. JAMA 2019;322:1381‚Äì91. https://doi.org/10.1001/jama.2019.14120
36. Fuster V, Garcia-Alvarez A, Devesa A, Mass V, Owen R, Quesada A, et al. Influence of 
subclinical atherosclerosis burden and progression on mortality. J Am Coll Cardiol 2024; 
84:1391‚Äì403. https://doi.org/10.1016/j.jacc.2024.06.045
37. Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, et al. Lp(a) (lipopro¬≠
tein[a]) concentrations and incident atherosclerotic cardiovascular disease: new in¬≠
sights from a large national biobank. Arterioscler Thromb Vasc Biol 2021;41:465‚Äì74. 
https://doi.org/10.1161/ATVBAHA.120.315291
38. Cholesterol Treatment Trialists Collaboration; Fulcher J, O‚ÄôConnell R, Voysey M, 
Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men 
and women: meta-analysis of individual data from 174,000 participants in 27 randomised 
trials. Lancet 2015;385:1397‚Äì405. https://doi.org/10.1016/S0140-6736(14)61368-4
39. Cholesterol Treatment Trialists Collaborators; Mihaylova B, Emberson J, Blackwell L, 
Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in 
people at low risk of vascular disease: meta-analysis of individual data from 27 rando¬≠
mised trials. Lancet 2012;380:581‚Äì90. https://doi.org/10.1016/S0140-6736(12)60367-5
40. Ruscica M, Sirtori CR, Carugo S, Banach M, Corsini A. Bempedoic acid: for whom and 
when. Curr Atheroscler Rep 2022;24:791‚Äì801. https://doi.org/10.1007/s11883-022- 
01054-2
41. Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific 
ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates ath¬≠
erosclerosis. Nat Commun 2016;7:13457. https://doi.org/10.1038/ncomms13457
42. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and 
efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019;380: 
1022‚Äì32. https://doi.org/10.1056/NEJMoa1803917
43. Bays HE, Baum SJ, Brinton EA, Plutzky J, Hanselman JC, Teng R, et al. Effect of bempe¬≠
doic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low- 
density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterol¬≠
emia not treated with statins. Am J Prev Cardiol 2021;8:100278. https://doi.org/10.1016/ 
j.ajpc.2021.100278
44. Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic 
acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia 
and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol 
2020;27:593‚Äì603. https://doi.org/10.1177/2047487319864671
45. Ray KK, Nicholls SJ, Li N, Louie MJ, Brennan D, Lincoff AM, et al. Efficacy and safety of 
bempedoic acid among patients with and without diabetes: prespecified analysis of the 
CLEAR outcomes randomised trial. Lancet Diabetes Endocrinol 2024;12:19‚Äì28. https:// 
doi.org/10.1016/S2213-8587(23)00316-9
46. Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian 
randomization study of ACLY and cardiovascular disease. N Engl J Med 2019;380: 
1033‚Äì42. https://doi.org/10.1056/NEJMoa1806747
47. Lincoff AM, Ray KK, Sasiela WJ, Haddad T, Nicholls SJ, Li N, et al. Comparative cardio¬≠
vascular benefits of bempedoic acid and statin drugs. J Am Coll Cardiol 2024;84:152‚Äì62. 
https://doi.org/10.1016/j.jacc.2024.04.048
48. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of 
Inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382:1507‚Äì19. 
https://doi.org/10.1056/NEJMoa1912387
49. Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, et al. 2023 Update on 
European Atherosclerosis Society Consensus statement on homozygous familial 
hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J 2023;44: 
2277‚Äì91. https://doi.org/10.1093/eurheartj/ehad197
50. Gaudet D, Greber-Platzer S, Reeskamp LF, Iannuzzo G, Rosenson RS, Saheb S, et al. 
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and effi¬≠
cacy. Eur Heart J 2024;45:2422‚Äì34. https://doi.org/10.1093/eurheartj/ehae325
51. Wiegman A, Greber-Platzer S, Ali S, Reijman MD, Brinton EA, Charng MJ, et al. 
Evinacumab for pediatric patients with homozygous familial hypercholesterolemia. 
Circulation 2024;149:343‚Äì53. https://doi.org/10.1161/CIRCULATIONAHA.123.065529
52. Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y, et al. Ezetimibe 
lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or 
older (EWTOPIA 75): a randomized, controlled trial. Circulation 2019;140: 
992‚Äì1003. https://doi.org/10.1161/CIRCULATIONAHA.118.039415
53. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy 
and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin in¬≠
tolerance: the GAUSS-3 randomized clinical trial. JAMA 2016;315:1580‚Äì90. https:// 
doi.org/10.1001/jama.2016.3608
54. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. 
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin 
rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 2015;9: 
758‚Äì69. https://doi.org/10.1016/j.jacl.2015.08.006
55. Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect 
of bempedoic acid vs placebo added to maximally tolerated statins on low-density 
lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR 
wisdom randomized clinical trial. JAMA 2019;322:1780‚Äì8. https://doi.org/10.1001/ 
jama.2019.16585
56. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early inten¬≠
sive vs a delayed conservative simvastatin strategy in patients with acute coronary syn¬≠
dromes: phase Z of the A to Z trial. JAMA 2004;292:1307‚Äì16. https://doi.org/10.1001/ 
jama.292.11.1307
57. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al. Early and late 
benefits of high-dose atorvastatin in patients with acute coronary syndromes: results 
from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1405‚Äì10. https://doi.org/ 
10.1016/j.jacc.2005.03.077
58. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC 
Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44: 
3720‚Äì826. https://doi.org/10.1093/eurheartj/ehad191
59. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC 
Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024; 
45:3415‚Äì537. https://doi.org/10.1093/eurheartj/ehae177
60. Rossello X, Bueno H, Pocock SJ, Van de Werf F, Danchin N, Annemans L, et al. 
Predictors of all-cause mortality and ischemic events within and beyond 1 year after 
an acute coronary syndrome: results from the EPICOR registry. Clin Cardiol 2019; 
42:111‚Äì9. https://doi.org/10.1002/clc.23116
61. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular 
risk in post-myocardial infarction patients: nationwide real world data demonstrate 
the importance of a long-term perspective. Eur Heart J 2015;36:1163‚Äì70. https:// 
doi.org/10.1093/eurheartj/ehu505
62. Steen DL, Khan I, Andrade K, Koumas A, Giugliano RP. Event rates and risk factors for 
recurrent cardiovascular events and mortality in a contemporary post acute coronary


<!-- PAGE 19 -->

### Page 19

syndrome population representing 239 234 patients during 2005 to 2018 in the 
United States. J Am Heart Assoc 2022;11:e022198. https://doi.org/10.1161/JAHA.121. 
022198
63. Schubert J, Lindahl B, Melhus H, Renlund H, Leosdottir M, Yari A, et al. Low-density 
lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients 
and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J 2021;42: 
243‚Äì52. https://doi.org/10.1093/eurheartj/ehaa1011
64. De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Z, Ryden L, et al. 
Management of dyslipidaemia in patients with coronary heart disease: results from 
the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019;285: 
135‚Äì46. https://doi.org/10.1016/j.atherosclerosis.2019.03.014
65. Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-wide cross- 
sectional observational study of lipid-modifying therapy use in secondary and primary 
care: the DA VINCI study. Eur J Prev Cardiol 2021;28:1279‚Äì89. https://doi.org/10.1093/ 
eurjpc/zwaa047
66. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. 
Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 
2015;372:2387‚Äì97. https://doi.org/10.1056/NEJMoa1410489
67. Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, et al. 
Evolocumab for early reduction of LDL cholesterol levels in patients with acute cor¬≠
onary syndromes (EVOPACS). J Am Coll Cardiol 2019;74:2452‚Äì62. https://doi.org/10. 
1016/j.jacc.2019.08.010
68. Leucker TM, Blaha MJ, Jones SR, Vavuranakis MA, Williams MS, Lai H, et al. Effect of 
evolocumab on atherogenic lipoproteins during the peri- and early postinfarction per¬≠
iod: a placebo-controlled, randomized trial. Circulation 2020;142:419‚Äì21. https://doi. 
org/10.1161/CIRCULATIONAHA.120.046320
69. Makhmudova U, Samadifar B, Maloku A, Haxhikadrija P, Geiling JA, Romer R, et al. 
Intensive lipid-lowering therapy for early achievement of guideline-recommended 
LDL-cholesterol levels in patients with ST-elevation myocardial infarction (‚ÄúJena auf 
Ziel‚Äù). Clin Res Cardiol 2023;112:1212‚Äì9. https://doi.org/10.1007/s00392-022-02147-3
70. Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, et al. Effect of evolo¬≠
cumab on coronary plaque phenotype and burden in statin-treated patients following 
myocardial infarction. JACC Cardiovasc Imaging 2022;15:1308‚Äì21. https://doi.org/10. 
1016/j.jcmg.2022.03.002
71. Raber L, Ueki Y, Otsuka T, Losdat S, Haner JD, Lonborg J, et al. Effect of alirocumab 
added to high-intensity statin therapy on coronary atherosclerosis in patients with 
acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA 2022; 
327:1771‚Äì81. https://doi.org/10.1001/jama.2022.5218
72. Schwartz GG, Gabriel Steg P, Bhatt DL, Bittner VA, Diaz R, Goodman SG, et al. Clinical 
efficacy and safety of alirocumab after acute coronary syndrome according to achieved 
level of low-density lipoprotein cholesterol: a propensity score-matched analysis of the 
ODYSSEY OUTCOMES trial. Circulation 2021;143:1109‚Äì22. https://doi.org/10.1161/ 
CIRCULATIONAHA.120.049447
73. Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, et al. Clinical 
efficacy and safety of achieving very low LDL-cholesterol concentrations with the 
PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. 
Lancet 2017;390:1962‚Äì71. https://doi.org/10.1016/S0140-6736(17)32290-0
74. Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Bujas-Bobanovic M, Diaz R, et al. 
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after 
acute coronary syndrome are associated with cardiovascular risk reduction: the 
ODYSSEY OUTCOMES trial. Eur Heart J 2023;44:1408‚Äì17. https://doi.org/10.1093/ 
eurheartj/ehad144
75. Schubert J, Leosdottir M, Lindahl B, Westerbergh J, Melhus H, Modica A, et al. Intensive 
early and sustained lowering of non-high-density lipoprotein cholesterol after myocar¬≠
dial infarction and prognosis: the SWEDEHEART registry. Eur Heart J 2024;45: 
4204‚Äì15. https://doi.org/10.1093/eurheartj/ehae576
76. Leosdottir M, Hagstrom E, Hadziosmanovic N, Norhammar A, Lindahl B, Hambraeus 
K, et al. Temporal trends in cardiovascular risk factors, lifestyle and secondary prevent¬≠
ive medication for patients with myocardial infarction attending cardiac rehabilitation 
in Sweden 2006‚Äì2019: a registry-based cohort study. BMJ Open 2023;13:e069770. 
https://doi.org/10.1136/bmjopen-2022-069770
77. Allahyari A, Jernberg T, Hagstrom E, Leosdottir M, Lundman P, Ueda P. Application of 
the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a re¬≠
cent myocardial infarction: a simulation study. Eur Heart J 2020;41:3900‚Äì9. https:// 
doi.org/10.1093/eurheartj/ehaa034
78. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. 
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a 
European Atherosclerosis Society Consensus Statement. Eur Heart J 2022;43: 
3925‚Äì46. https://doi.org/10.1093/eurheartj/ehac361
79. Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mor¬≠
tality. Eur Heart J 2019;40:2760‚Äì70. https://doi.org/10.1093/eurheartj/ehy902
80. Bjornson E, Adiels M, Taskinen MR, Burgess S, Chapman MJ, Packard CJ, et al. 
Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based gen¬≠
etic analysis. J Am Coll Cardiol 2024;83:385‚Äì95. https://doi.org/10.1016/j.jacc.2023.10.039
81. Marston NA, Melloni GEM, Murphy SA, Morze J, Kamanu FK, Ellinor PT, et al. 
Per-particle cardiovascular risk of lipoprotein(a) vs non-Lp(a) apolipoprotein 
B-containing lipoproteins. J Am Coll Cardiol 2024;83:470‚Äì2. https://doi.org/10.1016/j. 
jacc.2023.09.836
82. Welsh P, Welsh C, Celis-Morales CA, Brown R, Ho FK, Ferguson LD, et al. 
Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and es¬≠
timating benefits from novel interventions. Eur J Prev Cardiol 2022;28:1991‚Äì2000. 
https://doi.org/10.1093/eurjpc/zwaa063
83. Nordestgaard BG, Langsted A. Lipoprotein(a) and cardiovascular disease. Lancet 2024; 
404:1255‚Äì64. https://doi.org/10.1016/S0140-6736(24)01308-4
84. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels 
and improved cardiovascular risk prediction. J Am Coll Cardiol 2013;61:1146‚Äì56. 
https://doi.org/10.1016/j.jacc.2012.12.023
85. Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ische¬≠
mic stroke. J Am Coll Cardiol 2019;74:54‚Äì66. https://doi.org/10.1016/j.jacc.2019.03.524
86. Mehta A, Vasquez N, Ayers CR, Patel J, Hooda A, Khera A, et al. Independent associ¬≠
ation of lipoprotein(a) and coronary artery calcification with atherosclerotic cardio¬≠
vascular risk. J Am Coll Cardiol 2022;79:757‚Äì68. https://doi.org/10.1016/j.jacc.2021.11. 
058
87. Hedegaard BS, Bork CS, Kaltoft M, Klausen IC, Schmidt EB, Kamstrup PR, et al. 
Equivalent impact of elevated lipoprotein(a) and familial hypercholesterolemia in pa¬≠
tients with atherosclerotic cardiovascular disease. J Am Coll Cardiol 2022;80: 
1998‚Äì2010. https://doi.org/10.1016/j.jacc.2022.09.021
88. Thomas PE, Vedel-Krogh S, Kamstrup PR, Nordestgaard BG. Lipoprotein(a) is linked 
to atherothrombosis and aortic valve stenosis independent of C-reactive protein. Eur 
Heart J 2023;44:1449‚Äì60. https://doi.org/10.1093/eurheartj/ehad055
89. Thomas PE, Vedel-Krogh S, Nielsen SF, Nordestgaard BG, Kamstrup PR. 
Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, 
and major adverse limb events. J Am Coll Cardiol 2023;82:2265‚Äì76. https://doi.org/ 
10.1016/j.jacc.2023.10.009
90. Kraaijenhof JM, Nurmohamed NS, Nordestgaard AT, Reeskamp LF, Stroes ESG, 
G Kees Hovingh, et al. Low-density lipoprotein cholesterol, C-reactive protein, and li¬≠
poprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk 
study. Eur Heart J 2025. https://doi.org/10.1093/eurheartj/ehaf209
91. Simony SB, Mortensen MB, Langsted A, Afzal S, Kamstrup PR, Nordestgaard BG. Sex 
differences of lipoprotein(a) levels and associated risk of morbidity and mortality by 
age: the Copenhagen general population study. Atherosclerosis 2022;355:76‚Äì82. 
https://doi.org/10.1016/j.atherosclerosis.2022.06.1023
92. de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, et al. 
Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J 
Prev Cardiol 2022;29:779‚Äì92. https://doi.org/10.1093/eurjpc/zwab171
93. Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, et al. Baseline and 
on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: indi¬≠
vidual patient-data meta-analysis of statin outcome trials. Lancet 2018;392:1311‚Äì20. 
https://doi.org/10.1016/S0140-6736(18)31652-0
94. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, 
Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular 
disease. N Engl J Med 2020;382:244‚Äì55. https://doi.org/10.1056/NEJMoa1905239
95. O‚ÄôDonoghue ML, Rosenson RS, Gencer B, Lopez JAG, Lepor NE, Baum SJ, et al. Small 
interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med 2022; 
387:1855‚Äì64. https://doi.org/10.1056/NEJMoa2211023
96. Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, et al. Single 
ascending dose study of a short interfering RNA targeting lipoprotein(a) production in 
individuals with elevated plasma lipoprotein(a) levels. JAMA 2022;327:1679‚Äì87. https:// 
doi.org/10.1001/jama.2022.5050
97. Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, et al. Lepodisiran, an 
extended-duration short interfering RNA targeting lipoprotein(a): a randomized 
dose-ascending clinical trial. JAMA 2023;330:2075‚Äì83. https://doi.org/10.1001/jama. 
2023.21835
98. Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, et al. Muvalaplin, an oral 
small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial. 
JAMA 2023;330:1042‚Äì53. https://doi.org/10.1001/jama.2023.16503
99. Nicholls SJ, Ni W, Rhodes GM, Nissen SE, Navar AM, Michael LF, et al. Oral muvalaplin 
for lowering of lipoprotein(a): a randomized clinical trial. JAMA 2025;333:222‚Äì31. 
https://doi.org/10.1001/jama.2024.24017
100. Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, et al. Zerlasiran-a 
small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial. JAMA 
2024;332:1992‚Äì2002. https://doi.org/10.1001/jama.2024.21957
101. Berman AN, Biery DW, Besser SA, Singh A, Shiyovich A, Weber BN, et al. 
Lipoprotein(a) and major adverse cardiovascular events in patients with or without 
baseline atherosclerotic cardiovascular disease. J Am Coll Cardiol 2024;83:873‚Äì86. 
https://doi.org/10.1016/j.jacc.2023.12.031
102. Wadstrom BN, Pedersen KM, Wulff AB, Nordestgaard BG. Elevated remnant choles¬≠
terol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality. Eur 
Heart J 2023;44:1432‚Äì45. https://doi.org/10.1093/eurheartj/ehac822
103. Balling M, Afzal S, Davey Smith G, Varbo A, Langsted A, Kamstrup PR, et al. Elevated 
LDL triglycerides and atherosclerotic risk. J Am Coll Cardiol 2023;81:136‚Äì52. https:// 
doi.org/10.1016/j.jacc.2022.10.019
ESC Guidelines                                                                                                                                                                                               19


<!-- PAGE 20 -->

### Page 20

### 104 Raposeiras-Roubin S, Rossello X, Oliva B, Fernandez-Friera L, Mendiguren JM, Andres

V, et al. Triglycerides and residual atherosclerotic risk. J Am Coll Cardiol 2021;77: 
3031‚Äì41. https://doi.org/10.1016/j.jacc.2021.04.059
105. Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovas¬≠
cular disease and stroke. Cochrane Database Syst Rev 2015;2015:CD009580. https:// 
doi.org/10.1002/14651858.CD009580.pub2
106. Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, et al. Effects of 
combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563‚Äì74. 
https://doi.org/10.1056/NEJMoa1001282
107. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term 
fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mel¬≠
litus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849‚Äì61. https:// 
doi.org/10.1016/S0140-6736(05)67667-2
108. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D‚ÄôEmden MC, et al. Effect of fenofi¬≠
brate on amputation events in people with type 2 diabetes mellitus (FIELD study): a 
prespecified analysis of a randomised controlled trial. Lancet 2009;373:1780‚Äì8. 
https://doi.org/10.1016/S0140-6736(09)60698-X
109. Pradhan AD, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. 
Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 
2022;387:1923‚Äì34. https://doi.org/10.1056/NEJMoa2210645
110. Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC 
Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J 
2024;45:3538‚Äì700. https://doi.org/10.1093/eurheartj/ehae179
111. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. 
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J 
Med 2019;380:11‚Äì22. https://doi.org/10.1056/NEJMoa1812792
112. Olshansky B, Chung MK, Budoff MJ, Philip S, Jiao L, Doyle RT Jr, et al. Mineral oil: safety 
and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J Suppl 2020; 
22(Suppl J):J34‚Äì48. https://doi.org/10.1093/eurheartj/suaa117
113. Ridker PM, Rifai N, MacFadyen J, Glynn RJ, Jiao L, Steg PG, et al. Effects of randomized 
treatment with icosapent ethyl and a mineral oil comparator on interleukin-1beta, 
interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, 
homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a 
REDUCE-IT biomarker substudy. Circulation 2022;146:372‚Äì9. https://doi.org/10. 
1161/CIRCULATIONAHA.122.059410
114. U.S. Food & Drug Administration. Search Orphan Drug Designations and Approvals. 
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey= 
480815 (22 October 2024, date last accessed).
115. Sherratt SCR, Libby P, Dawoud H, Bhatt DL, Mason RP. Eicosapentaenoic acid im¬≠
proves endothelial nitric oxide bioavailability via changes in protein expression during 
inflammation. J Am Heart Assoc 2024;13:e034076. https://doi.org/10.1161/JAHA.123. 
034076
116. Sherratt SCR, Libby P, Bhatt DL, Mason RP. A biological rationale for the disparate ef¬≠
fects of omega-3 fatty acids on cardiovascular disease outcomes. Prostaglandins Leukot 
Essent Fatty Acids 2022;182:102450. https://doi.org/10.1016/j.plefa.2022.102450
117. Alexander VJ, Karwatowska-Prokopczuk E, Prohaska TA, Li L, Geary RS, 
Gouni-Berthold I, et al. Volanesorsen to prevent acute pancreatitis in hypertriglycer¬≠
idemia. N Engl J Med 2024;390:476‚Äì7. https://doi.org/10.1056/NEJMc2306575
118. Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. 
Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med 
2024;390:1770‚Äì80. https://doi.org/10.1056/NEJMoa2402309
119. Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne 
CM, et al. Olezarsen, acute pancreatitis, and Familial Chylomicronemia syndrome. N 
Engl J Med 2024;390:1781‚Äì92. https://doi.org/10.1056/NEJMoa2400201
120. Watts GF, Rosenson RS, Hegele RA, Goldberg IJ, Gallo A, Mertens A, et al. Plozasiran 
for managing persistent chylomicronemia and pancreatitis risk. N Engl J Med 2025;392: 
127‚Äì37. https://doi.org/10.1056/NEJMoa2409368
121. Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, et al. Plozasiran, an 
RNA interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med 
2024;391:899‚Äì912. https://doi.org/10.1056/NEJMoa2404143
122. Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atheroscler¬≠
otic cardiovascular disease in people living with HIV: systematic review and meta-analysis. 
Circulation 2018;138:1100‚Äì12. https://doi.org/10.1161/CIRCULATIONAHA.117.033369
123. Ntsekhe M, Baker JV. Cardiovascular disease among persons living with HIV: new in¬≠
sights into pathogenesis and clinical manifestations in a global context. Circulation 2023; 
147:83‚Äì100. https://doi.org/10.1161/CIRCULATIONAHA.122.057443
124. Triant VA, Perez J, Regan S, Massaro JM, Meigs JB, Grinspoon SK, et al. Cardiovascular 
risk prediction functions underestimate risk in HIV infection. Circulation 2018;137: 
2203‚Äì14. https://doi.org/10.1161/CIRCULATIONAHA.117.028975
125. Kentoffio K, Temu TM, Shakil SS, Zanni MV, Longenecker CT. Cardiovascular disease 
risk in women living with HIV. Curr Opin HIV AIDS 2022;17:270‚Äì8. https://doi.org/10. 
1097/COH.0000000000000756
126. University of Liverpool. HIV Drug Interactions. https://www.hiv-druginteractions.org/
(27 July 2024, date last accessed).
127. Negredo E, Molto J, Puig J, Cinquegrana D, Bonjoch A, Perez-Alvarez N, et al. 
Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in 
HIV-infected patients with poor response to statins. AIDS 2006;20:2159‚Äì64. https:// 
doi.org/10.1097/01.aids.0000247573.95880.db
128. Chow D, Chen H, Glesby MJ, Busti A, Souza S, Andersen J, et al. Short-term ezetimibe 
is well tolerated and effective in combination with statin therapy to treat elevated LDL 
cholesterol in HIV-infected patients. AIDS 2009;23:2133‚Äì41. https://doi.org/10.1097/ 
QAD.0b013e32833068e3
129. Saeedi R, Johns K, Frohlich J, Bennett MT, Bondy G. Lipid lowering efficacy and safety of 
ezetimibe combined with rosuvastatin compared with titrating rosuvastatin mono¬≠
therapy in HIV-positive patients. Lipids Health Dis 2015;14:57. https://doi.org/10. 
1186/s12944-015-0054-x
130. Boccara F, Kumar PN, Caramelli B, Calmy A, Lopez JAG, Bray S, et al. Evolocumab in 
HIV-infected patients with dyslipidemia: primary results of the randomized, double- 
blind BEIJERINCK study. J Am Coll Cardiol 2020;75:2570‚Äì84. https://doi.org/10.1016/ 
j.jacc.2020.03.025
131. Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, et al. Subclinical late car¬≠
diomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004;22: 
1864‚Äì71. https://doi.org/10.1200/JCO.2004.06.033
132. Nabati M, Janbabai G, Esmailian J, Yazdani J. Effect of rosuvastatin in preventing 
chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized, 
single-blind, placebo-controlled trial. J Cardiovasc Pharmacol Ther 2019;24:233‚Äì41. 
https://doi.org/10.1177/1074248418821721
133. Hundley WG, D‚ÄôAgostino R Jr, Crotts T, Craver K, Hackney MH, Jordan JH, et al. 
Statins and left ventricular ejection fraction following doxorubicin treatment. NEJM 
Evid 2022;1:10. https://doi.org/10.1056/EVIDoa2200097
134. Thavendiranathan P, Houbois C, Marwick TH, Kei T, Saha S, Runeckles K, et al. Statins 
to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk 
receiving anthracyclines. Eur Heart J Cardiovasc Pharmacother 2023;9:515‚Äì25. https:// 
doi.org/10.1093/ehjcvp/pvad031
135. Lyon AR, L√≥pez-Fern√°ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 
European Hematology Association (EHA), the European Society for Therapeutic 
Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society 
(IC-OS). Eur Heart J 2022;43:4229‚Äì361. https://doi.org/10.1093/eurheartj/ehac244
136. D‚ÄôAmario D, Laborante R, Bianchini E, Galli M, Ciliberti G, Mennuni M, et al. Statins as 
preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized 
controlled trials. Int J Cardiol 2023;391:131219. https://doi.org/10.1016/j.ijcard.2023. 
131219
137. Felix N, Nogueira PC, Silva IM, Costa TA, Campello CA, Stecca C, et al. 
Cardio-protective effects of statins in patients undergoing anthracycline-based chemo¬≠
therapy: an updated meta-analysis of randomized controlled trials. Eur J Intern Med 
2024;126:43‚Äì8. https://doi.org/10.1016/j.ejim.2024.04.007
138. Demonty I, Ras RT, van der Knaap HC, Duchateau GS, Meijer L, Zock PL, et al. 
Continuous dose-response relationship of the LDL-cholesterol-lowering effect of 
phytosterol intake. J Nutr 2009;139:271‚Äì84. https://doi.org/10.3945/jn.108.095125
139. The European Commission. Commission Regulation (EU) 2022/860 of 1 June 2022 
Amending Annex III to Regulation (EC) No 1925/2006 of the European Parliament and 
of the Council as Regards Monacolins From Red Yeast Rice. https://eur-lex.europa.eu/ 
eli/reg/2022/860/oj (17 August 2024, date last accessed).

<!-- 2025_Mental_Health_CVD.md -->

# ESC Guidelines: Mental Health CVD (2025)

**Source**: `2025_Mental_Health_CVD.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 70

---

## Table of Contents

- [2025 ESC Clinical Consensus Statement on mental health and cardiovascular disease: developed under the auspices of the ESC Clinical Practice Guidelines Committee](#2025-esc-clinical-consensus-statement-on-mental-he) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 5)*
  - [2. The scope of this consensus statement](#2-the-scope-of-this-consensus-statement) *(p. 6)*
    - [2.1. Methods employed in the consensus statement](#21-methods-employed-in-the-consensus-statement) *(p. 6)*
  - [3. Introduction](#3-introduction) *(p. 7)*
    - [3.1. The relationship between mental and cardiovascular health and disease](#31-the-relationship-between-mental-and-cardiovascu) *(p. 7)*
    - [3.2. Enduring problems](#32-enduring-problems) *(p. 9)*
    - [3.3. Aims of the document](#33-aims-of-the-document) *(p. 10)*
    - [3.4. The Psycho-Cardio team](#34-the-psycho-cardio-team) *(p. 10)*
    - [3.5. Section summary points and management consensus statements from Section 3](#35-section-summary-points-and-management-consensus) *(p. 11)*
  - [4. Impact of mental health on the risk of developing cardiovascular disease](#4-impact-of-mental-health-on-the-risk-of-developin) *(p. 11)*
    - [4.1. Positive mental health states as predictors of better cardiovascular health](#41-positive-mental-health-states-as-predictors-of-) *(p. 11)*
    - [4.2. Psychosocial stress](#42-psychosocial-stress) *(p. 11)*
    - [4.3. Work stress and unemployment](#43-work-stress-and-unemployment) *(p. 12)*
    - [4.4. Socioeconomic and subjective social status](#44-socioeconomic-and-subjective-social-status) *(p. 13)*
    - [4.5. Perceived discrimination](#45-perceived-discrimination) *(p. 13)*
    - [4.6. Mental stress through impaired social relationships](#46-mental-stress-through-impaired-social-relations) *(p. 13)*
      - [4.6.1. Adverse childhood experiences](#461-adverse-childhood-experiences) *(p. 13)*
      - [4.6.2. Partnership violence](#462-partnership-violence) *(p. 13)*
      - [4.6.3. Loneliness and social isolation](#463-loneliness-and-social-isolation) *(p. 13)*
    - [4.7. Mental health conditions and personality traits as risk factors for cardiovascular disease](#47-mental-health-conditions-and-personality-traits) *(p. 13)*
      - [4.7.1. Depression](#471-depression) *(p. 13)*
      - [4.7.2. Anxiety](#472-anxiety) *(p. 13)*
      - [4.7.3. Post-traumatic stress disorder](#473-post-traumatic-stress-disorder) *(p. 14)*
    - [4.8. Section summary points and management consensus statements from Section 4](#48-section-summary-points-and-management-consensus) *(p. 14)*
  - [5. Mental health and mental health conditions in people with cardiovascular disease](#5-mental-health-and-mental-health-conditions-in-pe) *(p. 14)*
    - [5.1. Impact of cardiovascular disease on mental health](#51-impact-of-cardiovascular-disease-on-mental-heal) *(p. 14)*
    - [5.2. Specific mental health conditions in people with cardiovascular disease: prevalence and prognostic impact](#52-specific-mental-health-conditions-in-people-wit) *(p. 14)*
      - [5.2.1. Depressive symptoms and depression](#521-depressive-symptoms-and-depression) *(p. 14)*
        - [5.2.1.1. Prevalence of depressive symptoms and depression in people with cardiovascular disease](#5211-prevalence-of-depressive-symptoms-and-depress) *(p. 15)*
        - [5.2.1.2. Impact of depressive symptoms and depression on cardiovascular disease prognosis](#5212-impact-of-depressive-symptoms-and-depression-) *(p. 15)*
        - [5.2.1.3. Impact of depressive symptoms/depression on self-management and adherence](#5213-impact-of-depressive-symptoms/depression-on-s) *(p. 16)*
      - [5.2.2. Anxiety](#522-anxiety) *(p. 16)*
        - [5.2.2.1. Prevalence of anxiety in people with cardiovascular disease](#5221-prevalence-of-anxiety-in-people-with-cardiova) *(p. 16)*
        - [5.2.2.2. Impact of anxiety on cardiovascular disease prognosis](#5222-impact-of-anxiety-on-cardiovascular-disease-p) *(p. 16)*
        - [5.2.2.3. Impact of anxiety on self-management and adherence](#5223-impact-of-anxiety-on-self-management-and-adhe) *(p. 16)*
      - [5.2.3. Cardiac disease-induced post-traumatic stress disorder/symptoms](#523-cardiac-disease-induced-post-traumatic-stress-) *(p. 16)*
        - [5.2.3.1. Prevalence of post-traumatic stress disorder in cardiovascular disease](#5231-prevalence-of-post-traumatic-stress-disorder-) *(p. 16)*
        - [5.2.3.2. Impact of post-traumatic stress disorder on cardiovascular disease prognosis](#5232-impact-of-post-traumatic-stress-disorder-on-c) *(p. 16)*
        - [5.2.3.3. Impact of post-traumatic stress disorder on self-management and adherence to medical recommendations](#5233-impact-of-post-traumatic-stress-disorder-on-s) *(p. 17)*
      - [5.2.4. Loneliness and living conditions](#524-loneliness-and-living-conditions) *(p. 17)*
      - [5.2.5. Chronic stress](#525-chronic-stress) *(p. 18)*
    - [5.3. Addressing the mental health needs of informal caregivers for people with cardiovascular disease](#53-addressing-the-mental-health-needs-of-informal-) *(p. 18)*
    - [5.4. Section summary points and management consensus statements from Section 5](#54-section-summary-points-and-management-consensus) *(p. 19)*
  - [6. Identification, prevention, and management of mental health issues in people with cardiovascular disease](#6-identification,-prevention,-and-management-of-me) *(p. 19)*
    - [6.1. Awareness of needs in people with cardiovascular disease](#61-awareness-of-needs-in-people-with-cardiovascula) *(p. 19)*
    - [6.2. Identification and screening](#62-identification-and-screening) *(p. 20)*
      - [6.2.1. Assessment of depression and anxiety](#621-assessment-of-depression-and-anxiety) *(p. 21)*
      - [6.2.2. Suggested approach to screening people with cardiovascular disease for psychological distress, depression, and anxiety](#622-suggested-approach-to-screening-people-with-ca) *(p. 22)*
      - [6.2.3. Challenges in specific cardiovascular conditions](#623-challenges-in-specific-cardiovascular-conditio) *(p. 22)*
      - [6.2.4. Assessment of subjective well-being and quality of life](#624-assessment-of-subjective-well-being-and-qualit) *(p. 23)*
    - [6.3. Management of mental health conditions in people with cardiovascular disease](#63-management-of-mental-health-conditions-in-peopl) *(p. 23)*
      - [6.3.1. Communication, education, and support for people with mental health conditions and cardiovascular disease](#631-communication,-education,-and-support-for-peop) *(p. 23)*
      - [6.3.2. Psychological interventions](#632-psychological-interventions) *(p. 24)*
      - [6.3.3. Psycho-education](#633-psycho-education) *(p. 24)*
      - [6.3.4. Social prescribing](#634-social-prescribing) *(p. 25)*
      - [6.3.5. Other psychological interventions](#635-other-psychological-interventions) *(p. 25)*
      - [6.3.6. Interventions for people with post-traumatic stress disorder](#636-interventions-for-people-with-post-traumatic-s) *(p. 26)*
      - [6.3.7. Lifestyle interventions](#637-lifestyle-interventions) *(p. 26)*
      - [6.3.8. Physical activity and exercise in people with cardiovascular disease and mental health conditions](#638-physical-activity-and-exercise-in-people-with-) *(p. 26)*
      - [6.3.9. Diet and nutrition approaches in cardiovascular disease and mental health conditions](#639-diet-and-nutrition-approaches-in-cardiovascula) *(p. 26)*
      - [6.3.10. Smoking cessation](#6310-smoking-cessation) *(p. 26)*
      - [6.3.11. Stress management techniques](#6311-stress-management-techniques) *(p. 27)*
      - [6.3.12. Sleep hygiene](#6312-sleep-hygiene) *(p. 27)*
    - [6.4. Tools and resources to support lifestyle change](#64-tools-and-resources-to-support-lifestyle-change) *(p. 27)*
      - [6.4.1. Digital health tools](#641-digital-health-tools) *(p. 27)*
      - [6.4.2. Motivational interviewing](#642-motivational-interviewing) *(p. 27)*
      - [6.4.3. Cardiac rehabilitation](#643-cardiac-rehabilitation) *(p. 28)*
    - [6.5. Medical interventions](#65-medical-interventions) *(p. 28)*
      - [6.5.1. Efficacy and safety of pharmacological treatment for mental health conditions in people with cardiovascular disease](#651-efficacy-and-safety-of-pharmacological-treatme) *(p. 28)*
      - [6.5.2. Use of specific medications in people with depression, anxiety, or post-traumatic stress disorders and cardiovascular disease](#652-use-of-specific-medications-in-people-with-dep) *(p. 28)*
      - [6.5.3. Use of antidepressants](#653-use-of-antidepressants) *(p. 28)*
      - [6.5.4. Use of anxiolytics, sedatives, and hypnotics](#654-use-of-anxiolytics,-sedatives,-and-hypnotics) *(p. 30)*
      - [6.5.5. Pharmacological treatment for mental health conditions in specific cardiovascular diseases](#655-pharmacological-treatment-for-mental-health-co) *(p. 30)*
        - [6.5.5.1. Ischaemic heart disease](#6551-ischaemic-heart-disease) *(p. 30)*
        - [6.5.5.2. Ventricular arrhythmias](#6552-ventricular-arrhythmias) *(p. 30)*
        - [6.5.5.3. Heart failure](#6553-heart-failure) *(p. 30)*
        - [6.5.5.4. Procedures (coronary artery bypass grafting, percutaneous coronary intervention)](#6554-procedures-(coronary-artery-bypass-grafting,-) *(p. 31)*
    - [6.6. Organization of care](#66-organization-of-care) *(p. 31)*
    - [6.7. Section summary points and management consensus statements from Section 6](#67-section-summary-points-and-management-consensus) *(p. 31)*
  - [7. Severe mental illness and cardiovascular disease](#7-severe-mental-illness-and-cardiovascular-disease) *(p. 32)*
    - [7.1. Cardiovascular risk in people with severe mental illness](#71-cardiovascular-risk-in-people-with-severe-menta) *(p. 32)*
    - [7.2. Prognosis in severe mental illness and cardiovascular disease](#72-prognosis-in-severe-mental-illness-and-cardiova) *(p. 32)*
    - [7.3. Increased cardiovascular disease risk in people with severe mental illness](#73-increased-cardiovascular-disease-risk-in-people) *(p. 33)*
      - [7.3.1. Lifestyle and biological risk factors](#731-lifestyle-and-biological-risk-factors) *(p. 33)*
      - [7.3.2. Medication-induced cardiovascular risk factors](#732-medication-induced-cardiovascular-risk-factors) *(p. 33)*
      - [7.3.3. Assessing cardiovascular disease risk](#733-assessing-cardiovascular-disease-risk) *(p. 35)*
    - [7.4. Gaps and disparities in the management of cardiovascular disease in people with severe mental illness](#74-gaps-and-disparities-in-the-management-of-cardi) *(p. 36)*
      - [7.4.1. Autonomy, communication, and informed consent](#741-autonomy,-communication,-and-informed-consent) *(p. 36)*
    - [7.5. Management of cardiovascular disease in people with severe mental illness](#75-management-of-cardiovascular-disease-in-people-) *(p. 36)*
      - [7.5.1. Management of modifiable risk factors](#751-management-of-modifiable-risk-factors) *(p. 36)*
      - [7.5.2. Diet, physical activity, and body weight control](#752-diet,-physical-activity,-and-body-weight-contr) *(p. 36)*
      - [7.5.3. Smoking cessation](#753-smoking-cessation) *(p. 37)*
      - [7.5.4. Pharmacological management](#754-pharmacological-management) *(p. 37)*
    - [7.6. Management of cardiovascular conditions in people with severe mental illness](#76-management-of-cardiovascular-conditions-in-peop) *(p. 37)*
      - [7.6.1. Rhythm disturbances](#761-rhythm-disturbances) *(p. 37)*
        - [7.6.1.1. QTc interval prolongation](#7611-qtc-interval-prolongation) *(p. 39)*
        - [7.6.1.2. Heart rate changes](#7612-heart-rate-changes) *(p. 39)*
      - [7.6.2. Clozapine-induced myocarditis](#762-clozapine-induced-myocarditis) *(p. 39)*
    - [7.7. Interventions to improve the management of people with severe mental illness and cardiovascular disease](#77-interventions-to-improve-the-management-of-peop) *(p. 41)*
    - [7.8. Section summary points and management consensus statements from Section 7](#78-section-summary-points-and-management-consensus) *(p. 41)*
  - [8. Mental health in specific populations and situations](#8-mental-health-in-specific-populations-and-situat) *(p. 42)*
    - [8.1. Sex and gender differences in mental health and cardiovascular disease](#81-sex-and-gender-differences-in-mental-health-and) *(p. 42)*
      - [8.1.1. Cardiovascular disease and mental health conditions in transgender individuals](#811-cardiovascular-disease-and-mental-health-condi) *(p. 43)*
      - [8.1.2. Sex and gender differences in mental health in people with obstructive coronary artery disease](#812-sex-and-gender-differences-in-mental-health-in) *(p. 43)*
      - [8.1.3. Sex and gender differences in mental health in ischaemia/angina with non-obstructive coronary arteries and coronary vasomotor disorders](#813-sex-and-gender-differences-in-mental-health-in) *(p. 43)*
      - [8.1.4. Sex and gender differences in mental health in people with takotsubo syndrome](#814-sex-and-gender-differences-in-mental-health-in) *(p. 43)*
      - [8.1.5. Sex and gender differences in mental health in people with heart failure](#815-sex-and-gender-differences-in-mental-health-in) *(p. 43)*
      - [8.1.6. Sex and gender differences in mental health in people with arrhythmias](#816-sex-and-gender-differences-in-mental-health-in) *(p. 44)*
      - [8.1.7. Mental health conditions associated with peri-partum cardiomyopathy](#817-mental-health-conditions-associated-with-peri-) *(p. 44)*
    - [8.2. Mental and cardiovascular health in older adults](#82-mental-and-cardiovascular-health-in-older-adult) *(p. 44)*
    - [8.3. Mental health and cardiovascular disease in people with frailty and multimorbidity](#83-mental-health-and-cardiovascular-disease-in-peo) *(p. 45)*
      - [8.3.1. Mental health and frailty](#831-mental-health-and-frailty) *(p. 45)*
      - [8.3.2. Mental health, cardiovascular disease, and multimorbidity](#832-mental-health,-cardiovascular-disease,-and-mul) *(p. 45)*
      - [8.3.3. Summary of evidence in older adults with cardiovascular disease and mental disorders](#833-summary-of-evidence-in-older-adults-with-cardi) *(p. 45)*
    - [8.4. Mental health and cardiovascular disease in socioeconomically deprived populations](#84-mental-health-and-cardiovascular-disease-in-soc) *(p. 46)*
      - [8.4.1. Mental health and cardiovascular disease in migrants and refugees](#841-mental-health-and-cardiovascular-disease-in-mi) *(p. 47)*
      - [8.4.2. Barriers to mental healthcare access](#842-barriers-to-mental-healthcare-access) *(p. 47)*
      - [8.4.3. Stigma in healthcare provision](#843-stigma-in-healthcare-provision) *(p. 48)*
      - [8.4.4. Community and policy interventions](#844-community-and-policy-interventions) *(p. 48)*
    - [8.5. Mental health and cardiovascular disease in people with cancer (cardio-oncology)](#85-mental-health-and-cardiovascular-disease-in-peo) *(p. 49)*
      - [8.5.1. Mental health in people with cancer and cardiovascular disease](#851-mental-health-in-people-with-cancer-and-cardio) *(p. 49)*
      - [8.5.2. Cancer survivors](#852-cancer-survivors) *(p. 49)*
      - [8.5.3. Advanced cancer disease](#853-advanced-cancer-disease) *(p. 49)*
      - [8.5.4. Cancer therapy-related cardiovascular toxicity](#854-cancer-therapy-related-cardiovascular-toxicity) *(p. 49)*
      - [8.5.5. Impact of cancer therapy on mental health](#855-impact-of-cancer-therapy-on-mental-health) *(p. 49)*
      - [8.5.6. Psychological interventions](#856-psychological-interventions) *(p. 49)*
      - [8.5.7. Lifestyle interventions in cardio-oncology](#857-lifestyle-interventions-in-cardio-oncology) *(p. 50)*
      - [8.5.8. Medical interventions (including pharmacological therapies)](#858-medical-interventions-(including-pharmacologic) *(p. 51)*
    - [8.6. Section summary points and management consensus statements from Section 8](#86-section-summary-points-and-management-consensus) *(p. 51)*
  - [9. Key messages](#9-key-messages) *(p. 51)*
  - [10. Gaps in knowledge](#10-gaps-in-knowledge) *(p. 52)*
    - [10.1. Knowledge gaps in relation to prevention and screening](#101-knowledge-gaps-in-relation-to-prevention-and-s) *(p. 52)*
    - [10.2. Knowledge gaps in relation to clinical management](#102-knowledge-gaps-in-relation-to-clinical-managem) *(p. 52)*
    - [10.3. Knowledge gaps in relation to special populations](#103-knowledge-gaps-in-relation-to-special-populati) *(p. 52)*
    - [10.4. Knowledge gaps in relation to healthcare systems and healthcare delivery](#104-knowledge-gaps-in-relation-to-healthcare-syste) *(p. 52)*
  - [11. Conclusions](#11-conclusions) *(p. 52)*
  - [12. Summary of mental health aspects in specific cardiovascular diseases](#12-summary-of-mental-health-aspects-in-specific-ca) *(p. 53)*
  - [13. Clinical cases and patient perspectives](#13-clinical-cases-and-patient-perspectives) *(p. 53)*
  - [14. Evidence tables](#14-evidence-tables) *(p. 53)*
  - [15. Data availability statement](#15-data-availability-statement) *(p. 53)*
  - [16. Author information](#16-author-information) *(p. 53)*
  - [Appendix](#appendix) *(p. 53)*
  - [References](#references) *(p. 54)*
  - [References](#references) *(p. 54)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2025 ESC Clinical Consensus Statement on 
mental health and cardiovascular disease: 
developed under the auspices of the ESC 
Clinical Practice Guidelines Committee
Developed by the task force on mental health and cardiovascular 
disease of the European Society of Cardiology (ESC)
Endorsed by the European Federation of Psychologists‚Äô Associations 
AISBL (EFPA), the European Psychiatric Association (EPA), and the 
International Society of Behavioral Medicine (ISBM)
Authors/Task Force Members: H√©ctor Bueno  *‚Ä†, (Chairperson) (Spain), 
Christi Deaton  *‚Ä†, (Chairperson) (United Kingdom), Marta Farrero  
‚Ä°, 
(Task Force Co-ordinator) (Spain), Faye Forsyth  
‚Ä°, (Task Force Co-ordinator) 
(United Kingdom), Frieder Braunschweig  
(Sweden), Sergio Buccheri (Sweden), 
Simona Dragan  
(Romania), Sofie Gevaert  
(Belgium), Claes Held  
(Sweden), 
Donata Kurpas  
(Poland), Karl-Heinz Ladwig  
(Germany), Christos D. Lionis  
(Greece), Angela H.E.M. Maas  
(Netherlands), Caius Ovidiu Mer»ôa  
(Romania), 
Richard Mindham  
(United Kingdom), Susanne S. Pedersen  
(Denmark), 
Martina Rojnic Kuzman  
1 (Croatia), Sebastian Szmit  
(Poland), Rod S. Taylor  
(United Kingdom), Izabella Uchmanowicz  
(Poland), Noa Vilchinsky  
2 (Israel), 
and ESC Scientific Document Group
¬© The European Society of Cardiology 2025. All rights reserved.
* Corresponding authors: H√©ctor Bueno, Multidisciplinary Translational Cardiovascular Research Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, and 
Cardiology Department, Hospital Universitario 12 de Octubre and Instituto de Investigaci√≥n Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain, and Facultad de Medicina, 
Universidad Complutense de Madrid, Madrid, Spain. Tel: +34 4531290, Extension 4110, E-mail: hbueno@cnic.es; and Christi Deaton, Public Health and Primary Care, University of 
Cambridge School of Clinical Medicine, Cambridge, United Kingdom. Tel: +44 1223 330300, E-mail: cd531@cam.ac.uk
‚Ä† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‚Ä° The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
1 Representing the European Psychiatric Association (EPA)
2 Representing the European Health Psychology Society (EHPS)
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Preventive Cardiology 
(EAPC), European Heart Rhythm Association (EHRA), and Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council of Cardio-Oncology.
Working Groups: Cardiovascular Pharmacotherapy.
Patient Forum
https://doi.org/10.1093/eurheartj/ehaf191
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Konstantinos C. Koskinas, (CPG Review Co-ordinator) (Switzerland), Pascal Vranckx, (CPG 
Review Co-ordinator) (Belgium), Marianna Adamo (Italy), Elena Arbelo (Spain), Folkert W. Asselbergs 
(Netherlands), Giuseppe Boriani (Italy), Margarita Brida (Croatia), Noeleen Burke (Ireland), Robert A. Byrne 
(Ireland), Ingrid de Laval (Sweden), Lidia Einsfeld (Brazil), Enrico Frigoli (Switzerland), Leonarda Galiuto (Italy), 
Estelle Gandjbakhch (France), Sherry L. Grace (Canada), Johannes Grand (Denmark), Bettina Heidecker 
(Germany), Mirjam Heldner (Switzerland), Charlotte Helmark (Denmark), Marwa Hemmat Gaber (Egypt), 
Loreena Hill (United Kingdom), Lisa Hynes2 (Ireland), Borja Ibanez (Spain), Stefan James (Sweden), 
Alexander Kharlamov (Netherlands), Hanne Kindermans (Belgium), Lars K√∏ber (Denmark), Ulf Landmesser 
(Germany), Gregory Y.H. Lip (United Kingdom), Emma F. Magavern (United Kingdom), John William McEvoy 
(Ireland), Paul McGreavy (United Kingdom), Borislava Mihaylova (United Kingdom), Inge Moelgaard (Denmark), 
Manuela Abreu (Portugal), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet (Belgium), Eva Prescott (Denmark), 
Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Annett Salzwedel (Germany), 
Anna Sannino (Germany), Eduard Shantsila (United Kingdom), Chantal Ski (United Kingdom), Andrew Steptoe2
(United Kingdom), Felix C. Tanner (Switzerland), Diogo Telles1 (Portugal), Ilonca Vaartjes (Netherlands), 
Berlinde von Kemp (Belgium), Christiaan Vrints (Belgium), and Katja Zeppenfeld (Netherlands)
All experts involved in the development of this Clinical Consensus Statement have submitted declarations of 
interest which are reported in a supplementary document to the Clinical Consensus Statement. See the European 
Heart Journal online or https://www.escardio.org/Guidelines for supplementary documents as well as evidence 
tables.
Disclaimer: This European Society of Cardiology (ESC) Clinical Consensus Statement was developed under the auspices of the ESC 
Clinical Practice Guidelines Committee and represents the views of the ESC and was produced after careful consideration of the scientific 
and medical knowledge and the evidence available at the time of its publication. The ESC is not responsible in the event of any 
contradiction, discrepancy and/or ambiguity between the ESC Guidelines and documents and any other official recommendations or 
guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. 
Health professionals are encouraged to take the ESC Clinical Consensus Statement fully into account when exercising their clinical 
judgement, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, 
the ESC Clinical Consensus Statement does not override, in any way whatsoever, the individual responsibility of health professionals to 
make appropriate and accurate decisions in consideration of each patient‚Äôs health condition and in consultation with that patient and, 
where appropriate and/or necessary, the patient‚Äôs caregiver. Nor does the ESC Clinical Consensus Statement exempt health 
professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the 
competent public health authorities, in order to manage each patient‚Äôs case in light of the scientifically accepted data pursuant to their 
respective ethical and professional obligations. It is also the health professional‚Äôs responsibility to verify the applicable rules and regulations 
relating to drugs and medical devices prior to making any clinical decision and to check whether a more recent version of this document 
exists. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.
Permissions: The content of this ESC Clinical Consensus Statement has been published for personal and educational use only. No 
commercial use is authorized. No part of the ESC Clinical Consensus Statement may be translated or reproduced in any form without 
written permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the 
publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC. For permissions, please 
e-mail: journals.permissions@oup.com.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords 
Mental health ‚Ä¢ Cardiovascular disease ‚Ä¢ Cardiovascular risk ‚Ä¢ Mental health conditions ‚Ä¢ Mental health disorders ‚Ä¢ 
Mental health screening ‚Ä¢ Stress ‚Ä¢ Depression ‚Ä¢ Anxiety ‚Ä¢ Post-traumatic stress disorder ‚Ä¢ Severe mental illness ‚Ä¢ 
Psycho-cardio team ‚Ä¢ Stepped care ‚Ä¢ Psychological therapy ‚Ä¢ Psychotropic drugs ‚Ä¢ Stigma
Table of contents
1. Preamble ...................................................................................................................... 5
2. The scope of this consensus statement ......................................................... 6
2.1. Methods employed in the consensus statement ..............................
6
3. Introduction ............................................................................................................... 7
3.1. The relationship between mental and cardiovascular health 
and disease .................................................................................................................
7
3.2. Enduring problems .........................................................................................
9
3.3. Aims of the document ............................................................................... 10


<!-- PAGE 3 -->

### Page 3

3.4. The Psycho-Cardio team .......................................................................... 10
3.5. Section summary points and management consensus 
statements from Section 3 ................................................................................. 11
4. Impact of mental health on the risk of developing cardiovascular 
disease ............................................................................................................................. 11
4.1. Positive mental health states as predictors of better 
cardiovascular health ........................................................................................... 11
4.2. Psychosocial stress ....................................................................................... 11
4.3. Work stress and unemployment .......................................................... 12
4.4. Socioeconomic and subjective social status ...................................... 13
4.5. Perceived discrimination ........................................................................... 13
4.6. Mental stress through impaired social relationships ..................... 13
4.6.1. Adverse childhood experiences ....................................................
13
4.6.2. Partnership violence ...........................................................................
13
4.6.3. Loneliness and social isolation ........................................................
13
4.7. Mental health conditions and personality traits as risk factors 
for cardiovascular disease .................................................................................. 13
4.7.1. Depression .............................................................................................
13
4.7.2. Anxiety .....................................................................................................
13
4.7.3. Post-traumatic stress disorder .......................................................
14
4.8. Section summary points and management consensus 
statements from Section 4 ................................................................................. 14
5. Mental health and mental health conditions in people with 
cardiovascular disease .............................................................................................. 14
5.1. Impact of cardiovascular disease on mental health ....................... 14
5.2. Specific mental health conditions in people with 
cardiovascular disease: prevalence and prognostic impact ................. 14
5.2.1. Depressive symptoms and depression .......................................
14
5.2.1.1. Prevalence of depressive symptoms and depression 
in people with cardiovascular disease ................................................
15
5.2.1.2. Impact of depressive symptoms and depression on 
cardiovascular disease prognosis ..........................................................
15
5.2.1.3. Impact of depressive symptoms/depression on self- 
management and adherence ..................................................................
16
5.2.2. Anxiety .....................................................................................................
16
5.2.2.1. Prevalence of anxiety in people with cardiovascular 
disease ..............................................................................................................
16
5.2.2.2. Impact of anxiety on cardiovascular disease prognosis
16
5.2.2.3. Impact of anxiety on self-management and adherence
16
5.2.3. Cardiac disease-induced post-traumatic stress disorder/ 
symptoms ............................................................................................................
16
5.2.3.1. Prevalence of post-traumatic stress disorder in 
cardiovascular disease ...............................................................................
16
5.2.3.2. Impact of post-traumatic stress disorder on 
cardiovascular disease prognosis ..........................................................
16
5.2.3.3. Impact of post-traumatic stress disorder on self- 
management and adherence to medical recommendations .....
17
5.2.4. Loneliness and living conditions .....................................................
17
5.2.5. Chronic stress .......................................................................................
18
5.3. Addressing the mental health needs of informal caregivers for 
people with cardiovascular disease ............................................................... 18
5.4. Section summary points and management consensus 
statements from Section 5 ................................................................................. 19
6. Identification, prevention, and management of mental health 
issues in people with cardiovascular disease .................................................. 19
6.1. Awareness of needs in people with cardiovascular disease ...... 19
6.2. Identification and screening ..................................................................... 20
6.2.1. Assessment of depression and anxiety ......................................
21
6.2.2. Suggested approach to screening people with 
cardiovascular disease for psychological distress, depression, 
and anxiety ..........................................................................................................
22
6.2.3. Challenges in specific cardiovascular conditions ....................
22
6.2.4. Assessment of subjective well-being and quality of life .......
23
6.3. Management of mental health conditions in people with 
cardiovascular disease ......................................................................................... 23
6.3.1. Communication, education, and support for people with 
mental health conditions and cardiovascular disease .......................
23
6.3.2. Psychological interventions ..............................................................
24
6.3.3. Psycho-education .................................................................................
24
6.3.4. Social prescribing .................................................................................
25
6.3.5. Other psychological interventions ...............................................
25
6.3.6. Interventions for people with post-traumatic stress 
disorder ................................................................................................................
26
6.3.7. Lifestyle interventions ........................................................................
26
6.3.8. Physical activity and exercise in people with 
cardiovascular disease and mental health conditions .......................
26
6.3.9. Diet and nutrition approaches in cardiovascular disease 
and mental health conditions ......................................................................
26
6.3.10. Smoking cessation .............................................................................
26
6.3.11. Stress management techniques ...................................................
27
6.3.12. Sleep hygiene ......................................................................................
27
6.4. Tools and resources to support lifestyle change ........................... 27
6.4.1. Digital health tools ..............................................................................
27
6.4.2. Motivational interviewing .................................................................
27
6.4.3. Cardiac rehabilitation .........................................................................
28
6.5. Medical interventions .................................................................................. 28
6.5.1. Efficacy and safety of pharmacological treatment for 
mental health conditions in people with cardiovascular disease .
28
6.5.2. Use of specific medications in people with depression, 
anxiety, or post-traumatic stress disorders and cardiovascular 
disease ...................................................................................................................
28
6.5.3. Use of antidepressants ......................................................................
28
6.5.4. Use of anxiolytics, sedatives, and hypnotics .............................
30
6.5.5. Pharmacological treatment for mental health conditions 
in specific cardiovascular diseases .............................................................
30
6.5.5.1. Ischaemic heart disease ............................................................
30
6.5.5.2. Ventricular arrhythmias ............................................................
30
6.5.5.3. Heart failure ..................................................................................
30
6.5.5.4. Procedures (coronary artery bypass grafting, 
percutaneous coronary intervention) ................................................
31
6.6. Organization of care ................................................................................... 31
6.7. Section summary points and management consensus 
statements from Section 6 ................................................................................. 31
7. Severe mental illness and cardiovascular disease .................................... 32
7.1. Cardiovascular risk in people with severe mental illness ............ 32
7.2. Prognosis in severe mental illness and cardiovascular disease .. 32
7.3. Increased cardiovascular disease risk in people with severe 
mental illness ........................................................................................................... 33
7.3.1. Lifestyle and biological risk factors ...............................................
33
7.3.2. Medication-induced cardiovascular risk factors ......................
33
7.3.3. Assessing cardiovascular disease risk ..........................................
35
7.4. Gaps and disparities in the management of cardiovascular 
disease in people with severe mental illness ............................................. 36
7.4.1. Autonomy, communication, and informed consent .............


<!-- PAGE 4 -->

### Page 4

7.5. Management of cardiovascular disease in people with severe 
mental illness ........................................................................................................... 36
7.5.1. Management of modifiable risk factors ......................................
36
7.5.2. Diet, physical activity, and body weight control .....................
36
7.5.3. Smoking cessation ...............................................................................
37
7.5.4. Pharmacological management ........................................................
37
7.6. Management of cardiovascular conditions in people with 
severe mental illness ............................................................................................ 37
7.6.1. Rhythm disturbances ..........................................................................
37
7.6.1.1. QTc interval prolongation ......................................................
39
7.6.1.2. Heart rate changes .....................................................................
39
7.6.2. Clozapine-induced myocarditis ......................................................
39
7.7. Interventions to improve the management of people with 
severe mental illness and cardiovascular disease ..................................... 41
7.8. Section summary points and management consensus 
statements from Section 7 ................................................................................. 41
8. Mental health in specific populations and situations .............................. 42
8.1. Sex and gender differences in mental health and 
cardiovascular disease ......................................................................................... 42
8.1.1. Cardiovascular disease and mental health conditions in 
transgender individuals ..................................................................................
43
8.1.2. Sex and gender differences in mental health in people 
with obstructive coronary artery disease ..............................................
43
8.1.3. Sex and gender differences in mental health in ischaemia/ 
angina with non-obstructive coronary arteries and coronary 
vasomotor disorders ......................................................................................
43
8.1.4. Sex and gender differences in mental health in people 
with takotsubo syndrome ............................................................................
43
8.1.5. Sex and gender differences in mental health in people 
with heart failure ..............................................................................................
43
8.1.6. Sex and gender differences in mental health in people 
with arrhythmias ..............................................................................................
44
8.1.7. Mental health conditions associated with peri-partum 
cardiomyopathy ................................................................................................
44
8.2. Mental and cardiovascular health in older adults ........................... 44
8.3. Mental health and cardiovascular disease in people with frailty 
and multimorbidity ............................................................................................... 45
8.3.1. Mental health and frailty ...................................................................
45
8.3.2. Mental health, cardiovascular disease, and multimorbidity
45
8.3.3. Summary of evidence in older adults with cardiovascular 
disease and mental disorders ......................................................................
45
8.4. Mental health and cardiovascular disease in socioeconomically 
deprived populations ........................................................................................... 46
8.4.1. Mental health and cardiovascular disease in migrants and 
refugees ................................................................................................................
47
8.4.2. Barriers to mental healthcare access ..........................................
47
8.4.3. Stigma in healthcare provision .......................................................
48
8.4.4. Community and policy interventions ..........................................
48
8.5. Mental health and cardiovascular disease in people with 
cancer (cardio-oncology) ................................................................................... 49
8.5.1. Mental health in people with cancer and cardiovascular 
disease ...................................................................................................................
49
8.5.2. Cancer survivors ..................................................................................
49
8.5.3. Advanced cancer disease ..................................................................
49
8.5.4. Cancer therapy-related cardiovascular toxicity ......................
49
8.5.5. Impact of cancer therapy on mental health .............................
49
8.5.6. Psychological interventions ..............................................................
49
8.5.7. Lifestyle interventions in cardio-oncology ................................
50
8.5.8. Medical interventions (including pharmacological 
therapies) .............................................................................................................
51
8.6. Section summary points and management consensus 
statements from Section 8 ................................................................................. 51
9. Key messages .......................................................................................................... 51
10. Gaps in knowledge ............................................................................................ 52
10.1. Knowledge gaps in relation to prevention and screening ........ 52
10.2. Knowledge gaps in relation to clinical management ................... 52
10.3. Knowledge gaps in relation to special populations ..................... 52
10.4. Knowledge gaps in relation to healthcare systems and 
healthcare delivery ................................................................................................ 52
11. Conclusions ........................................................................................................... 52
12. Summary of mental health aspects in specific cardiovascular 
diseases ........................................................................................................................... 53
13. Clinical cases and patient perspectives ..................................................... 53
14. Evidence tables .................................................................................................... 53
15. Data availability statement .............................................................................. 53
16. Author information ........................................................................................... 53
17. Appendix ................................................................................................................ 53
18. References ............................................................................................................. 54
List of tables
Table 1 Prevalence of depression/depressive symptoms in people 
with cardiovascular disease .................................................................................... 15
Table 2 Prevalence of anxiety/anxiety symptoms in people with 
cardiovascular disease .............................................................................................. 17
Table 3 Prevalence of post-traumatic stress disorder/post-traumatic 
stress symptoms in people with cardiovascular disease ........................... 18
Table 4 Psychometric properties of screening tools for anxiety and 
depression symptoms .............................................................................................. 22
Table 5 Timing and tools for screening anxiety and depression 
symptoms ...................................................................................................................... 22
Table 6 Summary of the negative effect of different antipsychotics on 
cardiovascular risk factors ...................................................................................... 35
Table 7 Management of psychotropic drugs with QT interval 
prolongation properties .......................................................................................... 41
List of figures
Figure 1 Concept of mental health within this consensus statement .... 7
Figure 2 Mental/cardiovascular health, disease interaction, and future 
directions .......................................................................................................................... 8
Figure 3 The Psycho-Cardio team ......................................................................... 9
Figure 4 The ACTIVE principles to improve mental health in 
cardiovascular care .................................................................................................... 10
Figure 5 Sources of psychosocial stress as risk factors for 
cardiovascular disease .............................................................................................. 12
Figure 6 Suggestions for supporting informal caregivers of people 
living with cardiovascular disease ........................................................................ 19
Figure 7 Visualization of an ‚Äòon demand‚Äô support system for people 
with cardiovascular disease to improve mental health ...................................... 20
Figure 8 Screening for mental health conditions in people with 
cardiovascular disease .............................................................................................. 21
Figure 9 Stepped care model for assessment and management of 
mental health conditions in people with cardiovascular disease ........... 24


<!-- PAGE 5 -->

### Page 5

Figure 10 Pharmacological management of cardiovascular disease 
and depression, anxiety, or post-traumatic stress disorders .................. 29
Figure 11 Severe mental illnesses ........................................................................ 33
Figure 12 Multifactorial aetiology of cardiovascular disease risk in 
people with severe mental illness ....................................................................... 34
Figure 13 Management of people with cardiovascular disease and 
severe mental illness ................................................................................................. 38
Figure 14 Management of people with severe mental illness and 
arrhythmias ................................................................................................................... 40
Figure 15 Sex and gender differences in the psycho-cardio interaction
42
Figure 16 Ageing, mental disorders, and cardiovascular disease ........... 46
Figure 17 Mechanisms through which socioeconomic deprivation 
contributes to cardiovascular risk ....................................................................... 47
Figure 18 Mental health challenges in migrant populations ..................... 48
Figure 19 Management of mental health in people with cardiovascular 
disease and cancer ......................................................................................................................
50
Abbreviations and acronyms
ACE
Adverse childhood experience
ACHD
Adult congenital heart disease
ACS
Acute coronary syndrome
ACTIVE
Acknowledge, Check, Tools, Implement, 
Venture, Evaluate
AF
Atrial fibrillation
AMI
Acute myocardial infarction
CABG
Coronary artery bypass graft
CAD
Coronary artery disease
CBT
Cognitive-behavioural therapy
CDI-PTSD
Cardiac disease-induced post-traumatic stress 
disorder
CDI-SF
Cardiac Distress Inventory-Short Form
CHD
Coronary heart disease
CI
Confidence interval
CODIACS-QoL
Comparison of Depression Interventions After 
Acute Coronary Syndrome: Quality of Life
CV
Cardiovascular
CVD
Cardiovascular disease
EAPC
European Association of Preventive 
Cardiology
EASD
European Association for the Study of 
Diabetes
ECG
Electrocardiogram
ECR
Exercise-based cardiac rehabilitation eHealth
Information and communication technologies 
for health
EMDR
Eye movement desensitization and 
reprocessing
ESC
European Society of Cardiology
GAD
Generalized Anxiety Disorder
HADS
Hospital Anxiety and Depression Scale
HDL
High-density lipoprotein
HF
Heart failure
HF-ACTION
Heart Failure-A Controlled Trial Investigating 
Outcomes of Exercise Training
HR
Hazard ratio
HRQoL
Health-related quality of life
HTx
Heart transplantation
ICD
Implantable cardioverter-defibrillator
IES
Impact of Event Scale
IHD
Ischaemic heart disease
INOCA
Ischaemia with non-obstructive coronary 
arteries
LDL
Low-density lipoprotein
MACE
Major adverse cardiac events
MAOI
Monoamine oxidase inhibitor mHealth
Mobile health
MI
Myocardial infarction
MINOCA
Myocardial infarction with non-obstructive 
coronary arteries
MotInt
Motivational interviewing
NYHA
New York Heart Association
OCEAN
Omega-3 Supplementation for Co-Morbid 
Depression and Heart Failure Treatment
OHCA
Out-of-hospital cardiac arrest
OR
Odds ratio
PAH
Pulmonary arterial hypertension
PCI
Percutaneous coronary intervention
PH
Pulmonary hypertension
PHQ
Patient Health Questionnaire
PTSD
Post-traumatic stress disorder
PTSS
Post-traumatic stress symptom
QoL
Quality of life
RCT
Randomized controlled trial
RR
Risk ratio
SCAD
Spontaneous coronary artery dissection
SCD
Sudden cardiac death
SDM
Shared decision-making
SES
Socioeconomic status
SMI
Severe mental illness
SNRI
Serotonin and norepinephrine reuptake 
inhibitor
SSRI
Selective serotonin reuptake inhibitor
SSS
Subjective social status
SWB
Subjective well-being
TCA
Tricyclic antidepressant
TTS
Takotsubo syndrome
VAD
Ventricular assist device
WHO
World Health Organization
1. Preamble
ESC Clinical Consensus Statements, developed under the auspices of 
the ESC Clinical Practice Guidelines Committee, evaluate and summar¬≠
ize available evidence with the aim of assisting health professionals in 
proposing the best diagnostic or therapeutic approach for an individual 
patient with a given condition. ESC Clinical Consensus Statements are 
intended for use by health professionals but do not override their indi¬≠
vidual responsibility to make appropriate and accurate decisions in con¬≠
sideration of each patient‚Äôs health condition and in consultation with 
the patient or the patient‚Äôs caregiver where appropriate and/or neces¬≠
sary. It is also the health professional‚Äôs responsibility to verify the rules 
and regulations applicable in each country to drugs and devices at the 
time of prescription and to respect the ethical rules of their profession.
ESC Clinical Consensus Statements represent the official position of 
the ESC on a given topic. ESC Policies and Procedures for formulating 
and issuing ESC Guidelines and documents developed under the 
ESC Guidelines                                                                                                                                                                                                 5


<!-- PAGE 6 -->

### Page 6

auspices of the ESC Clinical Practice Guidelines Committee can be found 
on the ESC website (https://www.escardio.org/Guidelines/Clinical- 
Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines).
This Task Force was selected by the ESC to include professionals in¬≠
volved with the medical care of patients with this pathology and to include 
patient representatives and methodologists. The selection procedure in¬≠
cluded an open call for authors and aimed to include members from 
across the whole of the ESC region and from relevant ESC Subspecialty 
Communities. Consideration was given to diversity and inclusion.
Clinical consensus statement Task Forces perform a critical review 
and evaluation of the published literature on diagnostic and therapeutic 
approaches including assessment of the risk‚Äìbenefit ratio. Evidence ta¬≠
bles summarizing key information from relevant studies are generated 
to facilitate the formulation of management consensus statements, to 
enhance their comprehension after publication, and to reinforce trans¬≠
parency in the clinical consensus statement development process. The 
tables are published in their own section of the ESC Clinical Consensus 
Statement and reference specific recommendation tables.
After an iterative process of deliberations, a modified Delphi process 
on all management consensus statements was conducted. The Task 
Force members ranked their level of agreement or disagreement 
with each management consensus statement using the Likert ordinal 
scale: strongly agree, agree, neither agree nor disagree, disagree, strong¬≠
ly disagree, recuse. Consensus of agreement was inferred if >75% of 
the respondents selected the options ‚Äòstrongly agree‚Äô or ‚Äòagree‚Äô.
The writing and reviewing panels provided declaration of interest 
forms for all relationships that might be perceived as real or potential 
sources of conflicts of interest. Their declarations of interest were re¬≠
viewed according to the ESC declaration of interest rules which can be 
found on the ESC website (http://www.escardio.org/doi) and were 
compiled in a report published in a supplementary document with 
the Clinical Consensus Statement. Funding for the development of 
ESC Clinical Consensus Statements is derived entirely from the ESC 
with no involvement of the healthcare industry.
The CPG Committee supervises and co-ordinates the preparation 
of new clinical consensus statements and approves their publication. In add¬≠
ition to review by the CPG Committee, ESC Clinical Consensus Statements 
undergo multiple rounds of double-blind peer review on a dedicated online 
review platform. The review is conducted by topic experts, including mem¬≠
bers from ESC National Cardiac Societies and from relevant ESC 
Subspecialty Communities. Guideline Task Forces consider all review com¬≠
ments and are required to respond to all those classified as major. After ap¬≠
propriate revisions, Task Force and the CPG Committee members 
approve the final document for publication in the European Heart Journal.
Unless otherwise stated, ESC Clinical Consensus Statement content 
refers to sex, understood as the biological condition of being male or 
female, defined by genes, hormones, and sexual organs. Off-label use 
of medication may be presented in this Guideline if a sufficient level 
of evidence shows that it can be considered medically appropriate 
for a given condition. However, decisions on off-label use must be 
made by the responsible health professional giving special consideration 
to ethical rules concerning healthcare, the specific situation of the pa¬≠
tient, patient consent, and country-specific health regulations.
2. The scope of this consensus 
statement
This consensus statement provides readers with insights into the extent 
and magnitude of the impact of mental health on cardiovascular disease 
(CVD) and vice versa. It also outlines how the negative impacts of this 
reciprocal relationship can be prevented or minimized. Clinical cardio¬≠
vascular (CV) practice often overlooks the impact of mental health and 
the importance of its inclusion in CV care; this needs to change. 
Therefore, this consensus statement sets out to be broad and ambi¬≠
tious. The high burden of concomitant CVD and mental health condi¬≠
tions requires a new integrated approach to caring for people with 
CVD. Cardiovascular health professionals need to develop collabora¬≠
tions with mental health professionals to provide guidance for practice 
and appropriate support for people with CVD and their caregivers. 
Whilst challenging, healthcare professionals are encouraged to pursue 
the implementation of the suggestions in this statement, regardless of 
their profession, clinical setting, or resources. Changes in the current 
models of care, with structure and resource adjustments, may require 
both centre-specific and country-specific measures. Consequently, the 
document adopts a global perspective and reviews the evidence 
on the association between mental and CV health, as well as tackling 
key aspects such as awareness, communication, screening, optimal 
management, stigma, gaps in evidence, and needs for research. A com¬≠
prehensive and inclusive perspective has also prompted the use of re¬≠
spectful language in healthcare.1 People with lived experience of CVD 
and mental health conditions have been central in the creation of this 
document, and their perspectives underpin the importance of changing 
practice, and emphasize the need for implementation of the steps sug¬≠
gested in this statement.
2.1. Methods employed in the consensus 
statement
This consensus document involved a multidisciplinary team of cardiol¬≠
ogists, nurses, general professionals, psychologists, psychiatrists, geria¬≠
tricians, and people with experience of mental health and CV 
conditions. It was developed under the auspices of the ESC Clinical 
Practice Guidelines Committee. The Task Force Chairs proposed the 
document structure; this was subsequently refined through group in¬≠
put, with section leaders ensuring consistency, coherence, and clinical 
relevance. Literature reviews are comprehensively presented within 
evidence tables. Relevant, clinically tangible information is summarized 
within the text for the benefit of the clinical professional. Multiple meet¬≠
ings were held to discuss the available evidence and the relative strength 
of that evidence.
On the basis of the evidence reviews and discussion, the Task Force 
identified that there is limited evidence to guide practice, despite the 
clear and important multidirectional interaction between mental health 
and CVD. As a result of the dearth of research, the Task Force adopted 
a modified Delphi process to generate main recommendations. The 
modified Delphi process is a structured communication technique 
that allows a group of experts to gather opinions on a given complex 
or controversial topic, for which there is insufficient evidence or incom¬≠
plete knowledge.2 The modified Delphi questionnaire included manage¬≠
ment consensus statements. These statements summarize factors from 
each section and typically consist of actions or practical suggestions that 
healthcare professionals should endeavor to implement in their prac¬≠
tice. As these are based on limited evidence, the Task Force members 
ranked their level of agreement or disagreement with each manage¬≠
ment consensus statement using the Likert ordinal scale: strongly agree, 
agree, neither agree nor disagree, disagree, strongly disagree, recuse. 
Consensus of agreement was inferred if >75% of the respondents se¬≠
lected the options ‚Äòstrongly agree‚Äô or ‚Äòagree‚Äô. Consensus was reached 
for all the proposed management consensus statements following the


<!-- PAGE 7 -->

### Page 7

first round of voting. A total of 34 management consensus statements 
are presented in this document. Section summary points represent im¬≠
portant components of the section that a healthcare professional 
should be aware of. They were also reviewed and revised by the 
Task Force, to ensure that they reflected the key elements of each sec¬≠
tion. Section summary points and management consensus statements 
are presented at the end of each section.
3. Introduction
3.1. The relationship between mental and 
cardiovascular health and disease
Mental health is an integral component of a person‚Äôs health. According 
to the World Health Organization (WHO), mental health is a state of 
mental well-being that enables people to cope with the stresses of life, 
realize their abilities, learn well and work well, and contribute to their 
community.3 Despite its importance, there is not a single agreed defin¬≠
ition for mental health.4
Although mental health and mental illness are sometimes considered 
as dual continua, for the purpose of this document, mental health is an 
overarching concept of a complex continuum spanning from optimal 
mental health with dominant features such as optimism, resilience, 
and well-being, to negative mental health states including severe mental 
illness (Figure 1).5 The nomenclature surrounding negative aspects and 
mental health disturbances also lacks consistent definitions. Mental 
health condition is a wide term that will be used in this document to 
refer to psychosocial difficulties and other mental states associated 
with distress, impairment in cognitive functioning, altered emotional re¬≠
sponses, altered behaviour, and risk of self-harm. Within mental health 
conditions, mental health disorders refer to mental health states char¬≠
acterized by a clinically significant disturbance in an individual‚Äôs cogni¬≠
tion, emotional regulation, or behaviour, usually associated with 
distress or impairment in important areas of functioning.3 Mental health 
disorders include severe mental illnesses (SMI) defined by a significantly 
impaired level of psychosocial functioning (Figure 1).6 In relation to the 
latter, we have drawn upon definitions and diagnostic criteria for men¬≠
tal health conditions that are specified in the International Classification 
of Diseases for Mortality and Morbidity Statistics, Eleventh Revision.7
Organic mental health disorders, such as cognitive impairment and de¬≠
mentia, are outside the scope of this document.
This consensus statement will address mental health conditions 
across the spectrum of severity and type, as both people with symp¬≠
toms of suboptimal mental health identified through screening, and 
people with manifest mental health disorders, are at high CVD risk. 
Core principles, across the spectrum of disease, are outlined. To illus¬≠
trate the impact and implementation of some of the key aspects of the 
document, the narratives of people living with CVD and clinical cases 
have been incorporated into the online document ‚ÄòClinical cases and 
patient perspectives‚Äô.






Mental health disorders


Figure 1 Concept of mental health within this consensus statement.  
ESC Guidelines                                                                                                                                                                                                 7


<!-- PAGE 8 -->

### Page 8

Mental health and mental health conditions interact with CV health 
(defined as the health of the heart and blood vessels)8 and CVD in a 
multidirectional way (Figure 2). For example: 
‚Ä¢ Positive features of mental health at an individual and societal level are 
associated with better CV health,9‚Äì11 while people with mental 
health conditions are more likely to be at greater risk of CVD.12
‚Ä¢ Acute CV events or chronic CVD impact on mental health, worsen¬≠
ing pre-existing mental conditions or triggering new conditions.13‚Äì16
‚Ä¢ The concurrence of CVD and mental health conditions may interact, 
worsening both mental health and CV prognosis.17‚Äì19
‚Ä¢ People with mental health conditions are often the most disadvan¬≠
taged, experiencing social and economic hardship as well as dealing 
with stigma, stereotypes, and prejudice.20
‚Ä¢ People with mental health disorders, particularly SMI, are more 
vulnerable, and are less likely to receive the same diagnostic 
and treatment efforts as persons without mental health condi¬≠
tions.21‚Äì26











	













¬Å
¬Å










Figure 2 Mental/cardiovascular health, disease interaction, and future directions. CV, cardiovascular. ACTIVE, Acknowledge, Check, (use validated) 
Tools, Implement, Venture, Evaluate (see Figure 4).


<!-- PAGE 9 -->

### Page 9

3.2. Enduring problems
Despite the strong association between mental health, CV health, and 
CVD, and its clinical relevance, there are multiple problems (Figure 2) 
including: 
‚Ä¢ Insufficient awareness among healthcare professionals of the preva¬≠
lence of mental health conditions in the population and their impact 
on increasing risk of developing CVD.27
‚Ä¢ Limited appreciation among healthcare professionals of the incidence 
and prevalence of mental health conditions and mental disorders 
among people with CVD and their impact on quality of life (QoL), 
therapeutic adherence, and CVD prognosis.27
‚Ä¢ Inadequate recognition of the stigma of SMI in society and in health¬≠
care, and its consequences for people coping with SMI, their family, 
and caregivers.28
‚Ä¢ Lack of systematic and appropriate screening, evaluation, communi¬≠
cation, and management of mental health, which are not integrated in 
routine clinical CV practice.29
‚Ä¢ Little knowledge and ongoing research about how to improve CV 
health and prevent CVD in people with mental health conditions 
and mental disorders.21‚Äì23,27
‚Ä¢ Limited evidence and ongoing research on the best ways to commu¬≠
nicate, promote, maintain, and improve mental health and resilience 
in people with CVD and their family members.30
‚Ä¢ Little guidance about how to improve the care of people with SMI, 
despite strong evidence that people with SMI and CVD have worse 
CV prevention, acute and chronic care, and prognosis.21,24‚Äì26
‚Ä¢ Limited awareness of the importance of family and caregivers and 
their needs, as both CVD and mental health conditions affect a per¬≠
son‚Äôs wider social network.31‚Äì34
Cardiovascular care is optimal when it is person-centred and seeks 
to improve overall health, not only CV but also mental health, as an in¬≠
tegral component. This approach needs to be integrated into routine 
practice as most current models of CV care do not consider mental 
health as a primary goal. To achieve this, healthcare professionals 
need more comprehensive information about mental health and how 
to deliver mental health sensitive, person-centred care. Furthermore, 
the mental health challenges experienced by family members and care¬≠
givers are often not recognized nor addressed.35 Central to this state¬≠
ment is the recognition that CV care professionals need to develop 
collaboration with mental health professionals in order to ensure opti¬≠
mal care and outcomes. Access to mental health services may vary, but 
the multidisciplinary CV team needs to include a collaborating mental 
health professional, psychologist, or psychiatrist to provide guidance 
for practice and appropriate support for people with CVD and their 
caregivers. In this consensus statement, we have called this the 
Psycho-Cardio team (Figure 3).






	



Figure 3 The Psycho-Cardio team.  
ESC Guidelines                                                                                                                                                                                                 9


<!-- PAGE 10 -->

### Page 10

3.3. Aims of the document
This document adopts a broad, summarizing approach, and provides 
key and consensus statements which collectively: 
‚Ä¢ Critically review the evidence on the association between mental and 
CV health.
‚Ä¢ Increase awareness of the clinical importance of the association be¬≠
tween mental and CV health.
‚Ä¢ Increase awareness and combat the stigma of mental health condi¬≠
tions and mental health disorders.
‚Ä¢ Promote increased mental health screening and better management 
for people with CVD and mental health conditions and support for 
caregivers.
‚Ä¢ Provide guidance on initial clinical, systemic, and organizational 
changes needed, as well as signposting future directions.
‚Ä¢ Identify gaps in evidence and research needed to improve the care for 
people with mental health conditions and CVD.
3.4. The Psycho-Cardio team
Multidisciplinary teams are needed to offer a holistic approach to health 
promotion and management in people with CVD and mental health 
conditions. In addition to CV and mental health professionals, the 
Psycho-Cardio team should be augmented by allied professionals, as ap¬≠
propriate.36 Care continuity should be ensured via co-ordination with 
the multidisciplinary primary care team, and psychosocial determinants 
and potential social interventions discussed with social workers and 
relevant professionals. All professionals should advocate for improved 
mental health and CV care; those with advocacy responsibilities within 
the public health and policy domain should ensure changes recom¬≠
mended here are priorities. A practical approach to change routine clin¬≠
ical CV care towards being more person-centred is to focus on 
awareness toward the person with CVD and caregivers‚Äô mental health, 
CV prevention, and care of people with mental health conditions fol¬≠
lowing the ACTIVE principles (Figure 4). 
‚Ä¢ First, acknowledge (A) the intricate relationship between mental 
health, CV health, and CVD, their common and specific determi¬≠
nants, and the influence that mental health conditions may have on 
prognosis and care equity. Particular attention is required to identify 
and eliminate potential bias, disparities and stigma associated with 
mental health conditions and disorders, particularly in those with SMI.
‚Ä¢ Second, check (C) systematically for the presence of symptoms of 
mental health conditions or mental health disorders at CV visits, 
and check CV risk factors during mental health visits.
‚Ä¢ Third, use validated tools (T) to assess mental and CV health 
status among people with CVD, and use tools to inform and 
educate about the importance of mental and CV health, and their 
relationships.



	





























 
Figure 4 The ACTIVE principles to improve mental health in cardiovascular care.


<!-- PAGE 11 -->

### Page 11

‚Ä¢ Fourth, implement (I) person-centred practices in CV care using 
evidence-based, stepped care approaches. These should be individua¬≠
lized to the person and their circumstances and recognize the im¬≠
portance of caregivers and caregivers‚Äô health status.
‚Ä¢ Fifth, venture (V) to convince professionals, managers, and people liv¬≠
ing with CVD, to obtain their collaboration, support, and resources 
to make the needed structural and functional changes to face this 
challenge. These will not occur spontaneously. Professionals and in¬≠
stitutions willing to improve CV and mental healthcare through col¬≠
laborative, person-centred models, with compassionate support for 
families and caregivers will undoubtedly face several barriers when 
implementing change.
‚Ä¢ Sixth, evaluate (E) the current status of routine CV care in each set¬≠
ting and estimate the needs for organizational, educational, and clin¬≠
ical support to implement the required changes. Progress in 
management and mental health outcomes will also have to be evalu¬≠
ated for quality assurance and improvement purposes. 
3.5. Section summary points and 
management consensus statements from 
Section 3
4. Impact of mental health on the 
risk of developing cardiovascular 
disease
This section focuses on the relationship between mental health and CV 
risk in individuals without known CVD. The aim is to elucidate for the 
healthcare professional the aetiological impact of psychosocial stress 
factors on the onset of CVD. The evidence, which includes large 
population-based studies and meta-analyses that adjust or control for 
concurrent somatic risk factors, is robust. Such evidence underscores 
the independent impact of psychosocial risk factors on the prediction 
of hard endpoints including all-cause mortality, and major adverse car¬≠
diac events (MACE).
4.1. Positive mental health states as 
predictors of better cardiovascular health
Subjective well-being (SWB) is an overarching term that covers dif¬≠
ferent aspects of positive mental affect states.3 An individual with 
SWB is satisfied with life, has a sense of purpose, and possesses 
meaning in life.37 Related features to positive affectivity encompass 
psychological well-being, high life satisfaction, joy, optimism, and 
happiness.38 Sexual health is also an important component of mental 
well-being and can be impaired both as a cause or as a consequence 
of mental and CV issues.39 Positive trait-like dispositions like sense 
of coherence, a person‚Äôs view of life, and capacity to respond to 
stressful situations,40 and other more psychobiological-driven per¬≠
sonality factors (i.e. emotional vitality, vigour, positive energy, and 
resilience) are further linked concepts employed in population- 
based studies.
Subjective well-being and related features have been advocated as 
protective states against premature mortality and morbidity, mainly fo¬≠
cusing on CVD conditions. Systematic review and meta-analytic evi¬≠
dence have shown favourable effects on mortality.41,42 In the largest 
meta-analysis, the survival impact of SWB was significant in both men 
and women, however, more protective in men.42 Positive affect was as¬≠
sociated with a lower risk of coronary heart disease (CHD),43 and op¬≠
timism with a lower incidence of heart failure (HF).44 Consecutive 
studies have demonstrated the importance of sexual well-being in over¬≠
all well-being in CVD.39 Lastly, negative affect, a component of SWB, 
has also been shown to increase incident CVD events, even after con¬≠
trolling for known confounders.45
Mechanistically, SWB may have stress-buffering properties that di¬≠
minish physiological hyper-responsiveness46 or exert protective CV ef¬≠
fects via a more balanced physiology (i.e. autonomic regulation, 
enhanced neuroendocrine functioning, reduced inflammation).47
Alternatively, SWB may result in greater engagement in healthy beha¬≠
viours,48 that in turn drive better social functioning, personal relation¬≠
ships, and QoL.49
4.2. Psychosocial stress
Psychosocial stress arises when an individual perceives and responds to 
a social demand (family issues, social isolation, financial pressures, and 
work) that exceeds an individual‚Äôs adaptive capacity or regulatory 
homeostatic range to cope.50,51 The same situation can be stressful 
for one person but not for another, due to psychological appraisal pro¬≠
cesses that typically operate outside of conscious awareness.52 In most 
cases, psychosocial stress results in an appropriate state of arousal 
SECTION SUMMARY POINTS
(i)
Mental health and mental health conditions interact with CV health 
and CVD in a multidirectional way.
(ii)
The coexistence of CVD and mental health conditions can create a 
mutual interaction that worsens both mental and CV health, 
leading to poorer outcomes.
(iii)
Routine CV clinical practice lacks integrated, systematic and 
appropriate screening, evaluation, communication, and 
management of mental health.
(iv)
There is limited evidence on the best ways to communicate, 
promote, maintain, and improve mental health and resilience in 
people with CVD and their family members.
(v)
The evidence base to guide practice in relation to the screening and 
management of mental health conditions in people with CVD is 
limited.
MANAGEMENT CONSENSUS STATEMENTS
(i)
Cardiovascular care is optimal if it is person-centred and seeks to 
improve overall health, not only CV but also mental health, as an 
integral component.
(ii)
A multidisciplinary team including mental health professionals, 
psychologists, and/or psychiatrists (Psycho-Cardio team) is needed 
in CV care to provide guidance for practice and appropriate mental 
health assessment, support, and management to people with CVD 
and their caregivers.
(iii)
Cardiovascular services should aspire to implement a Psycho-Cardio 
team approach, tailored to the local population, context, and 
resources.
(iv)
Implementing the ACTIVE principles is a practical approach to 
transform routine clinical CV care towards being more 
person-centred, integrating mental healthcare into routine CV 
practice to improve care.
¬© ESC 2025
ESC Guidelines                                                                                                                                                                                               11


<!-- PAGE 12 -->

### Page 12

and hyper-mobilization53 that is contextually applicable.52 However, 
clinically more important are long-term sustained stress conditions 
(chronic stress) which cause exacerbated pathophysiological changes 
in the heart and vasculature. Various psychosocial risk factors are de¬≠
scribed below and illustrated in Figure 5.
Psychosocial factors as a whole are as potent risk factors as conven¬≠
tional risk factors, with an adjusted odds ratio (OR) of 2.51 [95% con¬≠
fidence interval (CI) 2.15‚Äì2.93].54 Chronic psychological stress is 
associated with an increased risk of CVD.55 People experiencing their 
first myocardial infarction (MI) reported higher prevalence of stress 
(work home, financial, major life events) in the 12 months prior to ad¬≠
mission; the highest risk was for permanent stress at work (OR 2.14; 
99% CI 1.73‚Äì2.64). The increased risk is consistent across regions, 
ethnic groups, men, and women.56 Stress can trigger CVD events 
through: (i) changes in autonomic balance, (ii) alteration of neuroen¬≠
docrine axes, (iii) activation of inflammatory systems, and (iv) engage¬≠
ment in health-damaging behaviours like smoking and alcohol 
consumption.57 The latter typically cluster significantly with stress ex¬≠
posure.57 Management of psychosocial stress and promotion of men¬≠
tal well-being should therefore be integral parts of comprehensive CV 
healthcare and prevention.
4.3. Work stress and unemployment
Most individuals spend a major portion of their active lives in work envir¬≠
onments, which can be a source of psychosocial stress. A large-scale 
meta-analysis demonstrated that work stress/job strain was significantly as¬≠
sociated with a higher risk for CHD.58 In equally large prospective cohort 
studies, job strain was associated with shorter chronic disease-free life ex¬≠
pectancy,59 and loss of chronic disease-free life expectancy.60 Workplace 
bullying at baseline increased risk of CHD or stroke by 59% and by 25% 
over more than 12 years of follow-up in those who reported physical vio¬≠
lence or threat of violence at work after adjustment for confounders.61
Reduced life expectancy is likely driven through increased CVD risk 
factors. Strong evidence links work stress to increased risk of hyperten¬≠
sion,62 insomnia,63 and negative affectivity.64 Further, effects can be cu¬≠
mulative.65 Maladaptive compensatory behaviour patterns (smoking,66
physical inactivity,67 self-damaging alcohol consumption, and other un¬≠
healthy lifestyle patterns)68 also drive work-related stress burdens that 
can result in CVD.69 Unemployed persons have equally high prevalences 
of unhealthy lifestyles, biological CV risk factors, and CVD.70‚Äì73 Work 
stress is therefore an important mediator of CVD risk and outcome. If 
people with CVD voice concern about work stress, they should be 
appropriately counselled as suggested in Section 5.










	






	
	

¬Å
	



Figure 5 Sources of psychosocial stress as risk factors for cardiovascular disease. CVD, cardiovascular disease.


<!-- PAGE 13 -->

### Page 13

4.4. Socioeconomic and subjective social 
status
Low socioeconomic status (SES) is an independent risk factor for 
CVD.74 Subjective social status (SSS), which refers to the ‚Äòindividual‚Äôs 
perception of his or her own position in the social hierarchy‚Äô,75 is 
also an important mediator of CVD risk. Risk appears to be mediated 
through lifestyle pathways, however, it is increased via delayed or poor 
CVD management.76 Whilst healthcare professionals may be limited in 
their ability to address these factors, there remains a need to advocate 
for social policies to address inequalities in SES for those with such a 
remit.
4.5. Perceived discrimination
Lifetime discrimination (experiences of unfair treatment in various life 
domains) and everyday discrimination (frequency of day-to-day occur¬≠
rences of perceived unfair treatment), and related features like social 
stigmatization, have been linked to CVD.77 Multiple studies have de¬≠
monstrated that lifetime discrimination increases CVD risk or all-cause 
mortality even after adjustment for important confounders.77‚Äì80 The 
strength of the evidence suggests that discrimination is important, 
thus people describing discrimination in the clinical setting should be ap¬≠
propriately counselled in terms of prevention of health hazards.
4.6. Mental stress through impaired social 
relationships
There are multiple avenues through which mental stress can drive CVD 
risk and prognosis. Important categories of mental stress are summar¬≠
ized below.
4.6.1. Adverse childhood experiences
Adverse childhood experiences (ACEs) are broadly defined as ‚Äòchild¬≠
hood events, varying in severity and often chronic, occurring in a child‚Äôs 
family or social environment that cause harm or distress, thereby dis¬≠
rupting the child‚Äôs physical or psychological health and development‚Äô.81
These events include physical, sexual, or emotional abuse, neglect, care¬≠
giver mental illness, and domestic violence.81 Several studies comparing 
adults with and without ACEs exposure have shown higher incidence of 
CVD, type 2 diabetes mellitus, depression, and all-cause mortality.82‚Äì86
Healthcare professionals must be aware of the relationship between 
ACEs and CVD, and if described during clinical interview they should 
raise awareness to the potential health ramifications and refer these in¬≠
dividuals to the appropriate preventative services.
4.6.2. Partnership violence
Intimate partner violence is associated with a greater prevalence of 
mental health conditions,87 and appears to be an additional stressor 
that directly and indirectly impacts women‚Äôs CV health. However, 
the findings across studies are inconsistent.88 Although the evidence 
is more limited in males, experiences of intimate partner violence, 
whether as victim or perpetrator, have been linked to increased 
CVD risk.89
4.6.3. Loneliness and social isolation
Loneliness is defined as a ‚Äòsubjective negative experience that results 
from inadequate meaningful connections, where ‚Äúinadequate‚Äù refers 
to the discrepancy or unmet need between an individual‚Äôs preferred 
and actual experience‚Äô.90 Social isolation whilst conceptually similar 
is defined as ‚Äòan objective ‚Äúlack‚Äù or ‚Äúabsence‚Äù of social contact or 
relationships‚Äô.91 Evidence from meta-analyses and population-based 
cohort studies have determined that both loneliness and social 
isolation are associated with increased CVD risk.92,93 Healthcare 
professionals should be aware of the potential impact these experi¬≠
ences have on CVD risk. Social prescribing may be a potential inter¬≠
vention to improve social isolation and loneliness as discussed in 
Section 5.
4.7. Mental health conditions and 
personality traits as risk factors for 
cardiovascular disease
4.7.1. Depression
The WHO defines depressive disorder as a common mental condition 
that involves a low mood or loss of pleasure or interest in activities for 
long periods of time.94 Common symptoms are feelings of sadness, 
emptiness, hopelessness, having trouble concentrating, losing interest 
in things that one used to enjoy, feeling worthless, guilt, and experien¬≠
cing disrupted sleep.94 Depressive mood is a normal reaction to severe 
adverse life events and problems (i.e. divorce, job loss). Diagnostic cri¬≠
teria for depressive disorders are shown in Supplementary data online, 
Table S1. The prevalence of depression is estimated to be 4.4% in the 
general population (in total, 322 million globally) posing a significant 
public health challenge.94 Depression has been shown to be as strong 
a CV risk factor as traditional somatic risk factors.95,96 Large observa¬≠
tional and case-control studies demonstrate that depression is inde¬≠
pendently associated with incident CVD, all-cause mortality, and 
combined CVD/mortality outcome, with hazard ratios (HRs) or ORs 
ranging from 1.14 to 1.55.56,97 Meta-analyses have shown depression 
to confer increased risk for incident HF, new-onset and recurring atrial 
fibrillation (AF), ventricular tachycardia/fibrillation, and sudden cardiac 
death (SCD).98‚Äì101
4.7.2. Anxiety
Anxiety is an emotion characterized by worrying that may be accom¬≠
panied by non-specific physical and psychological symptoms such as 
restlessness, fatigue, difficulty concentrating, irritability, muscle tension, 
or sleep disturbances.102 If it is intense and sudden, anxiety may present 
as a panic attack, with palpitations, shortness of breath, dizziness, chest 
pain, lightheadedness, or a dying sensation lasting several minutes.103
Fear and anxiety are closely related phenomena, but differ in terms 
of their orientation in time. Anxiety is ‚Äòfuture-oriented‚Äô (i.e. perceived/ 
anticipated threats), whilst fear is a reaction to a perceived imminent 
threat in the present.104
Anxiety or fear-related disorders are characterized by excessive fear 
and anxiety that cause distress or impairment in functioning. These dis¬≠
orders include generalized anxiety, panic disorder, agoraphobia, specific 
phobia, social anxiety disorder, separation anxiety, selective mutism, 
and other related disorders. Multiple studies and meta-analyses have 
shown that anxiety and anxiety disorders (together or individually) 
are associated with increased risk of CVD and/or CV mortality.105‚Äì109
The relationship between anxiety and arrhythmias or HF is less clear 
with mixed findings.100,109‚Äì111 Panic disorders and panic attacks have 
also been associated with incident CVD events.112 Overall, evidence 
suggests that the link between anxiety or fear and CVD risk is suffi¬≠
cient that healthcare professionals should be aware of the relationship 
and consider early screening as clinically indicated. Diagnostic criteria 
for anxiety and fear-related disorders can be found in Supplementary 
data online, Table S2.
ESC Guidelines                                                                                                                                                                                               13


<!-- PAGE 14 -->

### Page 14

4.7.3. Post-traumatic stress disorder
Post-traumatic stress disorder (PTSD) is a complex and debilitating 
condition, often stemming from exposure to traumatic events that 
shatter a person‚Äôs sense of safety and security.113 Symptoms encom¬≠
pass intrusive thoughts, flashbacks, nightmares, and heightened arousal, 
all of which can severely impair an individual‚Äôs QoL.114 Onset of PTSD 
can occur at any time during the lifespan following exposure to a trau¬≠
matic event.
Post-traumatic stress disorder is an important risk factor for 
CVD, both in terms of its development and progression. PTSD 
among Armed Forces veterans has been linked to a 25%‚Äì50% 
higher risk of CVD, including HF, MI, and CVD mortality com¬≠
pared with those without PTSD, even after adjustment for de¬≠
pression and other factors.115‚Äì117 The mechanisms by which 
PTSD may increase CV risk are not fully understood. However, 
it has been shown that PTSD elicits psychological, physiological, 
and behavioural responses that lead to increased risk.118
Autonomic imbalance (increased activity of the sympathetic ner¬≠
vous system and decreased activity of the parasympathetic ner¬≠
vous system), damaged baroreflex function, and subsequent 
blood pressure dysregulation may also play a role.119 PTSD is 
also associated with elevated markers of inflammation,120 and of¬≠
ten associated with unhealthy diet and lifestyle, obesity, sleep dis¬≠
turbance, decreased physical activity, medication non-adherence, 
substance abuse, smoking, and alcohol abuse, all of which contrib¬≠
ute to poor CV health.121‚Äì123 Definition and characteristics of 
PTSD can be found in Supplementary data online, Table S3. 
Symptoms and suggested key questions to identify depression, 
anxiety, or PTSD can be found in Supplementary data online, 
Tables S4‚ÄìS6.
4.8. Section summary points and 
management consensus statements 
from Section 4
5. Mental health and mental health 
conditions in people with 
cardiovascular disease
The previous section focused on the analysis of CV risk associated with 
mental health conditions in individuals without CVD. This section ad¬≠
dresses the prevalence of mental health conditions among people 
with CVD, their impact on CV prognosis, self-management and adher¬≠
ence to medical recommendations, as well as the impact of CVD on the 
mental health of family members or caregivers.
5.1. Impact of cardiovascular disease on 
mental health
Cardiovascular disease can induce significant mental health conditions. 
The perceived characteristics of acute CV events, such as acute coronary 
syndrome (ACS) or arrhythmia, coupled with the threat of death and 
helplessness,124,125 may trigger intense negative emotional responses.126
Even when diagnostic criteria for mental health disorders are not met, 
people with CVD may experience existential concerns. These include 
fear of recurrence, apprehension about death, emotional and work- 
related stress, anger, grief, and worries about the well-being of family 
members.127,128 The need for complex treatment regimens and lifestyle 
changes negatively impacts QoL and general well-being, and may be dif¬≠
ficult to initiate and maintain.129 Combined with the perceived loss of 
health and independence, these factors may contribute to an increased 
risk of developing mental health conditions in people with CVD.
In some instances, these reactions and symptoms might become 
severe enough to warrant a diagnosis of a mental health disorder, 
such as depression, anxiety, and even cardiac disease-induced PTSD 
(CDI-PTSD).13,125,126 The prevalence of mental health conditions in 
people with CVD varies widely based on type of CVD, individual char¬≠
acteristics, life contexts, and assessment tools. Most importantly, these 
comorbid mental health conditions might impact self-management, 
adherence to medication prescriptions, diet, physical activity, and smok¬≠
ing cessation plans, overall outcomes, and even prognosis in people 
with CVD.125,126 This association is particularly evident with stress 
and depression, where 1 year healthcare costs for society are 33% 
higher compared with those with CVD.130 Therefore, it is imperative 
to inform and educate CV care professionals about the mental 
health-related consequences of CVD.
5.2. Specific mental health conditions in 
people with cardiovascular disease: 
prevalence and prognostic impact
5.2.1. Depressive symptoms and depression
It is important to differentiate depressive symptoms from depression as 
the term ‚Äòdepression‚Äô encompasses various meanings, spanning from 
temporary feelings of low mood to severe clinical conditions that are dis¬≠
abling, recurrent, and severe. Moreover, some individuals exhibit a per¬≠
sistently distressed personality with certain depressive traits. People 
coping with CVD may experience any of these distinct clusters of symp¬≠
toms, however, the most prevalent type of depression observed follow¬≠
ing ACS is an ‚Äòadjustment disorder with depressed mood‚Äô.131 People 
meeting the criteria for major depressive disorder are at elevated risk 
for subsequent events and often experience significantly diminished 
QoL. Consequently, these individuals require focused efforts for identi¬≠
fication, precise diagnosis, and dedicated management.132
SECTION SUMMARY POINTS
(i)
Indicators of positive mental health, such as optimism, 
happiness, and high life satisfaction are associated with lower 
CV risk.
(ii)
Hazardous psychosocial factors (e.g. social isolation, financial 
pressures, and work) are associated with increased risk of 
developing CVD.
(iii)
Mental health conditions such as depression, anxiety, and PTSD are 
associated with an increased risk of developing CVD.
(iv)
Healthcare professionals have a responsibility to: 
‚Ä¢ Be informed of these associations.
‚Ä¢ Be alert to these risk factors during consultation.
‚Ä¢ Inform, counsel, and refer individuals at risk as needed.
‚Ä¢ Advocate for system changes as appropriate.
MANAGEMENT CONSENSUS STATEMENTS
(i)
Management of psychosocial stress and promotion of mental 
well-being are essential components of integrated CV 
prevention.
(ii)
Screening for depression, anxiety, and PTSD is advised to be 
integrated into CV risk assessment.
¬© ESC 2025


<!-- PAGE 15 -->

### Page 15

5.2.1.1. Prevalence of depressive symptoms and depression in 
people with cardiovascular disease
Depression is one of the most common mental health conditions in 
people with CVD. The global prevalence of depression among people 
with CVD, as measured by various self-report questionnaires, is esti¬≠
mated to be 18%.14 It is more common among women and in older 
ages, yet healthy and physically functioning older adults are at lower 
risk of depression compared with young adults.14,133,134 Depression 
is associated with several negative lifestyle factors, such as smoking, al¬≠
cohol intake, physical inactivity, and unhealthy diet, as well as other 
CVD risk factors including diabetes and hypertension.135 These poten¬≠
tially modifiable risk factors are all associated with coronary artery dis¬≠
ease (CAD), MI, HF, stroke, and mortality.54 Table 1 presents examples 
of studies demonstrating how rates of depression vary based on the 
condition, diagnostic methods, and population demographics.
5.2.1.2. Impact of depressive symptoms and depression on 
cardiovascular disease prognosis
Depression is a known risk factor for poor prognosis among people 
with CVD. While one study did not find a significant impact of 
depression on CV or all-cause mortality after MI,156 more recent stud¬≠
ies suggest otherwise. For example, post-MI depression, though attenu¬≠
ated by severity, independently predicts a 22% higher all-cause 
mortality and 13% more CV events per standard deviation increase 
in depression z-score.157 Depression has been associated with an in¬≠
creased risk of non-fatal CV events, as well as all-cause mortality after 
ACS.17 Even 10 years after percutaneous coronary intervention (PCI) 
(‚àº50% elective), depression was associated with an increased risk for 
all-cause mortality.158 Depression is also a marker of poor prognosis 
in people with HF, where both depressive symptoms and depressive 
disorders have been prospectively linked to frequent hospitalizations, 
recurrent CV events, and mortality.18 The prospective associations be¬≠
tween elevated depressive symptoms or a depressive disorder and HF 
was associated with a two-fold increased risk of death or CV events.15
Depression at the start of exercise-based cardiac rehabilitation (ECR) 
was significantly associated with lower improvement in exercise capacity 
and QoL during rehabilitation.129 Depression and previous suicide at¬≠
tempts detected before or after heart transplantation (HTx) may impact 
long-term HTx outcomes (rejection, cardiac allograft vasculopathy, and 
death),159 probably related to increased non-adherence to medications.160
Table 1 Prevalence of depression/depressive symptoms in people with cardiovascular disease
CVD
Prevalence data
ACS/Post-MI
Depressive symptoms were reported by 31% of individuals following MI.136
The prevalence of depression at the time of hospitalization was 40% in women under 60 years, compared with 22% in 
men of the same age group. Among those over 60 years, the prevalence was 21% in women and 15% in men.137
In 8580 people with ACS from 22 European countries who were ‚â•6 months post-hospitalization,a depressive 
symptoms were more frequent in women (32.3%) than men (21.2%), with moderate/severe depression in 12.7% of 
women and 7.4% of men.138
Chronic HF
Clinically significant depression affected 21.5% of people with HF, ranging from 33.6% via questionnaires to 19.3% via 
interviews, and 11% in NYHA class I to 42% in NYHA class IV.15
Depression was more common in women with chronic HF (32.7% vs 26.1%), with rates of 11%‚Äì67% in women and 
7%‚Äì63% in men, and increased with higher NYHA functional class.15
Advanced HF and 
post-transplantation
Depression affects 25%‚Äì35% of individuals after HTx.139‚Äì141
Depression was reported in 35% of individuals pre-transplant and 26.3% post-transplant.140
Depression occurs in 15%‚Äì39% of people with ventricular assist devices, often exceeding clinical cut-offs, particularly in 
older people.114,142
People experiencing HTx had less depression than those with mechanical assist devices.143
AF
38% of people with AF met Beck Depression Inventory criteria for significant depression.144
ICD
Random-effects meta-analyses showed clinically relevant depression in 15.4% (95% CI 11.9%‚Äì18.9%) of people with an 
ICD at all timepoints post-insertion.145
The 2 year incidence of new-onset depression after ICD implantation was 11.3% in a national ICD registry.146
Depressive symptoms affected 20% of people with ICDs (12% mild, 6% moderate, 2% severe). Moderate to severe 
depression was more common in secondary prophylactic indications and in people experiencing ‚â•5 ICD shocks.147
People with ICDs and pacemakers had similarly increased levels of depression.148
ACHD
Individuals with ACHD have higher depression rates than the general population, with a weighted prevalence of 24% vs 15%.149
People with ACHD had a low and comparable suicide risk to the reference cohort.150
PH/PAH
In 2161 people with PH, the reported pooled prevalence of depression was 28% (95% CI 20.5‚Äì36.8).134
Smaller studies report depression prevalence in people with PAH ranging from 9% to 70%, linked to disease 
severity.151‚Äì155
¬© ESC 2025
ACHD, adult congenital heart disease; AF, atrial fibrillation; CI, confidence interval; CVD, cardiovascular disease; HF, heart failure; HTx, heart transplantation; ICD, implantable 
cardioverter-defibrillator; MI, myocardial infarction; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension.
aThis study included: (i) coronary artery bypass graft surgery (including emergency procedures for acute MI), (ii) percutaneous coronary intervention (including emergency procedures for 
acute MI), (iii) acute MI (ST-elevation and non-ST-elevation MI), and (iv) acute myocardial ischaemia without infarction (troponin-negative).
ESC Guidelines                                                                                                                                                                                               15


<!-- PAGE 16 -->

### Page 16

Depression is also related to increased adverse events in people with 
ventricular assist devices (VAD),161,162 and is a factor for negative out¬≠
comes among people coping with AF. In a meta-analysis consisting of 
seven cohort studies with 1070 AF people who underwent catheter ab¬≠
lation, depression before the procedure was independently associated 
with an increased risk of AF recurrence after ablation.163 Further, symp¬≠
toms of depression were the strongest independent predictor of future 
QoL post-ablation.144
5.2.1.3. Impact of depressive symptoms/depression on 
self-management and adherence
One possible path by which depression is associated with adverse out¬≠
comes among people with CVD is limited engagement in self-care prac¬≠
tices and lack of adherence, as depression is associated with challenges in 
self-management of CV medication, healthy lifestyle, ECR, and self- 
care.129,164‚Äì166 Kronish et al. reported that people with persistent de¬≠
pression were only half as likely to enrol in an ECR programme com¬≠
pared with those without persistent depression.167 People with 
persistent depression also showed lower rates of adherence to smoking 
cessation, taking medications, and exercising. A recent daily diary study 
demonstrated that on days when people attending ECR experienced ele¬≠
vated depression symptoms, they engaged in less physical activity and 
more sedentary behaviour.168 In a cohort study of individuals who under¬≠
went PCI (n = 124 443), participants with depression were 10% to 20% 
less likely to attain optimal adherence to Guideline-recommended med¬≠
ications compared with those without depression.169 Finally, a systematic 
review of quantitative studies indicated that even mild to moderate levels 
of depression were significantly associated with medication adherence in 
people with HF.170
5.2.2. Anxiety
5.2.2.1. Prevalence of anxiety in people with cardiovascular disease
Systematic reviews and meta-analyses have found prevalence of anx¬≠
iety among people with CVD to range from 28.9% to 32.9%.16,171
Higher rates are found using questionnaires (34.8% to 9%) compared 
with clinical diagnostic interviews (17%). The highest rates of anxiety 
disorder based on diagnostic interviews were reported in people with 
undifferentiated chest pain or palpitations (19%). Anxiety tended to 
be more prevalent among females compared with males (43% vs 
29.5%).171 As with depression, prevalence of anxiety varies by CV 
condition, method of diagnosis, and population demographics. 
Table 2 presents examples of studies demonstrating how rates of anx¬≠
iety vary based on the condition, diagnostic methods, and population 
demographics.
5.2.2.2. Impact of anxiety on cardiovascular disease prognosis
A meta-analysis estimating the effect of anxiety on CV outcomes in 
more than 30 000 people with CAD found that the impact depends 
on the timing, with no effect of anxiety in the first 2 months after 
ACS but with a negative effect on outcome in people with stable 
CAD.19 Generalized anxiety disorder, present in 5.5% of people 3 
months after acute MI (AMI), was associated with a two-fold increased 
risk of adverse outcomes (CV events and all-cause mortality) during a 
10 year follow-up period.184 There is little effect of anxiety symptoms 
alone on outcome in HF although comorbid anxiety and depression 
increase the risk for rehospitalization and mortality in people with 
HF.185‚Äì187 Among people with an implantable cardioverter-defibrillator 
(ICD), anxiety was a strong predictor of mortality with an OR of 4.17 in 
a cross-sectional national survey in Denmark.188
5.2.2.3. Impact of anxiety on self-management and adherence
Interestingly, anxiety, as opposed to depression, may encourage people 
to be adherent (e.g. to their medication regimen) and can have a posi¬≠
tive impact on clinical outcome in people with CVD.189,190 However, 
anxiety disorders are mostly linked with unhealthy lifestyle, poor adher¬≠
ence to lifestyle modification, and lower participation in ECR.138 One 
possible explanation of this trend is people with anxiety have a ten¬≠
dency to avoid reminders of the illness.191
5.2.3. Cardiac disease-induced post-traumatic stress 
disorder/symptoms
5.2.3.1. Prevalence of post-traumatic stress disorder in 
cardiovascular disease
Cardiac disease-induced PTSD, or post-traumatic stress symptoms 
(PTSS) defined as post-traumatic symptoms to full disorder emerging 
from an acute CV event or intervention, has a heterogeneous incidence 
among different types of CVD. Table 3 presents examples of studies 
demonstrating how rates of PTSD and PTSS vary based on the condi¬≠
tion, diagnostic methods, and population demographics.
5.2.3.2. Impact of post-traumatic stress disorder on cardiovascular 
disease prognosis
Cardiac disease-induced PTSS are linked to numerous adverse physical 
and emotional outcomes, including increased overall psychopathology 
and heightened mortality risk. However, due to the predominantly 
cross-sectional or retrospective nature of existing studies, distinguish¬≠
ing the effects of CDI-PTSS from those of the triggering event remains 
challenging. Nevertheless, the association between CDI-PTSS and ele¬≠
vated rates of mortality and CV events underscores the need for fur¬≠
ther research.13
Studies examining the implications of CDI-PTSS on subsequent 
MACE or all-cause mortality yielded mixed results. The severity of in¬≠
trusion symptoms (intrusive thoughts or images related to the traumat¬≠
ic event, nightmares, and flashbacks) measured 1 month after a first MI 
predicted recurrent MACE/all-cause mortality 42 months later.198
People scoring >11 on the intrusions dimension of the Impact of 
Event Scale (IES)199 had a three times higher risk of developing 
MACE and all-cause mortality than did those classified as low on this 
symptom cluster.198 Similarly, dissociative symptoms during hospitaliza¬≠
tion predict 15 year all-cause mortality among people with MI,200 and 
people with above-threshold PTSD-related symptoms at 6 months 
post-event had a 42%‚Äì50% prevalence of experiencing other serious 
CV events during the next 6 months compared with a 26%‚Äì32% preva¬≠
lence of the same among people without PTSS.201 Other studies found 
that PTSD measured 4 to 6 weeks post-MI was not predictive of MACE 
9 months later.202
Cardiac disease-induced PTSS predict non-fatal CVD-related hospital 
readmissions 1 to 4 years after a previous index MI.203 Increasing levels of 
CDI-PTSS, measured by the IES and PTSD Symptom Scale,204 are asso¬≠
ciated with CV readmissions.205 Further, people with IES-reported PTSS


<!-- PAGE 17 -->

### Page 17

are more than twice as likely as those without PTSS to be readmitted 
during the year following their MI.206 However, other studies showed 
that PTSD measured by the Post-traumatic Diagnostic Scale may not 
be associated with frequency of CVD-related hospital readmissions.207
5.2.3.3. Impact of post-traumatic stress disorder on 
self-management and adherence to medical recommendations
Evidence on CDI-PTSD and non-adherence is mixed, with some studies 
showing positive associations and others not.201,206,208‚Äì210 However, 
stronger evidence links CDI-PTSD to non-adherence to medication 
and physical activity.
5.2.4. Loneliness and living conditions
In a cross-sectional study of hospitalized people with various types of 
CVD, loneliness measured at discharge was associated with significantly 
worse outcomes in men and women.211 Moreover, loneliness pre¬≠
dicted all-cause mortality risk, which was almost three-fold among wo¬≠
men and two-fold among men. Living alone predicted CV event risk in 
men only (HR 1.39; 95% CI 1.05‚Äì1.85).211 In a prospective randomized 
controlled trial (RCT) in people with stable CHD, living alone was re¬≠
lated to a higher risk of CV death and the primary composite endpoint 
of non-fatal MI or non-fatal stroke. Being married, as compared with 
being widowed, was associated with a lower risk of CV death and 
the primary composite endpoint.212
Table 2 Prevalence of anxiety/anxiety symptoms in people with cardiovascular disease
CVD
Prevalence data
ACS/Post-MI
In an international cohort of people with CABG, PCI, post-MI, and ACS ‚â•6 months post-hospitalization, anxiety prevalence 
ranged from 12% to 42% in men and 22% to 64% in women, with moderate to severe anxietya in 11% of men and 23% of 
women.138
At 3 months post-MI, 10% reported high anxiety, dropping to reference population levelsb at 3‚Äì18 months.172
In people diagnosed with SCAD, 41% had mild anxiety and 16% moderate to severe anxiety by questionnaire. Higher anxiety 
scores were more common in women, younger individuals, those with lower resilience, and those closer to the event.173
Chronic HF
Up to 72% of people with HF experience anxiety, with pooled estimates of 56% for symptoms, 29% for clinically significant 
anxiety, and 13.1% for anxiety disorders. Prevalence was higher in studies with more female participants.174
People with HF face a higher risk of anxiety, with 23% experiencing symptoms and 32% having both anxiety and 
depression.175
Advanced HF and 
post-transplantation
The pooled prevalence of anxiety among people experiencing HTx was 11% (95% CI 3.8%‚Äì28.5%).176
AF
People with AF exhibited a 28% prevalence of anxiety at baseline, comparable to controls, with symptoms persisting in 37% 
after 6 months.144
Among people undergoing cardioversion or ablation, 30% reported clinically significant anxiety.177
ICD
Among OHCA survivors, anxiety was reported in 36% of women vs 20% of men, with higher rates in younger women 
(<55 years) than older women (43% vs 28%).178
At 18 months post-OHCA, 32% showed anxiety symptoms.179
A large-scale registry reported 20% anxiety among people experiencing OHCA.180
Random-effects meta-analysis found clinically relevant anxiety in 23% (95% CI 18.3%‚Äì27.0%) of people with an ICD at all 
timepoints post-insertion.145
New-onset anxiety incidence was 15% at 24 months post-ICD implantation, with higher rates in women and the secondary 
prevention setting.146,181
People with ICDs and pacemakers exhibited similarly elevated anxiety levels.148
ACHD
A review found anxiety symptoms to be common both immediately after CV events or surgery and during follow-up.182
Anxiety prevalence was higher in people with ACHD (13%) compared with a historical cohort of people with non-Hodgkin 
lymphoma and German reference values (6%).183
PH/PAH
A total of 24 studies with 2161 people with PH reported a pooled prevalence of 37% for anxiety (95% CI 28.7‚Äì46.4).134
Smaller studies reported anxiety prevalence in people with PAH ranging from 9% to 58%, linked to disease severity.151‚Äì154
Anxiety incidence was higher in people with PAH living in urban areas and in non-smokers or non-drinkers compared with 
their counterparts.154
¬© ESC 2025
ACHD, adult congenital heart disease; ACS, acute coronary syndrome; AF, atrial fibrillation; CABG, coronary artery bypass graft; CI, confidence interval; CV, cardiovascular; CVD, 
cardiovascular disease; HADS, Hospital Anxiety and Depression Scale; HF, heart failure; ICD, implantable cardioverter-defibrillator; MI, myocardial infarction; OHCA, out-of-hospital 
cardiac arrest; PAH, pulmonary arterial hypertension; PCI, percutaneous coronary intervention; PH, pulmonary hypertension; SCAD, spontaneous coronary artery dissection.
aHADS anxiety score ‚â•8.
bNorwegian population.
ESC Guidelines                                                                                                                                                                                               17


<!-- PAGE 18 -->

### Page 18

5.2.5. Chronic stress
Chronic stress, defined as the experience of physical and emotional im¬≠
balance determined by life events and conditions, was found in 58% of 
people with CVD based on a systematic review (five studies, n = 533).16
A large observational study (n = 3572) reported that perceived stress 
was significantly higher in women vs men at baseline and 1 month after 
MI.213 Perceived chronic stress was associated with worse recovery in 
overall QoL and mental status among people with MI.213
Recent studies have focused on the concept of CV distress, defined 
as ‚Äòa persistent negative emotional state rather than a transient state; involv¬≠
ing multiple psychosocial domains; that challenges a person‚Äôs capacity to 
cope with living with their heart condition, the treatment of the condition, 
and the resultant changes to daily living; and challenges the person‚Äôs sense 
of self and future orientation‚Äô.214 This study, using the Cardiac Distress 
Inventory-Short Form (CDI-SF), found significantly higher scores on 
the CDI-SF among younger people and women.214 People with HF 
and elevated stress levels may undergo a more challenging disease tra¬≠
jectory, characterized by a diminished QoL and heightened susceptibil¬≠
ity to adverse events.215 Indeed, people with HF reporting high stress 
levels had a higher likelihood of adverse events during the study 
period.216
5.3. Addressing the mental health needs of 
informal caregivers for people with 
cardiovascular disease
Following the initial diagnosis, people may be asked to implement sub¬≠
stantial lifestyle changes to reduce CV risk, prevent further disease pro¬≠
gression, and enhance QoL.217 Coping with CVD and embracing new 
habits can prove challenging, and for adults, the primary source of sup¬≠
port often comes from their informal caregivers, primarily their part¬≠
ners.218,219 Partners are usually the most available and accessible 
persons for support, physically during hospitalizations and medical vis¬≠
its, at home, and emotionally.220
The caregiving efforts of informal caregivers can exert a significant toll 
on themselves.31,35 Providing emotional and tangible support to a person 
coping with CVD may lead to caregiver emotional and/or physical strain. 
Some studies have identified mental health risks, such as increased levels 
of anxiety, depression, or CDI-PTSD among caregivers in the context of 
CVD.31‚Äì33,220 A recent review221 suggested that low to moderate levels 
of distress were common among family caregivers of people with CAD 
(prevalence ranging from 6% to 67% of caregivers). Family caregivers of 
people with HF cope with significantly higher physical and psychological 
health risks compared with non-caregivers.222 In the context of a VAD 
implantation, spouses have been found to have higher anxiety rates com¬≠
pared with the person with the VAD,223 as well as lower mental QoL as a 
consequence of VAD-related disturbances in sexual activity.224
Despite ample literature documenting the adverse effects of caregiv¬≠
ing, the person with CVD is seen as the sole focal point of attention and 
exclusive recipient of care, thus overlooking the needs of the informal 
caregiver.34 A shift in healthcare systems from focusing solely on indivi¬≠
duals to adopting a holistic approach that includes the individual and 
their families, is needed. Family caregivers are essential collaborators, 
as they often ensure people can build change into their lives and adhere 
to their treatment plans. Educating and supporting informal caregivers 
represents not only a mechanism for improving long-term outcomes, 
but also a means of reducing healthcare costs through the avoidance 
of repeat engagements with the health system.225,226 Most importantly, 
caring for informal caregivers not only benefits the person living with 
CVD and reduces medical costs, but also reflects a holistic approach 
to CV practice. By supporting informal caregivers, a compassionate 
and sustainable healthcare system of CVD management is fostered, 
which is essential for the long-term success. Different Psycho-Cardio 
team members engage with informal caregivers at varying levels. 
Every team member should remain mindful of the challenges faced by 
those who care for a person living with CVD. Figure 6 outlines specific 
actions the Psycho-Cardio team members can take to assess and alle¬≠
viate caregiver distress.
Table 3 Prevalence of post-traumatic stress disorder/post-traumatic stress symptoms in people with cardiovascular 
disease
CVD
Prevalence data
ACS/Post-MI
Clinically significant PTSD 12%, and PTSS prevalence 0%‚Äì26% depending on type of measurement.13,192
PTSD occurs in 7%‚Äì20% of people post-CABG.13
PTSD prevalence among people with SCAD ranged from 28% to 35%.173,193
Advanced HF and 
post-transplantation
PTSD occurs in 11%‚Äì19% of people post-HTx.13
ICD
12%‚Äì38% prevalence of PTSD in survivors of cardiac arrest.13,145,178
Experiencing ‚â•1 appropriate ICD shocks was an independent risk factor for PTSD  
(OR 6.0; 95% CI 1.45‚Äì24.63; P < 0.013).194
A single study found higher PTSD prevalence in people with ICD who experienced electric storms compared with 
those who did not.195
ACHD
1%‚Äì30% prevalence of PTSD in people with ACHD, varying by measurement and geographical region.196,197
Women and people with multiple medical encounters lacking psychosocial intervention are more likely to have 
PTSD.196
¬© ESC 2025
ACHD, adult congenital heart disease; ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CI, confidence interval; CVD, cardiovascular disease; HF, heart failure; HTx, heart 
transplantation; ICD, implantable cardioverter-defibrillator; MI, myocardial infarction; OR, odds ratio; PTSD, post-traumatic stress disorder; PTSS, post-traumatic stress symptom; SCAD, 
spontaneous coronary artery dissection.


<!-- PAGE 19 -->

### Page 19

5.4. Section summary points and 
management consensus statements from 
Section 5
6. Identification, prevention, and 
management of mental health 
issues in people with cardiovascular 
disease
6.1. Awareness of needs in people with 
cardiovascular disease
Depression and anxiety can easily be overlooked in the routine care of 
people with CVD and/or considered ‚Äònormal‚Äô reactions to the clinical 
and prognostic burden of their disease. Given the high prevalence of 
mental health conditions among people with CVD, and their impact 
on outcomes and adherence, the possibility of evaluating mental health 
status at some point during professional encounters can be considered 
a worthy strategy to improve health. People with CVD with potential 
symptoms of mental health conditions should undergo formal screen¬≠
ing and, at least, a low threshold for formal screening of mental health 
symptoms should be applied in people with CVD.
The recent manuscript ‚ÄòHow your patient is really feeling: the emotional 
hinterland of a cardiac diagnosis‚Äô, written by individuals with CVD, illumi¬≠
nates their experience.30 In this piece, people coping with CVD high¬≠
light challenges faced when diagnosed, gaps in care, and unmet 
needs.30 Priorities, such as the need for an on demand, accessible, tai¬≠
lored, and long-term multidisciplinary support network, are outlined. 
Suggestions for establishing the best possible person-centred support 
system and components for long-term support are outlined in 
Figure 7. Additional experiences of people coping with CVD, presented 
in the associated ‚ÄòClinical cases and patient perspectives‚Äô text, further 
highlight the importance of integrating mental health assessment within 
CVD care.


	

		

	

			
		






Figure 6 Suggestions for supporting informal caregivers of people living with cardiovascular disease.  
SECTION SUMMARY POINTS
(i)
There is a multidirectional association between CVD and mental 
health conditions such as depression, anxiety, and PTSD, increasing 
each other‚Äôs risk.
(ii)
Mental health conditions in people with CVD, such as depression, can 
negatively affect self-management, including adherence to medication 
and lifestyle changes, and are associated with worse outcomes.
(iii)
The effects of anxiety and PTSD on adherence and CV outcomes are 
less clear and might be time-dependent.
(iv)
Caregivers play an essential role in supporting their family members 
who cope with CVD to incorporate lasting lifestyle changes and to 
adhere to treatment plans: assessing and supporting caregivers 
well-being benefits both parties.
MANAGEMENT CONSENSUS STATEMENTS
(i)
It is reasonable to assess depression, anxiety, and PTSD in people 
with established CVD as they are highly prevalent and impact 
outcomes, and refer promptly to a professional when needed.
(ii)
Chronic stress and loneliness are associated with negative outcomes 
in people with CVD and should prompt referral if identified during 
clinical assessment.
(iii)
Incorporating informal caregiver well-being assessment and support 
is advisable in the holistic approach of mental and CV health.
¬© ESC 2025
ESC Guidelines                                                                                                                                                                                               19


<!-- PAGE 20 -->

### Page 20

6.2. Identification and screening
Taking a clinical history is an opportunity for the evaluation of potential 
symptoms and any history of mental health conditions. Conversations 
during the clinical course are further opportunities to identify previous¬≠
ly unrecognized symptoms, the appearance of new difficulties, manifes¬≠
tations of mental health conditions, or the need for help. These may 
indicate a requirement for more education relating to their condition(s) 
or support from social care services, which is not unusual in people with 
CVD.227
To ensure that people are being screened and treated for potential 
mental health conditions in addition to their underlying CVD, consider¬≠
ation needs to be given to: (i) who will screen, (ii) when screening 
should be performed, (iii) which screening tools should be used, and 
(iv) how often screening should occur (Figure 8). Given that resources 
may vary across countries, hospitals, and specialized and general prac¬≠
tices, a one-size-fits-all approach is unlikely to work. Collaboration with 
mental health professionals (the Psycho-Cardio team) can support de¬≠
veloping a protocol for screening and guiding referrals based on severity 






	







		





Figure 7 Visualization of an ‚Äòon demand‚Äô support system for people with cardiovascular disease to improve mental health. Cardiovascular disease support 
team on standby. People with cardiovascular disease, family members and caregivers access the relevant healthcare or allied professional, or other resources 
appropriate to their immediate need, the process is cyclical, allowing for repeat access as needed. Adapted from Mindham et al. with permission30.


<!-- PAGE 21 -->

### Page 21

of mental health conditions and local situation. Ideally, screening for 
anxiety and depression should be conducted following a new diagnosis 
of CVD or acute CV event, at least once during follow-up and period¬≠
ically (e.g. annually or when clinically indicated). Brief two-item screen¬≠
ing measures ensure that the time needed for initial screening is limited 
(see Section 5.2.1). 
‚Ä¢ When should the screening be done? Following a new diagnosis of CVD 
or acute CV event, periodically, at least once during follow-up, or 
when clinically indicated.
‚Ä¢ How should screening be done? Via use of any valid and reliable short 
screening tool, appropriate to the setting and context.
‚Ä¢ Who should screen? Any member of the Psycho-Cardio multidisciplin¬≠
ary team who are appropriately qualified to do so.
Of note, screening by itself does not help people with CVD but in¬≠
cludes responsibility to address and provide appropriate referral and 
treatment options. Further, it is important to acknowledge that screen¬≠
ing has been linked to psychological harms (worry and anxiety) that re¬≠
main underexplored in the context of CVD.228 A proposal for the who, 
when, and how of screening for mental health conditions in people with 
CVD is illustrated in Figure 8.
6.2.1. Assessment of depression and anxiety
Two-item screening tools, which only take a few minutes to answer, are 
the simplest way to assess depression and anxiety. We highlight three 
measures, the Whooley questions, the Patient Health Questionnaire 
(PHQ)-2, and the Generalized Anxiety Disorder (GAD)-2. Positive 
screens indicate the need for a longer screening measure. The 
Whooley questions are a two-item screening tool for the identification 
of depression that has shown high sensitivity and moderate specifi¬≠
city,229 making this measure a useful initial screening tool for depres¬≠
sion:32,230‚Äì233
The Whooley questions229
(i) During the past month, have you often been bothered by feeling 
down, depressed, or hopeless?
(ii) During the past month, have you often been bothered by little 
interest or pleasure in doing things?
‚ÄòYes‚Äô to one (or both) questions = positive test (requires further 
evaluation).
‚ÄòNo‚Äô to both questions = negative test (not depressed).
The two-item and seven-item GAD questionnaires, and the 
two-item and nine-item PHQ tools for depression are widely used 
with good sensitivity and specificity in people with CVD.234‚Äì237 The 
GAD and PHQ have been translated into many languages and their 
use does not require a license agreement. Their psychometric proper¬≠
ties are shown in Table 4.
Although it can be a challenging task to choose a screening tool, gen¬≠
eric questionnaires are widely used. It is key to find a screening tool that 
is valid and reliable for people with CVD. The Hospital Anxiety and 
Depression Scale (HADS) is widely used, including in people with 
CVD in the inpatient and outpatient setting. However, use of the 
HADS requires a license fee. The joint ESC societies statement on 
patient-reported outcome measures, referred to in Section 5.1.1,239
also notes the Cardiac Anxiety Questionnaire, Cardiac Depression 
Scale, and Cardiac Distress Inventory can be considered as possible 
measures.



	







¬Å
¬ç¬è¬ê¬ù
¬è
¬†¬≠¬Ä¬Ç¬É¬Ñ


¬è


¬è¬è


¬è
Figure 8 Screening for mental health conditions in people with cardiovascular disease. CVD, cardiovascular disease; GAD, Generalized Anxiety 
Disorder; PHQ, Patient Health Questionnaire.  
ESC Guidelines                                                                                                                                                                                               21


<!-- PAGE 22 -->

### Page 22

Mental health conditions can evolve over time and may be episodic. 
Therefore, professionals involved in the long-term management of peo¬≠
ple with CVD need to be aware of their mental well-being, and its 
changes so, ideally, its assessment should be seamlessly integrated 
into routine care (Table 5). Supplementary data online, Tables S4‚ÄìS6
offer examples of targeted questions that might be helpful to address 
specific aspects of depression, anxiety, and PTSD during clinical 
encounters.
The intensity of symptoms may also change over time. A recent 
study of people without distress at the time of ICD implant found 
that 14.5% developed new-onset anxiety and 11.3% new-onset de¬≠
pression during 24 months of follow-up.146 One cue that might be 
helpful is to monitor scores at the time of first screening (e.g. 
when being implanted with the ICD), as people with a high score 
at that time are more likely to also have an increased score at 
follow-up.240
The value of routine screening is still debated, therefore robust 
mandates have been avoided. The Comparison of Depression 
Interventions After Acute Coronary Syndrome: Quality of Life 
(CODIACS-QoL) RCT is one of few studies where screening for 
depression within 2‚Äì12 months post-ACS with or without providing 
depression treatment, did not alter quality-adjusted life years, 
depression-free days, or led to harm.235 Nonetheless, European and 
American Guidelines recommend assessment and screening for de¬≠
pression and anxiety (usually during hospitalization), although do 
not specify how often.132,241‚Äì244 Therefore, the optimal timing of 
screening within different CV conditions is not established. This 
Task Force considers it prudent to screen people after a new diagno¬≠
sis of CVD or a CV event, then periodically (e.g. annually and at least 
once during follow-up), and when clinical judgement indicates that it is 
needed (Table 5). Screening can be conducted during hospitalization if 
time permits.
6.2.2. Suggested approach to screening people with 
cardiovascular disease for psychological distress, 
depression, and anxiety
There are two ways in which people can be assessed: (i) by means of a 
clinical diagnostic interview, or (ii) screening by a questionnaire that can 
identify symptom levels but not deliver a diagnosis.
In clinical practice the diagnostic interview may be lengthy, requires 
specific expertise, and thus is likely untenable to perform as a routine 
practice in most clinical settings. However, given that elevated scores 
on a screening questionnaire as well as a diagnosis of depression or anx¬≠
iety increases the risk of morbidity, mortality, and poor QoL, question¬≠
naires are a reasonable starting point. High scores on a screening 
instrument should lead to referral to a mental health professional for 
assessment and/or diagnosis. Questionnaires also provide the means 
for monitoring changes in symptoms over time. As noted previously, 
there are several options with respect to questionnaires to choose 
from and it is important to know the reliability, validity, and appropriate 
usage of the instruments.
6.2.3. Challenges in specific cardiovascular conditions
In people with HF, depression and anxiety can easily be overlooked in 
routine care due to overlapping symptoms, such as fatigue, apathy, lack 
of energy, and sleep disorders. Thus, there is a risk that both people 
with HF and healthcare professionals may misinterpret the situation. 
Depression and anxiety can also be considered ‚Äònormal‚Äô reactions to 
the clinical and prognostic burden of HF. Although routine screening 
for mental health conditions using validated questionnaires and tools is 
advised during hospitalization and follow-up,29,241 it is still not clear 
when and where to screen people with HF. The diagnosis of mental 
health conditions can also be affected by the continuous fluctuations of 
HF symptoms that can interfere with mood and psychology.241,245,246
Table 5 Timing and tools for screening anxiety and depression symptoms
Timing of screening
Measurement
Anxiety symptoms
Depressive symptoms
(1)
Following a new diagnosis of CVD, a CV event or procedure. 
May be during hospitalization.
(2)
At follow-up (e.g. annually) to determine change from 
baseline or previous measurement
(3)
Anytime based on clinical judgement
GAD-2 followed by GAD-7 if positive
PHQ-2 followed by PHQ-9 if positive
¬© ESC 2025
CV, cardiovascular; CVD, cardiovascular disease; GAD, Generalized Anxiety Disorder; PHQ, Patient Health Questionnaire.
Table 4 Psychometric properties of screening tools for anxiety and depression symptoms
Psychometric property
Whooley questionsa
GAD-2b
PHQ-2b 
‚â•2 points
Sensitivity
95% (95% CI 88‚Äì97)
91%
97%
Specificity
65% (95% CI 56‚Äì74)
37%
48%
¬© ESC 2025
CI, confidence interval; GAD, Generalized Anxiety Disorder; PHQ, Patient Health Questionnaire.
aValidated in an unrestricted population, i.e. not specifically CVD.232
bValidated in an Australian population.238


<!-- PAGE 23 -->

### Page 23

Psychosocial assessment is an essential component of the evaluation 
of candidates for VAD, mainly aimed at identifying targets for treatment 
and improvement before the procedure, but also identifying potential 
contraindication in some candidates (e.g. uncontrolled psychiatric con¬≠
ditions, consistent non-adherence, active substance abuse). A consen¬≠
sus document on psychosocial assessment in advanced HF,247
endorsed by multiple societies, defined the main domains to evaluate as: 
‚Ä¢ Risk factors for poor post-HTx or VAD outcomes.
‚Ä¢ Capacity to engage in decision-making.
‚Ä¢ Personal and environmental resources.
‚Ä¢ Capacity to operate VAD.
Two scores have been used for psychosocial assessment in HTx: 
the Psychosocial Assessment of Candidates for Transplantation 
(PACT) and the Stanford Integrated Psychosocial Assessment for 
Transplantation (SIPAT). Both have shown good predictive capacity to 
identify people at risk of post-HTx non-adherence and psychosocial 
complications,248,249 although their impact on clinical outcomes is un¬≠
clear. These tools have not been validated in the VAD population.
Quality of life and mental health assessment are needed in people 
with pulmonary hypertension (PH) due to the high reported preva¬≠
lence of depression and anxiety (see Section 5, Tables 1 and 2), but there 
is lack of evidence on the ideal timing or specific method. The HADS 
may be a useful tool, since it was able to rule out anxiety and depression 
disorder with a negative predictive value of 90% in a PH population.250
6.2.4. Assessment of subjective well-being and quality 
of life
The WHO-5 questionnaire, available in 30 languages,251,252 can be used 
to assess SWB and does not require a license fee. A percentage score 
<50 (or a raw score <13) has been suggested as a cut-off for poor men¬≠
tal well-being and as an indication for further assessment for the pos¬≠
sible presence of a mental health condition (e.g. depressive disorder).
Patient-reported measures such as QoL are seen as essential in clin¬≠
ical practice as well as in clinical trials as ways to assess symptoms, func¬≠
tion, well-being, perspectives, and undisclosed problems. Several 
disease-specific QoL instruments are available, valid in specific condi¬≠
tions such as HF, ischaemic heart disease (IHD), AF, congenital heart 
disease, and PH. Generic measures such as the Short-Form 12 or 36 
or EuroQol 5-Dimension (EQ-5D) questionnaire are often used as 
well. Most QoL instruments include items related to mental health sta¬≠
tus as well as physical health, which can alert a healthcare professional 
to a need for screening for mental health conditions. These instruments 
are being incorporated into electronic medical records in some sys¬≠
tems, but implementation of regular QoL assessment is hindered by 
limited integration into clinical practice and interpretation of scores. 
However, electronic medical records and automated systems should 
in future simplify assessment of well-being, QoL, and mental health con¬≠
ditions at regular intervals. A full list of these measures can be found in a 
recent ESC statement on ‚ÄòPlacing patient-reported outcomes at the 
centre of CV clinical practice‚Äô.239
6.3. Management of mental health 
conditions in people with cardiovascular 
disease
Given the negative impact of poorer mental health on adherence to 
medication and lifestyle, QoL, prognosis, and costs, people with an in¬≠
creased symptom score on anxiety and/or depression questionnaires 
and those with a diagnosis of anxiety disorder, depression, or PTSD, 
should be considered potential candidates for receiving treatment. 
Although evidence is sparse that people with CVD screened for anxiety 
and depression and treated afterwards have a better prognosis,235 there 
are a few promising studies. A retrospective cohort study of people 
with depression who received psychotherapies via primary care services 
(n  = 636 955), reported that intervention-driven improvements in 
depression symptoms were associated with a lower risk of any-cause 
new-onset CVD (HR 0.88; 95% CI 0.86‚Äì0.89). Subanalyses suggested 
the association was greater in those <60 years of age.253 In recognition 
of the different levels of stress, anxiety, depression, and PTSD experi¬≠
enced, and therefore the different needs with respect to treatment, a 
stepped care approach (Figure 9) would be one way forward.254‚Äì257
Stepped care takes into account people‚Äôs preferences and can be adapted 
to symptom severity and resources available, and does not mean that all 
earlier steps need to be done before accessing higher level support.
6.3.1. Communication, education, and support for 
people with mental health conditions and 
cardiovascular disease
Effective communication is a cornerstone of healthcare delivery, foster¬≠
ing person-centred care, and addressing the complex interplay between 
mental and physical health.258 Proportional stress, anxiety, or fear may 
be normal reactions after a diagnosis of CVD, acute CV events, CV pro¬≠
cedures or interventions, or their complications. Empathy and active lis¬≠
tening are essential to understanding the potential difficulties and 
worries the person with CVD and their family members may face. It 
is important to recognize that challenges may not only be due to the 
physical consequences of CVD or its therapy. Rather, healthcare pro¬≠
fessionals must appreciate the full spectrum of mental and emotional 
consequences, as well as the impacts this may have on lifestyle, profes¬≠
sional, family, social, or economic factors as presented in the associated 
‚ÄòClinical cases and patient perspectives‚Äô document. Healthcare profes¬≠
sionals should ensure that people receive support for both physical and 
mental health needs, preventing or attenuating unwanted psychological 
or emotional reactions, and potentially improving therapeutic adher¬≠
ence and clinical outcomes.259
Open dialogue with people with CVD, family, and caregivers, 
adapted to their age, cultural level, beliefs, and preferences, is essen¬≠
tial.260 Answering questions, solving doubts and clarifying uncertainties 
is a key aspect of therapeutic relationships and may help prevent mis¬≠
understandings and irrational fears.261 While in ECR programmes there 
is more time and opportunity for communication, this may be challen¬≠
ging to deliver in acute or critical care and in outpatient care, where 
time pressure is constant. In these settings, time for high-quality com¬≠
munication should be facilitated.
Multiple individual, professional, condition-specific, and organization¬≠
al factors including health literacy, mental health issues, and time pres¬≠
sures, impact the quality of communication. The impact of mental 
health on communication may be particularly strong in people with 
SMI. Shared decision-making (SDM), in which the person coping with 
CVD and professionals discuss evidence and options for treatment, 
and people are supported to make informed decisions, is dependent 
on good communication. A systematic review and meta-analysis of in¬≠
terventions to increase SDM in CVD found that the interventions re¬≠
duced decisional conflict and increased knowledge across a wide 
range of CVD conditions and formats.262
Compassion in CVD care is an important element in communication 
and understanding. More information on compassionate care can be 
ESC Guidelines                                                                                                                                                                                               23


<!-- PAGE 24 -->

### Page 24

found in supplementary data online, and Table S7. Caregivers and family 
involvement can improve mental well-being and CV outcomes; a para¬≠
digm shift in the organization of care may be needed to include the per¬≠
son‚Äôs social environment into treatment. More information can be 
found in the supplementary data online.
6.3.2. Psychological interventions
A broad range of strategies, from cognitive-behavioural therapy (CBT), 
psycho-education, and mindfulness-based techniques to lifestyle modi¬≠
fication programmes and support groups, including internet-based in¬≠
terventions and mobile health (mHealth) solutions, have been 
proposed as psychological therapeutic options for people with CVD.263
6.3.3. Psycho-education
Psycho-education is an intervention with structured knowledge trans¬≠
fer about an illness and its treatment, integrating emotional and motiv¬≠
ational aspects to enable people to cope with the illness and to improve 
its treatment adherence and effectiveness.264 It is considered an im¬≠
portant component of treatment in both medical and mental health 
conditions.265 A psycho-educational approach is already embedded 
within multiple CV care settings, including ECR and secondary preven¬≠
tion programmes. It includes education on the underlying disease and 
current risk factors and suggestions for lifestyle modifications. Based 
on the results of a recent synthesis of RCTs (n = 8748 people 
post-MI or revascularization), a psycho-educational approach should in¬≠
tegrate several modes of delivery and preferably last for at least 3 
months.266 The effects of psycho-educational interventions on depres¬≠
sion and anxiety symptoms when combined in meta-analysis are large 
based on accepted thresholds.267
For people with arrhythmias and/or ICD for primary or secondary 
prevention, there are physical symptoms, such as sleep disturbance, fa¬≠
tigue, and also psychological fears (fear of shocks, worry about the fu¬≠
ture, and fear of ICD dysfunction) affecting QoL. Psycho-education 
improved the physical component summary of QoL but had no effect 
on mental component summary scores.268 In people with AF, 








	


¬Å


¬ç¬è
¬è¬è
¬ê¬ç¬ç
¬è
¬è
¬è
¬ç
¬ç¬è
¬è
¬è


¬è
¬ç
¬ç¬è
¬è









	
Figure 9 Stepped care model for assessment and management of mental health conditions in people with cardiovascular disease. CV, cardiovascular; 
CVD, cardiovascular disease; GAD, Generalized Anxiety Disorder; PHQ, Patient Health Questionnaire. Adapted from Pedersen et al with 
permission.254


<!-- PAGE 25 -->

### Page 25

reductions in serious adverse events [risk ratio (RR) 0.78; 95% CI 0.63‚Äì 
0.97], anxiety, depression, and health-related QoL (HRQoL) were ob¬≠
served with psycho-education, although the incidence of AF episodes 
was not affected.269
6.3.4. Social prescribing
Social prescribing is a transformative healthcare approach that connects 
people with non-medical resources to enhance their holistic well-being. 
The core idea behind social prescribing is to provide people with per¬≠
sonalized interventions that extend beyond traditional medical pre¬≠
scriptions, encompassing a spectrum of community-based activities 
and resources.270,271 The aim is to address diverse aspects of mental 
health, such as social isolation, loneliness, stress, and anxiety, by facilitat¬≠
ing access to supportive community activities. Social prescribing le¬≠
verages a variety of activities, ranging from arts workshops, music 
therapy, and group dance sessions to support networks, to enhance 
mental well-being and cultivate a sense of belonging and purpose.
Engagement in community activities, such as group dance, hiking, 
and cooking classes, combats feelings of isolation and fosters meaningful 
social interactions, thereby bolstering mental well-being.272,273
These community connections act as protective factors against stress 
and isolation, potentially enhancing mental health support for people 
with CVD. This can lead to reductions in depressive symptoms, im¬≠
provements in QoL, and better adherence to CV treatment plans.270
A systematic review of 17 studies involving 13 social prescribing inter¬≠
ventions with a total of 5036 participants found statistically significant 
improvements in mental health, general well-being, and QoL in 16 
of the studies.274 Despite these promising findings, more research fo¬≠
cusing specifically on people with CVD is necessary to draw reliable 
conclusions.
Interventions involving social professionals were found to be more 
effective for reducing anxiety and depression, while those involving 
health professionals had a greater impact on improving blood pressure 
and encouraging physical activity.275 Participating in arts, including visual 
art therapy and music therapy, has shown positive effects on mood and 
emotional regulation.276 Music, in particular, can be a powerful tool in 
reducing stress and enhancing mood in people with CVD. Activities 
such as gardening, green exercise, and nature walks have been effective 
in reducing systolic and diastolic blood pressure and have demonstrated 
moderate to large effects on depression and anxiety scores.275,277
These interventions also increase daily step counts, though the overall 
impact on physical activity time is still being evaluated.
Technology plays a pivotal role in facilitating social prescribing. 
Mobile apps and online platforms can recommend suitable social pre¬≠
scriptions based on personal profiles and mental health assessments, 
serving as valuable resources for people to explore options, engage 
in virtual support groups, and track their progress.278 Real-time data 
collection through these platforms allows healthcare professionals to 
monitor engagement and outcomes more effectively.279 Integrating so¬≠
cial prescribing into standard care pathways, fostering community part¬≠
nerships, and leveraging technology ensures efficient and personalized 
recommendations. This approach aligns with modern healthcare para¬≠
digms, emphasizing holistic well-being and personalized interventions, 
particularly for people with CVD dealing with mental health concerns, 
although more research is needed.280 There is growing evidence sup¬≠
porting the use of social prescribing in the management of CVD. 
Healthcare professionals should be aware of local social prescribing in¬≠
terventions and availability in their environment and refer when 
appropriate.
6.3.5. Other psychological interventions
A Cochrane systematic review and meta-analysis of RCTs of psycho¬≠
logical interventions for CHD including relaxation, cognitive techni¬≠
ques, emotional support and/or client-led discussion, and adjunct 
pharmacology, reported a reduction in CV mortality (from 7.3% to 
5.5%) with psychological interventions compared with usual care con¬≠
trols.281 No between-group differences were observed for the rates 
of total mortality, non-fatal MI, or revascularization procedures. 
Psychological interventions were found to achieve small to moderate 
improvements in depressive symptoms, anxiety, and stress compared 
with controls, although there remains some uncertainty in these 
estimates.281
Cognitive-behavioural therapy is a psychological intervention that fo¬≠
cuses on changing patterns of unhelpful thinking and behaviour.282 Two 
recent systematic reviews and meta-analyses assessing the efficacy of 
CBT-based interventions in RCTs in people with CAD showed that 
CBT-based interventions can reduce CV events, MI, and angina dur¬≠
ation and intensity at the end of follow-up. Findings varied by trials, 
with no effect on other clinical outcomes,283 but improving significantly 
psychological outcomes, such as depressive symptoms, anxiety, depres¬≠
sion, stress, and increasing vital satisfaction at the end of follow-up.284
A recent study assessing the effect of CBT has shown efficacy in im¬≠
proving AF-specific QoL for people with symptomatic paroxysmal AF. 
AF-CBT led to large improvements, reducing healthcare-related con¬≠
sumption by 56%, although the AF burden remained unchanged.285 A 
further RCT testing a CBT intervention in young people with CAD 
showed improvement in the total HADS score after 3 months, with dif¬≠
ferences maintained after 6 months. The intervention group also had 
greater adherence to ECR and more improvement in HRQoL at 6 
months. A significant reduction in CVD-related admissions at 12 
months was also observed.286
Recently, a multicentre study in which 250 people with AMI were 
randomized after PCI to either control or cognitive-behavioural stress 
management detected that the latter improves anxiety, depression, 
and QoL but does not affect MACE.287 However, another trial of 
362 people who had experienced a CVD event randomized to usual 
care or usual care plus CBT, found that CBT decreased the risk of re¬≠
current events including MI.288 Cognitive-based or external support 
coping mechanisms seem to attenuate the mental impact of PH, de¬≠
creasing anxiety or depression rates.289 This suggests a potential 
benefit for early identification and psychological intervention. In 
fact, psychosocial support has a Class I recommendation in the cur¬≠
rent ESC/European Respiratory Society (ERS) Guidelines for the diag¬≠
nosis and treatment of pulmonary hypertension,290 and is endorsed in 
the 2024 ESC Guidelines for the management of chronic coronary 
syndromes.242
Cognitive-behavioural therapy is safe and has shown to have benefi¬≠
cial effects in improving mental symptoms, in particular depression, and 
QoL in people with CVD and HF, and it could be a valid option due to 
the lack of potential side effects or drug interactions. However, a small 
qualitative study found that some people reported side effects, includ¬≠
ing discomfort with treatment and worsening of symptoms.287,289,291
Exposure therapy can be helpful for people with CVD, who due to 
their disease stop doing the things that they used to enjoy due to fear of 
another CV event, which may lead to depression. An example is a per¬≠
son who experiences an out-of-hospital cardiac arrest (OHCA) while 
cycling. Often this will cause anxiety and fear of taking up cycling again, 
as cycling is associated with OHCA. However, exposure therapy, 
where the therapist exposes the person gradually and in a safe way 
to situations and activities that they fear, is often helpful.292
ESC Guidelines                                                                                                                                                                                               25


<!-- PAGE 26 -->

### Page 26

Similarly, behavioural activation uses behaviours to influence emo¬≠
tional state as engaging in activities that increase social connections 
and feelings of well-being can decrease depression. A pragmatic RCT 
in 416 people with HF and comorbid depression compared the effect¬≠
iveness of antidepressant medication vs behavioural activation psycho¬≠
therapy. Both groups experienced equal benefits with close to a 50% 
reduction in depressive symptoms at 3, 6, and 12 months.293 People re¬≠
ceiving behavioural activation psychotherapy had significantly better 
physical HRQoL and HF-specific HRQoL. Although there is limited evi¬≠
dence within CVD, some people have reported that philosophical 
counselling (Supplementary data online, Table S8) can be a complemen¬≠
tary approach to other therapeutic strategies.
6.3.6. Interventions for people with post-traumatic 
stress disorder
Limited evidence on the prevention and management of CDI-PTSD is 
available. A comparison of eye movement desensitization and repro¬≠
cessing (EMDR) with imaginal exposure in 42 people with PTSD in¬≠
duced by life-threatening CV events, including surgery, MI, and 
cardiac arrest, showed EMDR significantly reduced CDI-PTSD symp¬≠
toms at 4 weeks and 6 months.294 Fifty-one people with PTSD symp¬≠
toms due to a CV event randomized to imaginal exposure or control 
group reported improved PTSD symptoms compared with the control 
group, although this difference was not statistically significant due to the 
small sample size. This initial study in the field of exposure psychothera¬≠
pies provides promising evidence for the safety of using this technique 
in people with CVD.295
In a more recent RCT designed to determine if trauma-focused 
counselling within 48 h of hospital admission could prevent the devel¬≠
opment of PTSS, 190 people with ACS experiencing distress were as¬≠
signed to either trauma-focused counselling (one session) or a general 
stress management active control group. Results showed fewer bene¬≠
ficial effects for the trauma-focused counselling group compared with 
the control group.296
6.3.7. Lifestyle interventions
Adopting a holistic approach that includes lifestyle changes can effect¬≠
ively improve mental health, CV well-being, risk factors, and CV out¬≠
comes.297‚Äì302 Examples of lifestyle changes include regular physical 
activity, a balanced diet, stress management techniques (such as mind¬≠
fulness and yoga), adequate sleep, and positive coping strategies.303,304
6.3.8. Physical activity and exercise in people with 
cardiovascular disease and mental health conditions
Physical activity encompasses a wide range of bodily movements that 
increase energy expenditure, including everyday tasks such as walking, 
household chores, and active commuting. Exercise is a more structured 
and purposeful form of physical activity designed to enhance or main¬≠
tain physical fitness. The benefits of exercise in people with CVD ex¬≠
tend beyond improving physical health; it also significantly enhances 
psychological well-being, including reassurance in those who are con¬≠
cerned for potential recurrences of their event or worsening of their 
disease. Exercise induces the release of endorphins and other neuroac¬≠
tive substances, contributing to mood improvement and stress reduc¬≠
tion.305 These effects are particularly beneficial for people with CVD, 
who often face psychological challenges in addition to their physical 
health issues.306 In people with CAD and depression, exercise has 
been shown to be an effective component of treatment. A network 
meta-analysis (33 RCTs, n = 7240) demonstrated that exercise, when 
combined with antidepressants and psychotherapy, significantly re¬≠
duced depressive symptoms at 8 weeks. The study suggested that while 
antidepressants remained effective at 26 weeks, the addition of exercise 
could enhance overall treatment efficacy.307
For people with HF, the Heart Failure-A Controlled Trial 
Investigating Outcomes of Exercise Training (HF-ACTION) demon¬≠
strated that exercise training led to a modest but significant decline in 
depression symptoms at both 3 and 12 months, as evidenced by im¬≠
provements in the Beck Depression Inventory score in the exercise 
group. The study emphasized that while exercise is beneficial, the 
type and duration should be tailored to functional capacity, with consid¬≠
erations for independent or supervised exercise programmes.308,309
In summary, exercise is a critical component of managing CVD in 
adults, particularly for those with HF and CAD. Its benefits include im¬≠
provements in both physical and mental health, which are crucial for en¬≠
hancing the overall QoL in people with CVD.
6.3.9. Diet and nutrition approaches in cardiovascular 
disease and mental health conditions
Dietary interventions and nutritional strategies hold promise for im¬≠
proving both CVD310 and mental health outcomes in individuals with 
CVD. However, the current evidence specifically addressing mental 
health improvements through dietary changes in this population is lim¬≠
ited, highlighting the need for more robust and targeted research to es¬≠
tablish clear recommendations.
Several dietary patterns have been explored for their potential men¬≠
tal health benefits in people with CVD. The Mediterranean diet, rich in 
fruits, vegetables, whole grains, and healthy fats, has been associated 
with lower rates of depression and cognitive decline in the general 
population, but data specific to people with CVD are still emer¬≠
ging.311,312 Some studies suggest that the anti-inflammatory properties 
of this diet could be beneficial, yet conclusive evidence in CVD popula¬≠
tions is lacking.313,314
Fasting interventions, including intermittent fasting and calorie re¬≠
striction, have also been examined for potential to improve mental 
health. While some studies report encouraging results, such as im¬≠
provements in mood and cognitive function, these findings are prelim¬≠
inary. The evidence is not yet strong enough to endorse one fasting 
method over another, particularly for individuals with psychiatric 
conditions.314,315
The Omega-3 Supplementation for Co-Morbid Depression and 
Heart Failure Treatment (OCEAN) trial reported that supplementa¬≠
tion with eicosapentaenoic acid and docosahexaenoic acid in people 
with HF (n = 108) led to positive changes in cognitive depressive symp¬≠
toms and social functioning. However, the small sample size and the use 
of soft endpoints suggest that these findings should be interpreted with 
caution, and larger, more definitive trials are needed.316
While dietary approaches and nutritional interventions are appealing 
for their potential dual benefits on CV and mental health in people with 
CVD, current evidence is insufficient to advise on diet interventions. 
More rigorous studies are needed to determine the most effective diet¬≠
ary strategies for improving mental health outcomes in this population.
6.3.10. Smoking cessation
Tobacco cessation offers significant CV health benefits, particularly for 
individuals with mental health conditions, including those with SMI. 
However, addressing tobacco use in this population is challenging due 
to the complex interplay between addiction and mental health issues. 
Sustained tobacco abstinence over 52 weeks can significantly reduce


<!-- PAGE 27 -->

### Page 27

the 10 year CV risk in people with SMI.317 Despite these CV benefits, 
individuals often face significant challenges post-cessation, such as not¬≠
able weight gain, which can contribute to high rates of obesity, diabetes, 
and hypertension.318 The addictive nature of tobacco use, especially in 
individuals with mental health conditions, necessitates treating tobacco 
use as an addiction and addressing it with comprehensive strategies.
Addressing tobacco cessation in individuals with mental health con¬≠
ditions requires a tailored approach. The Five A‚Äôs model (Ask, Advise, 
Assess, Assist, Arrange) is a structured method commonly used to en¬≠
courage and support tobacco cessation. However, it should be adapted 
to meet the unique needs of those with mental health conditions. For 
instance, healthcare professionals should be particularly attentive when 
assessing a person‚Äôs readiness to quit, considering his or her mental 
health status, and providing additional support and resources that ad¬≠
dress both their tobacco use and mental health needs.
Cognitive therapies, when combined with medication, have been 
shown to improve tobacco abstinence rates in adults, including those 
with mental health conditions. A review of 21 RCTs found that cogni¬≠
tive therapies combined with medication or nicotine replacement ther¬≠
apy are more effective than medication alone, although the quality of 
evidence varied.319 While tobacco cessation is crucial for improving 
CV and overall health in people with mental health conditions, it re¬≠
quires a nuanced and supportive approach that considers the complex¬≠
ities of addiction in this population.
6.3.11. Stress management techniques
Mindfulness,320 meditation,321 and progressive muscle relaxation322‚Äì324
are stress management techniques that have shown promise in foster¬≠
ing cognitive resilience, emotional regulation, and relaxation. However, 
their specific effects on people with CVD need careful consideration 
and evidence-based discussion.325‚Äì327
Mindfulness involves focused attention on the present moment, 
fostering cognitive resilience against stressors and aiding emotional regu¬≠
lation.320 A study of mindfulness on people with CVD showed improve¬≠
ments in psychological well-being and CV markers.325 Mindfulness-based 
interventions for adults aged 19 to 40 years in developed countries, in¬≠
cluding mindfulness-based stress reduction programmes, mindfulness- 
based cognitive therapy programmes, and the Learning 2 BREATHE 
(Body, Reflections/thoughts, Emotions, Attention, Tenderness, Habits, 
Empowerment) programme, generally improve well-being and can be ef¬≠
fectively implemented in a virtual format.325
Meditation focuses on controlled breathing or visualization, trigger¬≠
ing the parasympathetic nervous system to induce relaxation and re¬≠
duce stress hormones.321 A meta-analysis indicated that distress 
management, when combined with ECR, offers limited additional ef¬≠
fects, suggesting that meditation should be integrated cautiously with 
existing ECR programmes.328 A further study showed that meditation 
can reduce stress and improve CV health outcomes in people with 
CVD.326 Meditation and mindfulness, especially evidence-based forms 
like mindfulness-based stress reduction, can support people with 
CVD and their caregivers to reduce anxiety, depression, and pain. 
These practices have shown structural and functional brain changes, 
translate well across different populations, and offer a low-cost, bene¬≠
ficial method to complement treatment during this crisis.326
Progressive muscle relaxation involves sequentially tensing and re¬≠
leasing muscle groups to promote physical and mental relaxation, coun¬≠
tering stress-induced physiological manifestations such as elevated 
heart rate, increased blood pressure, and muscle tension.322‚Äì324
A study demonstrated that progressive muscle relaxation could reduce 
anxiety and improve heart rate variability in individuals with CVD.327
6.3.12. Sleep hygiene
Sleep quality is integral to both CV health and mental well-being, particu¬≠
larly in individuals with CVD. Poor sleep quality and insufficient sleep dur¬≠
ation are linked to various adverse CV outcomes, including mortality,329
atherosclerosis,330 hypertension, impaired glucose metabolism, and in¬≠
creased inflammatory markers, and associated with an elevated risk of 
mental health conditions such as depression and anxiety, which can fur¬≠
ther complicate the management of CVD.331‚Äì333 It is important for 
healthcare professionals to routinely inquire about sleep quality during 
clinical evaluations, given the significant impact of sleep on both CV 
and mental health. Interventions that improve sleep quality such as sleep 
hygiene measures and CBT for insomnia have been shown to improve 
mental health conditions.331 Healthcare professionals should encourage 
people to adopt specific sleep hygiene practices, such as maintaining a 
consistent sleep schedule, avoiding stimulants like caffeine or nicotine 
close to bedtime, limiting screen exposure in the evening, and creating 
a restful sleep environment with minimal noise and light.331 While wear¬≠
ables like smartwatches offer insights into sleep patterns, their diagnostic 
accuracy remains limited, and they should be complemented by validated 
clinical assessments and evidence-based interventions.
6.4. Tools and resources to support 
lifestyle change
6.4.1. Digital health tools
Among the many new mobile apps released every day for monitoring 
personal health data, only a minority have been scientifically validated 
on healthcare behavioural and clinical outcomes in the CV field. A sys¬≠
tematic review encompassing 39 studies of wearable devices in multiple 
CVDs found potential benefits mainly in lifestyle aspects like physical ac¬≠
tivity and smoking cessation. However, the same review highlighted 
safety, reliability, and regulation concerns.334 A systematic review and 
meta-analysis of mobile phone and mHealth interventions in people 
who had experienced a coronary event (20 studies, n = 4535) reported 
benefits in exercise capacity, physical activity, reductions in all-cause and 
CV readmissions, and improved physical and mental QoL.335 A 
meta-analysis evaluating the efficacy of a digital health intervention in peo¬≠
ple with CVD showed that telemonitoring reduced depression in people 
with HF and CAD, and device-based psychological education and training 
had a significant positive effect in reducing depression in people with 
CAD or ICD. Although the use of information and communication tech¬≠
nologies for health (eHealth) in daily practice is promising, there are still 
several barriers, including reimbursement challenges, digital literacy is¬≠
sues, and unequal access to digital technology (digital divide) in low- 
income countries or in remote areas as well as in the elderly.336
6.4.2. Motivational interviewing
Motivational interviewing (MotInt) is a person-centred counselling style 
for addressing the common problem of ambivalence about healthy life¬≠
style changes. It can be an effective counselling approach that bolsters 
motivation by resolving ambivalence. Motivational interviewing has 
shown efficacy in helping to make healthy behavioural changes and con¬≠
trol CV risk factors with some evidence that shows an effect on the 
management of depression.337 More information about MotInt can 
be found in the supplementary data online.
ESC Guidelines                                                                                                                                                                                               27


<!-- PAGE 28 -->

### Page 28

6.4.3. Cardiac rehabilitation
Cardiac rehabilitation is a comprehensive multicomponent programme 
of secondary prevention aiming to reduce CVD risk and optimize 
health and well-being. A key component of most cardiac rehabilitation 
programmes is structured exercise (ECR) along with other compo¬≠
nents such as assessment, education, psychosocial support, informa¬≠
tion, behavioural interventions, and risk factor management.338,339
Meta-analyses have shown that ECR is effective in improving mortality, 
morbidity, and HRQoL outcomes across multiple CV conditions,340‚Äì344
but few meta-analyses provide evidence of improvement in measures 
of mental health.343‚Äì345 These have found only weak evidence and small 
effects of ECR on depression and anxiety symptoms in people with 
CVD, even when psychological interventions were added.328,344‚Äì346
These results may be surprising given that psychosocial management 
is one of the core components of comprehensive ECR,347 and exercise 
has been shown to have beneficial effects on the risk for and symptoms 
of depression and anxiety. Possible explanations include lack of sys¬≠
tematic measurement of mental health outcomes, lack of recruitment 
of people with mental health conditions, and reluctance of people with 
mental health conditions to attend ECR or participate in studies. 
Screening for depression and anxiety in ECR is advocated,348 but has 
been found to be inconsistently implemented with variation across 
conditions and services.349 A position statement from the European 
Association of Preventive Cardiology (EAPC)348 advises screening 
for mental health conditions and referral to a psychologist or psych¬≠
iatrist when needed.
Exercise-based cardiac rehabilitation has the potential to benefit 
people with mild to moderate symptoms of depression, anxiety, 
and stress, but studies and evaluation are essential. One recent 
RCT trained ECR staff to deliver metacognitive therapy to people with 
CVD (n = 332) and demonstrated significant small to moderate improve¬≠
ment in depression and anxiety scores compared with ECR alone.350
Suggestions for ensuring mental health benefit from ECR include: 
‚Ä¢ Screening for mental health conditions by ECR staff at the start and 
end of programme.
‚Ä¢ Improving the implementation of screening through Guidelines com¬≠
bined with local/national initiatives to support screening.351
‚Ä¢ Determining optimal interventions in ECR to improve symptoms of 
mental health conditions, including who should deliver these.
‚Ä¢ Collaborating with mental health experts to ensure psychosocial 
support in ECR is robust and that referrals can be made when 
appropriate.
‚Ä¢ Evaluating mental health symptoms as an outcome in ECR. The EAPC 
advocates a goal of improvement of depression and anxiety symptom 
scores by 10% on valid measures.348
6.5. Medical interventions
Medical interventions including pharmacotherapy may be needed for 
people with CVD with diagnosed mental health conditions and for peo¬≠
ple with severe symptoms of depression, anxiety, or PTSD. Careful as¬≠
sessment of the risks and benefits and open dialogue as recommended 
in Section 6.3 will facilitate decision-making.
6.5.1. Efficacy and safety of pharmacological 
treatment for mental health conditions in people 
with cardiovascular disease
Studies evaluating the effectiveness of pharmacological treatment for 
mental health conditions in CV populations have shown inconsistent 
results. A systematic review and meta-analysis of 10 RCTs of anti¬≠
depressant treatment following ACS found no general improvement 
in all-cause mortality and recurrent MI while the risk of repeat hospital¬≠
ization was significantly reduced. However, in people with a concomi¬≠
tant diagnosis of depression, antidepressants decreased the odds of 
recurrent MI.352 A Cochrane review examining trials on psychological 
treatments and antidepressant drugs in adults with CAD and comorbid 
depression concluded that pharmacological interventions may have a 
large effect on end-of-treatment depression symptoms, while effects 
on mortality or CV endpoints were deemed uncertain.353
Studies on the safety of antidepressant medication in HF have yielded 
conflicting results. One meta-analysis indicated that the use of antide¬≠
pressants in people with HF is associated with an increased risk of all- 
cause death regardless of whether they have clinical depression or the 
type of antidepressants used.354 In contrast, a recent meta-analysis re¬≠
viewing studies of people with depression and known HF in both out¬≠
patient and hospital settings indicated that selective serotonin reuptake 
inhibitors (SSRIs) seem to be a safe treatment option.355 This analysis, 
however, was limited by the variety of study designs and mixed results 
for different antidepressants.
Given the inconsistency of findings across studies on the effective¬≠
ness of pharmacological treatment for mental health conditions in peo¬≠
ple with CVD, there is a clear need for larger and robust RCTs. 
Concerns about drug safety, CV side effects, and interactions between 
psychiatric medications and CVD treatments complicate this manage¬≠
ment and need to be clarified in future research.
6.5.2. Use of specific medications in people with 
depression, anxiety, or post-traumatic stress 
disorders and cardiovascular disease
In the treatment of depression, anxiety, and PTSD, antidepressants are 
the first-line pharmacological treatment, while additional medications 
including anxiolytics, sedatives, and hypnotics, may be used in the short 
term. Other drugs, such as mood stabilizers and antipsychotics, may 
also be used, depending on the severity of symptoms. A brief descrip¬≠
tion of the most common medications used for the treatment of mental 
health conditions is given in Supplementary data online, Table S9. 
Figure 10 provides an algorithm for the pharmacological treatment of 
depression, anxiety, and PTSD in CVD.
6.5.3. Use of antidepressants
‚Ä¢ The use of antidepressants in CVD populations requires careful se¬≠
lection of medications, dosage adjustments, and close monitoring 
due to potential side effects and clinically relevant drug interactions. 
In general, newer antidepressants are considered safe and asso¬≠
ciated with few serious long-term side effects in people with 
CVD.356‚Äì358 However, CVD side effects may occur and are typically 
exerted through noradrenergic activation resulting from the use of 
serotonin and norepinephrine reuptake inhibitors (SNRIs), nor¬≠
epinephrine reuptake inhibitors, noradrenergic and specific seroto¬≠
nergic antidepressants, that can cause orthostatic hypotension or 
hypertension.359
‚Ä¢ Weight gain (e.g. through mirtazapine use) may worsen CV risk.
‚Ä¢ QTc prolongation can increase the risk of polymorphic ventricular 
arrhythmias, which has been associated with some tricyclic antide¬≠
pressants (TCAs), SSRIs, and other antidepressants and bupropion, 
although the evidence is inconsistent.360 A large population study 
did not find an increased risk of arrhythmias for citalopram.361 A net¬≠
work meta-analysis demonstrated a low risk of ventricular


<!-- PAGE 29 -->

### Page 29

People with depression, anxiety or post-traumatic stress disorders
In remission or with mild symptoms
Moderate or severe according to
ICD-11 criteria 
Already on psychotropic therapy?
Psychiatric consultation
OÔ¨Äer psychological support or counselling  
Screening
New psychotropic/antidepressant medication.
Choice based on:  
‚Ä¢ Severity of 
 psychiatric 
 symptoms
‚Ä¢ Treatment 
 beneÔ¨Åt
‚Ä¢ Possible 
 medication 
 interactions
‚Ä¢ Possible CV
 side eÔ¨Äects
‚Ä¢ Lifetime 
 CVD risk
‚Ä¢ Comorbidities
‚Ä¢ Patient 
 preferences
‚Ä¢ Introduce SSRIs, SNRIs, or newer antidepressants 
 (excluding esketamine) for up to 4 weeks.
‚Ä¢ Gradual discontinuation of benzodiazepines is recommended 
 if used >1 month.
‚Ä¢ Avoid antidepressants in HF, except in severe depression 
 where risks of untreated depression outweigh HF risks.
Continuing medication or re-assessment.
Consider switching medication if associated 
with:
All:
Assess and manage CVD risk factors (including medication if needed)
Behavioural interventions to support healthy lifestyles
Special considerations
‚Ä¢ Weight 
 gain
‚Ä¢ Diabetes
‚Ä¢ QTc 
 prolongation
‚Ä¢ Dyslipidaemia
Figure 10 Pharmacological management of cardiovascular disease and depression, anxiety, or post-traumatic stress disorders. CV, cardiovascular; 
CVD, cardiovascular disease; HF, heart failure; ICD, International Classification of Diseases; SNRI, serotonin and norepinephrine reuptake inhibitor; 
SSRI, selective serotonin reuptake inhibitor.  
ESC Guidelines                                                                                                                                                                                               29


<!-- PAGE 30 -->

### Page 30

arrhythmia and SCD among people using antidepressants like SNRIs, 
SSRIs, and especially TCAs.362 Some antidepressants (mirtazapine, 
venlafaxine, trazodone) were not found to prolong the QTc interval 
in healthy volunteers.363‚Äì365
‚Ä¢ Reduction of heart rate variability has been associated with TCA 
use.366,367
‚Ä¢ Temporary increase in blood pressure immediately after administra¬≠
tion has been described with esketamine, which is indicated for 
treatment-resistant depression, however, it is not associated with 
long-term development of hypertension.368
Importantly, several pharmacokinetic and pharmacodynamic interac¬≠
tions between antidepressants and CV drugs may affect the efficacy 
and safety of treatment. Therefore, therapeutic drug monitoring, de¬≠
fined as the measurement and interpretation of drug concentrations 
in blood to optimize pharmacotherapy, is proposed in special clinical 
scenarios. It is particularly useful in cases of non-response at thera¬≠
peutic doses, uncertain drug adherence, suboptimal tolerability, or 
pharmacokinetic drug‚Äìdrug interactions. In people with mental health 
disorders, therapeutic drug monitoring has additional applications 
ranging from strongly recommended to potentially useful including 
use in children and adolescents, pregnant women, elderly people, in¬≠
dividuals with intellectual disabilities, people with substance abuse dis¬≠
orders, forensic psychiatric conditions, or people with known or 
suspected pharmacokinetic abnormalities.369
Many antidepressants and CV drugs are metabolized by cytochrome 
P450 (CYP) enzymes leading to potential interactions, which are dose 
dependent and can be exaggerated by smoking (Supplementary data 
online, Table S10). Smoking is a potent inducer of CYP1A2 enzymes 
with maximal increase by 10 or more cigarettes per day and decrease 
of CYP1A2 activity within 3 days after smoking cessation.370,371
Potential risks for interactions between antidepressants and CV drugs 
include beta-blockers and calcium channel blockers. For example, SSRIs 
inhibit the enzyme activity phase of the CYP pathway by blocking the 
active site of certain CYP isoenzymes, thereby reducing the metabolism 
of other drugs. This may lead, for example, to increased plasma levels of 
metoprolol with a risk of bradycardia or hypotension. Furthermore, 
amiodarone inhibits CYP2C9, CYP2D6, and CYP3A4, leading to po¬≠
tential interactions with both SSRIs and TCAs, requiring careful moni¬≠
toring for side effects.369
Notably, SSRIs and SNRIs can increase bleeding risk.372 However, 
there is little evidence that SSRIs increase the risk of clinically relevant 
bleedings or mortality.373 Further, SSRI interactions via the CYP isoen¬≠
zyme system can potentially increase the effects of warfarin and thus, 
the risk of major bleeding requiring close monitoring and management 
of risk factors for bleeding in people treated with both SSRI and vitamin 
K antagonists like warfarin.374 Although studies suggest that direct oral 
anticoagulants have lower potential for pharmacokinetic interactions 
with SSRIs, caution is also required with concomitant use of SSRI and 
direct oral anticoagulants, which showed a similarly increased risk 
of major bleeding as vitamin K antagonists.375,376 Potential interactions 
between antidepressants and drugs for SMI are summarized in 
Supplementary data online, Table S9.
6.5.4. Use of anxiolytics, sedatives, and hypnotics
Anxiolytics, sedatives, and hypnotics may be used to manage symptoms 
like anxiety and insomnia, which are common in the CVD population. 
However, potential benefits need to be balanced against risks, especially 
with long-term or high-dose use. If used, clinical evaluation should 
include assessment for suitability to switch to a safer alternative like 
SSRIs for anxiety, or CBT for insomnia. Further, these drugs are over¬≠
used and overprescribed worldwide in the general population and es¬≠
pecially among the elderly and people with mental health 
conditions.377 Benzodiazepine prescription, especially long-term or dai¬≠
ly use, has been linked to an increased risk of all-cause mortality.378,379
These findings may be partly explained by residual confounding.380
Some studies also suggested that benzodiazepines may elevate the 
risk of CV events and mortality, particularly in older adults.381
6.5.5. Pharmacological treatment for mental health 
conditions in specific cardiovascular diseases
6.5.5.1. Ischaemic heart disease
Pharmacological treatment for IHD in people with mental health condi¬≠
tions aims to reduce the symptoms of mental health conditions, improve 
CV outcomes, and reduce modifiable CV risk factors. In general, it is pref¬≠
erable to avoid benzodiazepines routinely for managing AMI,382 and to be 
cautious about adding medications given the potential for interactions 
and possible side effects. In people who smoke, bupropion or varenicline 
can be used as they are effective and safe in reducing smoking in the short 
term.383,384 If a person with depression is being treated with mirtazapine, 
switching to other antidepressant drugs with less propensity to induce 
weight gain may be considered, in consultation with psychiatrists.356
6.5.5.2. Ventricular arrhythmias
In people with ventricular arrhythmias, it is necessary to evaluate the 
link between arrhythmias and the use of reported antidepressants. In 
the context of clinical suspicion, it is preferable to switch to drugs 
with less propensity to cause ventricular arrhythmias. Several antide¬≠
pressants have shown a potential to change ventricular repolarization: 
(i) Citalopram/escitalopram possibly increase the risk of QTc pro¬≠
longation in dosages over 20 mg compared with placebo.
(ii) TCAs are associated with increased risk of QTc prolongation com¬≠
pared with newer antidepressants.
For more information on QTc prolongation associated with psycho¬≠
tropic drugs see Section 7.6.1.
6.5.5.3. Heart failure
In people with HF, the efficacy of antidepressant and/or antipsychotic drugs 
is not well established.385 Therefore, careful assessment of risks and ben¬≠
efits should be performed by a multidisciplinary Psycho-Cardio team be¬≠
fore initiation. Indeed, despite mental health conditions increasing the 
risk for adverse outcomes and mortality in people with HF, the indiscrim¬≠
inate use of antidepressants may increase the risk of CV side effects and 
drug interactions, especially among the elderly or frail. This is well summar¬≠
ized in a position paper endorsed by the EAPC.386 In addition, the use of 
antidepressants has been associated with an increased risk for all-cause and 
CV mortality, irrespective of the presence of clinical depression.354,387
If antidepressants are needed: 
‚Ä¢ SSRIs are considered the safer class of antidepressants to use in HF as 
they are associated with fewer adverse CV side effects (less likely to 
cause orthostatic hypotension or tachycardia, little effect on intraven¬≠
tricular conduction).388 However, SSRIs can cause QTc prolongation, 
especially citalopram and escitalopram (but also sertraline and fluoxet¬≠
ine), can increase the bleeding risk in elderly people receiving antiplate¬≠
let or anticoagulant medications through their inhibition of platelet 
aggregation/activation, and enhance gastric acid secretion.372,389,390


<!-- PAGE 31 -->

### Page 31

‚Ä¢ Due to their minimal inhibition of CYP enzymes, sertraline, citalo¬≠
pram, and escitalopram have a lower risk of drug interactions com¬≠
pared with fluvoxamine, fluoxetine, and paroxetine.
‚Ä¢ Monoamine oxidase inhibitors and TCAs should be avoided for the 
treatment of depression in HF as they may cause orthostatic hypo¬≠
tension, worsening HF, and ventricular arrhythmias.391
‚Ä¢ Venlafaxine and duloxetine should be used with caution in people 
with HF due to the small and contradictory evidence.392
The use of antidepressants in people with HF should be restricted to 
those with severe depression, where the risk of untreated depression 
outweighs the risk of taking antidepressants. The use of specific drugs 
for the treatment of HF can also be associated with the development 
of depression/anxiety: diuretics and nitrate esters are associated with 
a higher risk of depression in people with HF,393 while no increased 
risk of depression has been reported for beta-blockers (especially for 
the hydrophilic form since they do not significantly cross the blood/ 
brain barrier), statins, angiotensin-converting enzyme inhibitors, angio¬≠
tensin receptor blockers, aspirin, aldosterone antagonists, and sodium‚Äì 
glucose co-transporter-2 inhibitors.393,394
6.5.5.4. Procedures (coronary artery bypass grafting, percutaneous 
coronary intervention)
In general, the use of benzodiazepines is not indicated for PCI or cor¬≠
onary artery bypass grafting, but this consideration is based upon low- 
quality evidence.395,396 No specific recommendations are available for 
the use of psychotropic drugs.395
6.6. Organization of care
Healthcare is frequently fragmented by specialties, hindering efforts to 
provide holistic care that addresses physical and mental health condi¬≠
tions. New care models have sought to integrate physical healthcare 
into mental healthcare settings, and mental healthcare into settings fo¬≠
cused on physical conditions.397 Novel integrated programmes using 
remote delivery of mental health interventions and promoting psycho¬≠
logical well-being have garnered growing interest in the literature.398
Several RCTs have explored the effectiveness of collaborative care 
models in managing various health conditions. Co-ordinated or 
collaborative care of people with CVD and other conditions has been 
shown to improve CV risk factors, cardiometabolic disease control, gen¬≠
eral function, and symptoms of depression.399‚Äì402 A systematic review 
and meta-analysis of collaborative care in primary or community health¬≠
care settings (79 trials) reported significantly greater improvements in 
depression and anxiety in the short and long term, along with increased 
medication use, mental health components of QoL measure (SF-12, 
SF-36), and satisfaction.403 However, an RCT of a collaborative care pro¬≠
gramme for people with HF and depression did not show significant im¬≠
provements in clinical outcomes compared with enhanced usual care.404
An integrated adult congenital heart disease (ACHD) psychology service 
has been shown to reduce psychological distress, however, few people 
received full psychological assessment.405 A recent position paper ad¬≠
dresses the main mental health concerns in congenital heart disease 
and advocates the generation of models for the integration of mental 
health professionals in paediatric and ACHD teams.406
Although often delivered in primary care, collaborative care models 
have also been evaluated in rehabilitation facilities,407,408 and acute care 
hospitals.409 Collaborative care has been tested in mental health clinics 
and was found to improve physical health compared with usual care 
with no differences in overall QoL. Half of the effects on functioning 
were mediated through the effects of collaborative care on depression 
severity in people with bipolar depression.410,411
Collaborative care is usually delivered by nurses supported by a 
multidisciplinary team. Further study of novel applications of collabora¬≠
tive care and related interventions is warranted due to the potential of 
these programmes to improve management of CVD and mental health 
conditions and enable CV practices to deliver holistic care.398 In par¬≠
ticular, new models of integrated care with multidisciplinary teams 
(Psycho-Cardio team) and experts in improving mental health are 
needed in clinical CV care. The composition and function of these 
teams should be dynamic and flexible, adapted to the needs of people 
with CVD, their caregivers, clinical scenarios, and available resources. 
6.7. Section summary points and 
management consensus statements from 
Section 6
SECTION SUMMARY POINTS
(i)
Ideally, assessment of mental health status should be performed routinely within CVD clinical practice and implemented when the context of local capacity 
and capability allows.
(ii)
Depression and anxiety can easily be overlooked in the routine care of people with CVD and/or considered ‚Äònormal‚Äô reactions to individual clinical/ 
prognostic burden of disease.
(iii)
Clinical history can be used to identify mental health symptoms. If there is clinical suspicion, formal screening with validated tools is advised.
(iv)
Psycho-Cardio teams are needed to structure pathways for: 
‚Ä¢ Screening.
‚Ä¢ Referral.
‚Ä¢ Treatment of people with CVD and suspected or established mental health conditions.
(v)
Medical interventions including pharmacotherapy may be needed for people with CVD who are diagnosed with mental health conditions, especially for 
severe symptoms of depression, anxiety, or PTSD.
(vi)
In some people with CVD, combination therapy of psychological interventions plus medication may be useful.
Continued
ESC Guidelines                                                                                                                                                                                               31


<!-- PAGE 32 -->

### Page 32

### 7 Severe mental illness and

cardiovascular disease
7.1. Cardiovascular risk in people with 
severe mental illness
Severe mental illnesses are diseases defined by a significantly impaired 
level of psychosocial functioning and usually comprise disorders such 
as schizophrenia, bipolar disorder, and severe recurrent major 
depressive disorder6 (Figure 11). Definitions and characteristics of SMI ac¬≠
cording to ICD (International Classification of Diseases)-11 criteria,7 can 
be found in Supplementary data online, Table S11.
Individuals with schizophrenia and bipolar disorder have been 
found to live approximately 14.5 and 8‚Äì12 years less than their coun¬≠
terparts without SMI, respectively.412,413 All-cause mortality in people 
with SMI is more than 2.5 times higher compared with the general 
population,414 and the standardized mortality gap may be increasing 
over time.415 Cardiovascular disease plays a major role in cause- 
specific mortality among people with SMI,26 and SMI increases the in¬≠
cidence and prevalence of CVD. People with schizophrenia are at 
two- to three-fold higher risk of having CVD, particularly younger in¬≠
dividuals.12 In a large-scale meta-analysis (3 211 768 people with SMI; 
113 383 368 controls), the pooled prevalence of CVD was 9.9% and 
the cumulative incidence of CVD was 3.6% in people with SMI (me¬≠
dian follow-up 8.4 years), a significantly higher adjusted risk of CVD 
incidence compared with controls in longitudinal studies.12 People 
with schizophrenia have significantly higher rates of SCD, exceeding 
population rates by 11-fold.416 There is some evidence to suggest 
young adults with SMI may be at particular risk of increased CV 
events.417,418
7.2. Prognosis in severe mental illness and 
cardiovascular disease
The co-occurrence of SMI and CVD increases all-cause mortality risk 
and worsens CV prognosis. Observational studies suggest that, among 
people with SMI, the risk for CHD and CV mortality is up to 2.5 times 
higher in people with schizophrenia and bipolar disorder compared 
with controls, with larger effects in younger people.419 According to 
Danish national registry data, while trends in MI mortality rates declined 
over 1 and 5 years of follow-up, people with schizophrenia did not ex¬≠
perience the same decline in mortality rate following MI in long-term 
follow-up.420 People with SMI present clinically with HF 7 years earlier 
than the general population, and men with SMI and HF have excess 
mortality compared with men with HF without SMI. ICD implantation, 
cardiac resynchronization therapy, VAD implantation, and HTx 
are used at a similar rate in people with HF with reduced ejection frac¬≠
tion and SMI as those without SMI, but people with SMI experienced 
poorer prognosis following cardiac resynchronization therapy, VAD, 
and HTx.421
MANAGEMENT CONSENSUS STATEMENTS
(i)
Screening of mental health with validated screening tools is advised after a new diagnosis or CV event, at least once during follow-up and anytime based on 
clinical judgement of need.
(ii)
Initial simple screening with a two-item measure (i.e. Whooley questions, PHQ-2, GAD-2) can be incorporated into routine practice.
(iii)
A low threshold for mental health screening in people with CVD is advised, considering the high prevalence of mental health conditions in people with CVD 
and its impact on outcomes.
(iv)
Following an abnormal result in the initial screening, a longer validated screening instrument should be used to determine if condition severity is low, 
moderate, or high.
(v)
Psycho-Cardio teams must define who is responsible for the assessment of mental health conditions and how and when it will be done, tailoring it to the 
specific context and resources.
(vi)
Each Psycho-Cardio team may choose a particular screening tool after careful assessment of its validity, reliability, and applicability to their population, but 
standardized screening tools are preferred for mental health assessment.
(vii)
People scoring high on a screening questionnaire need referral for diagnostic assessment and appropriate treatment by a mental health professional.
(viii)
Applying a stepped care approach to manage mental health conditions in people with CVD is reasonable based on preferences, severity of symptoms and 
condition, and resources available.
(ix)
Developing and evaluating tailored intervention programmes aimed at alleviating distress of people coping with CVD and caregivers may be useful.
(x)
Lifestyle measures and psycho-education are useful for all people with CVD while psychological therapies may be helpful for people experiencing 
depression and/or anxiety.
(xi)
Cardiac rehabilitation is an opportunity to screen people for depression and anxiety and can contribute to improve mental health after CV events or be an 
opportunity to identify and manage mental health conditions.
(xii)
Avoiding benzodiazepines as first-line therapy in the management of anxiety and depression is advised.
(xiii)
Anxiolytics, sedatives, and hypnotics are overused and overprescribed in the general population, especially among the elderly and people with mental 
health conditions, so careful selection of indications is advisable.
(xiv)
Antidepressant use is advised for those with moderate to severe anxiety disorders and depression under the guidance of qualified mental health 
professionals.
(xv)
The use of antidepressants in HF is only advisable in severe depression symptoms where the risk of untreated depression outweighs the risk of taking 
antidepressants.
(xvi)
In people with ventricular arrhythmias, antidepressants associated with an increased propensity to prolong QTc (such as TCAs and possibly citalopram/ 
escitalopram in dosages over 20 mg), may be switched to newer antidepressants with better safety profiles.
(xvii)
Given the frequent interactions between antidepressants and CV drugs affecting their efficacy and safety, therapeutic drug monitoring is advisable to 
optimize pharmacotherapy and minimize potential side effects and clinically relevant drug interactions.
¬© ESC 2025


<!-- PAGE 33 -->

### Page 33

7.3. Increased cardiovascular disease risk 
in people with severe mental illness
The aetiology of CVD in people with SMI is multifactorial, involving gen¬≠
etic/biological, disease-specific and treatment-specific effects, lifestyle 
factors, and treatment disparities, which are mutually inter¬≠
twined.422,423 A summary of these factors is given in Figure 12, and de¬≠
scribed in the text below.
7.3.1. Lifestyle and biological risk factors
Risk factors including hypertension, diabetes mellitus, dyslipidaemia, 
obesity, and smoking, contribute to a significantly higher CV risk in 
people with SMI.424,425 Genetic/biological, disease-specific factors in¬≠
clude common genetic vulnerability for schizophrenia and diabetes, 
the effects of psychopathology such as negative and depressive symp¬≠
toms leading to sedentary lifestyle.424 Schizophrenia is associated 
with more than a three-fold risk of obesity compared with the 
general population,426 and metabolic syndrome and diabetes were 
also found to be more prevalent in people with schizophrenia and bi¬≠
polar disorder.426‚Äì429 Hypertension was found to be more prevalent 
in people with bipolar disorders, but not schizophrenia.430 Finally, 
people with schizophrenia had five times higher odds of smoking 
than the general population,431 up to 65% of people with schizophre¬≠
nia are smokers,432,433 and they have higher rates of alcohol addic¬≠
tion.434 People with SMI have not shown the same reduction of 
modifiable risk factors and resulting decrease in CVD mortality rates 
as the general population.419
7.3.2. Medication-induced cardiovascular risk factors
Disease-specific and medication-induced factors include side effects to 
medications, obesity, diabetes, hypertriglyceridaemia, and hypercholes¬≠
terolaemia.427,435‚Äì438 The effect of medication is not straightforward, as 
metabolic-induced side effects may not be independent predictors for 










	



	




	



	








	



	
	





























Figure 11 Severe mental illnesses.  
ESC Guidelines                                                                                                                                                                                               33


<!-- PAGE 34 -->

### Page 34

CVD in persons with SMI.438,439 A summary of data on CV risk asso¬≠
ciated with antipsychotic use is highlighted below: 
‚Ä¢ Current reports do not show that antipsychotics are associated 
with increased risk of MI or stroke in people with schizophrenia 
and bipolar disorder compared with placebo,440 despite previous 
meta-analyses.12,441
‚Ä¢ The use of long-acting antipsychotic medication and second- 
generation antipsychotics were found protective against all-cause 
mortality compared with no antipsychotic use. The largest effects 
were seen for second-generation long-acting injectable antipsycho¬≠
tics, clozapine, any long-acting injectable antipsychotics, and any 
second-generation antipsychotics.26 In a Finnish nationwide data¬≠
base study (median follow-up 14.1 years), CV mortality was significant¬≠
ly lower among patients with schizophrenia on any antipsychotic 
treatment compared with non-use. Several antipsychotics were asso¬≠
ciated with a significantly reduced CV death risk compared with 
non-use (long-acting injectable olanzapine and oral flupentixol) and 
the use of clozapine reduced all-cause mortality by 61% and CV death 
risk by 45% compared with non-use of antipsychotics.442 Findings were 
possibly explained by improved adherence to antipsychotics of people 
with SMI, as this has been associated with decreased discontinuation 
risk of antidiabetics, statins, antihypertensives, and beta-blockers in 
people with schizophrenia.443 The use of medication appears not to 
influence the cardiorespiratory fitness level of people with SMI receiv¬≠
ing treatment.444
Antipsychotics vary in their propensity to induce modifiable CVD 
risk factors. Most second-generation antipsychotics with wide receptor 
activity profiles (serotonin 5-HT2A, histamine H1, muscarinic M3), such 
as olanzapine, clozapine, and quetiapine, are associated with increased 
risk of weight gain and consequent metabolic syndrome, weight gain- 
related diabetes, and hypertriglyceridaemia.437
According to a 
meta-analysis of RCTs, olanzapine, clozapine, zotepine, sertindole, 






	



	
¬Å
¬ç

¬è¬ê
¬ù
¬†	



¬≠¬Ä			


¬Ç¬É¬Ñ¬Ñ	



Figure 12 Multifactorial aetiology of cardiovascular disease risk in people with severe mental illness. CV, cardiovascular; CVD, cardiovascular disease; 
SMI, severe mental illness. aChoose psychotropic drugs less likely to cause obesity and metabolic risk.


<!-- PAGE 35 -->

### Page 35

iloperidone, and quetiapine were found to be associated with worse 
metabolic profiles (weight gain, glucose increase, hypertriglyceridaemia, 
hypercholesterolaemia, and decrease of high-density lipoprotein chol¬≠
esterol) in short-term use.435 Zotepine, olanzapine, sertindole, caripra¬≠
zine, iloperidone, quetiapine, clozapine, and risperidone have been 
associated with the greatest weight gain (up to 3 kg), but nearly half 
of antipsychotics caused significantly more weight gain than pla¬≠
cebo.445,446 A summary of effects of antipsychotics on CVD modifiable 
risk factors is presented in Table 6.
7.3.3. Assessing cardiovascular disease risk
Widely used tools for CV risk assessment in the general population usu¬≠
ally underestimate the risk of CVD in the population with SMI.447
Significant differences in risk prediction screening tools such as metabolic 
syndrome concept, Systematic Coronary Risk Evaluation (SCORE) mod¬≠
el and two PRedIction and Management of cardiovascular Risk in 
peOple with SEvere mental illnesses (PRIMROSE) models, carry the 
risk of significant disparities in treatment initiation in people with 
SMI.447 Moreover, these models generally underestimate CV risk in 
adolescents with SMI.447,448 Finally, there is no consensus of which 
healthcare professionals should screen and monitor for CVD in SMI. 
While screening is usually in the domain of primary care, persons 
with SMI have overall low use of health services, therefore, 
mental health professionals may need to take the lead for screening,21
diagnostics,22,23 and treatment.21,24‚Äì26
Several practice Guidelines for the screening and monitoring of CV 
risk in people with schizophrenia are proposed but have been scarcely 
implemented. Position statements by the European Psychiatric 
Association, supported by the European Association for the Study of 
Diabetes (EASD), and the ESC have made recommendations for 
screening.449 We highlight the following as particularly important for 
people with SMI and CVD: 
‚Ä¢ Routine screening for CVD risk factors should be performed by psy¬≠
chiatrists and general practitioners at all stages of the disorder, re¬≠
gardless of age, with initial risk assessment carried out during the 
first visit and before the prescription of antipsychotics. Baseline risk 
assessment includes: 
‚ö¨Personal and family history of CVD or diabetes or related disease.
‚ö¨Lifestyle patterns: smoking and alcohol consumption, healthy diet, 
physical activity.
‚ö¨Weight, height, waist circumference, calculation of body mass 
index.
‚ö¨Fasting blood glucose and lipids (total cholesterol, low-density 
lipoprotein cholesterol, high-density lipoprotein cholesterol, 
triglycerides).
‚ö¨Blood pressure, heart rate.
‚Ä¢ All individuals with SMI taking antipsychotics should be actively mon¬≠
itored for modifiable risk factors at baseline, after 12 weeks, and at 
least annually thereafter.
‚Ä¢ People who have CV risk factors should be monitored at the start of 
a new treatment and re-assessed 6 and 12 weeks after initiation of a 
new antipsychotic drug, and periodically, depending on the presence 
of risk factors.449 In people with diabetes, monitoring should include 
glycated haemoglobin every 12 weeks.
‚Ä¢ After initiation of antipsychotics known to induce CV side effects [e.g. 
prolongation of QTc interval or tachycardia (see Section 7.6.1)], elec¬≠
trocardiogram (ECG) is advised at baseline, after 1 week, and after 6 
and 12 weeks, and annually thereafter.
Table 6 Summary of the negative effect of different antipsychotics on cardiovascular risk factors
Drug
Weight gain
Hyperglycaemia
LDL cholesterol
HDL cholesterol
Total cholesterol
Triglycerides
Haloperidol
0
++
ND
ND
++
++
Ziprasidone
0
+
0
0
+
+
Aripiprazole
+
++
+
+
++
+
Lurasidone
+
0
+
+
+
+
Cariprazine
+
++
0
+
0
+
Fluphenazine
+
ND
ND
ND
ND
ND
Amisulpride
+
0
ND
+++
++
++
Brexpiprazole
+
+
++
0
++
0
Flupentixol
+
ND
ND
ND
ND
ND
Asenapine
++
0
ND
ND
ND
ND
Risperidone
++
+
++
++
++
+
Paliperidone
++
+
++
++
++
+
Quetiapine
++
+
+++
++
+++
++
Iloperidone
++
++
ND
ND
+
++
Sertindole
+++
+
ND
ND
++
+
Zotepine
+++
+++
ND
ND
ND
+++
Clozapine
+++
+++
ND
ND
+++
+++
Olanzapine
+++
++
+++
+++
+++
+++
¬© ESC 2025
HDL, high-density lipoprotein; LDL, low-density lipoprotein; +, strength of effect; ND, no data.
ESC Guidelines                                                                                                                                                                                               35


<!-- PAGE 36 -->

### Page 36

7.4. Gaps and disparities in the 
management of cardiovascular disease in 
people with severe mental illness
The presence of SMI in itself does not explain the lifespan 
inequalities observed.450 Multiple factors have been identified including 
systemic barriers to prevention,310 screening,21 diagnosis,22,23 and 
treatment.21,24‚Äì26 Collectively, these lead to large healthcare disparities 
for people with SMI. Key studies confirm these inequalities persist in 
CVD.451‚Äì454 To overcome these barriers healthcare professionals 
need to be aware of, and address, system-level problems including stig¬≠
ma, stereotypes, prejudice, and diagnostic overshadowing (defined as 
the misattribution of physical symptoms to pre-existing psychological 
illnesses).455
7.4.1. Autonomy, communication, and informed 
consent
Communication between the CV team and people with SMI and CVD 
should follow similar principles as for people with CVD without SMI 
outlined in Section 6.3. For people with SMI, this may require a move 
away from the established ‚Äòbest interest‚Äô approach (healthcare profes¬≠
sionals know what is best), to a ‚Äòwill and preference‚Äô approach which 
prioritizes goals and values.456 This shift is particularly critical for people 
with SMI and CVD, who may experience heightened stigma or bias that 
can lead to paternalistic treatment. Respecting their will and preference 
not only affirms their human right to self-determination and dignity, but 
also allows them greater control over their care, promoting a sense of 
ownership in managing their health. The Psycho-Cardio team should 
develop a more proactive and person-centred approach in caring for 
persons with SMI including: 
‚Ä¢ Educating the people about their illness, warning signs, treatment, and 
management plan.
‚Ä¢ Including people with SMI and family/caregivers in the management 
plan using SDM.
‚Ä¢ Engaging people with SMI to participate in their care actively by in¬≠
cluding them in all forms of treatment (lifestyle modification pro¬≠
grammes, smoking cessation).
‚Ä¢ Encouraging people with SMI to check up regularly for CVD risks and 
CV symptoms.
‚Ä¢ Monitoring adherence to medication.
‚Ä¢ Reassuring and signposting to practical information or resources.
‚Ä¢ Asking if there is someone the person with SMI would like you to 
contact.
People with SMI are presumed to have capacity to consent to treat¬≠
ment unless there is reason to believe this is not the case. In those rare 
situations, a decision-making capacity assessment may be required, and 
this should be undertaken by the professionals involved in delivering the 
physical health intervention being proposed. Depending on jurisdiction, 
people with SMI may have appointed a decision-maker themselves or 
may have an advanced healthcare directive, so it is important to be 
aware of these issues and determine a person‚Äôs capacity to consent 
to treatment before proceeding.
If the person with SMI already has a legal guardian, they have the legal 
authority to sign medical informed consent, but different acts may be 
applied in different countries. People with SMI may have reduced ability 
to participate in the treatment processes due to the nature of SMI lead¬≠
ing to unintentional non-adherence. In severe active psychosis, the indi¬≠
vidual may not be able to communicate CV symptoms or may not be 
able to tolerate invasive investigations and/or therapies because of psy¬≠
chiatric symptoms.
Many people with SMI may become suitable for an invasive strategy and 
be clinically assessed for CV interventions. This may require an advocating 
and assertive approach by the management team, and close collaboration 
with liaising mental health professionals and general practitioners. The 
management of CAD in people with SMI should be discussed by the 
Psycho-Cardio team (Figure 3), with input from a psychiatrist. Many defi¬≠
ciencies in the management of CAD in people with SMI occur for obvious 
and at times insurmountable reasons. Consensus and collaboration 
among people with SMI, families, general practitioners/family physicians, 
CV specialists, and mental health professionals is essential for good prac¬≠
tice. General practitioners play a particularly relevant role in reviewing and 
optimizing the physical and mental health of people with SMI and CVD, 
being responsible for the integral process of care and co-ordinating 
care by the different specialists involved.
In the care of SMI, flexible assertive community treatment models 
usually ensure better availability of health services for persons with 
SMI and prominent psychiatric symptoms, but there is a lack of studies 
analysing the effects of these models in people with CVD.457,458
Interactive telemedicine (therapy delivered via video conferencing) 
was found comparable to in-person delivery in effectiveness, accept¬≠
ability, and cost in people with various mental health and substance 
abuse issues.459
7.5. Management of cardiovascular disease 
in people with severe mental illness
7.5.1. Management of modifiable risk factors
Management of modifiable risk factors in people with SMI follow the 
same principles as in people without SMI, such as education, behaviour¬≠
al counselling, lifestyle interventions, and peer and family support inter¬≠
ventions. Increased efficacy of interventions directed to improve CV 
risk in people with SMI is associated with: 
‚Ä¢ High intensity and high co-ordination.
‚Ä¢ Inclusion of both behavioural and pharmacological management, fol¬≠
lowing a multimorbidity approach.
Few studies, however, have evaluated interventions addressing one 
or more CVD risk factors in people with SMI.
7.5.2. Diet, physical activity, and body weight control
The diet of people with schizophrenia is often unhealthy, characterized 
as being poor in fibre and fruit, and rich in saturated fats with a high cal¬≠
oric intake.460 People with SMI are generally less physically active than 
the general population, performing significantly lower volumes of mod¬≠
erate to vigorous activity per day according to a meta-analysis of 69 
studies.424 Currently available studies in people with SMI indicate a 
beneficial effect of exercise and diet on CV risk, with interventions in¬≠
creasing weekly activity compared with no intervention.461 Significant 
improvements in fitness, psychiatric symptoms, and overall functioning 
were found in participants who attended 50% of physical activity ses¬≠
sions.462 The European Psychiatric Association (EPA) suggests that


<!-- PAGE 37 -->

### Page 37

physical activity should be regularly offered to people with SMI as a low 
risk and accessible way of improving health.463
In general, weight loss should be advised to people with SMI who 
have a body mass index ‚â•25 kg/m2 or a waist circumference ‚â•88 cm 
in women or ‚â•102 cm in men.449 The effectiveness of behavioural or 
integrative interventions to improve CV risk in people with SMI has 
had mixed results.422 Two of four studies reported a decrease in CV 
risk in the integrated care intervention group compared with control 
groups, however, two studies reported no difference.464‚Äì467
Glucose and lipid-related laboratory results were mainly reported as 
secondary outcome assessments in studies of weight management in¬≠
terventions. Metformin is the currently accepted first-line treatment 
of antipsychotic-associated weight gain, although not all people bene¬≠
fit.468 In 2020, the ESC in collaboration with the EASD updated their 
treatment algorithms to recommend the use of glucagon-like peptide-1 
receptor agonists and sodium‚Äìglucose co-transporter-2 inhibitors as 
alternate therapy options to metformin based on CV and renal co¬≠
morbidities independent of glycaemic control. However, there are still 
no data to support their use for antipsychotic-associated weight gain 
and diabetes.469 In a meta-analysis of 33 RCTs (3473 people with 
SMI), weight control was improved with behavioural interventions 
compared with control, metformin, anticonvulsive medications topira¬≠
mate and zonisamide, and adjunctive or antipsychotic switching to ari¬≠
piprazole (meta-analysis not possible). Evidence was insufficient for all 
other interventions and for effects on glucose and lipid control.470
7.5.3. Smoking cessation
Smoking cessation strategies for persons with SMI are similar to the gen¬≠
eral population as summarized previously (Section 6.3.10), including ap¬≠
propriate pharmacological therapy in combination with behavioural 
therapy. Brief behavioural interventions (motivational enhancement, per¬≠
sonalized feedback) have increased rates of pursuing nicotine 
dependence treatment compared with psycho-education in people 
with schizophrenia.471 Studies have confirmed the safety and efficacy 
of first-line smoking cessation pharmacotherapies, including varenicline, 
bupropion, nicotine replacement therapy, and nicotine patch monother¬≠
apy in individuals with and without schizophrenia or schizoaffective dis¬≠
orders.384,472‚Äì474 Although studies do not indicate a serious safety 
signal with varenicline or bupropion, there is a general risk of deterio¬≠
rated mental health in association with smoking cessation due to nicotine 
abstinence. People with previous mental health issues should be well in¬≠
formed and followed up carefully during smoking cessation interventions.
Maintenance of pharmacotherapeutic and behavioural treatment has 
been reported to significantly reduce relapse rates among smokers with 
schizophrenia.471 Smoking cessation has a double benefit effect as it also 
potentially enables the need for a lower dose of antipsychotic treatment. 
Specifically, smoking can influence the efficacy of multiple medications used 
in the treatment of SMI through CYP1A2 induction, reducing plasma levels 
of some drugs (Supplementary data online, Table S10). Therefore, smoking 
cessation may lead to increased plasma levels of these drugs (e.g. clozapine) 
and thus doses of medications may need to be reduced when someone 
stops smoking, in consultation with psychiatrist.
7.5.4. Pharmacological management
Psychiatric medication in people with SMI is prescribed long term with a 
variety of psychotropic medications, depending largely on the state of 
the disease and comorbidities. People with schizophrenia, other psych¬≠
otic disorders, and bipolar disorders are treated with antipsychotics, 
sometimes in combination with antidepressants, mood stabilizers, 
and frequently anxiolytics or sedatives. The same is true for severe re¬≠
current depression, where antipsychotics are added to antidepressants. 
CYP450 pharmacokinetic profiles of psychotropic medications can be 
found in Supplementary data online, Table S10.
While pharmacologic treatment in SMI is associated with decreased 
risk of CVD compared with no treatment, a rational pharmacotherapy 
is needed as some medications are associated with CV risks. As dis¬≠
cussed in Section 7.6 these include the development of CV side effects 
via receptor blockade of muscarinic receptors and adrenergic recep¬≠
tors and worsening modifiable CV risk factors.475
Rational pharmacotherapy for persons with SMI takes a multifactor¬≠
ial approach as outlined in the principles below: 
‚Ä¢ Use of monotherapy whenever possible.
‚Ä¢ Use of medication with lower propensity to induce or worsen CV risk.
‚Ä¢ Addition of medication to prevent CV risk factors (e.g. metformin or 
glucagon-like peptide-1 receptor agonists to prevent weight gain).
‚Ä¢ Consideration of possible drug interactions and monitoring for CV 
side effects upon initiation of a new drug.
‚Ä¢ Ensuring adequate adherence to psychiatric medication.
People with SMI respond to the same strategies to increase adher¬≠
ence as those without SMI, including simplifying medication regimens 
and use of behavioural interventions. Text message reminders, phone 
calls, electronic pill counters, and training family members can improve 
medication adherence in SMI populations.422
7.6. Management of cardiovascular 
conditions in people with severe mental 
illness
Managing CVD in people with SMI requires good communication and 
collaboration between mental health and CV specialists. Several factors 
that may help improve CVD management and secondary prevention in 
those with CV conditions are listed below and summarized in Figure 13. 
‚Ä¢ Raise awareness of specialists and primary care professionals regard¬≠
ing the importance of controlling CV risk factors.
‚Ä¢ Promote adherence to psychotropic drugs; long-acting injectables 
may help.
‚Ä¢ Decrease the number of psychotropic drugs if possible.
‚Ä¢ Switch to drugs with less propensity to induce metabolic syndrome, 
in consultation with psychiatrists and evaluation of relapse risk.476
‚Ä¢ Reinforce lifestyle modifications and prescribe CV prevention medi¬≠
cations as needed.
‚Ä¢ Addition of varenicline/bupropion or other forms of nicotine re¬≠
placement therapy combined with smoking cessation programmes 
in case of smoking.
7.6.1. Rhythm disturbances
People with SMI are at increased risk of developing supraventricular and 
ventricular arrhythmias, which may eventually lead to SCD. This in¬≠
creased arrhythmia risk is multifactorial, including distress resulting 
from the SMI, high prevalence of risk factors and unhealthy lifestyles, 
CV comorbidities commonly observed in SMI, and side effects of psy¬≠
chotropic medications. Furthermore, autonomic dysfunction, chronic 
inflammation, and oxidative stress are common in SMI and have been 
associated with an increased arrhythmia risk.423
‚Ä¢ Pre-existing arrhythmias or their development after the initiation of 
treatment can pose significant challenges to the medical management 
ESC Guidelines                                                                                                                                                                                               37


<!-- PAGE 38 -->

### Page 38

Assess individual‚Äôs mental health and cardiovascular risk
SMI in remission or with mild symptoms 
New or unremitted SMI
(moderate/severe) 
Is individual adherent to psychiatric and CVD treatment? 
‚Ä¢ Assess treatment
‚Ä¢ Support adherence 
 with behavioural
 interventionsa
‚Ä¢ Consider 
 long-acting
 injectables
‚Ä¢ Assess CV side eÔ¨Äects
 of psychotropic
 medication
‚Ä¢ Consider change in
 medication if
 CV eÔ¨Äects
‚Ä¢ Check for medication
 interactions 
‚Ä¢ Initiate therapeutic
 drug monitoring
 if required
Use a person-centred multidisciplinary approach with shared decision-making and collaboration among members of Psycho-Cardio team
Psychiatric consultation and introduction or change to psychotropic medication
‚Ä¢ Monitor ECG post initiation of new antipsychotics at week 1 and 6 
‚Ä¢ Assess risk factors, drug side eÔ¨Äects and interactions at week 6 and 12, then annually
‚Ä¢ Monitor adherence to CVD and antipsychotic therapy
‚Ä¢ Psycho-education, behavioural counselling to improve CV risk factors and adherence
‚Ä¢ CVD medications as indicated, consider change in medication if CV side eÔ¨Äectsc
‚Ä¢ Choose medication with less 
 propensity to cause metabolic
 syndrome if possible
‚Ä¢ Monotherapy if possibleb
‚Ä¢ Long-acting injectables may
 improve adherence
Figure 13 Management of people with cardiovascular disease and severe mental illness. CV, cardiovascular; CVD, cardiovascular disease; ECG, elec¬≠
trocardiogram; GLP-1 RA, glucagon-like peptide-1 receptor agonist; SGLT-2i, sodium‚Äìglucose co-transporter-2 inhibitor; SMI, severe mental illness. 
aVarenicline or bupropion can be used to support smoking cessation behavioural interventions. bMonotherapy for SMI if possible; antipsychotics 
with lower propensity to worsen CVD risk (psychiatrist to advise). ‚Üí choice based on severity of symptoms, risk of relapse, medication interactions, 
comorbidities, and person-centred/shared decision-making preferences. cGLP-1 RA and SGLT-2i for diabetes; Metformin first line for antipsychotic 
associated weight gain.


<!-- PAGE 39 -->

### Page 39

of SMI. The risk of SCD is significantly increased in people with SMI 
with estimates suggesting a two- to four-fold higher risk compared 
with the general population.298 Several medications prescribed to 
persons with SMI have potential pro-arrhythmic side effects and 
may cause or exacerbate atrial and ventricular tachycardia. Caution 
and careful monitoring are needed when prescribing potentially 
pro-arrhythmic drugs in people with known heart disease, with 
the following considerations: quetiapine, olanzapine, risperidone, ilo¬≠
peridone, ziprasidone, amisulpride, and sertindole increase the risk of 
QTc prolongation compared with placebo.477
‚Ä¢ Iloperidone, chlorpromazine, loxapine, risperidone, quetiapine, and pa¬≠
liperidone increase the risk of tachycardia compared with placebo.478
‚Ä¢ Low-potency first-generation antipsychotics and multi-acting 
receptor-targeted second-generation antipsychotic treatment (spe¬≠
cifically clozapine, chlorpromazine, olanzapine, quetiapine, and risper¬≠
idone) are associated with an increased risk of AF especially in those 
with hypertension, diabetes, or CAD although evidence is limited.479
‚Ä¢ Lithium may induce electrocardiographic changes and arrhythmias 
such as T-wave inversions, sinus bradycardia, sinoatrial block, PR pro¬≠
longation, incomplete bundle branch block, QTc prolongation, in¬≠
creased QT dispersion, the Brugada electrocardiographic pattern, 
and ventricular tachyarrhythmias.480
The risk of AF appears not to be generally increased among people 
with SMI after adjustment for sex and age, although this may reflect un¬≠
derdiagnosis of AF and misinterpretation of palpitation symp¬≠
toms.423,479,481 In a study from Korea, young adults (20‚Äì39 years) 
diagnosed with mental disorder had a higher risk of incident AF (ad¬≠
justed HR 1.53, 95% CI 1.44‚Äì1.62).482
7.6.1.1. QTc interval prolongation
QTc intervals can be prolonged in association with several antipsychot¬≠
ic drugs such as sertindole, amisulpride, ziprasidone, iloperidone, risper¬≠
idone, olanzapine, and quetiapine.477 This effect may be more common 
in women than men due to differences in pharmacokinetic profiles.483
A prolongation of the QTc interval increases the risk of torsades de 
pointes tachycardias and SCD. Therefore, a 12-lead ECG should be re¬≠
corded before and after initiation of antipsychotic drugs and further 
ECG controls performed on a yearly basis during long-term follow-up.
Prolonged QTc in response to antipsychotic medication may indicate 
acquired long QT syndrome and/or reveal an underlying genetic predis¬≠
position. Diagnosis and management of long QT syndrome in SMI 
should follow general Guidelines.484
‚Ä¢ Acquired long QT syndrome is usually defined by a QTc of >500 ms 
or a drug-induced change from baseline >60‚Äì70 ms.485
‚Ä¢ In people with QTc intervals >500 ms, suspected causal drugs should 
be stopped and switched to alternative medication with lower 
QT-prolonging properties and be evaluated by a cardiologist for 
underlying genetic conditions.
‚Ä¢ In cases of intermediate QTc prolongation (e.g. ‚â•470 ms in men; 
‚â•480 ms in women), dose reduction or switching to a different 
antipsychotic may be considered and repeated ECGs should be 
documented. Individualized risk-benefit assessments are useful, con¬≠
sidering the presence of additional risk factors for QT prolongation, 
symptoms, and the QT-prolonging potential of the prescribed 
medication.
‚Ä¢ Given that QT-prolonging effects are dose dependent, always aim for 
the lowest effective dose. Interactions with other QT-prolonging 
drugs like amiodarone, sotalol, or erythromycin should be avoided.
‚Ä¢ The inherent risk of QT prolongation associated with specific drugs is 
provided on the CredibleMeds website.486
‚Ä¢ QT prolongation may also be the effect of other reversible causes 
such as hypokalaemia, hypothyroidism, or bradycardia.
‚Ä¢ Sinus tachycardia is common in SMI, heart rate correction of the QT 
interval with the Fridericia formula is optimal, rather than Bazett‚Äôs 
formula which overestimates QT at higher heart rates.487
‚Ä¢ The measurement of QT intervals can be complicated by abnormal 
T-wave morphology requiring expert consultation for correct 
interpretation.477,483
7.6.1.2. Heart rate changes
Both tachycardia and bradycardia are side effects of antipsychotic medi¬≠
cation.478 Sinus tachycardia has been reported with most antipsychotic 
medications, including first- and second-generation therapies. It is most 
common with clozapine (17%‚Äì33%),488 but has usually a transient and 
benign course. However, possible medical causes of sinus tachycardia 
should be excluded. In those with symptoms, rate control with cardio- 
selective beta-blockers, calcium channel blockers, or ivabradine may be 
used. Persistent heart rates above 130 beats per minute (b.p.m) may in 
rare cases cause a tachycardiomyopathy, which is usually reversible by 
improved rate control.
Bradycardia is a rare side effect of antipsychotics, with incidence not 
significantly higher compared with controls.478 Bradycardia warrants 
careful clinical attention in people at risk, e.g. in those with pre-existing 
conduction disturbances or symptoms like dizziness or syncope.
Lithium has a unique mechanism of action and a narrow therapeutic 
window. Common side effects include sinus node dysfunction, bradycar¬≠
dia, conduction delays (e.g. atrioventricular block, bundle branch block) 
but also precordial T-wave changes including Brugada pattern, and QT 
prolongation. Prolonged use and high blood levels increase the complica¬≠
tion risk making maintenance of optimal lithium serum levels essential.480
Since lithium concentration is affected by sodium, conditions like dehy¬≠
dration or renal failure must be managed carefully. However, with appro¬≠
priate monitoring, lithium does not pose a significant CV risk.478,480
In summary, in people with SMI and arrhythmias, it is necessary to 
evaluate the link between arrhythmias and antipsychotics. If clinically 
suspected, switching to other drugs with less propensity to cause 
changes in heart rhythm may be appropriate, however, this must be ba¬≠
lanced against the risk of SMI relapse. Clozapine, as the only medication 
indicated in people with treatment-resistant schizophrenia, is often 
hard to switch due to a high risk of relapse. A decision algorithm is given 
in Figure 14 and additional information is provided in Table 7.
7.6.2. Clozapine-induced myocarditis
Although clozapine has been associated with an increased risk of develop¬≠
ing myocarditis and cardiomyopathy, reviews and meta-analyses show that 
event rates and death rates are low. Results are limited by inconsistency in 
the diagnostic criteria for myocarditis and cardiomyopathy.489 The odds of 
clozapine-induced myocarditis increased with concurrent sodium valpro¬≠
ate use, and possibly increasing age and higher clozapine dose.490
If clozapine-induced myocarditis or cardiomyopathy is suspected, 
treatment should be discontinued promptly and referred urgently to 
a cardiologist for diagnostic evaluation.491 People who have persistent 
tachycardia at rest, especially during the first 2 months of treatment, 
should be closely observed for other signs or symptoms of myocarditis 
or cardiomyopathy (palpitations, arrhythmias, symptoms mimicking MI, 
chest pain, and other unexplained symptoms of HF). However, special¬≠
ist advice and link with psychiatrists is needed to prevent inappropriate 
discontinuation of clozapine.
ESC Guidelines                                                                                                                                                                                               39


<!-- PAGE 40 -->

### Page 40

Management of speciÔ¨Åc arrhythmias
General advice
People with SMI and symptoms indicative of arrhythmia 
People with SMI and established arrhythmia diagnosis  
Indicated for treatment with psychotropic drug?
 ‚Ä¢ As for all people with SMI and CVD
 follow management and guidance
 from Psycho-Cardio teamb
Monitor for QT prolongation 
If persistent symptomatic arrhythmia
Diagnostic work-upa
‚Ä¢ Arrhythmia treatment according
 to ESC Guidelines
‚Ä¢ Check for other pro-arrhythmic
 risk factorsc
‚Ä¢ In case of QT prolongation: consider avoiding or switching medicationd
‚Ä¢ If drug with QT prolonging properties is chosen see relevant tablee
‚Ä¢ Address modiÔ¨Åable CV risk factors which may also increase the risk 
 of arrhythmias 
‚Ä¢ Follow-up by cardiologist
‚Ä¢ Ensure person-centred management approach  
‚Ä¢ Check for anxiety, depression, and symptom preoccupation related 
 to arrhythmia
‚Ä¢ Promote interventions to enhance arrhythmia coping skills
‚Ä¢ Exclude other
 medical causesf
 (incl myocarditis)
‚Ä¢ If asymptomatic: 
 wait for
 normalization
‚Ä¢ If symptomatic 
 or persistent
 HR >130 bpm:
 beta-blocker,
 alternatively
 verapamil
 or ivabradine
Sinus 
tachycardia
‚Ä¢ Management
 according to
 ESC Guidelines 
‚Ä¢ Consider
 ablation
 as Ô¨Årst-line
 treatment for
 AVNRT and
 AVRT
PSVT
‚Ä¢ Thromboembolic
 prophylaxis if
 needed
‚Ä¢ Choose
 rhythm or rate
 control according
 to ESC Guidelines
‚Ä¢ Caution with
 speciÔ¨Åc
 psychotropic
 drugsg
Atrial
Ô¨Åbrillation
VPB, VT
Bradycardia
‚Ä¢ Avoid other drugs
 causing
 bradycardia
‚Ä¢ For management
 in people taking
 Lithiumh 
‚Ä¢ Manage according
 to ESC Guidelines 
‚Ä¢ Re-evaluate
 potential drug
 side eÔ¨Äects
‚Ä¢ Consider
 avoiding
 or switching
 medication
‚Ä¢ Risk assessment
 by cardiologist
Figure 14 Management of people with severe mental illness and arrhythmias. AVNRT, atrioventricular nodal reentry tachycardia; AVRT, atrioven¬≠
tricular reentry tachycardia via accessory pathway; bpm, beats per minute; CV, cardiovascular; CVD, cardiovascular disease; ECG, electrocardiogram; 
ESC, European Society of Cardiology; HR, heart rate; PSVT, paroxysmal supraventricular tachycardia; SMI, severe mental illness; VPB, ventricular pre¬≠
mature beat; VT, ventricular tachycardia. aHistory, symptoms, status, 12-lead ECG, Holter-ECG and/or event recorder, echocardiography, blood test 
and other evaluation if appropriate. bSee Figure 13. cSuch as hypertension, heart failure, ischaemic heart disease, electrolyte imbalance, history of ar¬≠
rhythmia, or syncope, family history of sudden cardiac death. dSpecial caution with quetiapine, olanzapine, risperidone, iloperidone, amisulpride, ser¬≠
tindole. eSee Table 7. fSuch as anaemia, hyperthyroidism, infection/sepsis, pain. gSpecial caution with clozapine, chlorpromazine, olanzapine, 
quetiapine, risperidone. hSee Section 7.6.1.


<!-- PAGE 41 -->

### Page 41

7.7. Interventions to improve the 
management of people with severe mental 
illness and cardiovascular disease
Existing programmes of prevention, early detection, and treatment of 
CVD have not consistently and significantly improved the CV risk profile 
in people with schizophrenia and other SMI conditions.492 Poor motiv¬≠
ation, lack of insight and cognitive impairment, and limited participation 
in decision-making by persons with SMI may be contributing to non- 
adherence to prevention, diagnostic, and treatment programmes. 
Cardiovascular disease prevention and treatment programmes need to 
work with mental health experts to provide CVD screening and care 
that is accessible and appropriate for people with SMI.
7.8. Section summary points and 
management consensus statements from 
Section 7
Table 7 Management of psychotropic drugs with QT interval prolongation properties
Action
Supporting information
Assess symptoms
Typically, asymptomatic 
In case of torsades de pointes: palpitations, dizziness, syncope, cardiac arrest.
Diagnostic 
work-up
‚Ä¢ 12-lead ECG providing QTc at baseline and after 1, 6, and 12 weeks after initiating drug
‚Ä¢ ECG more often in case of QT prolongation
‚Ä¢ Use Fridericia formula for heart rate correction if there is tachycardia
‚Ä¢ Check electrolytes: potassium, calcium, magnesium
‚Ä¢ Ambulatory ECG monitoring in people with symptoms
‚Ä¢ Exclude possible inherited long QT syndrome.
Management
Special caution with: sertindole, amisulpride, ziprasidone, iloperidone, risperidone, olanzapine, and quetiapine 
‚Ä¢ Always aim for the lowest effective dose
‚Ä¢ Check for other QT-prolonging drugs
‚Ä¢ Check for drug interactions
‚Ä¢ Always special caution when new medication is started
‚Ä¢ Consult https://www.crediblemeds.org/ for specific information on QT-prolonging drug effects
‚Ä¢ Correct electrolyte imbalances
‚Ä¢ Address other reversible QT-prolonging factors (e.g. bradycardia, hypothyroidism, starvation/eating disorders, alcohol and substance 
abuse, myocardial ischaemia)
Note other non-reversible potentially QT-prolonging factors: heart failure, ventricular hypertrophy, recent conversion from atrial 
fibrillation, impaired hepatic/renal function, female sex, age over 65 years 
If QTc is prolonged (>470 ms) at baseline, treatment initiation is generally not recommended and should be carefully considered based 
on individualized risk-benefit assessment (Psycho-Cardio team)a.
Special 
precautions
Stop treatment with antipsychotic drug (and any other potentially QT-prolonging medication) if: 
‚Ä¢ QTc >500 msb
‚Ä¢ Increase in QTc >60‚Äì70 ms from baselinec.
¬© ESC 2025
ECG, electrocardiogram; QTc, corrected QT interval.
aQTc prolongation (>470 ms) during treatment warrants repeated ECG documentation and thorough evaluation of symptoms and additional risk factors for QT prolongation. Dose 
reduction or switching to a different antipsychotic drug may be considered in selected cases after individualized risk-benefit assessment (Psycho-Cardio team).
bRequest urgent consultation with Psycho-Cardio team/cardiologist.
cRequest urgent consultation with Psycho-Cardio team/cardiologist, repeat ECG.
SECTION SUMMARY POINTS
(i)
The presence of SMI increases CV risk, especially in younger people.
(ii)
Regular CV risk assessment is essential in people with SMI regardless 
of age, to prevent the development or progression of CVD, ideally 
Continued before the prescription of antipsychotics and, afterwards, periodically 
in all stages of illness.
(iii)
Management of CVD in people with SMI aims to reduce modifiable 
CV risk factors, including weight gain, diabetes, hypertension, 
dyslipidaemia, smoking, unhealthy diet, and sedentary lifestyle  
habits.
(iv)
CVD management in people with SMI benefits from optimizing SMI 
pharmacotherapy: (i) preferring monotherapy, (ii) using 
medications less likely to induce weight gain or other CV risks, (iii) 
monitoring for possible drug interactions and side effects, and (iv) 
ensuring medication adherence.
(v)
Efforts to alleviate the impact of psychosocial and stress-related 
factors are needed in people with SMI.
MANAGEMENT CONSENSUS STATEMENTS
(i)
Addressing stigma and managing CVD in people with SMI in 
accordance with CV Guidelines and best clinical practice is a 
responsibility of all healthcare professionals.
(ii)
CV care for people with SMI can be improved by following a holistic 
person-centred approach, involving close collaboration between the 
Psycho-Cardio team with psychiatrists, general practitioners, and 
sometimes other specialists to proactively facilitate the engagement of 
people with SMI in such programmes.
¬© ESC 2025
ESC Guidelines                                                                                                                                                                                               41


<!-- PAGE 42 -->

### Page 42

### 8 Mental health in specific

populations and situations
8.1. Sex and gender differences in mental 
health and cardiovascular disease
Biological (‚Äòsex‚Äô) and sociocultural (‚Äògender‚Äô) aspects may explain differ¬≠
ences or disparities between women and men in incidence, prevalence, 
presentation, diagnosis, management, and response to treatment in CV 
and mental health conditions (Figure 15). Sex reflects biological factors 
like genetics, anatomy, physiology, and hormones, while gender involves 
socially constructed norms shaping roles, relationships, and power dy¬≠
namics. Gender interacts with sex, affecting traits that define women, 
men, and intersex individuals. Pregnancy and menopause are clear ex¬≠
amples of the differential influence of sex and gender in CV and mental 
well-being. Multiple studies and analyses have shown that: 
‚Ä¢ Depression and anxiety are twice as prevalent in women, have increased 
more in women over the past two decades compared with men, and 
are important risk factors for ACS and CV mortality.94,493‚Äì495
‚Ä¢ Risk ratio for psychosocial factors is higher in women with CVD com¬≠
pared with men with CVD (RR 25.7 vs 21.7, respectively).56,496
‚Ä¢ The association between depression or anxiety and CVD risk is 
stronger in young and middle-aged women compared with men.94,497
‚Ä¢ Women experience a greater impact from chronic self-perceived 
stress and marital stress, whilst men are more affected by job-related 
stress.498
However, this has to be interpreted in the context of the following 
factors: (i) prevailing social norms may lead to underreporting of mental 
stress in men,499,500 and (ii) men may have better perceived health 
and less anxiety than women, despite reporting more health risk 
behaviours.501
Sex differences in stress response have been seen in animal and hu¬≠
man models.502,503 Although pre-clinical studies in rodents and neuro¬≠
biological studies in the past have predominantly been done in males, 
evidence of sex differences in neurobiological alterations in people 
with depression and anxiety is mounting.504‚Äì507 These are associated 
with genetic differences, inflammation, platelet activation, sympathetic 
function, and hormone-related receptor signalling pathways.




	





	






~¬Å¬ç
¬è



¬ê

¬ù¬†¬≠¬Ä¬Ç
¬†
¬É
¬ù


¬Ñ


¬Ö¬Ü¬á¬≠¬Ä¬è
¬†

¬à
¬†


¬à¬ù¬†¬≠¬Ä¬Ç¬è
¬è


¬â
¬ê

¬è¬≠¬Ä¬Ç
¬†


¬†¬à
¬ä¬ã
¬ù¬ù¬ã
¬ù

¬å¬é¬é
¬ç¬à¬ë¬í¬≠¬ù¬ì¬ù¬ë¬í¬≠¬ù
¬†

¬î¬è

¬ä

Figure 15 Sex and gender differences in the psycho-cardio interaction. AF, atrial fibrillation; ANOCA, angina with non-obstructive coronary arteries; 
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular disease; HF, heart failure; MI, myocardial infarction; 
(M)INOCA, (myocardial infarction) ischaemia with non-obstructive coronary arteries.


<!-- PAGE 43 -->

### Page 43

Some SES factors like educational level and sex-specific life events 
(i.e. pregnancy, sexual abuse, intimate partner violence), have a different 
impact on the stress response in women and men. Women have a high¬≠
er inflammatory response to stress compared with men, which is asso¬≠
ciated with future adverse CV outcomes in people with IHD.508 The 
association between menopause transition and depression remains 
contentious, although severe vasomotor symptoms are recognized as 
a contributing factor associated with depression.509,510 Hormonal 
changes during menopause transition frequently induce mood distur¬≠
bances, adversely impacting QoL and work performance.511,512
During peri-menopause but not in post-menopause, temporary hor¬≠
mone therapy may alleviate these symptoms.511,512
In men, erectile dysfunction has not only been shown to be a conse¬≠
quence of CVD, it is also a risk marker for future CVD.513 A recent 
meta-analysis demonstrated that sexual dysfunction is also a predictor 
of future CVD in women.514
8.1.1. Cardiovascular disease and mental health 
conditions in transgender individuals
Transgender individuals show a significantly higher risk for mental 
health conditions, including suicidality, social disintegration, and margin¬≠
alization, compared with non-transgender individuals.515 High rates of 
discrimination and low levels of social support predispose to addictive 
behaviours in transgender persons,516 but insufficient data are available 
to differentiate between transgender subgroups. Gender-affirming 
therapy, including sex hormones, aligns individuals with their gender 
identity, enhancing QoL.517 The psychosocial benefits of hormone 
therapy with an improved body image may result in healthier lifestyle 
choices. Evidence in the ageing transgender population suggests that 
both transgender men and women face a 40% higher risk of CVD com¬≠
pared with cisgender peers of the same birth sex.518‚Äì521 The hypercoa¬≠
gulable effect of exogenous sex hormones, alongside the increase in 
traditional CVD risk factors, may mediate this elevated risk.
8.1.2. Sex and gender differences in mental health in 
people with obstructive coronary artery disease
The impact of a life event like a diagnosis of CVD on mental stress af¬≠
fects all genders. However, long-term population studies evaluating 
their influence according to sex and gender are scarce. Negative stress 
leads more often to adverse lifestyle behaviours and substance use in 
men, whereas sociocultural inequalities, household problems, and 
ACEs more often negatively affect women with CVD.522 Countries 
with the highest levels of gender equity have reported some of the 
greatest reductions in 40 year CVD mortality rates.496,523
The negative impact of depression on obstructive CAD in women is 
relatively more severe in younger women (<55 years) than at older 
ages.510,524 Moreover, feminine gender roles, lower educational level, 
and distress-related psychological factors such as anxiety are important 
determinants of outcomes after ACS in both sexes.525 Meta-analyses of 
negative psychological factors on obstructive CAD found no significant 
differences among men and women.106,526 In clinical practice, however, 
sex and gender differences in heart‚Äìbrain interactions importantly con¬≠
tribute to different manifestations of stable and unstable IHD.507,527
8.1.3. Sex and gender differences in mental health in 
ischaemia/angina with non-obstructive coronary 
arteries and coronary vasomotor disorders
Psychological risk factors, including depression and anxiety are preva¬≠
lent among women with myocardial ischaemia or angina with non- 
obstructive coronary arteries (INOCA/ANOCA).56 Mental stress trig¬≠
gers endothelial dysfunction and inflammation.528‚Äì531 While some 
studies associate anxiety with INOCA/ANOCA, others found no link 
between depression or general anxiety and these conditions.532,533
Mental stress-induced ischaemia, more prevalent in women than 
men, correlates with adverse CV outcomes.534,535 This may be asso¬≠
ciated with worse long-term prognosis, particularly in women.536,537
The influence of mental stress on INOCA/ANOCA contributes to 
their underdiagnosis and undertreatment in women.538
Young women with a history of ACS have a two-fold higher likeli¬≠
hood of developing mental stress-induced myocardial ischaemia com¬≠
pared with men.535 Chronic mental stress is a significant trigger for 
spontaneous coronary artery dissection (SCAD), which is nine times 
more common in women.539‚Äì541 Emotional stressors are reported 
twice as frequently prior to SCAD-ACS as by other ACS cohorts.542,543
Since most people experiencing SCAD are relatively young (40‚Äì60 
years), rehabilitation should prioritize stress management, addressing 
work-life balance, and other present stressors. Psychological counsel¬≠
ling may be needed in selected people.
8.1.4. Sex and gender differences in mental health in 
people with takotsubo syndrome
Acute stress-induced takotsubo syndrome (TTS) occurs eight‚Äìnine times 
more frequently in women than in men, likely due to different coping 
strategies for stress.544 Women over 55 years of age are five times 
more likely to develop TTS compared with younger women, as risk is 
linked to increased sympathetic tone after menopause.545,546 While phys¬≠
ical stressors more often affect men, women are more likely to experience 
an emotional trigger.547,548 These different triggers suggest two categories 
of TTS:549 primary TTS, affecting women after emotional stress with lim¬≠
ited left ventricular dysfunction, and TTS triggered by physical stress, 
which causes more severe left ventricular dysfunction and a worse prog¬≠
nosis. The latter seems to affect women and men equally. A direct connec¬≠
tion between the brain and the heart associated with autonomic functions 
and regulation of the limbic system has been identified.550 Mental health 
conditions are common in people with TTS, indicating that combined psy¬≠
chotherapy and ECR could improve mental health and reduce negative 
thinking more effectively than ECR alone.350 People with pre-admission 
psychiatric disorders are at a higher risk of recurrent TTS.551 The use 
of SSRIs may help prevent recurrence in selected individuals.551
8.1.5. Sex and gender differences in mental health in 
people with heart failure
Women are underrepresented in most HF trials, leading to a lack of 
sex- and gender-specific data on the impact of mental health conditions. 
HF prevalence varies between the sexes: men typically present with HF 
with reduced ejection fraction following ACS, while women more often 
experience HF with preserved ejection fraction due to hypertension, 
obesity, and ageing.552 Sexual dimorphism is also evident in the expres¬≠
sion of hereditary cardiomyopathies and risk factors like breast cancer, 
and the potential treatment-induced cardiomyopathy. Additionally, 
there are sex-specific disorders such as peri-partum cardiomyopathy.
Psychological stress has received limited attention as a potential dis¬≠
ease modifier in HF. As HF with preserved ejection fraction often re¬≠
mains undiagnosed, this contributes additional stress on the affected 
predominantly female population. However, qualitative studies support 
the assertion of non-diagnosis burden.553,554 The progressive course of 
HF, with increasing functional limitations, further increases stress in 
both males and females.
ESC Guidelines                                                                                                                                                                                               43


<!-- PAGE 44 -->

### Page 44

Higher psychological stress and anxiety worsen HF out¬≠
comes.215,216,555,556 Women with HF, former smokers, those with low¬≠
er income, and people with obesity report higher perceived stress, as 
do people with New York Heart Association (NYHA) class II HF, com¬≠
pared with asymptomatic NYHA class I HF.215,557 Social determinants 
of health influence HF prevalence, with the highest rates of HF and re¬≠
lated readmissions observed in the most economically disadvantaged 
communities with more representation of women and individuals 
from ethnically diverse backgrounds.558
8.1.6. Sex and gender differences in mental health in 
people with arrhythmias
In people with AF, anxiety levels are significantly higher in women com¬≠
pared with men, potentially due to older age, living alone (e.g. divorced/ 
widowed), or comorbid conditions.559 Chronic AF increases anxiety, 
depression, and affects QoL in both genders, but the effect is more pro¬≠
nounced in women.560 Depression is more common in women with 
chronic AF,561 and affects the subjective burden of symptoms, suggest¬≠
ing that addressing psychological comorbidities may improve symptom 
management and HRQoL. Anxiety is an important trigger for AF recur¬≠
rence after cardioversion and ablation therapy.562
Women report higher levels of anxiety (general and ICD-related), 
and higher levels of body image concerns than men when having an 
ICD.563 They also express worries about damaging the ICD during 
breast cancer screening, which in addition may compromise the quality 
of mammography images.564
In a prospective observational study of OHCA survivors, females re¬≠
ported significantly higher symptoms of anxiety and PTSD compared 
with men, with younger women showing the highest symptom severity. 
No sex differences were observed for depression.178 In a cohort of 249 
people with ICD,565 most had relatively low distress scores at baseline 
(mean anxiety 4.23 ¬± 4.47; mean depression 5.60 ¬± 4.73). However, 
those who received a shock showed a worsening of PTSD symptom se¬≠
verity scores at 3 months (11%), 6 months (7%), and 12 months (7%).
8.1.7. Mental health conditions associated with 
peri-partum cardiomyopathy
Peri-partum cardiomyopathy is a serious condition with significant con¬≠
sequences for both mother and child, causing substantial psychological 
and social stress. Mental health conditions, including peri-natal psychi¬≠
atric illness such as major depression, panic disorder, and PTSD, can 
worsen prognosis. Screening, diagnosis, and multidisciplinary manage¬≠
ment of peri-partum cardiomyopathy-associated mental conditions 
are described in a recent dedicated ESC Heart Failure Association sci¬≠
entific statement.566
8.2. Mental and cardiovascular health in 
older adults
Countries across the globe are experiencing an exponential rise in the 
proportion of older persons (often defined as aged 60 years or more) in 
their population, such that the WHO predicts the number of people 
aged 80 years or older will triple between 2020 and 2050.567 With age¬≠
ing populations comes a growing burden of chronic condition manage¬≠
ment due in part to ‚Äòinflammageing‚Äô, whereby chronically raised blood 
inflammatory markers increase the risk of morbidity, disability, frailty, 
and early mortality.568,569 According to the Global Burden of Disease 
programme, both CVD and mental health disorders are on the 
rise.570,571 In older adults, the prevalence of depression (19.2%), anxiety 
(16.5%), and stress (13.9%) are already relatively high.572 However, 
specific mental health disorders like late-life depression are set to in¬≠
crease,573 which has implications for CVD management. A recent sys¬≠
tematic review and meta-analysis of 61 prospective cohort studies 
(198 589 older adults) found that late-life depression is associated 
with increased risk of CV mortality (RR 1.31, 95% CI 1.20‚Äì1.43).574
Whilst there is reasonable population-level data on individual condi¬≠
tions, the rates of mental health disorders within older adults with any 
type CVD and vice versa are not well known. Using HF as an exemplar, 
which is mostly a disease of older adults, it would seem that the global 
co-occurrence of CVD with mental disorders like depression is signifi¬≠
cant. One of the largest meta-analyses to date (149 studies, n = 305  
407, mean age 65.2 ¬± 7.1 years) determined that the prevalence of 
any severity depression in HF was 41.9%, and severe depression was 
28.1%.575 In older adults with AF, a meta-analysis of 26 studies deter¬≠
mined the rate of depression as 40.3% and anxiety as 33.6%.576 Such 
results suggest that the rates of depression may be significantly higher 
in older adults with co-existing CVD, compared with the previously de¬≠
scribed population norms for older adults (19.2% depression, 16.5% 
anxiety).572
Non-pharmacological therapies: given that suboptimal mental 
and CV health are common in older adults, it is necessary to develop 
interventions that work synergistically to improve outcomes in both 
conditions. Unfortunately, very few interventions have been trialled 
and thus clinical practice evidence is limited. One narrative review of in¬≠
tegrated physical-mental healthcare services for older people living with 
mental health diagnoses (9 studies, n = 1728) determined that such in¬≠
terventions improved a range of health outcomes, however, studies 
were not large nor robust.577 The majority of RCTs included in the 
Cochrane systematic review and meta-analysis of psychological inter¬≠
ventions discussed in Section 6, included older adults with comorbid 
CVD and mental disorders based on sample age (14 of 21 trials included 
adults ‚â•60 years, age range 56 to 71 years). This review suggests that 
multicomponent psychological interventions such as CBT, MotInt, 
and mindfulness can improve anxiety and depression in this population, 
however, it did not improve MACE.263 A Cochrane review of social 
network or social support interventions, both of which are postulated 
to be useful in CVD and mental health conditions, reported that in pre¬≠
dominantly older patients with CVD (median age 62.5 years) and co¬≠
morbidity (including concurrent anxiety and depression), there were 
no effects on CVD and psychological well-being outcomes.578
Pharmacological therapy: managing pharmacological treatments 
in elderly patients with both mental health disorders and CVD requires 
careful consideration of dose adjustments and potential drug interac¬≠
tions due to age-related changes in pharmacokinetics and pharmaco¬≠
dynamics. Ageing affects drug absorption, distribution, metabolism, 
and excretion. Reduced hepatic and renal function can alter drug clear¬≠
ance, necessitating dose adjustments. For instance, lower doses of ben¬≠
zodiazepines, antidepressants, and antipsychotics are often required due 
to increased sensitivity and risk of adverse effects.579 Individualized care, 
considering the patient‚Äôs overall health status, comorbidities, and 
personal health goals is needed. Selecting safer drug alternatives, 
adjusting doses, and vigilant monitoring for adverse effects and interac¬≠
tions while balancing efficacy and safety is advisable. Guidance on poten¬≠
tial toxicity and interactions per drug class is further discussed in Section 6. 
A summary focusing specifically on the elderly population follows. 
SSRIs and SNRIs are generally the preferred antidepressants due to 
their favourable side effect profiles. ECG monitoring may be needed, 
especially when combined with other QT-prolonging drugs such as 
antiarrhythmics. The combination of antipsychotics and antiarrhythmic 
drugs or other QT-prolonging agents requires careful monitoring.


<!-- PAGE 45 -->

### Page 45

Additionally, antipsychotics metabolized by the CYP system can interact 
with CV drugs like beta-blockers and statins, necessitating dose adjust¬≠
ments.580,581 Lithium can cause arrhythmias, so it requires regular mon¬≠
itoring of serum levels and renal function. It can interact with diuretics 
and angiotensin-converting enzyme inhibitors, increasing the risk of lith¬≠
ium toxicity.582 Benzodiazepines can cause sedation and respiratory de¬≠
pression, especially when combined with other central nervous system 
depressants.579,582,583
Polypharmacy is highly prevalent in elderly patients, increasing the 
risk of drug interactions. For example, combining central nervous sys¬≠
tem depressants with CV drugs can lead to additive effects, such as in¬≠
creased sedation or hypotension. Regular medication reviews and 
deprescribing where appropriate are essential to minimize these 
risks.584 Specific interactions with CV drugs need to be specially as¬≠
sessed. For example, antipsychotics can increase the risk of QT pro¬≠
longation, arrhythmias, or hypotension when combined with 
beta-blockers or antiarrhythmics.580,583 Antipsychotics can increase 
the risk of myalgia, myopathy, or creatine kinase elevation in combin¬≠
ation with statins.580
8.3. Mental health and cardiovascular 
disease in people with frailty and 
multimorbidity
8.3.1. Mental health and frailty
Frailty is a state of diminished physiologic reserve and increased vulner¬≠
ability to adverse health outcomes.585 It is a potentially reversible dy¬≠
namic state fluctuating over time in response to stressors and 
interventions. Its incidence increases with age and overlaps with multi¬≠
morbidity.585,586 Cardiovascular disease and frailty arise from similar 
causal mechanisms, and each increases the risk of the other condi¬≠
tion.569 Frailty has been found to affect 40%‚Äì80% of people with 
HF,587 and to have a pooled prevalence of 19% among individuals 
with IHD.588 The substantial prevalence of frailty among older adults 
with CVD and associated risks for adverse events such as falls necessi¬≠
tate increased awareness and evaluation by clinicians.589
Most brief screening tools used clinically to assess frailty focus on bio¬≠
medical domains, rather than including a more holistic approach. 
Comprehensive geriatric assessments are advised in older adults to as¬≠
sess multiple domains including psychological and socio-environmental 
contributors to frailty.585 Depression, anxiety, and frailty are associated 
with each other as seen in both observational and Mendelian random¬≠
ization studies, with a bidirectional relationship found between depres¬≠
sion and frailty.590,591 An analysis of 444 094 participants (median 
follow-up 7.8 years) determined that frailty resulted in over three times 
the risk for depression and twice the risk for anxiety in adjusted 
analyses.592
8.3.2. Mental health, cardiovascular disease, and 
multimorbidity
Multimorbidity is defined as the presence of two or more chronic con¬≠
ditions in one person.593 It is estimated to affect ‚àº40% of the world‚Äôs 
population,594 and incidence is predicted to rise in parallel with gains 
in life expectancy and trends in global population ageing.595 At the 
societal level, multimorbidity is associated with significant healthcare 
use,595 and related utilization costs.596 At the individual level, it results 
in loss of agency and isolation,597,598 which in turn can lead to vulner¬≠
ability, frailty, and a need for social care.599 When interrogated by dis¬≠
ease or disease clusters in population studies,600 and systematic 
review,601 people with multimorbidity appear to have a high burden 
of concurrent CVD and mental health disorders like depression. 
However, there is no consensus across multimorbidity cluster studies 
and results are dependent upon the measure and/or threshold used 
to define multimorbidity.602
The growing burden of multimorbidity and its complexity necessi¬≠
tates collaborative management. Given that CVD and mental health dis¬≠
orders are frequently highlighted as important contributors to 
multimorbidity, it is reasonable that clinicians working in these fields 
can and should drive improvements in care. Degenerative neurological 
diseases should be considered as part of the multimorbidity assessment, 
but this particular aspect is out of the scope of this document. Within 
the secondary care setting, the evidence presented in Section 6.6 is rele¬≠
vant to the management of multimorbidity, and the implementation of 
the Psycho-Cardio team would likely drive improvements in care and 
outcomes. However, there is an absence of empirical research con¬≠
ducted in the secondary care setting and trials of bespoke multimorbid¬≠
ity management models are urgently needed. Within the primary care 
setting, there have been mixed results in RCTs of integrated care mod¬≠
els. The largest trial to date (3D: Dimensions of health, Depression, and 
Drugs) which was conducted on older adults (mean age 71 years) failed 
to meet its primary or secondary endpoints.603 A Cochrane review and 
meta-analysis of interventions designed to improve outcomes in pa¬≠
tients with multimorbidity in the primary care or community setting 
(18 RCTs) reported that there was evidence that such interventions 
improved mental health outcomes, but there was no or very little im¬≠
pact on clinical, functional, and healthcare use outcomes.604 Overall, the 
evidence suggests these interventions are effective for improving men¬≠
tal health outcomes, however, further research is required to identify 
interventions that have dual effects (i.e. improve mental health and 
CVD outcomes).
8.3.3. Summary of evidence in older adults with 
cardiovascular disease and mental disorders
The older adult is at increased risk for the associated conditions of 
CVD, mental health conditions, multimorbidity, and frailty. These 
conditions along with polypharmacy increase the complexity of 
management and require expertise from the Psycho-Cardio team. 
Comprehensive geriatric assessment can highlight important issues 
and ensure that psychosocial domains are identified and addressed. 
The evidence for non-pharmacological interventions and integrated 
care models in older adults with CVD and mental disorders is het¬≠
erogeneous. However, based on the current evidence these inter¬≠
ventions appear to be effective in improving mental health 
outcomes, although they are less likely to significantly improve 
CVD outcomes. A summary of the core issues in the management 
of older adults with CVD, multimorbidity, and polypharmacy is pre¬≠
sented in Figure 16.
ESC Guidelines                                                                                                                                                                                               45


<!-- PAGE 46 -->

### Page 46

8.4. Mental health and cardiovascular 
disease in socioeconomically deprived 
populations
Individuals facing economic difficulties often experience increased 
stress, reduced access to healthcare, and limited opportunities for 
social engagement.605 The role of psychosocial stress, its determi¬≠
nants, and impact on mental health and CV risk have been presented 
in Section 4. Psychological stressors linked to socioeconomic depriv¬≠
ation can exacerbate the risk and progression of CV condi¬≠
tions.606,607 Concerns about financial or housing stability and other 
basic needs may amplify hormone stress responses, potentially accel¬≠
erating CVD progression while increasing the vulnerability to mental 
health conditions like depression and anxiety.608 Lower SES often 
correlates with unhealthy lifestyle behaviours, further exacerbating 
CVD risk. Research has consistently demonstrated that CVD and 
HF are significantly more prevalent among individuals with low SES, 
with disparities more pronounced in marginalized communities, 
where structural inequalities amplify the impact of socioeconomic 
deprivation on health outcomes.607,609 Socioeconomic deprivation 
status seems to be an important covariate in CV risk estimation mod¬≠
els while risk scores that exclude socioeconomic deprivation under- 
and overestimate risk in the most and least deprived individuals, 
respectively.606
Mental health conditions following CVD events are more common in 
individuals with lower SES. Mental health service utilization following an 
MI is more frequent among men and women living in areas with high 
ethnic concentration and material deprivation.610 Several factors have 
been postulated as potential mechanisms linking lower SES and higher 
risk of mental health conditions and CVD (Figure 17).
Health inequities are also more frequent among populations such as 
the homeless, individuals with substance use disorders, sex workers, 
and imprisoned individuals with the impact of exclusion being greater 
in females than in males.611 While addressing socioeconomic depriv¬≠
ation is beyond the scope of practice, it is reasonable for healthcare 
professionals to:








	











			





¬Å




¬ç


¬è¬ê



¬ù

¬è¬ê


¬ç
¬†



¬ç
¬Å


Figure 16 Ageing, mental disorders, and cardiovascular disease. CVD, cardiovascular disease.


<!-- PAGE 47 -->

### Page 47

‚Ä¢ Recognize that people facing socioeconomic deprivation may have in¬≠
creased risk of CVD and mental health conditions and may struggle 
to make healthy lifestyle changes.
‚Ä¢ Tailor lifestyle advice and behaviour change strategies to the specific 
challenges of individuals living in deprived areas.
‚Ä¢ Support policies and governmental action that ensure equitable ac¬≠
cess to physical and mental healthcare, healthy food, exercise, and 
safe places for walking.
‚Ä¢ Advocate for efforts to reduce environmental pollution.
8.4.1. Mental health and cardiovascular disease in 
migrants and refugees
Minority populations are often subject to discrimination, socioeconom¬≠
ic disadvantage, and inequity of access to optimal clinical care.612,613
Migrants and refugees, as vulnerable groups, are at increased risk 
of mental health conditions and disorders, often with greater preva¬≠
lence of CV risk factors and socioeconomic deprivation.614 Migrants 
in particular experience higher rates of CVD morbidity and mortality 
than host populations.615 War refugees are also at higher risk for 
CVD and mental health conditions, especially PTSD, though they pre¬≠
sent lower risk of suicide.613 Additionally, migrants and refugees often 
encounter language and cultural barriers, making engagement with 
community leaders essential for improving communication in cross- 
cultural consultations in healthcare.616 While stakeholders‚Äô involve¬≠
ment can reduce healthcare barriers, structural factors may limit 
the scope and sustainability of these improvements in practice.617
Mental health challenges in migrant populations are illustrated in 
Figure 18.
Healthcare professionals can support migrant groups with CVD and 
mental health conditions by: 
‚Ä¢ Adopting culturally sensitive approaches.
‚Ä¢ Collaborating with community stakeholders.
‚Ä¢ Tailoring community-based strategies to different ethnic groups.
8.4.2. Barriers to mental healthcare access
Socioeconomic deprivation creates significant barriers to accessing 
both mental healthcare and CV care for individuals with CVD, worsen¬≠
ing the challenges faced by this vulnerable group. Financial constraints, 
lack of insurance coverage, and transportation difficulties are major ob¬≠
stacles, with stigma surrounding mental health further exacerbating the 
problem. Despite high rates of depression and anxiety in this popula¬≠
tion, the utilization of mental health services remains low due to these 
barriers.606,618‚Äì624
Comprehensive strategies are needed to overcome these barriers 
and ensure equitable access to healthcare, including subsidizing mental 
health services, expanding insurance coverage, integrating mental 
healthcare into primary care settings, and investing in telehealth. High 
costs of therapy, medication, and other interventions can be prohibi¬≠
tive, deterring people with CVD from seeking needed care, with the fi¬≠
nancial burden of CVD care further limiting resources for mental health 
support.619






	











¬Å



¬Å




Figure 17 Mechanisms through which socioeconomic deprivation contributes to cardiovascular risk. CV, cardiovascular.  
ESC Guidelines                                                                                                                                                                                               47


<!-- PAGE 48 -->

### Page 48

Additionally, the lack of comprehensive health insurance coverage is a 
significant issue, with many socioeconomically disadvantaged individuals 
unable to afford out-of-pocket mental health services. This further per¬≠
petuates disparities in access to necessary mental healthcare.620
Addressing these challenges through enhanced service provision and 
support is essential for improving mental health outcomes in people 
with CVD from socioeconomically deprived backgrounds.
8.4.3. Stigma in healthcare provision
Mental health-related stigma is a major barrier to accessing healthcare, op¬≠
erating at three interconnected levels: structural, interpersonal, and intra¬≠
personal.625 Structural discrimination is reflected in the disparity between 
physical and mental healthcare provision, resulting in limited and poor- 
quality mental health services.626 Interpersonal stigma involves problems 
of knowledge (ignorance), attitudes (prejudice), and behaviour (discrimin¬≠
ation). Intrapersonal mental health stigma, or self-stigma, reduces help- 
seeking behaviour and further contributes to health disparities.627
Stigma affects all populations across different socioeconomic strata, 
contributing to mental health disparities. Effective interventions to re¬≠
duce stigma include social contact with individuals with mental health 
disorders and personal relationships, such as with friends or family 
members. Educational interventions, especially for general healthcare 
professionals with little or no formal mental health training, have shown 
promise in decreasing stigma.626 However, there is a significant re¬≠
search gap regarding effective interventions to prevent and combat 
structural and interpersonal stigma. Enhancing education to include 
training on mental health and stigma for healthcare professionals could 
be crucial in addressing these issues.
8.4.4. Community and policy interventions
Community-level and policy interventions are essential to reduce the 
adverse impact of socioeconomic deprivation on mental health in indi¬≠
viduals with and without CVD.607,628,629 Initiatives addressing dispar¬≠
ities include:








	




	





	



	





Figure 18 Mental health challenges in migrant populations.


<!-- PAGE 49 -->

### Page 49

‚Ä¢ Ensuring access to quality health education for socioeconomically 
disadvantaged individuals to improve mental and CV outcomes.
‚Ä¢ Creating job opportunities and implementing affordable housing in¬≠
itiatives and ensuring equitable access to healthcare services to ad¬≠
dress mental health needs,
‚Ä¢ Improving access to healthy foods and safe spaces for physical activity 
to reduce CVD risk.
‚Ä¢ Ensuring equitable access to healthcare services to address mental 
and CV health needs.
‚Ä¢ Integrating successful interventions into broader health systems and 
social policies to enhance mental and CV health support.630‚Äì637
8.5. Mental health and cardiovascular 
disease in people with cancer 
(cardio-oncology)
8.5.1. Mental health in people with cancer and 
cardiovascular disease
Chronic stress may contribute to cancer development.638 Cancer diag¬≠
nosis and treatment initiation may cause or intensify psychological dis¬≠
tress,639 leading to an increased risk of major CV events (HF, 
ischaemic stroke, ACS, AF), with the highest incidence appearing 6‚Äì12 
months after cancer diagnosis.640‚Äì642 People with a new diagnosis of can¬≠
cer experience significant stress and anxiety associated with an uncertain 
prognosis, which may even trigger suicidal ideations. In prostate cancer, 
the risk of CV death was increased during the first month after diagnosis 
(‚àºtwo-fold) and highest in people with metastatic cancer (‚àºthree- 
fold).642 New CV symptoms (e.g. venous thrombosis, pulmonary embol¬≠
ism, stroke, MI, TTS, arrhythmia) may appear with cancer,643 suggesting 
common underlying factors, such as chronic inflammation and thrombo¬≠
embolic disorders. However, the importance of stress may be crucial.
Takotsubo syndrome in people living with cancer is a notable ex¬≠
ample of a role of stress and anxiety in cardio-oncology.644‚Äì647 Three 
of the most important independent prognostic predictors of mortality 
in people with TTS include cancer history (HR 2.004; P = .004), physical 
stress as a trigger (HR 1.882; P = .012), and history of depression (HR 
1.622; P = .009).648 Takotsubo syndrome in people with prior in¬≠
trathoracic malignancies and radiation therapy carries a higher risk of 
cardiogenic shock, cardiac arrest, arrhythmia, stroke, respiratory fail¬≠
ure, and all-cause mortality.649
People with cancer and concomitant CVD may fear that their CVD will 
delay or prevent optimal cancer treatment. Cardio-oncology programmes 
aim to prevent such issues by ensuring proper CV management allowing 
optimal oncology therapy and providing a supportive network throughout 
the treatment phase.650 Psychologists, as an integral part of the 
cardio-oncology team, are essential to help people to cope with the psy¬≠
chological consequences of the disease and treatment. Physiotherapists 
and dietitians also play vital roles in empowerment and reassurance.
8.5.2. Cancer survivors
After radical anticancer treatment, where a good long-term prognosis 
is expected, stress may be related to the fear of cancer recurrence,651
or depression related to the complications of cancer or its treat¬≠
ment.652 Among childhood cancer survivors, stress/distress was asso¬≠
ciated with new-onset dysrhythmia (RR 2.87), perceived stress with 
hypertension (RR 1.42), PTSS and anxiety with dyslipidaemia (RR 
1.72 and 1.54, respectively).653 A significant relationship between se¬≠
vere psychological distress and CVD in cancer survivors was observed 
(OR 2.95), especially in younger females.654
8.5.3. Advanced cancer disease
Awareness of cancer progression can lead to depression, which may be 
worsened by cancer treatment-related toxicity.655 Cancer progression, 
fatigue, and therapy-related toxicity (haematological, endocrinological, 
neurological and particularly, cardiological) contribute to feelings of dis¬≠
couragement and depression.656 One in four people with advanced 
cancer, HF, chronic obstructive pulmonary disease, and/or human im¬≠
munodeficiency virus/acquired immunodeficiency syndrome may ex¬≠
perience mental health issues, including depression, alcohol abuse, 
PTSD, or anxiety disorders.657 Such conditions often coexist and 
may be observed in cardio-oncology.
8.5.4. Cancer therapy-related cardiovascular 
toxicity
People with pre-existing CVD are more sensitive to cancer therapy-related 
CV toxicity including CV dysfunction; however, stressors like anxiety can 
be an additional trigger.658 People with breast cancer who experienced 
cancer therapy-related CV dysfunction reported significant declines in 
physical, social, and psychosocial well-being, including overwhelming fatigue, 
mental burden of anxiety (fear of death, depression, stress, poor sleep qual¬≠
ity), and social challenges (lack of understanding and acceptance).659 Heart 
failure in breast cancer survivors is particularly linked to serious mental 
well-being deficits, especially in the early stages.660 This underscores the 
need for multidisciplinary cardio-oncological care models.659
8.5.5. Impact of cancer therapy on mental health
People in the cardio-oncology setting may experience neurotoxicity, in¬≠
cluding chemotherapy-induced cognitive dysfunction (‚Äòchemobrain‚Äô), 
particularly with cardiotoxic therapies, which correlates with increased 
fatigue and psychological distress.661 Potentially cardiotoxic cancer 
treatments with possible cognitive impairment include: chemotherapy 
(doxorubicin, paclitaxel, methotrexate, fluorouracil), hormone therap¬≠
ies (aromatase inhibitors, anti-oestrogen, androgen deprivation ther¬≠
apy), targeted therapies (antiangiogenic therapy), and immunotherapy 
(anti-CTLA-4, anti-PDL-1).662
Androgen deprivation therapy, a primary treatment for prostate can¬≠
cer, is associated with a higher risk of depression and psychiatric outpatient 
visits.663 Endocrine therapy for breast cancer may cause mood disor¬≠
ders,664 sleep problems,665 cognitive decline,666 fear of cancer recur¬≠
rence,667 emotional distress, and concern about appearance.668 Severe 
fear of cancer recurrence was associated with a higher risk of depression 
and lower QoL in breast cancer survivors.669
Chemotherapy-induced peripheral neuropathy significantly decreases 
QoL and impacts on mental health. Older (cisplatin and vinca alkaloids) 
and newer (taxanes, oxaliplatin) anticancer agents can be responsible for 
these neurological side effects. Oncology expert documents recommend 
antidepressants (e.g. venlafaxine, duloxetine),670 but these should be cho¬≠
sen following consideration of CVD risk (e.g. HF or arrhythmias/QTc pro¬≠
longation). Radiation, while essential in many cancer treatments, can 
induce CV toxicity671 and significant mental health issues.672 The 
Ontario Cancer Registry showed mental health conditions (anxiety, de¬≠
pression, and low well-being) were associated with higher comorbidity 
burden during radiation.673
8.5.6. Psychological interventions
One of the roles of cardio-oncology is to minimize the barriers to onco¬≠
logical treatment related to a person‚Äôs CVD. Providing simultaneous 
cardiology care can improve the psychological well-being of people 
dealing with both cancer and CVD. Cardio-oncologists should identify 
ESC Guidelines                                                                                                                                                                                               49


<!-- PAGE 50 -->

### Page 50

psychosocial distress, including depression, anxiety, anger, social 
isolation, marital/family distress, sexual dysfunction, and substance 
abuse. People in the cardio-oncology setting may benefit from multi¬≠
disciplinary team discussions, involving CV specialists, oncologists, and 
mental health professionals. Alternatively, they should be referred to 
mental health specialists, who can collaborate with the primary 
cardio-oncology team to support comprehensive care.674
8.5.7. Lifestyle interventions in cardio-oncology
A comprehensive approach is necessary in cardio-oncology, as both CV 
health and mental health should be monitored during and after cancer 
therapy. The essence of a cardio-oncology clinic resides in the availabil¬≠
ity of a doctor to address symptoms related to CV toxicity from 
oncological treatment or potential cancer relapse/progression, which 
may coexist.675 The benefits in cardio-oncology include recommending 
physical activity: 
‚Ä¢ Cancer survivors with CVD: an exercise-based programme can im¬≠
prove cardiorespiratory fitness and survival;676 ECR can improve de¬≠
pression scores in breast cancer survivors.677
‚Ä¢ In people with advanced or metastatic cancer,678 exercise interven¬≠
tions can lower mortality, and improve psychosocial function and 
sleep quality.679
‚Ä¢ Women with breast cancer receiving potentially cardiotoxic therap¬≠
ies may improve their mental health by a comprehensive CV risk re¬≠
duction programme.680





	


	











	
	



¬Å¬ç	¬Å
¬Å





¬è

¬è

¬ç	
¬ê¬ù

Figure 19 Management of mental health in people with cardiovascular disease and cancer. CVD, cardiovascular disease; PTSD, post-traumatic stress disorder.


<!-- PAGE 51 -->

### Page 51

8.5.8. Medical interventions (including 
pharmacological therapies)
There are no specific recommendations or evidence for the efficacy of 
psychiatric drugs in cardio-oncology. However, data from general car¬≠
diology and oncology can be extrapolated and implemented with care¬≠
ful consideration of specific requirements of people with cancer and 
CVD.
The frequency of ventricular arrhythmias increases in people with 
advanced cancer,681 with the risk compounded by coexisting heart 
disease.682 Psychiatric drugs (antipsychotics, antidepressants), CV 
drugs (especially antiarrhythmics), and oncological drugs may interact, 
leading to QTc prolongation, and increased bleeding risk.683
Therefore, it is important to avoid significant drug‚Äìdrug interactions 
to minimize side effects and prevent reduced effectiveness of cancer 
treatments due to altered plasma concentrations.680,683 There are 
potential positive indirect effects on mental health resulting from 
CV therapies: 
‚Ä¢ Treating cancer therapy-related CV dysfunction and cancer-related 
anaemia may decrease shortness of breath, easing anxiety and 
distress.684
‚Ä¢ Treatment of tachycardia/tachyarrhythmia or autonomic dysfunction 
due to radiotherapy, chemotherapy, or cancer, may improve psycho¬≠
logical symptoms.685‚Äì687
On the other hand, reducing anxiety and stress may lower blood 
pressure and help control hypertension in people living with cancer. 
A summary of the major management steps of mental health in 
cardio-oncology and the main management approaches is shown in 
Figure 19.
8.6. Section summary points and 
management consensus statements from 
Section 8
9. Key messages
(i) The interplay between mental and CV health should be known 
and acknowledged in order to provide a holistic and integrated 
care.
(ii) Healthcare professionals should aspire to implement an inte¬≠
grated Psycho-Cardio team approach that is tailored to the local 
needs.
(iii) The ACTIVE principles (Acknowledge, Check, Tools, Implement, 
Venture, Evaluate) can be used as a practical approach to imple¬≠
ment integrated mental healthcare into CV practice.
(iv) Screening for mental health conditions (mainly anxiety, depres¬≠
sion, and PTSD) and psychosocial risk factors could help improve 
CV risk assessment in healthy individuals.
(v) Screening for mental health conditions in people with CVD is im¬≠
portant since these are highly prevalent and associated with 
worse outcomes.
(vi) Initial screening may be performed with a two-item measure, 
followed by longer validated tools if it raises mental health 
concerns.
(vii) A stepped care approach for mental health in CVD is advisable: 
intensity of mental care should be tailored to individual need.
(viii) There is low to moderate certainty evidence that psychological in¬≠
terventions have an effect on depression, anxiety, and QoL in 
people with CVD. The evidence is weaker or non-existent for a 
reduction in MACE and mortality.
(ix) Pharmacological treatment with anxiolytics or antidepressants in 
people with CVD and mental health conditions should be balanced 
against risks, considering drug‚Äìdrug interactions and side effects.
(x) Caregivers of people with CVD, who play a key role in well-being 
and treatment adherence, often face mental health challenges 
themselves, highlighting the need for strategies to assess and sup¬≠
port their mental health.
(xi) People with SMI have a worse CV outcome. Efforts should be 
made to reduce stigma and provide optimal Guideline-directed 
CV care, with special attention to treatment adherence and clin¬≠
ically relevant drug‚Äìdrug interactions.
(xii) Specific characteristics (sex, gender, age, frailty, SES, comorbid¬≠
ities, co-medications) should be carefully assessed as they are 
modifiers of the interaction between CVD and mental health 
and may merit individualized approaches.
SECTION SUMMARY POINTS
(i)
Depression, anxiety, and chronic stress show higher prevalence in 
women compared with men and are associated with increased 
CVD risk.
(ii)
Women with CVD exhibit higher rates of mental health conditions, 
which are associated with worse outcomes, particularly depression.
(iii)
Sex differences in the multidirectional relationship between CV and 
mental health suggest a role of biological and sociocultural 
components (gender).
(iv)
Evaluation of mental health and frailty in elderly people with CVD is 
of utmost importance,
(v)
Socioeconomically deprived populations show higher rates of CVD 
and mental disorders and require special attention.
(vi)
Cancer, CVD, and mental disorders exhibit significant three-way 
relationships with shared risk factors.
Continued
MANAGEMENT CONSENSUS STATEMENTS
(i)
Psycho-Cardio teams may need to tailor their intervention to the 
specificities of the target population, with special attention to sex 
differences, age, frailty, and SES.
(ii)
The appropriateness of antidepressants, drug interactions and side 
effects in the multimorbid, elderly, and frail need careful evaluation 
by a multidisciplinary team.
(iii)
Migrants and refugees may benefit from directed proactive 
programmes to assess their CV and mental health due to the high 
prevalence of conditions and their potential difficulties to access the 
healthcare system.
¬© ESC 2025
ESC Guidelines                                                                                                                                                                                               51


<!-- PAGE 52 -->

### Page 52

### 10 Gaps in knowledge

There are substantial gaps in the knowledge of the multidirectional re¬≠
lationship between mental health, CV health, and CVD, and its mechan¬≠
isms. Further, optimal strategies to identify, prevent, and manage 
mental health conditions in people with CVD are lacking. These gaps 
not only include finding effective interventions to prevent and manage 
mental health conditions and ways to implement them, but also ways to 
change the system to provide integrative healthcare including mental 
and physical health. A summary of the main gaps across the broad do¬≠
mains covered in this document are outlined below.
10.1. Knowledge gaps in relation to 
prevention and screening
‚Ä¢ There is a lack of evidence-based, cost-effective, and tailored inter¬≠
ventions to improve psychosocial factors, mental health conditions, 
and mental well-being as preventive measures for CVD.
‚Ä¢ Determination of optimal screening protocols, including timing, fre¬≠
quency, and methods, for mental health conditions in people with 
CVD, and how these might vary by condition have not been established.
‚Ä¢ Screening-based treatment algorithms are not defined.
‚Ä¢ Data on the cost-effectiveness of interventions to identify, prevent, 
or treat mental health conditions in people with CVD are lacking.
10.2. Knowledge gaps in relation to clinical 
management
‚Ä¢ Feasibility, effectiveness, and sustainability of long-term non- 
pharmacological interventions, such as physical activity, psychother¬≠
apy, and social prescribing need to be established.
‚Ä¢ Evaluation of specific psychological interventions and their delivery 
methods, including digital health solutions, is needed.
‚Ä¢ Effective behavioural strategies for achieving behaviour change and 
improving CV risk profiles among people with mental disorders, in¬≠
cluding SMI, need to be developed and tested.
‚Ä¢ Understanding of the role of trauma-specific prevention or treat¬≠
ments for CVD-related PTSD is lacking.
‚Ä¢ Research into the mental health impact of caregiving for people with 
CVD, prevention of its negative consequences, and integration of in¬≠
terventions into routine CV care is needed.
‚Ä¢ Pharmacological research is needed to: 
‚ö¨Demonstrate the safety and efficacy of antidepressants and anti¬≠
psychotics in people with HF and their effects on CV clinical 
outcomes.
‚ö¨Explore the role of pharmacogenomics in stratifying treatment to 
minimize CV adverse effects and enhance psychiatric treatment 
efficacy.
‚ö¨Investigate the efficacy of psychiatric drugs in cardio-oncology.
10.3. Knowledge gaps in relation to special 
populations
‚Ä¢ Cardiovascular risk scores for people with SMI need to be recalibrated.
‚Ä¢ Randomized controlled trials of interventions for elderly people with 
comorbid CVD and mental health conditions are needed.
‚Ä¢ The efficacy of multidisciplinary approaches in improving outcomes 
for people with multimorbidity requires further research. 
10.4. Knowledge gaps in relation to 
healthcare systems and healthcare delivery
‚Ä¢ Development and testing of integrated or collaborative care models 
for people with coexisting CV and mental health conditions is 
needed.
‚Ä¢ Care pathways to streamline the management of people with 
CVD and mental health conditions need to be developed and 
evaluated.
‚Ä¢ Evaluation of community-level and policy interventions to address 
socioeconomic disparities impacting CV and mental health is 
essential.
11. Conclusions
This document provides a comprehensive review of the evidence of the 
critical interplay between mental and CV health and disease, emphasiz¬≠
ing the need to integrate mental health assessment and management 
into routine CV care. However, the consistency of definitions, mechan¬≠
isms of interactions, and optimal ways to investigate, prevent, or treat 
the negative impact of mental health on CVD and vice versa need fur¬≠
ther research.
Social and clinical efforts are needed to fight the stigma of mental 
health conditions in the population and in healthcare systems to reduce 
its impact on CV care. This is particularly urgent for people with SMI, in 
whom an extra effort is needed to reduce the major gaps in CV preven¬≠
tion, acute and chronic CV care. Awareness campaigns and educational 
programmes for CV care professionals, people with CVD, their care¬≠
givers and decision-makers will be needed.
Integrated CV care models with a holistic view of health need to be 
co-developed in hospital and outpatient CV care units, integrating and co- 
ordinating with mental health professionals, primary care and social care. 
These should be co-designed together with people with lived experience 
of CVD and their caregivers, and adapted to the local conditions and 
availability, individual characteristics and needs. Comprehensive ECR pro¬≠
grammes are good examples of care integration. Educational modules 
and specific training programmes designed by medical and nursing staff 
and allied health professionals, particularly mental health professionals, 
are warranted. Reimbursement models for the new models of care 
need to be addressed and implemented by local authorities.
Future research is needed to increase the knowledge of the multi¬≠
lateral interactions between mental health and CV health and obtain 
solid evidence for the prevention and management of the negative 
consequences of these interactions. This should include prospective 
longitudinal studies in the population, in people with different CVDs, 
and in people with mental health conditions, including those with 
SMI. There is an urgent need for RCTs, with larger and more diverse 
samples of individuals and types of CVD that test the effectiveness 
and safety of medical and non-medical interventions. These trials 
should include psychological, pharmacological, social, and other types 
of interventions to prevent or reduce negative mental and CV 
outcomes.


<!-- PAGE 53 -->

### Page 53

### 12 Summary of mental health

aspects in specific cardiovascular 
diseases
Summary information for the CVDs discussed in this consensus state¬≠
ment is provided in Supplementary data online, Tables S12‚ÄìS17.
13. Clinical cases and patient 
perspectives
Clinical cases and patient perspectives are available at European Heart 
Journal online.
14. Evidence tables
Evidence tables are available at European Heart Journal online.
15. Data availability statement
Supplementary data are available at European Heart Journal online.
16. Author information
Author/Task 
Force 
Member 
Affiliations: 
Frieder 
Braunschweig, Heart and Lung Diseases Unit, Department of 
Medicine (H7), Karolinska Institutet, Stockholm, Sweden, and 
Department of Cardiology, Heart and Vascular Center, Karolinska 
University Hospital, Stockholm, Sweden; Sergio Buccheri, 
Department of Medical Sciences, Cardiology and Uppsala Clinical 
Research Center, Uppsala University, Uppsala, Sweden; Simona 
Dragan, Cardiology, Victor Babes University of Medicine and 
Pharmacy, Timisoara, Romania, and Clinic of Cardiac Rehabilitation, 
Institute of Cardiovascular Diseases, Timisoara, Romania; Marta 
Farrero, Heart Failure Unit, Cardiology, Hospital Clinic Barcelona, 
Barcelona, Spain; Faye Forsyth, Department of Public Health and 
Primary Care, University of Cambridge, Cambridge, United Kingdom, 
and Department of Public Health and Primary Care, KU Leuven, 
Leuven, Belgium; Sofie Gevaert, Cardiology, Ghent University 
Hospital, Gent, Belgium; Claes Held, Uppsala Clinical Research 
Center, Uppsala University, Uppsala, Sweden, and Department of 
Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; 
Donata Kurpas, Division of Research Methodology, Department 
of Nursing, Wroclaw Medical University, Wroclaw, Poland; 
Karl-Heinz Ladwig, Department of Psychosomatic Medicine and 
Psychotherapy, Klinikum rechts der Isar, Technische Universit√§t 
M√ºnchen, Munich, Germany, and German Center for Cardiovascular 
Research (DZHK), Partnersite Munich Heart Alliance, Munich, 
Germany; Christos D. Lionis, Laboratory of Health and Society, 
School of Medicine, University of Crete, Greece, Heraklion, Crete, 
Greece, and University of Limassol, Cyprus; Angela H.E.M. Maas, 
Cardiology, 
Radboud 
University 
Medical 
Center, 
Nijmegen, 
Netherlands; Caius Ovidiu Mer»ôa, ESC Patient Forum, Sophia 
Antipolis, France; Richard Mindham, ESC Patient Forum, Sophia 
Antipolis, France; Susanne S. Pedersen, Department of 
Psychology, University of Southern Denmark, Odense, Denmark, and 
Department of Cardiology, Odense, Denmark; Martina Rojnic 
Kuzman, Department of Psychiatry and Psychological Medicine, 
Zagreb University Hospital Centre, Zagreb, Croatia, and Department 
of Psychiatry and Psychological Medicine, Zagreb School of Medicine, 
Zagreb, Croatia, and European Psychiatric Association, Strasbourg, 
France; Sebastian Szmit, Department of Cardio-Oncology, Centre 
of 
Postgraduate 
Medical 
Education, 
Warsaw, 
Poland, 
and 
Department of Cancer Diagnostics and Cardio-Oncology, Maria 
Sklodowska-Curie National Research Institute of Oncology, Warsaw, 
Poland; Rod S. Taylor, MRC/cso Social and Public Health Sciences 
Unit & Robertson Centre for Biostatistics, University of Glasgow, 
Glasgow, United Kingdom; Izabella Uchmanowicz, Department 
of Nursing, Faculty of Nursing and Midwifery, Wroclaw Medical 
University, Wroclaw, Poland, and Centre for Cardiovascular Health, 
Edinburgh Napier University, United Kingdom; and Noa Vilchinsky, 
Department of Psychology, Bar-Ilan University, Ramat-Gan, Israel.
17. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac 
Societies.
Document Reviewers: Konstantinos C. Koskinas (CPG Review 
Co-ordinator) 
(Switzerland), 
Pascal 
Vranckx 
(CPG 
Review 
Co-ordinator) (Belgium), Marianna Adamo (Italy), Elena Arbelo 
(Spain), Folkert W. Asselbergs (Netherlands), Giuseppe Boriani 
(Italy), Margarita Brida (Croatia), Noeleen Burke (Ireland), Robert 
A. Byrne (Ireland), Ingrid de Laval (Sweden), Lidia Einsfeld (Brazil), 
Enrico Frigoli (Switzerland), Leonarda Galiuto (Italy), Estelle 
Gandjbakhch (France), Sherry L. Grace (Canada), Johannes Grand 
(Denmark), 
Bettina 
Heidecker 
(Germany), 
Mirjam 
Heldner 
(Switzerland), Charlotte Helmark (Denmark), Marwa Hemmat Gaber 
(Egypt), Loreena Hill (United Kingdom), Lisa Hynes (Ireland), Borja 
Ibanez (Spain), Stefan James (Sweden), Alexander Kharlamov 
(Netherlands), Hanne Kindermans (Belgium), Lars K√∏ber (Denmark), 
Ulf Landmesser (Germany), Gregory Y.H. Lip (United Kingdom), 
Emma F. Magavern (United Kingdom), John William McEvoy (Ireland), 
Paul McGreavy (United Kingdom), Borislava Mihaylova (United 
Kingdom), Inge Moelgaard (Denmark), Manuela Abreu (Portugal), 
Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet (Belgium), Eva 
Prescott (Denmark), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Annett Salzwedel (Germany), Anna 
Sannino (Germany), Eduard Shantsila (United Kingdom), Chantal Ski 
(United Kingdom), Andrew Steptoe (United Kingdom), Felix 
C. Tanner (Switzerland), Diogo Telles (Portugal), Ilonca Vaartjes 
(Netherlands), Berlinde von Kemp (Belgium), Christiaan Vrints 
(Belgium), and Katja Zeppenfeld (Netherlands).
ESC National Cardiac Societies actively involved in the review 
process of the 2025 ESC Consensus Statement on Mental Health and 
Cardiovascular Disease:
Algeria: Algerian Society of Cardiology, Mohammed El Amine 
Bouzid; Azerbaijan: Azerbaijan Society of Cardiology, Emin Karimli; 
Belgium: Belgian Society of Cardiology, Michel De Pauw; Bosnia 
and Herzegovina: Association of Cardiologists of Bosnia and 
Herzegovina, Lamija Ferhatbegoviƒá; Bulgaria: Bulgarian Society of 
Cardiology, Kiril Karamfiloff; Croatia: Croatian Cardiac Society, 
Valentina Rickovic; Cyprus: Cyprus Society of Cardiology, Joseph 
Moutiris; Denmark: Danish Society of Cardiology, Ann Dorthe 
Zwisler; Egypt: Egyptian Society of Cardiology, Ahmed Elghalid; 
Estonia: Estonian Society of Cardiology, Alar Irs; France: French 
Society of Cardiology, Jean Jacques Monsuez; Georgia: Georgian 
Society of Cardiology, Rusudan Agladze; Germany: German 
ESC Guidelines                                                                                                                                                                                               53


<!-- PAGE 54 -->

### Page 54

Cardiac Society, Christoph Herrmann-Lingen; Greece: Hellenic 
Society of Cardiology, Athanasios Dritsas; Hungary: Hungarian 
Society of Cardiology, Endre Zima; Iceland: Icelandic Society of 
Cardiology, Hr√≥bjartur Karlsson; Israel: Israel Heart Society, Inbar 
Nardi Agmon; Italy: Italian Federation of Cardiology, Anna Vittoria 
Mattioli; Kazakhstan: Association of Cardiologists of Kazakhstan, 
Meiramgul Tundybayeva; Kosovo (Republic of): Kosovo Society 
of Cardiology, Shpend Elezi; Kyrgyzstan: Kyrgyz Society of 
Cardiology, Erkin Mirrakhimov; Latvia: Latvian Society of 
Cardiology, Iveta Mintale; Lithuania: Lithuanian Society of 
Cardiology, Tomas Lapinskas; Luxembourg: Luxembourg Society 
of Cardiology, Cristiana-Astra Banu; Moldova (Republic of): 
Moldavian Society of Cardiology, Valeriu Revenco; Morocco: 
Moroccan Society of Cardiology, Iliyasse Asfalou; Netherlands: 
Netherlands Society of Cardiology, Petra Kuijpers; North 
Macedonia: National Society of Cardiology of North Macedonia, 
Jorgo Kostov; Norway: Norwegian Society of Cardiology, Eva Rice; 
Poland: Polish Cardiac Society, Anna Mierzynska; Portugal: 
Portuguese Society of Cardiology, Manuela Abreu; Romania: 
Romanian Society of Cardiology, Florin Mitu; San Marino: San 
Marino Society of Cardiology, Luca Bertelli; Serbia: Cardiology 
Society of Serbia, Dusica Lecic Tosevski; Slovakia: Slovak Society of 
Cardiology, Zuzana Katreniakova; Slovenia: Slovenian Society of 
Cardiology, Zlatko Fras; Spain: Spanish Society of Cardiology, 
Raquel Campuzano; Sweden: Swedish Society of Cardiology, Joanna 
Hlebowicz; Switzerland: Swiss Society of Cardiology, Matthias 
Hermann; T√ºrkiye: Turkish Society of Cardiology, Baris Gungor; 
Ukraine: Ukrainian Association of Cardiology, Yuriy Sirenko; and 
Uzbekistan: Association of Cardiologists of Uzbekistan, Nargiza 
Makhkamova.
ESC Clinical Practice Guidelines (CPG) Committee: 
Ulf 
Landmesser 
(Chairperson) 
(Germany), 
Stefan 
James 
(Co-Chairperson) (Sweden), Marianna Adamo (Italy), Suleman 
Aktaa (United Kingdom), Folkert W. Asselbergs (Netherlands), 
Colin Baigent (United Kingdom), Michael A. Borger (Germany), 
Giuseppe Boriani (Italy), Margarita Brida (Croatia), Robert 
A. Byrne (Ireland), Estelle Gandjbakhch (France), Bettina Heidecker 
(Germany), Anja Hennemuth (Germany), Borja Ibanez (Spain), 
Peter J√ºni (United Kingdom), Gregory Y.H. Lip (United Kingdom), 
John William McEvoy (Ireland), Borislava Mihaylova (United 
Kingdom), Inge Moelgaard (Denmark), Lis Neubeck (United 
Kingdom), Eva Prescott (Denmark), Bianca Rocca (Italy), Xavier 
Rossello (Spain), Anna Sannino (Germany), Felix C. Tanner 
(Switzerland), Wojtek Wojakowski (Poland), and Katja Zeppenfeld 
(Netherlands).
18. References
1. Cox C, Fritz Z. Presenting complaint: use of language that disempowers patients. BMJ 
2022;377:e066720. https://doi.org/10.1136/bmj-2021-066720
2. Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: how to decide its 
appropriateness. World J Methodol 2021;11:116‚Äì29. https://doi.org/10.5662/wjm.v11. 
i4.116
3. World Health Organization. Comprehensive Mental Health Action Plan 2013‚Äì2030. 
2013. https://www.who.int/publications/i/item/9789240031029 (5 February 2024, 
date last accessed).
4. Manwell LA, Barbic SP, Roberts K, Durisko Z, Lee C, Ware E, et al. What is mental 
health? Evidence towards a new definition from a mixed methods multidisciplinary 
international survey. BMJ Open 2015;5:e007079. https://doi.org/10.1136/bmjopen- 
2014-007079
5. Chowdhury M. What is the Mental Health Continuum Model? 2019. https:// 
positivepsychology.com/mental-health-continuum-model/ (8 October 2024, date 
last accessed).
6. Peck MC, Scheffler RM. An analysis of the definitions of mental illness used in state 
parity laws. Psychiatr Serv 2002;53:1089‚Äì95. https://doi.org/10.1176/appi.ps.53.9. 
1089
7. World Health Organization. International Classification of Diseases, Eleventh Revision 
(ICD-11) 2022. https://icd.who.int/ (5 February 2024, date last accessed).
8. National Association of Chronic Disease Directors. Cardiovascular Health. https:// 
chronicdisease.org/page/cardiovascularhealth/ (20 June 2024, date last accessed).
9. Boehm JK, Kubzansky LD. The heart‚Äôs content: the association between positive psy¬≠
chological well-being and cardiovascular health. Psychol Bull 2012;138:655‚Äì91. https:// 
doi.org/10.1037/a0027448
10. Rozanski A. Behavioral cardiology: current advances and future directions. J Am Coll 
Cardiol 2014;64:100‚Äì10. https://doi.org/10.1016/j.jacc.2014.03.047
11. Kubzansky LD, Huffman JC, Boehm JK, Hernandez R, Kim ES, Koga HK, et al. Positive 
psychological well-being and cardiovascular disease: JACC health promotion series. J 
Am Coll Cardiol 2018;72:1382‚Äì96. https://doi.org/10.1016/j.jacc.2018.07.042
12. Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al. 
Prevalence, incidence and mortality from cardiovascular disease in patients with 
pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 pa¬≠
tients and 113,383,368 controls. World Psychiatry 2017;16:163‚Äì80. https://doi.org/10. 
1002/wps.20420
13. Vilchinsky N, Ginzburg K, Fait K, Foa EB. Cardiac-disease-induced PTSD (CDI-PTSD): 
a systematic review. Clin Psychol Rev 2017;55:92‚Äì106. https://doi.org/10.1016/j.cpr. 
2017.04.009
14. Rafiei S, Raoofi S, Baghaei A, Masoumi M, Doustmehraban M, Nejatifar Z, et al. 
Depression prevalence in cardiovascular disease: global systematic review and 
meta-analysis. BMJ Support Palliat Care 2023;13:281‚Äì9. https://doi.org/10.1136/ 
spcare-2022-003884
15. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a 
meta-analytic review of prevalence, intervention effects, and associations with clinical 
outcomes. J Am Coll Cardiol 2006;48:1527‚Äì37. https://doi.org/10.1016/j.jacc.2006.06.055
16. Karami N, Kazeminia M, Karami A, Salimi Y, Ziapour A, Janjani P. Global prevalence of 
depression, anxiety, and stress in cardiac patients: a systematic review and meta-analysis. 
J Affect Disord 2023;324:175‚Äì89. https://doi.org/10.1016/j.jad.2022.12.055
17. Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, 
et al. Depression as a risk factor for poor prognosis among patients with acute coron¬≠
ary syndrome: systematic review and recommendations: a scientific statement from 
the American Heart Association. Circulation 2014;129:1350‚Äì69. https://doi.org/10. 
1161/CIR.0000000000000019
18. Sokoreli I, de Vries JJ, Riistama JM, Pauws SC, Steyerberg EW, Tesanovic A, et al. 
Depression as an independent prognostic factor for all-cause mortality after a hospital 
admission for worsening heart failure. Int J Cardiol 2016;220:202‚Äì7. https://doi.org/10. 
1016/j.ijcard.2016.06.068
19. Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association be¬≠
tween anxiety and mortality in patients with coronary artery disease: a meta-analysis. Am 
Heart J 2015;170:1105‚Äì15. https://doi.org/10.1016/j.ahj.2015.09.013
20. Morgan AJ, Reavley NJ, Ross A, Too LS, Jorm AF. Interventions to reduce stigma to¬≠
wards people with severe mental illness: systematic review and meta-analysis. J 
Psychiatr Res 2018;103:120‚Äì33. https://doi.org/10.1016/j.jpsychires.2018.05.017
21. Heiberg IH, Jacobsen BK, Balteskard L, Bramness JG, Naess √ò, Ystrom E, et al. 
Undiagnosed cardiovascular disease prior to cardiovascular death in individuals with 
severe mental illness. Acta Psychiatr Scand 2019;139:558‚Äì71. https://doi.org/10.1111/ 
acps.13017
22. Marchand WE. Occurrence of painless myocardial infarction in psychotic patients. N 
Engl J Med 1955;253:51‚Äì5. https://doi.org/10.1056/NEJM195507142530202
23. Stubbs B, Thompson T, Acaster S, Vancampfort D, Gaughran F, Correll CU. 
Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experi¬≠
mental pain induction studies. Pain 2015;156:2121‚Äì31. https://doi.org/10.1097/j.pain. 
0000000000000304
24. De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, et al. Physical 
illness in patients with severe mental disorders. II. Barriers to care, monitoring and treat¬≠
ment guidelines, plus recommendations at the system and individual level. World 
Psychiatry 2011;10:138‚Äì51. https://doi.org/10.1002/j.2051-5545.2011.tb00036.x
25. Mitchell AJ, Lord O. Do deficits in cardiac care influence high mortality rates in schizo¬≠
phrenia? A systematic review and pooled analysis. J Psychopharmacol 2010;24:69‚Äì80. 
https://doi.org/10.1177/1359786810382056
26. Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al. 
Mortality in people with schizophrenia: a systematic review and meta-analysis of rela¬≠
tive risk and aggravating or attenuating factors. World Psychiatry 2022;21:248‚Äì71. 
https://doi.org/10.1002/wps.20994
27. Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR, et al. No health without men¬≠
tal health. Lancet 2007;370:859‚Äì77. https://doi.org/10.1016/S0140-6736(07)61238-0
28. Raj CT. The effectiveness of mental health disorder stigma-reducing interventions in 
the healthcare setting: an integrative review. Arch Psychiatr Nurs 2022;39:73‚Äì83. 
https://doi.org/10.1016/j.apnu.2022.03.005


<!-- PAGE 55 -->

### Page 55

29. Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and man¬≠
agement of depression in patients with cardiovascular disease: JACC state-of-the-art 
review. J Am Coll Cardiol 2019;73:1827‚Äì45. https://doi.org/10.1016/j.jacc.2019.01.041
30. Mindham R, Van Heetvelde M, Pedersen SS. How your patient is really feeling: the 
emotional hinterland of a cardiac diagnosis. Eur Heart J 2024;45:748‚Äì50. https://doi. 
org/10.1093/eurheartj/ehad840
31. George-Levi S, Vilchinsky N, Rafaeli E, Liberman G, Khaskiaa A, Mosseri M, et al. 
Caregiving styles and anxiety among couples: coping versus not coping with cardiac ill¬≠
ness. Anxiety Stress Coping 2017;30:107‚Äì20. https://doi.org/10.1080/10615806.2016. 
1206530
32. Fait K, Vilchinsky N, Dekel R, Levi N, Hod H, Matetzky S. Cardiac disease-induced post- 
traumatic stress symptoms (CDI-PTSS) among patients‚Äô partners. Stress Health 2017; 
33:169‚Äì76. https://doi.org/10.1002/smi.2686
33. van Wijnen HG, Rasquin SM, van Heugten CM, Verbunt JA, Moulaert VR. The impact 
of cardiac arrest on the long-term wellbeing and caregiver burden of family caregivers: 
a prospective cohort study. Clin Rehabil 2017;31:1267‚Äì75. https://doi.org/10.1177/ 
0269215516686155
34. Vilchinsky N. Unrecognized, undiagnosed, and untreated: cardiac-disease-induced 
PTSD among patients‚Äô partners. Front Psychol 2017;8:1265. https://doi.org/10.3389/ 
fpsyg.2017.01265
35. Revenson TA, Griva K, Luszczynska A, Morrison V, Panagopoulou E, Vilchinsky N, et al. 
Caregiving in the Illness Context. Hampshire, England: Spinger, 2016, 1‚Äì156.
36. Back M. A New Task Force for Allied Professionals in the European Society of Cardiology 
(ESC). 2020. https://www.escardio.org/Sub-specialty-communities/Association-of- 
Cardiovascular-Nursing-&-Allied-Professions/News/celebrating-allied-health- 
professionals-day#:‚àº:text=An%20ESC%20transversal%20Task%20Force,in% 
20cardiovascular%20disease%20management%20both (8 October 2024, date last 
accessed).
37. Solanes A, Albajes-Eizagirre A, Fullana MA, Fortea L, Fusar-Poli P, Torrent C, et al. Can 
we increase the subjective well-being of the general population? An umbrella review of 
the evidence. Rev Psiquiatr Salud Ment (Engl Ed) 2021;14:50‚Äì64. https://doi.org/10. 
1016/j.rpsm.2020.08.002
38. Levine GN, Cohen BE, Commodore-Mensah Y, Fleury J, Huffman JC, Khalid U, et al. 
Psychological health, well-being, and the mind-heart-body connection: a scientific 
statement from the American Heart Association. Circulation 2021;143:e763‚Äì83. 
https://doi.org/10.1161/CIR.0000000000000947
39. Levine GN, Steinke EE, Bakaeen FG, Bozkurt B, Cheitlin MD, Conti JB, et al. Sexual activity 
and cardiovascular disease: a scientific statement from the American Heart Association. 
Circulation 2012;125:1058‚Äì72. https://doi.org/10.1161/CIR.0b013e3182447787
40. Mc Gee SL, H√∂ltge J, Maercker A, Thoma MV. Sense of coherence and stress-related 
resilience: investigating the mediating and moderating mechanisms in the development 
of resilience following stress or adversity. Front Psychiatry 2018;9:378. https://doi.org/ 
10.3389/fpsyt.2018.00378
41. Chida Y, Steptoe A. Positive psychological well-being and mortality: a quantitative re¬≠
view of prospective observational studies. Psychosom Med 2008;70:741‚Äì56. https://doi. 
org/10.1097/PSY.0b013e31818105ba
42. Mart√≠n-Mar√≠a N, Miret M, Caballero FF, Rico-Uribe LA, Steptoe A, Chatterji S, et al. 
The impact of subjective well-being on mortality: a meta-analysis of longitudinal studies 
in the general population. Psychosom Med 2017;79:565‚Äì75. https://doi.org/10.1097/ 
PSY.0000000000000444
43. Davidson KW, Mostofsky E, Whang W. Don‚Äôt worry, be happy: positive affect and re¬≠
duced 10-year incident coronary heart disease: the Canadian Nova Scotia Health 
Survey. Eur Heart J 2010;31:1065‚Äì70. https://doi.org/10.1093/eurheartj/ehp603
44. Kim ES, Smith J, Kubzansky LD. Prospective study of the association between disposi¬≠
tional optimism and incident heart failure. Circ Heart Fail 2014;7:394‚Äì400. https://doi. 
org/10.1161/CIRCHEARTFAILURE.113.000644
45. Shimbo D, Cohen MT, McGoldrick M, Ensari I, Diaz KM, Fu J, et al. Translational re¬≠
search of the acute effects of negative emotions on vascular endothelial health: findings 
from a randomized controlled study. J Am Heart Assoc 2024;13:e032698. https://doi. 
org/10.1161/JAHA.123.032698
46. Rozanski A, Kubzansky LD. Psychologic functioning and physical health: a paradigm of 
flexibility. Psychosom Med 2005;67:S47‚Äì53. https://doi.org/10.1097/01.psy.0000164253. 
69550.49
47. Steptoe A, Wardle J, Marmot M. Positive affect and health-related neuroendocrine, 
cardiovascular, and inflammatory processes. Proc Natl Acad Sci USA 2005;102: 
6508‚Äì12. https://doi.org/10.1073/pnas.0409174102
48. Boehm JK, Chen Y, Koga H, Mathur MB, Vie LL, Kubzansky LD. Is optimism associated 
with healthier cardiovascular-related behavior? Meta-analyses of 3 health behaviors. 
Circ Res 2018;122:1119‚Äì34. https://doi.org/10.1161/CIRCRESAHA.117.310828
49. Lurz J, Ladwig KH. Mind and body interventions in cardiology: the importance of the 
brain-heart connection. Herz 2022;47:103‚Äì9. https://doi.org/10.1007/s00059-022- 
05104-y
50. Lazarus RS. Some principles of psychological stress and their relation to dentistry. J 
Dent Res 1966;45:1620‚Äì6. https://doi.org/10.1177/00220345660450060901
51. Kivim√§ki M, Bartolomucci A, Kawachi I. The multiple roles of life stress in metabolic 
disorders. Nat Rev Endocrinol 2023;19:10‚Äì27. https://doi.org/10.1038/s41574-022- 
00746-8
52. Ginty AT, Kraynak TE, Fisher JP, Gianaros PJ. Cardiovascular and autonomic reactivity 
to psychological stress: neurophysiological substrates and links to cardiovascular dis¬≠
ease. Auton Neurosci 2017;207:2‚Äì9. https://doi.org/10.1016/j.autneu.2017.03.003
53. Segerstrom SC, Miller GE. Psychological stress and the human immune system: a 
meta-analytic study of 30 years of inquiry. Psychol Bull 2004;130:601‚Äì30. https://doi. 
org/10.1037/0033-2909.130.4.601
54. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially 
modifiable risk factors associated with myocardial infarction in 52 countries (the 
INTERHEART study): case-control study. Lancet 2004;364:937‚Äì52. https://doi.org/ 
10.1016/S0140-6736(04)17018-9
55. Dar T, Radfar A, Abohashem S, Pitman RK, Tawakol A, Osborne MT. Psychosocial 
stress and cardiovascular disease. Curr Treat Options Cardiovasc Med 2019;21:23. 
https://doi.org/10.1007/s11936-019-0724-5
56. Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, et al. 
Association of psychosocial risk factors with risk of acute myocardial infarction in 
11119 cases and 13648 controls from 52 countries (the INTERHEART study): case- 
control study. Lancet 2004;364:953‚Äì62. https://doi.org/10.1016/S0140-6736(04)17019-0
57. Peterson PN. JAHA spotlight on psychosocial factors and cardiovascular disease. J Am 
Heart Assoc 2020;9:e017112. https://doi.org/10.1161/JAHA.120.017112
58. Kivim√§ki M, Nyberg ST, Batty GD, Fransson EI, Heikkil√§ K, Alfredsson L, et al. Job strain as 
a risk factor for coronary heart disease: a collaborative meta-analysis of individual partici¬≠
pant data. Lancet 2012;380:1491‚Äì7. https://doi.org/10.1016/S0140-6736(12)60994-5
59. Magnusson Hanson LL, Westerlund H, Chungkham HS, Vahtera J, Rod NH, 
Alexanderson K, et al. Job strain and loss of healthy life years between ages 50 and 
75 by sex and occupational position: analyses of 64 934 individuals from four prospect¬≠
ive cohort studies. Occup Environ Med 2018;75:486‚Äì93. https://doi.org/10.1136/ 
oemed-2017-104644
60. S√∏rensen JK, Framke E, Pedersen J, Alexanderson K, Bonde JP, Farrants K, et al. Work 
stress and loss of years lived without chronic disease: an 18-year follow-up of 1.5 mil¬≠
lion employees in Denmark. Eur J Epidemiol 2022;37:389‚Äì400. https://doi.org/10.1007/ 
s10654-022-00852-x
61. Xu T, Magnusson Hanson LL, Lange T, Starkopf L, Westerlund H, Madsen IEH, et al. 
Workplace bullying and workplace violence as risk factors for cardiovascular disease: a 
multi-cohort study. Eur Heart J 2019;40:1124‚Äì34. https://doi.org/10.1093/eurheartj/ 
ehy683
62. Landsbergis PA, Dobson M, Koutsouras G, Schnall P. Job strain and ambulatory blood 
pressure: a meta-analysis and systematic review. Am J Public Health 2013;103:e61‚Äì71. 
https://doi.org/10.2105/AJPH.2012.301153
63. Yang B, Wang Y, Cui F, Huang T, Sheng P, Shi T, et al. Association between insomnia 
and job stress: a meta-analysis. Sleep Breath 2018;22:1221‚Äì31. https://doi.org/10.1007/ 
s11325-018-1682-y
64. Rugulies R, Aust B, Madsen IE. Effort-reward imbalance at work and risk of depressive 
disorders. A systematic review and meta-analysis of prospective cohort studies. Scand J 
Work Environ Health 2017;43:294‚Äì306. https://doi.org/10.5271/sjweh.3632
65. Li J, Atasoy S, Fang X, Angerer P, Ladwig KH. Combined effect of work stress and im¬≠
paired sleep on coronary and cardiovascular mortality in hypertensive workers: the 
MONICA/KORA cohort study. Eur J Prev Cardiol 2021;28:220‚Äì6. https://doi.org/10. 
1177/2047487319839183
66. Heikkil√§ K, Nyberg ST, Fransson EI, Alfredsson L, De Bacquer D, Bjorner JB, et al. Job 
strain and tobacco smoking: an individual-participant data meta-analysis of 166,130 
adults in 15 European studies. PLoS One 2012;7:e35463. https://doi.org/10.1371/ 
journal.pone.0035463
67. Fransson EI, Heikkil√§ K, Nyberg ST, Zins M, Westerlund H, Westerholm P, et al. Job 
strain as a risk factor for leisure-time physical inactivity: an individual-participant 
meta-analysis of up to 170,000 men and women: the IPD-Work Consortium. Am J 
Epidemiol 2012;176:1078‚Äì89. https://doi.org/10.1093/aje/kws336
68. Heikkil√§ K, Nyberg ST, Fransson EI, Alfredsson L, De Bacquer D, Bjorner JB, et al. Job 
strain and alcohol intake: a collaborative meta-analysis of individual-participant data 
from 140,000 men and women. PLoS One 2012;7:e40101. https://doi.org/10.1371/ 
journal.pone.0040101
69. Heikkil√§ K, Fransson EI, Nyberg ST, Zins M, Westerlund H, Westerholm P, et al. Job 
strain and health-related lifestyle: findings from an individual-participant meta-analysis 
of 118,000 working adults. Am J Public Health 2013;103:2090‚Äì7. https://doi.org/10. 
2105/AJPH.2012.301090
70. Kaspersen SL, Pape K, Ose SO, Gunnell D, Bj√∏rngaard JH. Unemployment and initi¬≠
ation of psychotropic medication: a case-crossover study of 2 348 552 Norwegian em¬≠
ployees. Occup Environ Med 2016;73:719‚Äì26. https://doi.org/10.1136/oemed-2016- 
103578
71. Sanchez Rico M, Plessz M, Airagnes G, Ribet C, Hoertel N, Goldberg M, et al. 
Cardiovascular burden and unemployment: a retrospective study in a large population- 
based French cohort. PLoS One 2023;18:e0288747. https://doi.org/10.1371/journal. 
pone.0288747
ESC Guidelines                                                                                                                                                                                               55


<!-- PAGE 56 -->

### Page 56

72. Zagozdzon P, Parszuto J, Wrotkowska M, Dydjow-Bendek D. Effect of unemployment 
on cardiovascular risk factors and mental health. Occup Med (Lond) 2014;64:436‚Äì41. 
https://doi.org/10.1093/occmed/kqu044
73. Ahn J, Kim NS, Lee BK, Park J, Kim Y. Comparison of the physical and mental health 
problems of unemployed with employees in South Korea. Arch Environ Occup Health 
2021;76:163‚Äì72. https://doi.org/10.1080/19338244.2020.1783503
74. Wang T, Li Y, Zheng X. Association of socioeconomic status with cardiovascular dis¬≠
ease and cardiovascular risk factors: a systematic review and meta-analysis. Z Gesundh 
Wiss 2023;32:385‚Äì99. https://doi.org/10.1007/s10389-023-01825-4
75. Jackman MR, Jackman RW. An interpretation of the relation between objective and sub¬≠
jective social status. Am Sociol Rev 1973;38:569‚Äì82. https://doi.org/10.2307/2094408
76. Tang KL, Rashid R, Godley J, Ghali WA. Association between subjective social status 
and cardiovascular disease and cardiovascular risk factors: a systematic review and 
meta-analysis. BMJ Open 2016;6:e010137. https://doi.org/10.1136/bmjopen-2015- 
010137
77. Everson-Rose SA, Lutsey PL, Roetker NS, Lewis TT, Kershaw KN, Alonso A, et al. 
Perceived discrimination and incident cardiovascular events: the multi-ethnic study of 
atherosclerosis. Am J Epidemiol 2015;182:225‚Äì34. https://doi.org/10.1093/aje/kwv035
78. Lawrence WR, Jones GS, Johnson JA, Ferrell KP, Johnson JN, Shiels MS, et al. 
Discrimination experiences and all-cause and cardiovascular mortality: multi-ethnic 
study of atherosclerosis. Circ Cardiovasc Qual Outcomes 2023;16:e009697. https:// 
doi.org/10.1161/CIRCOUTCOMES.122.009697
79. Martos-M√©ndez MJ, Garc√≠a-Cid A, G√≥mez-Jacinto L, Hombrados-Mendieta I. Perceived 
discrimination, psychological distress and cardiovascular risk in migrants in Spain. Int J 
Environ Res Public Health 2020;17:4601. https://doi.org/10.3390/ijerph17124601
80. Harris LK, Berry DC, Cort√©s YI. Psychosocial factors related to cardiovascular disease 
risk in young African American women: a systematic review. Ethn Health 2022;27: 
1806‚Äì24. https://doi.org/10.1080/13557858.2021.1990218
81. Kalmakis KA, Chandler GE. Adverse childhood experiences: towards a clear concep¬≠
tual meaning. J Adv Nurs 2014;70:1489‚Äì501. https://doi.org/10.1111/jan.12329
82. Jakubowski KP, Cundiff JM, Matthews KA. Cumulative childhood adversity and adult 
cardiometabolic disease: a meta-analysis. Health Psychol 2018;37:701‚Äì15. https://doi. 
org/10.1037/hea0000637
83. Batty GD, Kivim√§ki M, Frank P. State care in childhood and adult mortality: a systematic 
review and meta-analysis of prospective cohort studies. Lancet Public Health 2022;7: 
e504‚Äì14. https://doi.org/10.1016/S2468-2667(22)00081-0
84. Liang Y, Ai S, Weng F, Feng H, Yang L, He Z, et al. Associations of childhood maltreat¬≠
ment and genetic risks with incident heart failure in later life. J Am Heart Assoc 2022;11: 
e026536. https://doi.org/10.1161/JAHA.122.026536
85. Jackson DB, Testa A, Woodward KP, Qureshi F, Ganson KT, Nagata JM. Adverse child¬≠
hood experiences and cardiovascular risk among young adults: findings from the 2019 
behavioral risk factor surveillance system. Int J Environ Res Public Health 2022;19:11710. 
https://doi.org/10.3390/ijerph191811710
86. Dong M, Giles WH, Felitti VJ, Dube SR, Williams JE, Chapman DP, et al. Insights into 
causal pathways for ischemic heart disease: adverse childhood experiences study. 
Circulation 2004;110:1761‚Äì6. https://doi.org/10.1161/01.CIR.0000143074.54995.7F
87. Chandan JS, Thomas T, Bradbury-Jones C, Russell R, Bandyopadhyay S, 
Nirantharakumar K, et al. Female survivors of intimate partner violence and risk of de¬≠
pression, anxiety and serious mental illness. Br J Psychiatry 2020;217:562‚Äì7. https://doi. 
org/10.1192/bjp.2019.124
88. Chandan JS, Thomas T, Bradbury-Jones C, Taylor J, Bandyopadhyay S, Nirantharakumar 
K. Risk of cardiometabolic disease and all-cause mortality in female survivors of domestic 
abuse. J Am Heart Assoc 2020;9:e014580. https://doi.org/10.1161/JAHA.119.014580
89. Clark CJ, Alonso A, Everson-Rose SA, Spencer RA, Brady SS, Resnick MD, et al. 
Intimate partner violence in late adolescence and young adulthood and subsequent 
cardiovascular risk in adulthood. Prev Med 2016;87:132‚Äì7. https://doi.org/10.1016/j. 
ypmed.2016.02.031
90. Prohaska T, Burholt V, Burns A, Golden J, Hawkley L, Lawlor B, et al. Consensus state¬≠
ment: loneliness in older adults, the 21st century social determinant of health? BMJ 
Open 2020;10:e034967. https://doi.org/10.1136/bmjopen-2019-034967
91. Newall NEG, Menec VH. A comparison of different definitions of social isolation using 
Canadian Longitudinal Study on Aging (CLSA) data. Ageing Soc 2020;40:2671‚Äì94. 
https://doi.org/10.1017/S0144686X19000801
92. Valtorta NK, Kanaan M, Gilbody S, Ronzi S, Hanratty B. Loneliness and social isolation 
as risk factors for coronary heart disease and stroke: systematic review and 
meta-analysis of longitudinal observational studies. Heart 2016;102:1009‚Äì16. https:// 
doi.org/10.1136/heartjnl-2015-308790
93. Liang YY, Chen Y, Feng H, Liu X, Ai QH, Xue H, et al. Association of social isolation and 
loneliness with incident heart failure in a population-based cohort study. JACC Heart 
Fail 2023;11:334‚Äì44. https://doi.org/10.1016/j.jchf.2022.11.028
94. World Health Organization. Depression and Other Common Mental Disorders: Global 
Health Estimates. Geneva: World Health Organization, 2017.
95. Ladwig KH, Baumert J, Marten-Mittag B, Lukaschek K, Johar H, Fang X, et al. Room for 
depressed and exhausted mood as a risk predictor for all-cause and cardiovascular mor¬≠
tality beyond the contribution of the classical somatic risk factors in men. Atherosclerosis 
2017;257:224‚Äì31. https://doi.org/10.1016/j.atherosclerosis.2016.12.003
96. Krittanawong C, Maitra NS, Qadeer YK, Wang Z, Fogg S, Storch EA, et al. Association 
of depression and cardiovascular disease. Am J Med 2023;136:881‚Äì95. https://doi.org/ 
10.1016/j.amjmed.2023.04.036
97. Rajan S, McKee M, Rangarajan S, Bangdiwala S, Rosengren A, Gupta R, et al. Association 
of symptoms of depression with cardiovascular disease and mortality in low-, middle-, 
and high-income countries. JAMA Psychiatry 2020;77:1052‚Äì63. https://doi.org/10.1001/ 
jamapsychiatry.2020.1351
98. Cao L, Sheng C, Luo G, Ou J. Depression as a risk factor for developing heart failure: a 
meta-analysis of prospective cohort studies. J Cardiovasc Nurs 2022;37:112‚Äì21. https:// 
doi.org/10.1097/JCN.0000000000000760
99. Shi S, Liu T, Liang J, Hu D, Yang B. Depression and risk of sudden cardiac death and 
arrhythmias: a meta-analysis. Psychosom Med 2017;79:153‚Äì61. https://doi.org/10. 
1097/PSY.0000000000000382
100. Wu H, Li C, Li B, Zheng T, Feng K, Wu Y. Psychological factors and risk of atrial fib¬≠
rillation: a meta-analysis and systematic review. Int J Cardiol 2022;362:85‚Äì92. https:// 
doi.org/10.1016/j.ijcard.2022.05.048
101. Gilman SE, Sucha E, Kingsbury M, Horton NJ, Murphy JM, Colman I. Depression and 
mortality in a longitudinal study: 1952‚Äì2011. CMAJ 2017;189:E1304‚Äì10. https://doi. 
org/10.1503/cmaj.170125
102. DeMartini J, Patel G, Fancher TL. Generalized anxiety disorder. Ann Intern Med 2019; 
170:ITC49‚Äì64. https://doi.org/10.7326/AITC201904020
103. Nechita D, Nechita F, Motorga R. A review of the influence the anxiety exerts on hu¬≠
man life. Rom J Morphol Embryol 2018;59:1045‚Äì51.
104. Steimer T. The biology of fear- and anxiety-related behaviors. Dialogues Clin Neurosci 
2002;4:231‚Äì49. https://doi.org/10.31887/DCNS.2002.4.3/tsteimer
105. Batelaan NM, Seldenrijk A, Bot M, van Balkom AJ, Penninx BW. Anxiety and new onset 
of cardiovascular disease: critical review and meta-analysis. Br J Psychiatry 2016;208: 
223‚Äì31. https://doi.org/10.1192/bjp.bp.114.156554
106. Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and risk of incident coronary 
heart disease: a meta-analysis. J Am Coll Cardiol 2010;56:38‚Äì46. https://doi.org/10. 
1016/j.jacc.2010.03.034
107. Janszky I, Ahnve S, Lundberg I, Hemmingsson T. Early-onset depression, anxiety, and risk 
of subsequent coronary heart disease: 37-year follow-up of 49,321 young Swedish men. J 
Am Coll Cardiol 2010;56:31‚Äì7. https://doi.org/10.1016/j.jacc.2010.03.033
108. Nabi H, Hall M, Koskenvuo M, Singh-Manoux A, Oksanen T, Suominen S, et al. 
Psychological and somatic symptoms of anxiety and risk of coronary heart disease: 
the health and social support prospective cohort study. Biol Psychiatry 2010;67: 
378‚Äì85. https://doi.org/10.1016/j.biopsych.2009.07.040
109. Emdin CA, Odutayo A, Wong CX, Tran J, Hsiao AJ, Hunn BH. Meta-analysis of anxiety 
as a risk factor for cardiovascular disease. Am J Cardiol 2016;118:511‚Äì9. https://doi.org/ 
10.1016/j.amjcard.2016.05.041
110. Fu Y, He W, Ma J, Wei B. Relationship between psychological factors and atrial fibril¬≠
lation: a meta-analysis and systematic review. Medicine (Baltimore) 2020;99:e19615. 
https://doi.org/10.1097/MD.0000000000019615
111. Gustad LT, Laugsand LE, Janszky I, Dalen H, Bjerkeset O. Symptoms of anxiety and de¬≠
pression and risk of heart failure: the HUNT study. Eur J Heart Fail 2014;16:861‚Äì70. 
https://doi.org/10.1002/ejhf.133
112. Smoller JW, Pollack MH, Wassertheil-Smoller S, Jackson RD, Oberman A, Wong ND, 
et al. Panic attacks and risk of incident cardiovascular events among postmenopausal 
women in the Women‚Äôs Health Initiative Observational Study. Arch Gen Psychiatry 
2007;64:1153‚Äì60. https://doi.org/10.1001/archpsyc.64.10.1153
113. Thakur A, Choudhary D, Kumar B, Chaudhary A. A review on post-traumatic stress 
disorder (PTSD): symptoms, therapies and recent case studies. Curr Mol Pharmacol 
2022;15:502‚Äì16. https://doi.org/10.2174/1874467214666210525160944
114. Sladen RN, Shulman MA, Javaid A, Hodgson C, Myles PS, McGiffin D, et al. 
Postdischarge functional capacity, health-related quality of life, depression, anxiety, 
and post-traumatic stress disorder in patients receiving a long-term left ventricular as¬≠
sist device. J Card Fail 2022;28:83‚Äì92. https://doi.org/10.1016/j.cardfail.2021.07.019
115. Beristianos MH, Yaffe K, Cohen B, Byers AL. PTSD and risk of incident cardiovascular 
disease in aging veterans. Am J Geriatr Psychiatry 2016;24:192‚Äì200. https://doi.org/10. 
1016/j.jagp.2014.12.003
116. Jacquet-Smailovic M, Brennsthul MJ, Denis I, Kirche A, Tarquinio C, Tarquinio C. 
Relationship between post-traumatic stress disorder and subsequent myocardial in¬≠
farction: a systematic review and meta-analysis. J Affect Disord 2022;297:525‚Äì35. 
https://doi.org/10.1016/j.jad.2021.10.056
117. Boscarino JA. A prospective study of PTSD and early-age heart disease mortality 
among Vietnam veterans: implications for surveillance and prevention. Psychosom 
Med 2008;70:668‚Äì76. https://doi.org/10.1097/PSY.0b013e31817bccaf
118. Krantz DS, Shank LM, Goodie JL. Post-traumatic stress disorder (PTSD) as a systemic 
disorder: pathways to cardiovascular disease. Health Psychol 2022;41:651‚Äì62. https:// 
doi.org/10.1037/hea0001127
119. Fu Q. Autonomic dysfunction and cardiovascular risk in post-traumatic stress disorder. 
Auton Neurosci 2022;237:102923. https://doi.org/10.1016/j.autneu.2021.102923
120. Peruzzolo TL, Pinto JV, Roza TH, Shintani AO, Anzolin AP, Gnielka V, et al. 
Inflammatory and oxidative stress markers in post-traumatic stress disorder:


<!-- PAGE 57 -->

### Page 57

a systematic review and meta-analysis. Mol Psychiatry 2022;27:3150‚Äì63. https://doi.org/ 
10.1038/s41380-022-01564-0
121. Edmondson D, Cohen BE. Posttraumatic stress disorder and cardiovascular disease. 
Progress in Cardiovascular Diseases 2013;55:548‚Äì56. https://doi.org/10.1016/j.pcad.2013. 
03.004
122. Kelly MM, Jensen KP, Sofuoglu M. Co-occurring tobacco use and posttraumatic stress 
disorder: smoking cessation treatment implications. Am J Addict 2015;24:695‚Äì704. 
https://doi.org/10.1111/ajad.12304
123. van den Berk-Clark C, Secrest S, Walls J, Hallberg E, Lustman PJ, Schneider FD, et al. 
Association between posttraumatic stress disorder and lack of exercise, poor diet, 
obesity, and co-occuring smoking: a systematic review and meta-analysis. Health 
Psychol 2018;37:407‚Äì16. https://doi.org/10.1037/hea0000593
124. Edmondson D. An enduring somatic threat model of posttraumatic stress disorder 
due to acute life-threatening medical events. Soc Personal Psychol Compass 2014;8: 
118‚Äì34. https://doi.org/10.1111/spc3.12089
125. Tully PJ, Harrison NJ, Cheung P, Cosh S. Anxiety and cardiovascular disease risk: a re¬≠
view. Curr Cardiol Rep 2016;18:120. https://doi.org/10.1007/s11886-016-0800-3
126. Shao M, Lin X, Jiang D, Tian H, Xu Y, Wang L, et al. Depression and cardiovascular dis¬≠
ease: shared molecular mechanisms and clinical implications. Psychiatry Res 2020;285: 
112802. https://doi.org/10.1016/j.psychres.2020.112802
127. Pedersen SS, Andersen CM, Burg M, Theuns D. Anger and long-term mortality and 
ventricular arrhythmias in patients with a first-time implantable cardioverter- 
defibrillator: data from the MIDAS study. Europace 2020;22:1054‚Äì61. https://doi. 
org/10.1093/europace/euaa083
128. Rosenstr√∏m S, Risom SS, Hove JD, Br√∏dsgaard A. Living with atrial fibrillation: a family 
perspective. Nurs Res Pract 2022;2022:7394445. https://doi.org/10.1155/2022/7394445
129. Bermudez T, Bierbauer W, Scholz U, Hermann M. Depression and anxiety in cardiac re¬≠
habilitation: differential associations with changes in exercise capacity and quality of life. 
Anxiety Stress Coping 2022;35:204‚Äì18. https://doi.org/10.1080/10615806.2021.1952191
130. Szpakowski N, Qiu F, Masih S, Kurdyak P, Wijeysundera HC. Economic impact of sub¬≠
sequent depression in patients with a new diagnosis of stable angina: a population-based 
study. J Am Heart Assoc 2017;6:e006911. https://doi.org/10.1161/JAHA.117.006911
131. Hare DL, Toukhsati SR, Johansson P, Jaarsma T. Depression and cardiovascular disease: a 
clinical review. Eur Heart J 2014;35:1365‚Äì72. https://doi.org/10.1093/eurheartj/eht462
132. Lichtman JH, Bigger JT Jr, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lesp√©rance F, 
et al. Depression and coronary heart disease: recommendations for screening, referral, 
and treatment: a science advisory from the American Heart Association Prevention 
Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, 
Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of 
Care and Outcomes Research: endorsed by the American Psychiatric Association. 
Circulation 2008;118:1768‚Äì75. https://doi.org/10.1161/circulationaha.108.190769
133. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic dis¬≠
eases, and decrements in health: results from the World Health Surveys. Lancet 2007; 
370:851‚Äì8. https://doi.org/10.1016/S0140-6736(07)61415-9
134. Mai AS, Lim OZH, Ho YJ, Kong G, Lim GEH, Ng CH, et al. Prevalence, risk factors and 
intervention for depression and anxiety in pulmonary hypertension: a systematic re¬≠
view and meta-analysis. Front Med (Lausanne) 2022;9:765461. https://doi.org/10. 
3389/fmed.2022.765461
135. Alosaimi N, Sherar LB, Griffiths P, Pearson N. Clustering of diet, physical activity and 
sedentary behaviour and related physical and mental health outcomes: a systematic re¬≠
view. BMC Public Health 2023;23:1572. https://doi.org/10.1186/s12889-023-16372-6
136. Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, et al. Prevalence of de¬≠
pression in survivors of acute myocardial infarction. J Gen Intern Med 2006;21:30‚Äì8. 
https://doi.org/10.1111/j.1525-1497.2005.00269.x
137. Mallik S, Spertus JA, Reid KJ, Krumholz HM, Rumsfeld JS, Weintraub WS, et al. 
Depressive symptoms after acute myocardial infarction: evidence for highest rates 
in younger women. Arch Intern Med 2006;166:876‚Äì83. https://doi.org/10.1001/ 
archinte.166.8.876
138. PajƒÖk A, Jankowski P, Kotseva K, Heidrich J, de Smedt D, De Bacquer D. Depression, 
anxiety, and risk factor control in patients after hospitalization for coronary heart dis¬≠
ease: the EUROASPIRE III Study. Eur J Prev Cardiol 2013;20:331‚Äì40. https://doi.org/10. 
1177/2047487312441724
139. Brown T, Chen S, Ou Z, McDonald N, Bennett-Murphy L, Schneider L, et al. Feasibility 
of assessing adolescent and young adult heart transplant recipient mental health and 
resilience using patient-reported outcome measures. J Acad Consult Liaison Psychiatry 
2022;63:153‚Äì62. https://doi.org/10.1016/j.jaclp.2021.08.002
140. de la Rosa A, Singer-Englar T, Hamilton MA, IsHak WW, Kobashigawa JA, Kittleson MM. 
The impact of depression on heart transplant outcomes: a retrospective single-center 
cohort study. Clin Transplant 2021;35:e14204. https://doi.org/10.1111/ctr.14204
141. Dew MA, Kormos RL, DiMartini AF, Switzer GE, Schulberg HC, Roth LH, et al. 
Prevalence and risk of depression and anxiety-related disorders during the first three 
years after heart transplantation. Psychosomatics 2001;42:300‚Äì13. https://doi.org/10. 
1176/appi.psy.42.4.300
142. Rossi Ferrario S, Panzeri A, Pistono M. Psychological difficulties of LVAD patients and 
caregivers: a follow up over one year from discharge. Artif Organs 2022;46:479‚Äì90. 
https://doi.org/10.1111/aor.14071
143. Heilmann C, Kaps J, Hartmann A, Zeh W, Anjarwalla AL, Beyersdorf F, et al. Mental 
health status of patients with mechanical aortic valves, with ventricular assist devices 
and after heart transplantation. Interact Cardiovasc Thorac Surg 2016;23:321‚Äì5. 
https://doi.org/10.1093/icvts/ivw111
144. Thrall G, Lip GY, Carroll D, Lane D. Depression, anxiety, and quality of life in patients 
with atrial fibrillation. Chest 2007;132:1259‚Äì64. https://doi.org/10.1378/chest.07-0036
145. Ghezzi ES, Sharman RLS, Selvanayagam JB, Psaltis PJ, Sanders P, Astley JM, et al. Burden 
of mood symptoms and disorders in implantable cardioverter defibrillator patients: a 
systematic review and meta-analysis of 39 954 patients. Europace 2023;25:euad130. 
https://doi.org/10.1093/europace/euad130
146. Pedersen SS, Nielsen JC, Wehberg S, J√∏rgensen OD, Riahi S, Haarbo J, et al. New onset 
anxiety and depression in patients with an implantable cardioverter defibrillator during 
24 months of follow-up (data from the national DEFIB-WOMEN study). Gen Hosp 
Psychiatry 2021;72:59‚Äì65. https://doi.org/10.1016/j.genhosppsych.2021.07.003
147. Ensslin C, Berg J, Hermes-Laufer J, Keller LS, Niederseer D, Pazhenkottil A, et al. 
Depressive symptoms in patients after primary and secondary prophylactic ICD im¬≠
plantation. Clin Res Cardiol 2022;111:1210‚Äì8. https://doi.org/10.1007/s00392-021- 
01940-w
148. Tagney J. A literature review comparing the experiences and emergent needs of adult 
patients with permanent pacemakers (PPMs) and implantable cardioverter defibrilla¬≠
tors (ICDs). J Clin Nurs 2010;19:2081‚Äì9. https://doi.org/10.1111/j.1365-2702.2009. 
03031.x
149. Andonian C, Beckmann J, Biber S, Ewert P, Freilinger S, Kaemmerer H, et al. Current 
research status on the psychological situation of adults with congenital heart disease. 
Cardiovasc Diagn Ther 2018;8:799‚Äì804. https://doi.org/10.21037/cdt.2018.12.06
150. Udholm S, Nyboe C, Lundbye-Christensen S, Nordentoft M, Hjortdal VE. Congenital 
heart disease and risk of suicide and self-harm: a Danish nationwide cohort study. J Am 
Heart Assoc 2020;9:e015735. https://doi.org/10.1161/JAHA.119.015735
151. Gu S, Hu H, Dong H. Systematic review of health-related quality of life in patients with 
pulmonary arterial hypertension. Pharmacoeconomics 2016;34:751‚Äì70. https://doi.org/ 
10.1007/s40273-016-0395-y
152. Halimi L, Marin G, Molinari N, Gamez AS, Boissin C, Suehs CM, et al. Impact of psy¬≠
chological factors on the health-related quality of life of patients treated for pulmonary 
arterial hypertension. J Psychosom Res 2018;105:45‚Äì51. https://doi.org/10.1016/j. 
jpsychores.2017.12.003
153. Pfeuffer-Jovic E, Joa F, Halank M, Krannich JH, Held M. Anxiety, depression and quality 
of life in pulmonary hypertension: a comparison of incident and prevalent cases. 
Respiration 2022;101:784‚Äì92. https://doi.org/10.1159/000524369
154. Zhang J, Yin Y, Wen Y, Shi F, Wang J. Anxiety and depression in patients with pulmon¬≠
ary arterial hypertension in northwest China: a cross-sectional study. Front Psychiatry 
2021;12:758120. https://doi.org/10.3389/fpsyt.2021.758120
155. Von Visger TT, Kuntz KK, Phillips GS, Yildiz VO, Sood N. Quality of life and psycho¬≠
logical symptoms in patients with pulmonary hypertension. Heart Lung 2018;47: 
115‚Äì21. https://doi.org/10.1016/j.hrtlng.2017.12.004
156. Lane D, Carroll D, Ring C, Beevers DG, Lip GY. Mortality and quality of life 12 months 
after myocardial infarction: effects of depression and anxiety. Psychosom Med 2001;63: 
221‚Äì30. https://doi.org/10.1097/00006842-200103000-00005
157. Meijer A, Conradi HJ, Bos EH, Anselmino M, Carney RM, Denollet J, et al. Adjusted 
prognostic association of depression following myocardial infarction with mortality 
and cardiovascular events: individual patient data meta-analysis. Br J Psychiatry 2013; 
203:90‚Äì102. https://doi.org/10.1192/bjp.bp.112.111195
158. van Dijk MR, Utens EM, Dulfer K, Al-Qezweny MN, van Geuns RJ, Daemen J, et al. 
Depression and anxiety symptoms as predictors of mortality in PCI patients at 10 
years of follow-up. Eur J Prev Cardiol 2016;23:552‚Äì8. https://doi.org/10.1177/ 
2047487315571889
159. Owen JE, Bonds CL, Wellisch DK. Psychiatric evaluations of heart transplant candi¬≠
dates: predicting post-transplant hospitalizations, rejection episodes, and survival. 
Psychosomatics 2006;47:213‚Äì22. https://doi.org/10.1176/appi.psy.47.3.213
160. Dew MA, Kormos RL, Roth LH, Murali S, DiMartini A, Griffith BP. Early post-transplant 
medical compliance and mental health predict physical morbidity and mortality one to 
three years after heart transplantation. J Heart Lung Transplant 1999;18:549‚Äì62. 
https://doi.org/10.1016/S1053-2498(98)00044-8
161. DeFilippis EM, Breathett K, Donald EM, Nakagawa S, Takeda K, Takayama H, et al. 
Psychosocial risk and its association with outcomes in continuous-flow left ventricular 
assist device patients. Circ Heart Fail 2020;13:e006910. https://doi.org/10.1161/ 
CIRCHEARTFAILURE.120.006910
162. Mullan C, Caraballo C, Ravindra NG, Miller PE, McCullough M, Brown K, et al. 
Psychiatric comorbidity and outcomes after left ventricular assist device implantation 
for end-stage heart failure. JACC Heart Fail 2020;8:569‚Äì77. https://doi.org/10.1016/j. 
jchf.2020.03.011
163. Zhuo C, Ji F, Lin X, Jiang D, Wang L, Tian H, et al. Depression and recurrence of atrial 
fibrillation after catheter ablation: a meta-analysis of cohort studies. J Affect Disord 
2020;271:27‚Äì32. https://doi.org/10.1016/j.jad.2020.03.118
164. Sin NL, Kumar AD, Gehi AK, Whooley MA. Direction of association between depres¬≠
sive symptoms and lifestyle behaviors in patients with coronary heart disease: the heart 
ESC Guidelines                                                                                                                                                                                               57


<!-- PAGE 58 -->

### Page 58

and soul study. Ann Behav Med 2016;50:523‚Äì32. https://doi.org/10.1007/s12160-016- 
9777-9
165. Tang HY, Sayers SL, Weissinger G, Riegel B. The role of depression in medication ad¬≠
herence among heart failure patients. Clin Nurs Res 2014;23:231‚Äì44. https://doi.org/10. 
1177/1054773813481801
166. Swardfager W, Herrmann N, Marzolini S, Saleem M, Farber SB, Kiss A, et al. Major de¬≠
pressive disorder predicts completion, adherence, and outcomes in cardiac rehabilita¬≠
tion: a prospective cohort study of 195 patients with coronary artery disease. J Clin 
Psychiatry 2011;72:1181‚Äì8. https://doi.org/10.4088/JCP.09m05810blu
167. Kronish IM, Rieckmann N, Halm EA, Shimbo D, Vorchheimer D, Haas DC, et al. 
Persistent depression affects adherence to secondary prevention behaviors after acute 
coronary syndromes. J Gen Intern Med 2006;21:1178‚Äì83. https://doi.org/10.1111/j. 
1525-1497.2006.00586.x
168. Bermudez T, Maercker A, Bierbauer W, Bernardo A, Fleisch-Silvestri R, Hermann M, 
et al. The role of daily adjustment disorder, depression and anxiety symptoms for the 
physical activity of cardiac patients. Psychol Med 2023;53:5992‚Äì6001. https://doi.org/ 
10.1017/S0033291722003154
169. Lapa ME, Swabe GM, Rollman BL, Muldoon MF, Thurston RC, Magnani JW. 
Assessment of depression and adherence to guideline-directed medical therapies fol¬≠
lowing percutaneous coronary intervention. JAMA Netw Open 2022;5:e2246317. 
https://doi.org/10.1001/jamanetworkopen.2022.46317
170. Poletti V, Pagnini F, Banfi P, Volpato E. The role of depression on treatment adherence 
in patients with heart failure‚Äìa systematic review of the literature. Curr Cardiol Rep 
2022;24:1995‚Äì2008. https://doi.org/10.1007/s11886-022-01815-0
171. Storer B, Kershaw KA, Braund TA, Chakouch C, Coleshill MJ, Haffar S, et al. Global 
prevalence of anxiety in adult cardiology outpatients: a systematic review and 
meta-analysis. Curr Probl Cardiol 2023;48:101877. https://doi.org/10.1016/j.cpcardiol. 
2023.101877
172. Hanssen TA, Nordrehaug JE, Eide GE, Bjelland I, Rokne B. Anxiety and depression after 
acute myocardial infarction: an 18-month follow-up study with repeated measures and 
comparison with a reference population. Eur J Cardiovasc Prev Rehabil 2009;16:651‚Äì9. 
https://doi.org/10.1097/HJR.0b013e32832e4206
173. Johnson AK, Hayes SN, Sawchuk C, Johnson MP, Best PJ, Gulati R, et al. Analysis of 
posttraumatic stress disorder, depression, anxiety, and resiliency within the unique 
population of spontaneous coronary artery dissection survivors. J Am Heart Assoc 
2020;9:e014372. https://doi.org/10.1161/JAHA.119.014372
174. Easton K, Coventry P, Lovell K, Carter LA, Deaton C. Prevalence and measurement of 
anxiety in samples of patients with heart failure: meta-analysis. J Cardiovasc Nurs 2016; 
31:367‚Äì79. https://doi.org/10.1097/JCN.0000000000000265
175. Dekker RL, Lennie TA, Doering LV, Chung ML, Wu JR, Moser DK. Coexisting anxiety 
and depressive symptoms in patients with heart failure. Eur J Cardiovasc Nurs 2014;13: 
168‚Äì76. https://doi.org/10.1177/1474515113519520
176. Loh AZH, Tan JSY, Tam JKC, Zhang MW, Ho CSH, Ho RC. Postoperative psychologic¬≠
al disorders among heart transplant recipients: a meta-analysis and meta-regression. 
Psychosom Med 2020;82:689‚Äì98. https://doi.org/10.1097/PSY.0000000000000833
177. Koleck TA, Mitha SA, Biviano A, Caceres BA, Corwin EJ, Goldenthal I, et al. Exploring 
depressive symptoms and anxiety among patients with atrial fibrillation and/or flutter 
at the time of cardioversion or ablation. J Cardiovasc Nurs 2021;36:470‚Äì81. https://doi. 
org/10.1097/JCN.0000000000000723
178. Grand J, Fuglsbjerg C, Borregaard B, Wagner MK, Kragh AR, Bekker-Jensen D, et al. 
Sex differences in symptoms of anxiety, depression, post-traumatic stress disorder, 
and cognitive function among survivors of out-of-hospital cardiac arrest. Eur Heart J 
Acute Cardiovasc Care 2023;12:765‚Äì73. https://doi.org/10.1093/ehjacc/zuad093
179. Peskine A, Cariou A, Hajage D, Deye N, Gu√©rot E, Dres M, et al. Long-term disabilities 
of survivors of out-of-hospital cardiac arrest: the Hanox study. Chest 2021;159: 
699‚Äì711. https://doi.org/10.1016/j.chest.2020.07.022
180. Joshi VL, Tang LH, Mikkelsen TB, Nielsen JF, Zinckernagel L, Borregaard B, et al. Does 
time heal fatigue, psychological, cognitive and disability problems in people who ex¬≠
perience an out-of-hospital cardiac arrest? Results from the DANCAS survey study. 
Resuscitation 2023;182:109639. https://doi.org/10.1016/j.resuscitation.2022.11.005
181. Frydensberg VS, Johansen JB, M√∂ller S, Riahi S, Wehberg S, Haarbo J, et al. Anxiety and 
depression symptoms in Danish patients with an implantable cardioverter- 
defibrillator: prevalence and association with indication and sex up to 2 years of follow- 
up (data from the national DEFIB-WOMEN study). Europace 2020;22:1830‚Äì40. 
https://doi.org/10.1093/europace/euaa176
182. Jackson JL, Leslie CE, Hondorp SN. Depressive and anxiety symptoms in adult congeni¬≠
tal heart disease: prevalence, health impact and treatment. Prog Cardiovasc Dis 2018;61: 
294‚Äì9. https://doi.org/10.1016/j.pcad.2018.07.015
183. Lebherz C, Frick M, Panse J, Wienstroer P, Brehmer K, Kerst G, et al. Anxiety and de¬≠
pression in adults with congenital heart disease. Front Pediatr 2022;10:906385. https:// 
doi.org/10.3389/fped.2022.906385
184. Roest AM, Zuidersma M, de Jonge P. Myocardial infarction and generalised anxiety dis¬≠
order: 10-year follow-up. Br J Psychiatry 2012;200:324‚Äì9. https://doi.org/10.1192/bjp. 
bp.111.103549
185. Celano CM, Villegas AC, Albanese AM, Gaggin HK, Huffman JC. Depression and anx¬≠
iety in heart failure: a review. Harv Rev Psychiatry 2018;26:175‚Äì84. https://doi.org/10. 
1097/HRP.0000000000000162
186. Alhurani AS, Dekker RL, Abed MA, Khalil A, Al Zaghal MH, Lee KS, et al. The associ¬≠
ation of co-morbid symptoms of depression and anxiety with all-cause mortality and 
cardiac rehospitalization in patients with heart failure. Psychosomatics 2015;56:371‚Äì80. 
https://doi.org/10.1016/j.psym.2014.05.022
187. Suzuki T, Shiga T, Kuwahara K, Kobayashi S, Suzuki S, Nishimura K, et al. Impact of clus¬≠
tered depression and anxiety on mortality and rehospitalization in patients with heart 
failure. J Cardiol 2014;64:456‚Äì62. https://doi.org/10.1016/j.jjcc.2014.02.031
188. Kikkenborg Berg S, Caspar Thygesen L, Hastrup Svendsen J, Vinggaard Christensen A, 
Zwisler AD. Anxiety predicts mortality in ICD patients: results from the cross- 
sectional national CopenHeartICD survey with register follow-up. Pacing Clin 
Electrophysiol 2014;37:1641‚Äì50. https://doi.org/10.1111/pace.12490
189. Cromhout PF, Christensen AV, J√∏rgensen MB, Ekholm O, Juel K, Svendsen JH, et al. 
Exploring the use of psychotropic medication in cardiac patients with and without anx¬≠
iety and its association with 1-year mortality. Eur J Cardiovasc Nurs 2022;21:612‚Äì9. 
https://doi.org/10.1093/eurjcn/zvab111
190. Grace SL, Abbey SE, Shnek ZM, Irvine J, Franche RL, Stewart DE. Cardiac rehabilitation 
II: referral and participation. Gen Hosp Psychiatry 2002;24:127‚Äì34. https://doi.org/10. 
1016/S0163-8343(02)00179-2
191. Eisenberg SA, Shen BJ, Schwarz ER, Mallon S. Avoidant coping moderates the associ¬≠
ation between anxiety and patient-rated physical functioning in heart failure patients. J 
Behav Med 2012;35:253‚Äì61. https://doi.org/10.1007/s10865-011-9358-0
192. Edmondson D, Richardson S, Falzon L, Davidson KW, Mills MA, Neria Y. 
Posttraumatic stress disorder prevalence and risk of recurrence in acute coronary syn¬≠
drome patients: a meta-analytic review. PLoS One 2012;7:e38915. https://doi.org/10. 
1371/journal.pone.0038915
193. Sumner JA, Kim ESH, Wood MJ, Chi G, Nolen J, Grodzinsky A, et al. Posttraumatic 
stress disorder after spontaneous coronary artery dissection: a report of the inter¬≠
national spontaneous coronary artery dissection registry. J Am Heart Assoc 2024;13: 
e032819. https://doi.org/10.1161/JAHA.123.032819
194. Kobayashi S, Nishimura K, Suzuki T, Shiga T, Ishigooka J. Post-traumatic stress disorder 
and its risk factors in Japanese patients living with implantable cardioverter defibrilla¬≠
tors: a preliminary examination. J Arrhythm 2014;30:105‚Äì10. https://doi.org/10.1016/ 
j.joa.2013.07.004
195. Kapa S, Rotondi-Trevisan D, Mariano Z, Aves T, Irvine J, Dorian P, et al. 
Psychopathology in patients with ICDs over time: results of a prospective study. 
Pacing Clin Electrophysiol 2010;33:198‚Äì208. https://doi.org/10.1111/j.1540-8159.2009. 
02599.x
196. Simeone RM, Downing KF, Bobo WV, Grosse SD, Khanna AD, Farr SL. Post-traumatic 
stress disorder, anxiety, and depression among adults with congenital heart defects. 
Birth Defects Res 2022;114:124‚Äì35. https://doi.org/10.1002/bdr2.1971
197. Harrison DJ, Kay J, Jacobsen RM, Londono-Obregon C, Yeung E, Kelly SL, et al. The 
burden of psychological trauma and post-traumatic stress disorder among adults 
with congenital heart disease: PTSD in ACHD. Am J Cardiol 2024;219:9‚Äì16. https:// 
doi.org/10.1016/j.amjcard.2024.03.007
198. Edmondson D, Rieckmann N, Shaffer JA, Schwartz JE, Burg MM, Davidson KW, et al. 
Posttraumatic stress due to an acute coronary syndrome increases risk of 42-month 
major adverse cardiac events and all-cause mortality. J Psychiatr Res 2011;45:1621‚Äì6. 
https://doi.org/10.1016/j.jpsychires.2011.07.004
199. Horowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of subjective stress. 
Psychosom Med 1979;41:209‚Äì18. https://doi.org/10.1097/00006842-197905000-00004
200. Ginzburg K, Kutz I, Koifman B, Roth A, Kriwisky M, David D, et al. Acute stress disorder 
symptoms predict all-cause mortality among myocardial infarction patients: a 15-year 
longitudinal study. Ann Behav Med 2016;50:177‚Äì86. https://doi.org/10.1007/s12160- 
015-9744-x
201. Shemesh E, Rudnick A, Kaluski E, Milovanov O, Salah A, Alon D, et al. A prospective 
study of posttraumatic stress symptoms and nonadherence in survivors of a myocar¬≠
dial infarction (MI). Gen Hosp Psychiatry 2001;23:215‚Äì22. https://doi.org/10.1016/ 
S0163-8343(01)00150-5
202. Pedersen SS, van Domburg RT, Larsen ML. The effect of low social support on short- 
term prognosis in patients following a first myocardial infarction. Scand J Psychol 2004; 
45:313‚Äì8. https://doi.org/10.1111/j.1467-9450.2004.00410.x
203. von K√§nel R, Hari R, Schmid JP, Wiedemar L, Guler E, Barth J, et al. Non-fatal cardio¬≠
vascular outcome in patients with posttraumatic stress symptoms caused by myocar¬≠
dial infarction. J Cardiol 2011;58:61‚Äì8. https://doi.org/10.1016/j.jjcc.2011.02.007
204. Foa EB, Riggs DS, Dancu CV, Rothbaum BO. Reliability and validity of a brief instru¬≠
ment for assessing post-traumatic stress disorder. J Trauma Stress 1993;6:459‚Äì73. 
https://doi.org/10.1007/BF00974317
205. Doerfler LA, Paraskos JA, Piniarski L. Relationship of quality of life and perceived control 
with posttraumatic stress disorder symptoms 3 to 6 months after myocardial infarction. 
J Cardiopulm Rehabil 2005;25:166‚Äì72. https://doi.org/10.1097/00008483-200505000- 
00008


<!-- PAGE 59 -->

### Page 59

206. Shemesh E, Yehuda R, Milo O, Dinur I, Rudnick A, Vered Z, et al. Posttraumatic stress, 
nonadherence, and adverse outcome in survivors of a myocardial infarction. Psychosom 
Med 2004;66:521‚Äì6. https://doi.org/10.1097/01.psy.0000126199.05189.86
207. Hari R, Begr√© S, Schmid JP, Saner H, Gander ML, von K√§nel R. Change over time in 
posttraumatic stress caused by myocardial infarction and predicting variables. J 
Psychosom Res 2010;69:143‚Äì50. https://doi.org/10.1016/j.jpsychores.2010.04.011
208. Zen AL, Whooley MA, Zhao S, Cohen BE. Post-traumatic stress disorder is associated 
with poor health behaviors: findings from the heart and soul study. Health Psychol 
2012;31:194‚Äì201. https://doi.org/10.1037/a0025989
209. Favaro A, Gerosa G, Caforio AL, Volpe B, Rupolo G, Zarneri D, et al. Posttraumatic 
stress disorder and depression in heart transplantation recipients: the relationship 
with outcome and adherence to medical treatment. Gen Hosp Psychiatry 2011;33: 
1‚Äì7. https://doi.org/10.1016/j.genhosppsych.2010.10.001
210. Sumner JA, Kronish IM, Pietrzak RH, Shimbo D, Shaffer JA, Parsons FE, et al. 
Dimensional structure and correlates of posttraumatic stress symptoms following sus¬≠
pected acute coronary syndrome. J Affect Disord 2015;186:178‚Äì85. https://doi.org/10. 
1016/j.jad.2015.06.013
211. Christensen AV, Juel K, Ekholm O, Thrys√∏e L, Thorup CB, Borregaard B, et al. 
Significantly increased risk of all-cause mortality among cardiac patients feeling lonely. 
Heart 2020;106:140‚Äì6. https://doi.org/10.1136/heartjnl-2019-315460
212. Hagstr√∂m E, Norlund F, Stebbins A, Armstrong PW, Chiswell K, Granger CB, et al. 
Psychosocial stress and major cardiovascular events in patients with stable coronary 
heart disease. J Intern Med 2018;283:83‚Äì92. https://doi.org/10.1111/joim.12692
213. Xu X, Bao H, Strait K, Spertus JA, Lichtman JH, D‚ÄôOnofrio G, et al. Sex differences in per¬≠
ceived stress and early recovery in young and middle-aged patients with acute myocardial 
infarction. Circulation 2015;131:614‚Äì23. https://doi.org/10.1161/CIRCULATIONAHA. 
114.012826
214. Le Grande MR, Murphy BM, Rogerson MC, Ski CF, Amerena J, Smith JA, et al. 
Development of a short form of the cardiac distress inventory. BMC Cardiovasc 
Disord 2023;23:408. https://doi.org/10.1186/s12872-023-03439-w
215. Harris KM, Jacoby DL, Lampert R, Soucier RJ, Burg MM. Psychological stress in heart 
failure: a potentially actionable disease modifier. Heart Fail Rev 2021;26:561‚Äì75. https:// 
doi.org/10.1007/s10741-020-10056-8
216. Endrighi R, Waters AJ, Gottlieb SS, Harris KM, Wawrzyniak AJ, Bekkouche NS, et al. 
Psychological stress and short-term hospitalisations or death in patients with heart fail¬≠
ure. Heart 2016;102:1820‚Äì5. https://doi.org/10.1136/heartjnl-2015-309154
217. Martire LM, Helgeson VS. Close relationships and the management of chronic illness: 
associations and interventions. Am Psychol 2017;72:601‚Äì12. https://doi.org/10.1037/ 
amp0000066
218. Knoll N, Scholz U, Ditzen B. Social support, family processes, and health. In: Revenson 
TA, Gurung RAR (eds.), The Handbook of Health Psychology. New York: Routledge, 
2019, 279‚Äì89.
219. Smith TW, Baucom BRW. Intimate relationships, individual adjustment, and coronary 
heart disease: implications of overlapping associations in psychosocial risk. Am Psychol 
2017;72:578‚Äì89. https://doi.org/10.1037/amp0000123
220. Randall G, Molloy GJ, Steptoe A. The impact of an acute cardiac event on the partners 
of patients: a systematic review. Health Psychol Rev 2009;3:1‚Äì84. https://doi.org/10. 
1080/17437190902984919
221. Bouchard K, Dans M, Higdon G, Quinlan B, Tulloch H. Caregiver distress and coronary 
artery disease: prevalence, risk, outcomes, and management. Curr Cardiol Rep 2022;24: 
2081‚Äì96. https://doi.org/10.1007/s11886-022-01810-5
222. Kitko L, McIlvennan CK, Bidwell JT, Dionne-Odom JN, Dunlay SM, Lewis LM, et al. 
Family caregiving for individuals with heart failure: a scientific statement from the 
American Heart Association. Circulation 2020;141:e864‚Äì78. https://doi.org/10.1161/ 
CIR.0000000000000768
223. Kugler C, Malehsa D, Schrader E, Tegtbur U, Guetzlaff E, Haverich A, et al. A multi- 
modal intervention in management of left ventricular assist device outpatients: dietary 
counselling, controlled exercise and psychosocial support. Eur J Cardiothorac Surg 2012; 
42:1026‚Äì32. https://doi.org/10.1093/ejcts/ezs206
224. Kugler C, Meng M, Rehn E, Morshuis M, Gummert JF, Tigges-Limmer K. Sexual activity 
in patients with left ventricular assist devices and their partners: impact of the device 
on quality of life, anxiety and depression. Eur J Cardiothorac Surg 2018;53:799‚Äì806. 
https://doi.org/10.1093/ejcts/ezx426
225. UK Carers. State of Caring Survey 2023‚ÄîThe Impact of Caring on Health. https://www. 
carersuk.org/reports/state-of-caring-survey-2023-the-impact-of-caring-on-health (23 
September 2024, date last accessed).
226. Buckner L, Yeandle S. Valuing Carers 2015 The Rising Value of Carers‚Äô Support. 2015. 
https://www.carersuk.org/reports/valuing-carers-2015-research-report/
(23 
September 2024, date last accessed).
227. Hopp FP, Camp JK, Perry TE. Addressing heart failure challenges through 
illness-informed social work. Health Soc Work 2015;40:201‚Äì8. https://doi.org/10. 
1093/hsw/hlv036
228. DeFrank JT, Barclay C, Sheridan S, Brewer NT, Gilliam M, Moon AM, et al. The psycho¬≠
logical harms of screening: the evidence we have versus the evidence we need. J Gen 
Intern Med 2015;30:242‚Äì8. https://doi.org/10.1007/s11606-014-2996-5
229. Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depres¬≠
sion. Two questions are as good as many. J Gen Intern Med 1997;12:439‚Äì45. https://doi. 
org/10.1046/j.1525-1497.1997.00076.x
230. Spitzer RL, Williams JB, Kroenke K, Linzer M, deGruy FV 3rd, Hahn SR, et al. Utility of a 
new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 
study. JAMA 1994;272:1749‚Äì56. https://doi.org/10.1001/jama.1994.03520220043029
231. Whooley MA. Screening for depression‚Äìa tale of two questions. JAMA Intern Med 
2016;176:436‚Äì8. https://doi.org/10.1001/jamainternmed.2015.8493
232. Bosanquet K, Bailey D, Gilbody S, Harden M, Manea L, Nutbrown S, et al. Diagnostic ac¬≠
curacy of the Whooley questions for the identification of depression: a diagnostic 
meta-analysis. BMJ Open 2015;5:e008913. https://doi.org/10.1136/bmjopen-2015-008913
233. Smith RD, Shing JSY, Lin J, Bosanquet K, Fong DYT, Lok KYW. Meta-analysis of diag¬≠
nostic properties of the Whooley questions to identify depression in perinatal women. 
J Affect Disord 2022;315:148‚Äì55. https://doi.org/10.1016/j.jad.2022.07.026
234. Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical set¬≠
tings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen 
Intern Med 2007;22:1596‚Äì602. https://doi.org/10.1007/s11606-007-0333-y
235. Kronish IM, Moise N, Cheung YK, Clarke GN, Dolor RJ, Duer-Hefele J, et al. Effect of 
depression screening after acute coronary syndromes on quality of life: the 
CODIACS-QoL randomized clinical trial. JAMA Intern Med 2020;180:45‚Äì53. https:// 
doi.org/10.1001/jamainternmed.2019.4518
236. Bolgeo T, Di Matteo R, Simonelli N, Dal Molin A, Lusignani M, Bassola B, et al. 
Psychometric properties and measurement invariance of the 7-item general anxiety 
disorder scale (GAD-7) in an Italian coronary heart disease population. J Affect 
Disord 2023;334:213‚Äì9. https://doi.org/10.1016/j.jad.2023.04.140
237. van den Houdt S, Albus C, Herrmann-Lingen C, Widdershoven J, Kupper N. Validity of 
a multidimensional comprehensive psychosocial screening instrument based on the 
ESC Cardiovascular Prevention Guidelines‚Äîevidence from the general and cardiovas¬≠
cular patient population. J Psychosom Res 2022;157:110791. https://doi.org/10.1016/j. 
jpsychores.2022.110791
238. Staples LG, Dear BF, Gandy M, Fogliati V, Fogliati R, Karin E, et al. Psychometric prop¬≠
erties and clinical utility of brief measures of depression, anxiety, and general distress: 
the PHQ-2, GAD-2, and K-6. Gen Hosp Psychiatry 2019;56:13‚Äì8. https://doi.org/10. 
1016/j.genhosppsych.2018.11.003
239. Moons P, Norekv√•l TM, Arbelo E, Borregaard B, Casadei B, Cosyns B, et al. Placing 
patient-reported outcomes at the centre of cardiovascular clinical practice: implica¬≠
tions for quality of care and management. Eur Heart J 2023;44:3405‚Äì22. https://doi. 
org/10.1093/eurheartj/ehad514
240. Pedersen SS, Wehberg S, Nielsen JC, Riahi S, Larroud√© C, Philbert BT, et al. Patients 
with an implantable cardioverter defibrillator at risk of poorer psychological health 
during 24 months of follow-up (results from the Danish national DEFIB-WOMEN 
study). Gen Hosp Psychiatry 2023;80:54‚Äì61. https://doi.org/10.1016/j.genhosppsych. 
2022.12.006
241. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B√∂hm M, et al. 2021 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. 
Eur Heart J 2021;42:3599‚Äì726. https://doi.org/10.1093/eurheartj/ehab368
242. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC 
Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024; 
45:3415‚Äì537. https://doi.org/10.1093/eurheartj/ehae177
243. Marx N, Federici M, Sch√ºtt K, M√ºller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC 
Guidelines for the management of cardiovascular disease in patients with diabetes. Eur 
Heart J 2023;44:4043‚Äì140. https://doi.org/10.1093/eurheartj/ehad192
244. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC 
Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44: 
3720‚Äì826. https://doi.org/10.1093/eurheartj/ehad191
245. Gorini A, Giuliani M, Raggio L, Barbieri S, Tremoli E. Depressive and anxiety symptoms 
screening in cardiac inpatients: a virtuous Italian approach to psychocardiology. Int J 
Environ Res Public Health 2020;17:5007. https://doi.org/10.3390/ijerph17145007
246. Barry LC, Kasl SV, Lichtman J, Vaccarino V, Krumholz HM. Social support and change in 
health-related quality of life 6 months after coronary artery bypass grafting. J Psychosom 
Res 2006;60:185‚Äì93. https://doi.org/10.1016/j.jpsychores.2005.06.080
247. Dew MA, DiMartini AF, Dobbels F, Grady KL, Jowsey-Gregoire SG, Kaan A, et al. The 
2018 ISHLT/APM/AST/ICCAC/STSW recommendations for the psychosocial evalu¬≠
ation of adult cardiothoracic transplant candidates and candidates for long-term mech¬≠
anical circulatory support. J Heart Lung Transplant 2018;37:803‚Äì23. https://doi.org/10. 
1016/j.healun.2018.03.005
248. Vandenbogaart E, Doering L, Chen B, Saltzman A, Chaker T, Creaser JW, et al. 
Evaluation of the SIPAT instrument to assess psychosocial risk in heart transplant can¬≠
didates: a retrospective single center study. Heart Lung 2017;46:273‚Äì9. https://doi.org/ 
10.1016/j.hrtlng.2017.04.005
249. Schneekloth TD, Hitschfeld MJ, Jowsey-Gregoire SG, Petterson TM, Dunlay SM, Niazi 
SK, et al. Psychosocial risk predicts new episode depression after heart transplant. 
Psychosomatics 2019;60:47‚Äì55. https://doi.org/10.1016/j.psym.2018.06.003
250. Olsson KM, Meltendorf T, Fuge J, Kamp JC, Park DH, Richter MJ, et al. Prevalence of 
mental disorders and impact on quality of life in patients with pulmonary arterial hyper¬≠
tension. Front Psychiatry 2021;12:667602. https://doi.org/10.3389/fpsyt.2021.667602
ESC Guidelines                                                                                                                                                                                               59


<!-- PAGE 60 -->

### Page 60

251. Topp CW, √òstergaard SD, S√∏ndergaard S, Bech P. The WHO-5 well-being index: a 
systematic review of the literature. Psychother Psychosom 2015;84:167‚Äì76. https:// 
doi.org/10.1159/000376585
252. Europe WHOROf. Wellbeing Measures in Primary Health Care/The DepCare Project: 
Report on a WHO meeting: Stockholm, Sweden, 12‚Äì3 February 1998. World Health 
Organization. Regional Office for Europe. 1998. https://iris.who.int/handle/10665/ 
349766 (16 June 2025, date last accessed).
253. Baou CE, Desai R, Cooper C, Marchant NL, Pilling S, Richards M, et al. Psychological ther¬≠
apies for depression and cardiovascular risk: evidence from national healthcare records in 
England. Eur Heart J 2023;44:1650‚Äì62. https://doi.org/10.1093/eurheartj/ehad188
254. Pedersen SS, Skov O, Ahm R. Are we getting closer to treating heart and mind to¬≠
gether and bridging the gap for individual patients attending cardiac rehabilitation? 
Eur Heart J 2023;44:997‚Äì9. https://doi.org/10.1093/eurheartj/ehac820
255. Ho FY, Yeung WF, Ng TH, Chan CS. The efficacy and cost-effectiveness of stepped 
care prevention and treatment for depressive and/or anxiety disorders: a systematic 
review and meta-analysis. Sci Rep 2016;6:29281. https://doi.org/10.1038/srep29281
256. Davidson KW, Bigger JT, Burg MM, Carney RM, Chaplin WF, Czajkowski S, et al. 
Centralized, stepped, patient preference-based treatment for patients with post-acute 
coronary syndrome depression: CODIACS vanguard randomized controlled trial. 
JAMA Intern Med 2013;173:997‚Äì1004. https://doi.org/10.1001/jamainternmed.2013.915
257. Davidson KW, Rieckmann N, Clemow L, Schwartz JE, Shimbo D, Medina V, et al. 
Enhanced depression care for patients with acute coronary syndrome and persistent de¬≠
pressive symptoms: coronary psychosocial evaluation studies randomized controlled 
trial. Arch Intern Med 2010;170:600‚Äì8. https://doi.org/10.1001/archinternmed.2010.29
258. Tehranineshat B, Rakhshan M, Torabizadeh C, Fararouei M. Compassionate care in 
healthcare systems: a systematic review. J Natl Med Assoc 2019;111:546‚Äì54. https:// 
doi.org/10.1016/j.jnma.2019.04.002
259. Okunrintemi V, Spatz ES, Di Capua P, Salami JA, Valero-Elizondo J, Warraich H, et al. 
Patient-provider communication and health outcomes among individuals with athero¬≠
sclerotic cardiovascular disease in the United States: medical expenditure panel survey 
2010 to 2013. Circ Cardiovasc Qual Outcomes 2017;10:e003635. https://doi.org/10. 
1161/CIRCOUTCOMES.117.003635
260. Zwack CC, Smith C, Poulsen V, Raffoul N, Redfern J. Information needs and commu¬≠
nication strategies for people with coronary heart disease: a scoping review. Int J 
Environ Res Public Health 2023;20:1723. https://doi.org/10.3390/ijerph20031723
261. Mentrup S, Harris E, Gomersall T, K√∂pke S, Astin F. Patients‚Äô experiences of cardiovas¬≠
cular health education and risk communication: a qualitative synthesis. Qual Health Res 
2020;30:88‚Äì104. https://doi.org/10.1177/1049732319887949
262. Mitropoulou P, Gr√ºner-Hegge N, Reinhold J, Papadopoulou C. Shared decision making 
in cardiology: a systematic review and meta-analysis. Heart 2022;109:34‚Äì9. https://doi. 
org/10.1136/heartjnl-2022-321050
263. Ski CF, Taylor RS, McGuigan K, Long L, Lambert JD, Richards SH, et al. Psychological 
interventions for depression and anxiety in patients with coronary heart disease, heart 
failure or atrial fibrillation. Cochrane Database Syst Rev 2024;4:CD013508. https://doi. 
org/10.1002/14651858.CD013508.pub3
264. Mou H, Lam SKK, Chien WT. The effects of a family-focused dyadic psychoeducational 
intervention for stroke survivors and their family caregivers: a randomised controlled 
trial. Int J Nurs Stud 2023;143:104504. https://doi.org/10.1016/j.ijnurstu.2023.104504
265. World Health Organization. Therapeutic Patient Education: An Introductory Guide. 
Copenhagen: WHO Regional Office for Europe; 2023. Licence: CC BY-NC-SA 3.0 IGO. 
https://www.who.int/europe/publications/i/item/9789289060219
(17 
December 
2024, date last accessed).
266. Shi W, Ghisi GLM, Zhang L, Hyun K, Pakosh M, Gallagher R. A systematic review, 
meta-analysis, and meta-regression of patient education for secondary prevention in 
patients with coronary heart disease: impact on psychological outcomes. Eur J 
Cardiovasc Nurs 2022;21:643‚Äì54. https://doi.org/10.1093/eurjcn/zvac001
267. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook 
for Systematic Reviews of Interventions Version 6.4 (Updated August 2023). Cochrane, 
2023. 2022. www.training.cochrane.org/handbook (24 May 2024, date last accessed).
268. Kao CW, Chen MY, Chen TY, Lin PH. Effect of psycho-educational interventions on 
quality of life in patients with implantable cardioverter defibrillators: a meta-analysis of 
randomized controlled trials. Health Qual Life Outcomes 2016;14:138. https://doi.org/ 
10.1186/s12955-016-0543-2
269. Palm P, Qvist I, Rasmussen TB, Christensen SW, H√•konsen SJ, Risom SS. Educational 
interventions to improve outcomes in patients with atrial fibrillation-a systematic re¬≠
view. Int J Clin Pract 2020;74:e13629. https://doi.org/10.1111/ijcp.13629
270. Whyne EZ, Woo J, Jeon-Slaughter H. The effects of subjective wellbeing and self-rated 
health on lifetime risk of cardiovascular conditions in women. Int J Environ Res Public 
Health 2023;20:6380. https://doi.org/10.3390/ijerph20146380
271. Araki K, Takahashi Y, Okada H, Nakayama T. Social prescribing from the patient‚Äôs per¬≠
spective: a literature review. J Gen Fam Med 2022;23:299‚Äì309. https://doi.org/10.1002/ 
jgf2.551
272. Liebmann M, Pitman A, Hsueh YC, Bertotti M, Pearce E. Do people perceive benefits 
in the use of social prescribing to address loneliness and/or social isolation? A qualita¬≠
tive meta-synthesis of the literature. BMC Health Serv Res 2022;22:1264. https://doi. 
org/10.1186/s12913-022-08656-1
273. Wood C, Chalmin-Pui LS, Smyth N, Rajcani J. Editorial: nature-based social prescrip¬≠
tions for improving health and wellbeing. Front Psychol 2022;13:1095064. https://doi. 
org/10.3389/fpsyg.2022.1095064
274. Cooper M, Avery L, Scott J, Ashley K, Jordan C, Errington L, et al. Effectiveness and active 
ingredients of social prescribing interventions targeting mental health: a systematic re¬≠
view. BMJ Open 2022;12:e060214. https://doi.org/10.1136/bmjopen-2021-060214
275. Nguyen PY, Astell-Burt T, Rahimi-Ardabili H, Feng X. Effect of nature prescriptions on 
cardiometabolic and mental health, and physical activity: a systematic review. Lancet 
Planet Health 2023;7:e313‚Äì28. https://doi.org/10.1016/S2542-5196(23)00025-6
276. Shukla A, Choudhari SG, Gaidhane AM, Quazi Syed Z. Role of art therapy in the pro¬≠
motion of mental health: a critical review. Cureus 2022;14:e28026. https://doi.org/10. 
7759/cureus.28026
277. Coventry PA, Brown JE, Pervin J, Brabyn S, Pateman R, Breedvelt J, et al. Nature-based 
outdoor activities for mental and physical health: systematic review and meta-analysis. 
SSM Popul Health 2021;16:100934. https://doi.org/10.1016/j.ssmph.2021.100934
278. Haleem A, Javaid M, Singh RP, Suman R. Telemedicine for healthcare: capabilities, fea¬≠
tures, barriers, and applications. Sens Int 2021;2:100117. https://doi.org/10.1016/j.sintl. 
2021.100117
279. Santo K, Redfern J. Digital health innovations to improve cardiovascular disease care. 
Curr Atheroscler Rep 2020;22:71. https://doi.org/10.1007/s11883-020-00889-x
280. Vidovic D, Reinhardt GY, Hammerton C. Can social prescribing foster individual and 
community well-being? A systematic review of the evidence. Int J Environ Res Public 
Health 2021;18:5276. https://doi.org/10.3390/ijerph18105276
281. Richards SH, Anderson L, Jenkinson CE, Whalley B, Rees K, Davies P, et al. 
Psychological interventions for coronary heart disease: Cochrane systematic review 
and meta-analysis. Eur J Prev Cardiol 2018;25:247‚Äì59. https://doi.org/10.1177/ 
2047487317739978
282. Thoma N, Pilecki B, McKay D. Contemporary cognitive behavior therapy: a review of 
theory, history, and evidence. Psychodyn Psychiatry 2015;43:423‚Äì61. https://doi.org/10. 
1521/pdps.2015.43.3.423
283. Mag√°n I, Jurado-Barba R, Casado L, Barnum H, Jeon A, Hernandez AV, et al. Efficacy of 
psychological interventions on clinical outcomes of coronary artery disease: systematic 
review and meta-analysis. J Psychosom Res 2022;153:110710. https://doi.org/10.1016/j. 
jpsychores.2021.110710
284. Mag√°n I, Casado L, Jurado-Barba R, Barnum H, Redondo MM, Hernandez AV, et al. 
Efficacy of psychological interventions on psychological outcomes in coronary artery 
disease: systematic review and meta-analysis. Psychol Med 2021;51:1846‚Äì60. https:// 
doi.org/10.1017/S0033291720000598
285. S√§rnholm J, Sk√∫lad√≥ttir H, R√ºck C, Axelsson E, Bonnert M, Bragesj√∂ M, et al. Cognitive 
behavioral therapy improves quality of life in patients with symptomatic paroxysmal 
atrial fibrillation. J Am Coll Cardiol 2023;82:46‚Äì56. https://doi.org/10.1016/j.jacc.2023. 
04.044
286. Holdgaard A, Eckhardt-Hansen C, Lassen CF, Kjesbu IE, Dall CH, Michaelsen KL, et al. 
Cognitive-behavioural therapy reduces psychological distress in younger patients with 
cardiac disease: a randomized trial. Eur Heart J 2023;44:986‚Äì96. https://doi.org/10. 
1093/eurheartj/ehac792
287. Chen B, Wen J, You D, Zhang Y. Implication of cognitive-behavioral stress manage¬≠
ment on anxiety, depression, and quality of life in acute myocardial infarction patients 
after percutaneous coronary intervention: a multicenter, randomized, controlled 
study. Ir J Med Sci 2024;193:101‚Äì9. https://doi.org/10.1007/s11845-023-03422-6
288. Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Sv√§rdsudd K. Randomized con¬≠
trolled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent 
cardiovascular events in patients with coronary heart disease: Secondary Prevention in 
Uppsala Primary Health Care project (SUPRIM). Arch Intern Med 2011;171:134‚Äì40. 
https://doi.org/10.1001/archinternmed.2010.510
289. Rawlings GH, Thompson AR, Armstrong I, Novakova B, Beail N. Coping styles asso¬≠
ciated with depression, health anxiety and health-related quality of life in pulmonary 
hypertension: cross-sectional analysis. BMJ Open 2022;12:e062564. https://doi.org/ 
10.1136/bmjopen-2022-062564
290. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 
ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur 
Heart J 2022;43:3618‚Äì731. https://doi.org/10.1093/eurheartj/ehac237
291. Wittmann L, Blomert E, Linden M. Patients‚Äô perception of side effects in cognitive- 
behavior, psychodynamic, and psychoanalytic outpatient psychotherapy. Psychother 
Res 2023;35:112‚Äì24. https://doi.org/10.1080/10503307.2023.2290029
292. Knowles KA, Tolin DF. Mechanisms of action in exposure therapy. Curr Psychiatry Rep 
2022;24:861‚Äì9. https://doi.org/10.1007/s11920-022-01391-8
293. IsHak WW, Hamilton MA, Korouri S, Diniz MA, Mirocha J, Hedrick R, et al. 
Comparative effectiveness of psychotherapy vs antidepressants for depression in 
heart failure: a randomized clinical trial. JAMA Netw Open 2024;7:e2352094. https:// 
doi.org/10.1001/jamanetworkopen.2023.52094
294. Arabia E, Manca ML, Solomon RM. EMDR for survivors of life-threatening cardiac 
events: results of a pilot study. J EMDR Prac Res 2011;5:2‚Äì13. https://doi.org/10. 
1891/1933-3196.5.1.2
295. Shemesh E, Annunziato RA, Weatherley BD, Cotter G, Feaganes JR, Santra M, et al. A 
randomized controlled trial of the safety and promise of cognitive-behavioral therapy


<!-- PAGE 61 -->

### Page 61

using imaginal exposure in patients with posttraumatic stress disorder resulting from 
cardiovascular illness. J Clin Psychiatry 2011;72:168‚Äì74. https://doi.org/10.4088/JCP. 
09m05116blu
296. von K√§nel R, Barth J, Princip M, Meister-Langraf RE, Schmid JP, Znoj H, et al. Early psy¬≠
chological counseling for the prevention of posttraumatic stress induced by acute cor¬≠
onary syndrome: the MI-SPRINT randomized controlled trial. Psychother Psychosom 
2018;87:75‚Äì84. https://doi.org/10.1159/000486099
297. Walsh R. Lifestyle and mental health. Am Psychol 2011;66:579‚Äì92. https://doi.org/10. 
1037/a0021769
298. Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental 
illness. Nat Rev Cardiol 2021;18:136‚Äì45. https://doi.org/10.1038/s41569-020-00463-7
299. Ng R, Sutradhar R, Yao Z, Wodchis WP, Rosella LC. Smoking, drinking, diet and phys¬≠
ical activity-modifiable lifestyle risk factors and their associations with age to first 
chronic disease. Int J Epidemiol 2020;49:113‚Äì30. https://doi.org/10.1093/ije/dyz078
300. Tsima BM, Opondo P, Mosepele M, Mautle E, Bilker WB, Gross R. Prevalence of the 
metabolic syndrome and associated factors among inpatients with severe mental ill¬≠
ness in Botswana: a cross-sectional study. BMC Cardiovasc Disord 2022;22:515. 
https://doi.org/10.1186/s12872-022-02939-5
301. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary 
care-led weight management for remission of type 2 diabetes (DiRECT): an open- 
label, cluster-randomised trial. Lancet 2018;391:541‚Äì51. https://doi.org/10.1016/ 
S0140-6736(17)33102-1
302. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, et al. Intensive 
lifestyle changes for reversal of coronary heart disease. JAMA 1998;280:2001‚Äì7. 
https://doi.org/10.1001/jama.280.23.2001
303. Caparr√≥s B, Masferrer L. Coping strategies and complicated grief in a substance use 
disorder sample. Front Psychol 2020;11:624065. https://doi.org/10.3389/fpsyg.2020. 
624065
304. Ghodeshwar GK, Dube A, Khobragade D. Impact of lifestyle modifications on cardio¬≠
vascular health: a narrative review. Cureus 2023;15:e42616. https://doi.org/10.7759/ 
cureus.42616
305. Basso JC, Suzuki WA. The effects of acute exercise on mood, cognition, neurophysi¬≠
ology, and neurochemical pathways: a review. Brain Plast 2017;2:127‚Äì52. https://doi. 
org/10.3233/BPL-160040
306. Callaghan P. Exercise: a neglected intervention in mental health care? J Psychiatr Ment 
Health Nurs 2004;11:476‚Äì83. https://doi.org/10.1111/j.1365-2850.2004.00751.x
307. Doyle F, Freedland KE, Carney RM, de Jonge P, Dickens C, Pedersen SS, et al. Hybrid 
systematic review and network meta-analysis of randomized controlled trials of inter¬≠
ventions for depressive symptoms in patients with coronary artery disease. Psychosom 
Med 2021;83:423‚Äì31. https://doi.org/10.1097/PSY.0000000000000944
308. Blumenthal JA, Babyak MA, O‚ÄôConnor C, Keteyian S, Landzberg J, Howlett J, et al. 
Effects of exercise training on depressive symptoms in patients with chronic heart fail¬≠
ure: the HF-ACTION randomized trial. JAMA 2012;308:465‚Äì74. https://doi.org/10. 
1001/jama.2012.8720
309. Ghosh RK, Ball S, Prasad V, Gupta A. Depression in heart failure: intricate relationship, 
pathophysiology and most updated evidence of interventions from recent clinical stud¬≠
ies. Int J Cardiol 2016;224:170‚Äì7. https://doi.org/10.1016/j.ijcard.2016.09.063
310. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B√§ck M, et al. 2021 ESC 
Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 
42:3227‚Äì337. https://doi.org/10.1093/eurheartj/ehab484
311. Rudzi≈Ñska A, Perera I, Gryglewska B, GƒÖsowski J, Piotrowicz K. Can the Mediterranean 
diet decrease the risk of depression in older persons‚Äîa systematic review. Psychiatr 
Pol 2023;57:339‚Äì54. https://doi.org/10.12740/PP/OnlineFirst/140465
312. Yin W, L√∂f M, Chen R, Hultman CM, Fang F, Sandin S. Mediterranean diet and depres¬≠
sion: a population-based cohort study. Int J Behav Nutr Phys Act 2021;18:153. https:// 
doi.org/10.1186/s12966-021-01227-3
313. Jacka FN, O‚ÄôNeil A, Opie R, Itsiopoulos C, Cotton S, Mohebbi M, et al. A randomised 
controlled trial of dietary improvement for adults with major depression (the ‚ÄòSMILES‚Äô 
trial). BMC Med 2017;15:23. https://doi.org/10.1186/s12916-017-0791-y
314. Granero R. Role of nutrition and diet on healthy mental state. Nutrients 2022;14:750. 
https://doi.org/10.3390/nu14040750
315. O‚ÄôNeil A, Quirk SE, Housden S, Brennan SL, Williams LJ, Pasco JA, et al. Relationship 
between diet and mental health in children and adolescents: a systematic review. Am J 
Public Health 2014;104:e31‚Äì42. https://doi.org/10.2105/AJPH.2014.302110
316. Jiang W, Whellan DJ, Adams KF, Babyak MA, Boyle SH, Wilson JL, et al. Long-chain 
omega-3 fatty acid supplements in depressed heart failure patients: results of the 
OCEAN trial. JACC Heart Fail 2018;6:833‚Äì43. https://doi.org/10.1016/j.jchf.2018.03.011
317. Thorndike AN, Achtyes ED, Cather C, Pratt S, Pachas GN, Hoeppner SS, et al. Weight 
gain and 10-year cardiovascular risk with sustained tobacco abstinence in smokers with 
serious mental illness: a subgroup analysis of a randomized trial. J Clin Psychiatry 2016; 
77:e320‚Äì6. https://doi.org/10.4088/JCP.15m10074
318. Okorare O, Evbayekha EO, Adabale OK, Daniel E, Ubokudum D, Olusiji SA, et al. 
Smoking cessation and benefits to cardiovascular health: a review of literature. 
Cureus 2023;15:e35966. https://doi.org/10.7759/cureus.35966
319. Denison E, Underland V, Mosd√∏l A, Vist G. Cognitive Therapies for Smoking Cessation: a 
Systematic Review. 2017. https://www.ncbi.nlm.nih.gov/books/NBK482098/ (13 January 
2024, date last accessed).
320. Schuman-Olivier Z, Trombka M, Lovas DA, Brewer JA, Vago DR, Gawande R, et al. 
Mindfulness and behavior change. Harv Rev Psychiatry 2020;28:371‚Äì94. https://doi. 
org/10.1097/HRP.0000000000000277
321. Zaccaro A, Piarulli A, Laurino M, Garbella E, Menicucci D, Neri B, et al. How breath- 
control can change your life: a systematic review on psycho-physiological correlates 
of slow breathing. Front Hum Neurosci 2018;12:353. https://doi.org/10.3389/fnhum. 
2018.00353
322. Yaribeygi H, Panahi Y, Sahraei H, Johnston TP, Sahebkar A. The impact of stress on body 
function: a review. EXCLI J 2017;16:1057‚Äì72. https://doi.org/10.17179/excli2017-480
323. Toussaint L, Nguyen QA, Roettger C, Dixon K, Offenb√§cher M, Kohls N, et al. 
Effectiveness of progressive muscle relaxation, deep breathing, and guided imagery 
in promoting psychological and physiological states of relaxation. Evid Based 
Complement Alternat Med 2021;2021:5924040. https://doi.org/10.1155/2021/5924040
324. Masih T, Dimmock JA, Epel E, Guelfi KJ. An 8-week relaxation program consisting of 
progressive muscle relaxation and mindfulness meditation to reduce stress and attenu¬≠
ate stress-driven eating. Appl Psychol Health Well Being 2020;12:188‚Äì211. https://doi. 
org/10.1111/aphw.12179
325. Xu J, Jo H, Noorbhai L, Patel A, Li A. Virtual mindfulness interventions to promote 
well-being in adults: a mixed-methods systematic review. J Affect Disord 2022;300: 
571‚Äì85. https://doi.org/10.1016/j.jad.2022.01.027
326. Behan C. The benefits of meditation and mindfulness practices during times of crisis 
such as COVID-19. Ir J Psychol Med 2020;37:256‚Äì8. https://doi.org/10.1017/ipm. 
2020.38
327. Koerten HR, Watford TS, Dubow EF, O‚ÄôBrien WH. Cardiovascular effects of brief 
mindfulness meditation among perfectionists experiencing failure. Psychophysiology 
2020;57:e13517. https://doi.org/10.1111/psyp.13517
328. Albus C, Herrmann-Lingen C, Jensen K, Hackbusch M, Munch N, Kuncewicz C, et al. 
Additional effects of psychological interventions on subjective and objective outcomes 
compared with exercise-based cardiac rehabilitation alone in patients with cardiovas¬≠
cular disease: a systematic review and meta-analysis. Eur J Prev Cardiol 2019;26: 
1035‚Äì49. https://doi.org/10.1177/2047487319832393
329. Shahrbabaki SS, Linz D, Hartmann S, Redline S, Baumert M. Sleep arousal burden is 
associated with long-term all-cause and cardiovascular mortality in 8001 
community-dwelling older men and women. Eur Heart J 2021;42:2088‚Äì99. https:// 
doi.org/10.1093/eurheartj/ehab151
330. Dom√≠nguez F, Fuster V, Fern√°ndez-Alvira JM, Fern√°ndez-Friera L, L√≥pez-Melgar B, 
Blanco-Rojo R, et al. Association of sleep duration and quality with subclinical athero¬≠
sclerosis. J Am Coll Cardiol 2019;73:134‚Äì44. https://doi.org/10.1016/j.jacc.2018.10.060
331. Scott AJ, Webb TL, Martyn-St James M, Rowse G, Weich S. Improving sleep quality 
leads to better mental health: a meta-analysis of randomised controlled trials. Sleep 
Med Rev 2021;60:101556. https://doi.org/10.1016/j.smrv.2021.101556
332. Miller MA, Howarth NE. Sleep and cardiovascular disease. Emerg Top Life Sci 2023;7: 
457‚Äì66. https://doi.org/10.1042/ETLS20230111
333. Vandekerckhove M, Wang YL. Emotion, emotion regulation and sleep: an intimate re¬≠
lationship. AIMS Neurosci 2017;5:1‚Äì17. https://doi.org/10.3934/Neuroscience.2018.1.1
334. Kulbayeva S, Tazhibayeva K, Seiduanova L, Smagulova I, Mussina A, Tanabayeva S, et al. 
The recent advances of mobile healthcare in cardiology practice. Acta Inform Med 2022; 
30:236‚Äì50. https://doi.org/10.5455/aim.2022.30.236-250
335. Cruz-Cobo C, Bernal-Jim√©nez M, V√°zquez-Garc√≠a R, Santi-Cano MJ. Effectiveness of 
mHealth interventions in the control of lifestyle and cardiovascular risk factors in pa¬≠
tients after a coronary event: systematic review and meta-analysis. JMIR Mhealth 
Uhealth 2022;10:e39593. https://doi.org/10.2196/39593
336. Takahashi EA, Schwamm LH, Adeoye OM, Alabi O, Jahangir E, Misra S, et al. An over¬≠
view of telehealth in the management of cardiovascular disease: a scientific statement 
from the American Heart Association. Circulation 2022;146:e558‚Äì68. https://doi.org/ 
10.1161/CIR.0000000000001107
337. Lee WW, Choi KC, Yum RW, Yu DS, Chair SY. Effectiveness of motivational inter¬≠
viewing on lifestyle modification and health outcomes of clients at risk or diagnosed 
with cardiovascular diseases: a systematic review. Int J Nurs Stud 2016;53:331‚Äì41. 
https://doi.org/10.1016/j.ijnurstu.2015.09.010
338. Ambrosetti M, Abreu A, Corr√† U, Davos CH, Hansen D, Frederix I, et al. Secondary 
prevention through comprehensive cardiovascular rehabilitation: from knowledge to 
implementation. 2020 update. A position paper from the Secondary Prevention and 
Rehabilitation Section of the European Association of Preventive Cardiology. Eur J 
Prev Cardiol 2021;28:460‚Äì95. https://doi.org/10.1177/2047487320913379
339. Salzwedel A, Jensen K, Rauch B, Doherty P, Metzendorf MI, Hackbusch M, et al. 
Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease pa¬≠
tients treated according to contemporary evidence based medicine: update of the 
Cardiac Rehabilitation Outcome Study (CROS-II). Eur J Prev Cardiol 2020;27: 
1756‚Äì74. https://doi.org/10.1177/2047487320905719
340. Dibben G, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, et al. 
Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database 
Syst Rev 2021;11:CD001800. https://doi.org/10.1002/14651858.CD001800.pub4
ESC Guidelines                                                                                                                                                                                               61


<!-- PAGE 62 -->

### Page 62

341. Morris NR, Kermeen FD, Jones AW, Lee JY, Holland AE. Exercise-based rehabilitation 
programmes for pulmonary hypertension. Cochrane Database Syst Rev 2023;3: 
CD011285. https://doi.org/10.1002/14651858.CD011285.pub3
342. Molloy C, Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, et al. Exercise-based cardiac 
rehabilitation for adults with heart failure. Cochrane Database Syst Rev 2024;3: 
CD003331. https://doi.org/10.1002/14651858.CD003331.pub6
343. Gr√ºnig E, MacKenzie A, Peacock AJ, Eichstaedt CA, Benjamin N, Nechwatal R, et al. 
Standardized exercise training is feasible, safe, and effective in pulmonary arterial 
and chronic thromboembolic pulmonary hypertension: results from a large 
European multicentre randomized controlled trial. Eur Heart J 2021;42:2284‚Äì95. 
https://doi.org/10.1093/eurheartj/ehaa696
344. An QY, Wang L, Yuan P, Zhao QH, Gong SG, Zhang R, et al. Effectiveness and safety of 
exercise training and rehabilitation in chronic thromboembolic pulmonary hyperten¬≠
sion: a systematic review and meta-analysis. Ann Palliat Med 2021;10:8134‚Äì46. 
https://doi.org/10.21037/apm-21-1758
345. Rutledge T, Redwine LS, Linke SE, Mills PJ. A meta-analysis of mental health treatments 
and cardiac rehabilitation for improving clinical outcomes and depression among pa¬≠
tients with coronary heart disease. Psychosom Med 2013;75:335‚Äì49. https://doi.org/ 
10.1097/PSY.0b013e318291d798
346. Zheng X, Zheng Y, Ma J, Zhang M, Zhang Y, Liu X, et al. Effect of exercise-based cardiac 
rehabilitation on anxiety and depression in patients with myocardial infarction: a sys¬≠
tematic review and meta-analysis. Heart Lung 2019;48:1‚Äì7. https://doi.org/10.1016/j. 
hrtlng.2018.09.011
347. Mehra VM, Gaalema DE, Pakosh M, Grace SL. Systematic review of cardiac rehabilita¬≠
tion guidelines: quality and scope. Eur J Prev Cardiol 2020;27:912‚Äì28. https://doi.org/10. 
1177/2047487319878958
348. Abreu A, Frederix I, Dendale P, Janssen A, Doherty P, Piepoli MF, et al. Standardization 
and quality improvement of secondary prevention through cardiovascular rehabilita¬≠
tion programmes in Europe: the avenue towards EAPC accreditation programme: a 
position statement of the Secondary Prevention and Rehabilitation Section of the 
European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2021;28: 
496‚Äì509. https://doi.org/10.1177/2047487320924912
349. Helmark C, Harrison A, Pedersen SS, Doherty P. Systematic screening for anxiety and 
depression in cardiac rehabilitation‚Äîare we there yet? Int J Cardiol 2022;352:65‚Äì71. 
https://doi.org/10.1016/j.ijcard.2022.02.004
350. Wells A, Reeves D, Capobianco L, Heal C, Davies L, Heagerty A, et al. Improving 
the effectiveness of psychological interventions for depression and anxiety in cardiac 
rehabilitation: PATHWAY-A single-blind, parallel, randomized, controlled trial of 
group metacognitive therapy. Circulation 2021;144:23‚Äì33. https://doi.org/10.1161/ 
CIRCULATIONAHA.120.052428
351. Egholm CL, Helmark C, Rossau HK, Munkeh√∏j P, Br√∏ndum S, Pedersen SS, et al. 
Implementation of systematic screening for anxiety and depression in cardiac rehabili¬≠
tation: real world lessons from a longitudinal study. J Psychosom Res 2022;158:110909. 
https://doi.org/10.1016/j.jpsychores.2022.110909
352. Sweda R, Siontis GCM, Nikolakopoulou A, Windecker S, Pilgrim T. Antidepressant 
treatment in patients following acute coronary syndromes: a systematic review and 
Bayesian meta-analysis. ESC Heart Fail 2020;7:3610‚Äì20. https://doi.org/10.1002/ehf2. 
12861
353. Tully PJ, Ang SY, Lee EJ, Bendig E, Bauerei√ü N, Bengel J, et al. Psychological and pharma¬≠
cological interventions for depression in patients with coronary artery disease. 
Cochrane Database Syst Rev 2021;12:CD008012. https://doi.org/10.1002/14651858. 
CD008012.pub4
354. He W, Zhou Y, Ma J, Wei B, Fu Y. Effect of antidepressants on death in patients with 
heart failure: a systematic review and meta-analysis. Heart Fail Rev 2020;25:919‚Äì26. 
https://doi.org/10.1007/s10741-019-09850-w
355. Hedrick R, Korouri S, Tadros E, Darwish T, Cortez V, Triay D, et al. The impact of anti¬≠
depressants on depressive symptom severity, quality of life, morbidity, and mortality in 
heart failure: a systematic review. Drugs Context 2020;9:2020-5-4. https://doi.org/10. 
7573/dic.2020-5-4
356. Galling B, Calsina Ferrer A, Abi Zeid Daou M, Sangroula D, Hagi K, Correll CU. Safety 
and tolerability of antidepressant co-treatment in acute major depressive disorder: re¬≠
sults from a systematic review and exploratory meta-analysis. Expert Opin Drug Saf 
2015;14:1587‚Äì608. https://doi.org/10.1517/14740338.2015.1085970
357. Behlke LM, Lenze EJ, Carney RM. The cardiovascular effects of newer antidepressants 
in older adults and those with or at high risk for cardiovascular diseases. CNS Drugs 
2020;34:1133‚Äì47. https://doi.org/10.1007/s40263-020-00763-z
358. Hughes JW, Kuhn TA, Ede D, Gathright EC, Josephson RA. Meta-analysis of anti¬≠
depressant pharmacotherapy in patients eligible for cardiac rehabilitation: 
ANTIDEPRESSANT AMBIVALENCE. J Cardiopulm Rehabil Prev 2022;42:434‚Äì41. 
https://doi.org/10.1097/HCR.0000000000000699
359. Park K, Kim S, Ko YJ, Park BJ. Duloxetine and cardiovascular adverse events: a system¬≠
atic review and meta-analysis. J Psychiatr Res 2020;124:109‚Äì14. https://doi.org/10. 
1016/j.jpsychires.2020.02.022
360. Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M, 
et al. A comparative study of QT prolongation with serotonin reuptake inhibitors. 
Psychopharmacology (Berl) 2017;234:3075‚Äì81. https://doi.org/10.1007/s00213-017- 
4685-7
361. Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J. Antidepressant 
use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using 
primary care database. BMJ 2016;352:i1350. https://doi.org/10.1136/bmj.i1350
362. Prasitlumkum N, Cheungpasitporn W, Tokavanich N, Ding KR, Kewcharoen J, 
Thongprayoon C, et al. Antidepressants and risk of sudden cardiac death: a network 
meta-analysis and systematic review. Med Sci (Basel) 2021;9:26. https://doi.org/10. 
3390/medsci9020026
363. Abbas R, Riley S, Nepal S, Bachinsky M, Lee KC, Chappell PB, et al. Lack of an effect of 
supratherapeutic dose of venlafaxine on cardiac repolarization in healthy subjects. Clin 
Pharmacol Drug Dev 2022;11:100‚Äì11. https://doi.org/10.1002/cpdd.989
364. Tellone V, Rosignoli MT, Picollo R, Dragone P, Del Vecchio A, Comandini A, et al. 
Effect of 3 single doses of trazodone on QTc interval in healthy subjects. J Clin 
Pharmacol 2020;60:1483‚Äì95. https://doi.org/10.1002/jcph.1640
365. Gurkan S, Liu F, Chain A, Gutstein DE. A study to assess the proarrhythmic potential of 
mirtazapine using concentration-QTc (C-QTc) analysis. Clin Pharmacol Drug Dev 2019; 
8:449‚Äì58. https://doi.org/10.1002/cpdd.605
366. Alvares GA, Quintana DS, Hickie IB, Guastella AJ. Autonomic nervous system dysfunc¬≠
tion in psychiatric disorders and the impact of psychotropic medications: a systematic 
review and meta-analysis. J Psychiatry Neurosci 2016;41:89‚Äì104. https://doi.org/10. 
1503/jpn.140217
367. Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, et al. 
Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. 
J Clin Psychiatry 2014;75:e441‚Äì9. https://doi.org/10.4088/JCP.13r08672
368. Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine 
use in depression: a systematic review. Lancet Psychiatry 2018;5:65‚Äì78. https://doi. 
org/10.1016/S2215-0366(17)30272-9
369. Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. 
Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: 
update 2017. Pharmacopsychiatry 2018;51:9‚Äì62. https://doi.org/10.1055/s-0043-116492
370. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of 
heavy smoking. Clin Pharmacol Ther 2004;76:178‚Äì84. https://doi.org/10.1016/j.clpt. 
2004.04.003
371. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, 
how, and when? Basic Clin Pharmacol Toxicol 2005;97:125‚Äì34. https://doi.org/10. 
1111/j.1742-7843.2005.pto_973160.x
372. Laporte S, Chapelle C, Caillet P, Beyens MN, Bellet F, Delavenne X, et al. Bleeding risk 
under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of 
observational studies. Pharmacol Res 2017;118:19‚Äì32. https://doi.org/10.1016/j.phrs. 
2016.08.017
373. Eckersley MJ, Sepehripour AH, Casula R, Punjabi P, Athanasiou T. Do selective sero¬≠
tonin reuptake inhibitors increase the risk of bleeding or mortality following coronary 
artery bypass graft surgery? A meta-analysis of observational studies. Perfusion 2018; 
33:415‚Äì22. https://doi.org/10.1177/0267659118765933
374. Rahman AA, Platt RW, Beradid S, Boivin JF, Rej S, Renoux C. Concomitant use of se¬≠
lective serotonin reuptake inhibitors with oral anticoagulants and risk of major bleed¬≠
ing. JAMA Netw Open 2024;7:e243208. https://doi.org/10.1001/jamanetworkopen. 
2024.3208
375. Rahman AA, He N, Rej S, Platt RW, Renoux C. Concomitant use of selective serotonin 
reuptake inhibitors and oral anticoagulants and risk of major bleeding: a systematic re¬≠
view and meta-analysis. Thromb Haemost 2023;123:54‚Äì63. https://doi.org/10.1055/a- 
1932-8976
376. Machado CM, Alves M, Caldeira D. Impact of selective serotonin-reuptake inhibitors in 
hemorrhagic risk in anticoagulated patients taking non-vitamin K antagonist anticoagu¬≠
lants: a systematic review and meta-analysis. J Clin Psychopharmacol 2023;43:267‚Äì72. 
https://doi.org/10.1097/JCP.0000000000001684
377. Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazep¬≠
ine misuse: a systematic review. Drug Alcohol Depend 2019;200:95‚Äì114. https://doi.org/ 
10.1016/j.drugalcdep.2019.02.033
378. Kripke DF, Langer RD, Kline LE. Hypnotics‚Äô association with mortality or cancer: a 
matched cohort study. BMJ Open 2012;2:e000850. https://doi.org/10.1136/bmjopen- 
2012-000850
379. Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, et al. Effect of anxiolytic and 
hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ 
2014;348:g1996. https://doi.org/10.1136/bmj.g1996
380. Patorno E, Glynn RJ, Levin R, Lee MP, Huybrechts KF. Benzodiazepines and risk of all 
cause mortality in adults: cohort study. BMJ 2017;358:j2941. https://doi.org/10.1136/ 
bmj.j2941
381. Liu S, Soedamah-Muthu SS, van Meerten SC, Kromhout D, Geleijnse JM, Giltay EJ. Use 
of benzodiazepine and Z-drugs and mortality in older adults after myocardial infarc¬≠
tion. Int J Geriatr Psychiatry 2023;38:e5861. https://doi.org/10.1002/gps.5861
382. von K√§nel R, Schmid JP, Meister-Langraf RE, Barth J, Znoj H, Schnyder U, et al. 
Pharmacotherapy in the management of anxiety and pain during acute coronary syn¬≠
dromes and the risk of developing symptoms of posttraumatic stress disorder. J Am 
Heart Assoc 2021;10:e018762. https://doi.org/10.1161/JAHA.120.018762


<!-- PAGE 63 -->

### Page 63

383. Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, et al. Cardiovascular safety 
of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. 
JAMA Intern Med 2018;178:622‚Äì31. https://doi.org/10.1001/jamainternmed.2018.0397
384. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. 
Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in 
smokers with and without psychiatric disorders (EAGLES): a double-blind, rando¬≠
mised, placebo-controlled clinical trial. Lancet 2016;387:2507‚Äì20. https://doi.org/10. 
1016/S0140-6736(16)30272-0
385. Das A, Roy B, Schwarzer G, Silverman MG, Ziegler O, Bandyopadhyay D, et al. 
Comparison of treatment options for depression in heart failure: a network 
meta-analysis. J Psychiatr Res 2019;108:7‚Äì23. https://doi.org/10.1016/j.jpsychires. 
2018.10.007
386. Ladwig K-H, Baghai TC, Doyle F, Hamer M, Herrmann-Lingen C, Kunschitz E, et al. 
Mental health-related risk factors and interventions in patients with heart failure: a pos¬≠
ition paper endorsed by the European Association of Preventive Cardiology (EAPC). 
Eur J Prev Cardiol 2022;29:1124‚Äì41. https://doi.org/10.1093/eurjpc/zwac006
387. Brouwers C, Christensen SB, Damen NL, Denollet J, Torp-Pedersen C, Gislason GH, 
et al. Antidepressant use and risk for mortality in 121,252 heart failure patients with or 
without a diagnosis of clinical depression. Int J Cardiol 2016;203:867‚Äì73. https://doi. 
org/10.1016/j.ijcard.2015.11.032
388. Watson K, Summers KM. Depression in patients with heart failure: clinical implications and 
management. Pharmacotherapy 2009;29:49‚Äì63. https://doi.org/10.1592/phco.29.1.49
389. de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: me¬≠
chanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging 
2011;28:345‚Äì67. https://doi.org/10.2165/11589340-000000000-00000
390. Braithwaite V, Gibson D, Holman J. Age stereotyping: are we oversimplifying the phe¬≠
nomenon? Int J Aging Hum Dev 1985;22:315‚Äì25. https://doi.org/10.2190/Q2TM-B9V7- 
HDBD-6X6H
391. Teply RM, Packard KA, White ND, Hilleman DE, DiNicolantonio JJ. Treatment of de¬≠
pression in patients with concomitant cardiac disease. Prog Cardiovasc Dis 2016;58: 
514‚Äì28. https://doi.org/10.1016/j.pcad.2015.11.003
392. Colucci VJ, Berry BD. Heart failure worsening and exacerbation after venlafaxine and 
duloxetine therapy. Ann Pharmacother 2008;42:882‚Äì7. https://doi.org/10.1345/aph. 
1L031
393. Zhang L, Bao Y, Tao S, Zhao Y, Liu M. The association between cardiovascular drugs 
and depression/anxiety in patients with cardiovascular disease: a meta-analysis. 
Pharmacol Res 2022;175:106024. https://doi.org/10.1016/j.phrs.2021.106024
394. Riemer TG, Villagomez Fuentes LE, Algharably EAE, Sch√§fer MS, Mangelsen E, F√ºrtig 
MA, et al. Do Œ≤-blockers cause depression?: Systematic review and meta-analysis of 
psychiatric adverse events during Œ≤-blocker therapy. Hypertension 2021;77:1539‚Äì48. 
https://doi.org/10.1161/HYPERTENSIONAHA.120.16590
395. Ghaeli P, Solduzian M, Vejdani S, Talasaz AH. Comparison of the effects of melatonin 
and oxazepam on anxiety levels and sleep quality in patients with 
ST-segment-elevation myocardial infarction following primary percutaneous coron¬≠
ary intervention: a randomized clinical trial. Ann Pharmacother 2018;52:949‚Äì55. 
https://doi.org/10.1177/1060028018776608
396. Astarcioglu MA, Sen T, Kilit C, Durmus HI, Gozubuyuk G, Agus HZ, et al. Procedural 
sedation during transradial coronary angiography to prevent spasm. Herz 2016;41: 
435‚Äì8. https://doi.org/10.1007/s00059-015-4373-5
397. Murphy KA, Dalcin A, McGinty EE, Goldsholl S, Heller A, Daumit GL. Applying care 
coordination principles to reduce cardiovascular disease risk factors in people with 
serious mental illness: a case study approach. Front Psychiatry 2021;12:742169. 
https://doi.org/10.3389/fpsyt.2021.742169
398. Huffman JC, Adams CN, Celano CM. Collaborative care and related interventions in 
patients with heart disease: an update and new directions. Psychosomatics 2018;59: 
1‚Äì18. https://doi.org/10.1016/j.psym.2017.09.003
399. Rollman BL, Belnap BH, LeMenager MS, Mazumdar S, Houck PR, Counihan PJ, et al. 
Telephone-delivered collaborative care for treating post-CABG depression: a rando¬≠
mized controlled trial. JAMA 2009;302:2095‚Äì103. https://doi.org/10.1001/jama.2009. 
1670
400. Katon WJ, Lin EH, Von Korff M, Ciechanowski P, Ludman EJ, Young B, et al. 
Collaborative care for patients with depression and chronic illnesses. N Engl J Med 
2010;363:2611‚Äì20. https://doi.org/10.1056/NEJMoa1003955
401. Huffman JC, Mastromauro CA, Beach SR, Celano CM, DuBois CM, Healy BC, et al. 
Collaborative care for depression and anxiety disorders in patients with recent cardiac 
events: the management of sadness and anxiety in cardiology (MOSAIC) randomized clin¬≠
ical trial. JAMA Intern Med 2014;174:927‚Äì35. https://doi.org/10.1001/jamainternmed.2014. 
739
402. Morgan MA, Coates MJ, Dunbar JA, Reddy P, Schlicht K, Fuller J. The TrueBlue model 
of collaborative care using practice nurses as case managers for depression alongside 
diabetes or heart disease: a randomised trial. BMJ Open 2013;3:e002171. https://doi. 
org/10.1136/bmjopen-2012-002171
403. Archer J, Bower P, Gilbody S, Lovell K, Richards D, Gask L, et al. Collaborative care for 
depression and anxiety problems. Cochrane Database Syst Rev 2012;10:CD006525. 
https://doi.org/10.1002/14651858.CD006525.pub2
404. Rollman BL, Anderson AM, Rothenberger SD, Abebe KZ, Ramani R, Muldoon MF, 
et al. Efficacy of blended collaborative care for patients with heart failure and comorbid 
depression: a randomized clinical trial. JAMA Intern Med 2021;181:1369‚Äì80. https://doi. 
org/10.1001/jamainternmed.2021.4978
405. Ferguson M, Kovacs AH. An integrated adult congenital heart disease psychology ser¬≠
vice. Congenit Heart Dis 2016;11:444‚Äì51. https://doi.org/10.1111/chd.12331
406. Kovacs AH, Brouillette J, Ibeziako P, Jackson JL, Kasparian NA, Kim YY, et al. 
Psychological outcomes and interventions for individuals with congenital heart disease: 
a scientific statement from the American Heart Association. Circ Cardiovasc Qual 
Outcomes 2022;15:e000110. https://doi.org/10.1161/HCQ.0000000000000110
407. Priegnitz J, Langheim E, Rademacher W, Schmitz C, K√∂llner V. Effectiveness of psycho¬≠
cardiological care in inpatient rehabilitation: a pilot study. Psychother Psychosom Med 
Psychol 2020;70:190‚Äì6. https://doi.org/10.1055/a-1023-4609
408. Langheim E, Schmitz C, K√∂llner V. Interdisciplinary psychocardiological rehabilita¬≠
tion: from model project to blueprint of the dual rehabilitation concept‚Äîfrom em¬≠
pirical values to scientific data. Rehabilitation (Stuttg) 2022;61:230‚Äì9. https://doi.org/ 
10.1055/a-1866-6781
409. Sadlonova M, L√∂ser JK, Celano CM, Kleiber C, Broschmann D, Herrmann-Lingen C. 
Changes in treatment outcomes in patients undergoing an integrated psychosomatic 
inpatient treatment: results from a cohort study. Front Psychiatry 2022;13:964879. 
https://doi.org/10.3389/fpsyt.2022.964879
410. van der Voort TY, van Meijel B, Goossens PJ, Renes J, Beekman AT, Kupka RW. 
Collaborative care for patients with bipolar disorder: a randomised controlled trial. 
BMC Psychiatry 2011;11:133. https://doi.org/10.1186/1471-244X-11-133
411. van der Voort TY, van Meijel B, Hoogendoorn AW, Goossens PJ, Beekman AT, Kupka 
RW. Collaborative care for patients with bipolar disorder: effects on functioning and 
quality of life. J Affect Disord 2015;179:14‚Äì22. https://doi.org/10.1016/j.jad.2015.03.005
412. Hjorth√∏j C, St√ºrup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life 
expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 
2017;4:295‚Äì301. https://doi.org/10.1016/S2215-0366(17)30078-0
413. Kessing LV, Vradi E, Andersen PK. Life expectancy in bipolar disorder. Bipolar Disord 
2015;17:543‚Äì8. https://doi.org/10.1111/bdi.12296
414. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease bur¬≠
den implications: a systematic review and meta-analysis. JAMA Psychiatry 2015;72: 
334‚Äì41. https://doi.org/10.1001/jamapsychiatry.2014.2502
415. Lomholt LH, Andersen DV, Sejrsgaard-Jacobsen C, √òzdemir CM, Graff C, Schjerning 
O, et al. Mortality rate trends in patients diagnosed with schizophrenia or bipolar dis¬≠
order: a nationwide study with 20 years of follow-up. Int J Bipolar Disord 2019;7:6. 
https://doi.org/10.1186/s40345-018-0140-x
416. Paratz ED, van Heusden A, Zentner D, Morgan N, Smith K, Thompson T, et al. Sudden 
cardiac death in people with schizophrenia: higher risk, poorer resuscitation profiles, 
and differing pathologies. JACC Clin Electrophysiol 2023;9:1310‚Äì8. https://doi.org/10. 
1016/j.jacep.2023.01.026
417. Park CS, Choi EK, Han KD, Ahn HJ, Kwon S, Lee SR, et al. Increased cardiovascular 
events in young patients with mental disorders: a nationwide cohort study. Eur J 
Prev Cardiol 2023;30:1582‚Äì92. https://doi.org/10.1093/eurjpc/zwad102
418. Rossom RC, Hooker SA, O‚ÄôConnor PJ, Crain AL, Sperl-Hillen JM. Cardiovascular 
risk for patients with and without schizophrenia, schizoaffective disorder, or bipo¬≠
lar disorder. J Am Heart Assoc 2022;11:e021444. https://doi.org/10.1161/JAHA.121. 
021444
419. Lambert AM, Parretti HM, Pearce E, Price MJ, Riley M, Ryan R, et al. Temporal trends in 
associations between severe mental illness and risk of cardiovascular disease: a system¬≠
atic review and meta-analysis. PLoS Med 2022;19:e1003960. https://doi.org/10.1371/ 
journal.pmed.1003960
420. Kugathasan P, Laursen TM, Gr√∏ntved S, Jensen SE, Aagaard J, Nielsen RE. Increased 
long-term mortality after myocardial infarction in patients with schizophrenia. 
Schizophr Res 2018;199:103‚Äì8. https://doi.org/10.1016/j.schres.2018.03.015
421. Polcwiartek C, Loewenstein D, Friedman DJ, Johansson KG, Graff C, S√∏rensen PL, 
et al. Clinical heart failure among patients with and without severe mental illness 
and the association with long-term outcomes. Circ Heart Fail 2021;14:e008364. 
https://doi.org/10.1161/CIRCHEARTFAILURE.121.008364
422. Goldfarb M, De Hert M, Detraux J, Di Palo K, Munir H, Music S, et al. Severe mental 
illness and cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol 2022; 
80:918‚Äì33. https://doi.org/10.1016/j.jacc.2022.06.017
423. Polcwiartek C, O‚ÄôGallagher K, Friedman DJ, Correll CU, Solmi M, Jensen SE, et al. 
Severe mental illness: cardiovascular risk assessment and management. Eur Heart J 
2024;45:987‚Äì97. https://doi.org/10.1093/eurheartj/ehae054
424. Vancampfort D, Firth J, Schuch FB, Rosenbaum S, Mugisha J, Hallgren M, et al. 
Sedentary behavior and physical activity levels in people with schizophrenia, bipolar 
disorder and major depressive disorder: a global systematic review and meta-analysis. 
World Psychiatry 2017;16:308‚Äì15. https://doi.org/10.1002/wps.20458
425. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, et al. Cardiorespiratory fitness 
as a quantitative predictor of all-cause mortality and cardiovascular events in healthy 
men and women: a meta-analysis. JAMA 2009;301:2024‚Äì35. https://doi.org/10.1001/ 
jama.2009.681
ESC Guidelines                                                                                                                                                                                               63


<!-- PAGE 64 -->

### Page 64

426. Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with 
schizophrenia. World J Diabetes 2017;8:390‚Äì6. https://doi.org/10.4239/wjd.v8.i8.390
427. Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of 
metabolic syndrome and its components in people with schizophrenia and related 
psychotic disorders, bipolar disorder and major depressive disorder: a systematic review 
and meta-analysis. World Psychiatry 2015;14:339‚Äì47. https://doi.org/10.1002/wps.20252
428. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin 
Psychiatry 2001;62:15‚Äì26. discussion 40‚Äì11. https://www.psychiatrist.com/jcp/ 
hyperglycemia-antipsychotic-medications/
429. Vuk A, Kuzman MR, Baretic M, Osvatic MM. Diabetic ketoacidosis associated with anti¬≠
psychotic drugs: case reports and a review of literature. Psychiatr Danub 2017;29: 
121‚Äì35. https://doi.org/10.24869/psyd.2017.121
430. Ayerbe L, Forgnone I, Addo J, Siguero A, Gelati S, Ayis S. Hypertension risk and clinical 
care in patients with bipolar disorder or schizophrenia; a systematic review and 
meta-analysis. J Affect Disord 2018;225:665‚Äì70. https://doi.org/10.1016/j.jad.2017.09.002
431. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association 
between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005;76: 
135‚Äì57. https://doi.org/10.1016/j.schres.2005.02.010
432. Fornaro M, Carvalho AF, De Prisco M, Mondin AM, Billeci M, Selby P, et al. The preva¬≠
lence, odds, predictors, and management of tobacco use disorder or nicotine depend¬≠
ence among people with severe mental illness: systematic review and meta-analysis. 
Neurosci Biobehav Rev 2022;132:289‚Äì303. https://doi.org/10.1016/j.neubiorev.2021. 
11.039
433. Ohi K, Shimada T, Kuwata A, Kataoka Y, Okubo H, Kimura K, et al. Smoking rates and 
number of cigarettes smoked per day in schizophrenia: a large cohort meta-analysis in 
a Japanese population. Int J Neuropsychopharmacol 2019;22:19‚Äì27. https://doi.org/10. 
1093/ijnp/pyy061
434. Hjorth√∏j C, √òstergaard ML, Benros ME, Toftdahl NG, Erlangsen A, Andersen JT, et al. 
Association between alcohol and substance use disorders and all-cause and cause- 
specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nation¬≠
wide, prospective, register-based study. Lancet Psychiatry 2015;2:801‚Äì8. https://doi. 
org/10.1016/S2215-0366(15)00207-2
435. Meyer JM, Correll CU. Increased metabolic potential, efficacy, and safety of emerging 
treatments in schizophrenia. CNS Drugs 2023;37:545‚Äì70. https://doi.org/10.1007/ 
s40263-023-01022-7
436. Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, et al. Diabetes 
mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: 
a systematic review and large scale meta-analysis. World Psychiatry 2016;15:166‚Äì74. 
https://doi.org/10.1002/wps.20309
437. Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. 
Comparative effects of 18 antipsychotics on metabolic function in patients with 
schizophrenia, predictors of metabolic dysregulation, and association with psycho¬≠
pathology: a systematic review and network meta-analysis. Lancet Psychiatry 2020;7: 
64‚Äì77. https://doi.org/10.1016/S2215-0366(19)30416-X
438. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular 
adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011;8:114‚Äì26. 
https://doi.org/10.1038/nrendo.2011.156
439. Correll CU, Kane JM, Manu P. Obesity and coronary risk in patients treated with 
second-generation antipsychotics. Eur Arch Psychiatry Clin Neurosci 2011;261: 
417‚Äì23. https://doi.org/10.1007/s00406-010-0177-z
440. Rotella F, Cassioli E, Calderani E, Lazzeretti L, Ragghianti B, Ricca V, et al. Long-term 
metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of rando¬≠
mized controlled trials. Eur Neuropsychopharmacol 2020;32:56‚Äì65. https://doi.org/10. 
1016/j.euroneuro.2019.12.118
441. Yu ZH, Jiang HY, Shao L, Zhou YY, Shi HY, Ruan B. Use of antipsychotics and risk of 
myocardial infarction: a systematic review and meta-analysis. Br J Clin Pharmacol 2016; 
82:624‚Äì32. https://doi.org/10.1111/bcp.12985
442. Taipale H, Tanskanen A, Meht√§l√§ J, Vattulainen P, Correll CU, Tiihonen J. 20-year 
follow-up study of physical morbidity and mortality in relationship to antipsychotic 
treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). 
World Psychiatry 2020;19:61‚Äì8. https://doi.org/10.1002/wps.20699
443. Solmi M, Tiihonen J, L√§hteenvuo M, Tanskanen A, Correll CU, Taipale H. 
Antipsychotics use is associated with greater adherence to cardiometabolic medica¬≠
tions in patients with schizophrenia: results from a nationwide, within-subject design 
study. Schizophr Bull 2022;48:166‚Äì75. https://doi.org/10.1093/schbul/sbab087
444. Vancampfort D, Van Damme T, Probst M, Firth J, Stubbs B, Basangwa D, et al. Physical 
activity is associated with the physical, psychological, social and environmental quality 
of life in people with mental health problems in a low resource setting. Psychiatry Res 
2017;258:250‚Äì4. https://doi.org/10.1016/j.psychres.2017.08.041
445. Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atyp¬≠
ical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009;70: 
1041‚Äì50. https://doi.org/10.4088/JCP.08r04392
446. Piras M, Chahma J, Ranjbar S, Laaboub N, Grosu C, Plessen KJ, et al. Is 
clozapine-induced weight gain dose-dependent? Results from a prospective cohort 
study. Schizophr Bull 2023;49:944‚Äì52. https://doi.org/10.1093/schbul/sbad009
447. Quadackers D, Liemburg E, Bos F, Doornbos B, Risselada A, Berger M, et al. 
Cardiovascular risk assessment methods yield unequal risk predictions: a large cross- 
sectional study in psychiatric secondary care outpatients. BMC Psychiatry 2023;23:536. 
https://doi.org/10.1186/s12888-023-05022-1
448. Perry BI, Upthegrove R, Crawford O, Jang S, Lau E, McGill I, et al. Cardiometabolic risk 
prediction algorithms for young people with psychosis: a systematic review and ex¬≠
ploratory analysis. Acta Psychiatr Scand 2020;142:215‚Äì32. https://doi.org/10.1111/ 
acps.13212
449. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, M√∂ller HJ. Cardiovascular disease 
and diabetes in people with severe mental illness position statement from the 
European Psychiatric Association (EPA), supported by the European Association for 
the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur 
Psychiatry 2009;24:412‚Äì24. https://doi.org/10.1016/j.eurpsy.2009.01.005
450. Chan JKN, Correll CU, Wong CSM, Chu RST, Fung VSC, Wong GHS, et al. Life ex¬≠
pectancy and years of potential life lost in people with mental disorders: a systematic 
review and meta-analysis. EClinicalMedicine 2023;65:102294. https://doi.org/10.1016/j. 
eclinm.2023.102294
451. Solmi M, Fiedorowicz J, Poddighe L, Delogu M, Miola A, H√∏ye A, et al. Disparities in 
screening and treatment of cardiovascular diseases in patients with mental disorders 
across the world: systematic review and meta-analysis of 47 observational studies. 
Am J Psychiatry 2021;178:793‚Äì803. https://doi.org/10.1176/appi.ajp.2021.21010031
452. Ayerbe L, Forgnone I, Foguet-Boreu Q, Gonz√°lez E, Addo J, Ayis S. Disparities in the 
management of cardiovascular risk factors in patients with psychiatric disorders: a sys¬≠
tematic review and meta-analysis. Psychol Med 2018;48:2693‚Äì701. https://doi.org/10. 
1017/S0033291718000302
453. Tan YY, Papez V, Chang WH, Mueller SH, Denaxas S, Lai AG. Comparing clinical trial 
population representativeness to real-world populations: an external validity analysis 
encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 
286 conditions in England. Lancet Healthy Longev 2022;3:e674‚Äì89. https://doi.org/10. 
1016/S2666-7568(22)00186-6
454. Chan JKN, Chu RST, Hung C, Law JWY, Wong CSM, Chang WC. Mortality, revascu¬≠
larization, and cardioprotective pharmacotherapy after acute coronary syndrome in 
patients with severe mental illness: a systematic review and meta-analysis. Schizophr 
Bull 2022;48:981‚Äì98. https://doi.org/10.1093/schbul/sbac070
455. Hallyburton A. Diagnostic overshadowing: an evolutionary concept analysis on the 
misattribution of physical symptoms to pre-existing psychological illnesses. Int J 
Ment Health Nurs 2022;31:1360‚Äì72. https://doi.org/10.1111/inm.13034
456. Szmukler G. ‚ÄúCapacity‚Äù, ‚Äúbest interests‚Äù, ‚Äúwill and preferences‚Äù and the UN conven¬≠
tion on the rights of persons with disabilities. World Psychiatry 2019;18:34‚Äì41. https:// 
doi.org/10.1002/wps.20584
457. Woesner ME, Marsh J, Kanofsky JD. The assertive community treatment team: an ap¬≠
propriate treatment for medical disorders that present with prominent psychiatric 
symptoms. Prim Care Companion CNS Disord 2014;16:10.4088/PCC.14br01639. 
https://doi.org/10.4088/PCC.14br01639
458. Spivak S, Mojtabai R, Green C, Firth T, Sater H, Cullen BA. Distribution and correlates of 
assertive community treatment (ACT) and ACT-like programs: results from the 2015 
N-MHSS. Psychiatr Serv 2019;70:271‚Äì8. https://doi.org/10.1176/appi.ps.201700561
459. Flodgren G, Rachas A, Farmer AJ, Inzitari M, Shepperd S. Interactive telemedicine: ef¬≠
fects on professional practice and health care outcomes. Cochrane Database Syst Rev 
2015;2015:CD002098. https://doi.org/10.1002/14651858.CD002098.pub2
460. Azad MC, Shoesmith WD, Al Mamun M, Abdullah AF, Naing DK, Phanindranath M, 
et al. Cardiovascular diseases among patients with schizophrenia. Asian J Psychiatr 
2016;19:28‚Äì36. https://doi.org/10.1016/j.ajp.2015.11.012
461. Masa-Font R, Fern√°ndez-San-Mart√≠n MI, Mart√≠n L√≥pez LM, Alba Mu√±oz AM, Oller 
Canet S, Mart√≠n Royo J, et al. The effectiveness of a program of physical activity and 
diet to modify cardiovascular risk factors in patients with severe mental illness after 
3-month follow-up: CAPiCOR randomized clinical trial. Eur Psychiatry 2015;30: 
1028‚Äì36. https://doi.org/10.1016/j.eurpsy.2015.09.006
462. Scheewe TW, Backx FJ, Takken T, J√∂rg F, van Strater AC, Kroes AG, et al. Exercise 
therapy improves mental and physical health in schizophrenia: a randomised con¬≠
trolled trial. Acta Psychiatr Scand 2013;127:464‚Äì73. https://doi.org/10.1111/acps.12029
463. Stubbs B, Vancampfort D, Hallgren M, Firth J, Veronese N, Solmi M, et al. EPA guidance 
on physical activity as a treatment for severe mental illness: a meta-review of the evi¬≠
dence and position statement from the European Psychiatric Association (EPA), sup¬≠
ported by the International Organization of Physical Therapists in Mental Health 
(IOPTMH). Eur Psychiatry 2018;54:124‚Äì44. https://doi.org/10.1016/j.eurpsy.2018.07.004
464. Jakobsen AS, Speyer H, N√∏rgaard HCB, Karlsen M, Birk M, Hjorth√∏j C, et al. Effect of 
lifestyle coaching versus care coordination versus treatment as usual in people with 
severe mental illness and overweight: two-years follow-up of the randomized 
CHANGE trial. PLoS One 2017;12:e0185881. https://doi.org/10.1371/journal.pone. 
0185881
465. Aschbrenner KA, Naslund JA, Gorin AA, Mueser KT, Browne J, Wolfe RS, et al. Group 
lifestyle intervention with mobile health for young adults with serious mental illness: a 
randomized controlled trial. Psychiatr Serv 2022;73:141‚Äì8. https://doi.org/10.1176/ 
appi.ps.202100047


<!-- PAGE 65 -->

### Page 65

466. Daumit GL, Dalcin AT, Dickerson FB, Miller ER, Evins AE, Cather C, et al. Effect of a 
comprehensive cardiovascular risk reduction intervention in persons with serious 
mental illness: a randomized clinical trial. JAMA Netw Open 2020;3:e207247. https:// 
doi.org/10.1001/jamanetworkopen.2020.7247
467. Druss BG, von Esenwein SA, Glick GE, Deubler E, Lally C, Ward MC, et al. Randomized 
trial of an integrated behavioral health home: the health outcomes management and 
evaluation (HOME) study. Am J Psychiatry 2017;174:246‚Äì55. https://doi.org/10.1176/ 
appi.ajp.2016.16050507
468. Prasad F, De R, Korann V, Chintoh AF, Remington G, Ebdrup BH, et al. Semaglutide for 
the treatment of antipsychotic-associated weight gain in patients not responding to 
metformin‚Äîa case series. Ther Adv Psychopharmacol 2023;13:20451253231165169. 
https://doi.org/10.1177/20451253231165169
469. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC 
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collab¬≠
oration with the EASD. Eur Heart J 2020;41:255‚Äì323. https://doi.org/10.1093/ 
eurheartj/ehz486
470. Gierisch JM, Nieuwsma JA, Bradford DW, Wilder CM, Mann-Wrobel MC, McBroom 
AJ, et al. Pharmacologic and behavioral interventions to improve cardiovascular risk 
factors in adults with serious mental illness: a systematic review and meta-analysis. J 
Clin Psychiatry 2014;75:e424‚Äì440. https://doi.org/10.4088/JCP.13r08558
471. Cather C, Pachas GN, Cieslak KM, Evins AE. Achieving smoking cessation in individuals 
with schizophrenia: special considerations. CNS Drugs 2017;31:471‚Äì81. https://doi.org/ 
10.1007/s40263-017-0438-8
472. Windle SB, Filion KB, Mancini JG, Adye-White L, Joseph L, Gore GC, et al. 
Combination therapies for smoking cessation: a hierarchical Bayesian meta-analysis. 
Am J Prev Med 2016;51:1060‚Äì71. https://doi.org/10.1016/j.amepre.2016.07.011
473. Cerimele JM, Durango A. Does varenicline worsen psychiatric symptoms in patients 
with schizophrenia or schizoaffective disorder? A review of published studies. J Clin 
Psychiatry 2012;73:e1039‚Äì47. https://doi.org/10.4088/JCP.11r07410
474. Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL, et al. Effects 
of moderate-dose treatment with varenicline on neurobiological and cognitive bio¬≠
markers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. 
Arch Gen Psychiatry 2011;68:1195‚Äì206. https://doi.org/10.1001/archgenpsychiatry. 
2011.83
475. Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Leclerc J, et al. Drug-induced 
arrhythmias: a scientific statement from the American Heart Association. Circulation 2020; 
142:e214‚Äì33. https://doi.org/10.1161/CIR.0000000000000905
476. Stroup TS, Byerly MJ, Nasrallah HA, Ray N, Khan AY, Lamberti JS, et al. Effects of 
switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year cor¬≠
onary heart disease risk and metabolic syndrome status: results from a randomized 
controlled trial. Schizophr Res 2013;146:190‚Äì5. https://doi.org/10.1016/j.schres.2013. 
01.013
477. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. 
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment 
of adults with multi-episode schizophrenia: a systematic review and network 
meta-analysis. Lancet 2019;394:939‚Äì51. https://doi.org/10.1016/S0140-6736(19)31135-3
478. Huhn M, Arndt T, Schneider-Thoma J, Leucht S. Effects of antipsychotics on heart 
rate in treatment of schizophrenia: a systematic review and meta-analysis. Ther Adv 
Psychopharmacol 
2022;12:20451253221097261. 
https://doi.org/10.1177/ 
20451253221097261
479. Chou RH, Lo LW, Liou YJ, Shu JH, Hsu HC, Liang Y, et al. Antipsychotic treatment is 
associated with risk of atrial fibrillation: a nationwide nested case-control study. Int J 
Cardiol 2017;227:134‚Äì40. https://doi.org/10.1016/j.ijcard.2016.11.185
480. Mehta N, Vannozzi R. Lithium-induced electrocardiographic changes: a complete re¬≠
view. Clin Cardiol 2017;40:1363‚Äì7. https://doi.org/10.1002/clc.22822
481. Farran D, Feely O, Ashworth M, Gaughran F. Anticoagulation therapy and outcomes in 
patients with atrial fibrillation and serious mental illness: a systematic review and 
meta-analysis. J Psychiatr Res 2022;156:737‚Äì53. https://doi.org/10.1016/j.jpsychires. 
2022.11.002
482. Ahn HJ, Lee SR, Choi EK, Bae NY, Ahn HJ, Kwon S, et al. Increased risk of incident atrial 
fibrillation in young adults with mental disorders: a nationwide population-based study. 
Heart Rhythm 2023;20:365‚Äì73. https://doi.org/10.1016/j.hrthm.2022.12.019
483. Tamargo J, Rosano G, Walther T, Duarte J, Niessner A, Kaski JC, et al. Gender differ¬≠
ences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother 2017; 
3:163‚Äì82. https://doi.org/10.1093/ehjcvp/pvw042
484. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 
ESC Guidelines for the management of patients with ventricular arrhythmias and 
the prevention of sudden cardiac death. Eur Heart J 2022;43:3997‚Äì4126. https://doi. 
org/10.1093/eurheartj/ehac262
485. Wilde AAM, Semsarian C, M√°rquez MF, Shamloo AS, Ackerman MJ, Ashley EA, et al. 
European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia 
Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society 
(LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac dis¬≠
eases. Europace 2022;24:1307‚Äì67. https://doi.org/10.1093/europace/euac030
486. Woosley RL, Heise CW, Gallo T, Woosley RD, Lambson J, Romero KA. www. 
CredibleMeds.org, QTdrugs List, AZCERT, 1457 E. Desert Garden Dr., Tucson, AZ 
85718. https://crediblemeds.org/ (23 September 2024, date last accessed).
487. Lambiase PD, de Bono JP, Schilling RJ, Lowe M, Turley A, Slade A, et al. British Heart 
Rhythm Society clinical practice guidelines on the management of patients developing 
QT prolongation on antipsychotic medication. Arrhythm Electrophysiol Rev 2019;8: 
161‚Äì5. https://doi.org/10.15420/aer.2019.8.3.G1
488. Nilsson BM, Edstr√∂m O, Lindstr√∂m L, Wernegren P, Bod√©n R. Tachycardia in patients 
treated with clozapine versus antipsychotic long-acting injections. Int Clin 
Psychopharmacol 2017;32:219‚Äì24. https://doi.org/10.1097/YIC.0000000000000169
489. Siskind D, Sidhu A, Cross J, Chua YT, Myles N, Cohen D, et al. Systematic review and 
meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy. Aust N 
Z J Psychiatry 2020;54:467‚Äì81. https://doi.org/10.1177/0004867419898760
490. Vickers M, Ramineni V, Malacova E, Eriksson L, McMahon K, Moudgil V, et al. Risk factors 
for clozapine-induced myocarditis and cardiomyopathy: a systematic review and 
meta-analysis. Acta Psychiatr Scand 2022;145:442‚Äì55. https://doi.org/10.1111/acps.13398
491. Authority MNZMaMDS. Clozapine and Cardiac Safety: Updated Advice for Prescribers. 
2003. https://www.medsafe.govt.nz/profs/PUarticles/clozcardiac.htm (8 July 2024, 
date last accessed).
492. Andrade C. cardiometabolic risks in schizophrenia and directions for intervention, 3: 
psychopharmacological interventions. J Clin Psychiatry 2016;77:e1090‚Äì4. https://doi. 
org/10.4088/JCP.16f11128
493. World Economic Forum. Global Gender Gap Report 2022. 2022. https://www3. 
weforum.org/docs/WEF_GGGR_2022.pdf (5 February 2024, date last accessed).
494. Mehta LS, Beckie TM, DeVon HA, Grines CL, Krumholz HM, Johnson MN, et al. 
Acute myocardial infarction in women: a scientific statement from the American 
Heart Association. Circulation 2016;133:916‚Äì47. https://doi.org/10.1161/CIR. 
0000000000000351
495. O‚ÄôNeil A, Fisher AJ, Kibbey KJ, Jacka FN, Kotowicz MA, Williams LJ, et al. Depression is 
a risk factor for incident coronary heart disease in women: an 18-year longitudinal 
study. J Affect Disord 2016;196:117‚Äì24. https://doi.org/10.1016/j.jad.2016.02.029
496. O‚ÄôNeil A, Scovelle AJ, Milner AJ, Kavanagh A. Gender/sex as a social determinant of cardio¬≠
vascular risk. Circulation 2018;137:854‚Äì64. https://doi.org/10.1161/CIRCULATIONAHA. 
117.028595
497. Shah AJ, Veledar E, Hong Y, Bremner JD, Vaccarino V. Depression and history of at¬≠
tempted suicide as risk factors for heart disease mortality in young individuals. Arch 
Gen Psychiatry 2011;68:1135‚Äì42. https://doi.org/10.1001/archgenpsychiatry.2011.125
498. Taylor JL, Makarem N, Shimbo D, Aggarwal B. Gender differences in associations be¬≠
tween stress and cardiovascular risk factors and outcomes. Gend Genome 2018;2: 
111‚Äì22. https://doi.org/10.1177/2470289718820845
499. Seidler ZE, Dawes AJ, Rice SM, Oliffe JL, Dhillon HM. The role of masculinity in men‚Äôs 
help-seeking for depression: a systematic review. Clin Psychol Rev 2016;49:106‚Äì18. 
https://doi.org/10.1016/j.cpr.2016.09.002
500. Berke DS, Liautaud M, Tuten M. Men‚Äôs psychiatric distress in context: understanding 
the impact of masculine discrepancy stress, race, and barriers to help-seeking. J 
Health Psychol 2022;27:946‚Äì60. https://doi.org/10.1177/1359105320977641
501. Moons P, Kovacs AH, Luyckx K, Thomet C, Budts W, Enomoto J, et al. 
Patient-reported outcomes in adults with congenital heart disease: inter-country vari¬≠
ation, standard of living and healthcare system factors. Int J Cardiol 2018;251:34‚Äì41. 
https://doi.org/10.1016/j.ijcard.2017.10.064
502. Hillerer KM, Neumann ID, Couillard-Despres S, Aigner L, Slattery DA. Sex-dependent 
regulation of hippocampal neurogenesis under basal and chronic stress conditions in 
rats. Hippocampus 2013;23:476‚Äì87. https://doi.org/10.1002/hipo.22107
503. Oyola MG, Handa RJ. Hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal 
axes: sex differences in regulation of stress responsivity. Stress 2017;20:476‚Äì94. https://doi. 
org/10.1080/10253890.2017.1369523
504. Pelletier R, Khan NA, Cox J, Daskalopoulou SS, Eisenberg MJ, Bacon SL, et al. Sex ver¬≠
sus gender-related characteristics: which predicts outcome after acute coronary syn¬≠
drome in the young? J Am Coll Cardiol 2016;67:127‚Äì35. https://doi.org/10.1016/j.jacc. 
2015.10.067
505. Bangasser DA, Cuarenta A. Sex differences in anxiety and depression: circuits and me¬≠
chanisms. Nat Rev Neurosci 2021;22:674‚Äì84. https://doi.org/10.1038/s41583-021- 
00513-0
506. Kivim√§ki M, Steptoe A. Effects of stress on the development and progression of cardiovas¬≠
cular disease. Nat Rev Cardiol 2018;15:215‚Äì29. https://doi.org/10.1038/nrcardio.2017.189
507. Rossi A, Mikail N, Bengs S, Haider A, Treyer V, Buechel RR, et al. Heart-brain interac¬≠
tions in cardiac and brain diseases: why sex matters. Eur Heart J 2022;43:3971‚Äì80. 
https://doi.org/10.1093/eurheartj/ehac061
508. Sullivan S, Young A, Hammadah M, Lima BB, Levantsevych O, Ko YA, et al. Sex differ¬≠
ences in the inflammatory response to stress and risk of adverse cardiovascular out¬≠
comes among patients with coronary heart disease. Brain Behav Immun 2020;90: 
294‚Äì302. https://doi.org/10.1016/j.bbi.2020.09.001
509. Maki PM, Kornstein SG, Joffe H, Bromberger JT, Freeman EW, Athappilly G, et al. 
Guidelines for the evaluation and treatment of perimenopausal depression: summary 
and recommendations. Menopause 2018;25:1069‚Äì85. https://doi.org/10.1097/GME.


<!-- PAGE 66 -->

### Page 66

510. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of de¬≠
pression during the menopausal transition: the Harvard study of moods and cycles. 
Arch Gen Psychiatry 2006;63:385‚Äì90. https://doi.org/10.1001/archpsyc.63.4.385
511. Rees M, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F, et al. Global consensus 
recommendations on menopause in the workplace: a European Menopause and 
Andropause Society (EMAS) position statement. Maturitas 2021;151:55‚Äì62. https:// 
doi.org/10.1016/j.maturitas.2021.06.006
512. Stute P, Spyropoulou A, Karageorgiou V, Cano A, Bitzer J, Ceausu I, et al. Management 
of depressive symptoms in peri- and postmenopausal women: EMAS position state¬≠
ment. Maturitas 2020;131:91‚Äì101. https://doi.org/10.1016/j.maturitas.2019.11.002
513. Corona G, Rastrelli G, Isidori AM, Pivonello R, Bettocchi C, Reisman Y, et al. Erectile 
dysfunction and cardiovascular risk: a review of current findings. Expert Rev Cardiovasc 
Ther 2020;18:155‚Äì64. https://doi.org/10.1080/14779072.2020.1745632
514. Dilixiati D, Cao R, Mao Y, Li Y, Dilimulati D, Azhati B, et al. Association between cardio¬≠
vascular disease and risk of female sexual dysfunction: a systematic review and 
meta-analysis. Eur J Prev Cardiol 2024;31:782‚Äì800. https://doi.org/10.1093/eurjpc/zwae042
515. Winter S, Diamond M, Green J, Karasic D, Reed T, Whittle S, et al. Transgender peo¬≠
ple: health at the margins of society. Lancet 2016;388:390‚Äì400. https://doi.org/10. 
1016/S0140-6736(16)00683-8
516. Ruppert R, Kattari SK, Sussman S. Review: prevalence of addictions among transgender 
and gender diverse subgroups. Int J Environ Res Public Health 2021;18:8843. https://doi. 
org/10.3390/ijerph18168843
517. Streed CG Jr, Beach LB, Caceres BA, Dowshen NL, Moreau KL, Mukherjee M, et al. 
Assessing and addressing cardiovascular health in people who are transgender and 
gender diverse: a scientific statement from the American Heart Association. 
Circulation 2021;144:e136‚Äì48. https://doi.org/10.1161/CIR.0000000000001003
518. Onasanya O, Iyer G, Lucas E, Lin D, Singh S, Alexander GC. Association between exogen¬≠
ous testosterone and cardiovascular events: an overview of systematic reviews. Lancet 
Diabetes Endocrinol 2016;4:943‚Äì56. https://doi.org/10.1016/S2213-8587(16)30215-7
519. Nota NM, Wiepjes CM, de Blok CJM, Gooren LJG, Kreukels BPC, den Heijer M. 
Occurrence of acute cardiovascular events in transgender individuals receiving hormone 
therapy. Circulation 2019;139:1461‚Äì2. https://doi.org/10.1161/CIRCULATIONAHA. 
118.038584
520. Getahun D, Nash R, Flanders WD, Baird TC, Becerra-Culqui TA, Cromwell L, et al. 
Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort 
study. Ann Intern Med 2018;169:205‚Äì13. https://doi.org/10.7326/M17-2785
521. van Zijverden LM, Wiepjes CM, van Diemen JJK, Thijs A, den Heijer M. Cardiovascular 
disease in transgender people: a systematic review and meta-analysis. Eur J Endocrinol 
2024;190:S13‚Äì24. https://doi.org/10.1093/ejendo/lvad170
522. Suglia SF, Koenen KC, Boynton-Jarrett R, Chan PS, Clark CJ, Danese A, et al. Childhood 
and adolescent adversity and cardiometabolic outcomes: a scientific statement from 
the American Heart Association. Circulation 2018;137:e15‚Äì28. https://doi.org/10. 
1161/CIR.0000000000000536
523. Aspelund T, Gudnason V, Magnusdottir BT, Andersen K, Sigurdsson G, Thorsson B, 
et al. Analysing the large decline in coronary heart disease mortality in the Icelandic 
population aged 25‚Äì74 between the years 1981 and 2006. PLoS One 2010;5: 
e13957. https://doi.org/10.1371/journal.pone.0013957
524. Shah AJ, Ghasemzadeh N, Zaragoza-Macias E, Patel R, Eapen DJ, Neeland IJ, et al. Sex 
and age differences in the association of depression with obstructive coronary artery 
disease and adverse cardiovascular events. J Am Heart Assoc 2014;3:e000741. https:// 
doi.org/10.1161/JAHA.113.000741
525. Le Bras A. Risk factors: mental stress puts women‚Äôs hearts at risk. Nat Rev Cardiol 2018; 
15:198. https://doi.org/10.1038/nrcardio.2018.23
526. Smaardijk VR, Lodder P, Kop WJ, van Gennep B, Maas A, Mommersteeg PMC. Sex- 
and gender-stratified risks of psychological factors for incident ischemic heart disease: 
systematic review and meta-analysis. J Am Heart Assoc 2019;8:e010859. https://doi.org/ 
10.1161/JAHA.118.010859
527. Regitz-Zagrosek V, Gebhard C. Gender medicine: effects of sex and gender on cardio¬≠
vascular disease manifestation and outcomes. Nat Rev Cardiol 2023;20:236‚Äì47. https:// 
doi.org/10.1038/s41569-022-00797-4
528. Vaccarino V, Badimon L, Bremner JD, Cenko E, Cubedo J, Dorobantu M, et al. 
Depression and coronary heart disease: 2018 position paper of the ESC working 
group on coronary pathophysiology and microcirculation. Eur Heart J 2020;41: 
1687‚Äì96. https://doi.org/10.1093/eurheartj/ehy913
529. Mehta PK, Thobani A, Vaccarino V. Coronary artery spasm, coronary reactivity, and 
their psychological context. Psychosom Med 2019;81:233‚Äì6. https://doi.org/10.1097/ 
PSY.0000000000000682
530. Waheed N, Elias-Smale S, Malas W, Maas AH, Sedlak TL, Tremmel J, et al. Sex differ¬≠
ences in non-obstructive coronary artery disease. Cardiovasc Res 2020;116:829‚Äì40. 
https://doi.org/10.1093/cvr/cvaa001
531. van der Meer RE, Maas AH. The role of mental stress in ischaemia with no obstructive 
coronary artery disease and coronary vasomotor disorders. Eur Cardiol 2021;16:e37. 
https://doi.org/10.15420/ecr.2021.20
532. Konst RE, Elias-Smale SE, Lier A, Bode C, Maas AH. Different cardiovascular risk fac¬≠
tors and psychosocial burden in symptomatic women with and without obstructive 
coronary artery disease. Eur J Prev Cardiol 2019;26:657‚Äì9. https://doi.org/10.1177/ 
2047487318814298
533. Rutledge T, Kenkre TS, Bittner V, Krantz DS, Thompson DV, Linke SE, et al. Anxiety 
associations with cardiac symptoms, angiographic disease severity, and healthcare util¬≠
ization: the NHLBI-sponsored Women‚Äôs Ischemia Syndrome Evaluation. Int J Cardiol 
2013;168:2335‚Äì40. https://doi.org/10.1016/j.ijcard.2013.01.036
534. Vaccarino V, Almuwaqqat Z, Kim JH, Hammadah M, Shah AJ, Ko YA, et al. Association 
of mental stress-induced myocardial ischemia with cardiovascular events in patients 
with coronary heart disease. JAMA 2021;326:1818‚Äì28. https://doi.org/10.1001/jama. 
2021.17649
535. Vaccarino V, Sullivan S, Hammadah M, Wilmot K, Al Mheid I, Ramadan R, et al. Mental 
stress-induced-myocardial ischemia in young patients with recent myocardial infarc¬≠
tion: sex differences and mechanisms. Circulation 2018;137:794‚Äì805. https://doi.org/ 
10.1161/CIRCULATIONAHA.117.030849
536. O‚ÄôRiordan A, Gallagher S, Howard S. Type D personality and cardiovascular reactivity 
to acute psychological stress: a systematic review and meta-analysis. Health Psychol 
2023;42:628‚Äì41. https://doi.org/10.1037/hea0001328
537. Mommersteeg PM, Pot I, Aarnoudse W, Denollet J, Widdershoven JW. Type D per¬≠
sonality and patient-perceived health in nonsignificant coronary artery disease: the 
TWeesteden mIld STenosis (TWIST) study. Qual Life Res 2013;22:2041‚Äì50. https:// 
doi.org/10.1007/s11136-012-0340-2
538. Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas A, et al. An EAPCI expert 
consensus document on ischaemia with non-obstructive coronary arteries in collabor¬≠
ation with European Society of Cardiology Working Group on Coronary 
Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders 
International Study Group. EuroIntervention 2021;16:1049‚Äì69. https://doi.org/10.4244/ 
EIJY20M07_01
539. Adlam D, Alfonso F, Maas A, Vrints C. European Society of Cardiology, acute cardio¬≠
vascular care association, SCAD study group: a position paper on spontaneous coron¬≠
ary artery dissection. Eur Heart J 2018;39:3353‚Äì68. https://doi.org/10.1093/eurheartj/ 
ehy080
540. Hayes SN, Tweet MS, Adlam D, Kim ESH, Gulati R, Price JE, et al. Spontaneous cor¬≠
onary artery dissection: JACC state-of-the-art review. J Am Coll Cardiol 2020;76: 
961‚Äì84. https://doi.org/10.1016/j.jacc.2020.05.084
541. Gurgoglione FL, Rizzello D, Giacalone R, Ferretti M, Vezzani A, Pfleiderer B, et al. 
Precipitating factors in patients with spontaneous coronary artery dissection: clinical, 
laboratoristic and prognostic implications. Int J Cardiol 2023;385:1‚Äì7. https://doi.org/ 
10.1016/j.ijcard.2023.05.027
542. Tofler GH, Kopel E, Klempfner R, Eldar M, Buckley T, Goldenberg I. Triggers and tim¬≠
ing of acute coronary syndromes. Am J Cardiol 2017;119:1560‚Äì5. https://doi.org/10. 
1016/j.amjcard.2017.02.022
543. Smaardijk VR, Mommersteeg PMC, Kop WJ, Pellegrini D, van Geuns RJ, Maas A. 
Psychological and clinical characteristics of patients with spontaneous coronary artery 
dissection: a case-control study. Int J Cardiol 2021;323:1‚Äì6. https://doi.org/10.1016/j. 
ijcard.2020.08.045
544. Lyon AR, Citro R, Schneider B, Morel O, Ghadri JR, Templin C, et al. Pathophysiology 
of Takotsubo syndrome: JACC state-of-the-art review. J Am Coll Cardiol 2021;77: 
902‚Äì21. https://doi.org/10.1016/j.jacc.2020.10.060
545. Dawson DK. Acute stress-induced (Takotsubo) cardiomyopathy. Heart 2018;104: 
96‚Äì102. https://doi.org/10.1136/heartjnl-2017-311579
546. Singh T, Khan H, Gamble DT, Scally C, Newby DE, Dawson D. Takotsubo syndrome: 
pathophysiology, emerging concepts, and clinical implications. Circulation 2022;145: 
1002‚Äì19. https://doi.org/10.1161/CIRCULATIONAHA.121.055854
547. Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International ex¬≠
pert consensus document on Takotsubo syndrome (part I): clinical characteristics, 
diagnostic criteria, and pathophysiology. Eur Heart J 2018;39:2032‚Äì46. https://doi. 
org/10.1093/eurheartj/ehy076
548. Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International ex¬≠
pert consensus document on Takotsubo syndrome (part ii): diagnostic workup, out¬≠
come, and management. Eur Heart J 2018;39:2047‚Äì62. https://doi.org/10.1093/ 
eurheartj/ehy077
549. Galiuto L, Crea F. Primary and secondary Takotsubo syndrome: pathophysiological de¬≠
terminant and prognosis. Eur Heart J Acute Cardiovasc Care 2020;9:690‚Äì3. https://doi. 
org/10.1177/2048872620963493
550. Templin C, H√§nggi J, Klein C, Topka MS, Hiestand T, Levinson RA, et al. Altered limbic 
and autonomic processing supports brain-heart axis in Takotsubo syndrome. Eur 
Heart J 2019;40:1183‚Äì7. https://doi.org/10.1093/eurheartj/ehz068
551. Pozzi G, D‚ÄôAmario D, Princi G, Ciliberti G, Irano A, Simone MV, et al. Pre-existing psy¬≠
chiatric morbidity is strongly associated to Takotsubo syndrome: a case-control study. 
Front Cardiovasc Med 2022;9:925459. https://doi.org/10.3389/fcvm.2022.925459
552. Pandey A, Omar W, Ayers C, LaMonte M, Klein L, Allen NB, et al. Sex and race differ¬≠
ences in lifetime risk of heart failure with preserved ejection fraction and heart failure 
with reduced ejection fraction. Circulation 2018;137:1814‚Äì23. https://doi.org/10.1161/ 
CIRCULATIONAHA.117.031622
553. Sowden E, Hossain M, Chew-Graham C, Blakeman T, Tierney S, Wellwood I, et al. 
Understanding the management of heart failure with preserved ejection fraction:


<!-- PAGE 67 -->

### Page 67

a qualitative multiperspective study. Br J Gen Pract 2020;70:e880‚Äì9. https://doi.org/10. 
3399/bjgp20X713477
554. Forsyth F, Blakeman T, Burt J, Chew-Graham CA, Hossain M, Mant J, et al. Cumulative 
complexity: a qualitative analysis of patients‚Äô experiences of living with heart failure 
with preserved ejection fraction. Eur J Cardiovasc Nurs 2023;22:529‚Äì36. https://doi. 
org/10.1093/eurjcn/zvac081
555. Endrighi R, Dimond AJ, Waters AJ, Dimond CC, Harris KM, Gottlieb SS, et al. 
Associations of perceived stress and state anger with symptom burden and functional 
status in patients with heart failure. Psychol Health 2019;34:1250‚Äì66. https://doi.org/ 
10.1080/08870446.2019.1609676
556. Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: 
JACC scientific statement. J Am Coll Cardiol 2023;81:1810‚Äì34. https://doi.org/10.1016/ 
j.jacc.2023.01.049
557. Cirelli MA, Lacerda MS, Lopes CT, de Lima Lopes J, de Barros A. Correlations between 
stress, anxiety and depression and sociodemographic and clinical characteristics 
among outpatients with heart failure. Arch Psychiatr Nurs 2018;32:235‚Äì41. https:// 
doi.org/10.1016/j.apnu.2017.11.008
558. Topel ML, Kim JH, Mujahid MS, Sullivan SM, Ko YA, Vaccarino V, et al. Neighborhood 
socioeconomic status and adverse outcomes in patients with cardiovascular disease. 
Am J Cardiol 2019;123:284‚Äì90. https://doi.org/10.1016/j.amjcard.2018.10.011
559. Polikandrioti M, Koutelekos I, Vasilopoulos G, Gerogianni G, Gourni M, Zyga S, et al. 
Anxiety and depression in patients with permanent atrial fibrillation: prevalence and 
associated factors. Cardiol Res Pract 2018;2018:7408129. https://doi.org/10.1155/ 
2018/7408129
560. Gleason KT, Dennison Himmelfarb CR, Ford DE, Lehmann H, Samuel L, Jain S, et al. 
Association of sex and atrial fibrillation therapies with patient-reported outcomes. 
Heart 2019;105:1642‚Äì8. https://doi.org/10.1136/heartjnl-2019-314881
561. von Eisenhart Rothe A, Hutt F, Baumert J, Breithardt G, Goette A, Kirchhof P, et al. 
Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial 
fibrillation patients: a longitudinal analysis‚Äîdata from the German Competence 
Network on Atrial Fibrillation. Europace 2015;17:1354‚Äì62. https://doi.org/10.1093/ 
europace/euv018
562. Du H, Yang L, Hu Z, Zhang H. Anxiety is associated with higher recurrence of atrial 
fibrillation after catheter ablation: a meta-analysis. Clin Cardiol 2022;45:243‚Äì50. 
https://doi.org/10.1002/clc.23753
563. Starrenburg A, Pedersen S, van den Broek K, Kraaier K, Scholten M, Van der Palen J. 
Gender differences in psychological distress and quality of life in patients with an 
ICD 1-year postimplant. Pacing Clin Electrophysiol 2014;37:843‚Äì52. https://doi.org/10. 
1111/pace.12357
564. Paap E, Witjes M, van Landsveld-Verhoeven C, Pijnappel RM, Maas AH, Broeders MJ. 
Mammography in females with an implanted medical device: impact on image quality, 
pain and anxiety. Br J Radiol 2016;89:20160142. https://doi.org/10.1259/bjr.20160142
565. Habiboviƒá M, Denollet J, Pedersen SS. Posttraumatic stress and anxiety in patients with 
an implantable cardioverter defibrillator: trajectories and vulnerability factors. Pacing 
Clin Electrophysiol 2017;40:817‚Äì23. https://doi.org/10.1111/pace.13090
566. Sliwa K, Rakisheva A, Viljoen C, Pfeffer T, Simpson M, Jackson AM, et al. Living with 
peripartum cardiomyopathy: a statement from the Heart Failure Association and 
the Association of Cardiovascular Nursing and Allied Professions of the European 
Society of Cardiology. Eur J Heart Fail 2024;26:2143‚Äì54. https://doi.org/10.1002/ejhf. 
3377
567. World Health Organization. Aging and Health: Key Facts. 2024. https://www.who.int/ 
news-room/fact-sheets/detail/ageing-and-health#:‚àº:text=By%202050%2C%20the% 
20world‚Äôs%20population,2050%20to%20reach%20426%20million (14 March 2025, 
date last accessed).
568. Forman DE, Maurer MS, Boyd C, Brindis R, Salive ME, Horne FM, et al. Multimorbidity 
in older adults with cardiovascular disease. J Am Coll Cardiol 2018;71:2149‚Äì61. https:// 
doi.org/10.1016/j.jacc.2018.03.022
569. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular dis¬≠
ease, and frailty. Nat Rev Cardiol 2018;15:505‚Äì22. https://doi.org/10.1038/s41569-018- 
0064-2
570. Wang MS, Deng JW, Geng WY, Zheng R, Xu HL, Dong Y, et al. Temporal trend and 
attributable risk factors of cardiovascular disease burden for adults 55 years and older 
in 204 countries/territories from 1990 to 2021: an analysis for the Global Burden of 
Disease Study 2021. Eur J Prev Cardiol 2024;32:539‚Äì52. https://doi.org/10.1093/ 
eurjpc/zwae384
571. Global, regional, and national burden of 12 mental disorders in 204 countries and terri¬≠
tories, 1990‚Äì2019: a systematic analysis for the Global Burden of Disease Study 2019. 
Lancet Psychiatry 2022;9:137‚Äì50. https://doi.org/10.1016/S2215-0366(21)00395-3
572. Jalali A, Ziapour A, Karimi Z, Rezaei M, Emami B, Kalhori RP, et al. Global prevalence of 
depression, anxiety, and stress in the elderly population: a systematic review and 
meta-analysis. BMC Geriatr 2024;24:809. https://doi.org/10.1186/s12877-024-05311-8
573. Sivertsen H, Bj√∏rkl√∏f GH, Engedal K, Selb√¶k G, Helvik AS. Depression and quality of life 
in older persons: a review. Dement Geriatr Cogn Disord 2015;40:311‚Äì39. https://doi.org/ 
10.1159/000437299
574. Wei J, Hou R, Zhang X, Xu H, Xie L, Chandrasekar EK, et al. The association of late-life 
depression with all-cause and cardiovascular mortality among community-dwelling 
older adults: systematic review and meta-analysis. Br J Psychiatry 2019;215:449‚Äì55. 
https://doi.org/10.1192/bjp.2019.74
575. Moradi M, Doostkami M, Behnamfar N, Rafiemanesh H, Behzadmehr R. Global preva¬≠
lence of depression among heart failure patients: a systematic review and 
meta-analysis. Curr Probl Cardiol 2022;47:100848. https://doi.org/10.1016/j.cpcardiol. 
2021.100848
576. Zhang S, Zhang N, Liu L, Zheng W, Ma ZL, Qiao SY, et al. Global epidemiology of mental 
disorder in atrial fibrillation between 1998‚Äì2021: a systematic review and meta-analysis. 
World J Psychiatry 2024;14:179‚Äì93. https://doi.org/10.5498/wjp.v14.i1.179
577. Beishon L, Hickey B, Desai B, Chithiramohan T, Evley R, Subramaniam H, et al. 
Integrated physical-mental healthcare services in specialist settings to improve out¬≠
comes for older people living with mental health diagnoses: a systematic review. Int 
J Geriatr Psychiatry 2024;39:e6146. https://doi.org/10.1002/gps.6146
578. Purcell C, Dibben G, Hilton Boon M, Matthews L, Palmer VJ, Thomson M, et al. Social 
network interventions to support cardiac rehabilitation and secondary prevention in 
the management of people with heart disease. Cochrane Database Syst Rev 2023;6: 
CD013820. https://doi.org/10.1002/14651858.CD013820.pub2
579. Anrys P, Petit AE, Thevelin S, Sallevelt B, Drenth C, Soiza RL, et al. An international 
consensus list of potentially clinically significant drug-drug interactions in older people. 
J Am Med Dir Assoc 2021;22:2121‚Äì33.e24. https://doi.org/10.1016/j.jamda.2021.03.019
580. Siwek M, Woro≈Ñ J, Gorostowicz A, Wordliczek J. Adverse effects of interactions be¬≠
tween antipsychotics and medications used in the treatment of cardiovascular disor¬≠
ders. Pharmacol Rep 2020;72:350‚Äì9. https://doi.org/10.1007/s43440-020-00058-6
581. Boyd C, Smith CD, Masoudi FA, Blaum CS, Dodson JA, Green AR, et al. Decision mak¬≠
ing for older adults with multiple chronic conditions: executive summary for the 
American Geriatrics Society guiding principles on the care of older adults with multi¬≠
morbidity. J Am Geriatr Soc 2019;67:665‚Äì73. https://doi.org/10.1111/jgs.15809
582. Pi√±a IL, Di Palo KE, Ventura HO. Psychopharmacology and cardiovascular disease. J Am 
Coll Cardiol 2018;71:2346‚Äì59. https://doi.org/10.1016/j.jacc.2018.03.458
583. Castaldelli-Maia JM, Hofmann C, Chagas ACP, Liprandi AS, Alcocer A, Andrade LH, 
et al. Major cardiac-psychiatric drug-drug interactions: a systematic review of the con¬≠
sistency of drug databases. Cardiovasc Drugs Ther 2021;35:441‚Äì54. https://doi.org/10. 
1007/s10557-020-06979-x
584. Sheikh-Taha M, Asmar M. Polypharmacy and severe potential drug-drug interactions 
among older adults with cardiovascular disease in the United States. BMC Geriatr 
2021;21:233. https://doi.org/10.1186/s12877-021-02183-0
585. Kim DH, Rockwood K. Frailty in older adults. N Engl J Med 2024;391:538‚Äì48. https:// 
doi.org/10.1056/NEJMra2301292
586. Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, et al. Frailty in cardi¬≠
ology: definition, assessment and clinical implications for general cardiology. A consen¬≠
sus document of the Council for Cardiology Practice (CCP), Association for Acute 
Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied 
Professions (ACNAP), European Association of Preventive Cardiology (EAPC), 
European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases 
(VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), 
Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, 
WG Thrombosis, of the European Society of Cardiology, European Primary Care 
Cardiology Society (EPCCS). Eur J Prev Cardiol 2022;29:216‚Äì27. https://doi.org/10. 
1093/eurjpc/zwaa167
587. Talha KM, Pandey A, Fudim M, Butler J, Anker SD, Khan MS. Frailty and heart failure: 
state-of-the-art review. J Cachexia Sarcopenia Muscle 2023;14:1959‚Äì72. https://doi.org/ 
10.1002/jcsm.13306
588. Liperoti R, Vetrano DL, Palmer K, Targowski T, Cipriani MC, Lo Monaco MR, et al. 
Association between frailty and ischemic heart disease: a systematic review and 
meta-analysis. BMC Geriatr 2021;21:357. https://doi.org/10.1186/s12877-021-02304-9
589. Savelieva I, Fumagalli S, Kenny RA, Anker S, Benetos A, Boriani G, et al. EHRA expert 
consensus document on the management of arrhythmias in frailty syndrome, en¬≠
dorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society 
(APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia 
Society of Southern Africa (CASSA). Europace 2023;25:1249‚Äì76. https://doi.org/10. 
1093/europace/euac123
590. Tan M, Bhanu C, Frost R. The association between frailty and anxiety: a systematic re¬≠
view. Int J Geriatr Psychiatry 2023;38:e5918. https://doi.org/10.1002/gps.5918
591. Zhu J, Zhou D, Nie Y, Wang J, Yang Y, Chen D, et al. Assessment of the bidirectional 
causal association between frailty and depression: a Mendelian randomization study. 
J Cachexia Sarcopenia Muscle 2023;14:2327‚Äì34. https://doi.org/10.1002/jcsm.13319
592. Suo X, Zhang J, Guo J, Liu Y, You J, Lyu Q, et al. (6 March, 2025) Frailty mediated the 
associations of fine particulate matter with depression and anxiety: findings from the 
UK Biobank. J Gerontol A Biol Sci Med Sci, https://doi.org/10.1093/gerona/glaf047
593. World Health Organization. WHO Clinical Consortium on Healthy Ageing. Report of 
Consortium Meeting 1‚Äì2 December 2016 in Geneva, Switzerland. 2016. https://www. 
who.int/publications/i/item/WHO-FWC-ALC-17.2 (5 February 2024, date last 
accessed).
594. Chowdhury SR, Chandra Das D, Sunna TC, Beyene J, Hossain A. Global and regional 
prevalence of multimorbidity in the adult population in community settings: 
ESC Guidelines                                                                                                                                                                                               67


<!-- PAGE 68 -->

### Page 68

a systematic review and meta-analysis. EClinicalMedicine 2023;57:101860. https://doi. 
org/10.1016/j.eclinm.2023.101860
595. Zhu Y, Edwards D, Mant J, Payne RA, Kiddle S. Characteristics, service use and mor¬≠
tality of clusters of multimorbid patients in England: a population-based study. BMC 
Med 2020;18:78. https://doi.org/10.1186/s12916-020-01543-8
596. Soley-Bori M, Ashworth M, Bisquera A, Dodhia H, Lynch R, Wang Y, et al. Impact of 
multimorbidity on healthcare costs and utilisation: a systematic review of the UK lit¬≠
erature. Br J Gen Pract 2021;71:e39‚Äì46. https://doi.org/10.3399/bjgp20X713897
597. Cottrell E, Yardley S. Lived experiences of multimorbidity: an interpretative meta- 
synthesis of patients‚Äô, general practitioners‚Äô and trainees‚Äô perceptions. Chronic Illn 
2015;11:279‚Äì303. https://doi.org/10.1177/1742395315574764
598. Coventry PA, Small N, Panagioti M, Adeyemi I, Bee P. Living with complexity; marshal¬≠
ling resources: a systematic review and qualitative meta-synthesis of lived experience 
of mental and physical multimorbidity. BMC Fam Pract 2015;16:171. https://doi.org/10. 
1186/s12875-015-0345-3
599. Van Wilder L, Devleesschauwer B, Clays E, De Buyser S, Van der Heyden J, 
Charafeddine R, et al. The impact of multimorbidity patterns on health-related quality 
of life in the general population: results of the Belgian Health Interview Survey. Qual Life 
Res 2022;31:551‚Äì65. https://doi.org/10.1007/s11136-021-02951-w
600. Garin N, Koyanagi A, Chatterji S, Tyrovolas S, Olaya B, Leonardi M, et al. Global multi¬≠
morbidity patterns: a cross-sectional, population-based, multi-country study. J Gerontol 
A Biol Sci Med Sci 2016;71:205‚Äì14. https://doi.org/10.1093/gerona/glv128
601. Sinnige J, Braspenning J, Schellevis F, Stirbu-Wagner I, Westert G, Korevaar J. The 
prevalence of disease clusters in older adults with multiple chronic diseases‚Äîa system¬≠
atic literature review. PLoS One 2013;8:e79641. https://doi.org/10.1371/journal.pone. 
0079641
602. Cuschieri S, Stranges S, Makovski TT. The different definitions of multimorbidity and 
their implications for research, surveillance, and policy. Eur J Public Health 2025;35: 
197‚Äì8. https://doi.org/10.1093/eurpub/ckae193
603. Salisbury C, Man MS, Bower P, Guthrie B, Chaplin K, Gaunt DM, et al. Management of 
multimorbidity using a patient-centred care model: a pragmatic cluster-randomised 
trial of the 3D approach. Lancet 2018;392:41‚Äì50. https://doi.org/10.1016/S0140- 
6736(18)31308-4
604. Smith SM, Wallace E, O‚ÄôDowd T, Fortin M. Interventions for improving outcomes in pa¬≠
tients with multimorbidity in primary care and community settings. Cochrane Database 
Syst Rev 2016;3:CD006560. https://doi.org/10.1002/14651858.CD006560.pub3
605. Pampel FC, Krueger PM, Denney JT. Socioeconomic disparities in health behaviors. 
Annu Rev Sociol 2010;36:349‚Äì70. https://doi.org/10.1146/annurev.soc.012809.102529
606. Kimenai DM, Pirondini L, Gregson J, Prieto D, Pocock SJ, Perel P, et al. Socioeconomic 
deprivation: an important, largely unrecognized risk factor in primary prevention 
of cardiovascular disease. Circulation 2022;146:240‚Äì8. https://doi.org/10.1161/ 
CIRCULATIONAHA.122.060042
607. Schultz WM, Kelli HM, Lisko JC, Varghese T, Shen J, Sandesara P, et al. Socioeconomic 
status and cardiovascular outcomes: challenges and interventions. Circulation 2018; 
137:2166‚Äì78. https://doi.org/10.1161/CIRCULATIONAHA.117.029652
608. Mariotti A. The effects of chronic stress on health: new insights into the molecular me¬≠
chanisms of brain-body communication. Future Sci OA 2015;1:FSO23. https://doi.org/ 
10.4155/fso.15.21
609. Deferio JJ, Breitinger S, Khullar D, Sheth A, Pathak J. Social determinants of health in 
mental health care and research: a case for greater inclusion. J Am Med Inform Assoc 
2019;26:895‚Äì9. https://doi.org/10.1093/jamia/ocz049
610. Foroughi I, Gupta N, Crouse DL. Healthcare service use for mood and anxiety disor¬≠
ders following acute myocardial infarction: a cohort study of the role of neighbour¬≠
hood socioenvironmental characteristics in a largely rural population. Int J Environ 
Res Public Health 2020;17:4939. https://doi.org/10.3390/ijerph17144939
611. Aldridge RW, Story A, Hwang SW, Nordentoft M, Luchenski SA, Hartwell G, et al. 
Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals 
with substance use disorders in high-income countries: a systematic review and 
meta-analysis. Lancet 2018;391:241‚Äì50. https://doi.org/10.1016/S0140-6736(17)31869-X
612. Hill L, Baruah R, Beattie JM, Bistola V, Castiello T, Celutkienƒó J, et al. Culture, ethnicity, 
and socio-economic status as determinants of the management of patients with ad¬≠
vanced heart failure who need palliative care: a clinical consensus statement from 
the Heart Failure Association (HFA) of the ESC, the ESC Patient Forum, and the 
European Association of Palliative Care. Eur J Heart Fail 2023;25:1481‚Äì92. https:// 
doi.org/10.1002/ejhf.2973
613. Thordardottir EB, Yin L, Hauksdottir A, Mittendorfer-Rutz E, Hollander AC, Hultman 
CM, et al. Mortality and major disease risk among migrants of the 1991‚Äì2001 Balkan 
wars to Sweden: a register-based cohort study. PLoS Med 2020;17:e1003392. https:// 
doi.org/10.1371/journal.pmed.1003392
614. Knappe F, Filippou K, Hatzigeorgiadis A, Morres ID, Tzormpatzakis E, Havas E, et al. 
Psychological well-being, mental distress, metabolic syndrome, and associated factors 
among people living in a refugee camp in Greece: a cross-sectional study. Front Public 
Health 2023;11:1179756. https://doi.org/10.3389/fpubh.2023.1179756
615. Agyemang C, van den Born BJ. Cardiovascular health and disease in migrant popula¬≠
tions: a call to action. Nat Rev Cardiol 2022;19:1‚Äì2. https://doi.org/10.1038/s41569- 
021-00644-y
616. Lionis C, Papadakaki M, Saridaki A, Dowrick C, O‚ÄôDonnell CA, Mair FS, et al. Engaging 
migrants and other stakeholders to improve communication in cross-cultural consult¬≠
ation in primary care: a theoretically informed participatory study. BMJ Open 2016;6: 
e010822. https://doi.org/10.1136/bmjopen-2015-010822
617. MacFarlane A, Dowrick C, Gravenhorst K, O‚ÄôReilly-de Br√∫n M, de Br√∫n T, van den 
Muijsenbergh M, et al. Involving migrants in the adaptation of primary care services 
in a ‚Äònewly‚Äô diverse urban area in Ireland: the tension between agency and structure. 
Health Place 2021;70:102556. https://doi.org/10.1016/j.healthplace.2021.102556
618. Packness A, Halling A, Simonsen E, Waldorff FB, Hastrup LH. Are perceived barriers to 
accessing mental healthcare associated with socioeconomic position among individuals 
with symptoms of depression? Questionnaire-results from the Lolland-Falster Health 
Study, a rural Danish population study. BMJ Open 2019;9:e023844. https://doi.org/10. 
1136/bmjopen-2018-023844
619. Finegan M, Firth N, Delgadillo J. Adverse impact of neighbourhood socioeconomic de¬≠
privation on psychological treatment outcomes: the role of area-level income and 
crime. Psychother Res 2020;30:546‚Äì54. https://doi.org/10.1080/10503307.2019. 
1649500
620. Novak P, Anderson AC, Chen J. Changes in health insurance coverage and barriers to 
health care access among individuals with serious psychological distress following the 
affordable care act. Adm Policy Ment Health 2018;45:924‚Äì32. https://doi.org/10.1007/ 
s10488-018-0875-9
621. Mirza NA, Hulko W. The complex nature of transportation as a key determinant of 
health in primary and community care restructuring initiatives in rural Canada. J 
Aging Stud 2022;60:101002. https://doi.org/10.1016/j.jaging.2022.101002
622. Ahmedani BK. Mental health stigma: society, individuals, and the profession. J Soc Work 
Values Ethics 2011;8:41‚Äì416.
623. Collopy CM, Cosh SM, Tully PJ. Screening and referral is not enough: a qualitative ex¬≠
ploration of barriers to access and uptake of mental health services in patients with 
cardiovascular diseases. BMC Health Serv Res 2021;21:49. https://doi.org/10.1186/ 
s12913-020-06030-7
624. Montgomery RM, Boucher EM, Honomichl RD, Powell TA, Guyton SL, Bernecker SL, 
et al. The effects of a digital mental health intervention in adults with cardiovascular 
disease risk factors: analysis of real-world user data. JMIR Cardio 2021;5:e32351. 
https://doi.org/10.2196/32351
625. Cook JE, Purdie-Vaughns V, Meyer IH, Busch JTA. Intervening within and across levels: 
a multilevel approach to stigma and public health. Soc Sci Med 2014;103:101‚Äì9. https:// 
doi.org/10.1016/j.socscimed.2013.09.023
626. Henderson C, Noblett J, Parke H, Clement S, Caffrey A, Gale-Grant O, et al. Mental 
health-related stigma in health care and mental health-care settings. Lancet Psychiatry 
2014;1:467‚Äì82. https://doi.org/10.1016/S2215-0366(14)00023-6
627. Clement S, Schauman O, Graham T, Maggioni F, Evans-Lacko S, Bezborodovs N, et al. 
What is the impact of mental health-related stigma on help-seeking? A systematic re¬≠
view of quantitative and qualitative studies. Psychol Med 2015;45:11‚Äì27. https://doi.org/ 
10.1017/S0033291714000129
628. Castillo EG, Ijadi-Maghsoodi R, Shadravan S, Moore E, Mensah MO 3rd, Docherty M, 
et al. Community interventions to promote mental health and social equity. Curr 
Psychiatry Rep 2019;21:35. https://doi.org/10.1007/s11920-019-1017-0
629. Mensah GA, Cooper RS, Siega-Riz AM, Cooper LA, Smith JD, Brown CH, et al. 
Reducing cardiovascular disparities through community-engaged implementation re¬≠
search: a National Heart, Lung, and Blood Institute workshop report. Circ Res 2018; 
122:213‚Äì30. https://doi.org/10.1161/CIRCRESAHA.117.312243
630. Mezzina R, Gopikumar V, Jenkins J, Saraceno B, Sashidharan SP. Social vulnerability and 
mental health inequalities in the ‚Äúsyndemic‚Äù: call for action. Front Psychiatry 2022;13: 
894370. https://doi.org/10.3389/fpsyt.2022.894370
631. Ozbay F, Johnson DC, Dimoulas E, Morgan CA, Charney D, Southwick S. Social sup¬≠
port and resilience to stress: from neurobiology to clinical practice. Psychiatry 
(Edgmont) 2007;4:35‚Äì40. https://doi.org/https://www.ncbi.nlm.nih.gov/pmc/articles/ 
PMC2921311/
632. Riegel B, Moser DK, Buck HG, Dickson VV, Dunbar SB, Lee CS, et al. Self-care for the 
prevention and management of cardiovascular disease and stroke: a scientific state¬≠
ment for healthcare professionals from the American Heart Association. J Am Heart 
Assoc 2017;6:e006997. https://doi.org/10.1161/JAHA.117.006997
633. Swope CB, Hern√°ndez D. Housing as a determinant of health equity: a conceptual mod¬≠
el. Soc Sci Med 2019;243:112571. https://doi.org/10.1016/j.socscimed.2019.112571
634. Gustavson AM, Lewinski AA, Fitzsimmons-Craft EE, Coronado GD, Linke SE, 
O‚ÄôMalley DM, et al. Strategies to bridge equitable implementation of telehealth. 
Interact J Med Res 2023;12:e40358. https://doi.org/10.2196/40358
635. Curiale C, Lenzi M, Gaboardi M, Marino C, Ronconi L, Demita S, et al. Homeless peo¬≠
ple‚Äôs recovery in housing first and traditional services: the role of working alliance in 
Italian housing services. J Community Psychol 2023;51:2758‚Äì73. https://doi.org/10. 
1002/jcop.23055
636. Belkin G, McCray C. ThriveNYC: delivering on mental health. Am J Public Health 2019; 
109:S156‚Äì63. https://doi.org/10.2105/AJPH.2019.305040
637. Walton-Moss B, Samuel L, Nguyen TH, Commodore-Mensah Y, Hayat MJ, Szanton SL. 
Community-based cardiovascular health interventions in vulnerable populations: a


<!-- PAGE 69 -->

### Page 69

systematic review. J Cardiovasc Nurs 2014;29:293‚Äì307. https://doi.org/10.1097/JCN. 
0b013e31828e2995
638. Dai S, Mo Y, Wang Y, Xiang B, Liao Q, Zhou M, et al. Chronic stress promotes cancer 
development. Front Oncol 2020;10:1492. https://doi.org/10.3389/fonc.2020.01492
639. Omari M, Amaadour L, El Asri A, Benbrahim Z, Mellas N, El Rhazi K, et al. Psychological 
distress and coping strategies in breast cancer patients under neoadjuvant therapy: a 
systematic review. Womens Health (Lond) 2024;20:17455057241276232. https://doi. 
org/10.1177/17455057241276232
640. Stabellini N, Cullen J, Bittencourt MS, Moore JX, Sutton A, Nain P, et al. Allostatic load/ 
chronic stress and cardiovascular outcomes in patients diagnosed with breast, lung, or 
colorectal cancer. J Am Heart Assoc 2024;13:e033295. https://doi.org/10.1161/JAHA. 
123.033295
641. Stabellini N, Cullen J, Bittencourt MS, Moore JX, Cao L, Weintraub NL, et al. Allostatic 
load and cardiovascular outcomes in males with prostate cancer. JNCI Cancer Spectr 
2023;7:pkad005. https://doi.org/10.1093/jncics/pkad005
642. Fang F, Keating NL, Mucci LA, Adami HO, Stampfer MJ, Valdimarsd√≥ttir U, et al. 
Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: 
cohort study in the United States. J Natl Cancer Inst 2010;102:307‚Äì14. https://doi. 
org/10.1093/jnci/djp537
643. Mƒôdrek S, Szmit S. Are cardiovascular comorbidities always associated with a worse 
prognosis in patients with lung cancer? Front Cardiovasc Med 2022;9:984951. https:// 
doi.org/10.3389/fcvm.2022.984951
644. Fang S, Wang Y, He PK, Han XN, Yang Y, Hong T, et al. Cardiogenic shock caused by 
Takotsubo syndrome complicated with severe anxiety: a case report and literature review. 
Medicine (Baltimore) 2021;100:e27812. https://doi.org/10.1097/MD.0000000000027812
645. Kinno R, Ono K. Takotsubo syndrome: optimizing care with a multidisciplinary ap¬≠
proach. J Multidiscip Healthc 2021;14:2487‚Äì99. https://doi.org/10.2147/JMDH.S283667
646. Desai A, Noor A, Joshi S, Kim AS. Takotsubo cardiomyopathy in cancer patients. 
Cardiooncology 2019;5:7. https://doi.org/10.1186/s40959-019-0042-9
647. da Silva Costa IBS, Figueiredo CS, Fonseca SMR, Bittar CS, de Carvalho Silva CMD, Rizk 
SI, et al. Takotsubo syndrome: an overview of pathophysiology, diagnosis and treat¬≠
ment with emphasis on cancer patients. Heart Fail Rev 2019;24:833‚Äì46. https://doi. 
org/10.1007/s10741-019-09813-1
648. Kim H, Senecal C, Lewis B, Prasad A, Rajiv G, Lerman LO, et al. Natural history and 
predictors of mortality of patients with Takotsubo syndrome. Int J Cardiol 2018; 
267:22‚Äì7. https://doi.org/10.1016/j.ijcard.2018.04.139
649. Desai R, Desai A, Abbas SA, Patel U, Bansod S, Damarlapally N, et al. National preva¬≠
lence, trends and outcomes of Takotsubo syndrome in hospitalizations with prior his¬≠
tory of mediastinal/intrathoracic cancer and radiation therapy. Int J Cardiol 2020;309: 
14‚Äì8. https://doi.org/10.1016/j.ijcard.2020.02.036
650. Herrmann J, Loprinzi C, Ruddy K. Building a cardio-onco-hematology program. Curr 
Oncol Rep 2018;20:81. https://doi.org/10.1007/s11912-018-0725-7
651. Podina IR, Todea D, Fodor LA. Fear of cancer recurrence and mental health: a com¬≠
prehensive meta-analysis. Psychooncology 2023;32:1503‚Äì13. https://doi.org/10.1002/ 
pon.6205
652. Yan G, Zhang Q, Yan Y, Zhang Y, Li Y, Liu M, et al. Trends in the prevalence and treat¬≠
ment of comorbid depression among US adults with and without cancer, 2005‚Äì2020. J 
Affect Disord 2023;340:743‚Äì50. https://doi.org/10.1016/j.jad.2023.08.091
653. Lubas MM, Wang M, Jefferies JL, Ness KK, Ehrhardt MJ, Krull KR, et al. The contribution 
of stress and distress to cardiovascular health in adult survivors of childhood cancer. 
Cancer Epidemiol Biomarkers Prev 2021;30:286‚Äì94. https://doi.org/10.1158/1055- 
9965.EPI-20-1183
654. Chan JSK, Satti DI, Dee EC, Sharma G, Virani SS, Liu T, et al. Association between psy¬≠
chological distress and cardiovascular health amongst cancer survivors in the United 
States: findings from nationally representative data. Eur J Prev Cardiol 2023;30:e74‚Äì7. 
https://doi.org/10.1093/eurjpc/zwad162
655. Gontijo Garcia GS, Meira KC, de Souza AH, Guimar√£es NS. Anxiety and depression 
disorders in oncological patients under palliative care at a hospital service: a cross- 
sectional study. BMC Palliat Care 2023;22:116. https://doi.org/10.1186/s12904-023- 
01233-1
656. Caruso R, Nanni MG, Riba M, Sabato S, Mitchell AJ, Croce E, et al. Depressive spectrum 
disorders in cancer: prevalence, risk factors and screening for depression: a critical re¬≠
view. Acta Oncol 2017;56:146‚Äì55. https://doi.org/10.1080/0284186X.2016.1266090
657. Garrido MM, Prigerson HG, Neupane S, Penrod JD, Johnson CE, Boockvar KS. Mental 
illness and mental healthcare receipt among hospitalized veterans with serious physical 
illnesses. J Palliat Med 2017;20:247‚Äì52. https://doi.org/10.1089/jpm.2016.0261
658. Lyon AR, L√≥pez-Fern√°ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 
European Hematology Association (EHA), the European Society for Therapeutic 
Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society 
(IC-OS). Eur Heart J 2022;43:4229‚Äì361. https://doi.org/10.1093/eurheartj/ehac244
659. Koop Y, van Zadelhof N, Maas A, Atsma F, El Messaoudi S, Vermeulen H. Quality of life 
in breast cancer patients with cancer treatment-related cardiac dysfunction: a 
qualitative study. Eur J Cardiovasc Nurs 2022;21:235‚Äì42. https://doi.org/10.1093/ 
eurjcn/zvab057
660. Harrison JM, Davis MA, Barton DL, Janz NK, Pressler SJ, Friese CR. Functional status 
and quality of life among breast cancer survivors with heart failure: results of the 
Medicare Health Outcomes Survey. Support Care Cancer 2017;25:2463‚Äì73. https:// 
doi.org/10.1007/s00520-017-3653-4
661. Ekels A, Oerlemans S, Schagen SB, Issa DE, Thielen N, Nijziel MR et al. The course of 
self-perceived cognitive functioning among patients with lymphoma and the co- 
occurrence with fatigue and psychological distress. J Cancer Surviv 2025;19:183‚Äì96. 
https://doi.org/10.1007/s11764-023-01458-2
662. Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, et al. Cancer-related cognitive im¬≠
pairment: an update on state of the art, detection, and management strategies in can¬≠
cer survivors. Ann Oncol 2019;30:1925‚Äì40. https://doi.org/10.1093/annonc/mdz410
663. Deka R, Rose BS, Bryant AK, Sarkar RR, Nalawade V, McKay R, et al. Androgen depriv¬≠
ation therapy and depression in men with prostate cancer treated with definitive ra¬≠
diation therapy. Cancer 2019;125:1070‚Äì80. https://doi.org/10.1002/cncr.31982
664. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy 
of hormone-responsive early breast cancer. Ann Oncol 2007;18:viii26‚Äì35. https://doi. 
org/10.1093/annonc/mdm263
665. Sung S, Min YH, Park SK, Lee SB. Hot flushes and sweating, sleep problems, joint and 
muscular discomfort, and physical and mental exhaustion in breast cancer survivors 
during the first 24 months of tamoxifen therapy: a prospective observational study. 
Front Oncol 2022;12:844926. https://doi.org/10.3389/fonc.2022.844926
666. Lee Meeuw Kjoe PR, Kieffer JM, Small BJ, Boogerd W, Schilder CM, van der Wall E, 
et al. Effects of tamoxifen and exemestane on cognitive function in postmenopausal 
patients with breast cancer. JNCI Cancer Spectr 2023;7:pkad022. https://doi.org/10. 
1093/jncics/pkad022
667. Park SK, Min YH. Fear of cancer recurrence in South Korean survivors of breast cancer 
who have received adjuvant endocrine therapy: a cross-sectional study. Front Psychol 
2023;14:1170077. https://doi.org/10.3389/fpsyg.2023.1170077
668. van Londen GJ, Beckjord EB, Dew MA, Cooper KL, Davidson NE, Bovbjerg DH, et al. 
Associations between adjuvant endocrine therapy and onset of physical and emotional 
concerns among breast cancer survivors. Support Care Cancer 2014;22:937‚Äì45. https:// 
doi.org/10.1007/s00520-013-2041-y
669. Koch L, Bertram H, Eberle A, Holleczek B, Schmid-H√∂pfner S, Waldmann A, et al. Fear 
of recurrence in long-term breast cancer survivors-still an issue. Results on prevalence, 
determinants, and the association with quality of life and depression from the cancer 
survivorship‚Äìa multi-regional population-based study. Psychooncology 2014;23: 
547‚Äì54. https://doi.org/10.1002/pon.3452
670. Davies A, Lum C, Raju R, Ansell E, Webber K, Segelov E. Anti-cancer therapy made 
easier: a 25-year update. Intern Med J 2021;51:473‚Äì80. https://doi.org/10.1111/imj. 
14878
671. Mitchell JD, Cehic DA, Morgia M, Bergom C, Toohey J, Guerrero PA, et al. 
Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert 
consensus statement from the International Cardio-Oncology Society. JACC 
CardioOncol 2021;3:360‚Äì80. https://doi.org/10.1016/j.jaccao.2021.06.003
672. Corrigan KL, Reeve BB, Salsman JM, Siembida EJ, Smith GL, Swartz MC, et al. 
Association of patient-reported health-related quality of life with physician-reported 
toxicities in adolescents and young adults receiving radiation therapy for cancer. JCO 
Oncol Pract 2023;19:610‚Äì9. https://doi.org/10.1200/OP.22.00852
673. Kwon JY, Kopec J, Sutherland JM, Lambert LK, Anis AH, Sawatzky R. Patient-reported 
mental health and well-being trajectories in oncology patients during radiation therapy: 
an exploratory retrospective cohort analysis using the Ontario Cancer Registry. Qual 
Life Res 2023;32:2899‚Äì909. https://doi.org/10.1007/s11136-023-03430-0
674. Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al. 
Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients 
and survivors: a scientific statement from the American Heart Association. Circulation 
2019;139:e997‚Äì1012. https://doi.org/10.1161/CIR.0000000000000679
675. Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, et al. 
Evaluation and management of cancer patients presenting with acute cardiovascular 
disease: a Clinical Consensus Statement of the Acute CardioVascular Care 
Association (ACVC) and the ESC council of Cardio-Oncology-part 2: acute heart fail¬≠
ure, acute myocardial diseases, acute venous thromboembolic diseases, and acute ar¬≠
rhythmias. Eur Heart J Acute Cardiovasc Care 2022;11:865‚Äì74. https://doi.org/10.1093/ 
ehjacc/zuac107
676. Williamson T, Moran C, Chirico D, Arena R, Ozemek C, Aggarwal S, et al. Cancer and 
cardiovascular disease: the impact of cardiac rehabilitation and cardiorespiratory fit¬≠
ness on survival. Int J Cardiol 2021;343:139‚Äì45. https://doi.org/10.1016/j.ijcard.2021. 
09.004
677. Dolan LB, Barry D, Petrella T, Davey L, Minnes A, Yantzi A, et al. The cardiac rehabili¬≠
tation model improves fitness, quality of life, and depression in breast cancer survi¬≠
vors. J Cardiopulm Rehabil Prev 2018;38:246‚Äì52. https://doi.org/10.1097/HCR.


<!-- PAGE 70 -->

### Page 70

678. Wilk M, Kepski J, Kepska J, Casselli S, Szmit S. Exercise interventions in metastatic can¬≠
cer disease: a literature review and a brief discussion on current and future perspec¬≠
tives. BMJ Support Palliat Care 2020;10:404‚Äì10. https://doi.org/10.1136/bmjspcare- 
2020-002487
679. Heywood R, McCarthy AL, Skinner TL. Efficacy of exercise interventions in patients 
with advanced cancer: a systematic review. Arch Phys Med Rehabil 2018;99: 
2595‚Äì620. https://doi.org/10.1016/j.apmr.2018.04.008
680. Fradley MG, Alomar M, Kilpatrick MW, Shields B, Tran N, Best A, et al. Patient re¬≠
ported physical and mental health changes associated with a comprehensive cardio¬≠
vascular risk reduction program for women with breast cancer receiving potentially 
cardiotoxic chemotherapy. Cardiooncology 2021;7:22. https://doi.org/10.1186/ 
s40959-021-00107-w
681. Enriquez A, Biagi J, Redfearn D, Boles U, Kamel D, Ali FS, et al. Increased incidence of 
ventricular arrhythmias in patients with advanced cancer and implantable cardioverter- 
defibrillators. JACC Clin Electrophysiol 2017;3:50‚Äì6. https://doi.org/10.1016/j.jacep.2016. 
03.001
682. Anker MS, Sanz AP, Zamorano JL, Mehra MR, Butler J, Riess H, et al. Advanced cancer 
is also a heart failure syndrome: a hypothesis. Eur J Heart Fail 2021;23:140‚Äì4. https:// 
doi.org/10.1002/ejhf.2071
683. Zamorano JL, Lancellotti P, Rodriguez Mu√±oz D, Aboyans V, Asteggiano R, Galderisi M, 
et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity devel¬≠
oped under the auspices of the ESC Committee for Practice Guidelines: The Task 
Force for cancer treatments and cardiovascular toxicity of the European Society of 
Cardiology (ESC). Eur Heart J 2016;37:2768‚Äì801. https://doi.org/10.1093/eurheartj/ 
ehw211
684. Shin J, Kober K, Yates P, Wong ML, Cooper BA, Paul SM, et al. Higher lifetime 
stress and symptom burden contribute to the occurrence of shortness of 
breath. Semin Oncol Nurs 2023;39:151471. https://doi.org/10.1016/j.soncn.2023. 
151471
685. Teng AE, Noor B, Ajijola OA, Yang EH. Chemotherapy and radiation-associated car¬≠
diac autonomic dysfunction. Curr Oncol Rep 2021;23:14. https://doi.org/10.1007/ 
s11912-020-01013-7
686. Coumbe BGT, Groarke JD. Cardiovascular autonomic dysfunction in patients with 
cancer. Curr Cardiol Rep 2018;20:69. https://doi.org/10.1007/s11886-018-1010-y
687. Lakoski SG, Jones LW, Krone RJ, Stein PK, Scott JM. Autonomic dysfunction in early 
breast cancer: incidence, clinical importance, and underlying mechanisms. Am Heart J 
2015;170:231‚Äì41. https://doi.org/10.1016/j.ahj.2015.05.014

<!-- 2025_Myocarditis_Pericarditis.md -->

# ESC Guidelines: Myocarditis Pericarditis (2025)

**Source**: `2025_Myocarditis_Pericarditis.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 90

---

## Table of Contents

- [2025 ESC Guidelines for the management of myocarditis and pericarditis](#2025-esc-guidelines-for-the-management-of-myocardi) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 7)*
  - [2. Introduction](#2-introduction) *(p. 8)*
    - [2.1. What is new](#21-what-is-new) *(p. 8)*
  - [3. Epidemiology, classification, stages, diagnostic criteria and aetiology](#3-epidemiology,-classification,-stages,-diagnostic) *(p. 11)*
    - [3.1. Epidemiology](#31-epidemiology) *(p. 11)*
    - [3.2. Classification and stages](#32-classification-and-stages) *(p. 11)*
    - [3.3. Diagnostic criteria](#33-diagnostic-criteria) *(p. 12)*
      - [3.3.1. Diagnostic criteria for myocarditis](#331-diagnostic-criteria-for-myocarditis) *(p. 12)*
      - [3.3.2. Diagnostic criteria for pericarditis](#332-diagnostic-criteria-for-pericarditis) *(p. 15)*
    - [3.4. Aetiology of myocarditis and pericarditis](#34-aetiology-of-myocarditis-and-pericarditis) *(p. 15)*
      - [3.4.1. Aetiology of myocarditis](#341-aetiology-of-myocarditis) *(p. 15)*
      - [3.4.2. Aetiology of pericarditis](#342-aetiology-of-pericarditis) *(p. 15)*
  - [4. Clinical presentation of inflammatory myopericardial syndrome](#4-clinical-presentation-of-inflammatory-myopericar) *(p. 15)*
    - [4.1. General symptoms and signs](#41-general-symptoms-and-signs) *(p. 19)*
    - [4.2. Clinical stages of myocarditis](#42-clinical-stages-of-myocarditis) *(p. 19)*
      - [4.2.1. Acute myocarditis](#421-acute-myocarditis) *(p. 19)*
      - [4.2.2. Fulminant myocarditis](#422-fulminant-myocarditis) *(p. 20)*
      - [4.2.3. Subacute myocarditis](#423-subacute-myocarditis) *(p. 20)*
      - [4.2.4. Chronic myocarditis](#424-chronic-myocarditis) *(p. 20)*
    - [4.3. Clinical presentations of myocarditis](#43-clinical-presentations-of-myocarditis) *(p. 20)*
      - [4.3.1. Chest pain presentation](#431-chest-pain-presentation) *(p. 20)*
      - [4.3.2. Heart failure presentation](#432-heart-failure-presentation) *(p. 22)*
      - [4.3.3. Presentation with arrhythmias](#433-presentation-with-arrhythmias) *(p. 22)*
      - [4.3.4. Sudden cardiac death](#434-sudden-cardiac-death) *(p. 22)*
      - [4.3.5. Presentation of myocarditis with a potential genetic background](#435-presentation-of-myocarditis-with-a-potential-g) *(p. 22)*
    - [4.4. Clinical stages of pericarditis](#44-clinical-stages-of-pericarditis) *(p. 22)*
      - [4.4.1. Acute pericarditis](#441-acute-pericarditis) *(p. 22)*
      - [4.4.2. Subacute pericarditis](#442-subacute-pericarditis) *(p. 25)*
      - [4.4.3. Chronic pericarditis](#443-chronic-pericarditis) *(p. 25)*
    - [4.5. Clinical presentations of pericarditis](#45-clinical-presentations-of-pericarditis) *(p. 25)*
      - [4.5.1. Dry pericarditis](#451-dry-pericarditis) *(p. 25)*
      - [4.5.2. Effusive pericarditis](#452-effusive-pericarditis) *(p. 25)*
      - [4.5.3. Effusive‚Äìconstrictive pericarditis](#453-effusive‚Äìconstrictive-pericarditis) *(p. 25)*
      - [4.5.4. Pericarditis with cardiac tamponade](#454-pericarditis-with-cardiac-tamponade) *(p. 25)*
      - [4.5.5. Constrictive pericarditis](#455-constrictive-pericarditis) *(p. 26)*
      - [4.5.6. Transient constrictive pericarditis](#456-transient-constrictive-pericarditis) *(p. 27)*
        - [4.5.6.1. Constrictive pathophysiology](#4561-constrictive-pathophysiology) *(p. 27)*
      - [4.5.7. Pericarditis with polyserositis](#457-pericarditis-with-polyserositis) *(p. 28)*
      - [4.5.8. Inflammatory vs non-inflammatory pericarditis](#458-inflammatory-vs-non-inflammatory-pericarditis) *(p. 28)*
        - [4.5.8.1. Inflammatory phenotype of pericarditis](#4581-inflammatory-phenotype-of-pericarditis) *(p. 28)*
        - [4.5.8.2. Non-inflammatory phenotype of pericarditis](#4582-non-inflammatory-phenotype-of-pericarditis) *(p. 28)*
  - [5. Diagnosis and diagnostic work-up](#5-diagnosis-and-diagnostic-work-up) *(p. 28)*
    - [5.1. Electrocardiogram](#51-electrocardiogram) *(p. 29)*
    - [5.2. Biomarkers](#52-biomarkers) *(p. 29)*
      - [5.2.1. Biomarkers in clinical routine](#521-biomarkers-in-clinical-routine) *(p. 29)*
      - [5.2.2. Biomarkers beyond clinical routine](#522-biomarkers-beyond-clinical-routine) *(p. 29)*
    - [5.3. Genetics](#53-genetics) *(p. 30)*
    - [5.4. Multimodality imaging](#54-multimodality-imaging) *(p. 31)*
    - [5.5. Echocardiography](#55-echocardiography) *(p. 31)*
      - [5.5.1. Echocardiography in myocarditis](#551-echocardiography-in-myocarditis) *(p. 31)*
      - [5.5.2. Echocardiography in pericarditis](#552-echocardiography-in-pericarditis) *(p. 31)*
    - [5.6. Cardiovascular magnetic resonance](#56-cardiovascular-magnetic-resonance) *(p. 32)*
    - [5.7. Computed tomography](#57-computed-tomography) *(p. 32)*
    - [5.8. Nuclear medicine](#58-nuclear-medicine) *(p. 33)*
    - [5.9. Endomyocardial and pericardial biopsy](#59-endomyocardial-and-pericardial-biopsy) *(p. 33)*
      - [5.9.1. Endomyocardial biopsy](#591-endomyocardial-biopsy) *(p. 33)*
      - [5.9.2. Pericardial biopsy](#592-pericardial-biopsy) *(p. 35)*
    - [5.10. Role of autopsy](#510-role-of-autopsy) *(p. 35)*
    - [5.11. Role of cardiac catheterization and coronary angiography](#511-role-of-cardiac-catheterization-and-coronary-a) *(p. 35)*
    - [5.12. Electro-anatomical mapping](#512-electro-anatomical-mapping) *(p. 36)*
  - [6. Therapy](#6-therapy) *(p. 36)*
    - [6.1. Non-pharmacological therapy for inflammatory myopericardial syndrome](#61-non-pharmacological-therapy-for-inflammatory-my) *(p. 36)*
    - [6.2. Pharmacological therapy](#62-pharmacological-therapy) *(p. 36)*
      - [6.2.1. Pharmacological therapy for myocarditis](#621-pharmacological-therapy-for-myocarditis) *(p. 36)*
        - [6.2.1.1. General principles](#6211-general-principles) *(p. 36)*
        - [6.2.1.2. Fulminant myocarditis](#6212-fulminant-myocarditis) *(p. 38)*
        - [6.2.1.3. Acute myocarditis](#6213-acute-myocarditis) *(p. 38)*
        - [6.2.1.4. Subacute and chronic myocarditis](#6214-subacute-and-chronic-myocarditis) *(p. 39)*
      - [6.2.2. Pharmacological therapy for pericarditis](#622-pharmacological-therapy-for-pericarditis) *(p. 39)*
        - [6.2.2.1. General principles](#6221-general-principles) *(p. 39)*
          - [6.2.2.1.1. Acute pericarditis (first episode)](#62211-acute-pericarditis-(first-episode)) *(p. 39)*
        - [6.2.2.2. Incessant and recurrent pericarditis](#6222-incessant-and-recurrent-pericarditis) *(p. 39)*
    - [6.3. Interventional techniques including circulatory support](#63-interventional-techniques-including-circulatory) *(p. 42)*
      - [6.3.1. Myocarditis](#631-myocarditis) *(p. 42)*
        - [6.3.1.1. Short-term mechanical circulatory support](#6311-short-term-mechanical-circulatory-support) *(p. 42)*
        - [6.3.1.2. Intra-aortic balloon pump](#6312-intra-aortic-balloon-pump) *(p. 42)*
      - [6.3.2. Pericarditis](#632-pericarditis) *(p. 42)*
        - [6.3.2.1. Pericardiocentesis and pericardial drainage](#6321-pericardiocentesis-and-pericardial-drainage) *(p. 42)*
        - [6.3.2.2. Percutaneous balloon pericardiotomy](#6322-percutaneous-balloon-pericardiotomy) *(p. 43)*
        - [6.3.2.3. Intrapericardial drug administration](#6323-intrapericardial-drug-administration) *(p. 43)*
        - [6.3.2.4. Pericardioscopy](#6324-pericardioscopy) *(p. 43)*
        - [6.3.2.5. Pericardial fluid analysis, pericardial and epicardial biopsy](#6325-pericardial-fluid-analysis,-pericardial-and-e) *(p. 43)*
        - [6.3.2.6. Circulatory support](#6326-circulatory-support) *(p. 43)*
    - [6.4. Surgical therapy](#64-surgical-therapy) *(p. 43)*
      - [6.4.1. Myocarditis](#641-myocarditis) *(p. 43)*
      - [6.4.2. Pericarditis](#642-pericarditis) *(p. 43)*
        - [6.4.2.1. Surgical pericardiocentesis](#6421-surgical-pericardiocentesis) *(p. 43)*
        - [6.4.2.2. Pericardiotomy/pericardial window](#6422-pericardiotomy/pericardial-window) *(p. 43)*
        - [6.4.2.3. Pericardiectomy](#6423-pericardiectomy) *(p. 44)*
    - [6.5. Management of arrhythmias and prevention of sudden cardiac death in myocarditis](#65-management-of-arrhythmias-and-prevention-of-sud) *(p. 44)*
      - [6.5.1. Role of active devices (wearable and implanted devices) in acute myocarditis](#651-role-of-active-devices-(wearable-and-implanted) *(p. 45)*
  - [7. Prognosis](#7-prognosis) *(p. 45)*
    - [7.1. Complications and outcomes for myocarditis](#71-complications-and-outcomes-for-myocarditis) *(p. 45)*
      - [7.1.1. Sequela and mortality in myocarditis](#711-sequela-and-mortality-in-myocarditis) *(p. 46)*
      - [7.1.2. Follow-up](#712-follow-up) *(p. 46)*
    - [7.2. Complications and outcomes for pericarditis](#72-complications-and-outcomes-for-pericarditis) *(p. 47)*
  - [8. Inflammatory myopericardial syndrome overlapping types: myopericarditis and perimyocarditis](#8-inflammatory-myopericardial-syndrome-overlapping) *(p. 48)*
    - [8.1. Inflammatory myopericardial syndrome in systemic disorders](#81-inflammatory-myopericardial-syndrome-in-systemi) *(p. 49)*
      - [8.1.1. Rheumatoid arthritis](#811-rheumatoid-arthritis) *(p. 49)*
      - [8.1.2. Systemic lupus erythematosus](#812-systemic-lupus-erythematosus) *(p. 49)*
      - [8.1.3. Antiphospholipid syndrome](#813-antiphospholipid-syndrome) *(p. 49)*
      - [8.1.4. Sj√∂gren's syndrome](#814-sj√∂gren's-syndrome) *(p. 49)*
      - [8.1.5. Systemic sclerosis](#815-systemic-sclerosis) *(p. 49)*
      - [8.1.6. Polymyositis and dermatomyositis](#816-polymyositis-and-dermatomyositis) *(p. 49)*
      - [8.1.7. Vasculitis](#817-vasculitis) *(p. 49)*
    - [8.2. Inflammatory myopericardial syndrome in COVID-19 disease](#82-inflammatory-myopericardial-syndrome-in-covid-1) *(p. 49)*
  - [9. Specific types of myocarditis](#9-specific-types-of-myocarditis) *(p. 50)*
    - [9.1. Lymphocytic myocarditis](#91-lymphocytic-myocarditis) *(p. 50)*
      - [9.1.1. Presentation](#911-presentation) *(p. 50)*
      - [9.1.2. Diagnosis and therapy](#912-diagnosis-and-therapy) *(p. 50)*
    - [9.2. Eosinophilic myocarditis](#92-eosinophilic-myocarditis) *(p. 50)*
      - [9.2.1. Presentation](#921-presentation) *(p. 50)*
      - [9.2.2. Diagnosis](#922-diagnosis) *(p. 50)*
      - [9.2.3. Therapy](#923-therapy) *(p. 50)*
    - [9.3. Giant-cell myocarditis](#93-giant-cell-myocarditis) *(p. 50)*
      - [9.3.1. Presentation](#931-presentation) *(p. 51)*
      - [9.3.2. Diagnosis](#932-diagnosis) *(p. 51)*
      - [9.3.3. Therapy](#933-therapy) *(p. 51)*
    - [9.4. Myocarditis in sarcoidosis](#94-myocarditis-in-sarcoidosis) *(p. 52)*
      - [9.4.1. Presentation](#941-presentation) *(p. 52)*
      - [9.4.2. Diagnosis](#942-diagnosis) *(p. 52)*
      - [9.4.3. Therapy](#943-therapy) *(p. 52)*
    - [9.5. Specific infectious myocarditis (Viruses, Lyme, Chagas)](#95-specific-infectious-myocarditis-(viruses,-lyme,) *(p. 53)*
      - [9.5.1. Viruses](#951-viruses) *(p. 53)*
        - [9.5.1.1. Presentation](#9511-presentation) *(p. 53)*
        - [9.5.1.2. Diagnosis](#9512-diagnosis) *(p. 53)*
        - [9.5.1.3. Therapy](#9513-therapy) *(p. 53)*
          - [9.5.1.3.1. Influenza virus](#95131-influenza-virus) *(p. 53)*
          - [9.5.1.3.2. Human immunodeficiency virus](#95132-human-immunodeficiency-virus) *(p. 53)*
      - [9.5.2. Lyme carditis](#952-lyme-carditis) *(p. 53)*
        - [9.5.2.1. Presentation](#9521-presentation) *(p. 53)*
        - [9.5.2.2. Diagnosis](#9522-diagnosis) *(p. 53)*
        - [9.5.2.3. Therapy](#9523-therapy) *(p. 53)*
      - [9.5.3. Chagas disease](#953-chagas-disease) *(p. 54)*
        - [9.5.3.1. Presentation](#9531-presentation) *(p. 54)*
        - [9.5.3.2. Diagnosis](#9532-diagnosis) *(p. 54)*
        - [9.5.3.3. Therapy](#9533-therapy) *(p. 54)*
    - [9.6. Drug- or vaccine-induced myocarditis](#96-drug--or-vaccine-induced-myocarditis) *(p. 54)*
      - [9.6.1. Drug-induced myocarditis](#961-drug-induced-myocarditis) *(p. 54)*
        - [9.6.1.1. Immune checkpoint inhibitor-induced myocarditis](#9611-immune-checkpoint-inhibitor-induced-myocardit) *(p. 54)*
          - [9.6.1.1.1. Presentation](#96111-presentation) *(p. 54)*
          - [9.6.1.1.2. Diagnosis](#96112-diagnosis) *(p. 54)*
          - [9.6.1.1.3. Therapy](#96113-therapy) *(p. 54)*
        - [9.6.1.2. Other drugs associated with myocarditis](#9612-other-drugs-associated-with-myocarditis) *(p. 55)*
      - [9.6.2. Vaccine-induced myocarditis](#962-vaccine-induced-myocarditis) *(p. 55)*
    - [9.7. Pregnancy-associated myocarditis](#97-pregnancy-associated-myocarditis) *(p. 55)*
      - [9.7.1. Presentation](#971-presentation) *(p. 55)*
      - [9.7.2. Diagnosis](#972-diagnosis) *(p. 55)*
      - [9.7.3. Therapy](#973-therapy) *(p. 55)*
  - [10. Inflammatory cardiomyopathy](#10-inflammatory-cardiomyopathy) *(p. 55)*
    - [10.1. Presentation](#101-presentation) *(p. 56)*
    - [10.2. Diagnosis](#102-diagnosis) *(p. 56)*
    - [10.3. Therapy](#103-therapy) *(p. 56)*
  - [11. Specific types of pericarditis](#11-specific-types-of-pericarditis) *(p. 56)*
    - [11.1. Tuberculous pericarditis](#111-tuberculous-pericarditis) *(p. 56)*
      - [11.1.1. Presentation](#1111-presentation) *(p. 56)*
      - [11.1.2. Diagnosis](#1112-diagnosis) *(p. 56)*
      - [11.1.3. Therapy](#1113-therapy) *(p. 57)*
    - [11.2. Pericardial involvement in neoplastic disease](#112-pericardial-involvement-in-neoplastic-disease) *(p. 58)*
      - [11.2.1. Presentation](#1121-presentation) *(p. 58)*
      - [11.2.2. Diagnosis](#1122-diagnosis) *(p. 58)*
      - [11.2.3. Therapy](#1123-therapy) *(p. 58)*
    - [11.3. Post-cardiac injury syndrome](#113-post-cardiac-injury-syndrome) *(p. 58)*
      - [11.3.1. Diagnosis](#1131-diagnosis) *(p. 59)*
      - [11.3.2. Therapy](#1132-therapy) *(p. 59)*
    - [11.4. Pericarditis and autoinflammatory diseases](#114-pericarditis-and-autoinflammatory-diseases) *(p. 59)*
    - [11.5. Purulent pericarditis](#115-purulent-pericarditis) *(p. 59)*
      - [11.5.1. Presentation](#1151-presentation) *(p. 60)*
      - [11.5.2. Diagnosis](#1152-diagnosis) *(p. 60)*
      - [11.5.3. Therapy](#1153-therapy) *(p. 60)*
    - [11.6. Incessant and recurrent pericarditis](#116-incessant-and-recurrent-pericarditis) *(p. 60)*
    - [11.7. Inflammatory and non-inflammatory pericardial effusion](#117-inflammatory-and-non-inflammatory-pericardial-) *(p. 60)*
      - [11.7.1. Classification and aetiology](#1171-classification-and-aetiology) *(p. 60)*
      - [11.7.2. Presentation](#1172-presentation) *(p. 60)*
      - [11.7.3. Diagnosis](#1173-diagnosis) *(p. 61)*
      - [11.7.4. Therapy](#1174-therapy) *(p. 62)*
      - [11.7.5. Prognosis and follow-up](#1175-prognosis-and-follow-up) *(p. 62)*
    - [11.8. Cardiac tamponade](#118-cardiac-tamponade) *(p. 62)*
      - [11.8.1. Presentation](#1181-presentation) *(p. 62)*
      - [11.8.2. Aetiology and diagnosis](#1182-aetiology-and-diagnosis) *(p. 62)*
      - [11.8.3. Therapy](#1183-therapy) *(p. 63)*
      - [11.8.4. Outcomes and prognosis](#1184-outcomes-and-prognosis) *(p. 63)*
    - [11.9. Pericardial constriction and constrictive pericarditis (calcified and non-calcified)](#119-pericardial-constriction-and-constrictive-peri) *(p. 63)*
      - [11.9.1. Introduction](#1191-introduction) *(p. 63)*
      - [11.9.2. Presentation](#1192-presentation) *(p. 63)*
      - [11.9.3. Diagnosis](#1193-diagnosis) *(p. 63)*
      - [11.9.4. Therapy](#1194-therapy) *(p. 64)*
    - [11.10. Effusive‚Äìconstrictive pericarditis](#1110-effusive‚Äìconstrictive-pericarditis) *(p. 64)*
      - [11.10.1. Introduction](#11101-introduction) *(p. 64)*
      - [11.10.2. Aetiology](#11102-aetiology) *(p. 64)*
      - [11.10.3. Presentation](#11103-presentation) *(p. 64)*
      - [11.10.4. Diagnosis](#11104-diagnosis) *(p. 64)*
      - [11.10.5. Treatment](#11105-treatment) *(p. 64)*
  - [12. Age- and sex-related aspects in inflammatory myopericardial syndrome](#12-age--and-sex-related-aspects-in-inflammatory-my) *(p. 64)*
    - [12.1. Sex distribution](#121-sex-distribution) *(p. 64)*
    - [12.2. Paediatric patients](#122-paediatric-patients) *(p. 65)*
      - [12.2.1. Myocarditis](#1221-myocarditis) *(p. 65)*
      - [12.2.2. Pericarditis](#1222-pericarditis) *(p. 65)*
    - [12.3. Pregnancy, lactation, and reproductive issues](#123-pregnancy,-lactation,-and-reproductive-issues) *(p. 65)*
    - [12.4. The elderly](#124-the-elderly) *(p. 66)*
    - [12.5. Physical activity in inflammatory myopericardial syndrome](#125-physical-activity-in-inflammatory-myopericardi) *(p. 66)*
      - [12.5.1. Mental health effect of restricting exercise](#1251-mental-health-effect-of-restricting-exercise) *(p. 66)*
    - [12.6. Multidisciplinary teams for the management of inflammatory myopericardial syndrome](#126-multidisciplinary-teams-for-the-management-of-) *(p. 66)*
  - [13. Advice for patients](#13-advice-for-patients) *(p. 67)*
  - [14. Tertiary referral centres for inflammatory myopericardial syndrome: feature and volume of activity](#14-tertiary-referral-centres-for-inflammatory-myop) *(p. 67)*
    - [14.1. Tertiary care centres](#141-tertiary-care-centres) *(p. 67)*
    - [14.2. Inflammatory myopericardial syndrome in regional centres](#142-inflammatory-myopericardial-syndrome-in-region) *(p. 67)*
    - [14.3. Hub-and-spoke model](#143-hub-and-spoke-model) *(p. 67)*
    - [14.4. Teamwork, competencies, and advances in imaging techniques](#144-teamwork,-competencies,-and-advances-in-imagin) *(p. 68)*
  - [15. Key messages](#15-key-messages) *(p. 68)*
    - [15.1. Aetiology](#151-aetiology) *(p. 68)*
    - [15.2. Clinical presentation and diagnosis](#152-clinical-presentation-and-diagnosis) *(p. 68)*
    - [15.3. Therapy](#153-therapy) *(p. 68)*
    - [15.4. Prognosis and outcomes](#154-prognosis-and-outcomes) *(p. 68)*
    - [15.5. Multidisciplinary team](#155-multidisciplinary-team) *(p. 68)*
  - [16. Gaps in evidence](#16-gaps-in-evidence) *(p. 68)*
    - [16.1. Myocarditis](#161-myocarditis) *(p. 68)*
    - [16.2. Pericarditis](#162-pericarditis) *(p. 69)*
  - [17. Sex differences](#17-sex-differences) *(p. 69)*
  - [18. ‚ÄòWhat to do‚Äô and ‚ÄòWhat not to do‚Äô messages from the Guidelines](#18-‚Äòwhat-to-do‚Äô-and-‚Äòwhat-not-to-do‚Äô-messages-from) *(p. 69)*
  - [19. Evidence tables](#19-evidence-tables) *(p. 72)*
  - [20. Data availability statement](#20-data-availability-statement) *(p. 72)*
  - [21. Author information](#21-author-information) *(p. 72)*
  - [Appendix](#appendix) *(p. 73)*
    - [ESC Scientific Document Group](#esc-scientific-document-group) *(p. 73)*
  - [References](#references) *(p. 74)*
  - [References](#references) *(p. 74)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2025 ESC Guidelines for the management 
of myocarditis and pericarditis 
Developed by the task force for the management of myocarditis and 
pericarditis of the European Society of Cardiology (ESC) 
Endorsed by the Association for European Paediatric and 
Congenital Cardiology (AEPC) and the European Association 
for Cardio-Thoracic Surgery (EACTS) 
Authors/Task Force Members: Jeanette Schulz-Menger  
‚Ä†,*, (Chairperson) 
(Germany), Valentino Collini  
‚Ä°, (Task Force Co-ordinator) (Italy), 
Jan Gr√∂schel  
‚Ä°, (Task Force Co-ordinator) (Germany), Yehuda Adler (Israel), 
Antonio Brucato  
(Italy), Vanessa Christian (United Kingdom),  
Vanessa M. Ferreira  
(United Kingdom), Estelle Gandjbakhch  
(France), 
Bettina Heidecker  
(Germany), Mathieu Kerneis  
(France), Allan L. Klein  
(United States of America), Karin Klingel  
(Germany), George Lazaros  
(Greece), Roberto Lorusso  
(Netherlands), Elena G. Nesukay  
(Ukraine), 
Kazem Rahimi  
(United Kingdom), Arsen D. Ristiƒá  
(Serbia), Marcin Rucinski  
(Poland), Leyla Elif Sade  
(United States of America), Hannah Schaubroeck 
(Belgium), Anne Grete Semb  
(Norway), Gianfranco Sinagra  
(Italy),  
Jens Jakob Thune  
(Denmark), Massimo Imazio  
‚Ä†,*, (Chairperson) (Italy), and 
the ESC Scientific Document Group 
* Corresponding authors: Jeanette Schulz-Menger, Charit√©‚ÄîUniversit√§tsmedizin Berlin, corporate member of Freie Universit√§t Berlin and Humboldt-Universit√§t zu Berlin, ECRC 
Experimental and Clinical Research Center, Berlin, Germany, and DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany, and Deutsches 
Herzzentrum der Charit√© Berlin, Germany, and Cardiology and Nephrology, HELIOS Hospital Berlin-Buch, Berlin, Germany. Tel: +4930450540611, E-mail: jeanette.schulz- 
menger@charite.de 
Massimo Imazio, Department of Medicine, University of Udine, and Cardiothoracic Department, University Hospital Santa Maria della Misericordia, ASUFC, Udine, Italy. Tel: +393296524271, 
E-mail: massimo.imazio@uniud.it 
‚Ä† The two Chairpersons contributed equally to the document and are joint corresponding authors. 
‚Ä° The two Task Force Co-ordinators contributed equally to the document. 
Author/Task Force Member affiliations are listed in author information. 
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix. 
ESC subspecialty communities having participated in the development of this document: 
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA). 
Councils: Council for Cardiology Practice, Council of Cardio-Oncology, Council on Basic Cardiovascular Science. 
Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Myocardial and Pericardial Diseases, Pulmonary Circulation and Right Ventricular Function. 
Patient Forum 
¬© The European Society of Cardiology 2025. All rights reserved.  
https://doi.org/10.1093/eurheartj/ehaf192 
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Elena Arbelo, (CPG Review Co-ordinator) (Spain), Cristina Basso, (CPG Review 
Co-ordinator) (Italy), Marianna Adamo (Italy), Suleman Aktaa (United Kingdom), Enrico Ammirati (Italy), 
Lisa Anderson (United Kingdom), Eloisa Arbustini (Italy), Emanuele Bobbio (Sweden), Giuseppe Boriani (Italy), 
Margarita Brida (Croatia), Robert A. Byrne (Ireland), Alida L.P. Caforio (Italy), Gh.-Andrei Dan (Romania), 
Fernando Dom√≠nguez (Spain), Suzanne Fredericks (Canada), Geeta Gulati (Norway), Borja Ibanez (Spain), 
Stefan James (Sweden), Alexander Kharlamov (Netherlands), Sabine Klaassen (Germany), Jolanda Kluin 
(Netherlands), Konstantinos C. Koskinas (Switzerland), Petr Kuchynka (Czech Republic), Vijay Kunadian (United 
Kingdom), Ulf Landmesser (Germany), Gregory Y.H. Lip (United Kingdom), Bernhard Maisch (Germany), 
Federica Marelli-Berg (United Kingdom), Pilar Martin (Spain), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Inge Moelgaard (Denmark), Saidi A. Mohiddin (United 
Kingdom), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet (Belgium), Giovanni Peretto (Italy), Kalliopi Pilichou 
(Italy), Nicolas Piriou (France), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), 
Xavier Rossello (Spain), Anna Sannino (Germany), Franziska Seidel1 (Germany), Felix C. Tanner (Switzerland), 
Witold Zbyszek Tomkowski (Poland), Ilonca Vaartjes (Netherlands), Sophie Van Linthout (Germany), 
Christiaan Vrints (Belgium), Romuald Wojnicz (Poland), and Katja Zeppenfeld (Netherlands) 
1 Representing the Association for European Paediatric and Congenital Cardiology (AEPC). 
All experts involved in the development of these guidelines have submitted declarations of interest, 
which are reported in a supplementary document to the guidelines. See the European Heart Journal online 
or https://www.escardio.org/Guidelines for supplementary documents as well as evidence tables. 
Disclaimer: The European Society of Cardiology (ESC) Guidelines represent the views of the ESC and were produced after careful 
consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in 
the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines 
issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals 
are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the 
implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way 
whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient‚Äôs 
health condition and in consultation with that patient and, where appropriate and/or necessary, the patient‚Äôs caregiver. Nor do the ESC 
Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or 
guidelines issued by the competent public health authorities, in order to manage each patient‚Äôs case in light of the scientifically accepted data 
pursuant to their respective ethical and professional obligations. It is also the health professional‚Äôs responsibility to verify the applicable rules and 
regulations relating to drugs and medical devices prior to making any clinical decision and to check whether a more recent version of this 
document exists. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect. 
Permissions: The content of these ESC Guidelines has been published for personal and educational use only. No commercial use is 
authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. 
Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal 
and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).  
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
Keywords 
Guidelines ‚Ä¢ Myocarditis ‚Ä¢ Pericarditis ‚Ä¢ Myopericarditis ‚Ä¢ Perimyocarditis ‚Ä¢ Diagnosis ‚Ä¢ Therapy ‚Ä¢ 
Echocardiography ‚Ä¢ Cardiac magnetic resonance ‚Ä¢ Multimodality imaging ‚Ä¢ Endomyocardial biopsy  
Table of contents 
1. Preamble ...................................................................................................................... 7 
2. Introduction ............................................................................................................... 8 
2.1. What is new .....................................................................................................
8 
3. Epidemiology, classification, stages, diagnostic criteria and aetiology
11 
3.1. Epidemiology .................................................................................................. 11 
3.2. Classification and stages ............................................................................ 11 
3.3. Diagnostic criteria ........................................................................................ 12 
3.3.1. Diagnostic criteria for myocarditis ...............................................
12 
3.3.2. Diagnostic criteria for pericarditis ................................................
15 
3.4. Aetiology of myocarditis and pericarditis .......................................... 15 
3.4.1. Aetiology of myocarditis ..................................................................
15 
3.4.2. Aetiology of pericarditis ...................................................................
15 
4. Clinical presentation of inflammatory myopericardial syndrome .... 15 
4.1. General symptoms and signs ................................................................... 19 
4.2. Clinical stages of myocarditis .................................................................. 19 
4.2.1. Acute myocarditis ...............................................................................
19 
4.2.2. Fulminant myocarditis ........................................................................
20 
4.2.3. Subacute myocarditis .........................................................................
20


<!-- PAGE 3 -->

### Page 3

4.2.4. Chronic myocarditis ...........................................................................
20 
4.3. Clinical presentations of myocarditis ................................................... 20 
4.3.1. Chest pain presentation ...................................................................
20 
4.3.2. Heart failure presentation ................................................................
22 
4.3.3. Presentation with arrhythmias .......................................................
22 
4.3.4. Sudden cardiac death .........................................................................
22 
4.3.5. Presentation of myocarditis with a potential genetic 
background .........................................................................................................
22 
4.4. Clinical stages of pericarditis ................................................................... 22 
4.4.1. Acute pericarditis .................................................................................
22 
4.4.2. Subacute pericarditis ..........................................................................
25 
4.4.3. Chronic pericarditis ............................................................................
25 
4.5. Clinical presentations of pericarditis .................................................... 25 
4.5.1. Dry pericarditis .....................................................................................
25 
4.5.2. Effusive pericarditis .............................................................................
25 
4.5.3. Effusive‚Äìconstrictive pericarditis ...................................................
25 
4.5.4. Pericarditis with cardiac tamponade ...........................................
25 
4.5.5. Constrictive pericarditis ....................................................................
26 
4.5.6. Transient constrictive pericarditis ................................................
27 
4.5.6.1. Constrictive pathophysiology ................................................
27 
4.5.7. Pericarditis with polyserositis .........................................................
28 
4.5.8. Inflammatory vs non-inflammatory pericarditis ......................
28 
4.5.8.1. Inflammatory phenotype of pericarditis ............................
28 
4.5.8.2. Non-inflammatory phenotype of pericarditis .................
28 
5. Diagnosis and diagnostic work-up ................................................................. 28 
5.1. Electrocardiogram ........................................................................................ 29 
5.2. Biomarkers ...................................................................................................... 29 
5.2.1. Biomarkers in clinical routine .........................................................
29 
5.2.2. Biomarkers beyond clinical routine .............................................
29 
5.3. Genetics ............................................................................................................ 30 
5.4. Multimodality imaging ................................................................................. 31 
5.5. Echocardiography ......................................................................................... 31 
5.5.1. Echocardiography in myocarditis ..................................................
31 
5.5.2. Echocardiography in pericarditis ...................................................
31 
5.6. Cardiovascular magnetic resonance ..................................................... 32 
5.7. Computed tomography ............................................................................. 32 
5.8. Nuclear medicine ......................................................................................... 33 
5.9. Endomyocardial and pericardial biopsy .............................................. 33 
5.9.1. Endomyocardial biopsy .....................................................................
33 
5.9.2. Pericardial biopsy .................................................................................
35 
5.10. Role of autopsy .......................................................................................... 35 
5.11. Role of cardiac catheterization and coronary angiography ..... 35 
5.12. Electro-anatomical mapping .................................................................. 36 
6. Therapy ..................................................................................................................... 36 
6.1. Non-pharmacological therapy for inflammatory 
myopericardial syndrome .................................................................................. 36 
6.2. Pharmacological therapy ........................................................................... 36 
6.2.1. Pharmacological therapy for myocarditis ..................................
36 
6.2.1.1. General principles .......................................................................
36 
6.2.1.2. Fulminant myocarditis ...............................................................
38 
6.2.1.3. Acute myocarditis .......................................................................
38 
6.2.1.4. Subacute and chronic myocarditis .......................................
39 
6.2.2. Pharmacological therapy for pericarditis ...................................
39 
6.2.2.1. General principles .......................................................................
39 
6.2.2.1.1. Acute pericarditis (first episode) .................................
39 
6.2.2.2. Incessant and recurrent pericarditis ...................................
39 
6.3. Interventional techniques including circulatory support ............. 42 
6.3.1. Myocarditis .............................................................................................
42 
6.3.1.1. Short-term mechanical circulatory support ....................
42 
6.3.1.2. Intra-aortic balloon pump .......................................................
42 
6.3.2. Pericarditis ..............................................................................................
42 
6.3.2.1. Pericardiocentesis and pericardial drainage .....................
42 
6.3.2.2. Percutaneous balloon pericardiotomy ...............................
43 
6.3.2.3. Intrapericardial drug administration ....................................
43 
6.3.2.4. Pericardioscopy ............................................................................
43 
6.3.2.5. Pericardial fluid analysis, pericardial and epicardial 
biopsy ...............................................................................................................
43 
6.3.2.6. Circulatory support ...................................................................
43 
6.4. Surgical therapy ............................................................................................. 43 
6.4.1. Myocarditis .............................................................................................
43 
6.4.2. Pericarditis ..............................................................................................
43 
6.4.2.1. Surgical pericardiocentesis ......................................................
43 
6.4.2.2. Pericardiotomy/pericardial window ....................................
43 
6.4.2.3. Pericardiectomy ...........................................................................
44 
6.5. Management of arrhythmias and prevention of sudden 
cardiac death in myocarditis ............................................................................. 44 
6.5.1. Role of active devices (wearable and implanted devices) in 
acute myocarditis .............................................................................................
45 
7. Prognosis .................................................................................................................. 45 
7.1. Complications and outcomes for myocarditis ................................ 45 
7.1.1. Sequela and mortality in myocarditis ..........................................
46 
7.1.2. Follow-up ................................................................................................
46 
7.2. Complications and outcomes for pericarditis ................................. 47 
8. Inflammatory myopericardial syndrome overlapping types: 
myopericarditis and perimyocarditis ................................................................. 48 
8.1. Inflammatory myopericardial syndrome in systemic disorders
49 
8.1.1. Rheumatoid arthritis ..........................................................................
49 
8.1.2. Systemic lupus erythematosus .......................................................
49 
8.1.3. Antiphospholipid syndrome ............................................................
49 
8.1.4. Sj√∂gren‚Äôs syndrome .............................................................................
49 
8.1.5. Systemic sclerosis ................................................................................
49 
8.1.6. Polymyositis and dermatomyositis ...............................................
49 
8.1.7. Vasculitis ..................................................................................................
49 
8.2. Inflammatory myopericardial syndrome in COVID-19 disease
49 
9. Specific types of myocarditis ............................................................................ 50 
9.1. Lymphocytic myocarditis .......................................................................... 50 
9.1.1. Presentation ...........................................................................................
50 
9.1.2. Diagnosis and therapy .......................................................................
50 
9.2. Eosinophilic myocarditis ............................................................................ 50 
9.2.1. Presentation ...........................................................................................
50 
9.2.2. Diagnosis .................................................................................................
50 
9.2.3. Therapy ....................................................................................................
50 
9.3. Giant-cell myocarditis ................................................................................. 50 
9.3.1. Presentation ...........................................................................................
51 
9.3.2. Diagnosis .................................................................................................
51 
9.3.3. Therapy ....................................................................................................
51 
9.4. Myocarditis in sarcoidosis ......................................................................... 52 
9.4.1. Presentation ...........................................................................................
52 
9.4.2. Diagnosis .................................................................................................
52 
9.4.3. Therapy ....................................................................................................
52 
9.5. Specific infectious myocarditis (Viruses, Lyme, Chagas) ............. 53 
9.5.1. Viruses ......................................................................................................
53 
9.5.1.1. Presentation ..................................................................................
53 
9.5.1.2. Diagnosis .........................................................................................


<!-- PAGE 4 -->

### Page 4

9.5.1.3. Therapy ...........................................................................................
53 
9.5.1.3.1. Influenza virus .......................................................................
53 
9.5.1.3.2. Human immunodeficiency virus ...................................
53 
9.5.2. Lyme carditis ..........................................................................................
53 
9.5.2.1. Presentation ..................................................................................
53 
9.5.2.2. Diagnosis .........................................................................................
53 
9.5.2.3. Therapy ...........................................................................................
53 
9.5.3. Chagas disease ......................................................................................
54 
9.5.3.1. Presentation ..................................................................................
54 
9.5.3.2. Diagnosis .........................................................................................
54 
9.5.3.3. Therapy ...........................................................................................
54 
9.6. Drug- or vaccine-induced myocarditis ................................................ 54 
9.6.1. Drug-induced myocarditis ................................................................
54 
9.6.1.1. Immune checkpoint inhibitor-induced myocarditis ......
54 
9.6.1.1.1. Presentation ..........................................................................
54 
9.6.1.1.2. Diagnosis ................................................................................
54 
9.6.1.1.3. Therapy ...................................................................................
54 
9.6.1.2. Other drugs associated with myocarditis .........................
55 
9.6.2. Vaccine-induced myocarditis ..........................................................
55 
9.7. Pregnancy-associated myocarditis ......................................................... 55 
9.7.1. Presentation ...........................................................................................
55 
9.7.2. Diagnosis .................................................................................................
55 
9.7.3. Therapy ....................................................................................................
55 
10. Inflammatory cardiomyopathy ..................................................................... 55 
10.1. Presentation ................................................................................................. 56 
10.2. Diagnosis ....................................................................................................... 56 
10.3. Therapy .......................................................................................................... 56 
11. Specific types of pericarditis .......................................................................... 56 
11.1. Tuberculous pericarditis ......................................................................... 56 
11.1.1. Presentation ........................................................................................
56 
11.1.2. Diagnosis ...............................................................................................
56 
11.1.3. Therapy .................................................................................................
57 
11.2. Pericardial involvement in neoplastic disease ................................ 58 
11.2.1. Presentation ........................................................................................
58 
11.2.2. Diagnosis ...............................................................................................
58 
11.2.3. Therapy .................................................................................................
58 
11.3. Post-cardiac injury syndrome ............................................................... 58 
11.3.1. Diagnosis ...............................................................................................
59 
11.3.2. Therapy .................................................................................................
59 
11.4. Pericarditis and autoinflammatory diseases ................................... 59 
11.5. Purulent pericarditis ................................................................................. 59 
11.5.1. Presentation ........................................................................................
60 
11.5.2. Diagnosis ...............................................................................................
60 
11.5.3. Therapy .................................................................................................
60 
11.6. Incessant and recurrent pericarditis .................................................. 60 
11.7. Inflammatory and non-inflammatory pericardial effusion ........ 60 
11.7.1. Classification and aetiology ...........................................................
60 
11.7.2. Presentation ........................................................................................
60 
11.7.3. Diagnosis ...............................................................................................
61 
11.7.4. Therapy .................................................................................................
62 
11.7.5. Prognosis and follow-up ................................................................
62 
11.8. Cardiac tamponade ................................................................................... 62 
11.8.1. Presentation ........................................................................................
62 
11.8.2. Aetiology and diagnosis ..................................................................
62 
11.8.3. Therapy .................................................................................................
63 
11.8.4. Outcomes and prognosis ..............................................................
63 
11.9. Pericardial constriction and constrictive pericarditis 
(calcified and non-calcified) ............................................................................... 63 
11.9.1. Introduction .........................................................................................
63 
11.9.2. Presentation ........................................................................................
63 
11.9.3. Diagnosis ...............................................................................................
63 
11.9.4. Therapy .................................................................................................
64 
11.10. Effusive‚Äìconstrictive pericarditis ...................................................... 64 
11.10.1. Introduction ......................................................................................
64 
11.10.2. Aetiology ............................................................................................
64 
11.10.3. Presentation ......................................................................................
64 
11.10.4. Diagnosis ............................................................................................
64 
11.10.5. Treatment ..........................................................................................
64 
12. Age- and sex-related aspects in inflammatory myopericardial 
syndrome ....................................................................................................................... 64 
12.1. Sex distribution ........................................................................................... 64 
12.2. Paediatric patients ..................................................................................... 65 
12.2.1. Myocarditis ...........................................................................................
65 
12.2.2. Pericarditis ............................................................................................
65 
12.3. Pregnancy, lactation, and reproductive issues ............................... 65 
12.4. The elderly .................................................................................................... 66 
12.5. Physical activity in inflammatory myopericardial syndrome .... 66 
12.5.1. Mental health effect of restricting exercise ...........................
66 
12.6. Multidisciplinary teams for the management of inflammatory 
myopericardial syndrome .................................................................................. 66 
13. Advice for patients ............................................................................................ 67 
14. Tertiary referral centres for inflammatory myopericardial 
syndrome: feature and volume of activity ....................................................... 67 
14.1. Tertiary care centres ................................................................................ 67 
14.2. Inflammatory myopericardial syndrome in regional centres .. 67 
14.3. Hub-and-spoke model ............................................................................. 67 
14.4. Teamwork, competencies, and advances in imaging 
techniques ................................................................................................................ 68 
15. Key messages ....................................................................................................... 68 
15.1. Aetiology ....................................................................................................... 68 
15.2. Clinical presentation and diagnosis .................................................... 68 
15.3. Therapy .......................................................................................................... 68 
15.4. Prognosis and outcomes ........................................................................ 68 
15.5. Multidisciplinary team .............................................................................. 68 
16. Gaps in evidence ................................................................................................. 68 
16.1. Myocarditis ................................................................................................... 68 
16.2. Pericarditis .................................................................................................... 69 
17. Sex differences .................................................................................................... 69 
18. ‚ÄòWhat to do‚Äô and ‚ÄòWhat not to do‚Äô messages from the Guidelines
69 
19. Evidence tables .................................................................................................... 72 
20. Data availability statement .............................................................................. 72 
21. Author information ........................................................................................... 72 
22. Appendix ................................................................................................................ 73 
ESC Scientific Document Group ........................................................................ 73 
23. References ............................................................................................................. 74 
Tables of Recommendations 
Recommendation Table 1 ‚Äî Recommendations for clinical 
evaluation of myocarditis and pericarditis (see Evidence Table 1) ....... 28 
Recommendation Table 2 ‚Äî Recommendations for genetic testing 
(see Evidence Table 2) ............................................................................................. 30


<!-- PAGE 5 -->

### Page 5

Recommendation Table 3 ‚Äî Recommendations for the use of 
cardiovascular magnetic resonance imaging (see Evidence Table 3) ... 32 
Recommendation Table 4 ‚Äî Recommendations for computed 
tomography (see Evidence Table 4) .................................................................. 32 
Recommendation Table 5 ‚Äî Recommendations for nuclear 
medicine (see Evidence Table 5) ......................................................................... 33 
Recommendation Table 6 ‚Äî Recommendations for 
endomyocardial biopsy (see Evidence Table 6) ............................................ 34 
Recommendation Table 7 ‚Äî Recommendations for autopsy (see 
Evidence Table 7) ....................................................................................................... 35 
Recommendation Table 8 ‚Äî Recommendations for 
electro-anatomical mapping (see Evidence Table 8) .................................. 36 
Recommendation Table 9 ‚Äî Recommendations for medical 
therapy in myocarditis (see Evidence Table 9) ............................................. 39 
Recommendation Table 10 ‚Äî Recommendations for medical 
therapy in pericarditis (see Evidence Table 10) ............................................ 42 
Recommendation Table 11 ‚Äî Recommendations for interventional 
techniques including circulatory support in myocarditis (see 
Evidence Table 11) .................................................................................................... 42 
Recommendation Table 12 ‚Äî Recommendations for interventional 
techniques in pericarditis (see Evidence Table 12) ..................................... 43 
Recommendation Table 13 ‚Äî Recommendations for surgical 
therapy (see Evidence Table 13) ......................................................................... 44 
Recommendation Table 14 ‚Äî Recommendations for management 
of arrhythmias and prevention of sudden cardiac death in 
myocarditis (see Evidence Table 14) ................................................................. 45 
Recommendation Table 15 ‚Äî Recommendations for risk 
stratification, complications, and outcomes of inflammatory 
myopericardial syndrome (see Evidence Table 15) .................................... 47 
Recommendation Table 16 ‚Äî Recommendations for giant-cell 
myocarditis (see Evidence Table 16) ................................................................. 51 
Recommendation Table 17 ‚Äî Recommendations for myocarditis in 
sarcoidosis (see Evidence Table 17) .................................................................. 52 
Recommendation Table 18 ‚Äî Recommendations for immune 
checkpoint inhibitor-associated myocarditis (see Evidence Table 18)
55 
Recommendation Table 19 ‚Äî Recommendations for inflammatory 
cardiomyopathy (see Evidence Table 19) ....................................................... 56 
Recommendation Table 20 ‚Äî Recommendations for tuberculous 
pericarditis (see Evidence Table 20) .................................................................. 57 
Recommendation Table 21 ‚Äî Recommendations for neoplastic 
pericardial involvement (see Evidence Table 21) ......................................... 58 
Recommendation Table 22 ‚Äî Recommendations for post-cardiac 
injury syndrome (see Evidence Table 22) ....................................................... 59 
Recommendation Table 23 ‚Äî Recommendations for purulent 
pericarditis (see Evidence Table 23) .................................................................. 60 
Recommendation Table 24 ‚Äî Recommendations for constrictive 
pericarditis (see Evidence Table 24) .................................................................. 64 
Recommendation Table 25 ‚Äî Recommendations for pregnancy, 
lactation, and reproductive issues (see Evidence Table 25) .................... 65 
Recommendation Table 26 ‚Äî Recommendations for physical 
activity and myocarditis/pericarditis (see Evidence Table 26) ................ 66 
Recommendation Table 27 ‚Äî Recommendations for 
multidisciplinary teams in myopericardial syndromes (see Evidence 
Table 27) ........................................................................................................................ 66  
List of tables 
Table 1 Classes of recommendations .................................................................. 7 
Table 2 Levels of evidence ........................................................................................ 8 
Table 3 Terminology and stages .......................................................................... 11 
Table 4 Diagnostic criteria and classification for inflammatory 
myopericardial syndrome ....................................................................................... 13 
Table 5 Histopathological criteria for myocarditis ...................................... 13 
Table 6 Red flags for the clinical diagnosis of myocarditis and 
pericarditis ..................................................................................................................... 16 
Table 7 Clinical risk stratification to guide work-up in inflammatory 
myopericardial syndrome ....................................................................................... 16 
Table 8 Causes of cardiac tamponade .............................................................. 25 
Table 9 Basic and advanced level assessment ................................................ 29 
Table 10 Classification of pericardial effusion ............................................... 31 
Table 11 Parameters for reporting by endomyocardial biopsy ............. 35 
Table 12 Therapy for specific forms of myocarditis .................................. 37 
Table 13 Specific initial dosing and duration of therapy for acute and 
recurrent pericarditis ............................................................................................... 40 
Table 14 Tapering of corticosteroids ............................................................... 40 
Table 15 Follow-up in inflammatory myopericardial syndrome after 
discharge ........................................................................................................................ 47 
Table 16 Indicators of non-viral aetiologies and complications 
(high-risk features or red flags in acute pericarditis) .................................. 48 
Table 17 Echocardiographic signs of cardiac tamponade ..................................... 62 
Table 18 Definitions and therapy of main constrictive pericardial 
syndromes ..................................................................................................................... 63 
Table 19 ‚ÄòWhat to do‚Äô and ‚ÄòWhat not to do‚Äô ............................................... 69  
List of figures 
Figure 1 Central illustration of the ESC guidelines on myocarditis and 
pericarditis ........................................................................................................................ 9 
Figure 2 Paradigm change in the clinical diagnosis of myocarditis ........ 10 
Figure 3 Stages of inflammatory myopericardial syndrome .................... 12 
Figure 4 Diagnostic criteria by cardiovascular magnetic resonance 
based on the updated Lake Louise criteria ..................................................... 14 
Figure 5 Diagnostic algorithm and triage for inpatient myocarditis ..... 17 
Figure 6 Diagnostic algorithm and triage for outpatient myocarditis . 18 
Figure 7 Diagnostic algorithm and triage for pericarditis ......................... 19 
Figure 8 Spectrum of myocarditis presentations and outcomes .......... 20 
Figure 9 Diagnostic algorithm for acute chest pain presentation ......... 21 
Figure 10 Diagnostic algorithm for acute heart failure presentation .. 23 
Figure 11 Diagnostic algorithm for arrhythmia presentation ................. 24 
Figure 12 Management of cardiac tamponade .............................................. 26 
Figure 13 Management of constriction ............................................................. 27 
Figure 14 The different courses of inflammatory myopericardial 
syndrome and the interplay between genetic background 
inflammation and autoimmunity beyond the initial infectious trigger . 31 
Figure 15 Histopathological findings in myocarditis .................................... 34 
Figure 16 Proposed algorithm of medical therapy for pericarditis in 
adults (not including interventional therapies and pericardiectomy) .. 41 
Figure 17 Follow-up and risk stratification after acute myocarditis 
with arrhythmic presentation ............................................................................... 48 
Figure 18 Stages of tuberculous pericarditis .................................................. 57 
Figure 19 Triage and management of pericardial effusion ....................... 61 
Figure 20 Multidisciplinary teams for inflammatory myopericardial 
syndrome ....................................................................................................................... 67  
Abbreviations and acronyms 
ACC 
American College of Cardiology 
ACS 
Acute coronary syndrome  
ESC Guidelines                                                                                                                                                                                                 5


<!-- PAGE 6 -->

### Page 6

ADA 
Adenosine deaminase 
AF 
Atrial fibrillation 
AM 
Acute myocarditis 
AMI 
Acute myocardial infarction 
AP 
Acute pericarditis 
ARVC 
Arrhythmogenic right ventricular cardiomyopathy 
ATG 
Anti-thymocyte globulin 
AVB 
Atrioventricular block 
B19V 
Parvovirus B19 
CAD 
Coronary artery disease 
CD 
Chagas disease 
CI 
Confidence interval 
CK 
Creatinine kinase 
CK-MB 
Creatinine kinase muscle-brain type 
CMP 
Cardiomyopathy 
CMR 
Cardiovascular magnetic resonance 
CMV 
Cytomegalovirus 
COVID-19 
Coronavirus disease 2019 
CP 
Constrictive pericarditis 
CPB 
Cardiopulmonary bypass 
CRT 
Cardiac resynchronization therapy 
CS 
Cardiac sarcoidosis 
CT 
Computed tomography 
CTLA-4 
Cytotoxic T-lymphocyte antigen 4 
CTP 
Cardiac tamponade 
DCM 
Dilated cardiomyopathy 
DNA 
Deoxyribonucleic acid 
DSP 
Desmoplakin 
EAM 
Electro-anatomical mapping 
EBV 
Epstein‚ÄìBarr virus 
ECG 
Electrocardiogram 
ECP 
Effusive‚Äìconstrictive pericarditis 
ECV 
Extracellular volume 
EF 
Ejection fraction 
EGPA 
Eosinophilic granulomatosis with polyangiitis 
EM 
Eosinophilic myocarditis 
EMB 
Endomyocardial biopsy 
ESC 
European Society of Cardiology 
ESR 
Erythrocyte sedimentation rate 
FDG-PET 
Fluorodeoxyglucose positron emission 
tomography 
FM 
Fulminant myocarditis 
FMF 
Familial Mediterranean fever 
GCM 
Giant-cell myocarditis 
GDMT 
Guideline-directed medical therapy 
GLS 
Global longitudinal strain 
HAART 
Highly active antiretroviral therapy 
HCM 
Hypertrophic cardiomyopathy 
HCV 
Hepatitis C virus 
HES 
Hypereosinophilic syndrome 
HF 
Heart failure 
HHV-6 
Human herpesvirus 6 
HIV 
Human immunodeficiency virus 
HR 
Hazard ratio 
hs-TnI 
High-sensitivity troponin I 
hs-TnT 
High-sensitivity troponin T 
HT 
Heart transplantation 
IABP 
Intra-aortic balloon pump 
ICD 
Implantable cardioverter-defibrillator  
ICI 
Immune checkpoint inhibitor 
ICU 
Intensive care unit 
IFN 
Interferon 
IL 
Interleukin 
IL-1RA 
Interleukin-1 receptor antagonist 
IL-1RL1 
IL-1 receptor-like 1 
IMPS 
Inflammatory myopericardial syndrome 
i.v. 
Intravenous 
IVIG 
Intravenous immunoglobulins 
JVP 
Jugular venous pressure 
LA 
Left atrial 
LAG-3 
Lymphocyte activation gene 3 
LC 
Lyme carditis 
LGE 
Late gadolinium enhancement 
LLC 
Lake Louise criteria 
LM 
Lymphocytic myocarditis 
LV 
Left ventricle 
LVAD 
Left ventricular assist device 
LVEF 
Left ventricular ejection fraction 
MACE 
Major adverse cardiac events 
MCS 
Mechanical circulatory support 
miRNAs 
MicroRNAs 
NDLVC 
Non-dilated left ventricular cardiomyopathy 
NLRP3 
NLR family pyrin domain containing 3 
NSAID 
Non-steroidal anti-inflammatory drug 
NSVT 
Non-sustained ventricular tachycardia 
NT-proBNP 
N-terminal prohormone of brain natriuretic 
peptide 
OR 
Odds ratio 
P/LP 
Pathogenic/likely pathogenic 
PaM 
Pregnancy-associated myocarditis 
PCIS 
Post-cardiac injury syndrome 
PCR 
Polymerase chain reaction 
PD-1 
Programmed cell death protein 1 
PD-L1 
Programmed death ligand 1 
PEff 
Pericardial effusion 
PPCM 
Peripartum cardiomyopathy 
PPS 
Post-pericardiotomy syndrome 
PVS 
Programmed ventricular stimulation 
RA 
Rheumatoid arthritis 
RAP 
Right atrial pressure 
RCM 
Restrictive cardiomyopathy 
RCT 
Randomized controlled trial 
RNA 
Ribonucleic acid 
RP 
Recurrent pericarditis 
RV 
Right ventricle 
SARS-CoV-2 
Severe acute respiratory syndrome coronavirus 2 
SCD 
Sudden cardiac death 
SLE 
Systemic lupus erythematosus 
SSc 
Systemic sclerosis 
TB 
Tuberculosis 
TDI 
Tissue Doppler imaging 
TF 
Task Force 
TNF-Œ± 
Tumour necrosis factor alpha 
TRAPS 
Tumour necrosis factor receptor-associated 
periodic syndrome 
TTE 
Transthoracic echocardiography 
uIFN-Œ≥ 
Unstimulated interferon gamma 
VA 
Ventricular arrhythmias


<!-- PAGE 7 -->

### Page 7

VA-ECMO 
Veno-arterial extracorporeal membrane oxygenation 
VAD 
Ventricular assist device 
VF 
Ventricular fibrillation 
VT 
Ventricular tachycardia 
WCD 
Wearable cardioverter-defibrillator 
WMA 
Wall motion abnormalities 
1. Preamble 
Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic 
approach for an individual patient with a given condition. ESC Guidelines 
are intended for use by health professionals but do not override their individual responsibility to make appropriate and accurate decisions in consideration of each patient‚Äôs health condition and in consultation with the 
patient or the patient‚Äôs caregiver where appropriate and/or necessary. It is 
also the health professional‚Äôs responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and to respect the ethical rules of their profession. 
ESC Guidelines represent the official position of the ESC on a given 
topic. Guideline topics are selected for updating after annual expert review of new evidence conducted by the ESC Clinical Practice 
Guidelines (CPG) Committee. ESC Policies and Procedures for formulating and issuing ESC Guidelines can be found on the ESC website 
(https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/ 
Guidelines-development/Writing-ESC-Guidelines). 
This guideline updates and replaces the previous version of the ESC 
Guidelines on pericarditis from 2015. For the first time it also covers 
myocarditis. This Task Force was selected by the ESC to include professionals involved with the medical care of patients with this pathology 
and to include patient representatives and methodologists. The selection procedure included an open call for authors and aimed to include 
members from across the whole of the ESC region and from relevant 
ESC Subspecialty Communities. Consideration was given to diversity 
and inclusion. 
Guidelines Task Forces perform a critical review and evaluation of 
the published literature on diagnostic and therapeutic approaches including assessment of the risk‚Äìbenefit ratio. Recommendations are 
based on major randomized trials and relevant systematic reviews 
and meta-analyses, when available. Systematic literature searches are 
conducted in cases of controversy or uncertainty to ensure that all 
key studies were considered. For recommendations related to diagnosis and prognosis, additional types of evidence are included, such as 
diagnostic accuracy studies and studies focused on the development 
and validation of prognostic models. The strength of each recommendation and the level of evidence supporting it are weighed and scored 
according to predefined criteria as outlined in Tables 1 and 2. 
Patient-reported outcome measures (PROMs) and patient-reported 
experience measures (PREMs) are also evaluated when available as 
the basis for recommendations and/or discussion in these guidelines. 
Evidence tables summarizing key information from relevant studies 
are generated to facilitate the formulation of recommendations, to enhance comprehension of recommendations after publication, and to 
reinforce transparency in the guidelines development process. The tables are published in their own section of ESC Guidelines and reference 
specific recommendation tables. 
After an iterative process of deliberations, a first Task Force vote 
on all recommendations is conducted prior to the initiation of rounds 
of review. A second Task Force vote on all recommendations is conducted after the final round of review and revision. For each vote, the 
Task Force follows ESC voting procedures and all recommendations 
require at least 75% agreement among voting members to be approved. Voting restrictions may be applied based on declarations of 
interests. 
Table 1 Classes of recommendations  
¬©



	




¬Å
	
	
¬ç¬è


¬ê
¬ù





	

¬è

 
¬†	¬ç¬è¬≠
¬è
	
¬Ä¬è


¬ê
	

	¬ç¬è


ESC Guidelines                                                                                                                                                                                                 7


<!-- PAGE 8 -->

### Page 8

The writing and reviewing panels provide declaration of interest 
forms for all relationships that might be perceived as real or potential 
sources of conflicts of interest. Their declarations of interest are reviewed according to the ESC declaration of interest rules, which can 
be found on the ESC website (http://www.escardio.org/doi) and are 
compiled in a report published in a supplementary document with 
the guidelines. Funding for the development of ESC Guidelines is derived entirely from the ESC with no involvement of the healthcare 
industry. 
The CPG Committee supervises and co-ordinates the preparation of 
new guidelines and approves their publication. In addition to review by 
the CPG Committee, ESC Guidelines undergo multiple rounds of 
double-blind peer review on a dedicated online review platform. The 
review is conducted by topic experts, including members from ESC 
National Cardiac Societies and from relevant ESC Subspecialty 
Communities. Guideline Task Forces consider all review comments 
and are required to respond to all those classified as major. After appropriate revisions, the Task Force and the CPG Committee members 
approve the final document for publication in the European Heart 
Journal. 
Unless otherwise stated, ESC Guidelines content refers to sex, 
understood as the biological condition of being male or female, defined 
by genes, hormones and sexual organs. Off-label use of medication may 
be presented in this guideline if a sufficient level of evidence shows that 
it can be considered medically appropriate for a given condition. 
However, decisions on off-label use must be made by the responsible 
health professional giving special consideration to ethical rules concerning healthcare, the specific situation of the patient, patient consent, and 
country-specific health regulations. 
2. Introduction 
Myocarditis and pericarditis are inflammatory diseases of the myocardium and pericardium, respectively, with potential overlap. These are 
the first ESC clinical practice guidelines covering the whole spectrum 
of these diseases. 
Herein, the Task Force (TF) introduces the term ‚Äòinflammatory myopericardial syndrome‚Äô (IMPS). IMPS is an umbrella term during the initial 
diagnostic process until a final diagnosis is made (Figure 1). It reflects the 
possible myocarditis‚Äìpericarditis overlap, aiming to increase the awareness of the spectrum of disease, and to allow timely diagnosis and better 
management. IMPS ranges from isolated myocarditis to isolated pericarditis through mixed forms with possible reciprocal involvement, such as 
myopericarditis and perimyocarditis. Both terms are commonly used in 
the medical literature, and defined in the 2015 ESC Guidelines for the 
diagnosis and management of pericardial diseases (see Section 8).1 
The rationale for the introduction of IMPS is that myocarditis and 
pericarditis have similar aetiologies and are anatomical contiguous 
structures with possible secondary involvement.2‚Äì5 
The field has experienced rapid growth, with position statements 
proposed by different cardiac societies.6‚Äì10 In the past, several consensus statements were provided, usually defining a proven myocarditis 
based on endomyocardial biopsy (EMB). Endomyocardial biopsy is 
able to detect the histological type, can identify some specific aetiologies, and can help to differentiate from non-inflammatory cardiomyopathies (CMPs).10 But nowadays multimodality imaging has become a 
cornerstone for the diagnosis of myocardial and pericardial inflammation and cardiovascular magnetic resonance (CMR) plays a crucial 
role, as reported in other ESC guidelines11‚Äì13 (Figure 2). 
The aim of these guidelines is to provide evidence-based guidance for 
clinical management of IMPS, to guide clinicians of all subspecialties 
from a clinical point of view, and to ensure qualified shared decision- 
making with patients (see Section 13 and Supplementary data online,  
Section 8). 
2.1. What is new 
Guidelines on pericarditis have been published twice before,1,15 while 
myocarditis will be covered for the first time in a guideline. The TF believes that combined guidelines with the recognition of the spectrum of 
disease are a step in a new direction, enabling a paradigm shift towards 
therapy based on the combined input from experts in inflammatory 
diseases of the myocardium and pericardium, with the support of a 
multidisciplinary team. In order to improve the awareness of the spectrum of disease, a new category, ‚Äòinflammatory myopericardial syndrome (IMPS)‚Äô, will be introduced as an umbrella term to increase 
the understanding of the potential myocarditis‚Äìpericarditis overlap.  
Table 2 Levels of evidence  







	
		
	


		
							
					
¬©¬Å¬ç¬è¬ç¬ê


<!-- PAGE 9 -->

### Page 9








	
















	








	



















¬Å¬ç¬Å

	
¬è


¬Å



¬ç

¬è

¬ê¬Å
¬ù

¬ê¬Å¬†
¬†
¬†


¬Å



¬ç¬ç¬è¬Å¬Å¬ê¬ù¬Å¬Å¬è








¬Å¬†
¬Å

¬è
¬≠¬ê¬Å¬Ä
¬è
¬ç
¬ç¬ê
¬≠
¬è¬Å


¬ù
¬Ä
¬≠¬≠¬Ä¬ù¬Ç
¬ù

¬Ç

¬Ä


¬Ä¬Ä



¬Ä¬Ä

¬É
¬ç

¬Å
¬Å¬Ñ
¬Å


¬Å¬ù
¬Å
Figure 1 Central illustration of the ESC guidelines on myocarditis and pericarditis. ECG, electrocardiogram; EMB, endomyocardial biopsy; IMPS, 
inflammatory myopericardial syndrome; SCD, sudden cardiac death; TTE, transthoracic echocardiography.   
ESC Guidelines                                                                                                                                                                                                 9


<!-- PAGE 10 -->

### Page 10

It is introduced as an entering diagnostic term to lead to a tailored work- 
up and individualized therapy. Patient-oriented case management is proposed in different settings such as diagnosis and therapy, as well as return 
to work and play avoiding strict time definitions, since the remission pathway differs from patient to patient. In addition, a novelty in the field of 
IMPS is the improved knowledge on its possible genetic background 
and its link to specific inherited CMPs. Furthermore, a paradigm shift 
will be introduced in its diagnostic management. This is reflecting the 
new capabilities of multimodality imaging, especially CMR, as it has changed clinical workflow during recent years. A similar change was introduced in the American College of Cardiology (ACC) consensus 
statement in 2024.9 Endomyocardial biopsy has its place and is needed 
if specific decisions are warranted. 
In comparison with the last ESC Guidelines for the diagnosis 
and management of pericardial diseases,1 the current understanding 
of the pathogenesis of pericarditis has greatly improved with new evidence on the importance of the interplay between inflammation and 
autoinflammatory mechanisms, the role of genetic background, and 
immune responses in patients with multiple recurrences. The identification of a positive family history, a poor response to colchicine, and 
a clinical presentation with an inflammatory or non-inflammatory 
phenotype are useful tools to guide the selection of patients for genetic testing and specific pharmacological options. A new class of drugs 
targeting interleukin-1 (IL-1), the so-called anti-IL-1 agents, has become available and is used in recurrent cases with a poor response 
to other conventional therapies. Nevertheless, we need to further improve our understanding of the pathogenesis of non-inflammatory disease forms. 
Moreover, diagnostic capabilities have increased, thanks to the role 
of multimodality imaging, allowing improved diagnostic accuracy and 






	


		






	



		

Figure 2 Paradigm change in the clinical diagnosis of myocarditis. CMR, cardiovascular magnetic resonance; EMB, endomyocardial biopsy. Both EMB 
and CMR can provide a definitive clinical diagnosis but with different indications. Details are given in Section 5. 2013 Reference: Caforio et al.10 2021 and 
2023 References: Keren et al., Law et al.6,14


<!-- PAGE 11 -->

### Page 11

individualized duration of therapies according to clinical and imaging 
findings. 
The TF recommends establishing a multidisciplinary IMPS team to 
ensure optimal patient care in complicated cases. 
We firmly believe that recognizing IMPS will enhance the understanding of these inflammatory conditions and hope it will inspire further research to advance personalized diagnostic and therapeutic 
approaches. 
3. Epidemiology, classification, 
stages, diagnostic criteria and 
aetiology 
3.1. Epidemiology 
Population-based studies of the incidence or prevalence of IMPS are 
limited, and most epidemiological studies assess disease burden and 
sequelae in selected patient groups, such as those admitted to hospital. However, such studies might underestimate the true disease 
burden. For example, the rate of patients diagnosed with acute myocarditis (AM) increases from 5% to 13% with the use of CMR among 
patients with angina-like symptoms and increased high-sensitivity 
troponin T (hs-TnT).16 A different registry reported an incidence 
of 6.3‚Äì8.6 per 100 000 inhabitants, mostly in young men.17 The current global burden of cardiovascular disease data reports a prevalence of 4.2‚Äì8.7 per 100 000 in the age range between 35 and 
39 years.18 Men and younger patients are more likely to be diagnosed, although this could reflect the diagnostic bias towards these 
patient groups.19 
In children <2 years of age, the sex distribution is balanced; in adolescents there is a male prevalence (about two-thirds of cases),20,21 
which is also maintained in adult patients, suggesting the importance 
of hormonal factors. 
The incidence of acute pericarditis (AP) is estimated to be about 3‚Äì 
32 cases per 100 000 person-years.22,23 Similar to myocarditis, men and 
younger individuals are more likely to be diagnosed. Recurrence occurs 
in about 20%‚Äì30% of patients within 18 months after a first episode 
of AP.24 The recurrence rate increases up to 50% after the first recurrence.25 Pericarditis is diagnosed in 0.2% of all cardiovascular in-hospital 
admissions and is responsible for 5% of emergency room admissions for 
chest pain.23 In the observational Epid√©miologie de la Douleur 
Thoracique (EPIDOULTHO) study, 3% of patients received a final diagnosis of IMPS.26 
3.2. Classification and stages 
The field of IMPS gained increasing awareness and interest during the 
coronavirus disease 2019 (COVID-19) pandemic.27 Research in the 
field of all forms of IMPS has a long history, and several terminologies 
exist. This is also reflected in the definition of stages. We are proposing 
a terminology from a clinical point of view with the intention of guiding 
the appropriate management of patients (Table 3). In addition, time 
frames for the stages (acute, subacute, and chronic) are suggested to 
be used for myocarditis and pericarditis. However, it is not always possible from a clinical point of view to identify the disease onset, for instance in subacute cases.1 
IMPS is characterized by different stages (see Figure 3). The course of 
the disease differs among patients. A patient may recover completely 
without any residuals, but others may develop complications, in some 
cases leading to death. Patients may not experience every stage. 
Complete remission can occur at every timepoint. However, a deep 
understanding of the respective stages is essential for appropriate 
therapeutic guidance. 
Table 3 Terminology and stages 
Terminology 
Definition  
IMPS 
Umbrella term for inflammatory myocardial 
and pericardial syndromes 
Myopericarditis 
Predominant pericarditisa 
Perimyocarditis 
Predominant myocarditisb 
Acute myocarditis 
Duration of symptoms ‚â§4 weeks 
Fulminant if: 
‚Ä¢ Acute onset28 and haemodynamically 
unstable patients requiring inotropes or 
mechanical circulatory support  
Complicated myocarditis 
AM and ‚â•1 of the following:28 
‚Ä¢ LVEF <50% on echocardiogram 
‚Ä¢ Sustained ventricular arrhythmias 
‚Ä¢ Advanced heart block 
‚Ä¢ Heart failure 
‚Ä¢ Cardiogenic shock 
Acute pericarditis 
Duration of symptoms ‚â§4 weeks 
Subacute/ongoing 
myocarditis 
Duration of symptoms >4 weeks to 
‚â§3 months 
Subacute/incessant 
pericarditisc 
Duration of symptoms >4 weeks to 
‚â§3 months 
Chronic myocarditis/ 
pericarditis 
Duration of symptoms >3 months 
Inflammatory 
cardiomyopathy 
Chronic myocarditis in association with cardiac 
dysfunction and ventricular remodelling with 
clinical phenotype of hypokinetic, either dilated 
or non-dilated cardiomyopathy with/without 
arrhythmogenic substrate 
Recurrent myocarditis/ 
pericarditis 
New symptoms or disease activity after clinical 
remission 
Remission without 
residuals 
Regression/absence of symptoms, 
normalization of ECG, biomarkers, imaging 
abnormalities (echocardiography and CMR) 
Remission with residuals 
Regression/absence of symptoms, persistence 
of abnormalities on ECG, biomarkers and/or 
imaging (functional and/or structural 
abnormalities in echocardiography or CMR) 
¬© ESC 2025
AM, acute myocarditis; CK-MB, creatine kinase muscle-brain type; CMR, cardiovascular 
magnetic resonance; ECG, electrocardiogram; IMPS, inflammatory myopericardial 
syndrome; LVEF, left ventricular ejection fraction. 
aPatients with definite criteria for pericarditis and elevated biomarkers of myocardial injury 
(high-sensitivity troponin I or T, CK-MB fraction) without newly developed regional or 
global impairment of left ventricular function in echocardiography or CMR. 
bPatients with definite criteria for pericarditis and elevated biomarkers of myocardial injury 
(high-sensitivity troponin I or T, CK-MB fraction) with newly developed regional or global 
impairment of left ventricular function in echocardiography or CMR. 
cIncessant/ongoing pericarditis: the term incessant pericarditis describes patients with 
persistent symptoms without a symptom-free interval of >4 weeks despite full-dose 
guideline-directed medical therapy (including corticosteroids), or those relapsing early 
during the tapering.   
ESC Guidelines                                                                                                                                                                                               11


<!-- PAGE 12 -->

### Page 12

3.3. Diagnostic criteria 
After the original proposed diagnostic criteria from the consensus paper 
in 2013,10 multimodality imaging, in particular CMR, has made a clinical, 
non-invasive diagnosis of myocarditis feasible. In accordance with the 
paradigm change (Figure 2), the TF proposes new diagnostic criteria and 
a new classification, following the system introduced in the 2023 ESC 
Guidelines for the management of endocarditis (Table 4).29 This clinically 
driven approach is based on a clinical presentation, with additional supportive findings, and positive CMR or EMB for myocarditis. Histopathological 
criteria and updated CMR Lake Louise criteria (LLC)30 are given in  
Table 5 and Figure 4, respectively. Similarly, diagnosis of pericarditis can 
be made with a clinical presentation, and more than one additional criterion. Cardiovascular magnetic resonance can also provide the non-invasive 
confirmation of the presence of pericarditis beyond clinical criteria. 
3.3.1. Diagnostic criteria for myocarditis 
Myocarditis can be clinically diagnosed as definite/possible with an 
appropriate clinical presentation and additional criterion, including 
CMR-proven or EMB-proven result (see details in Table 4). The additional criteria include common parameters in basic work-up, such as 
an electrocardiogram (ECG), which may show unspecific changes, including the whole spectrum of presentations from mimicking a myocardial infarction with ST elevation in non-coronary distribution, as well as 
rhythm abnormalities, or findings in echocardiography (see Section 5.5). 
Laboratory analysis of serum biomarkers usually shows elevation of 
markers of myocardial lesion, such as hs-TnT or high-sensitivity troponin I (hs-TnI). Biomarkers of heart failure (HF) (such as N-terminal prohormone of brain natriuretic peptide, NT-proBNP) are also needed to 
identify the severity of the disease, and suggest myocardial involvement. 
Depending on the individual case and risk (see Section 4), definitive 
diagnosis of myocarditis can be based on CMR (Figure 4) or EMB 
(Table 5). For EMB analysis quantitative immunohistochemistry criteria 
for inflammatory cells in lymphocytic myocarditis (LM) are under development. Asymptomatic cases may exist, e.g. vaccine- or drug-related 
cases, such as immune checkpoint inhibitor (ICI)-induced myocarditis, 
and are often underdiagnosed. 








	















¬Å

¬ç¬è¬ê




¬ù
¬†
¬≠¬ù
¬ù¬†

¬≠¬ù

¬†
¬Ä¬Ç

¬É¬Ñ
¬Ö¬Ü¬á

¬à


¬â



¬Ç

¬ä¬Ä
¬à
¬Ö

¬è¬è
¬Ü
¬ã
¬Ñ¬å¬é

¬ë¬é
¬ê





Figure 3 Stages of inflammatory myopericardial syndrome. AHA, anti-heart antibodies; AIDA, anti-intercalated disc antibodies.


<!-- PAGE 13 -->

### Page 13

Non-ischaemic myocardial inflammation can be diagnosed by CMR 
according to the updated LLC30 (see Figure 4). This is based on at least 
one T2-based criterion plus ideally one T1-based criterion. Having both 
a positive T2-based criterion and a T1-based criterion will increase specificity for diagnosing AM, but a diagnosis of possible myocarditis can 
still be made by having only one (i.e. T2-based or T1-based) criterion 
in an appropriate clinical scenario, although with less specificity. 
Supportive criteria include pericardial abnormalities (which, however, 
suggest concomitant pericarditis), and global or regional left ventricular 
(LV) systolic dysfunction on cine imaging. 
Table 4 Diagnostic criteria and classification for inflammatory myopericardial syndrome 
IMPS  
If diagnostic criteria for myocarditis and/or pericarditis are fulfilleda  
Myocarditis 
Pericarditis 
Definite 
Clinical presentationb and CMR- or EMB-proven 
Clinical presentationb with >1 additional criterion 
Possible 
Clinical presentationb with at least 1 additional criterion 
CMR- or EMB-uncertain or not available 
Clinical presentationb with 1 additional criterion 
Unlikely/rejected 
Only clinical presentationb without additional criteria 
Only clinical presentationb without additional criteria 
Additional criteria beyond clinical presentationsb  
Myocarditis 
Pericarditis 
Clinicalb 
Non-specific findings 
Pericardial rubs 
ECGc 
ST-T changes 
PR depression, widespread ST-segment elevation 
Biomarkers 
Troponin elevation 
C-reactive protein elevation 
Imagingd 
Abnormal strain, wall motion, reduced EF 
Myocardial oedema and/or LGE (CMR findings) 
New or worsening pericardial effusion 
Pericardial oedema and/or LGE (CMR findings) 
¬© ESC 2025
CMR, cardiovascular magnetic resonance; ECG, electrocardiogram; EF, ejection fraction; EMB, endomyocardial biopsy; IMPS, inflammatory myopericardial syndrome; LGE, late gadolinium 
enhancement; LLC, Lake Louise criteria. 
Clinical presentations include chest pain or infarct-like symptoms, arrhythmias, heart failure, aborted sudden cardiac death. 
Cardiovascular magnetic resonance categories: proven = 2 out of 2 updated LLC fulfilled (Figure 4); uncertain = only 1 out of 2 updated LLC fulfilled; rejected = negative CMR. 
EMB categories: proven, uncertain, rejected (according to pathologist consensus). 
aOne condition may be leading (see Section 8). 
bSee detailed description of clinical presentation in Section 4; rarely asymptomatic cases may be detected (e.g. drug-related with a distinct history, such as immune checkpoint inhibitors). 
cIf ECG changes always consider/exclude myocarditis. 
dSee additional Sections 5.4‚Äì5.7 for detailed description of imaging findings.  
Table 5 Histopathological criteria for myocarditis 
Term 
Predominant inflammatory cells 
Myocyte necrosis 
Infections 
PCR positive (viruses, etc.)  
Active lymphocytic myocarditis 
CD3+ T lymphocytes 
>7/mm2, 
CD68+ macrophages 
yes 
yes/no 
Persistent lymphocytic myocarditis 
CD3+ T lymphocytes 
>7/mm2, CD68+ macrophages 
yes 
yes/no 
Resolved lymphocytic myocarditis 
‚Äì 
no 
yes/no 
Eosinophilic myocarditis (acute stage) 
Eosinophils, CD3+ T lymphocytes, 
CD68+ macrophages 
yes 
yes/no 
Giant-cell myocarditis (acute stage) 
Eosinophils, 
CD68+ giant cells, CD3+ T lymphocytes, 
CD68+ macrophages 
yes 
no 
Sarcoidosis 
CD68+ giant cells, granuloma, 
CD3+ T lymphocytes, 
CD68+ macrophages 
yes/no 
no 
¬© ESC 2025
PCR, polymerase chain reaction.   
ESC Guidelines                                                                                                                                                                                               13


<!-- PAGE 14 -->

### Page 14






	






	


		












¬Å¬ç

¬Å¬ç

¬ç

¬è
¬Å¬ê

¬ù

¬†¬Å

		¬Å
¬ç



¬è	¬ê¬ù¬ê
¬ç

¬†¬≠
¬Ä¬≠¬Ç

¬†¬Ä
	¬ç¬Å
	
		¬Å
¬ç

¬É	¬ç¬ç
		
¬†¬Ä
	¬ç
¬Å	
¬†¬Ä
		
		¬Å
¬ç
¬Ñ	
¬è	¬ê¬ê
¬ù¬ê¬ç
¬Ñ	¬ç	
¬≠¬Ç
	
	¬Ä
¬Ä¬ç	
¬Ñ
		¬Ö

¬è	¬ê
	¬ê
¬ù¬ç
¬Ü	
¬Å
¬ç
¬Ü	
¬É¬ç
¬Ü	
¬†
¬Ä	
¬ç¬á¬á
¬à¬ê¬†¬à
	
¬≠¬Ä
¬ç
¬ç¬â
¬≠¬Ä
¬Å¬ç
¬ç¬â
	
¬ä¬Å

¬†¬Å
	
	
¬Å¬ã¬Å
¬å¬Ä

¬è¬Ä	
¬≠¬Å	¬Å	¬ç
¬å¬Ä¬ê
¬Ñ
¬Ç¬É¬Ñ¬É¬Å¬Ö¬É¬É¬Ü

Figure 4 Diagnostic criteria by cardiovascular magnetic resonance based on the updated Lake Louise criteria. CMR, cardiovascular magnetic resonance; ECV, extracellular volume; LGE, late gadolinium enhancement; LLC, Lake Louise criteria; LV, left ventricle; LVEF, left ventricular ejection fraction; 
RVEF, right ventricular ejection fraction; SI, signal intensity ratio.30 Presence of pericardial effusion suggests concomitant pericarditis.


<!-- PAGE 15 -->

### Page 15

Histopathological Dallas criteria,31 in addition to immunohistological 
staining to detect CD3+ T cells and CD68+ macrophages, are required 
to identify specific histological subtypes of myocarditis and to differentiate from phenocopies [e.g. arrhythmogenic right ventricular cardiomyopathy (ARVC)].32,33 New quantitative criteria are presently 
required, since the ESC criteria of ‚â•14 leucocytes/mm2 including 
‚â•7 CD3+ T cells/mm2 have been questioned by cardiopathologists.10 
In addition, molecular analysis of EMB and blood [including assessment 
of viral deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in peripheral leucocytes and in plasma] using quantitative polymerase chain 
reaction (PCR) is necessary to identify the aetiopathogenesis of myocarditis and allow targeted therapies (antiviral or immunosuppressive/ 
immunomodulatory), if clinically useful.10,32,34 Examples are given in 
Section 5.9.1. 
3.3.2. Diagnostic criteria for pericarditis 
Pericarditis is an inflammatory pericardial syndrome with or without 
pericardial effusion (PEff). The definite clinical diagnosis can be made 
with a clinical presentation and more than one additional criterion 
(Table 4). The main presenting symptom is usually chest pain 
(85%‚Äì90% of cases), which is typically sharp and pleuritic, improves 
by sitting up and leaning forward, and is exacerbated by inspiration, 
lying down, and deglutition, due to increased attrition between inflamed pericardial layers. Dyspnoea can be reported by the elderly, 
or right HF signs and symptoms in the case of pericarditis with constriction. Arrhythmic presentations are rare and are usually associated with atrial fibrillation (AF). Additional criteria include a 
pericardial friction rub (‚â§33% of cases), which is a superficial scratchy 
or squeaking sound, caused by friction between the two inflamed 
pericardial layers. Electrocardiogram changes have been historically 
reported as a typical hallmark of AP; however, the pericardium is 
electrically silent, so ECG changes imply concomitant inflammation 
of the myocardium, warranting investigation for concurrent myocarditis.35 On imaging, new or worsening PEff (up to 60% of cases), 
which is generally mild, might be detected. As pericarditis classically 
manifests with an inflammatory syndrome, elevated laboratory markers of inflammation, such as C-reactive protein (79%‚Äì90%),36 
erythrocyte sedimentation rate (ESR), and neutrophilic leucocytosis,37,38 can provide additional supportive criteria. The inflamed 
pericardium is neovascularized and contrast-enhanced on computed 
tomography (CT) and CMR. Cardiovascular magnetic resonance is 
superior for tissue characterization and can reveal pericardial oedema and/or pericardial late gadolinium enhancement (LGE), providing additional imaging criteria for the diagnosis. 
3.4. Aetiology of myocarditis and 
pericarditis 
Myocardial and pericardial diseases share mostly similar aetiologies (see  
Supplementary data online, Table S1). The aetiology of IMPS can be either infectious or non-infectious. These can trigger IMPS in a genetically 
predisposed individual by inflammatory/autoimmune mechanisms. 
However, the prevalence of each aetiology and the impact of the causative agent on the clinical course, prognosis, and therapeutic approach 
may differ between the two entities.1,10 
3.4.1. Aetiology of myocarditis 
The most common infectious aetiology is presumed to be viral.10,39,40 
Enteroviruses, adenoviruses, parvovirus B19 (B19V) and some 
herpesviruses [Epstein‚ÄìBarr virus (EBV), human herpesvirus 6 (HHV-6)], 
as well as influenza and coronaviruses, are the most common viruses 
associated with myocarditis (Supplementary data online, Table S1). 
Non-cytotoxic viruses trigger myocarditis indirectly by activating the immune system.41,42 Bacterial infection with Borrelia species [Lyme carditis 
(LC)] and parasitic infections, such as Trypanosoma cruzi [Chagas disease 
(CD)], are additional important aetiologies in specific regions of the globe. 
However, several non-infectious aetiologies should be recognized, 
including systemic diseases, autoimmune (or likely autoimmune) disorders [systemic lupus erythematosus (SLE), systemic sclerosis (SSc), 
rheumatoid arthritis (RA), eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES)], immune-mediated 
forms [such as LM, giant-cell myocarditis (GCM), eosinophilic myocarditis (EM), and cardiac sarcoidosis (CS)], inflammatory bowel disorders, drugs and toxic reactions (including ICI-associated myocarditis, 
see Section 9.6.1.1) and chest radiation, as well as genetic conditions 
such as inherited CMP (see Section 5.3);10,39 see Supplementary data 
online, Table S1.10 
3.4.2. Aetiology of pericarditis 
The aetiology largely depends on the epidemiological background, 
patient population, and clinical setting.1,10 Idiopathic or viral pericarditis is the most frequent aetiology in developed countries, 
ranging from 50% in inpatient settings to >80% in outpatient 
settings.43‚Äì48 Tuberculosis (TB) is responsible for about 70% of 
all cases, especially in human immunodeficiency (HIV)-infected patients, in regions where the disease is endemic. An increasing number of cases are related to interventional procedures and surgery 
[post-cardiac injury syndrome (PCIS)] due to the increased number 
of procedures performed and the ageing population.49 Other common causes include systemic inflammatory/autoimmune diseases 
and cancer (especially lung and breast cancer or lymphomas and 
leukaemia) (see Supplementary data online, Table S1).1 
About 5%‚Äì15% of patients with recurrence have genetic mutations, 
sometimes related to a monogenic autoinflammatory disease, mainly familial Mediterranean fever (FMF) and tumour necrosis factor receptor- 
associated periodic syndrome (TRAPS).50,51 A genetic predisposition 
and an autoinflammatory/immune-mediated pathogenesis are also suspected in patients with multiple recurrences. For additional information 
see Supplementary data online, Tables S2 and S3.50‚Äì52 
4. Clinical presentation of 
inflammatory myopericardial 
syndrome 
The term IMPS includes a spectrum of inflammatory diseases from 
isolated myocarditis to isolated pericarditis through a combination 
of both. IMPS should be used as an umbrella term during the initial 
diagnostic work-up until the final diagnosis is made. One of the major challenges for the diagnosis of IMPS is recognition itself, therefore the TF highlighted red flags (Table 6). These symptoms and 
signs should suggest IMPS. The red flags for IMPS are mainly clinical 
signs, accompanied by serological and/or imaging biomarkers, and 
are not equivalent to the risk. Red flags for IMPS are warning signs, 
aiming to raise the awareness of the disease. If there is a suspicion 
of IMPS, staging based on the risk assessment should be performed 
(Table 7).  
ESC Guidelines                                                                                                                                                                                               15


<!-- PAGE 16 -->

### Page 16

A fast and reliable diagnosis is crucial for proper management. The initial step involves triaging patients by assessing their risk factors and ruling 
out acute coronary syndrome (ACS), whenever indicated by the patient‚Äôs characteristics and clinical presentation. In addition, myocarditis 
warrants consideration whether the first contact was inpatient or 
outpatient.53,54 This approach is based on the different national 
healthcare systems, given that a patient may be first seen in an outpatient or inpatient setting (Figures 5‚Äì7). 
Table 7 Clinical risk stratification to guide work-up in inflammatory myopericardial syndrome 
Risk 
High risk 
Intermediate risk 
Low risk  
Myocarditis 
‚Ä¢ Acute HF/cardiogenic shock 
‚Ä¢ Dyspnoea NYHA III‚ÄìIV refractory 
to medical therapy 
‚Ä¢ Cardiac arrest/syncopea 
‚Ä¢ Ventricular fibrillation/sustained 
ventricular tachycardiaa 
‚Ä¢ High-level AV blocka 
‚Ä¢ New/progressive dyspnoea 
‚Ä¢ Non-sustained ventricular arrhythmias 
‚Ä¢ Persistent release or relapsing troponin 
Stable symptoms or oligosymptomatic  
Imaging criteria: 
Imaging criteria: 
Imaging criteria:  
‚Ä¢ Newly reduced LVEF (<40%)a 
‚Ä¢ Extensive LGE on CMRa 
‚Ä¢ Newly mildly reduced LVEF (41%‚Äì49%) 
and/or WMA 
‚Ä¢ Preserved LVEF (‚â•50%) and  
LGE ‚â•2 segments on CMR 
‚Ä¢ Preserved LVEF (‚â•50%) without LGE or limited 
LGE (<2 segments) on CMR 
Pericarditis 
‚Ä¢ Signs and symptoms of cardiac 
tamponade 
‚Ä¢ Fever (temperature >38¬∞C) 
‚Ä¢ Effusive‚Äìconstrictive pericarditis 
‚Ä¢ Failure of NSAID therapy 
‚Ä¢ Incessant pericarditis 
‚Ä¢ Signs and symptoms of right HF 
‚Ä¢ Response to adequate therapy within 1‚Äì2 weeks  
Imaging criteria: 
Imaging criteria: 
Imaging criteria:  
‚Ä¢ Large PEff (>20 mm end-diastole) 
‚Ä¢ Cardiac tamponade 
‚Ä¢ Extensive pericardial LGE on CMR 
‚Ä¢ Moderate‚Äìlarge PEff  
(10‚Äì20 mm end-diastole) 
‚Ä¢ Constrictive physiology regardless of the 
size of the effusion 
‚Ä¢ Absence or mild PEff 
‚Ä¢ Absence of pericardial LGE on CMR 
¬© ESC 2025
AV, atrioventricular; CMR, cardiovascular magnetic resonance; HF, heart failure; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; NSAID, non-steroidal 
anti-inflammatory drug; NYHA, New York Heart Association classification; PEff, pericardial effusion; WMA, wall motion abnormalities. 
aThese criteria do not lead directly towards endomyocardial biopsy; in these scenarios it is a case-by-case decision depending on the suspected underlying cause.  
Table 6 Red flags for the clinical diagnosis of myocarditis and pericarditis 
Myocarditis 
Pericarditis  
Recent or concomitant flu-like syndrome or gastroenteritis 
Infarct-like chest pain 
Palpitations 
HF symptoms 
ECG changesa 
Ventricular arrhythmias (isolated, complex) 
Syncope 
Haemodynamic instability 
Elevated markers of myocardial lesion (hs-Tn, CK-MB elevation) 
Elevated markers of HF (NT-proBNP) 
Abnormal wall motion, increased wall thickness and/or impaired systolic function 
on imaging 
CMR imaging with myocardial oedema and/or LGE 
Recent or concomitant flu-like syndrome or gastroenteritis 
Pleuritic/infarct-like chest pain 
Right HF symptoms and signs of constriction 
Fever 
Pericardial rubs 
C-reactive protein elevation 
Pericardial effusion 
Pleural effusion 
Polyserositis 
CMR imaging with pericardial oedema and/or LGE 
¬© ESC 2025
CK-MB, creatinine kinase muscle-brain type; CMR, cardiovascular magnetic resonance; ECG, electrocardiogram; HF, heart failure; hs-Tn; high-sensitivity troponin; LGE, late gadolinium 
enhancement; NT-proBNP, N-terminal prohormone of brain natriuretic peptide. 
aSee Section 5.1.


<!-- PAGE 17 -->

### Page 17

Obstructive CADc
Treat CAD
High-risk clinical featuresd
Stay on ward/ICU
Establish HF/AA therapy and/or treatment of speciÔ¨Åc aetiology
Outpatient follow-up
Patient with symptoms and signsa of myocarditis presenting to the emergency room
First-line assessment with history, physical examination, ECG,
transthoracic echocardiography, chest X-ray, laboratory assessmentb 
(Class I)
Low risk
Intermediate risk
Stay on ward and discharge when possible
(Class I)
Cardiovascular magnetic 
resonancee
(Class I)
Endomyocardial biopsyf
(Class I)
Admit to ward/ICU
(Class I)
Cardiovascular magnetic resonance
(if not done before) 
Improvement
Multidisciplinary
IMPS team discussion
Discharge if possible
Diagnosis
Complete risk classiÔ¨Åcationd
Further work-up
Further assessmentg
Possible
Rejected/unlikely
DeÔ¨Ånitive
High risk
Figure 5 Diagnostic algorithm and triage for inpatient myocarditis. AA, anti-arrhythmic therapy; CAD, coronary artery disease; CRP, C-reactive protein; ECG, electrocardiogram; HF, heart failure; ICU, intensive care unit; IMPS, inflammatory myopericardial syndrome; N, no; NT-proBNP, N-terminal 
prohormone of brain natriuretic peptide; Y, yes. aSee Table 6. bLaboratory testing including troponin, NT-proBNP, C-reactive protein, differential blood 
count. cInvasive coronary angiography or computed tomography angiography depending on clinical likelihood/probability. dSee Table 7. eConsider endomyocardial biopsy. fConsider cardiovascular magnetic resonance. gSee Table 9.   
ESC Guidelines                                                                                                                                                                                               17


<!-- PAGE 18 -->

### Page 18

Elevated troponin
Admit to ward
(Class I)
See inpatient algorithmc
Outpatient follow-up
Patient with symptoms and signsa of myocarditis presenting to the outpatient clinic
First-line assessment with history, physical examination, ECG, transthoracic echocardiography,
laboratory assessmentb
(Class I)
Outpatient treatment
Cardiovascular magnetic resonancee
(Class I)
Refer to hospital
Obstructive CADd
Treat CAD
See inpatient algorithmc
Low risk
Diagnosis
Complete risk classiÔ¨Åcationg
Further work-up
Further assessmentf
Possible
Rejected/unlikely
DeÔ¨Ånitive
Intermediate risk
High risk
Figure 6 Diagnostic algorithm and triage for outpatient myocarditis. CAD, coronary artery disease; CRP, C-reactive protein; ECG, electrocardiogram; N, no; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; Y, yes. aSee Table 6. bLaboratory testing including troponin, 
NT-proBNP, C-reactive protein, differential blood count. cSee Figure 5. dInvasive coronary angiography or computed tomography angiography depending on clinical likelihood/probability. eDepending on clinical situation (heart failure, arrhythmias) admit to ward. fSee Table 9. gSee Table 7.


<!-- PAGE 19 -->

### Page 19

4.1. General symptoms and signs 
The most common symptom of myocarditis and pericarditis is chest 
pain (sometimes with infarct-like features, especially for myocarditis, 
or pleuritic with respiratory changes, especially for pericarditis). 
Other common presentations include dyspnoea (myocarditis with HF 
presentation, but it is also the most common symptom in the elderly 
with pericarditis) and/or arrhythmias of different degrees (mainly ventricular for myocarditis and supraventricular and AF for pericarditis) 
and, less frequently, syncope. Flow charts are provided for each type 
to guide the diagnostic pathway (see Section 4.3). 
Some patients may present with persistent symptoms without remission and are labelled as patients with incessant/ongoing IMPS. 
4.2. Clinical stages of myocarditis 
4.2.1. Acute myocarditis 
Acute onset is defined as symptoms and signs lasting ‚â§4 weeks.28 In myocarditis, this entails AM and the subtype fulminant myocarditis (FM). 
The presentation of AM can vary from very mild symptoms 
to a life-threatening condition.10 The typical symptoms and signs at 
presentation include chest pain in >80% of cases, and dyspnoea in 
20%‚Äì50%, while fatigue, palpitations, and syncope are less common 
and are reported in about 5%.28,32,55 In the majority of cases (80%), 
symptoms are preceded by prodromes, such as fever (60%), gastrointestinal complaints (30%), or respiratory symptoms (25%).28,55,56 
Other extracardiac symptoms, depending on the underlying disease, 
can be present. Electrocardiogram is normal in a minority of patients 
(about 15%); most frequently, ST-segment elevation is present 
(57.5%), but other ST/T-segment changes can be found (23.5%), as 
well as conduction blocks (10%).28,55 
In most patients with acute presentation, cardiac enzymes [troponin 
T/I and creatinine kinase muscle-brain type (CK-MB)] are elevated.28,55 
Echocardiography is important for clinical evaluation as it might reveal 
signs of myocarditis, including increased wall thickness and echogenicity 
due to myocardial oedema. PEff is seen in up to 25% of patients, reflecting concomitant pericarditis or related to haemodynamic factors.28,55 
Outpatient follow-up
Response to therapy after 1‚àí2 week
Admission or close follow-up and aetiology search.
Patient with symptoms and signs of pericarditisa
First-line assessment with history, physical examination,
ECG, transthoracic echocardiography,
X-ray, routine blood test including CRP and troponin
(Class I)
High-risk featuresb
Low risk
Intermediate risk
High risk
Outpatient treatment
Admission,
aetiology search and anti-inÔ¨Çammatory therapy
Risk evaluationb
Figure 7 Diagnostic algorithm and triage for pericarditis. CRP, C-reactive protein; ECG, electrocardiogram; N, no; Y, yes. asee Table 6. bIf a patient has 
one or more prognostic predictors, as reported in Table 7, a high-risk patient must be admitted to hospital, and an aetiology search should be performed. Patients without high-risk features can be managed as outpatients without an aetiology search and admission if there is a good response to 
empirical anti-inflammatory therapy.   
ESC Guidelines                                                                                                                                                                                               19


<!-- PAGE 20 -->

### Page 20

4.2.2. Fulminant myocarditis 
Fulminant myocarditis (occurring in 3%‚Äì9%) is characterized by cardiogenic shock at presentation for which haemodynamic support is 
needed.28 Isolated right ventricle (RV) dysfunction is uncommon; however, biventricular failure occurs frequently in FM. Sustained ventricular 
arrhythmias (VA) may also occur in these patients (46.9%) and some 
present with sudden cardiac death (SCD) (25.8%).28,56,57 
In the majority of children with FM (usually <2 years of age), LV dysfunction with dilatation is present at initial presentation,40 while there is 
usually no LV dilatation in the early phase for adults. Concurrent viral 
infections can be common in these children. 
4.2.3. Subacute myocarditis 
The subacute stage refers to cases with symptoms lasting >1 month 
but ‚â§3 months. The symptoms are unspecific, and patients might either 
have a remission without residuals or might progress to chronic myocarditis or inflammatory CMP (see Section 10). 
4.2.4. Chronic myocarditis 
Chronic myocarditis is myocarditis persisting beyond 3 months.39 
Chronic myocarditis might reflect an intermediate stage possibly leading to inflammatory CMP, characterized by cardiac remodelling and 
some degree of ventricular dysfunction.10,39 
Milder forms may appear as hypokinetic non-dilated forms of CMP.39 
Moreover, an arrhythmogenic substrate, due to fibrosis, should be considered for the management of these patients.39,58 
Symptoms may be unremarkable in chronic myocarditis.10,39 
Dyspnoea and palpitations might be the leading symptoms.10,39 
Biomarkers of myocardial injury are usually within normal limits.59 
Notably, elevated C-reactive protein, hs-TnT, and impaired global longitudinal strain (GLS) have been associated with EMB-proven 
myocardial inflammation in patients with non-ischaemic HF.60 New 
quantitative CMR techniques have improved the diagnostic yield in patients with chronic myocarditis.61 
4.3. Clinical presentations of myocarditis 
Myocarditis is characterized by the heterogeneity of clinical manifestations (Figure 8); therefore, the diagnosis requires a high level of suspicion. The main patterns of clinical presentation are infarct-like chest 
pain (most frequent symptom), arrhythmias, and HF. Severity may 
range from asymptomatic/oligosymptomatic to severe life-threatening 
scenarios, such as severe HF or VA (potentially leading to SCD). A clinical classification based on presentation as high-risk or non-high-risk 
myocarditis (see Table 7) has been shown to meaningfully predict outcomes in large cohorts.28,62,63 Moreover, myocarditis, especially when 
recurrent, may represent the ‚Äòhot phase‚Äô of some CMPs [e.g. desmoplakin (DSP)-related ARVC].64 Details are given in Section 4.3.5. 
4.3.1. Chest pain presentation 
Chest pain is the most common form of clinical presentation (about 75% 
of unselected cases) in adolescents and adults.28 It is commonly associated 
with an increase in necrosis biomarkers, such as troponin, often with ECG 
alterations (especially ST-segment elevation), which may mimic ACS, despite the absence of significant obstructive coronary artery disease (CAD). 
These cases are often labelled as infarct-like.65 Patients with this presentation usually report a recent or concomitant viral infection, such as a respiratory tract infection or gastroenteritis, which often precedes 
myocarditis by several days to weeks (2‚Äì4 weeks). Usually, the presence 
of troponin release in the context of IMPS is not a negative prognostic 
marker, when associated with preserved biventricular function.4,66 
Patients presenting with chest pain and normal left ventricular ejection 
fraction (LVEF) without wall motion abnormalities (WMA), no VA, 
and complete resolution of ECG abnormalities in the short term can  





	






	



	



Figure 8 Spectrum of myocarditis presentations and outcomes. LGE, late gadolinium enhancement; SCD, sudden cardiac death. Image size correlates 
with presentation frequency (e.g. chest pain being the most common). Uncomplicated cases of myocarditis (about 75% of unselected cases) usually have 
spontaneous remission.28 In acute myocarditis diagnosed by endomyocardial biopsy, up to 50% of patients have spontaneous recovery, but up to 25% 
may have a persistent stable cardiac dysfunction, while 10%‚Äì25% have a progressive ventricular dysfunction, which could lead to end-stage dilated cardiomyopathy, heart transplantation, or death.9


<!-- PAGE 21 -->

### Page 21

be considered as having a low-risk presentation with an excellent long- 
term prognosis.4,28,62,66,67 There are possible exceptions to this general 
rule in a few cases with EM and GCM. Myocardial scarring as detected 
by CMR can be present in cases with preserved LVEF.3,68‚Äì70 Focal scarring 
of any cause was shown to be relevant for outcome, and small scars (e.g. 
<2 segments) after >6 months seemed to be more benign.71 
Nevertheless, long-term outcome data are missing. For a proposed workflow see Figure 9. 
Patient with acute chest pain
Clinical history and vital signs, 12-lead ECG, laboratory testinga, transthoracic echocardiography
(Class I)
CT angiography
(Class I)
DeÔ¨Ånite myocarditis
Suggestive of non cardiac causes or cardiomyopathies
Treat according to 
ACS GLc
Risk stratiÔ¨Åcationd
Further 
aetiological work-up
Endomyocardial biopsy
(Class I)
Cardiovascular magnetic resonanceg
(Class I)
Further aetiological work-up requiredh
No further work-up
Further work-upi
Red Ô¨Çags for IMPSb
Aetiological work-up
Coronary artery disease
Normal Ô¨Åndings
No further work-up
Invasive coronary angiography
(Class I)
Diagnostic criteria suggestive of myocarditis
Diagnostic criteria suggestive of pericarditis
Go to pericarditis algorithme
Clinical likelihood/probability of obstructive coronary artery disease
Clinical exclusion
Moderate
Low
High riskf
Non-high risk
If CAD not the sole explanation for the
 symptoms
Before discharge
High
Figure 9 Diagnostic algorithm for acute chest pain presentation. ACS, acute coronary syndrome; CAD, coronary artery disease; CRP, C-reactive 
protein; CT, computed tomography; ECG, electrocardiogram; GL, guideline; IMPS, inflammatory myopericardial syndrome; N, no; NT-proBNP, 
N-terminal prohormone of brain natriuretic peptide; Y, yes. aLaboratory testing including troponin, NT-proBNP, C-reactive protein, differential blood 
count. bSee Table 6. cReference: Byrne et al.72 dSee Table 7. eSee Figure 7. fConsider cardiovascular magnetic resonance. gConsider endomyocardial 
biopsy on a case-by-case basis. hDepending on the underlying cause and clinical need. iSee Sections 5, 8, 9, 10.   
ESC Guidelines                                                                                                                                                                                               21


<!-- PAGE 22 -->

### Page 22

4.3.2. Heart failure presentation 
Patients with myocarditis presenting with acute HF, in particular when 
associated with left ventricular dysfunction (LVEF ‚â§ 40%), should be 
considered as a high-risk group, and their prognosis largely depends 
on the short-term response to therapy.28,62 Clinical presentation 
may range from unexplained impaired ventricular function (with or 
without dilated LV), new onset or worsening HF (usually over 
2 weeks to 3 months), to rapidly progressive refractory HF and cardiogenic shock. Fulminant myocarditis presenting with HF has a higher 
rate of cardiac death and heart transplantation (HT) both in the short 
and long term, compared with patients with LV dysfunction without 
FM (see Section 4.2.2).56,73,74 In these scenarios, GCM and EM are independently associated with increased mortality.56,75 An algorithm 
for the proposed workflow is shown in Figure 10. As a central scheme, 
the workflow follows the CHAMPIT approach, provided in the 2021 
ESC Guidelines for the diagnosis and treatment of acute and chronic 
heart failure.12 One should be aware that arrhythmias can be a presentation of myocarditis, as well as an ‚Äòalternative cause‚Äô of HF outside 
the suspicion of myocarditis. 
4.3.3. Presentation with arrhythmias 
Patients with AM with new, recurrent, or unexplained arrhythmias 
may have a wide spectrum of symptoms, ranging from palpitations 
to syncope or life-threatening arrhythmias causing aborted 
SCD.10,76 Supraventricular arrhythmias, especially AF,63,77 are 
more common in the presence of concomitant pericarditis and 
PEff, while atrioventricular blocks (AVBs) or sustained VA are generally, but not exclusively, associated with LV dysfunction and HF. 
Patients with advanced AVB or sustained VA should be considered 
as high risk, even in the absence of LV dysfunction. Ventricular fibrillation (VF)/cardiac arrest occurs in about 2.5% of myocarditis-related 
hospitalizations.78 Patients with sustained VA during AM have a high 
risk of recurrence.79 
Patients with GCM (see Section 9.3) or CS (see Section 9.4) are at a 
high risk of VA, with a prevalence of >25%.80‚Äì82 
Scar-related VA can occur at any time during follow-up, even after 
inflammation resolution. However, polymorphic and irregular VA are 
more common during the active inflammatory phase, whereas monomorphic and regular VA are associated with healed myocarditis with residuals.83 Consistently, catheter ablation of ventricular tachycardia (VT) 
is more effective when performed in the post-inflammatory stage of the 
disease rather than during AM.84 
AVB is a common feature of myocarditis related to non-viral infections (i.e. CD, LC, diphtheria),85 and can also be an initial presentation 
of CS. In patients with arrhythmic presentation, genetic testing for CMP 
[ARVC/dilated CMP (DCM)/non-dilated left ventricular CMP 
(NDLVC)] should be considered (see Section 5.3). 
An algorithm for the proposed workflow is shown in Figure 11. 
4.3.4. Sudden cardiac death 
One of the causes of SCD in young adults is myocardial inflammation associated with fatal arrhythmias. Sudden cardiac death attributed to myocarditis among autopsied patients ranged from 1.1% to 
12%,87,88 and males show higher incidence rates of SCD than females, with an incidence rate ratio of 2.2.88 Most individuals are 
asymptomatic before SCD; however, between 18% and 48% of 
patients present with symptoms, including viral illness/malaise, syncope, nausea/abdominal pain, chest pain, and palpitations.87,88 Only 
5% show cardiac symptoms in conjunction with an infective process.87 These data highlight the need to suspect a diagnosis of myocarditis early enough. Late gadolinium enhancement in the mid-wall 
layer of the anteroseptal myocardial segments has been associated 
with higher rates of mortality and major VA, including SCD,3,89,90 
even in the presence of preserved LVEF. Septal involvement in myocarditis can be associated with a worse prognosis in the presence of 
a specific genetic background, such as pathogenic desmosomal gene 
variants (see Section 5.3).91,92 Further studies are necessary to confirm these data. 
4.3.5. Presentation of myocarditis with a potential 
genetic background 
A complex interaction between genetic background and inflammation 
might be responsible for the heterogeneity of the clinical presentation 
of myocarditis. An inflammatory stimulus of the heart might unveil an 
increased genetic susceptibility to develop overt LV dysfunction or arrhythmogenic phenotypes. In this setting it is important to consider 
additional features, such as a family history of myocarditis/pericarditis, 
CMP, or SCD. Autosomal dominant gene defects may be associated 
with myocarditis.93‚Äì95 Certain autosomal recessive defects in genes encoding various components of the cardiac structure can predispose 
young individuals to myocarditis.95,96 
Different studies reported that patients with myocarditis and evidence of pathogenic/likely pathogenic (P/LP) desmosomal gene variants (mostly with DSP variants) have a higher incidence of adverse 
cardiovascular events, especially myocarditis recurrence and VA, 
than patients without.91,94 Episodes of acute chest pain with troponin 
elevation and normal coronary arteries may occur in about 15% of 
patients with DSP mutations and are associated with LV LGE in about 
90% of cases.97 Specific genetic P/LP variants may increase the susceptibility to superimposed myocarditis in ARVC, which may be 
the first clinical presentation in the natural history of the disease.64,98 
The presence of so-called ‚Äòhot phases‚Äô (chest pain episodes accompanied by ECG changes and troponin release) represents a possible 
clinical presentation of ARVC, which often occurs in paediatric and 
young patients, as well as carriers of DSP genetic variants.99‚Äì101 
Currently, the role of ‚Äòhot phases‚Äô in disease progression, as well as 
in arrhythmic risk stratification, remains to be clarified. For more details see Section 5.3. 
4.4. Clinical stages of pericarditis 
4.4.1. Acute pericarditis 
Acute pericarditis is an inflammatory pericardial syndrome with or without 
PEff with an onset of ‚â§4 weeks. The clinical diagnosis is usually characterized by pleuritic and/or positional chest pain (>80% of cases). Dyspnoea is 
more common in the elderly.45,102 Physical examination may be characterized by pericardial friction rubs in up to one-third of cases, which could disappear with the presence of PEff. Pericardial effusion has been reported in 
up to 60% of cases, and it is usually mild. ECG changes, especially PR 
depression as an early sign and widespread ST-segment elevations, 
have been reported in up to 60% of cases, especially in young patients. 
This is suggestive of concomitant myocardial involvement, at least of 
mild degree.


<!-- PAGE 23 -->

### Page 23

Patient with signs and symptoms of acute heart failure
Clinical history and vital signs, 12-lead ECG, laboratory testinga, transthoracic echocardiography
(Class I)
Cardiogenic shock and/or respiratory failure
Admission to ICU 
acute Coronary syndrome
Hypertensive emergency
Arrhythmia
Mechanical
Pulmonary embolism
Infections 
Tamponade
Further 
work-up
Congestion/apparent HF
HF treatment
(Class I)
Red Ô¨Çags for myocarditisb
Suspected fulminant myocarditis
DeÔ¨Ånite myocarditis
Suggestive of non cardiac causes 
or cardiomyopathies
Endomyocardial 
biopsy
(Class I)
Cardiovascular magnetic 
resonancee
(Class I)
Further aetiological 
work-up requiredf
No further work-up
Further work-up including geneticsg
Aetiological work-up
Normal
Ô¨Åndings
No further 
work-up
Risk stratiÔ¨Åcationc
Before discharge
Simultaneously use CHAMPIT approach and whether congestion/apparent HF
High riskd
Non-high risk
Figure 10 Diagnostic algorithm for acute heart failure presentation. CRP, C-reactive protein; ECG, electrocardiogram; HF, heart failure; ICU, intensive care unit; N, no; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; Y, yes. aLaboratory testing including troponin, NT-proBNP, 
C-reactive protein, differential blood count. bSee Table 6. cSee Table 7. dConsider cardiovascular magnetic resonance. eIn stabilized heart failure patients, 
endomyocardial biopsy may be performed on a case-by-case basis. fDepending on the underlying cause and clinical need. gSee Sections 5, 8, 9, 10.   
ESC Guidelines                                                                                                                                                                                               23


<!-- PAGE 24 -->

### Page 24

Patient with new, recurrent or unexplained arrhythmias (any type)
Haemodynamic instability
Cardioversion/deÔ¨Åbrillation/
transcutaneous pacing/ALS
(Class I)
Clinical history and vital signs, 12-lead ECG, laboratory evaluationb, transthoracic echocardiography
(Class I)
Active myocarditis (based on initial CMR/EMB)
See speciÔ¨Åc sections
Type of initial arrhythmia at presentation
Repeat CMR 
within 6 months
(Class I)
Identify arrhythmia 
Risk stratiÔ¨Åcationd
Further aetiological 
work-up
Endomyocardial biopsy
(Class I)
Cardiovascular magnetic resonancef
(Class I)
Red Ô¨Çags for myocardial involvementc
DeÔ¨Ånite myocarditis
SpeciÔ¨Åc aetiology
ICD indicationsj
(Class I) (Class IIa) (Class IIb)
Further aetiological work-uph
Suggestive of non-cardiac causes 
or cardiomyopathies
Aetiological work-up
Normal Ô¨Åndings
No further work-up
Non-high risk
Obstructive CADa
Treat CAD
PM indicationi
Further work-up depending on activity
 (genetics, systemic disorders)
Catheter ablation
(Class IIa)
High riske
Before discharge
Ventricular arrhythmiag
Conduction blocks
Figure 11 Diagnostic algorithm for arrhythmia presentation. ALS, advanced life support; CAD, coronary artery disease; CMR, cardiovascular magnetic resonance; CRP, C-reactive protein; ECG, electrocardiogram; EMB, endomyocardial biopsy; ICD, implantable cardioverter-defibrillator; N, no; 
NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PM, pacemaker; Y, yes. aInvasive coronary angiography or computed tomography 
angiography depending on clinical likelihood/probability. bLaboratory testing including troponin, NT-proBNP, C-reactive protein, differential blood 
count. cSee Table 6. dSee Table 7. eConsider cardiovascular magnetic resonance. fConsider endomyocardial biopsy on a case-by-case basis. gSee 
Section 6.5 for wearable cardioverter-defibrillator. hSee Sections 5, 8, 9, 10. iSee Section 6.5 and Reference Glikson et al.86 jSee Section 6.5,  
Recommendation Table 14 and Reference Zeppenfeld et al.58


<!-- PAGE 25 -->

### Page 25

An inflammatory syndrome is usually present with fever of >38¬∞C 
(70%),37 elevated markers of inflammation (C-reactive protein) (80%‚Äì 
90%),36,37 ESR, neutrophil leucocytosis,37,38 and pericardial and/or pleural effusion (approximately 50%), often with lung atelectasis, leading to a 
possible diagnosis of pleuro-pneumonia,37,103 and less commonly, peritoneal involvement (13%).38 This presentation is labelled ‚Äòinflammatory 
phenotype‚Äô of AP. 
Cardiac enzymes are usually normal, but troponin may be elevated in 20%‚Äì30% of cases, due to concomitant myocarditis 
(myopericarditis).4 
4.4.2. Subacute pericarditis 
Subacute pericarditis refers to cases with persistent symptoms lasting 
>1 month and <3 months. This condition may directly progress to 
constrictive pericarditis (CP) within a few months and requires timely 
optimal medical therapy and close follow-up to prevent chronic 
evolution.104 
4.4.3. Chronic pericarditis 
Chronic pericarditis refers to cases lasting >3 months. In pericarditis, 
management of the patient during the acute phase is of paramount importance, not only for symptom relief but, most importantly, for prognostic purposes. Hospitalization of patients with AP and high-risk 
features allows the prompt identification and treatment of potentially 
life-threatening complications, such as cardiac tamponade (CTP).105 
Moreover, appropriate screening for specific aetiologies is the basis 
for tailored therapy. Progression of AP to subacute or chronic disease 
is sometimes unpredictable. Omission of colchicine administration and 
the use of high doses of corticosteroids with fast tapering are risk factors for recurrences or a chronic course of the disease.24,106‚Äì109 
Recently, scores that predict the individual risk of complicated pericarditis and chronicity have been proposed for the identification of subjects who require intensive therapy in terms of medication dose and 
length, as well as close follow-up.43,44,110 They require further validation 
in prospective, multicentre studies. 
In chronic forms, symptoms are similar to previous attack(s), 
but often milder.1 In unclear cases or in difficult-to-treat patients, 
CMR may be performed to assess the degree of inflammation and 
individualize medical therapy, especially before drug tapering or 
discontinuation.111,112 
Paradoxically, although chronic pericarditis significantly impairs quality of life, the rate of progression to CP is negligible (<1%) and is lower 
than the risk imposed by a single episode of AP, unless a specific aetiology is identified.105,113,114 
4.5. Clinical presentations of pericarditis 
Pericarditis is characterized by a wide spectrum of clinical presentations. 
The main presenting symptom of pericarditis is positional chest pain, 
which is reported in most affected individuals. Typical pericardial pain 
is sharp and is worse when coughing and taking a deep breath (pleuritic). 
Left trapezius ridge pain is a classic symptom of pericardial irritation and is 
transmitted through the phrenic nerve. Other less common symptoms 
include shortness of breath, fever, fatigue, and arrhythmia (e.g. AF). 
Pericardial effusion often accompanies pericarditis (>50% of cases). 
Other presentations include right HF-like symptoms [elevated jugular 
venous pressure (JVP), peripheral oedema, ascites] when constriction 
is present. Hypotension is a sign of CTP (which presents with Beck‚Äôs 
triad: hypotension, jugular venous distension, and muffled heart sounds). 
It is crucial to differentiate pericarditis from other diseases, such as ACS, 
congestive HF, pneumonia with pleuritis, pulmonary embolism, chronic 
obstructive pulmonary disease, and vasculitis. 
4.5.1. Dry pericarditis 
Dry pericarditis (40%‚Äì50% of cases), also referred to as ‚Äòpericarditis sicca‚Äô, is a form of pericarditis that is characterized by inflammation of the 
pericardium without the presence of PEff. It can begin insidiously or 
abruptly. It is usually not associated with a specific cause or a worse 
prognosis. 
4.5.2. Effusive pericarditis 
Effusive pericarditis (50%‚Äì60% of cases) is characterized by the concurrent presence of effusion.115 A moderate to large PEff is more commonly associated with a non-idiopathic aetiology. 
4.5.3. Effusive‚Äìconstrictive pericarditis 
Effusive‚Äìconstrictive pericarditis (ECP) is characterized by the concurrent presence of PEff, along with thickening and constriction of 
the pericardium that restricts the normal filling of the heart.116 
Effusive‚Äìconstrictive pericarditis occurs when constrictive physiology is uncovered following the drainage of a PEff with tamponade. 
The exact haemodynamic definition involves the right atrial pressure 
(RAP) failing to fall by ‚â•50% or to a level of <10 mmHg despite intrapericardial pressure being lowered to near 0 mmHg with removal of 
pericardial fluid via pericardiocentesis.110,116,117 Current multimodality imaging allows a clinical diagnosis of ECP without cardiac 
catheterization. 
4.5.4. Pericarditis with cardiac tamponade 
The two most serious complications of pericarditis are CTP and CP. 
Pericarditis with CTP is a life-threatening condition where inflammation 
of the pericardium leads to the accumulation of compressive pericardial 
fluid (Table 8).110,115 Symptoms may include chest discomfort, fatigue, 
and dyspnoea. Clinical signs include hypotension, tachycardia, raised 
JVP, pulsus paradoxus, muffled heart sounds, electrical alternans with 
decreased ECG voltage, and an enlarged cardiac silhouette on chest 
X-ray. The magnitude of clinical and haemodynamic abnormalities depends on the amount of pericardial fluid and rate of accumulation, 
the distensibility of the pericardium, and the compliance and filling pressures of the cardiac chambers118 (Figure 12). 
Table 8 Causes of cardiac tamponade  
Common causes (in order of relative frequency):  
(1) 
Neoplasm/malignancy  
(2) 
Iatrogenic/trauma  
(3) 
Pericarditis  
(4) 
Tuberculosis (most common in developing countries) 
Less common causes (in order of relative frequency):  
(1) 
Collagen vascular diseases (systemic lupus erythematosus, rheumatoid 
arthritis, scleroderma)  
(2) 
Pericardial injury syndrome  
(3) 
Acute myocardial infarction  
(4) 
Aortic dissection  
(5) 
Uraemia  
(6) 
Bacterial infection  
(7) 
Pneumopericardium 
¬© ESC 2025   
ESC Guidelines                                                                                                                                                                                               25


<!-- PAGE 26 -->

### Page 26

4.5.5. Constrictive pericarditis 
Pericardial constriction is a chronic condition characterized by a thickened, fibrotic, and often calcified pericardium that leads to impaired diastolic filling of the heart. It should be named CP when associated with 
pericarditis. Constrictive pericarditis is a consequence of chronic pericardial inflammation and is characterized by scarring, fibrosis, and loss 
of elasticity of the pericardium. The main symptoms are dyspnoea, 
oedema, orthopnoea, and fatigue. The classic clinical picture is usually 
characterized by isolated right HF with normal or nearly normal natriuretic peptide levels. Venous congestion, hepatomegaly, pleural effusions, and ascites may occur.110,115,119 Constrictive pericarditis should 
be treated empirically with anti-inflammatory therapy. Cases after failure of medical therapy and pericardial constriction without pericarditis 
should be referred for pericardiectomy without delay (Figure 13). 
Patient with deÔ¨Ånite diagnosis of cardiac tamponade
High-risk features 
(with cumulative score ‚â•6) 
Outpatient follow-up
Pericardial window
Improvement 
Postpone pericardiocentesis
Empiric anti-inÔ¨Çammatory therapy
Pericardiocentesis with drainage
Criteria for triage for patients with pericardial eÔ¨Äusion at risk for progression to cardiac tamponade
Imaging
Clinical presentation
Aetiology
Malignant disease 
2
Tuberculosis 
2
Recent radiotherapy 
1
Recent viral infection 
1
Recurrent PEÔ¨Ä 
1
Chronic terminal renal failure 
1
Immunosuppression 
1
Dysthyroidism 
 -1
Systemic autoimmune disease 
-1
Dyspnoea/tachypnoea                                     1
Orthopnoea                                                         3
Hypotension (CBP <95 mmHg)                  0.5
Progressive sinus tachycardia                         1
Oliguria                                                                 1
Pulsus paradoxus (>10 mmHg)                      2
Pericardial chest pain                                    0.5
Pericardial friction rub                                  0.5
Rapid worsening of symptoms                      2
Slow disease evolution                                  -1 
Cardiomegaly on chest x-ray 
1
Electrical alternans on ECG 
0.5
Microvoltage on ECG 
1
Circumferential large PEÔ¨Ä  
3
Moderate PEÔ¨Ä 
1
Small PEÔ¨Ä  
 -1
Right atrial collapse 
1
IVC dilated not collapsible 
1.5
Right ventricular collapse  
1.5
Left atrial collapse 
2
Mitral/tricuspid respiratory 
Ô¨Çow variations 
1
Swinging heart 
1
Figure 12 Management of cardiac tamponade. CBP, central blood pressure; ECG, electrocardiogram; IVC, inferior vena cava; N, no; PEff, pericardial 
effusion; Y, yes. Criteria are listed for the evaluation of patients by immediate or delayed pericardiocentesis based on expert consensus. Immediate 
pericardiocentesis should be considered if there are >6 points from at least two categories.


<!-- PAGE 27 -->

### Page 27

4.5.6. Transient constrictive pericarditis 
Transient constriction is CP with ongoing inflammation that can be reversed following anti-inflammatory treatment or that heals spontaneously. 
It develops with pericarditis with or without PEff (about 10% of 
cases) and resolves with anti-inflammatory therapy in >50% of 
cases.120,121 A trial of 3‚Äì6 months of anti-inflammatory therapy is recommended in patients with newly diagnosed CP before referral for 
pericardiectomy.122,123 Biomarkers (e.g. elevated C-reactive protein) 
and multimodality imaging, including CMR, are mandatory to detect 
pericardial inflammation. 
4.5.6.1. Constrictive pathophysiology 
It is important to distinguish constrictive pathophysiology from actual 
HF symptoms.115,120,121,124 There may be features of septal bounce, 
Concomitant pericarditis
Pericardiectomy
(Class I)
Persistence of constriction
Outpatient follow-up
Close follow-up within 1 month
Pericardiectomy
(Class I)
Patient with symptoms and signs of constrictiona
First-line assessment with history, physical examination,
ECG, transthoracic echocardiography, laboratory assessment,
CT (calciÔ¨Åcations) and CMR (inÔ¨Çammation)
(Class I)
DeÔ¨Ånite diagnosis of constriction
Admission and cardiac catheterization
Low riskb
Intermediate riskb
High risk
Outpatient treatment
Improvement
Outpatient follow-up
Admission
(Class I)
Empiric anti-inÔ¨Çammatory therapy for at least 3‚Äì6 months
(Class IIa)
Figure 13 Management of constriction. CMR, cardiovascular magnetic resonance; CT, computed tomography; ECG, electrocardiogram; N, no; Y, yes. 
Empirical anti-inflammatory therapy is warranted only for those with evidence of pericarditis (by clinical criteria, biomarkers, and/or imaging). Low risk: 
clinical remission after therapy/normalization of imaging findings. Intermediate risk: improved symptoms without complete remission/partial regression. 
High risk: persistent symptoms/persistent imaging signs of constriction. aSee Table 6. bSee Table 7.   
ESC Guidelines                                                                                                                                                                                               27


<!-- PAGE 28 -->

### Page 28

respiratory phase-dependent shift of the ventricular septum, and 
Doppler features of constriction without HF symptoms (see  
Supplementary data online, Section 2.4 and Figure S1). 
4.5.7. Pericarditis with polyserositis 
Pericarditis with polyserositis is characterized by inflammation of the 
pericardium and concurrent inflammation of other serous membranes 
lining major body cavities, such as the pleura and peritoneum.37,103,125,126 
4.5.8. Inflammatory vs non-inflammatory pericarditis 
In the context of pericarditis, the terms ‚Äòinflammatory‚Äô and ‚Äònon- 
inflammatory‚Äô phenotype refer to two distinct clinical presentations 
based on the underlying pathophysiological mechanisms. 
4.5.8.1. Inflammatory phenotype of pericarditis 
The inflammatory phenotype is characterized by inflammation of the 
pericardium with evidence of systemic inflammation. This phenotype 
is often associated with fever, and/or elevated systemic inflammatory 
markers (e.g. C-reactive protein), PEff, and/or pleural effusion. These 
forms typically respond well to targeted anti-inflammatory therapies, 
including colchicine and anti-IL-1 agents.37,127 
4.5.8.2. Non-inflammatory phenotype of pericarditis 
The non-inflammatory phenotype refers to the manifestation of pericarditis without C-reactive protein elevation or low elevation of markers of 
systemic inflammation (e.g. high-sensitivity C-reactive protein).127 This occurs in 10%‚Äì20% of patients with pericarditis.36 The pathogenesis of pericarditis with normal C-reactive protein is unknown and these cases are 
often difficult to treat. C-reactive protein is a sensitive albeit unspecific biomarker of inflammation mainly driven by IL-6. Moreover, in autoimmune 
diseases characterized by the type I interferon (IFN) gene signature, 
C-reactive protein appears to be an unreliable marker of inflammation.52 
5. Diagnosis and diagnostic 
work-up 
The diagnostic work-up in patients with suspected IMPS should be tailored based on the severity of clinical presentation, response to medical 
therapy, and individual risk (Table 7). It includes medical history, clinical/ 
physical exam, biomarkers (myocardial injury, systemic inflammation, 
and HF), ECG, and multimodality imaging. Endomyocardial biopsy has 
its place in dedicated clinical scenarios. For IMPS, routine viral serology 
is not recommended,1 except for HIV and hepatitis C virus (HCV), as 
well as for suspected bacterial infections (such as Borrelia spp., rickettsial, and T. cruzi infections). Echocardiography is the basic imaging method, followed by other techniques. Cardiovascular magnetic resonance 
is an advanced imaging test of increasing importance for detection of 
myocardial as well as pericardial injury.115,128 Most important is a 
patient-tailored approach, usually driven by the dominant symptoms. 
Flow charts (Figures 5‚Äì7 and 9‚Äì13) illustrate the proposed workflow 
in different clinical scenarios. If a patient presents with clinical symptoms suggestive of IMPS (Table 6), basic and advanced diagnostic assessments are recommended (see Table 9). 
Recommendation Table 1 ‚Äî Recommendations for 
clinical evaluation of myocarditis and pericarditis (see  
Evidence Table 1) 
Recommendations 
Classa 
Levelb  
Complete clinical evaluation, including history, 
physical examination, chest X-ray, biomarkersc, ECG, 
and echocardiography is recommended in all patients 
with a suspicion of myocarditis and/or pericarditis for 
the initial diagnostic assessment. 
I 
C 
CMR is recommended in patients with the clinical 
suspicion of myocarditis (using updated LL criteria)30 
and/or pericarditis for the non-invasive diagnosis of 
inflammatory reaction.110,115,129 
I 
B 
Hospital admission is recommended for patients 
with high-risk pericarditisd for monitoring and 
treatment.105,130 
I 
B 
Hospital admission is recommended for patients 
with moderate- to high-risk myocarditisd for 
monitoring and treatment. 
I 
C 
EMBe is recommended in patients with high-risk 
myocarditisd and/or haemodynamic instability, 
and/or in patients with intermediate-risk myocarditis 
not responding to conventional therapy in order to 
detect a specific histologic subtype and to assess the 
presence of viral genome for treatment.34,63,73,131 
I 
C 
Invasive coronary angiography or coronary CT, 
depending on clinical likelihood, is recommended in 
patients with IMPS if an acute coronary syndrome is 
suspected to rule out obstructive coronary artery 
disease. 
I 
C 
Hospital admission should be considered for patients 
with low-risk myocarditisd for monitoring and 
treatment. 
IIa 
C 
Pericardial or epicardial biopsy may be considered in 
relapsing pericardial effusion as part of the diagnostic 
work-up when the diagnosis cannot be reached with 
multimodality imaging and laboratory examinations. 
IIb 
C 
Routine serology is not recommended in patients 
with myocarditis and/or pericarditis for the 
evaluation of viral aetiology except for hepatitis C, 
HIV, and Lyme disease. 
III 
C 
¬© ESC 2025
CMR, cardiovascular magnetic resonance; CT, computed tomography; ECG, 
electrocardiogram; EMB, endomyocardial biopsy; HIV, human immunodeficiency virus; 
hs-TnI, high-sensitivity troponin I; hs-TnT, high-sensitivity troponin T; IMPS, 
inflammatory myopericardial syndrome; LL, Lake Louise; NT-proBNP, N-terminal 
prohormone of brain natriuretic peptide. 
aClass of recommendation. 
bLevel of evidence. 
cIncluding hs-TnT or hs-TnI, C-reactive protein, NT-proBNP. 
dSee Table 7. 
eContemporary evaluation of EMB should be based on histology, immunohistology, and 
molecular pathology for detection of viral infections in myocardial and blood samples 
(see also Table 11).


<!-- PAGE 29 -->

### Page 29

5.1. Electrocardiogram 
Dynamic changes in the ST segment are classic hallmarks of pericarditis and myocarditis. The most typical pattern includes widespread 
ST-segment elevation, reported in 20%‚Äì60% of cases (see  
Supplementary data online, Table S4). In pericarditis, ECG changes 
suggest concomitant myocardial involvement, and are indicative of 
inflammation of the subepicardium.35 These changes are more common in the initial phase and may be more frequent in younger patients. ST-segment depression and T-wave inversion may also be 
present, albeit less frequently than in patients with acute myocardial 
ischaemia,132 and may be related to the extent of myocardial 
damage.133,134 Diffuse depression of the PR segment is a classic early 
finding in AP. 
A decrease in the amplitude of QRS complexes on ECG can be 
observed in cases of AP and/or AM, especially with large effusions or 
extensive myocardial injury. Electrical alternans of the QRS complexes 
has been reported, attributed to fluctuation of the heart within a 
large effusion (swinging heart). Lengthening of the QT interval might occur in AM. 
Atrial fibrillation can occur in AP, especially in predisposed patients, 
in whom pericardial inflammation may be a trigger for supraventricular 
arrhythmias.77 In contrast, VA are more common in myocarditis. 
AVBs and intraventricular conduction defects, particularly right bundle branch blocks, are not uncommon (see Section 4.3.3, and  
Supplementary data online, Table S4) and may be associated with 
more severe presentations.135‚Äì137 
Electrocardiogram changes are highly dynamic and may evolve over a 
span of hours or days, with temporal progression varying significantly 
among patients. Typically, ST changes resolve; however, it is important 
to note that a normal ECG at presentation does not exclude the possibility of IMPS. 
5.2. Biomarkers 
5.2.1. Biomarkers in clinical routine 
Recommended biomarkers in IMPS include: 
‚Ä¢ Markers of inflammation (e.g. C-reactive protein): C-reactive 
protein is often increased in patients with pericarditis (up to 80%) 
and AM (up to 80%), and contributes to the diagnosis.28,36,138 
Negative results, however, do not exclude the diagnosis. In pericarditis, C-reactive protein is a marker of disease activity that could be 
used to guide the duration of anti-inflammatory therapy.36 
D-dimers are currently being investigated for their diagnostic and 
prognostic relevance.36,139,140 
‚Ä¢ Markers of myocardial lesions (e.g. troponin): Troponin is elevated in myocardial involvement, usually indicating cardiomyocyte 
necrosis. Assessment of baseline troponin is crucial to diagnose the 
severity of myocarditis. It is typically increased in infarct-like 
myocarditis. 
‚Ä¢ Markers of HF (BNP or NT-proBNP): Assessment of baseline level 
is recommended among patients with suspected myocarditis. This 
measurement can be repeated at discharge and during follow-up in 
an outpatient setting to assess the risk of clinical events. 
NT-proBNP can be used in patients with myocarditis as a predictive 
marker of HF among patients with normal or impaired LVEF.12  
5.2.2. Biomarkers beyond clinical routine 
Different biomarkers may help to identify a specific aetiology and to 
guide risk stratification. Most of them are not part of clinical routine, 
Table 9 Basic and advanced level assessment 
Basic assessment:  
History: potential causes and triggers (viral infection of upper respiratory or 
gastrointestinal tract, toxins, drug use, medications), recurrent symptoms, 
family history of IMPS/cardiomyopathy/SCD, and systemic 
inflammatory/autoimmune diseases 
Physical examination: assess clinical stability, symptoms (chest pain, HF 
symptoms, palpitations, syncope), malaise, general weakness and fatigue, 
pericardial friction rub, clinical symptoms/signs of CTP 
ECG: PR-segment depression, ST/T-wave changes, AVB, and ventricular 
arrhythmias 
Chest X-ray 
Basic laboratory data: 
Markers of myocardial lesion (e.g. hs-TnT/TnI) 
Markers of systemic inflammation (e.g. C-reactive protein, ESR, WBC count) 
Markers of heart failure (e.g. NT-proBNP) 
Complete blood count (including eosinophilic count) 
Renal function and electrolytes (e.g. sodium, potassium, creatinine) 
Thyroid function (e.g. TSH) 
Hepatic function and additional testing (e.g. lactate dehydrogenase, aspartate 
aminotransferase, alanine aminotransferase) 
Echocardiography including strain imaging 
Advanced assessment usually after admission: 
Coronary anatomy evaluation (if needed for differential diagnosis by invasive 
coronary angiography or coronary CT depending on the clinical likelihood of 
ACS) 
CMR to assess signs of myocardial and pericardial inflammation and/or fibrosis 
Arrhythmia screening depending on risk stratification (e.g. Holter-ECG) 
Additional laboratory parameters guided by clinical suspicion (e.g. if 
therapeutic consequences are expected) 
Dedicated genetic testing if indicated 
CT to assess concomitant pleuropulmonary diseases 
Specific myocarditis: EMB in high-risk cases and in intermediate-risk 
cases on a case-by-case decision to detect specific histology and some 
aetiologies if needed 
Specific pericarditis: diagnostic pericardiocentesis when indicateda 
¬© ESC 2025
ACS, acute coronary syndrome; AVB, atrioventricular block; CMR, cardiovascular magnetic 
resonance; CT, computed tomography; CTP, cardiac tamponade; ECG, electrocardiogram; 
EMB, endomyocardial biopsy; ESR, erythrocyte sedimentation rate; HF, heart failure; 
hs-TnT/TnI, high-sensitivity troponin T/I; IMPS, inflammatory myopericardial syndrome; 
NT-proBNP, N-terminal prohormone of brain natriuretic peptide; SCD, sudden cardiac 
death; TSH, thyroid-stimulating hormone; WBC, white blood cell. 
aSee Recommendation Table 12   
ESC Guidelines                                                                                                                                                                                               29


<!-- PAGE 30 -->

### Page 30

but could help based on a strong clinical suspicion,73 e.g. miR721 was 
shown to have a discriminatory capacity.141 
In specific circumstances, tumour necrosis factor alpha (TNF-Œ±), IL-1Œ≤, 
IL-6, and IL-17A may be of value. Similarly, in some cases, evaluation of 
cardio-specific antibodies may be helpful, according to the local laboratory availability. These include organ-specific anti-heart autoantibodies 
and anti-intercalated disc autoantibodies, as well as non-organ-specific 
serum autoantibodies.10 These autoantibodies, especially if found at 
high titres, may have a negative prognostic value.73,142 
Furthermore, a specific serum biomarker, i.e. the soluble form of the 
IL-1 receptor-like 1 (IL-1RL1), also known as ST2, was associated with a 
higher risk of severe HF among male myocarditis patients.143 Other 
biomarkers have been studied in myocarditis, including procollagen 
type III, gelsolin, soluble VCAM-1, galectin-3, serum alarmin S100A8/ 
S100A9, immunoglobulin free light chain, and heparin-binding protein, 
for both diagnostic and prognostic purposes. However, these biomarkers were evaluated among limited small cohorts and are clinically not 
routinely used.144,145 
5.3. Genetics 
Genetic testing is relatively new in the field of IMPS. There is a potential 
overlap with CMPs. Myocarditis and pericarditis will be discussed 
separately. 
There has been increasing evidence that gene variants coding for structural proteins, particularly desmosomal and sarcomeric proteins, may 
overlap with acute and recurrent myocarditis and affect disease severity.94,95 Furthermore, it has been shown that there is an overlap of gene 
variants predisposing to myocardial inflammation and inherited CMP 
(ARVC and NDLVC).13 In particular, myocardial inflammation may be detected in patients with inherited CMP using serum and imaging biomarkers.13 There is evidence that these patients are at higher risk for 
complicated myocarditis (Section 4.3.5).13,91,93,94 In a meta-analysis, the 
pooled prevalence of P/LP variants was 4.2% for uncomplicated myocarditis, whereas for complicated myocarditis the pooled prevalence was 22% 
and 45% in adults and children, respectively.95 Pathogenic/likely pathogenic 
variants in desmosomal genes were more common in uncomplicated 
myocarditis (64%), while variants in sarcomeric genes were more prevalent in complicated myocarditis (58% in adults and 71% in children).95 
A case series demonstrated a high proportion of definite or probable pathogenic variants in patients with myocarditis with RV involvement or sustained VA.146 Furthermore, DSP variants have 
been reported in familial recurrent myocarditis.147 Another study 
demonstrated overlap of gene variants in myocarditis and inherited 
CMP.96 
Identifying such gene variants has several clinical implications: 
(1) While in myocarditis there is a recommendation to defer on implantable cardioverter-defibrillator (ICD) placement during the 
acute phase of the disease, the threshold for ICD placement is lower in ARVC in cases of primary prevention.58 
(2) Gene variants predisposing to myocarditis have relevant implications for patients.147,148 Details are given in the 2023 ESC 
Guidelines for the management of cardiomyopathies.13 
(3) Cascade clinical and genetic screening for relatives and familial genetic counselling should be offered.93,149 
As scientific knowledge about gene variants and their potential 
pathophysiological role has been continuously increasing over recent years, comprehensive screening includes desmosomal and sarcomeric genes and some DCM-associated genes.64,91,96,146,150 For 
details, see 2023 ESC Guidelines for the management of cardiomyopathies.13 Nevertheless, it is not clear whether the inflammatory 
process acts as a trigger or is fully part of the pathophysiological process in inherited CMP.151 
Pathogenic/likely pathogenic variants have been identified in patients 
with recurrent pericarditis (RP), especially young patients, with a family 
history, multiple recurrences, inflammatory phenotype, and refractory 
or dependent on medical treatments. Recurrent pericarditis has been 
associated with genetic variants for monogenic autoinflammatory diseases (e.g. FMF, TRAPS), but also with genes related to the inflammatory response (Figure 14).50,51,152,153 
A recent study performed whole-exome sequencing in 108 patients 
with RP. Overall, about 15% of patients had variants in genes related to 
the inflammatory response, while up to 30% of patients carried variants 
in different cardiac genes, worthy of a deeper investigation.51 These 
data suggest a genetic predisposition in at least a subset of patients 
(positive family history of pericarditis or periodic fever, poor response 
to colchicine, multiple recurrences with inflammatory phenotype), and 
counselling may be offered.51,152 In these clinical scenarios, prolonged 
therapy with specific biological agents (e.g. anti-IL-1 agents) should be 
considered. 
Recommendation Table 2 ‚Äî Recommendations for 
genetic testing (see Evidence Table 2) 
Recommendations 
Classa 
Levelb  
It is recommended to obtain family history 
including pedigrees in cases of recurrent IMPS 
to provide clues to the underlying aetiology, 
determine inheritance pattern, and identify 
relatives at risk. 
I 
C 
Genetic testing should be considered in patients 
with definite myocarditis/pericarditis in 
cases of:50,51,64,94,150 
‚Ä¢ family history of IMPS, inherited or suspected 
cardiomyopathy 
‚Ä¢ severe ventricular arrhythmiac 
‚Ä¢ significant left/right LGE (e.g. ring-like pattern or 
septal LGE) or persistent LVEF systolic dysfunction 
‚Ä¢ recurrent myocarditis or persistent troponin 
elevation 
‚Ä¢ recurrent pericarditis with an inflammatory 
phenotype, refractory to conventional treatmentd, 
with the aim to detect an underlying genetic cause. 
IIa 
B 
¬© ESC 2025
IMPS, inflammatory myopericardial syndrome; IL, interleukin; LGE, late gadolinium 
enhancement; LVEF, left ventricular ejection fraction. 
aClass of recommendation. 
bLevel of evidence. 
cSee Section 4. 
dEspecially poor response to colchicine and anti-IL-1 agents.


<!-- PAGE 31 -->

### Page 31

5.4. Multimodality imaging 
The non-invasive diagnosis of IMPS relies on advanced cardiovascular imaging. An overview of the capabilities of different imaging modalities for 
the identification of pathophysiological components is provided in  
Supplementary data online, Table S5. Echocardiography is usually the 
first-step imaging modality and provides functional and morphological information. Cardiovascular magnetic resonance can better differentiate 
myocardial tissue and shows myocardial and pericardial inflammation, 
as well as different patterns of fibrosis. Fluorodeoxyglucose positron 
emission tomography (FDG-PET) is useful to detect disease activity, especially for CS (see Section 5.8). Computed tomography allows detection 
of calcification of the pericardium and its extent, as well as exclusion of 
CAD. The application of non-invasive imaging should guide therapeutic 
decision-making (see Section 4). 
5.5. Echocardiography 
Transthoracic echocardiography (TTE) is usually the initial imaging modality of choice for individuals with suspected IMPS, given its ability to 
identify myocardial and pericardial abnormalities, as well as concomitant valvular disease.115,124 
5.5.1. Echocardiography in myocarditis 
Patients with a suspicion of myocarditis should usually undergo standard 
TTE including speckle tracking or tissue Doppler imaging (TDI) at presentation. Transthoracic echocardiography helps monitor changes in cardiac chamber size, ventricular function, wall thickness, and PEff. In 
myocarditis, global ventricular dysfunction, diastolic dysfunction with 
preserved ejection fraction (EF), and regional WMA may occur.154,155 
Tissue Doppler imaging or strain imaging can be used in the setting of 
myocarditis and may indicate myocardial injury.156,157 Recent studies 
have shown that global longitudinal and circumferential strain (GLS 
and GCS) and strain rate were decreased in patients with AM, even 
with preserved EF.156 Strain may provide important prognostic information in AM.157 Regional GLS can be associated with scarring on 
CMR and can predict VA and outcomes in patients with AM.157 
Abnormal RV strain158 and left atrial (LA) strain159 have been detected 
in AM with preserved EF. 
5.5.2. Echocardiography in pericarditis 
Transthoracic echocardiography can detect the presence of PEff and 
assess its haemodynamic importance, as well as constrictive pathophysiology (Supplementary data online, Figure S1 and Table S6). 












	










	


Figure 14 The different courses of inflammatory myopericardial syndrome and the interplay between genetic background inflammation and autoimmunity beyond the initial infectious trigger. IMPS, inflammatory myopericardial syndrome.  
Table 10 Classification of pericardial effusion  
Onset 
Acute (‚â§4 weeks) 
Subacute (>4 weeks to ‚â§3 months) 
Chronic (>3 months) 
Sizea 
Mild: <10 mm 
Moderate: 10‚Äì20 mm 
Large: >20 mm 
Distribution 
Circumferential/loculated 
Composition 
Transudate/exudate 
¬© ESC 2025
aMaximal end-diastolic diameter.   
ESC Guidelines                                                                                                                                                                                               31


<!-- PAGE 32 -->

### Page 32

Acute pericarditis patients may have a normal-appearing TTE (40%‚Äì 
50% of cases in first episodes); however, the presence of new or worsening PEff is a diagnostic criterion for pericarditis.24,115,160 The size of 
PEff is assessed by the end-diastolic distance of the echo-free space between the epicardium and parietal pericardium (Table 10).115,128 It is recommended that images should include the extent and location of each 
effusion measurement, as this allows follow-up studies. Transthoracic 
echocardiography enables the recognition of CTP and the presence 
of constriction.115 
5.6. Cardiovascular magnetic resonance 
Cardiovascular magnetic resonance is the accepted gold standard for 
the quantification of biventricular function and detection of WMA. 
Cardiovascular magnetic resonance has the advantage of tissue differentiation, non-invasively detecting myocardial and pericardial inflammation, as well as fibrosis.30 The diagnostic targets in non-ischaemic 
myocardial inflammation include myocardial oedema, hyperaemia and 
capillary leak, and necrosis/fibrosis (see Supplementary data online,  
Figure S2).161‚Äì164 The diagnostic accuracy of CMR is higher if performed 
early in the time course of disease (best within the first 2 weeks). 
Myocardial oedema and changes due to inflammation lead to increased 
tissue water content that can be detected as increased signal intensities 
on T2-weighted imaging and/or T2 mapping; increased tissue free- 
water content will also lead to an increased signal in T1 mapping and 
extracellular volume (ECV) quantification. Myocyte necrosis and fibrosis can result in non-ischaemic (e.g. mid-wall, subepicardial, patchy) patterns of LGE, which do not typically follow a coronary artery 
distribution. The identification of myocarditis with chest pain presentation is less challenging than in HF and arrhythmic scenarios. The updated LLC, which include parametric mapping methods (T1/T2/ECV), 
should be applied for diagnosis, as the combined approach increases 
the diagnostic accuracy (see Figure 4).30 It is important to note that imaging evidence of myocardial inflammation does not provide the underlying histotype (see Supplementary data online, Figure S2). 
In the case of pericarditis, CMR detects thickening, oedema, and LGE 
of the pericardium.110,129,165 It is important to note that pericardial 
LGE may imply ongoing inflammation and neovascularization rather 
than simple scarring (see Supplementary data online, Figure S2). 
Cardiovascular magnetic resonance is helpful for an objective assessment of the degree of inflammatory involvement of the pericardium, 
either for first diagnoses or follow-up (for details see Figure 7 and  
Table 9). 
Given its physical properties, CMR is affected by ferromagnetic objects, such as valvular prosthesis and implants, resulting in artefacts. 
The same holds true for active MR-conditional devices, such as pacemakers, ICDs, and cardiac resynchronization therapy (CRT) pacemakers/defibrillators (P/Ds), but dedicated techniques are now 
available to achieve better diagnostic image quality in many cases.166 
Cardiovascular magnetic resonance could also be used in patients 
with non-conditional devices with a clear clinical indication if other imaging modalities are not helpful. In all cases, programming of the implanted device before and after the scan is warranted, as well as 
patient monitoring. 
Even in intubated patients, CMR scans are feasible in order to detect 
inflammation.167 If breath-hold capacities are reduced or the patient is 
uncooperative, fast imaging techniques and/or motion-corrected imaging have to be applied.168 
5.7. Computed tomography 
Computed tomography is an established tool for excluding CAD depending on the risk score and can be used in the diagnostic work-up 
according to current ESC guidelines.65,72,195 
Contrast-enhanced CT may be very useful to make an aetiological 
diagnosis in patients presenting with large PEff including tamponade.196 
Computed tomography is important before pericardiectomy for constriction to evaluate the anatomy and extent of calcifications as a higher 
burden of pericardial calcification has been associated with a better 
post-surgical outcome.197 Furthermore, anatomical abnormalities, 
such as pectus excavatum, can be identified.198 Meanwhile, CT in combination with FDG-PET plays a crucial role in the detection of CS 
(Section 9.4). 
Recommendation Table 3 ‚Äî Recommendations for the 
use of cardiovascular magnetic resonance imaging (see  
Evidence Table 3) 
Recommendations 
Classa 
Levelb  
Myocarditis 
CMR is recommended in patients with suspected 
myocarditis to reach a clinical diagnosis and to 
determine the cause of acute myocardial injury, 
including assessment of oedema, ischaemia, and 
necrosis/fibrosis/scarring.115,164,169‚Äì183 
I 
B 
CMR is recommended for follow-up at least within 
the first 6 months in patients with myocarditis to 
identify a healed or ongoing process, for risk 
stratification and personalized therapy, and to enable 
a return to exercise.10,62,184‚Äì186 
I 
C 
Pericarditis 
CMR is recommended in patients with suspected 
pericarditis when a diagnosis cannot be made using 
clinical criteria to assess evidence of pericardial 
thickening, oedema, LGE, and to assess the 
persistence of disease during follow-up in selected 
cases.110,129,165,187‚Äì194 
I 
B 
¬© ESC 2025
CMR, cardiovascular magnetic resonance; LGE, late gadolinium enhancement. 
aClass of recommendation. 
bLevel of evidence.  
Recommendation Table 4 ‚Äî Recommendations for 
computed tomography (see Evidence Table 4) 
Recommendations 
Classa 
Levelb  
CT is recommended to evaluate pericardial 
thickness, calcifications, masses, and loculated 
pericardial effusions, as well as concomitant 
pleuropulmonary diseases and chest 
abnormalities.193,197,199,200 
I 
C 
¬© ESC 2025
CT, computed tomography. Remaining recommendations for CT can be found in  
Recommendation Table 1. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 33 -->

### Page 33

5.8. Nuclear medicine 
Fluorodeoxyglucose uptake reflects metabolically active inflammatory 
cells in AM.201 
Fluorodeoxyglucose positron emission tomography can be considered as an alternative in patients when CMR is unsuitable because of 
an irregular heartbeat or device-related artefacts.202 Simultaneous/hybrid 
cardiac PET-CT/CMR imaging complement each other in the assessment of myocarditis compared with either approach alone.201,203 
Fluorodeoxyglucose positron emission tomography is also a powerful 
tool to detect and assess the extent of extracardiac involvement in sarcoidosis (see Section 9.4). 
Appropriate fasting before FDG-PET is a must to obtain reliable results.204 Typical preparation protocols include a high-fat and low- 
carbohydrate diet for 12‚Äì24 h followed by complete fasting other 
than water for the 6‚Äì12-h period prior to FDG injection. 
The role of nuclear imaging in pericarditis is less well established. The 
use of FDG-PET/CT in pericarditis is generally complementary and is 
most often implemented in cases where CMR cannot be used.205 
5.9. Endomyocardial and pericardial biopsy 
5.9.1. Endomyocardial biopsy 
Endomyocardial biopsy enables the identification of the underlying 
histological subtype of cardiac inflammation.10,34,207,208 However, non- 
invasive imaging methods have significantly improved, allowing the diagnosis of myocarditis by CMR. Therefore, the role of EMB in clinical 
practice has changed. Endomyocardial biopsy remains important for 
high-risk patients and in some intermediate cases when the knowledge 
of the histological subtype and the identification of a possible viral aetiology are important for targeted therapies (Figure 15).207,209 
Endomyocardial biopsy has potential complications (e.g. cardiac perforation/tamponade, thromboembolism, valvular trauma, severe arrhythmias, and death).9,210 Rates depend on the setting and centre experience 
and range between 0.6% and 5%,63,211 and increase up to 26% in FM 
cases on mechanical circulatory support (MCS).212 Children may have 
higher complication rates depending on age, the experience of the centre, and the site of the biopsy (LV or RV).63,213 On this basis, the clinical 
use of EMB should be tailored according to the risk‚Äìbenefit ratio. 
Histological and immunohistological investigations, as well as viral genome analysis, allow the identification of viral or immune-mediated LM, EM, 
GCM, and sarcoidosis.33,214,215 Moreover, EMB allows the identification of 
the inflammatory stages in association with the degree of myocardial necrosis and fibrosis. Endomyocardial biopsy is useful in the differential diagnosis of infiltrative/storage diseases (amyloidosis, haemochromatosis, 
glycogenosis), different CMPs, and genetic heart diseases33,216 if non- 
invasive imaging is inconclusive. This approach is consistent with other 
international position statements.9,210 Endomyocardial biopsy can be useful in cases of chronic CMP that is progressive or unresponsive to standard therapy. When FM, GCM or EM are suspected, early EMB is required 
to start immunosuppressive therapy rapidly and improve outcomes.57 In 
GCM, EMB has high sensitivity (80%‚Äì93%) and a positive predictive value 
(71%), especially if performed within 2‚Äì4 weeks from symptom onset.217 
In CS, EMB may have a low sensitivity (20%‚Äì30%) due to the focal nature 
of inflammatory lesions, but can be improved by guiding the EMB using 
CMR or electro-anatomical mapping (EAM).218‚Äì222 
Historically, diagnosis by EMB was based on the histological Dallas criteria in HE-stained heart tissue sections revealing myocytolysis and interstitial immune cells.223 However, since there is high interobserver 
variability, immunohistochemical detection of lymphocytes (CD3) and 
macrophages (CD68) can definitely increase sensitivity for the diagnosis 
of myocarditis.10,224‚Äì226 A recent meta-analysis indicates that the use of 
immunohistochemistry can increase the detection rate of inflammation 
in EMB specimens to ‚àº51%.227 A value of ‚â•14 leucocytes/mm2 with T 
lymphocytes of ‚â•7 cells/mm2 has been considered as the cut-off for 
the diagnosis of myocarditis.10 In acute LM, the number of T lymphocytes 
is generally higher (>25 cells/mm2).228 Additionally, the expression of 
MHC class II molecules in antigen-presenting macrophages and endothelial cells is routinely observed in EMB with myocarditis.33 Endomyocardial 
biopsy also enables the detection of viruses, such as enteroviruses, 
B19V,228 and herpesviruses, e.g. EBV and HHV-6, using quantitative real- 
time (RT)-PCR and in situ hybridization. It is likely that advances in molecular diagnostic techniques, such as next-generation sequencing, will 
help to identify potential new pathogens. Positive PCR results obtained 
on EMB have to be accompanied by a parallel investigation of blood samples collected at the time of the EMB to exclude acute systemic virus infection. In cases of acute cardiac and systemic virus infection, 
immunosuppressive therapy must be avoided. 
The most common site of EMB is the RV septum, but occasionally LV 
or biventricular EMB may be needed. The decision of the EMB site should 
be based on the clinical indication, findings of pre-procedural imaging, and 
operator expertise.229 A study of 755 patients with suspected myocarditis and non-ischaemic CMP (including infiltrative and storage disorders) 
indicated that biventricular EMB can increase diagnostic accuracy compared with selective LV or RV EMB.211 Sampling error is the major limitation of the diagnostic accuracy of EMB. The minimal number of 
required EMB samples for each technique is reported in Table 11.33 
It should be emphasized that PCR in EMB tissue and in situ hybridization can be used for identification of the viral agent, because viral serology concurs with the results of PCR in a minority of patients 
(‚àº4%) with myocarditis.230 With PCR, the rate of viral sequences detected in EMB specimens is up to 67%, although the rate varies widely 
among studies.63,228,231 The PCR tests for the detection of infectious 
agents must be performed in laboratories that are accredited and certified for the identification of viruses, bacteria, and parasites. The evaluation of these PCR results must be done in the context of histological/ 
immunohistological findings by pathologists with expertise in cardiovascular diseases. 
The timely communication of biopsy results is crucial for optimal 
therapeutic guidance. 
Targeted biopsies of an inflamed heart diagnosed using histology, immunohistochemistry, and molecular virology could be correlated with modern technologies, such as genomics, epigenomics, proteomics, and 
metabolomics to improve the diagnosis and therapy. Recommendations 
for EMB can be found in Recommendation Table 1. 
Recommendation Table 5 ‚Äî Recommendations for nuclear medicine (see Evidence Table 5) 
Recommendations 
Classa 
Levelb  
Carb-free 18F-FDG-PET or 18F-FDG-PET/CT should 
be considered for the diagnostic work-up in patients 
with suspected myocarditis and/or pericarditis in 
whom echocardiography and CMR are inconclusive 
for the clinical diagnosis.201,206 
IIa 
C 
¬© ESC 2025
CMR, cardiovascular magnetic resonance; CT, computed tomography; 18F-FDG-PET, 
[18F]-fluorodeoxyglucose positron emission tomography. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               33


<!-- PAGE 34 -->

### Page 34

Recommendation Table 6 ‚Äî Recommendations for endomyocardial biopsy (see Evidence Table 6) 
Recommendations 
Classa 
Levelb  
EMBc is recommended in patients with high-risk myocarditisd, and/or haemodynamic instability, and/or in patients with intermediate-risk 
myocarditis not responding to conventional therapy in order to detect a specific histologic subtype and to assess the presence of viral 
genome for treatment.34,63,73,131 
I 
C 
¬© ESC 2025
EMB, endomyocardial biopsy. 
aClass of recommendation. 
bLevel of evidence. 
cContemporary evaluation of EMB should be based on histology, immunohistology, and molecular pathology for detection of viral infections in myocardial and blood samples (see also  
Table 11). 
dSee Table 7.  

















	




	


	







¬µm
¬Å

¬ç
¬è¬ê
Figure 15 Histopathological findings in myocarditis. HE, haematoxylin eosin. (A‚ÄìC) Endomyocardial biopsy for acute lymphocytic myocarditis reveals 
cardiomyocyte necrosis (A, HE stain) and severe focal infiltration of CD3+ T cells (B) and CD68+ macrophages (C), as detected by immunohistochemistry. (D‚ÄìF) In chronic lymphocytic myocarditis, no cardiomyocyte injury is observed, but there is focal replacement fibrosis (D, HE) in the presence of 
CD3+ T cells (E) and CD68+ macrophages (F). (G‚ÄìI) In acute eosinophilic myocarditis, necrosis of cardiomyocytes is associated with numerous eosinophilic granulocytes (G, Giemsa stain), some CD3+ T cells (H), and numerous CD68+ macrophages (I). (J‚ÄìL) Areas with severe cardiomyocyte necrosis in 
the presence of extensive focal and diffuse infiltration of eosinophilic granulocytes (J, Giemsa stain), CD3+ T cells (K), and CD68+ macrophages and 
CD68+ giant cells (L) are typical of giant-cell myocarditis. (M‚ÄìO) Cardiac sarcoidosis is histologically characterized by the presence of granulomas, usually in the absence of cardiomyocyte necrosis (M, Giemsa stain), but with focal infiltration of CD3+ T cells (N) and numerous CD68+ macrophages and 
CD68+ giant cells (O).


<!-- PAGE 35 -->

### Page 35

5.9.2. Pericardial biopsy 
In clinical practice, pericardial biopsy is rarely indicated in complicated 
cases not responding to conventional anti-inflammatory therapy and 
with a high suspicion of a specific aetiology (e.g. primary pericardial tumours and metastases), which cannot be determined by non-invasive 
diagnostic methods. Pericardial biopsy can be performed by pericardioscopy (an endoscopic study of the pericardium that is available in a limited number of tertiary referral centres). It is more commonly 
performed with a thoracoscopic or surgical approach, usually during 
a pericardial drainage or a pericardial window.1,232 
5.10. Role of autopsy 
In autopsy studies of SCD, myocarditis has been described as a common finding, with incidences of myocarditis in children and adults ranging from 0.3% to 14.8%.87,88,233‚Äì235 In the majority of these studies, the 
incidence of myocarditis in SCD was higher in people aged under 
35 years.236,237 A nationwide unselected cohort of 14 294 deaths in 
Denmark suggested that 6% of all autopsied SCD was caused by myocarditis. Males have a significantly higher incidence.88 In the UK, between 1994 and 2022, myocarditis was reported as a rare cause of 
SCD in non-hospitalized individuals (1.1%) in 7702 consecutive cases 
of SCD. Here, the most common reported form was LM (56%), which 
corresponds well with data obtained from EMBs of patients with suspected myocarditis.10,63,87,238 
In the guidelines for the histopathological diagnosis of myocarditis, 
‚Äòfulminant‚Äô or ‚Äòmultifocal‚Äô myocarditis can be generally considered as a 
reliable or acceptable cause of death, especially when inflammation is 
the only substantial histopathological finding. This approach is endorsed 
by the Association of European Cardiovascular Pathology.239 
In addition to LM, other types of cardiac inflammation are observed 
in autopsies. In 558 of 49 612 (1.1%) forensic autopsies, myocarditis 
was detected by histology. In a Finnish study consisting of 351 patients 
with CS, 14% experienced fatal and aborted SCD as a presenting manifestation. In 64%, undiagnosed granulomas in the heart were the cause 
of fatalities.240 The likelihood that a case of unexplained SCD is caused 
by an underlying inherited disorder has led to the emerging role of genetic testing of DNA obtained at autopsy (also called molecular autopsy 
or post-mortem genetic testing).239 Therefore, pathologists play an important role in the identification of families at risk by reporting whether 
it is recommended to refer first-degree family members for clinical 
screening and/or to perform additional post-mortem genetic testing 
to identify the underlying cause of cardiac inflammation.241,242 Legal 
and ethical issues related to genetic testing in deceased subjects who 
did not give their consent are not universally regulated by law. 
5.11. Role of cardiac catheterization and 
coronary angiography 
Given the overlap of symptoms (especially chest pain), as well as the 
elevation of biomarkers (such as troponin in the case of myocardial involvement and NT-proBNP) and ECG changes, ACS is the main differential diagnosis for IMPS. Depending on the initial clinical assessment, 
ACS should be ruled out according to current guidelines (Figure 9). 
The recommended methods are coronary CT or invasive coronary 
angiography depending on likelihood of obstructive CAD.72,248 
Coronary angiography is preferable in patients with a high likelihood 
of ACS. It should be noted that CAD may coexist with myocarditis 
in particular scenarios, including EM and ICI-induced myocarditis.249‚Äì251 
Cardiac catheterization is also indicated to monitor and guide HF 
therapy, as well as the early need for more advanced support (HT or 
MCS) in the case of refractory haemodynamic deterioration.12 
Table 11 Parameters for reporting by endomyocardial 
biopsy 
Criteria 
Parameters for reporting  
Histology (paraffin-embedded EMB, 
at least 3 EMB) 
Presence and extent of 
cardiomyocyte necrosis, 
inflammation, fibrosis 
Immunohistology 
(paraffin-embedded EMB, at least 3 
myocardial samples) 
Presence, extent, localization, and 
typing of immune cells in the 
myocardium: CD3+ T lymphocytes, 
CD68+ macrophages 
(‚â•14 leucocytes/mm2 with T 
lymphocytes ‚â•7 cells/mm),10 
HLA-DR expression in immune 
cells and endothelial cells 
Molecular pathology [infections: 
RNAlater, snap-frozen tissue (1‚Äì2 
EMB), paraffin-embedded EMB]     
Blood 
Presence, typing, and quantification 
of DNA/RNA from infectious 
agents by q(RT)-PCR 
Viruses: mainly enteroviruses, 
parvovirus B19, human herpesvirus 6, 
Epstein‚ÄìBarr virus; Borrelia spp., 
Trypanosoma cruzia 
q(RT)-PCR for detection of 
systemic infections 
Molecular pathology (genetics: 
RNAlater, frozen tissue, 
paraffin-embedded EMB, blood) 
NGS for detection of pathogenic 
variants in cardiac genes, 
traditionally associated with 
cardiomyopathies (especially 
desmosomal and sarcomeric/ 
cytoskeletal genes) 
¬© ESC 2025
DNA, deoxyribonucleic acid; EMB, endomyocardial biopsy; HLA-DR, human leucocyte 
antigen‚ÄîDR isotype; NGS, next-generation sequencing; q(RT)-PCR, quantitative 
(real-time) polymerase chain reaction; RNA, ribonucleic acid. 
aSee Supplementary data online, Table S1.  
Recommendation Table 7 ‚Äî Recommendations for 
autopsy (see Evidence Table 7) 
Recommendations 
Classa 
Levelb  
Comprehensive autopsy is recommended in all 
patients <50 years of age with SCD to evaluate the 
presence of acute myocarditis as a cause and to 
detect potential underlying inherited cardiac 
diseases.87,243‚Äì246c 
I 
B 
Retaining samples suitable for DNA extraction and 
consulting a cardiac pathologist is recommended in 
cases of SCD, when an inherited cause is suspected, 
or the cause of death remains unexplained.243,247c 
I 
B 
¬© ESC 2025
DNA, deoxyribonucleic acid; SCD, sudden cardiac death. 
aClass of recommendation. 
bLevel of evidence. 
cIn line with the 2022 ESC Guidelines for the management of patients with ventricular 
arrhythmias and the prevention of sudden cardiac death.58   
ESC Guidelines                                                                                                                                                                                               35


<!-- PAGE 36 -->

### Page 36

For pericarditis, specific indications for cardiac catheterization include the differential diagnosis between restrictive CMP (RCM) or 
CP,252 when this differentiation cannot be done by multimodality imaging (see Supplementary data online, Section 2.6). 
5.12. Electro-anatomical mapping 
The diagnostic yield of traditional fluoroscopy-guided EMB in patients 
with suspected myocarditis may decrease with segmental or patchy 
myocardial involvement, as seen in CS. Electro-anatomical mapping, 
using bipolar and unipolar voltage mapping, allows the identification 
of low-voltage areas, which reflects abnormal myocardial tissue (scarring, inflammation), and therefore guides EMB.218‚Äì222 Unipolar 
EAM-guided EMB demonstrated a higher diagnostic yield than bipolar 
EAM (83% compared with 63%), consistent with the epicardial 
substrate.84,218,221 
A meta-analysis of 148 patients showed a higher diagnostic performance of EAM-guided EMB in CS compared with other forms of myocarditis. The sensitivity of any abnormal electrogram for a positive EMB 
was high (92%) but was associated with moderate specificity (58%).221 
Electro-anatomical mapping has demonstrated good sensitivity and 
specificity compared with CMR for the detection of pathological areas 
of the myocardium.218 The value of EAM to guide biopsy may be lower 
in AM as low-voltage areas correlate well with LGE, but not with oedema.253 There may also be discordance between low-voltage areas 
and LGE on CMR. However, the combination of unipolar/bipolar EAM 
with CMR findings increased the diagnosis yield of EMB,218 especially in 
CS.220 The EAM pattern may also help to differentiate between differential diagnoses, especially between CS and ARVC,254 as CS often involves 
the basal septum and exhibits a higher bipolar/unipolar low-voltage area 
ratio. The reported complication rate of EAM-guided EMB is <5%.218,221 
Programmed ventricular stimulation (PVS) has not been evaluated in 
the acute setting and should not be performed in the acute phase. It 
could be useful for arrhythmia stratification in selected patients with 
non-active myocarditis, with LGE and risk factors for ventricular arrythmias (Section 6.5).255 
6. Therapy 
The aim of medical therapy for IMPS is to relieve symptoms and to prevent complications, especially recurrences and mortality in complicated 
cases. Medical therapy targets include: (i) infectious agents; (ii) inflammation; (iii) immune-mediated processes; (iv) HF and ventricular 
dysfunction (in cases of myocarditis); (v) arrhythmias; and (vi) 
constriction (in cases of pericarditis). Treatments are individualized according to the specific case and the presumed or diagnosed pathogenesis, and specific therapeutic concepts will be discussed in the section 
covering specific causes. There may be differences depending on 
whether an isolated or a combined form is present. The current evidence is more focused on the isolated cases. For combined conditions, 
the leading one (myopericarditis or perimyocarditis) should guide the 
therapeutic decision-making and subsequent follow-up. 
6.1. Non-pharmacological therapy for 
inflammatory myopericardial syndrome 
An important non-pharmacological concept is the restriction of physical 
activity beyond sedentary activities until symptom resolution and clinical 
remission with normalization of inflammatory markers. This temporary 
limitation of physical activities should be individualized according to each 
patient, and the response to therapy until clinical remission. According 
to clinical presentation, at least 1 month is needed to reach clinical remission, but it can last longer. Depending on the stage and risk of the 
IMPS, physical activity should be tailored, and temporary restriction of 
physical activity is necessary in the acute phase of the disease (see 
Section 7). Previous consensus statements and guidelines11 have tried 
to provide a fixed time interval. This TF suggests personalizing the treatment until clinical remission based on a multiparametric assessment, 
which was also supported by the 2024 ACC expert consensus paper.9 
Clinical remission is defined as full regression of symptoms, as well as 
normalization of laboratory results (e.g. C-reactive protein, troponin levels) and investigations (ECG, evidence of PEff, CMR evidence of active 
inflammation) (Table 3). Additional testing (e.g. exercise testing and 
Holter monitoring) is recommended for patients with myocarditis for 
the detection of clinical remission. After a prolonged rest period, a gradual, monitored return to work and physical activity may be helpful, if necessary, guided by a qualified rehabilitation. Currently, evidence-based 
data are missing on this topic, and the decision must be individualized. 
6.2. Pharmacological therapy 
6.2.1. Pharmacological therapy for myocarditis 
6.2.1.1. General principles 
This section will focus on general aspects and non-aetiology-directed 
therapy. It should be recognized that evidence is very limited in this field 
and this document will provide guidance for clinical practice. 
Medical therapy of myocarditis is based on clinical presentation, case severity, and aetiology. It includes general supportive, non-aetiology-directed 
therapy (e.g. HF therapy),12,259 anti-arrhythmic therapy, and specific therapy (aetiology-directed therapy).58,260,261 Corticosteroids are considered 
for autoimmunity-associated cases to suppress the immune system, as first- 
line therapy in most cases. Severe cases are considered for MCS and HT. 
Uncomplicated cases of myocarditis usually present with chest pain 
and can be empirically treated with aspirin or non-steroidal anti- 
inflammatory drugs (NSAIDs) for the control of chest pain, if needed. 
This is supported by a small study showing no harm for patients treated 
with anti-inflammatory drugs.262 Concomitant use of colchicine is safe 
in patients with myopericarditis, preventing recurrences.263 In clinical 
practice, Œ≤-blockers are often used in patients with myocarditis. In a 
small study, Œ≤-blockers were associated with better outcomes, defined 
as freedom from cardiac death or HT.264 
Recommendation Table 8 ‚Äî Recommendations for 
electro-anatomical mapping (see Evidence Table 8) 
Recommendations 
Classa 
Levelb  
Electro-anatomical mapping should be considered in 
cases of suspected myocarditis (especially cardiac 
sarcoidosis) to guide endomyocardial 
biopsy.218,220,221,253,256‚Äì258 
IIa 
C 
¬© ESC 2025
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 37 -->

### Page 37

Several viruses can cause myocarditis and are mentioned in 
Section 3.4. The specific therapies for viral aetiologies can be found in 
Section 9.5 for influenza-, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-, and HIV-associated myocarditis. For specific 
aetiologies, refer to the subsections on LM (Section 9.1), EM 
(Section 9.2), GCM (Section 9.3), CS (Section 9.4), LC (Section 9.5.2), 
CD (Section 9.5.3), and ICI-associated myocarditis (Section 9.6.1.1). 
Specific medical therapies are summarized in Table 12. 
Table 12 Therapy for specific forms of myocarditis 
Lymphocytic myocarditis (virus-negative)  
1st line therapy 
Non-severe: prednisone 1 mg/kg/day p.o. then tapered 
Severe: i.v. methylprednisolone 7‚Äì14 mg/kg/day for 3 days, then 1 mg/kg/day p.o. 
2nd line therapy 
Oral corticosteroids + azathioprinea or mycophenolate mofetilb, cyclosporinec, methotrexated 
3rd line therapy 
IVIGe or plasmapheresisf 
Eosinophilic myocarditis 
1st line therapy 
Same as lymphocytic myocarditis + Treat EM-associated condition if identified 
2nd line therapy 
Same as lymphocytic myocarditis + Treat EM-associated condition if identified 
3rd line therapy 
‚Äì 
Giant-cell myocarditis 
1st line therapy 
Non-severe: prednisone 1 mg/kg/day p.o. then tapered 
Severe: i.v. methylprednisolone 7‚Äì14 mg/kg/day for 3 days, then 1 mg/kg/day p.o. + immunosuppressive 
(azathioprinea or mycophenolate mofetilb, cyclosporinec) 
2nd line therapy 
Antithymocyte Globulin (ATG)g cyclophosphamideh, rituximabi 
3rd line therapy 
‚Äì 
Cardiac sarcoidosis 
1st line therapy 
Non-severe: prednisone 1 mg/kg/day p.o., tapering from 40‚Äì60 mg daily 
Severe: i.v. methylprednisolone 7‚Äì14 mg/kg/day for 3 days, then 1 mg/kg/day p.o. 
2nd line therapy 
Methotrexated (1st choice), or azathioprinea mycophenolate mofetilb, cyclophosphamideh 
3rd line therapy 
Infliximabj or adalimumabk, rituximabi 
Lyme carditis 
1st line therapy 
(a) Oral antibiotics (mild cases): 
‚Äì Doxycycline 100 mg b.i.d. (14‚Äì21 days) 
‚Äì Amoxicillin 500 mg t.i.d. (14‚Äì21 days) 
‚Äì Cefuroxime axetil 500 mg b.i.d. (14‚Äì21 days) 
(b) i.v. antibiotics (severe cases): 
‚Äì Ceftriaxone 2 g/day (14‚Äì21 days) 
2nd line therapy 
i.v. antibiotics: 
Cefotaxime (2 g q8h √ó 14‚Äì21 days) or Penicillin G (18‚Äì24 MU/day i.v. q4h √ó 14‚Äì21 day) 
3rd line therapy 
‚Äì 
Chagas disease 
1st line therapy 
Benznidazole 5‚Äì7 mg/kg/day in 2 doses for 60 days 
Nifurtimox 8‚Äì10 mg/kg/day in 3 doses for 60‚Äì90 days 
2nd line therapy 
‚Äì 
3rd line therapy 
‚Äì                                                                                                                                                                    
Continued  
ESC Guidelines                                                                                                                                                                                               37


<!-- PAGE 38 -->

### Page 38

6.2.1.2. Fulminant myocarditis 
Fulminant myocarditis is a rare and severe presentation of myocarditis 
and a cause of cardiogenic shock, and should be treated accordingly 
with inotropic or vasopressor support or, if needed, MCS (see 
Section 6.3).265 It is crucial to be aware of the condition and, when 
needed, to refer patients to tertiary referral centres that can institute 
temporary MCS and perform early EMB. Early EMB has been independently associated with a lower rate of death or HT/left ventricular assist 
device (LVAD) at 1 year.57 The timely communication of biopsy results 
is crucial. Specific subtypes of FM (e.g. biopsy-proven non-infectious 
forms) may respond to immunosuppressive therapy in addition to 
guideline-directed medical care.12,34 An ongoing trial is evaluating corticosteroids for FM (ClinicalTrials.gov Identifier: NCT05150704). 
6.2.1.3. Acute myocarditis 
Acute myocarditis has a high rate of spontaneous recovery, especially in 
uncomplicated cases. In cases of AM diagnosed by EMB, up to 50% of 
patients have spontaneous recovery and up to 25% may have a persistent stable cardiac dysfunction. Only 10%‚Äì25% have a progressive ventricular dysfunction, which could lead to end-stage DCM, HT, or 
death.9 Treatment of AM depends on severity and clinical presentation. 
Risk stratification of these patients is mandatory to assess the required 
level of care. 
The acute phase of viral myocarditis (e.g. induced by cytolytic enteroviruses) is characterized by intense virus replication and myocyte necrosis and usually lasts for only a few days.266 Thus, early antiviral 
therapy directed against an identified virus is a potential therapeutic 
avenue to stop the development of viral myocarditis. The evidence 
on clinical application of antiviral agents is limited, and antiviral treatments should be agreed upon with an infectious disease expert as 
part of the IMPS team. 
Patients with AM show significant activation of the NLR family pyrin 
domain containing 3 (NLRP3) inflammasome in the heart, thus it is a 
potential therapeutic target in the acute phase of myocarditis.267 
Activation of NLRP3 functions as a rapid inducer of an inflammatory response through the production of IL-1Œ≤ and IL-18. Theoretically, promising agents are anti-IL-1 agents (anakinra, rilonacept, canakinumab) and 
colchicine,267 although human data on the effect of such agents in myocarditis are still limited. 
In humans, the first evidence has been reported using anakinra, an 
IL-1 receptor antagonist (IL-1RA) that improved heart function in selected cases of AM refractory to standard treatment. However, in 
the ARAMIS trial, anakinra failed to demonstrate a benefit in patients 
with suspected AM without a specific aetiology (NCT03018834).268 
The primary endpoint was the number of days alive free from any complication due to AM. The study had potential limitations related to the 
limited sample size, the inclusion of a low-risk population, and the short 
follow-up, but it proved that anakinra was safe in this setting. 
Regarding modulation of the immune response, further randomized 
studies are needed to assess treatment with intravenous immunoglobulins (IVIG) in AM for adults,269 since case series and retrospective analyses suggest a benefit in terms of transplant-free survival. Intravenous 
immunoglobulins are commonly prescribed in paediatric patients.269 In 
general, treatment of AM with corticosteroids is controversial, with the 
exception of ICI-induced myocarditis270 and EM.271 
ICI-induced myocarditis 
1st line therapy 
Withdraw ICI, reassess 
Non-severe: methylprednisolone 500‚Äì1000 mg/day √ó 3 days, then taper with oral prednisone 
Severe: i.v. methylprednisolone 7‚Äì14 mg/kg/day √ó 3 days, then 1 mg/kg/day 
2nd line therapy 
If no response in 24‚Äì48 h: mycophenolate mofetilb, ATGg abataceptl, alemtuzumabm 
3rd line therapy 
Infliximabj or adalimumabk, rituximabi 
¬© ESC 2025
ATG, anti-thymocyte globulins; b.i.d., twice daily; CTLA-4, cytotoxic T-lymphocyte antigen 4; EM, eosinophilic myocarditis; ICI, immune checkpoint inhibitor; IgG, immunoglobulin; IL, 
interleukin; i.v., intravenous; IVIG, intravenous immunoglobulins; p.o., by mouth; s.c., subcutaneous; t.i.d., three times daily; TNF-Œ±, tumour necrosis factor alpha. 
aAzathioprine (immunosuppressant purine analog): 1‚Äì2 mg/kg per day p.o. (typically 100‚Äì150 mg daily, in 1‚Äì2 divided doses, main target: lymphocytes). 
bMycophenolate mofetil (immunosuppressant that inhibits inosine monophosphate dehydrogenase, main target: lymphocytes): 500‚Äì1000 mg p.o. b.i.d. (total 1‚Äì2 g/day). 
cCyclosporine (calcineurin inhibitor that prevents IL-2 transcription in activated T-cells): ‚àº3‚Äì5 mg/kg/day p.o. (divided b.i.d.) adjusted to target trough levels ‚àº150‚Äì250 ng/mL. 
dMethotreaxate (antimetabolite that inhibits dihydrofolate reductase and other folate-dependent steps, reducing proliferation of active lymphocytes): 15‚Äì20 mg/week p.o. or s.c. (low-dose 
weekly, with folic acid supplementation). 
eIVIG (immunomodulatory therapy providing pooled IgG antibodies) = standard dose off-label 2 g/kg total dose, typically administered over 1 to 2 days; alternative dosing: 0.4 g/kg/day for 5 
consecutive days (less commonly used in myocarditis but sometimes used in autoimmune settings). 
fPlasmapheresis (therapeutic plasma exchange that filters out and removes circulating autoantibodies, immune complexes, and inflammatory mediators) 3‚Äì5 sessions in 5‚Äì10 days. 
gAntithymocyte Globulin (ATG; polyclonal anti-T-lymphocyte antibody that causes profound T-cell depletion): ‚àº1 mg/kg i.v., often given daily for 3‚Äì5 days. 
hCyclophosphamide (cytotoxic alkylating agent that crosslinks DNA in rapidly dividing cells, main target: lymphocytes): 600 mg/m¬≤ i.v. bolus on days 1, 15, and 30 (pulse therapy). 
iRituximab (monoclonal antibody against CD20 on B cells): 375 mg/m¬≤ i.v. weekly √ó 4 doses (1 month). 
jInfliximab (monoclonal antibody against TNF-Œ±): 5 mg/kg i.v. at weeks 0, 2, 6, then every ‚àº8 weeks (maintenance). 
kAdalimumab (anti-TNF-Œ± fully human monoclonal antibody) 40 mg SC every week (or every 2 weeks, per clinical response). 
lAbatacept (CTLA-4 Ig fusion protein that binds CD80/86 on antigen-presenting cells, blocking the CD28 co-stimulatory signal required for full T-cell activation): 500 mg i.v. every 2 weeks √ó 5 
doses (approximately 10 weeks). 
mAlemtuzumab (monoclonal antibody against CD52 on lymphocytes): 30 mg i.v. once (alternative: 15 mg i.v. daily for 2 days).  
Main mechanisms of action:  
‚Ä¢ T-cell suppression (e.g., corticosteroids, cyclosporine, abatacept)  
‚Ä¢ B-cell depletion (rituximab)  
‚Ä¢ Cytokine inhibition (TNF-Œ± blockers like infliximab, adalimumab)  
‚Ä¢ DNA synthesis inhibition (azathioprine, mycophenolate, methotrexate)  
‚Ä¢ Immunoglobulin replacement/modulation (IVIG)  
‚Ä¢ Plasma filtration (plasmapheresis)


<!-- PAGE 39 -->

### Page 39

The efficacy of combined immunosuppression (prednisone with either cyclosporine or azathioprine), compared with placebo, was assessed in a single randomized controlled trial (RCT) in patients with 
biopsy-proven AM of unspecified aetiology, since infectious causes 
were not excluded by PCR.272 The trial was designed to determine 
whether immunosuppressive therapy improved LV function in patients 
with AM. There was no significant difference in survival between the 
two groups (P = 0.96). The study had several limitations, such as small 
sample size and incomplete analysis of EMB based only on histopathology. However, in specific histopathological forms of AM, such as 
GCM, immunosuppressive drugs are recommended (see Sections 9.2 
and 9.3). 
6.2.1.4. Subacute and chronic myocarditis 
Chronic myocarditis may represent an intermediate stage between 
subacute myocarditis and inflammatory CMP. During chronic myocarditis, HF may develop, and guideline-directed medical therapy 
(GDMT) for HF is the cornerstone in the treatment of chronic myocarditis.12,259 Antiviral therapy has little benefit in the subacute and 
chronic stages of myocarditis,273 and the effects of immunomodulatory drugs on chronic myocarditis of unspecified aetiology are still 
controversial. 
6.2.2. Pharmacological therapy for pericarditis 
6.2.2.1. General principles 
The aims of medical therapy for pericarditis are to provide: (i) symptomatic care (mainly control of pericarditis chest pain); (ii) clinical remission; and (iii) prevention of complications, especially recurrences 
and constriction. 
Exercise restriction limits the heart rate and may be useful to reduce 
pericardial friction, which can be improved using drugs that reduce it 
(e.g. Œ≤-blockers or ivabradine for those who cannot receive or tolerate 
Œ≤-blockers) for patients with a resting heart rate of >75 b.p.m., and 
symptoms despite empirical anti-inflammatory therapy.274 
6.2.2.1.1. Acute pericarditis (first episode). The mainstay of medical 
therapy is empirical anti-inflammatory therapy using aspirin or NSAIDs 
at full anti-inflammatory doses with appropriate time intervals of administration (usually every 8 h) plus colchicine to reduce the risk of recurrences.24,25,108,275‚Äì278 Gastroprotection with a proton pump 
inhibitor is recommended using NSAIDs.279 
When aspirin and NSAIDs are contraindicated, or for specific indications, corticosteroids should be considered at low to moderate doses 
plus colchicine (see Tables 13 and 14). 
In cases of incomplete response to aspirin/NSAIDs and colchicine, 
corticosteroids may be added at low to moderate doses as triple therapy.1 In cases of recurrence, every effort should be made not to increase the dose or to reinstate corticosteroids. 
The use of colchicine on top of empirical anti-inflammatory therapy 
is supported by most of the published evidence, with the single exception of a small open-label trial that was probably underpowered to 
test the study hypothesis for patients with AP.281 Specific dosing 
and duration of therapy are summarized in Table 13. Monitoring of 
serum C-reactive protein and CMR imaging is recommended to assess 
clinical remission, guide the treatment length, and evaluate the response to therapy in more complicated and difficult-to-treat cases. 
In uncomplicated cases, clinical follow-up with/without echocardiography is sufficient. 
6.2.2.2. Incessant and recurrent pericarditis 
In patients with incessant pericarditis or RP, the mainstay of therapy 
is always colchicine in association with aspirin/NSAID or low to 
moderate doses of corticosteroids. For more difficult cases, chest 
pain can be controlled by a combination of aspirin or an NSAID 
plus corticosteroids at low to moderate doses and colchicine (triple 
therapy). The i.v. route should be considered to ensure a clinical response or to control symptoms in more difficult or resistant cases. 
Recommendation Table 9 ‚Äî Recommendations for 
medical therapy in myocarditis (see Evidence Table 9) 
Recommendations 
Classa 
Levelb  
Management of symptoms 
NSAIDs (together with proton pump inhibition) 
should be considered in patients with associated 
symptoms of pericarditis to reduce symptoms. 
IIa 
C 
Colchicine should be considered in patients with 
myopericarditis to reduce recurrences.263 
IIa 
B 
Management of heart failure 
Adherence to the ESC HF guidelines is 
recommended in cases of myocarditis with LV 
systolic dysfunction and/or HF to reduce symptoms 
and to improve LV function.12 
I 
C 
HF therapy should be considered in patients with 
myocarditis and LV systolic dysfunction for at least 
6 months upon complete LV functional recovery to 
stabilize LV function. 
IIa 
C 
Management of arrhythmias 
Œ≤-Blockers, with a continuation for at least 6 months, 
should be considered in patients with acute 
myocarditis, especially those with troponin elevation, 
to control symptoms and prevent arrhythmias. 
IIa 
C 
Anti-arrhythmic treatment should be considered in 
post-myocarditis patients with recurrent, 
symptomatic VT to reduce arrhythmic burden.58 
IIa 
C 
Immunosuppressive therapy 
Corticosteroids should be considered in patients 
with fulminant, non-infectious forms of myocarditis 
to stabilize the patients. 
IIa 
C                                                                                                   
Continued 
Corticosteroids may be considered in patients with 
acute myocarditis with impaired LVEF if refractory to 
standard HF therapy to stabilize patients. 
IIb 
C 
Routine use of immunosuppressive therapy is not 
recommended in acute myocarditis with preserved 
LV function because no outcome benefit has been 
shown. 
III 
C 
¬© ESC 2025
ESC, European Society of Cardiology; HF, heart failure; LV, left ventricle; LVEF, left 
ventricular ejection fraction; NSAID, non-steroidal anti-inflammatory drug; VT, 
ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               39


<!-- PAGE 40 -->

### Page 40

Patients who develop a recurrence during corticosteroid tapering 
should continue colchicine and receive an NSAID on top of this treatment instead of increasing the dose of corticosteroids. Which medication should be tapered first (corticosteroids or NSAID) depends on the 
specific clinical scenario (age, kidney function, haemorrhagic risk, and 
use of oral anticoagulants). 
For patients with corticosteroid dependence, colchicine resistance, 
and evidence of elevated C-reactive protein (baseline or subsequent 
episode), clinical trials and an international registry supported the use 
of an anti-IL-1 agent (anakinra or rilonacept).108,275,282‚Äì284 An 
advantage of these agents is the rapid onset of action and the possibility 
of rapid withdrawal of corticosteroids.285 There is evidence of efficacy 
with anti-IL-1 agent (anakinra or rilonacept) monotherapy.108,275,282‚Äì284 
However, concomitant use of colchicine could be helpful to reduce recurrences and prolong recurrence-free survival, providing a sequential 
block of the pro-inflammatory pathway leading to the generation of 
IL-1.286 Colchicine should be maintained and withdrawn as the last 
drug only after stable remission. Moreover, colchicine has the safest cardiovascular profile and is now proposed to prevent major adverse cardiac 
events (MACE) in patients with atherosclerotic cardiovascular diseases.248 In patients obtaining stable remission with a chronic low dose 
of corticosteroids (e.g. prednisone ‚â§5 mg or equivalent) plus colchicine, 
the decision of switching to IL-1 blocker treatment should be tailored to 
the patient on an individualized basis, taking into account several parameters (such as tolerability, age and sex issues, patient preference). 
The use of anti-IL-1 agents may be associated with a moderate increase 
in the overall risk of mild to moderate infections. Safety data on anti-IL-1 
agents are reassuring when considering new malignancy risk, whereas 
their safe administration in patients with known active malignancies has 
not been well investigated to date. 
There is limited evidence for other drugs for pericarditis. 
Azathioprine has been empirically used in patients with recurrences 
and a lack of response to first- and second-level options such as aspirin/NSAID, colchicine, and corticosteroids.287 However, this drug 
seems more appropriate as a steroid-sparing agent, and has limited efficacy for those with acute pain. Intravenous immunoglobulins have 
also been tested in patients with refractory RP after failure of first 
and second options, as well as anti-IL-1 agents. These drugs may be 
efficacious either for infectious or non-infectious aetiologies, since 
they are able to clear infectious agents and modulate the immune 
response.288 Both corticosteroids and immunoglobulins have been  
Table 13 Specific initial dosing and duration of therapy for acute and recurrent pericarditis 
Therapy 
Dosing 
Durationa 
Taperinga  
Aspirinb 
750‚Äì1000 mg 3 times daily 
1‚Äì2 weeks 
Decrease by 250 mg every 1‚Äì2 weeks 
Ibuprofenb 
600‚Äì800 mg 3 times daily 
1‚Äì2 weeks 
Decrease by 200 mg every 1‚Äì2 weeks 
Indomethacin 
25‚Äì50 mg 3 times daily 
1‚Äì2 weeks 
Decrease by 25 mg every 1‚Äì2 weeks 
Colchicineb 
0.5 mg once daily (<70 kg or severe renal impairment) or 0.5 mg 
twice daily 
3‚Äì6 months 
Not required 
Prednisone 
0.2‚Äì0.5 mg/kg/day 
2‚Äì4 weeks 
Several months 
Treatment for recurrences only: 
Azathioprine 
Starting with 1 mg/kg/day then gradually increased to 2‚Äì3 mg/kg/day 
Several months 
Several months 
IVIG 
400‚Äì500 mg/kg i.v. daily for 5 days 
5 days 
Not required 
Anakinra 
1‚Äì2 mg/kg/day up to 100 mg/day in adults 
At least 6 months/ 
>12 months 
Needed (at least 3‚Äì6 months)/ 
unknown 
Rilonaceptc 
320 mg once daily followed by 160 mg weekly 
¬© ESC 2025
IVIG, intravenous immunoglobulins; NSAID, non-steroidal anti-inflammatory drug. 
Treatment for recurrences only is highlighted in grey. 
aTherapy duration as initial dosing; for all treatments the attack dose is maintained until symptom resolution and normalization of inflammatory markers (e.g. C-reactive protein) and other 
investigations (electrocardiogram, echocardiogram) then tapering is recommended. It should be tailored to the single patient according to disease severity and patient response. Tapering is 
especially important for corticosteroids where tapering is particularly slow, especially below 15 mg/day, the common threshold for recurrences (see Table 14). Monitoring is essentially based 
on the assessment of blood count, creatinine, creatine kinase, transaminases, C-reactive protein, echocardiography. Anakinra should be tapered after clinical remission. Different schemes are 
adopted: e.g. reducing one dose per week every month; every other day full dose for at least 3 months then half-dose every other day for at least 3 months. 
bAspirin and ibuprofen are common first-level treatments for the first episode of pericarditis (acute pericarditis) associated with colchicine for at least 3 months. Aspirin is the preferred 
choice for patients with ischaemic heart disease. Indomethacin is usually considered for incessant/recurrent cases. In incessant/recurrent cases, colchicine is maintained for at least 
6 months. Aspirin/NSAID full dose is recommended for patients with normal or mildly reduced renal function. For those with moderate to severe renal impairment, dose adjustment or 
use of corticosteroids is recommended. 
cRilonacept is registered in the USA but is not currently available in Europe. Anakinra, due to its short half-life, may be the preferable choice in patients at increased risk of infections.  
Table 14 Tapering of corticosteroids 
Prednisone 
dosea 
Starting dose 
0.20‚Äì0.50 mg/ 
kg/daya 
Taperingb  
Prednisone 
daily dose 
>50 mg 
10 mg/day every 1‚Äì2 weeks  
50‚Äì25 mg 
5‚Äì10 mg/day every 1‚Äì2 weeks  
25‚Äì15 mg 
2.5 mg/day every 2‚Äì4 weeks  
<15 mg 
1.25‚Äì2.5 mg/day every 2‚Äì6 weeks 
¬© ESC 2025
aAvoid higher doses except for special cases, and only for a few days, with rapid tapering to 
25 mg/day. Prednisone 25 mg is equivalent to methylprednisolone 20 mg. 
bEvery decrease in prednisone dose should be done only if the patient is asymptomatic and 
C-reactive protein is normal, particularly for doses of <25 mg/day. 
Calcium intake (supplement plus oral intake) of 1200‚Äì1500 mg/day and vitamin D 
supplementation of 800‚Äì1000 IU/day should be offered to all patients receiving 
glucocorticoids. Moreover, bisphosphonates are recommended to prevent bone loss in 
all men aged ‚â•50 years and postmenopausal women in whom long-term treatment with 
glucocorticoids is initiated at a dose of ‚â•5.0‚Äì7.5 mg/day of prednisone or equivalent.280


<!-- PAGE 41 -->

### Page 41

proposed for a non-inflammatory presentation (so-called non- 
inflammatory phenotype).288,289 
More recently, hydroxychloroquine has shown a steroid-sparing effect and increased flare-free survival in RP in patients with colchicine resistance and corticosteroid dependence.290 Treatment duration with 
aspirin/NSAIDs and steroids should be extended in an individualized 
manner, and the tapering process should be slower than for a first episode of AP.1 
The dosing and duration of most common drugs used for pericarditis 
is summarized in Table 13, while the proposed algorithm of medical 
therapy for pericarditis (not including interventional therapies and pericardiectomy) is illustrated in Figure 16. 
Patient with acute pericarditis
Exercise-restriction and Ô¨Årst level therapya:
ASA or NSAID (usually ibuprofen or indomethacin) plus colchicine
(Class I)
Tapering of ASA/NSAID
and colchicineb for 3‚Äì6 months to reduce recurrence risk
Incessant/recurrent
If ASA/NSAID 
contraindicated 
or not tolerated
Response to medical therapy
Low to moderate doses of corticosteroids plus colchicine or triple medical therapy with corticosteroids, NSAID and colchicinec
(Class IIa)
Incessant/recurrent
Response to medical therapy
Tapering of corticosteroids and colchicineb for at least 6 months to reduce recurrence risk
Anti-IL-1 agents
(Anakinra or Rilonacept)
(Class I)d
If corticosteroids 
contraindicated 
or not tolerated
Figure 16 Proposed algorithm of medical therapy for pericarditis in adults (not including interventional therapies and pericardiectomy). ASA, acetyl 
salicylic acid; IL-1, interleukin-1; CRP, C-reactive protein; CMR, cardiovascular magnetic resonance; LOE, level of evidence; N, no; NSAID, non-steroidal 
anti-inflammatory drug; Y, yes. aASA is the first option if patients are already on antiplatelet therapy with ASA. Ibuprofen is usually preferred as the first 
NSAID. Try more than one agent to evaluate response. Gastroprotection with a proton pump inhibitor is always recommended with use of aspirin/ 
NSAID. bColchicine is recommended to prevent recurrence. Consider at least 3 months for the first episode of pericarditis and at least 6 months for 
incessant/recurrent cases. Colchicine to be withdrawn as last drug only after stable remission. Tapering is recommended to reduce the persistence/ 
recurrence of symptoms. Tapering is slower for corticosteroids. Colchicine tapering is usually not performed due to the duration of >3‚Äì6 months 
of therapy. Suggested schemes of tapering are reported in Table 12. For response to therapy we considered clinical remission. cLow to moderate 
dose of corticosteroids (e.g. prednisone 0.2‚Äì0.5 mg/kg/day or equivalent doses of an alternative corticosteroid). dClass I LOE A, Class IIa LOE C regardless of C-reactive protein levels if CMR evidence of pericardial inflammation.   
ESC Guidelines                                                                                                                                                                                               41


<!-- PAGE 42 -->

### Page 42

6.3. Interventional techniques including 
circulatory support 
6.3.1. Myocarditis 
6.3.1.1. Short-term mechanical circulatory support 
Myocarditis patients who present with rapid deterioration in haemodynamic status and rapidly progressive myocardial dysfunction are 
amongst those who respond best to temporary MCS.293 Among temporary MCS, veno-arterial extracorporeal membrane oxygenation 
(VA-ECMO) represents the most frequently applied or recommended 
approach, ranging from 75% to 85% of AM cases.75,294‚Äì296 Despite the 
high risk and markedly compromised state of patients undergoing 
VA-ECMO support for FM, the prognosis is rather favourable, with a 
high rate of myocardial recovery and patient survival. Several national 
and international multicentre studies showed in-hospital survival ranging from 61% to 72%,297‚Äì300 but no freedom from HT in patients 
with giant-cell FM.294 Temporary MCS should be performed early 
and in a timely manner in patients with FM with refractory cardiogenic 
shock because of the high likelihood of recovery. 
6.3.1.2. Intra-aortic balloon pump 
As mentioned, EMB should be performed as soon as possible, even in 
the presence of temporary MCS,212,295 and specific immunosuppressive therapy should be considered at least as an initial option, while determining the myocardial response.295 An intra-aortic balloon pump 
(IABP) should be considered in cardiogenic shock as first-line MCS 
with prompt escalation to more powerful MCS if haemodynamic and 
end-organ perfusion improvement is not observed within a short 
time (1 h maximum).295 
6.3.2. Pericarditis 
Pericardium-related interventional procedures are increasingly applied 
and require specific expertise.1,301 The use of percutaneous interventional techniques for pericarditis is not limited to perform percutaneous drainage, but also to obtain fluid samples for cytology and other 
pathological examinations (see Supplementary data online, Table S7). 
Moreover, interventional techniques are used to provide alternative 
treatment, such as balloon pericardiotomy or, less commonly, intrapericardial drug administration (e.g. corticosteroids or chemotherapy). 
6.3.2.1. Pericardiocentesis and pericardial drainage 
Percutaneous pericardiocentesis guided by echocardiography or fluoroscopy is indicated for CTP and symptomatic moderate to large PEffs 
Recommendation Table 10 ‚Äî Recommendations for 
medical therapy in pericarditis (see Evidence Table 10) 
Recommendations 
Classa 
Levelb  
Colchicine is recommended as first-line therapy 
in patients with pericarditis as an adjunct 
to aspirin/NSAID or corticosteroid therapy 
to reduce subsequent recurrences.24,25,108,275‚Äì278 
I 
A 
Anti-IL-1 agents (anakinra or rilonacept) are 
recommended for patients with recurrent 
pericarditis after failure of first-line therapies and 
corticosteroids and elevation of C-reactive protein 
levels to reduce recurrences and allow 
corticosteroid withdrawal.108,275,282‚Äì284 
I 
A 
High-dose aspirin or NSAIDs with proton pump 
inhibitors are recommended as first-line therapy in 
patients with pericarditis to control symptoms and 
reduce recurrences.291,292 
I 
B 
A Œ≤-blocker should be considered in symptomatic 
patients, despite full anti-inflammatory therapy, and 
heart rate at rest >75 b.p.m. in order to improve 
symptom control.274 
IIa 
C 
Anti-IL-1 agents (anakinra or rilonacept) should be 
considered in cases of incessant/recurrent 
pericarditis with evidence of pericardial inflammation 
on CMR after failure, contraindications, and 
intolerance to first-line therapies and corticosteroids 
regardless of C-reactive protein levels to reduce 
recurrences and allow corticosteroid withdrawal. 
IIa 
C 
Low- to medium-dosec corticosteroids should be 
considered for patients with pericarditis only in cases 
of contraindication/failure of aspirin/NSAIDs and 
colchicine, or when there is a specific indication to 
control symptoms and reduce recurrencesd. 
IIa 
C 
Hydroxychloroquine may be considered in patients 
with recurrent pericarditis refractory to standard 
therapy (including corticosteroids and anti-IL-1 
agents) to prolong recurrence-free survival.290 
IIb 
B 
Corticosteroids are not recommended as the first 
option for patients with pericarditis therapy without 
a specific indicationd. 
III 
C 
¬© ESC 2025
b.p.m., beats per minute; CMR, cardiovascular magnetic resonance; IL, interleukin; NSAID, 
non-steroidal anti-inflammatory drug. 
aClass of recommendation. 
bLevel of evidence. 
cSee Table 13. 
dFor example, systemic inflammatory disease on maintenance therapy with corticosteroids, 
post-pericardiotomy syndromes, post-vaccine pericarditis, severe renal failure, 
concomitant therapies interacting with NSAIDs such as oral anticoagulant.  
Recommendation Table 11 ‚Äî Recommendations for 
interventional techniques including circulatory support 
in myocarditis (see Evidence Table 11) 
Recommendations 
Classa 
Levelb  
A timely and dedicated Shock Team discussion is 
recommended in patients with myocarditis in the 
presence of haemodynamic compromise, to decide 
on the need for escalation to MCS and to determine 
a long-term management plan. 
I 
C 
Temporary MCSc should be considered in patients 
with myocarditis and cardiogenic shock or acute 
decompensation in chronic myocarditis to stabilize 
the patients. 
IIa 
C 
¬© ESC 2025
IABP, intra-aortic balloon pump; MCS, mechanical circulatory support; PLVAD, 
percutaneous left ventricular assist device; VA-ECMO, veno-arterial extracorporeal 
membrane oxygenation. 
aClass of recommendation. 
bLevel of evidence. 
cIABP, PLVAD, VA-ECMO.


<!-- PAGE 43 -->

### Page 43

not responding to medical therapy, or when a search for aetiological 
agents is needed (e.g. suspicion of cancer, bacterial infection). 
Whenever possible, pericardiocentesis should not drain a large amount 
of pericardial fluid (usually <500 mL) to prevent pericardial decompression syndrome. Complete drainage of the PEff can be achieved, 
leaving a drain to be removed when the daily drainage is <30 mL. 
Surgical drainage is required when percutaneous pericardiocentesis is 
not feasible or purulent effusion is present, to allow complete drainage 
of the effusion and prevent its organization. Clinical triage has been proposed to indicate urgent management.118 An overall score of >6 indicates the need for urgent pericardiocentesis, whereas a lower score 
suggests delaying the intervention (see Figure 12). 
Imaging is an essential component for guiding percutaneous pericardiocentesis. Under echocardiography, CT, or fluoroscopic guidance, 
a needle (usually 16‚Äì20 gauge) should be introduced into the sub- 
xyphoid space, although an apical or left-lateral approach might be 
used. The catheter should usually remain in situ for a few days, also 
based on the type and efficacy of concomitant systemic and/or topic 
pharmacological treatment.1 
6.3.2.2. Percutaneous balloon pericardiotomy 
Percutaneous balloon pericardiotomy represents a percutaneous alternative to the endoscopic or surgical pleuro-pericardial window, which allows relapsing pericardial fluid to be absorbed through the ample pleural 
serosa, especially as palliative and temporary relief.1 It should not be used 
as a first- or second-line intervention, but rather reserved for very rare 
cases, such as recurrent neoplastic PEff and CTP, as well as for absolute 
contraindications for surgery or in the case of a very poor quality of life in 
terminal patients (see Supplementary data online, Table S8).1 
6.3.2.3. Intrapericardial drug administration 
Percutaneous access to the pericardium is done using an intrapericardial 
catheter following pericardial drainage. It may be used to deliver drugs 
targeting different conditions. Anti-inflammatory agents have been delivered with some efficacy. Intrapericardial crystalloid triamcinolone, 
300 mg/m2 of body surface, can be used for autoreactive or recurrent 
PEffs that do not respond to other conventional therapies, and to avoid 
or limit systemic side effects of oral corticosteroids. Chemotherapeutics 
have also been delivered, such as cisplatin and thiotepa (usually for lung 
and breast cancer, respectively), with demonstrated reduction of PEff relapse.302‚Äì304 Currently, due to improved chemotherapy, the systemic 
route is favoured, and therapeutic planning should involve a multidisciplinary team with cardiologists and oncologists. 
Sclerosing agents, such as talc, to enhance pericardium‚Äìepicardium 
adherence and to reduce relapsing PEff, should not be used, because 
of reduced efficacy compared with a pericardial window or pericardiectomy, and the risk of inducing constriction.305,306 
6.3.2.4. Pericardioscopy 
This procedure is sometimes considered as part of the diagnostic work- 
up, allowing pericardial biopsy. Pericardial access is also increasingly 
used for mapping and ablation of the epicardial substrates of VA, 
with an improved success rate and avoidance of a surgical procedure. 
6.3.2.5. Pericardial fluid analysis, pericardial and epicardial biopsy 
Percutaneous pericardial access may be used also to provide fluid samples 
for pathological and pathogen examinations (bacterial or viral aetiology), 
and/or to perform pericardial as well as epicardial biopsies, particularly 
in cancer screening (see Supplementary data online, Table S7).1 
6.3.2.6. Circulatory support 
Mechanical circulatory support has been shown to be applied in up to 
12% of pericardiectomy patients with pre-procedural RV dilatation/ 
dysfunction,307‚Äì309 and is sometimes considered peri-operatively.307‚Äì 
309 The association of pre-procedural RV dilatation/dysfunction and reduced LV function also represent risk factors for a peri-procedural risk 
of early mortality, calling for timely and prophylactic MCS.308 
6.4. Surgical therapy 
6.4.1. Myocarditis 
The surgical treatment of myocarditis mainly accounts for HT, when there 
is no myocardial recovery. In addition to infective or autoimmune aetiologies, radiation-induced myopericarditis (usually secondary to haematological cancer) may contribute to the indications for such an 
intervention. Limited series of HTs due to radiation-induced myocarditis 
have been described with satisfactory results. Secondary malignancy, lung 
and kidney failure are negative prognostic factors for post-operative morbidity and mortality.310 A durable ventricular assist device (VAD) or a total 
artificial heart are other alternatives for advanced cardiac support.295 
6.4.2. Pericarditis 
6.4.2.1. Surgical pericardiocentesis 
Surgical pericardiocentesis is rarely performed for urgent/emergency 
conditions, but for large PEff requiring expeditious drainage, not achievable with percutaneous-based drainage (e.g. for purulent PEff or clot 
aspiration). 
6.4.2.2. Pericardiotomy/pericardial window 
These surgical procedures are carried out to create a connection, namely 
a pleuro-pericardial window, usually between the lateral or left posterior 
pericardium and the left pleura. The indication is relapsing PEff with 
haemodynamic compromise despite conservative treatment or percutaneous drainage. The pleuro-pericardial window is meant to promote drainage from the pericardium to the left pleural space.1 Such a window may be 
created by a small thoracotomy or endoscopically. In selected cases, a 
pericardial window can also be created in the peritoneal cavity. 
Recommendation Table 12 ‚Äî Recommendations for 
interventional techniques in pericarditis (see Evidence 
Table 12) 
Recommendations 
Classa 
Levelb  
Pericardiocentesis (echocardiography-, CT-, or 
fluoroscopy-guided) is recommended for cardiac 
tamponade, or suspected bacterial or neoplastic 
pericarditis, or symptomatic moderate to large 
pericardial effusion despite medical therapy. 
I 
C 
Surgical pericardial drainage is recommended in 
patients with pericardial effusion when percutaneous 
pericardiocentesis is not feasible or with purulent 
pericardial effusion to allow complete drainage and 
to prevent constriction. 
I 
C 
Surgical pleuro-pericardial window is recommended 
in patients with relapsing pericardial effusion despite 
medical therapy. 
I 
C 
¬© ESC 2025
CT, computed tomography. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               43


<!-- PAGE 44 -->

### Page 44

6.4.2.3. Pericardiectomy 
Pericardiectomy is the mainstay treatment for chronic constriction or 
CP not responding to anti-inflammatory therapy.311 Complete pericardiectomy is recommended for the management of CP, as it offers superior long-term outcomes and significantly reduces the risk of 
recurrences compared with partial anterior or anterophrenic pericardiectomy, which may leave residual constrictive tissue and contribute 
to persistent or recurrent symptoms. Due to the relative rarity of 
the condition, and the complexity of patients, pericardiectomy should 
be performed at high-volume centres that have the required expertise. 
Early pericardiectomy within 6 months after the onset of symptoms is 
associated with the lowest operative mortality.312,313 The occurrence of 
refractory RP and/or pericardial fluid formation, despite optimal medical 
and interventional therapy, is also considered a possible indication for 
surgical pericardiectomy. In the absence of a surgical plane for proper decortication, a pragmatic approach, named the waffle procedure, can be 
considered. This technique utilizes longitudinal and horizontal incisions 
to allow some relief of constriction. However, it usually offers only temporary improvement, with a high rate of recurrent constriction.314,315 
Extracorporeal circulation may be required in difficult operative conditions, such as extensive calcifications with a high risk of marked bleeding 
during pericardiectomy. Previous 2015 ESC guidelines recommended resection ‚Äòof as much as possible‚Äô of the pericardium with avoidance of cardiopulmonary bypass (CBP), using this only in circumstances of difficult 
control of bleeding.1 Cardiopulmonary bypass can play an important 
role in enabling safe and complete pericardiectomy, particularly in selected complex or high-risk cases. 
Pericardiectomy is commonly performed without CPB. However, 
CPB may be necessary in specific clinical scenarios. These include 
dense adhesions between the pericardium and the myocardium, 
particularly involving the posterior surface of the heart. CPB is 
also indicated in cases of haemodynamic instability during dissection. 
This is especially relevant when heart lifting is required to access the 
diaphragmatic or posterior pericardium. Additional indications 
include calcific constrictive pericarditis with myocardial involvement, challenging anatomical conditions, or the need for concomitant cardiac procedures, such as valve surgery or coronary artery 
bypass grafting. 
Possible benefits of CPB include providing a bloodless field and improved visibility for complete pericardial resection, especially posteriorly, avoiding myocardial injury by decompressing the heart during 
dissection, maintaining haemodynamic stability, particularly in patients 
with borderline cardiac output or tamponade physiology. However, 
the full heparinization required to perform CPB may, in some cases, 
favour bleeding generated by pericardial resection. Therefore, the 
indication for the use of CPB must always be taken into consideration 
intra-operatively and according to the anatomical as well as haemodynamic conditions encountered during the surgical procedure. It is, 
however, self-explanatory that a radical pericardiectomy, including 
also the posterior site of the pericardium, would be usually possible 
and advisable with the application of CPB. However, diaphragmatic 
pericardial resection may often be performed without CPB use, taking 
care to perform resection in a stepwise manner, without prolonging 
heart lifting and avoiding marked haemodynamic compromise. 
Heart transplantation is very rarely indicated in patients with CP. 
However, it may be considered as a last-resort option in highly selected, 
exceptional cases. This applies when pericardiectomy is not feasible or 
cannot be completed due to extensive pericardial calcification with myocardial involvement, prior surgeries, radiation therapy, or infections that 
have caused severe adhesions and scarring. Surgical inaccessibility of 
critical regions, such as the posterior pericardium, may also preclude 
complete resection. In some patients, persistent heart failure symptoms 
and progressive functional deterioration may occur despite maximal 
medical therapy and attempted pericardiectomy. In these cases, heart 
transplantation might be considered. 
It is also an option when coexistent myocardial disease or a mixed constrictive‚Äìrestrictive physiology is present, where pericardial resection 
would not be expected to improve symptoms or haemodynamic function. 
In CP, tricuspid regurgitation (TR) is a common finding due to chronic elevated right-sided pressures, annular dilation secondary to longstanding volume overload and atrial enlargement, tethering of leaflets 
due to pericardial constraint. When TR is present in patients undergoing pericardiectomy, leaving the valve unrepaired can lead to persistent 
right HF symptoms (e.g. oedema, ascites, fatigue), poorer functional recovery post-operatively, and higher long-term mortality, as shown in 
retrospective observational studies. During pericardiectomy, the tricuspid valve is accessible, and repair (usually annuloplasty) can be safely 
performed with minimal added risk‚Äîespecially when CP surgery is 
done under CPB. Thus, repair is recommended when TR is more 
than mild, and anatomy is suitable, and the patient is already undergoing 
pericardiectomy (i.e. no added surgery is required beyond access). 
Supporting evidence is limited. While RCTs are lacking, the recommendation is based on retrospective findings showing improved symptom 
relief and outcomes with combined surgery, and surgical principles in 
valve disease management but also the practicality and safety of valve 
repair when the chest is already open.311 
Contraindications for pericardiectomy may include severe hepatic 
dysfunction with cirrhosis and ascites, uncontrolled infection or sepsis, 
and other life-limiting diseases. In some situations, advanced therapy, 
such as HT, might be the only solution due to unfeasible cardiac decortication, because of extensive calcifications or a high risk of cardiac and 
major vascular injury during pericardiectomy (for predictors of outcomes after pericardiectomy see also Supplementary data online, 
Table S8 and Section 3.2). 
6.5. Management of arrhythmias and 
prevention of sudden cardiac death in 
myocarditis 
Patients with myocarditis are known to be vulnerable to life-threatening 
arrhythmias, and careful observation and management of patients according to the risk stratification is needed. In the 2022 ESC Guidelines 
for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death, significant attention was paid to active 
Recommendation Table 13 ‚Äî Recommendations for 
surgical therapy (see Evidence Table 13) 
Recommendations 
Classa 
Levelb  
Surgical pericardiectomy is recommended in patients 
with chronic pericardial constriction or persistent 
constrictive pericarditis despite medical therapy to 
improve symptoms and survival.312,313 
I 
C 
Tricuspid valve repair is recommended in patients 
with pericardial constriction and severe tricuspid 
valve regurgitation to improve symptoms and 
survival.316 
I 
C 
¬© ESC 2025
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 45 -->

### Page 45

and chronic myocarditis.58 In addition to these guidelines, our aim is to 
provide a special focus on several selected scenarios. 
6.5.1. Role of active devices (wearable and implanted 
devices) in acute myocarditis 
In AM, AVB may be reversible, and temporary pacing is often necessary in 
cases of haemodynamic compromise as a bridge to recovery.317 In this 
setting, temporary transvenous external pacing with an active lead can 
be used for patients who require prolonged temporary pacing.86,318‚Äì 
320 In the absence of recovery within a clinically reasonable period, definitive cardiac pacing is usually necessary in patients with persistent high- 
degree AVB. In patients with LV dysfunction needing frequent ventricular 
pacing, CRT or conduction system pacing may be helpful.86,321 
Permanent pacemaker placement can be considered in patients with 
AM for persisting high-degree AVB despite medical therapy. 
Sustained VA in the context of AM is a rare phenomenon,79 yet it 
poses a substantial risk of recurrence, persisting even after resolution 
of the acute phase. Studies indicate a high recurrence rate ranging 
from 28% to 60%, which appears higher in patients with monomorphic 
VT, chronically active myocarditis, anteroseptal LGE, and reduced 
LVEF.71,79,89,222,322‚Äì325 In myocarditis patients, polymorphic and irregular 
VA are more common during the active inflammatory phase, whereas 
monomorphic and regular VA are associated with healed myocarditis 
and scars.79,83,325 An arrhythmic presentation may raise suspicion of an 
underlying inherited CMP.95 GCM is associated with a high risk of life- 
threatening VA and ICD implantation can be considered.326 The use of 
a wearable cardioverter-defibrillator (WCD) is feasible in selected patients with AM at higher risk of VA, when waiting for recovery or with 
a temporary contraindication for ICD.327‚Äì330 The resolution of inflammation does not necessarily indicate the absence of risk, because myocardial fibrosis may constitute an arrhythmogenic substrate, 
predisposing a patient to VA long after the acute episode. On this basis, 
arrhythmia risk stratification should be performed in patients with persistent LGE after the acute phase.325 In patients with prior myocarditis, 
sustained or non-sustained VT during an exercise test performed 
6 months after the acute episode was found to be more common among 
those with an arrhythmic presentation, and was associated with subsequent adverse events, including malignant VA.331 Late gadolinium enhancement was also identified as a significant predictor of adverse 
events, including malignant arrhythmias, irrespective of LVEF, especially 
in an anteroseptal location.332‚Äì334 Implantable loop recorders can be useful for early detection of VA in selected patients.89 Details regarding oral 
anticoagulation can be found in the 2019 ESC Guidelines for the management of patients with supraventricular tachycardia, the 2022 ESC 
Guidelines for the management of patients with ventricular arrhythmias 
and the prevention of sudden cardiac death, and the 2024 ESC 
Guidelines for the management of atrial fibrillation.58,260,261 
7. Prognosis 
The current literature focuses on the single condition, but one could 
expect that a patient with concomitant involvement of the myocardium 
and pericardium will have a worse prognosis. However, current published evidence suggests that patients with uncomplicated pericarditis 
and myopericarditis have a good overall prognosis, despite combined 
involvement of the pericardium and myocardium.4,337 The TF expects 
that the introduction of the term IMPS will increase awareness and will 
lead to dedicated studies in this regard. 
7.1. Complications and outcomes for 
myocarditis 
One of the main prognostic factors is the initial clinical presentation of 
myocarditis (Figure 8). Low-risk myocarditis (about 75% of unselected 
cases) usually has a chest pain presentation with preserved biventricular 
function, and an overall benign short- and long-term prognosis.28 Acute 
complicated myocarditis with arrhythmic presentation, and especially 
HF presentation, has a worse prognosis.56 There is conflicting evidence 
Recommendation Table 14 ‚Äî Recommendations for 
management of arrhythmias and prevention of sudden 
cardiac death in myocarditis (see Evidence Table 14) 
Recommendations 
Classa 
Levelb  
Pacing in myocarditis 
Temporary transvenous external pacing should be 
considered in patients with acute myocarditis and 
high-degree conduction disorders as a bridge to 
recovery.86,317,335 
IIa 
C                                                                                                   
Continued 
WCD in myocarditis 
A WCD should be considered for 3‚Äì6 months in 
patients with sustained ventricular arrhythmia during 
the acute phase of myocarditis as a bridge to 
recovery.323,325,327‚Äì330 
IIa 
C 
Ablation in myocarditis 
Catheter ablation, performed in specialized centres, 
should be considered in post-myocarditis patients 
with recurrent symptomatic SMVT or ICD shocks in 
whom AAD are ineffective, not tolerated, or not 
desired.58 
IIa 
C 
ICD in myocarditis 
Secondary prevention 
ICD implantation is recommended in patients with 
non-activec myocarditis and haemodynamically 
not-tolerated sustained VT to prevent 
SCD.78,79,322,336 
I 
C 
ICD implantation should be considered in patients 
with non-activec myocarditis and haemodynamically 
tolerated sustained VT to prevent SCD.78,79,322,336 
IIa 
C 
ICD implantation may be considered in patients with 
acute myocarditis and sustained VA (VT/VF) in the 
acute phase to prevent SCD.71,79,89,222,323‚Äì325 
IIb 
C 
Primary prevention   
ICD implantation may be considered in patients 
with myocarditis after the acute phase (3‚Äì6 months) 
and persistent risk factors for VAd to prevent 
SCD.89,332‚Äì334,336. 
IIb 
C 
¬© ESC 2025
AAD, anti-arrhythmic drugs; CMR, cardiovascular magnetic resonance; ICD, implantable 
cardioverter-defibrillator; LGE, late gadolinium enhancement; LVEF, left ventricular 
ejection fraction; NSVT, non-sustained ventricular tachycardia; PVS, programmed 
ventricular stimulation; SCD, sudden cardiac death; SMVT, sustained monomorphic 
ventricular tachycardia; VA, ventricular arrhythmias; VF, ventricular fibrillation; VT, 
ventricular tachycardia; WCD, wearable cardioverter-defibrillator. 
aClass of recommendation. 
bLevel of evidence. 
cNon-active based on CMR evidence of activity (T2), see Figure 4. 
dNSVT, extensive LGE, unexplained syncope, positive PVS, reduced LVEF <50%.   
ESC Guidelines                                                                                                                                                                                               45


<!-- PAGE 46 -->

### Page 46

on the role of sex in the prognosis of IMPS.73 Women seem to have a 
more favourable prognosis than men in myocarditis.338 Young age and a 
previous myocarditis were independent relapse predictors. Fulminant 
onset, lower LVEF at presentation, distinct autoimmune features, especially in women, and high-titre organ-specific anti-heart autoantibodies 
and antinuclear autoantibodies were independent predictors of death 
and HT.73 Genetic predisposition may also increase the risk (see 
Section 5.3). 
The aetiology also plays a relevant role, e.g. EM, GCM and CS are 
associated with a worse prognosis (Sections 9.2‚Äì9.4). Outcomes are 
worse in patients with FM, in the case of late diagnosis and delayed 
interventions.57 Factors associated with increased mortality or HT 
are GCM, QRS duration of >120 ms on initial ECG, or the need 
for temporary MCS other than IABP.56 Biventricular dysfunction 
has been described as the main predictor of death or HT in 
myocarditis.63,66,73 
Multimodality imaging contributes to the assessment of prognosis. 
For example, myocarditis patients with normal CMR have a good 
prognosis.339 Late gadolinium enhancement on CMR at initial presentation is an important prognostic finding.340 In a multicentre study 
with AM and preserved EF, the presence of anteroseptal LGE in 
the mid-wall layer was the best independent predictor of the combined endpoint of cardiac death, appropriate ICD interventions, resuscitated cardiac arrest, and hospitalization for HF [odds ratio 
(OR) 2.73; 95% confidence interval (CI) 1.2‚Äì5.9; P = .01]. At a median 
follow-up of 4.3 years, 7.7% of these patients reached the combined 
endpoint.3 Anteroseptal LGE was the best independent predictor 
of SCD [hazard ratio (HR) 4.59; 95% CI 1.38‚Äì15.24; P = .01]. 
Myocardial fibrosis was present in 95% of patients with SCD, compared with 41% in patients without SCD.341 Additionally, major arrhythmic onset (sustained VT or VF), presence of fibrosis at EMB, 
and induction of major VA on PVS all predicted major arrhythmic 
events.63,73,255 
In another study, including patients with AM and life-threatening 
arrhythmias, positive LGE in two or more myocardial segments 
and absence of oedema on initial CMR were associated with an increased risk for recurrent major arrhythmic events, including SCD 
[HR 4.51 (95% CI 2.39‚Äì8.53) and HR 2.59 (95% CI 1.40‚Äì4.79), 
respectively].71 
Large studies are needed in the future to develop a risk stratification 
with a high negative predictive value for SCD and the need for ICD implantation. Variables for risk stratification for the progression to DCM 
are given in Supplementary data online, Table S9. 
7.1.1. Sequela and mortality in myocarditis 
The main long-term complications are evolution to DCM with subsequent HF and (recurrence of) VA, including SCD.76 LVEF recovery after myocarditis can be complete or partial. Recovery rates 
vary from 50% to 94% depending on the initial presentation.74 
These patients usually have a gradual deterioration of LVEF and 
subsequent dilation and might remain unrecognized and asymptomatic until development of overt HF. Myocarditis can cause 
about 10% of DCM.66 Patients with B19V AM present most often 
with an infarct-like syndrome, and may have a favourable long-term 
prognosis,342 but there is evidence describing cases with severe 
fatal outcomes.228 In contrast, patients with HHV-6 myocarditis 
(and especially those with B19V and HHV-6 co-infection) usually 
present with acute HF symptoms, and frequently progress to 
chronic HF.342 
Arrhythmias during myocarditis range from mild conduction abnormalities to life-threatening VT or VF, requiring medication and/ 
or device therapy (refer to Section 6.5). The risk of VA is independent 
of LVEF.83,343 
Myocarditis may have a significant mortality. Initial complicated 
presentation and histological subtype predict the risk. Outcomes 
are worse in patients with FM, with a reported mortality at 60 days 
of 24%.56,73 Mortality also depends on the underlying cause of FM. 
In a study of GCM survivors beyond 1 year, the combined rate of 
death, HT, VAD implantation, or GCM recurrence was 47% at 
5 years.344 Reported in-hospital mortality and long-term outcomes 
after an episode of AM vary.345 In a multicentre registry of patients 
with AM, complicated AM occurred in 27%, including 9% cases of 
FM. In-hospital mortality was 8.5%, compared with 0% in uncomplicated cases. Heart transplantation or LVAD was required in 
3% and 4% of patients, respectively. Heart transplantation or death 
occurred in 18% of complicated cases after 5 years. Recurrences 
or VA occurred in approximately 3%‚Äì9% of cases over a period 
of 19‚Äì90 months.28 In the recently reported contemporary ESC 
multicentre myocarditis registry of 581 patients with myocarditis, 
2.7% of patients died, 1.7% received a HT, 0.7% underwent VAD 
implantation, and 3.9% underwent ICD implantation at 1-year 
follow-up.62,63,73 
7.1.2. Follow-up 
Patients with low-risk myocarditis with chest pain presentation can be 
discharged when cardiac enzymes tend towards normalization. Time 
to recovery in AM varies from a few days to a few months. Relapses 
occur in about 10% of cases, with a 1-year recurrence rate of around 
5%.10,73,346 
Follow-up is recommended in all patients with myocarditis, with 
clinical assessment, ECG, Holter-ECG registration, exercise test (if 
no signs of ongoing inflammation), echocardiography, and CMR within 
at least 6 months after the index hospitalization (see Table 15).10,62 
The prognosis is determined by baseline and 6-month LV function, regardless of the initial clinical presentation.62,63,73 Cardiovascular magnetic resonance should be performed at least within the first 
6 months in patients with definite myocarditis to guide the timepoint 
for return to work, based on the individual case. 
It is generally accepted to wait 3‚Äì6 months after an acute episode 
of myocarditis to evaluate the need for an ICD. In some patients at 
high risk for VA (see Section 6.5.1),71 a WCD should be considered 
during follow-up as a bridge to recovery.58 Subsequently, after 
3‚Äì6 months of follow-up, the decision on whether or not to implant 
a definitive ICD is based on the individual patient, with increasing indication based on risk factors including genetic predisposition (see 
Section 5.3, Section 6.5.1; see Figure 17). In patients presenting with 
symptomatic VA, or heart block in GCM or CS, early consideration 
of an ICD is warranted.58 Recommendations concerning arrhythmias 
and SCD in specific forms of myocarditis are discussed in Section 6.5.58 
In uncomplicated cases, a follow-up at 6, 12, and 24 months is sufficient, while it should be prolonged and be lifelong in complicated cases 
or with residuals. 
See Supplementary data online, Section 8 for patient communication 
advice.


<!-- PAGE 47 -->

### Page 47

7.2. Complications and outcomes for 
pericarditis 
Risk stratification of patients with pericarditis must be performed at the 
initial presentation at the emergency department or in an ambulatory 
setting. Admission is recommended in high-risk cases.105,130 
Non-high-risk cases can be managed as outpatients with a close follow- 
up within 1 to 2 weeks (Figure 7). ECG changes (mainly widespread 
ST-segment elevation) and troponin elevation were usually not negative 
prognostic markers in this setting with an infarct-like presentation and 
preserved biventricular function.4,35 
In the real world, approximately 25% of patients diagnosed with AP 
present with at least one predictor of poor prognosis and require hospitalization.130 The in-hospital mortality rate for AP is around 1% on 
average, but can be higher in older patients and those with severe 
co-infections.23 
According to the clinical presentation, additional diagnostic work-up 
should be performed only for a specific clinical suspicion, the presence 
of high-risk features, or a lack/incomplete response to empirical anti- 
inflammatory therapy (Table 16). 
The usual course of AP is characterized by clinical remission 
after medical therapy within 4‚Äì6 weeks. The most common and 
problematic complication of pericarditis is RP, which affects 
20%‚Äì30% of patients not treated with colchicine. About 10% of 
patients may present with continued symptoms without clinical remission. Such cases have been labelled as ‚Äòincessant‚Äô, and may directly progress to constriction in few months,104 while this 
complication is extremely rare in idiopathic RP.114,347 A course 
with multiple recurrences is possible, but not usual in simple presumed viral pericarditis, and should prompt a search for an underlying cause (Figure 14). 
Cardiac tamponade is relatively rare in AP, as well as CP (<1% of 
cases). The risk for complications is related to the aetiology. For instance, the risk of CP is low after presumed viral/idiopathic pericarditis, 
intermediate for immune-mediated aetiologies, as well as PCIS and neoplastic pericarditis (2%‚Äì5%), and high for bacterial pericarditis (20%‚Äì 
30%), especially if purulent.347 
At least three scores43,44,348 have been proposed recently to identify patients at increased risk of developing complicated pericarditis 
and chronicity, requiring close follow-up (see Supplementary data 
online, Tables S2 and S3). However, these scores have not been validated or replicated in additional larger studies, and remain 
investigational. 
Recommendation Table 15 ‚Äî Recommendations for 
risk stratification, complications, and outcomes of inflammatory myopericardial syndrome (see Evidence 
Table 15) 
Recommendations 
Classa 
Levelb  
Follow-up with clinical assessment, biomarkersc, 
ECG, exercise test, Holter-ECG monitoring, 
echocardiography, and CMR at least within 6 months 
after the index hospitalization is recommended in all 
patients with myocarditis to identify a potential 
progression or new risk factors.62 
I 
C 
Long-term follow-up is recommended for patients 
with complicated myocarditisd to identify a potential 
progression or new complications.28,74 
I 
C 
Long-term follow-up is recommended for patients 
with incessant or recurrent pericarditis to identify a 
potential progression and new complications.104,347 
I 
C 
¬© ESC 2025
CMR, cardiovascular magnetic resonance; ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence. 
cAt least troponin. 
dSee definition of complicated myocarditis in Table 3.  
Table 15 Follow-up in inflammatory myopericardial syndrome after discharge   
Within 1 month 
Within 3‚Äì6 months 
12 months 
>1 year and long-term FUa  
Clinical evaluation and ECG 
Myocarditis 
X 
X 
X 
X 
Pericarditis 
X 
X 
X 
X 
Biomarkers (TnI, C-reactive protein) 
Myocarditis 
X 
X 
(X) 
(X) 
Pericarditis 
X 
X 
(X) 
(X) 
Rhythm 
(stress and/or Holter-ECG) 
Myocarditis 
‚Äì 
X 
(X) 
(X) 
Pericarditis 
‚Äì 
‚Äì 
‚Äì 
‚Äì 
Imaging myocarditis 
TTE 
Xb 
Xc 
Xc 
CMR 
Xb 
Xc 
Xc 
Imaging pericarditis 
TTE 
Xb 
Xc 
X 
CMR 
(X)b 
(X)d 
(X)d 
¬© ESC 2025
CMR, cardiovascular magnetic resonance; ECG, electrocardiogram; FU, follow-up; IMPS, inflammatory myopericardial syndrome; TnI, troponin I; TTE, transthoracic echocardiography. 
All follow-ups should be adapted to the clinical situation and severity. In round brackets, optional testing according to clinical presentation [(X), case-by-case decision]. 
aA long-term FU, e.g. after 2 years, is suggested only for complicated cases of IMPS, usually myocarditis. 
bIn complicated cases or if abnormal at 1 month, imaging should be repeated between 3 and 6 months. 
cIf abnormal at 6 months, imaging should be repeated within the next 6 months and/or in the next 12 months. 
dFollow-up proposed for uncomplicated cases of acute pericarditis. Long-term follow-up, tailored to the single patient, is recommended for high-risk cases.   
ESC Guidelines                                                                                                                                                                                               47


<!-- PAGE 48 -->

### Page 48

### 8 Inflammatory myopericardial

syndrome overlapping types: 
myopericarditis and 
perimyocarditis 
IMPS includes a spectrum of inflammatory diseases from isolated myocarditis to isolated pericarditis through a combination of both. IMPS 
should be used as an umbrella term, also covering overlapping forms 
of myocarditis and pericarditis.1 The diagnosis of predominant pericarditis with myocardial involvement, or ‚Äòmyopericarditis‚Äô, can be clinically 
established if patients with definite criteria for AP show elevated biomarkers of myocardial injury, without newly developed focal or diffuse 
impairment of LV function on TTE or CMR. The term myopericarditis 
indicates a primarily pericarditic syndrome with minor myocardial involvement, which describes the majority of combined pericarditis and 
myocarditis cases encountered in clinical practice. On the other 
hand, evidence of new-onset focal or diffuse reduction of LV function 
in patients with elevated myocardial biomarkers, and clinical criteria 
for AP, suggests predominant myocarditis with pericardial involvement,  








	









¬Å

¬ç

¬è

Figure 17 Follow-up and risk stratification after acute myocarditis with arrhythmic presentation. ICD, implantable cardioverter-defibrillator; LGE, 
late gadolinium enhancement; LV, left ventricle; LVEF, left ventricular ejection fraction; NSVT, non-sustained ventricular tachycardia; PVS, programmed 
ventricular stimulation; WCD, wearable cardioverter-defibrillator. Rarely for a high risk, cardioverter-defibrillator implantation may be considered before discharge (see text for detailed discussion). aAdditional risk factors (at least 1, increasing risk and indication with >1 or more): NSVT, extensive 
LGE, unexplained syncope, positive PVS, reduced LVEF of <50%.327‚Äì329  
Table 16 Indicators of non-viral aetiologies and 
complications (high-risk features or red flags in acute 
pericarditis) 
Major  
Fever >38¬∞C (HR 3.56) 
Subacute onset (HR 3.97) 
Large pericardial effusion (>20 mm on echocardiography) (HR 2.15) 
Cardiac tamponade (HR 2.15) 
Lack of response to aspirin or NSAID after at least 1 week of therapy 
(HR 2.50) 
Minor 
Pericarditis associated with myocarditis 
Immunodepression 
Trauma 
Oral anticoagulant therapy 
¬© ESC 2025
HR, hazard ratio; NSAID, non-steroidal anti-inflammatory drug. Major features have been validated 
in multivariable analysis in a prospective cohort study of patients with acute pericarditis.105


<!-- PAGE 49 -->

### Page 49

termed ‚Äòperimyocarditis‚Äô. The clinical management and outcomes of 
mixed forms follow the predominant involvement. At present, patients 
with myopericarditis can be treated as patients with pericarditis, while 
patients with perimyocarditis should be managed as patients with pure 
myocarditis. The knowledge in the field is rapidly evolving and ongoing 
trials and evidence will provide more updated guidance for clinical 
management. 
A common scenario with overlapping forms of myocarditis and pericarditis is represented by systemic immune disorders, which can affect 
either the myocardium or pericardium, or both. 
Several systemic inflammatory and autoimmune diseases may present 
with myocarditis, pericarditis, mixed forms, or PEff without pericarditis. 
Main conditions include RA, SLE, Sj√∂gren‚Äôs syndrome, SSc, polymyositis 
and dermatomyositis, and vasculitis (e.g. particularly EGPA). 
8.1. Inflammatory myopericardial 
syndrome in systemic disorders 
Inflammatory myopericardial syndrome may complicate several types 
of systemic diseases, generally immune-mediated,349,350 either with 
myocardial (myocarditis) or pericardial involvement (pericarditis and/ 
or PEff). Symptoms and signs that may raise the suspicion of a rheumatic autoimmune disease are family history, history of low-grade fever, 
joint symptoms, dry eyes and mouth, headache, lymphadenopathy, 
Raynaud phenomenon, skin rash, oral and genital aphthae, deep or 
superficial vein thrombosis, recurrent foetal losses, lymphopenia, and 
chronic increase of CK and other inflammatory markers. Targeted 
therapy should be applied, if a specific diagnosis is reached during the 
diagnostic work-up. 
8.1.1. Rheumatoid arthritis 
Pericarditis can be seen as part of the inflammatory activity in RA, and is 
often present concurrently with pleuritis. It is the most common cardiac 
manifestation, affecting up to 50% of patients, as detected on post- 
mortem examination. Myocarditis may also be present, and generally resolves if the disease is controlled.351 Anakinra, already registered for the 
treatment of RA, can be used also for related pericardial involvement. 
8.1.2. Systemic lupus erythematosus 
Pericarditis is the most common cardiac manifestation of SLE, reported 
in approximately 25% of patients, and it is included in the American 
Rheumatism Association/American College of Rheumatology (ARA/ 
ACR) classification criteria.352 Myocardial involvement in SLE affects 
about 5% of patients.353,354,355 Symptoms of IMPS are often non- 
specific, including elevated troponin, alterations on the ECG, LVEF abnormalities, and PEff. These manifestations are usually associated with 
typical symptoms of SLE, including fever, arthritis, nephritis, and skin 
rashes.356,357 The diagnosis can be supported by specific laboratory 
markers, as well as multimodality imaging, to guide the therapy.358,359 
Endomyocardial biopsy could be rarely considered in selected cases.349 
Cardiac tamponade occurs in less than 2% of cases, and CP is extremely 
rare. Cardiomyopathy is uncommon clinically, but autopsy studies 
found myocardial involvement in 40%‚Äì50% of patients. 
8.1.3. Antiphospholipid syndrome 
Antiphospholipid syndrome is associated with the presence of 
anti-cardiolipin and/or anti-Œ≤2-glycoprotein antibodies, and/or lupus 
anticoagulant, and may be the cause of myocardial dysfunction through 
various mechanisms. While myocarditis can manifest in this syndrome, 
mediated by autoimmune mechanism, myocardial damage can be also 
caused by microthrombotic phenomena.360,361 
8.1.4. Sj√∂gren‚Äôs syndrome 
In Sj√∂gren‚Äôs syndrome, the most common clinical manifestation of cardiac 
damage is pericarditis, which has been reported in less than one-third of 
cases. Myocarditis and myocardial fibrosis are also possible,362 and may 
occur associated with rhythm disturbances. Specific antibodies 
(anti-Ro/SSA) could also be identified in unexplained heart blocks.363 
8.1.5. Systemic sclerosis 
Inflammatory myopericardial syndrome is frequent in SSc,364 often clinically occult and, when symptomatic, the prognosis is poor. It may be 
related to ventricular dysfunction and/or structural damage of the 
microvascular bed, leading to repeated focal ischaemic injuries and irreversible myocardial fibrosis. It can be also due to a primary systemic 
myositic disease.349,365 Damage usually follows two pathways.366 The 
first one is linked to the production of collagen by activated fibroblasts 
at the myopericardial level, especially at the subepicardial level, with 
consequent fibrosis, valve stenosis, coronary spasms, and ischaemic 
events. The second pathway is caused by renal and pulmonary involvement, with severe cardiac consequences.367,368 Further research is 
needed to improve the understanding of IMPS in SSc.364 
8.1.6. Polymyositis and dermatomyositis 
The myocardium can be affected in inflammatory myopathies, such as 
polymyositis and dermatomyositis,369 with consequent myocardial 
hypertrophy, ischaemia, cardiac enlargement, and systolic and diastolic 
ventricular dysfunction.370 Cardiac involvement in inflammatory myopathies is clinically occult in most patients, but may be suspected by multimodality imaging371,372 and is related to poor outcome.370,372 
Myocarditis occurs in up to 30% of autopsied patients, with or without 
concomitant coronary or vessel vasculitis. Pericarditis is rarely reported 
in these patients. 
8.1.7. Vasculitis 
Myocardial involvement is prognostically relevant in vasculitis, particularly EGPA. In EGPA, about 15%‚Äì60% of patients present with cardiac 
disease350 including PEff, conduction disturbances, and motion abnormalities, as well as ACS, often due to coronary spasm, and EM (see 
Section 9.2). While cardiac involvement in EGPA often occurs early, it 
can be late in the course of the disease, and mainly affects anti- 
neutrophil cytoplasmic antibody (ANCA)-negative patients with high 
eosinophil counts. Myocardial and pericardial involvement is also possible in other vasculitis, especially in Kawasaki‚Äôs disease, where myocarditis is a common cardiovascular complication (see Supplementary data 
online, Figure S3).373 
Cooperation with specialists is important in all these systemic conditions to reach the correct diagnosis and to plan appropriate treatment. 
The diagnosis of EGPA may be particularly challenging.349 
8.2. Inflammatory myopericardial 
syndrome in COVID-19 disease 
The COVID-19 pandemic raised the awareness of IMPS, as in many patients the myocardium as well as the pericardium were affected. It is not 
proven whether the SARS-CoV-2 virus can directly damage cardiomyocytes or pericardiocytes, as it was suggested in cultivated human cardiomyocytes.374 Autopsy studies could only detect small amounts of virus  
ESC Guidelines                                                                                                                                                                                               49


<!-- PAGE 50 -->

### Page 50

in the myocardium and pericardium.375‚Äì379 The true estimate of 
COVID-19-associated IMPS is variable depending on CMR/ 
EMB-derived diagnosis ranging from 0.1‚Äì4.5/1000 cases380,381 up to 
2%‚Äì8% of cases in symptomatic patients.382 Symptoms as well as diagnostic work-up are similar to those described for general IMPS (see 
Sections 4 and 5). 
The predominant management of symptomatic complicated 
SARS-CoV-2-related IMPS is antiviral treatment for SARS-CoV-2 virus 
together with supportive therapy. Several immunosuppressive therapies, such as anti-IL-1 (anakinra and canakinumab) and anti-IL-6 (tocilizumab and sarilumab), have demonstrated promising results in critically ill 
patients hospitalized for COVID-19.383‚Äì385 In less severe cases, the key 
elements for treatments are those recommended for IMPS. More details can be found in Supplementary data online, Section 5.1.2. 
9. Specific types of myocarditis 
9.1. Lymphocytic myocarditis 
The diagnosis of LM is based on pathological criteria and reflects an inflammatory disease that may be caused by viruses, but also by other infectious agents, including bacteria (such as Borrelia spp.) and protozoa 
(such as T. cruzi).10 Furthermore, contemporary single-centre and multicentre cohort studies suggest that LM is more commonly non-infectious 
or immune-mediated/autoimmune.63,73 It is important to note that the 
aetiopathogenesis and outcome of viral LM varies considerably, based 
on the different infections. Cytolytic viruses, such as enteroviruses (e.g. 
coxsackieviruses and echoviruses), destroy cardiomyocytes and induce 
severe infiltration by macrophages and lymphocytes.386 In contrast to enteroviruses, vasculotropic B19V, which infects cardiac endothelial cells, 
but not cardiomyocytes, can also induce severe LM, especially in young 
children.228,387 High viral copy numbers (>500 viral DNA copies/¬µg of 
cardiac DNA) were found to be associated with cardiac inflammation 
and/or systemic infection.228,388 Low B19V DNA copy numbers in cardiac tissue rather reflect virus persistence, and are usually not related 
to cardiac inflammation. Lymphotropic viruses of the Herpesviridae family 
[HHV-6, EBV, human cytomegalovirus (CMV)], as well as HCV, influenza 
viruses, and SARS-CoV-2 may indirectly trigger myocarditis by activating 
the immune system.389 Regarding the aetiology and pathogenesis of myocarditis, microRNAs (miRNAs) may be promising diagnostic markers, as 
well as prognostic and therapeutic targets in myocarditis.141,390 
However, the precise role of miRNAs in myocarditis remains to be determined.391 In addition to infectious agents, organ-specific autoimmunity to heart autoantigens,66 different systemic immune-mediated 
diseases, toxic substances, and drugs, including ICIs, are known to induce 
different forms of acute and chronic LM.66 Immune-mediated myocarditis may occur with exclusive cardiac involvement or in the context of systemic immune-mediated diseases, such as SLE, SSc, and others.349,392 
Interestingly, genetic host susceptibilities have also been linked to cardiac 
dysfunction following myocarditis.91,150 
9.1.1. Presentation 
Since LM can be induced by various causes, there is no universal, specific 
clinical presentation. Instead, it must be considered in the context of 
the different diseases, in line with the stages of myocarditis. 
9.1.2. Diagnosis and therapy 
The diagnostic pathways were described above and vary depending on 
the cause. The diagnostic and therapeutic approach has to follow the 
clinical situation and the stages as described in Section 4 (see Table 12). 
9.2. Eosinophilic myocarditis 
Eosinophilic myocarditis is a rare form of myocarditis, characterized by 
eosinophilic infiltration of the myocardium. Underlying disorders that 
should be evaluated during the work-up of EM include: hypersensitivity 
and allergic reactions;271 immune-mediated disorders, in particular 
EGPA; undefined complex HES or its myeloproliferative variant; parasitic infections; and cancer.349 A meta-analysis of single cases or small 
case series reported a rate of in-hospital death of up to 22%, and a significantly increased occurrence of the hypersensitivity form, up to 
36%.271 
9.2.1. Presentation 
The clinical presentation of EM can be variable, ranging from oligosymptomatic to acute FM, or chronic RCM (Loeffler CMP or endomyocarditis).271 Nevertheless, prior study demonstrates that EM often has a 
fulminant presentation with abrupt impairment of LVEF, a high risk of 
malignant arrhythmias, and a high risk of thromboembolic complications, related to the formation of ventricular thrombi.271 Although 
EM is often accompanied by peripheral eosinophilia, it should be noted 
that this finding is absent in up to 25% of patients with EM, and may contribute to the underdiagnosis of EM. 
9.2.2. Diagnosis 
The diagnosis of EM can be established by either the EMB-proven presence of eosinophilic infiltration of the myocardium, or the presence of 
CMR-proven myocarditis with pathognomonic findings associated with 
peripheral eosinophilia (Supplementary data online, Figure S3). 
Furthermore, general clinical signs related to EGPA or HES disorders 
should be evaluated, such as an increased number of eosinophilic cells, 
history of asthma and sinusitis, and characteristic skin lesions. Left ventricular function may be preserved, and DCM can occur, but often the 
phenotype of RCM is present. On echocardiography, a typical finding is 
Loeffler endocarditis. In the diagnostic work-up, systemic screening for 
the above-mentioned aetiologies should be carried out systematically. 
9.2.3. Therapy 
The first-line therapy for EM is the administration of i.v. corticosteroids, 
but caution should be exercised if EM is caused by an infectious agent. 
The optimal dose and duration of corticosteroids are unclear, but it is 
proposed to administer a daily i.v. bolus of corticosteroids followed by 
dosage tapering in severe forms, while oral steroid administration (see  
Table 12) can be considered in patients with mild LV dysfunction.39,271 
The identification of an EM-associated condition is crucial to administer 
specific treatments, such as cyclophosphamide or IL-5 inhibitors in 
EGPA-related EM,34 imatinib in the myeloproliferative variant of 
platelet-derived growth factor receptor alpha (PDGFRA)-associated 
HES, or albendazole in Toxocara canis infection. In hypersensitivity/allergic EM, first-line therapy is to withdraw the potential cause of 
eosinophilia. 
Since endocavitary thrombi were reported in 12% of EM cases, the 
use of anticoagulation during the acute phase could be considered for 
the prevention of endocavitary thrombi.271 
9.3. Giant-cell myocarditis 
Giant-cell myocarditis is a very rare, but often rapidly progressive disease with a poor prognosis, with an ‚àº85% rate of death or HT at 
3 years.56,82 The incidence of GCM was reported to range from 
0.007% to 0.051% in autopsy studies; however, this number might


<!-- PAGE 51 -->

### Page 51

underestimate the true disease burden.393,394 Giant-cell myocarditis 
generally affects young and middle-aged adults without a sex predominance. In a large multicentre registry of GCM cases, patients were aged 
from 16 to 69 years at the time of diagnosis.82 
Giant-cell myocarditis is recognized as a non-infectious myosin-induced 
autoimmune form, as experimental models suggest,395 and an association 
with autoimmune disorders has been reported in ‚àº20% of cases.82 
9.3.1. Presentation 
Early symptoms of GCM might not differ from other types of myocarditis and vary widely at the time of presentation. In an international 
registry of 63 GCM patients, HF was the presenting symptom in 75% 
of cases.82 The initial manifestations might be progressive haemodynamic deterioration or cardiogenic shock, intractable arrhythmias, 
and SCD. The condition often progresses rapidly to death, often within 
days to months. A systematic analysis including 51 patients with GCM 
showed that the cumulative incidence of SCD (fatal or aborted) was 
22% at 1 year and 26% at 5 years after presentation, and the composite 
incidence of SCD or VT was 41% at 1 year and 55% at 5 years.326 
Other early GCM manifestations include bradyarrhythmias and cardiac 
conduction abnormalities, including complete AVB. In a study from 
Finland, 25% of individuals <55 years of age with clinically idiopathic 
heart block had GCM or CS on heart biopsy.396 The presence of AM 
complicated by treatment-resistant HF or cardiogenic shock, VA, and 
AVB should increase the clinical suspicion of GCM. 
9.3.2. Diagnosis 
Endomyocardial biopsy remains the gold-standard diagnostic modality 
for GCM and can identify these patients at an early stage.397,398 Patients 
diagnosed with GCM through EMB had a shorter symptom-onset-to- 
diagnosis time and milder heart damage than those diagnosed during 
HT.398 
The presence of multinucleated giant cells in the absence of well- 
organized granulomatous lesions in the myocardial biopsy specimen 
is the hallmark of GCM. The giant cells are typically located in the interstitium or around blood vessels and are characterized by their large size, 
multinucleation, and cytoplasmic granules. 
Giant-cell myocarditis is characterized by myocardial destruction 
mediated by a large number of T cells, macrophages, multinucleated 
giant cells, and eosinophils in EMB.39 Generally, the histological diagnosis of GCM is guided by myocyte necrosis, diffuse infiltration of inflammatory cells, and interstitial fibrosis.399,400 The severity of necrosis and 
fibrosis in EMB predicts the outcome.401 It is important to understand 
that one set of non-diagnostic EMB samples does not exclude GCM. 
The sensitivity of the first biopsy is 68% and increases to 93% when 
the biopsy is performed up to three times. Thus, repeated EMB should 
be considered when there is a high clinical suspicion of GCM.217 In a 
single-centre case series of GCM, LGE on CMR was present in 96% 
of cases, and its distribution correlated with the histology.401 Prompt 
EMB in the setting of suspected GCM can affect the choice of MCS, 
leading to an early listing for HT and consideration of cyclosporine- 
based immunosuppression.402 Administration of i.v. steroids prior to 
EMB may reduce the diagnostic yield of EMB. There should be an agreement in specialized centres to prioritize the evaluation of EMB, and to 
provide the results at least within 3 days, optimally within 8 h. 
9.3.3. Therapy 
As soon as GCM is suspected, immunosuppressive therapy should be initiated promptly to avoid disease progression and delay HT. It is crucial 
that the therapy should be initiated based on a strong clinical suspicion. 
Historically, the survival of patients with GCM without immunosuppression was about 3 months from symptom onset to death or HT. Many 
studies have shown that immunosuppression is useful for the treatment 
of GCM. Immunosuppressive therapy typically involves two or three 
drugs, including corticosteroids, and at least one, and usually two additional immunosuppressive agents (see Table 12). In GCM patients, immunosuppression with corticosteroid monotherapy is not associated 
with a prolongation of transplant-free survival.82 
Patients with GCM should receive the same guideline-based treatment for HF and arrhythmias as patients with heart disease from other 
causes.12,58 
Cyclosporine is the most commonly used immunosuppressant. In 
multiple retrospective and prospective studies, concomitant use of 
cyclosporine was associated with improved prognosis. Combining immunosuppressive therapy with corticosteroids and cyclosporine, 
azathioprine, or both improved transplant-free survival on average to 
12 months, while patients treated with corticosteroids alone survived 
on average 4 months.82 A cases series of GCM reported that 1-year 
transplant-free survival was 73% in patients who received corticosteroids and cyclosporine with or without muromonab-CD3, with a reported decrease of the degree of necrosis, cellular inflammation, and 
giant cells after 4 weeks of treatment.403 A systematic review of 27 
studies with 43 biopsy-proven GCM cases requiring MCS showed 
that the administration of immunosuppressive therapy prior to MCS 
implantation was associated with significantly better survival than treatment with MCS alone. Immunosuppression may reduce the severity of 
HF in these patients by preventing further autoimmune destruction of 
the myocardium.404 
Cessation or reduction of immunosuppression is associated with 
GCM recurrence as long as 8 years after diagnosis.344,403 
In a single-centre study, the risk of life-threatening VA in GCM patients exceeded 50% at 5 years after admission. Permanent ICD effectively terminated life-threatening ventricular tachyarrhythmias, and no 
GCM patient with the device suffered from a SCD.326 
Transplantation could be considered for GCM patients who fail to 
respond to GDMT and immunosuppression. A recent systematic review and meta-analysis of 499 patients with CS and 69 with GCM 
who underwent HT found that 1- and 5-year survival rates in GCM patients were similar to those in transplant recipients with other HF 
aetiologies.405 
Recommendation Table 16 ‚Äî Recommendations for 
giant-cell myocarditis (see Evidence Table 16) 
Recommendations 
Classa 
Levelb  
EMB is recommended in patients with suspected 
GCM due to unexplained new-onset HF of up to 
2 weeks associated with a normal or dilated left 
ventricle and new ventricular arrhythmias, second- 
or third-degree AVB, or failure to respond to usual 
care within 1 to 2 weeks to initiate specific 
treatment.402 
I 
C 
Combined immunosuppressive therapy is 
recommended in patients with a diagnosed GCM.217 
I 
C 
¬© ESC 2025
AVB, atrioventricular block; EMB, endomyocardial biopsy; GCM, giant-cell myocarditis; HF, 
heart failure. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               51


<!-- PAGE 52 -->

### Page 52

9.4. Myocarditis in sarcoidosis 
Cardiac sarcoidosis is a form of inflammatory heart disease, coexisting 
with systemic sarcoidosis in 5%‚Äì10% of cases,406 or rarely, in isolation. 
The aetiology of sarcoidosis is not well understood, but may involve an 
autoimmune response after certain trigger(s) and genetic predisposition, 
which leads to the formation of non-caseating granulomas in multiple organs, typically in the lungs.407 On histopathology, the granuloma consists 
of CD68+ macrophages, CD68+ giant cells, CD3+ T lymphocytes, and 
CD20+ B lymphocytes. It is characterized by inflammation, oedema, 
lymphocytic infiltration, and replacement fibrosis.408 Cardiac sarcoidosis 
is often subclinical, with an estimated cardiac involvement in around 25% 
of cases on autopsy series in patients with sarcoidosis.409,410 
9.4.1. Presentation 
Manifestations of CS may range from cardiac inflammation, conduction 
system disease, frequent ectopy, tachyarrhythmia, and HF, to SCD.407 
Cardiac sarcoidosis may mimic different cardiac phenotypes, including 
ARVC,254,411‚Äì413 DCM, and hypertrophic CMP (HCM), but may also 
occur in patients with normal cardiac function.414 Symptoms are non- 
specific, and often related to arrhythmias, especially AVBs and VTs. The 
challenge is to identify patients at risk, since SCD due to malignant arrhythmia is common.415,416 
9.4.2. Diagnosis 
The diagnostic algorithm of CS is different in patients with or without 
known extracardiac sarcoidosis. Pathognomonic findings in non- 
invasive imaging are sufficient for the diagnosis of CS in cases with 
known systemic sarcoidosis.417 In contrast, the diagnostic pathway in 
primary CS is more challenging, but typical multimodality imaging patterns are usually sufficient. Cardiac sarcoidosis can manifest as abnormalities on ECG, echocardiography, CMR, PET, EMB, and cardiac and 
inflammatory blood biomarkers (see Section 5.4). Electrocardiogram 
or cardiac rhythm monitoring may demonstrate conduction system abnormalities (such as AVB or bundle-branch block) and arrhythmias, including VT.418 Echocardiography may reveal regional WMA in a 
non-coronary distribution, septal thinning, and ventricular aneurysms. 
Endomyocardial biopsy may be helpful in selected patients, but negative 
results do not rule out CS due to potential sampling errors.419 
Endomyocardial biopsy guided by imaging or EAM may improve the 
diagnostic yield (see Section 5.12). 
Multimodality advanced cardiac imaging, such as CMR and FDG-PET, 
plays an increasing role in the management of suspected CS. Overall, 
compared with FDG-PET, CMR has higher sensitivity of 89%‚Äì95% vs 
84%, respectively, but similar specificity of 78%‚Äì85% vs 82%, respectively, for the diagnosis of CS.408,420‚Äì428 
On CMR, CS has a wide range of potential findings, and is often considered the ‚Äògreat mimicker‚Äô of various cardiac conditions, but the interventricular septum is often involved408 and the ‚Äòhook sign‚Äô429 is 
recognized to be associated with a high probability of CS. For more details, see Supplementary data online, Figure S3. A heavy burden of LGE is 
associated with a poorer prognosis and predisposes to VA, HF, and death 
in CS, and may guide clinical decision-making.430‚Äì436 Aside from LGE, the 
identification of ongoing myocardial inflammation is possible.30,437‚Äì441 
Fluorodeoxyglucose-positron emission tomography also allows detection of cardiac inflammation in CS.426 It requires careful patient preparation to suppress physiological 18F-FDG uptake. The classical finding is 
focal 18F-FDG uptake in the basal septum, with a concordant perfusion 
defect. Perfusion defects in the active stage of CS may be due to microvascular obstruction by inflammatory oedema, necrosis, or both, and are 
not necessarily located in the same region as the 18F-FDG uptake.427 
Hybrid PET-CMR may enable better detection of cardiac inflammation 
in a more comprehensive manner,440,442,443 but its availability is limited. 
Both CMR and PET may be used for imaging-guided EMB. 
The intensity and extent of FDG uptake on PET is of prognostic relevance.443‚Äì449 In a meta-analysis of 37 studies of patients with CS, LGE on 
CMR and FDG uptake on PET were both predictive of MACE (all-cause 
death, cardiac death and aborted SCD, VA, and HF hospitalization). 
Fluorodeoxyglucose-positron emission tomography has proved to 
be useful in predicting and monitoring the anti-inflammatory therapy 
response in sarcoidosis;204,450 however, the optimal timing for repeating PET studies for the assessment of treatment response is not well 
established. 
In addition to clinical assessment, imaging modalities should be used 
for the short- and long-term management of patients with CS. 
9.4.3. Therapy 
The treatment of CS is currently not standardized, and is based on 
patient-tailored assessment, often with multidisciplinary input.451 
Treatment is targeted at controlling cardiac inflammation, myocardial 
scarring and dysfunction.13,431‚Äì436 First-line therapy includes corticosteroids (see Table 12). 
Since resolution of conduction abnormalities with anti-inflammatory 
treatment remains unpredictable, definitive cardiac pacing is usually 
needed. AVB and the need for cardiac pacing are associated with a higher risk of sustained VA, which reached 31% at 5 years in the Finnish 
registry.416,452,453 Thus, it appears reasonable to propose an ICD 
with pacing ability rather than a pacemaker in CS patients with pacing 
indications. The risk of VA during follow-up is high in observational 
studies, in patients with low LVEF,416,452,454,455 presence of LGE on 
CMR,434,456‚Äì459 and positive PVS.456,460‚Äì464 There is a lack of data on 
the relationship between scarring extent and arrhythmia risk. 
Positron emission tomography-computed tomography may also help 
to stratify patients.465 
Heart transplantation could be considered in a subgroup of patients 
with CS, similarly to GCM.405 
Recommendation Table 17 ‚Äî Recommendations for 
myocarditis in sarcoidosis (see Evidence Table 17) 
Recommendations 
Classa 
Levelb  
Diagnosis 
CMR, using tissue characterization techniques, is 
recommended in patients with suspected CS to 
assess cardiac inflammation and myocardial 
involvement.408,421‚Äì425 
I 
B 
18F-FDG-PET is recommended for the diagnostic 
work-up, including detection of inflammation, as well 
as for follow-up and assessment of therapeutic 
response in patients with CS.426‚Äì428 
I 
B 
Therapy 
ICD implantation is recommended in patients with 
CS and sustained ventricular arrhythmia (VT/VF) or 
aborted CA to prevent SCD.58,396,416,454,455,466 
I 
B 
ICD implantation is recommended in patients with 
CS and LVEF ‚â§35% to prevent SCD.416,452,454,455 
I 
C                         
Continued


<!-- PAGE 53 -->

### Page 53

9.5. Specific infectious myocarditis 
(Viruses, Lyme, Chagas) 
9.5.1. Viruses 
A large variety of infectious agents (Supplementary data online, Table S1) 
can cause myocardial inflammation, but viruses are considered the most 
common cause among infectious forms of myocarditis. Data on the true 
prevalence of viral myocarditis are difficult to determine, since EMB is 
performed only in a subgroup of high-risk patients and in complicated 
cases. Moreover, a positive viral serological test does not imply myocardial infection and is not routinely recommended. Exceptions are HIV and 
HCV and for specific infections such as Lyme disease.10 The epidemiology of viral myocarditis has changed during the past three decades; 
while enteroviruses and adenoviruses have been considered the most 
common causes of viral myocarditis,468 vasculotropic viruses such as 
B19V,63,66,468 and lymphotropic viruses such as HHV-6 are increasingly 
found in EMB samples.342,469 The prognostic relevance of persistent 
B19V infection with low viral copy numbers remains controversial because its presence in myocardial tissue may not have direct pathogenetic 
significance,470,471 in contrast to acute B19V infection.228 
9.5.1.1. Presentation 
Symptoms vary according to the underlying cause and severity of disease. However, it generally follows the presentation of acute and 
chronic stages, as presented in Section 4. 
9.5.1.2. Diagnosis 
The diagnostic approach should follow the description outlined in 
Section 4 (Figures 5 and 6). The presence of more than 500 copies/Œºg 
of DNA in EMB is considered as the threshold for virus-related myocardial inflammation, and usually guides therapeutic choices (e.g. starting 
immunosuppression). Viral PCR analysis in EMB samples is performed 
to better characterize the pathological substrate causing myocarditis. 
If immunosuppression is needed, viral presence has to be ruled out 
by EMB.10 Contemporary PCR analysis for viral presence in EMB specimens and blood samples is utilized to rule out possible tissue 
contamination.10,469 
9.5.1.3. Therapy 
Data are insufficient to support antiviral therapy for AM, as well as treatment with IVIG for presumed viral myocarditis.472 Anti-herpesvirus 
drugs in patients with CMV or HHV-6 infection can be considered, although their efficacy has not been directly studied in patients with 
myocarditis.10 Treatment with type I IFN in patients with enterovirus 
has been suggested to increase viral clearance, but large trials are missing.273,473‚Äì475 Antiviral therapies have to be prescribed and managed in 
collaboration with an infectious diseases expert with shared decision- 
making in the IMPS team.1,472 
9.5.1.3.1. Influenza virus. Supportive management is the backbone of 
severe influenza treatment. Myocardial involvement is rare, but should 
be considered in patients of any age with chest pain, tachycardia, and 
haemodynamic instability within 2‚Äì4 weeks from symptom onset. 
The effect of antiviral therapy on myocarditis is not clear, although oseltamivir is utilized in both inpatient and outpatient settings. Peramivir 
and zanamivir are used only for hospitalized patients. There are individual case reports of successful treatment with neuraminidase inhibitors.476‚Äì479 Peramivir has often been used in combination with either 
oseltamivir480,481 or zanamivir.482 
9.5.1.3.2. Human immunodeficiency virus. The pathogenesis of 
HIV-associated myocarditis involves direct viral infection, co-infection 
with other viruses or bacteria, cytokine activity, side effects of highly 
active antiretroviral therapy (HAART), immune system dysregulation, 
and/or ischaemia. If HIV-associated myocarditis is diagnosed, therapy 
for HIV infection has to be started or continued. Highly active antiretroviral therapy has been reported to significantly decrease the incidence of cardiac involvement, especially pericarditis, arrhythmias, 
and DCM compared with patients treated with nucleoside reverse 
transcriptase inhibitors in a retrospective study of 1042 patients.483 
9.5.2. Lyme carditis 
Lyme carditis may be an early manifestation of Lyme borreliosis, a tick- 
borne disease, caused by Borrelia spp., which is one of the most common vector-borne diseases in the northern hemisphere. 
9.5.2.1. Presentation 
In cases of early disseminated infection, AM with possible associated 
pericarditis may occur, but LC is typically characterized by varying degrees of AVB, with third-degree AVB in approximately 25% of cases.484 
Chronic LC often shows manifested persistent symptoms and signs, 
such as fatigue, cognitive dysfunction, headaches, sleep disturbance, 
neuropsychiatric and musculoskeletal symptoms, electrical conduction 
delays, and DCM. 
9.5.2.2. Diagnosis 
The suspicious index in LC score has been proposed to evaluate the likelihood of high-degree AVB to be caused by LC. It allows categorization 
of patients into low-, intermediate- and high-risk categories.485 
Continuous ECG monitoring is required for patients presenting with 
syncope or with a PR interval of >300 ms, since this is a high-risk marker 
of progression to complete AVB.484 Serological tests are recommended 
for patients presenting with high-degree AVB and suspected LC. 
9.5.2.3. Therapy 
Atrioventricular block is often transient and typically resolves within 
1‚Äì2 weeks of antibiotic treatment, therefore permanent pacemaker 
placement is not warranted for AVB associated with LC before starting 
therapy. Intravenous therapy with ceftriaxone is the recommended 
first-line treatment for patients with LC and AV disturbances,486 followed by oral antibiotics (doxycycline, amoxicillin, or cefuroxime) for 
ICD implantation should be considered in patients 
with CS and LVEF >35% after resolution of the active 
phase with significant LGE, a history of arrhythmias, 
unexplained syncope, inducible sustained VA at PVS, 
or with persistent high-degree AVB to prevent 
SCD.416,434,452,453,456‚Äì464,467 
IIa 
C 
¬© ESC 2025
AVB, atrioventricular block; CA, cardiac arrest; CMR, cardiovascular magnetic resonance; 
CS, cardiac sarcoidosis; 18F-FDG-PET, [18F]-fluorodeoxyglucose positron emission 
tomography; ICD, implantable cardioverter-defibrillator; LGE, late gadolinium 
enhancement; LVEF, left ventricular ejection fraction; PVS, programmed ventricular 
stimulation; SCD, sudden cardiac death; VA, ventricular arrhythmias; VF, ventricular 
fibrillation; VT, ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               53


<!-- PAGE 54 -->

### Page 54

at least 14 days and up to 21 days (total antibiotic course), depending 
on the severity of clinical presentation and response to treatment. 
The prognosis for early-treated disseminated LC is favourable, 
with complete recovery occurring in most patients treated with 
antibiotics.484,487 
Although LC may resolve spontaneously, antibiotic therapy shortens 
the disease duration and prevents further complications. 
9.5.3. Chagas disease 
Chagas disease (CD) is a systemic disorder caused by the protozoan 
parasite T. cruzi, which is transmitted through a haematophagous triatomine insect vector in endemic areas, such as Latin America, and 
can be transmitted transplacentally, by infected blood, or even orally 
through ingestion of contaminated food and drinks. Current migration 
has made CD a global disease, and congenital transmission has become 
relevant in non-endemic areas, including Europe. 
9.5.3.1. Presentation 
Acutely infected individuals remain asymptomatic or show mild and 
non-specific symptoms. Intense direct tissue parasitism may result in 
AM in less than 5% of cases. Chagas disease may evolve into CMP in 
20%‚Äì30% of cases. Common findings in patients with Chagas CMP include brady- or tachyarrhythmias, dilated ventricles with regional 
(mainly inferior, inferolateral, or apical) or global systolic dysfunction, 
and thromboembolism. 
9.5.3.2. Diagnosis 
Diagnosis of CD requires a high clinical suspicion. Polymerase chain 
reaction testing is the most sensitive test in acute infection while, 
for diagnosing chronic CD, the combination of two serological tests 
with antigens that detect different antibodies against T. cruzi is preferable. Multimodality imaging is able to support the diagnosis, as often 
apical aneurysms with and without thrombi can be detected by 
CMR.488 
9.5.3.3. Therapy 
Eradication of the parasite is a target in early phases, and anti-parasitic 
treatment should be provided as soon as possible, following detection 
of an acute infection. In the BENEFIT (Benznidazole Evaluation for 
Interrupting Trypanosomiasis) trial, 2854 patients with Chagas CMP 
were randomized to either benznidazole or placebo for 80 days. 
Benznidazole significantly reduced serum parasite detection, but there 
was no significant reduction in clinical cardiac deterioration at 
5 years.489 Therefore, anti-trypanosomal treatment should not be routinely used in adult patients with chronic CMP, but it can be considered 
in early and mild forms490,491 (see Table 12). Patients with Chagas CMP 
should be treated according to HF guidelines. Chagas disease is associated with high morbidity and mortality, with an annual rate of cardiovascular death of 6%.492 In this population, the benefit of ICD in primary 
and secondary prevention is controversial, since observational studies 
did not demonstrate a mortality benefit compared with amiodarone.493 
However, a systematic review and meta-analysis showed that, in patients with previous VT, appropriate ICD interventions and electric 
storms were frequent, occurring at a rate of 25% and 9% per year, respectively, with an overall mortality of 9% per year.494 A case-based decision is warranted. 
9.6. Drug- or vaccine-induced myocarditis 
9.6.1. Drug-induced myocarditis 
9.6.1.1. Immune checkpoint inhibitor-induced myocarditis 
Immune checkpoint inhibitors have revolutionized cancer treatment 
and are approved in multiple cancer types. These agents are monoclonal antibodies blocking specific molecules that inhibit the immune 
response‚ÄîCTLA-4 (cytotoxic T-lymphocyte antigen 4), PD-1 (programmed cell death protein 1) and its ligand PD-L1 (programmed 
death ligand 1), and LAG-3 (lymphocyte activation gene 3)‚Äîstrongly 
enhancing T-cell responses against cancer. By activating the immune 
system, ICIs may induce immune-related adverse events, which can affect any organ. Myocarditis is one of the most feared complications,495‚Äì497 although rare, as it affects approximately 1% of treated 
patients, within the first weeks following the initiation of therapy.495 
Since a growing number of patients are eligible for ICI treatment, 
the absolute number of cases is increasing. One of the largest case series, including 122 patients with ICI-associated myocarditis, recorded 
early onset after treatment initiation (median 30 days), and up to 
50% mortality.496 A systematic analysis of the World Health 
Organization (WHO) pharmacovigilance database confirmed a high 
mortality rate up to 33%.498 
The main risk factor for ICI-induced AM is combination therapy with 
two types of ICI, such as an anti-CTLA-4, e.g. ipilimumab, combined 
with an anti-PD-1, e.g. nivolumab.499 
This complication affects mostly men495 and older patients (median 
age 65 years) with more comorbidities.28,495 Furthermore, if ICIs are 
combined with other cancer therapies, their toxicity aggravates. 
9.6.1.1.1. Presentation. Immune checkpoint inhibitor-induced myocarditis is especially arrhythmogenic, including a risk of conduction 
disorders, and HF with reduced EF occurs in about half of patients.500 
Myocarditis is frequently associated with peripheral myositis, which, 
when associated with respiratory failure, can negatively affect 
survival. 
9.6.1.1.2. Diagnosis. When suspected, rapid diagnostic triage is 
needed.495‚Äì497 Early diagnosis is extremely important, usually including laboratory tests and multimodality imaging (Section 5). The detection of a 
coexisting CAD in older patients should not refrain from further work-up 
for myocarditis (Table 4). In inconclusive cases an EMB can be necessary. 
For more details, see the 2022 ESC cardio-oncology guidelines.501 
9.6.1.1.3. Therapy. After diagnosis, immediate discontinuation of ICI 
and early (within the first 24 h) initiation of corticosteroids is warranted. Up to 50% of patients will be refractory to corticosteroids. In 
this situation, second-line immunosuppression treatments are necessary (see Table 12).502 In a prospective registry, the combination of ruxolitinib and high doses of abatacept, and screening for concurrent 
respiratory muscle failure, was associated with improved survival.502 
Long-term cardiovascular effects of ICIs become more and more relevant since a growing number of cancer patients are exposed to this 
therapy.503,504 Rechallenge with an ICI has to be considered following 
a multidisciplinary team discussion, based on factors such as the severity 
of the myocarditis, cancer prognosis, oncology treatment options, and 
patient preference.504,505 Details are given in the 2022 ESC guidelines 
for cardio-oncology.501


<!-- PAGE 55 -->

### Page 55

9.6.1.2. Other drugs associated with myocarditis 
Many drugs have been associated with myocarditis (see Supplementary 
data online, Table S10), especially clozapine.506 The reported incidence 
of clozapine-associated myocarditis ranges from 0.1% to 5%.507,508 
Drug-induced myocarditis may be associated with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.509 Treatment is 
based on discontinuation of the drug and use of corticosteroids. 
9.6.2. Vaccine-induced myocarditis 
In 2002 the ‚ÄòBrighton collaboration‚Äô was established with the aim to provide standards for the definition of adverse events after vaccination.510 
In a clinical context, different vaccines, apart from the SARS-CoV-2 
vaccine, have been associated with myocarditis. The main association 
is with smallpox vaccine,511 with data deriving mainly from the US military population. 
A systematic review reported cardiac events including IMPS after influenza vaccination, pneumococcal vaccine, and tetanus toxoid.512 
Few data reported myocarditis after receiving different vaccines (e.g. 
meningococcus, hepatitis A and B, diphtheria, poliovirus) (see  
Supplementary data online, Table S11).513‚Äì518 
A recent multicentre study reported good mid-term outcomes after 
COVID-19 vaccine-associated myocarditis without death or need for 
HT.519 More detailed information can be found in Supplementary 
data online, Section 5.1.2. 
9.7. Pregnancy-associated myocarditis 
Peripartum CMP (PPCM) is sometimes associated with myocardial inflammation, more common particularly in patients presenting with arrhythmias.520 Pregnancy-associated myocarditis (PaM) is a rare 
condition, and its incidence and prognosis varies regionally.521‚Äì523 
Nutritional deficiencies, viral myocarditis, and autoimmune processes 
have been postulated as triggers. Recent data support the role of 
neurohormonal changes of late pregnancy and delivery, as well as the 
role of genetic predisposition.524 
9.7.1. Presentation 
There is no clear distinction between the phenotype of PaM and PPCM. 
Women develop symptoms of HF during late pregnancy or after delivery, with the majority being diagnosed after delivery, typically in the first 
month post-partum. A minority of patients may present with pulmonary oedema, cardiogenic shock, severe arrhythmias,525 cardio- 
pulmonary arrest, thromboembolic complications, and brain injury. 
9.7.2. Diagnosis 
There are no specific studies for PaM, therefore the guidance for PPCM 
should be followed. Transthoracic echocardiography should be performed in any suspected case. In PPCM, LVEF is typically <45%.526 
Careful examination should be undertaken to clearly view the LV 
apex to detect intracardiac thrombi. Brain natriuretic peptide/ 
N-terminal prohormone of brain natriuretic peptide are usually markedly elevated.527‚Äì529 
Cardiovascular magnetic resonance imaging is an advanced imaging 
modality if echocardiogram is inadequate, but gadolinium-based contrast 
agents should be avoided during pregnancy.530‚Äì532 Cardiovascular magnetic resonance is crucial to differentiate underlying causes.533 The detection of active inflammation can be performed without application of 
contrast media in CMR (Figure 4). 
Peripartum CMP has been associated with a higher rate of recovery 
than other forms of HF with reduced EF,534 and remission frequently 
occurs within the first 3 to 6 months.535 Delayed recovery can also occur after 2 years.536,537 
9.7.3. Therapy 
There are no dedicated studies for PaM, so advice is based on published 
literature for PPCM. 
Treatment of HF is essential, with modifications to ensure foetal 
safety during pregnancy.521,538‚Äì540 
Low-molecular-weight heparins do not cross the placenta, and are 
preferred during pregnancy if the thromboembolic risk is high.541 
Direct oral anticoagulants are less well studied in pregnancy, and should 
be avoided. Anticoagulation should be continued until recovery of LV 
function. 
Bromocriptine has been shown to improve LVEF at 6 months, but 
the results are contradictory.521,542‚Äì545 
Following delivery, most HF medications are compatible with breastfeeding. Many patients may also relapse. Treatment withdrawal and incomplete recovery of LV function are risk factors for recurrences.546,547 
Lifelong treatment has not been proven to be necessary. 
Pre-conception counselling should include discussion of the potential 
risks of recurrent myocardial dysfunction, even after recovery.547 
Multidisciplinary teams are warranted for patient management.548,549 
10. Inflammatory cardiomyopathy 
Inflammatory CMP is defined by chronic myocarditis in association with 
cardiac dysfunction and ventricular remodelling, with a clinical hypokinetic phenotype, either dilated or non-dilated, with or without arrhythmogenic substrate. It can also manifest as the evolution of a prior 
myocarditis, whether treated or untreated. Inflammatory CMP is involved in the pathogenesis of DCM. It includes immune-mediated/autoimmune forms and infectious subtypes.12,550 A genetic predisposition is 
Recommendation Table 18 ‚Äî Recommendations for 
immune checkpoint inhibitor-associated myocarditis 
(see Evidence Table 18) 
Recommendations 
Classa 
Levelb  
Diagnostic triage within 24 h is recommendedc in 
patients with suspected myocarditis induced by ICI 
to initiate treatment rapidly.495,496,501,504 
I 
C 
Immediate disruption of ICI and administration of 
high-dosage corticosteroids are recommended in 
patients with ICI-associated myocarditis in order to 
stop the inflammatory reaction and stabilize the 
patient.504 
I 
C 
Second-line immunosuppression treatment should 
be considered in patients with steroid-refractory 
ICI-associated myocarditis.501,504 
IIa 
C 
Second-line immunosuppression treatment may be 
considered in patients with fulminant/severe 
ICI-associated myocarditis.501,504 
IIb 
C 
¬© ESC 2025
ICI, immune checkpoint inhibitor. 
aClass of recommendation. 
bLevel of evidence. 
cSee Figure 5.   
ESC Guidelines                                                                                                                                                                                               55


<!-- PAGE 56 -->

### Page 56

also important for the pathogenesis of inflammatory CMP.9 However, 
the rates, risk factors, and other characteristics of cases progressing 
from AM to chronic myocarditis or inflammatory CMP remain unknown. 
10.1. Presentation 
Patients with inflammatory CMP may present with new-onset/acute, 
subacute, or chronic HF. Although myocarditis resolves in >50% of 
cases, even spontaneously, approximately 25% of cases may present 
with persistent ventricular dysfunction, and more severe cases may 
progress to DCM.10 
10.2. Diagnosis 
A variety of clinical assessment, ECG, multimodality imaging, and, if 
needed, EMB can be used to reach a diagnosis. Persistent or chronic 
myocardial inflammation should be suspected in cases with non- 
ischaemic ventricular dysfunction associated with low QRS voltages, 
and persistent mild elevation of hs-TnT/TnI. The absence of significant 
remodelling may be observed in the early phase of the disease. This suspicion can be confirmed by multimodality imaging (echocardiography 
and CMR) and EMB, especially in the presence of myocardial oedema 
observed at CMR. Inflammatory CMP may be familial in rare cases. In 
these patients, genetic testing should be discussed. 
10.3. Therapy 
Guideline HF treatment is recommended in patients with inflammatory 
CMP.12,259 Medical therapy should be tailored to the underlying cause 
in case of systemic disorders, especially in autoimmune diseases. Only 
one RCT showed an improvement of cardiac function with immunosuppressive treatment in patients with virus-negative inflammatory 
CMP.551 Other non-randomized studies, often derived from single- 
centre and/or retrospective studies,34,131,551‚Äì555 suggest the efficacy 
of immunosuppression on top of optimized HF therapy, and support 
its safety. In patients with different immune-mediated myocarditis 
and HF, immunosuppressive therapy was safe.34,131,552‚Äì555 Therefore, 
the treatment should be based on histological/immunohistological 
and viral PCR examination of the biopsy specimens. 
In untreated cases, progression to DCM and transplantation or death 
are observed.10,39 
11. Specific types of pericarditis 
11.1. Tuberculous pericarditis 
In high-income countries, TB pericarditis accounts for up to 4% of pericardial disease, but it is increasing due to immigration. On the other hand, TB 
is the cause of clinically significant PEff in approximately 90% of 
HIV-infected and 50%‚Äì70% of non-HIV-infected individuals living in developing countries with a high prevalence of TB.556 It should be emphasized 
that most of the information on TB pericarditis comes from endemic 
areas in low-income countries and immunosuppressed patients.1 
Notably, the disease can occur at any age, and men are affected more frequently than women.48 Tuberculous pericarditis has an overall mortality 
rate of 17%‚Äì40% at 6 months after diagnosis.557 
11.1.1. Presentation 
Clinical presentations of TB pericardial involvement include AP (most 
commonly with PEff), ECP, and CP, with these manifestations representing consecutive stages of a unique process rather than independent 
conditions.558,559 Specifically, the evolution of TB pericarditis encompasses four stages (Figure 18). The first stage or dry stage of AP is without effusion, the second stage with PEff (this is the form most 
commonly encountered in clinical practice) in up to 80% of cases, the 
third stage with progressive absorption of effusion, and the fourth stage 
with pericardial constriction. In the effusive phase, pericardiocentesis 
usually yields bloody effusion, and effusive‚Äìconstrictive physiology 
may emerge after pericardial drainage. At this stage, lymphocytic exudate is mainly observed.560 The duration of each stage varies and depends on individual factors (e.g. HIV status), and early treatment may 
prevent progression. 
11.1.2. Diagnosis 
The diagnosis of TB pericarditis is challenging and in 15%‚Äì20% of cases 
the diagnosis may be missed.561 A ‚Äòdefinite‚Äô diagnosis of TB is based on 
the presence of tubercle bacilli in the pericardial fluid or on a histological sample of the pericardium, by culture or by PCR (Xpert MTB/RIF and 
RIF ultra) testing. A ‚Äòprobable‚Äô diagnosis is made when there is proof of 
TB elsewhere in a patient with unexplained pericarditis, a lymphocytic 
pericardial exudate with elevated unstimulated IFN-Œ≥ (uIFN-Œ≥), adenosine deaminase or lysozyme levels, and/or an appropriate response to 
antituberculosis therapy in endemic areas.558 In a meta-analysis, the 
sensitivity and specificity of adenosine deaminase, which is probably 
the most widely used biomarker, were 90% and 86%, respectively, 
for the diagnosis of TB pericarditis.562 Xpert MTB/RIF is highly specific 
(100%); however, it has a sensitivity of 64%, which increases to 78% 
when pericardial biopsy samples are employed.563,564 Pericardial fluid 
culture shows low sensitivity (53%‚Äì75%) and it is also time-consuming, 
needing more than 3 weeks to yield results. Interferon gamma offers superior accuracy for the diagnosis of microbiologically confirmed TB pericarditis compared with the adenosine deaminase (ADA) assay and the 
Xpert MTB/RIF test.563 In a meta-analysis, values of uIFN-Œ≥ in the pericardial fluid from studies using thresholds of 14‚Äì200 pg/mL showed very 
high sensitivity (97%) and specificity (99%) for the diagnosis of TB pericarditis, with a positive likelihood ratio of 187 and a negative likelihood 
ratio of 0.03.565 On the other hand, the tuberculin skin test and IFN-Œ≥ 
release assays are of limited value, especially in areas with a high burden 
of TB, since they cannot discriminate between previous exposure to 
Mycobacterium and active disease.566 A detailed approach is outlined 
in Supplementary data online, Table S12. 
Recommendation Table 19 ‚Äî Recommendations for 
inflammatory cardiomyopathy (see Evidence Table 19) 
Recommendations 
Classa 
Levelb  
Guideline-directed heart failure treatments are 
recommended in patients with inflammatory 
cardiomyopathy to improve and/or stabilize left 
ventricular function. 
I 
C 
Specific medical therapy for the potentially 
underlying systemic disease is recommended in 
inflammatory cardiomyopathy. 
I 
C 
Immunosuppressive therapy, guided by 
endomyocardial biopsy, should be considered in 
virus-negative inflammatory cardiomyopathies to 
suppress the autoimmune response.34,131,551‚Äì555 
IIa 
B 
¬© ESC 2025
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 57 -->

### Page 57

11.1.3. Therapy 
Medical treatment consists of a regimen including rifampicin, isoniazid, 
pyrazinamide, and ethambutol for at least 2 months, followed by isoniazid and rifampicin for an additional 4 months, which is effective in 
treating extrapulmonary TB.1,567 Treatment for ‚â•9 months gives no 
better results and has the disadvantages of increased cost and poor 
compliance.567 
However, it should be emphasized that, excluding isoniazid, poor 
drug penetration into the pericardial space is a matter of concern, 
also considering the emerging evidence of intrapericardial bacillary 
load and mortality.568 
With the prompt use of antitubercular medications, steroids (oral 
or intrapericardial), and the widespread use of pericardial drainage 
with or without intrapericardial fibrinolysis, the currently reported 
rates of CP are between 5% and 25%.569 Moreover, contemporary 
treatment has accounted for a 20% reduction in all-cause mortality.567,569‚Äì572 
Pericardial drainage by any means (pericardiocentesis or pericardial 
window) is recommended as an essential part of the work-up in patients with suspected TB pericarditis, both for diagnostic and therapeutic purposes.1 
Constriction generally develops in up to 50% of patients within 6 months of presentation prior to the introduction of effective TB therapy.1 Appropriate antibiotic therapy is essential to 
prevent this progression.570 In addition, two interventions 
may reduce the incidence of constriction: (i) intrapericardial 
urokinase; and (ii) high-dose adjunctive prednisolone for 
6 weeks.569,573 
However, the coexistence of TB and HIV infection requires special attention. Prednisolone was associated with an increased risk of 
HIV-associated malignancies.569 On this basis, it may be reasonable 
to use adjunctive corticosteroids in patients with TB pericarditis 
without HIV infection and to avoid them in HIV-infected 
individuals.569 
Figure 18 Stages of tuberculous pericarditis.  
Recommendation Table 20 ‚Äî Recommendations for 
tuberculous pericarditis (see Evidence Table 20) 
Recommendations 
Classa 
Levelb  
Diagnosis and treatment of tuberculous pericarditis and effusion 
Diagnostic pericardiocentesis is recommended in all 
patients with suspected tuberculous pericarditis 
when diagnosis is not confirmed by non-invasive tests 
to identify the aetiological agent in pericardial fluid.570 
I 
C 
Empirical antituberculosis chemotherapy is 
recommended in patients living in endemic areas 
with exudative pericardial effusion after excluding 
other causes to treat the most likely cause.567,570 
I 
C 
Standard antituberculosis multidrug treatment for 
6 months is recommended in patients with 
tuberculous pericarditis for the prevention of 
pericardial constriction.570 
I 
C 
Pericardiectomy is recommended in patients with 
tuberculous pericarditis if the condition is not improving 
or is deteriorating after 4‚Äì8 weeks of antituberculosis 
therapy to change the course of disease. 
I 
C 
Adjunctive steroid therapy should be considered in 
HIV-negative cases to prevent the development of 
constrictive TB pericarditis.569 
IIa 
C 
In non-endemic areas a pericardial biopsy may be 
considered in patients with >3 weeks of illness 
without aetiologic diagnosis. 
IIb 
C 
Empirical antituberculosis treatment is not 
recommended in patients living in non-endemic areas. 
III 
C 
¬© ESC 2025
HIV, human immunodeficiency virus; TB, tuberculosis. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               57


<!-- PAGE 58 -->

### Page 58

11.2. Pericardial involvement in neoplastic 
disease 
11.2.1. Presentation 
Neoplastic pericardial involvement is occasionally manifested by pericarditis or, more commonly, an isolated PEff (usually moderate to 
large, or CTP) with or without evident masses on imaging. It is usually 
related to metastatic lymphatic involvement (especially for lung cancer) or haematogenous spread (especially for breast cancer). In addition, lymphomas, leukaemias, and melanoma may affect the 
pericardium, as may cancer of contiguous organs (e.g. oesophageal 
cancer).574,575 Primary neoplastic disease of the pericardium is rare. 
Pericardial mesothelioma is the most common form, and it may present as ECP or CP in advanced cases. On this basis, the term ‚Äòneoplastic pericarditis‚Äô is often used incorrectly instead of ‚Äòneoplastic 
pericardial effusion‚Äô. 
11.2.2. Diagnosis 
The definitive diagnosis is based on the confirmation of malignant infiltration within the pericardial fluid by cytology (pericardiocentesis) 
or pericardial biopsy. A probable diagnosis may be achieved by the 
detection of tumour markers in the pericardial fluid (e.g. CEA, 
CYFRA 21-1, NSE, CA-19-9, CA-72-4, SCC, GATA3, and VEGF), although none of these tumour markers has been proven to be accurate enough for distinguishing malignant from benign effusions.576,577 
Evidence of malignant disease elsewhere and concomitant pericarditis or PEff is also suggestive, although in almost two-thirds of patients 
with documented malignancy, pericardial involvement is caused by 
non-malignant diseases,15 e.g. radiation,578,579 chemotherapy,580 or 
infections. Cytological analyses of pericardial fluid are mandatory 
for the confirmation of malignant pericardial disease.581 Analyses 
of pericardial fluid and less commonly pericardial or epicardial biopsies are essential for the confirmation of malignant pericardial 
disease. 
11.2.3. Therapy 
The management of these patients requires a multidisciplinary approach involving oncologists, cardiologists, and radiotherapists, as 
well as other specific subspecialty experts according to the type of 
cancer. 
General principles of treatment include systemic antineoplastic 
treatment as baseline therapy. Local antineoplastic treatment is based 
on tailored intrapericardial therapy according to the type of tumour 
(e.g. cisplatin is efficacious in lung cancer, thiotepa in breast cancer),582 
and intrapericardial instillation of cytostatic/sclerosing agents to prevent recurrences. Malignant PEffs show a high recurrence rate 
(>50%). Extended pericardial drainage can be necessary in patients 
with suspected or definite neoplastic PEff to prevent effusion recurrence and provide a route for intrapericardial therapy. Additional interventions for recurrent effusions may include pericardiotomy, 
pericardial window, and percutaneous balloon pericardiotomy. All 
techniques are palliative and aimed at improving the quality of life of patients with a poor short-term outcome. 
Radiation therapy is very effective in controlling malignant PEff in patients with radiosensitive tumours, such as lymphomas and leukaemias. 
In clinical practice, management is often palliative at late stages with 
advanced disease, and it is aimed only at the relief of symptoms rather 
than treatment of the underlying disease, considering the prognosis, 
and the overall quality of life of the patient. 
11.3. Post-cardiac injury syndrome 
The term PCIS is an umbrella term indicating a group of inflammatory pericardial syndromes, including late post-acute myocardial 
infarction (post-AMI) pericarditis (or Dressler syndrome), post- 
pericardiotomy syndrome (PPS), and post-traumatic pericarditis 
with or without bleeding. Currently several post-traumatic cases 
are iatrogenic and related to cardiovascular interventions.585,586 
Nowadays, Dressler syndrome appears in <1% of cases, mainly in 
larger infarctions and/or late reperfusion, typically 1‚Äì2 weeks after 
AMI.587 Notably, patients with a post-AMI PEff of >10 mm at end- 
diastole should be investigated for a possible subacute heart 
rupture.588,589 
In contrast, cases developing after cardiac device implantation or arrhythmia ablation (e.g. pericarditis appears in ‚àº10% of cases after AF 
ablation) are becoming increasingly common due to the growing 
number of invasive procedures.586,587,590,591 
Such syndromes are presumed to have an autoimmune pathogenesis 
triggered by pericardial bleeding and/or pleura incision.47,592 An 
immune-mediated pathogenesis is supported by a latent period, 
Recommendation Table 21 ‚Äî Recommendations for 
neoplastic 
pericardial 
involvement 
(see 
Evidence 
Table 21) 
Recommendations 
Classa 
Levelb  
Pericardiocentesis is recommended for patients with 
cardiac tamponade to relieve symptoms and 
establish the diagnosis of malignant pericardial 
effusion.576,583 
I 
C 
Extended pericardial drainage (3‚Äì6 days) is 
recommended in patients with suspected or definite 
neoplastic pericardial effusion to prevent effusion 
recurrence.576,583 
I 
B 
Cytological analysis of pericardial fluid is 
recommended in patients with neoplastic pericarditis 
for the confirmation of malignant pericardial 
disease.581 
I 
C 
Systemic antineoplastic treatment is recommended 
in confirmed cases of neoplastic aetiology to treat 
the primary and secondary metastatic neoplastic 
involvement.582 
I 
C 
Pericardiocentesis should be considered in patients 
with moderate to large pericardial effusion to 
establish the diagnosis of malignant pericardial 
effusion when the diagnosis cannot be reached by 
multimodality imaging.584 
IIa 
C 
Pericardial or epicardial biopsy may be considered in 
patients with suspected malignant pericardial disease 
when the diagnosis cannot be reached by 
multimodality imaging or cytological analysis, to 
confirm the diagnosis. 
IIb 
C 
Intrapericardial therapy, in agreement with the 
oncologist, may be considered in cases refractory to 
systemic antineoplastic treatment. 
IIb 
C 
¬© ESC 2025
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 59 -->

### Page 59

generally a few weeks, until the appearance of the first manifestations, 
the positive response to anti-inflammatory drugs, and the possibility of 
recurrences. 
11.3.1. Diagnosis 
According to proposed diagnostic criteria, the diagnosis of PCIS may be 
reached in the presence of at least two of the following five criteria: (i) 
fever without alternative causes; (ii) pericardial or pleuritic chest pain; 
(iii) pericardial or pleural rubs; (iv) evidence of PEff; and/or (v) pleural 
effusion with elevated C-reactive protein.593‚Äì595 
The rationale for proposing specific criteria is that these syndromes 
may have concomitant pleuro-pericardial involvement and possible pulmonary infiltrates, and are not simply pericarditis.595 Moreover, it is 
sometimes difficult to differentiate PCIS from the simple mechanical 
consequences of surgery (such as early pericardial or pleural effusion). 
The demonstration of inflammatory activity (e.g. C-reactive protein elevation) is essential to establish the diagnosis. Multimodality imaging can 
be helpful for the diagnosis of complicated cases (e.g. loculated effusions, evidence of inflammation). 
11.3.2. Therapy 
The same therapeutic scheme adopted for AP, essentially based on empirical anti-inflammatory therapy, is effective for all forms of PCIS, and 
may improve remission rates and reduce the risk of recurrences. In 
early post-AMI pericarditis, a 5‚Äì7-day course of aspirin seems the 
most reasonable option, in association with colchicine.587 
Different treatment strategies (namely aspirin, methylprednisolone, 
dexamethasone, and colchicine) have been adopted for the primary 
prevention of PPS, and the effects of such treatments have been addressed in a meta-analysis that showed that only colchicine was associated with a decreased risk of PPS (OR 0.38), sometimes, however, 
with an increased risk of gastrointestinal side effects.593,594,596‚Äì600 
Preventive administration of colchicine can be given after cardiac surgery using weight-adjusted doses (i.e. 0.5 mg once for patients 
‚â§70 kg and 0.5 mg twice daily for patients >70 kg) and without a loading dose for the prevention of PPS and continued for 1 month.596 
In this guideline document, the LOE for colchicine recommendation 
for the prevention of PPS is based on analysis of the available evidence 
from more than one RCT, systematic reviews and the consensus opinion of the TF members. 
Neither NSAIDs nor colchicine have to be administered for post- 
operative effusions in the absence of systemic inflammation.601,602 
Early post-operative PEffs are relatively common after cardiac surgery, 
and usually disappear spontaneously in 7‚Äì10 days.1 Asymptomatic small 
PEffs do not require treatment; however, moderate to large effusions 
(observed in one-third of cases) can progress to CTP at a rate of 
10% within 1 month after surgery and need pericardial decompression.603 Treatment of these asymptomatic effusions by NSAIDs has 
been shown to be ineffective [e.g. diclofenac in the Post-Operative 
Pericardial Effusion (POPE) trial], and may be associated with an increased risk of side effects.601 
The prognosis of PPS is generally good.600 In the largest published 
series on PPS patients after cardiac surgery, complication rates were 
low: <4% for recurrences; <2% for CTP; and no cases of constriction, 
although hospital stay may be prolonged in these patients.592 
Moreover, the development of CP has been reported in ‚àº3% of 
cases.347 Both early post-AMI pericarditis and Dressler syndrome are 
markers of larger infarct size, but without independent prognostic 
significance.587 
11.4. Pericarditis and autoinflammatory 
diseases 
Compared with the previous guidelines, it has become evident that some 
inflammatory forms of RP share similarities with genetic autoinflammatory diseases characterized by periodic fevers, e.g. FMF and TRAPS.50,51 
These are genetic disorders characterized by mutations of genes involved in the regulation of the inflammatory response, without involvement of specific T cells or autoantibodies.605 These disorders are 
usually detected in the paediatric population, although some patients experience disease onset during adulthood. The most common monogenic 
autoinflammatory syndromes include FMF, in which serositis episodes last 
only 1‚Äì3 days, and TRAPS, in which fever and symptoms last for weeks.605 
Mutations associated with these disorders have been reported in up to 
10% of patients with multiple recurrences, especially with a positive family 
history, and a poor response to colchicine.152 Recently, rare deleterious 
MEFV variants were observed more frequently in idiopathic RP than 
in ancestry-matched controls (allele frequency 9/200 vs 2932/129 200, 
P = 0.040).50 These conditions are characterized by the exaggerated production of IL-1 by the inflammasome. Familial occurrence of pericarditis 
has been reported among the relatives of idiopathic RP patients, ranging 
from 4%50 to 10%.113 These data suggest a genetic predisposition in at 
least a subset of patients; counselling may be warranted in these cases. 
11.5. Purulent pericarditis 
Purulent pericarditis, namely the most serious manifestation of bacterial pericarditis, is characterized by the macro- or microscopic presence 
of purulent PEff. It is an exceedingly rare form of pericarditis in the 
Western world, accounting for <1% of AP cases.606 It has a high mortality in untreated cases while, in optimally treated patients, the reported survival rate is approximately 15%‚Äì40%.606 
In developed countries, the most common organisms isolated in 
purulent pericarditis include staphylococci and streptococci, while 
Recommendation Table 22 ‚Äî Recommendations for 
post-cardiac injury syndrome (see Evidence Table 22) 
Recommendations 
Classa 
Levelb  
Anti-inflammatory therapy is recommended in 
patients with PCIS to hasten symptom remission and 
reduce recurrences.292,600 
I 
B 
IL-1 antagonists are recommended in patients with 
refractory PCIS to prevent recurrences and 
progression to constriction.604 
I 
B 
High-dose aspirin is recommended as the first-choice 
anti-inflammatory therapy for post-myocardial 
infarction pericarditis and in patients being already on 
antiplatelet therapy. 
I 
C 
Colchicine, started 48 to 72 h before cardiac surgery, 
should be considered for 1 month in patients after 
cardiac surgery for the prevention of PCIS if there 
are no contraindications and if it is tolerated.594,596 
IIa 
A 
Careful follow-up should be considered in patients 
with PCIS to exclude possible evolution towards 
constrictive pericarditis.347 
IIa 
C 
¬© ESC 2025
IL, interleukin; PCIS, post-cardiac injury syndrome. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               59


<!-- PAGE 60 -->

### Page 60

the predominant associated lesions are empyema (50%) or pneumonia 
(33%). In immunosuppressed patients or following thoracic surgery, the 
most frequently encountered bacterial/fungal agents are Staphylococcus 
aureus (30%) and fungi (20%), while anaerobic bacteria, originating from 
the oropharynx, have also been reported.607,608 
It should be stressed that in the modern era of iatrogenic and 
HIV-associated immunosuppression, more unusual organisms may account for pericardial infection.1,607 
11.5.1. Presentation 
Purulent pericarditis has generally manifested as a serious febrile disease, 
and the underlying sepsis may predominate, including septic shock.606‚Äì608 
Constrictive pericarditis complicates 20%‚Äì30% of cases.347 
11.5.2. Diagnosis 
Suspicion of purulent pericarditis is an indication for pericardial drainage 
independently from the haemodynamic status. Surgical pericardial drainage is recommended to allow complete removal of the fluid and prevent 
its organization and progression to constriction. Low pericardial-to-serum 
glucose ratio (mean 0.3) and elevated pericardial fluid white cell count 
with a high proportion of neutrophils (mean cell count 2.8/mL, 92% neutrophils) differentiate purulent from tuberculous (glucose ratio 0.7, mean 
cell count 1.7/mL, 50% neutrophils) and neoplastic pericarditis (glucose 
ratio 0.8, mean cell count 3.3/mL, 55% neutrophils). 
Fluid must be sent for bacterial, fungal, and tuberculous studies along 
with blood and tissue samples, as guided by the clinical presentation.1 
11.5.3. Therapy 
Intravenous antimicrobial therapy should be started empirically until 
microbiological results are available. Afterwards, pathogen-directed antibiotic therapy is warranted based on antibiotic susceptibility.1 The duration of antibiotic therapy should be individualized until fever and clinical 
signs resolve, with the minimum period of administration being 3 weeks. 
Purulent effusions are often heavily loculated and likely to rapidly reaccumulate. Subxiphoid pericardiotomy and rinsing of the pericardial cavity should be considered.15 This allows more complete drainage of the 
effusion, since loculations can be manually lysed. Intrapericardial fibrinolysis is a possible treatment for cases of loculated effusions to achieve adequate drainage.609 Fibrinolysis has been shown to prevent complications 
in approximately 86% of cases without fatal complications.573,609,610 In 
the unfortunate case that percutaneous measures fail to control infection, and worsening HF occurs along with constrictive physiology features, referral to surgical pericardiectomy is advised.610 
11.6. Incessant and recurrent pericarditis 
The TF proposes to adopt the term ‚Äòincessant‚Äô for cases of persistent 
symptoms without clear remission, and thus also to include cases of 
symptom persistence/recurrence during drug tapering. Recognition of 
these cases is of paramount importance, since they can directly progress 
to CP within a few months.104 Recurrent pericarditis is defined as a relapse after a documented first episode of AP, a symptom-free interval, 
complete discontinuation of anti-inflammatory therapy, and evidence 
of subsequent recurrence of pericarditis. Recurrence usually occurs within 18 months from the index episode, and is the most common and 
problematic complication of AP, ranging from 15% to 30% of cases after 
a first episode of pericarditis. It may increase to 50% after a first recurrence in patients with inadequate treatment of the first episode (e.g. 
too fast tapering, not treated with colchicine, treated with corticosteroids).25,611 In developed countries, the aetiology of recurrences is poorly 
known, and most cases are labelled as idiopathic. Historically, most cases 
were probably related to an autoinflammatory/autoimmune pathogenesis. This is based on the inflammatory/non-inflammatory phenotype, 
the latency from the acute attack (several weeks after the index episode), 
the presence of autoantibodies, and the response to anti-inflammatory/ 
immunosuppressive treatments.52,283,284,287 
11.7. Inflammatory and non-inflammatory 
pericardial effusion 
The normal pericardial sac contains 10‚Äì50 mL of pericardial fluid, a 
plasma ultrafiltrate that acts as a lubricant between the pericardial 
layers. Any pathological process that causes pericardial inflammation increases the amount of fluid, causing PEff (exudate). Alternative mechanisms causing PEff include decreased reabsorption following increased 
systemic venous pressure, as observed in congestive HF or pulmonary 
hypertension (transudate) or alternatively, decreased lymphatic drainage.612 The regimen of pressures in the epicardium and pericardial cavity is shown in Supplementary data online, Figure S4. 
11.7.1. Classification and aetiology 
The reported incidence and prevalence of PEff in developed countries is 
estimated at 3% and 6%‚Äì9%, respectively, based on echocardiographic 
laboratory records.613 Pericardial effusion was detected in 14% of subjects in a prospective registry of consecutive patients who underwent 
chest CT.198 
The classification of PEff is shown in Table 10. Echocardiography provides semiquantitative assessment of the effusion size, which is useful for 
estimating the risk of having a non-idiopathic aetiology and complications 
(see Supplementary data online, Figure S5).105 In the past three decades, 
six major surveys have been published on the characteristics of moderate 
to large PEff (see Supplementary data online, Table S13).556,614‚Äì618 
According to these series, many cases remain idiopathic in developed 
countries (up to 50%), while additional aetiologies include cancer 
(10%‚Äì32%), infections (15%‚Äì30%), iatrogenic causes (15%‚Äì20%), and 
connective tissue diseases (5%‚Äì15%), whereas TB is the dominant cause 
in developing countries (>60%), where TB is endemic.558 
11.7.2. Presentation 
A significant proportion of patients with PEff are asymptomatic, and PEff is 
an incidental finding during routine examination. The clinical presentation 
of PEff varies according to the speed of accumulation of fluid (see  
Supplementary data online, Figure S4). Classic symptoms include exertional 
dyspnoea progressing to orthopnoea, chest pain, and feeling of fullness. 
Recommendation Table 23 ‚Äî Recommendations for 
purulent pericarditis (see Evidence Table 23) 
Recommendations 
Classa 
Levelb  
Urgent pericardiocentesis and/or a surgical window 
is recommended in patients with suspicion of 
purulent pericarditis to establish a diagnosis.606 
I 
C 
Intrapericardial fibrinolysis should be considered in 
patients with purulent pericarditis to allow complete 
drainage of purulent fluid and to prevent 
constriction.573,610 
IIa 
B 
¬© ESC 2025
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 61 -->

### Page 61

Additional symptoms due to the compression of adjacent structures include nausea (diaphragm), dysphagia (oesophagus), hoarseness (recurrent laryngeal nerve), and hiccups (phrenic nerve).118,619 
11.7.3. Diagnosis 
Physical examination may be normal in patients without haemodynamic 
compromise. Echocardiography is the primary diagnostic tool for 
diagnosis, sizing, assessment of haemodynamic effects, and follow-up 
(see Supplementary data online, Figure S5).115,124 Advanced imaging 
(CT and CMR) provides valuable information concerning local inflammation, masses, associated chest abnormalities (e.g. pectus excavatum), 
loculated effusions, and systemic diseases.196,198,620 Pericardial effusion 
is often associated with known or unknown medical conditions (e.g. 
hypothyroidism) in up to 60% of cases, especially if moderate/large.615 
A practical routine evaluation for the triage of PEff is presented in  
Figure 19.1 
Concomitant pericarditis
Treat as pericarditis
Associated systemic disease 
Pericardiocentesis with drainage
Empiric anti-inÔ¨Çammatory therapy
Improvement
Outpatient follow-up and treatment 
according to 
speciÔ¨Åc aetiology
Pericardial eÔ¨Äusion
First-line assessment with history, physical examination, ECG,
chest X-ray transthoracic echocardiography, laboratory assessment 
Cardiac tamponade, symptomatic moderate to large pericardial eÔ¨Äusion with suspicion of neoplastic or bacterial aetiology
Admission, 
pericardiocentesis and aetiology search
Large (>20 mm) and chronic (>3 months) eÔ¨Äusion
Pericardial window
Treat the systemic 
condition
Symptomatic
Oupatient follow-up
Symptomatic
Fluid re-accumulation
Outpatient follow-up and treatment according to speciÔ¨Åc aetiology
Figure 19 Triage and management of pericardial effusion. ECG, electrocardiogram; N, no; Y, yes.   
ESC Guidelines                                                                                                                                                                                               61


<!-- PAGE 62 -->

### Page 62

Patients presenting with PEff without inflammatory marker elevation 
have an increased risk of a neoplastic aetiology (likelihood ratio 2.9).615 
In chronic effusions with no definite aetiology, and without inflammatory markers, empirical anti-inflammatory treatment is futile.1,621 In 
worsening large effusions without evidence of systemic inflammation, 
the exclusion of cancer with advanced imaging (mainly CT) is warranted.196 C-reactive protein should be measured before pericardiocentesis, since it can increase after the procedure.622 Notably, the 
classical Light criteria used for the classification of pleural effusions 
should not be applied to PEff due to the high rate of misclassification 
of fluids as exudates, since pericardial fluid is rich in mesothelial cells, 
proteins, albumin, and lactate dehydrogenase (LDH).623,624 
11.7.4. Therapy 
The treatment of PEff is shown in Figure 19. Therapy of PEff should be 
targeted at the aetiology, as much as possible. In the absence of pericardial inflammation (namely in the absence of C-reactive protein elevation 
and evidence of pericardial inflammation by an imaging technique) anti- 
inflammatory treatment is not recommended. According to recent 
data, the usefulness of pericardial drainage in asymptomatic or oligosymptomatic, large, chronic, idiopathic effusions without evidence of 
pericarditis has been revised.49,621 Conservative treatment improves 
outcomes, the risk of CTP being only 2.2%/year without reported 
deaths.625 In addition, survival after recurrence or complications is 
significantly better in patients treated conservatively without interventions. Nevertheless, if during follow-up the PEff becomes symptomatic 
and haemodynamic impairment is observed by echocardiography, 
drainage is warranted. 
11.7.5. Prognosis and follow-up 
The prognosis of PEff is essentially related to its aetiology.626 Moderate 
to large effusions are more common for specific aetiologies.105,615 In 
general, PEff should be considered as a marker of the severity of the 
underlying disease.584 Small, idiopathic, asymptomatic PEff have an 
overall good prognosis with a very low risk of complications, although 
not all studies concur.613 Those individuals should be reassured about 
the benign nature of the condition, and should not restrict their physical 
activity if C-reactive protein is normal.11 The follow-up of PEff is mainly 
based on the evaluation of symptoms, using focused echocardiography 
to assess size changes, and haemodynamic issues, as well as C-reactive 
protein. Asymptomatic patients with mild idiopathic effusions do not 
generally require specific monitoring. In asymptomatic patients with 
at least moderate effusions, a reasonable follow-up is every 6 months, 
ideally in specialized centres. The latter patients should be instructed to 
seek medical advice in case of symptom appearance, such as dyspnoea 
or fatigue, and/or chest pain suggesting pericarditis. 
11.8. Cardiac tamponade 
Cardiac tamponade is a pericardial syndrome occurring when PEff impairs diastolic filling of the heart until cardiac output is reduced. The 
size of the effusion as well as its distribution may vary. Since the pericardium is relatively stiff, if pericardial fluid collects quickly, such as in haemopericardium, the limit of pericardial stretching is reached quickly with 
volumes of 200‚Äì300 mL. In contrast, slowly accumulating PEff may reach 
1 to 2 L before the development of CTP (Supplementary data online,  
Figure S4). This pathophysiology explains that CTP is a last-drop phenomenon. Thus, a small increase of pericardial volume may precipitate the 
syndrome, and the aspiration of small amounts of pericardial fluid with 
pericardiocentesis may greatly improve the clinical condition.118 
Pericardial effusions are usually circumferential, but after trauma or 
cardiac surgery, they may be loculated and even be responsible for localized compression and the development of CTP. 
11.8.1. Presentation 
Beck identified a triad of signs, consisting of hypotension, increased JVP, 
and quiet heart sounds as presenting symptoms.118,619 
This triad was classically identified in ‚Äòsurgical tamponade‚Äô with acute 
CTP due to intrapericardial haemorrhage because of trauma, or myocardial/aortic rupture. Beck‚Äôs triad may be lacking in patients with ‚Äòmedical tamponade‚Äô with slowly accumulating pericardial fluid. Acute CTP is 
usually associated with tachycardia and low blood pressure 
(<90 mmHg) that is only slightly reduced in subacute, chronic tamponade.118,619 On physical examination, classical signs include neck vein distention with elevated JVP, pulsus paradoxus, and diminished heart 
sounds. Pulsus paradoxus is defined as an inspiratory reduction of the 
systolic blood pressure by at least 10 mmHg.118,619 Pulsus paradoxus 
is due to exaggerated ventricular interdependence occurring in CTP, 
when the overall volume of ventricles becomes unable to expand, 
and any change in the volume on one side of the heart causes opposite 
changes on the other side. On ECG, the patient usually shows tachycardia, low QRS voltages, and electrical alternans due to the damping effect 
of pericardial fluid and swinging heart.118,619 
11.8.2. Aetiology and diagnosis 
Cardiac tamponade shares the same causes of PEff. In clinical practice, 
the most common aetiologies include cancer, TB, purulent infections, 
trauma, iatrogenic complications of cardiovascular interventions (e.g. 
ablation of arrhythmias, device implantation, PCIS), acute aortic disease, 
systemic inflammatory diseases, and renal failure.118 In the setting of AP 
with a viral or idiopathic aetiology, CTP is rare (1%‚Äì2% of cases) and is 
more common with pericarditis associated with a non-idiopathic aetiology (20%).347 The diagnosis of CTP is a clinical diagnosis based on 
the combination of a suggestive history, symptoms, signs, and imaging 
confirmation by echocardiography (Table 17).118 
Table 17 Echocardiographic signs of cardiac tamponade 
Echocardiographic feature 
Sensitivity 
Specificity  
Large pericardial effusion with swinging 
heart 
n.a. 
n.a. 
Diastolic collapse of the RA 
50%‚Äì100% 
33%‚Äì100% 
Duration of diastolic collapse of the RA as 
a ratio of the cardiac cycle length >0.34 
>90% 
100% 
Diastolic collapse of the RV 
48%‚Äì100% 
72%‚Äì100% 
Respiratory changes of the mitral E 
velocity >25%‚Äì30%, tricuspid E velocity 
>40%‚Äì60% 
n.a. 
n.a. 
Inferior vena cava plethora (dilatation 
>20 mm and <50% reduction of diameter 
with respiratory phases), as well as hepatic 
vein dilatation 
97% 
40% 
¬© ESC 2025
n.a., not available; RA, right atrium, RV, right ventricle.


<!-- PAGE 63 -->

### Page 63

The diagnosis of CTP identifies high-risk patients with an increased 
risk of complications during follow-up and a high probability of a non- 
viral aetiology. The patients should be admitted for therapy and 
monitoring.1,105 
The definitive therapy is pericardiocentesis, which should be performed urgently according to the clinical presentation. 
11.8.3. Therapy 
The treatment for CTP is drainage of the pericardial fluid, preferably by 
needle pericardiocentesis with the use of echocardiographic or fluoroscopic guidance, and should be performed without delay in unstable patients. Alternatively, drainage is performed by a surgical approach, 
especially in situations such as purulent pericarditis, or urgent situations 
with bleeding into the pericardium. 
Pericardiocentesis should be performed by experienced operators 
trained/certified in acute cardiovascular care and carries a variable 
risk of complications from 4% to 10%, depending on type of monitoring, operator‚Äôs skill, and setting (emergent vs urgent vs elective). The 
most common complications include arrhythmias, coronary artery or 
cardiac chamber puncture, haemothorax, pneumothorax, pneumopericardium, and hepatic injury.1 Mechanical ventilation with positive airway pressure should be avoided in CTP. In addition, diuretic therapy 
should be avoided, and temporary fluid administration can be helpful 
to stabilize the patient while waiting for urgent pericardiocentesis. 
11.8.4. Outcomes and prognosis 
The prognosis of CTP is essentially related to its aetiology. Cardiac tamponade in patients with cancer and metastatic involvement of the pericardium has a bad short-term prognosis, since this is a sign of advanced 
disease. In contrast, patients with CTP and a final diagnosis of idiopathic 
pericarditis generally have a good long-term prognosis.1,105 
11.9. Pericardial constriction and 
constrictive pericarditis (calcified and 
non-calcified) 
11.9.1. Introduction 
Pericardial constriction is a chronic condition usually characterized by a 
thickened, fibrotic, and often calcified pericardium that leads to impaired diastolic filling of the heart. Constrictive pericarditis is 
constriction associated with pericarditis.114,119,347 There is a high risk 
of progression in bacterial pericarditis (20%‚Äì30%), especially purulent 
pericarditis, intermediate risk in immune-mediated pericarditis and 
neoplastic pericardial diseases (2%‚Äì5%), and a low risk in viral and idiopathic pericarditis (<1%).347 Cases of CP after pericardiectomy have 
been reported, especially after partial pericardiectomy.627‚Äì630 In developed countries, the most common reported causes are: viral or idiopathic (42%‚Äì49%); post-cardiac surgery (11%‚Äì37%); post-radiation 
therapy, mostly for breast cancer or Hodgkin‚Äôs disease (9%‚Äì31%); connective tissue disorders (3%‚Äì7%); post-infectious causes (purulent pericarditis or TB in 3%‚Äì6%); and miscellaneous causes (<10%). TB is a 
major cause of CP in developing countries.630,631 
11.9.2. Presentation 
The classical clinical presentation comprises signs and symptoms of 
right HF with preserved biventricular function without previous or concomitant myocardial disease. Subacute/chronic inflammatory pericarditis can evolve into CP, and the duration of progression from initial 
pericardial inflammation and the onset of constriction is variable.347 
Systolic dysfunction due to myocardial fibrosis or atrophy can aggravate 
the haemodynamic impairment in more advanced cases. 
In up to 20% of cases, constriction might be present with normal 
pericardial thickness, while advanced and classic cases demonstrate 
prominent pericardial thickening and calcifications.119 
11.9.3. Diagnosis 
The diagnosis is made by multimodality imaging methods, such as echocardiography, CT, and CMR (Figure 13). Cardiac catheterization should 
be considered only if non-invasive multimodality imaging methods are 
inconclusive.115,124,632,633 The Mayo Clinic has proposed specific diagnostic criteria, based on echocardiography to diagnose CP, that have 
been confirmed by other centres. They include the presence of septal 
bounce or ventricular septal shift with either medial e‚Äô of >8 cm/s or 
hepatic vein expiratory diastolic reversal ratio of >0.78 (sensitivity 
87%, specificity 91%; specificity may increase to 97% if all criteria are 
present with a corresponding decrease of sensitivity to 64%). In addition, respirophasic variation E-wave mitral inflow of >25%/tricuspid inflow of >40% can be recorded in these patients632,634 (see  
Supplementary data online, Figures S1, S5, and Table S14). The main reported constrictive syndromes are shown in Table 18. 
Table 18 Definitions and therapy of main constrictive pericardial syndromes 
Syndrome 
Definition 
Therapy  
Transient constriction  
(d.d. permanent constrictive pericarditis, restrictive CMP) 
Reversible pattern of constriction following 
spontaneous recovery or anti-inflammatory 
therapy 
A 3‚Äì6 month course of empirical 
anti-inflammatory medical therapy 
Effusive‚Äìconstrictive pericarditis 
(d.d. cardiac tamponade, constrictive pericarditis) 
Failure of the right atrial pressure to fall by 50% or 
to a level <10 mmHg after pericardiocentesis 
May be diagnosed also by non-invasive imaging 
Pericardiocentesis followed by medical therapy 
Surgery for persistent cases 
Chronic constriction  
(d.d. transient constriction, restrictive CMP) 
Persistent constriction after 3‚Äì6 months 
Radical pericardiectomy, medical therapy for 
advanced cases or high risk of surgery or mixed 
forms with myocardial involvement 
¬© ESC 2025
CMP, cardiomyopathy; d.d., differential diagnosis.   
ESC Guidelines                                                                                                                                                                                               63


<!-- PAGE 64 -->

### Page 64

11.9.4. Therapy 
Medical therapy is considered for specific aetiologies, such as TB, 
to prevent progression to constriction.558 Antituberculosis drugs 
may significantly reduce the risk of constriction from >80% 
to <10%.569 Anti-inflammatory therapy may help to resolve transient constriction in 10%‚Äì20% of cases of AP.121,122 In such cases, 
to identify patients with potentially reversible forms of constriction, pericarditis should be excluded by testing markers of inflammation (e.g. C-reactive protein) or looking for imaging evidence of 
pericardial inflammation (e.g. pericardial oedema and/or LGE on 
CMR). 
In advanced cases, medical therapy is supportive of controlling symptoms of congestion, but surgery should never be delayed to improve 
outcomes. 
Pericardiectomy is the standard therapy for symptomatic chronic 
constriction without inflammation or not responding to anti- 
inflammatory therapy (see Section 6.4.2). For milder disease or more 
advanced disease, or for those with radiation-induced disease, reduced 
EF, or advanced renal disease, caution is necessary. Radical pericardiectomy rather than anterior phrenic-to-phrenic pericardiectomy is warranted for the best outcomes.311,635‚Äì637 
In general, pericardiectomy has been seen as a high-risk surgery with 
operative mortality of 6%‚Äì10%. However, recent studies show better 
results for early surgery in high-volume centres. The risk is related to 
the aetiologies and other comorbidities. Idiopathic causes have the lowest risk of <1.5%.638‚Äì640 
11.10. Effusive‚Äìconstrictive pericarditis 
11.10.1. Introduction 
In ECP, pericardial fluid is present, and the scarred pericardium puts 
pericardial fluid under increased pressure, constricts the cardiac volumes, and leads to signs of CTP.116,117 Classically it is defined haemodynamically as failure of the RAP to fall by 50% or to a level below 
10 mmHg after pericardiocentesis.117 Modern multimodality imaging 
allows a non-invasive diagnosis without cardiac catheterization. 
11.10.2. Aetiology 
Limited data have been published on ECP, and it appears to be a common condition in developing countries.117 Idiopathic cases are most 
commonly found in developed countries, while TB appears to be the 
most common cause in developing countries. The other reported 
causes are neoplasia, radiation, chemotherapy, infections (mainly TB 
and purulent type), and post-surgical pericardial disease.641 
11.10.3. Presentation 
Clinical features of either CP or CTP, or sometimes both, are typically 
present in patients with ECP. In patients who appear to have uncomplicated CTP, the diagnosis usually becomes evident during pericardiocentesis.117 Tricuspid regurgitation or right HF may cause persistently 
elevated RAP after efficient pericardiocentesis. 
11.10.4. Diagnosis 
To diagnose ECP, non-invasive imaging may be valuable.641 Thickening of 
the epicardial‚Äìpericardial layer is responsible for the constrictive component. After pericardiocentesis for CTP, careful detection of constriction 
on Doppler findings can be reported.124 Without haemodynamic monitoring, ECP can also be suspected on echocardiography and CMR (see  
Supplementary data online, Table S14). Cardiovascular magnetic resonance may provide helpful information, especially in differentiating constriction from RCM (Table S14). An accurate evaluation of ventricular 
interdependence and septal bounce can be made by assessing ventricular 
coupling with echocardiography and/or real-time cine CMR.115 
Echo-Doppler findings indicating effusive constriction may be detected 
prior to pericardiocentesis.116,124 Currently, the diagnosis can be made 
using multimodality imaging without cardiac catheterization. 
11.10.5. Treatment 
Effusive constriction can often resolve spontaneously or be treated with 
anti-inflammatory therapies in the case of evidence of transient constriction.641 In resistant cases, visceral pericardiectomy must be performed, 
since the epicardial layer is responsible for constricting the heart. The visceral 
component of pericardiectomy requires sharp dissection of many small fragments until ventricular motion is improved. Only pericardial centres with experience and competency should perform pericardiectomy for CP. 
12. Age- and sex-related aspects in 
inflammatory myopericardial 
syndrome 
12.1. Sex distribution 
Acute myocarditis is more prevalent in males (75%‚Äì84%).17,28,73,78,642 
On the contrary, the male-to-female ratio is similar in fulminant cases 
(46% females).56,75,643 Sex differences in pericarditis are less evident, 
Recommendation Table 24 ‚Äî Recommendations for 
constrictive pericarditis (see Evidence Table 24) 
Recommendations 
Classa 
Levelb  
Diagnosis 
Multimodality imaging is recommended in all 
patients with suspected constrictive pericarditis to 
make the diagnosis and assess pericardial 
thickening, calcifications, and active  
inflammation.632 
I 
C 
Cardiac catheterization for haemodynamic 
assessment should be considered in patients with 
suspected constrictive pericarditis when 
multimodality imaging is inconclusive.633 
IIa 
C 
Therapy 
Anti-inflammatory therapy is recommended in 
haemodynamically stable patients with a transient or 
new diagnosis of constriction with concomitant 
evidence of pericardial inflammationc to prevent 
progression to constriction and avoid 
pericardiectomy.122,123 
I 
C 
Pericardiectomy is recommended in patients with 
permanent constriction if there is no active 
inflammation or anti-inflammatory treatment is not 
successful after 3‚Äì6 months.635,636 
I 
C 
¬© ESC 2025
CMR, cardiovascular magnetic resonance. 
aClass of recommendation. 
bLevel of evidence. 
ci.e. C-reactive protein elevation or pericardial enhancement on CMR.


<!-- PAGE 65 -->

### Page 65

with some studies showing a mild prevalence in males of 59% in AP.37 
Males aged 16‚Äì65 years are at higher risk of pericarditis (relative risk 
2.02) than females. On the other hand, the probability of pericarditis 
recurrence is higher in females (HR 1.67), probably due to the higher 
frequency of specific causes (e.g. autoimmune diseases).105 
12.2. Paediatric patients 
12.2.1. Myocarditis 
The annual incidence of myocarditis during childhood is between 1 and 
2 cases per 100 000 children.21,644,645 In children <6 years of age, the 
sex distribution was balanced, 50% each,20 but boys had a significantly 
higher incidence at ages 6 to 15 years.21 
The proposed diagnostic approach in adults applies also for children, 
including CMR (e.g. in the MYKKE registry).646 
There are conflicting data regarding the complication rates of EMB in 
children, with some studies reporting similar incidence of complications 
as in adults, both around 5%, mainly from RV sampling.40,63 Particular 
care should be taken in children aged <1 year and in the case of LV biopsies with reported complication rates up to 30%.213 
In particular, very young children are predisposed to severe myocarditis. Critically ill children admitted to the intensive care unit (ICU) 
mostly survived, if receiving high-resource therapies, including 
MCS.647 In a prospective multicentre registry it was shown that in acute 
HF and FM, MCS including VAD improved survival.648 Similar results 
have also been reported from Japan.649 
In infants, enteroviruses, such as Coxsackievirus, were found more 
commonly than in adults.649 A presumed viral aetiology was identified 
in 11%‚Äì50%,40,63 with a death or HT rate of 2%, similar to adults.21 In 
biopsy-proven myocarditis, the HT rate rises to 7%, and the mortality 
rate increases to 4%‚Äì6%.40 
Therapy for myocarditis in children is not well defined. In a 
meta-analysis evaluating corticosteroids, no mortality reduction was 
observed, but a significant improvement in LVEF was reached with 
the use of steroids in other studies.650‚Äì652 In a meta-analysis evaluating 
IVIG,628 treatment was not associated with better survival. This was 
also supported by a prospective trial653 and a multicentre cohort 
study.654 On the contrary, another meta-analysis655 in FM concluded 
that IVIG therapy (usually 1‚Äì2 g/kg over 24‚Äì48 h) significantly reduced 
in-hospital mortality and improved LVEF. 
Genetic evaluation might help in the future in differentiating subsets 
of children and tailoring therapies.93 
12.2.2. Pericarditis 
In children aged 12 years or less, the incidence of AP was 2.8/100 000 in a 
population study from 2009 to 2021.644 The diagnostic criteria (see  
Table 4), aetiologies, and risk of recurrences (see Tables S2 and S3) are 
similar to those reported in adults (see Supplementary data online,  
Table S1). Most paediatric cases of pericarditis are related to PPS, particularly after atrial septal defect closure. Compared with adults, children more 
commonly have an inflammatory phenotype.656 Non-steroidal anti- 
inflammatory drugs remain the mainstay of therapy at high dosages (see  
Supplementary data online, Table S15). Most paediatricians avoid aspirin. 
Colchicine halved recurrences in children, similarly as for adults.656,657 
The use of corticosteroids should be restricted even more than in adults, 
given that their side effects (including striae rubrae and growth impairment) are particularly deleterious in growing children. Anti-interleukin-1 
agents have been used for the first time in children with autoinflammatory 
diseases and then adopted for RP in them, representing a new therapeutic 
option, especially if they are corticosteroid-dependent. However, it is 
often difficult to withdraw these drugs when clinical remission is achieved; 
for instance, in one study only 15% of children were able to stop anti-IL-1 
agents after a mean follow-up of 2.6 years.658 Few paediatric patients were 
enrolled in RCTs testing anakinra and rilonacept.283,284 
12.3. Pregnancy, lactation, and 
reproductive issues 
There is very limited published evidence on this topic. There are only 
case reports for myocarditis,659‚Äì663 and one case series describing 
pregnant women with RP.664 Pregnancy-associated myocarditis is described in Section 9.7. Pericardial effusion is the most common manifestation of pericardial diseases during pregnancy. Effusions during 
pregnancy are typically benign, mild or moderate, and well tolerated, 
with spontaneous resolution after delivery, and no specific treatment 
is required in such cases. However, PEff may be associated with pre- 
eclampsia.665 Acute pericarditis is the second most common condition. 
Pre-conception counselling is essential in women of childbearing age 
with RP or previous myocarditis. In such cases, pregnancy should be 
planned in a phase of disease remission, and therapy should be reviewed. Pre-conception assessment should include multidisciplinary 
evaluation. Echocardiography is the preferred imaging method, while 
X-ray, CT scan, and CMR can be used in selected cases.666 
In patients with IMPS, vaginal delivery is not excluded in uncomplicated cases, while Caesarean section may be required in the presence 
of haemodynamic instability.666 Appropriate follow-up with a multidisciplinary team with experience in the field is recommended throughout 
pregnancy to ensure good maternal and foetal outcomes. 
High-dose aspirin or NSAIDs, such as ibuprofen and indomethacin, 
can be used up to the 20th week of gestation. Corticosteroids at the 
minimal effective dose can be given in patients with active pericarditis 
throughout pregnancy along with NSAIDs and in selected cases colchicine. Azathioprine and IVIG are compatible with pregnancy and breastfeeding. All these medications, apart from high-dose aspirin, may be 
used during lactation. Colchicine is compatible with pregnancy and 
breastfeeding, and it can be continued throughout pregnancy to prevent recurrences.664,667‚Äì669 The use of IL-1 blockers during pregnancy 
is controversial. Available literature data seem encouraging; however, 
the relevant studies are scant and retrospective. Despite the limited evidence, anakinra may be continued through conception, pregnancy, and 
lactation in women with rheumatic and musculoskeletal diseases who 
are not able to use alternative therapies.668‚Äì670 More details regarding 
drug dosages can be found in Supplementary data online, Table S16. 
There are no specific limitations for men with pericarditis who are 
planning to have children because they can safely continue 
therapy.667,668 
Recommendation Table 25 ‚Äî Recommendations for 
pregnancy, lactation, and reproductive issues (see  
Evidence Table 25) 
Recommendations 
Classa 
Levelb  
Pre-conception counselling is recommended in 
women with recurrent pericarditis or myocarditis to 
assess disease activity and to review therapy. 
I 
C 
NSAIDs should be considered in pregnant patients 
with pericarditis until the 20th week to treat an 
incessant/recurrent course.664 
IIa 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                               65


<!-- PAGE 66 -->

### Page 66

12.4. The elderly 
Myocarditis is more prevalent in young people, with a median age between 20 and 40 years.28,55,63,73 In a Swedish study, 64% patients 
were younger than 50 years of age. In this study, HF/DCM and deaths 
occurred more commonly in patients aged >50 years.17 Myocarditis is 
probably more commonly related to drugs in the elderly, e.g. ICIs28,495 
and clozapine.508 Age- and sex-based differences have been evaluated in 
two studies with AP, and one study with RP.45,102,671 In these studies, 
elderly patients less often had chest pain, fever, ST elevation, and PR depression. They had lower C-reactive protein values but dyspnoea, AF, 
and PEff were more common. Moreover, they received glucocorticoids 
more commonly, and had a lower risk of recurrences compared with 
younger patients. In the elderly, therapy compliance may be problematic, because of cognitive impairment and comorbidities, but the strongest predictor of non-adherence is the number of medications.672 
Non-steroidal anti-inflammatory drugs should be used cautiously; dosing should be adapted (e.g. colchicine dose should be halved in some 
cases), and attention should be paid to evaluate renal impairment and 
drug interactions. 
12.5. Physical activity in inflammatory 
myopericardial syndrome 
Patients with active IMPS are advised to restrict physical activity. It has 
been proposed that exercise can aggravate myocardial and pericardial 
inflammation through several mechanisms, including a tachycardia- 
mediated process. The importance of controlling heart rate is confirmed by observational studies, in which the empirical use of 
Œ≤-blockers to control heart rate in patients with pericarditis improved 
symptom control.274 Previous recommendations have made distinctions between athletes and non-athletes, providing arbitrary times for 
abstention from 3 to 6 months. This TF recommends an individualized 
approach, based on remission times. A complete clinical remission 
should be considered in athletes/non-athletes with normalization of 
symptoms, biomarkers, and imaging. 
During the acute stage of myocarditis, patients are advised to rest 
completely, since exercise has been associated with arrhythmias and 
SCD. To ensure resolution of the disease, recovery should be monitored, including clinical assessment, rhythm control, laboratory analysis, 
and multimodality imaging (see Table 15). A personalized prescription 
of exercise should be performed, based on the patient (athletes, non- 
athletes), and type of exercise. 
12.5.1. Mental health effect of restricting exercise 
Exercise restriction can affect patient mental health, especially in children and young adults. It can lead to frustration, sadness, and depression in patients. Freedom to exercise should be approached with 
shared decision-making, taking into account the risk vs benefit ratio in 
the single case. 
12.6. Multidisciplinary teams for the 
management of inflammatory 
myopericardial syndrome 
It is recommended to have a multidisciplinary team for high-risk cases 
with IMPS. The team should be composed of a clinical cardiologist, a 
CMR imaging specialist with expertise in IMPS, a pathologist with expertise in cardiovascular diseases, and additionally, depending on the 
case, a rheumatologist (or clinical immunologist), an infectious disease 
specialist, a geneticist (or a cardiologist with expertise in genetics), 
interventional cardiologists (including electrophysiologists), and a cardiac intensive care specialist. A cardiac surgeon might be involved subsequently when interventional or surgical decisions are anticipated. 
More details are given in Figure 20. It is of paramount importance 
that physicians develop competence and skills in IMPS to allow timely 
diagnosis and therapy for patients, since mixed forms are common in 
clinical practice. Patient involvement is important, particularly when 
the evidence is scarce to foster shared decision-making.375,673,674 
Anti-inflammatory therapies should be considered in 
patients with pericarditis during lactation to treat and 
prevent pericarditis with timing adjusted to reduce 
drug exposure of the breastfed infant. 
IIa 
C 
During pregnancy and breastfeeding, corticosteroids 
at the minimal effective dose (preferably up to 20 mg 
prednisone daily) should be considered in patients 
with active pericarditis, despite NSAID (if feasible), to 
prevent an incessant/recurrent course.664 
IIa 
C 
Colchicine may be considered in pregnant patients 
with pericarditis, especially in patients already 
receiving this drug to prevent recurrences. 
IIb 
C 
Anakinra may be considered through pregnancy and 
lactation in pregnant patients with recurrent 
pericarditis who are not able to use alternative 
therapies to prevent an incessant/recurrent course. 
IIb 
C 
¬© ESC 2025
NSAID, non-steroidal anti-inflammatory drug. 
aClass of recommendation. 
bLevel of evidence.  
Recommendation Table 26 ‚Äî Recommendations for 
physical activity and myocarditis/pericarditis (see  
Evidence Table 26) 
Recommendation 
Classa 
Levelb  
Restriction of physical exercise until remission, for at 
least 1 month, is recommended in athletes and 
non-athletes after IMPS using an individualized 
approach to accelerate recovery. 
I 
C 
¬© ESC 2025
IMPS, inflammatory myopericardial syndrome. 
aClass of recommendation. 
bLevel of evidence.  
Recommendation Table 27 ‚Äî Recommendations for 
multidisciplinary teams in myopericardial syndromes 
(see Evidence Table 27) 
Recommendations 
Classa 
Levelb  
A multidisciplinary team discussion at a referral 
centre is recommended in patients with high-risk/ 
complicated IMPS to provide a patient-tailored 
approach.375,673 
I 
C 
¬© ESC 2025
IMPS, inflammatory myopericardial syndrome. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 67 -->

### Page 67

### 13 Advice for patients

Specific patient education is mandatory for patients with IMPS. Advice 
should address the causes, rationale for treatment, possible complications, and outcomes. Inflammatory myopericardial syndrome affects 
young patients and may severely affect their quality of life. Specific advice should be provided on the need for rest during the acute phase of 
the disease, and the timing for return to physical activity and work, as 
well as benefits and risks associated with tailored immunosuppressive/immunomodulatory therapies, and when to contact the multidisciplinary team. Advice must be tailored to the specific social situation. 
Suitable language should be used, recognizing the patient‚Äôs educational 
status. Clarification based on images is preferrable. Care should be taken not to aggravate anxiety unnecessarily. An additional description 
and advice for patients with IMPS is provided in Supplementary data 
online, Section 8, Figure S6, and Table S17. A separate document dedicated to patients has been developed. 
14. Tertiary referral centres for 
inflammatory myopericardial 
syndrome: feature and volume of 
activity 
14.1. Tertiary care centres 
Tertiary care centres of excellence are extensive, renowned healthcare 
facilities that house specialized cardiology departments equipped to 
manage patients with IMPS. Leading institutions are recognized for their 
cardiovascular expertise and often handle patients with complex disease.674 Such centres have significant expertise in the diagnosis and 
therapy of myocarditis and pericarditis and are actively involved in research. They should be the referral centre of choice for complicated 
cases that cannot be managed by regional centres. Endomyocardial biopsy referral centres for deep investigation of EMB samples, including 
immunochemistry and molecular testing, should be identified at regional or national level. 
14.2. Inflammatory myopericardial 
syndrome in regional centres 
Most uncomplicated cases can be handled by regional centres, and depending on the healthcare systems, in outpatient departments. 
However, the crucial factor is the local expertise. At the same time, 
those with more severe pericarditis or myocarditis might need treatment at a hospital or tertiary care referral centre that has advanced 
multimodality imaging capacity and access to new therapeutic 
agents.674 
14.3. Hub-and-spoke model 
These centres should be capable of managing all care levels and adopt a 
hub-and-spoke model. Regardless of where care is provided, the goal is 
to sustain communication and collaboration throughout all healthcare 
system levels. The hub-and-spoke model aims to ease patient access 
to suitable care levels, promote care co-ordination, and drive quality 
enhancement for all patients with IMPS.674,675 









	






	

	

Figure 20 Multidisciplinary teams for inflammatory myopericardial syndrome. aFull team‚Äîtailored to the specific case.   
ESC Guidelines                                                                                                                                                                                               67


<!-- PAGE 68 -->

### Page 68

14.4. Teamwork, competencies, and 
advances in imaging techniques 
Building a contemporary multidisciplinary team requires knowledge of 
recent advancements in imaging techniques, as well as evidence-based 
strategies for drug, interventional, and surgical therapies.63,674‚Äì676 
The conventional organization of academic or practice departments often operates in isolation, hindering the requirements of diseases that 
demand the insights and skills of a diverse expert panel. These centres 
should endorse a comprehensive team setup that encourages regular, 
ongoing communication among all members. The role of physician-led 
vs nurse-led tertiary centres should be explored further674,675 in view 
of the increasing number and complexity of these patients, and the utility of monitoring inflammatory markers and serial monitoring of cardiac 
imaging, even in an outpatient setting. 
15. Key messages 
The recognition of the whole spectrum of IMPS is increasing within the 
medical community. This is based on a deeper understanding leading to 
a more systematic evaluation, as well as more data being generated by 
prospective trials. Although these entities have been explored for some 
time, the COVID-19 pandemic was the main trigger to increase the 
awareness on the spectrum of disease. Advanced multimodality imaging 
technologies, including CMR, allow a patient-tailored diagnostic and 
therapeutic approach. A major diagnostic paradigm change is the capability of reaching a clinical diagnosis of certainty by non-invasive multimodality imaging (CMR for myocarditis), while EMB remains important 
in selected intermediate- and high-risk cases, if a targeted specific therapy, based on specific histotypes or aetiologies, is needed. 
15.1. Aetiology 
Inflammatory myopericardial syndrome is a spectrum of inflammatory 
diseases with some common aetiologies, either infectious or non- 
infectious, that can affect either the myocardium (myocarditis) or pericardium (pericarditis) in isolated forms, or combined (myopericarditis 
and perimyocarditis). 
15.2. Clinical presentation and diagnosis 
In a large percentage of cases, myocarditis and pericarditis have a chest 
pain presentation, and generally preserved biventricular function with 
good outcomes. For myocarditis, complicated forms include those presenting with severe HF and arrhythmias. Nevertheless, uncomplicated 
presentations may also develop life-threatening complications, albeit 
less commonly, and therefore also may need fast management. 
For pericarditis, complicated cases include those with an incessant or 
recurrent course. Many cases with persistent symptoms may show 
constrictive physiology, which can be reversible after appropriate medical therapy. The diagnosis of non-high-risk cases is based on clinical 
evaluation, including ECG and biomarkers, with non-invasive confirmation of the clinical suspicion by evidence of inflammatory involvement 
using multimodality imaging (mainly echocardiography and CMR). 
Endomyocardial biopsy is recommended for intermediate- and high- 
risk cases on a case-by-case decision, only when results are expected 
to change management. 
15.3. Therapy 
The treatment of uncomplicated IMPS is empirical, aiming at the control 
of symptoms and prevention of complications. Anti-inflammatory 
drugs and colchicine are useful to control chest pain, while additional 
therapies should be guideline-directed for specific complicated courses. 
If a specific aetiology is identified, treatment should be targeted at the 
specific cause. In all cases of IMPS, restriction of physical activity is recommended in the acute phase, while return to work and physical activity should be individualized according to clinical remission times. 
15.4. Prognosis and outcomes 
The prognosis of IMPS varies. Most patients presenting with chest pain 
have a favourable outcome, although recurrences, especially for pericarditis, may severely affect the quality of life of patients and require 
long-term follow-up. For complicated cases of myocarditis with HF 
and arrhythmias, a tailored and individualized approach is warranted. 
Such patients require long-term follow-up, usually lifetime monitoring. 
15.5. Multidisciplinary team 
Management of patients with IMPS should usually be guided by a multidisciplinary team, which should be tailored to the specific patient. This 
team should be composed of different clinicians, all with expertise in 
cardiovascular diseases (e.g. imaging experts, a pathologist, a rheumatologist, an infectious disease specialist, a geneticist, interventional cardiologists, intensive care specialists, and surgeons). It is of paramount 
importance that physicians develop competence and skills either in 
myocarditis or pericarditis to allow timely diagnosis and therapy for patients, because mixed forms are common in clinical practice. 
16. Gaps in evidence 
The field of IMPS has significant knowledge gaps across all aspects, from 
pathogenesis to therapy. However, growing awareness has led to numerous ongoing studies. Advances in multimodality imaging have enabled a more comprehensive and non-invasive understanding of 
disease progression, opening the way to patient-tailored approaches. 
Despite these advancements, large-scale prospective multicentre trials 
with predefined outcome measures are lacking. These uncertainties are 
especially pronounced in chronic conditions, as well as in specific patient groups, such as children, women of childbearing age, during pregnancy, lactating women, and in the elderly. 
A further challenge is the handling of the return to work and physical 
activity as there is a need for a patient-specific approach, taking into 
consideration the individual risk. Lessons learned from other diseases 
should lead to less restrictive guidance in comparison with previous 
advice. 
16.1. Myocarditis 
Knowledge about myocarditis has evolved during recent years, as the 
different mechanisms are better understood. Several causes, such as 
viral and toxic ones, including chemotherapy, as well as systemic disorders, have been investigated, and targeted therapeutic approaches 
were proposed. However, further research into specific therapy is 
needed based on advanced diagnostic approaches. 
Nevertheless, a specific challenge for myocarditis is related to the 
low frequency of complications and the high rate of spontaneous remission. On this basis, clinical trials on medical therapy for myocarditis 
might be currently underpowered to assess the clinical benefit of a specific treatment with small sample sizes. In addition, many antiviral therapies are off-label for myocarditis and controlled trials are missing.


<!-- PAGE 69 -->

### Page 69

Currently, quantitative immunohistochemistry criteria for the diagnosis of LM are under discussion among cardio-pathologists to present 
more definite criteria for EMB. 
Furthermore, a better understanding of the pathogenic and prognostic role of viral loads is needed (e.g. active/causative vs latent/innocent 
bystanders in cardiac viral infections). 
Moreover, the role of genetic predisposition in recurrent myocarditis is not thoroughly clarified. Research into the role of genetic predisposition is evolving to change the classification of disease and may 
influence therapeutic pathways in the future. An increase of ‚Äòoverlapping‚Äô conditions, especially DCM and ARVC, can be expected and 
may change our understanding of the disease in the future. 
That means, more research is warranted on the prognosis and SCD 
risk stratification. 
16.2. Pericarditis 
There are significant knowledge gaps in individualized treatment and 
pathogenesis of various types of pericarditis, as well as the understanding of the interaction among genetic background, inflammation, and 
autoimmune mechanisms. Better knowledge of the pathogenesis of recurrences may also help to develop more targeted and individualized 
therapies. 
The genetic background requires further evaluation in complicated, 
recurrent cases and could be helpful to elucidate the mechanisms leading to incessant/recurrent forms. New therapeutic options should also 
be considered and evaluated in clinical trials to explore new drugs for 
more complicated, incessant, or recurrent cases to develop a more individualized and efficacious approach for the treatment of pericarditis. 
A significant management issue is the treatment of patients not responding to colchicine and anti-IL-1 agents, as well as the causes of 
drug dependence to maintain stable clinical remission, such as for corticosteroids and anti-IL-1 agents. 
Additional research is also warranted to understand the prognostic 
significance of persistent LGE of the pericardium. 
There are limited data to support the best timing of return to work 
and physical activity, and further research is needed on this topic with 
appropriate clinical trials or observational studies. 
17. Sex differences 
There is limited published evidence on this topic. Inflammatory myopericardial syndrome seems to affect males more than females from 
a young age. Myocarditis complicated by VA is more common in males, 
while in females, a relatively higher proportion of cases presents with 
complicated forms compared with males, and systemic autoimmune 
disorders are more commonly diagnosed. This was addressed in the 
relevant sections. The diagnostic approaches are similar, but care 
should be taken when applying normal values, especially in imaging. 
Medication should be adapted in women of childbearing age, pregnancy, 
and during lactation (more details are specified in specific sections). 
18. ‚ÄòWhat to do‚Äô and ‚ÄòWhat not to 
do‚Äô messages from the Guidelines 
Table 19 lists all Class I and Class III recommendations from the text 
alongside their level of evidence. 
Table 19 ‚ÄòWhat to do‚Äô and ‚ÄòWhat not to do‚Äô 
Recommendations 
Classa 
Levelb  
Recommendations for clinical evaluation of myocarditis and pericarditis 
Complete clinical evaluation, including history, physical examination, chest X-ray, biomarkers, ECG, and echocardiography is recommended 
in all patients with a suspicion of myocarditis and/or pericarditis for the initial diagnostic assessment. 
I 
C 
CMR is recommended in patients with the clinical suspicion of myocarditis (using updated LL criteria) and/or pericarditis for the 
non-invasive diagnosis of inflammatory reaction. 
I 
B 
Hospital admission is recommended for patients with high-risk pericarditis for monitoring and treatment. 
I 
B 
Hospital admission is recommended for patients with moderate- to high-risk myocarditis for monitoring and treatment. 
I 
C 
EMB is recommended in patients with high-risk myocarditis and/or haemodynamic instability, and/or in patients with intermediate-risk 
myocarditis not responding to conventional therapy in order to detect a specific histologic subtype and to assess the presence of viral 
genome for treatment. 
I 
C 
Invasive coronary angiography or coronary CT, depending on clinical likelihood, is recommended in patients with IMPS if an acute coronary 
syndrome is suspected to rule out obstructive coronary artery disease. 
I 
C 
Routine serology is not recommended in patients with myocarditis and/or pericarditis for the evaluation of viral aetiology except for 
hepatitis C, HIV and Lyme disease. 
III 
C 
Recommendations for genetic testing 
It is recommended to obtain family history including pedigrees in cases of recurrent IMPS to provide clues to the underlying aetiology, 
determine inheritance pattern, and identify relatives at risk. 
I 
C 
Recommendations for the use of cardiovascular magnetic resonance imaging 
Myocarditis 
CMR is recommended in patients with suspected myocarditis to reach a clinical diagnosis and to determine the cause of acute myocardial 
injury, including assessment of oedema, ischaemia, and necrosis/fibrosis/scarring. 
I 
B                       
Continued  
ESC Guidelines                                                                                                                                                                                               69


<!-- PAGE 70 -->

### Page 70

CMR is recommended for follow-up at least within the first 6 months in patients with myocarditis to identify a healed or ongoing process, 
for risk stratification and personalized therapy, and to enable a return to exercise. 
I 
C 
Pericarditis 
CMR is recommended in patients with suspected pericarditis when a diagnosis cannot be made using clinical criteria to assess evidence of 
pericardial thickening, oedema, LGE, and to assess the persistence of disease during follow-up in selected cases. 
I 
B 
Recommendations for computed tomography 
CT is recommended to evaluate pericardial thickness, calcifications, masses, and loculated pericardial effusions, as well as concomitant 
pleuropulmonary diseases and chest abnormalities. 
I 
C 
Recommendations for endomyocardial biopsy 
EMB is recommended in patients with high-risk myocarditis, and/or haemodynamic instability, and/or in patients with intermediate-risk 
myocarditis not responding to conventional therapy in order to detect a specific histologic subtype and to assess the presence of viral 
genome for treatment. 
I 
C 
Recommendations for autopsy 
Comprehensive autopsy is recommended in all patients <50 years of age with SCD to evaluate the presence of acute myocarditis as a cause 
and to detect potential underlying inherited cardiac diseases. 
I 
B 
Retaining samples suitable for DNA extraction and consulting a cardiac pathologist is recommended in cases of SCD, when an inherited 
cause is suspected, or the cause of death remains unexplained. 
I 
B 
Recommendations for medical therapy in myocarditis 
Management of heart failure 
Adherence to the ESC HF guidelines is recommended in cases of myocarditis with LV systolic dysfunction and/or HF to reduce symptoms 
and to improve LV function. 
I 
C 
Immunosuppressive therapy 
Routine use of immunosuppressive therapy is not recommended in acute myocarditis with preserved LV function because no outcome 
benefit has been shown. 
III 
C 
Recommendations for medical therapy in pericarditis 
Colchicine is recommended as first-line therapy in patients with pericarditis as an adjunct to aspirin/NSAID or corticosteroid therapy to 
reduce subsequent recurrences. 
I 
A 
Anti-IL-1 agents (anakinra or rilonacept) are recommended for patients with recurrent pericarditis after failure of first-line therapies and 
corticosteroids, and elevation of C-reactive protein levels to reduce recurrences and allow corticosteroid withdrawal. 
I 
A 
High-dose aspirin or NSAIDs with proton pump inhibitors are recommended as first-line therapy in patients with pericarditis to control 
symptoms and reduce recurrences. 
I 
B 
Corticosteroids are not recommended as the first option for patients with pericarditis therapy without a specific indication. 
III 
C 
Recommendations for interventional techniques, including circulatory support in myocarditis 
A timely and dedicated Shock Team discussion is recommended in patients with myocarditis in the presence of haemodynamic 
compromise, to decide on the need for escalation to MCS and to determine a long-term management plan. 
I 
C 
Recommendations for interventional techniques in pericarditis 
Pericardiocentesis (echocardiography CT-, or fluoroscopy-guided) is recommended for cardiac tamponade, or suspected bacterial or 
neoplastic pericarditis, or symptomatic moderate to large pericardial effusion despite medical therapy. 
I 
C 
Surgical pericardial drainage is recommended in patients with pericardial effusion when percutaneous pericardiocentesis is not feasible or 
with purulent pericardial effusion to allow complete drainage and to prevent constriction. 
I 
C 
Surgical pleuro-pericardial window is recommended in patients with relapsing pericardial effusion despite medical therapy. 
I 
C 
Recommendations for surgical therapy 
Surgical pericardiectomy is recommended in patients with chronic pericardial constriction or persistent constrictive pericarditis despite 
medical therapy to improve symptoms and survival. 
I 
C 
Tricuspid valve repair is recommended in patients with pericardial constriction and severe tricuspid valve regurgitation to improve 
symptoms and survival. 
I 
C 
Recommendations for management of arrhythmias and prevention of sudden cardiac death in myocarditis 
ICD in myocarditis‚Äîsecondary prevention 
ICD implantation is recommended in patients with non-active myocarditis and haemodynamically not-tolerated sustained VT to prevent 
SCD. 
I 
C                         
Continued


<!-- PAGE 71 -->

### Page 71

Recommendations for risk stratification, complications, and outcomes of inflammatory myopericardial syndrome 
Follow-up with clinical assessment, biomarkers, ECG, exercise test, Holter-ECG monitoring, echocardiography, and CMR at least within 
6 months after the index hospitalization is recommended in all patients with myocarditis to identify a potential progression or new risk 
factors. 
I 
C 
Long-term follow-up is recommended for patients with complicated myocarditis to identify a potential progression or new complications. 
I 
C 
Long-term follow-up is recommended for patients with incessant or recurrent pericarditis to identify a potential progression and new 
complications. 
I 
C 
Recommendations for giant-cell myocarditis 
EMB is recommended in patients with suspected GCM due to unexplained new-onset HF of up to 2 weeks associated with a normal or 
dilated left ventricle and new ventricular arrhythmias, second- or third-degree AVB, or failure to respond to usual care within 1 to 2 weeks 
to initiate specific treatment. 
I 
C 
Combined immunosuppressive therapy is recommended in patients with a diagnosed GCM. 
I 
C 
Recommendations for myocarditis in sarcoidosis 
Diagnosis 
CMR, using tissue characterization techniques, is recommended in patients with suspected CS to assess cardiac inflammation and 
myocardial involvement. 
I 
B 
18F-FDG-PET is recommended for the diagnostic work-up, including detection of inflammation, as well as for follow-up and assessment of 
therapeutic response in patients with CS. 
I 
B 
Therapy 
ICD implantation is recommended in patients with CS and sustained ventricular arrhythmia (VT/VF) or aborted CA to prevent SCD. 
I 
B 
ICD implantation is recommended in patients with CS and LVEF ‚â§35% to prevent SCD. 
I 
C 
Recommendations for immune checkpoint inhibitor-associated myocarditis 
Diagnostic triage within 24 h is recommended in patients with suspected myocarditis induced by ICI to initiate treatment rapidly. 
I 
C 
Immediate disruption of ICI and administration of high-dosage corticosteroids are recommended in patients with ICI-associated myocarditis 
in order to stop the inflammatory reaction and stabilize the patient. 
I 
C 
Recommendations for inflammatory cardiomyopathy 
Guideline-directed HF treatments are recommended in patients with inflammatory cardiomyopathy to improve and/or stabilize left 
ventricular function. 
I 
C 
Specific medical therapy for the potentially underlying systemic disease is recommended in inflammatory cardiomyopathy. 
I 
C 
Recommendations for tuberculous pericarditis 
Diagnosis and treatment of tuberculous pericarditis and effusion 
Diagnostic pericardiocentesis is recommended in all patients with suspected tuberculous pericarditis when diagnosis is not confirmed by 
non-invasive tests to identify the aetiological agent in pericardial fluid. 
I 
C 
Empirical antituberculosis chemotherapy is recommended in patients living in endemic areas with exudative pericardial effusion after 
excluding other causes to treat the most likely cause. 
I 
C 
Standard antituberculosis multidrug treatment for 6 months is recommended in patients with tuberculous pericarditis for the prevention of 
pericardial constriction. 
I 
C 
Pericardiectomy is recommended in patients with tuberculous pericarditis if the condition is not improving or is deteriorating after 
4‚Äì8 weeks of antituberculosis therapy to change the course of disease. 
I 
C 
Empirical antituberculosis treatment is not recommended in patients living in non-endemic areas. 
III 
C 
Recommendations for neoplastic pericardial involvement 
Pericardiocentesis is recommended for patients with cardiac tamponade to relieve symptoms and establish the diagnosis of malignant 
pericardial effusion. 
I 
C 
Extended pericardial drainage (3‚Äì6 days) is recommended in patients with suspected or definite neoplastic pericardial effusion to prevent 
effusion recurrence. 
I 
B 
Cytological analysis of pericardial fluid is recommended in patients with neoplastic pericarditis for the confirmation of malignant pericardial 
disease. 
I 
C 
Systemic antineoplastic treatment is recommended in confirmed cases of neoplastic aetiology to treat the primary and secondary metastatic 
neoplastic involvement. 
I 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                               71


<!-- PAGE 72 -->

### Page 72

### 19 Evidence tables

Evidence tables are available at the European Heart Journal online. 
20. Data availability statement 
No new data were generated or analysed in support of this research. 
21. Author information 
Author/Task Force Member Affiliations: Valentino Collini, 
Cardiology, 
Cardiothoracic 
Department, 
Santa 
Maria 
della 
Misericordia University Hospital, Udine, Italy; Jan Gr√∂schel, Charit√© 
‚ÄîUniversit√§tsmedizin Berlin, corporate member of Freie Universit√§t 
Berlin and Humboldt-Universit√§t zu Berlin, ECRC Experimental and 
Clinical Research Center, Berlin, Germany, and DZHK (German 
Centre for Cardiovascular Research), partner site Berlin, Berlin, 
Germany, and Deutsches Herzzentrum der Charit√©, Klinik f√ºr 
Kardiologie, Angiologie und Intensivmedizin, Berlin, Germany; 
Yehuda Adler, Sackler Medical School, Tel Aviv University, Tel 
Aviv, Israel; Antonio Brucato, Department of biomedical and clinical sciences, University of Milano, Fatebenefratelli Hospital, Milano, 
Italy; Vanessa Christian (United Kingdom), ESC Patient Forum, 
Sophia Antipolis, France; Vanessa M. Ferreira, Oxford Centre 
for Clinical Magnetic Resonance Research (OCMR), University of 
Oxford, Oxford, United Kingdom; Estelle Gandjbakhch, 
Cardiology Departement, Sorbonne Universit√©, APHP, H√¥pital 
Piti√© Salp√™tri√®re, Paris, France, and Referral Center for Inherited 
Cardiac Diseases, APHP, H√¥pital Piti√© Salp√™tri√®re, Paris, France, 
and Inserm 1166, IHU ICAN, Paris, France; Bettina Heidecker, 
Deutsches Herzzentrum der Charit√©, Universit√§tsmedizin Berlin, 
Berlin, Germany, and Berlin Institute of Health (BIH), Charit√©, 
Universit√§tsmedizin Berlin, Berlin, Germany, and DZHK (German 
Centre for Cardiovascular Research), partner site Berlin, Berlin, 
Germany; Mathieu Kerneis, Sorbonne Universit√©, Paris, France, 
and ACTION Group, Paris, France, and UMRS 1166 Inserm, Paris, 
France, and Institute of Cardiology, H√¥pital Piti√©-Salp√™tri√®re,  
Recommendations for post-cardiac injury syndrome 
Anti-inflammatory therapy is recommended in patients with PCIS to hasten symptom remission and reduce recurrences. 
I 
B 
IL-1 antagonists are recommended in patients with refractory PCIS to prevent recurrences and progression to constriction. 
I 
B 
High-dose aspirin is recommended as the first-choice anti-inflammatory therapy for post-myocardial infarction pericarditis and in patients 
already on antiplatelet therapy. 
I 
C 
Recommendations for purulent pericarditis 
Urgent pericardiocentesis and/or a surgical window is recommended in patients with suspicion of purulent pericarditis to establish a 
diagnosis. 
I 
C 
Recommendations for constrictive pericarditis 
Diagnosis 
Multimodality imaging is recommended in all patients with suspected constrictive pericarditis to make the diagnosis and assess pericardial 
thickening, calcifications, and active inflammation. 
I 
C 
Therapy 
Anti-inflammatory therapy is recommended in haemodynamically stable patients with a transient or new diagnosis of constriction with 
concomitant evidence of pericardial inflammation to prevent progression to constriction and avoid pericardiectomy. 
I 
C 
Pericardiectomy is recommended in patients with permanent constriction if there is no active inflammation or anti-inflammatory treatment 
is not successful after 3‚Äì6 months. 
I 
C 
Recommendations for pregnancy, lactation, and reproductive issues 
Pre-conception counselling is recommended in women with recurrent pericarditis or myocarditis to assess disease activity and to review 
therapy. 
I 
C 
Recommendations for physical activity and myocarditis/pericarditis 
Restriction of physical exercise until remission, for at least 1 month, is recommended in athletes and non-athletes after IMPS using an 
individualized approach to accelerate recovery. 
I 
C 
Recommendations for multidisciplinary teams in myopericardial syndromes 
A multidisciplinary team discussion at a referral centre is recommended in patients with high-risk/complicated IMPS to provide a 
patient-tailored approach. 
I 
C 
¬© ESC 2025
AVB, atrioventricular block; CA, cardiac arrest; CMR, cardiovascular magnetic resonance; CS, cardiac sarcoidosis; CT, computed tomography; DNA, deoxyribonucleic acid; ECG, 
electrocardiogram; EMB, endomyocardial biopsy; ESC, European Society of Cardiology; 18F-FDG-PET, [18F]-fluorodeoxyglucose positron emission tomography; GCM, giant-cell 
myocarditis; HF, heart failure; HIV, human immunodeficiency virus; ICD, implantable cardioverter-defibrillator; ICI, immune checkpoint inhibitor; IL, interleukin; IMPS; inflammatory 
myopericardial syndrome; LGE, late gadolinium enhancement; LV, left ventricle; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; NSAID, non-steroidal 
anti-inflammatory drug; PCIS, post-cardiac injury syndrome; SCD; sudden cardiac death; VF, ventricular fibrillation; VT, ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 73 -->

### Page 73

Assistance Publique-H√¥pitaux de Paris (AP-HP), Paris, France; Allan 
L. Klein, Center for the diagnosis of pericardial disease, department 
of cardiovascular medicine, heart, vascular and thoracic institute, 
Cleveland clinic, Cleveland, Ohio, United States of America; Karin 
Klingel, Institute for Pathology and Neuropathology, University 
Hospital Tuebingen, Tuebingen, Germany; George Lazaros, 
Cardiology, School of medicine, Hippokration General Hospital, 
National and Kapodistrian University of Athens, Athens, Greece; 
Roberto Lorusso, Cardio-Thoracic Surgery, Maastricht University 
Medical Centre, Maastricht, Netherlands, and Cardiovascular Research 
Institute Maastricht, Maastricht, Netherlands; Elena G. Nesukay, 
Department of non-coronary heart diseases, rheumatology and therapy, 
National scientific center ‚ÄúThe M.D. Strazhesko institute of cardiology, 
clinical and regenerative medicine‚Äù, Kiev, Ukraine; Kazem Rahimi, 
Nuffield department of women‚Äôs and reproductive health, University 
of Oxford, Oxford, United Kingdom; Arsen D. Ristiƒá, Department 
of Cardiology, University Clinical Center of Serbia, Belgrade, Serbia, 
and Faculty of Medicine, Belgrade University, Belgrade, Serbia; Marcin 
Rucinski (Poland), ESC Patient Forum, Sophia Antipolis, France; 
Leyla Elif Sade, School of Medicine, University of Pittsburgh, 
Pittsburgh, PA, United States of America, and Department of 
Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA, 
United States of America; Hannah Schaubroeck, Intensive Care 
Unit, Ghent University Hospital, Ghent, Belgium; Anne Grete 
Semb, Department of research and innovation, REMEDY centre, 
Diakonhjemmet Hospital, Oslo, Norway; Gianfranco Sinagra, 
Center 
for 
Diagnosis 
and 
Treatment 
of 
Cardiomyopathies, 
Cardiothoracovascular Department, Azienda Sanitaria Universitaria 
Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy; Jens 
Jakob Thune, Department of cardiology, Copenhagen University 
Hospital‚ÄîBispebjerg and Frederiksberg, Copenhagen, Denmark, and 
Department of clinical medicine, University of Copenhagen, 
Copenhagen, Denmark. 
22. Appendix 
ESC Scientific Document Group 
Includes Document Reviewers and ESC National Cardiac Societies. 
Document 
Reviewers: 
Elena 
Arbelo 
(CPG 
Review 
Co-ordinator) (Spain), Cristina Basso (CPG Review Co-ordinator) 
(Italy), Marianna Adamo (Italy), Suleman Aktaa (United Kingdom), 
Enrico Ammirati (Italy), Lisa Anderson (United Kingdom), Eloisa 
Arbustini (Italy), Emanuele Bobbio (Sweden), Giuseppe Boriani (Italy), 
Margarita Brida (Croatia), Robert A. Byrne (Ireland), Alida L.P. 
Caforio (Italy), Gh.-Andrei Dan (Romania), Fernando Dom√≠nguez 
(Spain), Suzanne Fredericks (Canada), Geeta Gulati (Norway), Borja 
Ibanez (Spain), Stefan James (Sweden), Alexander Kharlamov 
(Netherlands), 
Sabine 
Klaassen 
(Germany), 
Jolanda 
Kluin 
(Netherlands), Konstantinos C. Koskinas (Switzerland), Petr 
Kuchynka (Czech Republic), Vijay Kunadian (United Kingdom), Ulf 
Landmesser (Germany), Gregory Y.H. Lip (United Kingdom), 
Bernhard 
Maisch 
(Germany), 
Federica 
Marelli-Berg 
(United 
Kingdom), Pilar Martin (Spain), John William McEvoy (Ireland), 
Borislava Mihaylova (United Kingdom), Richard Mindham (United 
Kingdom), Inge Moelgaard (Denmark), Saidi A. Mohiddin (United 
Kingdom), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet 
(Belgium), Giovanni Peretto (Italy), Kalliopi Pilichou (Italy), Nicolas 
Piriou (France), Eva Prescott (Denmark), Amina Rakisheva 
(Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Anna 
Sannino (Germany), Franziska Seidel (Germany), Felix C. Tanner 
(Switzerland), Witold Zbyszek Tomkowski (Poland), Ilonca 
Vaartjes (Netherlands), Sophie Van Linthout (Germany), Christiaan 
Vrints (Belgium), Romuald Wojnicz (Poland), Katja Zeppenfeld 
(Netherlands) 
ESC National Cardiac Societies actively involved in the review 
process of the ESC Guidelines for the management of myocarditis and 
pericarditis: 
Albania: Albanian Society of Cardiology, Albana Doko Banushi; 
Algeria: Algerian Society of Cardiology, Mohammed Chettibi; 
Armenia: Armenian Cardiologists Association, Hamayak S. Sisakian; 
Azerbaijan: Azerbaijan Society of Cardiology, Ogtay Musayev; 
Belgium: Belgian Society of Cardiology, Bernard P. Paelinck; Bosnia 
and Herzegovina: Association of Cardiologists of Bosnia and 
Herzegovina, Alden Begiƒá; Bulgaria: Bulgarian Society of Cardiology, 
Yvaylo Daskalov; Croatia: Croatian Cardiac Society, Bosko Skoric; 
Cyprus: Cyprus Society of Cardiology, Marios Ioannides; Czechia: 
Czech Society of Cardiology, Tomas Palecek; Denmark: Danish 
Society of Cardiology, Kasper Rossing; Egypt: Egyptian Society of 
Cardiology, Haytham Soliman Ghareeb; Estonia: Estonian Society of 
Cardiology, Ulvi Hinto; Finland: Finnish Cardiac Society, Markku 
Kupari; France: French Society of Cardiology, Emmanuelle 
Berthelot; Georgia: Georgian Society of Cardiology, Vaja Agladze; 
Germany: German Cardiac Society, Brenda Gerull; Greece: 
Hellenic Society of Cardiology, Alexandros Kasiakogias; Hungary: 
Hungarian Society of Cardiology, Hajnalka V√°g√≥; Iceland: Icelandic 
Society of Cardiology, Inga J√≥na Ingimarsd√≥ttir; Ireland: Irish 
Cardiac Society, Emer Joyce; Israel: Israel Heart Society, Sorel 
Goland; Italy: Italian Federation of Cardiology, Enrico Fabris; 
Kazakhstan: Association of Cardiologists of Kazakhstan, Murat 
Amanzholovich Mukarov; Kosovo (Republic of): Kosovo Society 
of Cardiology, Ibadete Byty√ßi; Kyrgyzstan: Kyrgyz Society 
of Cardiology, Erkin Mirrakhimov, Latvia: Latvian Society of 
Cardiology, Ginta Kamzola; Lebanon: Lebanese Society of 
Cardiology, Naji J. Abirached; Libya: Libyan Cardiac Society, Aiman 
M. Smer; Lithuania: Lithuanian Society of Cardiology, Vaida 
Mizariene; Luxembourg: Luxembourg Society of Cardiology, 
Andrei Codreanu; Malta: Maltese Cardiac Society, Tiziana Felice; 
Moldova (Republic of): Moldavian Society of Cardiology, 
Eleonora Boris Vataman; Morocco: Moroccan Society of 
Cardiology, Aida Soufiani; Netherlands: Netherlands Society of 
Cardiology, Geertruida Petronella Bijvoet; North Macedonia: 
National Society of Cardiology of North Macedonia, Irena Mitevska; 
Norway: Norwegian Society of Cardiology, Haavard Ravnestad; 
Poland: Polish Cardiac Society, Karol Kami≈Ñski; Portugal: 
Portuguese Society of Cardiology, Nuno Cardim; Romania: 
Romanian Society of Cardiology, Oliviana Geavlete; San Marino: 
San Marino Society of Cardiology, Emidio Troiani; Serbia: 
Cardiology Society of Serbia, Marija Zdravkovic; Slovakia: Slovak 
Society of Cardiology, Marcela Dankova; Slovenia: Slovenian Society 
of Cardiology, Andreja ƒåerne ƒåerƒçek; Spain: Spanish Society 
of Cardiology, Fernando Dom√≠nguez; Sweden: Swedish Society of 
Cardiology, Gabriel Arefalk; Switzerland: Swiss Society of 
Cardiology, 
Philip 
Haaf; 
Syrian 
Arab 
Republic: 
Syrian 
Cardiovascular Association, Mohammed Yassin Bani Marjeh; 
T√ºrkiye: Turkish Society of Cardiology, Baris Kilicaslan; Ukraine: 
Ukrainian Association of Cardiology, Sergii Cherniuk; United 
Kingdom of Great Britain and Northern Ireland: British 
Cardiovascular Society, Saidi A. Mohiddin, Uzbekistan: Association 
of Cardiologists of Uzbekistan, Amayak Kevorkov  
ESC Guidelines                                                                                                                                                                                               73


<!-- PAGE 74 -->

### Page 74

ESC Clinical Practice Guidelines (CPG) Committee: Ulf 
Landmesser (Chairperson) (Germany), Stefan James (Co-Chairperson) 
(Sweden), Marianna Adamo (Italy), Suleman Aktaa (United Kingdom), 
Folkert W. Asselbergs (Netherlands), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Giuseppe Boriani (Italy), Margarita Brida 
(Croatia), Robert A. Byrne (Ireland), Estelle Gandjbakhch (France), 
Bettina Heidecker (Germany), Anja Hennemuth (Germany), Borja 
Ibanez (Spain), Peter J√ºni (United Kingdom), Gregory Y.H. Lip (United 
Kingdom), John William McEvoy (Ireland), Borislava Mihaylova (United 
Kingdom), Inge Moelgaard (Denmark), Lis Neubeck (United Kingdom), 
Eva Prescott (Denmark), Bianca Rocca (Italy), Xavier Rossello (Spain), 
Anna Sannino (Germany), Felix C. Tanner (Switzerland), Wojtek 
Wojakowski (Poland), Katja Zeppenfeld (Netherlands) 
Contributor either withdrew or was engaged in only a part of the review process: Gerhard Poelzl  (Austria) 
23. References 
1. Adler Y, Charron P, Imazio M, Badano L, Bar√≥n-Esquivias G, Bogaert J, et al. 2015 ESC 
Guidelines for the diagnosis and management of pericardial diseases: the task force for 
the diagnosis and management of pericardial diseases of the European Society of 
Cardiology (ESC) Endorsed by: the European Association for Cardio-Thoracic 
Surgery (EACTS). Eur Heart J 2015;36:2921‚Äì64. https://doi.org/10.1093/eurheartj/ 
ehv318 
2. Adamopoulos S, Miliopoulos D, Karavidas A, Nikolaou M, Lazaros G, Gkouziouta A, 
et al. HEllenic Registry on Myocarditis SyndromES on behalf of Hellenic Heart 
Failure Association: the HERMES-HF registry. ESC Heart Fail 2020;7:3676‚Äì84.  
https://doi.org/10.1002/ehf2.12894 
3. Aquaro GD, Perfetti M, Camastra G, Monti L, Dellegrottaglie S, Moro C, et al. Cardiac 
MR with late gadolinium enhancement in acute myocarditis with preserved systolic 
function: ITAMY study. J Am Coll Cardiol 2017;70:1977‚Äì87. https://doi.org/10.1016/j. 
jacc.2017.08.044 
4. Imazio M, Brucato A, Barbieri A, Ferroni F, Maestroni S, Ligabue G, et al. Good prognosis for pericarditis with and without myocardial involvement: results from a multicenter, prospective cohort study. Circulation 2013;128:42‚Äì9. https://doi.org/10. 
1161/CIRCULATIONAHA.113.001531 
5. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes 
of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1265‚Äì73. https://doi.org/10. 
1001/jamacardio.2020.3557 
6. Keren A, Asleh R, Birati EY, Ben Gal T, Arad M. Definition and diagnosis of acute myocarditis: a position statement of the Israel Heart Society. Isr Med Assoc J 2023;25: 
519‚Äì24. 
7. Montera MW, Marcondes-Braga FG, Sim√µes MV, Moura LAZ, Fernandes F, Mangine S, 
et al. Brazilian Society of Cardiology guideline on myocarditis‚Äî2022. Arq Bras Cardiol 
2022;119:143‚Äì211. https://doi.org/10.36660/abc.20220412 
8. Nagai T, Inomata T, Kohno T, Sato T, Tada A, Kubo T, et al. JCS 2023 guideline on the 
diagnosis and treatment of myocarditis. Circ J 2023;87:674‚Äì754. https://doi.org/10. 
1253/circj.CJ-22-0696 
9. Writing Committee; Drazner MH, Bozkurt B, Cooper LT, Aggarwal NR, Basso C, et al. 
2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis: a report of the American College of Cardiology 
Solution Set Oversight Committee. J Am Coll Cardiol 2025;85:391‚Äì431. https://doi.org/ 
10.1016/j.jacc.2024.10.080 
10. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. 
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group 
on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636‚Äì48, 2648a‚Äì48d.  
https://doi.org/10.1093/eurheartj/eht210 
11. Pelliccia A, Sharma S, Gati S, B√§ck M, B√∂rjesson M, Caselli S, et al. 2020 ESC Guidelines 
on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 
2021;42:17‚Äì96. https://doi.org/10.1093/eurheartj/ehaa605 
12. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B√∂hm M, et al. 
heart failure. Eur Heart J 2021;42:3599‚Äì726. https://doi.org/10.1093/eurheartj/ 
ehab368 
13. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 
44:3503‚Äì626. https://doi.org/10.1093/eurheartj/ehad194 
14. Law YM, Lal AK, Chen S, ƒåih√°kov√° D, Cooper LT, Deshpande S, et al. Diagnosis and 
management of myocarditis in children: a scientific statement from the American 
Heart Association. Circulation 2021;144:e123‚Äì35. https://doi.org/10.1161/CIR. 
0000000000001001 
15. Maisch B, Seferoviƒá PM, Ristiƒá AD, Erbel R, Rienm√ºller R, Adler Y, et al. Guidelines on 
the diagnosis and management of pericardial diseases executive summary: the task 
force on the diagnosis and management of pericardial diseases of the European 
Society of Cardiology. Eur Heart J 2004;25:587‚Äì610. https://doi.org/10.1016/j.ehj. 
2004.02.002 
16. Patriki D, Gresser E, Manka R, Emmert MY, L√ºscher TF, Heidecker B. Approximation 
of the incidence of myocarditis by systematic screening with cardiac magnetic resonance imaging. JACC Heart Fail 2018;6:573‚Äì9. https://doi.org/10.1016/j.jchf.2018.03.002 
17. Fu M, Kontogeorgos S, Thunstr√∂m E, Zverkova Sandstr√∂m T, Kroon C, Bollano E, et al. 
Trends in myocarditis incidence, complications and mortality in Sweden from 2000 to 
2014. Sci Rep 2022;12:1810. https://doi.org/10.1038/s41598-022-05951-z 
18. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. 
Global burden of cardiovascular diseases and risk factors, 1990‚Äì2019: update from 
the GBD 2019 study. J Am Coll Cardiol 2020;76:2982‚Äì3021. https://doi.org/10.1016/j. 
jacc.2020.11.010 
19. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases 
and injuries in 188 countries, 1990‚Äì2013: a systematic analysis for the Global Burden 
of Disease Study 2013. Lancet 2015;386:743‚Äì800. https://doi.org/10.1016/S0140- 
6736(15)60692-4 
20. Messroghli DR, Pickardt T, Fischer M, Opgen-Rhein B, Papakostas K, B√∂cker D, et al. 
Toward evidence-based diagnosis of myocarditis in children and adolescents: rationale, 
design, and first baseline data of MYKKE, a multicenter registry and study platform. Am 
Heart J 2017;187:133‚Äì44. https://doi.org/10.1016/j.ahj.2017.02.027 
21. Arola A, Pikkarainen E, Sipil√§ JO, Pyk√§ri J, Rautava P, Kyt√∂ V. Occurrence and features 
of childhood myocarditis: a nationwide study in Finland. J Am Heart Assoc 2017;6: 
e005306. https://doi.org/10.1161/JAHA.116.005306 
22. Imazio M, Cecchi E, Demichelis B, Chinaglia A, Ierna S, Demarie D, et al. 
Myopericarditis versus viral or idiopathic acute pericarditis. Heart 2008;94:498‚Äì501.  
https://doi.org/10.1136/hrt.2006.104067 
23. Kyt√∂ V, Sipil√§ J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation 2014;130:1601‚Äì6. https://doi.org/10.1161/ 
CIRCULATIONAHA.114.010376 
24. Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, et al. A randomized 
trial of colchicine for acute pericarditis. N Engl J Med 2013;369:1522‚Äì8. https://doi. 
org/10.1056/NEJMoa1208536 
25. Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, et al. Efficacy and safety of 
colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet 2014;383:2232‚Äì7.  
https://doi.org/10.1016/S0140-6736(13)62709-9 
26. Charpentier S, Beaune S, Joly LM, Khoury A, Duchateau F-X, Briot R, et al. 
Management of chest pain in the French emergency healthcare system: the prospective observational EPIDOULTHO study. Eur J Emerg Med 2018;25:404‚Äì10. https://doi. 
org/10.1097/MEJ.0000000000000481 
27. Sexson Tejtel SK, Munoz FM, Al-Ammouri I, Savorgnan F, Guggilla RK, Khuri-Bulos N, 
et al. Myocarditis and pericarditis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2022;40:1499‚Äì511. https:// 
doi.org/10.1016/j.vaccine.2021.11.074 
28. Ammirati E, Cipriani M, Moro C, Raineri C, Pini D, Sormani P, et al. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis: 
Multicenter Lombardy Registry. Circulation 2018;138:1088‚Äì99. https://doi.org/10. 
1161/CIRCULATIONAHA.118.035319 
29. Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023 
ESC Guidelines for the management of endocarditis. Eur Heart J 2023;44: 
3948‚Äì4042. https://doi.org/10.1093/eurheartj/ehad193 
30. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. 
Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert 
recommendations. J Am Coll Cardiol 2018;72:3158‚Äì76. https://doi.org/10.1016/j.jacc. 
2018.09.072 
31. Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol 1987;18:619‚Äì24. https://doi.org/ 
10.1016/s0046-8177(87)80363-5 
32. Tsch√∂pe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. 
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol 2021;18:169‚Äì93. https://doi.org/10.1038/s41569-020-00435-x 
33. Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G, et al. 2011 Consensus 
statement on endomyocardial biopsy from the Association for European 
Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc 
Pathol 2012;21:245‚Äì74. https://doi.org/10.1016/j.carpath.2011.10.001 
34. Caforio ALP, Giordani AS, Baritussio A, Marcolongo D, Vicenzetto C, Tarantini G, 
et al. Long-term efficacy and safety of tailored immunosuppressive therapy in immune- 
mediated biopsy-proven myocarditis: a propensity-weighted study. Eur J Heart Fail 
2024;26:1175‚Äì85. https://doi.org/10.1002/ejhf.3220


<!-- PAGE 75 -->

### Page 75

35. Imazio M, Squarotti GB, Andreis A, Agosti A, Millesimo M, Frea S, et al. Diagnostic and 
prognostic role of the electrocardiogram in patients with pericarditis. Heart 2022;108: 
1474‚Äì8. https://doi.org/10.1136/heartjnl-2021-320443 
36. Imazio M, Brucato A, Maestroni S, Cumetti D, Dominelli A, Natale G, et al. Prevalence 
of C-reactive protein elevation and time course of normalization in acute pericarditis: 
implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation 2011; 
123:1092‚Äì7. https://doi.org/10.1161/CIRCULATIONAHA.110.986372 
37. Pisacreta AM, Mascolo R, Nivuori M, Dominioni CC, Gabiati C, Trotta L, et al. Acute 
pericarditis with pleuropulmonary involvement, fever and elevated C-reactive protein: 
a systemic autoinflammatory disease? A cohort study. Eur J Intern Med 2023;113:45‚Äì8.  
https://doi.org/10.1016/j.ejim.2023.03.034 
38. Tombetti E, Casarin F, Bizzi E, Bezer S, Mascolo R, Pallini G, et al. Relapsing pericarditis: 
peripheral blood neutrophilia, lymphopenia and high neutrophil-to-lymphocyte ratio 
herald acute attacks, high-grade inflammation, multiserosal involvement, and predict 
multiple recurrences. Int J Rheum Dis 2023;26:337‚Äì43. https://doi.org/10.1111/1756- 
185X.14523 
39. Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al. 
Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail 2020;13:e007405. https://doi.org/10.1161/ 
CIRCHEARTFAILURE.120.007405 
40. Seidel F, Opgen-Rhein B, Rentzsch A, Boehne M, Wannenmacher B, Boecker D, et al. 
Clinical characteristics and outcome of biopsy-proven myocarditis in children‚Äîresults 
of the German prospective multicentre registry ‚ÄòMYKKE‚Äô. Int J Cardiol 2022;357: 
95‚Äì104. https://doi.org/10.1016/j.ijcard.2022.03.026 
41. K√ºhl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with 
‚Äòidiopathic‚Äô left ventricular dysfunction. Circulation 2005;111:887‚Äì93. https://doi.org/ 
10.1161/01.CIR.0000155616.07901.35 
42. Ukimura A, Satomi H, Ooi Y, Kanzaki Y. Myocarditis associated with influenza A 
H1N1pdm2009. Influenza Res Treat 2012;2012:351979. https://doi.org/10.1155/ 
2012/351979 
43. Lazarou E, Lazaros G, Antonopoulos AS, Imazio M, Vasileiou P, Karavidas A, et al. A 
risk score for pericarditis recurrence. Eur J Clin Invest 2021;51:e13602. https://doi. 
org/10.1111/eci.13602 
44. Imazio M, Andreis A, Lubian M, Lazaros G, Lazarou E, Brucato A, et al. The Torino 
Pericarditis Score: a new-risk stratification tool to predict complicated pericarditis. 
Intern Emerg Med 2021;16:1921‚Äì6. https://doi.org/10.1007/s11739-021-02803-y 
45. Lazaros G, Antonopoulos AS, Lazarou E, Vlachopoulos C, Vogiatzi G, Vassilopoulos D, 
et al. Age- and sex-based differences in patients with acute pericarditis. Eur J Clin Invest 
2021;51:e13392. https://doi.org/10.1111/eci.13392 
46. Vecchi√© A, Chiabrando JG, Dell MS, Bonaventura A, Mauro AG, Wohlford G, et al. 
Clinical presentation and outcomes of acute pericarditis in a large urban hospital in 
the United States of America. Chest 2020;158:2556‚Äì67. https://doi.org/10.1016/j. 
chest.2020.07.039 
47. Gouriet F, Levy P-Y, Casalta J-P, Zandotti C, Collart F, Lepidi H, et al. Etiology of pericarditis in a prospective cohort of 1162 cases. Am J Med 2015;128:784.e1‚Äìe8. https:// 
doi.org/10.1016/j.amjmed.2015.01.040 
48. Mayosi BM, Wiysonge CS, Ntsekhe M, Volmink JA, Gumedze F, Maartens G, et al. 
Clinical characteristics and initial management of patients with tuberculous pericarditis 
in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI 
Africa) registry. BMC Infect Dis 2006;6:2. https://doi.org/10.1186/1471-2334-6-2 
49. Conte E, Tamanini S, Bizzi E, Maestroni S, Cumetti D, Novembre ML, et al. 
Post-cardiac injury syndrome and pericardial effusion recurrence after pericardial effusion drainage in chronic idiopathic pericardial effusion. Eur J Intern Med 2024;123: 
132‚Äì7. https://doi.org/10.1016/j.ejim.2024.01.024 
50. Peet CJ, Rowczenio D, Omoyinmi E, Papadopoulou C, Mapalo BRR, Wood MR, et al. 
Pericarditis and autoinflammation: a clinical and genetic analysis of patients with idiopathic recurrent pericarditis and monogenic autoinflammatory diseases at a national 
referral center. J Am Heart Assoc 2022;11:e024931. https://doi.org/10.1161/JAHA. 
121.024931 
51. Imazio M, Faletra F, Zucco J, Mio C, Carraro M, Gava AM, et al. Genetic variants in patients with recurrent pericarditis. J Cardiovasc Med (Hagerstown) 2024;25:799‚Äì804.  
https://doi.org/10.2459/JCM.0000000000001669 
52. Caforio ALP, Brucato A, Doria A, Brambilla G, Angelini A, Ghirardello A, et al. 
Anti-heart and anti-intercalated disk autoantibodies: evidence for autoimmunity in 
idiopathic recurrent acute pericarditis. Heart 2010;96:779‚Äì84. https://doi.org/10. 
1136/hrt.2009.187138 
53. Basso C. Myocarditis. N Engl J Med 2022;387:1488‚Äì500. https://doi.org/10.1056/ 
NEJMra2114478 
54. Ammirati E, Moslehi JJ. Diagnosis and treatment of acute myocarditis: a review. JAMA 
2023;329:1098‚Äì113. https://doi.org/10.1001/jama.2023.3371 
55. Younis A, Matetzky S, Mulla W, Masalha E, Afel Y, Chernomordik F, et al. Epidemiology 
characteristics and outcome of patients with clinically diagnosed acute myocarditis. Am 
J Med 2020;133:492‚Äì9. https://doi.org/10.1016/j.amjmed.2019.10.015 
56. Ammirati E, Veronese G, Brambatti M, Merlo M, Cipriani M, Potena L, et al. Fulminant 
versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2019;74:299‚Äì311. https://doi.org/10.1016/j.jacc.2019.04.063 
57. Huang F, Ammirati E, Ponnaiah M, Montero S, Raimbault V, Abrams D, et al. Fulminant 
myocarditis proven by early biopsy and outcomes. Eur Heart J 2023;44:5110‚Äì24.  
https://doi.org/10.1093/eurheartj/ehad707 
58. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 
ESC Guidelines for the management of patients with ventricular arrhythmias and 
the prevention of sudden cardiac death: developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac 
death of the European Society of Cardiology (ESC) Endorsed by the Association for 
European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2022;43: 
3997‚Äì4126. https://doi.org/10.1093/eurheartj/ehac262 
59. Berg J, Kottwitz J, Baltensperger N, Kissel CK, Lovrinovic M, Mehra T, et al. Cardiac 
magnetic resonance imaging in myocarditis reveals persistent disease activity despite 
normalization of cardiac enzymes and inflammatory parameters at 3-month follow-up. 
Circ Heart Fail 2017;10:e004262. https://doi.org/10.1161/CIRCHEARTFAILURE.117. 
004262 
60. Schwuchow-Thonke S, G√∂bel S, Emrich T, Schmitt VH, Fueting F, Klank C, et al. 
Increased C reactive protein, cardiac troponin I and GLS are associated with myocardial inflammation in patients with non-ischemic heart failure. Sci Rep 2021;11:3008.  
https://doi.org/10.1038/s41598-021-82592-8 
61. Krumm P, Brendel JM, Klingel K, M√ºller KAL, K√ºbler J, Gr√§ni C, et al. Using multiparametric cardiac magnetic resonance to phenotype and differentiate biopsy-proven 
chronic from healed myocarditis and dilated cardiomyopathy. J Clin Med 2022;11: 
5047. https://doi.org/10.3390/jcm11175047 
62. Anzini M, Merlo M, Sabbadini G, Barbati G, Finocchiaro G, Pinamonti B, et al. 
Long-term evolution and prognostic stratification of biopsy-proven active myocarditis. 
Circulation 
2013;128:2384‚Äì94. 
https://doi.org/10.1161/CIRCULATIONAHA.113. 
003092 
63. Caforio ALP, Kaski JP, Gimeno JR, Elliott PM, Laroche C, Tavazzi L, et al. 
Endomyocardial biopsy: safety and prognostic utility in paediatric and adult myocarditis 
in the European Society of Cardiology EURObservational Research Programme 
Cardiomyopathy and Myocarditis Long-Term Registry. Eur Heart J 2024;45: 
2548‚Äì69. https://doi.org/10.1093/eurheartj/ehae169 
64. Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J, Lopez-Cuenca D, 
Sanchez-Munoz JJ, Oliva-Sandoval MJ, et al. Genetics of myocarditis in arrhythmogenic 
right ventricular dysplasia. Heart Rhythm 2015;12:766‚Äì73. https://doi.org/10.1016/j. 
hrthm.2015.01.001 
65. Collet J-P, Thiele H, Barbato E, Barth√©l√©my O, Bauersachs J, Bhatt DL, et al. 2020 ESC 
Guidelines for the management of acute coronary syndromes in patients presenting 
without persistent ST-segment elevation. Eur Heart J 2021;42:1289‚Äì367. https://doi. 
org/10.1093/eurheartj/ehaa575 
66. Caforio ALP, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, et al. A prospective 
study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007;28:1326‚Äì33. https://doi.org/10.1093/ 
eurheartj/ehm076 
67. Buiatti A, Merlo M, Pinamonti B, De Biasio M, Bussani R, Sinagra G. Clinical presentation and long-term follow-up of perimyocarditis. J Cardiovasc Med (Hagerstown) 2013; 
14:235‚Äì41. https://doi.org/10.2459/JCM.0b013e328351da6e 
68. Abdel-Aty H, Boy√© P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D, et al. 
Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol 
2005;45:1815‚Äì22. https://doi.org/10.1016/j.jacc.2004.11.069 
69. Zagrosek A, Abdel-Aty H, Boy√© P, Wassmuth R, Messroghli D, Utz W, et al. Cardiac 
magnetic resonance monitors reversible and irreversible myocardial injury in myocarditis. JACC Cardiovasc Imaging 2009;2:131‚Äì8. https://doi.org/10.1016/j.jcmg.2008.09. 
014 
70. Gr√∂schel J, Bhoyroo Y, Blaszczyk E, Trauzeddel RF, Viezzer D, Saad H, et al. Different 
impacts on the heart after COVID-19 infection and vaccination: insights from cardiovascular magnetic resonance. Front Cardiovasc Med 2022;9:916922. https://doi.org/10. 
3389/fcvm.2022.916922 
71. Gentile P, Merlo M, Peretto G, Ammirati E, Sala S, Della Bella P, et al. Post-discharge 
arrhythmic risk stratification of patients with acute myocarditis and life-threatening 
ventricular tachyarrhythmias. Eur J Heart Fail 2021;23:2045‚Äì54. https://doi.org/10. 
1002/ejhf.2288 
72. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC 
Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44: 
3720‚Äì826. https://doi.org/10.1093/eurheartj/ehad191 
73. Baritussio A, Schiavo A, Basso C, Giordani AS, Cheng C-Y, Pontara E, et al. Predictors 
of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction and serum autoantibodies. Eur J Heart Fail 2022;24:1033‚Äì44.  
https://doi.org/10.1002/ejhf.2496  
ESC Guidelines                                                                                                                                                                                               75


<!-- PAGE 76 -->

### Page 76

74. Ammirati E, Cipriani M, Lilliu M, Sormani P, Varrenti M, Raineri C, et al. Survival and left 
ventricular function changes in fulminant versus nonfulminant acute myocarditis. 
Circulation 2017;136:529‚Äì45. https://doi.org/10.1161/CIRCULATIONAHA.117.026386 
75. Kondo T, Okumura T, Shibata N, Imaizumi T, Dohi K, Izawa H, et al. Differences in 
prognosis and cardiac function according to required percutaneous mechanical circulatory support and histological findings in patients with fulminant myocarditis: insights 
from the CHANGE PUMP 2 study. J Am Heart Assoc 2022;11:e023719. https://doi.org/ 
10.1161/JAHA.121.023719 
76. Peretto G, Sala S, Rizzo S, De Luca G, Campochiaro C, Sartorelli S, et al. Arrhythmias in 
myocarditis: state of the art. Heart Rhythm 2019;16:793‚Äì801. https://doi.org/10.1016/j. 
hrthm.2018.11.024 
77. Imazio M, Lazaros G, Picardi E, Vasileiou P, Orlando F, Carraro M, et al. Incidence and 
prognostic significance of new onset atrial fibrillation/flutter in acute pericarditis. Heart 
2015;101:1463‚Äì7. https://doi.org/10.1136/heartjnl-2014-307398 
78. Shah Z, Mohammed M, Vuddanda V, Ansari MW, Masoomi R, Gupta K. National 
trends, gender, management, and outcomes of patients hospitalized for myocarditis. 
Am J Cardiol 2019;124:131‚Äì6. https://doi.org/10.1016/j.amjcard.2019.03.036 
79. Rosier L, Zouaghi A, Barr√© V, Martins R, Probst V, Marijon E, et al. High risk of sustained 
ventricular arrhythmia recurrence after acute myocarditis. J Clin Med 2020;9:848.  
https://doi.org/10.3390/jcm9030848 
80. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated 
with cardiac sarcoidosis. Heart Rhythm 2014;11:1305‚Äì23. https://doi.org/10.1016/j. 
hrthm.2014.03.043 
81. Bobbio E, Hjalmarsson C, Bj√∂rkenstam M, Polte CL, Oldfors A, Lindstr√∂m U, et al. 
Diagnosis, management, and outcome of cardiac sarcoidosis and giant cell myocarditis: 
a Swedish single center experience. BMC Cardiovasc Disord 2022;22:192. https://doi. 
org/10.1186/s12872-022-02639-0 
82. Cooper LT, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis‚Äînatural history 
and treatment. N Engl J Med 1997;336:1860‚Äì66. https://doi.org/10.1056/ 
NEJM199706263362603 
83. Peretto G, Sala S, Rizzo S, Palmisano A, Esposito A, De Cobelli F, et al. Ventricular arrhythmias in myocarditis: characterization and relationships with myocardial inflammation. J Am Coll Cardiol 2020;75:1046‚Äì57. https://doi.org/10.1016/j.jacc.2020.01.036 
84. Peretto G, Sala S, Basso C, Rizzo S, Radinovic A, Frontera A, et al. Inflammation as a 
predictor of recurrent ventricular tachycardia after ablation in patients with myocarditis. J Am Coll Cardiol 2020;76:1644‚Äì56. https://doi.org/10.1016/j.jacc.2020.08.012 
85. van der Linde MR. Lyme carditis: clinical characteristics of 105 cases. Scand J Infect Dis 
Suppl 1991;77:81‚Äì4. https://doi.org/10.3109/inf.1991.23.suppl-77.01 
86. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 
ESC guidelines on cardiac pacing and cardiac resynchronization therapy: developed by 
the Task Force on cardiac pacing and cardiac resynchronization therapy of the 
European Society of Cardiology (ESC) With the special contribution of the 
European Heart Rhythm Association (EHRA). Eur Heart J 2021;42:3427‚Äì520.  
https://doi.org/10.1093/eurheartj/ehab364 
87. Bhatia RT, Finocchiaro G, Westaby J, Chatrath N, Behr ER, Papadakis M, et al. 
Myocarditis and sudden cardiac death in the community: clinical and pathological insights from a national registry in the United Kingdom. Circ Arrhythm Electrophysiol 
2023;16:e012129. https://doi.org/10.1161/CIRCEP.123.012129 
88. Lynge TH, Nielsen TS, Gregers Winkel B, Tfelt-Hansen J, Banner J. Sudden cardiac 
death caused by myocarditis in persons aged 1‚Äì49 years: a nationwide study of 14  
294 deaths in Denmark. Forensic Sci Res 2019;4:247‚Äì56. https://doi.org/10.1080/ 
20961790.2019.1595352 
89. Peretto G, Mazzone P, Paglino G, Marzi A, Tsitsinakis G, Rizzo S, et al. Continuous electrical monitoring in patients with arrhythmic myocarditis: insights from a referral center. J Clin Med 2021;10:5142. https://doi.org/10.3390/jcm10215142 
90. Baritussio A, Cheng C-Y, Simeti G, Ocagli H, Lorenzoni G, Giordani AS, et al. CMR 
predictors of favorable outcome in myocarditis: a single-center experience. J Clin 
Med 2024;13:1229. https://doi.org/10.3390/jcm13051229 
91. Ammirati E, Raimondi F, Piriou N, Sardo Infirri L, Mohiddin SA, Mazzanti A, et al. Acute 
myocarditis associated with desmosomal gene variants. JACC Heart Fail 2022;10: 
714‚Äì27. https://doi.org/10.1016/j.jchf.2022.06.013 
92. Kontorovich AR, Tang Y, Patel N, Georgievskaya Z, Shadrina M, Williams N, et al. 
Burden of cardiomyopathic genetic variation in lethal pediatric myocarditis. Circ 
Genom Precis Med 2021;14:e003426. https://doi.org/10.1161/CIRCGEN.121.003426 
93. Seidel F, Holtgrewe M, Al-Wakeel-Marquard N, Opgen-Rhein B, Dartsch J, Herbst C, 
et al. Pathogenic variants associated with dilated cardiomyopathy predict outcome in 
pediatric myocarditis. Circ Genom Precis Med 2021;14:e003250. https://doi.org/10. 
1161/CIRCGEN.120.003250 
94. Lota AS, Hazebroek MR, Theotokis P, Wassall R, Salmi S, Halliday BP, et al. Genetic 
architecture of acute myocarditis and the overlap with inherited cardiomyopathy. 
Circulation 2022;146:1123‚Äì34. https://doi.org/10.1161/CIRCULATIONAHA.121. 
058457 
95. Monda E, Bakalakos A, Cannie D, O‚ÄôMahony C, Syrris P, Kaski JP, et al. Prevalence of 
pathogenic variants in cardiomyopathy-associated genes in acute myocarditis: a 
systematic review and meta-analysis. JACC Heart Fail 2024;12:1101‚Äì11. https://doi. 
org/10.1016/j.jchf.2024.02.012 
96. Belkaya S, Kontorovich AR, Byun M, Mulero-Navarro S, Bajolle F, Cobat A, et al. 
Autosomal recessive cardiomyopathy presenting as acute myocarditis. J Am Coll 
Cardiol 2017;69:1653‚Äì65. https://doi.org/10.1016/j.jacc.2017.01.043 
97. Smith ED, Lakdawala NK, Papoutsidakis N, Aubert G, Mazzanti A, McCanta AC, et al. 
Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy 
distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. 
Circulation 2020;141:1872‚Äì84. https://doi.org/10.1161/CIRCULATIONAHA.119. 
044934 
98. Peretto G, De Luca G, Villatore A, Di Resta C, Sala S, Palmisano A, et al. Multimodal 
detection and targeting of biopsy-proven myocardial inflammation in genetic cardiomyopathies: a pilot report. JACC Basic Transl Sci 2023;8:755‚Äì65. https://doi.org/10. 
1016/j.jacbts.2023.02.018 
99. Bariani R, Cipriani A, Rizzo S, Celeghin R, Bueno Marinas M, Giorgi B, et al. ‚ÄòHot phase‚Äô 
clinical presentation in arrhythmogenic cardiomyopathy. Europace 2021;23:907‚Äì17.  
https://doi.org/10.1093/europace/euaa343 
100. Bariani R, Rigato I, Cipriani A, Bueno Marinas M, Celeghin R, Basso C, et al. 
Myocarditis-like episodes in patients with arrhythmogenic cardiomyopathy: a systematic review on the so-called hot-phase of the disease. Biomolecules 2022;12:1324.  
https://doi.org/10.3390/biom12091324 
101. Bassetto G, Merlo M, Dal Ferro M, Setti M, Paldino A, Collesi C, et al. Apoptosis, a useful marker in the management of hot-phase cardiomyopathy? Eur J Heart Fail 2024;26: 
590‚Äì7. https://doi.org/10.1002/ejhf.3173 
102. Collini V, Siega Vignut L, Angriman F, Braidotti G, De Biasio M, Imazio M. Age-stratified 
patterns in clinical presentation, treatment and outcomes in acute pericarditis: a retrospective cohort study. Heart 2024;110:1139‚Äì44. https://doi.org/10.1136/heartjnl- 
2024-324214 
103. Lazaros G, Antonopoulos AS, Imazio M, Solomou E, Lazarou E, Vassilopoulos D, et al. 
Clinical significance of pleural effusions and association with outcome in patients hospitalized with a first episode of acute pericarditis. Intern Emerg Med 2019;14:745‚Äì51.  
https://doi.org/10.1007/s11739-019-02041-3 
104. Imazio M, Pivetta E, Andreis A, Serra C, Carbone F, Masoero M, et al. Incessant pericarditis as a risk factor for complicated pericarditis and hospital admission. Circulation 
2021;143:401‚Äì2. https://doi.org/10.1161/CIRCULATIONAHA.120.051156 
105. Imazio M, Cecchi E, Demichelis B, Ierna S, Demarie D, Ghisio A, et al. Indicators of 
poor prognosis of acute pericarditis. Circulation 2007;115:2739‚Äì44. https://doi.org/ 
10.1161/CIRCULATIONAHA.106.662114 
106. Imazio M, Brucato A, Cumetti D, Brambilla G, Demichelis B, Ferro S, et al. 
Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation. Circulation 2008;118:667‚Äì71. https://doi.org/10.1161/CIRCULATIONAHA. 
107.761064 
107. Lazaros G, Antonopoulos AS, Vlachopoulos C, Oikonomou E, Karavidas A, 
Chrysochoou C, et al. Predictors of switching from nonsteroidal anti-inflammatory 
drugs to corticosteroids in patients with acute pericarditis and impact on clinical outcome. Hellenic J Cardiol 2019;60:357‚Äì63. https://doi.org/10.1016/j.hjc.2018.04.001 
108. Melendo-Viu M, March√°n-Lopez √Å, Guarch CJ-L, Roub√≠n SR, Abu-Assi E, Meneses RT, 
et al. A systematic review and meta-analysis of randomized controlled trials evaluating 
pharmacologic therapies for acute and recurrent pericarditis. Trends Cardiovasc Med 
2023;33:319‚Äì26. https://doi.org/10.1016/j.tcm.2022.02.001 
109. Artom G, Koren-Morag N, Spodick DH, Brucato A, Guindo J, Bayes-de-Luna A, et al. 
Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing 
recurrent pericarditis: a multi-centre all-case analysis. Eur Heart J 2005;26:723‚Äì27.  
https://doi.org/10.1093/eurheartj/ehi197 
110. Klein AL, Wang TKM, Cremer PC, Abbate A, Adler Y, Asher C, et al. Pericardial diseases: international position statement on new concepts and advances in multimodality cardiac imaging. JACC Cardiovasc Imaging 2024;17:937‚Äì88. https://doi.org/10.1016/j. 
jcmg.2024.04.010 
111. Chiabrando JG, Bonaventura A, Vecchi√© A, Wohlford GF, Mauro AG, Jordan JH, et al. 
Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll 
Cardiol 2020;75:76‚Äì92. https://doi.org/10.1016/j.jacc.2019.11.021 
112. Cremer PC, Tariq MU, Karwa A, Alraies MC, Benatti R, Schuster A, et al. Quantitative 
assessment of pericardial delayed hyperenhancement predicts clinical improvement in 
patients with constrictive pericarditis treated with anti-inflammatory therapy. Circ 
Cardiovasc Imaging 2015;8:e003125. https://doi.org/10.1161/CIRCIMAGING.114. 
003125 
113. Brucato A, Brambilla G, Moreo A, Alberti A, Munforti C, Ghirardello A, et al. 
Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. Am J 
Cardiol 2006;98:267‚Äì71. https://doi.org/10.1016/j.amjcard.2006.01.086 
114. Imazio M, Brucato A, Adler Y, Brambilla G, Artom G, Cecchi E, et al. Prognosis of idiopathic recurrent pericarditis as determined from previously published reports. Am J 
Cardiol 2007;100:1026‚Äì8. https://doi.org/10.1016/j.amjcard.2007.04.047 
115. Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B, et al. American Society 
of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for 
Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed


<!-- PAGE 77 -->

### Page 77

Tomography. J Am Soc Echocardiogr 2013;26:965‚Äì1012.e15. https://doi.org/10.1016/j. 
echo.2013.06.023 
116. Miranda WR, Newman DB, Sinak LJ, Espinosa RE, Anavekar NS, Goel K, et al. Pre- and 
post-pericardiocentesis echo-Doppler features of effusive-constrictive pericarditis 
compared with cardiac tamponade and constrictive pericarditis. Eur Heart J 
Cardiovasc Imaging 2019;20:298‚Äì306. https://doi.org/10.1093/ehjci/jey081 
117. Sagrist√†-Sauleda J, Angel J, S√°nchez A, Permanyer-Miralda G, Soler-Soler J. 
Effusive-constrictive pericarditis. N Engl J Med 2004;350:469‚Äì75. https://doi.org/10. 
1056/NEJMoa035630 
118. Ristiƒá AD, Imazio M, Adler Y, Anastasakis A, Badano LP, Brucato A, et al. Triage strategy for urgent management of cardiac tamponade: a position statement of the 
European Society of Cardiology Working Group on Myocardial and Pericardial 
Diseases. Eur Heart J 2014;35:2279‚Äì84. https://doi.org/10.1093/eurheartj/ehu217 
119. Talreja DR, Edwards WD, Danielson GK, Schaff HV, Tajik AJ, Tazelaar HD, et al. 
Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. 
Circulation 2003;108:1852‚Äì7. https://doi.org/10.1161/01.CIR.0000087606.18453.FD 
120. Sagrist√†-Sauleda J, Permanyer-Miralda G, Candell-Riera J, Angel J, Soler-Soler J. 
Transient cardiac constriction: an unrecognized pattern of evolution in effusive acute 
idiopathic pericarditis. Am J Cardiol 1987;59:961‚Äì6. https://doi.org/10.1016/0002- 
9149(87)91134-9 
121. Haley JH, Tajik AJ, Danielson GK, Schaff HV, Mulvagh SL, Oh JK. Transient constrictive 
pericarditis: causes and natural history. J Am Coll Cardiol 2004;43:271‚Äì75. https://doi. 
org/10.1016/j.jacc.2003.08.032 
122. Sato K, Ayache A, Kumar A, Cremer PC, Griffin B, Popovic ZB, et al. Improvement in 
left ventricular mechanics following medical treatment of constrictive pericarditis. 
Heart 2021;107:828‚Äì35. https://doi.org/10.1136/heartjnl-2020-317304 
123. Feng D, Glockner J, Kim K, Martinez M, Syed IS, Araoz P, et al. Cardiac magnetic resonance imaging pericardial late gadolinium enhancement and elevated inflammatory 
markers can predict the reversibility of constrictive pericarditis after antiinflammatory 
medical therapy: a pilot study. Circulation 2011;124:1830‚Äì7. https://doi.org/10.1161/ 
CIRCULATIONAHA.111.026070 
124. Cosyns B, Plein S, Nihoyanopoulos P, Smiseth O, Achenbach S, Andrade MJ, et al. 
European Association of Cardiovascular Imaging (EACVI) position paper: multimodality imaging in pericardial disease. Eur Heart J Cardiovasc Imaging 2015;16:12‚Äì31. https:// 
doi.org/10.1093/ehjci/jeu128 
125. Lopalco G, Venerito V, Brucato A, Emmi G, Giacomelli R, Cauli A, et al. Anakinra effectiveness in refractory polyserositis: an Italian multicenter study. Joint Bone Spine 
2022;89:105299. https://doi.org/10.1016/j.jbspin.2021.105299 
126. Kilic A, Varkal MA, Durmus MS, Yildiz I, Yƒ±ldƒ±rƒ±m ZNY, Turunc G, et al. Relationship 
between clinical findings and genetic mutations in patients with familial 
Mediterranean fever. Pediatr Rheumatol Online J 2015;13:59. https://doi.org/10.1186/ 
s12969-015-0057-1 
127. Kumar S, Khubber S, Reyaldeen R, Agrawal A, Cremer PC, Imazio M, et al. Advances in 
imaging and targeted therapies for recurrent pericarditis: a review. JAMA Cardiol 2022; 
7:975‚Äì85. https://doi.org/10.1001/jamacardio.2022.2584 
128. Habib G, Bucciarelli-Ducci C, Caforio ALP, Cardim N, Charron P, Cosyns B, et al. 
Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus 
document in collaboration with the ‚ÄòWorking group on myocardial and pericardial diseases‚Äô of the European Society of Cardiology Endorsed by The Indian Academy of 
Echocardiography. Eur Heart J Cardiovasc Imaging 2017;18:1090‚Äì121. https://doi.org/ 
10.1093/ehjci/jex034 
129. Imazio M, Pivetta E, Palacio Restrepo S, Sormani P, Pedrotti P, Quarta G, et al. 
Usefulness of cardiac magnetic resonance for recurrent pericarditis. Am J Cardiol 
2020;125:146‚Äì51. https://doi.org/10.1016/j.amjcard.2019.09.026 
130. Imazio M, Demichelis B, Parrini I, Giuggia M, Cecchi E, Gaschino G, et al. Day-hospital 
treatment of acute pericarditis: a management program for outpatient therapy. J Am 
Coll Cardiol 2004;43:1042‚Äì46. https://doi.org/10.1016/j.jacc.2003.09.055 
131. Chimenti C, Russo MA, Frustaci A. Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial. Eur Heart J 2022; 
43:3463‚Äì73. https://doi.org/10.1093/eurheartj/ehac348 
132. Rao K, De Silva K, Sood A, Denniss AR, Hsu C-J. Predicting patients with troponin positive chest pain and unobstructed coronary arteries with electrocardiogram, troponin 
kinetics and GRACE score. Heart Lung Circ 2022;31:1219‚Äì27. https://doi.org/10.1016/ 
j.hlc.2022.05.040 
133. De Lazzari M, Zorzi A, Baritussio A, Siciliano M, Migliore F, Susana A, et al. Relationship 
between T-wave inversion and transmural myocardial edema as evidenced by cardiac 
magnetic resonance in patients with clinically suspected acute myocarditis: clinical and 
prognostic implications. J Electrocardiol 2016;49:587‚Äì95. https://doi.org/10.1016/j. 
jelectrocard.2016.04.002 
134. Nucifora G, Miani D, Di Chiara A, Piccoli G, Artico J, Puppato M, et al. Infarct-like acute 
myocarditis: relation between electrocardiographic findings and myocardial damage as 
assessed by cardiac magnetic resonance imaging. Clin Cardiol 2013;36:146‚Äì52. https:// 
doi.org/10.1002/clc.22088 
135. Wang Z, Wang Y, Lin H, Wang S, Cai X, Gao D. Early characteristics of fulminant myocarditis vs non-fulminant myocarditis: a meta-analysis. Medicine (Baltimore) 2019;98: 
e14697. https://doi.org/10.1097/MD.0000000000014697 
136. Ukena C, Mahfoud F, Kindermann I, Kandolf R, Kindermann M, B√∂hm M. Prognostic 
electrocardiographic parameters in patients with suspected myocarditis. Eur J Heart 
Fail 2011;13:398‚Äì405. https://doi.org/10.1093/eurjhf/hfq229 
137. Jhamnani S, Fuisz A, Lindsay J. The spectrum of electrocardiographic manifestations of 
acute myocarditis: an expanded understanding. J Electrocardiol 2014;47:941‚Äì7. https:// 
doi.org/10.1016/j.jelectrocard.2014.07.018 
138. Baritussio A, Cheng C-Y, Lorenzoni G, Basso C, Rizzo S, De Gaspari M, et al. A 
machine-learning model for the prognostic role of C-reactive protein in myocarditis. 
J Clin Med 2022;11:7068. https://doi.org/10.3390/jcm11237068 
139. Lazaros G, Vlachakis PK, Theofilis P, Dasoula FE, Imazio M, Lazarou E, et al. D-dimer as 
a diagnostic and prognostic plasma biomarker in patients with a first episode of acute 
pericarditis. Eur J Intern Med 2023;19:2133‚Äì9. https://doi.org/10.1016/j.ejim.2023.06. 
017 
140. Mauro A, Bizzi E, Wu MA, Mascolo R, Chirico C, Conte E, et al. D-dimer and procalcitonin in patients with recurrent pericarditis: a prospective study. Intern Emerg Med 
2024;19:2133‚Äì9. https://doi.org/10.1007/s11739-024-03712-6 
141. Blanco-Dom√≠nguez R, S√°nchez-D√≠az R, de la Fuente H, Jim√©nez-Borreguero LJ, 
Matesanz-Mar√≠n A, Rela√±o M, et al. A novel circulating microRNA for the detection 
of acute myocarditis. N Engl J Med 2021;384:2014‚Äì27. https://doi.org/10.1056/ 
NEJMoa2003608 
142. Caforio ALP, De Luca G, Baritussio A, Seguso M, Gallo N, Bison E, et al. Serum organ- 
specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers 
of cardiac involvement in systemic sclerosis: frequency, clinical and prognostic correlates. 
Diagnostics (Basel) 2021;11:2165. https://doi.org/10.3390/diagnostics11112165 
143. Coronado MJ, Bruno KA, Blauwet LA, Tsch√∂pe C, Cunningham MW, Pankuweit S, 
et al. Elevated sera sST2 is associated with heart failure in men ‚â§50 years old with myocarditis. J Am Heart Assoc 2019;8:e008968. https://doi.org/10.1161/JAHA.118.008968 
144. M√ºller I, Vogl T, K√ºhl U, Krannich A, Banks A, Trippel T, et al. Serum alarmin S100A8/ 
S100A9 levels and its potential role as biomarker in myocarditis. ESC Heart Fail 2020;7: 
1442‚Äì51. https://doi.org/10.1002/ehf2.12760 
145. M√ºller I, Vogl T, Pappritz K, Miteva K, Savvatis K, Rohde D, et al. Pathogenic role of the 
damage-associated molecular patterns S100A8 and S100A9 in Coxsackievirus 
B3-induced myocarditis. Circ Heart Fail 2017;10:e004125. https://doi.org/10.1161/ 
CIRCHEARTFAILURE.117.004125 
146. Ader F, Surget E, Charron P, Redheuil A, Zouaghi A, Maltret A, et al. Inherited cardiomyopathies revealed by clinically suspected myocarditis: highlights from genetic testing. 
Circ Genom Precis Med 2020;13:e002744. https://doi.org/10.1161/CIRCGEN.119. 
002744 
147. Poller W, Haas J, Klingel K, K√ºhnisch J, Gast M, Kaya Z, et al. Familial recurrent myocarditis triggered by exercise in patients with a truncating variant of the desmoplakin 
gene. J Am Heart Assoc 2020;9:e015289. https://doi.org/10.1161/JAHA.119.015289 
148. Ollitrault P, Al Khoury M, Troadec Y, Calcagno Y, Champ-Rigot L, Ferchaud V, et al. 
Recurrent acute myocarditis: an under-recognized clinical entity associated with the 
later diagnosis of a genetic arrhythmogenic cardiomyopathy. Front Cardiovasc Med 
2022;9:998883. https://doi.org/10.3389/fcvm.2022.998883 
149. Piriou N, Marteau L, Kyndt F, Serfaty JM, Toquet C, Le Gloan L, et al. Familial screening 
in case of acute myocarditis reveals inherited arrhythmogenic left ventricular cardiomyopathies. ESC Heart Fail 2020;7:1520‚Äì33. https://doi.org/10.1002/ehf2.12686 
150. Artico J, Merlo M, Delcaro G, Cannat√† A, Gentile P, De Angelis G, et al. Lymphocytic 
myocarditis: a genetically predisposed disease? J Am Coll Cardiol 2020;75:3098‚Äì100.  
https://doi.org/10.1016/j.jacc.2020.04.048 
151. Verdonschot JAJ, Heymans SRB. Dilated cardiomyopathy: second hits knock-down the 
heart. Eur Heart J 2024;45:500‚Äì1. https://doi.org/10.1093/eurheartj/ehad778 
152. Cantarini L, Lucherini OM, Brucato A, Barone L, Cumetti D, Iacoponi F, et al. Clues to 
detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among 
patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin 
Res Cardiol 2012;101:525‚Äì31. https://doi.org/10.1007/s00392-012-0422-8 
153. Brucato A, Shinar Y, Brambilla G, Robbiolo L, Ferrioli G, Patrosso MC, et al. Idiopathic 
recurrent acute pericarditis: familial Mediterranean fever mutations and disease evolution in a large cohort of Caucasian patients. Lupus 2005;14:670‚Äì4. https://doi.org/10. 
1191/0961203305lu2197oa 
154. Felker GM, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Baughman KL, et al. 
Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 
2000;36:227‚Äì32. https://doi.org/10.1016/s0735-1097(00)00690-2 
155. Pinamonti B, Alberti E, Cigalotto A, Dreas L, Salvi A, Silvestri F, et al. Echocardiographic 
findings in myocarditis. Am J Cardiol 1988;62:285‚Äì91. https://doi.org/10.1016/0002- 
9149(88)90226-3 
156. Uppu SC, Shah A, Weigand J, Nielsen JC, Ko HH, Parness IA, et al. Two-dimensional 
speckle-tracking-derived segmental peak systolic longitudinal strain identifies regional 
myocardial involvement in patients with myocarditis and normal global left ventricular 
systolic function. Pediatr Cardiol 2015;36:950‚Äì9. https://doi.org/10.1007/s00246-015- 
1105-9 
157. Sperlongano S, D‚ÄôAmato A, Tagliamonte E, Russo V, Desiderio A, Ilardi F, et al. Acute 
myocarditis: prognostic role of speckle tracking echocardiography and comparison 
with cardiac magnetic resonance features. Heart Vessels 2022;37:121‚Äì31. https://doi. 
org/10.1007/s00380-021-01893-0  
ESC Guidelines                                                                                                                                                                                               77


<!-- PAGE 78 -->

### Page 78

158. Ben-Joya D, Kaplan A, Baruch G, Rothschild E, Beer G, Banai S, et al. The prevalence of 
abnormal right ventricle speckle strain in the setting of acute myocarditis and preserved left ventricle function. Int J Cardiovasc Imaging 2023;39:1231‚Äì8. https://doi. 
org/10.1007/s10554-023-02829-7 
159. Meindl C, Paulus M, Poschenrieder F, Hamer OW, Zeman F, Maier LS, et al. Left atrial 
strain parameters derived by echocardiography are impaired in patients with acute 
myocarditis and preserved systolic left ventricular function. Int J Cardiovasc Imaging 
2023;39:1157‚Äì65. https://doi.org/10.1007/s10554-023-02827-9 
160. Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, et al. Colchicine in 
addition to conventional therapy for acute pericarditis: results of the COlchicine for 
acute PEricarditis (COPE) trial. Circulation 2005;112:2012‚Äì6. https://doi.org/10. 
1161/CIRCULATIONAHA.105.542738 
161. Iles LM, Ellims AH, Llewellyn H, Hare JL, Kaye DM, McLean CA, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging 2015;16:14‚Äì22. https://doi.org/10.1093/ 
ehjci/jeu182 
162. Miller CA, Naish JH, Bishop P, Coutts G, Clark D, Zhao S, et al. Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. Circ Cardiovasc Imaging 2013;6:373‚Äì83. https://doi.org/10. 
1161/CIRCIMAGING.112.000192 
163. Voigt A, Elgeti T, Durmus T, Idiz ME, Butler C, Beling M, et al. Cardiac magnetic resonance imaging in dilated cardiomyopathy in adults‚Äîtowards identification of myocardial inflammation. Eur Radiol 2011;21:925‚Äì35. https://doi.org/10.1007/s00330- 
010-1985-2 
164. Lurz P, Luecke C, Eitel I, F√∂hrenbach F, Frank C, Grothoff M, et al. Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: the 
MyoRacer-Trial. J Am Coll Cardiol 2016;67:1800‚Äì11. https://doi.org/10.1016/j.jacc. 
2016.02.013 
165. Zurick AO, Bolen MA, Kwon DH, Tan CD, Popovic ZB, Rajeswaran J, et al. Pericardial 
delayed hyperenhancement with CMR imaging in patients with constrictive pericarditis 
undergoing surgical pericardiectomy: a case series with histopathological correlation. 
JACC Cardiovasc Imaging 2011;4:1180‚Äì91. https://doi.org/10.1016/j.jcmg.2011.08.011 
166. Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ, Nagel E. 
Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson 2020;22:17. https://doi.org/10.1186/s12968-020- 
00607-1 
167. Muehlberg F, Blaszczyk E, Will K, Wilczek S, Brederlau J, Schulz-Menger J. 
Characterization of critically ill patients with septic shock and sepsis-associated cardiomyopathy using cardiovascular MRI. ESC Heart Fail 2022;9:2147‚Äì56. https://doi.org/10. 
1002/ehf2.13938 
168. Gr√∂schel J, Ammann C, Zange L, Viezzer D, Forman C, Schmidt M, et al. Fast acquisition of left and right ventricular function parameters applying cardiovascular magnetic 
resonance in clinical routine‚Äîvalidation of a 2-shot compressed sensing cine sequence. Scand Cardiovasc J 2022;56:266‚Äì75. https://doi.org/10.1080/14017431.2022. 
2099010 
169. Mileva N, Paolisso P, Gallinoro E, Fabbricatore D, Munhoz D, Bergamaschi L, et al. 
Diagnostic and prognostic role of cardiac magnetic resonance in MINOCA: systematic 
review and meta-analysis. JACC Cardiovasc Imaging 2023;16:376‚Äì89. https://doi.org/10. 
1016/j.jcmg.2022.12.029 
170. Machanahalli Balakrishna A, Ismayl M, Thandra A, Walters R, Ganesan V, Anugula D, 
et al. Diagnostic value of cardiac magnetic resonance imaging and intracoronary optical 
coherence tomography in patients with a working diagnosis of myocardial infarction 
with non-obstructive coronary arteries‚Äîa systematic review and meta-analysis. 
Curr Probl Cardiol 2023;48:101126. https://doi.org/10.1016/j.cpcardiol.2022.101126 
171. Hausvater A, Smilowitz NR, Li B, Redel-Traub G, Quien M, Qian Y, et al. Myocarditis in 
relation to angiographic findings in patients with provisional diagnoses of MINOCA. 
JACC Cardiovasc Imaging 2020;13:1906‚Äì13. https://doi.org/10.1016/j.jcmg.2020.02.037 
172. Tornvall P, Gerbaud E, Behaghel A, Chopard R, Collste O, Laraudogoitia E, et al. 
Myocarditis or ‚Äòtrue‚Äô infarction by cardiac magnetic resonance in patients with a clinical 
diagnosis of myocardial infarction without obstructive coronary disease: a 
meta-analysis of individual patient data. Atherosclerosis 2015;241:87‚Äì91. https://doi. 
org/10.1016/j.atherosclerosis.2015.04.816 
173. Bohnen S, Radunski UK, Lund GK, Kandolf R, Stehning C, Schnackenburg B, et al. 
Performance of T1 and T2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging 
2015;8:e003073. https://doi.org/10.1161/CIRCIMAGING.114.003073 
174. Khanna S, Amarasekera AT, Li C, Bhat A, Chen HHL, Gan GCH, et al. The utility of 
cardiac magnetic resonance imaging in the diagnosis of adult patients with acute myocarditis: a systematic review and meta-analysis. Int J Cardiol 2022;363:225‚Äì39. https:// 
doi.org/10.1016/j.ijcard.2022.06.047 
175. Jia Z, Wang L, Jia Y, Liu J, Zhao H, Huo L, et al. Detection of acute myocarditis using T1 
and T2 mapping cardiovascular magnetic resonance: a systematic review and 
meta-analysis. J Appl Clin Med Phys 2021;22:239‚Äì48. https://doi.org/10.1002/acm2. 
13365 
176. Blissett S, Chocron Y, Kovacina B, Afilalo J. Diagnostic and prognostic value of cardiac 
magnetic resonance in acute myocarditis: a systematic review and meta-analysis. Int J 
Cardiovasc Imaging 2019;35:2221‚Äì9. https://doi.org/10.1007/s10554-019-01674-x 
177. Pan JA, Lee YJ, Salerno M. Diagnostic performance of extracellular volume, native T1, 
and T2 mapping versus Lake Louise criteria by cardiac magnetic resonance for detection of acute myocarditis: a meta-analysis. Circ Cardiovasc Imaging 2018;11:e007598.  
https://doi.org/10.1161/CIRCIMAGING.118.007598 
178. Wei S, Fu J, Chen L, Yu S. Performance of cardiac magnetic resonance imaging for diagnosis of myocarditis compared with endomyocardial biopsy: a meta-analysis. Med Sci 
Monit 2017;23:3687‚Äì96. https://doi.org/10.12659/msm.902155 
179. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, et al. 
Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. 
Lancet 2012;379:453‚Äì60. https://doi.org/10.1016/S0140-6736(11)61335-4 
180. Greenwood JP, Ripley DP, Berry C, McCann GP, Plein S, Bucciarelli-Ducci C, et al. 
Effect of care guided by cardiovascular magnetic resonance, myocardial perfusion scintigraphy, or NICE guidelines on subsequent unnecessary angiography rates: the 
CE-MARC 2 randomized clinical trial. JAMA 2016;316:1051‚Äì60. https://doi.org/10. 
1001/jama.2016.12680 
181. Nagel E, Greenwood JP, McCann GP, Bettencourt N, Shah AM, Hussain ST, et al. 
Magnetic resonance perfusion or fractional flow reserve in coronary disease. N Engl 
J Med 2019;380:2418‚Äì28. https://doi.org/10.1056/NEJMoa1716734 
182. Arai AE, Schulz-Menger J, Berman D, Mahrholdt H, Han Y, Bandettini WP, et al. 
Gadobutrol-enhanced cardiac magnetic resonance imaging for detection of coronary 
artery disease. J Am Coll Cardiol 2020;76:1536‚Äì47. https://doi.org/10.1016/j.jacc.2020. 
07.060 
183. Kwong RY, Ge Y, Steel K, Bingham S, Abdullah S, Fujikura K, et al. Cardiac magnetic 
resonance stress perfusion imaging for evaluation of patients with chest pain. J Am 
Coll Cardiol 2019;74:1741‚Äì55. https://doi.org/10.1016/j.jacc.2019.07.074 
184. Bohm P, Scharhag J, Meyer T. Data from a nationwide registry on sports-related sudden cardiac deaths in Germany. Eur J Prev Cardiol 2016;23:649‚Äì56. https://doi.org/10. 
1177/2047487315594087 
185. Pelliccia A, Solberg EE, Papadakis M, Adami PE, Biffi A, Caselli S, et al. 
Recommendations for participation in competitive and leisure time sport in athletes 
with cardiomyopathies, myocarditis, and pericarditis: position statement of the 
Sport Cardiology Section of the European Association of Preventive Cardiology 
(EAPC). Eur Heart J 2019;40:19‚Äì33. https://doi.org/10.1093/eurheartj/ehy730 
186. Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NAM, et al. 
Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific 
statement from the American Heart Association and American College of Cardiology. 
Circulation 2015;132:e273‚Äì80. https://doi.org/10.1161/CIR.0000000000000239 
187. Sechtem U, Tscholakoff D, Higgins CB. MRI of the normal pericardium. AJR Am J 
Roentgenol 1986;147:239‚Äì44. https://doi.org/10.2214/ajr.147.2.239 
188. Stark DD, Higgins CB, Lanzer P, Lipton MJ, Schiller N, Crooks LE, et al. Magnetic resonance imaging of the pericardium: normal and pathologic findings. Radiology 1984; 
150:469‚Äì74. https://doi.org/10.1148/radiology.150.2.6691103 
189. Tscholakoff D, Sechtem U, de Geer G, Schmidt H, Higgins CB. Evaluation of pleural 
and pericardial effusions by magnetic resonance imaging. Eur J Radiol 1987;7:169‚Äì74. 
190. Power JA, Thompson DV, Rayarao G, Doyle M, Biederman RWW. Cardiac magnetic 
resonance radiofrequency tissue tagging for diagnosis of constrictive pericarditis: a 
proof of concept study. J Thorac Cardiovasc Surg 2016;151:1348‚Äì55. https://doi.org/ 
10.1016/j.jtcvs.2015.12.035 
191. Gastl M, Sokolska JM, Polacin M, Gotschy A, von Spiczak Brzezinski J, Alkadhi H, et al. 
Parametric mapping CMR for the measurement of inflammatory reactions of the pericardium. Open Heart 2022;9:e001919. https://doi.org/10.1136/openhrt-2021-001919 
192. Conte E, Agalbato C, Lauri G, Mushtaq S, Cia AD, Bonomi A, et al. Cardiac MRI after 
first episode of acute pericarditis: a pilot study for better identification of high risk patients. Int J Cardiol 2022;354:63‚Äì7. https://doi.org/10.1016/j.ijcard.2022.03.007 
193. Young PM, Glockner JF, Williamson EE, Morris MF, Araoz PA, Julsrud PR, et al. MR imaging findings in 76 consecutive surgically proven cases of pericardial disease with CT 
and pathologic correlation. Int J Cardiovasc Imaging 2012;28:1099‚Äì109. https://doi.org/ 
10.1007/s10554-011-9916-0 
194. Taylor AM, Dymarkowski S, Verbeken EK, Bogaert J. Detection of pericardial inflammation with late-enhancement cardiac magnetic resonance imaging: initial results. Eur 
Radiol 2006;16:569‚Äì74. https://doi.org/10.1007/s00330-005-0025-0 
195. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 
ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur 
Heart J 2020;41:407‚Äì77. https://doi.org/10.1093/eurheartj/ehz425 
196. Maggiolini S, De Carlini CC, Ferri LA, Colombo GI, Gentile G, Meles E, et al. The role of 
early contrast-enhanced chest computed tomography in the aetiological diagnosis of 
patients presenting with cardiac tamponade or large pericardial effusion. Eur Heart J 
Cardiovasc Imaging 2016;17:421‚Äì8. https://doi.org/10.1093/ehjci/jev225 
197. Lee Y-H, Kim SM, Kim EK, Park S-J, Lee S-C, Park SW, et al. Pattern of pericardial calcification determines mid-term postoperative outcomes after pericardiectomy in


<!-- PAGE 79 -->

### Page 79

chronic constrictive pericarditis. Int J Cardiol 2023;387:131133. https://doi.org/10. 
1016/j.ijcard.2023.131133 
198. Conte E, Agalbato C, Lauri G, Mushtaq S, Carollo C, Bonomi A, et al. Prevalence and 
prognosis of pericardial effusion in patients affected by pectus excavatum: a case- 
control study. Int J Cardiol 2021;344:179‚Äì83. https://doi.org/10.1016/j.ijcard.2021.10. 
005 
199. Bogaert J, Meyns B, Dymarkowski S, Sinnaeve P, Meuris B. Calcified constrictive pericarditis: prevalence, distribution patterns, and relationship to the myocardium. JACC 
Cardiovasc Imaging 2016;9:1013‚Äì4. https://doi.org/10.1016/j.jcmg.2015.08.011 
200. Azzu A, Morosin M, Antonopoulos AS, Capoccia M, Rosendahl U, Mohiaddin R. 
Cardiac decompression by pericardiectomy for constrictive pericarditis: multimodality 
imaging to identify patients at risk for prolonged inotropic support. J Cardiovasc Imaging 
2021;29:361‚Äì72. https://doi.org/10.4250/jcvi.2020.0223 
201. Peretto G, Busnardo E, Ferro P, Palmisano A, Vignale D, Esposito A, et al. Clinical applications of FDG-PET scan in arrhythmic myocarditis. JACC Cardiovasc Imaging 2022; 
15:1771‚Äì80. https://doi.org/10.1016/j.jcmg.2022.02.029 
202. Palmisano A, Vignale D, Peretto G, Busnardo E, Calcagno C, Campochiaro C, et al. 
Hybrid FDG-PET/MR or FDG-PET/CT to detect disease activity in patients with persisting arrhythmias after myocarditis. JACC Cardiovasc Imaging 2021;14:288‚Äì92. https:// 
doi.org/10.1016/j.jcmg.2020.03.009 
203. Hanneman K, Kadoch M, Guo HH, Jamali M, Quon A, Iagaru A, et al. Initial experience with 
simultaneous 18F-FDG PET/MRI in the evaluation of cardiac sarcoidosis and myocarditis. 
Clin Nucl Med 2017;42:e328‚Äì34. https://doi.org/10.1097/RLU.0000000000001669 
204. Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL, et al. 
Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in 
cardiac sarcoid detection and therapy monitoring. J Nucl Med 2017;58:1341‚Äì53.  
https://doi.org/10.2967/jnumed.117.196287 
205. Salom√§ki SP, Hohenthal U, Kemppainen J, Piril√§ L, Saraste A. Visualization of pericarditis by fluorodeoxyglucose PET. Eur Heart J Cardiovasc Imaging 2014;15:291. https:// 
doi.org/10.1093/ehjci/jet179 
206. Nensa F, Kloth J, Tezgah E, Poeppel TD, Heusch P, Goebel J, et al. Feasibility of 
FDG-PET in myocarditis: comparison to CMR using integrated PET/MRI. J Nucl 
Cardiol 2018;25:785‚Äì94. https://doi.org/10.1007/s12350-016-0616-y 
207. Basso C, Calabrese F, Angelini A, Carturan E, Thiene G. Classification and histological, 
immunohistochemical, and molecular diagnosis of inflammatory myocardial disease. 
Heart Fail Rev 2013;18:673‚Äì81. https://doi.org/10.1007/s10741-012-9355-6 
208. Murphy L, McGuckin M, Giblin G, Keogh A, McGovern B, Fabre A, et al. The role of 
endomyocardial biopsy in suspected myocarditis in the contemporary era: a 10-year 
National Transplant Centre experience. Cardiovasc Pathol 2021;54:107366. https:// 
doi.org/10.1016/j.carpath.2021.107366 
209. Lu ZA, Aubry MC, Fallon JT, Fishbein MC, Giordano C, Klingel K, et al. Myocarditis and 
endomyocardial biopsy: achieving consensus diagnosis on 100 cases. Cardiovasc Pathol 
2023;62:107492. https://doi.org/10.1016/j.carpath.2022.107492 
210. Seferoviƒá PM, Tsutsui H, McNamara DM, Ristiƒá AD, Basso C, Bozkurt B, et al. Heart 
Failure Association of the ESC, Heart Failure Society of America and Japanese Heart 
Failure Society position statement on endomyocardial biopsy. Eur J Heart Fail 2021; 
23:854‚Äì71. https://doi.org/10.1002/ejhf.2190 
211. Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, et al. 
Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 2010;122:900‚Äì9.  
https://doi.org/10.1161/CIRCULATIONAHA.109.924167 
212. van der Boon R, den Dekker W, Meuwese CL, Lorusso R, von der Th√ºsen J, 
Constantinescu AC, et al. Safety of endomyocardial biopsy in new-onset acute heart 
failure requiring veno-arterial extracorporeal membrane oxygenation. Circ Heart Fail 
2021;14:e008387. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008387 
213. Mueller GC, Michel-Behnke I, Knirsch W, Haas NA, Abdul-Khaliq H, Gitter R, et al. 
Feasibility, safety and diagnostic impact of endomyocardial biopsies for the diagnosis 
of myocardial disease in children and adolescents. EuroIntervention 2018;14: 
1089‚Äì95. https://doi.org/10.4244/EIJ-D-18-00128 
214. De Gaspari M, Larsen BT, d‚ÄôAmati G, Kreutz K, Basso C, Michaud K, et al. Diagnosing 
myocarditis in endomyocardial biopsies: survey of current practice. Cardiovasc Pathol 
2023;64:107494. https://doi.org/10.1016/j.carpath.2022.107494 
215. Gartshteyn Y, Tamargo M, Fleischer S, Kapoor T, Li J, Askanase A, et al. 
Endomyocardial biopsies in the diagnosis of myocardial involvement in systemic lupus 
erythematosus. Lupus 2020;29:199‚Äì204. https://doi.org/10.1177/0961203319897116 
216. Heymans S, Lakdawala NK, Tsch√∂pe C, Klingel K. Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches. Lancet 2023;402:998‚Äì1011.  
https://doi.org/10.1016/S0140-6736(23)01241-2 
217. Kandolin R, Lehtonen J, Salmenkivi K, R√§is√§nen-Sokolowski A, Lommi J, Kupari M. 
Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined 
immunosuppression. 
Circ 
Heart 
Fail 
2013;6:15‚Äì22. 
https://doi.org/10.1161/ 
CIRCHEARTFAILURE.112.969261 
218. Casella M, Dello Russo A, Bergonti M, Catto V, Conte E, Sommariva E, et al. Diagnostic 
yield of electroanatomic voltage mapping in guiding endomyocardial biopsies. Circulation 
2020;142:1249‚Äì60. https://doi.org/10.1161/CIRCULATIONAHA.120.046900 
219. Casella M, Pizzamiglio F, Dello Russo A, Carbucicchio C, Al-Mohani G, Russo E, et al. 
Feasibility of combined unipolar and bipolar voltage maps to improve sensitivity of endomyocardial biopsy. Circ Arrhythm Electrophysiol 2015;8:625‚Äì32. https://doi.org/10. 
1161/CIRCEP.114.002216 
220. Ezzeddine FM, Kapa S, Rosenbaum A, Blauwet L, Deshmukh AJ, AbouEzzeddine OF, 
et al. Electrogram-guided endomyocardial biopsy yield in patients with suspected cardiac sarcoidosis and relation to outcomes. J Cardiovasc Electrophysiol 2021;32:2486‚Äì95.  
https://doi.org/10.1111/jce.15191 
221. Vaidya VR, Abudan AA, Vasudevan K, Shantha G, Cooper LT, Kapa S, et al. The efficacy 
and safety of electroanatomic mapping-guided endomyocardial biopsy: a systematic 
review. J Interv Card Electrophysiol 2018;53:63‚Äì71. https://doi.org/10.1007/s10840- 
018-0410-7 
222. Pelargonio G, Pinnacchio G, Narducci ML, Pieroni M, Perna F, Bencardino G, et al. long- 
term arrhythmic risk assessment in biopsy-proven myocarditis. JACC Clin Electrophysiol 
2020;6:574‚Äì82. https://doi.org/10.1016/j.jacep.2019.12.010 
223. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ, et al. 
Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 
1987;1:3‚Äì14. 
224. Schnitt SJ, Ciano PS, Schoen FJ. Quantitation of lymphocytes in endomyocardial biopsies: use and limitations of antibodies to leukocyte common antigen. Hum Pathol 1987; 
18:796‚Äì800. https://doi.org/10.1016/s0046-8177(87)80053-9 
225. Linder J, Cassling RS, Rogler WC, Wilson JE, Markin RS, Sears TD, et al. 
Immunohistochemical characterization of lymphocytes in uninflamed ventricular myocardium. Implications for myocarditis. Arch Pathol Lab Med 1985;109:917‚Äì20. 
226. Ohta-Ogo K, Sugano Y, Ogata S, Nakayama T, Komori T, Eguchi K, et al. Myocardial 
T-lymphocytes as a prognostic risk-stratifying marker of dilated cardiomyopathy‚Äîresults of the multicenter registry to investigate inflammatory cell infiltration in dilated 
cardiomyopathy in tissues of endomyocardial biopsy (INDICATE study). Circ J 2022; 
86:1092‚Äì101. https://doi.org/10.1253/circj.CJ-21-0529 
227. Katzmann JL, Schlattmann P, Rigopoulos AG, Noutsias E, Bigalke B, Pauschinger M, 
et al. Meta-analysis on the immunohistological detection of inflammatory cardiomyopathy in endomyocardial biopsies. Heart Fail Rev 2020;25:277‚Äì94. https://doi.org/10. 
1007/s10741-019-09835-9 
228. Pelzl L, Mantino S, Sauter M, Manuylova T, Vogel U, Klingel K. Lymphocytic myocarditis 
in children with parvovirus B19 infection: pathological and molecular insights. 
Biomedicines 2024;12:1909. https://doi.org/10.3390/biomedicines12081909 
229. Stiermaier T, F√∂hrenbach F, Klingel K, Kandolf R, Boudriot E, Sandri M, et al. 
Biventricular endomyocardial biopsy in patients with suspected myocarditis: feasibility, 
complication rate and additional diagnostic value. Int J Cardiol 2017;230:364‚Äì70.  
https://doi.org/10.1016/j.ijcard.2016.12.103 
230. Mahfoud F, G√§rtner B, Kindermann M, Ukena C, Gadomski K, Klingel K, et al. Virus 
serology in patients with suspected myocarditis: utility or futility? Eur Heart J 2011; 
32:897‚Äì903. https://doi.org/10.1093/eurheartj/ehq493 
231. Heidecker B, Williams SH, Jain K, Oleynik A, Patriki D, Kottwitz J, et al. Virome sequencing in patients with myocarditis. Circ Heart Fail 2020;13:e007103. https://doi.org/10. 
1161/CIRCHEARTFAILURE.120.007103 
232. Maisch B, Rupp H, Ristic A, Pankuweit S. Pericardioscopy and epi- and pericardial biopsy‚Äîa new window to the heart improving etiological diagnoses and permitting targeted intrapericardial therapy. Heart Fail Rev 2013;18:317‚Äì28. https://doi.org/10.1007/ 
s10741-013-9382-y 
233. Ding Z, Yang M, Wang Y, Wu S, Qiu X, Liu Q. Retrospective analysis of 769 cases of 
sudden cardiac death from 2006 to 2015: a forensic experience in China. Forensic Sci 
Med Pathol 2017;13:336‚Äì41. https://doi.org/10.1007/s12024-017-9888-z 
234. Vassalini M, Verzeletti A, Restori M, De Ferrari F. An autopsy study of sudden cardiac 
death in persons aged 1‚Äì40 years in Brescia (Italy). J Cardiovasc Med (Hagerstown) 2016; 
17:446‚Äì53. https://doi.org/10.2459/JCM.0000000000000234 
235. Wu Y, Ai M, Bardeesi ASA, Zhang L, Wu Q, Yin K, et al. The forensic pathological analysis of sport-related sudden cardiac death in Southern China. Forensic Sci Res 2020;5: 
47‚Äì54. https://doi.org/10.1080/20961790.2017.1319785 
236. Wang H, Yao Q, Zhu S, Zhang G, Wang Z, Li Z, et al. The autopsy study of 553 cases of 
sudden cardiac death in Chinese adults. Heart Vessels 2014;29:486‚Äì95. https://doi.org/ 
10.1007/s00380-013-0388-0 
237. Doolan A, Langlois N, Semsarian C. Causes of sudden cardiac death in young 
Australians. Med J Aust 2004;180:110‚Äì2. https://doi.org/10.5694/j.1326-5377.2004. 
tb05830.x 
238. Harris KM, Mackey-Bojack S, Bennett M, Nwaudo D, Duncanson E, Maron BJ. Sudden 
unexpected death due to myocarditis in young people, including athletes. Am J Cardiol 
2021;143:131‚Äì4. https://doi.org/10.1016/j.amjcard.2020.12.028 
239. Basso C, Aguilera B, Banner J, Cohle S, d‚ÄôAmati G, de Gouveia RH, et al. Guidelines for 
autopsy investigation of sudden cardiac death: 2017 update from the Association for 
European Cardiovascular Pathology. Virchows Arch 2017;471:691‚Äì705. https://doi.org/ 
10.1007/s00428-017-2221-0 
240. Ekstr√∂m K, Lehtonen J, Nordenswan H-K, M√§yr√§np√§√§ MI, R√§is√§nen-Sokolowski A, 
Kandolin R, et al. Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical 
and cause-of-death registries. Eur Heart J 2019;40:3121‚Äì8. https://doi.org/10.1093/ 
eurheartj/ehz428  
ESC Guidelines                                                                                                                                                                                               79


<!-- PAGE 80 -->

### Page 80

241. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA 
expert consensus statement on the state of genetic testing for the channelopathies 
and cardiomyopathies. This document was developed as a partnership between the 
Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). 
Heart Rhythm 2011;8:1308‚Äì39. https://doi.org/10.1016/j.hrthm.2011.05.020 
242. Wilhelm M, Bolliger SA, Bartsch C, Fokstuen S, Gr√§ni C, Martos V, et al. Sudden cardiac 
death in forensic medicine‚ÄîSwiss recommendations for a multidisciplinary approach. 
Swiss Med Wkly 2015;145:w14129. https://doi.org/10.4414/smw.2015.14129 
243. de Noronha SV, Behr ER, Papadakis M, Ohta-Ogo K, Banya W, Wells J, et al. The importance of specialist cardiac histopathological examination in the investigation of 
young sudden cardiac deaths. Europace 2014;16:899‚Äì907. https://doi.org/10.1093/ 
europace/eut329 
244. De Gaspari M, Fedeli U, Saia M, Carturan E, Pilichou K, Corrado D, et al. Rate and cause 
of sudden cardiac death in the young during the COVID-19 pandemic and vaccination. 
Circulation 
2023;148:2069‚Äì71. 
https://doi.org/10.1161/CIRCULATIONAHA.123. 
066270 
245. du Long R, Fronczek J, Niessen HWM, van der Wal A, de Boer H. The histopathological spectrum of myocardial inflammation in relation to circumstance of death: a retrospective cohort study in clinical and forensic autopsies. Forensic Sci Res 2022;7:238‚Äì46.  
https://doi.org/10.1080/20961790.2021.1989793 
246. Li L, Zhang Y, Burke A, Xue A, Zhao Z, Fowler D, et al. Demographic, clinical and 
pathological features of sudden deaths due to myocarditis: results from a state-wide 
population-based autopsy study. Forensic Sci Int 2017;272:81‚Äì6. https://doi.org/10. 
1016/j.forsciint.2016.12.037 
247. Gulino SP, Burns K, Gunther WM, MacLeod H. Improving forensic pathologic investigation of sudden death in the young: tools, guidance, and methods of cardiovascular 
dissection from the sudden death in the young case registry. Acad Forensic Pathol 
2018;8:347‚Äì91. https://doi.org/10.1177/1925362118782077 
248. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC 
guidelines for the management of chronic coronary syndromes. Eur Heart J 2024; 
45:3415‚Äì537. https://doi.org/10.1093/eurheartj/ehae177 
249. Nowatzke J, Guedeney P, Palaskas N, Lehmann L, Ederhy S, Zhu H, et al. Coronary 
artery disease and revascularization associated with immune checkpoint blocker myocarditis: report from an international registry. Eur J Cancer 2022;177:197‚Äì205. https:// 
doi.org/10.1016/j.ejca.2022.07.018 
250. Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 2020;142:2299‚Äì311. https://doi.org/10.1161/CIRCULATIONAHA.120. 
049981 
251. Z√∂ller B, Ji J, Sundquist J, Sundquist K. Risk of coronary heart disease in patients with 
cancer: a nationwide follow-up study from Sweden. Eur J Cancer 2012;48:121‚Äì8.  
https://doi.org/10.1016/j.ejca.2011.09.015 
252. Jain CC, Miranda WR, El Sabbagh A, Nishimura RA. A simplified method for the diagnosis of constrictive pericarditis in the cardiac catheterization laboratory. JAMA Cardiol 
2022;7:100‚Äì4. https://doi.org/10.1001/jamacardio.2021.3478 
253. Casella M, Gasperetti A, Compagnucci P, Narducci ML, Pelargonio G, Catto V, et al. 
Different phases of disease in lymphocytic myocarditis: clinical and electrophysiological 
characteristics. JACC Clin Electrophysiol 2023;9:314‚Äì26. https://doi.org/10.1016/j.jacep. 
2022.10.004 
254. Hoogendoorn JC, Sramko M, Venlet J, Siontis KC, Kumar S, Singh R, et al. 
Electroanatomical voltage mapping to distinguish right-sided cardiac sarcoidosis 
from arrhythmogenic right ventricular cardiomyopathy. JACC Clin Electrophysiol 
2020;6:696‚Äì707. https://doi.org/10.1016/j.jacep.2020.02.008 
255. Peretto G, Sala S, Basso C, Della Bella P. Programmed ventricular stimulation in patients with active vs previous arrhythmic myocarditis. J Cardiovasc Electrophysiol 
2020;31:692‚Äì701. https://doi.org/10.1111/jce.14374 
256. Haanschoten DM, Adiyaman A, ‚Äòt Hart NA, Jager PL, Elvan A. Value of 3D mapping- 
guided endomyocardial biopsy in cardiac sarcoidosis: case series and narrative review 
on the value of electro-anatomic mapping-guided endomyocardial biopsies. Eur J Clin 
Invest 2021;51:e13497. https://doi.org/10.1111/eci.13497 
257. Muser D, Santangeli P, Liang JJ, Castro SA, Magnani S, Hayashi T, et al. Characterization 
of the electroanatomic substrate in cardiac sarcoidosis: correlation with imaging findings of scar and inflammation. JACC Clin Electrophysiol 2018;4:291‚Äì303. https://doi.org/ 
10.1016/j.jacep.2017.09.175 
258. Liang JJ, Hebl VB, DeSimone CV, Madhavan M, Nanda S, Kapa S, et al. Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy 
for suspected cardiac sarcoidosis and myocarditis. JACC Heart Fail 2014;2:466‚Äì73.  
https://doi.org/10.1016/j.jchf.2014.03.015 
259. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B√∂hm M, et al. 2023 
Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute 
and chronic heart failure. Eur Heart J 2023;44:3627‚Äì39. https://doi.org/10.1093/ 
eurheartj/ehad195 
260. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 
Heart J 2024;45:3314‚Äì414. https://doi.org/10.1093/eurheartj/ehae176 
261. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstr√∂m-Lundqvist C, et al. 2019 
ESC guidelines for the management of patients with supraventricular tachycardia. The 
Task Force for the management of patients with supraventricular tachycardia of the 
European Society of Cardiology (ESC). Eur Heart J 2020;41:655‚Äì720. https://doi.org/ 
10.1093/eurheartj/ehz467 
262. Berg J, Lovrinovic M, Baltensperger N, Kissel CK, Kottwitz J, Manka R, et al. 
Non-steroidal anti-inflammatory drug use in acute myopericarditis: 12-month clinical 
follow-up. Open Heart 2019;6:e000990. https://doi.org/10.1136/openhrt-2018-000990 
263. Collini V, De Martino M, Andreis A, De Biasio M, Gaspard F, Paneva E, et al. Efficacy and 
safety of colchicine for the treatment of myopericarditis. Heart 2024;110:735‚Äì9.  
https://doi.org/10.1136/heartjnl-2023-323484 
264. Kindermann I, Kindermann M, Kandolf R, Klingel K, B√ºltmann B, M√ºller T, et al. 
Predictors of outcome in patients with suspected myocarditis. Circulation 2008;118: 
639‚Äì48. https://doi.org/10.1161/CIRCULATIONAHA.108.769489 
265. Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J, et al. Epidemiology, 
pathophysiology and contemporary management of cardiogenic shock‚Äîa position 
statement from the Heart Failure Association of the European Society of 
Cardiology. Eur J Heart Fail 2020;22:1315‚Äì41. https://doi.org/10.1002/ejhf.1922 
266. Heymans S, Van Linthout S, Kraus SM, Cooper LT, Ntusi NAB. Clinical characteristics 
and mechanisms of acute myocarditis. Circ Res 2024;135:397‚Äì411. https://doi.org/10. 
1161/CIRCRESAHA.124.324674 
267. Pappritz K, Lin J, El-Shafeey M, Fechner H, K√ºhl U, Alogna A, et al. Colchicine prevents 
disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the 
cardiosplenic axis. ESC Heart Fail 2022;9:925‚Äì41. https://doi.org/10.1002/ehf2.13845 
268. Kerneis M, Cohen F, Combes A, Amoura Z, Pare C, Brugier D, et al. Rationale and design of the ARAMIS trial: anakinra versus placebo, a double blind randomized controlled trial for the treatment of acute myocarditis. Arch Cardiovasc Dis 2023;116: 
460‚Äì6. https://doi.org/10.1016/j.acvd.2023.07.004 
269. Li Y, Yu Y, Chen S, Liao Y, Du J. Corticosteroids and intravenous immunoglobulin in 
pediatric myocarditis: a meta-analysis. Front Pediatr 2019;7:342. https://doi.org/10. 
3389/fped.2019.00342 
270. Chen HS, Wang W, Wu SN, Liu JP. Corticosteroids for viral myocarditis. Cochrane 
Database Syst Rev 2013;2013:CD004471. https://doi.org/10.1002/14651858. 
CD004471.pub3 
271. Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E. Eosinophilic 
myocarditis: characteristics, treatment, and outcomes. J Am Coll Cardiol 2017;70: 
2363‚Äì75. https://doi.org/10.1016/j.jacc.2017.09.023 
272. Mason JW, O‚ÄôConnell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, et al. 
A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995;333: 
269‚Äì75. https://doi.org/10.1056/NEJM199508033330501 
273. Schultheiss H-P, Piper C, Sowade O, Waagstein F, Kapp J-F, Wegscheider K, et al. 
Betaferon in chronic viral cardiomyopathy (BICC) trial: effects of interferon-Œ≤ treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol 2016;105: 
763‚Äì73. https://doi.org/10.1007/s00392-016-0986-9 
274. Imazio M, Andreis A, Agosti A, Piroli F, Avondo S, Casula M, et al. Usefulness of beta- 
blockers to control symptoms in patients with pericarditis. Am J Cardiol 2021;146: 
115‚Äì9. https://doi.org/10.1016/j.amjcard.2021.01.032 
275. Avondo S, Andreis A, Casula M, Biondi-Zoccai G, Imazio M. Pharmacologic treatment 
of acute and recurrent pericarditis: a systematic review and meta-analysis of controlled 
clinical trials. Panminerva Med 2021;63:314‚Äì23. https://doi.org/10.23736/S0031-0808. 
21.04263-4 
276. Lutschinger LL, Rigopoulos AG, Schlattmann P, Matiakis M, Sedding D, Schulze PC, 
et al. Meta-analysis for the value of colchicine for the therapy of pericarditis and of 
postpericardiotomy syndrome. BMC Cardiovasc Disord 2019;19:207. https://doi.org/ 
10.1186/s12872-019-1190-4 
277. Li Y-L, Qiao S-B, Wang J-Y, Chen Y-M, Luo J, Zhang H-F. Colchicine in addition to conventional therapy for pericarditis recurrence: an update meta-analysis. Herz 2016;41: 
630‚Äì8. https://doi.org/10.1007/s00059-016-4410-z 
278. Papageorgiou N, Briasoulis A, Lazaros G, Imazio M, Tousoulis D. Colchicine for prevention and treatment of cardiac diseases: a meta-analysis. Cardiovasc Ther 2017;35: 
10‚Äì18. https://doi.org/10.1111/1755-5922.12226 
279. Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018;3: 
231‚Äì41. https://doi.org/10.1016/S2468-1253(18)30037-2 
280. Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 
American College of Rheumatology guideline for the prevention and treatment of 
glucocorticoid-induced osteoporosis. Arthritis Rheumatol 2023;75:2088‚Äì102. https:// 
doi.org/10.1002/art.42646 
281. Sambola A, Roca Luque I, Merc√© J, Alguersuari J, Francisco-Pascual J, Garc√≠a-Dorado D, 
et al. Colchicine administered in the first episode of acute idiopathic pericarditis: a randomized multicenter open-label study. Rev Esp Cardiol (Engl Ed) 2019;72:709‚Äì16.  
https://doi.org/10.1016/j.rec.2018.11.016 
282. Imazio M, Andreis A, Piroli F, Lazaros G, Gattorno M, Lewinter M, et al. 
Anti-interleukin 1 agents for the treatment of recurrent pericarditis: a systematic


<!-- PAGE 81 -->

### Page 81

review and meta-analysis. Heart 2021;107:1240‚Äì5. https://doi.org/10.1136/heartjnl- 
2020-318869 
283. Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, et al. Phase 3 trial of 
interleukin-1 trap rilonacept in recurrent pericarditis. N Engl J Med 2021;384:31‚Äì41.  
https://doi.org/10.1056/NEJMoa2027892 
284. Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, et al. Effect of 
anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. JAMA 2016;316: 
1906‚Äì12. https://doi.org/10.1001/jama.2016.15826 
285. Brucato A, Wheeler A, Luis SA, Abbate A, Cremer PC, Zou L, et al. Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis. 
Heart 2023;109:297‚Äì304. https://doi.org/10.1136/heartjnl-2022-321328 
286. Collini V, Andreis A, De Biasio M, De Martino M, Isola M, Croatto N, et al. Efficacy of 
colchicine in addition to anakinra in patients with recurrent pericarditis. Open Heart 
2024;11:e002599. https://doi.org/10.1136/openhrt-2023-002599 
287. Vianello F, Cinetto F, Cavraro M, Battisti A, Castelli M, Imbergamo S, et al. Azathioprine 
in isolated recurrent pericarditis: a single centre experience. Int J Cardiol 2011;147: 
477‚Äì8. https://doi.org/10.1016/j.ijcard.2011.01.027 
288. Imazio M, Lazaros G, Picardi E, Vasileiou P, Carraro M, Tousoulis D, et al. Intravenous 
human immunoglobulins for refractory recurrent pericarditis: a systematic review of 
all published cases. J Cardiovasc Med (Hagerstown) 2016;17:263‚Äì9. https://doi.org/10. 
2459/JCM.0000000000000260 
289. Marcolongo R, Russo R, Laveder F, Noventa F, Agostini C. Immunosuppressive therapy prevents recurrent pericarditis. J Am Coll Cardiol 1995;26:1276‚Äì9. https://doi.org/ 
10.1016/0735-1097(95)00302-9 
290. Lazaros G, Antonopoulos AS, Antonatou K, Skendros P, Ritis K, Hadziyannis E, et al. 
Hydroxychloroquine for colchicine-resistant glucocorticoid-dependent idiopathic recurrent pericarditis: a pilot observational prospective study. Int J Cardiol 2020;311: 
77‚Äì82. https://doi.org/10.1016/j.ijcard.2020.03.069 
291. Lotrionte M, Biondi-Zoccai G, Imazio M, Castagno D, Moretti C, Abbate A, et al. 
International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences. Am Heart J 2010;160: 
662‚Äì70. https://doi.org/10.1016/j.ahj.2010.06.015 
292. Horneffer PJ, Miller RH, Pearson TA, Rykiel MF, Reitz BA, Gardner TJ. The effective 
treatment of postpericardiotomy syndrome after cardiac operations. A randomized 
placebo-controlled trial. J Thorac Cardiovasc Surg 1990;100:292‚Äì6. https://doi.org/10. 
1016/S0022-5223(19)35571-0 
293. Atluri P, Ullery BW, MacArthur JW, Goldstone AB, Fairman AS, Hiesinger W, et al. 
Rapid onset of fulminant myocarditis portends a favourable prognosis and the ability 
to bridge mechanical circulatory support to recovery. Eur J Cardiothorac Surg 2013; 
43:379‚Äì82. https://doi.org/10.1093/ejcts/ezs242 
294. Montero S, Aissaoui N, Tadi√© J-M, Bizouarn P, Scherrer V, Persichini R, et al. Fulminant 
giant-cell myocarditis on mechanical circulatory support: management and outcomes 
of a French multicentre cohort. Int J Cardiol 2018;253:105‚Äì12. https://doi.org/10.1016/ 
j.ijcard.2017.10.053 
295. Bernhardt AM, Copeland H, Deswal A, Gluck J, Givertz MM; Task Force 1; et al. The 
International Society for Heart and Lung Transplantation/Heart Failure Society of 
America Guideline on Acute Mechanical Circulatory Support. J Heart Lung 
Transplant 2023;42:e1‚Äìe64. https://doi.org/10.1016/j.healun.2022.10.028 
296. Lorusso R, Shekar K, MacLaren G, Schmidt M, Pellegrino V, Meyns B, et al. ELSO interim 
guidelines for venoarterial extracorporeal membrane oxygenation in adult cardiac patients. ASAIO J 2021;67:827‚Äì44. https://doi.org/10.1097/MAT.0000000000001510 
297. Lorusso R, Centofanti P, Gelsomino S, Barili F, Di Mauro M, Orlando P, et al. 
Venoarterial extracorporeal membrane oxygenation for acute fulminant myocarditis 
in adult patients: a 5-year multi-institutional experience. Ann Thorac Surg 2016;101: 
919‚Äì26. https://doi.org/10.1016/j.athoracsur.2015.08.014 
298. Mirabel M, Luyt C-E, Leprince P, Trouillet J-L, L√©ger P, Pavie A, et al. Outcomes, long- 
term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support. Crit Care Med 2011;39:1029‚Äì35. https://doi. 
org/10.1097/CCM.0b013e31820ead45 
299. Diddle JW, Almodovar MC, Rajagopal SK, Rycus PT, Thiagarajan RR. Extracorporeal 
membrane oxygenation for the support of adults with acute myocarditis. Crit Care 
Med 2015;43:1016‚Äì25. https://doi.org/10.1097/CCM.0000000000000920 
300. Nunez JI, Grandin EW, Reyes-Castro T, Sabe M, Quintero P, Motiwala S, et al. 
Outcomes with peripheral venoarterial extracorporeal membrane oxygenation for 
suspected acute myocarditis: 10-year experience from the extracorporeal life support 
organization registry. Circ Heart Fail 2023;16:e010152. https://doi.org/10.1161/ 
CIRCHEARTFAILURE.122.010152 
301. Strobbe A, Adriaenssens T, Bennett J, Dubois C, Desmet W, McCutcheon K, et al. 
Etiology and long-term outcome of patients undergoing pericardiocentesis. J Am 
Heart Assoc 2017;6:e007598. https://doi.org/10.1161/JAHA.117.007598 
302. Maisch B, Ristiƒá AD, Pankuweit S, Neubauer A, Moll R. Neoplastic pericardial effusion. 
Efficacy and safety of intrapericardial treatment with cisplatin. Eur Heart J 2002;23: 
1625‚Äì31. https://doi.org/10.1053/euhj.2002.3328 
303. Martinoni A, Cipolla CM, Cardinale D, Civelli M, Lamantia G, Colleoni M, et al. 
Long-term results of intrapericardial chemotherapeutic treatment of malignant 
pericardial effusions with thiotepa. Chest 2004;126:1412‚Äì6. https://doi.org/10.1378/ 
chest.126.5.1412 
304. Colleoni M, Martinelli G, Beretta F, Marone C, Gallino A, Fontana M, et al. Intracavitary 
chemotherapy with thiotepa in malignant pericardial effusions: an active and well- 
tolerated regimen. J Clin Oncol 1998;16:2371‚Äì6. https://doi.org/10.1200/JCO.1998. 
16.7.2371 
305. Kunitoh H, Tamura T, Shibata T, Imai M, Nishiwaki Y, Nishio M, et al. A randomised 
trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer 
(JCOG9811). Br J Cancer 2009;100:464‚Äì9. https://doi.org/10.1038/sj.bjc.6604866 
306. Shepherd FA, Morgan C, Evans WK, Ginsberg JF, Watt D, Murphy K. Medical management of malignant pericardial effusion by tetracycline sclerosis. Am J Cardiol 1987;60: 
1161‚Äì6. https://doi.org/10.1016/0002-9149(87)90411-5 
307. Beckmann E, Ismail I, Cebotari S, Busse A, Martens A, Shrestha M, et al. Right-sided 
heart failure and extracorporeal life support in patients undergoing pericardiectomy 
for constrictive pericarditis: a risk factor analysis for adverse outcome. Thorac 
Cardiovasc Surg 2017;65:662‚Äì70. https://doi.org/10.1055/s-0036-1593817 
308. Busch C, Penov K, Amorim PA, Garbade J, Davierwala P, Schuler GC, et al. Risk factors 
for mortality after pericardiectomy for chronic constrictive pericarditis in a large 
single-centre cohort. Eur J Cardiothorac Surg 2015;48:e110‚Äì6. https://doi.org/10. 
1093/ejcts/ezv322 
309. Vondran M, Rylski B, Berezowski M, Polycarpou A, Born F, Guenther S, et al. 
Preemptive extracorporeal life support for surgical treatment of severe constrictive 
pericarditis. Ann Thorac Surg 2019;108:1376‚Äì81. https://doi.org/10.1016/j.athoracsur. 
2019.03.105 
310. Saxena P, Joyce LD, Daly RC, Kushwaha SS, Schirger JA, Rosedahl J, et al. Cardiac transplantation for radiation-induced cardiomyopathy: the Mayo Clinic experience. Ann 
Thorac Surg 2014;98:2115‚Äì21. https://doi.org/10.1016/j.athoracsur.2014.06.056 
311. Al-Kazaz M, Klein AL, Oh JK, Crestanello JA, Cremer PC, Tong MZ, et al. Pericardial 
diseases and best practices for pericardiectomy: JACC state-of-the-art review. J Am 
Coll Cardiol 2024;84:561‚Äì80. https://doi.org/10.1016/j.jacc.2024.05.048 
312. Vistarini N, Chen C, Mazine A, Bouchard D, Hebert Y, Carrier M, et al. Pericardiectomy 
for constrictive pericarditis: 20 years of experience at the Montreal Heart Institute. Ann 
Thorac Surg 2015;100:107‚Äì13. https://doi.org/10.1016/j.athoracsur.2015.02.054 
313. Lee S, Lee J, Joo S, Park YK, Kim KM, Jung JC, et al. Impact of pericardial calcification on 
early postoperative outcomes after pericardiectomy: a retrospective observational 
study. J Cardiothorac Surg 2024;19:449. https://doi.org/10.1186/s13019-024-02842-4 
314. Yamamoto N, Ohara K, Nie M, Torii S, Inoue N, Miyaji K. For what type of constrictive 
pericarditis is the waffle procedure effective? Asian Cardiovasc Thorac Ann 2011;19: 
115‚Äì8. https://doi.org/10.1177/0218492311399496 
315. Matsuura K, Mogi K, Takahara Y. Off-pump waffle procedure using an ultrasonic scalpel for constrictive pericarditis. Eur J Cardiothorac Surg 2015;47:e220‚Äì2. https://doi.org/ 
10.1093/ejcts/ezu554 
316. Calderon-Rojas RD, Greason KL, King KS, Luis SA, Oh JK, Stulak JM, et al. Outcomes of 
tricuspid valve operation at the time of pericardiectomy for constrictive pericarditis. 
Ann Thorac Surg 2021;111:1252‚Äì7. https://doi.org/10.1016/j.athoracsur.2020.06.106 
317. Li T-T, Cheng J. Clinical analysis of temporary pacemaker implantation in 13 children. 
Transl Pediatr 2022;11:174‚Äì82. https://doi.org/10.21037/tp-21-586 
318. Suarez K, Banchs JE. A review of temporary permanent pacemakers and a comparison 
with conventional temporary pacemakers. J Innov Card Rhythm Manag 2019;10: 
3652‚Äì61. https://doi.org/10.19102/icrm.2019.100506 
319. Braun MU, Rauwolf T, Bock M, Kappert U, Boscheri A, Schnabel A, et al. Percutaneous 
lead implantation connected to an external device in stimulation-dependent patients 
with systemic infection‚Äîa prospective and controlled study. Pacing Clin 
Electrophysiol 2006;29:875‚Äì9. https://doi.org/10.1111/j.1540-8159.2006.00454.x 
320. Zei PC, Eckart RE, Epstein LM. Modified temporary cardiac pacing using transvenous 
active fixation leads and external re-sterilized pulse generators. J Am Coll Cardiol 2006; 
47:1487‚Äì9. https://doi.org/10.1016/j.jacc.2006.01.006 
321. Chung MK, Patton KK, Lau C-P, Forno ARJD, Al-Khatib SM, Arora V, et al. 2023 HRS/ 
APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm 2023;20:e17‚Äì91. https://doi.org/10.1016/j.hrthm. 
2023.03.1538 
322. Casella M, Bergonti M, Narducci ML, Persampieri S, Gasperetti A, Conte E, et al. Prior 
myocarditis and ventricular arrhythmias: the importance of scar pattern. Heart Rhythm 
2021;18:589‚Äì96. https://doi.org/10.1016/j.hrthm.2020.12.016 
323. Rav-Acha M, Shah K, Hasin T, Gumuser E, Tovia-Brodie O, Shauer A, et al. Incidence 
and predictors for recurrence of ventricular arrhythmia presenting during acute myocarditis: a multicenter study. JACC Clin Electrophysiol 2024;10:1161‚Äì74. https://doi.org/ 
10.1016/j.jacep.2024.02.027 
324. Sasko B, Patschan D, Nordbeck P, Seidlmayer L, Andresen H, J√§nsch M, et al. Secondary 
prevention of potentially life-threatening arrhythmia using implantable cardioverter 
defibrillators in patients with biopsy-proven viral myocarditis and preserved ejection 
fraction. Cardiology 2021;146:213‚Äì21. https://doi.org/10.1159/000511120 
325. Peretto G, Sala S, Carturan E, Rizzo S, Villatore A, De Luca G, et al. Clinical profiling and 
outcomes of viral myocarditis manifesting with ventricular arrhythmias. Eur Heart J 
Open 2023;3:oead132. https://doi.org/10.1093/ehjopen/oead132  
ESC Guidelines                                                                                                                                                                                               81


<!-- PAGE 82 -->

### Page 82

326. Ekstr√∂m K, Lehtonen J, Kandolin R, R√§is√§nen-Sokolowski A, Salmenkivi K, Kupari M. 
Incidence, risk factors, and outcome of life-threatening ventricular arrhythmias in giant 
cell myocarditis. Circ Arrhythm Electrophysiol 2016;9:e004559. https://doi.org/10.1161/ 
CIRCEP.116.004559 
327. Tscholl V, Wielander D, Kelch F, Stroux A, Attanasio P, Tsch√∂pe C, et al. Benefit of a 
wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis. ESC Heart Fail 2021;8:2428‚Äì37. https://doi.org/10.1002/ehf2. 
13353 
328. Blaschke F, Lacour P, Dang PL, Parwani AS, Hohendanner F, Walter T, et al. Wearable 
cardioverter-defibrillator: friend or foe in suspected myocarditis? ESC Heart Fail 2021; 
8:2591‚Äì6. https://doi.org/10.1002/ehf2.13340 
329. W√§√ünig NK, G√ºnther M, Quick S, Pfluecke C, Rottst√§dt F, Szymkiewicz SJ, 
et al. Experience with the wearable cardioverter-defibrillator in patients at high risk 
for sudden cardiac death. Circulation 2016;134:635‚Äì43. https://doi.org/10.1161/ 
CIRCULATIONAHA.115.019124 
330. El-Battrawy I, Koepsel K, Tenbrink D, Kovacs B, Dreher TC, Blockhaus C, et al. Use of 
the wearable cardioverter-defibrillator among patients with myocarditis and reduced 
ejection fraction or ventricular tachyarrhythmia: data from a multicenter registry. J Am 
Heart Assoc 2023;12:e030615. https://doi.org/10.1161/JAHA.123.030615 
331. Peretto G, Gulletta S, Slavich M, Campochiaro C, Vignale D, De Luca G, et al. Exercise 
stress test late after arrhythmic versus nonarrhythmic presentation of myocarditis. 
J Pers Med 2022;12:1702. https://doi.org/10.3390/jpm12101702 
332. Yang F, Wang J, Li W, Xu Y, Wan K, Zeng R, et al. The prognostic value of late gadolinium enhancement in myocarditis and clinically suspected myocarditis: systematic review and meta-analysis. Eur Radiol 2020;30:2616‚Äì26. https://doi.org/10.1007/s00330- 
019-06643-5 
333. Georgiopoulos G, Figliozzi S, Sanguineti F, Aquaro GD, di Bella G, Stamatelopoulos K, 
et al. Prognostic impact of late gadolinium enhancement by cardiovascular magnetic 
resonance in myocarditis. Circ Cardiovasc Imaging 2021;14:e011492. https://doi.org/ 
10.1161/CIRCIMAGING.120.011492 
334. Schumm J, Greulich S, Wagner A, Gr√ºn S, Ong P, Bentz K, et al. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. 
J Cardiovasc Magn Reson 2014;16:14. https://doi.org/10.1186/1532-429X-16-14 
335. Salamanca J, D√≠ez-Villanueva P, Mart√≠nez P, Cecconi A, Gonz√°lez de Marcos B, Reyes G, 
et al. COVID-19 ‚Äòfulminant myocarditis‚Äô successfully treated with temporary mechanical circulatory support. JACC Cardiovasc Imaging 2020;13:2457‚Äì9. https://doi.org/10. 
1016/j.jcmg.2020.05.003 
336. Pavlicek V, Kindermann I, Wintrich J, Mahfoud F, Klingel K, B√∂hm M, et al. Ventricular 
arrhythmias and myocardial inflammation: long-term follow-up of patients with suspected myocarditis. Int J Cardiol 2019;274:132‚Äì7. https://doi.org/10.1016/j.ijcard. 
2018.07.142 
337. Imazio M, Brucato A, Spodick DH, Adler Y. Prognosis of myopericarditis as determined from previously published reports. J Cardiovasc Med (Hagerstown) 2014;15: 
835‚Äì9. https://doi.org/10.2459/JCM.0000000000000082 
338. Castrichini M, Porcari A, Baggio C, Gagno G, Maione D, Barbati G, et al. Sex differences 
in natural history of cardiovascular magnetic resonance- and biopsy-proven lymphocytic myocarditis. ESC Heart Fail 2022;9:4010‚Äì9. https://doi.org/10.1002/ehf2.14102 
339. Gr√ºn S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, et al. Long-term 
follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete 
recovery. J Am Coll Cardiol 2012;59:1604‚Äì15. https://doi.org/10.1016/j.jacc.2012.01. 
007 
340. Ammirati E, Varrenti M, Sormani P, Bernasconi D, Moro C, Grosu A, et al. Long-term 
prognostic performance of cardiac magnetic resonance imaging markers versus complicated clinical presentation after an acute myocarditis. Int J Cardiol 2024;417:132567.  
https://doi.org/10.1016/j.ijcard.2024.132567 
341. Greulich S, Seitz A, M√ºller KAL, Gr√ºn S, Ong P, Ebadi N, et al. Predictors of mortality in 
patients with biopsy-proven viral myocarditis: 10-year outcome data. J Am Heart Assoc 
2020;9:e015351. https://doi.org/10.1161/JAHA.119.015351 
342. Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, et al. 
Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. 
Circulation 
2006;114:1581‚Äì90. 
https://doi.org/10.1161/CIRCULATIONAHA.105. 
606509 
343. Narducci ML, Pelargonio G, La Rosa G, Inzani F, d‚ÄôAmati G, Novelli V, et al. Role of 
extensive diagnostic workup in young athletes and nonathletes with complex ventricular arrhythmias. Heart Rhythm 2020;17:230‚Äì7. https://doi.org/10.1016/j.hrthm.2019. 
08.022 
344. Maleszewski JJ, Orellana VM, Hodge DO, Kuhl U, Schultheiss H-P, Cooper LT. 
Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J 
Cardiol 2015;115:1733‚Äì8. https://doi.org/10.1016/j.amjcard.2015.03.023 
345. Kim M-J, Jung HO, Kim H, Bae Y, Lee SY, Jeon DS. 10-Year survival outcome after clinically suspected acute myocarditis in adults: a nationwide study in the pre-COVID-19 
era. PLoS One 2023;18:e0281296. https://doi.org/10.1371/journal.pone.0281296 
346. Kyt√∂ V, Sipil√§ J, Rautava P. Rate and patient features associated with recurrence of 
acute myocarditis. Eur J Intern Med 2014;25:946‚Äì50. https://doi.org/10.1016/j.ejim. 
2014.11.001 
347. Imazio M, Brucato A, Maestroni S, Cumetti D, Belli R, Trinchero R, et al. Risk of constrictive pericarditis after acute pericarditis. Circulation 2011;124:1270‚Äì5. https://doi. 
org/10.1161/CIRCULATIONAHA.111.018580 
348. Yesilyaprak A, Kumar AK, Agrawal A, Furqan MM, Verma BR, Syed AB, et al. Predicting 
long-term clinical outcomes of patients with recurrent pericarditis. J Am Coll Cardiol 
2024;84:1193‚Äì204. https://doi.org/10.1016/j.jacc.2024.05.072 
349. Caforio ALP, Adler Y, Agostini C, Allanore Y, Anastasakis A, Arad M, et al. Diagnosis 
and management of myocardial involvement in systemic immune-mediated diseases: a 
position statement of the European Society of Cardiology Working Group on 
Myocardial and Pericardial Disease. Eur Heart J 2017;38:2649‚Äì62. https://doi.org/10. 
1093/eurheartj/ehx321 
350. Cheng C-Y, Baritussio A, Giordani AS, Iliceto S, Marcolongo R, Caforio ALP. 
Myocarditis in systemic immune-mediated diseases: prevalence, characteristics and 
prognosis. A systematic review. Autoimmun Rev 2022;21:103037. https://doi.org/10. 
1016/j.autrev.2022.103037 
351. Mavrogeni S, Bratis K, Sfendouraki E, Papadopoulou E, Kolovou G. Myopericarditis, 
as the first sign of rheumatoid arthritis relapse, evaluated by cardiac magnetic resonance. Inflamm Allergy Drug Targets 2013;12:206‚Äì11. https://doi.org/10.2174/ 
1871528111312030008 
352. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71: 
1400‚Äì12. https://doi.org/10.1002/art.40930 
353. Jia E, Geng H, Liu Q, Xiao Y, Zhang Y, Xie J, et al. Cardiac manifestations of Han 
Chinese patients with systemic lupus erythematosus: a retrospective study. Ir J Med 
Sci 2019;188:801‚Äì6. https://doi.org/10.1007/s11845-018-1934-7 
354. Tanwani J, Tselios K, Gladman DD, Su J, Urowitz MB. Lupus myocarditis: a single center 
experience and a comparative analysis of observational cohort studies. Lupus 2018;27: 
1296‚Äì302. https://doi.org/10.1177/0961203318770018 
355. Thomas G, Cohen Aubart F, Chiche L, Haroche J, Hi√© M, Hervier B, et al. Lupus myocarditis: initial presentation and longterm outcomes in a multicentric series of 29 patients. J Rheumatol 2017;44:24‚Äì32. https://doi.org/10.3899/jrheum.160493 
356. Mathian A, Mouries-Martin S, Dorgham K, Devilliers H, Yssel H, Garrido Castillo L, 
et al. Ultrasensitive serum interferon-Œ± quantification during SLE remission identifies 
patients at risk for relapse. Ann Rheum Dis 2019;78:1669‚Äì76. https://doi.org/10. 
1136/annrheumdis-2019-215571 
357. Mathian A, Mouries-Martin S, Dorgham K, Devilliers H, Barnabei L, Ben Salah E, et al. 
Monitoring disease activity in systemic lupus erythematosus with single-molecule array 
digital enzyme-linked immunosorbent assay quantification of serum interferon-Œ±. 
Arthritis Rheumatol 2019;71:756‚Äì65. https://doi.org/10.1002/art.40792 
358. du Toit R, Herbst PG, Ackerman C, Pecoraro AJ, Claassen D, Cyster HP, et al. 
Outcome of clinical and subclinical myocardial injury in systemic lupus erythematosus‚Äîa prospective cohort study. Lupus 2021;30:256‚Äì68. https://doi.org/10.1177/ 
0961203320976960 
359. Hinojar R, Foote L, Sangle S, Marber M, Mayr M, Carr-White G, et al. Native T1 and T2 
mapping by CMR in lupus myocarditis: disease recognition and response to treatment. 
Int J Cardiol 2016;222:717‚Äì26. https://doi.org/10.1016/j.ijcard.2016.07.182 
360. Sacr√© K, Brihaye B, Hyafil F, Serfaty J-M, Escoubet B, Zennaro M-C, et al. Asymptomatic 
myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study. Arthritis Rheum 2010;62:2093‚Äì100. https://doi.org/10. 
1002/art.27488 
361. Pineton de Chambrun M, Larcher R, P√®ne F, Argaud L, Mayaux J, Jamme M, et al. 
In-hospital mortality-associated factors in patients with thrombotic antiphospholipid 
syndrome requiring ICU admission. Chest 2020;157:1158‚Äì66. https://doi.org/10. 
1016/j.chest.2019.11.010 
362. Yong WC, Sanguankeo A, Upala S. Association between primary Sjogren‚Äôs syndrome, 
arterial stiffness, and subclinical atherosclerosis: a systematic review and meta-analysis. 
Clin Rheumatol 2019;38:447‚Äì55. https://doi.org/10.1007/s10067-018-4265-1 
363. Lazzerini PE, Murthy Ginjupalli VK, Srivastava U, Bertolozzi I, Bacarelli MR, Verrengia 
D, et al. Anti-Ro/SSA antibodies blocking calcium channels as a potentially reversible 
cause of atrioventricular block in adults. JACC Clin Electrophysiol 2023;9:1631‚Äì48.  
https://doi.org/10.1016/j.jacep.2023.03.007 
364. Bruni C, Buch MH, Furst DE, De Luca G, Djokovic A, Dumitru RB, et al. Primary systemic sclerosis heart involvement: a systematic literature review and preliminary data- 
driven, consensus-based WSF/HFA definition. J Scleroderma Relat Disord 2022;7:24‚Äì32.  
https://doi.org/10.1177/23971983211053246 
365. Krumm P, Mueller KAL, Klingel K, Kramer U, Horger MS, Zitzelsberger T, et al. 
Cardiovascular magnetic resonance patterns of biopsy proven cardiac involvement 
in systemic sclerosis. J Cardiovasc Magn Reson 2016;18:70. https://doi.org/10.1186/ 
s12968-016-0289-3 
366. De Luca G, Campochiaro C, De Santis M, Sartorelli S, Peretto G, Sala S, et al. Systemic 
sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. Rheumatology (Oxford) 2020;59:2523‚Äì33. https://doi. 
org/10.1093/rheumatology/kez658 
367. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic 
sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian


<!-- PAGE 83 -->

### Page 83

patients. Medicine (Baltimore) 2002;81:139‚Äì53. https://doi.org/10.1097/00005792- 
200203000-00004 
368. Bruni C, Buch MH, Djokovic A, De Luca G, Dumitru RB, Giollo A, et al. Consensus on 
the assessment of systemic sclerosis-associated primary heart involvement: World 
Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, 
and follow-up assessment. J Scleroderma Relat Disord 2023;8:169‚Äì82. https://doi.org/ 
10.1177/23971983231163413 
369. Fairley JL, Wicks I, Peters S, Day J. Defining cardiac involvement in idiopathic inflammatory myopathies: a systematic review. Rheumatology (Oxford) 2021;61:103‚Äì20. https:// 
doi.org/10.1093/rheumatology/keab573 
370. Dank√≥ K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients 
with idiopathic inflammatory myopathies according to clinical features: a longitudinal 
study of 162 cases. Medicine (Baltimore) 2004;83:35‚Äì42. https://doi.org/10.1097/01. 
md.0000109755.65914.5e 
371. Allanore Y, Vignaux O, Arnaud L, Pu√©chal X, Pavy S, Duboc D, et al. Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related 
myocarditis evaluated by magnetic resonance imaging. Ann Rheum Dis 2006;65: 
249‚Äì52. https://doi.org/10.1136/ard.2005.038679 
372. Zhang L, Wang G, Ma L, Zu N. Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review. Clin Cardiol 2012;35:686‚Äì91. https://doi.org/10.1002/clc. 
22026 
373. Groh M, Masciocco G, Kirchner E, Kristen A, Pellegrini C, Varnous S, et al. Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churg‚Äì 
Strauss syndrome). J Heart Lung Transplant 2014;33:842‚Äì50. https://doi.org/10.1016/ 
j.healun.2014.02.023 
374. Bojkova D, Wagner JUG, Shumliakivska M, Aslan GS, Saleem U, Hansen A, et al. 
SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. 
Cardiovasc Res 2020;116:2207‚Äì15. https://doi.org/10.1093/cvr/cvaa267 
375. Peretto G, Villatore A, Rizzo S, Esposito A, De Luca G, Palmisano A, et al. The spectrum of COVID-19-associated myocarditis: a patient-tailored multidisciplinary approach. J Clin Med 2021;10:1974. https://doi.org/10.3390/jcm10091974 
376. Weckbach LT, Curta A, Bieber S, Kraechan A, Brado J, Hellmuth JC, et al. Myocardial 
inflammation and dysfunction in COVID-19-associated myocardial injury. Circ 
Cardiovasc Imaging 2021;14:e012220. https://doi.org/10.1161/CIRCIMAGING.120. 
011713 
377. Basso C, Leone O, Rizzo S, De Gaspari M, van der Wal A, Aubry M-C, et al. 
Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J 2020;41:3827‚Äì35. https://doi.org/10.1093/ 
eurheartj/ehaa664 
378. Halushka MK, Vander Heide RS. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. Cardiovasc Pathol 2021;50: 
107300. https://doi.org/10.1016/j.carpath.2020.107300 
379. Lindner D, Fitzek A, Br√§uninger H, Aleshcheva G, Edler C, Meissner K, et al. 
Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy 
cases. JAMA Cardiol 2020;5:1281‚Äì5. https://doi.org/10.1001/jamacardio.2020.3551 
380. Aquaro GD, Licordari R, Todiere G, Ianni U, Dellegrotaglie S, Restivo L, et al. Incidence 
of acute myocarditis and pericarditis during the coronavirus disease 2019 pandemic: 
comparison with the prepandemic period. J Cardiovasc Med (Hagerstown) 2022;23: 
447‚Äì53. https://doi.org/10.2459/JCM.0000000000001330 
381. Boehmer TK, Kompaniyets L, Lavery AM, Hsu J, Ko JY, Yusuf H, et al. Association between COVID-19 and myocarditis using hospital-based administrative data‚ÄîUnited 
States, March 2020‚ÄìJanuary 2021. MMWR Morb Mortal Wkly Rep 2021;70:1228‚Äì32.  
https://doi.org/10.15585/mmwr.mm7035e5 
382. Daniels CJ, Rajpal S, Greenshields JT, Rosenthal GL, Chung EH, Terrin M, et al. 
Prevalence of clinical and subclinical myocarditis in competitive athletes with recent 
SARS-CoV-2 infection: results from the big ten COVID-19 cardiac registry. JAMA 
Cardiol 2021;6:1078‚Äì87. https://doi.org/10.1001/jamacardio.2021.2065 
383. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. 
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. 
Lancet Rheumatol 2020;2:e325‚Äì31. https://doi.org/10.1016/S2665-9913(20)30127-2 
384. REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol 
AD, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N 
Engl J Med 2021;384:1491‚Äì502. https://doi.org/10.1056/NEJMoa2100433 
385. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association 
between early treatment with tocilizumab and mortality among critically ill patients 
with COVID-19. JAMA Intern Med 2021;181:41‚Äì51. https://doi.org/10.1001/ 
jamainternmed.2020.6252 
386. Klingel K, Hohenadl C, Canu A, Albrecht M, Seemann M, Mall G, et al. Ongoing 
enterovirus-induced myocarditis is associated with persistent heart muscle infection: 
quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl 
Acad Sci U S A 1992;89:314‚Äì8. https://doi.org/10.1073/pnas.89.1.314 
387. Schowengerdt KO, Ni J, Denfield SW, Gajarski RJ, Bowles NE, Rosenthal G, et al. 
Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation 1997;96: 
3549‚Äì54. https://doi.org/10.1161/01.cir.96.10.3549 
388. Bock C-T, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J 
Med 2010;362:1248‚Äì9. https://doi.org/10.1056/NEJMc0911362 
389. Huang C-H, Vallejo JG, Kollias G, Mann DL. Role of the innate immune system in acute 
viral myocarditis. Basic Res Cardiol 2009;104:228‚Äì37. https://doi.org/10.1007/s00395- 
008-0765-5 
390. Corsten MF, Papageorgiou A, Verhesen W, Carai P, Lindow M, Obad S, et al. 
MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury 
and dysfunction during acute viral myocarditis. Circ Res 2012;111:415‚Äì25. https://doi. 
org/10.1161/CIRCRESAHA.112.267443 
391. Goldberg L, Tirosh-Wagner T, Vardi A, Abbas H, Pillar N, Shomron N, et al. Circulating 
microRNAs: a potential biomarker for cardiac damage, inflammatory response, and 
left ventricular function recovery in pediatric viral myocarditis. J Cardiovasc Transl 
Res 2018;11:319‚Äì28. https://doi.org/10.1007/s12265-018-9814-0 
392. Mueller KAL, Mueller II, Eppler D, Zuern CS, Seizer P, Kramer U, et al. Clinical and 
histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy. PLoS One 2015;10:e0126707. https://doi.org/10.1371/journal.pone. 
0126707 
393. Wakafuji S, Okada R. Twenty year autopsy statistics of myocarditis incidence in Japan. 
Jpn Circ J 1986;50:1288‚Äì93. https://doi.org/10.1253/jcj.50.1288 
394. Vaideeswar P, Cooper LT. Giant cell myocarditis: clinical and pathological features in 
an Indian population. Cardiovasc Pathol 2013;22:70‚Äì4. https://doi.org/10.1016/j. 
carpath.2012.06.003 
395. Caforio ALP, Angelini A, Blank M, Shani A, Kivity S, Goddard G, et al. Passive transfer of 
affinity-purified anti-heart autoantibodies (AHA) from sera of patients with myocarditis induces experimental myocarditis in mice. Int J Cardiol 2015;179:166‚Äì77. https://doi. 
org/10.1016/j.ijcard.2014.10.165 
396. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as 
causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm 
Electrophysiol 2011;4:303‚Äì9. https://doi.org/10.1161/CIRCEP.110.959254 
397. Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation 2016;134:e579‚Äìe646. https:// 
doi.org/10.1161/CIR.0000000000000455 
398. Liu S, Zheng L, Shen L, Wu L, Yao Y. Clinical identification and characteristic analysis of 
giant cell myocarditis in 12 cases. Front Cardiovasc Med 2021;8:649094. https://doi.org/ 
10.3389/fcvm.2021.649094 
399. Okura Y, Dec GW, Hare JM, Kodama M, Berry GJ, Tazelaar HD, et al. A clinical and 
histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. 
J Am Coll Cardiol 2003;41:322‚Äì9. https://doi.org/10.1016/s0735-1097(02)02715-8 
400. Berthelot-Richer M, O‚ÄôConnor K, Bernier M, Trahan S, Couture C, Dubois M, et al. 
When should we consider the diagnosis of giant cell myocarditis? Revisiting ‚Äòclassic‚Äô 
echocardiographic and clinical features of this rare pathology. Exp Clin Transplant 
2014;12:565‚Äì8. https://doi.org/10.6002/ect.2013.0218 
401. Ekstr√∂m K, Lehtonen J, Kandolin R, R√§is√§nen-Sokolowski A, Salmenkivi K, Kupari M. 
Long-term outcome and its predictors in giant cell myocarditis. Eur J Heart Fail 
2016;18:1452‚Äì8. https://doi.org/10.1002/ejhf.606 
402. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of 
endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and 
the European Society of Cardiology. Endorsed by the Heart Failure Society of America 
and the Heart Failure Association of the European Society of Cardiology. J Am Coll 
Cardiol 2007;50:1914‚Äì31. https://doi.org/10.1016/j.jacc.2007.09.008 
403. Cooper LT, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC, et al. 
Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008;102: 
1535‚Äì9. https://doi.org/10.1016/j.amjcard.2008.07.041 
404. Patel PM, Saxena A, Wood CT, O‚ÄôMalley TJ, Maynes EJ, Entwistle JWC, et al. 
Outcomes of mechanical circulatory support for giant cell myocarditis: a systematic 
review. J Clin Med 2020;9:3905. https://doi.org/10.3390/jcm9123905 
405. Bobbio E, Bj√∂rkenstam M, Nwaru BI, Giallauria F, Hessman E, Bergh N, et al. Short- and 
long-term outcomes after heart transplantation in cardiac sarcoidosis and giant-cell 
myocarditis: a systematic review and meta-analysis. Clin Res Cardiol 2022;111: 
125‚Äì40. https://doi.org/10.1007/s00392-021-01920-0 
406. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Bresnitz EA, et al. 
Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir 
Crit Care Med 2001;164:1885‚Äì9. https://doi.org/10.1164/ajrccm.164.10.2104046 
407. Lehtonen J, Uusitalo V, P√∂yh√∂nen P, M√§yr√§np√§√§ MI, Kupari M. Cardiac sarcoidosis: 
phenotypes, diagnosis, treatment, and prognosis. Eur Heart J 2023;44:1495‚Äì510.  
https://doi.org/10.1093/eurheartj/ehad067 
408. Okasha O, Kazmirczak F, Chen K-HA, Farzaneh-Far A, Shenoy C. Myocardial involvement in patients with histologically diagnosed cardiac sarcoidosis: a systematic review 
and meta-analysis of gross pathological images from autopsy or cardiac transplantation 
cases. J Am Heart Assoc 2019;8:e011253. https://doi.org/10.1161/JAHA.118.011253 
409. Iwai K, Tachibana T, Takemura T, Matsui Y, Kitalchi M, Kawabata Y. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol 
Jpn 1993;43:372‚Äì6. https://doi.org/10.1111/j.1440-1827.1993.tb01148.x  
ESC Guidelines                                                                                                                                                                                               83


<!-- PAGE 84 -->

### Page 84

410. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 
38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 1995;119: 
167‚Äì72. 
411. Philips B, Madhavan S, James CA, te Riele ASJM, Murray B, Tichnell C, et al. 
Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: 
distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol 
2014;7:230‚Äì6. https://doi.org/10.1161/CIRCEP.113.000932 
412. Gasperetti A, Rossi VA, Chiodini A, Casella M, Costa S, Akdis D, et al. Differentiating 
hereditary arrhythmogenic right ventricular cardiomyopathy from cardiac sarcoidosis 
fulfilling 2010 ARVC task force criteria. Heart Rhythm 2021;18:231‚Äì8. https://doi.org/ 
10.1016/j.hrthm.2020.09.015 
413. Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, Lazzari MD, et al. 
Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria. Int J Cardiol 2020; 
319:106‚Äì14. https://doi.org/10.1016/j.ijcard.2020.06.005 
414. Bagwan IN, Hooper LVB, Sheppard MN. Cardiac sarcoidosis and sudden death. The 
heart may look normal or mimic other cardiomyopathies. Virchows Arch 2011;458: 
671‚Äì8. https://doi.org/10.1007/s00428-010-1003-8 
415. Athwal PSS, Chhikara S, Ismail MF, Ismail K, Ogugua FM, Kazmirczak F, et al. 
Cardiovascular magnetic resonance imaging phenotypes and long-term outcomes in 
patients with suspected cardiac sarcoidosis. JAMA Cardiol 2022;7:1057‚Äì66. https:// 
doi.org/10.1001/jamacardio.2022.2981 
416. Azoulay L-D, Waintraub X, Haroche J, Amoura Z, Cohen Aubart F. Factors associated 
with implantable cardioverter defibrillators appropriate therapy in cardiac sarcoidosis: 
a meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis 2020;37:17‚Äì23. https://doi.org/10. 
36141/svdld.v37i1.8271 
417. Sharma R, Kouranos V, Cooper LT, Metra M, Ristic A, Heidecker B, et al. Management 
of cardiac sarcoidosis. Eur Heart J 2024;45:2697‚Äì726. https://doi.org/10.1093/ 
eurheartj/ehae356 
418. Selan JC, Michaelson M, Fanburg BL, Estes NAM. Evaluation and management of heart 
rhythm disturbances due to cardiac sarcoidosis. Heart Lung Circ 2014;23:1100‚Äì9.  
https://doi.org/10.1016/j.hlc.2014.07.065 
419. Ardehali H, Howard DL, Hariri A, Qasim A, Hare JM, Baughman KL, et al. A positive 
endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients 
with initially unexplained cardiomyopathy. Am Heart J 2005;150:459‚Äì63. https://doi. 
org/10.1016/j.ahj.2004.10.006 
420. Kouranos V, Tzelepis GE, Rapti A, Mavrogeni S, Aggeli K, Douskou M, et al. 
Complementary role of CMR to conventional screening in the diagnosis and prognosis 
of cardiac sarcoidosis. JACC Cardiovasc Imaging 2017;10:1437‚Äì47. https://doi.org/10. 
1016/j.jcmg.2016.11.019 
421. Adhaduk M, Paudel B, Khalid MU, Ashwath M, Mansour S, Liu K. Comparison of cardiac magnetic resonance imaging and fluorodeoxyglucose positron emission tomography in the assessment of cardiac sarcoidosis: meta-analysis and systematic review. 
J Nucl Cardiol 2023;30:1574‚Äì87. https://doi.org/10.1007/s12350-022-03129-8 
422. Orii M, Tanimoto T, Ota S, Takagi H, Tanaka R, Fujiwara J, et al. Diagnostic accuracy of 
cardiac magnetic resonance imaging for cardiac sarcoidosis in complete heart block patients implanted with magnetic resonance-conditional pacemaker. J Cardiol 2020;76: 
191‚Äì7. https://doi.org/10.1016/j.jjcc.2020.02.014 
423. Stanton KM, Ganigara M, Corte P, Celermajer DS, McGuire MA, Torzillo PJ, et al. The 
utility of cardiac magnetic resonance imaging in the diagnosis of cardiac sarcoidosis. 
Heart Lung Circ 2017;26:1191‚Äì9. https://doi.org/10.1016/j.hlc.2017.02.021 
424. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of 
myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969‚Äì77.  
https://doi.org/10.1161/CIRCULATIONAHA.109.851352 
425. Zhang J, Li Y, Xu Q, Xu B, Wang H. Cardiac magnetic resonance imaging for diagnosis 
of cardiac sarcoidosis: a meta-analysis. Can Respir J 2018;2018:7457369. https://doi. 
org/10.1155/2018/7457369 
426. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 
18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012;53:241‚Äì8. https://doi.org/10. 
2967/jnumed.111.090662 
427. Dweck MR, Abgral R, Trivieri MG, Robson PM, Karakatsanis N, Mani V, et al. Hybrid 
magnetic resonance imaging and positron emission tomography with fluorodeoxyglucose to diagnose active cardiac sarcoidosis. JACC Cardiovasc Imaging 2018;11:94‚Äì107.  
https://doi.org/10.1016/j.jcmg.2017.02.021 
428. Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 
18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989‚Äì98.  
https://doi.org/10.2967/jnumed.104.013352 
429. Vita T, Okada DR, Veillet-Chowdhury M, Bravo PE, Mullins E, Hulten E, et al. 
Complementary value of cardiac magnetic resonance imaging and positron emission 
tomography/computed tomography in the assessment of cardiac sarcoidosis. Circ 
Cardiovasc Imaging 2018;11:e007030. https://doi.org/10.1161/CIRCIMAGING.117. 
007030 
430. Agoston-Coldea L, Kouaho S, Sacre K, Dossier A, Escoubet B, Chillon S, et al. High 
mass (>18 g) of late gadolinium enhancement on CMR imaging is associated with major cardiac events on long-term outcome in patients with biopsy-proven extracardiac 
sarcoidosis. Int J Cardiol 2016;222:950‚Äì6. https://doi.org/10.1016/j.ijcard.2016.07.233 
431. Greulich S, Deluigi CC, Gloekler S, Wahl A, Z√ºrn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc 
Imaging 2013;6:501‚Äì11. https://doi.org/10.1016/j.jcmg.2012.10.021 
432. Nadel J, Lancefield T, Voskoboinik A, Taylor AJ. Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with 
long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J Cardiovasc 
Imaging 2015;16:634‚Äì41. https://doi.org/10.1093/ehjci/jeu294 
433. Murtagh G, Laffin LJ, Beshai JF, Maffessanti F, Bonham CA, Patel AV, et al. Prognosis of 
myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging 
2016;9:e003738. https://doi.org/10.1161/CIRCIMAGING.115.003738 
434. Coleman GC, Shaw PW, Balfour PC, Gonzalez JA, Kramer CM, Patel AR, et al. 
Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis. 
JACC Cardiovasc Imaging 2017;10:411‚Äì20. https://doi.org/10.1016/j.jcmg.2016.05.009 
435. Smedema J-P, van Geuns R-J, Ector J, Heidbuchel H, Ainslie G, Crijns HJGM. Right ventricular involvement and the extent of left ventricular enhancement with magnetic resonance predict adverse outcome in pulmonary sarcoidosis. ESC Heart Fail 2018;5: 
157‚Äì71. https://doi.org/10.1002/ehf2.12201 
436. Velangi PS, Chen K-HA, Kazmirczak F, Okasha O, von Wald L, Roukoz H, et al. Right 
ventricular abnormalities on cardiovascular magnetic resonance imaging in patients 
with sarcoidosis. JACC Cardiovasc Imaging 2020;13:1395‚Äì405. https://doi.org/10. 
1016/j.jcmg.2019.12.011 
437. Greulich S, Kitterer D, Latus J, Aguor E, Steubing H, Kaesemann P, et al. 
Comprehensive cardiovascular magnetic resonance assessment in patients with sarcoidosis and preserved left ventricular ejection fraction. Circ Cardiovasc Imaging 
2016;9:e005022. https://doi.org/10.1161/CIRCIMAGING.116.005022 
438. Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G, Nagel E. T1 and T2 mapping 
in recognition of early cardiac involvement in systemic sarcoidosis. Radiology 2017;285: 
63‚Äì72. https://doi.org/10.1148/radiol.2017162732 
439. Crouser ED, Ruden E, Julian MW, Raman SV. Resolution of abnormal cardiac MRI T2 
signal following immune suppression for cardiac sarcoidosis. J Investig Med 2016;64: 
1148‚Äì50. https://doi.org/10.1136/jim-2016-000144 
440. Greulich S, Gatidis S, Gr√§ni C, Blankstein R, Glatthaar A, Mezger K, et al. Hybrid cardiac 
magnetic resonance/fluorodeoxyglucose positron emission tomography to differentiate active from chronic cardiac sarcoidosis. JACC Cardiovasc Imaging 2022;15:445‚Äì56.  
https://doi.org/10.1016/j.jcmg.2021.08.018 
441. Crouser ED, Ono C, Tran T, He X, Raman SV. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med 
2014;189:109‚Äì12. https://doi.org/10.1164/rccm.201309-1668LE 
442. Cheung E, Ahmad S, Aitken M, Chan R, Iwanochko RM, Balter M, et al. Combined simultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the 
diagnosis and prognosis of suspected cardiac sarcoidosis. Eur J Hybrid Imaging 2021; 
5:24. https://doi.org/10.1186/s41824-021-00119-w 
443. Wicks EC, Menezes LJ, Barnes A, Mohiddin SA, Sekhri N, Porter JC, et al. Diagnostic 
accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis. Eur 
Heart J Cardiovasc Imaging 2018;19:757‚Äì67. https://doi.org/10.1093/ehjci/jex340 
444. Aitken M, Davidson M, Chan MV, Urzua Fresno C, Vasquez LI, Huo YR, et al. 
Prognostic value of cardiac MRI and FDG PET in cardiac sarcoidosis: a systematic review and meta-analysis. Radiology 2023;307:e222483. https://doi.org/10.1148/radiol. 
222483 
445. Mc Ardle BA, Birnie DH, Klein R, de Kemp RA, Leung E, Renaud J, et al. Is there an 
association between clinical presentation and the location and extent of myocardial 
involvement of cardiac sarcoidosis as assessed by 18F-fluorodoexyglucose positron 
emission tomography? Circ Cardiovasc Imaging 2013;6:617‚Äì26. https://doi.org/10. 
1161/CIRCIMAGING.112.000289 
446. Muser D, Santangeli P, Castro SA, Liang JJ, Enriquez A, Werner TJ, et al. Prognostic role 
of serial quantitative evaluation of 18F-fluorodeoxyglucose uptake by PET/CT in patients with cardiac sarcoidosis presenting with ventricular tachycardia. Eur J Nucl 
Med Mol Imaging 2018;45:1394‚Äì404. https://doi.org/10.1007/s00259-018-4001-8 
447. Ahmed AI, Abebe AT, Han Y, Alnabelsi T, Agrawal T, Kassi M, et al. The prognostic role 
of cardiac positron emission tomography imaging in patients with sarcoidosis: a systematic review. J Nucl Cardiol 2021;28:1545‚Äì52. https://doi.org/10.1007/s12350-021- 
02681-z 
448. Flores RJ, Flaherty KR, Jin Z, Bokhari S. The prognostic value of quantitating and localizing F-18 FDG uptake in cardiac sarcoidosis. J Nucl Cardiol 2020;27:2003‚Äì10. https:// 
doi.org/10.1007/s12350-018-01504-y 
449. Sperry BW, Tamarappoo BK, Oldan JD, Javed O, Culver DA, Brunken R, et al. 
Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F‚Äì 
FDG PET scans for suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2018;11: 
336‚Äì45. https://doi.org/10.1016/j.jcmg.2017.04.020 
450. Osborne MT, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC, et al. 
Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with 
cardiac sarcoidosis. J Nucl Cardiol 2014;21:166‚Äì74. https://doi.org/10.1007/s12350- 
013-9828-6


<!-- PAGE 85 -->

### Page 85

451. Birnie D, Beanlands RSB, Nery P, Aaron SD, Culver DA, DeKemp RA, et al. Cardiac 
sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT). Am Heart J 
2020;220:246‚Äì52. https://doi.org/10.1016/j.ahj.2019.10.003 
452. Nordenswan H-K, Lehtonen J, Ekstr√∂m K, Kandolin R, Simonen P, M√§yr√§np√§√§ M, et al. 
Outcome of cardiac sarcoidosis presenting with high-grade atrioventricular block. Circ 
Arrhythm 
Electrophysiol 
2018;11:e006145. 
https://doi.org/10.1161/CIRCEP.117. 
006145 
453. Halawa A, Jain R, Turagam MK, Kusumoto FM, Woldu HG, Gautam S. Outcome of 
implantable cardioverter defibrillator in cardiac sarcoidosis: a systematic review and 
meta-analysis. J Interv Card Electrophysiol 2020;58:233‚Äì42. https://doi.org/10.1007/ 
s10840-020-00705-1 
454. Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR, et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc 
Electrophysiol 2012;23:925‚Äì9. https://doi.org/10.1111/j.1540-8167.2012.02350.x 
455. Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC, et al. 
Long-term follow-up of patients with cardiac sarcoidosis and implantable 
cardioverter-defibrillators. Heart Rhythm 2012;9:884‚Äì91. https://doi.org/10.1016/j. 
hrthm.2012.02.010 
456. Franke KB, Marshall H, Kennewell P, Pham H-D, Tully PJ, Rattanakosit T, et al. Risk and 
predictors of sudden death in cardiac sarcoidosis: a systematic review and 
meta-analysis. Int J Cardiol 2021;328:130‚Äì40. https://doi.org/10.1016/j.ijcard.2020.11. 
044 
457. Mathijssen H, Bakker ALM, Balt JC, Akdim F, van Es HW, Veltkamp M, et al. Predictors 
of appropriate implantable cardiac defibrillator therapy in cardiac sarcoidosis. J 
Cardiovasc Electrophysiol 2022;33:1272‚Äì80. https://doi.org/10.1111/jce.15484 
458. Crawford T, Mueller G, Sarsam S, Prasitdumrong H, Chaiyen N, Gu X, et al. Magnetic 
resonance imaging for identifying patients with cardiac sarcoidosis and preserved or 
mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ 
Arrhythm Electrophysiol 2014;7:1109‚Äì15. https://doi.org/10.1161/CIRCEP.113.000156 
459. Shafee MA, Fukuda K, Wakayama Y, Nakano M, Kondo M, Hasebe Y, et al. Delayed 
enhancement on cardiac magnetic resonance imaging is a poor prognostic factor in patients with cardiac sarcoidosis. J Cardiol 2012;60:448‚Äì53. https://doi.org/10.1016/j.jjcc. 
2012.08.002 
460. Mehta D, Mori N, Goldbarg SH, Lubitz S, Wisnivesky JP, Teirstein A. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol 2011;4:43‚Äì8. https://doi.org/10.1161/ 
CIRCEP.110.958322 
461. Okada DR, Smith J, Derakhshan A, Gowani Z, Zimmerman SL, Misra S, et al. 
Electrophysiology study for risk stratification in patients with cardiac sarcoidosis and 
abnormal cardiac imaging. Int J Cardiol Heart Vasc 2019;23:100342. https://doi.org/10. 
1016/j.ijcha.2019.03.002 
462. Adhaduk M, Paudel B, Liu K, Ashwath M, Giudici M. The role of electrophysiology 
study in risk stratification of cardiac sarcoidosis patients: meta-analyses and systemic 
review. Int J Cardiol 2022;349:55‚Äì61. https://doi.org/10.1016/j.ijcard.2021.11.061 
463. Zipse MM, Tzou WS, Schuller JL, Aleong RG, Varosy PD, Tompkins C, et al. 
Electrophysiologic testing for diagnostic evaluation and risk stratification in patients 
with suspected cardiac sarcoidosis with preserved left and right ventricular systolic 
function. J Cardiovasc Electrophysiol 2019;30:1939‚Äì48. https://doi.org/10.1111/jce. 
14058 
464. Tandon P, Mosleh T, Mustafa A, Miodownik H, Miller M, Morgenthau AS. Utility of 
electrophysiologic testing for sudden death risk stratification in cardiac sarcoidosis patients with mildly impaired left ventricular function. Respir Med 2022;191:106712.  
https://doi.org/10.1016/j.rmed.2021.106712 
465. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329‚Äì36. https://doi.org/10. 
1016/j.jacc.2013.09.022 
466. Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, et al. Efficacy and safety of 
implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients 
with cardiac sarcoidosis. Europace 2013;15:347‚Äì54. https://doi.org/10.1093/europace/ 
eus316 
467. Stevenson A, Bray JJH, Tregidgo L, Ahmad M, Sharma A, Ng A, et al. Prognostic value of 
late gadolinium enhancement detected on cardiac magnetic resonance in cardiac sarcoidosis. JACC Cardiovasc Imaging 2023;16:345‚Äì57. https://doi.org/10.1016/j.jcmg.2022. 
10.018 
468. Veronese G, Ammirati E, Brambatti M, Merlo M, Cipriani M, Potena L, et al. Viral genome search in myocardium of patients with fulminant myocarditis. Eur J Heart Fail 
2020;22:1277‚Äì80. https://doi.org/10.1002/ejhf.1738 
469. Sinagra G, Porcari A, Gentile P, Artico J, Fabris E, Bussani R, et al. Viral presence-guided 
immunomodulation in lymphocytic myocarditis: an update. Eur J Heart Fail 2021;23: 
211‚Äì6. https://doi.org/10.1002/ejhf.1969 
470. Moimas S, Zacchigna S, Merlo M, Buiatti A, Anzini M, Dreas L, et al. Idiopathic dilated 
cardiomyopathy and persistent viral infection: lack of association in a controlled study 
using a quantitative assay. Heart Lung Circ 2012;21:787‚Äì93. https://doi.org/10.1016/j. 
hlc.2012.07.013 
471. Stewart GC, Lopez-Molina J, Gottumukkala RVSRK, Rosner GF, Anello MS, Hecht JL, 
et al. Myocardial parvovirus B19 persistence: lack of association with clinicopathologic 
phenotype in adults with heart failure. Circ Heart Fail 2011;4:71‚Äì8. https://doi.org/10. 
1161/CIRCHEARTFAILURE.110.958249 
472. Robinson J, Hartling L, Vandermeer B, Sebastianski M, Klassen TP. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane 
Database Syst Rev 2020;8:CD004370. https://doi.org/10.1002/14651858.CD004370. 
pub4 
473. K√ºhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, et al. 
Interferon-Œ≤ treatment eliminates cardiotropic viruses and improves left ventricular 
function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003;107:2793‚Äì8. https://doi.org/10.1161/01.CIR.0000072766. 
67150.51 
474. K√ºhl U, Lassner D, von Schlippenbach J, Poller W, Schultheiss H-P. Interferon-beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol 2012;60: 
1295‚Äì6. https://doi.org/10.1016/j.jacc.2012.06.026 
475. Schultheiss H-P, Bock C-T, Aleshcheva G, Baumeier C, Poller W, Escher F. 
Interferon-Œ≤ suppresses transcriptionally active parvovirus B19 infection in viral cardiomyopathy: a subgroup analysis of the BICC-trial. Viruses 2022;14:444. https://doi. 
org/10.3390/v14020444 
476. Cobas M, Abbo L, Santos M, Baccini-Jauregui C, Pham S. Successful management of 
fulminant influenza A subtype H1N1 myocarditis. BMJ Case Rep 2010;2010: 
bcr0220102763. https://doi.org/10.1136/bcr.02.2010.2763 
477. Baik SH, Jeong HS, Kim SJ, Yoon YK, Sohn JW, Kim MJ. A case of influenza associated 
fulminant myocarditis successfully treated with intravenous peramivir. Infect 
Chemother 2015;47:272‚Äì7. https://doi.org/10.3947/ic.2015.47.4.272 
478. Jahns F-P, Ben-Hamouda N, Kirsch M, Roumy A, Liaudet L. Intravenous zanamivir for 
influenza myocarditis and enteral malabsorption. Crit Care 2018;22:332. https://doi. 
org/10.1186/s13054-018-2263-y 
479. Mazzitelli M, Garofalo E, Bruni A, Barreca GS, Quirino A, Giancotti A, et al. Severe 
myocarditis due to influenza A(H1N1)pdm09 viral infection in a young woman successfully treated with intravenous zanamivir: a case report. Clin Case Rep 2019;7: 
2336‚Äì40. https://doi.org/10.1002/ccr3.2499 
480. Yoshimizu N, Tominaga T, Ito T, Nishida Y, Wada Y, Sohmiya K, et al. Repetitive fulminant influenza myocarditis requiring the use of circulatory assist devices. Intern Med 
2014;53:109‚Äì14. https://doi.org/10.2169/internalmedicine.53.1117 
481. Khouzam RN, Parizianu C, Hafiz AM, Chawla S, Schwartz R. Fulminant myocarditis associated with novel H1N1 influenza A. Heart Lung 2011;40:566‚Äì8. https://doi.org/10. 
1016/j.hrtlng.2011.01.004 
482. Ito N, Sato M, Momoi N, Aoyagi Y, Endo K, Chishiki M, et al. Influenza A H1N1 
pdm09-associated myocarditis during zanamivir therapy. Pediatr Int 2015;57:1172‚Äì4.  
https://doi.org/10.1111/ped.12712 
483. Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D. Impact of highly active 
antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000; 
40:282‚Äì4. https://doi.org/10.1053/jinf.2000.0672 
484. Steere AC, Batsford WP, Weinberg M, Alexander J, Berger HJ, Wolfson S, et al. Lyme 
carditis: cardiac abnormalities of Lyme disease. Ann Intern Med 1980;93:8‚Äì16. https:// 
doi.org/10.7326/0003-4819-93-1-8 
485. Besant G, Wan D, Yeung C, Blakely C, Branscombe P, Suarez-Fuster L, et al. Suspicious 
index in Lyme carditis: systematic review and proposed new risk score. Clin Cardiol 
2018;41:1611‚Äì6. https://doi.org/10.1002/clc.23102 
486. Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero-Rosenfeld ME, 
Auwaerter PG, et al. Clinical Practice Guidelines by the Infectious Diseases Society 
of America (IDSA), American Academy of Neurology (AAN), and American 
College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis, and 
treatment of Lyme disease. Arthritis Care Res (Hoboken) 2021;73:1‚Äì9. https://doi.org/ 
10.1002/acr.24495 
487. Costello JM, Alexander ME, Greco KM, Perez-Atayde AR, Laussen PC. Lyme carditis in 
children: presentation, predictive factors, and clinical course. Pediatrics 2009;123: 
e835‚Äì841. https://doi.org/10.1542/peds.2008-3058 
488. Nunes MCP, Badano LP, Marin-Neto JA, Edvardsen T, Fern√°ndez-Golf√≠n C, 
Bucciarelli-Ducci C, et al. Multimodality imaging evaluation of Chagas disease: an expert consensus of Brazilian Cardiovascular Imaging Department (DIC) and the 
European Association of Cardiovascular Imaging (EACVI). Eur Heart J Cardiovasc 
Imaging 2018;19:459‚Äì60. https://doi.org/10.1093/ehjci/jex154 
489. Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A, Rosas F, et al. 
Randomized trial of benznidazole for chronic Chagas‚Äô cardiomyopathy. N Engl J Med 
2015;373:1295‚Äì306. https://doi.org/10.1056/NEJMoa1507574 
490. P√©rez-Molina JA, P√©rez-Ayala A, Moreno S, Fern√°ndez-Gonz√°lez MC, Zamora J, 
L√≥pez-Velez R. Use of benznidazole to treat chronic Chagas‚Äô disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009;64:1139‚Äì47. https://doi.org/10. 
1093/jac/dkp357 
491. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006;144:724‚Äì34. https://doi.org/10. 
7326/0003-4819-144-10-200605160-00006  
ESC Guidelines                                                                                                                                                                                               85


<!-- PAGE 86 -->

### Page 86

492. Chadalawada S, Rassi A, Samara O, Monzon A, Gudapati D, Vargas Barahona L, et al. 
Mortality risk in chronic Chagas cardiomyopathy: a systematic review and 
meta-analysis. ESC Heart Fail 2021;8:5466‚Äì81. https://doi.org/10.1002/ehf2.13648 
493. Carmo AAL, de Sousa MR, Agudelo JF, Boersma E, Rocha MOC, Ribeiro ALP, et al. 
Implantable cardioverter-defibrillator in Chagas heart disease: a systematic review 
and meta-analysis of observational studies. Int J Cardiol 2018;267:88‚Äì93. https://doi. 
org/10.1016/j.ijcard.2018.05.091 
494. Rassi FM, Minohara L, Rassi A, Correia LCL, Marin-Neto JA, Rassi A, et al. Systematic 
review and meta-analysis of clinical outcome after implantable cardioverter- 
defibrillator therapy in patients with Chagas heart disease. JACC Clin Electrophysiol 
2019;5:1213‚Äì23. https://doi.org/10.1016/j.jacep.2019.07.003 
495. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. 
Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 
2018;71:1755‚Äì64. https://doi.org/10.1016/j.jacc.2018.02.037 
496. Salem J-E, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. 
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018;19:1579‚Äì89.  
https://doi.org/10.1016/S1470-2045(18)30608-9 
497. Suzuki Y, Kaneko H, Tamura Y, Okada A, Fujiu K, Michihata N, et al. Cardiovascular 
events after the initiation of immune checkpoint inhibitors. Heliyon 2023;9:e16373.  
https://doi.org/10.1016/j.heliyon.2023.e16373 
498. Nguyen LS, Cooper LT, Kerneis M, Funck-Brentano C, Silvain J, Brechot N, et al. 
Systematic analysis of drug-associated myocarditis reported in the World Health 
Organization pharmacovigilance database. Nat Commun 2022;13:25. https://doi.org/ 
10.1038/s41467-021-27631-8 
499. Liu M, Cheng X, Ni R, Zheng B, Huang S, Yang J. Cardiotoxicity of immune checkpoint 
inhibitors: a frequency network meta-analysis. Front Immunol 2022;13:1006860.  
https://doi.org/10.3389/fimmu.2022.1006860 
500. Pradhan R, Nautiyal A, Singh S. Diagnosis of immune checkpoint inhibitor-associated 
myocarditis: a systematic review. Int J Cardiol 2019;296:113‚Äì21. https://doi.org/10. 
1016/j.ijcard.2019.07.025 
501. Lyon AR, L√≥pez-Fern√°ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 
European Hematology Association (EHA), the European Society for Therapeutic 
Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society 
(IC-OS). Eur Heart J 2022;43:4229‚Äì361. https://doi.org/10.1093/eurheartj/ehac244 
502. Salem J-E, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, et al. 
Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov 2023;13: 
1100‚Äì15. https://doi.org/10.1158/2159-8290.CD-22-1180 
503. L‚ÄôOrphelin J-M, Dollalille C, Akroun J, Alexandre J, Dompmartin A. Cardiovascular immunotoxicity associated with immune checkpoint inhibitors in metastatic melanoma. 
Cancers (Basel) 2023;15:2170. https://doi.org/10.3390/cancers15072170 
504. Tocchetti CG, Farmakis D, Koop Y, Andres MS, Couch LS, Formisano L, et al. 
Cardiovascular toxicities of immune therapies for cancer‚Äîa scientific statement of 
the Heart Failure Association (HFA) of the ESC and the ESC Council of 
Cardio-Oncology. Eur J Heart Fail 2024;26:2055‚Äì76. https://doi.org/10.1002/ejhf.3340 
505. Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 2020;6:865‚Äì71. https://doi.org/10.1001/jamaoncol.2020.0726 
506. Clapham E, Reutfors J, Linder M, Brandt L, Sundstr√∂m J, Bod√©n R. The association between exposure to clozapine, olanzapine, and quetiapine and the outcomes perimyocarditis and heart failure: a population-based cohort study. Psychiatry Res 2023;326: 
115336. https://doi.org/10.1016/j.psychres.2023.115336 
507. Sandarsh S, Bishnoi RJ, Shashank RB, Miller BJ, Freudenreich O, McEvoy JP. Monitoring 
for myocarditis during treatment initiation with clozapine. Acta Psychiatr Scand 2021; 
144:194‚Äì200. https://doi.org/10.1111/acps.13328 
508. Siskind D, Sidhu A, Cross J, Chua Y-T, Myles N, Cohen D, et al. Systematic review and 
meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy. Aust N 
Z J Psychiatry 2020;54:467‚Äì81. https://doi.org/10.1177/0004867419898760 
509. Seree-aphinan C, Assanangkornchai N, Nilmoje T. Prolonged extracorporeal membrane oxygenation support in a patient with drug reaction with eosinophilia and systemic symptoms syndrome-associated fulminant myocarditis‚Äîa case report and 
literature review. Heart Int 2020;14:112‚Äì7. https://doi.org/10.17925/HI.2020.14.2.112 
510. Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U, et al. The Brighton 
Collaboration: addressing the need for standardized case definitions of adverse events 
following immunization (AEFI). Vaccine 2002;21:298‚Äì302. https://doi.org/10.1016/ 
s0264-410x(02)00449-8 
511. Engler RJM, Montgomery JR, Spooner CE, Nelson MR, Collins LC, Ryan MA, et al. 
Myocarditis and pericarditis recovery following smallpox vaccine 2002‚Äì2016: a comparative observational cohort study in the military health system. PLoS One 2023;18: 
e0283988. https://doi.org/10.1371/journal.pone.0283988 
512. Parmar K, Subramanyam S, Del Rio-Pertuz G, Sethi P, Argueta-Sosa E. Cardiac adverse 
events after vaccination‚Äîa systematic review. Vaccines (Basel) 2022;10:700. https:// 
doi.org/10.3390/vaccines10050700 
513. Thanjan MT, Ramaswamy P, Lai WW, Lytrivi ID. Acute myopericarditis after multiple 
vaccinations in an adolescent: case report and review of the literature. Pediatrics 2007; 
119:e1400‚Äì3. https://doi.org/10.1542/peds.2006-2605 
514. Dilber E, Karag√∂z T, Aytemir K, Ozer S, Alehan D, Oto A, et al. Acute myocarditis associated with tetanus vaccination. Mayo Clin Proc 2003;78:1431‚Äì3. https://doi.org/10. 
4065/78.11.1431-a 
515. Boccara F, Benhaiem-Sigaux N, Cohen A. Acute myopericarditis after diphtheria, tetanus, and polio vaccination. Chest 2001;120:671‚Äì2. https://doi.org/10.1378/chest.120. 
2.671 
516. Barton M, Finkelstein Y, Opavsky MA, Ito S, Ho T, Ford-Jones LE, et al. Eosinophilic 
myocarditis temporally associated with conjugate meningococcal C and hepatitis B 
vaccines in children. Pediatr Infect Dis J 2008;27:831‚Äì5. https://doi.org/10.1097/INF. 
0b013e31816ff7b2 
517. Lu J, Zhang X, Xu H, Li Z. Inspiration to mRNA-based COVID-19 vaccination: serious 
adverse case reports with hepatitis B vaccine in real-world. Front Pediatr 2022;10: 
888686. https://doi.org/10.3389/fped.2022.888686 
518. Nagano N, Yano T, Fujita Y, Koyama M, Hasegawa R, Nakata J, et al. Hemodynamic 
collapse after influenza vaccination: a vaccine-induced fulminant myocarditis? Can J 
Cardiol 2020;36:1554.e5‚Äìe7. https://doi.org/10.1016/j.cjca.2020.05.005 
519. Jain SS, Anderson SA, Steele JM, Wilson HC, Muniz JC, Soslow JH, et al. Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in 
the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) 
multicenter study. EClinicalMedicine 2024;76:102809. https://doi.org/10.1016/j.eclinm. 
2024.102809 
520. Peretto G, Micaglio E, Ciconte G, Maia M, Luzzi M, Cariello M, et al. The ‚Äòarrhythmic‚Äô 
presentation of peripartum cardiomyopathy: case series and critical review of the literature. Front Cardiovasc Med 2024;11:1362692. https://doi.org/10.3389/fcvm.2024. 
1362692 
521. Hoevelmann J, Engel ME, Muller E, Hohlfeld A, B√∂hm M, Sliwa K, et al. A global perspective on the management and outcomes of peripartum cardiomyopathy: a systematic 
review and meta-analysis. Eur J Heart Fail 2022;24:1719‚Äì36. https://doi.org/10.1002/ 
ejhf.2603 
522. Gunderson EP, Croen LA, Chiang V, Yoshida CK, Walton D, Go AS. Epidemiology of 
peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstet Gynecol 
2011;118:583‚Äì91. https://doi.org/10.1097/AOG.0b013e318229e6de 
523. Karaye KM, Ishaq NA, Sa‚Äôidu H, Balarabe SA, Talle MA, Isa MS, et al. Incidence, clinical 
characteristics, and risk factors of peripartum cardiomyopathy in Nigeria: results from 
the PEACE Registry. ESC Heart Fail 2020;7:235‚Äì43. https://doi.org/10.1002/ehf2.12562 
524. Goli R, Li J, Brandimarto J, Levine LD, Riis V, McAfee Q, et al. Genetic and phenotypic 
landscape of peripartum cardiomyopathy. Circulation 2021;143:1852‚Äì62. https://doi. 
org/10.1161/CIRCULATIONAHA.120.052395 
525. Mallikethi-Reddy S, Akintoye E, Trehan N, Sharma S, Briasoulis A, Jagadeesh K, et al. 
Burden of arrhythmias in peripartum cardiomyopathy: analysis of 9841 hospitalizations. Int J Cardiol 2017;235:114‚Äì7. https://doi.org/10.1016/j.ijcard.2017.02.084 
526. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current 
state of knowledge on aetiology, diagnosis, management, and therapy of peripartum 
cardiomyopathy: a position statement from the Heart Failure Association of the 
European Society of Cardiology Working Group on peripartum cardiomyopathy. 
Eur J Heart Fail 2010;12:767‚Äì78. https://doi.org/10.1093/eurjhf/hfq120 
527. Tanous D, Siu SC, Mason J, Greutmann M, Wald RM, Parker JD, et al. B-type natriuretic 
peptide in pregnant women with heart disease. J Am Coll Cardiol 2010;56:1247‚Äì53.  
https://doi.org/10.1016/j.jacc.2010.02.076 
528. Esbrand FD, Zafar S, Panthangi V, Cyril Kurupp AR, Raju A, Luthra G, et al. Utility of 
N-terminal (NT)-brain natriuretic peptide (proBNP) in the diagnosis and prognosis of 
pregnancy associated cardiovascular conditions: a systematic review. Cureus 2022;14: 
e32848. https://doi.org/10.7759/cureus.32848 
529. Li W, Li H, Long Y. Clinical characteristics and long-term predictors of persistent left 
ventricular systolic dysfunction in peripartum cardiomyopathy. Can J Cardiol 2016;32: 
362‚Äì8. https://doi.org/10.1016/j.cjca.2015.07.733 
530. Arora NP, Mahajan N, Mohamad T, Kottam A, Afonso LC, Danrad R, et al. Cardiac 
magnetic resonance imaging in peripartum cardiomyopathy. Am J Med Sci 2014;347: 
112‚Äì7. https://doi.org/10.1097/MAJ.0b013e31828155e3 
531. Ordovas KG, Baldassarre LA, Bucciarelli-Ducci C, Carr J, Fernandes JL, Ferreira VM, 
et al. Cardiovascular magnetic resonance in women with cardiovascular disease: position statement from the Society for Cardiovascular Magnetic Resonance (SCMR). J 
Cardiovasc Magn Reson 2021;23:52. https://doi.org/10.1186/s12968-021-00746-z 
532. Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association between MRI 
exposure during pregnancy and fetal and childhood outcomes. JAMA 2016;316: 
952‚Äì61. https://doi.org/10.1001/jama.2016.12126 
533. Schelbert EB, Elkayam U, Cooper LT, Givertz MM, Alexis JD, Briller J, et al. Myocardial 
damage detected by late gadolinium enhancement cardiac magnetic resonance is uncommon in peripartum cardiomyopathy. J Am Heart Assoc 2017;6:e005472. https:// 
doi.org/10.1161/JAHA.117.005472 
534. Cooper LT, Mather PJ, Alexis JD, Pauly DF, Torre-Amione G, Wittstein IS, et al. 
Myocardial recovery in peripartum cardiomyopathy: prospective comparison with


<!-- PAGE 87 -->

### Page 87

recent onset cardiomyopathy in men and nonperipartum women. J Card Fail 2012;18: 
28‚Äì33. https://doi.org/10.1016/j.cardfail.2011.09.009 
535. McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study 
(investigations of pregnancy-associated cardiomyopathy). J Am Coll Cardiol 2015;66: 
905‚Äì14. https://doi.org/10.1016/j.jacc.2015.06.1309 
536. Biteker M, √ñzlek B, √ñzlek E, √áil C, √áelik O, Doƒüan V, et al. Predictors of early and delayed recovery in peripartum cardiomyopathy: a prospective study of 52 patients. J 
Matern Fetal Neonatal Med 2020;33:390‚Äì7. https://doi.org/10.1080/14767058.2018. 
1494146 
537. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin 
Proc 2005;80:1602‚Äì6. https://doi.org/10.4065/80.12.1602 
538. Moulig V, Pfeffer TJ, Ricke-Hoch M, Schlothauer S, Koenig T, Schwab J, et al. Long-term 
follow-up in peripartum cardiomyopathy patients with contemporary treatment: low 
mortality, high cardiac recovery, but significant cardiovascular co-morbidities. Eur J 
Heart Fail 2019;21:1534‚Äì42. https://doi.org/10.1002/ejhf.1624 
539. Sliwa K, Azibani F, Baard J, Osman A, Z√ºhlke L, Lachmann A, et al. Reducing late maternal death due to cardiovascular disease‚Äîa pragmatic pilot study. Int J Cardiol 2018; 
272:70‚Äì6. https://doi.org/10.1016/j.ijcard.2018.07.140 
540. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, Veltmann C, Coats AJS, Crespo-Leiro MG, 
et al. Current management of patients with severe acute peripartum cardiomyopathy: 
practical guidance from the Heart Failure Association of the European Society of 
Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2016;18: 
1096‚Äì105. https://doi.org/10.1002/ejhf.586 
541. Fu K, Zhang H, Chen N, Hu Y, Xiao J, Zhang X, et al. Risk factors for intracardiac 
thrombus in peripartum cardiomyopathy: a retrospective study in China. ESC Heart 
Fail 2023;10:148‚Äì58. https://doi.org/10.1002/ehf2.14158 
542. Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A, et al. 
Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 2017;38:2671‚Äì9. https://doi.org/10.1093/eurheartj/ehx355 
543. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema J-P, Becker A, et al. Evaluation of 
bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a 
proof-of-concept pilot study. Circulation 2010;121:1465‚Äì73. https://doi.org/10.1161/ 
CIRCULATIONAHA.109.901496 
544. Kumar A, Ravi R, Sivakumar RK, Chidambaram V, Majella MG, Sinha S, et al. Prolactin 
inhibition in peripartum cardiomyopathy: systematic review and meta-analysis. Curr 
Probl Cardiol 2023;48:101461. https://doi.org/10.1016/j.cpcardiol.2022.101461 
545. Trongtorsak A, Kittipibul V, Mahabir S, Ibrahim M, Saint Croix GR, Hernandez GA, 
et al. Effects of bromocriptine in peripartum cardiomyopathy: a systematic review 
and meta-analysis. Heart Fail Rev 2022;27:533‚Äì43. https://doi.org/10.1007/s10741- 
021-10185-8 
546. Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal 
of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019;393: 
61‚Äì73. https://doi.org/10.1016/S0140-6736(18)32484-X 
547. Codsi E, Rose CH, Blauwet LA. Subsequent pregnancy outcomes in patients with peripartum cardiomyopathy. Obstet Gynecol 2018;131:322‚Äì7. https://doi.org/10.1097/ 
AOG.0000000000002439 
548. Meng M-L, Arendt KW, Banayan JM, Bradley EA, Vaught AJ, Hameed AB, et al. 
Anesthetic care of the pregnant patient with cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2023;147:e657‚Äì73. https://doi. 
org/10.1161/CIR.0000000000001121 
549. De Backer J, Haugaa K. 2025 ESC Guidelines for the management of cardiovascular 
disease and pregnancy. Eur Heart J. 2011;32:3147‚Äì97. https://doi.org/10.1093/ 
eurheartj/ehr218 
550. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O‚ÄôConnell J, et al. Report 
of the 1995 World Health Organization/International Society and Federation of 
Cardiology Task Force on the definition and classification of cardiomyopathies. 
Circulation 1996;93:841‚Äì2. https://doi.org/10.1161/01.cir.93.5.841 
551. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the 
TIMIC study. Eur Heart J 2009;30:1995‚Äì2002. https://doi.org/10.1093/eurheartj/ 
ehp249 
552. Escher F, K√ºhl U, Lassner D, Poller W, Westermann D, Pieske B, et al. Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy. Clin Res Cardiol 2016;105:1011‚Äì20.  
https://doi.org/10.1007/s00392-016-1011-z 
553. Merken J, Hazebroek M, Van Paassen P, Verdonschot J, Van Empel V, Knackstedt C, 
et al. Immunosuppressive therapy improves both short- and long-term prognosis in 
patients with virus-negative nonfulminant inflammatory cardiomyopathy. Circ Heart 
Fail 2018;11:e004228. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004228 
554. De Luca G, Campochiaro C, Sartorelli S, Peretto G, Sala S, Palmisano A, et al. Efficacy 
and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: a prospective cohort study. J Autoimmun 2020;106:102330. https://doi.org/10. 
1016/j.jaut.2019.102330 
555. Peretto G, Sala S, De Luca G, Marcolongo R, Campochiaro C, Sartorelli S, et al. 
Immunosuppressive therapy and risk stratification of patients with myocarditis presenting with ventricular arrhythmias. JACC Clin Electrophysiol 2020;6:1221‚Äì34. https:// 
doi.org/10.1016/j.jacep.2020.05.013 
556. Reuter H, Burgess LJ, Doubell AF. Epidemiology of pericardial effusions at a large academic hospital in South Africa. Epidemiol Infect 2005;133:393‚Äì9. https://doi.org/10. 
1017/s0950268804003577 
557. Mayosi BM, Wiysonge CS, Ntsekhe M, Gumedze F, Volmink JA, Maartens G, et al. 
Mortality in patients treated for tuberculous pericarditis in sub-Saharan Africa. S Afr 
Med J 2008;98:36‚Äì40. 
558. Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. Circulation 2005;112: 
3608‚Äì16. https://doi.org/10.1161/CIRCULATIONAHA.105.543066 
559. Isiguzo G, Du Bruyn E, Howlett P, Ntsekhe M. Diagnosis and management of tuberculous pericarditis: what is new? Curr Cardiol Rep 2020;22:2. https://doi.org/10.1007/ 
s11886-020-1254-1 
560. Ntsekhe M, Mayosi BM. Tuberculous pericarditis with and without HIV. Heart Fail Rev 
2013;18:367‚Äì73. https://doi.org/10.1007/s10741-012-9310-6 
561. Noubiap JJ, Agbor VN, Ndoadoumgue AL, Nkeck JR, Kamguia A, Nyaga UF, et al. 
Epidemiology of pericardial diseases in Africa: a systematic scoping review. Heart 
2019;105:180‚Äì8. https://doi.org/10.1136/heartjnl-2018-313922 
562. Xie DL, Cheng B, Sheng Y, Jin J. Diagnostic accuracy of adenosine deaminase for tuberculous pericarditis: a meta-analysis. Eur Rev Med Pharmacol Sci 2015;19:4411‚Äì8. https:// 
doi.org/10.18632/eurrev_2015_19_22_4411 
563. Pandie S, Peter JG, Kerbelker ZS, Meldau R, Theron G, Govender U, et al. Diagnostic 
accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared 
to adenosine deaminase and unstimulated interferon-Œ≥ in a high burden setting: a prospective study. BMC Med 2014;12:101. https://doi.org/10.1186/1741-7015-12-101 
564. Yu G, Ye B, Chen D, Zhong F, Chen G, Yang J, et al. Comparison between the diagnostic validities of Xpert MTB/RIF and interferon-Œ≥ release assays for tuberculous pericarditis using pericardial tissue. PLoS One 2017;12:e0188704. https://doi.org/10.1371/ 
journal.pone.0188704 
565. Liu C, Cui Y-L, Ding C-M, Wu Y-H, Li H-L, Liu X-F, et al. Diagnostic accuracy of 
interferon-gamma in pericardial effusions for tuberculous pericarditis: a meta-analysis. 
J Thorac Dis 2018;10:854‚Äì60. https://doi.org/10.21037/jtd.2017.12.107 
566. Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, et al. 
Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in 
HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune 
Defic Syndr 2011;56:230‚Äì38. https://doi.org/10.1097/QAI.0b013e31820b07ab 
567. Wiysonge CS, Ntsekhe M, Thabane L, Volmink J, Majombozi D, Gumedze F, et al. 
Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev 2017; 
9:CD000526. https://doi.org/10.1002/14651858.CD000526.pub2 
568. Pasipanodya JG, Mubanga M, Ntsekhe M, Pandie S, Magazi BT, Gumedze F, et al. 
Tuberculous pericarditis is multibacillary and bacterial burden drives high mortality. 
EBioMedicine 2015;2:1634‚Äì9. https://doi.org/10.1016/j.ebiom.2015.09.034 
569. Mayosi BM, Ntsekhe M, Bosch J, Pandie S, Jung H, Gumedze F, et al. Prednisolone and 
Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med 2014;371: 
1121‚Äì30. https://doi.org/10.1056/NEJMoa1407380 
570. Reuter H, Burgess LJ, Louw VJ, Doubell AF. The management of tuberculous pericardial effusion: experience in 233 consecutive patients. Cardiovasc J S Afr 2007;18:20‚Äì5. 
571. Strang JI, Kakaza HH, Gibson DG, Girling DJ, Nunn AJ, Fox W. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. 
Lancet 1987;2:1418‚Äì22. https://doi.org/10.1016/s0140-6736(87)91127-5 
572. Strang JIG, Nunn AJ, Johnson DA, Casbard A, Gibson DG, Girling DJ. Management of 
tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up. QJM 2004;97:525‚Äì35. https://doi.org/10.1093/qjmed/hch086 
573. Cui H-B, Chen X-Y, Cui C-C, Shou X-L, Liu X, Yao X-W, et al. Prevention of pericardial constriction by transcatheter intrapericardial fibrinolysis with urokinase. Chin Med 
Sci J 2005;20:5‚Äì10. https://doi.org/10.1016/j.chinmedsci.2005.01.002 
574. Maisch B, Ristic A, Pankuweit S. Evaluation and management of pericardial effusion in 
patients with neoplastic disease. Prog Cardiovasc Dis 2010;53:157‚Äì63. https://doi.org/ 
10.1016/j.pcad.2010.06.003 
575. Imazio M, Demichelis B, Parrini I, Favro E, Beqaraj F, Cecchi E, et al. Relation of acute 
pericardial disease to malignancy. Am J Cardiol 2005;95:1393‚Äì4. https://doi.org/10. 
1016/j.amjcard.2005.01.094 
576. Pawlak Cie≈õlik A, Szturmowicz M, Fija≈Çkowska A, GƒÖtarek J, Gralec R, 
B≈Çasi≈Ñska-Przerwa K, et al. Diagnosis of malignant pericarditis: a single centre experience. Kardiol Pol 2012;70:1147‚Äì53. https://doi.org/10.33963/v.kp.79064 
577. Karatolios K, Pankuweit S, Maisch B. Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion. Heart Fail Rev 2013;18:337‚Äì44. https:// 
doi.org/10.1007/s10741-012-9327-x 
578. Wang K, Eblan MJ, Deal AM, Lipner M, Zagar TM, Wang Y, et al. Cardiac toxicity after 
radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation 
trials delivering 70 to 90 Gy. J Clin Oncol 2017;35:1387‚Äì94. https://doi.org/10.1200/ 
JCO.2016.70.0229 
579. Takata N, Kataoka M, Hamamoto Y, Tsuruoka S, Kanzaki H, Uwatsu K, et al. Risk factors for pericardial effusion after chemoradiotherapy for thoracic esophageal cancer-  
ESC Guidelines                                                                                                                                                                                               87


<!-- PAGE 88 -->

### Page 88

comparison of four-field technique and traditional two opposed fields technique. J 
Radiat Res 2018;59:291‚Äì7. https://doi.org/10.1093/jrr/rry029 
580. Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, et al. 
Evaluation and management of cancer patients presenting with acute cardiovascular 
disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC Council of Cardio-Oncology‚ÄîPart 1: acute coronary syndromes 
and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care 2021;10:947‚Äì59.  
https://doi.org/10.1093/ehjacc/zuab056 
581. Saab J, Hoda RS, Narula N, Hoda SA, Geraghty BE, Nasar A, et al. Diagnostic yield of 
cytopathology in evaluating pericardial effusions: clinicopathologic analysis of 419 specimens. Cancer Cytopathol 2017;125:128‚Äì37. https://doi.org/10.1002/cncy.21790 
582. Numico G, Cristofano A, Occelli M, Sicuro M, Mozzicafreddo A, Fea E, et al. Prolonged 
drainage and intrapericardial bleomycin administration for cardiac tamponade secondary to cancer-related pericardial effusion. Medicine (Baltimore) 2016;95:e3273. https:// 
doi.org/10.1097/MD.0000000000003273 
583. Kim SR, Kim EK, Cho J, Chang S-A, Park S-J, Lee S-C, et al. Effect of anti-inflammatory 
drugs on clinical outcomes in patients with malignant pericardial effusion. J Am Coll 
Cardiol 2020;76:1551‚Äì61. https://doi.org/10.1016/j.jacc.2020.08.003 
584. De Filippo O, Gatti P, Rettegno S, Iannaccone M, D‚ÄôAscenzo F, Lazaros G, et al. Is pericardial effusion a negative prognostic marker? Meta-analysis of outcomes of pericardial 
effusion. J Cardiovasc Med (Hagerstown) 2019;20:39‚Äì45. https://doi.org/10.2459/JCM. 
0000000000000720 
585. Gatzoulis K, Archontakis S, Tsiachris D, Lazaros G, Apostolopoulos T, Zervopoulos G, 
et al. Post-cardiac injury syndrome after permanent electronic cardiac device implantation. Incidence, presentation, management and long-term prognosis. Int J Cardiol 
2014;174:163‚Äì4. https://doi.org/10.1016/j.ijcard.2014.03.170 
586. Nakhla S, Mentias A, Rymer C, Hussein A, Wazni O, Rickard J, et al. Acute pericarditis 
after atrial fibrillation ablation: incidence, characteristics, and risk factors. Heart Rhythm 
2022;3:248‚Äì51. https://doi.org/10.1016/j.hroo.2022.02.008 
587. Imazio M, Negro A, Belli R, Beqaraj F, Forno D, Giammaria M, et al. Frequency and 
prognostic significance of pericarditis following acute myocardial infarction treated 
by primary percutaneous coronary intervention. Am J Cardiol 2009;103:1525‚Äì9.  
https://doi.org/10.1016/j.amjcard.2009.01.366 
588. Figueras J, Juncal A, Carballo J, Cortadellas J, Soler JS. Nature and progression of pericardial effusion in patients with a first myocardial infarction: relationship to age and free 
wall rupture. Am Heart J 2002;144:251‚Äì8. https://doi.org/10.1067/mhj.2002.123840 
589. Figueras J, Barrab√©s JA, Serra V, Cortadellas J, Lid√≥n R-M, Carrizo A, et al. Hospital 
outcome of moderate to severe pericardial effusion complicating ST-elevation 
acute myocardial infarction. Circulation 2010;122:1902‚Äì9. https://doi.org/10. 
1161/CIRCULATIONAHA.109.934968 
590. Mohanty S, Mohanty P, Kessler D, Gianni C, Baho KK, Morris T, et al. Impact of colchicine monotherapy on the risk of acute pericarditis following atrial fibrillation ablation. JACC Clin Electrophysiol 2023;9:1051‚Äì9. https://doi.org/10.1016/j.jacep.2023.01. 
037 
591. Lehto J, Kiviniemi T, Gunn J, Airaksinen J, Rautava P, Kyt√∂ V. Occurrence of postpericardiotomy syndrome: association with operation type and postoperative mortality 
after open-heart operations. J Am Heart Assoc 2018;7:e010269. https://doi.org/10. 
1161/JAHA.118.010269 
592. Imazio M, Brucato A, Rovere ME, Gandino A, Cemin R, Ferrua S, et al. Contemporary 
features, risk factors, and prognosis of the post-pericardiotomy syndrome. Am J Cardiol 
2011;108:1183‚Äì7. https://doi.org/10.1016/j.amjcard.2011.06.025 
593. Finkelstein Y, Shemesh J, Mahlab K, Abramov D, Bar-El Y, Sagie A, et al. Colchicine for 
the prevention of postpericardiotomy syndrome. Herz 2002;27:791‚Äì4. https://doi.org/ 
10.1007/s00059-002-2376-5 
594. Imazio M, Trinchero R, Brucato A, Rovere ME, Gandino A, Cemin R, et al. COlchicine 
for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J 2010;31:2749‚Äì54. https:// 
doi.org/10.1093/eurheartj/ehq319 
595. Imazio M, Brucato A, Ferrazzi P, Spodick DH, Adler Y. Postpericardiotomy syndrome: 
a proposal for diagnostic criteria. J Cardiovasc Med (Hagerstown) 2013;14:351‚Äì3.  
https://doi.org/10.2459/JCM.0b013e328353807d 
596. Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the 
COPPS-2 randomized clinical trial. JAMA 2014;312:1016‚Äì23. https://doi.org/10. 
1001/jama.2014.11026 
597. Gill PJ, Forbes K, Coe JY. The effect of short-term prophylactic acetylsalicylic acid on 
the incidence of postpericardiotomy syndrome after surgical closure of atrial septal 
defects. Pediatr Cardiol 2009;30:1061‚Äì7. https://doi.org/10.1007/s00246-009-9495-1 
598. Mott AR, Fraser CD, Kusnoor AV, Giesecke NM, Reul GJ, Drescher KL, et al. The effect of short-term prophylactic methylprednisolone on the incidence and severity of 
postpericardiotomy syndrome in children undergoing cardiac surgery with cardiopulmonary bypass. J Am Coll Cardiol 2001;37:1700‚Äì6. https://doi.org/10.1016/s0735- 
1097(01)01223-2 
599. Bunge JJH, van Osch D, Dieleman JM, Jacob KA, Kluin J, van Dijk D, et al. Dexamethasone 
for the prevention of postpericardiotomy syndrome: a DExamethasone for Cardiac 
Surgery substudy. Am Heart J 2014;168:126‚Äì31.e1. https://doi.org/10.1016/j.ahj.2014. 
03.017 
600. Imazio M, Brucato A, Markel G, Cemin R, Trinchero R, Spodick DH, et al. Meta-analysis 
of randomized trials focusing on prevention of the postpericardiotomy syndrome. Am J 
Cardiol 2011;108:575‚Äì9. https://doi.org/10.1016/j.amjcard.2011.03.087 
601. Meurin P, Tabet JY, Thabut G, Cristofini P, Farrokhi T, Fischbach M, et al. Nonsteroidal 
anti-inflammatory drug treatment for postoperative pericardial effusion: a multicenter 
randomized, double-blind trial. Ann Intern Med 2010;152:137‚Äì43. https://doi.org/10. 
7326/0003-4819-152-3-201002020-00004 
602. Meurin P, Lelay-Kubas S, Pierre B, Pereira H, Pavy B, Iliou MC, et al. Colchicine for postoperative pericardial effusion: a multicentre, double-blind, randomised controlled trial. 
Heart 2015;101:1711‚Äì6. https://doi.org/10.1136/heartjnl-2015-307827 
603. Meurin P, Weber H, Renaud N, Larrazet F, Tabet JY, Demolis P, et al. Evolution of the 
postoperative pericardial effusion after day 15: the problem of the late tamponade. 
Chest 2004;125:2182‚Äì7. https://doi.org/10.1378/chest.125.6.2182 
604. Andreis A, Imazio M, Giustetto C, Brucato A, Adler Y, De Ferrari GM. Anakinra for 
constrictive pericarditis associated with incessant or recurrent pericarditis. Heart 
2020;106:1561‚Äì5. https://doi.org/10.1136/heartjnl-2020-316898 
605. Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I, et al. Classification 
criteria for autoinflammatory recurrent fevers. Ann Rheum Dis 2019;78:1025‚Äì32.  
https://doi.org/10.1136/annrheumdis-2019-215048 
606. Sagrist√†-Sauleda J, Barrab√©s JA, Permanyer-Miralda G, Soler-Soler J. Purulent pericarditis: review of a 20-year experience in a general hospital. J Am Coll Cardiol 1993;22: 
1661‚Äì5. https://doi.org/10.1016/0735-1097(93)90592-o 
607. Rubin RH, Moellering RC. Clinical, microbiologic and therapeutic aspects of purulent 
pericarditis. Am J Med 1975;59:68‚Äì78. https://doi.org/10.1016/0002-9343(75)90323-x 
608. Brook I, Frazier EH. Microbiology of acute purulent pericarditis. A 12-year experience 
in a military hospital. Arch Intern Med 1996;156:1857‚Äì60. https://doi.org/10.1001/ 
archinte.1996.00440150113013 
609. Wiyeh AB, Ochodo EA, Wiysonge CS, Kakia A, Awotedu AA, Ristic A, et al. A systematic review of the efficacy and safety of intrapericardial fibrinolysis in patients with pericardial effusion. Int J Cardiol 2018;250:223‚Äì8. https://doi.org/10.1016/j.ijcard.2017.10. 
049 
610. Augustin P, Desmard M, Mordant P, Lasocki S, Maury J-M, Heming N, et al. Clinical review: intrapericardial fibrinolysis in management of purulent pericarditis. Crit Care 
2011;15:220. https://doi.org/10.1186/cc10022 
611. Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med 2011;155:409‚Äì14.  
https://doi.org/10.7326/0003-4819-155-7-201110040-00359 
612. Vogiatzidis K, Zarogiannis SG, Aidonidis I, Solenov EI, Molyvdas P-A, Gourgoulianis KI, 
et al. Physiology of pericardial fluid production and drainage. Front Physiol 2015;6:62.  
https://doi.org/10.3389/fphys.2015.00062 
613. Mitiku TY, Heidenreich PA. A small pericardial effusion is a marker of increased mortality. Am Heart J 2011;161:152‚Äì7. https://doi.org/10.1016/j.ahj.2010.10.007 
614. Corey GR, Campbell PT, Van Trigt P, Kenney RT, O‚ÄôConnor CM, Sheikh KH, et al. 
Etiology of large pericardial effusions. Am J Med 1993;95:209‚Äì13. https://doi.org/10. 
1016/0002-9343(93)90262-n 
615. Sagrist√†-Sauleda J, Merc√© J, Permanyer-Miralda G, Soler-Soler J. Clinical clues to the 
causes of large pericardial effusions. Am J Med 2000;109:95‚Äì101. https://doi.org/10. 
1016/s0002-9343(00)00459-9 
616. Levy P-Y, Corey R, Berger P, Habib G, Bonnet J-L, Levy S, et al. Etiologic diagnosis of 
204 pericardial effusions. Medicine (Baltimore) 2003;82:385‚Äì91. https://doi.org/10. 
1097/01.md.0000101574.54295.73 
617. Ma W, Liu J, Zeng Y, Chen S, Zheng Y, Ye S, et al. Causes of moderate to large pericardial effusion requiring pericardiocentesis in 140 Han Chinese patients. Herz 2012; 
37:183‚Äì7. https://doi.org/10.1007/s00059-011-3428-5 
618. Abdallah R, Atar S. Etiology and characteristics of large symptomatic pericardial effusion in a community hospital in the contemporary era. QJM 2014;107:363‚Äì8. https:// 
doi.org/10.1093/qjmed/hct255 
619. Roy CL, Minor MA, Brookhart MA, Choudhry NK. Does this patient with a pericardial 
effusion have cardiac tamponade? JAMA 2007;297:1810‚Äì8. https://doi.org/10.1001/ 
jama.297.16.1810 
620. Cremer PC, Kumar A, Kontzias A, Tan CD, Rodriguez ER, Imazio M, et al. Complicated 
pericarditis: understanding risk factors and pathophysiology to inform imaging and 
treatment. J Am Coll Cardiol 2016;68:2311‚Äì28. https://doi.org/10.1016/j.jacc.2016.07. 
785 
621. Lazaros G, Antonopoulos AS, Lazarou E, Vlachopoulos C, Foukarakis E, Androulakis A, 
et al. Long-term outcome of pericardial drainage in cases of chronic, large, hemodynamically insignificant, C-reactive protein negative, idiopathic pericardial effusions. 
Am J Cardiol 2020;126:89‚Äì93. https://doi.org/10.1016/j.amjcard.2020.03.035 
622. Lazaros G, Oikonomou V, Oikonomou E, Aznaouridis K, Vlachopoulos C, Vogiatzi G, 
et al. Recurrence of pericardial effusion after pericardiocentesis: does catheter- 
induced acute pericardial inflammation play a role? Am J Med Sci 2021;361:676‚Äì8.  
https://doi.org/10.1016/j.amjms.2020.10.012


<!-- PAGE 89 -->

### Page 89

623. Buoro S, Tombetti E, Ceriotti F, Simon C, Cugola D, Seghezzi M, et al. What is the normal composition of pericardial fluid? Heart 2021;107:1584‚Äì90. https://doi.org/10. 
1136/heartjnl-2020-317966 
624. Imazio M, Biondo A, Ricci D, Boffini M, Pivetta E, Brucato A, et al. Contemporary biochemical analysis of normal pericardial fluid. Heart 2020;106:541‚Äì4. https://doi.org/10. 
1136/heartjnl-2018-314574 
625. Imazio M, Lazaros G, Valenti A, De Carlini CC, Maggiolini S, Pivetta E, et al. Outcomes 
of idiopathic chronic large pericardial effusion. Heart 2019;105:477‚Äì81. https://doi.org/ 
10.1136/heartjnl-2018-313532 
626. Fr√∂hlich GM, Keller P, Schmid F, Wolfrum M, Osranek M, Falk C, et al. 
Haemodynamically irrelevant pericardial effusion is associated with increased mortality 
in patients with chronic heart failure. Eur Heart J 2013;34:1414‚Äì23. https://doi.org/10. 
1093/eurheartj/eht006 
627. Porta-S√°nchez A, Sagrist√†-Sauleda J, Ferreira-Gonz√°lez I, Torrents-Fern√°ndez A, 
Roca-Luque I, Garc√≠a-Dorado D. Constrictive pericarditis: etiologic spectrum, patterns of clinical presentation, prognostic factors, and long-term follow-up. Rev Esp 
Cardiol (Engl Ed) 2015;68:1092‚Äì100. https://doi.org/10.1016/j.rec.2014.12.018 
628. Ling LH, Oh JK, Schaff HV, Danielson GK, Mahoney DW, Seward JB, et al. Constrictive 
pericarditis in the modern era: evolving clinical spectrum and impact on outcome after 
pericardiectomy. Circulation 1999;100:1380‚Äì6. https://doi.org/10.1161/01.cir.100.13.1380 
629. Bertog SC, Thambidorai SK, Parakh K, Schoenhagen P, Ozduran V, Houghtaling PL, 
et al. Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy. J Am Coll Cardiol 2004;43:1445‚Äì52. https://doi.org/10.1016/j.jacc.2003.11.048 
630. Mutyaba AK, Balkaran S, Cloete R, du Plessis N, Badri M, Brink J, et al. Constrictive pericarditis requiring pericardiectomy at Groote Schuur Hospital, Cape Town, South 
Africa: causes and perioperative outcomes in the HIV era (1990‚Äì2012). J Thorac 
Cardiovasc Surg 2014;148:3058‚Äì65.e1. https://doi.org/10.1016/j.jtcvs.2014.07.065 
631. Yang J, Xiang W, He R, Zhang P. Tuberculous constrictive pericarditis: ‚Äòarmored heart‚Äô. 
QJM 2024;117:679‚Äì80. https://doi.org/10.1093/qjmed/hcae101 
632. Welch TD, Ling LH, Espinosa RE, Anavekar NS, Wiste HJ, Lahr BD, et al. 
Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circ 
Cardiovasc Imaging 2014;7:526‚Äì34. https://doi.org/10.1161/CIRCIMAGING.113.001613 
633. Talreja DR, Nishimura RA, Oh JK, Holmes DR. Constrictive pericarditis in the modern 
era: novel criteria for diagnosis in the cardiac catheterization laboratory. J Am Coll 
Cardiol 2008;51:315‚Äì9. https://doi.org/10.1016/j.jacc.2007.09.039 
634. Qamruddin S, Alkharabsheh SK, Sato K, Kumar A, Cremer PC, Chetrit M, et al. 
Differentiating constriction from restriction (from the Mayo Clinic echocardiographic 
criteria). Am J Cardiol 2019;124:932‚Äì8. https://doi.org/10.1016/j.amjcard.2019.06.002 
635. Saito T, Fukushima S, Yamasaki T, Kawamoto N, Tadokoro N, Kakuta T, et al. 
Pericardiectomy for constrictive pericarditis at a single Japanese center: 20 years of experience. Gen Thorac Cardiovasc Surg 2022;70:430‚Äì8. https://doi.org/10.1007/s11748- 
021-01718-x 
636. Choi MS, Jeong DS, Oh JK, Chang S-A, Park S-J, Chung S. Long-term results of radical 
pericardiectomy for constrictive pericarditis in Korean population. J Cardiothorac Surg 
2019;14:32. https://doi.org/10.1186/s13019-019-0845-7 
637. George TJ, Arnaoutakis GJ, Beaty CA, Kilic A, Baumgartner WA, Conte JV. 
Contemporary etiologies, risk factors, and outcomes after pericardiectomy. Ann 
Thorac Surg 2012;94:445‚Äì51. https://doi.org/10.1016/j.athoracsur.2012.03.079 
638. Tzani A, Doulamis IP, Tzoumas A, Avgerinos DV, Koudoumas D, Siasos G, et al. 
Meta-analysis of population characteristics and outcomes of patients undergoing pericardiectomy for constrictive pericarditis. Am J Cardiol 2021;146:120‚Äì7. https://doi.org/ 
10.1016/j.amjcard.2021.01.033 
639. Faiza Z, Prakash A, Namburi N, Johnson B, Timsina L, Lee LS. Fifteen-year experience 
with pericardiectomy at a tertiary referral center. J Cardiothorac Surg 2021;16:180.  
https://doi.org/10.1186/s13019-021-01561-4 
640. Gillaspie EA, Stulak JM, Daly RC, Greason KL, Joyce LD, Oh J, et al. A 20-year experience with isolated pericardiectomy: analysis of indications and outcomes. J Thorac 
Cardiovasc Surg 2016;152:448‚Äì58. https://doi.org/10.1016/j.jtcvs.2016.03.098 
641. Ntsekhe M, Shey Wiysonge C, Commerford PJ, Mayosi BM. The prevalence and outcome of effusive constrictive pericarditis: a systematic review of the literature. 
Cardiovasc J Afr 2012;23:281‚Äì5. https://doi.org/10.5830/CVJA-2011-072 
642. Thevathasan T, Kenny MA, Gaul AL, Paul J, Krause FJ, Lech S, et al. Sex and age characteristics in acute or chronic myocarditis. a descriptive, multicenter cohort study. 
JACC Adv 2024;3:100857. https://doi.org/10.1016/j.jacadv.2024.100857 
643. Kanaoka K, Onoue K, Terasaki S, Nakano T, Nakai M, Sumita Y, et al. Features and outcomes of histologically proven myocarditis with fulminant presentation. Circulation 
2022;146:1425‚Äì33. https://doi.org/10.1161/CIRCULATIONAHA.121.058869 
644. Conte E, Leoni O, Ammirati E, Imazio M, Brucato A. Incidence of myocarditis and pericarditis considered as separate clinical events over the years and post-SARS-CoV2 vaccination in adults and children. Eur J Intern Med 2023;115:140‚Äì2. https://doi.org/10. 
1016/j.ejim.2023.06.002 
645. Klugman D, Berger JT, Sable CA, He J, Khandelwal SG, Slonim AD. Pediatric patients 
hospitalized with myocarditis: a multi-institutional analysis. Pediatr Cardiol 2010;31: 
222‚Äì8. https://doi.org/10.1007/s00246-009-9589-9 
646. Pitak B, Opgen-Rhein B, Schubert S, Reineker K, Wiegand G, Boecker D, et al. 
Cardiovascular magnetic resonance in children with suspected myocarditis: current 
practice and applicability of adult protocols. Cardiol Young 2022;32:1957‚Äì65. https:// 
doi.org/10.1017/S1047951121005291 
647. Peng DM, Kwiatkowski DM, Lasa JJ, Zhang W, Banerjee M, Mikesell K, et al. 
Contemporary care and outcomes of critically-ill children with clinically diagnosed 
myocarditis. J Card Fail 2023;30:350‚Äì8. https://doi.org/10.1016/j.cardfail.2023.04.010 
648. Schubert S, Opgen-Rhein B, Boehne M, Weigelt A, Wagner R, M√ºller G, et al. Severe 
heart failure and the need for mechanical circulatory support and heart transplantation 
in pediatric patients with myocarditis: results from the prospective multicenter registry 
‚ÄòMYKKE‚Äô. Pediatr Transplant 2019;23:e13548. https://doi.org/10.1111/petr.13548 
649. Matsuura H, Ichida F, Saji T, Ogawa S, Waki K, Kaneko M, et al. Clinical features of acute 
and fulminant myocarditis in children ‚Äì 2nd Nationwide Survey by Japanese Society of 
Pediatric Cardiology and Cardiac Surgery. Circ J 2016;80:2362‚Äì8. https://doi.org/10. 
1253/circj.CJ-16-0234 
650. Yao Q, Zhan S. Corticosteroid in anti-inflammatory treatment of pediatric acute myocarditis: a systematic review and meta-analysis. Ital J Pediatr 2023;49:30. https://doi.org/ 
10.1186/s13052-023-01423-w 
651. Camargo PR, Snitcowsky R, da Luz PL, Mazzieri R, Higuchi ML, Rati M, et al. Favorable 
effects of immunosuppressive therapy in children with dilated cardiomyopathy and active myocarditis. Pediatr Cardiol 1995;16:61‚Äì8. https://doi.org/10.1007/BF00796819 
652. Aziz KU, Patel N, Sadullah T, Tasneem H, Thawerani H, Talpur S. Acute viral myocarditis: role of immunosuppression: a prospective randomised study. Cardiol Young 2010; 
20:509‚Äì15. https://doi.org/10.1017/S1047951110000594 
653. Lin M-S, Tseng Y-H, Chen M-Y, Chung C-M, Tsai M-H, Wang P-C, et al. In-hospital and 
post-discharge outcomes of pediatric acute myocarditis underwent after high-dose 
steroid or intravenous immunoglobulin therapy. BMC Cardiovasc Disord 2019;19:10.  
https://doi.org/10.1186/s12872-018-0981-3 
654. Butts RJ, Boyle GJ, Deshpande SR, Gambetta K, Knecht KR, Prada-Ruiz CA, et al. 
Characteristics of clinically diagnosed pediatric myocarditis in a contemporary multi- 
center cohort. Pediatr Cardiol 2017;38:1175‚Äì82. https://doi.org/10.1007/s00246-017- 
1638-1 
655. Huang X, Sun Y, Su G, Li Y, Shuai X. Intravenous immunoglobulin therapy for acute 
myocarditis in children and adults. Int Heart J 2019;60:359‚Äì65. https://doi.org/10. 
1536/ihj.18-299 
656. Imazio M, Brucato A, Pluymaekers N, Breda L, Calabri G, Cantarini L, et al. Recurrent 
pericarditis in children and adolescents: a multicentre cohort study. J Cardiovasc Med 
(Hagerstown) 2016;17:707‚Äì12. https://doi.org/10.2459/JCM.0000000000000300 
657. Alsabri M, Elsayed SM, Elsnhory AB, Abouelmagd K, Ayyad M, Alqeeq BF, et al. Efficacy 
and safety of colchicine in pediatric pericarditis: a systematic review and future directions. Pediatr Cardiol 2024; https://doi.org/10.1007/s00246-024-03606-6 
658. Caorsi R, Insalaco A, Bovis F, Martini G, Cattalini M, Chinali M, et al. Pediatric recurrent 
pericarditis: appropriateness of the standard of care and response to IL-1 blockade. J 
Pediatr 2023;256:18‚Äì26.e8. https://doi.org/10.1016/j.jpeds.2022.11.034 
659. Sunohara D, Motoki H, Saigusa T, Ebisawa S, Okada A, Ando H, et al. Biopsy detection 
and clinical management of acute lymphocytic myocarditis in pregnancy. J Cardiol Cases 
2019;20:164‚Äì7. https://doi.org/10.1016/j.jccase.2019.07.010 
660. Veronese G, Nonini S, Cannata A, Aresta F, Olivieri G, Montrasio E, et al. Fulminant 
lymphocytic myocarditis during pregnancy treated with temporary mechanical circulatory supports and aggressive immunosuppression. Circ Heart Fail 2022;15: 
e009810. https://doi.org/10.1161/CIRCHEARTFAILURE.122.009810 
661. Moore RC, Briery CM, Rose CH, Skelton TN, Martin JN. Lymphocytic myocarditis 
presenting as nausea, vomiting, and hepatic dysfunction in the first trimester of pregnancy. Obstet Gynecol 2006;108:815‚Äì7. https://doi.org/10.1097/01.AOG.0000216016. 
91685.52 
662. Marceau A, McGinnis JM, Derakhshan F, Liu YA, Sathananthan G, Sosa Cazales AC, 
et al. Interdisciplinary approach to an unusual case of myocarditis in pregnancy. CJC 
Open 2019;1:103‚Äì5. https://doi.org/10.1016/j.cjco.2019.02.001 
663. Movva R, Brown SB, Morris DL, Figueredo VM. Anakinra for myocarditis in juvenile 
idiopathic arthritis. Tex Heart Inst J 2013;40:623‚Äì5. 
664. Brucato A, Pluymaekers N, Tombetti E, Rampello S, Maestroni S, Lucianetti M, et al. 
Management of idiopathic recurrent pericarditis during pregnancy. Int J Cardiol 2019; 
282:60‚Äì5. https://doi.org/10.1016/j.ijcard.2019.02.003 
665. Pouta AM, R√§s√§nen JP, Airaksinen KE, Vuolteenaho OJ, Laatikainen TJ. Changes in maternal heart dimensions and plasma atrial natriuretic peptide levels in the early puerperium of normal and pre-eclamptic pregnancies. Br J Obstet Gynaecol 1996;103: 
988‚Äì92. https://doi.org/10.1111/j.1471-0528.1996.tb09548.x 
666. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstr√∂m-Lundqvist C, C√≠fkov√° 
R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165‚Äì241. https://doi.org/10.1093/ 
eurheartj/ehy340 
667. Schreiber K, Frishman M, Russell MD, Dey M, Flint J, Allen A, et al. British Society for 
Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice. Rheumatology 2023;62: 
e89‚Äìe104. https://doi.org/10.1093/rheumatology/keac552 
668. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin 
MD, et al. 2020 American College of Rheumatology Guideline for the management  
ESC Guidelines                                                                                                                                                                                               89


<!-- PAGE 90 -->

### Page 90

of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 
2020;72:529‚Äì56. https://doi.org/10.1002/art.41191 
669. G√∂testam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers 
C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795‚Äì810. https:// 
doi.org/10.1136/annrheumdis-2015-208840 
670. Russell MD, Dey M, Flint J, Davie P, Allen A, Crossley A, et al. British Society for 
Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology 2023;62: 
e48‚Äìe88. https://doi.org/10.1093/rheumatology/keac551 
671. Bizzi E, Cavaleri F, Mascolo R, Conte E, Maggiolini S, Decarlini CC, et al. Recurrent pericarditis in older adults: clinical and laboratory features and outcome. J Am Geriatr Soc 
2024;72:3467‚Äì75. https://doi.org/10.1111/jgs.19150 
672. Pasina L, Brucato AL, Falcone C, Cucchi E, Bresciani A, Sottocorno M, et al. Medication 
non-adherence among elderly patients newly discharged and receiving polypharmacy. 
Drugs Aging 2014;31:283‚Äì9. https://doi.org/10.1007/s40266-014-0163-7 
673. Peretto G, De Luca G, Campochiaro C, Palmisano A, Busnardo E, Sartorelli S, et al. 
Telemedicine in myocarditis: evolution of a mutidisciplinary ‚Äòdisease unit‚Äô at the time 
of COVID-19 pandemic. Am Heart J 2020;229:121‚Äì6. https://doi.org/10.1016/j.ahj. 
2020.07.015 
674. Aldajani A, B√©rub√© M, Mardigyan V. How and why to set up a pericardial disease clinic. 
Can J Cardiol 2023;39:1149‚Äì51. https://doi.org/10.1016/j.cjca.2023.04.028 
675. Mizia-Stec K, Charron P, Gimeno Blanes JR, Elliott P, Kaski JP, Maggioni AP, et al. 
Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis 
of cardiomyopathy: the ESC EORP cardiomyopathy/myocarditis registry. Eur Heart J 
Cardiovasc Imaging 2021;22:781‚Äì9. https://doi.org/10.1093/ehjci/jeaa329 
676. Kaski JP, Norrish G, Gimeno Blanes JR, Charron P, Elliott P, Tavazzi L, et al. 
Cardiomyopathies in children and adolescents: aetiology, management, and outcomes 
in the European Society of Cardiology EURObservational Research Programme 
Cardiomyopathy and Myocarditis Registry. Eur Heart J 2024;45:1443‚Äì54. https://doi. 
org/10.1093/eurheartj/ehae109

<!-- 2025_Pregnancy_CVD.md -->

# ESC Guidelines: Pregnancy CVD (2025)

**Source**: `2025_Pregnancy_CVD.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 107

---

## Table of Contents

- [2025 ESC Guidelines for the management of cardiovascular disease and pregnancy](#2025-esc-guidelines-for-the-management-of-cardiova) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 7)*
  - [2. Introduction](#2-introduction) *(p. 8)*
    - [2.1. Why we need new Guidelines on cardiovascular disease and pregnancy](#21-why-we-need-new-guidelines-on-cardiovascular-di) *(p. 8)*
    - [2.2. Why these Guidelines are important](#22-why-these-guidelines-are-important) *(p. 8)*
    - [2.3. What is new](#23-what-is-new) *(p. 8)*
    - [2.4. What has changed](#24-what-has-changed) *(p. 11)*
  - [3. General considerations](#3-general-considerations) *(p. 12)*
    - [3.1. Epidemiology](#31-epidemiology) *(p. 12)*
    - [3.2. Physiology of pregnancy](#32-physiology-of-pregnancy) *(p. 12)*
  - [4. The Pregnancy Heart Team](#4-the-pregnancy-heart-team) *(p. 14)*
    - [4.1. Concept and requirements](#41-concept-and-requirements) *(p. 14)*
    - [4.2. Pre-pregnancy counselling and family planning](#42-pre-pregnancy-counselling-and-family-planning) *(p. 14)*
      - [4.2.1. Risk assessment](#421-risk-assessment) *(p. 14)*
        - [4.2.1.1. Maternal risk assessment](#4211-maternal-risk-assessment) *(p. 14)*
      - [4.2.2. Genetic counselling](#422-genetic-counselling) *(p. 14)*
        - [4.2.2.1. Pre-natal and pre-implantation diagnosis](#4221-pre-natal-and-pre-implantation-diagnosis) *(p. 14)*
      - [4.2.3. Reproductive technology](#423-reproductive-technology) *(p. 14)*
      - [4.2.4. Contraception](#424-contraception) *(p. 21)*
      - [4.2.5. Termination of pregnancy including psychological support](#425-termination-of-pregnancy-including-psychologic) *(p. 21)*
    - [4.3. Diagnostic methods in pregnancy](#43-diagnostic-methods-in-pregnancy) *(p. 23)*
      - [4.3.1. Electrocardiogram, including mobile rhythm devices](#431-electrocardiogram,-including-mobile-rhythm-dev) *(p. 23)*
      - [4.3.2. Echocardiography](#432-echocardiography) *(p. 23)*
      - [4.3.3. Cardiopulmonary exercise testing](#433-cardiopulmonary-exercise-testing) *(p. 23)*
      - [4.3.4. Biomarkers](#434-biomarkers) *(p. 23)*
      - [4.3.5. Ionizing radiation exposure](#435-ionizing-radiation-exposure) *(p. 23)*
        - [4.3.5.1. Chest radiography](#4351-chest-radiography) *(p. 23)*
        - [4.3.5.2. Computed tomography and nuclear medicine imaging](#4352-computed-tomography-and-nuclear-medicine-ima) *(p. 23)*
        - [4.3.5.3. Cardiac catheterization](#4353-cardiac-catheterization) *(p. 24)*
      - [4.3.6. Cardiovascular magnetic resonance](#436-cardiovascular-magnetic-resonance) *(p. 24)*
    - [4.4. Foetal assessment](#44-foetal-assessment) *(p. 24)*
      - [4.4.1. Risk of foetal/obstetric complications](#441-risk-of-foetal/obstetric-complications) *(p. 24)*
      - [4.4.2. Screening for congenital heart disease in the foetus](#442-screening-for-congenital-heart-disease-in-the-) *(p. 24)*
      - [4.4.3. Assessing foetal well-being](#443-assessing-foetal-well-being) *(p. 24)*
      - [4.4.4. Foetal assessment of heritable primary arrhythmias](#444-foetal-assessment-of-heritable-primary-arrhyth) *(p. 25)*
    - [4.5. Timing and mode of delivery](#45-timing-and-mode-of-delivery) *(p. 25)*
      - [4.5.1. Timing of delivery](#451-timing-of-delivery) *(p. 25)*
      - [4.5.2. Induction of labour](#452-induction-of-labour) *(p. 25)*
      - [4.5.3. Vaginal or caesarean delivery](#453-vaginal-or-caesarean-delivery) *(p. 25)*
      - [4.5.4. Haemodynamic monitoring during delivery](#454-haemodynamic-monitoring-during-delivery) *(p. 25)*
      - [4.5.5. Anaesthesia/analgesia](#455-anaesthesia/analgesia) *(p. 25)*
      - [4.5.6. Delivery in women on anticoagulants](#456-delivery-in-women-on-anticoagulants) *(p. 26)*
        - [4.5.6.1. Planned delivery](#4561-planned-delivery) *(p. 26)*
        - [4.5.6.2. Urgent delivery on therapeutic anticoagulation](#4562-urgent-delivery-on-therapeutic-anticoagulatio) *(p. 26)*
          - [4.5.6.2.1. Delivery on vitamin K antagonists](#45621-delivery-on-vitamin-k-antagonists) *(p. 26)*
          - [4.5.6.2.2. Delivery on heparin](#45622-delivery-on-heparin) *(p. 26)*
        - [4.5.6.3. Restarting anticoagulation after delivery](#4563-restarting-anticoagulation-after-delivery) *(p. 26)*
      - [4.5.7. Endocarditis prophylaxis for delivery](#457-endocarditis-prophylaxis-for-delivery) *(p. 26)*
    - [4.6. Post-partum monitoring and complications](#46-post-partum-monitoring-and-complications) *(p. 28)*
      - [4.6.1. Monitoring](#461-monitoring) *(p. 28)*
      - [4.6.2. Breastfeeding and lactation](#462-breastfeeding-and-lactation) *(p. 28)*
      - [4.6.3. Complications](#463-complications) *(p. 28)*
        - [4.6.3.1. Haemorrhage](#4631-haemorrhage) *(p. 28)*
        - [4.6.3.2. Psychological reactions, post-partum depression](#4632-psychological-reactions,-post-partum-depressi) *(p. 28)*
  - [5. Drugs during pregnancy and lactation](#5-drugs-during-pregnancy-and-lactation) *(p. 28)*
    - [5.1. General principles](#51-general-principles) *(p. 28)*
      - [5.1.1. Pharmacokinetics and pharmacodynamics in pregnancy](#511-pharmacokinetics-and-pharmacodynamics-in-pregn) *(p. 28)*
      - [5.1.2. Pharmacogenetics](#512-pharmacogenetics) *(p. 28)*
      - [5.1.3. Newborn drug exposure in breast milk](#513-newborn-drug-exposure-in-breast-milk) *(p. 28)*
    - [5.2. Drug classes in pregnancy](#52-drug-classes-in-pregnancy) *(p. 28)*
      - [5.2.1. Anticoagulants](#521-anticoagulants) *(p. 28)*
        - [Low-molecular-weight heparin treatment regimen glossary](#low-molecular-weight-heparin-treatment-regimen-glo) *(p. 29)*
        - [5.2.1.1. Vitamin K antagonists](#5211-vitamin-k-antagonists) *(p. 29)*
        - [5.2.1.2. Low-molecular-weight heparins](#5212-low-molecular-weight-heparins) *(p. 30)*
          - [5.2.1.2.1. Low-molecular-weight heparin dosing](#52121-low-molecular-weight-heparin-dosing) *(p. 30)*
          - [5.2.1.2.2. Once-daily vs twice-daily administration](#52122-once-daily-vs-twice-daily-administration) *(p. 30)*
        - [5.2.1.3. Unfractionated heparin](#5213-unfractionated-heparin) *(p. 30)*
        - [5.2.1.4. Fondaparinux](#5214-fondaparinux) *(p. 30)*
        - [5.2.1.5. Direct oral anticoagulants](#5215-direct-oral-anticoagulants) *(p. 30)*
      - [5.2.2. Antiplatelet treatment](#522-antiplatelet-treatment) *(p. 31)*
      - [5.2.3. Diuretics and SGLT2 inhibitors](#523-diuretics-and-sglt2-inhibitors) *(p. 31)*
      - [5.2.4. Pulmonary hypertension](#524-pulmonary-hypertension) *(p. 31)*
      - [5.2.5. Anti-arrhythmic agents](#525-anti-arrhythmic-agents) *(p. 31)*
      - [5.2.6. Calcium channel blockers](#526-calcium-channel-blockers) *(p. 31)*
      - [5.2.7. Renin‚Äìangiotensin‚Äìaldosterone system inhibitors](#527-renin‚Äìangiotensin‚Äìaldosterone-system-inhibitor) *(p. 32)*
      - [5.2.8. Lipid-lowering agents](#528-lipid-lowering-agents) *(p. 32)*
      - [5.2.9. Beta-adrenergic blocking agents](#529-beta-adrenergic-blocking-agents) *(p. 32)*
      - [5.2.10. Immunosuppressants](#5210-immunosuppressants) *(p. 32)*
      - [5.2.11. Neuroactive drugs](#5211-neuroactive-drugs) *(p. 32)*
      - [5.2.12. Obstetric drugs in patients with cardiovascular disease](#5212-obstetric-drugs-in-patients-with-cardiovascul) *(p. 32)*
    - [5.3. Internet databases](#53-internet-databases) *(p. 32)*
    - [5.4. List of drugs](#54-list-of-drugs) *(p. 32)*
  - [6. Pregnancy in women with cardiomyopathies and primary arrhythmia syndromes](#6-pregnancy-in-women-with-cardiomyopathies-and-pri) *(p. 34)*
    - [6.1. Cardiomyopathies](#61-cardiomyopathies) *(p. 34)*
      - [6.1.1. Dilated cardiomyopathy and non-dilated left ventricular cardiomyopathy](#611-dilated-cardiomyopathy-and-non-dilated-left-ve) *(p. 34)*
      - [6.1.2. Arrhythmogenic right ventricular cardiomyopathy](#612-arrhythmogenic-right-ventricular-cardiomyopath) *(p. 34)*
      - [6.1.3. Hypertrophic cardiomyopathy](#613-hypertrophic-cardiomyopathy) *(p. 34)*
        - [6.1.3.1. Treatment of hypertrophic cardiomyopathy in pregnancy](#6131-treatment-of-hypertrophic-cardiomyopathy-in-p) *(p. 34)*
        - [6.1.3.2. Left ventricular outflow tract obstruction](#6132-left-ventricular-outflow-tract-obstruction) *(p. 34)*
      - [6.1.4. Hypertrabeculation of the left ventricle](#614-hypertrabeculation-of-the-left-ventricle) *(p. 35)*
      - [6.1.5. Labour and delivery in cardiomyopathies](#615-labour-and-delivery-in-cardiomyopathies) *(p. 35)*
    - [6.2. Primary arrhythmia syndromes](#62-primary-arrhythmia-syndromes) *(p. 35)*
      - [6.2.1. Long QT syndrome](#621-long-qt-syndrome) *(p. 35)*
      - [6.2.2. Brugada syndrome](#622-brugada-syndrome) *(p. 36)*
      - [6.2.3. Catecholaminergic polymorphic ventricular tachycardia](#623-catecholaminergic-polymorphic-ventricular-tac) *(p. 36)*
      - [6.2.4. Short QT syndrome](#624-short-qt-syndrome) *(p. 36)*
      - [6.2.5. Labour and delivery in primary arrhythmia syndromes](#625-labour-and-delivery-in-primary-arrhythmia-synd) *(p. 36)*
  - [7. Peripartum cardiomyopathy](#7-peripartum-cardiomyopathy) *(p. 37)*
    - [7.1. Epidemiology](#71-epidemiology) *(p. 37)*
    - [7.2. Mechanisms](#72-mechanisms) *(p. 37)*
    - [7.3. Diagnosis and clinical interventions](#73-diagnosis-and-clinical-interventions) *(p. 37)*
    - [7.4. Outcomes](#74-outcomes) *(p. 39)*
  - [8. Pregnancy in women with aortopathies](#8-pregnancy-in-women-with-aortopathies) *(p. 39)*
    - [8.1. Women with heritable thoracic aortic disease](#81-women-with-heritable-thoracic-aortic-disease) *(p. 39)*
      - [8.1.1. Marfan syndrome](#811-marfan-syndrome) *(p. 40)*
      - [8.1.2. Loeys‚ÄìDietz syndrome](#812-loeys‚Äìdietz-syndrome) *(p. 40)*
      - [8.1.3. Vascular Ehlers‚ÄìDanlos syndrome](#813-vascular-ehlers‚Äìdanlos-syndrome) *(p. 40)*
      - [8.1.4. Non-syndromic heritable thoracic aortic diseases](#814-non-syndromic-heritable-thoracic-aortic-diseas) *(p. 40)*
      - [8.1.5. Aortic disease with no identifiable (likely) pathogenic variant](#815-aortic-disease-with-no-identifiable-(likely)-p) *(p. 40)*
    - [8.2. Turner syndrome](#82-turner-syndrome) *(p. 40)*
    - [8.3. Bicuspid aortic valve disease](#83-bicuspid-aortic-valve-disease) *(p. 40)*
    - [8.4. Aortic aneurysms other than root or ascending aorta](#84-aortic-aneurysms-other-than-root-or-ascending-a) *(p. 41)*
    - [8.5. Aortic dissection](#85-aortic-dissection) *(p. 41)*
    - [8.6. Management](#86-management) *(p. 41)*
    - [8.7. Cardiac surgery during pregnancy](#87-cardiac-surgery-during-pregnancy) *(p. 42)*
  - [9. Pregnancy in women with known congenital heart disease](#9-pregnancy-in-women-with-known-congenital-heart-d) *(p. 43)*
  - [10. Pregnancy in women with pulmonary arterial hypertension](#10-pregnancy-in-women-with-pulmonary-arterial-hype) *(p. 47)*
    - [10.1. Pre-existing pulmonary arterial hypertension](#101-pre-existing-pulmonary-arterial-hypertension) *(p. 47)*
      - [10.1.1. Maternal and foetal risk](#1011-maternal-and-foetal-risk) *(p. 47)*
      - [10.1.2. Counselling and contraception](#1012-counselling-and-contraception) *(p. 47)*
      - [10.1.3. Management during pregnancy](#1013-management-during-pregnancy) *(p. 47)*
    - [10.2. New diagnosis in pregnancy](#102-new-diagnosis-in-pregnancy) *(p. 48)*
    - [10.3. Delivery in women with pulmonary arterial hypertension](#103-delivery-in-women-with-pulmonary-arterial-hype) *(p. 48)*
      - [10.3.1. Peri- and post-partum monitoring](#1031-peri--and-post-partum-monitoring) *(p. 48)*
  - [11. Venous thromboembolism in pregnancy and post-partum](#11-venous-thromboembolism-in-pregnancy-and-post-pa) *(p. 48)*
    - [11.1. Epidemiology and maternal risk](#111-epidemiology-and-maternal-risk) *(p. 48)*
    - [11.2. Risk factors for pregnancy-related venous thromboembolism](#112-risk-factors-for-pregnancy-related-venous-thro) *(p. 48)*
    - [11.3. Prevention of venous thromboembolism](#113-prevention-of-venous-thromboembolism) *(p. 49)*
      - [11.3.1. Pregnant women with no prior indications for long-term anticoagulation](#1131-pregnant-women-with-no-prior-indications-for-) *(p. 49)*
      - [11.3.2. Pregnant women with prior indication for long-term anticoagulation](#1132-pregnant-women-with-prior-indication-for-long) *(p. 49)*
    - [11.4. Management of acute venous thromboembolism](#114-management-of-acute-venous-thromboembolism) *(p. 49)*
      - [11.4.1. Clinical presentation and diagnosis](#1141-clinical-presentation-and-diagnosis) *(p. 49)*
        - [11.4.1.1. Deep vein thrombosis](#11411-deep-vein-thrombosis) *(p. 49)*
        - [11.4.1.2. Pulmonary embolism](#11412-pulmonary-embolism) *(p. 50)*
      - [11.4.2. Treatment of venous thromboembolism in pregnancy](#1142-treatment-of-venous-thromboembolism-in-pregna) *(p. 50)*
    - [11.5. Management of delivery and the post-partum period](#115-management-of-delivery-and-the-post-partum-per) *(p. 52)*
  - [12. Pregnancy in women with acquired heart disease](#12-pregnancy-in-women-with-acquired-heart-disease) *(p. 52)*
    - [12.1. Acute chest pain in pregnancy](#121-acute-chest-pain-in-pregnancy) *(p. 52)*
    - [12.2. Coronary artery disease](#122-coronary-artery-disease) *(p. 52)*
      - [12.2.1. Acute coronary syndrome](#1221-acute-coronary-syndrome) *(p. 52)*
        - [12.2.1.1. Coronary artery disease epidemiology and aetiology](#12211-coronary-artery-disease-epidemiology-and-aet) *(p. 52)*
        - [12.2.1.2. Presentation and diagnosis](#12212-presentation-and-diagnosis) *(p. 54)*
        - [12.2.1.3. Pregnancy-associated spontaneous coronary artery dissection](#12213-pregnancy-associated-spontaneous-coronary-ar) *(p. 54)*
      - [12.2.2. Coronary artery interventions](#1222-coronary-artery-interventions) *(p. 54)*
      - [12.2.3. Chronic coronary syndromes in pregnancy](#1223-chronic-coronary-syndromes-in-pregnancy) *(p. 54)*
      - [12.2.4. Management and delivery](#1224-management-and-delivery) *(p. 54)*
    - [12.3. Hypertensive disorders](#123-hypertensive-disorders) *(p. 55)*
      - [12.3.1. Definition and classification of hypertension in pregnancy](#1231-definition-and-classification-of-hypertension) *(p. 56)*
        - [12.3.1.1. Pre-eclampsia/eclampsia](#12311-pre-eclampsia/eclampsia) *(p. 56)*
      - [12.3.2. Diagnosis and risk assessment](#1232-diagnosis-and-risk-assessment) *(p. 56)*
        - [12.3.2.1. Blood pressure measurement](#12321-blood-pressure-measurement) *(p. 56)*
        - [12.3.2.2. Laboratory tests](#12322-laboratory-tests) *(p. 56)*
      - [12.3.3. Management of hypertension in pregnancy](#1233-management-of-hypertension-in-pregnancy) *(p. 56)*
        - [12.3.3.1. Non-pharmacological management](#12331-non-pharmacological-management) *(p. 56)*
        - [12.3.3.2. Pharmacological treatment](#12332-pharmacological-treatment) *(p. 57)*
          - [12.3.3.2.1. Mild hypertension (BP 140/90 ‚Äì 159/109 mmHg)](#123321-mild-hypertension-(bp-140/90-‚Äì-159/109-mmhg) *(p. 57)*
          - [12.3.3.2.2. Pre-eclampsia](#123322-pre-eclampsia) *(p. 57)*
          - [12.3.3.2.3. Severe hypertension (BP ‚âß160/110 mmHg)](#123323-severe-hypertension-(bp-‚âß160/110-mmhg)) *(p. 60)*
      - [12.3.4. Hypertension and delivery](#1234-hypertension-and-delivery) *(p. 60)*
    - [12.4. Arrhythmias](#124-arrhythmias) *(p. 61)*
      - [12.4.1. Supraventricular arrhythmias](#1241-supraventricular-arrhythmias) *(p. 61)*
        - [12.4.1.1. New-onset narrow QRS tachycardia ](#12411-new-onset-narrow-qrs-tachycardia-) *(p. 61)*
        - [12.4.1.2. Atrial fibrillation including anticoagulation](#12412-atrial-fibrillation-including-anticoagulatio) *(p. 62)*
        - [12.4.1.3. Pre-existing supraventricular tachycardia](#12413-pre-existing-supraventricular-tachycardia) *(p. 63)*
      - [12.4.2. Ventricular arrhythmias](#1242-ventricular-arrhythmias) *(p. 64)*
      - [12.4.3. Cardioversion, ablation, and device implantation, and implantable cardioverter defibrillator management](#1243-cardioversion,-ablation,-and-device-implantat) *(p. 64)*
        - [12.4.3.1. Electrical cardioversion](#12431-electrical-cardioversion) *(p. 64)*
        - [12.4.3.2. Catheter ablation](#12432-catheter-ablation) *(p. 64)*
        - [12.4.3.3. Device implantation](#12433-device-implantation) *(p. 65)*
        - [12.4.3.4. Implantable cardioverter defibrillator management](#12434-implantable-cardioverter-defibrillator-manag) *(p. 66)*
      - [12.4.4. Cardiac arrest](#1244-cardiac-arrest) *(p. 68)*
      - [12.4.5. Bradycardia](#1245-bradycardia) *(p. 69)*
        - [12.4.5.1. Sinus node dysfunction](#12451-sinus-node-dysfunction) *(p. 69)*
        - [12.4.5.2. Atrioventricular block](#12452-atrioventricular-block) *(p. 69)*
        - [12.4.5.3. Management of sinus node dysfunction and atrioventricular block](#12453-management-of-sinus-node-dysfunction-and-atr) *(p. 69)*
    - [12.5. Valvular heart disease](#125-valvular-heart-disease) *(p. 69)*
      - [12.5.1. Stenotic native valve lesions](#1251-stenotic-native-valve-lesions) *(p. 69)*
        - [12.5.1.1. Mitral valve stenosis](#12511-mitral-valve-stenosis) *(p. 70)*
          - [12.5.1.1.1. Management](#125111-management) *(p. 70)*
          - [12.5.1.1.2. Interventions](#125112-interventions) *(p. 70)*
          - [12.5.1.1.3. Delivery](#125113-delivery) *(p. 70)*
          - [12.5.1.1.4. Post-partum](#125114-post-partum) *(p. 70)*
        - [12.5.1.2. Valvular aortic stenosis](#12512-valvular-aortic-stenosis) *(p. 70)*
          - [12.5.1.2.1. Management](#125121-management) *(p. 70)*
      - [12.5.2. Regurgitant native valve lesions](#1252-regurgitant-native-valve-lesions) *(p. 70)*
        - [12.5.2.1. Mitral and aortic valve regurgitation](#12521-mitral-and-aortic-valve-regurgitation) *(p. 70)*
          - [12.5.2.1.1. Management](#125211-management) *(p. 70)*
        - [12.5.2.2. Arrhythmogenic mitral valve prolapse](#12522-arrhythmogenic-mitral-valve-prolapse) *(p. 70)*
        - [12.5.2.3. Tricuspid regurgitation](#12523-tricuspid-regurgitation) *(p. 71)*
      - [12.5.3. Prosthetic valves](#1253-prosthetic-valves) *(p. 72)*
        - [12.5.3.1. Bioprosthetic valves](#12531-bioprosthetic-valves) *(p. 72)*
        - [12.5.3.2. Mechanical valves](#12532-mechanical-valves) *(p. 72)*
          - [12.5.3.2.1. Anticoagulation during pregnancy](#125321-anticoagulation-during-pregnancy) *(p. 73)*
          - [12.5.3.2.2. Mechanical valve thrombosis](#125322-mechanical-valve-thrombosis) *(p. 73)*
          - [12.5.3.2.3. Anticoagulation during delivery in women with mechanical heart valves](#125323-anticoagulation-during-delivery-in-women-wi) *(p. 73)*
      - [12.5.4. Endocarditis prophylaxis](#1254-endocarditis-prophylaxis) *(p. 75)*
    - [12.6. Heart failure](#126-heart-failure) *(p. 75)*
      - [12.6.1. Chronic heart failure](#1261-chronic-heart-failure) *(p. 75)*
      - [12.6.2. Acute heart failure (including cardiogenic shock)](#1262-acute-heart-failure-(including-cardiogenic-sh) *(p. 75)*
    - [12.7. Special populations](#127-special-populations) *(p. 77)*
      - [12.7.1. Heart transplantation](#1271-heart-transplantation) *(p. 77)*
      - [12.7.2. Cardio-oncology](#1272-cardio-oncology) *(p. 77)*
        - [12.7.2.1 Gestational cancer](#12721-gestational-cancer) *(p. 77)*
        - [12.7.2.2 Pregnancy in cancer survivors](#12722-pregnancy-in-cancer-survivors) *(p. 78)*
  - [13. Adverse pregnancy outcomes and long-term management](#13-adverse-pregnancy-outcomes-and-long-term-manage) *(p. 78)*
    - [13.1. Adverse pregnancy outcomes](#131-adverse-pregnancy-outcomes) *(p. 78)*
      - [13.1.1. Post-partum hypertensive disorders](#1311-post-partum-hypertensive-disorders) *(p. 78)*
      - [13.1.2. Gestational diabetes mellitus](#1312-gestational-diabetes-mellitus) *(p. 78)*
      - [13.1.3. Pre-term birth](#1313-pre-term-birth) *(p. 78)*
      - [13.1.4. Small for gestational age](#1314-small-for-gestational-age) *(p. 78)*
      - [13.1.5. Pregnancy loss and placental abruption](#1315-pregnancy-loss-and-placental-abruption) *(p. 78)*
    - [13.2. Breastfeeding](#132-breastfeeding) *(p. 78)*
    - [13.3. Women's Heart Clinics](#133-women's-heart-clinics) *(p. 79)*
  - [14. Key messages](#14-key-messages) *(p. 81)*
  - [15. Gaps in evidence](#15-gaps-in-evidence) *(p. 82)*
  - [16. ‚ÄòWhat to do‚Äô and ‚Äòwhat not to do‚Äô messages from the Guidelines](#16-‚Äòwhat-to-do‚Äô-and-‚Äòwhat-not-to-do‚Äô-messages-from) *(p. 83)*
  - [17. Evidence tables](#17-evidence-tables) *(p. 83)*
  - [18. Data availability statement](#18-data-availability-statement) *(p. 83)*
  - [19. Author information](#19-author-information) *(p. 88)*
  - [Appendix](#appendix) *(p. 88)*
  - [References](#references) *(p. 89)*
  - [References](#references) *(p. 89)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2025 ESC Guidelines for the management 
of cardiovascular disease and pregnancy 
Developed by the task force on the management of cardiovascular 
disease and pregnancy of the European Society of Cardiology (ESC) 
Endorsed by the European Society of Gynecology (ESG) 
Authors/Task Force Members: Julie De Backer  *‚Ä†, (Chairperson) (Belgium), 
Kristina H. Haugaa  *‚Ä†, (Chairperson) (Norway), Nina Eide Hasselberg  
‚Ä°, 
(Task Force Co-ordinator) (Norway), Mich√®le de Hosson  
‚Ä°, (Task Force 
Co-ordinator) (Belgium), Margarita Brida  
(Croatia), Silvia Castelletti  
(Italy), 
Matthew Cauldwell  
(United Kingdom), Elisabetta Cerbai  
(Italy), Lia Crotti  
(Italy), Natasja M.S. de Groot  
(Netherlands), Mette-Elise Estensen  
(Norway),  
Eva S. Goossens  
(Belgium), Bernhard Haring  
(Germany), Donata Kurpas  
(Poland), Carmel M. McEniery  
(United Kingdom), Sanne A.E. Peters  
(Netherlands), Amina Rakisheva  
(Kazakhstan), Antonia Sambola  
(Spain), 
Oliver Schlager  
(Austria), Florian S. Schoenhoff  
(Switzerland), 
Tommaso Simoncini  
1 (Italy), Fran√ßoise Steinbach (France), Isabella Sudano  
(Switzerland), Lorna Swan  
(United Kingdom), Anne Marie Valente  
(United States of America), and ESC Scientific Document Group 
* Corresponding authors: Julie De Backer, Cardiology, Ghent University Hospital, Ghent, Belgium, and Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium. 
Tel: +3293323344, E-mail: julie.debacker@ugent.be. Kristina H. Haugaa, Department of Cardiology, Oslo University Hospital, Oslo, Norway, and Institute for Clinical Medicine, 
University of Oslo, Oslo, Norway. Tel: +4723070000, E-mail: kristina.haugaa@medisin.uio.no. 
‚Ä† The two Chairpersons contributed equally to the document and are joint corresponding authors. 
‚Ä° The two Task Force Co-ordinators contributed equally to the document. 
Author/Task Force Member affiliations are listed in author information. 
1 Representing the European Society of Gynecology (ESG) 
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix. 
ESC subspecialty communities having participated in the development of this document: 
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA). 
Councils: Council on Cardiovascular Genomics, Council on Hypertension. 
Working Groups: Adult Congenital Heart Disease, Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Myocardial and Pericardial Diseases, 
Pulmonary Circulation and Right Ventricular Function, Thrombosis. 
Patient Forum 
Disclaimer The European Society of Cardiology (ESC) Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and 
the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other 
official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are 
encouraged to take the ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions 
in consideration of each patient‚Äôs health condition and in consultation with that patient and, where appropriate and/or necessary, the patient‚Äôs caregiver. Nor do the ESC Guidelines exempt 
health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to 
manage each patient‚Äôs case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional‚Äôs responsibility to verify the 
applicable rules and regulations relating to drugs and medical devices prior to making any clinical decision and to check whether a more recent version of this document exists. The ESC warns 
readers that the technical language may be misinterpreted and declines any responsibility in this respect. 
Permissions The content of these ESC Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be 
translated or reproduced in any form without written permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher 
of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com). 
¬© The European Society of Cardiology 2025. All rights reserved.  
https://doi.org/10.1093/eurheartj/ehaf193 
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Werner Budts, (CPG Review Co-ordinator) (Belgium), Karen Sliwa,  
(CPG Review Co-ordinator) (South Africa), Marianna Adamo (Italy), Elena Arbelo (Spain), Eloisa Arbustini (Italy), 
Giuseppe Boriani (Italy), Antonio Brucato (Italy), Sergio Buccheri (Sweden), Alessandra Bura Riviere (France), 
Pavel Calda1 (Czech Republic), G.-Andrei Dan (Romania), Konstantinos Dimopoulos (United Kingdom), 
Alexandra Frogoudaki (Greece), Estelle Gandjbakhch (France), Eva Gerdts (Norway), Sofie A Gevaert (Belgium), 
Bruna Gigante (Sweden), Bettina Heidecker (Germany), Borja Ibanez (Spain), Stefan James (Sweden), 
Mark Johnson (United Kingdom), Peter J√ºni (United Kingdom), Jolanda Kluin (Netherlands), Lars K√∏ber 
(Denmark), Konstantinos C. Koskinas (Switzerland), Greg Lip (United Kingdom), Emma F. Magavern  
(United Kingdom), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham 
(United Kingdom), Inge Moelgaard (Denmark), Philip Moons (Belgium), Jens Cosedis Nielsen (Denmark),  
Ntobeko A. B. Ntusi (South Africa), Agnes A. Pasquet (Belgium), Tatjana Potpara (Serbia), Eva Prescott 
(Denmark), Bianca Rocca (Italy), Jolien Roos-Hesselink (Netherlands), Xavier Rossell√≥ (Spain), Anna Sannino 
(Germany), Felix Tanner (Switzerland), Ulf Landmesser (Germany), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Katja Zeppenfeld (Netherlands), and Dayenne Zwaagman (Netherlands) 
All experts involved in the development of these guidelines have submitted declarations of interest 
which are reported in a supplementary document to the guidelines. See the European Heart Journal online or  
https://www.escardio.org/Guidelines for supplementary documents as well as evidence tables.  
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
Keywords 
Guidelines ‚Ä¢ Pregnancy ‚Ä¢ Cardiovascular ‚Ä¢ Heart failure ‚Ä¢ Arrhythmias ‚Ä¢ Genetic counselling ‚Ä¢ Risk stratification ‚Ä¢ 
Pregnancy heart team ‚Ä¢ Cardiomyopathies ‚Ä¢ Drugs in pregnancy ‚Ä¢ Aortic disease ‚Ä¢ Adult congenital heart disease ‚Ä¢ 
Peripartum cardiomyopathy ‚Ä¢ Hypertensive disorders of pregnancy ‚Ä¢ Adverse pregnancy outcomes  
Table of contents 
1. Preamble ...................................................................................................................... 7 
2. Introduction ............................................................................................................... 8 
2.1. Why we need new Guidelines on cardiovascular disease and 
pregnancy ...................................................................................................................
8 
2.2. Why these Guidelines are important ....................................................
8 
2.3. What is new .....................................................................................................
8 
2.4. What has changed ....................................................................................... 11 
3. General considerations ....................................................................................... 12 
3.1. Epidemiology .................................................................................................. 12 
3.2. Physiology of pregnancy ............................................................................ 12 
4. The Pregnancy Heart Team ............................................................................. 14 
4.1. Concept and requirements ...................................................................... 14 
4.2. Pre-pregnancy counselling and family planning ............................... 14 
4.2.1. Risk assessment ....................................................................................
14 
4.2.1.1. Maternal risk assessment .........................................................
14 
4.2.2. Genetic counselling .............................................................................
14 
4.2.2.1. Pre-natal and pre-implantation diagnosis ..........................
14 
4.2.3. Reproductive technology .................................................................
14 
4.2.4. Contraception .......................................................................................
21 
4.2.5. Termination of pregnancy including psychological  
support .................................................................................................................
21 
4.3. Diagnostic methods in pregnancy ......................................................... 23 
4.3.1. Electrocardiogram, including mobile rhythm devices ...........
23 
4.3.2. Echocardiography ................................................................................
23 
4.3.3. Cardiopulmonary exercise testing ...............................................
23 
4.3.4. Biomarkers ..............................................................................................
23 
4.3.5. Ionizing radiation exposure .............................................................
23 
4.3.5.1. Chest radiography ......................................................................
23 
4.3.5.2. Computed tomography and nuclear medicine  
imaging .............................................................................................................
23 
4.3.5.3. Cardiac catheterization .............................................................
24 
4.3.6. Cardiovascular magnetic resonance ............................................
24 
4.4. Foetal assessment ......................................................................................... 24 
4.4.1. Risk of foetal/obstetric complications .........................................
24 
4.4.2. Screening for congenital heart disease in the foetus ............
24 
4.4.3. Assessing foetal well-being ..............................................................
24 
4.4.4. Foetal assessment of heritable primary arrhythmias ............
25 
4.5. Timing and mode of delivery .................................................................. 25 
4.5.1. Timing of delivery ................................................................................
25 
4.5.2. Induction of labour .............................................................................
25 
4.5.3. Vaginal or caesarean delivery .........................................................
25 
4.5.4. Haemodynamic monitoring during delivery .............................
25 
4.5.5. Anaesthesia/analgesia .........................................................................
25 
4.5.6. Delivery in women on anticoagulants ........................................
26 
4.5.6.1. Planned delivery ...........................................................................
26 
4.5.6.2. Urgent delivery on therapeutic anticoagulation ............
26 
4.5.6.2.1. Delivery on vitamin K antagonists ...............................
26 
4.5.6.2.2. Delivery on heparin ...........................................................
26 
4.5.6.3. Restarting anticoagulation after delivery ...........................
26 
4.5.7. Endocarditis prophylaxis for delivery ..........................................
26 
4.6. Post-partum monitoring and complications ..................................... 28 
4.6.1. Monitoring ..............................................................................................
28 
4.6.2. Breastfeeding and lactation ..............................................................
28 
4.6.3. Complications .......................................................................................
28 
4.6.3.1. Haemorrhage ................................................................................
28 
4.6.3.2. Psychological reactions, post-partum depression .........
28


<!-- PAGE 3 -->

### Page 3

5. Drugs during pregnancy and lactation ......................................................... 28 
5.1. General principles ........................................................................................ 28 
5.1.1. Pharmacokinetics and pharmacodynamics in pregnancy ....
28 
5.1.2. Pharmacogenetics ................................................................................
28 
5.1.3. Newborn drug exposure in breast milk ....................................
28 
5.2. Drug classes in pregnancy ........................................................................ 28 
5.2.1. Anticoagulants .......................................................................................
28 
5.2.1.1. Vitamin K antagonists ................................................................
29 
5.2.1.2. Low-molecular-weight heparins ...........................................
30 
5.2.1.2.1. Low-molecular-weight heparin dosing ......................
30 
5.2.1.2.2. Once-daily vs twice-daily administration ..................
30 
5.2.1.3. Unfractionated heparin ............................................................
30 
5.2.1.4. Fondaparinux ................................................................................
30 
5.2.1.5. Direct oral anticoagulants .......................................................
30 
5.2.2. Antiplatelet treatment .......................................................................
31 
5.2.3. Diuretics and SGLT2 inhibitors .....................................................
31 
5.2.4. Pulmonary hypertension ...................................................................
31 
5.2.5. Anti-arrhythmic agents ......................................................................
31 
5.2.6. Calcium channel blockers .................................................................
31 
5.2.7. Renin‚Äìangiotensin‚Äìaldosterone system inhibitors ................
32 
5.2.8. Lipid-lowering agents .........................................................................
32 
5.2.9. Beta-adrenergic blocking agents ....................................................
32 
5.2.10. Immunosuppressants .......................................................................
32 
5.2.11. Neuroactive drugs ............................................................................
32 
5.2.12. Obstetric drugs in patients with cardiovascular disease ..
32 
5.3. Internet databases ........................................................................................ 32 
5.4. List of drugs .................................................................................................... 32 
6. Pregnancy in women with cardiomyopathies and primary 
arrhythmia syndromes ............................................................................................. 34 
6.1. Cardiomyopathies ........................................................................................ 34 
6.1.1. Dilated cardiomyopathy and non-dilated left ventricular 
cardiomyopathy ................................................................................................
34 
6.1.2. Arrhythmogenic right ventricular cardiomyopathy ..............
34 
6.1.3. Hypertrophic cardiomyopathy ......................................................
34 
6.1.3.1. Treatment of hypertrophic cardiomyopathy in 
pregnancy .......................................................................................................
34 
6.1.3.2. Left ventricular outflow tract obstruction .......................
34 
6.1.4. Hypertrabeculation of the left ventricle ....................................
35 
6.1.5. Labour and delivery in cardiomyopathies .................................
35 
6.2. Primary arrhythmia syndromes .............................................................. 35 
6.2.1. Long QT syndrome ............................................................................
35 
6.2.2. Brugada syndrome ..............................................................................
36 
6.2.3. Catecholaminergic polymorphic ventricular  
tachycardia ..........................................................................................................
36 
6.2.4. Short QT syndrome ...........................................................................
36 
6.2.5. Labour and delivery in primary arrhythmia syndromes ......
36 
7. Peripartum cardiomyopathy ............................................................................ 37 
7.1. Epidemiology .................................................................................................. 37 
7.2. Mechanisms ..................................................................................................... 37 
7.3. Diagnosis and clinical interventions ...................................................... 37 
7.4. Outcomes ........................................................................................................ 39 
8. Pregnancy in women with aortopathies ..................................................... 39 
8.1. Women with heritable thoracic aortic disease ............................... 39 
8.1.1. Marfan syndrome .................................................................................
40 
8.1.2. Loeys‚ÄìDietz syndrome .....................................................................
40 
8.1.3. Vascular Ehlers‚ÄìDanlos syndrome ...............................................
40 
8.1.4. Non-syndromic heritable thoracic aortic diseases ................
40 
8.1.5. Aortic disease with no identifiable (likely) pathogenic 
variant ...................................................................................................................
40 
8.2. Turner syndrome ......................................................................................... 40 
8.3. Bicuspid aortic valve disease .................................................................... 40 
8.4. Aortic aneurysms other than root or ascending aorta ............... 41 
8.5. Aortic dissection ........................................................................................... 41 
8.6. Management ................................................................................................... 41 
8.7. Cardiac surgery during pregnancy ........................................................ 42 
9. Pregnancy in women with known congenital heart disease ..............
43 
10. Pregnancy in women with pulmonary arterial hypertension .......... 47 
10.1. Pre-existing pulmonary arterial hypertension ............................... 47 
10.1.1. Maternal and foetal risk ..................................................................
47 
10.1.2. Counselling and contraception ...................................................
47 
10.1.3. Management during pregnancy ...................................................
47 
10.2. New diagnosis in pregnancy ................................................................. 48 
10.3. Delivery in women with pulmonary arterial hypertension ..... 48 
10.3.1. Peri- and post-partum monitoring ............................................
48 
11. Venous thromboembolism in pregnancy and post-partum ............. 48 
11.1. Epidemiology and maternal risk .......................................................... 48 
11.2. Risk factors for pregnancy-related venous thromboembolism
48 
11.3. Prevention of venous thromboembolism ....................................... 49 
11.3.1. Pregnant women with no prior indications for long-term 
anticoagulation ..................................................................................................
49 
11.3.2. Pregnant women with prior indication for long-term 
anticoagulation ..................................................................................................
49 
11.4. Management of acute venous thromboembolism ....................... 49 
11.4.1. Clinical presentation and diagnosis ............................................
49 
11.4.1.1. Deep vein thrombosis ............................................................
49 
11.4.1.2. Pulmonary embolism ..............................................................
50 
11.4.2. Treatment of venous thromboembolism in pregnancy ...
50 
11.5. Management of delivery and the post-partum period .............. 52 
12. Pregnancy in women with acquired heart disease .............................. 52 
12.1. Acute chest pain in pregnancy ............................................................. 52 
12.2. Coronary artery disease ......................................................................... 52 
12.2.1. Acute coronary syndrome ............................................................
52 
12.2.1.1. Coronary artery disease epidemiology and aetiology
52 
12.2.1.2. Presentation and diagnosis ...................................................
54 
12.2.1.3. Pregnancy-associated spontaneous coronary artery 
dissection ........................................................................................................
54 
12.2.2. Coronary artery interventions ....................................................
54 
12.2.3. Chronic coronary syndromes in pregnancy ..........................
54 
12.2.4. Management and delivery ..............................................................
54 
12.3. Hypertensive disorders ........................................................................... 55 
12.3.1. Definition and classification of hypertension in pregnancy
56 
12.3.1.1. Pre-eclampsia/eclampsia ........................................................
56 
12.3.2. Diagnosis and risk assessment .....................................................
56 
12.3.2.1. Blood pressure measurement .............................................
56 
12.3.2.2. Laboratory tests ........................................................................
56 
12.3.3. Management of hypertension in pregnancy ..........................
56 
12.3.3.1. Non-pharmacological management ..................................
56 
12.3.3.2. Pharmacological treatment ..................................................
57 
12.3.3.2.1. Mild hypertension (BP 140/90 ‚Äì 159/109 mmHg)
57 
12.3.3.2.2. Pre-eclampsia .....................................................................
57 
12.3.3.2.3. Severe hypertension (BP ‚â•160/110 mmHg) .......
60 
12.3.4. Hypertension and delivery ............................................................
60 
12.4. Arrhythmias ................................................................................................. 61 
12.4.1. Supraventricular arrhythmias .......................................................


<!-- PAGE 4 -->

### Page 4

12.4.1.1. New-onset narrow QRS tachycardia .............................
61 
12.4.1.2. Atrial fibrillation including anticoagulation .....................
62 
12.4.1.3. Pre-existing supraventricular tachycardia .......................
63 
12.4.2. Ventricular arrhythmias ..................................................................
64 
12.4.3. Cardioversion, ablation, and device implantation, and 
implantable cardioverter defibrillator management ..........................
64 
12.4.3.1. Electrical cardioversion ..........................................................
64 
12.4.3.2. Catheter ablation ......................................................................
64 
12.4.3.3. Device implantation .................................................................
65 
12.4.3.4. Implantable cardioverter defibrillator management ..
66 
12.4.4. Cardiac arrest .....................................................................................
68 
12.4.5. Bradycardia ..........................................................................................
69 
12.4.5.1. Sinus node dysfunction ..........................................................
69 
12.4.5.2. Atrioventricular block .............................................................
69 
12.4.5.3. Management of sinus node dysfunction and 
atrioventricular block ................................................................................
69 
12.5. Valvular heart disease .............................................................................. 69 
12.5.1. Stenotic native valve lesions .........................................................
69 
12.5.1.1. Mitral valve stenosis .................................................................
70 
12.5.1.1.1. Management .......................................................................
70 
12.5.1.1.2. Interventions ......................................................................
70 
12.5.1.1.3. Delivery ................................................................................
70 
12.5.1.1.4. Post-partum .......................................................................
70 
12.5.1.2. Valvular aortic stenosis ..........................................................
70 
12.5.1.2.1. Management .......................................................................
70 
12.5.2. Regurgitant native valve lesions ...................................................
70 
12.5.2.1. Mitral and aortic valve regurgitation ................................
70 
12.5.2.1.1. Management .......................................................................
70 
12.5.2.2. Arrhythmogenic mitral valve prolapse ............................
70 
12.5.2.3. Tricuspid regurgitation ...........................................................
71 
12.5.3. Prosthetic valves ................................................................................
72 
12.5.3.1. Bioprosthetic valves .................................................................
72 
12.5.3.2. Mechanical valves ......................................................................
72 
12.5.3.2.1. Anticoagulation during pregnancy ............................
73 
12.5.3.2.2. Mechanical valve thrombosis ......................................
73 
12.5.3.2.3. Anticoagulation during delivery in women with 
mechanical heart valves .......................................................................
73 
12.5.4. Endocarditis prophylaxis ................................................................
75 
12.6. Heart failure ................................................................................................. 75 
12.6.1. Chronic heart failure .......................................................................
75 
12.6.2. Acute heart failure (including cardiogenic shock) ...............
75 
12.7. Special populations .................................................................................... 77 
12.7.1. Heart transplantation ......................................................................
77 
12.7.2. Cardio-oncology ................................................................................
77 
12.7.2.1 Gestational cancer ....................................................................
77 
12.7.2.2 Pregnancy in cancer survivors ..............................................
78 
13. Adverse pregnancy outcomes and long-term management ............ 78 
13.1. Adverse pregnancy outcomes .............................................................. 78 
13.1.1. Post-partum hypertensive disorders ........................................
78 
13.1.2. Gestational diabetes mellitus .......................................................
78 
13.1.3. Pre-term birth ....................................................................................
78 
13.1.4. Small for gestational age .................................................................
78 
13.1.5. Pregnancy loss and placental abruption ..................................
78 
13.2. Breastfeeding ............................................................................................... 78 
13.3. Women‚Äôs Heart Clinics .......................................................................... 79 
14. Key messages ....................................................................................................... 81 
15. Gaps in evidence ................................................................................................. 82 
16. ‚ÄòWhat to do‚Äô and ‚Äòwhat not to do‚Äô messages from the Guidelines
83 
17. Evidence tables .................................................................................................... 83 
18. Data availability statement .............................................................................. 83 
19. Author information ........................................................................................... 88 
20. Appendix ................................................................................................................ 88 
21. References ............................................................................................................. 89 
Tables of Recommendations 
Recommendation Table 1 ‚Äî Recommendations for counselling, 
pregnancy risk assessment, contraception, assisted reproductive 
technology, and the involvement of a Pregnancy Heart Team (see 
Evidence Table 1) .................................................................................................. 22 
Recommendation Table 2 ‚Äî Recommendations for diagnostic 
methods in pregnancy (see Evidence Table 2) .............................................. 24 
Recommendation Table 3 ‚Äî Recommendations for timing and 
mode of delivery (see Evidence Table 3) ........................................................
26 
Recommendation Table 4 ‚Äî Recommendation for direct oral 
anticoagulants and pregnancy ............................................................................... 31 
Recommendation Table 5 ‚Äî Recommendations for 
cardiomyopathies and pregnancy ........................................................................ 35 
Recommendation Table 6 ‚Äî Recommendations for primary 
arrhythmia syndromes and pregnancy (see Evidence Tables 4‚Äì6) ...... 36 
Recommendation Table 7 ‚Äî Recommendations for peripartum 
cardiomyopathy (see Evidence Table 7) .......................................................... 39 
Recommendation Table 8 ‚Äî Recommendations for aortopathies, 
cardiac surgery, and pregnancy ............................................................................ 42 
Recommendation Table 9 ‚Äî Recommendations for congenital 
heart disease and pregnancy (see Evidence Table 8) ................................. 47 
Recommendation Table 10 ‚Äî Recommendations for pulmonary 
arterial hypertension and pregnancy ................................................................. 48 
Recommendation Table 11 ‚Äî Recommendations for venous 
thromboembolic diseases and pregnancy (see Evidence Tables 9 and 
10) .................................................................................................................................... 52 
Recommendation Table 12 ‚Äî Recommendations for coronary 
artery disease and pregnancy (see Evidence Table 11) ............................. 55 
Recommendation Table 13 ‚Äî Recommendations for hypertensive 
disorders and pregnancy (see Evidence Tables 12‚Äì17) ............................
60 
Recommendation Table 14 ‚Äî Recommendations for 
supraventricular tachycardia and pregnancy .................................................. 64 
Recommendation Table 15 ‚Äî Recommendations for ventricular 
tachycardia, device implantation, catheter ablation, and pregnancy .... 67 
Recommendation Table 16 ‚Äî Recommendations for cardiac arrest 
and pregnancy ............................................................................................................. 69 
Recommendation Table 17 ‚Äî Recommendation for congenital 
atrioventricular block and pregnancy ................................................................ 69 
Recommendation Table 18 ‚Äî Recommendations for native valve 
disease and pregnancy ............................................................................................. 72 
Recommendation Table 19 ‚Äî Recommendations for prosthetic 
valves and pregnancy (see Evidence Table 18) ............................................. 73 
Recommendation Table 20 ‚Äî Recommendations for chronic and 
acute heart failure and pregnancy (see Evidence Table 19) .................... 75 
Recommendation Table 21 ‚Äî Recommendations for heart 
transplantation and pregnancy ............................................................................. 77 
Recommendation Table 22 ‚Äî Recommendations for 
cardio-oncology and pregnancy ........................................................................... 78 
Recommendation Table 23 ‚Äî Recommendations for  
long-term effects of adverse pregnancy outcomes (see Evidence 
Tables 20 and 21) ...................................................................................................... 81


<!-- PAGE 5 -->

### Page 5

List of tables 
Table 1 Classes of recommendations .................................................................. 7 
Table 2 Levels of evidence ........................................................................................ 8 
Table 3 Updates of the 2025 Guidelines on cardiovascular disease 
and pregnancy ................................................................................................................ 9 
Table 4 New recommendations ............................................................................ 9 
Table 5 Revised recommendations .................................................................... 11 
Table 6 Modified World Health Organization 2.0 classification of 
maternal cardiovascular risk .................................................................................. 16 
Table 7 Pre-implantation and pre-natal options and implications ........ 20 
Table 8 Overview of benefits and risks of different methods of 
contraception in women with cardiovascular disease ............................... 21 
Table 9 Predictors of neonatal events in pregnancies of women with 
cardiovascular disease .............................................................................................. 25 
Table 10 List of anticoagulation regimens and disease entities in 
which they are indicated ......................................................................................... 29 
Table 11 Dosing regimens for the commonly used 
low-molecular-weight heparins ............................................................................ 30 
Table 12 Risks, monitoring, and management during pregnancy and 
delivery in women with congenital heart disease ........................................ 44 
Table 13 Reasons for antepartum/post-partum thromboprophylaxis
49 
Table 14 Hypertensive disorders of pregnancy ............................................ 55 
Table 15 Risk factors for pre-eclampsia .......................................................... 56 
Table 16 ‚ÄòWhat to do‚Äô and ‚Äòwhat not to do‚Äô ................................................. 83  
List of figures 
Figure 1 Physiology of haemodynamic changes, and changes in 
electrocardiogram and echocardiography during and post pregnancy
13 
Figure 2 Central illustration. Role of Pregnancy Heart Team in 
pregnancy pathway .................................................................................................... 15 
Figure 3 Composition of the core and expanded case-based 
Pregnancy Heart Team ............................................................................................ 19 
Figure 4 Pre-conception counselling and genetic aspects ........................ 20 
Figure 5 Management of urgent delivery in women under 
anticoagulants .............................................................................................................. 27 
Figure 6 Choice of medication during pregnancy (left) and during 
lactation and breastfeeding (right) ...................................................................... 33 
Figure 7 Risk factors and management of peripartum cardiomyopathy
38 
Figure 8 Thresholds for prophylactic surgical treatment prior to 
pregnancy of aortic root/ascending aneurysm (above the line) and 
recommended mode of delivery according to aortic diameter 
(below the line) ........................................................................................................... 41 
Figure 9 Algorithm for the diagnosis and treatment of deep vein 
thrombosis during pregnancy ............................................................................... 50 
Figure 10 Algorithm for the diagnosis and treatment of pulmonary 
embolism in pregnancy in stable (A) and unstable women (B) ............. 51 
Figure 11 Management of chest pain during pregnancy and within 6 
months post-partum ................................................................................................ 53 
Figure 12A Management of hypertension and pre-eclampsia in the 
emergency ward ......................................................................................................... 57 
Figure 12B Proteinuria assessment and diagnosis of pre-eclampsia .... 58 
Figure 12C Monitoring and treatment of hypertension and pre- 
eclampsia ........................................................................................................................ 59 
Figure 13 Arrhythmogenesis in pregnant women ....................................... 61 
Figure 14 Management of narrow QRS tachycardia in pregnant 
women ............................................................................................................................ 62 
Figure 15 Management of atrial fibrillation and atrial flutter in 
pregnancy ...................................................................................................................... 63 
Figure 16 Management of ventricular tachycardias in pregnancy ......... 65 
Figure 17 Management of pacemaker and implantable cardioverter 
defibrillator and pregnancy .................................................................................... 66 
Figure 18 Management of implantable cardioverter defibrillator 
shocks in pregnancy .................................................................................................. 67 
Figure 19 Management of cardiac arrest in pregnancy .............................. 68 
Figure 20 Valvular heart disease and pregnancy ........................................... 71 
Figure 21 Management of anticoagulants during the different stages 
of pregnancy in women with mechanical heart valves .............................. 74 
Figure 22 Management of acute heart failure and cardiogenic shock 
in pregnancy and up to 6 months post-partum ........................................... 76 
Figure 23 Multidisciplinary approach of adverse pregnancy outcomes
79 
Figure 24 Algorithm for the management of new-onset post-partum 
hypertension ................................................................................................................ 80 
Figure 25 Algorithm for the management of adverse pregnancy 
outcomes ....................................................................................................................... 80  
Abbreviations and acronyms 
ACE-(I) 
Angiotensin-converting enzyme(-inhibitor) 
ACHD 
Adult congenital heart disease 
ACS 
Acute coronary syndrome 
ADR 
Adverse drug reaction 
AF 
Atrial fibrillation 
AFL 
Atrial flutter 
AHF 
Acute heart failure 
AHT 
Arterial hypertension 
ALARA 
As low as reasonably achievable 
ALT 
Alanine transaminase 
AMVP 
Arrhythmic mitral valve prolapse 
APO 
Adverse pregnancy outcomes 
aPTT 
Activated partial thromboplastin time 
ARB 
Angiotensin receptor blocker 
ARNI 
Angiotensin receptor/neprilysin inhibitor 
ARVC 
Arrhythmogenic right ventricular 
cardiomyopathy 
ASA 
Acetylsalicylic acid 
ASCVD 
Atherosclerotic cardiovascular disease 
ASD 
Atrial septal defect 
ASI 
Aortic size index 
AST 
Aspartate aminotransferase 
AV 
Atrioventricular 
AV(N)RT 
Atrioventricular (nodal) re-entry tachycardia 
AVSD 
Atrioventricular septal defect 
BAV 
Bicuspid aortic valve 
B-blocker 
Beta-blocker 
b.i.d. 
Bis in die (twice a day) 
BMI 
Body mass index 
BNP 
B-type natriuretic peptide 
BP 
Blood pressure 
b.p.m. 
Beats per minute 
BrS 
Brugada syndrome 
CABG 
Coronary artery bypass graft 
CAD 
Coronary artery disease 
CARPREG II 
Cardiac Disease in Pregnancy study II 
CCB 
Calcium channel blocker 
CCS 
Chronic coronary syndromes 
CI 
Confidence interval 
CMP 
Cardiomyopathy 
CMR 
Cardiovascular magnetic resonance  
ESC Guidelines                                                                                                                                                                                                 5


<!-- PAGE 6 -->

### Page 6

CO 
Cardiac output 
COR 
Class of recommendation 
CPG 
Clinical Practice Guidelines 
CPR 
Cardiopulmonary resuscitation 
CPVT 
Catecholaminergic polymorphic ventricular 
tachycardia 
CT 
Computed tomography 
cTnI 
Cardiac troponin I 
cTnT 
Cardiac troponin T 
CTPA 
Computed tomography pulmonary angiography 
CTRCD 
Cancer-therapy-related cardiac dysfunction 
CVD 
Cardiovascular disease 
DAPT 
Dual antiplatelet therapy 
DCM 
Dilated cardiomyopathy 
DOAC 
Direct oral anticoagulant 
DVT 
Deep vein thrombosis 
ECG 
Electrocardiogram 
ECMO 
Extracorporeal membrane oxygenation 
EF 
Ejection fraction 
EORP 
EURObservational Research Programme 
ERA 
Endothelin receptor antagonist 
ESC 
European Society of Cardiology 
ESH 
European Society of Hypertension 
FAT 
Focal atrial tachycardia 
FDA 
Food and Drug Administration 
FFP 
Fresh frozen plasma 
GDM 
Gestational diabetes mellitus 
HCM 
Hypertrophic cardiomyopathy 
HELLP 
Haemolysis, elevated liver enzymes, low platelet 
count 
HF 
Heart failure 
HFrEF 
Heart failure with reduced ejection fraction 
HLA 
Human leucocyte antigen 
HR 
Heart rate 
HTAD 
Heritable thoracic aortic disease 
ICD 
Implantable cardioverter defibrillator 
INR 
International normalized ratio 
IU 
International unit 
IUGR 
Intrauterine growth restriction 
IUD 
Intrauterine device 
i.v. 
Intravenous 
IVF 
In vitro fertilization 
LA 
Left artery 
LDL 
Low-density lipoprotein 
LDS 
Loeys‚ÄìDietz syndrome 
LMWH 
Low-molecular-weight heparin 
LQT1/2/3 
Long QT syndrome type 1, 2, or 3 
LQTS 
Long QT syndrome 
LV 
Left ventricle 
LVAD 
Left ventricular assist device 
LVEDD 
Left ventricular end-diastolic diameter 
LVEF 
Left ventricular ejection fraction 
LVH 
Left ventricular hypertrophy 
LVOT(O) 
Left ventricular outflow tract (obstruction) 
MACE 
Major adverse cardiovascular events 
MFS 
Marfan syndrome 
MHV 
Mechanical heart valve 
MINOCA 
Myocardial infarction with non-obstructive 
coronary arteries  
MR 
Mitral valve regurgitation 
MRA 
Mineralocorticoid receptor antagonist 
mU 
Milliunit 
mWHO 
modified World Health Organization 
NA 
Not applicable 
NDLVC 
Non-dilated left ventricular cardiomyopathy 
NP 
Natriuretic peptide (NT-proBNP and BNP) 
NSAID 
Non-steroidal anti-inflammatory drug 
nsHTAD 
Non-syndromic heritable thoracic aortic disease 
NSTE ACS 
Non-ST-elevation acute coronary syndrome 
NT-proBNP 
N-terminal pro-brain natriuretic peptide 
NYHA 
New York Heart Association 
o.d. 
Omni die (once a day) 
oGTT 
Oral glucose tolerance test 
OR 
Odds ratio 
P/LP 
Pathogenic/likely pathogenic 
PAH 
Pulmonary arterial hypertension 
PAP 
Pulmonary arterial pressure 
PASP 
Pulmonary arterial systolic pressure 
PCI 
Percutaneous coronary intervention 
PE 
Pulmonary embolism 
PH 
Pulmonary hypertension 
PlGF 
Placental growth factor 
p.o. 
Per os (by mouth) 
PPCM 
Peripartum cardiomyopathy 
PPH 
Post-partum haemorrhage 
PREM 
Patient-reported experience measure 
PROM 
Patient-reported outcome measure 
PV 
Pulmonary valve 
QRS 
Q, R, and S waves 
RBC 
Red blood cell 
RID 
Relative infant dose 
ROPAC 
Registry of Pregnancy and Cardiac Disease 
ROSC 
Return of spontaneous circulation 
RV 
Right ventricle 
RVEF 
Right ventricular ejection fraction 
RVH 
Right ventricular hypertrophy 
RVOT(O) 
Right ventricular outflow tract (obstruction) 
RVOT-VT 
Right ventricular outflow tract ventricular 
tachycardia 
SBP 
Systolic blood pressure 
SCAD 
Spontaneous coronary artery dissection 
SGA 
Small for gestational age 
SGLT2 
Sodium‚Äìglucose co-transporter-2 
SPAP 
Systolic pulmonary artery pressure 
SpO2 
Oxygen saturation 
SQTS 
Short QT syndrome 
STEMI 
ST-elevation myocardial infarction 
SVT 
Supraventricular tachycardia 
TAD 
Thoracic aortic disease 
TAVI 
Transcatheter aortic valve implantation 
TGA 
Transposition of the great arteries 
TOF 
Tetralogy of Fallot 
TPVI 
Transcatheter pulmonary valve implementation 
TR 
Tricuspid regurgitation 
TS 
Turner syndrome 
TTE 
Transthoracic echocardiogram 
UACR 
Urine albumin‚Äìcreatinine ratio 
UFH 
Unfractionated heparin


<!-- PAGE 7 -->

### Page 7

VA-ECMO 
Veno-arterial extracorporeal membrane 
oxygenation 
VF 
Ventricular fibrillation 
VHD 
Valvular heart disease 
VKA 
Vitamin K antagonist 
VSD 
Ventricle septal defect 
VT 
Ventricular tachycardia 
VTE 
Venous thromboembolism 
WCD 
Wearable cardioverter defibrillator 
WHO 
World Health Organization 
WPW 
Wolff‚ÄìParkinson‚ÄìWhite 
1. Preamble 
Guidelines evaluate and summarize available evidence with the aim 
of assisting health professionals in proposing the best diagnostic or 
therapeutic approach for an individual patient with a given condition. 
European Society of Cardiology (ESC) Guidelines are intended for 
use by health professionals but do not override their individual responsibility to make appropriate and accurate decisions in consideration of each patient‚Äôs health condition and in consultation with the 
patient or the patient‚Äôs caregiver where appropriate and/or necessary. It is also the health professional‚Äôs responsibility to verify the 
rules and regulations applicable in each country to drugs and devices 
at the time of prescription and to respect the ethical rules of their 
profession. 
ESC Guidelines represent the official position of the ESC on a given 
topic. Guideline topics are selected for updating after annual expert review of new evidence conducted by the ESC Clinical Practice 
Guidelines (CPG) Committee. European Society of Cardiology 
Policies and Procedures for formulating and issuing ESC Guidelines 
can be found on the ESC website (https://www.escardio.org/ 
Guidelines/Clinical-Practice-Guidelines/Guidelines-development/ 
Writing-ESC-Guidelines). 
This guideline updates and replaces the previous version from 2018. 
This Task Force was selected by the ESC to include professionals 
involved with the medical care of patients with this pathology and to include patient representatives and methodologists. The selection procedure included an open call for authors and aimed to include members from 
across the whole of the ESC region and from relevant ESC Subspecialty 
Communities. Consideration was given to diversity and inclusion. 
Guidelines Task Forces perform a critical review and evaluation of 
the published literature on diagnostic and therapeutic approaches 
including assessment of the risk‚Äìbenefit ratio. Recommendations 
are based on major randomized trials and relevant systematic reviews and meta-analyses, when available. Systematic literature 
searches are conducted in cases of controversy or uncertainty to 
ensure that all key studies were considered. For recommendations 
related to diagnosis and prognosis, additional types of evidence 
are included, such as diagnostic accuracy studies and studies focused 
on the development and validation of prognostic models. The 
strength of each recommendation and the level of evidence supporting it are weighed and scored according to predefined criteria as 
outlined in Tables 1 and 2. Patient-reported outcome measures 
(PROMs) and patient-reported experience measures (PREMs) are 
also evaluated when available as the basis for recommendations 
and/or discussion in these guidelines. 
Evidence tables summarizing key information from relevant studies 
are generated to facilitate the formulation of recommendations, to enhance comprehension of recommendations after publication, and to 
Table 1 Classes of recommendations  
¬©



	




¬Å
	
	
¬ç¬è


¬ê
¬ù





	

¬è

 
¬†	¬ç¬è¬≠
¬è
	
¬Ä¬è


¬ê
	

	¬ç¬è


ESC Guidelines                                                                                                                                                                                                 7


<!-- PAGE 8 -->

### Page 8

reinforce transparency in the guidelines‚Äô development process. The tables are published in their own section of ESC Guidelines and reference 
specific recommendation tables. 
After an iterative process of deliberations, a first Task Force vote on all 
recommendations is conducted prior to the initiation of rounds of review. A second Task Force vote on all recommendations is conducted 
after the final round of review and revision. For each vote, the Task 
Force follows ESC voting procedures and all recommendations require 
at least 75% agreement among voting members to be approved. 
Voting restrictions may be applied based on declarations of interests. 
The writing and reviewing panels provide declaration of interest 
forms for all relationships that might be perceived as real or potential 
sources of conflicts of interest. Their declarations of interest are reviewed according to the ESC declaration of interest rules, which can 
be found on the ESC website (http://www.escardio.org/doi) and are 
compiled in a report published in a supplementary document with the 
guidelines. Funding for the development of ESC Guidelines is derived entirely from the ESC with no involvement of the healthcare industry. 
The CPG Committee supervises and coordinates the preparation of 
new guidelines and approves their publication. In addition to review by 
the CPG Committee, ESC Guidelines undergo multiple rounds of 
double-blind peer review on a dedicated online review platform. The review is conducted by topic experts, including members from ESC 
National Cardiac Societies and from relevant ESC Subspecialty 
Communities. Guideline Task Forces consider all review comments 
and are required to respond to all those classified as major. After appropriate revisions, the Task Force and the CPG Committee members approve the final document for publication in the European Heart Journal. 
Unless otherwise stated, ESC Guidelines content refers to sex, 
understood as the biological condition of being male or female, defined 
by genes, hormones, and sexual organs. Off-label use of medication may 
be presented in this guideline if a sufficient level of evidence shows that 
it can be considered medically appropriate for a given condition. 
However, decisions on off-label use must be made by the responsible 
health professional giving special consideration to ethical rules concerning healthcare, the specific situation of the patient, patient consent, and 
country-specific health regulations. 
2. Introduction 
2.1. Why we need new Guidelines on 
cardiovascular disease and pregnancy 
Since the previous version of these Guidelines was published in 2018, 
new evidence has emerged, and clinical focus has changed in various aspects, requiring an updated discussion. These include the importance of 
the Pregnancy Heart Team, the modalities for pre-pregnancy counselling and risk stratification, and drugs during pregnancy, lactation and/or 
breastfeeding, and post-partum stages. In Table 3, the most relevant updates are listed with their respective rationale. 
2.2. Why these Guidelines are important 
Cardiovascular disease (CVD) is a major cause of maternal mortality 
and morbidity. With these new Guidelines we wish to provide updated 
evidence-based guidance for patients and caregivers. Reducing maternal 
mortality and morbidity is a key priority of the World Health 
Organization (WHO). 
In managing maternal and foetal health, it is essential to balance the 
risks and benefits of maternal and foetal therapeutic needs. Due to 
the scarcity of prospective or randomized studies within this field, 
which often cannot be performed for ethical reasons, most recommendations in these Guidelines are based on evidence level 
C. Consequently, there is an ongoing need for more registries, such 
as the Registry of Pregnancy and Cardiac Disease (ROPAC) and the 
European Surveillance of Congenital Anomalies network, and prospective studies to enhance our understanding in this area. 
2.3. What is new 
As mentioned in Section 2.1, this new version of the guidelines not only 
includes an update to several recommendations (Table 4) but also introduces a structural revision. See Supplementary data online 
(Table S1) for a detailed overview of the new recommendations. 
Below we discuss the key updates per section, highlighting a selection 
of new and revised recommendations along with their rationale. 
Table 2 Levels of evidence  







	
		
	


		
							
					
¬©¬Å¬ç¬è¬ç¬ê


<!-- PAGE 9 -->

### Page 9

Table 3 Updates of the 2025 Guidelines on cardiovascular disease and pregnancy 
Topic 
New information 
Rationale  
Pregnancy Heart Teama 
Broader acceptance, dedicated section 
Ensure comprehensive care throughout reproductive 
stagesb 
Risk stratificationa,c 
mWHO 2.0 classification, refined and expanded 
clinical categories 
More data have emerged, necessitating more nuanced risk 
assessment for patient counselling1,2 
Clinical data and research 
ROPAC3‚Äì12 and PPCM13‚Äì17 registries 
Cardiomyopathies 
Primary arrhythmia syndromes 
New or updated clinical management 
Clinical scenarios 
Algorithms for management of clinical situations in 
pregnant women 
Provide practical information for the clinical cardiologist 
Genetic testing and counselling 
Advancements in testing and pre-implantation 
procedures 
Incorporation of latest management of genetic testing and 
counselling 
Revision of contraindications (COR III) for 
pregnancy in women classified as mWHO 
class IV 
Emphasis on the critical role of comprehensive 
counselling by the Pregnancy Heart Team (COR I) 
Recognition of a woman‚Äôs autonomy in making 
reproductive choices 
Promoting a detailed and transparent dialogue about the 
heightened risks and encouraging shared decision-making 
Adverse pregnancy outcomes (APO) 
Increased focus on long-term outcomes 
Evidence supports the need for thorough discussion and 
management of APOs18 
¬© ESC 2025
COR, class of recommendation; mWHO, modified World Health Organization; PPCM, peripartum cardiomyopathy; ROPAC, Registry of Pregnancy and Cardiac Disease. 
aSee Section 4. 
bSee Figure 2. 
cSee Table 6.  
Table 4 New recommendations 
Recommendations 
Classa 
Levelb  
Section 4. The Pregnancy Heart Team 
Although the concept of the Pregnancy Heart Team was previously part of the general principles, it has now been given its own dedicated section, which covers all 
aspects from pre-conception through to the postpartum period. 
A discussion by the Pregnancy Heart Team about the high risk of maternal mortality or morbidity and the related high foetal risk is 
recommended for women with mWHO 2.0 class IV conditions, including a shared decision-making process for pregnancy termination, 
involving psychological support. 
I 
C 
It is recommended that women with CVD of mWHO 2.0 class II‚ÄìIII and above are evaluated and managed by a Pregnancy Heart Team from 
pre-pregnancy onwards through pregnancy and post-partum. 
I 
C 
Measurement of BNP and NT-proBNP levels should be considered prior to pregnancy in women with HF of any aetiology, including 
previous PPCM, cardiomyopathy, ACHD, and PAH, and be monitored during pregnancy according to the underlying disorder and in case of 
new-onset or worsening symptoms. 
IIa 
B 
Section 5. Drugs during pregnancy and lactation 
Given the importance of medication use throughout this document, this section has been brought forward and revised. The former comprehensive medication 
table has been moved to the Supplementary data online, and we provide a summary figure (Figure 6) listing the (contra)indicated medications. 
Section 6. Pregnancy in women with cardiomyopathies and primary arrhythmia syndromes 
This section has been expanded since 2018 for advice in specific cardiomyopathies and primary arrhythmias. 
Vaginal delivery is recommended in most women with CMPs, unless there are obstetric indications for caesarean section, severe HF 
(EF <30% and/or NYHA class III/IV), uncontrolled arrhythmias, or severe outflow obstruction (‚â•50 mmHg) in women with HCM, or in 
women presenting in labour on VKAs. 
I 
C 
In women with DCM and worsening of EF during pregnancy, counselling on the risk of recurrence during a subsequent pregnancy is 
recommended in all cases, even after recovery of LV function. 
I 
C 
It is recommended that women with HCM with symptomatic LV dysfunction (EF <50%) and or severe LVOTO (‚â•50 mmHg) wishing to 
become pregnant are counselled by the Pregnancy Heart Team regarding the high risk of pregnancy-related adverse events. 
I 
C 
Myosin inhibitors are not recommended in women during pregnancy due to lack of safety data. 
III 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                                 9


<!-- PAGE 10 -->

### Page 10

Beta-blockers, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy in 
women with LQTS. 
I 
B 
It is recommended to continue beta-blocker therapy during lactation in women with LQTS to reduce arrhythmic risk. 
I 
B 
Pre-pregnancy dose beta-blockers of nadolol or propranolol is recommended in patients with LQT2, particularly in the post-partum period, 
which represents a high-risk period for life-threatening arrhythmias. 
I 
B 
Beta-blockers, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy and 
lactation in women with CPVT. 
I 
C 
Flecainide, in addition to beta-blockers, is recommended in women with CPVT who experience cardiac events, such as syncope, VT, or 
cardiac arrest during pregnancy. 
I 
C 
Section 7. Peripartum cardiomyopathy 
We have provided a separate section on PPCM in these guidelines. 
Genetic counselling and testing should be considered in women with PPCM. 
IIa 
C 
When a reversible course of HF is assumed, treatment in accordance with HF guidelines should be considered for at least 12 months after 
complete LV recovery (normalization of LV volumes and EF). 
IIa 
C 
Section 8. Pregnancy in women with aortopathies 
Since 2018, significant evidence has emerged in the context of heritable thoracic aortic disease (HTAD), supporting a more gene- and variant-based approach, 
which has been incorporated in this version of the guidelines. 
It is recommended that women with a history of aortic dissection or -surgery have pre-pregnancy counselling about the high risk by an 
extended Pregnancy Heart Team considering the presence and type of genetic variant, aortic morphology, growth rate, and aetiology of 
aortic dissection. 
I 
C 
Section 9. Pregnancy in women with known congenital heart disease 
This section has undergone a major update based on recent reports, which have been summarized in a clear and concise table. 
It is recommended that all women with Fontan circulation who wish to become pregnant receive counselling from the Pregnancy Heart 
Team regarding the high risk of pregnancy-related adverse events. 
I 
C 
Section 10. Pregnancy in women with pulmonary arterial hypertension 
This subject is now covered in a separate section in these guidelines, in line with growing insights into management. 
It is recommended that women of childbearing potential with PAH wishing to become pregnant are counselled by a multidisciplinary team regarding 
the very high risk of pregnancy-related adverse events, encouraging a shared decision-making process about whether to become pregnant. 
I 
C 
Section 11. Venous thromboembolism in pregnancy and post-partum 
Guidance on the involvement of an expert team and more prompt initiation of treatment are now provided in dedicated flowcharts and recommendations. 
In pregnant women or women in the post-partum period with suspicion of venous thromboembolism (VTE) [deep vein thrombosis (DVT) 
and/or PE], an immediate formal diagnostic assessment with validated methods is recommended and should not be postponed. 
I 
B 
Section 12. Pregnancy in women with acquired heart disease 
Recommendations for emergency situations are provided for acquired heart diseases in addition to the new sections on cardio-oncology and heart transplantation. 
Recommendations for coronary artery disease and pregnancy 
In pregnant women with chest pain, it is recommended to exclude life-threatening cardiovascular conditions, including PE, ACS (including 
SCAD), and acute aortic syndrome. 
I 
C 
The duration of DAPT (aspirin and clopidogrel) in pregnant women undergoing coronary stent implantation is recommended to be the 
same as in non-pregnant women, with an individual approach considering ischaemic risk and delivery-related bleeding risks. 
I 
C 
Continuation of statins may be considered during pregnancy in women with established ASCVD. 
IIb 
C 
Recommendations for hypertensive disorders and pregnancy 
It is recommended to aim for systolic BP <140 mmHg and diastolic BP <90 mmHg in pregnant women. 
I 
B 
In severe hypertension, drug treatment with i.v. labetalol, urapidil, nicardipine, or oral short acting nifedipine or methyldopa is 
recommended for acute reduction in blood pressure. Intravenous hydralazine is a second-line option. 
I 
C 
Recommendations for supraventricular tachycardia and pregnancy 
Therapeutic anticoagulation with LMWH is recommended for pregnant women with persistent or permanent AF at elevated 
thromboembolic risk. 
I 
C 
Flecainide, in addition to beta-blockers, should be considered for long-term AF rhythm control in pregnancy. 
IIa 
C 
Recommendation for ventricular tachycardia, device implantation and catheter ablation and pregnancy 
When performing catheter ablation during pregnancy, the use of non-fluoroscopic mapping and navigation systems should be considered. 
IIa 
C                         
Continued


<!-- PAGE 11 -->

### Page 11

2.4. What has changed 
Table 5 lists the recommendations with a revised Class of 
Recommendation since the 2018 Guidelines for the management 
of cardiovascular diseases during pregnancy. See Supplementary 
data online (Table S2) for a detailed overview of all modified 
recommendations. 
Recommendations for cardiac arrest and pregnancy 
Continuous manual left uterine displacement during CPR in pregnant women (‚â•20 weeks) with cardiac arrest is recommended to relieve 
aortocaval compression. 
I 
C 
It is recommended to establish i.v. access above the diaphragm to ensure that the i.v. therapy is not obstructed by the gravid uterus. 
I 
C 
It is recommended that no drugs are withheld in pregnant women with cardiac arrest due to concerns of teratogenicity. 
I 
C 
Recommendation for congenital atrioventricular block and pregnancy 
In pregnant women with asymptomatic congenital AV block, normal cardiac anatomy and function, a narrow QRS complex, and ventricular 
rate (‚â•50 b.p.m.) a prophylactic temporary pacemaker during delivery is not recommended. 
III 
C 
Recommendation for native valve disease and pregnancy 
Valve surgery during pregnancy should only be considered when there is a maternal mortality risk and other treatment options have failed. 
IIa 
C 
Recommendation for prosthetic valves disease and pregnancy 
It is recommended that a care plan documenting the agreed anticoagulant strategy (including the decision to continue VKAs or converting to 
therapeutic-dose LMWH in the first trimester) is in place for women of childbearing age with a MHV prior to pregnancy or as soon as 
pregnancy is recognized. 
I 
C 
Recommendations for chronic and acute heart failure and pregnancy 
Inotropes and/or vasopressors are recommended in pregnant women with cardiogenic shock with levosimendan, dobutamine, and 
milrinone as recommended agents. 
I 
C 
ACE-Is, ARBs, ARNIs, MRAs, ivabradine, and SGLT2 inhibitors are not recommended during pregnancy due to adverse foetal effects. 
III 
C 
Recommendations for heart transplantation and pregnancy 
It is recommended to postpone pregnancy until at least 1 year after heart transplantation, taking individual risk factors into account. 
I 
C 
In women with a heart transplant, it is recommended that immunosuppression serum drug levels are monitored during pregnancy every 4 weeks 
until the 32nd week, then every 2 weeks until the 36th week, then weekly until delivery and for 6‚Äì12 months after delivery to guide dosing. 
I 
C 
Recommendation for cardio-oncology and pregnancy 
It is recommended that pregnant women with cancer who require cardiotoxic cancer therapy are jointly managed by the Pregnancy Heart 
Team and the cardio-oncology team. 
I 
C 
Section 13. Long-term effects of adverse pregnancy outcomes 
This is a completely new section in the guidelines, reflecting the growing recognition of the importance of APOs. 
It is recommended to undertake a cardiovascular risk assessment in women with APOs, to recognize and document APOs when CVD risk is 
evaluated in women, and to provide counselling on the importance of healthy lifestyle choices that optimize cardiovascular health. 
I 
B 
¬© ESC 2025
ACE-I, angiotensin-converting enzyme inhibitor; ACHD, adult congenital heart disease; ACS, acute coronary syndrome; AF, atrial fibrillation; APO, adverse pregnancy outcomes; ARB, 
angiotensin receptor blocker; ARNI, angiotensin receptor/neprilysin inhibitor; ASCVD, atherosclerotic cardiovascular disease; AV, atrioventricular; BNP, brain natriuretic peptide; BP, 
blood pressure; CMP; cardiomyopathy; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CVD, cardiovascular disease; DAPT, dual 
antiplatelet therapy; DCM, dilated cardiomyopathy; DVT, deep vein thrombosis; EF, ejection fraction; HCM, hypertrophic cardiomyopathy; HF, heart failure; HTAD, heritable thoracic 
aortic disease; i.v., intravenous; LMWH, low-molecular-weight heparin; LQT2, long QT syndrome type 2; LQTS, long QT syndrome; LV, left ventricle; LVOTO, left ventricular outflow 
tract obstruction; MHV, mechanical heart valve; MRA, mineralocorticoid receptor antagonist; mWHO, modified World Health Organization; NT-proBNP, N-terminal pro-brain 
natriuretic peptide; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PE, pulmonary embolism; PPCM, peripartum cardiomyopathy; SCAD, spontaneous 
coronary artery dissection; SGLT2, sodium‚Äìglucose co-transporter-2; VKA, vitamin K antagonist; VT, ventricular tachycardia; VTE, venous thromboembolism. 
aClass of recommendation. 
bLevel of evidence.  
Table 5 Revised recommendations 
Recommendations in 2018 
Classa 
Levelb 
Recommendations in 2025 
Classa 
Levelb  
Section 4. The Pregnancy Heart Team 
Prophylactic antibiotic therapy to prevent endocarditis 
during delivery is not recommended. 
III 
C 
Systemic antibiotic prophylaxis may be considered for 
delivery in women at high risk. 
IIb 
C 
Section 6. Recommendations for cardiomyopathies and pregnancy 
In patients with HCM, it is recommended that 
beta-blockers are continued in women who used them 
before pregnancy. 
I 
C 
Continuation of beta-blockers should be considered 
during pregnancy in women with CMPs, with close 
follow-up of foetal growth. 
IIa 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                               11


<!-- PAGE 12 -->

### Page 12

### 3 General considerations

3.1. Epidemiology 
Within high-income countries the number of pregnancies and deliveries in 
women with acquired, congenital, or inherited CVD is growing significantly.19‚Äì21 This trend originates from several factors: higher maternal age at 
first pregnancy, a growing number of women with congenital heart disease 
reaching childbearing age, and a rising prevalence of cardiovascular comorbidities.19‚Äì21 Globally, up to 4% of pregnancies are complicated by 
CVD, rising to 10% when including hypertensive disorders.22‚Äì25 
Maternal CVD is now the leading cause of non-obstetric mortality in pregnant women24,26, accounting for 33% of pregnancy-related deaths worldwide.25,27,28 In women with pre-existing CVD, up to 16% of pregnancies 
are complicated by CVD.29‚Äì32 Notably, 68% of pregnancy-related deaths 
caused by CVD are preventable.33 Women with CVD during pregnancy 
face higher risk of cardiac events later in life, making secondary prevention 
crucial.25 Adverse neonatal outcomes occur in ‚àº25% of these pregnancies 
in women with CVD34,35 with high rates of obstetric complications (17%) 
and maternal mortality/morbidity (11%).34,35 Of note, recent research indicates that pre-existing CVD in the mother is associated with an increased risk of CVD in her children, and this association is unlikely to be 
explained by unmeasured familial or genetic factors.36 
3.2. Physiology of pregnancy 
Pregnancy induces physiological changes in the cardiovascular system to 
meet the increased metabolic needs of the mother and foetus (Figure 1). 
These changes occur from the early stages of pregnancy onward. Starting 
at 6 weeks of gestation, stroke volume and cardiac output (CO) increase 
Section 8. Recommendations for aortopathies, cardiac surgery, and pregnancy 
Pregnancy is not recommended in patients with 
vascular Ehlers‚ÄìDanlos syndrome. 
III 
C 
It is recommended that women with vascular Ehlers‚Äì 
Danlos syndrome wishing to become pregnant are 
counselled regarding the very high risk of 
pregnancy-related adverse events by a multidisciplinary 
team, considering family history, genetic variant, and 
previous vascular events. 
I 
C 
Beta-blocker therapy throughout pregnancy should be 
considered in women with Marfan syndrome and other 
heritable thoracic aortic diseases. 
IIa 
C 
Beta-blocker therapy throughout pregnancy and in the 
post-partum period is recommended in women with 
MFS and other HTADs. 
I 
C 
Section 9. Recommendations for congenital heart disease and pregnancy 
Patients with a systemic right ventricle (Mustard/ 
Senning or congenitally corrected TGA), in NYHA class 
III/IV, systemic ventricular dysfunction (EF <40%), or 
severe TR should be advised against pregnancy. 
IIa 
C 
It is recommended that women with a systemic RV 
(Mustard/Senning or congenitally corrected TGA), in 
NYHA class III/IV, systemic ventricular dysfunction 
(EF <40%), or severe TR wishing to become pregnant 
are counselled by the Pregnancy Heart Team regarding 
the high risk of pregnancy-related adverse events. 
I 
C 
Section 12. Recommendations for acquired heart disease and pregnancy 
An invasive management strategy should be considered 
for NSTE ACS with high-risk criteria. 
IIa 
C 
It is recommended to manage pregnant women with 
ACS in the same way as non-pregnant women, including 
diagnostic investigations and interventions. 
I 
C 
Catheter ablation with electro-anatomical systems 
should be considered in experienced centres in cases of 
drug-refractory and poorly tolerated SVT. 
IIa 
C 
Catheter ablation may be considered in pregnant 
women with recurrent, long symptomatic SVT or with 
contraindications to pharmacological therapies. 
IIb 
C 
Balloon aortic valvuloplasty should be considered 
during pregnancy in patients with severe aortic stenosis 
and severe symptoms. 
IIa 
C 
In very selected symptomatic pregnant women with 
severe aortic stenosis not responding to medical 
therapy, non-surgical options such as balloon 
valvuloplasty or TAVI may be considered. 
IIb 
C 
A bioprosthesis should be considered in young women 
contemplating pregnancy. 
IIa 
C 
A bioprosthetic valve is recommended (over a 
mechanical valve) in young women contemplating 
pregnancy requiring a valve prosthesis. 
I 
B 
During the second and third trimesters, LMWH with 
anti-factor Xa level monitoring and dose adjustment 
(see separate recommendations) may be considered in 
women who need a high dose of VKA after patient 
information and consent. 
IIb 
C 
During the second and third trimesters until the 36th 
week, continuing VKAs should be considered in women 
with prosthetic heart valves at higher risk of thrombosis. 
IIa 
C 
¬© ESC 2025
ACS, acute coronary syndrome; CMP, cardiomyopathy; EF, ejection fraction; HCM, hypertrophic cardiomyopathy; HTAD, heritable thoracic aortic disease; LMWH, low-molecular-weight 
heparin; MFS, Marfan syndrome; NSTE ACS, non-ST-elevation myocardial infarction; NYHA, New York Heart Association; RV, right ventricle; SVT, supraventricular tachycardia; TAVI, 
transcatheter aortic valve implantation; TGA, transposition of the great arteries; TR, tricuspid regurgitation; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 13 -->

### Page 13

by 30%‚Äì50%, and heart rate increases by 10‚Äì20 beats per minute. 
Peripheral vascular resistance decreases by 20%‚Äì50%.37 
Left and right atrial and ventricular diameters and volumes increase 
while ventricular function is preserved.38 Blood pressure and CO increase during labour.39 After delivery, the uterus contracts, and CO 
drops rapidly to ‚àº15%‚Äì25% above normal. A gradual decrease of 
CO follows over the next 3‚Äì4 weeks and reaches pre-pregnancy levels 
at ‚àº6 weeks post-partum. 
In women with heart disease, left and right ventricular adaptation to 
pregnancy can be suboptimal and can lead to heart failure (HF) and 
atrial and ventricular tachyarrhythmias. Atrial arrhythmias may develop 
in response to cardiac stretch and hormonal changes in pregnancy and 
may not be well tolerated in women with CVD. The haemodynamic 
and hormonal changes during pregnancy are risk factors for aortic dissection in women with aortopathy.40 Pregnancy is a hypercoagulable 
state associated with an increased risk of thromboembolism.41 
Increased activity of gastrointestinal‚Äìhepatic metabolism, liver enzyme 
systems, glomerular filtration rate and plasma volume, changes in protein binding, and decreased serum albumin levels all contribute to 
changes in the pharmacokinetics of many drugs.42 









		

	



	



¬Å	
	¬ç

	
		
¬è

¬è
¬è

¬ê



	
¬ù¬†
¬≠
¬ù¬†
¬Ä¬Ç¬É


¬Ä¬Ñ¬ù
¬Ä¬Ñ
¬Ö¬Ñ¬Ü

¬á	
¬à


¬Ç



¬Ä¬Ñ¬ù¬â
¬Ö¬Ñ¬ù¬â
¬á¬Ç


¬Ö




¬ä
¬â¬ã
¬å
Figure 1 Physiology of haemodynamic changes, and changes in electrocardiogram and echocardiography during and post pregnancy. BP, blood pressure; 
ECG, electrocardiogram; LA, left atrium; LV, left ventricle; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; RV, right 
ventricle; RVEF, right ventricular ejection fraction; SPAP, systolic pulmonary artery pressure.   
ESC Guidelines                                                                                                                                                                                               13


<!-- PAGE 14 -->

### Page 14

### 4 The Pregnancy Heart Team

4.1. Concept and requirements 
The central role of the Pregnancy Heart Team is illustrated in  
Figure 2. The concept of the Pregnancy Heart Team was first introduced in the 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.43 It has become an established 
component in the care of women with CVD or those who develop 
cardiovascular problems during pregnancy.44‚Äì49 This care provision 
commences prior to pregnancy and persists through the post- 
partum period. Research has shown that management by a 
Pregnancy Heart Team is associated with favourable maternal, foetal, 
and healthcare services outcomes, including lowered maternal mortality and readmission rates and subsequently improved patient 
safety.50 Institutional Pregnancy Heart Teams should be established 
in referral hospitals, taking into account the geographical regions, 
disciplines represented, and numbers of births, as well as sociocultural aspects.44,45,47‚Äì49 Maintaining a balance between the need for 
follow-up by such teams and the workload on these teams is crucial, 
emphasizing the importance of carefully selecting women who should 
be directed to a Pregnancy Heart Team. Patient selection is best accomplished by a risk assessment using the modified World Health 
Organization (mWHO) 2.0 classification (Table 6). The Pregnancy 
Heart Team should encompass a core team that can be expanded 
with other experts (see Figure 3), tailored to women‚Äôs physical and 
mental health or emerging complications.53 
The primary responsibilities of the Pregnancy Heart Team encompass 
risk assessment, collaborative care plan development, continuous 
progress monitoring, coordination, patient education, and psychological counselling. A staged approach is recommended, from 
pre-conception and pregnancy through to labour, delivery, and 
post-partum care. Promoting shared decision-making is essential 
at all stages. Not every hospital needs to establish a dedicated 
Pregnancy Heart Team, but each hospital should establish communication and collaboration with nearby expert teams, optimizing 
emergency and elective referral pathways within a shared-approach 
care model. 
4.2. Pre-pregnancy counselling and family 
planning 
Women should receive pre-pregnancy counselling and education about 
the maternal, foetal, and transmission risk(s).54 In adolescents diagnosed 
with congenital or inherited heart disease, tailored discussions about reproductive health should start early, ideally from menarche. Girls and women with congenital heart disease may not demonstrate appropriate 
understanding of safe contraception and pregnancy risk. High rates of unintended pregnancies (up to 45%) have been reported in adolescents 
with congenital heart disease.55 Transition programmes showed improved disease-related knowledge levels in adolescents with congenital 
heart disease.56‚Äì58 
4.2.1. Risk assessment 
A personalized pregnancy-related risk assessment is needed in all women with CVD and should encompass the specific cardiovascular diagnosis, functional status, and medication regimen, as well as non-cardiac 
risk factors such as maternal age, smoking history, comorbidities, body 
mass index (BMI), obstetric history, logistical care aspects, maternal 
ethnicity, and socioeconomic status. It is also crucial to integrate foetal 
and obstetric outcomes with specific cardiovascular considerations. 
Maternal preferences should be thoroughly explored as part of the 
shared decision-making process. 
4.2.1.1. Maternal risk assessment 
Depending on the diagnosis, a cardiovascular assessment may include imaging, biomarker-level assessment, and functional testing. Cardiopulmonary 
exercise testing can be useful for pre-pregnancy risk stratification.59,60 
Assessment may include re-evaluation after discontinuation of teratogenic 
medications and whether pre-pregnancy intervention is required. 
Various scoring systems are available to assess maternal risk and foetal 
risk. These do not fully explore the interaction with non-cardiac risk factors, 
only focus on maternal cardiac events, and have mainly been validated in 
higher-income countries. Further adaptation and validation in other countries may be required.51 Despite these limitations, disease-specific risks can 
be effectively assessed using the mWHO classification, validated as the 
best-available risk assessment model.1,61 However, the mWHO classification is oriented towards adult congenital heart disease (ACHD) and identifying those at the highest risk. Therefore, the mWHO 2.0 classification has 
now been expanded with other CVDs and refined by integrating the 
Cardiac Disease in Pregnancy study (CARPREG) II (Table 6).52 Specific expertise and collaborative management by a Pregnancy Heart Team is mandatory for all women with a condition of mWHO 2.0 class II‚ÄìIII or above. 
4.2.2. Genetic counselling 
Several CVDs have a genetic basis, including heritable cardiac conditions 
such as some aortopathies, channelopathies, cardiomyopathies, congenital 
heart disease, and subsets of pulmonary arterial hypertension (PAH) and 
thromboembolic disease. Most show autosomal dominant inheritance 
with a 50% transmission risk. Knowledge of an underlying pathogenic/likely 
pathogenic (P/LP) variant (adjusted terminology for mutation) is of increasing importance to better assess pregnancy-related outcomes and to adjust 
management (Figure 4).62,63 Therefore, it is recommended that genetic 
testing for CVD is performed pre-pregnancy in a specialized cardiogenetic 
centre or a network model with access to a multidisciplinary team, involving appropriately trained professionals with expertise in genetic testing 
methodology, sequence variant interpretation, clinical application of genetic testing, and pre- and post-testing genetic counselling about the transmission risk and the variable expression of an inherited genetic condition.64,65 
4.2.2.1. Pre-natal and pre-implantation diagnosis 
A timely discussion about pre-implantation (or pre-gestational) genetic 
testing and pre-natal testing should be offered to every woman and/or 
couple when there is a known parental monogenic or chromosomal abnormality. Pre-implantation genetic testing requires in vitro fertilization 
(IVF). The modalities of pre-natal and pre-implantation testing, including 
precautions, are summarized in Table 7. The decision whether to pursue pre-implantation or pre-natal genetic testing should include consideration of a spectrum of aspects related to the disease, including 
cultural, religious, and legal issues, but also accessibility of required techniques and expertise.67 Counselling should be provided at an experienced centre with an expert multidisciplinary team. An individualized 
approach is required to ensure autonomous choice and informed 
decision-making within the local ethical and legal framework. Several 
of these options take time and require early referral. 
4.2.3. Reproductive technology 
Infertility rates in most women with CVD are similar to 
those in the general population, but managing infertility and 
medically assisted reproductive treatment is more complex.68


<!-- PAGE 15 -->

### Page 15






	




















¬Å¬ç¬è¬ê
¬ù
¬†	

¬≠¬Ä
¬Ç


	¬Ä¬É
	
¬≠
¬Ñ¬Ö¬Ä¬Ü	
¬≠¬É¬Ü
¬á	
¬à
	
¬≠
¬≠
	
¬â	

	¬Ä¬É

	
¬ä

	
Figure 2 Central illustration. Role of Pregnancy Heart Team in pregnancy pathway. CMP, cardiomyopathy; mWHO, modified World Health Organization.   
ESC Guidelines                                                                                                                                                                                               15


<!-- PAGE 16 -->

### Page 16

Table 6 Modified World Health Organization 2.0 classification of maternal cardiovascular risk  
mWHO 2.0 I 
mWHO 2.0 II 
mWHO 2.0 II‚ÄìIII 
mWHO 2.0 III 
mWHO 2.0 IV  
Diagnosis 
Ventricular (dys)function + pulmonary hypertension   
Mild left ventricular 
impairment: EF >45%. 
Significantly impaired 
RV (subpulmonary) 
function. 
Moderate left 
ventricular impairment: 
EF 30%‚Äì45%. 
Previous PPCM with 
not more than mild 
residual left ventricular 
impairment. 
Severe left ventricular 
impairment: EF <30% 
or NYHA class III/IV. 
Previous PPCM with 
more than mild left 
ventricular 
impairment.  
PAH. 
Arrhythmias 
Atrial or ventricular 
ectopic beats, isolated. 
Most 
supraventricular 
arrhythmias. 
Bradycardia 
requiring 
pacemaker. 
Low-risk LQTS: no 
previous events + on 
full dose beta-blocker 
therapy. 
Low-risk CPVT: well 
controlled by medical 
therapy. 
BrS with no previous 
events. 
Sustained ventricular 
tachycardia from any 
aetiology. 
LQT2 (post-partum). 
Symptomatic CPVT 
and LQTS not 
adequately controlled 
by therapy. 
BrS with previous 
events.  
Cardiomyopathy 
HCM: genotype-positive 
+ phenotype-negative.  
Low-risk ARVC: 
genotype-positive + no 
or mild phenotype. 
HCM without 
complications. 
DCM/NDLVC with 
normal or mild left 
ventricular 
impairment: EF >45%. 
ARVC with moderate/ 
severe disease. 
HCM with arrhythmic 
and/or moderate 
haemodynamic 
complications. 
DCM/NDLVC with 
moderate left 
ventricular impairment: 
EF 30%‚Äì45%. 
DCM/NDLVC with 
severe left ventricular 
impairment: EF <30% 
or NYHA class III/IV. 
HCM with 
symptomatic severe 
outflow tract 
obstruction: 
‚â•50 mmHg. 
HCM with severely 
symptomatic LV 
dysfunction (EF <50%). 
Congenital heart disease 
Successfully repaired 
simple lesions without 
significant residual 
(haemodynamic) 
complications (atrial or 
ventricular septal defect, 
patent ductus arteriosus, 
anomalous pulmonary 
venous drainage). 
Unoperated 
uncomplicated 
atrial or ventricular 
septal defect. 
Repaired tetralogy 
of Fallot without 
significant residual 
haemodynamic/ 
arrhythmic lesions. 
Transposition of 
the great arteries 
with arterial switch 
without significant 
residual lesions. 
Repaired 
atrioventricular septal 
defect without 
significant residual 
lesions. 
Uncomplicated 
Ebstein anomaly: mild 
to moderate TR, no 
tricuspid stenosis, no 
accessory pathway. 
Unrepaired cyanotic 
heart disease (not 
Eisenmenger). 
Systemic RV with good 
or mildly decreased 
ventricular function. 
Uncomplicated Fontan 
circulation: good 
ventricular function, no 
significant valve disease 
or arrhythmias, good 
exercise tolerance, and 
normal arterial 
saturations. 
Ebstein anomaly with 
any complication. 
Systemic RV with 
moderate or severely 
decreased ventricular 
function. 
Fontan with any 
complication. 
Eisenmenger 
syndrome.                                       
Continued


<!-- PAGE 17 -->

### Page 17

mWHO 2.0 I 
mWHO 2.0 II 
mWHO 2.0 II‚ÄìIII 
mWHO 2.0 III 
mWHO 2.0 IV  
Valvular heart disease 
Small or mild 
‚Ä¢ pulmonary stenosis 
‚Ä¢ mitral valve prolapse 
without significant 
regurgitation.  
Native, homograft or 
tissue valve disease not 
considered mWHO 
2.0 I or IV: mild mitral 
stenosis, moderate 
aortic stenosis. 
Moderate valvular 
regurgitation. 
Uncomplicated 
mechanical valve with 
stable well controlled 
INRs. 
Moderate mitral stenosis. 
Severe asymptomatic 
aortic stenosis. 
Severe left-sided valvular 
regurgitation. 
Severe mitral stenosis. 
Severe symptomatic 
aortic stenosis. 
Aortopathy 
Non-HTAD mild aortic 
dilatation (<40 mm). 
Turner syndrome 
without 
cardiovascular 
features (BAV, 
coarctation, AHT, 
aortic dilatation). 
Marfan or other 
HTAD syndrome 
without aortic 
dilatation. 
Aorta <45 mm in BAV 
pathology. 
Repaired coarctation. 
Moderate aortic 
dilatation: 40‚Äì45 mm in 
Marfan syndrome or 
other HTAD; 
45‚Äì50 mm in BAV, 
Turner syndrome ASI 
20‚Äì25 mm/m2, other 
aortic dilatation 
<50 mm. 
Marfan with previous 
aortic root replacement. 
Previous aortic 
dissection with stable 
diameter. 
Severe aortic 
dilatation: >45 mm in 
Marfan syndrome or 
other HTAD, 
>50 mm in BAV, 
ASI >25 mm/m2 in 
Turner syndrome, 
other aortic dilatation 
>50 mm. 
Vascular Ehlers‚Äì 
Danlos syndrome. 
Severe (re)coarctation. 
Previous aortic 
dissection with 
increasing diameter. 
Acquired + coronary heart disease + other    
Prior SCAD. 
Prior ischaemic cardiac 
event (STEMI/NSTE 
ACS). 
Prior adverse pregnancy 
outcome requiring 
hospitalization. 
Prior adverse 
cardiovascular effects of 
cancer treatment.  
Risk 
No detectable increased 
risk of maternal mortality 
and no/mild increased risk 
in morbidity. 
Small increased risk 
of maternal 
mortality or 
moderate increase 
in morbidity. 
Intermediate increased 
risk of maternal 
mortality or moderate 
to severe increase in 
morbidity. 
Significantly increased 
risk of maternal 
mortality or severe 
morbidity. 
Extremely high risk of 
maternal mortality or 
severe morbidity. 
Average 
maternal 
cardiac 
event 
ratesa 
Van Hagen 
et al. 
(2016)51 
9.9% 
7.7% 
17.7% 
28.9% 
50.3% 
Silversides 
et al. 
(2018)52 
3.1% 
21.7% 
12.8% 
21.1% 
35.6% 
Individualize each maternal risk with the modifiers belowb (derived from CARPREG II)52 
CARPREG II score: 1 point 
‚Ä¢ No prior cardiac intervention indicated 
‚Ä¢ Late pregnancy assessment 
CARPREG II score: 2 points 
‚Ä¢ Ventricular dysfunction 
‚Ä¢ High-risk left-sided valve disease or outflow 
tract obstruction 
‚Ä¢ Pulmonary hypertension 
‚Ä¢ Coronary artery disease 
‚Ä¢ High-risk aortopathy 
CARPREG II score: 3 points 
‚Ä¢ Prior cardiac event or arrhythmias 
‚Ä¢ Baseline NYHA III/IV or cyanosis 
‚Ä¢ Mechanical valve                                                                
Continued  
ESC Guidelines                                                                                                                                                                                               17


<!-- PAGE 18 -->

### Page 18

mWHO 2.0 I 
mWHO 2.0 II 
mWHO 2.0 II‚ÄìIII 
mWHO 2.0 III 
mWHO 2.0 IV  
Involvement of the 
Pregnancy Heart 
Team 
No 
No 
Yes 
Yes 
Yes 
Counselling 
Yes (by regular healthcare 
professional) 
Yes (by regular 
healthcare 
professional) 
Yes: expert counselling 
by Pregnancy Heart 
Team is required 
Yes: expert counselling 
by Pregnancy Heart 
Team is required 
Yes: expert 
counselling by 
Pregnancy Heart 
Team is required, with 
clear and thorough 
discussion of very high 
pregnancy risk and 
shared 
decision-making 
process for 
termination if 
pregnancy occurs 
Obstetric and cardiac 
care during 
pregnancy 
Local hospital 
Local hospital 
Shared care with local 
hospital + Pregnancy 
Heart Team 
Care led by Pregnancy 
Heart Team 
Care led by Pregnancy 
Heart Team 
Location of delivery 
Local hospital 
Local hospital 
Shared care with local 
hospital + Pregnancy 
Heart Team. Location 
depends on CV status 
and evolution of 
pregnancy 
Expert centre, care led 
by Pregnancy Heart 
Team 
Expert centre, care led 
by Pregnancy Heart 
Team 
¬© ESC 2025
AHT, arterial hypertension; ARVC, arrhythmogenic right ventricular cardiomyopathy; ASI, aortic size index; BAV, bicuspid aortic valve; BrS, Brugada syndrome; CARPREG II, Cardiac Disease 
in Pregnancy study II; CPVT, catecholaminergic polymorphic ventricular tachycardia; CV, cardiovascular; DCM, dilated cardiomyopathy; EF, ejection fraction; HCM, hypertrophic 
cardiomyopathy; HTAD, heritable thoracic aortic diseases; INR, international normalized ratio; LQTS, long QT syndrome; LQT2, long QT syndrome type 2; LV, left ventricle; mWHO, 
modified World Health Organization; NDLVC, non-dilated left ventricular cardiomyopathy; NSTE ACS, non-ST-elevation acute coronary syndrome; NYHA, New York Heart 
Association; PAH, pulmonary arterial hypertension; PPCM, peripartum cardiomyopathy; RV, right ventricle; SCAD, spontaneous coronary artery dissection; STEMI, ST-elevation 
myocardial infarction; TR, tricuspid regurgitation. 
aDefinition of cardiac events: cardiac arrest, cardiac death, arrhythmia requiring treatment, left/right heart failure, thromboembolic event, aortic dissection, acute coronary syndrome, or 
hospitalization for cardiac reason. Endocarditis only in van Hagen et al.51 



	

	

	

	

	





¬Å
¬ç
¬è
¬ê¬ù
¬ê¬ù
¬ê¬†



bEstimation of maternal adverse cardiac event rate with integration of CARPREG II score. Reprinted from Silversides et al.52 with permission from Elsevier.


<!-- PAGE 19 -->

### Page 19

Nevertheless, women with CVD requesting reproductive treatment 
should not be turned down based on assumed cardiovascular risk until their case has been discussed in a multidisciplinary setting involving 
the Pregnancy Heart Team. 
Assisted reproduction has added risks above those of pregnancy 
alone; superovulation is pro-thrombotic and can be complicated by ovarian hyperstimulation syndrome, with marked fluid shifts and a high 
thrombosis risk. All women with CVD who are embarking on fertility 
treatment should have an individual risk assessment for venous thromboembolism (VTE) given the risk associated with these techniques.69 The 
risk of ovarian hyperstimulation syndrome can be reduced by careful cycle monitoring, using a low-dose follicle-stimulating hormone in combination with a gonadotropin-releasing hormone antagonist. Transferring 
a single embryo is strongly advised in women with CVD, as carrying 
multiple gestations is associated with greater cardiovascular changes 
and more maternal and foetal complications.70,71 
In women with mWHO 2.0 class III conditions or those who are anticoagulated (Table 6), the risk of complications from superovulation is 
very high. It is therefore recommended that these women have a full 
pre-pregnancy assessment by a Pregnancy Heart Team prior to the 

















	







	


¬Å¬ç
¬è
	

	

¬ê



	

¬Å

¬ù
	












































	








Figure 3 Composition of the core and expanded case-based Pregnancy Heart Team. MDT, multidisciplinary team.   
ESC Guidelines                                                                                                                                                                                               19


<!-- PAGE 20 -->

### Page 20













	



¬Å¬ç¬è¬ê¬è
¬ù¬†¬≠¬Ä¬Ç
¬É
¬Ñ¬≠¬Ö¬†¬Ü¬≠¬á¬≠
¬Å¬Ä¬≠¬á¬à


¬≠¬Ä¬Ç
	


	
	

Figure 4 Pre-conception counselling and genetic aspects. ARVC, arrhythmogenic right ventricular cardiomyopathy; CPVT, catecholaminergic polymorphic 
ventricular tachycardia; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LQTS, long QT syndrome; PAH, pulmonary arterial 
hypertension.  
Table 7 Pre-implantation and pre-natal options and implications  
Pre-implantation genetic 
diagnosis 
IVF procedure followed by biopsy and genetic testing of a single cell of the embryo. Embryo transfer with success rate of 
25%‚Äì30% (dependent on mother‚Äôs age and fertility). 
Risks to mother and offspring of IVF, such as multiple birth, premature labour and low birth weight, as well as side effects of 
hormonal treatment. 
Availability, expense and methods differ across countries. 
Chorionic villus sampling 
Transcervical or transabdominal sampling of the chorionic villi at the end of the first trimester. 
Procedure-related foetal loss rate ‚àº0.2%.66 
Amniocentesis 
Direct sampling of amniotic fluid after 15 weeks of gestation. 
Procedure-related foetal loss rate ‚àº0.1%.66 
¬© ESC 2025
Adopted from the 2023 ESC Guidelines for the management of cardiomyopathies.60 
IVF, in vitro fertilization.


<!-- PAGE 21 -->

### Page 21

procedure, including an evaluation of the risk of hormonal treatment. 
The option of natural cycle IVF should be considered. Hysteroscopy 
and laparoscopy can be life-threatening procedures in women with specific cardiac conditions, such as a Fontan circulation, and should only be 
undertaken in an experienced centre with appropriate support. 
Fertility treatment should be avoided in women with mWHO 2.0 
class IV conditions. 
4.2.4. Contraception 
To ensure informed decision-making about pregnancy, accurate 
counselling about contraception should be provided to all girls 
and women of childbearing age with CVD, starting from menarche, 
to prevent unplanned pregnancies. An overview of the benefits and 
risks of different types of contraception in women with CVD is provided in Table 8. 
4.2.5. Termination of pregnancy including 
psychological support 
It is strongly recommended to consider and discuss termination of 
pregnancy with women whose risk is classified as mWHO 2.0 class 
IV due to the exceptionally elevated risk of maternal and foetal mortality or severe morbidity.83 Efforts should be made to minimize delays for women seeking pregnancy termination because the risk of 
procedure-related complications increases as gestational age advances. Surgical methods are often preferred, but pharmacological 
methods remain an option until the ninth week of pregnancy.83 
Given the emotional and psychological impact of pregnancy termination, it is crucial to provide professional psychosocial support, which 
plays a significant role in reducing adverse mental health outcomes.89 
At the same time a discussion should be held regarding appropriate 
contraception. 
Table 8 Overview of benefits and risks of different methods of contraception in women with cardiovascular disease 
Method 
Benefits 
Cardiovascular 
risks 
Cautious use and contraindications 
Contraceptive 
efficacy  
Hormonal oral contraceptives 
Progestin-only oral 
contraceptives 
Minimal/no impact 
on coagulation 
factors 
Safe CV risk 
profile72,73 
Mild fluid retention 
LQTS not on beta-blockers74,75 
++ (general) 
+++ (for 
drospirenone)73 
Combined oral 
contraceptives76,77 
Regular 
menstruation with 
reduced blood loss 
VTE, hypertension 
and altered lipid 
profilea 
Known dyslipidaemia78 
Pre-existing hypertension79 
Obesity80 
Cyanosis 
MHV 
Fontan circulation 
Risk factors for ACS81 
+++ 
Long-acting reversible contraceptives 
Levonorgestrel-releasing 
IUD 
‚Üì Menstrual bleeding 
and iron loss 
None specified 
Vasovagal responses on insertion and 
removal (done by gynaecologist) ‚Üí caution 
and monitoring with availability of 
anaesthesiologist recommended in PAH and 
Fontan circulation82 
Safest and most 
effective option 
+++ 
Smaller levonorgestrel IUD 
‚Üì Menstrual bleeding 
and iron loss 
Easier to insert 
‚Üì Risk of vasovagal 
responses 
None specified 
‚Äî 
+++ 
Copper IUD 
‚Üì Cost 
‚Äî 
‚Üë Intensity of menstrual bleeding 
+++ 
Etonogestrel-releasing 
subcutaneous implants 
No pelvic infection 
risk 
None specified 
Surgical subcutaneous insertion (in the 
forearm with local anaesthesia‚Äîoutpatient 
procedure) 
+++ 
Depot 
medroxyprogesterone 
acetate injection83 
Lighter menses 
Increased VTE risk, 
weight gain 
Irregular bleeding 
++ 
Barrier methods 
‚Äî 
‚Üì Pelvic infection risk84 
‚Äî 
None specified 
+                                                 
Continued  
ESC Guidelines                                                                                                                                                                                               21


<!-- PAGE 22 -->

### Page 22

Permanent sterilization 
Tubal ligation 
Vasectomy 
Permanent 
Anaesthetic and 
procedural risks 
Non-reversible 
+++ 
Emergency contraception 
Oral contraceptive pills to delay ovulation 
Ulipristal acetate 
‚Üë Effectiveness than 
levonorgestrel 
No ‚Üë thrombosis 
risk85‚Äì87 
None specified 
+++ (only if taken 
before ovulation) 
Levonorgestrel 
single dose of 1.5 mg <72 h after 
unprotected intercourse 
‚Äî 
No ‚Üë thrombosis risk 
None specified 
++ (only if taken before 
ovulation) 
Contraceptive device 
Copper IUD 
<120 h after unprotected intercourse 
‚Äî 
‚Äî 
None specified 
+++ (in addition to 
ongoing 
contraception)85‚Äì88 
¬© ESC 2025
ACS, acute coronary syndrome; CV, cardiovascular; IUD, intrauterine device; LQTS, long QT syndrome; mg, milligram; MHV: mechanical heart valve; PAH, pulmonary arterial hypertension; 
VTE, venous thromboembolism. 
‚Üë increase ‚Üì decrease. 
aHigher in combined oral contraceptive pills containing ethyniloestradiol compared to natural oestradiol or oestetrol.  
Recommendation Table 1 ‚Äî Recommendations for counselling, pregnancy risk assessment, contraception, assisted reproductive technology, and the involvement of a Pregnancy Heart Team (see Evidence Table 1) 
Recommendations 
Classa 
Levelb  
Maternal risk assessment 
It is recommended to perform a risk assessment in all women with CVD of childbearing age using the mWHO 2.0 classificationc.44,45,47‚Äì49,54 
I 
C 
A discussion by the Pregnancy Heart Team about the high risk of maternal mortality or morbidity and the related high foetal risk is 
recommended for women with mWHO 2.0c class IV conditions, including a shared decision-making process for pregnancy termination, 
involving psychological support.65 
I 
C 
It is recommended that women with CVD of mWHO 2.0c class II‚ÄìIII and above are evaluated and managed by a Pregnancy Heart Team 
from pre-pregnancy onwards through pregnancy and post-partum.44,45,47‚Äì49,54 
I 
C 
Methods of contraception 
It is recommended that women with CVD of mWHO 2.0c class II and above, or those at risk of developing CVD, receive individualized 
advice to determine the most suitable contraception method, including emergency contraception.90,91 
I 
C 
Progestin-only treatment, contraceptive implants, and/or levonorgestrel IUDs should be considered when there is any risk of 
thromboembolic events.73,92‚Äì94 
IIa 
B 
Genetic counselling 
Assessment by a clinical geneticist prior to pregnancy is recommended in women fulfilling diagnostic criteria for inherited cardiovascular 
disease to guide risk stratification and pre-natal genetic testing.63,95 
I 
C 
Pre-conception genetic counselling is recommended in couples with heritable CVD, whether genetic testing is being considered or not. It is 
recommended that this counselling is provided by an appropriately trained healthcare professional within a multidisciplinary team that offers 
psychological support and education to encourage decision-making.63,95 
I 
C 
Reproductive technology 
It is recommended that single embryo transfer is performed in women with CVD.70,71 
I 
C 
Pregnancy termination 
It is recommended to offer women with CVD access to termination of pregnancy that is tailored to their cardiac condition to minimize the 
risks of the procedure.83 
I 
C 
¬© ESC 2025
CVD, cardiovascular disease; IUD, intrauterine device; mWHO, modified WHO. 
aClass of recommendation. 
bLevel of evidence. 
cThe mWHO 2.0 classification is the updated mWHO classification from the 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy43 and described in Table 6.


<!-- PAGE 23 -->

### Page 23

4.3. Diagnostic methods in pregnancy 
The pros and cons of the primary cardiovascular diagnostic methods 
for diagnosing cardiovascular disease in pregnancy are described here. 
Pre-pregnancy evaluation is covered in the risk assessment section 
(Section 4.2.1). 
4.3.1. Electrocardiogram, including mobile rhythm 
devices 
Pregnant women may present changes in their surface electrocardiogram (ECG), including increased heart rate, minor leftward QRS axis 
shift (15‚Äì20 degrees), slightly decreased (20 ms) PR interval, prominent 
Q waves in II, III, and aVF, and flat or inverted T-waves in III, aVF, V1, V2, 
and V3 (Figure 1).96‚Äì98 
A 12-lead ECG is part of the standard evaluation of pregnant women 
presenting with new-onset cardiac signs or symptoms or suspected arrhythmia. In pregnant women presenting with syncope or palpitations, 
long-term Holter monitoring or implantable loop recorders should be 
considered as additional diagnostic tools. As pregnant women are more 
prone to arrhythmias, the threshold to perform long-term ambulatory 
rhythm monitoring should be low. 
4.3.2. Echocardiography 
Transthoracic echocardiography (TTE) is the first-line imaging method 
used in pregnancy.99,100 Physiological changes in cardiac geometry and 
functioning are expected during pregnancy (Figure 1).99,101‚Äì103 These 
are greatest early in the third trimester and resolve early post-partum. 
Agitated saline contrast should not be used during pregnancy, given 
the risk of placental infarction due to microbubble embolism, resulting 
in foetal distress.99,104 Relevant foetal exposure to intravenous (i.v.) 
echocardiographic contrast agents is not expected due to their very 
short half-life.105 Nevertheless, these agents should only be used selectively because studies during pregnancy or lactation are lacking.99 
Transoesophageal echocardiography is relatively safe, but the potential 
risks and benefits must be weighed individually, including the risk of emesis/aspiration and sudden increase in intra-abdominal pressure. 
Speckle-tracking echocardiography is a useful method to detect subclinical myocardial abnormalities in pregnancy.106,107 
4.3.3. Cardiopulmonary exercise testing 
If there is suspicion of new-onset CVD during pregnancy, submaximal 
exercise testing (at 80% of predicted maximal heart rate) can be useful 
to assess cardiovascular response to exercise. There is no evidence that 
exercise testing increases the risk of spontaneous miscarriage.108,109 
Stress echocardiography using bicycle ergometry may improve diagnostic specificity. The use of pharmacologic stress agents (e.g. dobutamine) 
should be avoided.99,110 There is no evidence supporting a preference 
for treadmill over bicycle exercise testing during pregnancy. The choice 
should be based on women‚Äôs individual risk factors, contraindications, 
pregnancy stage, and local availability of testing and expertise. 
4.3.4. Biomarkers 
Throughout pregnancy and the early post-partum stages, natriuretic 
peptide [NP: B-type natriuretic peptide (BNP) and N-terminal pro- 
brain natriuretic peptide (NT-proBNP)] values within the normal range 
have a strong negative predictive value for heart failure whereas the 
positive predictive value tends to be lower.111,112 In women with pre- 
existing cardiomyopathy, ACHD, or valvular heart disease, baseline as a 
minimum and serial NP measurements on an individualized basis should 
be considered to diagnose cardiac complications during pregnancy and 
post-partum.113‚Äì118 
Although cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are 
essential in diagnosing myocardial ischaemia, standardized values in pregnancy and post-partum have not been established.112,119 Therefore, routine use of troponins alone during pregnancy is not recommended. 
D-dimer testing has relevance in the diagnosis of VTE (see Section  
11), taking into account the physiological increase during pregnancy, 
particularly in the third trimester. 
4.3.5. Ionizing radiation exposure 
Risks of ionizing radiation exposure are highest during organogenesis 
and decrease with time.120,121 Exposing the foetus to radiation doses 
>150‚Äì200 mGy may result in intrauterine growth restriction (IUGR), 
congenital malformations (in particular of the central nervous system), 
and malignancies. If possible, procedures should be delayed at least until 
the completion of major organogenesis (>12 weeks of gestation). 
However, the safety of the woman is important and should guide the 
clinical decision. All radiation doses to the foetus must be kept ‚Äòas 
low as reasonably achievable‚Äô (ALARA) (preferably <50 mGy) and 
should be clearly documented. Manoeuvres to minimize radiation are: 
(i) use echo guidance when possible; (ii) place the source as far and 
the receiver as close as possible to the patient; (iii) use only low-dose 
fluoroscopy (7.5 frames per second or lower); (iv) favour anteroposterior projections; (v) avoid direct radiation of the abdominal region (abdominal shielding is of limited benefit due to internal scatter from 
thoracic tissues rather than direct foetal irradiation); (vi) collimate as 
tightly as possible to the area of interest; (vii) minimize fluoroscopy 
time; and (viii) ensure the procedure is performed by an experienced 
cardiologist.122‚Äì126 Iodinated contrast can cross the placenta, but has 
not been reported to have teratogenic effects.127 The potential risk 
of congenital hypothyroidism is unclear but no abnormalities of foetal 
thyroid function after application have been reported.122,128,129 
4.3.5.1. Chest radiography 
The chest radiograph is a practical and readily available diagnostic tool 
for evaluating cardiopulmonary diseases. The foetal dose from chest 
radiography is <0.01 mGy. Nevertheless, it should only be performed 
in symptomatic women if other methods fail to clarify the cause of 
the symptoms. 
Lung ultrasound is a valuable tool for diagnosing pleural effusion, pulmonary oedema, pneumothorax, and pneumonia. However, there is 
currently a lack of data about the regular ultrasound pattern during 
pregnancy,130,131 and lung ultrasound is therefore not recommended 
as an alternative to chest radiography. 
Protection of the foetus is governed by radiological standards. Both 
the technician and the radiologist should act accordingly. 
4.3.5.2. Computed tomography and nuclear medicine  
imaging 
The radiation dose to the foetus from a chest computed tomography 
(CT) or pulmonary CT angiography is estimated at 0.02 mGy.121 
Technetium-99m, used for ventilation‚Äìperfusion lung scanning for detection of pulmonary embolism, results in an embryonic or foetal exposure of <5 mGy, which is considered a safe dose in pregnancy. 
Computed tomography or nuclear medicine techniques are generally  
ESC Guidelines                                                                                                                                                                                               23


<!-- PAGE 24 -->

### Page 24

not recommended during pregnancy. However, if such techniques are 
necessary because other diagnostic tools are insufficient or not readily 
available for the diagnosis in question, they should not be withheld from 
a pregnant patient.100,132 
4.3.5.3. Cardiac catheterization 
Cardiac catheterization is seldom needed during pregnancy but may be 
necessary for specific diagnostic and interventional purposes. Foetal 
compromise decreases with gestational age. The highest risk is <20 
weeks gestation and is proportional to the radiation dose, with no reports of foetal anomalies or loss when exposure is <50 mGy.133,134 
Most coronary procedures can be performed within these dose limits 
and radiation exposure to the foetus itself is estimated to be lower than 
20%. The radial approach by an experienced operator is preferable and 
every effort to reduce radiation exposure should be made. 
4.3.6. Cardiovascular magnetic resonance 
Cardiovascular magnetic resonance (CMR) is advised if other non-invasive 
diagnostic measures are insufficient to provide a clinical diagnosis and is 
preferable to radiation-based imaging modalities.99,100,135 It seems prudent 
to avoid a scanner strength higher than 1.5 tesla due to the greater energy 
deposition in tissue. Evidence regarding gadolinium-based contrast in pregnancy is controversial and its use should be avoided unless absolutely necessary.135‚Äì137 Excretion of gadolinium-based agents into breast milk is 
limited (<0.04% of an i.v. dose within the first 24 h, with 1%‚Äì2% absorption).138 Lactating women receiving intravascular gadolinium should discontinue lactation for 24 h.133,138,139 
4.4. Foetal assessment 
4.4.1. Risk of foetal/obstetric complications 
The typical increase in CO during pregnancy may not occur optimally in some women with CVD, potentially affecting uteroplacental 
blood flow. These and other cardiovascular risk factors contribute 
to an increased risk of obstetric and foetal complications, including 
foetal loss, stillbirth, pre-term birth, pre-eclampsia, and IUGR.140 
Furthermore, the severity of obstetric and foetal outcomes varies 
depending on the maternal risk as defined in the mWHO 2.0 classification. Adverse outcomes are more frequent in women with a 
higher mWHO 2.0 classification, emphasizing the importance of 
risk stratification, comprehensive counselling, and multidisciplinary 
management, including neonatology expertise.2,134,140 Notably, pulmonary hypertension (PH) represents one of the highest risks for 
obstetric and foetal complications.141 The main predictors of neonatal complications are indicated in Table 9. 
4.4.2. Screening for congenital heart disease in the 
foetus 
Foetal echocardiography should routinely be offered at 18‚Äì22 weeks 
when parents have congenital heart disease. This will detect up to 
80% of significant congenital cardiac defects.142‚Äì144 
4.4.3. Assessing foetal well-being 
Detailed anatomical foetal assessment is required in women using cardiac 
medication with teratogenic effects (see Section 5 for more details).145 
Recommendation Table 2 ‚Äî Recommendations for diagnostic methods in pregnancy (see Evidence Table 2) 
Recommendations 
Classa 
Levelb  
Echocardiography 
Transthoracic echocardiography is recommended as first-line imaging tool in any pregnant woman with unexplained or new cardiovascular 
signs or symptoms.99 
I 
C 
Biomarkers 
Measurement of BNP and NT-proBNP levels should be considered prior to pregnancy in women with HF of any aetiology, including 
previous PPCM, cardiomyopathy, ACHD, and PAH, and be monitored during pregnancy according to the underlying disorder and in case of 
new-onset or worsening symptoms.114 
IIa 
B 
Ionizing radiation 
It is recommended to limit exposure to all medical ionizing radiation doses to ALARA levels.121 
I 
C 
It is recommended to keep the radiation dose to the foetus as low as possible (preferably <50 mGy), particularly if the foetus is in the field of 
view.120,121 
I 
C 
A CT scan should be considered for PE when clinical benefits outweigh the risks to the mother and foetus.100,121,132 
IIa 
C 
A chest radiograph may be considered as a first-line imaging tool if other methods are not successful in clarifying the cause of dyspnoea. 
IIb 
C 
Coronary angiography with minimal radiation may be considered during pregnancy if potential benefits outweigh the risks. 
IIb 
C 
Cardiovascular magnetic resonance 
Discontinuation of lactation for 24 h should be considered in women in whom i.v. gadolinium is required.133,139 
IIa 
C 
CMR imaging without gadolinium contrast should be considered for a definitive, clinically relevant diagnosis during pregnancy, if other 
non-invasive diagnostic measures are not sufficient.135,136 
IIa 
C 
¬© ESC 2025
ACHD, adult congenital heart disease; ALARA, as low as reasonably achievable; BNP, B-type natriuretic peptide; CMR, cardiovascular magnetic resonance; CT, computed tomography; HF, 
heart failure; i.v., intravenous; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; PE, pulmonary embolism; PPCM, peripartum cardiomyopathy. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 25 -->

### Page 25

In women with beta-blocker exposure, higher small for gestational age 
(SGA) rates and, more rarely, bradycardia have been reported, indicating the need for appropriate foetal monitoring.12,146 Foetal ductus venosus Doppler velocity is a useful adjunct to evaluate foetal well-being and 
determine the time to delivery in cases of increased risk of IUGR.147 
4.4.4. Foetal assessment of heritable primary 
arrhythmias 
In families with primary arrhythmia, the foetus may present with arrhythmias. Therefore, the foetal heart rate should be assessed at baseline 
and during each pre-natal visit and compared against gestation-specific 
norms. In pregnancies complicated by suspected primary arrhythmia- 
related foetal arrhythmias, complete foetal echocardiography, typically 
performed at 20‚Äì22 weeks, is recommended to evaluate heart anatomy, 
ventricular function, and the arrhythmia mechanism.148 Foetal magnetocardiography, if available, offers valuable insights into arrhythmia type and 
severity and monitors anti-arrhythmic drug therapy, as it captures all cardiac time intervals (P, QRS, T-wave) between 17 and 24 weeks of gestation. It is currently the only method to detect repolarization 
abnormalities, such as QT interval prolongation.149 
4.5. Timing and mode of delivery 
An individualized delivery plan should be made that covers the needs 
for induction of labour, labour management, delivery, and post-partum 
surveillance, in shared decision-making with the pregnant women. This 
delivery plan should be widely accessible to the patient, her partner, and 
relevant health professionals, and should be placed in the patient‚Äôs 
(electronic) health record. 
4.5.1. Timing of delivery 
Pregnant women with CVD are more likely to have comorbidities and 
experience adverse events during delivery than those without CVD, 
and require additional monitoring and care.150 Any maternal benefit 
of early term delivery (from 37 weeks 0 days to 38 weeks 6 days of gestation) should be weighed against the increased likelihood of adverse 
foetal outcomes.151 Induction of labour between 39 and 40 weeks reduces the risk of emergency caesarean section by 12% and the risk of 
stillbirth by 50% in women without CVD. The benefit is likely to be 
greater for women with CVD who have higher rates of obstetric complications.152,153 In the absence of maternal or foetal indications for 
early birth, induction of labour before 39 weeks should be reserved 
for obstetrical indications.154 
4.5.2. Induction of labour 
Mechanical methods, prostaglandin E1 analogue (misoprostol), 
slow-release formulation of 10 mg prostaglandin E2 (dinoprostone), 
oxytocin, and artificial rupture of membranes are all considered safe 
to induce labour.4,155,156 High-dose (600 mg) misoprostol does not affect cardiac parameters in women without heart disease, although 
there remains a theoretical risk of coronary vasospasm and arrhythmias.155 Dinoprostone may cause profound hypotension, but only 
when injected blindly into the myometrium, and this route of administration should be avoided.157 The use of an additional 2 IU of oxytocin 
for the management of the third stage in women with CVD has no cardiac consequences and is associated with significantly lower blood 
loss.158 In women at high risk (mWHO 2.0 classes III‚ÄìIV), oxytocin is 
generally considered as a first-line uterotonic, misoprostol and carboprost are second line (see Supplementary data online, Table S3).159 
Mechanical methods such as a cervical ripening balloon might be preferable in women where a drop in systemic vascular resistance would be 
detrimental.160 If membranes are ruptured, augmentation of labour 
should be immediate to reduce the risk of infection and should be undertaken with oxytocin to minimize the number of vaginal examinations.4 
4.5.3. Vaginal or caesarean delivery 
Vaginal delivery is associated with less blood loss and lower risk of infections and venous thromboembolism and should be advised for 
most women.161 Planned caesarean section does not confer any advantage over planned vaginal delivery in terms of maternal outcomes and 
may be associated with adverse foetal outcomes.162,163 
Caesarean section is the preferred mode of delivery for obstetric indications and for women presenting in labour who use or have used 
vitamin K antagonist (VKA) within the past 2 weeks, with high-risk aortopathy (mWHO 2.0 class III), with hypertrophic cardiomyopathy 
(HCM) and severe left ventricle outflow tract obstruction, or in acute 
intractable HF.43 
4.5.4. Haemodynamic monitoring during delivery 
Pulse oximetry, blood pressure monitoring, and continuous ECG monitoring may help detect early signs of decompensation, arrhythmias, and 
ischaemia in women with significant CVD and identify those in whom 
delivery should be expedited.164 Arterial lines should be reserved for 
those women who have haemodynamic instability or are at risk of it. 
A right-heart catheter is of uncertain benefit, is associated with complications, and should be avoided in most cases. Minimally invasive CO 
monitoring is preferable, where possible.110 
4.5.5. Anaesthesia/analgesia 
Analgesia is crucial for labour in pregnant women with CVD to reduce 
physical stress. Neuraxial methods are very effective analgesic blocks. 
The onset of conventional epidural analgesia is relatively slow (¬±15 min) 
and allows for careful titration of a local anaesthetic‚Äìopioid mix.165 
Spinal analgesia is suitable for women with high-risk CVD, where a faster 
onset of sympathetic block is desirable.166 Combined spinal‚Äìepidural 
analgesia typically has a faster onset time (¬±5 min). However, adverse 
effects such as hypotension and foetal heart rate abnormalities occur 
more quickly and are more pronounced. Different techniques for administering low-concentration, high-volume local anaesthetic‚Äìopioid regimens allow maintenance of epidural analgesia through the epidural 
Table 9 Predictors of neonatal events in pregnancies of women with cardiovascular disease 
Predictors of neonatal events  
NYHA class III/IV or cyanosis during baseline pre-natal visit 
Maternal left heart obstruction 
Low maternal oxygen saturation (<90%) 
Multiple gestations 
Use of anticoagulants 
Cardiac medication before pregnancy 
Mechanical valve prosthesis 
Maternal cardiac event during pregnancy 
Maternal decline in CO during pregnancy 
¬© ESC 2025
Derived from the 2018 ESC Guidelines for the management of cardiovascular 
diseases during pregnancy.43 
CO, cardiac output; NYHA, New York Heart Association.   
ESC Guidelines                                                                                                                                                                                               25


<!-- PAGE 26 -->

### Page 26

catheter. Whenever an epidural catheter is in situ in a high-risk woman, 
higher doses can be administered for conversion to caesarean section, 
avoiding airway and other complications of general anaesthesia. In women 
at risk of dural ectasia, including Marfan syndrome, extra caution and management in an expert centre is essential. Furthermore, a pre-delivery consultation with the anaesthesia team is needed.167 When neuraxial analgesia 
is contraindicated due to conditions such as systemic anticoagulation or 
spinal deformities, opioids (i.v. remifentanil) are an alternative despite 
the risk of hypoventilation and apnoea.168,169 Single-shot spinal analgesia 
is common in caesarean delivery for its simplicity and effectiveness.167 
4.5.6. Delivery in women on anticoagulants 
4.5.6.1. Planned delivery 
In women with mechanical heart valves (MHVs) taking VKAs, suspension of VKAs and bridging with heparin [either therapeutic-dose 
low-molecular-weight heparin (LMWH) or i.v. unfractionated heparin 
(UFH)] is recommended at least 2 weeks before planned delivery 
(see also Section 5 and Section 12). This is because of the slow metabolism of VKA in the foetus. If therapeutic-dose LMWH is used, one 
strategy is to switch to i.v. therapeutic UFH at least 36 h before planned 
delivery.170 In these settings the target activated partial thromboplastin 
time (aPTT) is ‚â•2 times control values. UFH can then be stopped 4‚Äì6 h 
before surgery (in case of caesarean section) or before insertion of regional anaesthesia or anticipated vaginal delivery. For women who are 
on therapeutic-dose LMWH for non-MHV indications, dosing can be 
omitted for 24 h prior to caesarean section or anticipated vaginal delivery with no need for bridging. In women with MHVs who are on 
LMWH and aspirin in combination, consideration should be given to 
stopping aspirin 4 days before delivery.170 
4.5.6.2. Urgent delivery on therapeutic anticoagulation 
Managing women who are anticoagulated during delivery is complex 
and needs an individualized approach. Figure 5 gives an overview, but 
again each scenario may need a more tailored solution. 
4.5.6.2.1. Delivery on vitamin K antagonists. If women require urgent delivery and have been taking VKAs within the last 2 weeks, 
then delivery by caesarean section is recommended to reduce the 
risk of foetal intracranial bleeding. When urgent delivery is required, 
preventing bleeding complications with administration of i.v. four-factor 
prothrombin complex concentrate (4F-PCC), depending on the international normalized ratio (INR) (25 U/kg for a therapeutic INR range of 
2‚Äì4) is the preferred method for rapid INR normalization. If necessary, 
vitamin K should be given.171,172 If 4F-PCC is not available, fresh frozen 
plasma (FFP) is an alternative, but it takes longer to reverse an elevated 
INR and requires a larger fluid challenge.171,173. The involvement of an 
expert haematologist in these scenarios is essential, in addition to the 
Pregnancy Heart Team. The foetus may remain anticoagulated for 8‚Äì 
10 days after discontinuation of maternal VKAs, and may need to be given FFP and higher doses of vitamin K.170 
4.5.6.2.2. Delivery on heparin. If delivery occurs after recent administration of heparin (e.g. within 4‚Äì6 h of UFH, with non-normalized aPTT, 
or within 12 h of therapeutic LMWH) protamine sulfate should be given. 
Neutralization of LMWH varies between products and may be less effective.174 Protamine dosage depends on timing after the last dose of 
LMWH (1 mg/1 mg enoxaparin <8 h; 0.5 mg/1 mg enoxaparin >8 h). 
For UFH, 1 mg of protamine per 100 units of heparin is needed.175 
In addition to the level of anticoagulation, the decision to reverse anticoagulation should also be related to the bleeding risk, which is higher 
with conditions such as placental abruption, placenta previa, and multiple previous caesarean sections. 
4.5.6.3. Restarting anticoagulation after delivery 
The decision to restart anticoagulation post-delivery is challenging and 
must balance risk of bleeding and risk of thrombosis. Anaesthetic, cardiac, 
haematology, and obstetric teams may have different priorities, but all 
need to be actively involved in decision-making, which should also involve 
the patient. Late obstetric bleeding (>24 h) is common,176 as was also 
confirmed in recent data from the ROPAC III trial177 (bleeding on 
mean post-partum day 3.6), suggesting that these events occur at a 
time when heparin is being used at the same time as the VKA is being reintroduced. Restarting UFH (aPTT levels ‚â•2 times the control) or low/ 
intermediate doses of LMWH are all valid options.170 Techniques to reduce bleeding risk include active management of the third stage of labour 
with oxytocin. Recently, the effect of adding 2 IU oxytocin over 10 min to 
a standard treatment of low-dose infusion for 4 h [10 IU of oxytocin in 
500 mL of normal saline given i.v. at 36 mL/h for 4 h (12 mU/min)] was 
analysed. The addition of 2 IU of oxytocin was not associated with any 
greater derangement in cardiovascular measures, but with a significantly 
lower volume of blood loss.158 VKA should only be started 7‚Äì14 days 
or later post-partum to reduce the risk of late bleeding.170 
4.5.7. Endocarditis prophylaxis for delivery 
Systemic antibiotics according to the 2023 ESC Guidelines for the management of endocarditis may be considered for delivery in women at 
high risk of endocarditis.178 
Recommendation Table 3 ‚Äî Recommendations for timing and mode of delivery (see Evidence Table 3) 
Recommendations 
Classa 
Levelb  
Timing and mode of delivery 
Vaginal delivery is recommended in most women with CVD.161‚Äì163 
I 
B 
Systemic antibiotic prophylaxis may be considered for delivery in women at high riskc.178 
IIb 
C 
Routine induction of labour prior to 39 weeks is not recommended in women with stable CVD.44,154 
III 
C 
Delivery in women on anticoagulants 
It is recommended that the timing of delivery is planned to ensure safe and effective peripartum anticoagulation. 
I 
C 
It is recommended to discontinue VKAs and start therapeutic-dose LMWH or adjusted-dose i.v. UFH at the 36th week of gestation or 2 
weeks before the planned delivery.179 
I 
C 
In women at low riskd on therapeutic-dose LMWH, neuraxial anaesthesia and vaginal delivery (or caesarean section for obstetric 
indications) is recommended 24 h after the last dose of LMWH.180 
I 
C                         
Continued


<!-- PAGE 27 -->

### Page 27

Woman on therapeutic anticoagulants arriving in established labour¬†
After delivery,¬† postpone the switch from heparin back to oral anticoagulants until 7‚Äì14 days post-partum when the wound area has healed, in consultation with the Pregnancy Heart Team
(Class I)
Post-delivery
If  neuraxial anaesthesia catheter insertion was traumatic do not start therapeutic¬†dose anticoagulation for at least 24 h after removal¬†
VKA
Stop VKA and check INR
i.v. UFH
LMWH
Stop LMWH¬†
Prepare RBC
Give 4F-PCC
(FFP if 4F-PCC not available)
Consider vitamin K
Caesarean section with general anaesthesia for foetal protection ¬†
(Class I)
Stop UFH 
Delivery in next 
24 h
Delivery in next 
4‚Äì6 h and aPTT 
not normalized
Consider protamine sulfate
Proceed with neuraxial anaesthesia and vaginal delivery unless obstetric indication for caesarean section
(Class I)
Actively manage the third stage with oxytocin to reduce risk of PPH
(Class IIa)
Consider caesarean section with general anaesthesia
Figure 5 Management of urgent delivery in women under anticoagulants. aPTT, activated partial thromboplastin time; FFP, fresh frozen plasma; INR, international normalized ratio; i.v., intravenous; LMWH, low-molecular-weight heparin; 4F-PCC, four-factor prothrombin complex concentrate; N, no; PPH, 
post-partum haemorrhage; RBC, red blood cell; UFH, unfractionated heparin; VKA, vitamin K antagonist; Y, yes.  
In women at high riskd, it is recommended to convert LMWH to i.v. UFH at least 36 h prior to delivery and stop the UFH infusion 4‚Äì6 h 
prior to anticipated delivery. The aPTT should be normal before regional anaesthesia.180 
I 
C 
If delivery starts while the mother is on VKAs or <2 weeks after discontinuation of VKAs, caesarean section is recommended for foetal 
protection. 
I 
C 
Post-delivery, it is recommended that the decision to restart LMWH or UFH is made after discussion with the Pregnancy Heart Team and 
the woman who gave birth.170 
I 
C 
It is recommended to postpone the switch from heparin back to oral anticoagulants until 7‚Äì14 days post-partum when the wound area has 
healed, in consultation with the Pregnancy Heart Team.177 
I 
C 
In women on therapeutic-dose LMWH, planned delivery should be considered at around 39 weeks to avoid the risk of spontaneous labour 
while fully anticoagulated. 
IIa 
C 
In women who are on antenatal anticoagulation, active management of the third stage of labour with oxytocin should be considered.158 
IIa 
C 
¬© ESC 2025
aPTT, activated partial thromboplastin time; CVD, cardiovascular disease; i.v., intravenous; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cPatients with prosthetic cardiac valves or a history of infective endocarditis, or cardiac transplant patients with residual valve defects. 
dSee Table 10.   
ESC Guidelines                                                                                                                                                                                               27


<!-- PAGE 28 -->

### Page 28

4.6. Post-partum monitoring and 
complications 
4.6.1. Monitoring 
The post-partum period is associated with significant haemodynamic 
changes and fluid shifts. Hence, women are at risk of adverse outcomes, 
such as hypertension, HF, or stroke.181,182 Post-partum management 
must be individualized and depends on the woman‚Äôs underlying CVD, 
risk or presence of arrhythmias and HF symptoms, and the course during pregnancy and delivery. For women at the highest HF risk or with 
HF symptoms during pregnancy or delivery, admission to an intensive 
(cardiac) care unit during the first 24‚Äì48 h for haemodynamic monitoring should be considered.183 Early ambulation is important to reduce 
the thromboembolism risk. 
In women with hypertensive disorders of pregnancy, blood pressure 
should be monitored in hospital (or with an equivalent level of outpatient surveillance) for 72 h after birth and checked again 7‚Äì10 days 
post-partum. Optimizing blood pressure levels from the immediate 
post-partum period until the first post-natal months could help prevent 
the development of hypertension and improve long-term cardiovascular health.184 
4.6.2. Breastfeeding and lactation 
Throughout these Guidelines, the term ‚Äòlactation‚Äô (including not only 
breastfeeding but also other methods such as pumping) is used as the 
default term in most sections, especially where it encompasses a broader scope, such as in medication-related contexts. We use ‚Äòbreastfeeding‚Äô specifically in sections where the focus is on the act of nursing or 
direct feeding at the breast, particularly when discussing its physiological 
and long-term health outcomes. 
Breastfeeding is a global priority because interruption of lactation is 
associated with adverse health outcomes for the woman and her child, 
including higher maternal risks of breast cancer, ovarian cancer, diabetes, and hypertension, and greater infant risks of infectious and metabolic disease.185,186 
Inhibition of lactation can be obtained with standard doses of cabergoline in general, or bromocriptine in peripartum cardiomyopathy (PPCM). 
Several drugs are contraindicated during lactation (see Figure 6 in 
Section 5 and Supplementary data online, Table S4). 
4.6.3. Complications 
4.6.3.1. Haemorrhage 
Post-partum haemorrhage (PPH) is more frequently reported in women with CVD.187 To reduce the risk of PPH, an active third stage of 
labour with early cord clamping and administration of oxytocin to deliver the placenta should be pursued. Maternal anaemia is a known risk 
factor for PPH, so anaemia should be managed aggressively in the antenatal period. 
At the time of delivery, a slow i.v. infusion of 2 IU oxytocin over 10 
min immediately after birth, followed by 12 mU/min for 4 h, reduces 
the PPH risk and has a minimal impact on cardiovascular parameters.158 
In cases of PPH that are refractory to medical treatment, additional devices may be used, such as the Bakri intrauterine balloon, uterine compression sutures, or further haemostatic measures including uterine 
artery embolization or hysterectomy. 
4.6.3.2. Psychological reactions, post-partum depression 
Although the general risk of post-partum depression among new 
mothers in the general population is ‚àº10%‚Äì20%, this risk increases 
with underlying health conditions such as CVD, where ‚àº1 in 
3 mothers have reported symptoms of depression in the post- 
partum period.188 Those with PPCM are particularly vulnerable to 
depression.189‚Äì191 These findings emphasize the critical need for 
early detection, regular mental health screening and the necessity 
of holistic care models with psychological support and tailored 
interventions.191,192 
5. Drugs during pregnancy and 
lactation 
5.1. General principles 
5.1.1. Pharmacokinetics and pharmacodynamics in 
pregnancy 
Physiological adaptation of maternal organ systems to pregnancy 
affects the pharmacokinetics and pharmacodynamics of potentially 
all medical treatments, including cardiovascular drugs (see Section  
3.2).146,193,194 
5.1.2. Pharmacogenetics 
An overlap between individual genotypes associated with drug effects 
and pregnancy-induced modifications (e.g. liver enzymes) may unmask 
adverse effects or require careful titration, in particular for drugs that 
lead to severe adverse drug reactions (ADRs). As an example, warfarin can cause severe ADR at the maternal (bleeding, thrombosis) 
and/or foetal level (embryotoxicity, teratogenesis).195 The most notable cases refer to the polymorphisms of CYP2D6, associated with different phenotypes (extensive, ultrarapid, or poor metabolizers), 
leading to diverse pharmacokinetics/pharmacodynamics of drugs 
used in pregnancy such as beta-blockers (e.g. labetalol, metoprolol), 
antidepressants (e.g. fluoxetine, paroxetine), and analgesic drugs 
(e.g. tramadol, codeine).194 Poor and ultrarapid metabolizers may experience extreme variations in drug plasma level and bioavailability, 
and hence in their effects.195 
5.1.3. Newborn drug exposure in breast milk 
The exposure of the newborn to maternal drugs via breast milk is expressed as a percentage value, calculated as the dose taken by the infant compared either to the therapeutic dose of the same drug (often 
unknown for newborns) or the maternal weight-adjusted dose.196 
The ‚Äòrelative infant dose‚Äô (RID) depends on the relative amount of 
drug secreted in the milk (milk-to-plasma concentration ratio) and 
the quantity of milk intake (the standard is 150 mL/kg/day) on a 
body weight basis.196 The dose per kg of the infant is compared to 
the maternal dose per kg over the same period. A RID lower than 
5%‚Äì10% is generally considered safe (see Figure 6; Supplementary 
data online; Table S4; and LactMed database).197 
5.2. Drug classes in pregnancy 
5.2.1. Anticoagulants 
The use of anticoagulants during pregnancy represents a complex 
balance of risks and benefits, influenced by specific indications, 
and hampered by low-quality evidence. Indications for anticoagulation in pregnancy are diverse and covered in different sections in 
these Guidelines. In this section, we cover drug-specific aspects 
and dosing regimens that explicitly pertain to the setting of 
pregnancy.


<!-- PAGE 29 -->

### Page 29

Low-molecular-weight heparin treatment regimen glossary 
To ensure consistency throughout these Guidelines, we apply the following wording about LMWH treatment‚Äîany deviations from these 
standards are clearly indicated in the specific sections: 
‚Ä¢ Prophylactic-dose LMWH refers to low fixed doses with adjustment 
for extremes of body weight.198 
‚Ä¢ Therapeutic-dose LMWH refers to high doses typically reserved for 
treatment of VTE (Section 11) and thrombosis prevention in 
MHVs (Section 12).  
An individualized shared decision-making approach with careful consideration of maternal thrombosis risk vs foetopathy is needed, and 
strategies will vary from prophylactic dosing of LMWH to correctly 
dosed VKAs. Regional differences, also related to lower availability of 
anti-factor Xa level monitoring in low- and middle-income countries 
as indicated by the ROPAC III study, also need to be taken into account. 
Interestingly, this study shows that despite higher monitoring and better resource availability, the risk of thrombosis was higher in high- 
income countries, specifically due to higher use of treatment regimens 
with therapeutic LMWH.177 Haemorrhagic complications in the 
mother can occur with all regimens.199 Table 10 lists the regimens 
and disease entities in which anticoagulants are indicated. 
5.2.1.1. Vitamin K antagonists 
Vitamin K antagonists cross the placenta and are associated with embryopathy and foetopathy risk, even at low doses. They will therefore 
be switched to LMWHs in most pregnant women, with the only exception being women with atrial fibrillation (AF) in the context of moderate to severe mitral valve stenosis or MHVs, given the lower thrombosis 
risk with VKAs compared to LMWH in the latter (see Section 12).179,200 
Women receiving chronic VKAs who are contemplating pregnancy 
need counselling regarding avoidance of the potential teratogenic effects. When switching (usually to LMWH) is desired, this should take 
place as soon after conception as possible. 
Vitamin K antagonist embryopathy is thought to be related to interference with embryonic ossification.201,202 Adverse impact is highest in 
the first trimester (0.6%‚Äì12% of embryopathy) and much lower but 
persisting in later stages of pregnancy (0.7%‚Äì2% risk of foetopathy, 
e.g. central nervous anomalies, intracranial haemorrhage).200,203,204 
The risk of embryopathy in the first trimester depends on the VKA 
dose. The risk was 0.45%‚Äì0.9% in pregnancies with low-dose warfarin 
according to two systematic reviews.199,205 In this setting, low-dose refers to the dose necessary to maintain the appropriate INR (according 
to current guidelines this equals doses of ‚â§5 mg of warfarin, ‚â§2 mg/day 
acenocoumarol, ‚â§3 mg/day phenprocoumon).43 This approach may be 
seen as a reasonable balance between the risks to the mother with 
Table 10 List of anticoagulation regimens and disease entities in which they are indicated 
Indication 
Type of 
anticoagulant 
Dosing 
Timing  
Low thrombosis risk 
VTE prevention/no indication for oral 
anticoagulationa 
LMWH 
Prophylactic dose 
o.d. 
Uncomplicated Fontan circulationb 
LMWH  
Prophylactic dose 
o.d. 
Intermediate thrombosis risk 
VTE (DVT/PE) during pregnancya 
LMWH 
Therapeutic dose 
o.d. or 
b.i.d. 
Persistent/permanent AF at elevated 
thromboembolic riskc 
LMWH 
Therapeutic dose 
o.d. or 
b.i.d. 
Decreased ventricular function (EF <35%) and/ or 
intracardiac thrombusd 
LMWH 
Therapeutic dose 
o.d. or 
b.i.d. 
High thrombosis risk 
Mechanical heart valvese 
1. First trimester 
Low VKA dose to achieve required INRf 
First trimester: VKA or 
LMWH 
INR: weekly to every 2 weeks 
LMWH: dose adjusted to peak anti-factor Xa level 
b.i.d. 
High VKA dose to achieve required INR 
Switch to LMWH 
Dose adjusted to peak anti-factor Xa level (weekly until 
threshold, every 2‚Äì4 weeks thereafter) 
b.i.d. 
2. From week 13: shared decision  
(a) 
Continue/switch to VKA with weekly to every 2 weeks INR  
(b) 
Continue LMWH with dose adjustment as above 
Delivery: refer to Section 4.5.6.2. (for urgent delivery) and Section 4.5.6.1 (for planned delivery) 
¬© ESC 2025
AF, atrial fibrillation; b.i.d., is in die (twice a day); DVT, deep vein thrombosis; EF, ejection fraction; INR, international normalized ratio; LMWH, low-molecular-weight heparin; o.d., omni die 
(once a day); PE, pulmonary embolism; VKA, vitamin K antagonist; VTE, venous thromboembolism. 
aRefer to Section 11 Venous thromboembolism. 
bRefer to Section 9 Pregnancy in women with congenital heart disease. 
cRefer to section 12.4.1.2. Atrial fibrillation including anticoagulation. 
dRefer to section 12.6 Heart failure. 
eRefer to Section 12.5.3.2 Mechanical heart valves. 
f‚â§5 mg of warfarin; ‚â§2 mg/day acenocoumarol, ‚â§3 mg/day phenprocoumon.43   
ESC Guidelines                                                                                                                                                                                               29


<!-- PAGE 30 -->

### Page 30

MHV and the foetus.170,200,204,206,207 Due to incomplete development 
of liver metabolism, the INR takes longer to normalize in the foetus and 
neonate than in the mother, which is why VKA should be discontinued 
2 weeks before delivery (see Section 4). 
If the indication of anticoagulation is non-MHV, such as 
pregnancy-related VTE, VKAs are not recommended. In case of pre- 
existing VKA or direct oral anticoagulant (DOAC) therapy due to previous VTE, VKAs and DOACs should be replaced by LMWH when 
pregnancy is planned or at recognition of pregnancy.208 
Vitamin K antagonists are safe during lactation209 and are recommended in all women with MHVs given their superior anticoagulant 
properties in avoiding valve thrombosis.179,200 
5.2.1.2. Low-molecular-weight heparins 
Embryopathy or foetopathy has not been reported with LMWHs, even 
in therapeutic doses, but thromboembolic complications in women 
with MHVs are higher than with VKAs (8.7%, 5.8%, and 2.7% for 
LMWH, UFH, and VKA, respectively).179,200 LMWHs appear less likely 
to induce heparin-induced thrombocytopenia compared with UFH, although this has not been studied in pregnancy.210 
Data on optimal dosing and frequency of administration in pregnancy 
are scarce and mostly limited to the setting of VTE and MHV. 
5.2.1.2.1. Low-molecular-weight heparin dosing. In women with 
MHVs, slightly higher starting doses are suggested to ensure minimal 
delay in reaching the target range (See Table 11).176 
For prophylactic-dose LMWH, a fixed low-dose LMWH regimen can 
be used in most cases.207 In women with acute VTE requiring therapeutic LMWH dose, routine anti-factor Xa monitoring has not been 
shown to affect clinical outcomes despite fluctuations of anti-factor 
Xa levels during pregnancy, and should only be considered in women 
with renal insufficiency or obesity, where adjustment for body weight 
may result in overdosing.211‚Äì213 Underweight patients show a low 
prevalence of antepartum or post-partum VTE214 and do not require 
specific recommendations compared to patients with normal 
weight.215 
Monitoring of anti-factor Xa levels is essential in women with MHVs 
on therapeutic-dose LMWH: at least weekly until target level is 
achieved or when there is a below target level at any stage, and regular 
monitoring thereafter (e.g. every 2‚Äì4 weeks depending on stability) 
(see Section 12.5.3.2). Recommended peak anti-factor Xa levels should 
be individualized based on type and location of the valve (between 1.0 
and 1.2 U/mL) and additional trough level measurement may be indicated in selected cases with increased thrombosis risk (see Section  
12.5.3.2).216 
5.2.1.2.2. Once-daily vs twice-daily administration. In pregnant women with confirmed acute VTE, no clear benefit of a twice-daily 
LMWH administration vs a once-daily administration has been demonstrated.217,218 Thus, either using a once- or twice-daily regimen, each 
one resulting in a therapeutic dose, is reasonable. 
Twice-daily administration at slightly higher doses is the usual therapeutic dosing regimen for pregnant women with MHVs.177 There is insufficient evidence for the use of LMWH injections more frequently 
than twice daily. 
5.2.1.3. Unfractionated heparin 
Intravenous UFH, although not crossing the placenta, is associated with 
higher risks of thrombocytopenia and osteoporosis compared with 
LMWH. The risk of valve thrombosis during pregnancy with subcutaneous UFH is unacceptably high and its use is not recommended.219 
In women with MHVs in whom VKAs cannot be continued, intravenous UFH is only indicated when anti-factor Xa monitoring is not possible during the first trimester and at the time of delivery (see Section  
4.5.6). However, intravenous heparin dosing is challenging, requiring 
hospitalization and multiple daily blood tests to achieve an aPTT ‚â•2 
times control values. 
5.2.1.4. Fondaparinux 
In women requiring prophylaxis of VTE, good outcomes with subcutaneous fondaparinux were reported in an observational study of 65 
pregnancies and a retrospective analysis in 84 women with one or 
more previous pregnancies.220,221 Its use can be considered if there is 
an allergy or adverse response to LMWH (prophylactic dose: 2.5 mg 
daily; therapeutic dose: up to 10 mg daily)221‚Äì223 (see Section 11). 
5.2.1.5. Direct oral anticoagulants 
Direct oral anticoagulants have shown better bleeding profiles than a 
LMWH or VKA regimen across diverse indications in non-pregnant populations. Outcome data on their use in pregnancy are scarce and inconsistently captured in pharmacovigilance databases, indicating a 
need for a more robust system of reporting.224,225 The foetal effects 
of DOACs are controversial.226,227 Animal and in vitro studies showed 
that dabigatran, rivaroxaban, and apixaban crossed the placenta.228‚Äì230 
Prescription information based on these data reported variable adverse 
effects in pregnant rodents and rabbits: post-implantation loss, maternal bleeding, or malformation at >4 times the recommended maternal 
doses (see Supplementary data online, Table S4). Counselling women 
on DOACs who are planning a pregnancy is advised, considering the 
complexity of pre- and post-conceptional switches to alternative 
Table 11 Dosing regimens for the commonly used low-molecular-weight heparins  
Enoxaparin 
Dalteparin 
Tinzaparin 
Target  
Prophylactic LMWH 
Body weight 
50‚Äì100 kg 
4000 IU o.d. 
5000 IU o.d. 
4500 IU o.d. 
NA 
Therapeutic LMWH 
(non-MHV) 
150 IU/kg o.d. 
200 IU/kg o.d. 
175 IU/kg o.d. 
NA 
Therapeutic LMWH 
MHV 
125 IU/kg b.i.d. (starting dose) 
then 100 IU/kg b.i.d. 
125 IU/kg (starting dose) b.i.d. 
then 100 IU/kg b.i.d. 
250 IU /kg (starting dose) 
then 175 IU/kg o.d. 
0.8‚Äì1.2 U/mL anti-factor Xa 
(4‚Äì6 h post administration) 
¬© ESC 2025
b.i.d., bis in die (twice a day); IU, international units; LMWH, low-molecular-weight heparin; MHV, mechanical heart valve; NA, not applicable; o.d., omni die (once a day).


<!-- PAGE 31 -->

### Page 31

regimens (LMWH, VKA) and the risk of VTE recurrence.227 DOACs 
may have an edge over VKAs, such as rapid reversal in case of premature delivery and a short antepartum interruption period, due to their 
reversible inhibition of procoagulant factors. The oral route is an advantage over LMWHs. However, evidence of safety is lacking for specific 
DOAC antidotes (andexanet alfa, idarucizumab) in pregnant women 
and can only be inferred from pre-clinical studies. After uncertain initial 
reports on foetotoxicity,224 a recent retrospective cohort study (mainly in women exposed to rivaroxaban) does not support a high risk of 
embryotoxicity.231 It should be highlighted that despite promising studies, clinical evidence on the benefits and risks of DOACs for the mother 
and foetus is scarce and needed, and their foetal safety over VKAs during the second and third trimesters has not been established. DOACs 
are not recommended in pregnancy and they should only be used in the 
absence of any other option in consultation with the Pregnancy Heart 
Team and the haematology team. Based on current data there is no absolute indication to interrupt pregnancy in the case of accidental 
exposure.227,232 
During lactation, alternative drugs should be preferred to DOACs 
due to the paucity of data. However, there are relevant differences between the agents. In studies on lactating women treated with apixaban, 
the concentration in milk was significantly higher than that of rivaroxaban: the milk-to-plasma ratio was >12%,233 and the weight-adjusted infant doses 14%‚Äì20%.234 Dabigatran etexilate mesylate, the orally 
available prodrug, is poorly excreted to the milk after biotransformation to dabigatran, and its oral absorption by the neonatal gastrointestinal tract is likely negligible. In two breastfed neonates of women 
receiving dabigatran, the maximum drug concentrations in the neonates‚Äô plasma were 100 000 times below the levels that would have a 
significant effect on coagulation indices.235 In lactating women treated 
with 15‚Äì20 mg/day rivaroxaban, the breastfed infant would receive a 
low dose, corresponding to 1.3%‚Äì5% of the maternal weight-adjusted 
dosage.233,236‚Äì238 Therefore, dabigatran and rivaroxaban may be taken 
cautiously during lactation. Signs of bleeding should be monitored in 
neonates of lactating mothers taking dabigatran. 
5.2.2. Antiplatelet treatment 
No teratogenic effect is reported for aspirin doses up to 300 mg daily. 
Clopidogrel is considered safe if dual antiplatelet therapy (DAPT) is 
needed for the shortest possible duration.239,240 Ticagrelor is contraindicated due to embryotoxicity. Prasugrel may be considered during 
pregnancy in special populations including poor metabolizers in 
whom the prodrug clopidogrel has limited effect.241,242 The use of 
glycoprotein IIb/IIIa inhibitors (eptifibatide and tirofiban) should only 
be used in pregnancy if strictly necessary.240 
5.2.3. Diuretics and SGLT2 inhibitors 
Diuretics may be used in pregnancy to treat systemic hypertension especially in emergencies or HF-related volume overload conditions. 
Care must be taken to monitor for reduction in plasma volume or 
CO, and decrease in placental perfusion. 
Pre-clinical data on SGLT2 inhibitors showed that they cross the placenta243 and exposure to these drugs may cause foetal damage in rodents, especially during the second and third trimesters.244 SGLT2 
inhibitors should be stopped before pregnancy and during lactation. 
5.2.4. Pulmonary hypertension 
Parenteral prostaglandin analogues (i.v. epoprostenol, treprostinil) can 
be used in pregnant women with significant right ventricle (RV) dysfunction, while recognizing that these agents may interfere with platelet aggregation and may promote bleeding.245 Oral phosphodiesterase 5 
inhibitors (e.g. sildenafil, tadalafil) can also be used, while recognizing 
the potential side effects of pre-term delivery and SGA babies.246 
Combination therapy with sildenafil and inhaled iloprost has also 
been reported.247 Calcium channel blockers should be continued during pregnancy for women with vasodilator-responsive PAH and normal 
RV function. Endothelin receptor antagonists (ERAs, e.g. bosentan, ambrisentan, macitentan) should not be used in pregnancy due to their 
teratogenic potential. There are few data on the safety of agents 
such as bosentan and sildenafil in the post-partum period for lactating 
mothers; however, successful cases have been reported.248,249 
5.2.5. Anti-arrhythmic agents 
For women without structural heart disease, anti-arrhythmic drugs (such 
as flecainide, sotalol, and ibutilide) can be used for the prevention or termination of AF and atrial flutter (AFL).250,251 Beta-blockers are considered safe, especially lipophilic compounds (labetalol, metoprolol, and 
propranolol). In pregnant women with AF and concomitant congestive 
HF, digoxin may be an alternative option for rate control. Amiodarone 
can cause foetal abnormalities, bradycardia, and thyroid dysfunction, 
and its routine use is contraindicated during pregnancy, but may be 
used as single dose in emergencies like ventricular tachycardia (VT) 
storm. There are no restrictions on amiodarone use in cardiac arrest.252 
5.2.6. Calcium channel blockers 
The safety and efficacy of nifedipine [the originator of dihydropyridine 
calcium channel blockers (CCBs)] as an antihypertensive in pregnancy 
has largely been proved in comparison with other antihypertensive 
treatments (see Section 12.3). A meta-analysis of 22 randomized control trials with 2595 participants found that nifedipine was significantly 
more effective at reducing patients‚Äô high blood pressure compared 
with other antihypertensive drugs (labetalol, hydralazine, methyldopa) 
in hypertensive patients.253 Foetal, neonatal, and maternal safety 
outcomes were not statistically different between nifedipine and comparators, except for maternal headache and flushing.253 A randomized 
controlled trial compared oral regimens with nifedipine, labetalol, 
or methyldopa in women requiring antihypertensive therapy due to 
severe hypertension. It found that the primary outcome of blood pressure control within 6 h with no adverse outcome was more common 
with nifedipine or labetalol than with methyldopa254. Amlodipine 
showed safety and efficacy similar to nifedipine.255 Studies on the non- 
dihydropyridine CCB diltiazem are inadequate and significant potential 
teratogenic effects have been demonstrated in rodents and rabbits. 
The drug passes in milk, reaching relevant infant concentrations. 
Therefore, diltiazem is not recommended in pregnancy and lactation. 
Oral verapamil is considered safe; no teratogenicity has been observed. 
The drug is excreted at low levels in milk, <1% of the mother‚Äôs weight- 
adjusted dosage. 
Recommendation Table 4 ‚Äî Recommendation for direct oral anticoagulants and pregnancy 
Recommendation 
Classa 
Levelb  
DOACs are not recommended during pregnancy. 
III 
C 
¬© ESC 2025
DOAC, direct oral anticoagulants. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               31


<!-- PAGE 32 -->

### Page 32

5.2.7. Renin‚Äìangiotensin‚Äìaldosterone system 
inhibitors 
Angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), angiotensin receptor/neprilysin inhibitors 
(ARNIs), and renin inhibitors can cause foetal malformations, 
IUGR and death, and are contraindicated in pregnancy. Caution 
should be recommended to childbearing women, especially in the 
absence of effective contraception. Captopril, enalapril, and benazepril are safe during lactation,146 whereas ARBs are not recommended. Candesartan may be an exception.256 Aldosterone 
antagonists, canrenone, and spironolactone can have anti- 
androgenetic effects and are contraindicated in pregnancy. 
Spironolactone is considered safe during lactation because of extensive metabolism to canrenone, thus the infant would receive less 
than 1% of the mother‚Äôs daily dosage of canrenone.257 Case reports 
of eplerenone in pregnant women with resistant hypertension identified no adverse effects.258‚Äì261 
5.2.8. Lipid-lowering agents 
Diagnosis of maternal hypercholesterolaemia at the first trimester or 
familial hypercholesterolaemia have adverse consequences for both 
foetus and mother.262 Low-density lipoprotein (LDL) levels increase 
by ‚àº30%‚Äì50%, high-density lipoprotein cholesterol by 20%‚Äì40%, 
and triglycerides by 50%‚Äì100% during pregnancy262, so referring 
to reference range as for routine testing is of limited clinical use. 
Previously, lipid-lowering treatment was usually discontinued during 
pregnancy because of limited safety data.43 Having been contraindicated in pregnancy since 1987, statins now remain contraindicated 
only during lactation. In July 2021 the United States Food and 
Drug Administration (FDA)263 stated that the evidence was insufficient to conclude that a risk of miscarriage is increased with statins 
and requested removal of the contraindication.264 Continuing 
with statins may therefore be considered during pregnancy in women with familial hypercholesterolaemia or established atherosclerotic cardiovascular disease (ASCVD) (see Section 12.2).265 
Furthermore, inadvertent conception during statin therapy does 
not require pregnancy termination but should prompt close follow- 
up. Bile acid binding sequestrants265 and LDL apheresis265 can be 
considered in women with familial hypercholesterolaemia. PCSK9 
inhibitors and ezetimibe are not recommended during pregnancy 
due to lack of clinical data.266 Bempedoic acid has a strong contraindication and therefore women are recommended contraception 
during its use. 
5.2.9. Beta-adrenergic blocking agents 
Beta-blocker use during early pregnancy has not been associated with 
an increased risk of congenital malformations.250,267,268 Recent data 
from ROPAC indicate higher SGA rates in women with beta-blocker 
exposure (15.3% vs 9.3%, P < .001). With metoprolol as reference, labetalol (0.2, 95% CI 0.1‚Äì0.4) was the least likely to cause SGA, and 
atenolol (2.3, 95% CI 1.1‚Äì4.9) the most.12 Labetalol and lipophilic 
drugs (metoprolol, propranolol, carvedilol) are preferred due to 
high first-pass metabolism, as well as beta-1-selective drugs (bisoprolol, metoprolol), which reduce the risk of hypoglycaemia in addition to 
reduced IUGR. Nadolol and pindolol are also safe in the case of arrhythmic events in cardiomyopathies and channelopathies (see 
Section 6).269‚Äì271 Of note, the metabolism of metoprolol (and perhaps 
other oral lipophilic beta-blockers) was significantly higher in mid and 
late pregnancy than post-partum, likely due to enzymatic induction 
during pregnancy.272 Changes in dosage (dose and frequency) are likely required if inadequate clinical responses are encountered.272 
Atenolol causes severe growth restriction, bradycardia, and hypoglycaemia and is not recommended.250,268,272,273 
Propranolol, metoprolol (combined with hydralazine), and labetalol 
had the lowest and sotalol the highest risk of neonatal bradycardia during lactation.274 For the lipophilic beta-blockers, milk level was <1% of 
the maternal weight-adjusted dose, thus reducing the risks associated 
with neonatal exposure during lactation.272 
5.2.10. Immunosuppressants 
The balance between maternal and foetal safety is challenging for immunosuppressant therapy, especially for women with heart transplantation. Medication can pass to the milk and expose neonates 
and infants to adverse drug effects. Changes in maternal physiology 
impact the pharmacokinetics of immunosuppressant drugs (see 
Section 3.2).275 Calcineurin inhibitors (e.g. cyclosporine, tacrolimus), 
mammalian target of rapamycin inhibitors (e.g. everolimus, sirolimus), 
and azathioprine are the drugs of choice during pregnancy and lactation, which should not be discouraged. Mycophenolate derivatives increase the risk of miscarriage and foetal malformations especially 
during the first trimester and should be discontinued at least 6 weeks 
before conception.276,277 
5.2.11. Neuroactive drugs 
Selective serotonin reuptake inhibitors, including sertraline, can be taken safely during pregnancy and lactation.278 Zuranolone, a synthetic 
form of the neurosteroid allopregnanolone, has recently been approved for the treatment of post-partum depression. No information 
is available on its safety in patients with CVD. Zuranolone is excreted in 
the milk and lactation should be avoided in the absence of safety 
data.279 
5.2.12. Obstetric drugs in patients with 
cardiovascular disease 
Drugs for inducing ovulation, including follicle-stimulating hormone and 
luteinizing hormone or combinations, are associated with an increased 
risk of deep vein thrombosis (DVT) and PE, due to the sharp rise in oestrogen levels during follicle recruitment,280 but no other immediate cardiovascular side effects are known. 
5.3. Internet databases 
See Supplementary data online, Internet databases. 
5.4. List of drugs 
See Supplementary data online, Table S4.


<!-- PAGE 33 -->

### Page 33





	


¬Å¬ç¬è
¬Å¬ê¬ù¬†¬≠¬ù¬Ä

¬Ç¬É
¬Ñ
¬Ö¬Ü
	¬Ñ
¬Å¬ê¬ù¬Ä

¬Ç¬É
¬†¬≠¬ù
	¬Ñ¬á¬Ñ

¬Ñ

¬Ä

	¬Ñ¬à¬â
	¬Ç¬Ö¬ä

¬ã¬ã¬å	¬É¬é¬ã
¬Ä



¬å	¬É¬é
¬ã¬ã¬ã
¬á
¬Ñ¬Ñ
¬Ñ
¬á
¬Ñ

¬Ñ
¬â¬ë

¬ù¬ë¬ã¬â¬ë¬â¬â¬ã





	
¬ù¬ë¬ã¬â¬ë¬â¬â¬ã
¬â¬ë¬à¬ä










¬í




¬ë
¬â
¬Å¬ç¬è
¬í


¬ë¬â¬Å¬ç¬è


¬ã¬â¬ë


¬ë¬â¬à¬ì¬Ä¬Ñ¬ë
¬î¬ï¬ä

¬ã¬â¬ë
¬ç
¬ë¬â
¬Å¬ê¬ù¬†¬≠¬ù¬à¬ä
¬Ç¬É
¬à¬â¬á
¬ä
¬Å¬ê¬ù¬Ç¬É
¬ñ¬í
¬å¬í¬ó


¬â¬ë¬ã
¬Ñ¬ë





¬Å¬ç¬è



¬Ñ¬í

¬Ñ
¬í

¬ë

¬ó

¬ë
 



		
	



	
	

	


	


	

Figure 6 Choice of medication during pregnancy (left) and during lactation and breastfeeding (right). ACE-I, angiotensin-converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; ARNI, angiotensin receptor/neprilysin inhibitor; ASA, acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; DOAC, 
direct oral anticoagulant; LMWH, low-molecular-weight heparin; MRA, mineralocorticoid receptor antagonist; PCSK9-I, proprotein convertase subtilisin/kexin 
type 9 inhibitor; SGLT2-I, sodium‚Äìglucose co-transporter-2 inhibitors; UFH, unfractionated heparin; VKA, vitamin K antagonist; wk, week. 
First/safest choice in pregnancy, lactation and breastfeeding. 
Second choice in pregnancy, lactation, and breastfeeding. 
Evidence of foetal or infant 
toxicity or no data on safety. aExcept candesartan. bSee text for details.   
ESC Guidelines                                                                                                                                                                                               33


<!-- PAGE 34 -->

### Page 34

### 6 Pregnancy in women with

cardiomyopathies and primary 
arrhythmia syndromes 
6.1. Cardiomyopathies 
Cardiomyopathies are characterized by disease-specific structural abnormalities and increased risk of ventricular and supraventricular arrhythmias. The risk associated with pregnancy in a woman with 
cardiomyopathy can be estimated using the mWHO 2.0 classification 
(Table 6). Pre-pregnancy, women with cardiomyopathies should be 
clinically evaluated to optimize treatment, avoid contraindicated drugs, 
and assess the risk of heart failure and arrhythmias. Indicated procedures, including implantable cardioverter defibrillator (ICD) implantation, should be performed before pregnancy. 60 
Genetic counselling is recommended before pregnancy to explain 
the probability of genetic transmission, risks for the mother, foetus, 
and child, and the possibilities of pre-implantation and pre-natal genetic 
testing (Table 7).60,281 Women with cardiomyopathies should be managed by the Pregnancy Heart Team, including a cardiologist with expertise in cardiomyopathies and arrhythmias. 
6.1.1. Dilated cardiomyopathy and non-dilated left 
ventricular cardiomyopathy 
In women with dilated cardiomyopathy (DCM) and non-dilated left ventricle (LV) cardiomyopathy (NDLVC), severe systolic LV dysfunction, 
New York Heart Association (NYHA) functional class III/IV, RV failure, 
sustained ventricular arrhythmias, AF, and/or severe mitral valve regurgitation (MR) are high-risk criteria for major adverse cardiovascular events 
during pregnancy.282 In contrast, women with mild LV dysfunction, good 
functional status, no arrhythmias, and no history of cardiac events are 
likely to have an uncomplicated pregnancy.282 
Therapy should be modified before pregnancy. ACE-Is, ARBs, 
mineralocorticoid receptor antagonists (MRAs), sacubitril/valsartan, and 
SGLT2 inhibitors are all contraindicated during pregnancy. Pre-pregnancy 
risk stratification should include temporary withdrawal of contraindicated 
medication with close monitoring (see Section 12.6 Heart failure). 
Beta-blockers should be continued with close monitoring of foetal growth. 
If anticoagulation is needed for AF or evidence of an intracardiac thrombus, 
LMWH should be used (see Section 5 for dosing regimens). 
Data about genotype-specific management during pregnancy are 
scarce but one study evaluated the risk of pregnancy and progression 
of cardiomyopathy in women with lamin A/C (LMNA) P/LP variants.283 
A small subset of women experienced arrhythmias during pregnancy although a history of pregnancy was not associated with long-term adverse disease progression.283 
More information is included in Sections 7, 12.4, and 12.6. 
6.1.2. Arrhythmogenic right ventricular 
cardiomyopathy 
Several observational studies and registries have shown that pregnancies in women with arrhythmogenic right ventricular cardiomyopathy 
(ARVC) are generally well tolerated with good foetal outcomes and 
no cardiac mortality when receiving optimal surveillance and therapy.284,285 Delivery was usually vaginal and appeared safe. Sustained 
ventricular arrhythmias were reported in 5% of pregnancies and HF 
in 13%. Neither increased arrhythmia burden or ICD shocks were observed.284 Beta-blocker therapy should be continued during pregnancy 
(with the exception of atenolol) or could be started in pregnancy if 
needed. The two most used anti-arrhythmic drugs in previous studies, 
beside beta-blockers, were flecainide and sotalol. Both drugs have a 
long record of safety. However, sotalol should be used with caution 
in women with reduced ejection fraction (EF) and with careful corrected QT interval (QTc) monitoring.60 Sotalol also has a beta-blocker 
effect, necessitating monitoring of foetal growth.286,287 Amiodarone is 
contraindicated in pregnancy. In women at high arrhythmic risk, an ICD 
should be implanted, preferably before pregnancy (see Section 12.4). 
Two large studies of women with ARVC showed that pre-pregnancy 
phenotypical severity, rather than pregnancy itself, was the primary risk 
factor. Pregnancy was uneventful in the overwhelming majority.288,289 
Pregnancy did not seem to accelerate long-term progression of the 
ARVC phenotype.288 
6.1.3. Hypertrophic cardiomyopathy 
Hypertrophic cardiomyopathy290 is the most common inherited cardiomyopathy and is often caused by variants in sarcomeric genes.60 Phenocopies 
such as Anderson‚ÄìFabry disease and Danon disease290 are X-linked and 
therefore the cardiac phenotype tends to be milder and occurs later in 
life in females than males, making pregnancy usually uneventful.291‚Äì293 
Despite higher maternal mortality in women with HCM compared 
with the general population, absolute maternal mortality is low (0.5%) 
and confined to women at particularly high risk (Table 6).294,295 Data 
from the ROPAC registry showed that despite overall good outcomes, 
23% of pregnant women with HCM developed major cardiac events, including VT (10%) and AF (1.7%), mostly in women already identified as 
high risk prior to pregnancy.296 A recent systematic review including 
1624 women confirmed low neonatal mortality (0.2%) and stillbirths 
(1%) in pregnant women with HCM.297 A study including 242 women 
with HCM found that pregnancy was not a modifier of the long-term 
outcomes and pregnancy was well tolerated.298 Risk factors for major adverse cardiovascular events were advanced NYHA class and 
higher age at diagnosis.298 Left atrium diameter as a risk factor has 
been reported with conflicting results.298,299 
6.1.3.1. Treatment of hypertrophic cardiomyopathy in pregnancy 
Ongoing beta-blocker therapy should be continued during pregnancy. 
Atenolol should be replaced before pregnancy (Section 5.2.6). Atrial fibrillation is poorly tolerated in HCM patients in general due to the risk of 
haemodynamic decompensation, and medical or electrical cardioversion of AF during pregnancy should be considered. Beta-blockers 
should be started during pregnancy when new symptoms occur [e.g. 
due to left ventricular outflow tract obstruction (LVOTO)], for rate 
control in AF, and to suppress ventricular arrhythmias. Verapamil is 
the second choice of drug when beta-blockers are not tolerated. 
6.1.3.2. Left ventricular outflow tract obstruction 
Left ventricular outflow tract (LVOT) gradients may increase slightly 
during pregnancy and were previously associated with increased cardiac events including arrhythmias and HF.300 However, subsequent 
studies have not confirmed this association.296,298 
In women with obstructive HCM, it is recommended to evaluate gradient in basal condition, with exercise and the Valsalva manoeuvre, before pregnancy and with only the medications allowed during 
pregnancy, to identify those needing septal reduction therapy before 
pregnancy.60 Disopyramide may cause uterine contractions and is not 
recommended in pregnancy and should be discontinued unless the benefits outweigh foetal risk. Data on the safety of alcohol septal ablation 
during pregnancy are limited to a few case reports.60,301,302


<!-- PAGE 35 -->

### Page 35

Myosin inhibitors (e.g. mavacamten) have not been tested in pregnancy and animal studies have shown foetal toxicity.303 Therefore, 
contraception is recommended while on this treatment. Mavacamten 
may interact with hormonal contraception and therefore adding intrauterine or barrier contraception to hormonal contraception may be 
considered. Myosin inhibitor treatment should be discontinued at least 
6 months before planning pregnancy304 (see Supplementary data 
online, Table S4). 
6.1.4. Hypertrabeculation of the left ventricle 
Hypertrabeculation in isolation identified during pregnancy can be the 
simple consequence of an increased preload, can resolve after pregnancy, and cannot be used to make a diagnosis of cardiomyopathy.60 
Patients with hypertrabeculation and associated HCM, DCM, or 
NDLVC should follow the same recommendation as patients with 
the specific cardiomyopathy.60 
6.1.5. Labour and delivery in cardiomyopathies 
Labour and delivery may be associated with acute pain, adrenaline release, and need for urgent administration of anaesthetic drugs, and 
therefore haemodynamic monitoring and continuous telemetry monitoring during and after delivery is often warranted. In the absence of obstetric contraindications, vaginal delivery is generally recommended. 
Neuraxial anaesthesia reduces pain and therefore reduces adrenergic 
activation and arrhythmic risk. 
In HCM, peripheral vasodilatation is poorly tolerated in women 
with severe LVOT obstruction (LVOTO) and therefore epidural 
and spinal anaesthesia should be applied cautiously. Low-risk 
LVOTO cases may have a spontaneous labour and vaginal delivery. 
Caesarean section may be the preferred option in women with severe 
LVOTO. 
6.2. Primary arrhythmia syndromes 
In general, women with primary arrhythmia syndromes tolerate pregnancy well. Genetic counselling is recommended before pregnancy, 
as discussed in Section 6.1. A complete clinical re-evaluation, optimization of treatment, and ICD evaluation should be undertaken prior to 
pregnancy.252 Indicated treatment should be continued throughout 
pregnancy and in the post-partum period. 
6.2.1. Long QT syndrome 
Long QT syndrome (LQTS) is the most common channelopathy.307 All patients with LQTS should take beta-blockers, with propranolol and nadolol 
being the most effective.308 Additional therapies include left cardiac sympathetic denervation309 and mexiletine for LQT3252 and LQT2.310,311 The 
foetal risk of mexiletine treatment is unknown, and decisions on treatment 
during pregnancy should be a shared decision with the woman. 
Retrospective studies312‚Äì316 show that women with LQTS were not at 
higher risk of cardiac events during pregnancy itself, but had an increased risk 
Recommendation Table 5 ‚Äî Recommendations for 
cardiomyopathies and pregnancy 
Recommendations 
Classa 
Levelb  
Clinical cardiological surveillance (ECG, 
echocardiogram, and Holter ECG monitoring) is 
recommended during pregnancy in women with 
CMPs, depending on individual risk. 
I 
C 
Vaginal delivery is recommended in most women 
with CMPs, unless there are obstetric indications for 
caesarean section, severe HF (EF <30% and/or 
NYHA class III/IV), uncontrolled arrhythmias, or 
severe outflow obstruction (‚â•50 mmHg) in women 
with HCM, or in women presenting in labour on 
VKAs.60 
I 
C 
Continuation of beta-blockersc should be considered 
during pregnancy in women with CMPs, with close 
follow-up of foetal growth.60 
IIa 
C 
Dilated cardiomyopathy 
In women with DCM and worsening of EF during 
pregnancy, counselling on the risk of recurrence 
during a subsequent pregnancy is recommended in all 
cases, even after recovery of LV function.43 
I 
C                                                                                                   
Continued 
Arrhythmogenic right ventricular cardiomyopathy 
Flecainide, in addition to beta-blockers, should be 
considered as the anti-arrhythmic drug of choice in 
pregnant women with ARVC.148 
IIa 
C 
Sotalol may be considered as an anti-arrhythmic drug 
in pregnant women with ARVC, with careful 
evaluation of QTc and while monitoring for foetal 
bradycardia and foetal growth and neonate 
hypoglycaemia. 
IIb 
C 
Hypertrophic cardiomyopathy 
It is recommended to use the same risk stratification 
protocol for ventricular arrhythmias in pregnant 
women with HCM as for non-pregnant women with 
HCM.43 
I 
C 
It is recommended to start beta-blockersc in women 
with HCM who develop symptoms due to outflow 
tract obstruction or arrhythmia during pregnancy.43 
I 
C 
It is recommended that women with HCM with 
symptomatic LV dysfunction (EF <50%) and or 
severe LVOTO (‚â•50 mmHg) wishing to become 
pregnant are counselled by the Pregnancy Heart 
Team regarding the high risk of pregnancy-related 
adverse events.294,295 
I 
C 
Cardioversion for AF should be considered in 
pregnant women with HCM.43,305 
IIa 
C 
Disopyramide may be considered in pregnant 
women with HCM only when the potential benefits 
outweigh the risk of uterine contractions.305,306 
IIb 
C 
Myosin inhibitors are not recommended in women 
during pregnancy due to lack of safety data.303,304 
III 
C 
¬© ESC 2025
AF, atrial fibrillation; ARVC, arrhythmogenic right ventricular cardiomyopathy; CMP, 
cardiomyopathy; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection 
fraction; HCM, hypertrophic cardiomyopathy; HF, heart failure; LV, left ventricular; 
LVOTO, left ventricular outflow tract obstruction; NYHA, New York Heart 
Association; QTc, corrected QT interval; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cExcept for atenolol.   
ESC Guidelines                                                                                                                                                                                               35


<!-- PAGE 36 -->

### Page 36

in the post-partum period (up to 12 months), especially for those with 
LQT2. Beta-blocker therapy was associated with risk reduction in all the 
studies. Women with LQTS should therefore start beta-blockers at pregnancy or continue beta-blockers at pre-pregnancy dose, with propranolol 
or nadolol as drugs of choice. Beta-blockers should be continued in the post- 
partum period, particularly in the case of women with LQT2 due to the increased arrhythmic risk. It should be noted that nadolol has a higher excretion in breast milk than propranolol, with a relative infant dose of 4%‚Äì7%.317 
Therefore, nadolol is generally not the preferred beta-blocker during lactation. However, arrhythmic risk can be high in LQTS, and nadolol is one of the 
drugs of choice; thereofore, a careful weighting of benefit against harm is appropriate. Change of beta-blocker therapy after delivery should be avoided, 
as this is a vulnerable phase. Therefore, a change from nadolol to propranolol should ideally be evaluated before pregnancy. High dosages of nadolol 
during lactation may require monitoring of the infant for bradycardia. 
Women with LQTS should always avoid QT-prolonging drugs (see  
www.crediblemeds.org)318. Women with LQTS should be promptly 
treated for hypokalaemia and hypomagnesaemia, which is relevant in 
pregnancy-related hyperemesis, causing electrolyte disturbances and 
failure to absorb oral medications. All anti-emetic medications are 
QT-prolonging. Electrocardiogram monitoring should be performed 
if anti-emetic therapy is absolutely required. 
Long QT syndrome can manifest very early in life, even during the foetal period, and can be a cause of stillbirth319,320 (Section 4.5.1). A neonatal 
ECG should be performed post-delivery and after 2 weeks to avoid overdiagnosis due to transiently prolonged QT interval during the first 7‚Äì10 
days of life.321 Genetic screening for familiar genetic variants should be 
performed as soon as possible (e.g. from chordal blood). If the newborn 
is affected by LQTS, beta-blocker therapy should be started immediately. 
6.2.2. Brugada syndrome 
Men with Brugada syndrome (BrS) are more often symptomatic than 
women.322 The only retrospective study on pregnant women with 
BrS did not show an increased risk of cardiac events during pregnancy 
and the post-partum period.323 All patients with BrS should avoid contraindicated drugs (see www.brugadadrugs.org),324 large meals, or excess alcohol, and promptly treat fever and its causes.325 If there are 
symptoms during pregnancy, quinidine therapy should be considered 
with monitoring of hepatic function and blood count in the mother. 
6.2.3. Catecholaminergic polymorphic ventricular  
tachycardia 
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is 
mainly caused by P/LP in the RYR2 gene.252 The only retrospective 
study published, involving 96 women and 228 pregnancies, did not 
show an increased risk of cardiac events during pregnancy and the post- 
partum period.326 
Beta-blockers are the mainstay of therapy, with additive flecainide if 
needed.322,327 Nadolol and propranolol are beta-blockers of choice and 
should be continued during pregnancy and lactation. As in LQTS, the 
higher excretion of nadolol in breast milk should be noted (Section  
6.2.1). Left cardiac sympathetic denervation is a valuable anti- 
arrhythmic option that should be performed in experienced centres 
before pregnancy if indicated.328 Implantable cardioverter defibrillators 
are indicated in a minority of patients with CPVT. 
6.2.4. Short QT syndrome 
Short QT syndrome (SQTS) is a rare channelopathy characterized by 
short QT and increased risk of life-threatening arrhythmias and 
AF.329 There are no case reports or studies published on pregnancy 
in women with SQTS. When choosing an anti-arrhythmic drug during 
pregnancy, quinidine is the best option in the absence of more robust 
data.330 
6.2.5. Labour and delivery in primary arrhythmia 
syndromes 
In all primary arrhythmia syndromes, delivery should be planned with 
heart rhythm monitoring, electrolyte control, and post-operative 
ECG monitoring until all anaesthetic drugs have been eliminated. 
Labour and delivery may be associated with acute pain, adrenaline 
release, and urgent administration of anaesthetic drugs, and therefore 
continuous telemetry monitoring is often warranted. In the absence 
of obstetric contraindications, vaginal delivery is generally recommended. Neuraxial anaesthesia reduces pain and therefore adrenergic 
activation which is specifically important in LQTS and CPVT. Women 
with LQTS and CPVT should continue beta-blocker therapy during labour and delivery. In women with CPVT, it is reasonable to keep 
the heart rate under the threshold for premature ventricular contraction onset during delivery, typically 100‚Äì110 b.p.m.331,332 Anaesthetic 
drugs for LQTS should be selected according to the CredibleMeds 
website (www.crediblemeds.org). 
In BrS, propofol and local anaesthetics with sodium-blocking agents 
(e.g. lidocaine) carry a theoretical risk of triggering arrhythmias. Case 
reports have indicated uneventful delivery with neuraxial anaesthesia 
in women with BrS.333 Thiopental and inhalation anaesthesia have so 
far not been associated with adverse events.324,333 Anaesthestic drugs 
should be chosen according the BrugadaDrugs website (www. 
brugadadrugs.org). 
Recommendation Table 6 ‚Äî Recommendations for primary arrhythmia syndromes and pregnancy (see Evidence 
Tables 4‚Äì6) 
Recommendations 
Classa 
Levelb  
Monitoring and treatment of hypokalaemia and hypomagnesaemia is recommended in pregnant women with primary arrhythmia 
syndromes suffering from hyperemesis.334 
I 
C 
Long QT syndrome 
Beta-blockersc, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy in 
women with LQTS.312‚Äì316,335 
I 
B 
It is recommended to continue beta-blocker therapy during lactation in women with LQTS to reduce arrhythmic risk.148,336 
I 
B 
Pre-pregnancy beta-blocker dose of nadolol or propranolol, is recommended in women with LQT2, particularly in the post-partum period, 
which represents a high-risk period for life-threatening arrhythmias.148,313,315 
I 
B                         
Continued


<!-- PAGE 37 -->

### Page 37

### 7 Peripartum cardiomyopathy

7.1. Epidemiology 
Peripartum cardiomyopathy is a potentially life-threatening condition 
defined as HF with reduced left ventricular ejection fraction (LVEF) 
<45%, without any other cause of HF, that occurs mainly during the 
peripartum period or in the months following delivery, termination, 
or miscarriage.339 Peripartum cardiomyopathy is essentially a diagnosis 
of exclusion and requires urgent management. 
Worldwide, PPCM is a complication of 1 of 2000 births,340 but incidence rates vary depending on the geographical region, ethnicity, and 
socioeconomic factors, with an incidence of 1‚Äì4/1000 births in the 
United States of America341,342 and 10/1000 births in the north- 
western region of Nigeria.343 Recent data from 49 countries showed 
that most women presented with PPCM in the post-partum 
stage.344‚Äì346 Risk factors for PPCM are shown in Figure 7. 
7.2. Mechanisms 
Recent trials suggest a ‚Äòmultiple hit‚Äô theory for developing PPCM, with 
an accumulation of genetic and environmental risk factors (Figure 7). An 
overrepresentation of genetic variants in TTN, FLNC, BAG3, and DSP 
genes have been found in up to 15% of women with PPCM, with 
TTN truncating variants being the most common.347,348 The prevalence 
of these four genes in women with PPCM was comparable to the 
prevalence in DCM cohorts, supporting the similarity between PPCM 
and DCM. Genetic testing should therefore be considered in women 
with PPCM. 
There is growing evidence that several pathophysiological mechanisms in PPCM converge on a common pathway, which involves inflammation, unbalanced oxidative stress, and the generation of the 
anti-angiogenic 16 kDa prolactin. The 16 kDa prolactin induces 
endothelial dysfunction and damage, and subsequently leads to HF. 
Blocking prolactin with the dopamine D2 receptor agonist bromocriptine has emerged as a potential disease-specific therapy for 
PPCM.344,349‚Äì352 Additionally, the systemic or local increase in other 
anti-angiogenic factors, such as the soluble fms-like tyrosine kinase-1 
(sFlt-1) receptor, contributes to both local and widespread vascular 
dysfunction.353 
7.3. Diagnosis and clinical interventions 
Peripartum cardiomyopathy may present as subtle manifestations 
but most women with PPCM present with acute heart failure 
(AHF) with severe symptoms (NYHA III/IV). Mild to moderate symptomatic cases of PPCM are often mistaken for physiological changes 
associated with pregnancy, especially in the post-partum period. 
Myocarditis is a differential diagnosis and should be excluded by 
CMR.354 Women with PPCM and pre-eclampsia had a higher risk 
of adverse neonatal outcome but also a higher likelihood of left ventricular recovery (LVEF ‚â•50%).15 Diagnostic measures in a woman 
with suspected PPCM should include ECG, NPs, and echocardiography. The management strategy should be discussed within the 
Pregnancy Heart Team, considering maternal and foetal outcomes 
(Figure 7). Foetal prematurity and low birth weight are common in 
mothers with PPCM, and children of these mothers have a 3.4 times 
higher incidence of cardiovascular disease and 5 times higher 
mortality.355 
Treatment of AHF caused by PPCM follows the main principles 
of AHF management during and after pregnancy (Section 12.6). 
Mechanical circulatory support should be considered in women with 
persistent cardiogenic shock despite medical treatment.356,357 
Most medications used in the management of HF are foetotoxic and 
thus contraindicated during pregnancy (i.e. ACE-Is, ARBs, MRAs, and 
SGLT2 inhibitors).339 In the post-partum period, full HF treatment 
In women carrying a LQTS P/LP variant and who are phenotype-negative, use of beta-blockersc during pregnancy, post-partum, and 
lactation should be considered.148 
IIa 
C 
Left cardiac sympathetic denervation should be considered before pregnancy in high-risk woman with LQTS who are not adequately 
protected by pharmacological therapies or who have appropriate ICD shocks despite optimal medical therapy.252 
IIa 
C 
Brugada syndrome 
Quinidine therapy should be considered in pregnant women with BrS who have arrhythmic events during pregnancy.337,338 
IIa 
C 
Catecholaminergic polymorphic ventricular tachycardia 
Beta-blockersc, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy and 
lactation in women with CPVT.43,148,252 
I 
C 
Flecainide, in addition to beta-blockers, is recommended in women with CPVT who experience cardiac events such as syncope, VT, or 
cardiac arrest during pregnancy. 
I 
C 
It is recommended that women with CPVT who are stable on beta-blockers (nadolol or propranolol as drugs of choice) and flecainide 
before pregnancy continue both drugs during pregnancy and post-partum. 
I 
C 
The use of beta-blockersc during pregnancy and lactation should be considered in phenotype-negative women with a CPVT P/LP variant.148 
IIa 
C 
Left cardiac sympathetic denervation should be considered before pregnancy in high-risk women with CPVT who are not adequately 
protected by pharmacological therapies or with appropriate ICD shocks despite optimal medical therapy.252 
IIa 
C 
Short QT syndrome 
It should be considered to continue quinidine therapy in women with SQTS throughout pregnancy and the post-partum period.148 
IIa 
C 
Quinidine therapy should be considered in pregnant women with SQTS and arrhythmic events during pregnancy.148 
IIa 
C 
¬© ESC 2025
BrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; ICD, implantable cardioverter defibrillator; LQTS, long QT syndrome, LQT2, long QT syndrome type 
2; P/LP, pathogenic/likely pathogenic; SQTS, short QT syndrome; VT, ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence. 
cExcept for atenolol.   
ESC Guidelines                                                                                                                                                                                               37


<!-- PAGE 38 -->

### Page 38

can be initiated, except if lactation and breastfeeding are necessary for 
nutritional reasons, in which case ARBs and SGLT2 inhibitors should be 
avoided. Spironolactone is considered safe (see Section 5.2.7 and  
Figure 7). 
In addition to HF treatment, the prolactin production suppressing 
agent bromocriptine may be considered in women with PPCM 
(Figure 7).358‚Äì360 A secondary effect of bromocriptine is stopping 
lactation, which enables the possibility of full HF treatment of the 
mother that is not breastfeeding. The downsides of stopping lactation 
as PPCM treatment include psychological implications for the mother 
and the source of nutrition for the infant. These considerations indicate 
that women with moderate and severe HF in PPCM are the preferred 
candidates for bromocriptine treatment. A recent multi-centre randomized study comparing two different bromocriptine dosages in women 



	








¬Å



¬ç

	


	¬Å	




			¬ç
¬è
	

	
¬ê¬ù¬†

¬≠¬Ä¬Ç¬É
¬Å¬Ç

¬Å	
¬Å¬Ñ
	

¬Ö	¬Ñ
¬Ü	
		
¬á¬Å	¬ç¬†
¬Ö	¬†
¬à¬â	¬á¬á¬Å¬ä
¬è
		¬Å
¬à¬â	¬á¬á¬ä
¬ã




¬å¬Ä
¬â¬é¬ë
¬é	
	

¬í¬è¬ì¬è¬î¬â¬é
¬è¬è¬è¬â¬é
¬ê¬≠¬É¬ï¬É


¬í
	
¬é	¬ç		
	¬Ä
¬Ñ
¬î¬Å¬ç
¬ç¬Ä	
¬è		¬Å¬Ä
Figure 7 Risk factors and management of peripartum cardiomyopathy. CMR, cardiac magnetic resonance imaging; HF, heart failure; LVEF, left ventricular 
ejection fraction; P/LP, pathogenic/likely pathogenic; PPCM, peripartum cardiomyopathy. aIn specific cases.


<!-- PAGE 39 -->

### Page 39

with severe PPCM (2.5 mg daily for 1 week vs 5 mg daily for 2 weeks 
followed by 2.5 mg daily for 6 weeks) observed a high LV recovery 
rate at 6 months. No significant differences were observed between 
treatment over 1 week and 8 weeks, suggesting that a 1 week addition 
of bromocriptine to standard heart failure treatment would be beneficial.358 There are limited data on the use of bromocriptine in pregnant 
women with PPCM and cardiogenic shock.339,361 Personalized bromocriptine treatment, with dose adjustments to effectively suppress prolactin, may be a viable therapeutic option in these specific cases. Adding 
LMWH (in prophylactic doses at a minimum) to bromocriptine should 
be considered to reduce the thromboembolic risk.362 
7.4. Outcomes 
Risk stratification is crucial to determine the appropriate level of care for 
women diagnosed with PPCM (Figure 7). Key indicators to identify individuals at risk of complications include LVEF <30%, LV end-diastolic 
diameter >60 mm, biventricular dysfunction, ECG QT interval prolongation, delayed diagnosis, and Middle Eastern or African ethnicity and/or 
geography.344 Additional parameters such as age (>40 or <20 years), 
antepartum diagnosis, haemodynamic parameters at presentation, and 
cardiac biomarkers can further refine risk stratification. 
PPCM may cause ventricular tachyarrhythmias and patients should 
therefore be monitored.363,364 As ‚àº50% of women with PPCM recover 
within 1 year after delivery, a wearable cardioverter defibrillator (WCD) 
for pregnant women with LVEF <35% at risk of sudden cardiac death 
may be considered to provide bridging therapy to recovery.365,366 
Myocardial recovery after PPCM, defined as LVEF >50%, has been 
shown to occur in 46% (25%‚Äì62% according to geographical region) 
of women at 6 months.16 Full HF treatment should be given during the 
first year after complete LV function recovery. Stepwise discontinuation 
of HF therapy may be considered after 1 year if complete myocardial recovery is achieved, assuming that no genetic predisposition has been 
identified.339,367 However, recent data indicated higher risk of LVEF relapse during subsequent pregnancies in PPCM women who had discontinued their HF medication.368 Left ventricular assist device (LVAD) or 
heart transplantation have been reported in up to 10% of PPCM cases, 
with inferior survival rates compared to other age-adjusted heart transplant recipients.340 
Outcomes after PPCM differ globally.344 The EURObservational 
Research Programme‚Äôs (EORP) PPCM registry reported low mortality 
rates369 of 2.4% 1 month after diagnosis.370 However, the mortality 
rate at 6 months was 6%, with HF and cardiac arrest as the most frequent causes of death.16 At 1 year follow-up, death from any cause occurred in 8% of women, with regional variations (Europe 5%, Africa 6%, 
Asia‚ÄìPacific 9%, Middle East 19%; P < .001).17 
Women with a previous PPCM diagnosis face a notably elevated risk 
of poor outcomes. In the most recent EORP paper following women 
with subsequent pregnancies after PPCM, risk of maternal mortality 
was lower than in previous reports, at 2% at 198 days after delivery.368 
More than mild LV dysfunction before a new pregnancy increases the risk 
of LVEF deterioration, but also women with recovered LV functions remained at risk of relapse.368 In women planning a new pregnancy after a 
previous PPCM and with only mild LV dysfunction, stress echo without 
contraindicated HF medication may be helpful to further stratify risk. 
Having a good contractile reserve after HF medication has been discontinued may be an encouraging prognostic sign.371 If planning a new pregnancy after PPCM, discontinuation of beta-blocking therapy may not be 
advisable, and restarting beta-blocking therapy may be beneficial at a subsequent pregnancy, irrespective of baseline LV systolic function.368 
8. Pregnancy in women with 
aortopathies 
Acute arterial dissection during pregnancy occurs in 5.5/100 000 live 
births, with the aorta being the third most frequent location (19.8%) 
after coronary artery dissection (38.2%) and vertebral artery dissection 
(22.9%).378 A large cohort study reported an aortic dissection rate of 
5.5 per million women during pregnancy and post-partum, compared 
with 1.4 per million during the equivalent period 1 year later.40 
Although rare, acute aortic syndromes carry high foetal and maternal 
morbidity and mortality risks.378,379 Arterial dissections occur antenatally in 15%, intrapartum in 23%, and post-partum in 62% of cases.378 
Most pregnancy-related aortic dissections occur in women who are unaware of their underlying aortic disease380 and events rarely occur in 
women who have been monitored according to guidelines.7 The risk 
of peripartum dissection in more distal aortic segments remains after 
prior aortic root replacement.381 The mechanism for dissection during 
pregnancy is unclear. Given the high post-partum prevalence, haemodynamic changes alone do not fully explain the increased risk and hormonal influences are likely involved. 
8.1. Women with heritable thoracic aortic 
disease 
The number of genes associated with heritable thoracic aortic disease 
(HTAD) is steadily increasing. Although there is clear evidence for an 
increased risk of aortic dissection in HTAD, recent data from the 
Recommendation Table 7 ‚Äî Recommendations for 
peripartum cardiomyopathy (see Evidence Table 7) 
Recommendations 
Classa 
Levelb  
Counselling for women with PPCM about the risk of 
recurrence during a subsequent pregnancy and about 
contraception is recommended in all cases, even 
after recovery of LV function (LVEF >50%).355,369 
I 
C 
Adding at least prophylactic LMWH treatment to 
bromocriptine treatment in women with PPCM 
should be considered.358,362,372,373 
IIa 
C 
Genetic counselling and testing should be considered 
in women with PPCM.60 
IIa 
C 
When a reversible course of HF is assumed, 
treatment in accordance with HF guidelines should 
be considered for at least 12 months after complete 
LV recovery (normalization of LV volumes and 
EF).339,345,368,374 
IIa 
C 
Bromocriptine treatment may be considered in 
addition to optimal HF treatment to enhance 
recovery of LV function in women with PPCM.358‚Äì 
360,366,375,376 
IIb 
B 
The use of a WCD may be considered in women 
with PPCM and LVEF <35%.377 
IIb 
C 
¬© ESC 2025
EF, ejection fraction; HF, heart failure; LMWH, low-molecular-weight heparin; LV, left 
ventricle; LVEF, left ventricular ejection fraction; PPCM, peripartum cardiomyopathy; 
WCD, wearable cardioverter defibrillator. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               39


<!-- PAGE 40 -->

### Page 40

ROPAC III study showed that the aortic dissection incidence rate (3.5%) 
in pregnant women with HTAD was lower than previously reported.382 
Phenotypes and outcomes between different genes and variants vary, 
are of clinical importance, and impose differences in management with 
regard to the extent of imaging, surveillance, and referral for surgery.62,383 Clinical and genetic entities for which data are available are 
discussed below and included in Figure 8. 
8.1.1. Marfan syndrome 
Marfan syndrome (MFS) is caused by P/LP variants in FBN1. 
Pregnancy-associated cardiovascular events include aortic and coronary 
artery dissection as well as rapid aortic growth necessitating surgery.384 
Aortic event rates can reach up to 10%. Although type A dissections 
mainly occur in undiagnosed women, often with aortic diameters exceeding surgical thresholds,389 type B dissections remain unpredictable 
and can occur even after prophylactic root replacement.390 Women diagnosed earlier in life have a lower risk of dissection.391 More dissections 
occur during the post-partum period than during pregnancy or at delivery.384,392 Event rates and overall maternal mortality are low in women 
under guidelines-based follow-up.7,390 Studies have shown stable aortic 
root diameters during pregnancy in women with diameters between 40 
and 45 mm.384,393 No significant difference in aortic events is noted between ever-pregnant and never-pregnant women,384,392 but most data 
come from patients in highly controlled environments. 
8.1.2. Loeys‚ÄìDietz syndrome 
Loeys‚ÄìDietz syndrome (LDS) is linked to P/LP variants in six genes: 
TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB2, and TGFB3. Aortic outcomes 
in LDS vary by gene and variant,64 leading to gene-specific recommendations for aortic root surgery thresholds.62,383,388 Planned pregnancy is a 
known risk factor, but data on dissection risk during pregnancy, including 
diameters at dissection, are limited. Cases of type B dissection after aortic 
root replacement have been reported.394 A higher incidence of haemorrhagic events, reported in earlier studies,395 was not corroborated in a 
recent ROPAC III study.382 Although pregnancy data for women with 
LDS are sparse, recent reports suggest favourable maternal and foetal 
outcomes with appropriate counselling and surveillance.395 The lack of 
data about aortic diameters at dissection during pregnancy limits high- 
level recommendations for prophylactic aortic root surgery thresholds. 
8.1.3. Vascular Ehlers‚ÄìDanlos syndrome 
With a reported pregnancy-related mortality rate of 5% and life- 
threatening vascular events in up to 10% of pregnancies, women with 
vascular Ehlers‚ÄìDanlos syndrome undeniably have high-risk pregnancies.396 Pregnancy-related complications include vascular dissection 
or rupture, uterine rupture, perineal tears, haemorrhage, and premature birth. However, pregnancy and delivery do not seem to affect 
overall survival rates in women with vascular Ehlers‚ÄìDanlos syndrome.397 The risk may be lower for some women with specific genetic 
variants, null mutations, and normal vascular imaging.398,399 Celiprolol is 
recommended (also in normotensive women), given the very high risk 
of dissections and the benefit demonstrated in non-pregnant populations.7 Shared decision-making is crucial for these women. A ROPAC 
study included four women with vascular Ehlers‚ÄìDanlos syndrome 
who experienced pregnancy without adverse maternal events.7 Based 
on data from a recent systematic review, caesarean section at 37 weeks 
should be scheduled to avoid obstetrical complications.400 Women 
with vascular Ehlers‚ÄìDanlos syndrome should be counselled on pregnancy risk and monitored by a Pregnancy Heart Team. 
8.1.4. Non-syndromic heritable thoracic aortic 
diseases 
The number of genes linked to non-syndromic heritable thoracic aortic 
diseases (nsHTAD) is growing, including those rarely associated with 
extra-aortic features such as MYLK, ACTA2, MYH11, and PRKG1.401,402 
For most cases, specific pregnancy management recommendations are 
limited. Pragmatically, prophylactic surgery in nsHTAD is recommended 
at a diameter >45 mm. In women with variants in PRKG1, certain ACTA2 
variants, or additional risk factors that carry a high dissection risk at small 
diameters, such as hypertension or family history of dissection at smaller 
diameters, surgery may be considered at lower diameters (>40 mm).386 
8.1.5. Aortic disease with no identifiable (likely) 
pathogenic variant 
It is unclear whether young women with known aortic disease in whom 
genetic screening fails to identify a P/LP variant truly have a lower dissection risk than those with a known variant. The term ‚Äòsporadic aneurysm‚Äô is discouraged, as an aneurysm may stem from a heritable disorder 
even without a family history. Recent data from a large cohort of type A 
aortic dissection patients <30 years of age showed a near dichotomy 
between HTAD and unknown hypertension as probable dissection 
causes.403 
8.2. Turner syndrome 
Approximately 50% of women with Turner syndrome (TS) have 
cardiovascular manifestations, including aortic dilatation, bicuspid aortic 
valve (BAV), aortic coarctation, elongated aortic arch, and partial abnormal pulmonary venous return.404,405 All women with TS present 
a generalized arteriopathy and TS itself is an independent risk factor 
for thoracic aortic dilatation. Aortic dissection risk (85% type A and 
15% type B) increases with increasing diameters and can be reduced 
by following treatment guidelines.406‚Äì409 Risk factors include hypertension, BAV, and coarctation. In women with TS and an aortic size index 
(ASI) ‚â•25 mm/m2, aortic height index ‚â•25 mm/m or a z-score >4, the 
increased dissection risk and the option of surgery before pregnancy 
should be discussed with the patient and the Pregnancy Heart Team, 
taking the other risk factors into account.410‚Äì412 Spontaneous pregnancy can occur in women with mosaic TS, but assisted fertility techniques are now more common. Timely cardiovascular evaluation 
before fertility treatment is very important. Higher rates of adverse 
events during pregnancy and post-partum have been reported 
including hypertensive disease, gestational diabetes, haemorrhage, and 
SGA babies.413,414 Caesarean section rates of up to 67% have been 
reported.414 
8.3. Bicuspid aortic valve disease 
Available data for patients with BAV indicate a low risk of aortic events 
if the aorta is <45 mm. Data on pregnancy in women with diameters of 
45‚Äì50 mm are limited.7,415 Recent data on patients with BAV demonstrate a higher risk of dissection in those with a ‚Äòroot phenotype‚Äô compared to those with a primarily ascending aorta involvement.416,417 
When counselling these patients, it is important to note that BAV 
does not exclude the possibility of nsHTAD.


<!-- PAGE 41 -->

### Page 41

8.4. Aortic aneurysms other than root or 
ascending aorta 
Currently there are no recommendations for prophylactic surgery before conceiving except for the aortic root and ascending aorta. Recently 
published guidelines recommended surgery for the undissected aortic 
arch, descending and abdominal aorta at 50 mm in patients with 
Marfan syndrome,62 but no specific guidelines for management in pregnancy are available. 
8.5. Aortic dissection 
Data about pregnancy in women with a history of aortic dissection are 
scarce. ROPAC II and III included 11 and 9 women, respectively, with a 
previous dissection and reported no maternal mortality. However, two 
women in ROPAC III had a recurrent aortic event.7,382 Adverse events 
are likely low in women with a history of traumatic or iatrogenic dissection and probably also for those with a maximum aortic diameter of 
<40 mm and documented stable follow-up. Obviously there is a selection bias, as many women with complex aortic disease choose not to 
have children independent of the risk of progression of aortic disease. 
8.6. Management 
Women with aortic disease should be managed by a multidisciplinary 
team with experts from both the Pregnancy Heart Team and the aortic team who are experienced in diagnostic pathways, medical and surgical management of aortopathies in the ante-, peri-, and post-partum 
periods. Institutional protocols for the management of pregnancy- 
related aortic events should be available and a shared-decision model 
needs to be applied. Imaging of the entire aorta (CT or CMR) in women with known or suspected aortic disease is recommended and 
can reasonably be performed for most clinical scenarios within the 
6 months prior to pregnancy. CMR without gadolinium is recommended in pregnant women with known aortopathy, without pre- 
pregnancy imaging. In all women with aortic disease, strict blood 
pressure control is recommended. Specific target values for this specific situation have not been studied‚Äîin the general population 
it is recommended that treated systolic blood pressure values be targeted to 120‚Äì129 mmHg to reduce CVD, provided the treatment is 
well tolerated.388,418 In women with genetic aortopathies, treatment 
with beta-blockers throughout pregnancy should be considered 
with foetal growth monitoring. Women who used beta-blockers 





		


¬Å¬ç¬è

¬ê¬ù¬†¬≠¬ç

¬Ä¬≠¬Ç

¬Ç¬ê

¬ê¬ê

¬ê¬ê

¬Ç¬ê
¬ê¬ê
¬ê¬É¬ê

¬Ä¬≠¬Ç

¬†¬≠¬ç¬Ñ¬Ñ¬Å¬ê

¬ê¬ù¬†¬≠¬ç

¬Å¬ç¬è

¬Å¬ç¬è

¬Ö		
¬Ö
		


Figure 8 Thresholds for prophylactic surgical treatment prior to pregnancy of aortic root/ascending aneurysm (above the line) and recommended mode of 
delivery according to aortic diameter (below the line). BAV, bicuspid aortic valve; LDS, Loeys‚ÄìDietz syndrome; MFS, Marfan syndrome, nsHTAD, non- 
syndromic heritable thoracic aortic disease; P/LP, pathogenic/likely pathogenic; TAD, thoracic aortic disease; w/o, without. aRisk factors: family history of 
dissection, rapid aortic growth (‚â•3 mm/year), uncontrolled hypertension. bRoot phenotype to be added to the other risk factors. Based on Narula 
et al.,384 Wallace et al.,385 Regalado et al.,386 Jondeau et al.,387 Mazzolai et al.,388 and Isselbacher et al.62.   
ESC Guidelines                                                                                                                                                                                               41


<!-- PAGE 42 -->

### Page 42

throughout pregnancy in the ROPAC III study gave birth to infants 
with a significantly lower birth weight than women who did not.382 
Specific thresholds for pre-conception aortic root surgery are illustrated in Figure 8. 
The mode of delivery needs to be informed by the patient‚Äôs history, 
presence and type of gene/variant, and aortic diameter. The primary 
aim of intrapartum management in women with aortic disease is to reduce the cardiovascular stress of labour and delivery. Caesarean section 
may be considered in women with a maximum diameter of >45 mm 
and those with a history of dissection. In women with an aortic diameter <40 mm, vaginal delivery is recommended. In women with MFS, 
LDS, and vascular Ehlers‚ÄìDanlos syndrome, pre-delivery anaesthesiology consultation is recommended to consider precautions for dural 
ectasia and scoliosis (including possible previous surgery).419 In general, 
an individualized approach is favoured.383 Given the peak risk of a dissection at day 6 post-partum, it may be appropriate for women to stay 
in hospital for 1 week post-partum.420 
8.7. Cardiac surgery during pregnancy 
Prophylactic cardiac surgery in women who are planning a pregnancy is far 
more common than urgent or emergency surgery during pregnancy. 
Aortic surgery is the most frequently performed procedure during pregnancy, followed by surgery for aortic and mitral valve disease. Key 
pregnancy-related pathologies include prosthetic valve thrombosis and 
endocarditis. The decision to perform surgery with extracorporeal circulation and cardioplegic arrest during pregnancy is highly individualized with no 
specific guidelines available. A recent meta-analysis421 reported a maternal 
mortality rate of 7.3% consistent across trimesters, and no difference in maternal mortality if caesarean section was performed. Overall foetal mortality was 26.5%, lowest during third trimester surgeries (10.3%). Caesarean 
section before surgery significantly reduces foetal mortality. The decision 
to perform a caesarean section prior to surgery should be based on foetal 
viability and the level of medical care available rather than on a fixed gestational age. This is particularly crucial in acute type A aortic dissection. 
Hypothermic distal circulatory arrest increases foetal mortality.422 
Recommendation Table 8 ‚Äî Recommendations for aortopathies, cardiac surgery, and pregnancy 
Recommendations 
Classa 
Levelb  
Counselling 
It is recommended that women with aortic disease have counselling about the risk of aortic dissection in pregnancy and the post-partum 
period.404,423 
I 
C 
It is recommended that women with a history of aortic dissection or -surgery have pre-pregnancy counselling about the high risk by an 
extended Pregnancy Heart Teamc considering the presence and type of genetic variant, aortic morphology, growth rate, and aetiology of 
aortic dissection.7,381,424 
I 
C 
It is recommended that women with vascular Ehlers‚ÄìDanlos syndrome wishing to become pregnant are counselled regarding the very high 
risk of pregnancy-related adverse events by a multidisciplinary team, considering family history, genetic variant, and previous vascular 
events.7,396,397,425 
I 
C 
Imaging 
Imaging of the entire aortad (CT or CMR) is recommended before pregnancy in women with known or suspected aortic disease.390,424,426 
I 
C 
In women with aortic dilatation related to BAV, imaging (with TTE, and CMR/CT if needed) of the aortic root, ascending aorta, and 
descending aorta (to rule out coarctation) is recommended before pregnancy.427,428 
I 
C 
In women with low-risk aortic disease (mWHO 2.0 classes II and II‚ÄìIII), one-time echocardiographic imaging between 20 and 30 weeks of 
gestation and imaging at 6 months post-partum is recommended.393,429 
I 
C 
In women with moderate to high-risk aortic disease (mWHO 2.0 classes III and IV), repeated echocardiographic imaging every 4‚Äì12 weeks 
(depending on diagnosis and severity of dilatation) is recommended during pregnancy and until 6 months post-partum.393,429,430 
I 
C 
CMR (without gadolinium) imaging of the entire aorta is recommended in pregnant women at risk of or with known aortic dilatation who 
have not had recent pre-pregnancy cross sectional imaging.135 
I 
C 
Treatment‚Äîmedical 
When a woman with known aortic dilatation, history of dissection, or P/LP variant associated with aortic disease becomes pregnant, strict 
and individualized BP control is recommended.431,432 
I 
C 
Beta-blocker therapye throughout pregnancy and in the post-partum period is recommended in women with MFS and other HTADs.433 
I 
C 
Celiprolol is recommended in women with vascular Ehlers‚ÄìDanlos syndrome during pregnancy and lactation.434 
I 
C 
Treatment‚Äîintervention/surgical 
It is recommended that indications for pre-pregnancy aortic root and/or ascending aortic surgery are guided by aortic morphology, 
underlying pathology, family history, genetic variant, previous vascular events, and patient‚Äôs preference.62,383 
I 
C 
It is recommended that centres managing pregnancies in women with moderate to high-risk aortic disease (mWHO 2.0 class III/IV) can 
provide cardiovascular surgery in case of peripartum adverse events.435,436 
I 
C 
Specific conditions 
In women with MFS and aortic root diameters >45 mm, surgery before pregnancy is recommended.380,424 
I 
C 
In women with LDS with P/LP variants in TGFBR1, TGFBR2, and aortic root diameters ‚â•45 mm, surgery before pregnancy is 
recommended.437‚Äì439 
I 
C                         
Continued


<!-- PAGE 43 -->

### Page 43

### 9 Pregnancy in women with known

congenital heart disease 
Congenital heart disease is present in 0.8%‚Äì0.9% of live births, with significant geographical variation.448,449 Nowadays, most children born with congenital heart disease reach fertile age, even those with complex lesions, 
making adult congenital heart disease (ACHD) one of the most frequent 
CVDs during pregnancy.450 Discussions about family planning, contraception, pregnancy risk (mWHO 2.0‚Äîsee Table 6), and life expectancy are essential and should start early, preferably during the transition to adult life.2 
In the prospective ROPAC registry, most women with ACHD (n =  
3295) had a relatively favourable pregnancy outcome, with an overall 
mortality rate of 0.2% and trends improving from 2007 to 2017.2 
Heart failure rates were low in ROPAC, with differences according 
to disease complexity (13% in severe, 5%‚Äì6% in less-complex lesions). 
Arrhythmia rates were low overall (2%). Women with uncorrected 
ACHD more often have maternal and foetal complications.451 
Women with ACHD experiencing complications during pregnancy 
and post-partum may also be at higher risk of late cardiac events.451 
Pre-pregnancy evaluation should at least include routine blood tests, 
ECG, TTE, and cardiopulmonary exercise testing. As mentioned in 
Section 4, the increased transmission risk should be discussed, and genetic counselling should be offered.452 The level and timing of the pre- 
pregnancy cardiovascular evaluation and follow-up during pregnancy 
depend on the mWHO 2.0 class (see Table 6), taking the anatomical 
and functional status into account. 
Optimization of cardiac status and any comorbidities should take place 
prior to pregnancy. This includes guideline-directed elective surgery or/and 
In women with nsHTAD with P/LP variants in MYH11, ACTA2, PRKG1, or MYLK, and aortic root diameters ‚â•45 mm, surgery before 
pregnancy is recommended.385,386,440 
I 
C 
In women with BAV and aortic root or ascending aortic diameter ‚â•50 mm, surgery before pregnancy is recommended.441,442 
I 
C 
In women without an identifiable P/LP variant with aortic root or ascending aortic diameters ‚â•50 mm, surgery before pregnancy is 
recommended. 
I 
C 
In women with HTAD and aortic arch, descending aortic, or abdominal aortic diameters ‚â•50 mm, surgery before pregnancy should be 
considered.392,443 
IIa 
C 
In women with LDS with P/LP variants in TGFB2, TGFB3, SMAD2, and SMAD3, and aortic root diameters ‚â•45 mm, surgery before pregnancy 
should be considered.437‚Äì439 
IIa 
C 
In women with BAV and root phenotype or family history of aortic aneurysm or dissection, surgery before pregnancy should be considered 
if the aorta is ‚â•45 mm. 
IIa 
C 
In women without an identifiable P/LP variant with aortic root or ascending aortic aneurysm ‚â•45 mm, surgery before pregnancy should be 
considered in the presence of a family history of aortic aneurysm, aortic dissection, uncontrolled arterial hypertension, or on patient‚Äôs 
preference. 
IIa 
C 
In women with MFS and aortic root diameters between 40 and 45 mm, surgery before pregnancy may be considered if risk factors (growth 
>3 mm/year, family history of aortic dissection) are present.444 
IIb 
C 
In women with LDS with P/LP variants in TGFBR1 or TGFBR2 and aortic root diameters ‚â•40 mm, surgery before pregnancy may be 
considered.387,437,445,446 
IIb 
C 
In women with nsHTAD and aortic root diameters ‚â•40‚Äì44 mm, surgery before pregnancy may be considered depending on the genetic 
variant, family history, and aortic growth rate.385,386,440 
IIb 
C 
Delivery 
In women with an aorta <40 mm, vaginal delivery is recommended.163 
I 
C 
In women with vascular Ehlers‚ÄìDanlos syndrome, caesarean section at 37 weeks is recommended for obstetrical reasons.400 
I 
C 
In women with an aorta 40‚Äì45 mm, vaginal delivery with epidural anaesthesia and an expedited second stage should be considered. 
IIa 
C 
In women with an aorta ‚â•45 mm, caesarean section should be considered. 
IIa 
C 
In women with acute, subacute, or chronic aortic dissection, caesarean section should be considered. 
IIa 
C 
In women with an aorta 40‚Äì45 mm, caesarean section may be considered. 
IIb 
C 
The use of ergometrine post-delivery is not recommended in women with aortopathy. 
III 
C 
Cardiac surgery during pregnancy 
Delivery before cardiac surgery should be considered as soon as the foetus is viable, taking gestational age, comorbidities, and the available 
level of neonatal care into account.163,421,435,447 
IIa 
C 
Cardiac surgery may be considered during pregnancy when conservative and medical therapy has failed, and in situations that threaten the 
mother‚Äôs life or that are not amenable to percutaneous treatment. 
IIb 
C 
¬© ESC 2025
BAV, bicuspid aortic valve; BP, blood pressure; CMR, cardiovascular magnetic resonance imaging; CT, computed tomography; HTAD, heritable thoracic aortic disease; LDS, Loeys‚ÄìDietz 
syndrome; MFS, Marfan syndrome; mWHO, modified World Health Organization; nsHTAD, non-syndromic heritable thoracic aortic disease; P/LP, pathogenic/likely pathogenic; TTE, 
transthoracic echocardiogram. 
aClass of recommendation. 
bLevel of evidence. 
cExtended Pregnancy Heart Team: regular team + multidisciplinary aortic team‚Äîsee also Section 4.1. 
dIn women with vascular Ehlers‚ÄìDanlos syndrome and LDS, imaging should encompass the entire aorta, including supra-aortic vessels as well as iliac and femoral arteries. 
eSee Section 5.2.9 for beta-blocker choice.   
ESC Guidelines                                                                                                                                                                                               43


<!-- PAGE 44 -->

### Page 44

intervention of significant haemodynamic lesions (native or residual),21 as 
well as optimizing medical therapy and healthy lifestyle choices. 
The timing and mode of delivery should be decided by the 
Pregnancy Heart Team, for all women with a condition of mWHO 
2.0 class II‚ÄìIII or above. In general, vaginal delivery is the preferred delivery mode in women with ACHD.163 Post-partum monitoring should 
be individualized based on the woman‚Äôs underlying ACHD, risk or 
presence of arrhythmias and/or HF, and the course during pregnancy 
and delivery. High-risk women or those with HF symptoms during 
pregnancy or delivery should be considered for intensive (cardiac) 
care admission for haemodynamic monitoring.183 For more details 
about managing the various delivery stages, including post-partum, 
see Sections 4.5 and 4.6.1. 
A summary of relevant disease-specific considerations, maternal and 
foetal complications, monitoring, and management during pregnancy 
are listed in Table 12. 
Table 12 Risks, monitoring, and management during pregnancy and delivery in women with congenital heart disease 
ACHD 
Maternal Risk 
Obstetric and foetal 
risk 
Monitoring 
Pregnancy management and 
delivery  
Left ventricular outflow tract obstruction (LVOTO) 
Coarctation of the 
aorta 
‚Ä¢ ‚Üë Complication risk if residual 
obstruction (gradient 
>20 mmHg, aortic lumen 
<12 mm), clinical signs of HF, 
LVEF <40%, NYHA class>19 
‚Ä¢ ‚Üë Risk of aortic dissection 
(if aneurysm present) 
‚Ä¢ Uncontrolled hypertension9 
‚Ä¢ ‚Üë Miscarriage rate453 
‚Ä¢ Pre-term birth and low 
birth weight in 9%9 
‚Ä¢ Close BP monitoring 
‚Äîalso early 
post-partum 
‚Ä¢ Pre-pregnancy CMR 
and treatment of 
residual lesions454 
‚Ä¢ Treat hypertensiona 
‚Ä¢ Consider bed rest, hospital 
admission and stenting in case of 
severe symptomatic 
(re)coarctation (including 
refractory hypertension or 
maternal/foetal compromise)455 
‚Ä¢ Vaginal delivery preferred unless 
aneurysm, HF, severe hypertension 
Subvalvular, valvular and supravalvular aortic stenosis: see Section 12.5.1b and Section 8.3c for BAV related aortic disease. 
Women with serial left heart obstructive lesions have higher maternal cardiovascular event rates.456 
Shunt lesions 
ASD 
‚Ä¢ Low risk in (un)repaired ASD 
(if no PAH)457 
Unrepaired ASD: 
‚Ä¢ ‚Üë Risk of arrhythmia (4%)457 
‚Ä¢ Paradoxical embolism 
(2%‚Äì5%)457,458 
‚Ä¢ Rare457 
‚Ä¢ Unrepaired ASD 457,458: 
‚Ä¢ SGA (21%) 
‚Ä¢ Foetal/perinatal 
mortality (2%‚Äì3%) 
‚Ä¢ Pre-eclampsia (7%) 
Unrepaired and 
uncomplicated ASD: 
consider TTE at 
28‚Äì32 weeks457 
‚Ä¢ Large and/or haemodynamically 
significant ASD: closure 
pre-pregnancy21 
‚Ä¢ Unrepaired ASD: 
‚Ä¢ Consider ASA or prophylactic 
LMWHd for paradoxical 
embolism prevention 
‚Ä¢ Consider device closure in 
pregnancy only for recurrent 
stroke on medical therapy 
VSD and patent 
ductus arteriosus 
Low risk in small or repaired 
lesions with normal LV and no 
PAHe 
No evidence for ‚Üë risk 
Unrepaired and 
uncomplicated VSD: 
consider TTE at 
28‚Äì32 weeks 
Vaginal delivery is preferred 
AVSD 
‚Ä¢ Low risk in repaired AVSD 
without significant residual 
lesions 
‚Ä¢ Arrhythmia and ‚Üë AV valve 
regurgitation and HF if 
residual left AV valve 
regurgitation459,460 
‚Ä¢ ‚Üë Paradoxical emboli risk in 
unoperated (partial) AVSD 
‚Ä¢ Offspring mortality in 
6% primarily due to 
recurrence of the 
congenital heart 
disease459 
Unrepaired and 
uncomplicated AVSD: 
consider TTE at 
28‚Äì32 weeks 
‚Üë FU frequency in 
significant valve 
regurgitation, PAH, ‚Üì 
ventricular function, or ‚Üë 
NYHA class461 
‚Ä¢ Residual shunt: see ASD and/or 
VSD 
‚Ä¢ ‚Üë AV valve regurgitation and/or HFf 
‚Ä¢ PAHe 
‚Ä¢ Delivery: see ASD and VSD 
Pulmonary valve and RVOT disease 
RVOTO/PV stenosis 
‚Ä¢ Mild to moderate: low risk 
‚Ä¢ Severe: RV failure and 
arrhythmia21 
‚Ä¢ Very low complication 
risk462,463 
‚Ä¢ Mild to moderate: 
‚Ä¢ TTE at 28‚Äì32 weeks 
‚Ä¢ Severe stenosis: 
Pre-pregnancy severe RVOTO (Doppler 
peak gradient>64 mmHg) or/and any 
signs of right HF:                                                    
Continued


<!-- PAGE 45 -->

### Page 45

‚Ä¢ (Bi)monthly TTE 
(focused on RV 
function) 
‚Ä¢ Intervention (at any level of the 
RVOT)21 
Severe symptomatic PV stenosis (not 
responding to bed rest and conservative 
management): 
‚Ä¢ Consider transcatheter balloon 
valvotomy21 
Consider caesarean section in severe 
RVOTO/PV stenosis463 
PV regurgitation 
‚Ä¢ ‚Üë Risk when impaired RV 
function462 
‚Ä¢ Premature birth463 
Bimonthly TTE if severe 
PV regurgitation and ‚Üì 
RV function  
Post pulmonary valve 
replacement (surgical 
or transcatheter 
without severe 
stenosis/regurgitation) 
‚Ä¢ Low risk463‚Äì466 
‚Ä¢ Very low complication 
risk462,463 
TTE at 28‚Äì32 weeks 
Vaginal delivery is preferred 
Repaired TOF  
‚Ä¢ Low risk if no residual 
lesions467 
‚Ä¢ ‚Üë Risk of arrhythmia and HF 
(7%‚Äì10%) if pulmonary 
regurgitation, ‚Üì RV function, 
severe RVOTO467,468 
‚Ä¢ 15% risk of foetal and 
obstetric complications, 
mainly pre-term delivery 
and low birth weight467 
‚Ä¢ Low foetal mortality 
(0.7%)467 
‚Ä¢ Recurrence risk in the 
offspring in 22q11 
deletion syndrome: 50% 
‚Ä¢ First trimester and at 
28‚Äì32 weeks FU with 
TTE (increase FU 
depending on 
functional status) 
‚Ä¢ RV failure management: 
Bed rest and diuretics 
‚Ä¢ Arrhythmia managementg 
‚Ä¢ Severe PV stenosis/regurgitation: 
see above 
‚Ä¢ Vaginal delivery is preferred 
Consider caesarean section in severe 
RVOTO/PV stenosis 
Ebstein anomaly  
‚Ä¢ Overall MACE rate in 
ROPAC 9.9% 
‚Ä¢ Low risk in mild/ moderate 
Ebstein 
‚Ä¢ (Very) high risk when 
pre-pregnancy HF, cyanosis 
due to atrial shunt 
‚Ä¢ ‚Üë Arrhythmia risk due to 
accessory pathways469 
‚Ä¢ Foetal risk is related to ‚Üì 
maternal CO and 
cyanosis3,469: 
‚Ä¢ Miscarriage 
‚Ä¢ Pre-term birth 
(20%‚Äì24%) 
‚Ä¢ Neonatal death (3%) 
‚Ä¢ PPH 
‚Ä¢ Recurrence risk (5%) 
‚Ä¢ Mild to moderate: 
baseline and 28‚Äì32 
weeks assessment with 
TTE and ECG 
‚Ä¢ Severe: monthly/ 
bimonthly TTE & ECG 
‚Ä¢ Monitor for 
arrhythmias if 
palpitations 
‚Ä¢ Severe tricuspid regurgitation with 
HF can usually be managed 
medically 
‚Ä¢ Treat arrhythmias promptlyg 
‚Ä¢ Appropriate pre-pregnancy 
counselling about very high risk of 
MACE when HF and/or cyanosis    
Transposition of the great arteries 
TGA after atrial 
switch (Mustard or 
Senning) and CCTGA 
‚Ä¢ High pregnancy risk‚ÄîMACE 
rate up to 28% in 
retrospective series470‚Äî 
lower risk in ROPAC6: Atrial 
and ventricular arrhythmias in 
6.7%, HF in 10% 
‚Ä¢ Atrial arrhythmias often 
poorly tolerated 
‚Ä¢ Baffle leaks may lead to 
desaturation and paradoxical 
embolism471 
‚Ä¢ Predictors of MACE: 
symptoms of HF before 
pregnancy and systemic RV EF 
<40%6 
‚Ä¢ Foetal risks associated 
with maternal CO and 
saturation 
‚Ä¢ Pre-term birth (21%) 
‚Ä¢ Low birth weight 
(18%‚Äì21%)6,472,473 
‚Ä¢ Rare foetal and neonatal 
death (1%)474 
‚Ä¢ PPH (7%)6 
‚Ä¢ According to 
anatomical and 
functional status: TTE 
every 1‚Äì3 months and 
serial NP 
‚Ä¢ Holter monitoring if 
palpitations 
‚Ä¢ Pre-pregnancy counselling about 
very high risk if NYHA class III/IV, 
systemic RV EF <40%, more than 
moderate tricuspid regurgitation, 
or treated HF472,473,475 
‚Ä¢ Treat HF primarily with medical 
therapyh 
‚Ä¢ Promptly treat arrhythmiag 
‚Ä¢ Consider prolonged post-partum 
monitoring (48‚Äì72 h) and early 
post-partum FU given the ‚Üë risk of 
post-partum HF 
No clear evidence for long-term 
deterioration or ‚Üë cardiovascular 
events associated with pregnancy6,476 
TGA with arterial 
switch 
‚Ä¢ Low risk 
‚Ä¢ Ventricular arrhythmias 
(2.5%‚Äì7%), HF (2%‚Äì4%)8 
‚Ä¢ Low rate of prematurity 
or foetal loss474,477 
‚Ä¢ Consider TTE at 20 
weeks 
‚Ä¢ Intensify if ‚Üì ventricular 
function, ‚Üë aortic 
‚Ä¢ Vaginal delivery is preferred 
‚Ä¢ Surgery before pregnancy when 
the neo-aortic root is 
>55 mm21,478or if severe ARf                                    
Continued  
ESC Guidelines                                                                                                                                                                                               45


<!-- PAGE 46 -->

### Page 46

regurgitation and ‚Üë 
aortic dilatation 
Single ventricle physiology palliated with Fontan circulation  
High pregnancy risk 
CV events479: 
‚Ä¢ Supraventricular arrhythmias 
(8%‚Äì11%) 
‚Ä¢ HF (4%‚Äì14%) 
Risk factors:479 
‚Ä¢ Oxygen saturations <85% 
‚Ä¢ ‚Üì Ventricular function 
‚Ä¢ Arrhythmias 
‚Ä¢ Significant valvular disease 
‚Ä¢ NYHA class III/IV 
‚Ä¢ FALD 
‚Üë Very high foetal 
complication risk:479‚Äì483 
‚Ä¢ Low live birth rate (56%) 
‚Ä¢ Miscarriages (45%‚Äì54%) 
‚Ä¢ SGA (20%‚Äì55%) 
‚Ä¢ Premature birth (59%‚Äì 
72%) 
‚Ä¢ Neonatal death (5%‚Äì 
18%) 
Obstetric risk: 
‚Ä¢ Hypertension (14%) 
‚Ä¢ PPH (13%) 
‚Ä¢ According to 
anatomical and 
functional status: TTE 
every 1‚Äì3 months and 
serial NP484 
‚Ä¢ FU in specialized 
ACHD centre 
‚Ä¢ Pre-pregnancy counselling about 
very high risk especially if any risk 
factor (see maternal risk) 
‚Ä¢ Pregnancy may be well tolerated 
and successful in a subset of 
women with single ventricle and 
Fontan circulation without 
complications479,480,485‚Äì487 
‚Ä¢ ASA and/or LMWH (depending on 
the presence of complications) 
should be considered in shared 
decision484 
‚Ä¢ Atrial tachyarrhythmias should be 
promptly treated with 
cardioversioni 
Labour/delivery with preload dependent 
circulation:461 
‚Ä¢ Epidural with slow titration 
‚Ä¢ Labour in left lateral decubitus 
position 
‚Ä¢ Low thresholds for assisted second 
stage (‚Üì Valsalva duration) 
‚Ä¢ i.v. air filter (if fenestration or 
significant venovenous collaterals) 
Unrepaired cyanotic ACHD (without pulmonary hypertension)  
HF, thrombosis, arrhythmia and 
endocarditis in ‚â•15%488 
Degree of maternal 
hypoxaemia is the most 
important predictor of 
foetal outcome: 
10% foetal loss if resting 
maternal blood saturation 
>90%, 
chance of a live birth 12% if 
maternal oxygen 
saturation<85%489 
FU in expert centre 
‚Ä¢ Pre-pregnancy counselling about 
very high risk especially if maternal 
resting saturation <85%489 
‚Ä¢ i.v. air filter 
¬© ESC 2025
ACHD, adult congenital heart disease; ASA, acetylsalicylic acid; ASD, atrial septal defect; AV, atrioventricular; AVSD, atrioventricular septal defect; BAV, bicuspid aortic valve; BP, blood 
pressure; CCTGA, congenitally corrected transposition of the great arteries; CMR, cardiovascular magnetic resonance; CO, cardiac output; CV, cardiovascular; ECG, electrocardiogram; 
EF, ejection fraction; FALD, Fontan-associated liver disease; FU, follow-up; HF, heart failure; i.v., intravenous; LMWH, low-molecular-weight heparin; LV, left ventricle; LVEF, left 
ventricular ejection fraction; LVOTO, left ventricular outflow tract obstruction; MACE: major adverse cardiovascular events; NP, natriuretic peptide; NYHA, New York Heart 
Association; PAH, pulmonary arterial hypertension; PPH, post-partum haemorrhage; PV, pulmonary valve; ROPAC, Registry of Pregnancy and Cardiac Disease; RV, right ventricle, 
RVOTO, right ventricle outflow tract obstruction; SGA, small for gestational age; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; TTE, transthoracic echocardiogram; 
VSD, ventricle septal defect. 
‚Üë increase ‚Üì decrease. 
aRefer to Section 12.3 Hypertensive disorders. 
bRefer to Section 12.5.1 Stenotic native valve lesions. 
cRefer to Section 8.3 Bicuspid aortic valve disease. 
dRefer to Section 5 Drugs during pregnancy and lactation. 
eRefer to Section 10 Pregnancy in women with pulmonary arterial hypertension. 
fRefer to Section 12.5.2 Regurgitant native valve lesions. 
gRefer to Section 12.4 Arrhythmias. 
hRefer to Section 12.6 Heart failure. 
iRefer to Section 12.4.3 Cardioversion, ablation, and device implantation and implantable cardioverter defibrillator management.


<!-- PAGE 47 -->

### Page 47

### 10 Pregnancy in women with

pulmonary arterial hypertension 
Pulmonary hypertension (PH) is defined as a mean pulmonary 
arterial pressure >20 mmHg, derived from invasive right-heart catheterization, and is classified by aetiology and pathophysiology.490 
Pulmonary arterial hypertension (PAH) is pre-capillary PH characterized by a pulmonary vascular resistance >2 Wood units and pulmonary arterial wedge pressure ‚â§15 mmHg. Untreated, idiopathic PAH 
results in death within a median of 2.8 years, but with PAH therapies, 
median survival extends to over 7 years.491,492 There is a preponderance of females in the incidence of PAH, and this includes women of 
childbearing age. The first clinical manifestations may be seen in 
pregnancy.493 
Women with PAH should be managed by a Pregnancy Heart Team, 
and a PH expert experienced in diagnostic pathways, medical treatment, and anticoagulation management from the ante- to the peri- 
and post-partum period. 
10.1. Pre-existing pulmonary arterial 
hypertension 
In women with PAH, maternal and foetal outcomes vary according to the 
PAH subset. With improved treatment of PAH and a multidisciplinary 
approach during pregnancy and the peri-partum period, maternal mortality has declined but remains high, ranging from 11% to 25%.2,490,494,495 
10.1.1. Maternal and foetal risk 
Although there is no safe cut-off for elevated pulmonary artery pressure and risk, pregnancies with mild PAH and vasoreactive PAH 
seem to have better maternal and foetal outcomes than those with 
moderate to severe PAH.141,496‚Äì498 Women with severe PAH, non- 
vasoreactive idiopathic PAH, and Eisenmenger syndrome have the highest risk of maternal and foetal mortality.496,497,499‚Äì502 As the clinical 
course of PAH during pregnancy remains associated with unforeseeable risks and pregnancy may accelerate PAH progression, all women 
with PAH496 wishing to become pregnant should be counselled by a 
multidisciplinary team regarding the very high risk of pregnancy-related 
adverse events. 
Women with Eisenmenger syndrome are unlikely to tolerate pregnancy due to additional risks of RV failure and paradoxical emboli. 
Chronic cyanosis may worsen due to systemic vasodilatation during 
pregnancy, an increased right-to-left shunt, and decreased pulmonary 
blood flow. 
Foetal and neonatal mortality risk is high in women with PAH, mainly related to pre-term delivery, reduced maternal CO, and/or hypoxaemia.503 Miscarriage is common. If oxygen saturation is >90%, there 
is usually a better foetal outcome (10% foetal loss). If oxygen saturation is <85%, miscarriage, IUGR, prematurity, and foetal death are 
common (live birth rate of only 12%).504,505 
10.1.2. Counselling and contraception 
Women of childbearing potential with PAH should be counselled 
at the time of diagnosis about the very high risk and uncertainties associated with becoming pregnant. Clear advice against becoming 
pregnant, including referral for psychological support if needed, 
and clear contraceptive advice are required, taking into account the 
woman‚Äôs individual needs. Reduced efficacy of hormonal contraceptives should be carefully considered and discussed with women treated with ERAs, as well as the addition of barrier methods for 
contraception.490,493 
10.1.3. Management during pregnancy 
When pregnancy occurs, termination should be discussed. Rigorous 
planning with the optimization of targeted PAH therapies and close 
monitoring are key in managing women with PAH who wish to continue with the pregnancy after appropriate counselling on the high maternal and foetal risks. 
Bed rest may be required in symptomatic women, and it may be appropriate to avoid additional risk factors (such as air travel). Right-heart 
catheterization can be performed to assist management in women 
showing deterioration. 
Diuretics may be needed in women with HF, and iron deficiency 
should be treated.43 It is recommended to stop ERAs, riociguat, and 
selexipag because of potential or unknown teratogenicity.43,490 
PAH therapies that can be used during pregnancy include 
phosphodiesterase-5 inhibitors and prostacyclin analogues. Sildenafil 
is used in the vast majority of women and is combined with a prostacyclin analogue depending on the disease severity. The subset of women with true vasodilator responsiveness who are well controlled on 
CCB therapy should continue taking this during pregnancy.43,490,506 
Recommendation Table 9 ‚Äî Recommendations for 
congenital heart disease and pregnancy (see Evidence 
Table 8) 
Recommendations 
Classa 
Levelb  
Vaginal delivery is recommended in most women 
with ACHD.161,163 
I 
B 
It is recommended that all women with Fontan 
circulation who wish to become pregnant receive 
counselling from the Pregnancy Heart Team 
regarding the high risk of pregnancy-related adverse 
events.479,480,484,486,487 
I 
C 
It is recommended that women with a systemic RV 
(Mustard/Senning or congenitally corrected TGA), in 
NYHA class III/IV, systemic ventricular dysfunction 
(EF <40%), or severe TR wishing to become 
pregnant are counselled by the Pregnancy Heart 
Team regarding the high risk of pregnancy-related 
adverse events.473‚Äì475 
I 
C 
In women with significant haemodynamic lesions, 
discussion about guideline-directed interventions is 
recommended prior to pregnancy. 
I 
C 
¬© ESC 2025
ACHD, adult congenital heart disease; EF, ejection fraction; NYHA, New York Heart 
Association; RV, right ventricle; TGA, transposition of the great arteries; TR, tricuspid 
regurgitation. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               47


<!-- PAGE 48 -->

### Page 48

In women with Eisenmenger syndrome, caution is warranted when 
administering drugs that may lead to sudden systemic vasodilation or 
a risk of paradoxical air embolism (i.v. line filters should be used for 
i.v. therapies). Thromboembolism is a major risk, and anticoagulation 
regimens (type and dosage) should be considered individually, balancing the risk of bleeding vs VTE at each stage of pregnancy. LMWH 
is most commonly used. Regular follow-up is advisable, initially every 
2‚Äì4 weeks and then weekly in the third trimester. Women need to be 
monitored for increasing hypoxaemia and symptoms of HF, including 
breathlessness, syncope, and congestion. Regular echocardiography 
and blood testing, including NP levels, can provide evidence of HF 
where appropriate. 
10.2. New diagnosis in pregnancy 
The usual diagnostic algorithm as per the 2022 ESC/ERS Guidelines 
for the diagnosis and treatment of pulmonary hypertension should 
be followed in a pregnant woman with suspected PAH. Right-heart 
catheterization should be considered if there is diagnostic uncertainty in identifying de novo PAH in pregnancy and to assist with important therapeutic decisions.490 If this is required, it should be 
performed in a specialized centre. An individualized approach is required for starting PAH therapies. Many centres start therapy with 
oral sildenafil. Close follow-up by an experienced Pregnancy Heart 
Team with a PH expert is needed and prompt escalation of PAH 
therapy, usually with i.v. epoprostenol, is indicated depending on 
the disease severity. 
10.3. Delivery in women with pulmonary 
arterial hypertension 
A detailed delivery plan, including the optimal mode and timing of delivery, should be provided on a timely basis by the Pregnancy Heart 
Team with a PH expert. Early delivery, with careful tracking of foetal 
growth, is often required in women with progressive, decompensated 
HF not responding to PAH therapies and to reduce the risk of an unplanned birth outside an expert centre.245 Therapeutic LMWH 
should be stopped 24 h prior to any mode of delivery to reduce 
the risk of maternal haemorrhage. Caesarean section providing for 
a more controlled delivery may be preferred over vaginal delivery.494,507 Regional anaesthesia is usually favoured over general 
anaesthesia. 
10.3.1. Peri- and post-partum monitoring 
Due to the rapid changes in haemodynamics, the post-partum period is 
particularly high risk, with the majority of maternal mortality occurring 
after delivery.245 During delivery and post-delivery, women should be 
monitored in the intensive care setting with ECG, pulse oximetry, 
CO monitoring, meticulous fluid balance with central venous pressure 
monitoring, and optimization of RV function all important determinants 
of a good outcome. Women remain at high risk for many months after 
delivery, and individualized counselling is required to discuss the need 
for ongoing therapies and the avoidance of future pregnancies. In women with severe PAH and those who had complications during pregnancy and/or delivery, optimization of PAH therapies should be 
prioritized over lactation. 
11. Venous thromboembolism in 
pregnancy and post-partum 
11.1. Epidemiology and maternal risk 
Venous thromboembolism includes PE and DVT. The pooled incidence of 
pregnancy-related VTE (including post-partum) is 1.2 per 1000 deliveries510, and it is a major cause of pregnancy-related morbidity and mortality.510 Pregnancy-related VTE has a fatality rate of 0.68% and a recurrence 
rate (during pregnancy and post-partum) of 4.27%, which is higher post- 
partum.510 A documented assessment of VTE risk factors is recommended before or in early pregnancy. The VTE risk is highest in the third 
trimester and in the first 6 weeks post-partum.510 Mortality in 
pregnancy-related VTE is associated with CVD, hypertension, twin gestation, pre-term birth, caesarean section, transfusion, and black ethnicity.511 
11.2. Risk factors for pregnancy-related 
venous thromboembolism 
Pregnancy is accompanied by physiological changes leading to an 
increased VTE risk. First, increased procoagulant activity as well as decreased physiological anticoagulant and fibrinolytic activity result in a hypercoagulable state.512,513 Second, the expanding uterus causes 
mechanical compression of the inferior vena cava and the pelvic veins, 
leading to impeded venous flow.512,513 In addition, non-pregnancy- 
related and pregnancy- or delivery-related conditions may modify the individual VTE risk (see Supplementary data online, Table S5). 
In pregnancy, as well as in the early post-partum period, an emerging 
suspicion of VTE requires immediate diagnostic clarification. 
Recommendation Table 10 ‚Äî Recommendations for 
pulmonary arterial hypertension and pregnancy 
Recommendations 
Classa 
Levelb  
It is recommended that women of childbearing 
potential with PAH wishing to become pregnant are 
counselled by a multidisciplinary team regarding the 
very high risk of pregnancy-related adverse events, 
encouraging a shared decision-making process about 
whether to become pregnant.490 
I 
C 
It is recommended to provide clear contraceptive 
advice to women of childbearing potential with 
PAH.490 
I 
C 
For women with PAH requiring pregnancy 
termination, it is recommended to perform this in 
PH centres.490 
I 
C 
Right-heart catheterization should be considered 
during pregnancy if there is diagnostic uncertainty or 
to assist with important therapeutic decisions.490 
IIa 
C 
Endothelin receptor antagonists, riociguat, and 
selexipag are not recommended during 
pregnancy.490,508,509 
III 
C 
¬© ESC 2025
PAH, pulmonary arterial hypertension; PH, pulmonary hypertension. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 49 -->

### Page 49

11.3. Prevention of venous 
thromboembolism 
Thromboprophylaxis follows an individualized risk assessment weighing 
the VTE risk against the bleeding risk ante- and post-partum. 
11.3.1. Pregnant women with no prior indications for 
long-term anticoagulation 
If prevention and treatment of VTE are initiated in the antepartum period, continuation for up to 6 weeks post-partum should be considered. 
In women with low-risk thrombophilia without a history of VTE, routine antepartum thromboprophylaxis is not required.514 In women 
with a history of VTE or a high-risk thrombophilia, medical thromboprophylaxis is recommended (Table 13). In women with ovarian hyperstimulation syndrome after in vitro fertilization, thromboprophylaxis is 
recommended during the first trimester.515,516 
The drug class of choice for the prevention and treatment of 
pregnancy-related VTE is LMWH.517,518 Fondaparinux may be considered as an alternative. A randomized controlled trial comparing a 
weight-adjusted intermediate-dose LMWH with a fixed low-dose 
LMWH regimen found that weight adjustment did not reduce the 
risk of recurrent VTE in the combined ante- and post-partum periods.519 Post-hoc analyses suggested a higher efficacy of weight-adjusted 
intermediate-dose LMWH in the post-partum period only, but this 
needs to be confirmed by future studies. In morbidly obese women, 
weight-based prophylactic dosing (considering anti-factor Xa measurement) instead of fixed dosing might be more appropriate.198 
11.3.2. Pregnant women with prior indication for 
long-term anticoagulation 
In case of pre-existing oral anticoagulation therapy due to previous 
VTE, oral anticoagulation (DOAC or VKA) should be replaced by 
LMWH at recognition of pregnancy.517 
11.4. Management of acute venous 
thromboembolism 
11.4.1. Clinical presentation and diagnosis 
11.4.1.1. Deep vein thrombosis 
The expanding uterus potentially reduces the blood flow in the iliocaval 
veins. In addition, a constitutional narrowing of the left-sided common 
iliac vein between the spine and the crossing artery could contribute to 
an increased risk of left-sided iliofemoral thrombosis.520 The clinical 
LEFt criteria (L = Left, symptoms in the left leg; E = Edema, calf circumference difference ‚â•2 cm; Ft = First trimester of presentation) may be 
used to identify low risk of pregnancy-related DVT.521,522 In pregnant 
women with suspicion of acute DVT, immediate diagnostic clarification 
is indicated (Figure 9). 
Table 13 Reasons for antepartum/post-partum thromboprophylaxis 
Medical conditions 
Antepartum thromboprophylaxis 
Post-partum thromboprophylaxis  
History of unprovoked VTE 
History of hormone-associated VTE 
Homozygous factor V Leiden mutation 
Heterozygous factor V Leiden mutation 
Homozygous prothrombin gene mutation 
a 
Heterozygous prothrombin gene mutation 
Antithrombin deficiency 
a 
a 
Antiphospholipid syndrome 
b 
Protein C or S deficiency 
a 
Combined thrombophilia 
¬© ESC 2025
Adapted from Nichols et al.213 under the terms of the Creative Commons Attribution-NonCommercial-No Derivatives License (CC BY NC ND). 
VTE, venous thromboembolism. 
= yes; 
= no; 
= no clear evidence to administer or not‚Äîto be individualized.  
aWith family history of VTE (to be considered without family history of VTE). 
bWith history of VTE or pregnancy loss.   
ESC Guidelines                                                                                                                                                                                               49


<!-- PAGE 50 -->

### Page 50

11.4.1.2. Pulmonary embolism 
Clinical signs and symptoms of PE in pregnancy do not differ from those of 
PE in non-pregnant women. The diagnostic approach in haemodynamically 
stable pregnant women with suspicion of PE aims to reduce the need for 
computed tomography pulmonary angiography (CTPA) by implementing 
additional diagnostic strategies, such as clinical features, D-dimer, and venous ultrasound. Levels of D-dimer increase physiologically up to 39% per 
trimester.524 A multinational study demonstrated the efficiency of a diagnostic strategy involving clinical probability, D-dimer measurements 
(threshold <500 ¬µg/L), and peripheral venous compression ultrasound 
to reduce the need for CTPA.525 Using both the YEARS criteria (1, clinical 
signs of acute DVT; 2, haemoptysis; 3, PE is the most likely diagnosis) and 
adapted D-dimer thresholds allows a further reduction in the need for 
CTPA (D-dimer threshold if YEARS criteria present <500 ¬µg/L, if 
YEARS criteria absent <1000 ¬µg/L).526 Another meta-analysis confirmed 
the value of including D-dimer in a diagnostic algorithm to rule out PE in 
pregnant women with suspicion of PE (Figure 10).527 
11.4.2. Treatment of venous thromboembolism 
in pregnancy 
In pregnant women with a suspicion of VTE, anticoagulation with therapeutic LMWH should be commenced immediately, even before imaging, 
until the diagnosis of VTE is either excluded or confirmed. In pregnant women with confirmed acute VTE, therapeutic anticoagulation with weight- 
adjusted LMWH based on early pregnancy weight is recommended by 
using either a twice-daily or a once-daily regimen, each one resulting in 
a therapeutic daily dose518 (see also Section 5.2.1). Currently, there is insufficient evidence to favour once- or twice-daily regimens.217,218,518 
Suspicion of pregnancy-related 
Deep vein thrombosis 
Administration of Ô¨Årst therapeutic dose of LMWH
if anticipated diagnostic delay
(Class IIa) 
Venous ultrasound compression ultrasound of infrainguinal veins and ultrasound of iliac veins
Serial venous ultrasound scans
(2 exams within 7 days)
or MR-venography
Positive
Positive
Negative
Negative
Inconclusive
Diagnosis of DVT
Therapeutic dose LMWH
(Class I)
AND
Consultation with
Pregnancy Heart Team including a vascular specialist and a haematologist
(Class I)
No DVT
Figure 9 Algorithm for the diagnosis and treatment of deep vein thrombosis during pregnancy. DVT, deep vein thrombosis; LMWH, low-molecular-weight 
heparin, MR, magnetic resonance. Adapted from Chan et al.523


<!-- PAGE 51 -->

### Page 51

Stable patient with clinical suspicion of pulmonary embolism
No PE
Venous ultrasound compression ultrasound of infrainguinal veins and ultrasound of iliac veins   
Diagnosis of PE
Search for alternative causes of instability 
Therapeutic dose anticoagulation
Evaluation of reperfusion strategy
A
B
Administration of Ô¨Årst therapeutic dose of LMWH
if anticipated diagnostic delay
(Class IIa) 
AND
D-Dimer
Diagnosis of DVT
Positive
Negative
Chest X-ray
CTPA
Inconclusive
Positive
Therapeutic dose
LMWH
(Class I) 
Consultation with Pregnancy Heart
Team including a vascular specialist and a haematologist
(Class I)
Consultation with
Pregnancy Heart Team including a vascular specialist and a haematologist
(Class I)
AND
Unstable patient with suspicion of pregnancy-related pulmonary embolism
Administration of Ô¨Årst therapeutic dose of
UFH or LMWH
(Class IIa)   
AND
AND
TTE
CTPA
Negative
RV dysfunction
No RV dysfunction
Diagnosis of PE
Positive
AND
Positive
Positive
Negative
No PE
if CTPA not available
Negative
Perfusion lung scan 
Negative or inconclusive
Figure 10 Algorithm for the diagnosis and treatment of pulmonary embolism in pregnancy in stable (A) and unstable women (B). CTPA, computed tomography pulmonary angiography; DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; RV, right ventricle; TTE, 
transthoracic echocardiogram; UFH, unfractionated heparin. Adapted from Barrios et al.528 with permission from Elsevier.   
ESC Guidelines                                                                                                                                                                                               51


<!-- PAGE 52 -->

### Page 52

Despite fluctuations of anti-factor Xa levels during pregnancy, routine 
anti-factor Xa monitoring does not affect clinical outcomes and should 
only be considered in women with renal insufficiency or obesity.211‚Äì213 
Fondaparinux may be considered as an alternative. In unstable pregnant 
women with PE, UFH may be used in the initial phase of therapeutic 
anticoagulation. 
After delivery, therapeutic-dose anticoagulation should be administered 
for a minimum of 6 weeks, up to an overall duration of 3 months, except 
for cases in which an indefinite duration of anticoagulation is indicated.510,529 LMWH or VKAs may be given during lactation. A more detailed discussion of anticoagulants in the lactation period can be found in 
Section 5. Thrombolytic or interventional treatment of PE is not recommended in the peripartum period and should only be considered in women 
with high-risk PE after consultation with a specialized multidisciplinary 
team. In pregnant women with acute iliofemoral DVT, interventional 
thrombus removal should not routinely be performed. Data on the effectiveness and risks of the placement of temporary inferior vena cava filters 
for the prevention of PE in pregnant women are limited but appear to 
be comparable to non-pregnant women. Due to limited data and potential 
complications associated with the inferior vena cava filters, their placement 
should be limited to recurrent VTE despite appropriate anticoagulation or 
contraindication to therapeutic-dose anticoagulation therapy.530,531 
11.5. Management of delivery and the 
post-partum period 
For pregnant women receiving a prophylactic dose of anticoagulation, 
there is no specific need for a planned delivery. However, pregnant women receiving a therapeutic dose of anticoagulation need a planned delivery with prior discontinuation of LMWH to prevent spontaneous 
delivery in a period of full anticoagulation. Details for the management 
of anticoagulation during pregnancy and delivery, including for VTE, are 
provided in Sections 4.5.6. and 5.2.1. 
12. Pregnancy in women with 
acquired heart disease 
12.1. Acute chest pain in pregnancy 
Diagnostic evaluation for chest pain in pregnant women 
follows the same protocol as in non-pregnant women, including 
clinical examination, ECG, biomarkers and echocardiography 
(Figure 11).207,537,538 Importantly, spontaneous coronary artery 
dissection (SCAD) is a more prevalent cause of chest pain during 
pregnancy and in the early post-partum period than in non- 
pregnant women.539 
Treatment and management of the specific differential diagnoses 
should follow established respective guidelines. The specificity of 
D-dimer is reduced during pregnancy540,541 and women should not 
undergo chest CT based solely on D-dimer levels (Section 11). In suspected acute aortic syndromes, there should be a low threshold for 
aortic CT and consultation with the aortic team in emergencies 
(Section 8).542 
12.2. Coronary artery disease 
12.2.1. Acute coronary syndrome 
12.2.1.1. Coronary artery disease epidemiology and aetiology 
Acute coronary syndromes (ACS) are a major cause of maternal 
death in developed countries, accounting for 20% of cardiovascular 
deaths.543 The risk of ACS is three to four times higher in pregnant 
women than in non-pregnant women of reproductive age,544 and 
mortality is estimated at 5%.545 Because the age at giving birth is 
increasing overall, ACS in pregnancy may become more common.546 Although ACS can occur at any stage of pregnancy, it is 
more common in the third trimester or post-partum.544 Classic 
ASCVD risk factors are associated with ACS during pregnancy. 
Recommendation Table 11 ‚Äî Recommendations for venous thromboembolic diseases and pregnancy (see Evidence 
Tables 9 and 10) 
Recommendations 
Classa 
Levelb  
For pregnant or post-partum women at high riskc of VTE, a prophylactic fixed dose of LMWH is recommended over a higher 
weight-adjusted dose to reduce the risk of VTE.519 
I 
B 
In pregnant women or women in the post-partum period with suspicion of VTE (DVT and/or PE), an immediate formal diagnostic 
assessment with validated methods is recommended and should not be postponed.525,526 
I 
B 
In pregnant women or women in the post-partum period with newly diagnosed VTE (DVT and/or PE), the involvement of the Pregnancy 
Heart Team, including a vascular specialist and a haematologist, is recommended. 
I 
C 
In pregnant or post-partum women with a diagnosis of VTE without haemodynamic instability, anticoagulation is recommended by using 
therapeutic-dose LMWH based on early pregnancy body weight.212,532 
I 
C 
In pregnant women or women in the post-partum period with a strong clinical suspicion of VTE, initiation of treatment with a therapeutic 
dose of LMWH should be considered until the presence of VTE has been ruled out or confirmed. 
IIa 
C 
In pregnant or post-partum women with a diagnosis of acute high-risk PE,d a catheter-based reperfusion strategy or systemic thrombolysis 
should be considered.533‚Äì535 
IIa 
C 
In pregnant or post-partum women with a diagnosis of acute high-risk PE,d surgical thrombectomy may be considered as an alternative to a 
catheter-based approach or systemic thrombolysis.533‚Äì535 
IIb 
C 
¬© ESC 2025
DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; VTE, venous thromboembolism. 
aClass of recommendation. 
bLevel of evidence. 
cSee Supplementary data online, Table S5 for VTE risk factors. 
dAccording to the Pulmonary Embolism Severity Index from the 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism.536


<!-- PAGE 53 -->

### Page 53

Management of chest pain during pregnancy and up to 6 months post-partum
‚Ä¢ Check for vital signs
‚Ä¢ Perform: ECG, hs-cTn, TTE
‚Ä¢ Assess: week of gestation, cardiovascular risk factors, previous CAD, DVT, family history of DVT/PE, 
 family history of aortic disease  
a
Suspicion of 
Other cause of chest pain 
Acute coronary syndrome 
Pulmonary embolism 
Acute aortic syndrome 
CT
Consult aortic team 
Go to algorithm 
on PE 
Check diÔ¨Äerential diagnoses e.g.:  
‚Ä¢ Myocarditis and pericarditis
‚Ä¢ Gastroesophageal reÔ¨Çux
‚Ä¢ Amniotic Ô¨Çuid embolism
‚Ä¢ Musculoskeletal pain
Non-high risk
High-risk
Very high-risk
Inpatient invasive strategy
Immediate invasive strategy 
Selective invasive strategy
Diagnosis of
ASCVD
SCAD
MINOCA
Takotsubo
Additional examinations
Haemodynamically stable
Haemodynamically unstable or ongoing ischaemia
Conservative management 
PCIb or CABG or conservative management
PCIb or urgent
CABG
Figure 11 Management of chest pain during pregnancy and within 6 months post-partum. ASCVD, atherosclerotic cardiovascular disease; B-blocker, beta- 
blocker; CABG, coronary artery bypass graft; CAD, coronary artery disease; CT, computed tomography; DVT, deep venous thrombosis; ECG, electrocardiogram; EF, ejection fraction; hs-cTn, high sensitivity cardiac troponin; i.v., intravenous; MINOCA, myocardial infarction with non-obstructive coronary arteries; o.d., once a day; PCI, percutaneous coronary intervention; PE; pulmonary embolism; SCAD, spontaneous coronary artery dissection; TTE, 
transthoracic echocardiogram. aIn patients without very high or high-risk features and a low index of suspicion for unstable angina. bDual anti-platelet therapy: 
clopidogrel: loading dose of 300‚Äì600 mg orally, followed by an oral maintenance dose of 75 mg o.d. Aspirin: loading dose of 150‚Äì300 mg orally or 75‚Äì250 mg 
i.v. if oral ingestion is not possible, followed by an oral maintenance dose of 75‚Äì100 mg o.d.   
ESC Guidelines                                                                                                                                                                                               53


<!-- PAGE 54 -->

### Page 54

Additional risk factors are pre-eclampsia, thrombophilia, transfusion, post-partum infection, multiparity, and PPH. Pregnancies 
that required fertility treatment have not been shown to have an 
increased risk of ACS.547 
Pregnancy-associated SCAD is the single most frequent cause of ACS 
during pregnancy and post-partum (43%),548 followed by atherosclerotic 
lesion (27%), coronary embolism (17%), and vasospasm (2%).239 
Coronary thromboembolism may be due to pregnancy-related hypercoagulability and paradoxical embolization.549 Vasospasm has been associated with the use of ergot derivatives prescribed for lactation 
suppression or to treat PPH.549 
12.2.1.2. Presentation and diagnosis 
Clinical presentation of ACS in pregnancy is the same as in the non- 
pregnant population. However, pregnant women with SCAD tend 
to have a more severe clinical presentation than women with 
non-SCAD ACS.550‚Äì553 
An ACS in pregnancy should be suspected in women presenting with 
cardiac arrest, acute onset chest pain, dyspnoea, ischaemic changes on 
ECG, or elevated cardiac biomarkers.551,554 Diagnostic evaluation 
should follow ACS strategies (Figure 11).555‚Äì557 Major ischaemic ECG 
changes due to pregnancy itself are not expected (Figure 1). 
Invasive coronary angiography during pregnancy should be reserved 
for those with ACS, or when other diagnostic methods are inappropriate. ECG changes, such as transient ST-segment depression and T-wave 
inversion can be normal during pregnancy, but a serum troponin rise 
suggests myocardial injury as in non-pregnant women. ST elevation is 
not normal in pregnancy and warrants urgent attention.558 
ST-elevation myocardial infarction (STEMI) in pregnant women involves the anterior wall in 70%‚Äì80% of cases.239,558 In more than half 
the cases, a reduction of LVEF <40% is observed, leading to a high incidence of complications.20 Myocardial infarction with non-obstructive 
coronary arteries (MINOCA) should be considered a working diagnosis 
warranting further investigation.559 
12.2.1.3. Pregnancy-associated spontaneous coronary artery 
dissection 
Pregnancy-associated SCAD affects 1.81 per 100 000 pregnancies560 
and may occur at any time during or after pregnancy, although >70% 
occur early post-partum, most commonly within the first week.550 
Multiple predisposing factors have been described, including oestrogen 
and progesterone surges causing structural changes to the coronary tunica media. SCAD predominantly occurs in the left-sided coronaries, 
with multivessel involvement.561 
Percutaneous coronary intervention (PCI) in SCAD is associated 
with an increased risk of complications, particularly iatrogenic dissection and haematoma extension.562 For this reason, a conservative approach to revascularization is advised in clinically stable women with 
SCAD without active or ongoing ischaemia.539,563 If SCAD involves 
the left main coronary artery or proximal vessels, a coronary artery bypass graft (CABG) may be considered depending on technical considerations and local expertise.539 A multidisciplinary team should 
decide whether the patient is a candidate for PCI or CABG. 
Optimal medical management following SCAD is unknown but is 
currently being investigated in an ongoing clinical trial.562 Limited observational data suggest that beta-blockers (e.g. labetalol) and avoiding 
hypertension may be associated with a lower risk of recurrent 
SCAD.564,565 The role of antiplatelet therapies in conservatively managed SCAD has been controversial, with evidence favouring single 
antiplatelet therapy with aspirin.563,566 Women with a history of 
SCAD should be carefully counselled regarding the risk of recurrent 
events in subsequent pregnancy.567,568 
12.2.2. Coronary artery interventions 
The indications for acute revascularization are comparable to those 
for non-pregnant women. In patients with high or very high-risk ACS, 
immediate coronary angiography and PCI, if indicated, are recommended.557 Moreover, an early invasive strategy with coronary angiography is recommended for pregnant women with a confirmed or a 
working diagnosis of non-ST-elevation ACS (NSTE ACS) and with a 
high index of suspicion for unstable angina. In atherosclerotic lesions557 
PCI is indicated when there is ongoing or recurrent chest pain, haemodynamic instability, or ongoing ischaemia due to functionally significant 
coronary stenoses or acute occlusions.122 
The choice of coronary stents should not be different from that for 
non-pregnant women. Duration of DAPT should follow recommendations for non-pregnant patients with an individual approach considering ischaemic and delivery-related risks, including bleeding risk during delivery 
and neuraxial anaesthesia. Stents approved for short DAPT may be preferred during pregnancy in specific cases according to gestational age and 
timing of delivery. In the case of coronary embolism, thrombo-aspiration 
and/or a simple angioplasty can be performed.43,569 Invasive procedures 
should follow the ALARA principle (see Section 4.3.5). 
Systemic thrombolysis may be an alternative reperfusion strategy if 
timely PCI is not available. Recombinant tissue plasminogen activator 
does not cross the placenta but can induce bleeding complications, including subplacental. 
12.2.3. Chronic coronary syndromes in pregnancy 
Pregnant women with chronic coronary syndromes (CCS) are at high 
risk of adverse maternal and foetal outcomes: 32% have cardiovascular 
complications (including 9% with ischaemic cardiovascular complications) and there is 2% maternal mortality.570 The CARPREG II score, 
now also included in the mWHO 2.0 classification (Table 6, Section  
4), highlights the high risk of CCS as a predictor of maternal complications. When counselling women with CCS, pregnancy can preferably be 
considered when there is no residual ischaemia or LV dysfunction 12 
months after an index event. 
12.2.4. Management and delivery 
Women with ACS or CCS should be managed by a Pregnancy Heart 
Team. Treatment should be tailored to the underlying pathophysiology, 
although foetal considerations may affect the choice of therapy.50,571 
All pregnant women with ACS and their foetus should be monitored 
at an intensive cardiac care unit. 
The mode of delivery in a patient with gestational ACS or CCS 
should be determined by obstetric considerations and the clinical status 
of the mother. A vaginal delivery is indicated in most women with obstructive coronary artery disease (CAD). Vaginal delivery eliminates the 
potential risks associated with general anaesthesia and a major surgical 
procedure. Clopidogrel must be withheld a minimum of 5 days before 
neuraxial anaesthesia to reduce the risk of epidural hematoma.572 An 
elective caesarean section avoids a long or stressful labour and allows 
better control of the time of delivery. A plan for emergency delivery 
of a potentially viable foetus in case of sudden maternal deterioration 
should also be established. An arbitrary minimum time to delivery in 
stable women is at 2 weeks after ACS.18 
Lipid-lowering and antiplatelet therapy are described in Section 5.


<!-- PAGE 55 -->

### Page 55

12.3. Hypertensive disorders 
Hypertensive disorders of pregnancy are the second most common medical complications (after PPH), affecting 5%‚Äì15% of pregnancies worldwide, and are a major cause of maternal, foetal, and neonatal morbidity 
and mortality.583 Hypertensive disorders in pregnancy include pre-existing 
hypertension (chronic hypertension), gestational hypertension, and pre- 
eclampsia (Table 14). Over recent years an upward incidence trend has 
been observed due to older age at first childbirth and rising prevalence 
of obesity.586,587 Maternal risks include placental abruption, stroke, 
multiple organ failure, and disseminated intravascular coagulation.588 
Table 14 Hypertensive disorders of pregnancy 
A. Pre-existing (chronic) hypertension  
Hypertension which either precedes pregnancy or develops before 20 weeks gestation, usually persisting >6 weeks post-partum, and which may be associated with 
proteinuria.  
(1) 
Primary hypertension  
(2) 
Secondary hypertension  
(3) 
White-coat hypertension  
(4) 
Masked hypertension  
B. Gestational hypertension 
Hypertension which develops after 20 weeks gestation and usually resolves within 6 weeks post-partum. 
Transient gestational hypertension 
Usually detected in the clinic but then settles with repeated BP measurements taken over several hours; associated with a 40% risk of developing true gestational 
hypertension or pre-eclampsia in the remainder of the pregnancy, thus requiring careful follow-up. 
C. Pre-eclampsia 
Gestational hypertension accompanied by one or more of the following new-onset conditions at or after 20 weeks gestation: 
‚Ä¢ Proteinuria [urinary albumin excretion in a 24 h urine sample >0.3 g/day or UACR in a random spot urine sample >30 mg/mmol (0.3 mg/mg)] 
‚Ä¢ Other maternal organ dysfunction including: 
‚Ä¢ Acute kidney injury (serum creatinine ‚â•90 Œºmol/L; 1 mg/dL) 
‚Ä¢ Liver dysfunction (elevated ALT or AST >40 IU/L; >0.67 Œºkat/L with or without right upper quadrant or epigastric abdominal pain) 
‚Ä¢ Neurological complications (e.g. eclampsia/convulsions, altered mental status, blindness, stroke, clonus, severe headaches, persistent visual scotomata) 
‚Ä¢ Haematological complications (platelet count <150 000/ŒºL, disseminated intravascular coagulation, haemolysis) 
‚Ä¢ Uteroplacental dysfunction (IUGR, abnormal umbilical artery Doppler waveform analysis, or stillbirth).  
D. Pre-existing hypertension + superimposed pre-eclampsia 
Pre-existing hypertension associated with any of the above maternal organ dysfunctions consistent with pre-eclampsia or a further increase in BP with new-onset 
proteinuria. 
E. Antenatally unclassifiable hypertension 
When BP is first recorded after 20 weeks gestation and hypertension is diagnosed, reassessment is necessary at or after 6 weeks post-partum. If hypertension 
resolves, it should be reclassified as gestational hypertension, whereas if hypertension persists, it should be reclassified as pre-existing/chronic hypertension. 
¬© ESC 2025
Based on Mancia et al.584 and McEvoy et al.585 
ALT, alanine transaminase; AST, aspartate aminotransferase; BP, blood pressure; IUGR, intrauterine growth restriction; UACR, urine albumin‚Äìcreatinine ratio.  
Recommendation Table 12 ‚Äî Recommendations for coronary artery disease and pregnancy (see Evidence Table 11) 
Recommendations 
Classa 
Levelb  
In pregnant women with chest pain, it is recommended to exclude life-threatening cardiovascular conditions, including PE, ACS (including 
SCAD), and acute aortic syndrome.538,539 
I 
C 
It is recommended to manage pregnant women with ACS in the same way as non-pregnant women, including diagnostic investigations and 
interventions.557 
I 
C 
Low-dose ASA is recommended as the antiplatelet treatment of choice during pregnancy and lactation when single antiplatelet treatment is 
indicated.573‚Äì579 
I 
B 
If DAPT is required, clopidogrel is recommended as the P2Y12 inhibitor of choice during pregnancy.239 
I 
C 
The duration of DAPT (aspirin and clopidogrel) in pregnant women undergoing coronary stent implantation is recommended to be the 
same as in non-pregnant women, with an individual approach considering ischaemic risk and delivery-related bleeding risks.239 
I 
C 
A vaginal delivery should be considered in most pregnant women with ACS, depending on LV function and clinical symptoms. 
IIa 
C 
Continuation of statins may be considered during pregnancy in women with established ASCVD.580‚Äì582 
IIb 
C 
¬© ESC 2025
ACS, acute coronary syndrome; ASA, acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; DAPT, dual antiplatelet therapy; LV, left ventricular; PE, pulmonary embolism; SCAD, 
spontaneous coronary artery dissection. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               55


<!-- PAGE 56 -->

### Page 56

The foetus is at high risk of IUGR prematurity, and intrauterine death 
(25%, 27%, and 4%, respectively, in cases of pre-eclampsia).589 
12.3.1. Definition and classification of hypertension in 
pregnancy 
Hypertension in pregnancy is typically defined as systolic blood pressure (BP) of ‚â•140 mmHg and/or diastolic BP of ‚â•90 mmHg,585 
measured using repeated BP readings in the office or hospital on 
two separate occasions or ‚â•15 min apart in severe hypertension 
(‚â•160/110 mmHg).584,590 
12.3.1.1. Pre-eclampsia/eclampsia 
Pre-eclampsia is defined as gestational hypertension complicated by 
new onset of the laboratory or clinical changes reported in Table 14 
at or after 20 weeks. Eclampsia is defined as the new onset of seizures 
or coma in a pregnant woman with pre-eclampsia.584,585 
The combination of haemolysis, thrombocytopenia, and elevated 
transaminases defines HELLP syndrome, which is usually considered 
to be a variant of pre-eclampsia.43 Risk factors for pre-eclampsia are described in Table 15. 
12.3.2. Diagnosis and risk assessment 
12.3.2.1. Blood pressure measurement 
Maternal BP should be assessed at each encounter and should be measured 
in the sitting position (or the left lateral recumbent position during labour) 
with an appropriately sized arm cuff at heart level and using Korotkoff V for 
diastolic BP. Mercury sphygmomanometers remain the gold standard for BP 
measurement in pregnancy as automatic devices tend to under-record BP 
and are unreliable in severe pre-eclampsia. Only automatic devices specifically validated for pregnancy should be used.584,591 
The diagnosis of hypertension in pregnancy by ambulatory BP monitoring is superior to office BP measurements or home BP monitoring 
for the prediction of pregnancy outcomes.584,592 Ambulatory BP monitoring avoids unnecessary treatment of white-coat hypertension, and is 
useful in the management of high-risk pregnant women with hypertension and those with diabetic or hypertensive nephropathy.593,594 Either 
home BP monitoring or office BP measurements may be used alternatively or complementarily to diagnose hypertensive disorders during 
pregnancy in women at risk of pre-eclampsia. 
However, among pregnant women with pre-existing or gestational 
hypertension, home BP monitoring is not associated with better BP 
control compared with scheduled office BP measurements.584,595,596 
Either can be used for BP monitoring.595,596 
12.3.2.2. Laboratory tests 
Basic laboratory investigations recommended for monitoring hypertensive disorders of pregnancy include urinalysis, blood count, haematocrit, liver enzymes, serum creatinine, and serum uric acid. All 
pregnant women should be assessed for proteinuria in early pregnancy 
to detect pre-existing renal disease and, in the second half of pregnancy, 
to screen for pre-eclampsia.43 
In addition to basic laboratory tests, the following investigations may 
be considered: 
‚Ä¢ Ultrasound of the adrenals, and plasma and urinary fractionated metanephrine assays. 
‚Ä¢ Doppler ultrasound of uterine arteries (after 20 weeks of gestation).597 
‚Ä¢ A ratio of soluble fms-like tyrosine kinase-1 (sFlt-1) to placental 
growth factor (PlGF) of <38 can be used to reliably exclude the development of pre-eclampsia over the next 7 days when clinically 
suspected.43,598  
If women with chronic hypertension are suspected of developing 
pre-eclampsia, testing for PlGF may help rule out pre-eclampsia between 20 and 36 weeks.599,600 
12.3.3. Management of hypertension in pregnancy 
Management of hypertension in pregnancy depends on the woman‚Äôs 
BP and gestational age, and the presence of associated maternal and foetal risk factors.601,602 In pregnant women with BP >160/110 mmHg, hospital admission is recommended603 (Figure 12A). If BP is ‚â•140‚Äì159/90‚Äì 
99 mmHg, BP control is mandatory with a BP target of <140/90 mmHg. 
In two large trials,583,604 tight diastolic BP control (<85‚Äì90 mmHg) in 
women with pre-existing hypertension was superior to less tight diastolic BP control (<100‚Äì105 mmHg) and caused no harm. 
In pregnant women with diagnosed hypertension, blood tests, clinical 
examination, and assessment of proteinuria are mandatory and should 
be repeated regularly.599 If a urine dipstick is positive or borderline for 
proteinuria, and symptoms and laboratory tests (including biomarker 
assessment) are indicative of pre-eclampsia, the diagnosis of pre- 
eclampsia can be made and hospital admission is recommended where 
there are clinical concerns.599 
12.3.3.1. Non-pharmacological management 
Pregnant women with hypertension should be advised to follow a 
healthy lifestyle including physical activity, smoking cessation, a healthy 
diet, and control of body weight. Lifestyle changes before and during 
pregnancy may ameliorate both maternal and foetal risks.605 Salt restriction is not advised to reduce hypertensive disorders during pregnancy, but it is reasonable for women with pre-existing hypertension 
to continue with a low sodium diet.584 Unless contraindicated, aerobic 
exercise should be recommended in pregnant women with hypertension to maintain ideal body weight and reduce adverse pregnancy 
Table 15 Risk factors for pre-eclampsia 
High risk factors for pre-eclampsia  
Hypertensive disorders during a previous pregnancy 
Chronic hypertension 
Chronic kidney disease 
Type 1 or type 2 diabetes mellitus 
Autoimmune diseases such as systemic lupus erythematosus or 
antiphospholipid syndrome 
Assisted reproductive therapy in the current pregnancy 
Moderate risk factors for pre-eclampsia 
Nulliparity 
Age ‚â•40 years 
Pregnancy interval of more than 10 years 
BMI ‚â•35 kg/m2 at the first visit 
Family history of pre-eclampsia 
Multi-foetal pregnancy 
¬© ESC 2025
Based on Mancia et al.584 and McEvoy et al.585 
BMI, body mass index.


<!-- PAGE 57 -->

### Page 57

outcomes.606 Obese women are advised to avoid an increase in weight 
of more than ‚àº7 kg from pre-conception.601 
Calcium supplements are recommended for the prevention of pre- 
eclampsia in women with a low dietary intake of calcium (<600 mg/ 
day),607 where low-dose calcium supplementation (<1 g/day) has 
been shown to be as effective as high-dose (‚â•1 g/day).608 
12.3.3.2. Pharmacological treatment 
12.3.3.2.1. Mild hypertension (BP 140/90 ‚Äì 159/109 mmHg). In 
mild gestational hypertension it seems reasonable to initiate treatment 
at BP values of 140/90 mmHg,583,609 whereas a diastolic BP reduction 
to <80 mmHg is not recommended. 
Methyldopa, beta-blockers (most data are available for labetalol), 
and dihydropyridine CCBs (most data are available for nifedipine) 
are the drugs of choice for mild gestational and pre-existing 
hypertension.584 
ACE-Is, ARBs, and direct renin inhibitors are strictly contraindicated. 
Diuretics are not advised in gestational hypertension and pre-eclampsia, 
due to the reduction of intravascular volume and reduction of uteroplacental perfusion and thereby possible foetal adverse effects. 
12.3.3.2.2. Pre-eclampsia. Pre-eclampsia may require hospital admission, but not all women will require ongoing hospitalization and care 
should be individualized (Figure 12B and Figure 12C). Women with 
at least one high-risk factor or two moderate-risk factors for pre- 
eclampsia (Table 15) should be advised to take 75‚Äì150 mg aspirin daily 
at bedtime from week 12 to week 36/37.599,610 We advise discontinuation of low-dose aspirin at week 36/37 when the aspirin indication is 
pre-eclampsia. 
Pre-eclampsia with severe features (severe hypertension with or 
without proteinuria, any hypertension grade with neurological, haematological, or cardiovascular complications, liver dysfunction, or renal 
dysfunction) should be managed with a magnesium sulfate infusion 
to prevent eclampsia, in addition to early delivery.43,611 Magnesium 
toxicity can present with cardiac effects, including ECG interval 
changes (prolonged PR, QRS, and QT intervals) at magnesium levels 
of 2.5‚Äì5 mmol/L, and can progress to atrioventricular (AV) nodal conduction block, bradycardia, hypotension, and cardiac arrest at levels of 
6‚Äì10 mmol/L. If magnesium toxicity is suspected, it is recommended 
to stop the magnesium infusion and give 30 mL i.v. calcium gluconate.612‚Äì614 
Management of pregnant women with hypertension
BP 140/90 to 159/109 mmHg
BP ‚â•160/‚â•110 mmHg
Admission to hospital
(Class I)
Do not admit routinely
Proteinuria or maternal organ dysfunction or 
uteroplacental dysfunctiona
Pre-eclampsia
Aim for BP <140/90 mmHg 
(Class I)
Evaluate level of care
Regular monitoringb
Figure 12A Management of hypertension and pre-eclampsia in the emergency ward. BP, blood pressure; N, no; Y, yes.  
a See Figure 12B.  
b See Figure 12C.   
ESC Guidelines                                                                                                                                                                                               57


<!-- PAGE 58 -->

### Page 58

Hypertension (BP ‚â•140/90 mmHg) 
Pre-eclampsia diagnosed
Proteinuria
Evaluate
Albumin/creatinine ratio ‚â•8 mg/mmol 
Protein/creatinine ratio ‚â•30 mg/mmol 
OR
One or more clinical features of pre-eclampsia
OR
Symptoms
‚Ä¢ Headache
‚Ä¢ Vision problems
‚Ä¢ Breathing problems
‚Ä¢ Severe pain below 
 the ribs
‚Ä¢ Vomiting
‚Ä¢ Oedema
‚Ä¢ Trouble urinating
 
Laboratory
Biomarker sFlt-1/PIGF ‚â•85
or PIGF <12 pg/mL
Positive
Positive
Inconclusive
Uteroplacental dysfunction (foetal growth restriction,
abnormal umbilical artery Doppler waveform analysis, 
or stillbirth)
OR
‚Ä¢ Haemolysis
‚Ä¢ Deterioration of renal
 function
‚Ä¢ Abnormal liver tests
‚Ä¢ Falling platelet count
 
Figure 12B Proteinuria assessment and diagnosis of pre-eclampsia. BP, blood pressure; PlGF, placental growth factor; sFLt-1, soluble fms-like tyrosine 
kinase-1.


<!-- PAGE 59 -->

### Page 59

Monitoring and treatment of hypertension and pre-eclampsia
BP 140/90‚àí159/109
mmHg
BP ‚â•160/110
mmHg
Pre-eclampsia
Hypertension
BP 140/90‚àí159/109
mmHg
BP ‚â•160/110
mmHg
Every
15‚àí30 min
At least every 48 h
(more frequently if admitted)
Every
15‚àí30 min
Once or twice
 a week
Once or twice a week
Daily
Only repeat if clinically indicated
BP monitoring schedule
Screening for proteinuria
Once a week
OÔ¨Äer PIGF-based testing once,
if pre-eclampsia is suspected
Twice a week
3 times a week
Blood tests: full blood count,  liver function, renal function
Treatment 
p.o. labetalola or metoprololb
(Class I)
Monitoring p.o. methyldopac
(Class I)
i.v. labetalol,  i.v. nicardipine,
 i.v. urapidil, i.v. Mg++
(Class I)
p.o. nifedipined
(Class I)
Figure 12C Monitoring and treatment of hypertension and pre-eclampsia. Mg, magnesium; PlGF, placental growth factor; p.o., per oral.  
aLabetalol 100 mg p.o. b.i.d. bMetoprolol 100 mg p.o. b.i.d. cMethyldopa 250 mg p.o. b.i.d./t.i.d. dNifedipine 5‚Äì10 mg p.o. 10 mg p.o. if >160/110 mmHg.   
ESC Guidelines                                                                                                                                                                                               59


<!-- PAGE 60 -->

### Page 60

12.3.3.2.3. Severe hypertension (BP ‚â•160/110 mmHg). In severe 
hypertension, assessment and gradual BP reduction to <160/ 
110 mmHg is mandatory in a hospital setting. Continuous cardiotocographic monitoring is also compulsory. The selection of antihypertensive drugs and the route of administration depend on initial diagnosis, 
expected delivery time, presence or absence of pre-eclampsia, and 
the preferences and experience of the attending physicians.43,611 
Recent comprehensive meta-analyses comparing commonly used antihypertensive drugs (e.g. oral nifedipine, labetalol, methyldopa) 
(Figure 12C) showed they had similar efficacy in lowering BP in severe 
hypertension in pregnancy, with nifedipine showing superiority in some 
studies (see Section 5.2.6).43,253,254,611,615 Nifedipine also has the advantage of wider distribution, availability, and lower pricing. Available data 
showed that hydralazine is less effective than other drugs and is associated with more side effects.616 Hydralazine is therefore a second-line 
option to be used only if other drugs are not available. 
In cases of pre-eclampsia with severe features, persistent severe 
hypertension, or recurrent severe hypertension despite orally administered agents, i.v. administration of labetalol (or nicardipine) is advised. Intravenous urapidil can also be used but may not be available 
in all countries.611,617,618 Sodium nitroprusside is the drug of last resort because prolonged treatment is associated with an increased 
risk of foetal cyanide poisoning.619 The drug of choice when 
pre-eclampsia is associated with pulmonary oedema is nitroglycerine 
(glyceryl trinitrate), given as an i.v. infusion of 5 Œºg/min, gradually 
increasing every 3‚Äì5 min to a maximum dose of 100 Œºg/min, in combination with diuretics.43,611 
12.3.4. Hypertension and delivery 
A recent randomized controlled trial from the United Kingdom found 
that once a diagnosis of pre-eclampsia was made in women with late 
pre-term pre-eclampsia (34‚Äì37 weeks), there was a lower rate of maternal morbidity and less severe maternal hypertension when delivery 
was planned to occur within the next 48 h.620 However, a greater proportion of neonates were admitted to the neonatal intensive care unit 
compared to mothers who were managed from an earlier stage. 
Decisions around timing of delivery should be individualized considering 
both maternal and foetal well-being. If well managed hypertension 
alone, delivery should be planned around 39 weeks of gestation. 
When choosing the mode of delivery, the clinical scenario should 
take into consideration the current gestational age and a full foetal assessment, as well as the preference of the mother. If induction of labour is to be considered, continuous foetal monitoring is required. 
Women with severe pre-eclampsia benefit from neuraxial anaesthesia 
to reduce the hypertensive response to pain. Additionally, an epidural 
will provide adequate anaesthesia should a caesarean delivery be 
required. 
After delivery, methyldopa should be avoided due to the risk of 
post-partum depression. Methyldopa should be stopped within 2 
days after delivery and changed to an alternative treatment. 
Recommendation Table 13 ‚Äî Recommendations for hypertensive disorders and pregnancy (see Evidence Tables 
12‚Äì17) 
Recommendations 
Classa 
Levelb  
It is recommended to aim for systolic BP <140 mmHg and diastolic BP <90 mmHg in pregnant women.583,585,609 
I 
B 
Systolic BP ‚â•160 mmHg or diastolic BP ‚â•110 mmHg in a pregnant woman is an emergency, and treatment in a hospital setting is 
recommended.43,584 
I 
C 
Low-dose aspirin (75‚Äì150 mg daily) is recommended in women at moderate or high risk of pre-eclampsia (i.e. at least one high-risk factor or 
two moderate-risk factors for pre-eclampsia) from weeks 12 to 36/37.610,621,622 
I 
A 
In women with gestational hypertension, initiation of drug treatment is recommended at systolic BP ‚â•140 mmHg or diastolic BP 
‚â•90 mmHg.c583‚Äì585,609 
I 
B 
Methyldopa is recommended for the treatment of hypertension in pregnancy.623,624 
I 
B 
Labetalol, metoprolol, and dihydropyridine CCBs are recommended for the treatment of hypertension in pregnancy.623 
I 
C 
In severe hypertension, drug treatment with i.v. labetalol, urapidil, nicardipine, or oral short acting nifedipine or methyldopa is 
recommended for acute reduction in blood pressure.625,626 Intravenous hydralazine is a second-line option. 
I 
C 
In pre-eclampsia associated with pulmonary oedema, nitroglycerine given as an i.v. infusion is recommended.627 
I 
C 
In women with pre-eclampsia without severe features, delivery is recommended at 37 weeks.620,628 
I 
B 
It is recommended to expedite delivery in women with pre-eclampsia associated with adverse markers such as haemostatic disorders.629 
I 
C 
In women with gestational hypertension, delivery is recommended at 39 weeks.620,628 
I 
B 
Ambulatory BP or home BP monitoring should be considered to exclude white-coat and masked hypertension, which are common in 
pregnancy. 
IIa 
C 
Home BP monitoring may be considered as an adjunct to office BP measurements in pregnant women to detect new-onset hypertension or 
for monitoring BP control.595,596 
IIb 
B 
¬© ESC 2025
BP, blood pressure; CCB, calcium channel blocker; i.v, intravenous. 
aClass of recommendation. 
bLevel of evidence. 
cOffice BP measurements.


<!-- PAGE 61 -->

### Page 61

12.4. Arrhythmias 
The number of pregnant women presenting with arrhythmia is rising 
due to increasing age at pregnancy and cardiovascular risk factors 
such as obesity, hypertension, diabetes, and CAD in pregnant women.630 Haemodynamic, metabolic, and hormonal changes, and 
changes in autonomic function may contribute to increased arrhythmogenesis during pregnancy and women with prior history of arrhythmia 
may experience worsening of symptoms during pregnancy 
(Figure 13).630 Arrhythmia may have serious effects on the health of 
both the mother and the foetus and should be treated similarly to arrhythmias in non-pregnant women. 
12.4.1. Supraventricular arrhythmias 
12.4.1.1. New-onset narrow QRS tachycardia  
New-onset narrow QRS (<120 ms) tachycardias in pregnancy are 
treated according to haemodynamic stability. In all cases with 
haemodynamic instability caused by any supraventricular tachycardia 
(SVT) including AF and AFL, synchronized, direct current cardioversion is indicated (Figure 14).631 The foetal heart rate should be closely 
monitored after cardioversion.632 In haemodynamically stable narrow QRS tachycardias, the use of vagal manoeuvres (modified 
Valsalva manoeuvre, carotid sinus massage) may terminate an atrioventricular (nodal) re-entry tachycardia (AV(N)RT) arrhythmia.633 





	











		

	
¬Å
¬ç

		
¬è
¬è


	
¬ê

¬è

¬ù

	
	
	

	


	
Figure 13 Arrhythmogenesis in pregnant women. CV; cardiovascular.   
ESC Guidelines                                                                                                                                                                                               61


<!-- PAGE 62 -->

### Page 62

If these manoeuvres fail, i.v. adenosine (6‚Äì18 mg bolus) is recommended for termination of AV(N)RT. Intravenous beta-1-selective 
blockers (preferably metoprolol) can be administered for all SVTs, 
which either terminate the SVT or slow AV conduction and thereby 
the ventricular rate.634 Intravenous beta-1-selective blockers (metoprolol), non-dihydropyridine CCBs (verapamil), and digoxin can be 
used safely.635 In stable patients without structural heart disease, flecainide and ibutilide may be considered for termination of AF and 
AFL (Figure 15). In patients with congenital disease, synchronized, 
direct current cardioversion may be preferred. 
12.4.1.2. Atrial fibrillation including anticoagulation 
The incidence of arrhythmias among pregnant women is increasing, 
with AF being the most clinically relevant.252,271,636 Atrial enlargement 
during pregnancy is accompanied by increased atrial function and both 
size and function of the left atrium reverse after normal pregnancy.637 
Atrial fibrillation is more frequent in pregnant women at older age, with 
high BMI638, with ACHD, or with predisposing acquired conditions (e.g. 
hypertension, HF).637 Compared to women <25 years of age, the 
odds ratio (OR) of AF episodes was 5.2 in women aged ‚â•40, and the 
OR was higher in the third compared to the first trimester.638 Rapid 
atrioventricular conduction of AF may have serious haemodynamic 
consequences for both mother and foetus. Atrial fibrillation during 
pregnancy is associated with increased maternal death.639 Atrial flutter 
in pregnant women most often occurs in the presence of ACHD or 
valvular heart disease (VHD) and in metabolic disturbances such as 
thyrotoxicosis or electrolyte disturbances. 
Direct current cardioversion in pregnancy is required in haemodynamically unstable patients with monitoring of foetal heart rate 
(Figure 15).250,268,271 Rhythm control is the preferred AF treatment 
strategy during pregnancy. For women with structurally normal hearts, 
anti-arrhythmic drugs (e.g. flecainide and sotalol, see Section 5.2.5) are 
not associated with foetal harm, although sotalol‚Äôs beta-blocker effect 
necessitates monitoring of foetal growth.250,268,271 There are minimal 
data on the use of propafenone during pregnancy, but this sodium channel blocker may be considered if flecainide is not available. Intravenous 
ibutilide or flecainide may be considered for termination of AFL and AF 
in haemodynamically stable patients.640 
The indication for anticoagulation with LMWH before cardioversion 
or the need for transoesophageal echocardiography should be evaluated as in non-pregnant women and be maintained for at least 4 weeks 
after cardioversion.636,641 
Management of narrow QRS tachycardia in pregnant women
Haemodynamically unstable SVT
Electrical cardioversion
(Class I)
Vagal manoeuvres:
Valsalva manoeuvre,
carotid sinus massage
(Class I)
i.v. beta-blockersb e.g. metoprololc
(Class I)
i.v. verapamild
(Class IIa)
Pad position:
sterno-apical/
antero-posterior 
Avoid breast tissue
Foetal heart rate monitoring i.v. adenosinea
(Class I) 
If sinus rhythm not achieved
OR
Haemodynamically stable SVT
Figure 14 Management of narrow QRS tachycardia in pregnant women. i.v., intravenous; SVT, supraventricular tachycardia. aAdenosine 6‚Äì18 mg bolus. 
bAtenolol contraindicated. cMetoprolol 2.5‚Äì15 mg. dVerapamil 2.5‚Äì10 mg bolus over 5 min.


<!-- PAGE 63 -->

### Page 63

When a rate control strategy is needed in the case of (long-standing) 
persistent or permanent AF, beta-blockers, verapamil, or digoxin 
should be used, also in combination, taking into consideration the concomitant conditions affecting the mother.271,642 
Atrial fibrillation is a strong risk factor for cardioembolic events, 
and the hypercoagulable state of pregnancy may increase this risk. In 
pregnant women with persistent or permanent AF, the decision to anticoagulate is the same as in non-pregnant women and depends on the 
risk of thromboembolic events according to the CHA2DS2-VA score 
[congestive heart failure, hypertension, age ‚â•75 (doubled), diabetes, 
stroke (doubled), vascular disease, age 65‚Äì74].643 The CHA2DS2-VA 
score threshold of ‚â•2 to anticoagulate has not been validated in 
pregnancy.643,644 DOACs are contraindicated in pregnancy. The presence of mechanical valves or moderate to severe mitral stenosis require 
VKA (see Section 5.2.1 and Section 12.5). 
12.4.1.3. Pre-existing supraventricular tachycardia 
In women with AVNRT, atrioventricular re-entry tachycardia (AVRT), 
and focal atrial tachycardia (FAT), chronic oral prophylaxis can be 
achieved with beta-blockers (metoprolol) or verapamil. For women 
with drug-refractory SVT or who have a contraindication to these 
drugs, flecainide or sotalol are reasonable alternatives, as is propafenone if flecainide is not available. 
Management of atrial Ô¨Åbrillation and atrial Ô¨Çutter in pregnant women
Haemodynamically unstable AF/AFL
Electrical cardioversion
(Class I)
i.v. Ô¨Çecainidee
(Class IIb)
i.v. ibutilidef
(Class IIb)
Avoid amiodarone or dronedarone 
AF/AFL with pre-excitation and high ventricular rates
Haemodynamically stable AF/AFL
Severe structural heart disease
Pharmacological cardioversion
Acute rate control i.v.
beta-blockersa e.g. metoprololb
(Class I)
i.v.
verapamilc
(Class IIa)
i.v. digoxind
(Class IIa)
OR
OR
Figure 15 Management of atrial fibrillation and atrial flutter in pregnancy. AF, atrial fibrillation; AFL, atrial flutter; i.v., intravenous; N, no; SVT, supraventricular tachycardia; Y, yes. aAtenolol: contraindicated. bMetoprolol: 2.5‚Äì15 mg. cVerapamil: 2.5‚Äì1 mg bolus over 5 min. dDigoxin: 0.5 mg bolus, 0.75‚Äì1.5 mg 
over 24 h in divided doses. eFlecainide: 2 mg/kg over 10 min. fIbutilide: <60 kg: 0.01 mg/kg over 10 min, repeated after 10 min if necessary; ‚â•60 kg: 1 mg over 
10 min, repeated after 10 min if necessary.   
ESC Guidelines                                                                                                                                                                                               63


<!-- PAGE 64 -->

### Page 64

In pregnant women with AVRT and Wolff‚ÄìParkinson‚ÄìWhite (WPW) 
syndrome, arrhythmia episodes can be prevented by using oral flecainide, 
or propafenone when flecainide is not available. When AV-nodal blocking 
agents are used in WPW syndrome and AF occurs, the risk of rapid ventricular rates is increased. However, in pregnant women without documented AF, with known orthodromic AVRT, and with intermittent 
pre-excitation, long-term AV blockade is acceptable for prevention. 
If catheter ablation treatment is necessary, it should be performed by 
experienced operators in a centre equipped with non-fluoroscopic 
mapping techniques (Section 12.4.3.2). 
12.4.2. Ventricular arrhythmias 
New-onset VT and ventricular fibrillation (VF) arising during pregnancy 
are rare (18 per 100 000 pregnancy-related hospitalizations).652 The 
most common type of VT in pregnant women is idiopathic VT originating 
from the right ventricular outflow tract (RVOT) (Figure 16). When new- 
onset VT develops during the last 6 weeks of pregnancy or during the first 
month post-partum, underlying PPCM should be excluded.370 
The use of amiodarone is not recommended in pregnancy and 
should be limited to women with refractory or life-threatening arrhythmias that cannot be controlled with any other anti-arrhythmic therapy. 
If administered, it requires close monitoring for potential side effects in 
the foetus, such as bradycardia or IUGR. 
In women with known underlying substrates for VT, beta-blockers 
are recommended for prevention of VT.148,252 In case of refractoriness 
or contraindications to beta-blockers, anti-arrhythmic therapy with flecainide, sotalol, or quinidine is recommended, with the choice of drug 
based on the underlying cardiac substrate (Figure 16).148,252 Idiopathic 
RVOT-VT can be prevented with beta-blockers or verapamil.653 
When this is ineffective, flecainide654 or sotalol650,655‚Äì659 are safe options to consider for prophylaxis of idiopathic RVOT-VT. 
Recommendations on the acute management of ventricular arrhythmias during pregnancy are described in the 2022 ESC Guidelines for the 
management of patients with ventricular arrhythmias and the prevention of sudden cardiac death, and are depicted in Figure 16.252 
12.4.3. Cardioversion, ablation, and device 
implantation, and implantable cardioverter 
defibrillator management 
12.4.3.1. Electrical cardioversion 
Electrical cardioversion is safe and effective in all pregnancy phases as it 
does not affect foetal circulation or induce foetal arrhythmia. In pregnancy there are no changes in transthoracic impedance compared to 
non-pregnant women,660 and shock energies delivered should therefore be the same as in non-pregnant patients. The foetal heart rate 
should be monitored after cardioversion.631,632,661,662 
12.4.3.2. Catheter ablation 
Catheter ablation in pregnant women should preferably be performed 
after the first trimester in a centre with experience in non-fluoroscopic 
Recommendation Table 14 ‚Äî Recommendations for supraventricular tachycardia and pregnancy 
Acute management of SVT and AF 
Classa 
Levelb  
Immediate electrical cardioversion is recommended for acute treatment of SVT with haemodynamic instability. 
I 
C 
Vagal manoeuvres and i.v. adenosine are recommended for conversion of haemodynamically stable supraventricular tachycardias.645 
I 
C 
Intravenous beta-blockersc (e.g. metoprolol) are recommended as the first-line option for acute rate control in pregnant women with AF or 
AF with preserved LVEF and rapid ventricular rate.646 
I 
C 
Intravenous digoxin or verapamil (if preserved LVEF) should be considered as a second-line option for initial rate control in pregnant 
women with AF or AFL and rapid ventricular rate.635 
IIa 
C 
Ibutilide or flecainide may be considered for termination of AF and AFL in pregnant women without structural heart disease.640,647 
IIb 
C 
Long-term management of SVT and AF 
Therapeutic anticoagulation with LMWH is recommended for pregnant women with persistent or permanent AF at elevated 
thromboembolic risk.636,641 
I 
C 
Beta-1-selective blockersc are recommended for rate control in pregnant women with AF, AFL, or FAT.146,271,648 
I 
C 
Beta-1-selective blockersc or verapamil are recommended for the prevention of SVT in women without pre-excitation on resting 
ECG.146,268,649 
I 
C 
Flecainide or propafenone are recommended for the prevention of arrhythmias in pregnant women with WPW syndrome.650 
I 
C 
Digoxin or verapamil should be considered for rate control in pregnant women with AF, AFL, or FAT when beta-blockers fail or are not 
tolerated.146,271,645 
IIa 
C 
Flecainide, in addition to beta-blockers, should be considered for long-term AF rhythm control in pregnancy.250,268,271,640 
IIa 
C 
Sotalol may be considered for rhythm management of AF and AFL with controlling for pro-arrhythmic risk factors as in non-pregnant 
women.651 
IIb 
C 
Catheter ablation may be considered in pregnant women with recurrent, long symptomatic SVT, or with contraindications to 
pharmacological therapies. 
IIb 
C 
¬© ESC 2025
AF, atrial fibrillation; AFL, atrial flutter; ECG, electrocardiogram; FAT, focal atrial tachycardia; i.v., intravenous; LMWH, low-molecular-weight heparin; LVEF, left ventricular ejection fraction; 
SVT, supraventricular tachycardia; WPW, Wolff‚ÄìParkinson‚ÄìWhite. 
aClass of recommendation. 
bLevel of evidence. 
cExcept for atenolol.


<!-- PAGE 65 -->

### Page 65

electro-anatomical mapping and catheter navigation systems.663‚Äì665 
Catheter ablation for drug-refractory and poorly tolerated VT or for 
recurrent drug-refractory AVNRT, AVRT, FAT, cavotricuspid isthmus- 
dependent AFL, and certain benign right-sided VTs may be considered 
to avoid potentially harmful anti-arrhythmic drug effects during pregnancy, although it has no role in AF.664,666 
12.4.3.3. Device implantation 
An ICD is indicated in pregnant women who are at high risk of sudden 
cardiac death.252 Implantation of a device is not associated with a higher risk of major complications and can be performed safely,667,668 particularly after 8 weeks of gestation. During implantation, radiation 
exposure should be minimized following the ALARA principle (see 
Management of ventricular tachycardia in pregnancy
Pharmacological acute conversion and/or management of recurrent VT/VF
Electrical cardioversion
(Class I)
Idiopathic
RVOT-VT
i.v. beta-blockers
(Class IIa)
i.v adenosine
(Class IIa)
i.v. procainamide
(Class IIa)
i.v. beta-blockers
(routine usage)
Long QT or
Torsade de
Pointes VT
Remove 
precipitating 
factors
Overdrive pacing i.v. Mg++/K+
i.v. beta-blockers
(e.g. propranolol)
(Class I)
Brugada 
syndrome i.v. isoproterenol p.o. quinidine
(Class IIa)
Idiopathic VF
i.v. verapamil p.o. quinidine
Failure of pharmacologic conversion/control i.v. isoproterenol
Structural heart disease i.v. beta-blockers
(routine usage)
Unknown/ 
other aetiology
Fascicular VT
i.v verapamil
(Class IIa)
CPVT
i.v. beta-blockers
(Class I)
Figure 16 Management of ventricular tachycardias in pregnancy. CPVT, catecholaminergic polymorphic ventricular tachycardia; i.v., intravenous; N, no; 
RVOT, right ventricular outflow tract; VF, ventricular fibrillation; VT, ventricular tachycardia; Y, yes. See Supplementary data online (Table S6) for medication 
dosages. Adapted from Zeppenfeld et al.252.   
ESC Guidelines                                                                                                                                                                                               65


<!-- PAGE 66 -->

### Page 66

Section 4.3.5) or with non-fluoroscopic imaging techniques.669 
Women with an ICD should maintain their regular ICD care throughout pregnancy.669 
12.4.3.4. Implantable cardioverter defibrillator management 
Routine ICD interrogation and guidance are recommended prior to delivery. Management of pregnant women with an ICD or pacemaker is 
summarized in Figures 17 and 18. 
Women with structural heart disease are at higher risk of atrial and 
ventricular tachyarrhythmias during pregnancy.670 Consequently, pregnant women with ICDs may present with either an inappropriate shock 
(due to e.g. lead defects, new-onset supraventricular tachyarrhythmias, 
or technical issues such as T-wave oversensing or noise sensing) or an 
appropriate ICD shock caused by ventricular tachyarrhythmias. In case 
of tachyarrhythmia, triggering events such as HF, electrolyte abnormalities, ischaemia, or infectious disease should be ruled out, as with non- 
pregnant women. Depending on the underlying cause, therapy consists 
of device reprogramming or initiating or adapting anti-arrhythmic drug 
therapy. In the case of drug-refractory arrhythmias or serious anti- 
arrhythmic drug side effects, catheter ablation may be considered in experienced centres.664 
Most data indicate that maternal ICD shocks do not have major foetal adverse effects.668,671 The approach to pregnant women presenting 
with ICD shocks is no different from non-pregnant women 
(Figure 18).252 
A WCD may be considered when pregnant women have an ICD indication from reversible conditions.365,672‚Äì674 





	

	








¬Å





	
¬Å
	
¬ç
	











¬è









¬ê



	
¬ç
	

	¬è¬Å
¬ç
¬ê
¬ù

¬ç
¬ù



¬Å



Figure 17 Management of pacemaker and implantable cardioverter defibrillator and pregnancy. b.p.m., beats per minute; ICD, implantable cardioverter 
defibrillator; VF, ventricular fibrillation; VT, ventricular tachycardia. aPatients with an increase in arrhythmias during pregnancy, history of ventricular tachyarrhythmias. bSingle zone configuration: VT detection at 250 b.p.m., prolonged detection duration, e.g. 30 out of 40 beats.


<!-- PAGE 67 -->

### Page 67

Management of implantable cardioverter deÔ¨Åbrillator shocks during pregnancy
ICD interrogation
Appropriate shocks
VT/VF
Programmer available
Inappropriate shocks
Haemodynamically stable
Reprogramme to avoid T-wave oversensing
Reprogramme to discriminate 
SVT
Position magnet over the ICD
Start advanced life support
(see related section)
Identify and treat triggers 
Anti-arrhythmic drug therapy 
(see related section)
If serious side eÔ¨Äects or drug refractoriness,
consider catheter ablation
(Class IIb)
Device reprogramming
Figure 18 Management of implantable cardioverter defibrillator shocks in pregnancy. ICD, implantable cardioverter defibrillator; N, no; SVT, supraventricular tachycardia; VF, ventricular fibrillation; VT, ventricular tachycardia; Y, yes.  
Recommendation Table 15 ‚Äî Recommendations for 
ventricular tachycardia, device implantation, catheter 
ablation, and pregnancy 
Recommendations 
Classa 
Levelb  
Immediate electrical cardioversion is recommended 
for both unstable and stable ventricular 
tachycardias.252 
I 
C 
Beta-blockers or verapamil are recommended for 
the prevention of idiopathic sustained VT. 
I 
C 
If an ICD, pacemaker, or resynchronization therapy 
device is indicated during pregnancy, implantation is 
recommended with optimal radiation 
protection.667,675 
I 
C 
In idiopathic RVOT-VT, flecainide should be 
considered if beta-blockers fail, to prevent 
recurrence. 
IIa 
C                                                                                                   
Continued 
For acute conversion of haemodynamically stable 
sustained VTs during pregnancy, i.v. beta-blocker, 
adenosine (idiopathic RVOT-VT), verapamil 
(fascicular VT), procainamide, or overdrive 
ventricular pacing (ICD lead) should be 
considered.252,653,676‚Äì678 
IIa 
C 
When performing catheter ablation during 
pregnancy, the use of non-fluoroscopic mapping and 
navigation systems should be considered.663‚Äì665 
IIa 
C 
Catheter ablation with electro-anatomical mapping 
systems may be considered in experienced centres in 
the case of sustained drug-refractory, recurrent, and/ 
or poorly tolerated VT if there are no other 
alternatives. 
IIb 
C 
¬© ESC 2025
ICD, implantable cardioverter defibrillator; i.v., intravenous; RVOT, right ventricular 
outflow tract; VT ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               67


<!-- PAGE 68 -->

### Page 68

12.4.4. Cardiac arrest 
Maternal cardiac arrest occurs in 8/100 000 hospitalizations in the United 
States of America679 and 7.6/100 000 pregnancies in the Netherlands.680 
Haemorrhage and anaesthetic complications are the most common 
overall causes of cardiac arrest,681 and HF, ACS, arrhythmias, aortic dissection, and PE are the most common cardiovascular causes of cardiac 
arrest.682,683 
Because most of the underlying causes of cardiac arrest in pregnancy 
tend to be reversible, pregnant women have better outcomes than non- 
pregnant women.684 Basic cardiac arrest resuscitation principles apply 
to pregnant women, although some differences should be considered.684 If cardiac arrest occurs beyond 20 weeks of pregnancy, left lateral manual displacement of the uterus or left lateral position of the 
woman is indicated to avoid aortocaval compression (Figure 19).684,685 
Chest compressions should be according to basic life support guidelines. 
Management of cardiac arrest in pregnancy
Potential aetiology
‚Ä¢ Anaesthetic complications 
‚Ä¢ Bleeding
‚Ä¢ Cardiovascular causes 
‚Ä¢ Drugs
‚Ä¢ Amniotic Ô¨Çuid embolism
‚Ä¢ Pulmonary embolism 
‚Ä¢ Eclampsia
Obstetric interventions
If no ROSC after
4 min of resuscitation eÔ¨Äorts and foetus is viable, immediate caesarean section
(Class IIa)
Maternal interventions
Neonatal Team
Pregnancy-speciÔ¨Åc
In women with Mg++
infusion (pre-eclampsia):¬†
Stop Mg++ infusion and administer calcium gluconatea
In resuscitated pregnant women,
temperature control¬†on an individual basis
Not pregnancy-speciÔ¨Åc
Airway management
Continuous manual left uterus displacement
(Class I)
i.v. access above diaphragm
(Class I)
Chest compressions as in non-pregnant
(Class I)
Anterolateral deÔ¨Åbrillator pad placement with the lateral pad placed under the breast
(Class I)
DeÔ¨Åbrillation protocol as in non-pregnant
(Class I)
Drug choices and doses as in non-pregnant
(Class I)
Figure 19 Management of cardiac arrest in pregnancy. i.v., intravenous; ROSC, return of spontaneous circulation. a30 mL calcium gluconate 10% solution.


<!-- PAGE 69 -->

### Page 69

In post-arrest care, the full left lateral decubitus position is recommended. The use of device-assisted chest compressions in pregnancy 
is currently not recommended due to lack of data.684 Importantly, no 
drugs should be withheld because of concerns about teratogenicity.614,686 Foetal monitoring after cardiac arrest is mandatory. 
Emergency caesarean section should be immediately prepared for 
and considered when initial resuscitation fails.682 If this is not feasible, 
rapid maternal transfer is advised to an appropriate clinical setting 
with uninterrupted resuscitation. 
12.4.5. Bradycardia 
12.4.5.1. Sinus node dysfunction 
Sinus bradycardia due to sinus node dysfunction is uncommon in 
pregnant women who do not have structural heart disease. In 
the second trimester, symptomatic bradycardia may occur as a result of a reduction in systemic resistance, but this rarely requires 
treatment. Symptomatic bradycardia during pregnancy may be 
caused by the supine hypotensive syndrome, defined as a systolic 
BP decrease of >15 mmHg due to compression of the inferior 
vena cava by the uterus.690 Management depends on the underlying 
cause, severity of symptoms, and potential risks to both the mother 
and the foetus. 
12.4.5.2. Atrioventricular block 
Mobitz type I AV block is common in pregnant women and rarely 
progresses during pregnancy.691 There are no data on progression 
of congenital AV conduction block during pregnancy and vaginal 
delivery does not cause extra risk for mothers who are asymptomatic, haemodynamically stable, and have a normal cardiac anatomy and function.691 Prophylactic placement of temporary 
pacemaker wires is not usually indicated but is an individualized 
decision. 
12.4.5.3. Management of sinus node dysfunction and 
atrioventricular block 
In acute, life-threatening settings, bradycardia should be treated as in 
non-pregnancy. Isoproterenol can be used when benefits outweigh 
risks. It is not known if it is excreted in human milk. Pacing indications 
(temporary and permanent) do not differ between pregnant and 
non-pregnant women and can be found in the 2021 ESC 
Guidelines on cardiac pacing and cardiac resynchronization therapy.692 Pacemakers can be implanted safely during pregnancy using 
standard methods with minimal fluoroscopy or non-fluoroscopic 
methods.675,693‚Äì695 
12.5. Valvular heart disease 
During childbearing years VHD is usually either congenital or rheumatic 
in cause. Complications during pregnancy include new-onset AF, which 
can lead to deterioration in cardiac function, an increased risk of 
thromboembolic events, and heart failure.696,697 Women with valve 
disease should have access to pre-conception counselling and their cardiac condition should be optimized. This may include pre-pregnancy 
intervention or surgery for those with symptoms or severe disease 
(Figure 20), in keeping with the 2021 ESC/EACTS Guidelines for the 
management of valvular heart disease.698 Dedicated tools for risk stratification may be needed in the setting of rheumatic heart disease.697 
12.5.1. Stenotic native valve lesions 
Stenotic valve lesions limit the ability to increase CO during pregnancy. 
The result of this may be presentation with symptoms for the first time 
during pregnancy. Serial TTE in pregnancy will usually demonstrate an 
increase in valve gradient of up to 50% due to the normal 
pregnancy-related increase in CO.699 
Recommendation Table 16 ‚Äî Recommendations for 
cardiac arrest and pregnancy 
Recommendation 
Classa 
Levelb  
Continuous manual left uterine displacement during 
CPR in pregnant women (‚â•20 weeks) with cardiac 
arrest is recommended to relieve aortocaval 
compression.614 
I 
C 
It is recommended to establish i.v. access above the 
diaphragm to ensure that the i.v. therapy is not 
obstructed by the gravid uterus.614 
I 
C 
It is recommended to perform the same chest 
compressions and defibrillation protocols in 
pregnant as in non-pregnant women.554,614,687 
I 
C 
Anterolateral defibrillator pad placement is 
recommended with the lateral pad placed under the 
breast.614,660 
I 
C 
It is recommended that no drugs are withheld in 
pregnant women with cardiac arrest due to concerns 
of teratogenicity.686 
I 
C 
Immediate caesarean section at the site of the arrest 
should be considered and immediately prepared if 
ROSC has not been achieved in the mother after 
4 min of resuscitative efforts and if the foetus is 
viable, taking gestational age, comorbidities, and 
the available level of medical care into 
account.614,688,689 
IIa 
C 
¬© ESC 2025
CPR, cardiopulmonary resuscitation; i.v, intravenous; ROSC, return of spontaneous 
circulation. 
aClass of recommendation. 
bLevel of evidence.  
Recommendation Table 17 ‚Äî Recommendation for 
congenital atrioventricular block and pregnancy 
Recommendation 
Classa 
Levelb  
In pregnant women with asymptomatic congenital 
AV block, normal cardiac anatomy and function, a 
narrow QRS complex, and ventricular rate 
(‚â•50 b.p.m.), a prophylactic temporary pacemaker 
during delivery is not recommended.691 
III 
C 
¬© ESC 2025
AV, atrioventricular; b.p.m., beats per minute; QRS, Q, R, and S waves. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               69


<!-- PAGE 70 -->

### Page 70

12.5.1.1. Mitral valve stenosis 
Mitral valve stenosis is a common cause of HF during pregnancy.11 Mild 
stenosis is usually well tolerated.11 However, symptoms may occur if 
the valve area is <1.5 cm2. Maternal mortality in mitral stenosis is higher 
in those with NYHA >II, systolic pulmonary arterial pressure (PAP) 
>30 mmHg, severe stenosis, older age, and in low-income countries11,696,700 (Figure 20). Foetal risks include increased rates of premature delivery, IUGR, and foetal death, especially in highly symptomatic 
mothers (NYHA III/IV).701 
12.5.1.1.1. Management. Diagnosis is as per usual criteria.698 
During pregnancy, valve area by 2D-planimetry is thought to be 
more reliable than flow-dependent measures, because higher stroke 
volume and tachycardia will increase the measured gradient across 
the valve.702 Mitral valve anatomy, especially the presence of subvalvar involvement or the presence of MR, is important if considering 
intervention. 
If signs or symptoms of PH are present, activity restriction should be 
suggested, and beta-blockers and/or diuretics should be started. 
Anticoagulation regimens should be individualized. Therapeutic anticoagulation with full therapeutic-dose LMWH or VKA (see Section 5) 
is indicated in those with AF, left atrial clot, or a previous embolism. 
Anticoagulation should be considered in those with significant mitral 
stenosis, spontaneous echo contrast in the left atrium, dilated left atrium with left atrial volume index >60 mL/mL2, or those in HF. 
12.5.1.1.2. Interventions. Pre-pregnancy intervention should be considered in those with significant stenosis (valve area <1.5 cm2). Before 
and during pregnancy, percutaneous mitral balloon commissurotomy is 
the primary intervention in those who remain in NYHA III/IV or with 
severe PAP elevation despite medical therapy.703 Balloon techniques 
are highly successful during pregnancy unless there is complex subvalvar 
involvement. Closed commissurotomy is rarely used but is an alternative. Open valve surgery should only be used when there is a risk to maternal life and other options are not possible or have failed.704 
12.5.1.1.3. Delivery. Vaginal delivery is the preferred option. 
Caesarean section is preferred in cases of severe mitral stenosis and 
for those with refractory HF. Delivery is a time of increased risk of 
HF and thrombotic events.182 
12.5.1.1.4. Post-partum. Close monitoring is needed in the days following delivery and diuretics may be required to treat fluid overload. The long- 
term outcome depends on the risk of valve progression and the success of 
commissurotomy if performed. Lifelong follow-up is required. 
12.5.1.2. Valvular aortic stenosis 
Bicuspid aortic valve disease is a common cause of valvular aortic stenosis in 
women of childbearing age. The outcome is related to the baseline severity 
of the stenotic lesion. Women with severe stenosis and those with symptoms prior to pregnancy have a 1 in 4 risk of developing HF during pregnancy.703 Exercise testing and measurement of NP can be used to 
stratify risk prior to pregnancy. Those with symptomatic severe aortic stenosis should be offered intervention prior to pregnancy. Risk-stratifying 
those with asymptomatic aortic stenosis is more challenging. Left ventricular systolic dysfunction, or effort limitation on exercise testing, indicate that 
intervention before pregnancy should be considered.698 
Women with severe aortic stenosis contemplating pregnancy should 
be counselled regarding the risks and offered surgery if they prefer. 
Despite this, maternal mortality is rare for those under expert 
care.703 The risk of sudden death in those with severe stenosis is increased but difficult to quantify. BAV-associated aortopathy is discussed in Section 8.3. 
12.5.1.2.1. Management. Medical therapy has a limited role in 
symptomatic aortic stenosis. Diuretics may help those with HF or 
high filling pressures, but caution should be exercised. In women 
with severe symptomatic aortic stenosis, rest and possibly hospital admission should be considered. Intervention should be considered in 
women with persisting symptoms including angina or with new ST 
changes on ECG. In symptomatic pregnant women with severe aortic 
stenosis not responding to medical therapy, non-surgical options such 
as balloon valvuloplasty or transcatheter aortic valve implantation 
(TAVI) may be considered during pregnancy.705,706 Procedures 
should be performed in an experienced valve centre. If no catheter- 
based options are available, surgical valve replacement or repair is recommended. If the foetus is at a viable gestation, taking account of 
other comorbidities and the available level of neonatal care, delivery 
should occur prior to valve intervention. These complex decisions 
should be discussed with the full Pregnancy Heart Team.707 Cardiac 
surgery with cardiopulmonary bypass is associated with at least a 
20% risk of foetal loss.708 
Vaginal delivery is the preferred mode of delivery for the majority of 
women. In those with severe symptomatic aortic stenosis, caesarean 
delivery should be considered. Early post-partum HF may develop. 
For pulmonary stenosis, see Section 9 on congenital heart disease. 
12.5.2. Regurgitant native valve lesions 
Valve regurgitation is generally better tolerated than valve stenosis in 
pregnancy. Increased maternal and foetal event rates can be seen in 
those with severe regurgitation.709 
12.5.2.1. Mitral and aortic valve regurgitation 
Women with valve regurgitation and either symptoms or LV 
dysfunction incur an increased risk of HF, occurring in 20%‚Äì25% 
of those with at least moderate regurgitation.182,710 Acute regurgitant 
lesions are often less well tolerated than chronic regurgitation.710 
12.5.2.1.1. Management. Diuretics can be used in those with severe 
symptomatic mitral or aortic regurgitation. Cardiac surgery is rarely required during pregnancy. Vaginal delivery is preferred unless the 
mother is in refractory HF. 
12.5.2.2. Arrhythmogenic mitral valve prolapse 
Arrhythmic mitral valve prolapse (AMVP) is defined as the presence of 
mitral valve prolapse and arrhythmia symptoms or signs, such as frequent ventricular premature contractions or complex ventricular arrhythmias.711 The arrhythmias may arise from myocardial fibrosis 
resulting from prolonged and increased stretch of papillary muscles 
and of the inferolateral LV wall by the prolapsing valves. 
Several reports have included female sex as a risk factor for severe 
arrhythmic events.711 Other risk factors include syncope, the presence of mitral annular disjunction, late gadolinium enhancement 
on CMR, complex ventricular arrhythmias, including non-sustained 
ventricular tachycardia, syncope, T-wave inversions in the inferolateral ECG leads, bi-leaflet mitral valve prolapse, and reduced LVEF. 
Little is known about the effect of pregnancy in women with AMVP, 
but altered loading conditions may lead to increased tension in mitral


<!-- PAGE 71 -->

### Page 71

valve apparatus and thereby increased risk of ventricular arrhythmias. 
A recent publication indicated increased arrhythmic risk during pregnancy in women with AMVP and life-threatening ventricular 
arrhythmias.712 
It is recommended that women with AMVP undergo pre-conception 
counselling and optimization of medication. Medical treatment includes 
anti-arrhythmic therapy with, for example, beta-blockers and/or flecainide.713 If started pre-pregnancy, treatment should continue during pregnancy with close follow-up and arrhythmic monitoring. A pregnant 
woman with AMVP should be monitored during pregnancy at a tertiary 
centre with experience in AMVP and with periodic Holter monitoring 
to identify a potential increase in arrhythmic burden.711 Risk stratification 
for ICD implantation should follow the consensus for AMVP in general.711 
12.5.2.3. Tricuspid regurgitation 
Medical treatment for tricuspid regurgitation is usually not required 
but during pregnancy diuretics and medication for rhythm management may be needed. Surgery for isolated TR in pregnancy is rarely 
indicated except for the setting of endocarditis. 
Stenosis



Regurgitation



Regurgitation




	





	



	¬Å
¬ç¬è¬ê¬ù¬†



¬Å



Regurgitation

Stenosis
	
¬≠
¬Å	




	





	

¬ç

¬ù¬Ä¬è		
¬ç
¬ê¬Ä¬Ç
	
¬Å
		
	
Poor RV function
Ebstein anomaly


Figure 20 Valvular heart disease and pregnancy. ECG, electrocardiogram; LV, left ventricle; LVH, left ventricular hypertrophy; PASP, pulmonary arterial 
systolic pressure; RV, right ventricle; RVH, right ventricular hypertrophy. Red flags indicate high-risk features.   
ESC Guidelines                                                                                                                                                                                               71


<!-- PAGE 72 -->

### Page 72

12.5.3. Prosthetic valves 
When a woman of childbearing age or a girl requires valve surgery, 
careful consideration should be given to the possibility of future pregnancies. When appropriate, the discussion regarding valve choice 
should involve the Pregnancy Heart Team. In general, valve repair, 
valve-in-valve, or non-mechanical valves are preferable, avoiding the 
need for anticoagulation. Data from the ROPAC III study, focusing 
on prosthetic valves, show that the chance of an uncomplicated pregnancy with a live birth in women with a MHV was 54%, compared to 
79% in women with a tissue valve.177 Regional differences, especially between high-income and low- and middle-income countries, need to be 
acknowledged, as also indicated in a recent study from Madras in India 
(M-PAC registry) describing pregnancy outcomes in 70 women with a 
prosthetic heart valve.717 A very high foetal death rate and major adverse cardiovascular events (MACE) rate (40% and 34%, respectively),717 including a high number of valve thromboses, is believed to 
relate not only to differences in organization of care, but also to underlying valvular disease, with more rheumatic heart disease in low- and 
middle-income countries. The Ross procedure in aortic valve disease 
is an alternative option to be considered. In the absence of aortic dilatation, pregnancy risk is low after the Ross procedure.718 
12.5.3.1. Bioprosthetic valves 
Prior to pregnancy, a full assessment of valve function should be 
performed. Many women are on lifetime low-dose aspirin treatment, 
and this should be continued during pregnancy unless there is a contraindication. If there is severe valve dysfunction prior to pregnancy, 
reintervention should be considered. However, in this setting 
the risk of pregnancy with the current valve dysfunction should be balanced against the risk of the new valve being proposed. Mechanical 
valve implantation should be avoided when possible. Transcatheter 
valve-in-valve intervention may have a role in extending the lifespan 
of a failing bioprosthetic valve in a young woman contemplating pregnancy. In a recent retrospective study of CARPREG data, 215 pregnancies in 101 women who had implanted bioprosthetic valves prior to 
pregnancy were described. More than a quarter had some degree of 
valvar dysfunction, although the time since the last valve replacement 
surgery was only 6 ¬± 3 years on average. Bioprosthetic valve dysfunction was more than twice as common in women with left-sided as opposed to right-sided valves.719 
The chance of a pregnancy without serious adverse events and a live 
birth in women with a bioprosthetic valve is 79%.177 When significant 
bioprosthetic dysfunction is present, the risk of complications can be 
significant, especially if associated with severe stenosis or ventricular 
dysfunction. There is no compelling evidence that pregnancy is associated with accelerated valve deterioration. 
12.5.3.2. Mechanical valves 
Pregnant women with MHVs are exposed to a high risk of complications (mWHO 2.0 risk classification ‚â•III). The chances of an event-free 
pregnancy with a live birth were only 58% in the initial ROPAC II study 
and showed no improvement after 8 years in the ROPAC III study 
(54%).177,204 Thrombotic complications occur in 9%‚Äì24% and bleeding 
complications in 20%‚Äì30% of the cases in the ROPAC III and a United 
Kingdom study, respectively.176,177 Women with a mechanical valve in 
the mitral position are especially at risk of adverse outcomes, including 
mortality.177 
All women with MHVs should be fully counselled pre-pregnancy regarding the risks and benefits of the various anticoagulation regimens. 
When planning the optimal anticoagulation strategy, logistical issues, 
Recommendation Table 18 ‚Äî Recommendations for native valve disease and pregnancy 
Recommendations 
Classa 
Levelb  
Intervention is recommended before pregnancy in symptomatic patients with severe aortic stenosis.698 
I 
C 
Intervention is recommended before pregnancy in women with mitral stenosis and a valve area <1.5 cm2. 698,701,714 
I 
C 
In pregnant women with symptomatic mitral stenosis or pulmonary hypertension, restricted activities and beta-blockers are 
recommended.20 
I 
C 
In pregnant women with mitral stenosis, diuretics are recommended when congestive symptoms persist despite beta-blockers.20 
I 
C 
Full therapeutic-dose anticoagulation is recommended in women with mitral stenosis complicated by AF, left atrial thrombus, or prior 
embolism. 
I 
C 
Surgical treatment is recommended before pregnancy in women with severe aortic or mitral regurgitation with symptoms, impaired 
ventricular function, or marked ventricular dilatation.698,715 
I 
C 
Diuretics are recommended in pregnant women with regurgitant lesions when symptoms or signs of congestion occur. 
I 
C 
Intervention should be considered before pregnancy in those with asymptomatic severe aortic stenosis after counselling on the risks and 
benefits.698 
IIa 
C 
Percutaneous mitral commissurotomy for mitral stenosis should be considered in pregnant women with severe symptoms or systolic 
pulmonary artery pressure >50 mmHg despite medical therapy.698 
IIa 
C 
Valve surgery during pregnancy should only be considered when there is a maternal mortality risk and other treatment options have 
failed.421 
IIa 
C 
In very selected symptomatic pregnant women with severe aortic stenosis not responding to medical therapy, non-surgical options such as 
balloon valvuloplasty or TAVI may be considered.716 
IIb 
C 
¬© ESC 2025
AF, atrial fibrillation; TAVI, transcatheter aortic valve implantation. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 73 -->

### Page 73

such as access to timely anti-factor Xa level testing and maternal ability to 
adhere to treatment regimens, need to be considered. 
12.5.3.2.1. Anticoagulation during pregnancy. The most effective 
regimen in preventing maternal thrombotic complications is the continuous use of VKAs. Thrombotic events not only compromise the 
mother but also jeopardize the baby.170,200,204,206,720,721 However, 
there remain concerns about the foetal impact of VKAs. Data from 
the ROPAC III study indicated a higher risk of miscarriage in VKA 
users.177 As discussed in Section 5, the foetal risk of VKAs is in part 
dose-related. Although there is no safe dose for the foetus, event rates 
are reduced when lower doses of VKA are used.200 For these reasons, 
continuation of VKAs should be considered when the risk of thrombosis is high and the dose required to achieve the target INR is low 
(see Section 5). Target INRs are unchanged from non-pregnant values.698 INR monitoring should be weekly or every 2 weeks (see 
Section 5). 
The alternative strategy is switching to therapeutic-dose LMWH 
(twice daily) until the 12th week of pregnancy with a monitoring 
plan. The target peak levels of anti-factor Xa should be discussed individually and vary between 1 and 1.2 IU/mL. The value of trough anti- 
factor Xa levels is less clear. Adjusting dosing to obtain levels of 
>0.6 IU/mL has been suggested, however, with little evidence.170,216 
Dosing regimens for therapeutic LMWH are provided in Section 5. 
In women with a very high thrombotic risk, the addition of low-dose 
acetylsalicylic acid (ASA) should be considered.170 In rare circumstances, such as the unavailability of anti-factor Xa level testing, i.v. 
UFH can be used. Target aPTT levels with a prolongation of ‚â•2 times 
the control can be challenging to achieve and may require multiple adjustments of dosing and prolonged inpatient care. In the majority of 
cases, VKAs will be the favoured therapy in the second and third trimesters to minimize the maternal risks after the period of embryogenesis.176,204 Despite this, some women will choose to remain on 
therapeutic-dose LMWH throughout pregnancy. The management 
of anticoagulants during pregnancy in women with MHVs is summarized in Figure 21. 
12.5.3.2.2. Mechanical valve thrombosis. Regular maternal cardiac 
ultrasound should be performed during pregnancy to assess valve function and rule out valve thrombosis. Imaging once per trimester will usually suffice unless there is pre-existing valve dysfunction or HF. Changes 
in valve gradient that exceed the usual increase due to changing cardiac 
output should be investigated. Symptoms such as new HF, embolic 
event, or syncope need urgent assessment. Changes in valve clicks 
and new murmurs should also trigger investigation. Transthoracic and 
transoesophageal echocardiography, fluoroscopy, and CT can all be 
used to assess MHV leaflet movement. 
Valve thrombosis has a high maternal mortality. Its management is 
comparable with management in non-pregnant women. In a subacute 
setting, optimizing anticoagulation with UFH and re-establishing a 
therapeutic INR with VKA may be sufficient. Thrombolysis may be considered, especially in non-critically ill women, when surgery is not immediately available for critically ill women, and in right-sided prosthetic 
valve thrombosis.698 Urgent intervention is often required in acute 
thrombosis with obstruction or severe regurgitation.722 This is associated with high maternal and foetal risks. There is a clear survival benefit for the foetus without increasing maternal mortality if cardiac 
surgery is performed after caesarean section. Therefore, the optimal 
treatment strategy, as determined by the Pregnancy Heart Team, will 
depend on type of valve involved, haemodynamic stability of the 
mother, and gestational age.421 
12.5.3.2.3. Anticoagulation during delivery in women with mechanical heart valves. The management of delivery for women with 
MHV is discussed in Section 4.5.6. These are high-risk deliveries with significant bleeding complications. 
Recommendation Table 19 ‚Äî Recommendations for prosthetic valves and pregnancy (see Evidence Table 18) 
Recommendations 
Classa 
Levelb  
A bioprosthetic valve is recommended (over a mechanical valve) in young women contemplating pregnancy requiring a valve prosthesis.177 
I 
B 
It is recommended that the type of valve surgery or intervention for a woman contemplating pregnancy is chosen in consultation with the 
Pregnancy Heart Team. 
I 
C 
Women with mechanical heart valves 
It is recommended that a care plan documenting the agreed anticoagulant strategy (including the decision to continue VKAs or converting to 
therapeutic-dose LMWH in the first trimester) is in place for women of childbearing age with an MHV prior to pregnancy or as soon as 
pregnancy is recognized.170 
I 
C 
It is recommended that pregnant women with an MHV are managed by the Pregnancy Heart Team.170 
I 
C 
In pregnant women on VKAs, it is recommended to perform INR monitoring weekly or at a minimum every 2 weeks. 
I 
C 
In pregnant women with MHVs on therapeutic-dose LMWH, it is recommended to check peak anti-factor Xa levels and to target levels 
according to individualized risk. 
I 
C 
During the second and third trimesters until the 36th week, continuing VKAs should be considered in women with prosthetic heart valves at 
higher risk of thrombosis. 
IIa 
C 
During the second and third trimesters, continuing LMWH with anti-factor Xa level monitoring and dose adjustment may be considered in 
women at lower risk of thrombosis. 
IIb 
C 
LMWH is not recommended when anti-factor Xa level monitoring is not available. 
III 
C 
¬© ESC 2025
INR, international normalized ratio; LMWH, low-molecular-weight heparin; MHV, mechanical heart valve; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               73


<!-- PAGE 74 -->

### Page 74

Management of pregnant women with mechanical heart valves by the Pregnancy Heart Team (Class I) 
Good control of anticoagulation with therapeutic INRs
Pregnancy Heart Team decision taking into account: 
Counsel that pregnancy risks are very high 
Discuss pregnancy alternatives
Dose-adjusted LMWH
Continue VKA
Continuous i.v. UFH
(rarely used) 
‚Ä¢ No high-risk of valve 
 thrombosis (See box below)
‚Ä¢ High dose VKA
‚Ä¢ Availability of 
 anti-factor Xa testing
‚Ä¢ High risk of valve thrombosis 
 (See box below)
‚Ä¢ VKA dosea
‚Ä¢ Maternal choice
‚Ä¢ High-risk of valve 
 thrombosis (See box below)
‚Ä¢ Only if high VKA dose and/or 
 no anti-factor Xa testing 
 available
Pregnancy Heart Team decision taking into account: 
VKA
(usual care)
Second/third trimester
First trimester (risk of embryopathy)
High risk of valve thrombosis
VKA, if higher risk of valve thrombosis
(Class IIa)
Right sided valves
Mitral valve replacement
Atrial Ô¨Åbrillation
Poor LV function
Previous thrombotic events
Valve dysfunction especially 
stenosis
Other clotting risks (smoker)
Older generation valves 
‚Ä¢ High risk of valve thrombosis (See box below)
‚Ä¢ Maternal choice
Dose-adjusted LMWH, if
(Class IIb)
‚Ä¢ Lower risk of valve thrombosis
‚Ä¢ Availability of anti-factor Xa testing
‚Ä¢ High-risk of valve thrombosis (See box below)
Last 2 weeks of pregnancy and deliveryb
Figure 21 Management of anticoagulants during the different stages of pregnancy in women with mechanical heart valves. INR, international normalized 
ratio; i.v., intravenous; LMWH, low-molecular-weight heparin; LV, left ventricle; N, no; UFH, unfractionated heparin; VKA, vitamin K antagonist; Y, yes. aSee  
Table 10. bSee Figure 5 and Section 4.5.7.


<!-- PAGE 75 -->

### Page 75

12.5.4. Endocarditis prophylaxis 
Infective endocarditis during pregnancy is a rare yet severe event associated with maternal and foetal morbidity and mortality. An increasing risk factor is represented by i.v. drug abuse associated with the 
opioid epidemic in the United States of America.723 The most common pathogens are Staphylococcus (74%) and Serratia (13%).724 A recent comparison across antepartum, delivery, and post-partum 
maternity-associated infective endocarditis showed the 60-day mortality rate was highest in the delivery subgroup and the rate of valve 
replacements was highest in post-partum cases.725 Antibiotics should 
be given according to guidelines,178,726 laboratory data on culture and 
antibiotic sensitivity, and the differential foetal toxicity of antibiotics 
(see Section 5). 
12.6. Heart failure 
12.6.1. Chronic heart failure 
Heart failure complicates 11% of pregnancies in women with pre-existing 
heart disease and has an in-hospital maternal mortality rate of 9%.2 
Specific pre-pregnancy counselling is needed for women with ventricular 
dysfunction irrespective of the cause. As many HF medications are contraindicated in pregnancy (see Section 5), modifying the drug regimen pre- 
pregnancy should be part of pregnancy risk stratification, with reassessment 
after at least 3 months.727 Contractile reserve off HF therapy, measured by 
stress echocardiography, can be used for reassessing ventricular function.371 
Two peaks of HF deterioration occur in pregnancy: at 23‚Äì30 weeks and 
peri-delivery.182 Pre-conception counselling should include a discussion of 
management if there is a clinical deterioration during the first peak. Early delivery due to maternal cardiac deterioration will impact foetal outcomes. 
Patients with mild ventricular dysfunction may tolerate pregnancy with 
no increase in symptoms. However, those with worse than mild ventricular dysfunction (mWHO 2.0 class >II) (Table 6) require expert care from 
the Pregnancy Heart Team, with additional input from the advanced HF 
team including transplant and mechanical circulatory support experts. 
Women with pre-existing severe HF (LVEF <30%, mWHO 2.0 class 
IV) are at high risk of maternal morbidity and mortality and account for 
up to 15% of maternal deaths globally.2,728 
Assessment of patients with pre-existing HF includes regular assessment of symptoms, echocardiography, and NP at intervals determined 
by the severity of HF and other non-cardiac issues. 
12.6.2. Acute heart failure (including cardiogenic shock) 
Acute heart failure can develop in women without pre-existing heart 
disease as can be the case in PPCM (Section 7), or secondary in women 
with known cardiac disease such as cardiomyopathy, ischaemic heart 
disease, ACHD, and severe VHD. The diagnosis can be challenging because the symptoms and signs of AHF can be misinterpreted as changes 
due to pregnancy (Figure 22).349,729 Pregnant women presenting with 
AHF require urgent hospital admission. These patients should be referred to an expert centre with established advanced HF care, including 
on-site surgery and mechanical circulatory support or even a transplant 
programme as backup. 
In case of cardiogenic shock, recommended inotropic agents include levosimendan,730 dobutamine, and milrinone (Figure 22). Levosimendan is 
administered as a continuous infusion without an initial loading dose. 
Dobutamine is an option, whereas adrenaline should be avoided. 
Milrinone may be an alternative if benefits outweigh the risk, due to 
placental transfer (see Supplementary data online, Table S2). Mechanical 
circulatory support [preferably veno-arterial extracorporeal membrane 
oxygenation (VA-ECMO)731] should be considered in case of severe 
refractory cardiogenic shock.339 In cardiogenic shock, urgent delivery by 
caesarean section with combined spinal/epidural analgesia or general anaesthesia is recommended.732‚Äì734 
Milder cases of acute HF can be treated with oral diuretics, 
b1-selective beta-blockers (bisoprolol, metoprolol succinate), hydralazine, and oral nitrates. Diuretics (loop diuretics and thiazides if required) should be used with caution due to a potential reduction in 
uterine blood flow, but may be necessary in pulmonary congestion 
or echocardiographic signs of high LV end-diastolic pressure.732 
Recommendation Table 20 ‚Äî Recommendations for 
chronic and acute heart failure and pregnancy (see  
Evidence Table 19) 
Chronic heart failure 
Classa 
Levelb  
It is recommended that women with HFrEF are 
advised about the risk of deterioration of cardiac 
function during pregnancy and peripartum.34 
I 
C 
In pregnant women with HFrEF, it is recommended 
that non-selective beta-blockers are switched to 
beta-1-selective blockers (metoprolol, bisoprolol) 
with close maternal and foetal 
monitoring.733,734,738,739 
I 
C 
Anticoagulation with therapeutic doses of LMWH is 
recommended in pregnant women with intracardiac 
thrombus or decreased LV function with EF <35%.216 
I 
C 
It is recommended to optimize HF guideline-directed 
medical therapy after delivery, taking contraindicated 
drugs during lactation into accountc.339,734 
I 
C 
Due to the high metabolic demands of lactation, 
avoiding lactation may be considered in women with 
severe HF.360,733 
IIb 
C 
ACE-Is, ARBs, ARNIs, MRAs, ivabradine, and SGLT2 
inhibitors are not recommended during pregnancy 
due to adverse foetal effects. 
III 
C 
Acute heart failure 
Inotropes and/or vasopressors are recommended in 
pregnant women with cardiogenic shock with 
levosimendan, dobutamine, and milrinone as 
recommended agents.730 
I 
C 
Urgent delivery with caesarean section is 
recommended in pregnant women with cardiogenic 
shock as soon as the foetus is viable, taking 
gestational age, comorbidities, and the available level 
of medical care into account.689 
I 
C 
Early transfer of pregnant women in cardiogenic 
shock to a facility providing mechanical circulatory 
support should be considered.345,740 
IIa 
C 
Preventing lactation may be considered in women 
with severe HF due to the high metabolic demands of 
lactation.360 
IIb 
B 
¬© ESC 2025
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, 
angiotensin receptor/neprilysin inhibitor; EF, ejection fraction; HF, heart failure; HFrEF, heart 
failure with reduced ejection fraction; LMWH, low-molecular-weight heparin; LV, left ventricle; 
MRA, mineralocorticoid receptor antagonist; SGLT2, sodium‚Äìglucose co-transporter-2. 
aClass of recommendation. 
bLevel of evidence. 
cSee Figure 6 and Supplementary data online, Table S2.   
ESC Guidelines                                                                                                                                                                                               75


<!-- PAGE 76 -->

### Page 76

Management of acute heart failure and cardiogenic shock in pregnancy and up to 6 months post-partum
Assess HF severitya
Delivered
Preload optimization:¬†
volume versus diuretics
-initiate nitrates if
SBP >110 mmHg
Severe HF or cardiogenic shock
No severe HF or cardiogenic shock
Oxygen optimization:
non-invasive mechanical 
ventilation 
or invasive ventilation,
if¬†SpO2 <95%
Add inotropes and/or vasopressors; 
levosimendan without loading dose,
dobutamine or 
milrinone
(Class I)
Urgent delivery by caesarean section in case of cardiogenic shock
(Class I)
If delivered:
Bromocriptineb
(Class IIb)
In PPCM
Anticoagulant therapy
(heparin/LMWH) to reduce thromboembolic events if bromocriptine is used
(Class IIa) 
MCS (preferably VA-ECMO or LVAD), in accordance with local availability and team experience;
‚Äòbridge-to-recovery‚Äô or as ‚Äòbridge-to-bridge‚Äô in case of refractory cardiogenic shock.
ACE-I, ARB,
ARNI,
beta-blocker,
MRA,
SGLT2-I,
diuretic
(Class I)
Ivabradine
Hydralazine,
nitrate,
beta-blocker,
(bisoprolol,
metoprolol succinate),
diuretic 
ACE-I, ARB,
ARNI, MRA
 ivabradine,
and SGLT2-I
(Class III)
Consider 
vaginal delivery with epidural analgesia
(Class I)
No recovery
Heart transplantation
Consider corticosteroids for foetal lung maturation if  <35 weeks of gestation 
Figure 22 Management of acute heart failure and cardiogenic shock in pregnancy and up to 6 months post-partum. ACE-I, angiotensin-converting enzyme 
inhibitors; ARB, angiotensin receptor blockers; ARNI, angiotensin receptor/neprilysin inhibitor; b.p.m., beats per minute; HF, heart failure; HR, heart rate; 
LMWH, low-molecular-weight heparin; LVAD, left ventricular assist device; MCS, mechanical circulatory support; MRA, mineralocorticoid receptor antagonist; PPCM, peripartum cardiomyopathy; SGLT2-I, sodium‚Äìglucose co-transporter-2 inhibitor; SBP, systolic blood pressure; SpO2, oxygen saturation; 
VA-ECMO, veno-arterial extracorporeal membrane oxygenation. aAssessment of heart failure severity: SBP <90 mmHg; HR >130 b.p.m. or <45 b.p.m.; 
respiratory rate >25/min; SpO2 <90%; Blood lactate >2.0 mmol/L; low central‚Äìvenous oxygen saturation <60% (if available); altered mental state; cold, 
clammy, mottled skin; oliguria <0.5 mL/kg/h. bBromocriptine: starting dose 2.5 mg twice daily with up-titration if needed.


<!-- PAGE 77 -->

### Page 77

Beta-blockers should be initiated and gradually up-titrated to the maximum tolerated dose.345,357,732‚Äì734 ACE-Is, ARBs, ARNIs, MRAs, ivabradine, SGLT2 inhibitors, and atenolol are contraindicated during 
pregnancy due to adverse effects on the foetus. Hydralazine and nitrates appear safe.43,345,357,733,734 
In the post-partum period, the use of ivabradine to control the heart 
rate may be considered in addition to beta-blockers, or if there is a 
contraindication for beta-blockers.43,339,735,736 In HF with a reversible 
cause, HF treatment in accordance with guidelines should be recommended for at least 12 months after full LV recovery, followed by gradual tapering350 (see also Section 7). Women with pregnancy-associated 
HF should be counselled about the risks of recurrence in subsequent 
pregnancies.737 
12.7. Special populations 
12.7.1. Heart transplantation 
Successful pregnancies have been reported in women with heart 
transplantation, but these pregnancies carry a higher risk. Before 
transplantation and before a post-transplantation pregnancy, women should be counselled about maternal and foetal risks, including the risks of rejection, infection, graft dysfunction, and potential 
teratogenicity of drugs. Based on the individual risk factors, it is 
recommended to postpone pregnancy until at least 1 year after 
transplantation.275 Women with heart transplantation are at 
higher risk of experiencing cardiometabolic complications during 
pregnancy such as pre-eclampsia, gestational diabetes, hypertension, decreased kidney function, and infections.741‚Äì745 The risk 
of complications is lower in women with normal graft function 
and no signs of rejection. Pre-pregnancy evaluation should include 
standard assessments and, if clinically indicated, coronary angiography, right-heart catheterization, and endomyocardial biopsy.741‚Äì745 
All drugs should be reviewed before pregnancy275 and mycophenolic acid therapy275,741 should be avoided due to the teratogenic risk. In 
cases where the father has the same human leucocyte antigen (HLA) 
as the donated heart, there is a risk of developing donor-specific antibodies.746,747 Therefore, consideration should be given to performing 
paternal HLA testing before conception. 
During pregnancy, changes in maternal metabolism can affect the 
serum drug levels of immunosuppression therapy.748 Close monitoring 
of serum drug levels is recommended.275 Echocardiographic evaluations are recommended to assess graft function during pregnancy. 
Foetal growth should be regularly evaluated due to the risk of lower 
birth weight.745 Vaginal delivery should be considered in stable 
patients.745 
Close monitoring of cardiac function, immunosuppression, 
and donor-specific antibodies is necessary until 6‚Äì12 months after 
delivery due to the risk of post-pregnancy rejection.275,741,749‚Äì751 
Lactation may be possible in patients on immunosuppressive drugs, 
depending on the type of medication (see Section 5.2.10). 
12.7.2. Cardio-oncology 
12.7.2.1 Gestational cancer 
Gestational cancer is defined as cancer that occurs during pregnancy or 
within 12 months after delivery. The occurrence is ‚àº1 in 1000 pregnancies, with a possible rise in incidence as maternal childbearing age increases. The most frequent cancers affecting pregnant women are 
breast cancer, cervical and ovarian cancer, lymphoma, leukaemia, colorectal cancer, and melanoma.752‚Äì754 Women diagnosed with cancer 
during pregnancy should be evaluated and considered by a multidisciplinary team. Both the effect of pregnancy on the cancer and the effect of 
the cancer on the pregnancy should be evaluated. Patients should be 
followed in centres with neonatal units in case of premature delivery. 
The baseline assessment prior to chemotherapy, and the monthly or 
bimonthly follow-up during chemotherapy, should include clinical history, 
physical examination, ECG, cardiac biomarkers, and TTE in the context of 
physiological haemodynamic changes during pregnancy.107,755,756 LVEF, 
NP serial measurements,756 and high-sensitivity cTn can be used for monitoring of cancer-therapy-related cardiac dysfunction (CTRCD).734,756 
Chemotherapy given during the first trimester is associated with a high 
risk of malformation (up to 20%) and miscarriage. Chemotherapy is often 
avoided after 34 weeks of gestation to provide a ‚â•3 week window between the last chemotherapy and delivery. Cytotoxic chemotherapies 
provide different risk profiles during the second and third trimesters.752,754 
The suggested chemotherapy treatments for pregnant women with cancer are summarized in the 2022 ESC Guidelines on cardio-oncology.757 
Recommendation Table 21 ‚Äî Recommendations for 
heart transplantation and pregnancy 
Recommendations 
Classa 
Levelb  
It is recommended to postpone pregnancy until at 
least 1 year after heart transplantation, taking 
individual risk factors into account.275,741 
I 
C 
In women with a heart transplant, it is recommended 
that immunosuppression serum drug levels are 
monitored during pregnancy every 4 weeks until the 
32nd week, then every 2 weeks until the 36th week, 
then weekly until delivery, and for 6‚Äì12 months after 
delivery to guide dosing.275 
I 
C 
It is recommended to perform weekly monitoring of 
donor-specific antibodies for at least 6‚Äì12 months 
after delivery.275,741,749‚Äì751 
I 
C 
Paternal HLA testing prior to conception should be 
considered due to the risk of developing 
donor-specific antibodies.746,747 
IIa 
C 
Mycophenolic acid therapy is not recommended in 
pregnancy and should be discontinued 6 weeks 
before conception.275,741 
III 
C 
¬© ESC 2025
HLA, human leucocyte antigen. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               77


<!-- PAGE 78 -->

### Page 78

###### 12.7.2.2 Pregnancy in cancer survivors

Improved cancer treatments have led to an increased number of women with pregnancies after oncological therapy. Previous treatment 
with anthracycline chemotherapy or chest radiotherapy implies a 
15-fold increased lifetime risk of developing HF. Furthermore, both 
the cancer and the cancer treatment have an impact on fertility, pregnancy outcomes, and cardiovascular health. The major risk factors for 
cardiovascular events during pregnancy in cancer survivors include 
CTRCD (28%; 47.4 times higher odds), younger age at cancer diagnosis,758,759 higher cumulative doses of anthracycline, and greater duration between cancer treatment and first pregnancy.758,759 
13. Adverse pregnancy outcomes 
and long-term management 
Adverse pregnancy outcomes (APO), including gestational hypertensive disorders, pre-eclampsia, gestational diabetes mellitus (GDM), 
small or large for gestational age babies, or pre-term birth are a group 
of interrelated disorders that share common pathways.760 Placental 
dysfunction and oxidative stress in the context of cardiometabolic, genetic, or environmental risk factors may cause APOs.761 A multidisciplinary care approach is essential (Figure 23)761,762 for optimizing 
modifiable cardiovascular risk factors after all APOs.761,762 
13.1. Adverse pregnancy outcomes 
13.1.1. Post-partum hypertensive disorders 
Hypertension in the post-partum period is most common in women 
with antenatal hypertensive disorders, but it can also develop de novo 
in the post-partum period. New-onset or de novo post-partum pre- 
eclampsia is increasingly recognized as an important contributor to maternal morbidity and mortality in the post-partum period (Figure 24).763 
Women with pregnancy-related hypertensive disorders, most notably pre-eclampsia, have a higher incidence of several CVDs, including 
CAD, stroke, and HF.762,764 Treatment for uncomplicated post-partum 
hypertension (first 6 weeks after delivery) includes nifedipine and labetalol (metoprolol if labetalol is unavailable).764 A small randomized controlled trial showed that administration of furosemide in the first 5 days 
post-partum in women with gestational hypertension and pre- 
eclampsia significantly reduced the prevalence of persistently elevated 
BP at 7 days.765 Methyldopa should be avoided because of the risk of 
post-partum depression.602,766 Agents used for the management of 
acute, severe hypertension in the post-partum period are similar to 
those used during pregnancy and include labetalol, hydralazine, and nifedipine (see Sections 5 and 12).767 For women with persistent hypertension, antihypertensive therapy should be initiated with reference to 
lactating status following current guidelines (see Section 5).584,585,767 
13.1.2. Gestational diabetes mellitus 
Gestational diabetes mellitus is characterized by glucose intolerance 
that is first recognized during pregnancy.768 Haemoglobin A1c testing 
may help to identify women at high risk.768,769 Women with GDM 
have a sharply increased risk of developing type 2 diabetes later in life 
and a significantly higher likelihood of experiencing adverse cardiovascular events.770‚Äì772 Women with GDM are recommended to undergo 
a formal oral glucose tolerance test (oGTT) 6‚Äì12 weeks post-partum 
with a repeat assessment at 6‚Äì12 months (Figure 25). Thereafter, regular annual follow-up with glucose tolerance monitoring is recommended.773‚Äì775 
13.1.3. Pre-term birth 
Pre-term delivery occurs after 20 and before the completion of 37 
weeks of gestation, regardless of birth weight. There are strong associations between pre-term delivery (alone or with pregnancy-related 
hypertensive disorders), CVD, and mortality.771,772 Women with pre- 
term deliveries are more likely to have an increasing BP trajectory after 
pregnancy and to be affected by accelerated atherosclerosis independent of traditional CVD risk factors.776,777 The earlier pre-term delivery 
occurs, the more strongly it is associated with hypertension and CVD in 
later life. The relationship of pre-term birth to type 2 diabetes mellitus 
and dyslipidaemia is inconsistent. 
13.1.4. Small for gestational age 
Delivering a SGA baby (weight <10th percentile) has not been consistently related to an increased CVD risk, but has been associated with 
hypertension and diabetes.761,771,772 Conversely, large for gestational 
age babies (weight >90th percentile) have been reported to increase 
maternal CVD risk, but the evidence is limited.761 
13.1.5. Pregnancy loss and placental abruption 
Placental abruption, spontaneous pregnancy loss or stillbirth, and foetal 
loss after 28 weeks of gestation have been associated with an increased 
risk of future CVD, with a particularly high risk of hypertension and type 
2 diabetes mellitus.771,778 One or more terminations are associated 
with a higher CVD risk, however, with limited evidence.779 
13.2. Breastfeeding 
Breastfeeding fosters the recovery of maternal physiological systems to their 
pre-conception state. Breastfeeding women have a better cardiometabolic 
profile, and breastfeeding up to 12 months after childbirth has been shown 
to lower future risk of CVD and mortality,780‚Äì783 potentially due to lowered 
BP.784‚Äì787 Longer breastfeeding periods are associated with better CVD outcomes.782,784,788‚Äì790 The role of breastfeeding for women who experienced 
an APO is less clear, but it also appears to have beneficial effects.789,791,792 
There is inconclusive evidence about the beneficial effects of breastfeeding 
on the cardiovascular health of older women (i.e. aged ‚â•55 years).720,788,793,794 
Recommendation Table 22 ‚Äî Recommendations for 
cardio-oncology and pregnancy 
Recommendations 
Classa 
Levelb  
It is recommended that pregnant women with cancer 
who require cardiotoxic cancer therapy are jointly 
managed by the Pregnancy Heart Team and the 
cardio-oncology team.43 
I 
C 
Cardiac troponin and NP measurements may be 
considered at baseline and during anthracycline 
chemotherapy in pregnant women with 
cancer.734,756 
IIb 
C 
¬© ESC 2025
NP, natriuretic peptide. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 79 -->

### Page 79

13.3. Women‚Äôs Heart Clinics 
Post-partum care is often segmented and only carried out by obstetricians. A longer duration of post-partum care, including cardiovascular risk assessment and counselling on CVD risk prevention, 
is likely to lower the long-term risk of CVD in women with an 
APO (Figure 25).762,795 Pregnancy Heart Teams and the potential 
establishment of Women‚Äôs Heart Clinics focusing on women of all 
ages with CVD are necessary to span the care up to post-partum.795 
Seamless communication between the various healthcare providers 
(e.g. obstetrician, cardiologist, internist, family physician) and multidisciplinary management of APOs is critical for long-term care and 
the woman‚Äôs future health.761,796,797 






	











	

	













¬Å
¬ç¬è¬ê


¬ù	¬†
¬ê

Figure 23 Multidisciplinary approach of adverse pregnancy outcomes. CAD, coronary artery disease; CVD, cardiovascular disease. aSee Section 13.3 on 
Women‚Äôs Heart Clinics.   
ESC Guidelines                                                                                                                                                                                               79


<!-- PAGE 80 -->

### Page 80








	



	




¬Å¬ç	

¬Å

¬è	¬ê
¬ç¬ù¬ù
	
¬†¬≠‚â•¬Ä¬Ç¬É¬Ñ¬É¬Å¬Ö
¬ù
	
¬ù
¬ù

¬Ü



	
¬á

Figure 24 Algorithm for the management of new-onset post-partum hypertension. BP, blood pressure.  



	










	

	
	

¬Å¬ç
¬è	¬ê¬ù	
¬†

¬≠

¬è¬Ä
¬Ç¬É¬ê¬ù¬Ä
¬è	
¬ê¬ù	
¬Ñ
¬Ö¬Ü
		

	
Figure 25 Algorithm for the management of adverse pregnancy outcomes. CVD, cardiovascular disease.


<!-- PAGE 81 -->

### Page 81

### 14 Key messages

‚Ä¢ A Pregnancy Heart Team should be involved in the risk assessment, counselling and management of women in mWHO 2.0 
class ‚â•II‚ÄìIII from pre-conception to the late post-partum. 
Each woman should have a detailed delivery plan agreed in 
advance. 
‚Ä¢ In women with known CVD, a complete clinical re-evaluation 
should take place pre-pregnancy to estimate risk, optimize treatment, consider and evaluate the removal of contraindicated drugs, 
and reduce the probability of complications. 
‚Ä¢ Women and their partner (if any) should be offered structured 
psychosocial support during the entire trajectory, especially 
for those at high risk and those considering pregnancy 
termination. 
‚Ä¢ Women with known heritable cardiovascular disorders should be 
counselled about the transmission risk, including the option for assisted reproductive technology. 
‚Ä¢ Management of women with CVD who are pregnant or wishing 
to become pregnant should be individualized and performed according to a shared decision-making model, respecting the woman‚Äôs 
autonomy. 
‚Ä¢ Women in mWHO 2.0 class IV should be comprehensively 
counselled about the very high pregnancy risk, being careful 
to promote a detailed and transparent dialogue about the 
heightened maternal and foetal risks associated with pregnancy. 
A shared decision-making process is essential, allowing for informed choices, including the consideration of pregnancy termination if necessary. 
‚Ä¢ Vaginal delivery is the first choice for the majority of women with 
CVD. 
‚Ä¢ In a life-threatening situation, treatments such as defibrillation, interventions, acute coronary revascularization, mechanical circulatory support, and medication should be the same as in 
non-pregnant women, irrespective of contraindications. 
‚Ä¢ The use of non-invasive imaging tests with ionizing radiation during 
pregnancy should only be performed when the benefits clearly outweigh the maternal and foetal risk, and if the result will significantly 
modify the medical management. 
‚Ä¢ In women with LQTS and CPVT, the continuation of beta-blockers 
throughout pregnancy with monitoring of foetal growth is recommended (atenolol is the only contraindicated beta-blocker). 
Beta-blockers of choice are propranolol and nadolol. 
‚Ä¢ In women with LQT2, post-partum is a distinct high-risk period, 
and therefore full dosage of beta-blockers is strongly recommended. 
‚Ä¢ Genetic testing should be considered in PPCM. 
‚Ä¢ In women with PPCM and DCM, subsequent pregnancy is not recommended if LV function does not normalize. 
‚Ä¢ Genetic testing in women with aortic disease wishing to conceive is 
recommended and management should be based on the presence 
and type of P/LP variant. 
‚Ä¢ Women with the following ACHD lesions should be provided with 
expert counselling and education by a Pregnancy Heart Team, with 
clear and thorough discussion of the very high pregnancy risk and 
the need for a shared decision-making process: 
‚ö¨Systemic RV, in NYHA class III‚ÄìIV, ventricular dysfunction 
(EF <40%), more than moderate TR, or treated HF; 
‚ö¨A Fontan circulation and oxygen saturation <85%, reduced ventricular function, severe arrhythmias, or in NYHA class III‚ÄìIV. 
‚Ä¢ There is no safe cut-off value for elevated pulmonary artery pressure in pregnancy. 
Recommendation Table 23 ‚Äî Recommendations for long-term effects of adverse pregnancy outcomes (see Evidence 
Tables 20 and 21) 
Recommendations 
Classa 
Levelb  
It is recommended to undertake a cardiovascular risk assessment in women with APOs, to recognize and document APOs when CVD risk is 
evaluated in women, and to provide counselling on the importance of healthy lifestyle choices that optimize cardiovascular health.771,772 
I 
B 
In women with persistent post-partum hypertension beyond 6 weeks to 3 months post-partum, initiation of antihypertensive therapy with 
reference to lactating status is recommended following current guidelines.584,602,798 
I 
B 
In cases where adoption of healthy lifestyle choices alone is inadequate to control post-partum glucose levels, initiation of pharmacotherapy 
following current guidelines is recommended.773,774,799 
I 
C 
It is recommended that women with a history of GDM undergo a formal oGTT 6‚Äì12 weeks post-partum with a repeat assessment at 6‚Äì12 
months and regular annual follow-up visits to screen for diabetes.773,774,800 
I 
C 
Nifedipine and labetalol (metoprolol if labetalol is unavailable) are recommended as treatments for uncomplicated post-partum 
hypertension in the first 6 weeks after delivery.602,766,767 
I 
C 
In women with a history of any APO, cardiovascular risk assessment should be considered at 3 months post-partum with repeat assessment 
at 6‚Äì12 months after implementation of appropriate lifestyle interventions, and regular long-term follow-up thereafter.761,795 
IIa 
C 
Breastfeeding may be considered in order to lower the future cardiovascular risk in women with APOs.789,791,792 
IIb 
C 
¬© ESC 2025
APO, adverse pregnancy outcomes; CVD, cardiovascular disease; GDM, gestational diabetes mellitus; oGTT, oral glucose tolerance test. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               81


<!-- PAGE 82 -->

### Page 82

‚Ä¢ Women of childbearing potential with PAH should be counselled at 
the time of diagnosis about the risks and uncertainties associated 
with becoming pregnant. 
‚Ä¢ Any suspicion of VTE, including DVT and PE, requires an immediate 
formal assessment with validated diagnostic tests by a multidisciplinary specialized team. 
‚Ä¢ LMWH is the agent of choice for prophylaxis and treatment of VTE 
in pregnancy. 
‚Ä¢ When treating women with HF during pregnancy, it should be 
noted that several drugs [ACE-Is, ARBs, direct renin inhibitors, sacubitril‚Äìvalsartan (ARNIs), MRAs, and SGLT2 inhibitors] are not recommended. When inotropes or more advanced treatment is 
necessary, referral to an expert centre is recommended. 
‚Ä¢ When possible, mechanical valves should be avoided in girls and women of childbearing age. 
‚Ä¢ Methyldopa, labetalol, and CCBs are recommended for the treatment of hypertension in pregnancy. 
‚Ä¢ Women at high or moderate risk of pre-eclampsia should be advised to additionally take 75‚Äì100 mg of ASA daily from weeks 12 
to 36/37. 
‚Ä¢ After cardiac transplantation, it is recommended to postpone pregnancy for at least 1 year, taking individual risk factors into account. 
‚Ä¢ Women with APOs should be informed about long-term risks and 
preventive strategies and offered appropriate follow-up, including 
psychosocial support (if necessary).  
15. Gaps in evidence 
Pre-pregnancy counselling and evaluation 
‚Ä¢ Data on the adverse effects of assisted reproductive treatment in 
women with CVD are lacking. 
Diagnostic methods 
‚Ä¢ There is a lack of data on the safety of echocardiographic contrast 
agents during pregnancy or lactation. 
‚Ä¢ There are controversial data on the use of gadolinium-based contrast agents in pregnancy. 
‚Ä¢ There are no clear cut-offs for NT-proBNP levels during pregnancy. 
‚Ä¢ There are no normative values of cTnI and cTnT in pregnancy and 
the post-partum period. 
‚Ä¢ There is a lack of data on normal lung ultrasound pattern during 
pregnancy. 
Drugs during pregnancy and lactation 
‚Ä¢ Safety data of DOACs and antidotes (idarucizumab, andexanet alfa, 
cirapantag) in pregnancy are lacking. 
‚Ä¢ Safety data of newer anti-arrhythmic drugs and rate-controlling 
drugs (vernakalant, ivabradine, landiolol) in pregnancy are lacking.  
Cardiomyopathy and primary arrhythmia syndromes 
‚Ä¢ The available data on gene-specific management during pregnancy in 
different cardiomyopathies and primary arrhythmia syndromes are 
limited. 
Peripartum cardiomyopathy 
‚Ä¢ The potential for recovery of cardiac function in PPCM remains unclear and the risks in subsequent pregnancies are not well defined. 
Aortopathies 
‚Ä¢ More data are needed to correctly estimate the pregnancy risk in 
women with previous aortic dissection and/or aortic root surgery. 
‚Ä¢ Risk factors for aortic dissection in the post-partum period are 
poorly understood, making counselling about this difficult. 
‚Ä¢ It is unclear whether a distinction between root and ascending 
phenotype in women with BAV should lead to a different threshold 
for prophylactic surgery (as in non-pregnant women). 
Congenital heart disease 
‚Ä¢ More data are needed to estimate the risk and the long-term effects 
of pregnancy (including multiple pregnancies), especially in women 
with a Fontan circulation or univentricular hearts. 
‚Ä¢ Risk factors for the development of heart failure and arrhythmias 
in pregnant women with (systemic) right-heart failure are poorly 
understood. 
Pulmonary hypertension 
‚Ä¢ Defining the optimal timing to start or escalate PAH therapies in 
pregnancy complicated with PAH remains challenging. 
Venous thromboembolism 
‚Ä¢ Data on risk stratification of VTE in pregnancy are limited, specifically in those with other pre-existing comorbidities. 
‚Ä¢ Data on the use of anticoagulant agents (other than LMWH) are 
limited, just as data on the efficacy and safety of inferior vena cava 
filters and catheter-based thrombectomy (in PE). 
Acquired heart disease 
‚Ä¢ The foetal risks associated with the newer HF medications remain 
unclear, particularly regarding exposure during different trimesters. 
‚Ä¢ The optimal tools to stratify risk of recurrence for atherosclerotic 
and SCAD ACS are unknown. 
‚Ä¢ Physiopathological mechanisms of SCAD in pregnancy are 
unknown. 
‚Ä¢ Optimal treatment of SCAD during pregnancy is not well 
established. 
‚Ä¢ There is scarce evidence about the necessity of using statins during 
pregnancy in women with cardiovascular risk or established ASCVD. 
‚Ä¢ Optimal anticoagulation strategies for women with MHVs during 
pregnancy remain uncertain. 
‚Ä¢ The role of anti-factor Xa level monitoring needs to be determined. 
Women‚Äôs Heart Clinics 
‚Ä¢ Optimal strategies for surveillance and follow-up of women with 
APOs are unclear. 
‚Ä¢ It is unclear how social determinants of health (the environmental 
factors that affect how people live, learn, and work) affect APOs. 
‚Ä¢ There is a need for studies exploring models of post-natal care, 
starting from the initial antenatal visit through to the end of the 
post-partum period.


<!-- PAGE 83 -->

### Page 83

‚Ä¢ Further research is needed to identify risk factors for 
pregnancy-related depression and poor health behaviour engagement in women with CVD, enabling the development of tailored interventions to improve their health and quality of life.  
16. ‚ÄòWhat to do‚Äô and ‚Äòwhat not to 
do‚Äô messages from the Guidelines 
Table 16 lists all Class I and Class III recommendations from the text 
alongside their level of evidence. 
17. Evidence tables 
Evidence tables are available at European Heart Journal 
online. 
18. Data availability statement 
No new data were generated or analysed in support of this 
research. 
Table 16 ‚ÄòWhat to do‚Äô and ‚Äòwhat not to do‚Äô 
Recommendations 
Classa 
Levelb  
4. The Pregnancy Heart Team 
Counselling, pregnancy risk assessment, contraception, assisted reproductive technology, and the involvement of a Pregnancy Heart 
Team 
It is recommended to perform a risk assessment in all women with CVD of childbearing age using the mWHO 2.0 classification. 
I 
C 
A discussion by the Pregnancy Heart Team about the high risk of maternal mortality or morbidity and the related high foetal risk is 
recommended for women with mWHO 2.0 class IV conditions, including a shared decision-making process for pregnancy termination, 
involving psychological support. 
I 
C 
It is recommended that women with CVD of mWHO 2.0 class II‚ÄìIII and above are evaluated and managed by a Pregnancy Heart Team from 
pre-pregnancy onwards through pregnancy and post-partum. 
I 
C 
It is recommended that women with CVD of mWHO 2.0 class II and above, or those at risk of developing CVD, receive individualized advice 
to determine the most suitable contraception method, including emergency contraception. 
I 
C 
Assessment by a clinical geneticist prior to pregnancy is recommended in women fulfilling diagnostic criteria for inherited cardiovascular 
disease to guide risk stratification and pre-natal genetic testing. 
I 
C 
Pre-conception genetic counselling is recommended in couples with heritable CVD, whether genetic testing is being considered or not. It is 
recommended that this counselling is provided by an appropriately trained healthcare professional within a multidisciplinary team that offers 
psychological support and education to encourage decision-making. 
I 
C 
It is recommended that single embryo transfer is performed in women with CVD. 
I 
C 
It is recommended to offer women with CVD access to termination of pregnancy that is tailored to their cardiac condition to minimize the 
risks of the procedure. 
I 
C 
Diagnostic methods in pregnancy 
Transthoracic echocardiography is recommended as first-line imaging tool in any pregnant woman with unexplained or new cardiovascular 
signs or symptoms. 
I 
C 
It is recommended to limit exposure to all medical ionizing radiation doses to ALARA levels. 
I 
C 
It is recommended to keep the radiation dose to the foetus as low as possible (preferably <50 mGy), particularly if the foetus is in the field of 
view. 
I 
C 
Timing and mode of delivery 
Vaginal delivery is recommended in most women with CVD. 
I 
B 
Routine induction of labour prior to 39 weeks is not recommended in women with stable CVD. 
III 
C 
It is recommended that the timing of delivery is planned to ensure safe and effective peripartum anticoagulation. 
I 
C 
It is recommended to discontinue VKAs and start therapeutic-dose LMWH or adjusted-dose i.v. UFH at the 36th week of gestation or 2 
weeks before the planned delivery. 
I 
C 
In women at low risk on therapeutic-dose LMWH, neuraxial anaesthesia and vaginal delivery (or caesarean section for obstetric indications) 
is recommended 24 h after the last dose of LMWH. 
I 
C 
In women at high risk, it is recommended to convert LMWH to i.v. UFH at least 36 h prior to delivery and stop the UFH infusion 4‚Äì6 h prior 
to anticipated delivery. The aPTT should be normal before regional anaesthesia. 
I 
C 
If delivery starts while the mother is on VKAs or <2 weeks after discontinuation of VKAs, caesarean section is recommended for foetal 
protection. 
I 
C 
Post-delivery, it is recommended that the decision to restart LMWH or UFH is made after discussion with the Pregnancy Heart Team and 
the woman who gave birth. 
I 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                               83


<!-- PAGE 84 -->

### Page 84

It is recommended to postpone the switch from heparin back to oral anticoagulants until 7‚Äì14 days post-partum when the wound area has 
healed, in consultation with the Pregnancy Heart Team. 
I 
C 
5. Drugs during pregnancy and lactation 
Direct oral anticoagulants and pregnancy 
DOACs are not recommended during pregnancy. 
III 
C 
6. Pregnancy in women with cardiomyopathies and primary arrhythmia syndromes 
Cardiomyopathies and pregnancy 
Clinical cardiological surveillance (ECG, echocardiogram, and Holter ECG monitoring) is recommended during pregnancy in women with 
CMPs, depending on individual risk. 
I 
C 
Vaginal delivery is recommended in most women with CMPs, unless there are obstetric indications for caesarean section, severe HF 
(EF <30% and/or NYHA class III/IV), uncontrolled arrhythmias, or severe outflow obstruction (‚â•50 mmHg) in women with HCM, or in 
women presenting in labour on VKAs. 
I 
C 
In women with DCM and worsening of EF during pregnancy, counselling on the risk of recurrence during a subsequent pregnancy is 
recommended in all cases, even after recovery of LV function. 
I 
C 
It is recommended to use the same risk stratification protocol for ventricular arrhythmias in pregnant women with HCM as for 
non-pregnant women with HCM. 
I 
C 
It is recommended to start beta-blockers in women with HCM who develop symptoms due to outflow tract obstruction or arrhythmia 
during pregnancy. 
I 
C 
It is recommended that women with HCM with symptomatic LV dysfunction (EF <50%) and or severe LVOTO (‚â•50 mmHg) wishing to 
become pregnant are counselled by the Pregnancy Heart Team regarding the high risk of pregnancy-related adverse events. 
I 
C 
Myosin inhibitors are not recommended in women during pregnancy due to lack of safety data. 
III 
C 
Primary arrhythmia syndromes and pregnancy 
Monitoring and treatment of hypokalaemia and hypomagnesaemia is recommended in pregnant women with primary arrhythmia 
syndromes suffering from hyperemesis. 
I 
C 
Beta-blockers, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy in 
women with LQTS. 
I 
B 
It is recommended to continue beta-blocker therapy during lactation in women with LQTS to reduce arrhythmic risk. 
I 
B 
Pre-pregnancy dose beta-blocker of nadolol or propranolol are recommended in women with LQT2, particularly in the post-partum 
period, which represents a high-risk period for life-threatening arrhythmias. 
I 
B 
Beta-blockers, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy and 
lactation in women with CPVT. 
I 
C 
Flecainide, in addition to beta-blockers, is recommended in women with CPVT who experience cardiac events such as syncope, VT, or 
cardiac arrest, during pregnancy. 
I 
C 
It is recommended that women with CPVT who are stable on beta-blockers (nadolol or propranolol as drugs of choice) and flecainide 
before pregnancy, continue both drugs also during pregnancy and post-partum. 
I 
C 
7. Peripartum cardiomyopathy 
Counselling for women with PPCM about the risk of recurrence during a subsequent pregnancy and about contraception is recommended 
in all cases, even after recovery of LV function (LVEF >50%). 
I 
C 
8. Pregnancy in women with aortopathies 
It is recommended that women with aortic disease have counselling about the risk of aortic dissection in pregnancy and the post-partum 
period. 
I 
C 
It is recommended that women with a history of aortic dissection or -surgery have pre-pregnancy counselling about the high risk by an 
extended Pregnancy Heart Team considering the presence and type of genetic variant, aortic morphology, growth rate, and aetiology of 
aortic dissection. 
I 
C 
It is recommended that women with vascular Ehlers‚ÄìDanlos syndrome wishing to become pregnant are counselled regarding the very high 
risk of pregnancy-related adverse events by a multidisciplinary team, considering family history, genetic variant, and previous vascular events. 
I 
C 
Imaging of the entire aorta (CT or CMR) is recommended before pregnancy in women with known or suspected aortic disease. 
I 
C 
In women with aortic dilatation related to BAV, imaging (with TTE, and CMR/CT if needed) of the aortic root, ascending aorta, and 
descending aorta (to rule out coarctation) is recommended before pregnancy. 
I 
C 
In women with low-risk aortic disease (mWHO 2.0 classes II and II‚ÄìIII), one-time echocardiographic imaging between 20 and 30 weeks of 
gestation and imaging at 6 months post-partum is recommended. 
I 
C                         
Continued


<!-- PAGE 85 -->

### Page 85

In women with moderate to high-risk aortic disease (mWHO 2.0 classes III and IV), repeated echocardiographic imaging every 4‚Äì12 weeks 
(depending on diagnosis and severity of dilatation) is recommended during pregnancy and until 6 months post-partum. 
I 
C 
CMR (without gadolinium) imaging of the entire aorta is recommended in pregnant women at risk of or with known aortic dilatation who 
have not had recent pre-pregnancy cross-sectional imaging. 
I 
C 
It is recommended that centres managing pregnancies in women with moderate to high-risk aortic disease (mWHO 2.0 class III/IV) can 
provide cardiovascular surgery in case of peripartum adverse events. 
I 
C 
When a woman with known aortic dilatation, history of dissection, or P/LP variant associated with aortic disease becomes pregnant, strict 
and individualized BP control is recommended. 
I 
C 
Beta-blocker therapy throughout pregnancy and in the post-partum period is recommended in women with MFS and other HTADs. 
I 
C 
Celiprolol is recommended in women with vascular Ehlers‚ÄìDanlos syndrome during pregnancy and lactation. 
I 
C 
It is recommended that indications for pre-pregnancy aortic root and/or ascending aortic surgery are guided by aortic morphology, 
underlying pathology, family history, genetic variant, previous vascular events, and patient‚Äôs preference. 
I 
C 
In women with MFS and aortic root diameters >45 mm, surgery before pregnancy is recommended. 
I 
C 
In women with LDS with P/LP variants in TGFBR1, TGFBR2, and aortic root diameters ‚â•45 mm, surgery before pregnancy is recommended. 
I 
C 
In women with nsHTAD with P/LP variants in MYH11, ACTA2, PRKG1, or MYLK, and aortic root diameters ‚â•45 mm, surgery before 
pregnancy is recommended. 
I 
C 
In women with BAV and aortic root or ascending aortic diameter ‚â•50 mm, surgery before pregnancy is recommended. 
I 
C 
In women without an identifiable P/LP variant with aortic root or ascending aortic diameters ‚â•50 mm, surgery before pregnancy is 
recommended. 
I 
C 
In women with an aorta <40 mm, vaginal delivery is recommended. 
I 
C 
In women with vascular Ehlers‚ÄìDanlos syndrome, caesarean section at 37 weeks is recommended for obstetrical reasons. 
I 
C 
The use of ergometrine post-delivery is not recommended in women with aortopathy. 
III 
C 
9. Pregnancy in women with known congenital heart disease 
Vaginal delivery is recommended in most women with ACHD. 
I 
B 
It is recommended that all women with Fontan circulation who wish to become pregnant receive counselling from the Pregnancy Heart 
Team regarding the high risk of pregnancy-related adverse events. 
I 
C 
It is recommended that women with a systemic RV (Mustard/Senning or congenitally corrected TGA), in NYHA class III/IV, systemic 
ventricular dysfunction (EF <40%), or severe TR wishing to become pregnant are counselled by the Pregnancy Heart Team regarding the 
high risk of pregnancy-related adverse events. 
I 
C 
In women with significant haemodynamic lesions, discussion about guideline-directed interventions is recommended prior to pregnancy. 
I 
C 
10. Pregnancy in women with pulmonary arterial hypertension 
It is recommended that women of childbearing potential with PAH wishing to become pregnant are counselled by a multidisciplinary team 
regarding the very high risk of pregnancy-related adverse events, encouraging a shared decision-making process about whether to become 
pregnant. 
I 
C 
It is recommended to provide clear contraceptive advice to women of childbearing potential with PAH. 
I 
C 
For women with PAH requiring pregnancy termination, it is recommended to perform this in PH centres. 
I 
C 
Endothelin receptor antagonists, riociguat, and selexipag are not recommended during pregnancy. 
III 
C 
11. Venous thromboembolism in pregnancy and post-partum 
For pregnant or post-partum women at high risk of VTE, a prophylactic fixed dose of LMWH is recommended over a higher 
weight-adjusted dose to reduce the risk of VTE. 
I 
B 
In pregnant women or women in the post-partum period with suspicion of VTE (DVT and/or PE), an immediate formal diagnostic 
assessment with validated methods is recommended and should not be postponed. 
I 
B 
In pregnant women or women in the post-partum period with newly diagnosed VTE (DVT and/or PE), the involvement of the Pregnancy 
Heart Team, including a vascular specialist and a haematologist, is recommended. 
I 
C 
In pregnant or post-partum women with a diagnosis of VTE without haemodynamic instability, anticoagulation is recommended by using 
therapeutic-dose LMWH based on early pregnancy body weight. 
I 
C 
12. Pregnancy in women with acquired heart disease 
Coronary artery disease and pregnancy 
In pregnant women with chest pain, it is recommended to exclude life-threatening cardiovascular conditions, including PE, ACS (including 
SCAD), and acute aortic syndrome. 
I 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                               85


<!-- PAGE 86 -->

### Page 86

It is recommended to manage pregnant women with ACS in the same way as non-pregnant women, including diagnostic investigations and 
interventions. 
I 
C 
Low-dose ASA is recommended as the antiplatelet treatment of choice during pregnancy and lactation when single antiplatelet treatment is 
indicated. 
I 
B 
If DAPT is required, clopidogrel is recommended as the P2Y12 inhibitor of choice during pregnancy. 
I 
C 
The duration of DAPT (aspirin and clopidogrel) in pregnant women undergoing coronary stent implantation is recommended to be the 
same as in non-pregnant women, with an individual approach considering ischaemic risk and delivery-related bleeding risks. 
I 
C 
Hypertensive disorders and pregnancy 
It is recommended to aim for systolic BP <140 mmHg and diastolic BP <90 mmHg in pregnant women. 
I 
B 
Systolic BP ‚â•160 mmHg or diastolic BP ‚â•110 mmHg in a pregnant woman is an emergency, and treatment in a hospital setting is 
recommended. 
I 
C 
Low-dose aspirin (75‚Äì150 mg daily) is recommended in women at moderate or high risk of pre-eclampsia (i.e. at least one high risk factor or 
two moderate risk factors for pre-eclampsia) from weeks 12 to 36/37. 
I 
A 
In women with gestational hypertension, initiation of drug treatment is recommended at systolic BP ‚â•140 mmHg or diastolic 
BP ‚â•90 mmHg. 
I 
B 
Methyldopa is recommended for the treatment of hypertension in pregnancy. 
I 
B 
Labetalol, metoprolol, and dihydropyridine calcium channel blockers are recommended for the treatment of hypertension in pregnancy. 
I 
C 
In severe hypertension, drug treatment with i.v. labetalol, urapidil, nicardipine, or oral short-acting nifedipine or methyldopa is 
recommended for acute reduction in blood pressure. Intravenous hydralazine is a second-line option. 
I 
C 
In pre-eclampsia associated with pulmonary oedema, nitroglycerine given as an i.v. infusion is recommended. 
I 
C 
In women with pre-eclampsia without severe features, delivery is recommended at 37 weeks. 
I 
B 
It is recommended to expedite delivery in women with pre-eclampsia associated with adverse markers such as haemostatic disorders. 
I 
C 
In women with gestational hypertension, delivery is recommended at 39 weeks. 
I 
B 
Supraventricular tachycardia and pregnancy 
Immediate electrical cardioversion is recommended for acute treatment of SVT with haemodynamic instability. 
I 
C 
Vagal manoeuvres and i.v. adenosine are recommended for conversion of haemodynamically stable supraventricular tachycardias. 
I 
C 
Intravenous beta-blockers (metoprolol) are recommended as the first-line option for acute rate control in pregnant women with AF or AF 
with preserved LVEF and rapid ventricular rate. 
I 
C 
Therapeutic anticoagulation with LMWH is recommended for pregnant women with persistent or permanent AF at elevated 
thromboembolic risk. 
I 
C 
Beta-1-selective blockers are recommended for rate control in pregnant women with AF, AFL, or FAT. 
I 
C 
Beta-1-selective blockers or verapamil are recommended for the prevention of SVT in women without pre-excitation on resting ECG. 
I 
C 
Flecainide or propafenone are recommended for the prevention of arrhythmias in pregnant women with WPW syndrome. 
I 
C 
Ventricular tachycardia, device implantation, catheter ablation, and pregnancy 
Immediate electrical cardioversion is recommended for both unstable and stable ventricular tachycardias. 
I 
C 
Beta-blockers or verapamil are recommended for the prevention of idiopathic sustained VT. 
I 
C 
If an ICD, pacemaker, or resynchronization therapy device is indicated during pregnancy, implantation is recommended with optimal 
radiation protection. 
I 
C 
Cardiac arrest and pregnancy 
Continuous manual left uterine displacement during CPR in pregnant women (‚â•20 weeks) with cardiac arrest is recommended to relieve 
aortocaval compression. 
I 
C 
It is recommended to establish i.v. access above the diaphragm to ensure that the i.v. therapy is not obstructed by the gravid uterus. 
I 
C 
It is recommended to perform the same chest compressions and defibrillation protocols in pregnant as in non-pregnant women. 
I 
C 
Anterolateral defibrillator pad placement is recommended with the lateral pad placed under the breast. 
I 
C 
It is recommended that no drugs are withheld in pregnant women with cardiac arrest due to concerns of teratogenicity. 
I 
C 
Congenital atrioventricular block and pregnancy 
In pregnant women with asymptomatic congenital AV block, normal cardiac anatomy and function, a narrow QRS complex, and ventricular 
rate (>50 b.p.m.), a prophylactic temporary pacemaker during delivery is not recommended. 
III 
C 
Native valve disease and pregnancy 
Intervention is recommended before pregnancy in symptomatic patients with severe aortic stenosis. 
I 
C 
Intervention is recommended before pregnancy in women with mitral stenosis and a valve area <1.5 cm2. 
I 
C                         
Continued


<!-- PAGE 87 -->

### Page 87

In pregnant women with symptomatic mitral stenosis or pulmonary hypertension, restricted activities and beta-blockers are recommended. 
I 
C 
In pregnant women with mitral stenosis, diuretics are recommended when congestive symptoms persist despite beta-blockers. 
I 
C 
Full therapeutic-dose anticoagulation is recommended in women with mitral stenosis complicated by AF, left atrial thrombus, or prior 
embolism. 
I 
C 
Surgical treatment is recommended before pregnancy in women with severe aortic or mitral regurgitation with symptoms, impaired 
ventricular function, or marked ventricular dilatation. 
I 
C 
Diuretics are recommended in pregnant women with regurgitant lesions when symptoms or signs of congestion occur. 
I 
C 
Prosthetic valves and pregnancy 
A bioprosthetic valve is recommended (over a mechanical valve) in young women contemplating pregnancy requiring a valve prosthesis. 
I 
B 
It is recommended that the type of valve surgery or intervention for a woman contemplating pregnancy is chosen in consultation with the 
Pregnancy Heart Team. 
I 
C 
It is recommended that a care plan documenting the agreed anticoagulant strategy (including the decision to continue VKAs or converting to 
therapeutic-dose LMWH in the first trimester) is in place for women of childbearing age with an MHV prior to pregnancy or as soon as 
pregnancy is recognized. 
I 
C 
It is recommended that pregnant women with an MHV are managed by the Pregnancy Heart Team. 
I 
C 
In pregnant women on VKAs, it is recommended to perform INR monitoring weekly or at a minimum every 2 weeks. 
I 
C 
In pregnant women with MHVs on therapeutic-dose LMWH, it is recommended to check peak anti-factor Xa levels and to target levels 
according to individualized risk. 
I 
C 
LMWH is not recommended when anti-factor Xa level monitoring is not available. 
III 
C 
Chronic and acute heart failure and pregnancy 
It is recommended that women with HFrEF are advised about the risk of deterioration of cardiac function during pregnancy and peripartum. 
I 
C 
In pregnant women with HFrEF, it is recommended that non-selective beta-blockers are switched to beta-1-selective blockers (metoprolol, 
bisoprolol) with close maternal and foetal monitoring. 
I 
C 
Anticoagulation with therapeutic doses of LMWH is recommended in pregnant women with intracardiac thrombus or decreased LV 
function with EF <35%. 
I 
C 
It is recommended to optimize HF guideline-directed medical therapy after delivery, taking contraindicated drugs during lactation into 
account. 
I 
C 
Urgent delivery with caesarean section is recommended in pregnant women with cardiogenic shock as soon as the foetus is viable, taking 
gestational age, comorbidities, and the available level of medical care into account. 
I 
C 
Inotropes and/or vasopressors are recommended in pregnant women with cardiogenic shock with levosimendan, dobutamine, and 
milrinone as recommended agents. 
I 
C 
ACE-Is, ARBs, ARNIs, MRAs, ivabradine, and SGLT2 inhibitors are not recommended during pregnancy due to adverse foetal effects. 
III 
C 
Heart transplantation and pregnancy 
It is recommended to postpone pregnancy until at least 1 year after heart transplantation, taking individual risk factors into account. 
I 
C 
In women with a heart transplant, it is recommended that immunosuppression serum drug levels are monitored during pregnancy every 4 
weeks until the 32nd week, then every 2 weeks until the 36th week, then weekly until delivery, and for 6‚Äì12 months after delivery to guide 
dosing. 
I 
C 
It is recommended to perform weekly monitoring of donor-specific antibodies for at least 6‚Äì12 months after delivery. 
I 
C 
Mycophenolic acid therapy is not recommended in pregnancy and should be discontinued 6 weeks before conception. 
III 
C 
Cardio-oncology and pregnancy 
It is recommended that pregnant women with cancer who require cardiotoxic cancer therapy are jointly managed by the Pregnancy Heart 
Team and the cardio-oncology team. 
I 
C 
13. Long-term effects of adverse pregnancy outcomes 
It is recommended to undertake a cardiovascular risk assessment in women with APOs, to recognize and document APOs when CVD risk is 
evaluated in women, and to provide counselling on the importance of healthy lifestyle choices that optimize cardiovascular health. 
I 
B 
In women with persistent post-partum hypertension beyond 6 weeks to 3 months post-partum, initiation of antihypertensive therapy with 
reference to lactating status is recommended following current guidelines. 
I 
B 
In cases where adoption of healthy lifestyle choices alone is inadequate to control post-partum glucose levels, initiation of pharmacotherapy 
following current guidelines is recommended. 
I 
C 
It is recommended that women with a history of GDM undergo a formal oGTT 6‚Äì12 weeks post-partum with a repeat assessment at 6‚Äì12 
months and regular annual follow-up visits to screen for diabetes. 
I 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                               87


<!-- PAGE 88 -->

### Page 88

### 19 Author information

Author/Task Force Member Affiliations: Nina Eide 
Hasselberg, Department of Cardiology, Oslo University Hospital, 
Rikshospitalet, Oslo, Norway; Mich√®le de Hosson, Cardiology, 
Ghent University Hospital, Ghent, Belgium; Margarita Brida, 
Department of Rehabilitation and Sports Medicine, Faculty of 
Medicine, University of Rijeka, Rijeka, Croatia, and Adult Congenital 
Heart Disease Centre, Royal Brompton and Harefield Trust and 
Imperial College, London, United Kingdom; Silvia Castelletti, 
Cardiology Department, IRCCS Istituto Auxologico Italiano, Milan, 
Italy; Matthew Cauldwell, Obstetrics, St George‚Äôs Hospital, 
London, United Kingdom; Elisabetta Cerbai, Department of 
Neurosciences, Psychology, Drug Research and Child Health, 
University of Florence, Florence, Italy, and European Laboratory for 
Non-Linear Spectroscopy, LENS, Sesto Fiorentino, Italy; Lia Crotti, 
Department of Cardiology, Cardiomyopathy Unit, Center for 
Cardiac Arrhythmias of Genetic Origin and Laboratory of 
Cardiovascular Genetics, IRCCS, Istituto Auxologico Italiano, Milan, 
Italy, and Department of Medicine and Surgery, University of 
Milano-Bicocca, Milan, Italy; Natasja M.S. de Groot, Unit 
Translational Electrophysiology, Department of Cardiology, Erasmus 
University Medical Center, Rotterdam, Netherlands; Mette-Elise 
Estensen, Department of Cardiology, Oslo University Hospital, 
Oslo, Norway; Eva S. Goossens, Centre for Research and 
Innovation in Care, Department of Nursing and Midwifery, Faculty of 
Medicine and Health Sciences, University of Antwerp, Antwerp, 
Belgium, and Department of Public Health and Primary Care, KU 
Leuven, Leuven, Belgium, and Department of Patient Care, Antwerp 
University Hospital, UZA, Antwerp; Bernhard Haring, Klinik f√ºr 
Innere Medizin III, Saarland University, Homburg, Germany; Donata 
Kurpas, Division of Research Methodology, Department of Nursing, 
Wroclaw 
Medical 
University, 
Wroclaw, 
Poland; 
Carmel 
M. McEniery, Department of Medicine, University of Cambridge, 
Cambridge, United Kingdom; Sanne A.E. Peters, Julius Center for 
Health Sciences and Primary Care, University Medical Center 
Utrecht, Utrecht, Netherlands, and The George Institute for Global 
Health, School of Public Health, Imperial College London, London, 
United Kingdom, and The George Institute for Global Health, 
University of New South Wales, Sydney, Australia; Amina 
Rakisheva, Cardiology Department, City Cardiology Center, 
Almaty, Kazakhstan; Antonia Sambola, Acute Cardiac Care Unit, 
Department of Cardiology, Vall d'Hebron University Hospital, 
Barcelona, Spain; Oliver Schlager, Division of Angiology, 
Department of Medicine II, Medical University of Vienna, Vienna, 
Austria; Florian S. Schoenhoff, Department of Cardiac Surgery, 
Inselspital, University Hospital Bern, University of Bern, Bern, 
Switzerland; Tommaso Simoncini, Department of Clinical and 
Experimental Medicine, University of Pisa, Pisa, Italy; Fran√ßoise 
Steinbach, ESC Patient Forum, Sophia Antipolis, France; Isabella 
Sudano, Cardiology, University Hospital Zurich University Heart 
Center, Zurich, Switzerland, and University of Zurich, Switzerland; 
Lorna Swan, Scottish Adult Congenital Cardiac Service, Golden 
Jubilee National Hospital, Glasgow, United Kingdom; Anne Marie 
Valente, Cardiology, Boston Children‚Äôs Hospital, Boston, MA, 
United States of America, and Medicine, Brigham and Women‚Äôs 
Hospital, Boston, United States of America, MA, and Medicine and 
Pediatrics, Harvard Medical School, Boston, MA, United States of 
America. 
20. Appendix 
ESC Scientific Document Group 
Includes Document Reviewers and ESC National Cardiac Societies. 
Document 
Reviewers: 
Werner 
Budts 
(CPG 
Review 
Co-ordinator) (Belgium), Karen Sliwa (CPG Review Co-ordinator) 
(South Africa), Marianna Adamo (Italy), Elena Arbelo (Spain), Eloisa 
Arbustini (Italy), Giuseppe Boriani (Italy), Antonio Brucato (Italy), 
Sergio Buccheri (Sweden), Alessandra Bura Riviere (France), Pavel 
Calda (Czech Republic), G.-Andrei Dan (Romania), Konstantinos 
Dimopoulos (United Kingdom), Alexandra Frogoudaki (Greece), 
Estelle Gandjbakhch (France), Eva Gerdts (Norway), Sofie A Gevaert 
(Belgium), Bruna Gigante (Sweden), Bettina Heidecker (Germany), 
Borja Ibanez (Spain), Stefan James (Sweden), Mark Johnson (United 
Kingdom), Peter J√ºni (United Kingdom), Jolanda Kluin (Netherlands), 
Lars K√∏ber (Denmark), Konstantinos C. Koskinas (Switzerland), Greg 
Lip (United Kingdom), Emma F. Magavern (United Kingdom), Bill 
McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard 
Mindham (United Kingdom), Inge Moelgaard (Denmark), Philip 
Moons (Belgium), Jens Cosedis Nielsen (Denmark), Ntobeko 
A. B. Ntusi (South Africa), Agnes A. Pasquet (Belgium), Tatjana 
Potpara (Serbia), Eva Prescott (Denmark), Bianca Rocca (Italy), Jolien 
Roos-Hesselink (Netherlands), Xavier Rossell√≥ (Spain), Anna Sannino 
Nifedipine and labetalol (metoprolol if labetalol is unavailable) are recommended as treatments for uncomplicated post-partum 
hypertension in the first 6 weeks after delivery. 
I 
C 
¬© ESC 2025
ACE-I, angiotensin-converting enzyme inhibitor; ACHD, congenital heart disease; ACS, acute coronary syndrome; AF, atrial fibrillation; AFL, atrial flutter; ALARA, as low as reasonably 
achievable; aPTT, activated partial thromboplastin time; APO, adverse pregnancy outcome; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor/neprilysin inhibitor; ASA, 
acetylsalicylic acid; AV, atrioventricular; BAV, bicuspid aortic valve; BP, blood pressure; CMP; cardiomyopathy; CMR, cardiovascular magnetic resonance; CPR, cardiopulmonary 
resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CT, computed tomography; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; DCM, dilated 
cardiomyopathy; DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; ECG, electrocardiogram; EF, ejection fraction; FAT, focal atrial tachycardia; GDM, gestational diabetes 
mellitus; HCM, hypertrophic cardiomyopathy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HTAD, heritable thoracic aortic disease; ICD, implantable 
cardioverter defibrillator; INR, international normalized ratio; i.v., intravenous; LDS, Loeys‚ÄìDietz syndrome; LMWH, low-molecular-weight heparin; LQT2, long QT syndrome type 2; 
LQTS, long QT syndrome; LV, left ventricle; LVEF, left ventricular ejection fraction; LVOTO, left ventricular outflow tract obstruction; MFS, Marfan syndrome; MHV, mechanical heart 
valve; MRA, mineralocorticoid receptor antagonist; mWHO, modified World Health Organization; nsHTAD, non-syndromic heritable thoracic aortic disease; NYHA, New York Heart 
Association; oGTT, oral glucose tolerance test; PAH, pulmonary arterial hypertension; PE, pulmonary embolism; PH, pulmonary hypertension; P/LP, pathogenic/likely pathogenic; PPCM, 
peripartum cardiomyopathy; RV, right ventricle; SCAD, spontaneous coronary artery dissection; SGLT2, sodium‚Äìglucose co-transporter-2; SVT, supraventricular tachycardia; TGA, 
transposition of the great arteries; TR, tricuspid regurgitation; TTE, transthoracic echocardiogram; UFH, unfractionated heparin; VKA, vitamin K antagonist; VT, ventricular tachycardia; 
VTE, venous thromboembolism; WPW, Wolff‚ÄìParkinson‚ÄìWhite. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 89 -->

### Page 89

(Germany), Felix Tanner (Switzerland), Ulf Landmesser (Germany), 
Ilonca Vaartjes (Netherlands), Christiaan Vrints (Belgium), Katja 
Zeppenfeld (Netherlands), Dayenne Zwaagman (Netherlands) 
ESC National Cardiac Societies actively involved in the review 
process of the 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy: 
Albania: Albanian Society of Cardiology, Aurel Demiraj; Algeria: 
Algerian Society of Cardiology, Nora Henine; Armenia: Armenian 
Cardiologists Association, Hamlet G. Hayrapetyan; Austria: 
Austrian Society of Cardiology, Noemi Pavo; Azerbaijan: 
Azerbaijan Society of Cardiology, Gulane Aghayeva; Belgium: 
Belgian Society of Cardiology, Agnes A. Pasquet; Bosnia and 
Herzegovina: Association of Cardiologists of Bosnia and 
Herzegovina, Milan Gluhoviƒá; Bulgaria: Bulgarian Society of 
Cardiology, Nina Gotcheva; Croatia: Croatian Cardiac Society, 
Bosko Skoric; Cyprus: Cyprus Society of Cardiology, Maria 
Karakyriou; Czechia: Czech Society of Cardiology, Zuzana 
Motovska; Denmark: Danish Society of Cardiology, Dorte 
Guldbrand Nielsen; Egypt: Egyptian Society of Cardiology, Ghada 
Youssef; Estonia: Estonian Society of Cardiology, Maarja Maser; 
Finland: Finnish Cardiac Society, Sanna Laurila; France: French 
Society of Cardiology, Bernard Iung; Georgia: Georgian Society of 
Cardiology, Khatuna Jalabadze; Germany: German Cardiac Society, 
Stephanie Fichtner; Greece: Hellenic Society of Cardiology, 
Alexandra Frogoudaki; Hungary: Hungarian Society of Cardiology, 
Olga Hajnalka Balint; Iceland: Icelandic Society of Cardiology, √û√≥rd√≠s 
J√≥na Hrafnkelsd√≥ttir; Ireland: Irish Cardiac Society, Paul F. Brennan; 
Israel: Israel Heart Society, Rafael Kuperstein; Italy: Italian 
Federation of Cardiology, Gabriele Egidy Assenza; Kazakhstan: 
Association of Cardiologists of Kazakhstan, Gulnara Junusbekova; 
Kosovo (Republic of): Kosovo Society of Cardiology, Pranvera 
Ibrahimi; Kyrgyzstan: Kyrgyz Society of Cardiology, Saamay 
Abilova; Latvia: Latvian Society of Cardiology, Oskars Kalejs; 
Lebanon: Lebanese Society of Cardiology, Georges Saad√©; Libya: 
Libyan Cardiac Society, Hanan Taher Bugaigis; Lithuania: 
Lithuanian Society of Cardiology, J≈´ratƒó Barysienƒó; Luxembourg: 
Luxembourg Society of Cardiology, Rouguiatou Sow; Malta: Maltese 
Cardiac Society, Maryanne Caruana; Moldova (Republic of): 
Moldavian Society of Cardiology, Lilia David; Morocco: Moroccan 
Society of Cardiology, Aatif Benyass; Netherlands: Netherlands 
Society of Cardiology, Anastasia D. Egorova; North Macedonia: 
National Society of Cardiology of North Macedonia, Marijan 
Bosevski; Norway: Norwegian Society of Cardiology, Elisabeth 
Leirgul; Poland: Polish Cardiac Society, Olga Trojnarska; Portugal: 
Portuguese Society of Cardiology, Rita Ilh√£o Moreira; Romania: 
Romanian Society of Cardiology, Ruxandra Jurcut; San Marino: San 
Marino Society of Cardiology, Marco Zavatta; Serbia: Cardiology 
Society of Serbia, Aleksandra Ilic; Slovakia: Slovak Society of 
Cardiology, Juraj Dubrava; Slovenia: Slovenian Society of 
Cardiology, Katja Prok≈°elj; Spain: Spanish Society of Cardiology, 
Milagros Pedreira P√©rez; Sweden: Swedish Society of Cardiology, 
Christina 
Christersson; 
Switzerland: 
Swiss 
Society 
of 
Cardiology, Matthias Greutmann; Syrian Arab Republic: Syrian 
Cardiovascular Association, Elias Barakat; Tunisia: Tunisian Society 
of Cardiology and Cardiovascular Surgery, Meriam Drissa; T√ºrkiye: 
Turkish Society of Cardiology, Alev Arat Ozkan; Ukraine: Ukrainian 
Association of Cardiology, Olena I Mitchenko; United Kingdom of 
Great Britain and Northern Ireland: British Cardiovascular 
Society, 
Dawn 
L. 
Adamson; 
Uzbekistan: 
Association 
of 
Cardiologists of Uzbekistan, Feruza Zakirova 
ESC Clinical Practice Guidelines (CPG) Committee: Ulf 
Landmesser (Chairperson) (Germany), Stefan James (Co-Chairperson) 
(Sweden), Marianna Adamo (Italy), Suleman Aktaa (United Kingdom), 
Folkert W. Asselbergs (Netherlands), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Giuseppe Boriani (Italy), Margarita Brida 
(Croatia), Robert A. Byrne (Ireland), Estelle Gandjbakhch (France), 
Bettina Heidecker (Germany), Anja Hennemuth (Germany), Borja 
Ibanez (Spain), Peter J√ºni (United Kingdom), Gregory Y.H. Lip (United 
Kingdom), John William McEvoy (Ireland), Borislava Mihaylova (United 
Kingdom), Inge Moelgaard (Denmark), Lis Neubeck (United Kingdom), 
Eva Prescott (Denmark), Bianca Rocca (Italy), Xavier Rossello (Spain), 
Anna Sannino (Germany), Felix C. Tanner (Switzerland), Wojtek 
Wojakowski (Poland), Katja Zeppenfeld (Netherlands) 
21. References 
1. Bredy C, Deville F, Huguet H, Picot MC, De La Villeon G, Abassi H, et al. Which risk 
score best predicts cardiovascular outcome in pregnant women with congenital heart 
disease? Eur Heart J Qual Care Clin Outcomes 2023;9:177‚Äì83. https://doi.org/10.1093/ 
ehjqcco/qcac019 
2. Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, et al. Pregnancy 
outcomes in women with cardiovascular disease: evolving trends over 10 years in the 
ESC Registry Of Pregnancy And Cardiac disease (ROPAC). Eur Heart J 2019;40: 
3848‚Äì55. https://doi.org/10.1093/eurheartj/ehz136 
3. van der Zande JA, Tutarel O, Ramlakhan KP, van der Bosch AE, Bordese R, Zengin E, 
et al. Pregnancy outcomes in women with Ebstein‚Äôs anomaly: data from the Registry Of 
Pregnancy And Cardiac disease (ROPAC). Open Heart 2023;10:e002406. https://doi. 
org/10.1136/openhrt-2023-002406 
4. Wander G, van der Zande JA, Patel RR, Johnson MR, Roos-Hesselink J. Pregnancy in 
women with congenital heart disease: a focus on management and preventing the 
risk of complications. Expert Rev Cardiovasc Ther 2023;21:587‚Äì99. https://doi.org/10. 
1080/14779072.2023.2237886 
5. Ramlakhan KP, Malham√© I, Marelli A, Rutz T, Goland S, Franx A, et al. Hypertensive 
disorders of pregnant women with heart disease: the ESC EORP ROPAC registry. 
Eur Heart J 2022;43:3749‚Äì61. https://doi.org/10.1093/eurheartj/ehac308 
6. Tutarel O, Baris L, Budts W, Gamal Abd-El Aziz M, Liptai C, Majdalany D, et al. 
Pregnancy outcomes in women with a systemic right ventricle and transposition of 
the great arteries results from the ESC-EORP Registry Of Pregnancy And Cardiac disease (ROPAC). Heart 2022;108:117‚Äì23. https://doi.org/10.1136/heartjnl-2020- 
318685 
7. Campens L, Baris L, Scott NS, Broberg CS, Bondue A, Jondeau G, et al. Pregnancy outcome in thoracic aortic disease data from the Registry Of Pregnancy And Cardiac disease. Heart 2021;107:1704‚Äì9. https://doi.org/10.1136/heartjnl-2020-318183 
8. Tutarel O, Ramlakhan KP, Baris L, Subirana MT, Bouchardy J, Nemes A, et al. 
Pregnancy outcomes in women after arterial switch operation for transposition of 
the great arteries: results from ROPAC (Registry Of Pregnancy And Cardiac disease) 
of the European Society of Cardiology EURObservational research programme. J Am 
Heart Assoc 2021;10:e018176. https://doi.org/10.1161/JAHA.120.018176 
9. Ramlakhan KP, Tobler D, Greutmann M, Schwerzmann M, Baris L, Yetman AT, et al. 
Pregnancy outcomes in women with aortic coarctation. Heart 2020;107:290‚Äì8.  
https://doi.org/10.1136/heartjnl-2020-317513 
10. Baris L, Hakeem A, Moe T, Cornette J, Taha N, Farook F, et al. Acute coronary syndrome and ischemic heart disease in pregnancy: data from the EURObservational 
Research Programme-European Society of Cardiology Registry of Pregnancy and 
Cardiac Disease. J Am Heart Assoc 2020;9:e015490. https://doi.org/10.1161/JAHA. 
119.015490 
11. van Hagen IM, Thorne SA, Taha N, Youssef G, Elnagar A, Gabriel H, et al. Pregnancy 
outcomes in women with rheumatic mitral valve disease: results from the Registry Of 
Pregnancy And Cardiac disease. Circulation 2018;137:806‚Äì16. https://doi.org/10.1161/ 
CIRCULATIONAHA.117.032561 
12. Ramlakhan KP, Roos-Hesselink JW, Basso T, Greenslade J, Flint RB, Krieger EV, et al. 
Perinatal outcomes after in-utero exposure to beta-blockers in women with heart disease: data from the ESC EORP Registry Of Pregnancy And Cardiac disease (ROPAC). 
Int J Cardiol 2024;410:132234. https://doi.org/10.1016/j.ijcard.2024.132234 
13. Kodogo V, Viljoen C, Hoevelmann J, Chakafana G, Tromp J, Farhan HA, et al. 
Proteomic profiling in patients with peripartum cardiomyopathy: a biomarker study 
of the ESC EORP PPCM registry. JACC Heart Fail 2023;11:1708‚Äì25. https://doi.org/ 
10.1016/j.jchf.2023.07.028 
14. Tromp J, Jackson AM, Abdelhamid M, Fouad D, Youssef G, Petrie MC, et al. 
Thromboembolic events in peripartum cardiomyopathy: results from the ESC 
EORP PPCM registry. Eur J Heart Fail 2023;25:1464‚Äì6. https://doi.org/10.1002/ejhf.


<!-- PAGE 90 -->

### Page 90

15. Jackson AM, Petrie MC, Frogoudaki A, Laroche C, Gustafsson F, Ibrahim B, et al. 
Hypertensive disorders in women with peripartum cardiomyopathy: insights from 
the ESC EORP PPCM registry. Eur J Heart Fail 2021;23:2058‚Äì69. https://doi.org/10. 
1002/ejhf.2264 
16. Sliwa K, Petrie MC, van der Meer P, Mebazaa A, Hilfiker-Kleiner D, Jackson AM, et al. 
Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. Eur Heart J 2020;41:3787‚Äì97. https:// 
doi.org/10.1093/eurheartj/ehaa455 
17. Jackson AM, Bauersachs J, Petrie MC, van der Meer P, Laroche C, Farhan HA, et al. 
Outcomes at one year in women with peripartum cardiomyopathy: findings from 
the ESC EORP PPCM registry. Eur J Heart Fail 2024;26:34‚Äì42. https://doi.org/10. 
1002/ejhf.3055 
18. Davis MB, Arendt K, Bello NA, Brown H, Briller J, Epps K, et al. Team-based care of 
women with cardiovascular disease from pre-conception through pregnancy and 
postpartum: JACC focus seminar 1/5. J Am Coll Cardiol 2021;77:1763‚Äì77. https://doi. 
org/10.1016/j.jacc.2021.02.033 
19. Opotowsky AR, Siddiqi OK, D‚ÄôSouza B, Webb GD, Fernandes SM, Landzberg MJ. 
Maternal cardiovascular events during childbirth among women with congenital heart 
disease. Heart 2012;98:145‚Äì51. https://doi.org/10.1136/heartjnl-2011-300828 
20. Elkayam U, Goland S, Pieper PG, Silverside CK. High-risk cardiac disease in pregnancy: 
part I. J Am Coll Cardiol 2016;68:396‚Äì410. https://doi.org/10.1016/j.jacc.2016.05.048 
21. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, et al. 
2021;42:563‚Äì645. https://doi.org/10.1093/eurheartj/ehaa554 
22. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33: 
130‚Äì7. https://doi.org/10.1053/j.semperi.2009.02.010 
23. Sliwa K, B√∂hm M. Incidence and prevalence of pregnancy-related heart disease. 
Cardiovasc Res 2014;101:554‚Äì60. https://doi.org/10.1093/cvr/cvu012 
24. Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-related mortality in the 
United States, 2011‚Äì2013. Obstet Gynecol 2017;130:366‚Äì73. https://doi.org/10.1097/ 
AOG.0000000000002114 
25. Kotit S, Yacoub M. Cardiovascular adverse events in pregnancy: a global perspective. 
Glob Cardiol Sci Pract 2021;2021:e202105. https://doi.org/10.21542/gcsp.2021.5 
26. Majmundar M, Doshi R, Patel KN, Zala H, Kumar A, Kalra A. Prevalence, trends, and 
outcomes of cardiovascular diseases in pregnant patients in the USA: 2010‚Äì19. Eur 
Heart J 2023;44:726‚Äì37. https://doi.org/10.1093/eurheartj/ehac669 
27. Nair M, Nelson-Piercy C, Knight M. Indirect maternal deaths: UK and global perspectives. Obstet Med 2017;10:10‚Äì5. https://doi.org/10.1177/1753495X16689444 
28. WHO. The WHO Application of ICD-10 to Deaths During Pregnancy, Childbirth and 
Puerperium: ICD MM. https://www.who.int/publications/i/item/9789241548458 (25 
August 2023, date last accessed). 
29. Alkema L, Chou D, Hogan D, Zhang S, Moller AB, Gemmill A, et al. Global, regional, 
and national levels and trends in maternal mortality between 1990 and 2015, with 
scenario-based projections to 2030: a systematic analysis by the UN maternal mortality estimation inter-agency group. Lancet 2016;387:462‚Äì74. https://doi.org/10.1016/ 
S0140-6736(15)00838-7 
30. MacDorman MF, Declercq E, Cabral H, Morton C. Recent increases in the U.S. maternal mortality rate: disentangling trends from measurement issues. Obstet Gynecol 2016; 
128:447‚Äì55. https://doi.org/10.1097/AOG.0000000000001556 
31. Ferranti EP, Jones EJ, Hernandez TL. Pregnancy reveals evolving risk for cardiometabolic disease in women. J Obstet Gynecol Neonatal Nurs 2016;45:413‚Äì25. https://doi. 
org/10.1016/j.jogn.2016.02.004 
32. Brown HL, Smith GN. Pregnancy complications, cardiovascular risk factors, and future 
heart disease. Obstet Gynecol Clin North Am 2020;47:487‚Äì95. https://doi.org/10.1016/j. 
ogc.2020.04.009 
33. CDC. Report From Nine Maternal Mortality Review Committees. https://stacks.cdc.gov/ 
view/cdc/51660 (12 December 2024, date last accessed). 
34. Siu SC, Sermer M, Colman JM, Alvarez AN, Mercier LA, Morton BC, et al. Prospective 
multicenter study of pregnancy outcomes in women with heart disease. Circulation 
2001;104:515‚Äì21. https://doi.org/10.1161/hc3001.093437 
35. Drenthen W, Boersma E, Balci A, Moons P, Roos-Hesselink JW, Mulder BJ, et al. 
Predictors of pregnancy complications in women with congenital heart disease. Eur 
Heart J 2010;31:2124‚Äì32. https://doi.org/10.1093/eurheartj/ehq200 
36. Hossin MZ, Kazamia K, Fax√©n J, Rudolph A, Johansson K, Sandstr√∂m A, et al. 
Pre-existing maternal cardiovascular disease and the risk of offspring cardiovascular 
disease from infancy to early adulthood. Eur Heart J 2024;45:4111‚Äì23. https://doi. 
org/10.1093/eurheartj/ehae547 
37. Sanghavi M, Rutherford JD. Cardiovascular physiology of pregnancy. Circulation 2014; 
130:1003‚Äì8. https://doi.org/10.1161/CIRCULATIONAHA.114.009029 
38. Estensen ME, Beitnes JO, Grindheim G, Aaberge L, Smiseth OA, Henriksen T, et al. 
Altered maternal left ventricular contractility and function during normal pregnancy. 
Ultrasound Obstet Gynecol 2013;41:659‚Äì66. https://doi.org/10.1002/uog.12296 
39. Ouzounian JG, Elkayam U. Physiologic changes during normal pregnancy and delivery. 
Cardiol Clin 2012;30:317‚Äì29. https://doi.org/10.1016/j.ccl.2012.05.004 
40. Kamel H, Roman MJ, Pitcher A, Devereux RB. Pregnancy and the risk of aortic dissection or rupture: a cohort-crossover analysis. Circulation 2016;134:527‚Äì33. https://doi. 
org/10.1161/CIRCULATIONAHA.116.021594 
41. Cerneca F, Ricci G, Simeone R, Malisano M, Alberico S, Guaschino S. Coagulation and 
fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined 
with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol 1997;73:31‚Äì6. https://doi. 
org/10.1016/S0301-2115(97)02734-6 
42. Pieper PG. Use of medication for cardiovascular disease during pregnancy. Nat Rev 
Cardiol 2015;12:718‚Äì29. https://doi.org/10.1038/nrcardio.2015.172 
43. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstr√∂m-Lundqvist C, C√≠fkov√° 
R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165‚Äì241. https://doi.org/10.1093/ 
eurheartj/ehy340 
44. Easter SR, Valente AM, Economy KE. Creating a multidisciplinary pregnancy heart 
team. Curr Treat Options Cardiovasc Med 2020;22:3. https://doi.org/10.1007/s11936- 
020-0800-x 
45. Luc√† F, Colivicchi F, Parrini I, Russo MG, Di Fusco SA, Ceravolo R, et al. The role of the 
pregnancy heart team in clinical practice. Front Cardiovasc Med 2023;10:1135294.  
https://doi.org/10.3389/fcvm.2023.1135294 
46. Miller HE, Do SC, Cruz G, Panelli DM, Leonard SA, Girsen A, et al. Addressing postpartum contraception practices utilizing a multidisciplinary pregnancy heart team approach. AJOG Glob Rep 2022;2:100100. https://doi.org/10.1016/j.xagr.2022.100100 
47. Sharma G, Ying W, Silversides CK. The importance of cardiovascular risk assessment 
and pregnancy heart team in the management of cardiovascular disease in pregnancy. 
Cardiol Clin 2021;39:7‚Äì19. https://doi.org/10.1016/j.ccl.2020.09.002 
48. Stephens EH, Dearani JA, Overman DM, Deyle DR, Rose CH, Ashikhmina E, et al. 
Pregnancy heart team: a lesion-specific approach. J Thorac Cardiovasc Surg 2023;166: 
221‚Äì30. https://doi.org/10.1016/j.jtcvs.2022.12.016 
49. Wolfe DS. Introduction to building the cardio-obstetric team. Clin Obstet Gynecol 
2020;63:791‚Äì8. https://doi.org/10.1097/GRF.0000000000000557 
50. Magun E, DeFilippis EM, Noble S, LaSala A, Waksmonski C, D‚ÄôAlton ME, et al. 
Cardiovascular care for pregnant women with cardiovascular disease. J Am Coll 
Cardiol 2020;76:2102‚Äì13. https://doi.org/10.1016/j.jacc.2020.08.071 
51. van Hagen IM, Boersma E, Johnson MR, Thorne SA, Parsonage WA, Escribano Sub√≠as 
P, et al. Global cardiac risk assessment in the Registry Of Pregnancy And Cardiac disease: results of a registry from the European Society of Cardiology. Eur J Heart Fail 
2016;18:523‚Äì33. https://doi.org/10.1002/ejhf.501 
52. Silversides CK, Grewal J, Mason J, Sermer M, Kiess M, Rychel V, et al. Pregnancy outcomes in women with heart disease: the CARPREG II study. J Am Coll Cardiol 2018;71: 
2419‚Äì30. https://doi.org/10.1016/j.jacc.2018.02.076 
53. American College of Obstetricians and Gynecologists‚Äô Presidential Task Force on 
Pregnancy and Heart Disease and Committee on Practice Bulletins‚ÄîObstetrics. 
ACOG practice bulletin no. 212: pregnancy and heart disease. Obstet Gynecol 2019; 
133:e320‚Äì56. https://doi.org/10.1097/AOG.0000000000003243 
54. Nana M, Stannard MT, Nelson-Piercy C, Williamson C. The impact of preconception 
counselling on maternal and fetal outcomes in women with chronic medical conditions: a systematic review. Eur J Intern Med 2023;108:52‚Äì9. https://doi.org/10.1016/j. 
ejim.2022.11.003 
55. Deng LX, Gleason LP, Awh K, Khan AM, Drajpuch D, Fuller S, et al. Too little too late? 
Communication with patients with congenital heart disease about challenges of adult 
life. Congenit Heart Dis 2019;14:534‚Äì40. https://doi.org/10.1111/chd.12778 
56. Ricci P, Dimopoulos K, Bouchard M, Zhiya CC, Meira VC, Pool D, et al. Transition to 
adult care of young people with congenital heart disease: impact of a service on knowledge and self-care skills, and correlates of a successful transition. Eur Heart J Qual Care 
Clin Outcomes 2023;9:351‚Äì7. https://doi.org/10.1093/ehjqcco/qcad014 
57. Bratt EL, Mora MA, Sparud-Lundin C, Saarij√§rvi M, Burstr√∂m √Ö, Skogby S, et al. 
Effectiveness of the STEPSTONES transition program for adolescents with congenital 
heart disease‚Äîa randomized controlled trial. J Adolesc Health 2023;73:655‚Äì63. https:// 
doi.org/10.1016/j.jadohealth.2023.02.019 
58. de Hosson M, De Groote K, Hecke AV, De Wolf D, Vandekerckhove K, Mosquera LM, 
et al. Evaluation of a nurse-led multi-component transition program for adolescents 
with congenital heart disease. Patient Educ Couns 2024;118:108028. https://doi.org/ 
10.1016/j.pec.2023.108028 
59. Buys R, Cornelissen V, Van De Bruaene A, Stevens A, Coeckelberghs E, Onkelinx S, 
et al. Measures of exercise capacity in adults with congenital heart disease. Int J 
Cardiol 2011;153:26‚Äì30. https://doi.org/10.1016/j.ijcard.2010.08.030 
60. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 
44:3503‚Äì626. https://doi.org/10.1093/eurheartj/ehad194 
61. Balci A, Sollie-Szarynska KM, van der Bijl AG, Ruys TP, Mulder BJ, Roos-Hesselink JW, 
et al. Prospective validation and assessment of cardiovascular and offspring risk models 
for pregnant women with congenital heart disease. Heart 2014;100:1373‚Äì81. https:// 
doi.org/10.1136/heartjnl-2014-305597 
62. Isselbacher EM, Preventza O, Hamilton Black J, 3rd, Augoustides JG, Beck AW, Bolen 
MA, et al. 2022 ACC/AHA Guideline for the diagnosis and management of aortic


<!-- PAGE 91 -->

### Page 91

disease: a report of the American Heart Association/American College of Cardiology 
Joint Committee on clinical practice guidelines. Circulation 2022;146:e334‚Äì482. https:// 
doi.org/10.1161/CIR.0000000000001106 
63. Wilde AAM, Semsarian C, M√°rquez MF, Shamloo AS, Ackerman MJ, Ashley EA, et al. 
European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia 
Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society 
(LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace 2022;24:1307‚Äì67. https://doi.org/10.1093/europace/euac030 
64. Regalado ES, Morris SA, Braverman AC, Hostetler EM, De Backer J, Li R, et al. 
Comparative risks of initial aortic events associated with genetic thoracic aortic disease. J Am Coll Cardiol 2022;80:857‚Äì69. https://doi.org/10.1016/j.jacc.2022.05.054 
65. Reuter C, Grove ME, Orland K, Spoonamore K, Caleshu C. Clinical cardiovascular genetic counselors take a leading role in team-based variant classification. J Genet Couns 
2018;27:751‚Äì60. https://doi.org/10.1007/s10897-017-0175-7 
66. Akolekar R, Beta J, Picciarelli G, Ogilvie C, D‚ÄôAntonio F. Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and 
meta-analysis. Ultrasound Obstet Gynecol 2015;45:16‚Äì26. https://doi.org/10.1002/uog. 
14636 
67. Yeates L, McDonald K, Burns C, Semsarian C, Carter S, Ingles J. Decision-making and 
experiences of preimplantation genetic diagnosis in inherited heart diseases: a qualitative study. Eur J Hum Genet 2022;30:187‚Äì93. https://doi.org/10.1038/s41431-021- 
00963-1 
68. Dhalwani NN, Fiaschi L, West J, Tata LJ. Occurrence of fertility problems presenting to 
primary care: population-level estimates of clinical burden and socioeconomic inequalities across the UK. Hum Reprod 2013;28:960‚Äì8. https://doi.org/10.1093/humrep/ 
des451 
69. Goualou M, Noumegni S, de Moreuil C, Le Guillou M, De Coninck G, Hoffmann C, 
et al. Venous thromboembolism associated with assisted reproductive technology: a 
systematic review and meta-analysis. Thromb Haemost 2023;123:283‚Äì94. https://doi. 
org/10.1055/s-0042-1760255 
70. Kametas NA, McAuliffe F, Krampl E, Chambers J, Nicolaides KH. Maternal cardiac 
function in twin pregnancy. Obstet Gynecol 2003;102:806‚Äì15. https://doi.org/10. 
1016/s0029-7844(03)00807-x 
71. Ombelet W, Martens G, De Sutter P, Gerris J, Bosmans E, Ruyssinck G, et al. Perinatal 
outcome of 12,021 singleton and 3108 twin births after non-IVF-assisted reproduction: a cohort study. Hum Reprod 2006;21:1025‚Äì32. https://doi.org/10.1093/humrep/ 
dei419 
72. Glisic M, Shahzad S, Tsoli S, Chadni M, Asllanaj E, Rojas LZ, et al. Association between 
progestin-only contraceptive use and cardiometabolic outcomes: a systematic review 
and meta-analysis. Eur J Prev Cardiol 2018;25:1042‚Äì52. https://doi.org/10.1177/ 
2047487318774847 
73. Palacios S, Colli E, Regidor PA. Efficacy and cardiovascular safety of the new estrogen- 
free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime. BMC 
Womens Health 2020;20:218. https://doi.org/10.1186/s12905-020-01080-9 
74. Vink AS, Wilde AAM. Oral contraceptives and their effect on arrhythmogenesis in long 
QT syndrome: does it matter? Heart Rhythm 2022;19:49‚Äì50. https://doi.org/10.1016/j. 
hrthm.2021.08.007 
75. Goldenberg I, Younis A, Huang DT, Yoruk A, Rosero SZ, Cutter K, et al. Use of oral 
contraceptives in women with congenital long QT syndrome. Heart Rhythm 2022;19: 
41‚Äì8. https://doi.org/10.1016/j.hrthm.2021.07.058 
76. Lidegaard √ò, L√∏kkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke 
and myocardial infarction with hormonal contraception. N Engl J Med 2012;366: 
2257‚Äì66. https://doi.org/10.1056/NEJMoa1111840 
77. Chen MJ, Jensen JT, Kaunitz AM, Achilles SL, Zatik J, Weyers S, et al. Tolerability and 
safety of the estetrol/drospirenone combined oral contraceptive: pooled analysis of 
two multicenter, open-label phase 3 trials. Contraception 2022;116:44‚Äì50. https:// 
doi.org/10.1016/j.contraception.2022.10.004 
78. Dragoman M, Curtis KM, Gaffield ME. Combined hormonal contraceptive use among 
women with known dyslipidemias: a systematic review of critical safety outcomes. 
Contraception 2016;94:280‚Äì7. https://doi.org/10.1016/j.contraception.2015.08.002 
79. WHO. Medical Eligibility Criteria for Contraceptive Use. https://www.who.int/ 
publications/i/item/9789241549158 (29 January 2025, date last accessed). 
80. Horton LG, Simmons KB, Curtis KM. Combined hormonal contraceptive use among 
obese women and risk for cardiovascular events: a systematic review. Contraception 
2016;94:590‚Äì604. https://doi.org/10.1016/j.contraception.2016.05.014 
81. Siagian SN, Christianto C, Angellia P, Holiyono HI. The risk factors of acute coronary 
syndrome in young women: a systematic review and meta-analysis. Curr Cardiol Rev 
2023;19:e161122210969. https://doi.org/10.2174/1573403X19666221116113208 
82. Abarbanell G, Tepper NK, Farr SL. Safety of contraceptive use among women with 
congenital heart disease: a systematic review. Congenit Heart Dis 2019;14:331‚Äì40.  
https://doi.org/10.1111/chd.12752 
83. Lindley KJ, Bairey Merz CN, Davis MB, Madden T, Park K, Bello NA. Contraception and 
reproductive planning for women with cardiovascular disease: JACC focus seminar 5/ 
5. J Am Coll Cardiol 2021;77:1823‚Äì34. https://doi.org/10.1016/j.jacc.2021.02.025 
84. Greydanus DE, Dodich C. Pelvic inflammatory disease in the adolescent: a poignant, 
perplexing, potentially preventable problem for patients and physicians. Curr Opin 
Pediatr 2015;27:92‚Äì9. https://doi.org/10.1097/MOP.0000000000000183 
85. Upadhya KK. Emergency contraception. Pediatrics 2019;144:e20193149. https://doi. 
org/10.1542/peds.2019-3149 
86. Gemzell-Danielsson K, Rabe T, Cheng L. Emergency contraception. Gynecol Endocrinol 
2013;29:1‚Äì14. https://doi.org/10.3109/09513590.2013.774591 
87. Jesam C, Cochon L, Salvatierra AM, Williams A, Kapp N, Levy-Gompel D, et al. A prospective, open-label, multicenter study to assess the pharmacodynamics and safety of 
repeated use of 30 mg ulipristal acetate. Contraception 2016;93:310‚Äì6. https://doi.org/ 
10.1016/j.contraception.2015.12.015 
88. Turok DK, Gero A, Simmons RG, Kaiser JE, Stoddard GJ, Sexsmith CD, et al. 
Levonorgestrel vs. copper intrauterine devices for emergency contraception. N Engl 
J Med 2021;384:335‚Äì44. https://doi.org/10.1056/NEJMoa2022141 
89. Mecdi Kaydirak M, Aslan E. Efficacy of nursing support in the pre- and postmedical termination of pregnancy phases: a randomized study. Omega (Westport) 2021;84:51‚Äì68.  
https://doi.org/10.1177/0030222819877791 
90. Haberer K, Silversides CK. Congenital heart disease and women‚Äôs health across the life 
span: focus on reproductive issues. Can J Cardiol 2019;35:1652‚Äì63. https://doi.org/10. 
1016/j.cjca.2019.10.009 
91. Lewis R, Tanton C, Mercer CH, Mitchell KR, Palmer M, Macdowall W, et al. 
Heterosexual practices among young people in Britain: evidence from three national 
surveys of sexual attitudes and lifestyles. J Adolesc Health 2017;61:694‚Äì702. https://doi. 
org/10.1016/j.jadohealth.2017.07.004 
92. Jatlaoui TC, Riley HEM, Curtis KM. The safety of intrauterine devices among young 
women: a systematic review. Contraception 2017;95:17‚Äì39. https://doi.org/10.1016/j. 
contraception.2016.10.006 
93. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of 
venous thromboembolic events in women taking progestin-only contraception: a 
meta-analysis. BMJ 2012;345:e4944. https://doi.org/10.1136/bmj.e4944 
94. Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME. A systematic review 
and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet 2018;141:287‚Äì94. https://doi.org/10.1002/ijgo.12455 
95. Morales A, Allain DC, Arscott P, James E, MacCarrick G, Murray B, et al. At the heart of 
the pregnancy: what prenatal and cardiovascular genetic counselors need to know 
about maternal heart disease. J Genet Couns 2017;26:669‚Äì88. https://doi.org/10. 
1007/s10897-017-0081-z 
96. Sunitha M, Chandrasekharappa S, Brid SV. Electrocradiographic QRS axis, Q wave and 
T-wave changes in 2nd and 3rd trimester of normal pregnancy. J Clin Diagn Res 2014;8: 
BC17‚Äì21. https://doi.org/10.7860/JCDR/2014/10037.4911 
97. Madras V, Challa N. Electrocardiographic variations during three trimesters of normal 
pregnancy. Int J Res Med Sci 2015;3:2218‚Äì22. https://doi.org/10.18203/2320-6012. 
ijrms20150605 
98. Uma V, Devi M. Electrocardiographic changes during the third trimester of pregnancy: 
a cross sectional study. Sch J App Med Sci 2016;4:3054‚Äì7. https://doi.org/10.36347/ 
sjams.2016.v04i08.062 
99. Bello NA, Bairey Merz CN, Brown H, Davis MB, Dickert NW, El Hajj SC, et al. 
Diagnostic cardiovascular imaging and therapeutic strategies in pregnancy: JACC focus 
seminar 4/5. J Am Coll Cardiol 2021;77:1813‚Äì22. https://doi.org/10.1016/j.jacc.2021.01. 
056 
100. American College of Obstetricians and Gynecologists‚Äô Committee on Obstetric 
Practice. Committee opinion no. 656: guidelines for diagnostic imaging during pregnancy and lactation. Obstet Gynecol 2016;127:e75‚Äì80. https://doi.org/10.1097/AOG. 
0000000000001316 
101. Desai DK, Moodley J, Naidoo DP. Echocardiographic assessment of cardiovascular 
hemodynamics in normal pregnancy. Obstet Gynecol 2004;104:20‚Äì9. https://doi.org/ 
10.1097/01.AOG.0000128170.15161.1d 
102. Sadaniantz A, Kocheril AG, Emaus SP, Garber CE, Parisi AF. Cardiovascular changes in 
pregnancy evaluated by two-dimensional and Doppler echocardiography. J Am Soc 
Echocardiogr 1992;5:253‚Äì8. https://doi.org/10.1016/S0894-7317(14)80345-3 
103. Mesa A, Jessurun C, Hernandez A, Adam K, Brown D, Vaughn WK, et al. Left ventricular diastolic function in normal human pregnancy. Circulation 1999;99:511‚Äì7. https:// 
doi.org/10.1161/01.CIR.99.4.511 
104. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al. Guidelines 
for performing a comprehensive transthoracic echocardiographic examination in 
adults: recommendations from the American Society of Echocardiography. J Am Soc 
Echocardiogr 2019;32:1‚Äì64. https://doi.org/10.1016/j.echo.2018.06.004 
105. Porter TR, Mulvagh SL, Abdelmoneim SS, Becher H, Belcik JT, Bierig M, et al. Clinical 
applications of ultrasonic enhancing agents in echocardiography: 2018 American 
Society of Echocardiography guidelines update. J Am Soc Echocardiogr 2018;31: 
241‚Äì74. https://doi.org/10.1016/j.echo.2017.11.013 
106. Popescu MR, Bouariu A, Ciobanu AM, GicƒÉ N, Panaitescu AM. Pregnancy complications lead to subclinical maternal heart dysfunction‚Äîthe importance and benefits of 
follow-up using speckle tracking echocardiography. Medicina (Kaunas) 2022;58:296.  
https://doi.org/10.3390/medicina58020296  
ESC Guidelines                                                                                                                                                                                               91


<!-- PAGE 92 -->

### Page 92

107. Savu O, Jurcu≈£ R, Giu≈ücƒÉ S, van Mieghem T, Gussi I, Popescu BA, et al. Morphological 
and functional adaptation of the maternal heart during pregnancy. Circ Cardiovasc 
Imaging 2012;5:289‚Äì97. https://doi.org/10.1161/CIRCIMAGING.111.970012 
108. ACOG committee opinion no. 650: physical activity and exercise during pregnancy 
and the postpartum period. Obstet Gynecol 2015;126:e135‚Äì42. https://doi.org/10. 
1097/AOG.0000000000001214 
109. Wowdzia JB, Davenport MH. Cardiopulmonary exercise testing during pregnancy. 
Birth Defects Res 2021;113:248‚Äì64. https://doi.org/10.1002/bdr2.1796 
110. Lui GK, Silversides CK, Khairy P, Fernandes SM, Valente AM, Nickolaus MJ, et al. Heart 
rate response during exercise and pregnancy outcome in women with congenital heart 
disease. Circulation 2011;123:242‚Äì8. https://doi.org/10.1161/CIRCULATIONAHA. 
110.953380 
111. Mayama M, Yoshihara M, Uno K, Tano S, Takeda T, Ukai M, et al. Factors influencing 
brain natriuretic peptide levels in healthy pregnant women. Int J Cardiol 2017;228: 
749‚Äì53. https://doi.org/10.1016/j.ijcard.2016.11.111 
112. Sarma AA, Aggarwal NR, Briller JE, Davis M, Economy KE, Hameed AB, et al. The utilization and interpretation of cardiac biomarkers during pregnancy: JACC: advances expert panel. JACC Adv 2022;1:100064. https://doi.org/10.1016/j.jacadv.2022.100064 
113. Esbrand FD, Zafar S, Panthangi V, Cyril Kurupp AR, Raju A, Luthra G, et al. Utility of 
N-terminal (NT)-brain natriuretic peptide (proBNP) in the diagnosis and prognosis of 
pregnancy associated cardiovascular conditions: a systematic review. Cureus 2022;14: 
e32848. https://doi.org/10.7759/cureus.32848 
114. Sheikh M, Ostadrahimi P, Salarzaei M, Parooie F. Cardiac complications in pregnancy: a 
systematic review and meta-analysis of diagnostic accuracy of BNP and N-terminal 
pro-BNP. Cardiol Ther 2021;10:501‚Äì14. https://doi.org/10.1007/s40119-021-00230-w 
115. Afshani N, Moustaqim-Barrette A, Biccard BM, Rodseth RN, Dyer RA. Utility of B-type 
natriuretic peptides in preeclampsia: a systematic review. Int J Obstet Anesth 2013;22: 
96‚Äì103. https://doi.org/10.1016/j.ijoa.2012.11.001 
116. Chang SA, Khakh P, Janzen M, Lee T, Kiess M, Rychel V, et al. Trending cardiac biomarkers during pregnancy in women with cardiovascular disease. Circ Heart Fail 2022;15: 
e009018. https://doi.org/10.1161/CIRCHEARTFAILURE.121.009018 
117. Siegmund AS, Pieper PG, Bouma BJ, Rosenberg FM, Groen H, Bilardo CM, et al. Early 
N-terminal pro-B-type natriuretic peptide is associated with cardiac complications and 
function during pregnancy in congenital heart disease. Neth Heart J 2021;29:262‚Äì72.  
https://doi.org/10.1007/s12471-021-01540-3 
118. Kampman MA, Balci A, van Veldhuisen DJ, van Dijk AP, Roos-Hesselink JW, 
Sollie-Szarynska KM, et al. N-terminal pro-B-type natriuretic peptide predicts cardiovascular complications in pregnant women with congenital heart disease. Eur Heart J 
2014;35:708‚Äì15. https://doi.org/10.1093/eurheartj/eht526 
119. Shivvers SA, Wians FH Jr, Keffer JH, Ramin SM. Maternal cardiac troponin I levels during normal labor and delivery. Am J Obstet Gynecol 1999;180:122‚Äì7. https://doi.org/10. 
1016/S0002-9378(99)70161-4 
120. Kumar R, De Jesus O. Radiation Effects on the Fetus. Treasure Island, FL: StatPearls 
Publishing, 2023. 
121. Wakeford R, Little MP. Risk coefficients for childhood cancer after intrauterine irradiation: a review. Int J Radiat Biol 2003;79:293‚Äì309. https://doi.org/10.1080/ 
0955300031000114729 
122. Khaing PH, Buchanan GL, Kunadian V. Diagnostic angiograms and percutaneous coronary interventions in pregnancy. Interv Cardiol 2020;15:e04. https://doi.org/10.15420/ 
icr.2020.02 
123. Ntusi NA, Samuels P, Moosa S, Mocumbi AO. Diagnosing cardiac disease during pregnancy: imaging modalities. Cardiovasc J Afr 2016;27:95‚Äì103. https://doi.org/10.5830/ 
CVJA-2016-022 
124. Damilakis J, Theocharopoulos N, Perisinakis K, Manios E, Dimitriou P, Vardas P, et al. 
Conceptus radiation dose and risk from cardiac catheter ablation procedures. 
Circulation 2001;104:893‚Äì7. https://doi.org/10.1161/hc5790.094909 
125. Dauer LT, Thornton RH, Miller DL, Damilakis J, Dixon RG, Marx MV, et al. Radiation 
management for interventions using fluoroscopic or computed tomographic guidance 
during pregnancy: a joint guideline of the Society of Interventional Radiology and the 
Cardiovascular and Interventional Radiological Society of Europe with endorsement 
by the Canadian Interventional Radiology Association. J Vasc Interv Radiol 2012;23: 
19‚Äì32. https://doi.org/10.1016/j.jvir.2011.09.007 
126. Colletti PM, Lee KH, Elkayam U. Cardiovascular imaging of the pregnant patient. AJR 
Am J Roentgenol 2013;200:515‚Äì21. https://doi.org/10.2214/AJR.12.9864 
127. Webb JA, Thomsen HS, Morcos SK. The use of iodinated and gadolinium contrast 
media during pregnancy and lactation. Eur Radiol 2005;15:1234‚Äì40. https://doi.org/ 
10.1007/s00330-004-2583-y 
128. Thomsen HS. European Society of Urogenital Radiology (ESUR) guidelines on the safe 
use of iodinated contrast media. Eur J Radiol 2006;60:307‚Äì13. https://doi.org/10.1016/j. 
ejrad.2006.06.020 
129. Bourjeily G, Chalhoub M, Phornphutkul C, Alleyne TC, Woodfield CA, Chen KK. 
Neonatal thyroid function: effect of a single exposure to iodinated contrast medium 
in utero. Radiology 2010;256:744‚Äì50. https://doi.org/10.1148/radiol.10100163 
130. Krawczyk P, Jastrzƒôbska A, Sa≈Çapa K, Szczeklik W, Andres J. Abnormal lung ultrasound 
pattern during labor: a prospective cohort pilot study. J Clin Ultrasound 2019;47:261‚Äì6.  
https://doi.org/10.1002/jcu.22692 
131. Arbeid E, Demi A, Brogi E, Gori E, Giusto T, Soldati G, et al. Lung ultrasound pattern is 
normal during the last gestational weeks: an observational pilot study. Gynecol Obstet 
Invest 2017;82:398‚Äì403. https://doi.org/10.1159/000448140 
132. Hendriks BMF, Schnerr RS, Milanese G, Jeukens C, Niesen S, Eijsvoogel NG, et al. 
Computed tomography pulmonary angiography during pregnancy: radiation dose of 
commonly used protocols and the effect of scan length optimization. Korean J Radiol 
2019;20:313‚Äì22. https://doi.org/10.3348/kjr.2017.0779 
133. Committee opinion no. 723: guidelines for diagnostic imaging during pregnancy 
and lactation. Obstet Gynecol 2017;130:e210‚Äì6. https://doi.org/10.1097/AOG. 
0000000000002355 
134. Park K, Bairey Merz CN, Bello NA, Davis M, Duvernoy C, Elgendy IY, et al. 
Management of women with acquired cardiovascular disease from pre-conception 
through pregnancy and postpartum: JACC focus seminar 3/5. J Am Coll Cardiol 2021; 
77:1799‚Äì812. https://doi.org/10.1016/j.jacc.2021.01.057 
135. Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association between MRI 
exposure during pregnancy and fetal and childhood outcomes. JAMA 2016;316: 
952‚Äì61. https://doi.org/10.1001/jama.2016.12126 
136. Bird ST, Gelperin K, Sahin L, Bleich KB, Fazio-Eynullayeva E, Woods C, et al. 
First-trimester exposure to gadolinium-based contrast agents: a utilization study of 
4.6 million U.S. pregnancies. Radiology 2019;293:193‚Äì200. https://doi.org/10.1148/ 
radiol.2019190563 
137. Jabehdar Maralani P, Kapadia A, Liu G, Moretti F, Ghandehari H, Clarke SE, et al. 
Canadian Association of Radiologists recommendations for the safe use of MRI 
during pregnancy. Can Assoc Radiol J 2022;73:56‚Äì67. https://doi.org/10.1177/ 
08465371211015657 
138. Sachs HC. The transfer of drugs and therapeutics into human breast milk: an update on 
selected topics. Pediatrics 2013;132:e796‚Äì809. https://doi.org/10.1542/peds.2013- 
1985 
139. Cova MA, Stacul F, Quaranta R, Guastalla P, Salvatori G, Banderali G, et al. Radiological 
contrast media in the breastfeeding woman: a position paper of the Italian Society of 
Radiology (SIRM), the Italian Society of Paediatrics (SIP), the Italian Society of 
Neonatology (SIN) and the Task Force on Breastfeeding, Ministry of Health, Italy. 
Eur Radiol 2014;24:2012‚Äì22. https://doi.org/10.1007/s00330-014-3198-6 
140. Lee JS, Choi ES, Hwang Y, Lee KS, Ahn KH. Preterm birth and maternal heart disease: a 
machine learning analysis using the Korean national health insurance database. PLoS 
One 2023;18:e0283959. https://doi.org/10.1371/journal.pone.0283959 
141. Piao C, Wang W-J, Deng Y, Wang K. Clinical outcomes of pulmonary hypertension in 
pregnancy among women with congenital heart disease in China. J Matern Fetal 
Neonatal Med 2023;36:2183349. https://doi.org/10.1080/14767058.2023.2183349 
142. Thaman R, Varnava A, Hamid MS, Firoozi S, Sachdev B, Condon M, et al. Pregnancy 
related complications in women with hypertrophic cardiomyopathy. Heart 2003;89: 
752‚Äì6. https://doi.org/10.1136/heart.89.7.752 
143. Mozumdar N, Rowland J, Pan S, Rajagopal H, Geiger MK, Srivastava S, et al. Diagnostic 
accuracy of fetal echocardiography in congenital heart disease. J Am Soc Echocardiogr 
2020;33:1384‚Äì90. https://doi.org/10.1016/j.echo.2020.06.017 
144. Moon-Grady AJ, Donofrio MT, Gelehrter S, Hornberger L, Kreeger J, Lee W, et al. 
Guidelines and recommendations for performance of the fetal echocardiogram: an update from the American Society of Echocardiography. J Am Soc Echocardiogr 2023;36: 
679‚Äì723. https://doi.org/10.1016/j.echo.2023.04.014 
145. Gelson E, Johnson M. Effect of maternal heart disease on pregnancy outcomes. Expert 
Rev Obstet Gynecol 2010;5:605‚Äì17. https://doi.org/10.1586/eog.10.49 
146. Halpern DG, Weinberg CR, Pinnelas R, Mehta-Lee S, Economy KE, Valente AM. Use of 
medication for cardiovascular disease during pregnancy: JACC state-of-the-art review. 
J Am Coll Cardiol 2019;73:457‚Äì76. https://doi.org/10.1016/j.jacc.2018.10.075 
147. Lees CC, Marlow N, van Wassenaer-Leemhuis A, Arabin B, Bilardo CM, Brezinka C, 
et al. 2 year neurodevelopmental and intermediate perinatal outcomes in infants 
with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet 
2015;385:2162‚Äì72. https://doi.org/10.1016/S0140-6736(14)62049-3 
148. Joglar JA, Kapa S, Saarel EV, Dubin AM, Gorenek B, Hameed AB, et al. 2023 HRS expert 
consensus statement on the management of arrhythmias during pregnancy. Heart 
Rhythm 2023;20:e175‚Äì264. https://doi.org/10.1016/j.hrthm.2023.05.017 
149. Donofrio MT, Moon-Grady AJ, Hornberger LK, Copel JA, Sklansky MS, Abuhamad A, 
et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the 
American Heart Association. Circulation 2014;129:2183‚Äì242. https://doi.org/10.1161/ 
01.cir.0000437597.44550.5d 
150. Schlichting LE, Insaf TZ, Zaidi AN, Lui GK, Van Zutphen AR. Maternal comorbidities 
and complications of delivery in pregnant women with congenital heart disease. 
J Am Coll Cardiol 2019;73:2181‚Äì91. https://doi.org/10.1016/j.jacc.2019.01.069 
151. Rouse CE, Easter SR, Duarte VE, Drakely S, Wu FM, Valente AM, et al. Timing of delivery in women with cardiac disease. Am J Perinatol 2022;39:1196‚Äì203. https://doi.org/ 
10.1055/s-0040-1721716 
152. Mishanina E, Rogozinska E, Thatthi T, Uddin-Khan R, Khan KS, Meads C. Use of labour 
induction and risk of cesarean delivery: a systematic review and meta-analysis. CMAJ 
2014;186:665‚Äì73. https://doi.org/10.1503/cmaj.130925 
153. Roos-Hesselink JW, Ruys TP, Stein JI, Thil√©n U, Webb GD, Niwa K, et al. Outcome of 
pregnancy in patients with structural or ischaemic heart disease: results of a registry of


<!-- PAGE 93 -->

### Page 93

the European Society of Cardiology. Eur Heart J 2013;34:657‚Äì65. https://doi.org/10. 
1093/eurheartj/ehs270 
154. Mok T, Woods A, Small A, Canobbio MM, Tandel MD, Kwan L, et al. Delivery timing 
and associated outcomes in pregnancies with maternal congenital heart disease at 
term. J Am Heart Assoc 2022;11:e025791. https://doi.org/10.1161/JAHA.122.025791 
155. Ramsey PS, Hogg BB, Savage KG, Winkler DD, Owen J. Cardiovascular effects of intravaginal misoprostol in the mid trimester of pregnancy. Am J Obstet Gynecol 2000; 
183:1100‚Äì2. https://doi.org/10.1067/mob.2000.108886 
156. Lee S, Cauldwell M, Wendler R. Cardiac effects of drugs used for induction of labour 
and prevention and treatment of postpartum haemorrhage. Int J Cardiol Congenit Heart 
Dis 2021;5:100208. https://doi.org/10.1016/j.ijcchd.2021.100208 
157. Kilpatrick AW, Thorburn J. Severe hypotension due to intramyometrial injection of 
prostaglandin E2. Anaesthesia 1990;45:848‚Äì9. https://doi.org/10.1111/j.1365-2044. 
1990.tb14569.x 
158. Cauldwell M, Steer PJ, Swan L, Uebing A, Gatzoulis MA, Johnson MR. The management 
of the third stage of labour in women with heart disease. Heart 2017;103:945‚Äì51.  
https://doi.org/10.1136/heartjnl-2016-310607 
159. NICE. Intrapartum Care for Women With Existing Medical Conditions or Obstetric 
Complications and Their Babies. https://www.nice.org.uk/guidance/ng121/chapter/ 
recommendations#management-of-the-third-stage-of-labour-for-women-with- 
heart-disease (8 June 2024, date last accessed). 
160. Perloff J. Congenital Heart Disease in Adult. 2nd edn. Philadelphia, PA: Saunders 
Company, 1998. 
161. Easter SR, Rouse CE, Duarte V, Hynes JS, Singh MN, Landzberg MJ, et al. Planned vaginal delivery and cardiovascular morbidity in pregnant women with heart disease. Am J 
Obstet Gynecol 2020;222:77.e1‚Äìe11. https://doi.org/10.1016/j.ajog.2019.07.019 
162. Angeli L, Fieni S, Dall‚ÄôAsta A, Ghi T, De Carolis S, Sorrenti S, et al. Mode of delivery and 
peripartum outcome in women with heart disease according to the ESC guidelines: an 
Italian multicenter study. J Matern Fetal Neonatal Med 2023;36:2184221. https://doi. 
org/10.1080/14767058.2023.2184221 
163. Ruys TP, Roos-Hesselink JW, Pijuan-Dom√®nech A, Vasario E, Gaisin IR, Iung B, et al. Is a 
planned caesarean section in women with cardiac disease beneficial? Heart 2015;101: 
530‚Äì6. https://doi.org/10.1136/heartjnl-2014-306497 
164. Meng M-L, Arendt KW. Obstetric anesthesia and heart disease: practical clinical 
considerations. 
Anesthesiology 
2021;135:164‚Äì83. 
https://doi.org/10.1097/ALN. 
0000000000003833 
165. Hill NE, Granlund B. Anesthesia for Labor, Delivery, and Cesarean Section in High-Risk 
Heart Disease. Treasure Island, FL: StatPearls Publishing, 2023. 
166. Rahmati J, Shahriari M, Shahriari A, Nataj M, Shabani Z, Moodi V. Effectiveness of spinal 
analgesia for labor pain compared with epidural analgesia. Anesth Pain Med 2021;11: 
e113350. https://doi.org/10.5812/aapm.113350 
167. Roofthooft E, Rawal N, Van de Velde M. Current status of the combined spinal‚Äìepidural technique in obstetrics and surgery. Best Pract Res Clin Anaesthesiol 2023;37: 
189‚Äì98. https://doi.org/10.1016/j.bpa.2023.04.004 
168. Wise J. Maternity care: remifentanil is recommended as alternative to epidural in draft 
guidance. BMJ 2023;381:946. https://doi.org/10.1136/bmj.p946 
169. NICE. Intrapartum Care. https://www.nice.org.uk/guidance/ng235/resources/intrapartum- 
care-pdf-66143897812933 (26 November 2024, date last accessed). 
170. Lester W, Walker N, Bhatia K, Ciantar E, Banerjee A, Trinder J, et al. British Society for 
Haematology guideline for anticoagulant management of pregnant individuals with 
mechanical heart valves. Br J Haematol 2023;202:465‚Äì78. https://doi.org/10.1111/bjh. 
18781 
171. Hood C, Goldstein JN, Milling TJ, Refaai MA, Bajcic P, Goldstein B, et al. INR and vitamin K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma. Blood Adv 2023;7:2206‚Äì13. https://doi.org/10.1182/bloodadvances.2022009015 
172. Condeni MS, Weant KA, Neyens RR, Eriksson EA, Miano TA. Safety and efficacy of 
fixed versus variable-dose prothrombin complex concentrate for emergent reversal 
of vitamin K antagonists: a systematic review and meta-analysis. Am J Emerg Med 
2024;77:91‚Äì105. https://doi.org/10.1016/j.ajem.2023.11.066 
173. Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, et al. 
Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. 
A systematic review and meta-analysis. Thromb Haemost 2016;116:879‚Äì90. https://doi. 
org/10.1160/TH16-04-0266 
174. Schroeder M, Hogwood J, Gray E, Mulloy B, Hackett AM, Johansen KB. Protamine neutralisation of low molecular weight heparins and their oligosaccharide components. 
Anal Bioanal Chem 2011;399:763‚Äì71. https://doi.org/10.1007/s00216-010-4220-8 
175. Thomas S, Makris M. The reversal of anticoagulation in clinical practice. Clin Med (Lond) 
2018;18:314‚Äì9. https://doi.org/10.7861/clinmedicine.18-4-314 
176. Vause S, Clarke B, Tower CL, Hay C, Knight M. Pregnancy outcomes in women with 
mechanical prosthetic heart valves: a prospective descriptive population based study 
using the United Kingdom Obstetric Surveillance System (UKOSS) data collection system. BJOG 2017;124:1411‚Äì9. https://doi.org/10.1111/1471-0528.14478 
177. van der Zande A, Ramlakhan K, Gnararaj J, Al Farhan H, Malhame I, Otto C, et al. 
Pregnancy and anticoagulation in women with a prosthetic heart valve: data from 
the ESC EORP Registry Of Pregnancy And Cardiac disease (ROPAC) III. Eur Heart J 
2025, https://doi.org/10.1093/eurheartj/ehaf265 
178. Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023 
ESC Guidelines for the management of endocarditis. Eur Heart J 2023;44: 
3948‚Äì4042. https://doi.org/10.1093/eurheartj/ehad193 
179. D‚ÄôSouza R, Ostro J, Shah PS, Silversides CK, Malinowski A, Murphy KE, et al. 
Anticoagulation for pregnant women with mechanical heart valves: a systematic review 
and meta-analysis. Eur Heart J 2017;38:1509‚Äì16. https://doi.org/10.1093/eurheartj/ 
ehx032 
180. Leffert L, Butwick A, Carvalho B, Arendt K, Bates SM, Friedman A, et al. The Society for 
Obstetric Anesthesia and Perinatology Consensus Statement on the anesthetic management of pregnant and postpartum women receiving thromboprophylaxis or higher 
dose anticoagulants. Anesth Analg 2018;126:928‚Äì44. https://doi.org/10.1213/ANE. 
0000000000002530 
181. Khedagi AM, Bello NA. Hypertensive disorders of pregnancy. Cardiol Clin 2021;39: 
77‚Äì90. https://doi.org/10.1016/j.ccl.2020.09.005 
182. Ruys TP, Roos-Hesselink JW, Hall R, Subirana-Dom√®nech MT, Grando-Ting J, 
Estensen M, et al. Heart failure in pregnant women with cardiac disease: data from 
the ROPAC. Heart 2014;100:231‚Äì8. https://doi.org/10.1136/heartjnl-2013-304888 
183. Canobbio MM, Warnes CA, Aboulhosn J, Connolly HM, Khanna A, Koos BJ, et al. 
Management of pregnancy in patients with complex congenital heart disease: a scientific statement for healthcare professionals from the American Heart Association. 
Circulation 2017;135:e50‚Äì87. https://doi.org/10.1161/CIR.0000000000000458 
184. Giorgione V, Cauldwell M, Thilaganathan B. Pre-eclampsia and cardiovascular disease: 
from pregnancy to postpartum. Eur Cardiol 2023;18:e42. https://doi.org/10.15420/ecr. 
2022.56 
185. ACOG committee opinion no. 756: optimizing support for breastfeeding as part of 
obstetric practice. Obstet Gynecol 2018;132:e187‚Äì96. https://doi.org/10.1097/AOG. 
0000000000002890 
186. Kitt JA, Fox RL, Cairns AE, Mollison J, Burchert HH, Kenworthy Y, et al. Short-term 
postpartum blood pressure self-management and long-term blood pressure control: 
a randomized controlled trial. Hypertension 2021;78:469‚Äì79. https://doi.org/10.1161/ 
HYPERTENSIONAHA.120.17101 
187. Cauldwell M, Von Klemperer K, Uebing A, Swan L, Steer PJ, Gatzoulis M, et al. Why is 
post-partum haemorrhage more common in women with congenital heart disease? Int 
J Cardiol 2016;218:285‚Äì90. https://doi.org/10.1016/j.ijcard.2016.05.068 
188. Wang Z, Liu J, Shuai H, Cai Z, Fu X, Liu Y, et al. Mapping global prevalence of depression among postpartum women. Transl Psychiatry 2021;11:543. https://doi.org/10. 
1038/s41398-021-01663-6 
189. Hutchens J, Frawley J, Sullivan EA. Quality of life and mental health of women who had 
cardiac disease in pregnancy and postpartum. BMC Pregnancy Childbirth 2022;22:797.  
https://doi.org/10.1186/s12884-022-05123-x 
190. Donnenwirth JA, Hess R, Ross R. Post-traumatic stress, depression, and quality of life 
in women with peripartum cardiomyopathy. MCN Am J Matern Child Nurs 2020;45: 
176‚Äì82. https://doi.org/10.1097/NMC.0000000000000614 
191. Rosman L, Salmoirago-Blotcher E, Cahill J, Wuensch KL, Sears SF. Depression and 
health behaviors in women with peripartum cardiomyopathy. Heart Lung 2017;46: 
363‚Äì8. https://doi.org/10.1016/j.hrtlng.2017.05.004 
192. Roberts L, Davis GK, Homer CSE. Depression, anxiety, and post-traumatic stress disorder following a hypertensive disorder of pregnancy: a narrative literature review. 
Front Cardiovasc Med 2019;6:147. https://doi.org/10.3389/fcvm.2019.00147 
193. Ramlakhan KP, Johnson MR, Roos-Hesselink JW. Pregnancy and cardiovascular disease. Nat Rev Cardiol 2020;17:718‚Äì31. https://doi.org/10.1038/s41569-020-0390-z 
194. Eke AC. An update on the physiologic changes during pregnancy and their impact on 
drug pharmacokinetics and pharmacogenomics. J Basic Clin Physiol Pharmacol 2022;33: 
581‚Äì98. https://doi.org/10.1515/jbcpp-2021-0312 
195. Haas DM. Pharmacogenetics and individualizing drug treatment during pregnancy. 
Pharmacogenomics 2014;15:69‚Äì78. https://doi.org/10.2217/pgs.13.228 
196. Verstegen RHJ, Anderson PO, Ito S. Infant drug exposure via breast milk. Br J Clin 
Pharmacol 2022;88:4311‚Äì27. https://doi.org/10.1111/bcp.14538 
197. Drugs and Lactation Database (LactMed). https://www.ncbi.nlm.nih.gov/books/ 
NBK501922/ (29 January 2025, date last accessed). 
198. Overcash RT, Somers AT, LaCoursiere DY. Enoxaparin dosing after cesarean delivery 
in morbidly obese women. Obstet Gynecol 2015;125:1371‚Äì6. https://doi.org/10.1097/ 
AOG.0000000000000873 
199. Xu Z, Fan J, Luo X, Zhang WB, Ma J, Lin YB, et al. Anticoagulation regimens during 
pregnancy in patients with mechanical heart valves: a systematic review and 
meta-analysis. Can J Cardiol 2016;32:1248.e1‚Äìe9. https://doi.org/10.1016/j.cjca.2015. 
11.005 
200. Steinberg ZL, Dominguez-Islas CP, Otto CM, Stout KK, Krieger EV. Maternal and fetal 
outcomes of anticoagulation in pregnant women with mechanical heart valves. J Am 
Coll Cardiol 2017;69:2681‚Äì91. https://doi.org/10.1016/j.jacc.2017.03.605 
201. Ferreira S, Costa R, Malveiro D, Vieira F, Tuna M. Warfarin embryopathy: balancing 
maternal and fetal risks with anticoagulation therapy. Pediatr Neonatol 2018;59: 
534‚Äì5. https://doi.org/10.1016/j.pedneo.2018.02.005 
202. Wainwright H, Beighton P. Warfarin embryopathy: fetal manifestations. Virchows Arch 
2010;457:735‚Äì9. https://doi.org/10.1007/s00428-010-0982-9  
ESC Guidelines                                                                                                                                                                                               93


<!-- PAGE 94 -->

### Page 94

203. Soma-Pillay P, Nene Z, Mathivha TM, Macdonald AP. The effect of warfarin dosage on 
maternal and fetal outcomes in pregnant women with prosthetic heart valves. Obstet 
Med 2011;4:24‚Äì7. https://doi.org/10.1258/om.2010.100067 
204. van Hagen IM, Roos-Hesselink JW, Ruys TP, Merz WM, Goland S, Gabriel H, et al. 
Pregnancy in women with a mechanical heart valve: data of the European Society of 
Cardiology Registry Of Pregnancy And Cardiac disease (ROPAC). Circulation 2015; 
132:132‚Äì42. https://doi.org/10.1161/CIRCULATIONAHA.115.015242 
205. Hassouna A, Allam H. Limited dose warfarin throughout pregnancy in patients with 
mechanical heart valve prosthesis: a meta-analysis. Interact Cardiovasc Thorac Surg 
2014;18:797‚Äì806. https://doi.org/10.1093/icvts/ivu009 
206. G√ºner A, Kal√ßƒ±k M, G√ºrsoy MO, G√ºnd√ºz S, Astarcƒ±oƒülu MA, Bayam E, et al. 
Comparison of different anticoagulation regimens regarding maternal and fetal outcomes in pregnant patients with mechanical prosthetic heart valves (from the multicenter ANATOLIA-PREG registry). Am J Cardiol 2020;127:113‚Äì9. https://doi.org/10. 
1016/j.amjcard.2020.04.010 
207. Jakobsen C, Larsen JB, Fuglsang J, Hvas AM. Mechanical heart valves, pregnancy, and 
bleeding: a systematic review and meta-analysis. Semin Thromb Hemost 2023;49: 
542‚Äì52. https://doi.org/10.1055/s-0042-1756707 
208. Schaefer C, Hannemann D, Meister R, El√©fant E, Paulus W, Vial T, et al. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost 
2006;95:949‚Äì57. https://doi.org/10.1160/TH06-02-0108 
209. Clark SL, Porter TF, West FG. Coumarin derivatives and breast-feeding. Obstet Gynecol 
2000;95:938‚Äì40. https://doi.org/10.1016/s0029-7844(00)00809-7 
210. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688‚Äì98. https://doi. 
org/10.1056/NEJM199709043371007 
211. Friedrich E, Hameed AB. Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy. J Perinatol 2010;30:253‚Äì7. https://doi.org/10.1038/ 
jp.2009.164 
212. McDonnell BP, Glennon K, McTiernan A, O‚ÄôConnor HD, Kirkham C, Kevane B, et al. 
Adjustment of therapeutic LMWH to achieve specific target anti-FXa activity does not 
affect outcomes in pregnant patients with venous thromboembolism. J Thromb 
Thrombolysis 2017;43:105‚Äì11. https://doi.org/10.1007/s11239-016-1409-5 
213. Nichols KM, Henkin S, Creager MA. Venous thromboembolism associated with pregnancy: JACC focus seminar. J Am Coll Cardiol 2020;76:2128‚Äì41. https://doi.org/10. 
1016/j.jacc.2020.06.090 
214. Butwick AJ, Bentley J, Leonard SA, Carmichael SL, El-Sayed YY, Stephansson O, et al. 
Prepregnancy maternal body mass index and venous thromboembolism: a population- 
based cohort study. BJOG 2019;126:581‚Äì8. https://doi.org/10.1111/1471-0528.15567 
215. Gigante B, Tamargo J, Agewall S, Atar D, Ten Berg J, Campo G, et al. Update on antithrombotic therapy and body mass. A clinical consensus statement of the ESC 
Working Group on cardiovascular pharmacotherapy and the ESC Working Group 
on thrombosis. Eur Heart J Cardiovasc Pharmacother 2024;10:614‚Äì183. https://doi. 
org/10.1093/ehjcvp/pvae064 
216. Pacheco LD, Saade G, Shrivastava V, Shree R, Elkayam U. Society for Maternal‚ÄìFetal 
Medicine consult series #61: anticoagulation in pregnant patients with cardiac disease. 
Am J Obstet Gynecol 2022;227:B28‚Äì43. https://doi.org/10.1016/j.ajog.2022.03.036 
217. Voke J, Keidan J, Pavord S, Spencer NH, Hunt BJ. The management of antenatal 
venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. Br J Haematol 2007;139:545‚Äì58. https://doi.org/10.1111/j.1365- 
2141.2007.06826.x 
218. Knight M. Antenatal pulmonary embolism: risk factors, management and outcomes. 
BJOG 2008;115:453‚Äì61. https://doi.org/10.1111/j.1471-0528.2007.01622.x 
219. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical 
heart valves: a systematic review of the literature. Arch Intern Med 2000;160:191‚Äì6.  
https://doi.org/10.1001/archinte.160.2.191 
220. De Carolis S, di Pasquo E, Rossi E, Del Sordo G, Buonomo A, Schiavino D, et al. 
Fondaparinux in pregnancy: could it be a safe option? A review of the literature. 
Thromb Res 2015;135:1049‚Äì51. https://doi.org/10.1016/j.thromres.2015.04.001 
221. Dempfle CE, Koscielny J, Lindhoff-Last E, Linnemann B, Bux-Gewehr I, Kappert G, 
et al. Fondaparinux pre-, peri-, and/or postpartum for the prophylaxis/treatment of venous 
thromboembolism 
(FondaPPP). 
Clin 
Appl 
Thromb 
Hemost 
2021;27: 
10760296211014575. https://doi.org/10.1177/10760296211014575 
222. Mazzolai L, Hohlfeld P, Spertini F, Hayoz D, Schapira M, Duchosal MA. Fondaparinux is 
a safe alternative in case of heparin intolerance during pregnancy. Blood 2006;108: 
1569‚Äì70. https://doi.org/10.1182/blood-2006-03-009548 
223. Gerhardt A, Zotz RB, Stockschlaeder M, Scharf RE. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism 
and intolerance to low-molecular-weight heparins and heparinoids. Thromb Haemost 
2007;97:496‚Äì7. https://doi.org/10.1160/TH06-10-0577 
224. Beyer-Westendorf J, Michalski F, Tittl L, Middeldorp S, Cohen H, Abdul Kadir R, et al. 
Pregnancy outcome in patients exposed to direct oral anticoagulants‚Äîand the challenge of event reporting. Thromb Haemost 2016;116:651‚Äì8. https://doi.org/10.1160/ 
TH16-04-0305 
225. Sessa M, Mascolo A, Callr√©us T, Capuano A, Rossi F, Andersen M. Direct-acting oral 
anticoagulants (DOACs) in pregnancy: new insight from VigiBase(¬Æ). Sci Rep 2019; 
9:7236. https://doi.org/10.1038/s41598-019-43715-4 
226. Steinberg ZL, Krieger EV. Reply: the anticoagulation conundrum of mechanical heart 
valves in pregnancy: should DOACs be considered? J Am Coll Cardiol 2017;70: 
3074‚Äì5. https://doi.org/10.1016/j.jacc.2017.09.1139 
227. Beyer-Westendorf J, Marten S. Reproductive issues in women on direct oral anticoagulants. Res Pract Thromb Haemost 2021;5:e12512. https://doi.org/10.1002/rth2.12512 
228. Wang L, He K, Maxwell B, Grossman SJ, Tremaine LM, Humphreys WG, et al. Tissue 
distribution and elimination of [14C]apixaban in rats. Drug Metab Dispos 2011;39: 
256‚Äì64. https://doi.org/10.1124/dmd.110.036442 
229. Bapat P, Kedar R, Lubetsky A, Matlow JN, Aleksa K, Berger H, et al. Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. 
Obstet Gynecol 2014;123:1256‚Äì61. https://doi.org/10.1097/AOG.0000000000000277 
230. Bapat P, Pinto LS, Lubetsky A, Berger H, Koren G. Rivaroxaban transfer across the 
dually perfused isolated human placental cotyledon. Am J Obstet Gynecol 2015;213: 
710.e1‚Äìe6. https://doi.org/10.1016/j.ajog.2015.06.065 
231. Beyer-Westendorf J, Tittl L, Bistervels I, Middeldorp S, Schaefer C, Paulus W, et al. Safety 
of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study. 
Lancet Haematol 2020;7:e884‚Äì91. https://doi.org/10.1016/S2352-3026(20)30327-6 
232. Ueberham L, Hindricks G. Anticoagulation in special patient populations with atrial fibrillation. Herz 2021;46:323‚Äì8. https://doi.org/10.1007/s00059-021-05042-1 
233. Zhao Y, Arya R, Couchman L, Patel JP. Are apixaban and rivaroxaban distributed into 
human breast milk to clinically relevant concentrations? Blood 2020;136:1783‚Äì5.  
https://doi.org/10.1182/blood.2020006231 
234. Datta P, Bramnik A, Rewers-Felkins K, Krutsch K, Baker T, Hale TW. Transfer of apixaban into human milk. Obstet Gynecol 2021;137:1080‚Äì2. https://doi.org/10.1097/AOG. 
0000000000004388 
235. Ayuk P, Kampouraki E, Truemann A, Sidgwick F, McDonald L, Bingham J, et al. 
Investigation of dabigatran secretion into breast milk: implications for oral thromboprophylaxis in post-partum women. Am J Hematol 2020;95:E10‚Äì3. https://doi.org/10. 
1002/ajh.25652 
236. Wiesen MH, Blaich C, M√ºller C, Streichert T, Pfister R, Michels G. The direct factor Xa 
inhibitor rivaroxaban passes into human breast milk. Chest 2016;150:e1‚Äì4. https://doi. 
org/10.1016/j.chest.2016.01.021 
237. Saito J, Kaneko K, Yakuwa N, Kawasaki H, Yamatani A, Murashima A. Rivaroxaban concentration in breast milk during breastfeeding: a case study. Breastfeed Med 2019;14: 
748‚Äì51. https://doi.org/10.1089/bfm.2019.0230 
238. Muysson M, Marshall K, Datta P, Rewers-Felkins K, Baker T, Hale TW. Rivaroxaban 
treatment in two breastfeeding mothers: a case series. Breastfeed Med 2020;15: 
41‚Äì3. https://doi.org/10.1089/bfm.2019.0124 
239. Elkayam U, Jalnapurkar S, Barakkat MN, Khatri N, Kealey AJ, Mehra A, et al. 
Pregnancy-associated acute myocardial infarction: a review of contemporary experience in 150 cases between 2006 and 2011. Circulation 2014;129:1695‚Äì702. https:// 
doi.org/10.1161/CIRCULATIONAHA.113.002054 
240. Argentiero D, Savonitto S, D‚ÄôAndrea P, Iacovelli F. Ticagrelor and tirofiban in pregnancy and delivery: beyond labels. J Thromb Thrombolysis 2020;49:145‚Äì8. https://doi. 
org/10.1007/s11239-019-01939-1 
241. Serna Candel C, Hellstern V, Beitlich T, Aguilar P√©rez M, B√§zner H, Henkes H. 
Management of a decompensated acute-on-chronic intracranial venous sinus thrombosis. Ther Adv Neurol Disord 2019;12:1756286419895157. https://doi.org/10.1177/ 
1756286419895157 
242. Bauer ME, Bauer ST, Rabbani AB, Mhyre JM. Peripartum management of dual antiplatelet therapy and neuraxial labor analgesia after bare metal stent insertion for acute 
myocardial infarction. Anesth Analg 2012;115:613‚Äì5. https://doi.org/10.1213/ANE. 
0b013e31825ab374 
243. Kuoni S, Steiner R, Saleh L, Lehmann R, Ochsenbein-K√∂lble N, Sim√µes-W√ºst AP. 
Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin 
during pregnancy: an ex vivo human placenta perfusion and in vitro study. Biomed 
Pharmacother 2024;171:116177. https://doi.org/10.1016/j.biopha.2024.116177 
244. Muller DRP, Stenvers DJ, Malekzadeh A, Holleman F, Painter RC, Siegelaar SE. Effects 
of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring 
outcomes: a systematic review of the evidence. Front Endocrinol (Lausanne) 2023;14: 
1215356. https://doi.org/10.3389/fendo.2023.1215356 
245. Hemnes AR, Kiely DG, Cockrill BA, Safdar Z, Wilson VJ, Al Hazmi M, et al. Statement 
on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research 
Institute. Pulm Circ 2015;5:435‚Äì65. https://doi.org/10.1086/682230 
246. Cesta CE, Segovia Chac√≥n S, Engeland A, Broe A, Damkier P, Furu K, et al. Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in 
Scandinavia. Acta Obstet Gynecol Scand 2021;100:2111‚Äì8. https://doi.org/10.1111/ 
aogs.14251 
247. Horng M, Mohammad I, Smith ZR, Awdish RL, Cajigas HR. Inhaled iloprost for chronic 
thromboembolic pulmonary hypertension (CTEPH) during pregnancy: a case report. 
Pharmacotherapy 2016;36:e142‚Äì7. https://doi.org/10.1002/phar.1793 
248. Tokg√∂z HC, Kaymaz C, Poci N, Akbal √ñ Y, √ñzt√ºrk S. A successful cesarean delivery 
without fetal or maternal morbidity in an eisenmenger patient with cor triatriatum sinistrum, double-orifice mitral valve, large ventricular septal defect, and single ventricle 
who was under long-term bosentan treatment. Turk Kardiyol Dern Ars 2017;45:184‚Äì8.  
https://doi.org/10.5543/tkda.2016.17747


<!-- PAGE 95 -->

### Page 95

### 249 Nauwelaerts N, Ceulemans M, Deferm N, Eerdekens A, Lammens B, Armoudjian Y,

et al. Case report: bosentan and sildenafil exposure in human milk‚Äîa contribution 
from the ConcePTION project. Front Pharmacol 2022;13:881084. https://doi.org/10. 
3389/fphar.2022.881084 
250. Duan L, Ng A, Chen W, Spencer HT, Nguyen J, Shen AY, et al. Œ≤-Blocker exposure in 
pregnancy and risk of fetal cardiac anomalies. JAMA Intern Med 2017;177:885‚Äì7.  
https://doi.org/10.1001/jamainternmed.2017.0608 
251. van der Zande JA, Cornette JMJ, Roos-Hesselink JW, Flint RB. Maternal, fetal, neonatal 
and breastmilk flecainide concentration during maternal therapy and lactation: a case 
report. Int Breastfeed J 2023;18:21. https://doi.org/10.1186/s13006-023-00559-z 
252. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 
ESC Guidelines for the management of patients with ventricular arrhythmias and 
the prevention of sudden cardiac death. Eur Heart J 2022;43:3997‚Äì4126. https://doi. 
org/10.1093/eurheartj/ehac262 
253. George R, Thomas C, Joy CA, Varghese B, Undela K, Adela R. Comparative efficacy 
and safety of oral nifedipine with other antihypertensive medications in the management of hypertensive disorders of pregnancy: a systematic review and meta-analysis 
of randomized controlled trials. J Hypertens 2022;40:1876‚Äì86. https://doi.org/10. 
1097/HJH.0000000000003233 
254. Easterling T, Mundle S, Bracken H, Parvekar S, Mool S, Magee LA, et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet 
2019;394:1011‚Äì21. https://doi.org/10.1016/S0140-6736(19)31282-6 
255. Yin J, Mei Z, Shi S, Du P, Qin S. Nifedipine or amlodipine? The choice for hypertension 
during pregnancy: a systematic review and meta-analysis. Arch Gynecol Obstet 2022; 
306:1891‚Äì900. https://doi.org/10.1007/s00404-022-06504-5 
256. Coberger ED, Jensen BP, Dalrymple JM. Transfer of candesartan into human breast milk. 
Obstet Gynecol 2019;134:481‚Äì4. https://doi.org/10.1097/AOG.0000000000003446 
257. Phelps DL, Karim A. Spironolactone: relationship between concentrations of dethioacetylated metabolite in human serum and milk. J Pharm Sci 1977;66:1203. https://doi. 
org/10.1002/jps.2600660841 
258. Saito J, Mito A, Yakuwa N, Kaneko K, Kawasaki H, Suzuki T, et al. Eplerenone levels in 
maternal serum, cord blood, and breast milk during pregnancy and lactation. Hypertens 
Res 2021;44:879‚Äì81. https://doi.org/10.1038/s41440-021-00621-5 
259. Gehlert J, Morton A. Eplerenone as a treatment for resistant hypertension in pregnancy. Obstet Med 2021;14:35‚Äì8. https://doi.org/10.1177/1753495X19825967 
260. Gunganah K, Carpenter R, Drake WM. Eplerenone use in primary aldosteronism during pregnancy. Clin Case Rep 2016;4:81‚Äì2. https://doi.org/10.1002/ccr3.355 
261. Morton A, Laurie J. Eplerenone in the management of resistant hypertension with obstructive sleep apnoea in pregnancy. Pregnancy Hypertens 2017;7:54‚Äì5. https://doi.org/ 
10.1016/j.preghy.2016.12.001 
262. Mulder J, Kusters DM, Roeters van Lennep JE, Hutten BA. Lipid metabolism during 
pregnancy: consequences for mother and child. Curr Opin Lipidol 2024;35:133‚Äì40. 
263. FDA. FDA Requests Removal of Strongest Warning Against Using Cholesterol-Lowering 
Statins During Pregnancy; Still Advises Most Pregnant Patients Should Stop Taking 
Statins. 
https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-requests-removal- 
strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy 
(14 
August 2024, date last accessed). 
264. Mauricio R, Khera A. Statin use in pregnancy: is it time for a paradigm shift? Circulation 
2022;145:496‚Äì8. https://doi.org/10.1161/CIRCULATIONAHA.121.058983 
265. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. 
Guidelines on the use of therapeutic apheresis in clinical practice‚Äîevidence-based approach from the writing committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 2016;31:149‚Äì62. https://doi.org/10.1002/jca.21470 
266. Ardissino M, Slob EAW, Reddy RK, Morley AP, Schuermans A, Hill P, et al. Genetically 
proxied low-density lipoprotein cholesterol lowering via PCSK9-inhibitor drug targets 
and risk of congenital malformations. Eur J Prev Cardiol 2024;31:955‚Äì65. https://doi.org/ 
10.1093/eurjpc/zwad402 
267. Wu Y, Yao JW, Xu LJ, Chen M, Wan L. Risk of congenital malformations in offspring of 
women using Œ≤-blockers during early pregnancy: an updated meta-analysis of observational studies. Br J Clin Pharmacol 2021;87:806‚Äì15. https://doi.org/10.1111/bcp.14561 
268. Bateman BT, Heide-J√∏rgensen U, Einarsd√≥ttir K, Engeland A, Furu K, Gissler M, et al. 
Œ≤-Blocker use in pregnancy and the risk for congenital malformations: an international 
cohort study. Ann Intern Med 2018;169:665‚Äì73. https://doi.org/10.7326/M18-0338 
269. Welzel T, Donner B, van den Anker JN. Intrauterine growth retardation in pregnant 
women with long QT syndrome treated with beta-receptor blockers. Neonatology 
2021;118:406‚Äì15. https://doi.org/10.1159/000516845 
270. Peltenburg PJ, Kallas D, Bos JM, Lieve KVV, Franciosi S, Roston TM, et al. An international multicenter cohort study on Œ≤-blockers for the treatment of symptomatic 
children with catecholaminergic polymorphic ventricular tachycardia. Circulation 
2022;145:333‚Äì44. https://doi.org/10.1161/CIRCULATIONAHA.121.056018 
271. Tamirisa KP, Elkayam U, Briller JE, Mason PK, Pillarisetti J, Merchant FM, et al. 
Arrhythmias in pregnancy. JACC Clin Electrophysiol 2022;8:120‚Äì35. https://doi.org/10. 
1016/j.jacep.2021.10.004 
272. Ryu RJ, Eyal S, Easterling TR, Caritis SN, Venkataraman R, Hankins G, et al. 
Pharmacokinetics of metoprolol during pregnancy and lactation. J Clin Pharmacol 
2016;56:581‚Äì9. https://doi.org/10.1002/jcph.631 
273. Lip GY, Beevers M, Churchill D, Shaffer LM, Beevers DG. Effect of atenolol on birth 
weight. Am J Cardiol 1997;79:1436‚Äì8. https://doi.org/10.1016/S0002-9149(97)00163-X 
274. de Bruin R, van Dalen SL, Franx SJ, Ramaswamy VV, Simons SHP, Flint RB, et al. The risk 
for neonatal hypoglycemia and bradycardia after beta-blocker use during pregnancy or 
lactation: a systematic review and meta-analysis. Int J Environ Res Public Health 2022;19: 
9616. https://doi.org/10.3390/ijerph19159616 
275. Kittleson MM, DeFilippis EM, Bhagra CJ, Casale JP, Cauldwell M, Coscia LA, et al. 
Reproductive health after thoracic transplantation: an ISHLT expert consensus statement. J Heart Lung Transplant 2023;42:e1‚Äì42. https://doi.org/10.1016/j.healun.2022.10. 
009 
276. Le HL, Francke MI, Andrews LM, de Winter BCM, van Gelder T, Hesselink DA. Usage 
of tacrolimus and mycophenolic acid during conception, pregnancy, and lactation, and 
its implications for therapeutic drug monitoring: a systematic critical review. Ther Drug 
Monit 2020;42:518‚Äì31. https://doi.org/10.1097/FTD.0000000000000769 
277. Coscia LA, Armenti DP, King RW, Sifontis NM, Constantinescu S, Moritz MJ. Update 
on the teratogenicity of maternal mycophenolate mofetil. J Pediatr Genet 2015;4: 
42‚Äì55. https://doi.org/10.1055/s-0035-1556743 
278. Lebin LG, Novick AM. Selective serotonin reuptake inhibitors (SSRIs) in pregnancy: an 
updated review on risks to mother, fetus, and child. Curr Psychiatry Rep 2022;24: 
687‚Äì95. https://doi.org/10.1007/s11920-022-01372-x 
279. Walkery A, Leader LD, Cooke E, VandenBerg A. Review of allopregnanolone agonist 
therapy for the treatment of depressive disorders. Drug Des Devel Ther 2021;15: 
3017‚Äì26. https://doi.org/10.2147/DDDT.S240856 
280. Henriksson P. Cardiovascular problems associated with IVF therapy. J Intern Med 2021; 
289:2‚Äì11. https://doi.org/10.1111/joim.13136 
281. Wallet T, Legrand L, Isnard R, Gandjbakhch E, Pousset F, Proukhnitzky J, et al. 
Pregnancy and cardiac maternal outcomes in women with inherited cardiomyopathy: 
interest of the CARPREG II risk score. ESC Heart Fail 2024;11:1506‚Äì14. https://doi.org/ 
10.1002/ehf2.14694 
282. Grewal J, Siu SC, Ross HJ, Mason J, Balint OH, Sermer M, et al. Pregnancy outcomes in 
women with dilated cardiomyopathy. J Am Coll Cardiol 2009;55:45‚Äì52. https://doi.org/ 
10.1016/j.jacc.2009.08.036 
283. Castrini AI, Skj√∏lsvik E, Estensen ME, Almaas VM, Skulstad H, Lyseggen E, et al. 
Pregnancy and progression of cardiomyopathy in women with LMNA genotype- 
positive. J Am Heart Assoc 2022;11:e024960. https://doi.org/10.1161/JAHA.121. 
024960 
284. Hodes AR, Tichnell C, Te Riele AS, Murray B, Groeneweg JA, Sawant AC, et al. 
Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. Heart 2016;102:303‚Äì12. https://doi.org/10.1136/heartjnl-2015-308624 
285. Gandjbakhch E, Varlet E, Duthoit G, Fressart V, Charron P, Himbert C, et al. Pregnancy 
and newborn outcomes in arrhythmogenic right ventricular cardiomyopathy/dysplasia. 
Int J Cardiol 2018;258:172‚Äì8. https://doi.org/10.1016/j.ijcard.2017.11.067 
286. Ermakov S, Scheinman M. Arrhythmogenic right ventricular cardiomyopathy‚Äîantiarrhythmic therapy. Arrhythm Electrophysiol Rev 2015;4:86‚Äì9. https://doi.org/10.15420/ 
AER.2015.04.02.86 
287. Ermakov S, Gerstenfeld EP, Svetlichnaya Y, Scheinman MM. Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 2017;14:564‚Äì9. https://doi.org/10.1016/j.hrthm.2016.12. 
010 
288. Castrini AI, Lie √ò, Leren IS, Estensen ME, Stokke MK, Kl√¶boe LG, et al. Number of 
pregnancies and subsequent phenotype in a cross-sectional cohort of women with arrhythmogenic cardiomyopathy. Eur Heart J Cardiovasc Imaging 2019;20:192‚Äì8. https:// 
doi.org/10.1093/ehjci/jey061 
289. Platonov PG, Castrini AI, Svensson A, Christiansen MK, Gilljam T, Bundgaard H, et al. 
Pregnancies, ventricular arrhythmias, and substrate progression in women with arrhythmogenic right ventricular cardiomyopathy in the Nordic ARVC registry. 
Europace 2020;22:1873‚Äì9. https://doi.org/10.1093/europace/euaa136 
290. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 
ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the 
task force for the diagnosis and management of hypertrophic cardiomyopathy of 
the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733‚Äì79. https://doi. 
org/10.1093/eurheartj/ehu284 
291. Licordari R, Trimarchi G, Teresi L, Restelli D, Lofrumento F, Perna A, et al. Cardiac 
magnetic resonance in HCM phenocopies: from diagnosis to risk stratification and 
therapeutic management. J Clin Med 2023;12:3481. https://doi.org/10.3390/ 
jcm12103481 
292. Boucek D, Jirikowic J, Taylor M. Natural history of Danon disease. Genet Med 2011;13: 
563‚Äì8. https://doi.org/10.1097/GIM.0b013e31820ad795 
293. Pasqualucci D, Maiani S, Perra F, Cau M, Coiana A, Bianco P, et al. Danon disease in a 
Sardinian family: different aspects of the same mutation-a case report. Eur Heart J Case 
Rep 2023;7:ytad237. https://doi.org/10.1093/ehjcr/ytad237  
ESC Guidelines                                                                                                                                                                                               95


<!-- PAGE 96 -->

### Page 96

294. Autore C, Conte MR, Piccininno M, Bernab√≤ P, Bonfiglio G, Bruzzi P, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;40: 
1864‚Äì9. https://doi.org/10.1016/S0735-1097(02)02495-6 
295. Schinkel AF. Pregnancy in women with hypertrophic cardiomyopathy. Cardiol Rev 
2014;22:217‚Äì22. https://doi.org/10.1097/CRD.0000000000000010 
296. Goland S, van Hagen IM, Elbaz-Greener G, Elkayam U, Shotan A, Merz WM, et al. 
Pregnancy in women with hypertrophic cardiomyopathy: data from the European 
Society of Cardiology initiated Registry Of Pregnancy And Cardiac disease 
(ROPAC). Eur Heart J 2017;38:2683‚Äì90. https://doi.org/10.1093/eurheartj/ehx189 
297. Moolla M, Mathew A, John K, Yogasundaram H, Alhumaid W, Campbell S, et al. 
Outcomes of pregnancy in women with hypertrophic cardiomyopathy: a systematic 
review. Int J Cardiol 2022;359:54‚Äì60. https://doi.org/10.1016/j.ijcard.2022.04.034 
298. Fumagalli C, Zocchi C, Cappelli F, Celata A, Tassetti L, Sasso L, et al. Impact of pregnancy on the natural history of women with hypertrophic cardiomyopathy. Eur J Prev 
Cardiol 2024;31:3‚Äì10. https://doi.org/10.1093/eurjpc/zwad257 
299. Musumeci MB, Spirito P, Conte MR, Lillo R, Devoto E, Francia P, et al. Clinical course of 
pregnancy and long-term follow-up after delivery in hypertrophic cardiomyopathy. J 
Am Coll Cardiol 2021;77:1262‚Äì4. https://doi.org/10.1016/j.jacc.2020.12.055 
300. L‚Äô√âcuyer √â, Codsi E, Mongeon FP, Dore A, Morin F, Leduc L. Perinatal and cardiac outcomes of women with hypertrophic cardiomyopathy. J Matern Fetal Neonatal Med 
2022;35:8625‚Äì30. https://doi.org/10.1080/14767058.2021.1990883 
301. Gi WT, Amr A, Sedaghat-Hamedani F, Kayvanpour E, Mohr I, Meder M, et al. Two 
hearts at risk: emergency alcohol septal ablation in a pregnant woman with decompensated HOCM. JACC Case Rep 2020;2:139‚Äì44. https://doi.org/10.1016/j.jaccas.2019.11. 
053 
302. Shaikh A, Bajwa T, Bush M, Tajik AJ. Successful alcohol septal ablation in a pregnant 
patient with symptomatic hypertrophic obstructive cardiomyopathy. J Cardiol Cases 
2018;17:151‚Äì4. https://doi.org/10.1016/j.jccase.2017.12.009 
303. Bello J, Pellegrini MV. Mavacamten. In: StatPearls. Treasure Island, FL: StatPearls 
Publishing, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK582152/ 
(3 April 2025 date last accessed) 
304. European Medicines Agency https://www.ema.europa.eu/en/documents/product- 
information/camzyos-epar-product-information_en.pdf (3 April 2025, date last 
accessed). 
305. Maisch B, Mahrholdt H. The 2014 ESC Guidelines on the diagnosis and management of 
hypertrophic cardiomyopathy: what is new? Herz 2014;39:919‚Äì30. https://doi.org/10. 
1007/s00059-014-4177-z 
306. Tadmor OP, Keren A, Rosenak D, Gal M, Shaia M, Hornstein E, et al. The effect of disopyramide on uterine contractions during pregnancy. Am J Obstet Gynecol 1990;162: 
482‚Äì6. https://doi.org/10.1016/0002-9378(90)90416-5 
307. Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G, et al. 
Prevalence of the congenital long-QT syndrome. Circulation 2009;120:1761‚Äì7.  
https://doi.org/10.1161/CIRCULATIONAHA.109.863209 
308. Chockalingam P, Crotti L, Girardengo G, Johnson JN, Harris KM, van der Heijden JF, 
et al. Not all beta-blockers are equal in the management of long QT syndrome types 
1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol 2012;60: 
2092‚Äì9. https://doi.org/10.1016/j.jacc.2012.07.046 
309. Dusi V, Pugliese L, De Ferrari GM, Odero A, Crotti L, Dagradi F, et al. Left cardiac sympathetic denervation for long QT syndrome: 50 years‚Äô experience provides guidance 
for management. JACC Clin Electrophysiol 2022;8:281‚Äì94. https://doi.org/10.1016/j. 
jacep.2021.09.002 
310. Bos JM, Crotti L, Rohatgi RK, Castelletti S, Dagradi F, Schwartz PJ, et al. Mexiletine 
shortens the QT interval in patients with potassium channel-mediated type 2 long 
QT syndrome. Circ Arrhythm Electrophysiol 2019;12:e007280. https://doi.org/10. 
1161/CIRCEP.118.007280 
311. Crotti L, Neves R, Dagradi F, Musu G, Giannetti F, Bos JM, et al. Therapeutic efficacy of 
mexiletine for long QT syndrome type 2: evidence from human induced pluripotent 
stem cell-derived cardiomyocytes, transgenic rabbits, and patients. Circulation 2024; 
150:531‚Äì43. https://doi.org/10.1161/CIRCULATIONAHA.124.068959 
312. Rashba EJ, Zareba W, Moss AJ, Hall WJ, Robinson J, Locati EH, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. 
LQTS Investigators. Circulation 1998;97:451‚Äì6. https://doi.org/10.1161/01.CIR.97.5.451 
313. Khositseth A, Tester DJ, Will ML, Bell CM, Ackerman MJ. Identification of a common 
genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm 2004;1:60‚Äì4. https://doi.org/10.1016/j.hrthm.2004.01.006 
314. Heradien MJ, Goosen A, Crotti L, Durrheim G, Corfield V, Brink PA, et al. Does pregnancy increase cardiac risk for LQT1 patients with the KCNQ1-A341V mutation? J Am 
Coll Cardiol 2006;48:1410‚Äì5. https://doi.org/10.1016/j.jacc.2006.05.060 
315. Seth R, Moss AJ, McNitt S, Zareba W, Andrews ML, Qi M, et al. Long QT syndrome 
and pregnancy. J Am Coll Cardiol 2007;49:1092‚Äì8. https://doi.org/10.1016/j.jacc.2006. 
09.054 
316. Ishibashi K, Aiba T, Kamiya C, Miyazaki A, Sakaguchi H, Wada M, et al. Arrhythmia risk 
and Œ≤-blocker therapy in pregnant women with long QT syndrome. Heart 2017;103: 
1374‚Äì9. https://doi.org/10.1136/heartjnl-2016-310617 
317. Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clinical pharmacokinetic considerations. Clin Pharmacokinet 1988;14:217‚Äì40. https://doi.org/10.2165/00003088- 
198814040-00003 
318. Long QT Drugs Database. https://www.crediblemeds.org/ (29 January 2025, date last 
accessed). 
319. Cuneo BF, Kaizer AM, Clur SA, Swan H, Herberg U, Winbo A, et al. Mothers with long 
QT syndrome are at increased risk for fetal death: findings from a multicenter international study. Am J Obstet Gynecol 2020;222:263.e1‚Äìe11. https://doi.org/10.1016/j. 
ajog.2019.09.004 
320. Crotti L, Tester DJ, White WM, Bartos DC, Insolia R, Besana A, et al. Long QT 
syndrome-associated mutations in intrauterine fetal death. JAMA 2013;309: 
1473‚Äì82. https://doi.org/10.1001/jama.2013.3219 
321. Schwartz PJ, Garson A, Jr., Paul T, Stramba-Badiale M, Vetter VL, Wren C. Guidelines 
for the interpretation of the neonatal electrocardiogram. A task force of the European 
Society of Cardiology. Eur Heart J 2002;23:1329‚Äì44. https://doi.org/10.1053/euhj. 
2002.3274 
322. Schwartz PJ, Ackerman MJ, Antzelevitch C, Bezzina CR, Borggrefe M, Cuneo BF, et al. 
Inherited cardiac arrhythmias. Nat Rev Dis Primers 2020;6:58. https://doi.org/10.1038/ 
s41572-020-0188-7 
323. Rodr√≠guez-Ma√±ero M, Casado-Arroyo R, Sarkozy A, Leysen E, Sieira JA, Namdar M, 
et al. The clinical significance of pregnancy in Brugada syndrome. Rev Esp Cardiol 
(Engl Ed) 2014;67:176‚Äì80. https://doi.org/10.1016/j.rec.2013.06.023 
324. Brugada Drugs Database. www.brugadadrugs.org (29 January 2025, date last accessed). 
325. Talib S, van de Poll SW. Brugada syndrome diagnosed after Ramadan. Lancet 2013; 
382:100. https://doi.org/10.1016/S0140-6736(13)60810-7 
326. Cheung CC, Lieve KV, Roston TM, van der Ree MH, Deyell MW, Andrade JG, et al. 
Pregnancy in catecholaminergic polymorphic ventricular tachycardia. JACC Clin 
Electrophysiol 2019;5:387‚Äì94. https://doi.org/10.1016/j.jacep.2018.10.019 
327. Kannankeril PJ, Moore JP, Cerrone M, Priori SG, Kertesz NJ, Ro PS, et al. Efficacy of 
flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: 
a randomized clinical trial. JAMA Cardiol 2017;2:759‚Äì66. https://doi.org/10.1001/ 
jamacardio.2017.1320 
328. De Ferrari GM, Dusi V, Spazzolini C, Bos JM, Abrams DJ, Berul CI, et al. Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation. Circulation 2015;131:2185‚Äì93. https://doi.org/10.1161/ 
CIRCULATIONAHA.115.015731 
329. Crotti L, Odening KE, Sanguinetti MC. Heritable arrhythmias associated with abnormal 
function of cardiac potassium channels. Cardiovasc Res 2020;116:1542‚Äì56. https://doi. 
org/10.1093/cvr/cvaa068 
330. Bjerregaard P. Diagnosis and management of short QT syndrome. Heart Rhythm 2018; 
15:1261‚Äì7. https://doi.org/10.1016/j.hrthm.2018.02.034 
331. Ahmed A, Phillips JR. Teenage pregnancy with catecholaminergic polymorphic ventricular tachycardia and documented ICD discharges. Clin Case Rep 2016;4:361‚Äì5.  
https://doi.org/10.1002/ccr3.366 
332. Romagano MP, Qui√±ones JN, Ahnert A, Martinez R, Smulian JC. Catecholaminergic 
polymorphic ventricular tachycardia in pregnancy. Obstet Gynecol 2016;127:735‚Äì9.  
https://doi.org/10.1097/AOG.0000000000001333 
333. Kloesel B, Ackerman MJ, Sprung J, Narr BJ, Weingarten TN. Anesthetic management of 
patients with Brugada syndrome: a case series and literature review. Can J Anaesth 
2011;58:824‚Äì36. https://doi.org/10.1007/s12630-011-9546-y 
334. Roston TM, van der Werf C, Cheung CC, Grewal J, Davies B, Wilde AAM, et al. Caring 
for the pregnant woman with an inherited arrhythmia syndrome. Heart Rhythm 2020; 
17:341‚Äì8. https://doi.org/10.1016/j.hrthm.2019.08.004 
335. Tanaka H, Katsuragi S, Tanaka K, Sawada M, Iwanaga N, Yoshimatsu J, et al. Maternal 
and neonatal outcomes in labor and at delivery when long QT syndrome is present. J 
Matern Fetal Neonatal Med 2016;29:1117‚Äì9. https://doi.org/10.3109/14767058.2015. 
1036023 
336. Hammond BH, El Assaad I, Herber JM, Saarel EV, Cantillon D, Aziz PF. Contemporary 
maternal and fetal outcomes in the treatment of LQTS during pregnancy: is nadolol 
bad for the fetus? Heart Rhythm 2022;19:1516‚Äì21. https://doi.org/10.1016/j.hrthm. 
2022.05.001 
337. Sharif-Kazemi MB, Emkanjoo Z, Tavoosi A, Kafi M, Kheirkhah J, Alizadeh A, et al. 
Electrical storm in Brugada syndrome during pregnancy. Pacing Clin Electrophysiol 
2011;34:e18‚Äì21. https://doi.org/10.1111/j.1540-8159.2010.02740.x 
338. Giustetto C, Cerrato N, Dusi V, Angelini F, De Ferrari G, Gaita F. The Brugada syndrome: pharmacological therapy. Eur Heart J Suppl 2023;25:C32‚Äì7. https://doi.org/ 
10.1093/eurheartjsupp/suad036 
339. Bauersachs J, K√∂nig T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A, 
et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a 
position statement from the Heart Failure Association of the European Society of 
Cardiology study group on peripartum cardiomyopathy. Eur J Heart Fail 2019;21: 
827‚Äì43. https://doi.org/10.1002/ejhf.1493 
340. Arany Z. Peripartum cardiomyopathy. N Engl J Med 2024;390:154‚Äì64. https://doi.org/ 
10.1056/NEJMra2306667


<!-- PAGE 97 -->

### Page 97

341. Mielniczuk LM, Williams K, Davis DR, Tang AS, Lemery R, Green MS, et al. Frequency 
of peripartum cardiomyopathy. Am J Cardiol 2006;97:1765‚Äì8. https://doi.org/10.1016/j. 
amjcard.2006.01.039 
342. Brar SS, Khan SS, Sandhu GK, Jorgensen MB, Parikh N, Hsu JW, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 2007;100: 
302‚Äì4. https://doi.org/10.1016/j.amjcard.2007.02.092 
343. Karaye KM, Ishaq NA, Sa‚Äôidu H, Balarabe SA, Talle MA, Isa MS, et al. Incidence, clinical 
characteristics, and risk factors of peripartum cardiomyopathy in Nigeria: results from 
the PEACE registry. ESC Heart Fail 2020;7:235‚Äì43. https://doi.org/10.1002/ehf2.12562 
344. Sliwa K, Bauersachs J, Arany Z, Spracklen TF, Hilfiker-Kleiner D. Peripartum cardiomyopathy: from genetics to management. Eur Heart J 2021;42:3094‚Äì102. https://doi.org/ 
10.1093/eurheartj/ehab458 
345. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, Veltmann C, Coats AJ, Crespo-Leiro MG, 
et al. Current management of patients with severe acute peripartum cardiomyopathy: 
practical guidance from the Heart Failure Association of the European Society of 
Cardiology study group on peripartum cardiomyopathy. Eur J Heart Fail 2016;18: 
1096‚Äì105. https://doi.org/10.1002/ejhf.586 
346. Viljoen C, Hoevelmann J, Sliwa K. Peripartum cardiomyopathy in Europe: new insights 
from the UK. Eur Heart J 2023;44:5142‚Äì5. https://doi.org/10.1093/eurheartj/ehad724 
347. Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 2016;374: 
233‚Äì41. https://doi.org/10.1056/NEJMoa1505517 
348. Goli R, Li J, Brandimarto J, Levine LD, Riis V, McAfee Q, et al. Genetic and phenotypic 
landscape of peripartum cardiomyopathy. Circulation 2021;143:1852‚Äì62. https://doi. 
org/10.1161/CIRCULATIONAHA.120.052395 
349. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current 
state of knowledge on aetiology, diagnosis, management, and therapy of peripartum 
cardiomyopathy: a position statement from the Heart Failure Association of the 
European Society of Cardiology working group on peripartum cardiomyopathy. Eur 
J Heart Fail 2010;12:767‚Äì78. https://doi.org/10.1093/eurjhf/hfq120 
350. Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J. Peripartum cardiomyopathy: 
current management and future perspectives. Eur Heart J 2015;36:1090‚Äì7. https:// 
doi.org/10.1093/eurheartj/ehv009 
351. Hilfiker-Kleiner D, Sliwa K. Pathophysiology and epidemiology of peripartum cardiomyopathy. Nat Rev Cardiol 2014;11:364‚Äì70. https://doi.org/10.1038/nrcardio.2014.37 
352. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, et al. Cardiac angiogenic imbalance 
leads to peripartum cardiomyopathy. Nature 2012;485:333‚Äì8. https://doi.org/10. 
1038/nature11040 
353. Ricke-Hoch M, Pfeffer TJ, Hilfiker-Kleiner D. Peripartum cardiomyopathy: basic mechanisms and hope for new therapies. Cardiovasc Res 2020;116:520‚Äì31. https://doi. 
org/10.1093/cvr/cvz252 
354. Schelbert EB, Elkayam U, Cooper LT, Givertz MM, Alexis JD, Briller J, et al. Myocardial 
damage detected by late gadolinium enhancement cardiac magnetic resonance is uncommon in peripartum cardiomyopathy. J Am Heart Assoc 2017;6:e005472. https:// 
doi.org/10.1161/JAHA.117.005472 
355. Jackson AM, Macartney M, Brooksbank K, Brown C, Dawson D, Francis M, et al. A 
20-year population study of peripartum cardiomyopathy. Eur Heart J 2023;44: 
5128‚Äì41. https://doi.org/10.1093/eurheartj/ehad626 
356. Gevaert S, Van Belleghem Y, Bouchez S, Herck I, De Somer F, De Block Y, et al. Acute 
and critically ill peripartum cardiomyopathy and ‚Äòbridge to‚Äô therapeutic options: a single 
center experience with intra-aortic balloon pump, extra corporeal membrane oxygenation and continuous-flow left ventricular assist devices. Crit Care 2011;15:R93. https:// 
doi.org/10.1186/cc10098 
357. Mebazaa A, Tolppanen H, Mueller C, Lassus J, DiSomma S, Baksyte G, et al. Acute heart 
failure and cardiogenic shock: a multidisciplinary practical guidance. Intensive Care Med 
2016;42:147‚Äì63. https://doi.org/10.1007/s00134-015-4041-5 
358. Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A, et al. 
Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 2017;38:2671‚Äì9. https://doi.org/10.1093/eurheartj/ehx355 
359. Trongtorsak A, Kittipibul V, Mahabir S, Ibrahim M, Saint Croix GR, Hernandez GA, 
et al. Effects of bromocriptine in peripartum cardiomyopathy: a systematic review 
and meta-analysis. Heart Fail Rev 2022;27:533‚Äì43. https://doi.org/10.1007/s10741- 
021-10185-8 
360. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation of 
bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a 
proof-of-concept pilot study. Circulation 2010;121:1465‚Äì73. https://doi.org/10.1161/ 
CIRCULATIONAHA.109.901496 
361. Sieweke JT, Pfeffer TJ, Berliner D, K√∂nig T, Hallbaum M, Napp LC, et al. Cardiogenic 
shock complicating peripartum cardiomyopathy: importance of early left ventricular 
unloading and bromocriptine therapy. Eur Heart J Acute Cardiovasc Care 2020;9: 
173‚Äì82. https://doi.org/10.1177/2048872618777876 
362. Radakrishnan A, Dokko J, Pastena P, Kalogeropoulos AP. Thromboembolism in peripartum cardiomyopathy: a systematic review. J Thorac Dis 2024;16:645‚Äì60. https://doi. 
org/10.21037/jtd-23-945 
363. Carlson S, Schultz J, Ramu B, Davis MB. Peripartum cardiomyopathy: risks diagnosis 
and management. J Multidiscip Healthc 2023;16:1249‚Äì58. https://doi.org/10.2147/ 
JMDH.S372747 
364. Puri A, Sethi R, Singh B, Dwivedi S, Narain V, Saran R, et al. Peripartum cardiomyopathy 
presenting with ventricular tachycardia: a rare presentation. Indian Pacing Electrophysiol 
J 2009;9:186‚Äì9. PMID: 19471599 
365. Saltzberg MT, Szymkiewicz S, Bianco NR. Characteristics and outcomes of 
peripartum versus nonperipartum cardiomyopathy in women using a wearable 
cardiac defibrillator. J Card Fail 2012;18:21‚Äì7. https://doi.org/10.1016/j.cardfail.2011. 
09.004 
366. McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study 
(investigations of pregnancy-associated cardiomyopathy). J Am Coll Cardiol 2015;66: 
905‚Äì14. https://doi.org/10.1016/j.jacc.2015.06.1309 
367. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:207‚Äì21. https://doi.org/ 
10.1016/j.jacc.2019.11.014 
368. Sliwa K, Jackson A, Viljoen C, Damasceno A, Mbanze I, Farhan HA, et al. Pregnancies in 
women after peri-partum cardiomyopathy: the global European Society of Cardiology 
EuroObservational research programme peri-partum cardiomyopathy registry. Eur 
Heart J 2025;46:1031‚Äì40. https://doi.org/10.1093/eurheartj/ehaf006 
369. Sliwa K, Petrie MC, Hilfiker-Kleiner D, Mebazaa A, Jackson A, Johnson MR, 
et al. Long-term prognosis, subsequent pregnancy, contraception and overall 
management of peripartum cardiomyopathy: practical guidance paper from the 
Heart Failure Association of the European Society of Cardiology study group on 
peripartum cardiomyopathy. Eur J Heart Fail 2018;20:951‚Äì62. https://doi.org/10. 
1002/ejhf.1178 
370. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, Petrie MC, Maggioni AP, Laroche C, 
et al. Clinical characteristics of patients from the worldwide registry on 
peripartum cardiomyopathy (PPCM): EURObservational research programme in conjunction with the Heart Failure Association of the European Society of Cardiology 
study group on PPCM. Eur J Heart Fail 2017;19:1131‚Äì41. https://doi.org/10.1002/ 
ejhf.780 
371. Fett JD, Fristoe KL, Welsh SN. Risk of heart failure relapse in subsequent pregnancy 
among peripartum cardiomyopathy mothers. Int J Gynaecol Obstet 2010;109:34‚Äì6.  
https://doi.org/10.1016/j.ijgo.2009.10.011 
372. Desplantie O, Tremblay-Gravel M, Avram R, Marquis-Gravel G, Ducharme A, 
Jolicoeur EM. The medical treatment of new-onset peripartum cardiomyopathy: a systematic review of prospective studies. Can J Cardiol 2015;31:1421‚Äì6. https://doi.org/10. 
1016/j.cjca.2015.04.029 
373. Haghikia A, Podewski E, Berliner D, Sonnenschein K, Fischer D, Angermann CE, et al. 
Rationale and design of a randomized, controlled multicentre clinical trial to evaluate 
the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy. Clin Res Cardiol 2015;104:911‚Äì7. https://doi.org/10.1007/s00392-015- 
0869-5 
374. van der Meer P, van Essen B, Viljoen C, B√∂hm M, Jackson A, Hilfiker-Kleiner D, et al. 
Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP 
PPCM registry. Eur Heart J 2025;46:1017‚Äì27. https://doi.org/10.1093/eurheartj/ 
ehae559 
375. Haghikia A, Podewski E, Libhaber E, Labidi S, Fischer D, Roentgen P, et al. Phenotyping 
and outcome on contemporary management in a German cohort of patients with 
peripartum cardiomyopathy. Basic Res Cardiol 2013;108:366. https://doi.org/10. 
1007/s00395-013-0366-9 
376. Tremblay-Gravel M, Marquis-Gravel G, Avram R, Desplantie O, Ducharme A, Bibas L, 
et al. The effect of bromocriptine on left ventricular functional recovery in peripartum 
cardiomyopathy: insights from the BRO-HF retrospective cohort study. ESC Heart Fail 
2019;6:27‚Äì36. https://doi.org/10.1002/ehf2.12376 
377. Duncker D, Haghikia A, K√∂nig T, Hohmann S, Gutleben KJ, Westenfeld R, et al. Risk for 
ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function‚Äîvalue of the wearable cardioverter/defibrillator. Eur J Heart Fail 
2014;16:1331‚Äì6. https://doi.org/10.1002/ejhf.188 
378. Beyer SE, Dicks AB, Shainker SA, Feinberg L, Schermerhorn ML, Secemsky EA, et al. 
Pregnancy-associated arterial dissections: a nationwide cohort study. Eur Heart J 
2020;41:4234‚Äì42. https://doi.org/10.1093/eurheartj/ehaa497 
379. Tanaka H, Kamiya CA, Horiuchi C, Morisaki H, Tanaka K, Katsuragi S, et al. Aortic dissection during pregnancy and puerperium: a Japanese nationwide survey. J Obstet 
Gynaecol Res 2021;47:1265‚Äì71. https://doi.org/10.1111/jog.14657 
380. Braverman AC, Mittauer E, Harris KM, Evangelista A, Pyeritz RE, Brinster D, et al. 
Clinical features and outcomes of pregnancy-related acute aortic dissection. JAMA 
Cardiol 2021;6:58‚Äì66. https://doi.org/10.1001/jamacardio.2020.4876 
381. Sayama S, Takeda N, Iriyama T, Inuzuka R, Maemura S, Fujita D, et al. Peripartum type B 
aortic dissection in patients with Marfan syndrome who underwent aortic root replacement: a case series study. BJOG 2018;125:487‚Äì93. https://doi.org/10.1111/ 
1471-0528.14635 
382. Peters P, van der Zande A, De Backer J, Jondeau G, Ahmad O, Richardson M, et al. 
Pregnancy outcomes in women with heritable thoracic aortic disease: data from the  
ESC Guidelines                                                                                                                                                                                               97


<!-- PAGE 98 -->

### Page 98

EORP ESC Registry of Pregnancy and Cardiac disease (ROPAC) III. Eur Heart J Qual 
Care Clin Outcomes 2025; DOI: 10.1093/ehjqcco/qcaf038 
383. Czerny M, Grabenw√∂ger M, Berger T, Aboyans V, Della Corte A, Chen EP, et al. 
EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of 
the aortic organ. Eur J Cardiothorac Surg 2024;65:ezad426. https://doi.org/10.1093/ 
ejcts/ezad426 
384. Narula N, Devereux RB, Malonga GP, Hriljac I, Roman MJ. Pregnancy-related aortic 
complications in women with Marfan syndrome. J Am Coll Cardiol 2021;78:870‚Äì9.  
https://doi.org/10.1016/j.jacc.2021.06.034 
385. Wallace SE, Regalado ES, Gong L, Janda AL, Guo DC, Russo CF, et al. MYLK pathogenic 
variants aortic disease presentation, pregnancy risk, and characterization of pathogenic 
missense variants. Genet Med 2019;21:144‚Äì51. https://doi.org/10.1038/s41436-018- 
0038-0 
386. Regalado ES, Guo DC, Estrera AL, Buja LM, Milewicz DM. Acute aortic dissections 
with pregnancy in women with ACTA2 mutations. Am J Med Genet A 2014;164A: 
106‚Äì12. https://doi.org/10.1002/ajmg.a.36208 
387. Jondeau G, Ropers J, Regalado E, Braverman A, Evangelista A, Teixedo G, et al. 
International registry of patients carrying TGFBR1 or TGFBR2 mutations: results of 
the MAC (Montalcino Aortic Consortium). Circ Cardiovasc Genet 2016;9:548‚Äì58.  
https://doi.org/10.1161/CIRCGENETICS.116.001485 
388. Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC 
Guidelines for the management of peripheral arterial and aortic diseases: developed by 
the task force on the management of peripheral arterial and aortic diseases of the 
European Society of Cardiology (ESC) endorsed by the European Association for 
Cardio-Thoracic Surgery (EACTS), the European Reference Network on rare multisystemic vascular diseases (VASCERN), and the European Society of Vascular 
Medicine (ESVM). Eur Heart J 2024;45:3538‚Äì700. https://doi.org/10.1093/eurheartj/ 
ehae179 
389. Groth KA, Nielsen BB, Sheyanth IN, Gravholt CH, Andersen NH, Stochholm K. 
Maternal health and pregnancy outcome in diagnosed and undiagnosed Marfan syndrome: a registry-based study. Am J Med Genet A 2021;185:1414‚Äì20. https://doi.org/ 
10.1002/ajmg.a.62122 
390. Cauldwell M, Steer PJ, Curtis SL, Mohan A, Dockree S, Mackillop L, et al. Maternal and 
fetal outcomes in pregnancies complicated by Marfan syndrome. Heart 2019;105: 
1725‚Äì31. https://doi.org/10.1136/heartjnl-2019-314817 
391. Claus J, Schoof L, Mir TS, Kammal AL, Sch√∂n G, Kutsche K, et al. Late diagnosis of 
Marfan syndrome is associated with unplanned aortic surgery and cardiovascular 
death. J Thorac Cardiovasc Surg 2025;169:1201‚Äì9.e33. https://doi.org/10.1016/j.jtcvs. 
2024.09.016 
392. Nucera M, Heinisch PP, Langhammer B, Jungi S, Mihalj M, Schober P, et al. The impact 
of sex and gender on aortic events in patients with Marfan syndrome. Eur J Cardiothorac 
Surg 2022;62:ezac305. https://doi.org/10.1093/ejcts/ezac305 
393. Meijboom LJ, Vos FE, Timmermans J, Boers GH, Zwinderman AH, Mulder BJ. 
Pregnancy and aortic root growth in the Marfan syndrome: a prospective study. Eur 
Heart J 2005;26:914‚Äì20. https://doi.org/10.1093/eurheartj/ehi103 
394. Sayama S, Iriyama T, Takeda N, Yamauchi H, Toshimitsu M, Seyama T, et al. Proposed 
management policy for pregnant women with Loeys‚ÄìDietz syndrome following 
prophylactic aortic root replacement based on experience from a tertiary care center. 
Int Heart J 2022;63:176‚Äì9. https://doi.org/10.1536/ihj.21-341 
395. Cauldwell M, Steer PJ, Curtis S, Mohan AR, Dockree S, Mackillop L, et al. Maternal and 
fetal outcomes in pregnancies complicated by the inherited aortopathy Loeys‚ÄìDietz 
syndrome. BJOG 2019;126:1025‚Äì31. https://doi.org/10.1111/1471-0528.15670 
396. Bowen JM, Hernandez M, Johnson DS, Green C, Kammin T, Baker D, et al. Diagnosis 
and management of vascular Ehlers‚ÄìDanlos syndrome: experience of the UK national 
diagnostic service, Sheffield. Eur J Hum Genet 2023;31:749‚Äì60. https://doi.org/10.1038/ 
s41431-023-01343-7 
397. Murray ML, Pepin M, Peterson S, Byers PH. Pregnancy-related deaths and complications in women with vascular Ehlers‚ÄìDanlos syndrome. Genet Med 2014;16: 
874‚Äì80. https://doi.org/10.1038/gim.2014.53 
398. Pepin MG, Schwarze U, Rice KM, Liu M, Leistritz D, Byers PH. Survival is affected by 
mutation type and molecular mechanism in vascular Ehlers‚ÄìDanlos syndrome (EDS 
type IV). Genet Med 2014;16:881‚Äì8. https://doi.org/10.1038/gim.2014.72 
399. Frank M, Adham S, Seigle S, Legrand A, Mirault T, Henneton P, et al. Vascular Ehlers‚Äì 
Danlos syndrome: long-term observational study. J Am Coll Cardiol 2019;73:1948‚Äì57.  
https://doi.org/10.1016/j.jacc.2019.01.058 
400. Haem T, Benson B, Dernoncourt A, Gondry J, Schmidt J, Foulon A. Vascular Ehlers‚Äì 
Danlos syndrome and pregnancy: a systematic review. BJOG 2024;131:1620‚Äì9.  
https://doi.org/10.1111/1471-0528.17893 
401. Renard M, Francis C, Ghosh R, Scott AF, Witmer PD, Ad√®s LC, et al. Clinical validity of 
genes for heritable thoracic aortic aneurysm and dissection. J Am Coll Cardiol 2018;72: 
605‚Äì15. https://doi.org/10.1016/j.jacc.2018.04.089 
402. Arnaud P, Hanna N, Benarroch L, Aubart M, Bal L, Bouvagnet P, et al. Genetic diversity 
and pathogenic variants as possible predictors of severity in a French sample of nonsyndromic heritable thoracic aortic aneurysms and dissections (nshTAAD). GIM 2019; 
21:2015‚Äì24. https://doi.org/10.1038/s41436-019-0444-y 
403. Luehr M, Yildiz M, Ma WG, Heck R, Polycarpou A, Jassar A, et al. Acute type A aortic 
dissection in adolescents and young adults under 30 years of age: demographics, aetiology and postoperative outcomes of 139 cases. Eur J Cardiothorac Surg 2023;63: 
ezad112. https://doi.org/10.1093/ejcts/ezad112 
404. Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, et al. 
Clinical practice guidelines for the care of girls and women with Turner syndrome: 
proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J 
Endocrinol 2017;177:G1‚ÄìG70. https://doi.org/10.1530/EJE-17-0430 
405. Silberbach M, Roos-Hesselink JW, Andersen NH, Braverman AC, Brown N, Collins 
RT, et al. Cardiovascular health in Turner syndrome: a scientific statement from the 
American Heart Association. Circ Genomic Precis Med 2018;11:e000048. https://doi. 
org/10.1161/HCG.0000000000000048 
406. Duijnhouwer AL, Bons LR, Timmers H, van Kimmenade RRL, Snoeren M, 
Timmermans J, et al. Aortic dilatation and outcome in women with Turner syndrome. 
Heart 2019;105:693‚Äì700. https://doi.org/10.1136/heartjnl-2018-313716 
407. Meccanici F, Schotte MH, Snoeren M, Bons LR, van den Hoven AT, Kardys I, et al. 
Aortic dilation and growth in women with Turner syndrome. Heart 2022;109: 
102‚Äì10. https://doi.org/10.1136/heartjnl-2022-320922 
408. Galian-Gay L, Rodriguez-Palomares JF. Turner syndrome and aortic complications: 
more benign than previously thought. Heart 2022;109:82‚Äì3. https://doi.org/10.1136/ 
heartjnl-2022-321330 
409. Gravholt CH, Andersen NH, Christin-Maitre S, Davis SM, Duijnhouwer A, Gawlik A, 
et al. Clinical practice guidelines for the care of girls and women with Turner syndrome. Eur J Endocrinol 2024;190:G53‚Äì151. https://doi.org/10.1093/ejendo/lvae050 
410. Carlson M, Airhart N, Lopez L, Silberbach M. Moderate aortic enlargement and bicuspid aortic valve are associated with aortic dissection in Turner syndrome: report of the 
international turner syndrome aortic dissection registry. Circulation 2012;126:2220‚Äì6.  
https://doi.org/10.1161/CIRCULATIONAHA.111.088633 
411. Carlson M, Silberbach M. Dissection of the aorta in Turner syndrome: two cases and 
review of 85 cases in the literature. J Med Genet 2007;44:745‚Äì9. https://doi.org/10. 
1136/jmg.2007.052019 
412. Matura LA, Ho VB, Rosing DR, Bondy CA. Aortic dilatation and dissection in Turner 
syndrome. 
Circulation 
2007;116:1663‚Äì70. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.106.685487 
413. Grewal J, Valente AM, Egbe AC, Wu FM, Krieger EV, Sybert VP, et al. Cardiovascular 
outcomes of pregnancy in Turner syndrome. Heart 2021;107:61‚Äì6. https://doi.org/10. 
1136/heartjnl-2020-316719 
414. Cauldwell M, Steer PJ, Adamson D, Alexander C, Allen L, Bhagra C, et al. Pregnancies in 
women with Turner syndrome: a retrospective multicentre UK study. BJOG 2022;129: 
796‚Äì803. https://doi.org/10.1111/1471-0528.17025 
415. Galian-Gay L, Pijuan-Domenech A, Cantalapiedra-Romero J, Serrano B, Goya M, Maiz 
N, et al. Pregnancy-related aortic complications in women with bicuspid aortic valve. 
Heart 2023;109:1153‚Äì8. https://doi.org/10.1136/heartjnl-2022-322328 
416. Ganapathi AM, Ranney DN, Peterson MD, Lindsay ME, Patel HJ, Pyeritz RE, et al. 
Location of aortic enlargement and risk of type A dissection at smaller diameters. 
J Am Coll Cardiol 2022;79:1890‚Äì7. https://doi.org/10.1016/j.jacc.2022.02.053 
417. Kalogerakos PD, Zafar MA, Li Y, Mukherjee SK, Ziganshin BA, Rizzo JA, et al. Root dilatation is more malignant than ascending aortic dilation. J Am Heart Assoc 2021;10: 
e020645. https://doi.org/10.1161/JAHA.120.020645 
418. Blood Pressure Lowering Treatment Trialists‚Äô Collaboration. Age-stratified and 
blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for 
the prevention of cardiovascular disease and death: an individual participant-level 
data meta-analysis. Lancet 2021;398:1053‚Äì64. https://doi.org/10.1016/S0140- 
6736(21)01921-8 
419. Weinstein J, Shinfeld A, Simchen M, Cahan T, Frogel J, Arad M, et al. Anesthesia in parturients presenting with Marfan syndrome. Isr Med Assoc J 2021;23:437‚Äì40. PMID: 34251127 
420. Curtis SL, Swan L. Aortopathy in pregnancy. Heart 2022;108:1851‚Äì7. https://doi.org/ 
10.1136/heartjnl-2021-319828 
421. van Steenbergen GJ, Tsang QHY, van der Heijden OWH, Vart P, Rodwell L, 
Roos-Hesselink JW, et al. Timing of cardiac surgery during pregnancy: a patient-level 
meta-analysis. Eur Heart J 2022;43:2801‚Äì11. https://doi.org/10.1093/eurheartj/ehac234 
422. Liu H, Yang L, Chen CY, Qian SC, Ma LY, Diao YF, et al. Management strategies and 
outcomes in pregnancy-related acute aortic dissection: a multicentre cohort study in 
China. Heart 2024;110:1298‚Äì306. https://doi.org/10.1136/heartjnl-2024-324009 
423. Curry RA, Gelson E, Swan L, Dob D, Babu-Narayan SV, Gatzoulis MA, et al. Marfan 
syndrome and pregnancy: maternal and neonatal outcomes. BJOG 2014;121:610‚Äì7.  
https://doi.org/10.1111/1471-0528.12515 
424. Roman MJ, Pugh NL, Hendershot TP, Devereux RB, Dietz H, Holmes K, et al. Aortic 
complications associated with pregnancy in Marfan syndrome: the NHLBI national 
registry of genetically triggered thoracic aortic aneurysms and cardiovascular conditions (GenTAC). J Am Heart Assoc 2016;5:e004052. https://doi.org/10.1161/JAHA. 
116.004052 
425. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of 
Ehlers‚ÄìDanlos syndrome type IV, the vascular type. N Engl J Med 2000;342:673‚Äì80.  
https://doi.org/10.1056/NEJM200003093421001


<!-- PAGE 99 -->

### Page 99

426. Kuperstein R, Cahan T, Yoeli-Ullman R, Ben Zekry S, Shinfeld A, Simchen MJ. Risk of 
aortic dissection in pregnant patients with the Marfan syndrome. Am J Cardiol 2017; 
119:132‚Äì7. https://doi.org/10.1016/j.amjcard.2016.09.024 
427. Kang JW, Song HG, Yang DH, Baek S, Kim DH, Song JM, et al. Association between 
bicuspid aortic valve phenotype and patterns of valvular dysfunction and bicuspid aortopathy: comprehensive evaluation using MDCT and echocardiography. JACC 
Cardiovasc Imaging 2013;6:150‚Äì61. https://doi.org/10.1016/j.jcmg.2012.11.007 
428. Della Corte A, Bancone C, Buonocore M, Dialetto G, Covino FE, Manduca S, et al. 
Pattern of ascending aortic dimensions predicts the growth rate of the aorta in patients with bicuspid aortic valve. JACC Cardiovasc Imaging 2013;6:1301‚Äì10. https:// 
doi.org/10.1016/j.jcmg.2013.07.009 
429. Donnelly RT, Pinto NM, Kocolas I, Yetman AT. The immediate and long-term impact 
of pregnancy on aortic growth rate and mortality in women with Marfan syndrome. 
J Am Coll Cardiol 2012;60:224‚Äì9. https://doi.org/10.1016/j.jacc.2012.03.051 
430. Le≈õniak-Sobelga A, Tracz W, KostKiewicz M, Podolec P, Pasowicz M. Clinical and 
echocardiographic assessment of pregnant women with valvular heart diseases‚Äîmaternal and fetal outcome. Int J Cardiol 2004;94:15‚Äì23. https://doi.org/10.1016/j.ijcard. 
2003.03.017 
431. Whelton P, Carey R, Aronow W, Casey D, Collins K, Dennison Himmelfarb C, et al. 
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline 
for the prevention, detection, evaluation, and management of high blood pressure 
in adults: executive summary: a report of the American College of Cardiology/ 
American Heart Association task force on clinical practice guidelines. Circulation 
2018;138:e426‚Äì83. https://doi.org/10.1161/CIR.0000000000000597 
432. Seely EW, Ecker J. Chronic hypertension in pregnancy. Circulation 2014;129:1254‚Äì61.  
https://doi.org/10.1161/CIRCULATIONAHA.113.003904 
433. Roberts EA, Pistner A, Osobamiro O, Banning S, Shalhub S, Albright C, et al. 
Beta-blocker use during pregnancy correlates with less aortic root dilatation in patients with Marfan‚Äôs syndrome. Aorta (Stamford) 2023;11:63‚Äì70. https://doi.org/10. 
1055/a-2072-0469 
434. Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers‚ÄìDanlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet 2010;376:1476‚Äì84. https:// 
doi.org/10.1016/S0140-6736(10)60960-9 
435. Zhu JM, Ma WG, Peterss S, Wang LF, Qiao ZY, Ziganshin BA, et al. Aortic dissection in 
pregnancy: management strategy and outcomes. Ann Thorac Surg 2017;103:1199‚Äì206.  
https://doi.org/10.1016/j.athoracsur.2016.08.089 
436. Rommens KL, Sandhu HK, Miller CC, 3rd, Cecchi AC, Prakash SK, Saqib NU, et al. 
In-hospital outcomes and long-term survival of women of childbearing age with aortic 
dissection. J Vasc Surg 2021;74:1135‚Äì42.e1. https://doi.org/10.1016/j.jvs.2021.03.028 
437. Gouda P, Kay R, Habib M, Aziz A, Aziza E, Welsh R. Clinical features and complications 
of Loeys‚ÄìDietz syndrome: a systematic review. Int J Cardiol 2022;362:158‚Äì67. https:// 
doi.org/10.1016/j.ijcard.2022.05.065 
438. Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, et al. TGFB2 mutations 
cause familial thoracic aortic aneurysms and dissections associated with mild systemic 
features of Marfan syndrome. Nat Genet 2012;44:916‚Äì21. https://doi.org/10.1038/ng. 
2348 
439. Marsili L, Overwater E, Hanna N, Baujat G, Baars MJH, Boileau C, et al. Phenotypic 
spectrum of TGFB3 disease-causing variants in a Dutch‚ÄìFrench cohort and first report 
of a homozygous patient. Clin Genet 2020;97:723‚Äì30. https://doi.org/10.1111/cge. 
13700 
440. Shalhub S, Regalado ES, Guo DC, Milewicz DM. The natural history of type B aortic 
dissection in patients with PRKG1 mutation c.530G>A (p.Arg177Gln). J Vasc Surg 
2019;70:718‚Äì23. https://doi.org/10.1016/j.jvs.2018.12.032 
441. McKellar SH, MacDonald RJ, Michelena HI, Connolly HM, Sundt TM, 3rd. Frequency of 
cardiovascular events in women with a congenitally bicuspid aortic valve in a single 
community and effect of pregnancy on events. Am J Cardiol 2011;107:96‚Äì9. https:// 
doi.org/10.1016/j.amjcard.2010.08.061 
442. Wojnarski CM, Svensson LG, Roselli EE, Idrees JJ, Lowry AM, Ehrlinger J, et al. Aortic 
dissection in patients with bicuspid aortic valve-associated aneurysms. Ann Thorac Surg 
2015;100:1666‚Äì73. discussion 1673‚Äì4. https://doi.org/10.1016/j.athoracsur.2015.04. 
126 
443. den Hartog AW, Franken R, Zwinderman AH, Timmermans J, Scholte AJ, van den Berg 
MP, et al. The risk for type B aortic dissection in Marfan syndrome. J Am Coll Cardiol 
2015;65:246‚Äì54. https://doi.org/10.1016/j.jacc.2014.10.050 
444. Minsart AF, Mongeon FP, Laberge AM, Morin F, Dore A, Leduc L. Obstetric and cardiac outcomes in women with Marfan syndrome and an aortic root diameter ‚â§ 45 
mm. Eur J Obstet Gynecol Reprod Biol 2018;230:68‚Äì72. https://doi.org/10.1016/j. 
ejogrb.2018.09.012 
445. Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, et al. Aneurysm 
syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006;355: 
788‚Äì98. https://doi.org/10.1056/NEJMoa055695 
446. van Hagen IM, van der Linde D, van de Laar IM, Mui√±o Mosquera L, De Backer J, 
Roos-Hesselink JW. Pregnancy in women with SMAD3 mutation. J Am Coll Cardiol 
2017;69:1356‚Äì8. https://doi.org/10.1016/j.jacc.2016.12.029 
447. Wang Z, Sun H, Zhang C, Lu L, Zhang L, Wang D. Outcomes of acute type A aortic 
dissection repair during pregnancy. Int J Gynaecol Obstet 2023;161:927‚Äì33. https://doi. 
org/10.1002/ijgo.14586 
448. van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, 
et al. Birth prevalence of congenital heart disease worldwide: a systematic review and 
meta-analysis. J Am Coll Cardiol 2011;58:2241‚Äì7. https://doi.org/10.1016/j.jacc.2011.08. 
025 
449. Liu Y, Chen S, Z√ºhlke L, Black GC, Choy MK, Li N, et al. Global birth prevalence of 
congenital heart defects 1970‚Äì2017: updated systematic review and meta-analysis 
of 260 studies. Int J Epidemiol 2019;48:455‚Äì63. https://doi.org/10.1093/ije/dyz009 
450. Erikssen G, Liest√∏l K, Seem E, Birkeland S, Saatvedt KJ, Hoel TN, et al. Achievements in 
congenital heart defect surgery: a prospective, 40-year study of 7038 patients. Circulation 
2015;131:337‚Äì46. discussion 346. https://doi.org/10.1161/CIRCULATIONAHA.114. 
012033 
451. Balint OH, Siu SC, Mason J, Grewal J, Wald R, Oechslin EN, et al. Cardiac outcomes 
after pregnancy in women with congenital heart disease. Heart 2010;96:1656‚Äì61.  
https://doi.org/10.1136/hrt.2010.202838 
452. De Backer J, Bondue A, Budts W, Evangelista A, Gallego P, Jondeau G, et al. Genetic 
counselling and testing in adults with congenital heart disease: a consensus document 
of the ESC Working Group of grown-up congenital heart disease, the ESC Working 
Group on aorta and peripheral vascular disease and the European Society of 
Human Genetics. Eur J Prev Cardiol 2020;27:1423‚Äì35. https://doi.org/10.1177/ 
2047487319854552 
453. Vriend JW, Drenthen W, Pieper PG, Roos-Hesselink JW, Zwinderman AH, van 
Veldhuisen DJ, et al. Outcome of pregnancy in patients after repair of aortic coarctation. Eur Heart J 2005;26:2173‚Äì8. https://doi.org/10.1093/eurheartj/ehi338 
454. Jimenez-Juan L, Krieger EV, Valente AM, Geva T, Wintersperger BJ, Moshonov H, et al. 
Cardiovascular magnetic resonance imaging predictors of pregnancy outcomes in women with coarctation of the aorta. Eur Heart J Cardiovasc Imaging 2014;15:299‚Äì306.  
https://doi.org/10.1093/ehjci/jet161 
455. Ciresi CM, Patel PR, Asdell SM, Hopkins KA, Hoyer MH, Kay WA. Management of severe coarctation of the aorta during pregnancy. JACC Case Rep 2020;2:116‚Äì9. https:// 
doi.org/10.1016/j.jaccas.2019.11.060 
456. Fuchs M, Zaidi AN, Rose J, Sisk T, Daniels CJ, Bradley EA. Location matters: left heart 
obstruction in pregnancy. Eur J Obstet Gynecol Reprod Biol 2016;196:38‚Äì43. https://doi. 
org/10.1016/j.ejogrb.2015.10.026 
457. Bredy C, Mongeon FP, Leduc L, Dore A, Khairy P. Pregnancy in adults with repaired/ 
unrepaired atrial septal defect. J Thorac Dis 2018;10:S2945‚Äì52. https://doi.org/10. 
21037/jtd.2017.10.130 
458. Zuber M, Gautschi N, Oechslin E, Widmer V, Kiowski W, Jenni R. Outcome of pregnancy in women with congenital shunt lesions. Heart 1999;81:271‚Äì5. https://doi.org/ 
10.1136/hrt.81.3.271 
459. Drenthen W, Pieper PG, van der Tuuk K, Roos-Hesselink JW, Voors AA, Mostert B, 
et al. Cardiac complications relating to pregnancy and recurrence of disease in the offspring of women with atrioventricular septal defects. Eur Heart J 2005;26:2581‚Äì7.  
https://doi.org/10.1093/eurheartj/ehi439 
460. Mendelson MA. Pregnancy in women with left-to-right cardiac shunts: any risk? Int J 
Cardiol Congenit Heart Dis 2021;5:100209. https://doi.org/10.1016/j.ijcchd.2021. 
100209 
461. Lindley KJ, Bairey Merz CN, Asgar AW, Bello NA, Chandra S, Davis MB, et al. 
Management of women with congenital or inherited cardiovascular disease from pre- 
conception through pregnancy and postpartum: JACC focus seminar 2/5. J Am Coll 
Cardiol 2021;77:1778‚Äì98. https://doi.org/10.1016/j.jacc.2021.02.026 
462. Greutmann M, Von Klemperer K, Brooks R, Peebles D, O‚ÄôBrien P, Walker F. 
Pregnancy outcome in women with congenital heart disease and residual haemodynamic lesions of the right ventricular outflow tract. Eur Heart J 2010;31:1764‚Äì70.  
https://doi.org/10.1093/eurheartj/ehq157 
463. Romeo JLR, Takkenberg JJM, Roos-Hesselink JW, Hanif M, Cornette JMJ, van Leeuwen 
WJ, et al. Outcomes of pregnancy after right ventricular outflow tract reconstruction 
with an allograft conduit. J Am Coll Cardiol 2018;71:2656‚Äì65. https://doi.org/10.1016/j. 
jacc.2018.03.522 
464. Romeo JLR, Papageorgiou G, Takkenberg JJM, Roos-Hesselink JW, van Leeuwen WJ, 
Cornette JMJ, et al. Influence of pregnancy on long-term durability of allografts in right 
ventricular outflow tract. J Thorac Cardiovasc Surg 2020;159:1508‚Äì16.e1. https://doi. 
org/10.1016/j.jtcvs.2019.08.083 
465. Duarte VE, Graf JA, Marshall AC, Economy KE, Valente AM. Transcatheter pulmonary 
valve performance during pregnancy and the postpartum period. JACC Case Rep 2020; 
2:847‚Äì51. https://doi.org/10.1016/j.jaccas.2020.02.029 
466. Kozicka U, Wero≈Ñski K, Ru≈ºy≈Ç≈Ço W, Demkow M, Kowalski M, ≈öpiewak M, et al. 
Pregnancy after transcatheter pulmonary valve implantation. Can J Cardiol 2017;33: 
1737.e5‚Äì.e7. https://doi.org/10.1016/j.cjca.2017.08.010 
467. Baris L, Ladouceur M, Johnson MR, Kozelj M, Festa P, Caruana M, et al. Pregnancy in 
tetralogy of fallot data from the ESC EORP ROPAC registry. IJC Congenital Heart 
Disease 2021;2:100059. https://doi.org/10.1016/j.ijcchd.2020.100059 
468. Balci A, Drenthen W, Mulder BJ, Roos-Hesselink JW, Voors AA, Vliegen HW, et al. 
Pregnancy in women with corrected tetralogy of fallot: occurrence and predictors  
ESC Guidelines                                                                                                                                                                                               99


<!-- PAGE 100 -->

### Page 100

of adverse events. Am Heart J 2011;161:307‚Äì13. https://doi.org/10.1016/j.ahj.2010.10. 
027 
469. Lima FV, Koutrolou-Sotiropoulou P, Yen TY, Stergiopoulos K. Clinical characteristics 
and outcomes in pregnant women with Ebstein anomaly at the time of delivery in the 
USA: 2003‚Äì2012. Arch Cardiovasc Dis 2016;109:390‚Äì8. https://doi.org/10.1016/j.acvd. 
2016.01.010 
470. Horiuchi C, Kamiya CA, Ohuchi H, Miyoshi T, Tsuritani M, Iwanaga N, et al. Pregnancy 
outcomes and mid-term prognosis in women after arterial switch operation for 
dextro-transposition of the great arteries‚Äîtertiary hospital experiences and review 
of literature. J Cardiol 2019;73:247‚Äì54. https://doi.org/10.1016/j.jjcc.2018.11.007 
471. Canobbio MM, Morris CD, Graham TP, Landzberg MJ. Pregnancy outcomes after atrial 
repair for transposition of the great arteries. Am J Cardiol 2006;98:668‚Äì72. https://doi. 
org/10.1016/j.amjcard.2006.03.050 
472. Bowater SE, Selman TJ, Hudsmith LE, Clift PF, Thompson PJ, Thorne SA. Long-term 
outcome following pregnancy in women with a systemic right ventricle: is the deterioration due to pregnancy or a consequence of time? Congenit Heart Dis 2013;8:302‚Äì7.  
https://doi.org/10.1111/chd.12001 
473. Harada G, Inai K, Shimada E, Ishido M, Shinohara T, Ogawa M. Management of pregnancy and delivery in women with transposition of the great arteries after atrial switch 
operation: a 16-year single-center experience. J Obstet Gynaecol Res 2022;48:351‚Äì9.  
https://doi.org/10.1111/jog.15111 
474. Pizula J, Devera J, Ng TMH, Yeung SL, Thangathurai J, Herrick N, et al. Outcome of 
pregnancy in women with D-transposition of the great arteries: a systematic review. 
J Am Heart Assoc 2022;11:e026862. https://doi.org/10.1161/JAHA.122.026862 
475. Trigas V, Nagdyman N, Pildner von Steinburg S, Oechslin E, Vogt M, Berger F, et al. 
Pregnancy-related obstetric and cardiologic problems in women after atrial switch operation for transposition of the great arteries. Circ J 2014;78:443‚Äì9. https://doi.org/10. 
1253/circj.CJ-12-1051 
476. Mahdi N-A, Guerma L, Desrosiers-Gagnon C, Dore A, Mongeon F-P, Mond√©sert B, 
et al. Sex-related differences and influence of pregnancy in transposition of great arteries with systemic right ventricle. JACC Adv 2024;3:101015. https://doi.org/10.1016/j. 
jacadv.2024.101015 
477. Stoll VM, Drury NE, Thorne S, Selman T, Clift P, Chong H, et al. Pregnancy outcomes 
in women with transposition of the great arteries after an arterial switch operation. 
JAMA Cardiol 2018;3:1119‚Äì22. https://doi.org/10.1001/jamacardio.2018.2747 
478. Kirzner J, Pirmohamed A, Ginns J, Singh HS. Long-term management of the arterial 
switch patient. Curr Cardiol Rep 2018;20:68. https://doi.org/10.1007/s11886-018- 
1012-9 
479. Sobhani NC, Corbetta-Rastelli CM, Agarwal A, D‚ÄôAlton ME, Friedman AM, Wen T. 
Delivery trends and obstetric outcomes in patients with fontan circulation. Am J 
Obstet Gynecol MFM 2023;5:100921. https://doi.org/10.1016/j.ajogmf.2023.100921 
480. Bartczak-Rutkowska A, Tomkiewicz-PajƒÖk L, Kawka-Paciorkowska K, Bajorek N, 
Ciep≈Çucha A, Ropacka-Lesiak M, et al. Pregnancy outcomes in women after the fontan 
procedure. J Clin Med 2023;12:783. https://doi.org/10.3390/jcm12030783 
481. Cauldwell M, Steer PJ, Bonner S, Asghar O, Swan L, Hodson K, et al. Retrospective UK 
multicentre study of the pregnancy outcomes of women with a Fontan repair. Heart 
2018;104:401‚Äì6. https://doi.org/10.1136/heartjnl-2017-311763 
482. Garcia Ropero A, Baskar S, Roos Hesselink JW, Girnius A, Zentner D, Swan L, et al. 
Pregnancy in women with a fontan circulation: a systematic review of the literature. 
Circ 
Cardiovasc 
Qual 
Outcomes 
2018;11:e004575. 
https://doi.org/10.1161/ 
CIRCOUTCOMES.117.004575 
483. Girnius A, Zentner D, Valente AM, Pieper PG, Economy KE, Ladouceur M, et al. 
Bleeding and thrombotic risk in pregnant women with Fontan physiology. Heart 
2021;107:1390‚Äì7. https://doi.org/10.1136/heartjnl-2020-317397 
484. Wolfe NK, Sabol BA, Kelly JC, Dombrowski M, Benhardt AC, Fleckenstein J, et al. 
Management of Fontan circulation in pregnancy: a multidisciplinary approach to 
care. Am J Obstet Gynecol MFM 2021;3:100257. https://doi.org/10.1016/j.ajogmf.2020. 
100257 
485. Khan A, Kim YY. Pregnancy in complex CHD: focus on patients with Fontan circulation 
and patients with a systemic right ventricle. Cardiol Young 2015;25:1608‚Äì14. https://doi. 
org/10.1017/S1047951115002279 
486. Montanaro C, Boyle S, Wander G, Johnson MR, Roos-Hesselink JW, Patel R, et al. 
Pregnancy in patients with the Fontan operation. Eur J Prev Cardiol 2024;31: 
1336‚Äì44. https://doi.org/10.1093/eurjpc/zwae157 
487. Breviario S, Krishnathasan K, Dimopoulos K, Gribaudo E, Constantine A, Li W, et al. 
Pregnancy in women with a Fontan circulation: short and long-term outcomes. Int J 
Cardiol 2024;415:132445. https://doi.org/10.1016/j.ijcard.2024.132445 
488. Ladouceur M, Benoit L, Basquin A, Radojevic J, Hauet Q, Hascoet S, et al. How pregnancy impacts adult cyanotic congenital heart disease: a multicenter observational 
study. Circulation 2017;135:2444‚Äì7. https://doi.org/10.1161/CIRCULATIONAHA. 
116.027152 
489. Presbitero P, Somerville J, Stone S, Aruta E, Spiegelhalter D, Rabajoli F. Pregnancy in 
cyanotic congenital heart disease. Outcome of mother and fetus. Circulation 1994; 
89:2673‚Äì6. https://doi.org/10.1161/01.CIR.89.6.2673 
490. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 
ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur 
Heart J 2022;43:3618‚Äì731. https://doi.org/10.1093/eurheartj/ehac237 
491. McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, et al. 
Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013; 
62:D51‚Äì9. https://doi.org/10.1016/j.jacc.2013.10.023 
492. Sitbon O, Sattler C, Bertoletti L, Savale L, Cottin V, Ja√Øs X, et al. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J 2016;47:1727‚Äì36.  
https://doi.org/10.1183/13993003.02043-2015 
493. Cheron C, McBride SA, Antigny F, Girerd B, Chouchana M, Chaumais M-C, et al. Sex 
and gender in pulmonary arterial hypertension. Eur Respir Rev 2021;30:200330. https:// 
doi.org/10.1183/16000617.0330-2020 
494. Luo J, Shi H, Xu L, Su W, Li J. Pregnancy outcomes in patients with pulmonary arterial 
hypertension: a retrospective study. Medicine (Baltimore) 2020;99:e20285. https://doi. 
org/10.1097/MD.0000000000020285 
495. Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 
2009;30:256‚Äì65. https://doi.org/10.1093/eurheartj/ehn597 
496. Ma R, Gao H, Cui J, Shi H, Yang Z, Jin Z, et al. Pregnancy feasibility in women with mild 
pulmonary arterial hypertension: a systematic review and meta-analysis. BMC 
Pregnancy Childbirth 2023;23:427. https://doi.org/10.1186/s12884-023-05752-w 
497. Zhang Q, Zhu F, Shi G, Hu C, Zhang W, Huang P, et al. Maternal outcomes among pregnant women with congenital heart disease-associated pulmonary hypertension. 
Circulation 2023;147:549‚Äì61. https://doi.org/10.1161/CIRCULATIONAHA.122.057987 
498. Lai W, Ding Y, Wen L. Long-term outcomes of pregnant women with pulmonary 
hypertension diagnosed by echocardiography: a retrospective cohort study in a single 
center from China. Pulm Circ 2021;11:2045894020966876. https://doi.org/10.1177/ 
2045894020966876 
499. Lv C, Huang Y, Liao G, Wu L, Chen D, Gao Y. Pregnancy outcomes in women with 
pulmonary hypertension: a retrospective study in China. BMC Pregnancy Childbirth 
2023;23:16. https://doi.org/10.1186/s12884-023-05353-7 
500. Sharma B, Sikka P, Chopra S, Bansal R, Suri V, Aggarwal N, et al. Pregnancy in 
Eisenmenger syndrome: a case series from a tertiary care hospital of Northern 
India. 
Cardiol 
Young 
2023;33:2185‚Äì2189. 
https://doi.org/10.1017/ 
S1047951122004152 
501. Su JY, Chen HF, Wang SM. Pregnancy outcome analysis of 94 patients with pulmonary 
arterial hypertension during pregnancy. Eur Rev Med Pharmacol Sci 2022;26:1970‚Äì7.  
https://doi.org/10.26355/eurrev_202203_28345 
502. Liu Y, Li Y, Zhang J, Zhang D, Li J, Zhao Y, et al. Maternal and fetal outcomes of pregnant women with pulmonary arterial hypertension associated with congenital heart 
disease in Beijing, China: a retrospective study. Pulm Circ 2022;12:e12079. https:// 
doi.org/10.1002/pul2.12079 
503. Sliwa K, van Hagen IM, Budts W, Swan L, Sinagra G, Caruana M, et al. Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac 
disease (ROPAC) of the European Society of Cardiology. Eur J Heart Fail 2016;18: 
1119‚Äì28. https://doi.org/10.1002/ejhf.594 
504. Li Q, Dimopoulos K, Liu T, Xu Z, Liu Q, Li Y, et al. Peripartum outcomes in a large population of women with pulmonary arterial hypertension associated with congenital heart 
disease. Eur J Prev Cardiol 2019;26:1067‚Äì76. https://doi.org/10.1177/2047487318821246 
505. Shu T, Feng P, Liu X, Wen L, Chen H, Chen Y, et al. Multidisciplinary team managements and clinical outcomes in patients with pulmonary arterial hypertension during 
the perinatal period. Front Cardiovasc Med 2021;8:795765. https://doi.org/10.3389/ 
fcvm.2021.795765 
506. Chen GC, Gao H, Zhang L, Tong T. Evaluation of therapeutic efficacy of anticoagulant 
drugs for patients with venous thromboembolism during pregnancy: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2019;238:7‚Äì11. https://doi.org/ 
10.1016/j.ejogrb.2019.04.038 
507. Kamp JC, von Kaisenberg C, Greve S, Winter L, Park DH, Fuge J, et al. Pregnancy in 
pulmonary arterial hypertension: midterm outcomes of mothers and offspring. J 
Heart Lung Transplant 2021;40:229‚Äì33. https://doi.org/10.1016/j.healun.2020.12.002 
508. de Raaf MA, Beekhuijzen M, Guignabert C, Vonk Noordegraaf A, Bogaard HJ. 
Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension. Reprod Toxicol 2015;56:45‚Äì51. https://doi.org/10.1016/j.reprotox.2015.06.048 
509. Amann U, Nadine W, Kollhorst B, Haug U. Prescribing of endothelin receptor antagonists and riociguat in women of childbearing age in a large German claims database study. 
Reprod Toxicol 2023;119:108415. https://doi.org/10.1016/j.reprotox.2023.108415 
510. Kourlaba G, Relakis J, Kontodimas S, Holm MV, Maniadakis N. A systematic review and 
meta-analysis of the epidemiology and burden of venous thromboembolism among 
pregnant women. Int J Gynaecol Obstet 2016;132:4‚Äì10. https://doi.org/10.1016/j.ijgo. 
2015.06.054 
511. Abbasi N, Balayla J, Laporta DP, Kezouh A, Abenhaim HA. Trends, risk factors and 
mortality among women with venous thromboembolism during labour and delivery: 
a population-based study of 8 million births. Arch Gynecol Obstet 2014;289:275‚Äì84.  
https://doi.org/10.1007/s00404-013-2923-8 
512. Bourjeily G, Paidas M, Khalil H, Rosene-Montella K, Rodger M. Pulmonary embolism in 
pregnancy. Lancet 2010;375:500‚Äì12. https://doi.org/10.1016/S0140-6736(09)60996-X


<!-- PAGE 101 -->

### Page 101

513. Bukhari S, Fatima S, Barakat AF, Fogerty AE, Weinberg I, Elgendy IY. Venous thromboembolism during pregnancy and postpartum period. Eur J Intern Med 2022;97:8‚Äì17.  
https://doi.org/10.1016/j.ejim.2021.12.013 
514. Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M, et al. 
Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational 
open-label randomised trial. Lancet 2014;384:1673‚Äì83. https://doi.org/10.1016/ 
S0140-6736(14)60793-5 
515. Sennstr√∂m M, Rova K, Hellgren M, Hjertberg R, Nord E, Thurn L, et al. 
Thromboembolism and in vitro fertilization‚Äîa systematic review. Acta Obstet 
Gynecol Scand 2017;96:1045‚Äì52. https://doi.org/10.1111/aogs.13147 
516. Rova K, Passmark H, Lindqvist PG. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful 
cycles. Fertil Steril 2012;97:95‚Äì100. https://doi.org/10.1016/j.fertnstert.2011.10.038 
517. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis 
and treatment of venous thromboembolism in pregnancy: a systematic review of 
safety and efficacy. Blood 2005;106:401‚Äì7. https://doi.org/10.1182/blood-2005-02- 
0626 
518. Romualdi E, Dentali F, Rancan E, Squizzato A, Steidl L, Middeldorp S, et al. 
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic 
review and a meta-analysis of the literature. J Thromb Haemost 2013;11:270‚Äì81.  
https://doi.org/10.1111/jth.12085 
519. Bistervels IM, Buchm√ºller A, Wiegers HMG, N√≠ √Åinle F, Tardy B, Donnelly J, et al. 
Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and 
post-partum women with a history of venous thromboembolism (Highlow study): 
an open-label, multicentre, randomised, controlled trial. Lancet 2022;400:1777‚Äì87.  
https://doi.org/10.1016/S0140-6736(22)02128-6 
520. Chan WS, Spencer FA, Ginsberg JS. Anatomic distribution of deep vein thrombosis in 
pregnancy. Cmaj 2010;182:657‚Äì60. https://doi.org/10.1503/cmaj.091692 
521. Chan WS, Lee A, Spencer FA, Crowther M, Rodger M, Ramsay T, et al. Predicting deep 
venous thrombosis in pregnancy: out in ‚ÄúLEFt‚Äù field? Ann Intern Med 2009;151:85‚Äì92.  
https://doi.org/10.7326/0003-4819-151-2-200907210-00004 
522. Righini M, Jobic C, Boehlen F, Broussaud J, Becker F, Jaffrelot M, et al. Predicting deep 
venous thrombosis in pregnancy: external validation of the LEFT clinical prediction 
rule. Haematologica 2013;98:545‚Äì8. https://doi.org/10.3324/haematol.2012.072009 
523. Chan WS, Spencer FA, Lee AY, Chunilal S, Douketis JD, Rodger M, et al. Safety of withholding anticoagulation in pregnant women with suspected deep vein thrombosis following negative serial compression ultrasound and iliac vein imaging. CMAJ 2013;185: 
E194‚Äì200. https://doi.org/10.1503/cmaj.120895 
524. Kline JA, Williams GW, Hernandez-Nino J. D-dimer concentrations in normal pregnancy: new diagnostic thresholds are needed. Clin Chem 2005;51:825‚Äì9. https://doi. 
org/10.1373/clinchem.2004.044883 
525. Righini M, Robert-Ebadi H, Elias A, Sanchez O, Le Moigne E, Schmidt J, et al. Diagnosis 
of pulmonary embolism during pregnancy: a multicenter prospective management 
outcome study. Ann Intern Med 2018;169:766‚Äì73. https://doi.org/10.7326/M18-1670 
526. van der Pol LM, Tromeur C, Bistervels IM, Ni Ainle F, van Bemmel T, Bertoletti L, et al. 
Pregnancy-adapted YEARS algorithm for diagnosis of suspected pulmonary embolism. 
N Engl J Med 2019;380:1139‚Äì49. https://doi.org/10.1056/NEJMoa1813865 
527. Bellesini M, Robert-Ebadi H, Combescure C, Dedionigi C, Le Gal G, Righini M. D-dimer 
to rule out venous thromboembolism during pregnancy: a systematic review and 
meta-analysis. J Thromb Haemost 2021;19:2454‚Äì67. https://doi.org/10.1111/jth.15432 
528. Barrios D, Rosa-Salazar V, Morillo R, Nieto R, Fern√°ndez S, Zamorano JL, et al. 
Prognostic significance of right heart thrombi in patients with acute symptomatic pulmonary embolism: systematic review and meta-analysis. Chest 2017;151:409‚Äì16.  
https://doi.org/10.1016/j.chest.2016.09.038 
529. Parunov LA, Soshitova NP, Ovanesov MV, Panteleev MA, Serebriyskiy II. Epidemiology 
of venous thromboembolism (VTE) associated with pregnancy. Birth Defects Res C 
Embryo Today 2015;105:167‚Äì84. https://doi.org/10.1002/bdrc.21105 
530. Harris SA, Velineni R, Davies AH. Inferior vena cava filters in pregnancy: a systematic 
review. J Vasc Interv Radiol 2016;27:354‚Äì60.e8. https://doi.org/10.1016/j.jvir.2015.11. 
024 
531. Bistervels IM, Buchm√ºller A, Tardy B. Inferior vena cava filters in pregnancy: safe or sorry? Front Cardiovasc Med 2022;9:1026002. https://doi.org/10.3389/fcvm.2022.1026002 
532. G√°ndara E, Carrier M, Rodger MA. Management of pregnancy associated venous- 
thromboembolism: a survey of practices. Thromb J 2014;12:12. https://doi.org/10. 
1186/1477-9560-12-12 
533. Ho VT, Dua A, Lavingia K, Rothenberg K, Rao C, Desai SS. Thrombolysis for venous 
thromboembolism during pregnancy: a literature review. Vasc Endovascular Surg 2018; 
52:527‚Äì34. https://doi.org/10.1177/1538574418777822 
534. Rodriguez D, Jerjes-Sanchez C, Fonseca S, Garcia-Toto R, Martinez-Alvarado J, 
Panneflek J, et al. Thrombolysis in massive and submassive pulmonary embolism during 
pregnancy and the puerperium: a systematic review. J Thromb Thrombolysis 2020;50: 
929‚Äì41. https://doi.org/10.1007/s11239-020-02122-7 
535. Martillotti G, Boehlen F, Robert-Ebadi H, Jastrow N, Righini M, Blondon M. Treatment 
options for severe pulmonary embolism during pregnancy and the postpartum period: 
a systematic review. J Thromb Haemost 2017;15:1942‚Äì50. https://doi.org/10.1111/jth. 
13802 
536. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 
ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 
2020;41:543‚Äì603. https://doi.org/10.1093/eurheartj/ehz405 
537. Kaur G, Oliveira-Gomes D, Rivera FB, Gulati M. Chest pain in women: considerations 
from the 2021 AHA/ACC chest pain guideline. Curr Probl Cardiol 2023;48:101697.  
https://doi.org/10.1016/j.cpcardiol.2023.101697 
538. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 
AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart 
Association Joint Committee on clinical practice guidelines. Circulation 2021;144: 
e368‚Äì454. https://doi.org/10.1161/CIR.0000000000001029 
539. Hayes SN, Kim ESH, Saw J, Adlam D, Arslanian-Engoren C, Economy KE, et al. 
Spontaneous coronary artery dissection: current state of the science: a scientific statement from the American Heart Association. Circulation 2018;137:e523‚Äì57. https://doi. 
org/10.1161/CIR.0000000000000564 
540. Siennicka A, K≈Çysz M, Che≈Çstowski K, Tabaczniuk A, Marcinowska Z, Tarnowska P, et al. 
Reference values of D-dimers and fibrinogen in the course of physiological pregnancy: 
the potential impact of selected risk factors-a pilot study. Biomed Res Int 2020;2020: 
3192350. https://doi.org/10.1155/2020/3192350 
541. Sadeghi S, Golshani M, Safaeian B. New cut-off point for D-dimer in the diagnosis of 
pulmonary embolism during pregnancy. Blood Res 2021;56:150‚Äì5. https://doi.org/10. 
5045/br.2021.2021069 
542. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al. 2014 
ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering 
acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The 
task force for the diagnosis and treatment of aortic diseases of the European Society of 
Cardiology (ESC). Eur Heart J 2014;35:2873‚Äì926. https://doi.org/10.1093/eurheartj/ 
ehu281 
543. Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, et al. Saving 
mothers‚Äô lives: reviewing maternal deaths to make motherhood safer: 2006‚Äì2008. 
The eighth report of the confidential enquiries into maternal deaths in the United 
Kingdom. BJOG 2011;118:1‚Äì203. https://doi.org/10.1111/j.1471-0528.2010.02847.x 
544. James AH, Jamison MG, Biswas MS, Brancazio LR, Swamy GK, Myers ER. Acute myocardial infarction in pregnancy: a United States population-based study. Circulation 
2006;113:1564‚Äì71. https://doi.org/10.1161/CIRCULATIONAHA.105.576751 
545. Smilowitz NR, Gupta N, Guo Y, Zhong J, Weinberg CR, Reynolds HR, et al. Acute 
myocardial infarction during pregnancy and the puerperium in the United States. 
Mayo Clin Proc 2018;93:1404‚Äì14. https://doi.org/10.1016/j.mayocp.2018.04.019 
546. Markson F, Shamaki RG, Antia A, Osabutey A, Ogunniyi MO. Trends in the incidence 
and in-patient outcomes of acute myocardial infarction in pregnancy: insights from the 
national inpatient sample. Am Heart J Plus 2023;34:100318. https://doi.org/10.1016/j. 
ahjo.2023.100318 
547. Dayan N, Filion KB, Okano M, Kilmartin C, Reinblatt S, Landry T, et al. Cardiovascular 
risk following fertility therapy: systematic review and meta-analysis. J Am Coll Cardiol 
2017;70:1203‚Äì13. https://doi.org/10.1016/j.jacc.2017.07.753 
548. Tweet MS, Lewey J, Smilowitz NR, Rose CH, Best PJM. (August 1, 2020) 
Pregnancy-associated myocardial infarction: prevalence, causes, and interventional 
management. Circ Cardiovasc Interv. 2020;13:292‚Äì304:e008687. DOI: 10.1161/ 
CIRCINTERVENTIONS.120.008687 
549. Roth A, Elkayam U. Acute myocardial infarction associated with pregnancy. J Am Coll 
Cardiol 2008;52:171‚Äì80. https://doi.org/10.1016/j.jacc.2008.03.049 
550. Tweet MS, Hayes SN, Codsi E, Gulati R, Rose CH, Best PJM. Spontaneous coronary 
artery dissection associated with pregnancy. J Am Coll Cardiol 2017;70:426‚Äì35.  
https://doi.org/10.1016/j.jacc.2017.05.055 
551. Havakuk O, Goland S, Mehra A, Elkayam U. Pregnancy and the risk of spontaneous 
coronary artery dissection: an analysis of 120 contemporary cases. Circ Cardiovasc 
Interv 2017;10:e004941. https://doi.org/10.1161/CIRCINTERVENTIONS.117.004941 
552. Koul AK, Hollander G, Moskovits N, Frankel R, Herrera L, Shani J. Coronary artery 
dissection during pregnancy and the postpartum period: two case reports and review 
of literature. Catheter Cardiovasc Interv 2001;52:88‚Äì94. https://doi.org/10.1002/1522- 
726X(200101)52:1<88::AID-CCD1022>3.0.CO;2-P 
553. Al-Hussaini A, Abdelaty A, Gulsin GS, Arnold JR, Garcia-Guimaraes M, 
Premawardhana D, et al. Chronic infarct size after spontaneous coronary artery dissection: implications for pathophysiology and clinical management. Eur Heart J 2020; 
41:2197‚Äì205. https://doi.org/10.1093/eurheartj/ehz895 
554. Jeejeebhoy FM, Zelop CM, Lipman S, Carvalho B, Joglar J, Mhyre JM, et al. Cardiac arrest in pregnancy: a scientific statement from the American Heart Association. 
Circulation 2015;132:1747‚Äì73. https://doi.org/10.1161/CIR.0000000000000300 
555. Wagner SM, Waldman IN, Karikari KA, Kunselman AR, Smith ER, Deimling TA. The 
impact of pregnancy on the evaluation of chest pain and shortness of breath in the 
emergency department. J Acute Med 2018;8:149‚Äì53. https://doi.org/10.6705/j.jacme. 
201812_8(4).0002  
ESC Guidelines                                                                                                                                                                                            101


<!-- PAGE 102 -->

### Page 102

556. Katja Prokselj MB. Cardiovascular imaging in pregnancy. Int J Cardiol Congenit Heart Dis 
2021;5:100235. https://doi.org/10.1016/j.ijcchd.2021.100235 
557. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC 
Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44: 
3720‚Äì826. https://doi.org/10.1093/eurheartj/ehad191 
558. Moran C, Ni Bhuinneain M, Geary M, Cunningham S, McKenna P, Gardiner J. 
Myocardial ischaemia in normal patients undergoing elective caesarean section: a peripartum assessment. Anaesthesia 2001;56:1051‚Äì8. https://doi.org/10.1111/j.1365- 
2044.2001.02271.x 
559. Tamis-Holland JE, Jneid H, Reynolds HR, Agewall S, Brilakis ES, Brown TM, et al. 
Contemporary diagnosis and management of patients with myocardial infarction in 
the absence of obstructive coronary artery disease: a scientific statement from the 
American Heart Association. Circulation 2019;139:e891‚Äì908. https://doi.org/10. 
1161/CIR.0000000000000670 
560. Faden MS, Bottega N, Benjamin A, Brown RN. A nationwide evaluation of spontaneous coronary artery dissection in pregnancy and the puerperium. Heart 2016;102: 
1974‚Äì9. https://doi.org/10.1136/heartjnl-2016-309403 
561. Chan N, Premawardhana D, Al-Hussaini A, Wood A, Bountziouka V, Kotecha D, et al. 
Pregnancy and spontaneous coronary artery dissection: lessons from survivors and nonsurvivors. Circulation 2022;146:69‚Äì72. https://doi.org/10.1161/CIRCULATIONAHA. 
122.059635 
562. Alfonso F, de la Torre Hern√°ndez JM, Ib√°√±ez B, Sabat√© M, Pan M, Gulati R, et al. 
Rationale and design of the BA-SCAD (beta-blockers and antiplatelet agents in patients 
with spontaneous coronary artery dissection) randomized clinical trial. Rev Esp Cardiol 
(Engl Ed) 2022;75:515‚Äì22. https://doi.org/10.1016/j.recesp.2021.08.002 
563. Adlam D, Alfonso F, Maas A, Vrints C. European Society of Cardiology, Acute 
Cardiovascular Care Association, SCAD study group: a position paper on spontaneous coronary artery dissection. Eur Heart J 2018;39:3353‚Äì68. https://doi.org/10. 
1093/eurheartj/ehy080 
564. Saw J, Humphries K, Aymong E, Sedlak T, Prakash R, Starovoytov A, et al. Spontaneous 
coronary artery dissection: clinical outcomes and risk of recurrence. J Am Coll Cardiol 
2017;70:1148‚Äì58. https://doi.org/10.1016/j.jacc.2017.06.053 
565. Tweet MS, Olin JW. Insights into spontaneous coronary artery dissection: can recurrence be prevented? J Am Coll Cardiol 2017;70:1159‚Äì61. https://doi.org/10.1016/j.jacc. 
2017.07.726 
566. Cerrato E, Giacobbe F, Quadri G, Macaya F, Bianco M, Mori R, et al. Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection 
from the multicentre DISCO registry. Eur Heart J 2021;42:3161‚Äì71. https://doi.org/ 
10.1093/eurheartj/ehab372 
567. Cauldwell M, Steer PJ, von Klemperer K, Kaler M, Grixti S, Hale J, et al. Maternal and 
neonatal outcomes in women with history of coronary artery disease. Heart 2020; 
106:380‚Äì6. https://doi.org/10.1136/heartjnl-2019-315325 
568. Hayes SN, Tweet MS, Adlam D, Kim ESH, Gulati R, Price JE, et al. Spontaneous coronary artery dissection: JACC state-of-the-art review. J Am Coll Cardiol 2020;76: 
961‚Äì84. https://doi.org/10.1016/j.jacc.2020.05.084 
569. Janssen E, de Leeuw PW, Maas A. Spontaneous coronary artery dissections and associated predisposing factors: a narrative review. Neth Heart J 2019;27:246‚Äì51. https:// 
doi.org/10.1007/s12471-019-1235-4 
570. Lameijer H, Burchill LJ, Baris L, Ruys TP, Roos-Hesselink JW, Mulder BJM, et al. 
Pregnancy in women with pre-existent ischaemic heart disease: a systematic review 
with individualised patient data. Heart 2019;105:873‚Äì80. https://doi.org/10.1136/ 
heartjnl-2018-314364 
571. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC 
Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024; 
45:3415‚Äì537. https://doi.org/10.1093/eurheartj/ehae177 
572. Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. 
Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: 
American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines 
(fourth edition). Reg Anesth Pain Med 2018;43:263‚Äì309. https://doi.org/10.1097/AAP. 
0000000000000763 
573. Bettiol A, Avagliano L, Lombardi N, Crescioli G, Emmi G, Urban ML, et al. 
Pharmacological interventions for the prevention of fetal growth restriction: a systematic review and network meta-analysis. Clin Pharmacol Ther 2021;110:189‚Äì99. https:// 
doi.org/10.1002/cpt.2164 
574. D‚ÄôAntonio F, Khalil A, Rizzo G, Fichera A, Herrera M, Buca D, et al. Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic 
review and meta-analysis. Am J Obstet Gynecol MFM 2023;5:100803. https://doi.org/10. 
1016/j.ajogmf.2022.100803 
575. Datta P, Rewers-Felkins K, Kallem RR, Baker T, Hale TW. Transfer of low dose aspirin into 
human milk. J Hum Lact 2017;33:296‚Äì9. https://doi.org/10.1177/0890334417695207 
576. Grab D, Paulus WE, Erdmann M, Terinde R, Oberhoffer R, Lang D, et al. Effects of low- 
dose aspirin on uterine and fetal blood flow during pregnancy: results of a randomized, 
placebo-controlled, double-blind trial. Ultrasound Obstet Gynecol 2000;15:19‚Äì27.  
https://doi.org/10.1046/j.1469-0705.2000.00009.x 
577. Jiang Y, Chen Z, Chen Y, Wei L, Gao P, Zhang J, et al. Low-dose aspirin use during pregnancy may be a potential risk for postpartum hemorrhage and increased blood loss: a 
systematic review and meta-analysis. Am J Obstet Gynecol MFM 2023;5:100878. https:// 
doi.org/10.1016/j.ajogmf.2023.100878 
578. Turner JM, Robertson NT, Hartel G, Kumar S. Impact of low-dose aspirin on adverse 
perinatal outcome: meta-analysis and meta-regression. Ultrasound Obstet Gynecol 
2020;55:157‚Äì69. https://doi.org/10.1002/uog.20859 
579. Van Doorn R, Mukhtarova N, Flyke IP, Lasarev M, Kim K, Hennekens CH, et al. Dose of 
aspirin to prevent preterm preeclampsia in women with moderate or high-risk factors: 
a systematic review and meta-analysis. PLoS One 2021;16:e0247782. https://doi.org/10. 
1371/journal.pone.0247782 
580. Chang JC, Chen YJ, Chen IC, Lin WS, Chen YM, Lin CH. Perinatal outcomes after statin 
exposure during pregnancy. JAMA Netw Open 2021;4:e2141321. https://doi.org/10. 
1001/jamanetworkopen.2021.41321 
581. Karadas B, Uysal N, Erol H, Acar S, Koc M, Kaya-Temiz T, et al. Pregnancy outcomes 
following maternal exposure to statins: a systematic review and meta-analysis. Br J Clin 
Pharmacol 2022;88:3962‚Äì76. https://doi.org/10.1111/bcp.15423 
582. Botha TC, Pilcher GJ, Wolmarans K, Blom DJ, Raal FJ. Statins and other lipid-lowering 
therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: a 
retrospective review of 39 pregnancies. Atherosclerosis 2018;277:502‚Äì7. https://doi. 
org/10.1016/j.atherosclerosis.2018.05.038 
583. Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, et al. Treatment for 
mild chronic hypertension during pregnancy. N Engl J Med 2022;386:1781‚Äì92. https:// 
doi.org/10.1056/NEJMoa2201295 
584. Mancia G, Kreutz R, Brunstr√∂m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH 
Guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the 
International Society of Hypertension (ISH) and the European Renal Association (ERA). J 
Hypertens 2023;41:1874‚Äì2071. https://doi.org/10.1097/HJH.0000000000003480 
585. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 
ESC Guidelines for the management of elevated blood pressure and hypertension. Eur 
Heart J 2024;45:3912‚Äì4018. https://doi.org/10.1093/eurheartj/ehae178 
586. Oli√© V, Moutengou E, Grave C, Deneux-Tharaux C, Regnault N, Kretz S, et al. 
Prevalence of hypertensive disorders during pregnancy in France (2010‚Äì2018): the nationwide CONCEPTION study. J Clin Hypertens (Greenwich) 2021;23:1344‚Äì53. https:// 
doi.org/10.1111/jch.14254 
587. Ford ND, Cox S, Ko JY, Ouyang L, Romero L, Colarusso T, et al. Hypertensive disorders in pregnancy and mortality at delivery hospitalization‚ÄîUnited States, 2017‚Äì 
2019. MMWR Morb Mortal Wkly Rep 2022;71:585‚Äì91. https://doi.org/10.15585/ 
mmwr.mm7117a1 
588. Malham√© I, Nerenberg K, McLaughlin K, Grandi SM, Daskalopoulou SS, Metcalfe A. 
Hypertensive disorders and cardiovascular severe maternal morbidity in the US, 2015‚Äì 
2019. JAMA Netw Open 2024;7:e2436478. https://doi.org/10.1001/jamanetworkopen. 
2024.36478 
589. Villar J, Carroli G, Wojdyla D, Abalos E, Giordano D, Ba‚Äôaqeel H, et al. Preeclampsia, 
gestational hypertension and intrauterine growth restriction, related or independent 
conditions? Am J Obstet Gynecol 2006;194:921‚Äì31. https://doi.org/10.1016/j.ajog. 
2005.10.813 
590. National high blood pressure education program working group report on high blood 
pressure in pregnancy. Am J Obstet Gynecol 1990;163:1691‚Äì712. https://doi.org/10. 
1016/0002-9378(90)90653-O 
591. Stergiou GS, O‚ÄôBrien E, Myers M, Palatini P, Parati G. STRIDE BP: an international initiative for accurate blood pressure measurement. J Hypertens 2020;38:395‚Äì9. https:// 
doi.org/10.1097/HJH.0000000000002289 
592. Penny JA, Halligan AW, Shennan AH, Lambert PC, Jones DR, de Swiet M, et al. 
Automated, ambulatory, or conventional blood pressure measurement in pregnancy: 
which is the better predictor of severe hypertension? Am J Obstet Gynecol 1998;178: 
521‚Äì6. https://doi.org/10.1016/S0002-9378(98)70432-6 
593. Ilic A, Ilic DJ, Tadic S, Stefanovic M, Stojsic-Milosavljevic A, Pavlovic K, et al. Influence of 
non-dipping pattern of blood pressure in gestational hypertension on maternal cardiac 
function, hemodynamics and intrauterine growth restriction. Pregnancy Hypertens 
2017;10:34‚Äì41. https://doi.org/10.1016/j.preghy.2017.05.003 
594. Iliƒá ƒê, Iliƒá A, Stoj≈°iƒá S, Stoj≈°iƒá-Milosavljeviƒá A, Papoviƒá J, Grkoviƒá D, et al. Effect of dipping 
pattern of gestational hypertension onmaternal symptoms and physical findings, birth 
weight and preterm delivery. Acta Clin Croat 2021;60:641‚Äì50. https://doi.org/10. 
20471/acc.2021.60.04.11 
595. Chappell LC, Tucker KL, Galal U, Yu LM, Campbell H, Rivero-Arias O, et al. Effect of 
self-monitoring of blood pressure on blood pressure control in pregnant individuals 
with chronic or gestational hypertension: the BUMP 2 randomized clinical trial. 
JAMA 2022;327:1666‚Äì78. https://doi.org/10.1001/jama.2022.4726 
596. Tucker KL, Mort S, Yu LM, Campbell H, Rivero-Arias O, Wilson HM, et al. Effect of 
self-monitoring of blood pressure on diagnosis of hypertension during higher-risk 
pregnancy: the BUMP 1 randomized clinical trial. JAMA 2022;327:1656‚Äì65. https:// 
doi.org/10.1001/jama.2022.4712 
597. Cnossen JS, Morris RK, ter Riet G, Mol BW, van der Post JA, Coomarasamy A, et al. 
Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. Cmaj 2008; 
178:701‚Äì11. https://doi.org/10.1503/cmaj.070430


<!-- PAGE 103 -->

### Page 103

598. Kifle MM, Dahal P, Vatish M, Cerdeira AS, Ohuma EO. The prognostic utility of soluble 
fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for 
predicting preeclampsia: a secondary analysis of data from the INSPIRE trial. BMC 
Pregnancy Childbirth 2022;22:520. https://doi.org/10.1186/s12884-022-04817-6 
599. NICE. Hypertension in Adults: Diagnosis and Management. https://www.nice.org.uk/ 
guidance/ng136 (10 April 2024, date last accessed). 
600. Patel D, Yulia A. Placental growth factor testing for pre-eclampsia. Case Rep Womens 
Health 2022;33:e00387. https://doi.org/10.1016/j.crwh.2022.e00387 
601. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ 
ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39: 
3021‚Äì104. https://doi.org/10.1093/eurheartj/ehy339 
602. C√≠fkov√° R, Johnson MR, Kahan T, Brguljan J, Williams B, Coca A, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and 
the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother 2020;6: 
384‚Äì93. https://doi.org/10.1093/ehjcvp/pvz082 
603. Wu P, Green M, Myers JE. Hypertensive disorders of pregnancy. BMJ 2023;381: 
e071653. https://doi.org/10.1136/bmj-2022-071653 
604. Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 2015;372:407‚Äì17. https:// 
doi.org/10.1056/NEJMoa1404595 
605. Thangaratinam S, Rogozinska E, Jolly K, Glinkowski S, Roseboom T, Tomlinson JW, 
et al. Effects of interventions in pregnancy on maternal weight and obstetric outcomes: 
meta-analysis of randomised evidence. BMJ 2012;344:e2088. https://doi.org/10.1136/ 
bmj.e2088 
606. Santos S, Voerman E, Amiano P, Barros H, Beilin LJ, Bergstr√∂m A, et al. Impact of maternal body mass index and gestational weight gain on pregnancy complications: an individual participant data meta-analysis of European, North American and Australian 
cohorts. BJOG 2019;126:984‚Äì95. https://doi.org/10.1111/1471-0528.15661 
607. Liu YH, Zhang YS, Chen JY, Wang ZJ, Liu YX, Li JQ, et al. Comparative effectiveness of 
prophylactic strategies for preeclampsia: a network meta-analysis of randomized controlled trials. Am J Obstet Gynecol 2023;228:535‚Äì46. https://doi.org/10.1016/j.ajog. 
2022.10.014 
608. Woo Kinshella ML, Sarr C, Sandhu A, Bone JN, Vidler M, Moore SE, et al. Calcium for 
pre-eclampsia prevention: a systematic review and network meta-analysis to guide 
personalised antenatal care. BJOG 2022;129:1833‚Äì43. https://doi.org/10.1111/1471- 
0528.17222 
609. Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to 
moderate hypertension during pregnancy. Cochrane Database Syst Rev 2018;10: 
CD002252. https://doi.org/10.1002/14651858.CD002252.pub4 
610. Rolnik DL, Wright D, Poon LC, O‚ÄôGorman N, Syngelaki A, de Paco Matallana C, et al. 
Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J 
Med 2017;377:613‚Äì22. https://doi.org/10.1056/NEJMoa1704559 
611. Deng NJ, Xian-Yu CY, Han RZ, Huang CY, Ma YT, Li HJ, et al. Pharmaceutical administration for severe hypertension during pregnancy: network meta-analysis. Front 
Pharmacol 2022;13:1092501. https://doi.org/10.3389/fphar.2022.1092501 
612. Poole JH, Long J. Maternal mortality‚Äîa review of current trends. Crit Care Nurs Clin 
North Am 2004;16:227‚Äì30. https://doi.org/10.1016/j.ccell.2004.02.009 
613. McDonnell NJ. Cardiopulmonary arrest in pregnancy: two case reports of successful 
outcomes in association with perimortem cesarean delivery. Br J Anaesth 2009;103: 
406‚Äì9. https://doi.org/10.1093/bja/aep176 
614. Vanden Hoek TL, Morrison LJ, Shuster M, Donnino M, Sinz E, Lavonas EJ, et al. Part 12: 
cardiac arrest in special situations: 2010 American Heart Association guidelines for 
cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2010; 
122:S829‚Äì61. https://doi.org/10.1161/CIRCULATIONAHA.110.971069 
615. Bone JN, Sandhu A, Abalos ED, Khalil A, Singer J, Prasad S, et al. Oral antihypertensives for 
nonsevere pregnancy hypertension: systematic review, network meta- and trial sequential 
analyses. Hypertension 2022;79:614‚Äì28. https://doi.org/10.1161/HYPERTENSIONAHA. 
121.18415 
616. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003;327:955‚Äì60.  
https://doi.org/10.1136/bmj.327.7421.955 
617. Awaludin A, Rahayu C, Daud NAA, Zakiyah N. Antihypertensive medications for severe hypertension in pregnancy: a systematic review and meta-analysis. Healthcare 
(Basel) 2022;10:325. https://doi.org/10.3390/healthcare10020325 
618. Dooley M, Goa KL. Urapidil. A reappraisal of its use in the management of hypertension. Drugs 1998;56:929‚Äì55. https://doi.org/10.2165/00003495-199856050-00016 
619. Naulty J, Cefalo RC, Lewis PE. Fetal toxicity of nitroprusside in the pregnant ewe. Am J 
Obstet Gynecol 1981;139:708‚Äì11. https://doi.org/10.1016/0002-9378(81)90492-0 
620. Chappell LC, Brocklehurst P, Green ME, Hunter R, Hardy P, Juszczak E, et al. Planned 
early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): 
a randomised controlled trial. Lancet 2019;394:1181‚Äì90. https://doi.org/10.1016/ 
S0140-6736(19)31963-4 
621. Rolnik DL, Nicolaides KH, Poon LC. Prevention of preeclampsia with aspirin. Am J 
Obstet Gynecol 2022;226:S1108‚Äì19. https://doi.org/10.1016/j.ajog.2020.08.045 
622. Wang Y, Guo X, Obore N, Ding H, Wu C, Yu H. Aspirin for the prevention of preeclampsia: a systematic review and meta-analysis of randomized controlled studies. 
Front Cardiovasc Med 2022;9:936560. https://doi.org/10.3389/fcvm.2022.936560 
623. Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA, 
et al. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. Hypertension 2022; 
79:e21‚Äì41. https://doi.org/10.1161/HYP.0000000000000208 
624. Hoeltzenbein M, Beck E, Fietz AK, Wernicke J, Zinke S, Kayser A, et al. Pregnancy outcome after first trimester use of methyldopa: a prospective cohort study. Hypertension 
2017;70:201‚Äì8. https://doi.org/10.1161/HYPERTENSIONAHA.117.09110 
625. Lindheimer MD, Taler SJ, Cunningham FG. Hypertension in pregnancy. J Am Soc 
Hypertens 2010;4:68‚Äì78. https://doi.org/10.1016/j.jash.2010.03.002 
626. Antza C, Dimou C, Doundoulakis I, Akrivos E, Stabouli S, Haidich AB, et al. The flipside 
of hydralazine in pregnancy: a systematic review and meta-analysis. Pregnancy 
Hypertens 2020;19:177‚Äì86. https://doi.org/10.1016/j.preghy.2020.01.011 
627. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens 2014;4: 
105‚Äì45. https://doi.org/10.1016/j.preghy.2014.01.003 
628. Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, et al. 
Induction of labour versus expectant monitoring for gestational hypertension or 
mild pre-eclampsia after 36 weeks‚Äô gestation (HYPITAT): a multicentre, open-label 
randomised controlled trial. Lancet 2009;374:979‚Äì88. https://doi.org/10.1016/ 
S0140-6736(09)60736-4 
629. Churchill D, Duley L, Thornton JG, Moussa M, Ali HS, Walker KF. Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks‚Äô gestation. 
Cochrane Database Syst Rev 2018;10:CD003106. https://doi.org/10.1002/14651858. 
CD003106.pub3 
630. Kuklina E, Callaghan W. Chronic heart disease and severe obstetric morbidity among 
hospitalisations for pregnancy in the USA: 1995‚Äì2006. BJOG 2011;118:345‚Äì52. https:// 
doi.org/10.1111/j.1471-0528.2010.02743.x 
631. Cauldwell M, Adamson D, Bhatia K, Bhagra C, Bolger A, Everett T, et al. Direct current 
cardioversion in pregnancy: a multicentre study. BJOG 2023;130:1269‚Äì74. https://doi. 
org/10.1111/1471-0528.17457 
632. Barnes EJ, Eben F, Patterson D. Direct current cardioversion during pregnancy should 
be performed with facilities available for fetal monitoring and emergency caesarean 
section. BJOG 2002;109:1406‚Äì7. https://doi.org/10.1046/j.1471-0528.2002.02113.x 
633. Senarath S, Nanayakkara P, Beale AL, Watts M, Kaye DM, Nanayakkara S. Diagnosis 
and management of arrhythmias in pregnancy. Europace 2022;24:1041‚Äì51. https:// 
doi.org/10.1093/europace/euab297 
634. Li JM, Nguyen C, Joglar JA, Hamdan MH, Page RL. Frequency and outcome of arrhythmias complicating admission during pregnancy: experience from a high-volume and 
ethnically-diverse obstetric service. Clin Cardiol 2008;31:538‚Äì41. https://doi.org/10. 
1002/clc.20326 
635. Miyoshi T, Maeno Y, Hamasaki T, Inamura N, Yasukochi S, Kawataki M, et al. Antenatal 
therapy for fetal supraventricular tachyarrhythmias: multicenter trial. J Am Coll Cardiol 
2019;74:874‚Äì85. https://doi.org/10.1016/j.jacc.2019.06.024 
636. Lindley KJ, Judge N. Arrhythmias in pregnancy. Clin Obstet Gynecol 2020;63:878‚Äì92.  
https://doi.org/10.1097/GRF.0000000000000567 
637. Chen YC, Voskoboinik A, Gerche A, Marwick TH, McMullen JR. Prevention of pathological atrial remodeling and atrial fibrillation: JACC state-of-the-art review. J Am Coll 
Cardiol 2021;77:2846‚Äì64. https://doi.org/10.1016/j.jacc.2021.04.012 
638. Lee MS, Chen W, Zhang Z, Duan L, Ng A, Spencer HT, et al. Atrial fibrillation and atrial 
flutter in pregnant women‚Äîa population-based study. J Am Heart Assoc 2016;5: 
e003182. https://doi.org/10.1161/JAHA.115.003182 
639. Chokesuwattanaskul R, Thongprayoon C, Bathini T, O‚ÄôCorragain OA, Sharma K, 
Prechawat S, et al. Incidence of atrial fibrillation in pregnancy and clinical significance: 
a meta-analysis. Adv Med Sci 2019;64:415‚Äì22. https://doi.org/10.1016/j.advms.2019. 
07.003 
640. Chauveau S, Le Vavasseur O, Morel E, Dulac A, Chevalier P. Flecainide is a safe and 
effective treatment for pre-excited atrial fibrillation rapidly conducted to the ventricle 
in pregnant women: a case series. Eur Heart J Case Rep 2019;3:ytz066. https://doi.org/ 
10.1093/ehjcr/ytz066 
641. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr√∂m-Lundqvist C, et al. 2020 
ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the 
task force for the diagnosis and management of atrial fibrillation of the European 
Society of Cardiology (ESC) developed with the special contribution of the 
European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42: 
373‚Äì498. https://doi.org/10.1093/eurheartj/ehaa612 
642. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns H, et al. 2024 
ESC Guidelines for the management of atrial fibrillation developed in collaboration 
with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 
2024;45:3314‚Äì414. https://doi.org/10.1093/eurheartj/ehae176 
643. Teppo K, Lip GYH, Airaksinen KEJ, Halminen O, Haukka J, Putaala J, et al. Comparing 
CHA(2)DS(2)-VA and CHA(2)DS(2)-VASc scores for stroke risk stratification in patients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish  
ESC Guidelines                                                                                                                                                                                            103


<!-- PAGE 104 -->

### Page 104

AntiCoagulation in Atrial Fibrillation (FinACAF) cohort. Lancet Reg Health Eur 2024; 
43:100967. https://doi.org/10.1016/j.lanepe.2024.100967 
644. Goland S, Elkayam U. Anticoagulation in pregnancy. Cardiol Clin 2012;30:395‚Äì405.  
https://doi.org/10.1016/j.ccl.2012.05.003 
645. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstr√∂m-Lundqvist C, et al. 2019 
ESC Guidelines for the management of patients with supraventricular tachycardiathe 
task force for the management of patients with supraventricular tachycardia of the 
European Society of Cardiology (ESC). Eur Heart J 2020;41:655‚Äì720. https://doi.org/ 
10.1093/eurheartj/ehz467 
646. Amsterdam EA, Kulcyski J, Ridgeway MG. Efficacy of cardioselective beta-adrenergic 
blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias. J Clin Pharmacol 1991;31:714‚Äì8. https://doi.org/10.1002/j. 
1552-4604.1991.tb03765.x 
647. Ramlakhan KP, Kauling RM, Schenkelaars N, Segers D, Yap SC, Post MC, et al. 
Supraventricular arrhythmia in pregnancy. Heart 2022;108:1674‚Äì81. https://doi.org/ 
10.1136/heartjnl-2021-320451 
648. Ghosh N, Luk A, Derzko C, Dorian P, Chow CM. The acute treatment of maternal 
supraventricular tachycardias during pregnancy: a review of the literature. J Obstet 
Gynaecol Can 2011;33:17‚Äì23. https://doi.org/10.1016/S1701-2163(16)34767-3 
649. Tanaka K, Tanaka H, Kamiya C, Katsuragi S, Sawada M, Tsuritani M, et al. Beta-blockers 
and fetal growth restriction in pregnant women with cardiovascular disease. Circ J 
2016;80:2221‚Äì6. https://doi.org/10.1253/circj.CJ-15-0617 
650. Jaeggi ET, Carvalho JS, De Groot E, Api O, Clur SA, Rammeloo L, et al. Comparison of 
transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. Circulation 2011; 
124:1747‚Äì54. https://doi.org/10.1161/CIRCULATIONAHA.111.026120 
651. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, et al. Amiodarone versus 
sotalol for atrial fibrillation. N Engl J Med 2005;352:1861‚Äì72. https://doi.org/10.1056/ 
NEJMoa041705 
652. Vaidya VR, Arora S, Patel N, Badheka AO, Patel N, Agnihotri K, et al. Burden of arrhythmia in pregnancy. Circulation 2017;135:619‚Äì21. https://doi.org/10.1161/ 
CIRCULATIONAHA.116.026681 
653. Cleary-Goldman J, Salva CR, Infeld JI, Robinson JN. Verapamil-sensitive idiopathic left 
ventricular tachycardia in pregnancy. J Matern Fetal Neonatal Med 2003;14:132‚Äì5.  
https://doi.org/10.1080/jmf.14.2.132.135 
654. Frohn-Mulder IM, Stewart PA, Witsenburg M, Den Hollander NS, Wladimiroff JW, 
Hess J. The efficacy of flecainide versus digoxin in the management of fetal supraventricular tachycardia. Prenat Diagn 1995;15:1297‚Äì302. https://doi.org/10.1002/pd. 
1970151309 
655. Alsaied T, Baskar S, Fares M, Alahdab F, Czosek RJ, Murad MH, et al. First-line antiarrhythmic transplacental treatment for fetal tachyarrhythmia: a systematic review and 
meta-analysis. J Am Heart Assoc 2017;6:e007164. https://doi.org/10.1161/JAHA.117. 
007164 
656. van der Heijden LB, Oudijk MA, Manten GT, ter Heide H, Pistorius L, Freund MW. 
Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up. 
Ultrasound Obstet Gynecol 2013;42:285‚Äì93. https://doi.org/10.1002/uog.12390 
657. Shah A, Moon-Grady A, Bhogal N, Collins KK, Tacy T, Brook M, et al. Effectiveness of 
sotalol as first-line therapy for fetal supraventricular tachyarrhythmias. Am J Cardiol 
2012;109:1614‚Äì8. https://doi.org/10.1016/j.amjcard.2012.01.388 
658. Oudijk MA, Michon MM, Kleinman CS, Kapusta L, Stoutenbeek P, Visser GH, et al. 
Sotalol in the treatment of fetal dysrhythmias. Circulation 2000;101:2721‚Äì6. https:// 
doi.org/10.1161/01.CIR.101.23.2721 
659. Davis RL, Eastman D, McPhillips H, Raebel MA, Andrade SE, Smith D, et al. Risks of 
congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf 2011;20:138‚Äì45.  
https://doi.org/10.1002/pds.2068 
660. Nanson J, Elcock D, Williams M, Deakin CD. Do physiological changes in pregnancy 
change defibrillation energy requirements? Br J Anaesth 2001;87:237‚Äì9. https://doi. 
org/10.1093/bja/87.2.237 
661. Wang YC, Chen CH, Su HY, Yu MH. The impact of maternal cardioversion on fetal 
haemodynamics. Eur J Obstet Gynecol Reprod Biol 2006;126:268‚Äì9. https://doi.org/10. 
1016/j.ejogrb.2005.11.021 
662. Brown O. Direct current cardioversion during pregnancy. BJOG 2003;110:713‚Äì4.  
https://doi.org/10.1046/j.1471-0528.2003.03807.x 
663. Chen G, Sun G, Xu R, Chen X, Yang L, Bai Y, et al. Zero-fluoroscopy catheter ablation 
of severe drug-resistant arrhythmia guided by Ensite NavX system during pregnancy: 
two case reports and literature review. Medicine (Baltimore) 2016;95:e4487. https:// 
doi.org/10.1097/MD.0000000000004487 
664. Driver K, Chisholm CA, Darby AE, Malhotra R, Dimarco JP, Ferguson JD. Catheter ablation of arrhythmia during pregnancy. J Cardiovasc Electrophysiol 2015;26:698‚Äì702.  
https://doi.org/10.1111/jce.12675 
665. Mladoniczky S, Nagy Z, F√∂ldesi C, Som Z, B√°lint HO, K√∂rnyei L, et al. Case series of 
catheter-based arrhythmia ablation in 13 pregnant women. Clin Cardiol 2023;46: 
942‚Äì9. https://doi.org/10.1002/clc.24072 
666. Szumowski L, Szufladowicz E, Orczykowski M, Bodalski R, Derejko P, Przybylski A, 
et al. Ablation of severe drug-resistant tachyarrhythmia during pregnancy. J 
Cardiovasc Electrophysiol 2010;21:877‚Äì82. https://doi.org/10.1111/j.1540-8167.2010. 
01727.x 
667. Miyoshi T, Kamiya CA, Katsuragi S, Ueda H, Kobayashi Y, Horiuchi C, et al. Safety and 
efficacy of implantable cardioverter-defibrillator during pregnancy and after delivery. 
Circ J 2013;77:1166‚Äì70. https://doi.org/10.1253/circj.CJ-12-1275 
668. Natale A, Davidson T, Geiger MJ, Newby K. Implantable cardioverter-defibrillators and 
pregnancy: a safe combination? Circulation 1997;96:2808‚Äì12. https://doi.org/10.1161/ 
01.CIR.96.9.2808 
669. Abello M, Peinado R, Merino JL, Gnoatto M, Mateos M, Silvestre J, et al. Cardioverter 
defibrillator implantation in a pregnant woman guided with transesophageal echocardiography. Pacing Clin Electrophysiol 2003;26:1913‚Äì4. https://doi.org/10.1046/j.1460- 
9592.2003.00293.x 
670. Silversides CK, Harris L, Haberer K, Sermer M, Colman JM, Siu SC. Recurrence rates of 
arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on 
fetal and neonatal outcomes. Am J Cardiol 2006;97:1206‚Äì12. https://doi.org/10.1016/j. 
amjcard.2005.11.041 
671. Boul√© S, Ovart L, Marqui√© C, Botcherby E, Klug D, Kouakam C, et al. Pregnancy in women with an implantable cardioverter-defibrillator: is it safe? Europace 2014;16: 
1587‚Äì94. https://doi.org/10.1093/europace/euu036 
672. Duncker D, K√∂nig T, Hohmann S, Bauersachs J, Veltmann C. Avoiding untimely implantable cardioverter/defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter/defibrillator-the PROLONG 
study. J Am Heart Assoc 2017;6:e004512. https://doi.org/10.1161/JAHA.116.004512 
673. Duncker D, Westenfeld R, Konrad T, Pfeffer T, Correia de Freitas CA, Pfister R, et al. 
Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy 
with low ejection fraction: a German multi-centre analysis. Clin Res Cardiol 2017; 
106:582‚Äì9. https://doi.org/10.1007/s00392-017-1090-5 
674. Olic JJ, St√∂llberger C, Schukro C, Odening KE, Reuschel E, Fischer M, et al. Usage of the 
wearable cardioverter-defibrillator during pregnancy. Int J Cardiol Heart Vasc 2022;41: 
101066. https://doi.org/10.1016/j.ijcha.2022.101066 
675. Tuzcu V, Gul EE, Erdem A, Kamali H, Saritas T, Karadeniz C, et al. Cardiac interventions 
in pregnant patients without fluoroscopy. Pediatr Cardiol 2015;36:1304‚Äì7. https://doi. 
org/10.1007/s00246-015-1181-x 
676. Gorgels AP, van den Dool A, Hofs A, Mulleneers R, Smeets JL, Vos MA, et al. 
Comparison of procainamide and lidocaine in terminating sustained monomorphic 
ventricular tachycardia. Am J Cardiol 1996;78:43‚Äì6. https://doi.org/10.1016/S0002- 
9149(96)00224-X 
677. Komura S, Chinushi M, Furushima H, Hosaka Y, Izumi D, Iijima K, et al. Efficacy of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Circ J 2010;74:864‚Äì9. https://doi.org/10.1253/circj.CJ-09-0932 
678. Ortiz M, Mart√≠n A, Arribas F, Coll-Vinent B, Del Arco C, Peinado R, et al. Randomized 
comparison of intravenous procainamide vs. intravenous amiodarone for the acute 
treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J 
2017;38:1329‚Äì35. https://doi.org/10.1093/eurheartj/ehw230 
679. Mhyre JM, Tsen LC, Einav S, Kuklina EV, Leffert LR, Bateman BT. Cardiac arrest during 
hospitalization for delivery in the United States, 1998‚Äì2011. Anesthesiology 2014;120: 
810‚Äì8. https://doi.org/10.1097/ALN.0000000000000159 
680. Schaap TP, Overtoom E, van den Akker T, Zwart JJ, van Roosmalen J, Bloemenkamp 
KWM. Maternal cardiac arrest in The Netherlands: a nationwide surveillance study. Eur 
J Obstet Gynecol Reprod Biol 2019;237:145‚Äì50. https://doi.org/10.1016/j.ejogrb.2019. 
04.028 
681. Zelop CM, Einav S, Mhyre JM, Martin S. Cardiac arrest during pregnancy: ongoing clinical conundrum. Am J Obstet Gynecol 2018;219:52‚Äì61. https://doi.org/10.1016/j.ajog. 
2017.12.232 
682. McCartney CJ, Dark A. Caesarean delivery during cardiac arrest in late pregnancy. 
Anaesthesia 1998;53:310‚Äì1. https://doi.org/10.1046/j.1365-2044.1998.00413.x 
683. Zelop CM, Einav S, Mhyre JM, Lipman SS, Arafeh J, Shaw RE, et al. Characteristics and 
outcomes of maternal cardiac arrest: a descriptive analysis of Get with the guidelines 
data. Resuscitation 2018;132:17‚Äì20. https://doi.org/10.1016/j.resuscitation.2018.08. 
029 
684. Mogos MF, Salemi JL, Spooner KK, McFarlin BL, Salihu HM. Differences in mortality 
between pregnant and nonpregnant women after cardiopulmonary resuscitation. 
Obstet Gynecol 2016;128:880‚Äì8. https://doi.org/10.1097/AOG.0000000000001629 
685. Archer TL, Suresh P, Shapiro AE. Cardiac output measurement, by means of electrical 
velocimetry, may be able to determine optimum maternal position during gestation, 
labour and caesarean delivery, by preventing vena caval compression and maximising 
cardiac output and placental perfusion pressure. Anaesth Intensive Care 2011;39: 
308‚Äì11. https://doi.org/10.1177/0310057X1103900225 
686. Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr Drug Metab 
2009;10:520‚Äì9. https://doi.org/10.2174/138920009788897993 
687. Berg RA, Hemphill R, Abella BS, Aufderheide TP, Cave DM, Hazinski MF, et al. Part 5: 
adult basic life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2010;122: 
S685‚Äì705. https://doi.org/10.1161/CIRCULATIONAHA.110.970939


<!-- PAGE 105 -->

### Page 105

688. Dijkman A, Huisman CM, Smit M, Schutte JM, Zwart JJ, van Roosmalen JJ, et al. Cardiac 
arrest in pregnancy: increasing use of perimortem caesarean section due to emergency 
skills training? BJOG 2010;117:282‚Äì7. https://doi.org/10.1111/j.1471-0528.2009.02461.x 
689. Katz V, Balderston K, DeFreest M. Perimortem cesarean delivery: were our assumptions correct? Am J Obstet Gynecol 2005;192:1916‚Äì20. discussion 1920‚Äì1921. https:// 
doi.org/10.1016/j.ajog.2005.02.038 
690. Kim DR, Wang E. Prevention of supine hypotensive syndrome in pregnant women 
treated with transcranial magnetic stimulation. Psychiatry Res 2014;218:247‚Äì8.  
https://doi.org/10.1016/j.psychres.2014.04.001 
691. Hidaka N, Chiba Y, Fukushima K, Wake N. Pregnant women with complete atrioventricular block: perinatal risks and review of management. Pacing Clin Electrophysiol 2011; 
34:1161‚Äì76. https://doi.org/10.1111/j.1540-8159.2011.03177.x 
692. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 
ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 
2021;42:3427‚Äì520. https://doi.org/10.1093/eurheartj/ehab364 
693. G√ºdal M, Kervancioƒülu C, Oral D, G√ºrel T, Erol C, Sonel A. Permanent pacemaker implantation in a pregnant woman with the guidance of ECG and two-dimensional echocardiography. Pacing Clin Electrophysiol 1987;10:543‚Äì5. https://doi.org/10.1111/j.1540- 
8159.1987.tb04518.x 
694. Chua KCM, Lim ETS, Chong DTT, Tan BY, Ho KL, Ching CK. Implantation of a dual- 
chamber permanent pacemaker in a pregnant patient guided by intracardiac echocardiography and electroanatomic mapping. HeartRhythm Case Rep 2017;3:542‚Äì5. https:// 
doi.org/10.1016/j.hrcr.2017.09.003 
695. Hartz J, Clark BC, Ito S, Sherwin ED, Berul CI. Transvenous nonfluoroscopic pacemaker implantation during pregnancy guided by 3-dimensional electroanatomic mapping. HeartRhythm Case Rep 2017;3:490‚Äì2. https://doi.org/10.1016/j.hrcr.2017.07.020 
696. Kumari A, Kumar K, Kumar Sinha A. The pattern of valvular heart diseases in India during pregnancy and its outcomes. Cureus 2021;13:e16394. https://doi.org/10.7759/ 
cureus.16394 
697. Baghel J, Keepanasseril A, Pillai AA, Mondal N, Jeganathan Y, Kundra P. Prediction of 
adverse cardiac events in pregnant women with valvular rheumatic heart disease. 
Heart 2020;106:1400‚Äì6. https://doi.org/10.1136/heartjnl-2020-316648 
698. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/ 
EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43: 
561‚Äì632. https://doi.org/10.1093/eurheartj/ehab395 
699. Samiei N, Amirsardari M, Rezaei Y, Parsaee M, Kashfi F, Hantoosh Zadeh S, et al. 
Echocardiographic evaluation of hemodynamic changes in left-sided heart valves in 
pregnant women with valvular heart disease. Am J Cardiol 2016;118:1046‚Äì52.  
https://doi.org/10.1016/j.amjcard.2016.07.005 
700. Diao M, Kane A, Ndiaye MB, Mbaye A, Bodian M, Dia MM, et al. Pregnancy in women 
with heart disease in sub-Saharan Africa. Arch Cardiovasc Dis 2011;104:370‚Äì4. https:// 
doi.org/10.1016/j.acvd.2011.04.001 
701. Hameed A, Karaalp IS, Tummala PP, Wani OR, Canetti M, Akhter MW, et al. The effect 
of valvular heart disease on maternal and fetal outcome of pregnancy. J Am Coll Cardiol 
2001;37:893‚Äì9. https://doi.org/10.1016/S0735-1097(00)01198-0 
702. Bortnick AE, Levine LD. Valvular heart disease in pregnancy. Clin Obstet Gynecol 2020; 
63:910‚Äì22. https://doi.org/10.1097/GRF.0000000000000570 
703. Orwat S, Diller GP, van Hagen IM, Schmidt R, Tobler D, Greutmann M, et al. Risk of 
pregnancy in moderate and severe aortic stenosis: from the multinational ROPAC 
registry. J Am Coll Cardiol 2016;68:1727‚Äì37. https://doi.org/10.1016/j.jacc.2016.07.750 
704. Elassy SM, Elmidany AA, Elbawab HY. Urgent cardiac surgery during pregnancy: a continuous challenge. Ann Thorac Surg 2014;97:1624‚Äì9. https://doi.org/10.1016/j. 
athoracsur.2013.10.067 
705. Myerson SG, Mitchell AR, Ormerod OJ, Banning AP. What is the role of balloon dilatation for severe aortic stenosis during pregnancy? J Heart Valve Dis 2005;14:147‚Äì50. 
706. Yagel O, Alter R, Nissan B, Zwas DR, Rosenbloom JI, Eyal O, et al. A pregnant woman 
with severe symptomatic aortic stenosis: how should we treat? JACC Case Rep 2024; 
29:102205. https://doi.org/10.1016/j.jaccas.2023.102205 
707. Herzig MS, McIlvaine S, Feinberg L, Spiel MH, Carroll BJ. Outcomes of bicuspid aortic 
valve in pregnancy. Am J Cardiol 2024;221:74‚Äì6. https://doi.org/10.1016/j.amjcard. 
2024.04.038 
708. Pomini F, Mercogliano D, Cavalletti C, Caruso A, Pomini P. Cardiopulmonary bypass 
in pregnancy. Ann Thorac Surg 1996;61:259‚Äì68. https://doi.org/10.1016/0003- 
4975(95)00818-7 
709. Minhas AS, Rahman F, Gavin N, Cedars A, Vaught AJ, Zakaria S, et al. Cardiovascular 
and obstetric delivery complications in pregnant women with valvular heart disease. 
Am J Cardiol 2021;158:90‚Äì7. https://doi.org/10.1016/j.amjcard.2021.07.038 
710. Ducas RA, Javier DA, D‚ÄôSouza R, Silversides CK, Tsang W. Pregnancy outcomes in women with significant valve disease: a systematic review and meta-analysis. Heart 2020; 
106:512‚Äì9. https://doi.org/10.1136/heartjnl-2019-315859 
711. Sabbag A, Essayagh B, Barrera JDR, Basso C, Berni A, Cosyns B, et al. EHRA expert 
consensus statement on arrhythmic mitral valve prolapse and mitral annular disjunction complex in collaboration with the ESC Council on valvular heart disease and 
the European Association of Cardiovascular Imaging endorsed by the Heart Rhythm 
Society, by the Asia Pacific Heart Rhythm Society, and by the Latin American Heart 
Rhythm Society. Europace 2022;24:1981‚Äì2003. https://doi.org/10.1093/europace/ 
euac125 
712. Sabbag A, Aabel EW, Castrini AI, Siontis KC, Laredo M, Nizard J, et al. Mitral valve prolapse: arrhythmic risk during pregnancy and postpartum. Eur Heart J 2024;45:1831‚Äì9.  
https://doi.org/10.1093/eurheartj/ehae224 
713. Aabel EW, Dejgaard LA, Chivulescu M, Helle-Valle TM, Edvardsen T, Hasselberg NE, 
et al. Flecainide in patients with arrhythmic mitral valve syndrome: a case series. Heart 
Rhythm 2023;20:635‚Äì6. https://doi.org/10.1016/j.hrthm.2022.12.024 
714. Roos-Hesselink JW, van der Zande JA, Johnson MR. Pregnancy outcomes in women 
with heart disease: how to improve? Eur Heart J 2023;44:1541‚Äì3. https://doi.org/10. 
1093/eurheartj/ehad035 
715. Tornos P, Sambola A, Permanyer-Miralda G, Evangelista A, Gomez Z, Soler-Soler J. 
Long-term outcome of surgically treated aortic regurgitation: influence of guideline adherence toward early surgery. J Am Coll Cardiol 2006;47:1012‚Äì7. https://doi.org/10. 
1016/j.jacc.2005.10.049 
716. Kuchibhatla A, Soghrati N, Saleh Y, Rushing G, Halim MA, Pelletier M, et al. 
Transcatheter or surgical aortic valve replacement in pregnant women? A comprehensive review of the current literature. J Invasive Cardiol 2025;37. https://doi.org/10. 
25270/jic/24.00065 
717. Justin Paul G, Anne Princy S, Anju S, Anita S, Cecily Mary M, Gnanavelu G, et al. 
Pregnancy outcomes in women with heart disease: the Madras Medical College 
Pregnancy And Cardiac (M-PAC) registry from India. Eur Heart J 2023;44:1530‚Äì40.  
https://doi.org/10.1093/eurheartj/ehad003 
718. Carvajal HG, Lindley KJ, Shah T, Brar AK, Barger PM, Billadello JJ, et al. Impact of pregnancy on autograft dilatation and aortic valve function following the Ross procedure. 
Congenit Heart Dis 2018;13:217‚Äì21. https://doi.org/10.1111/chd.12554 
719. Wichert-Schmitt B, Grewal J, Malinowski AK, Pfaller B, Losenno KL, Kiess MC, et al. 
Outcomes of pregnancy in women with bioprosthetic heart valves with or without 
valve dysfunction. J Am Coll Cardiol 2022;80:2014‚Äì24. https://doi.org/10.1016/j.jacc. 
2022.09.019 
720. Jacobson LT, Hade EM, Collins TC, Margolis KL, Waring ME, Van Horn LV, et al. 
Breastfeeding history and risk of stroke among parous postmenopausal women in 
the women‚Äôs health initiative. J Am Heart Assoc 2018;7:e008739. https://doi.org/10. 
1161/JAHA.118.008739 
721. Daughety MM, Zilberman-Rudenko J, Shatzel JJ, McCarty OJT, Raghunathan V, 
DeLoughery TG. Management of anticoagulation in pregnant women with mechanical 
heart valves. Obstet Gynecol Surv 2020;75:190‚Äì8. https://doi.org/10.1097/OGX. 
0000000000000751 
722. √ñzkan M, √áakal B, Karakoyun S, G√ºrsoy OM, √áevik C, Kal√ßƒ±k M, et al. Thrombolytic 
therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low- 
dose, slow infusion of tissue-type plasminogen activator. Circulation 2013;128:532‚Äì40.  
https://doi.org/10.1161/CIRCULATIONAHA.113.001145 
723. Countouris ME, Marino AL, Raymond M, Hauspurg A, Berlacher KL. Infective endocarditis in pregnancy: a contemporary cohort. Am J Perinatol 2024;41:e230‚Äì5. https://doi. 
org/10.1055/a-1877-5763 
724. Sinner GJ, Annabathula R, Viquez K, Alnabelsi TS, Leung SW. Infective endocarditis in 
pregnancy from 2009 to 2019: the consequences of injection drug use. Infect Dis (Lond) 
2021;53:633‚Äì9. https://doi.org/10.1080/23744235.2021.1912821 
725. Dagher MM, Eichenberger EM, Addae-Konadu KL, Dotters-Katz SK, Kohler CL, 
Fowler VG, et al. Maternal and fetal outcomes associated with infective endocarditis 
in pregnancy. Clin Infect Dis 2021;73:1571‚Äì9. https://doi.org/10.1093/cid/ciab533 
726. Izewski JM, Bell BZ, Haas DM. Antibiotics in labor and delivery. Obstet Gynecol Clin 
North Am 2023;50:137‚Äì50. https://doi.org/10.1016/j.ogc.2022.10.011 
727. Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal 
of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019;393: 
61‚Äì73. https://doi.org/10.1016/S0140-6736(18)32484-X 
728. Rakisheva A, Sliwa K, Bauersachs J, Van Linthout S, Chopra VK, Bayes-Genis A, et al. 
Multidisciplinary care of peripartum heart failure: a scientific statement of the Heart 
Failure Association of the ESC. Eur J Heart Fail 2024;26:742‚Äì53. https://doi.org/10. 
1002/ejhf.3246 
729. Sliwa K, Anthony J. Late maternal deaths: a neglected responsibility. Lancet 2016;387: 
2072‚Äì3. https://doi.org/10.1016/S0140-6736(16)30391-9 
730. Labbene I, Arrigo M, Tavares M, Hajjej Z, Brand√£o JL, Tolppanen H, et al. Decongestive 
effects of levosimendan in cardiogenic shock induced by postpartum cardiomyopathy. 
Anaesth Crit Care Pain Med 2017;36:39‚Äì42. https://doi.org/10.1016/j.accpm.2016.02. 
009 
731. Wong RW, Seasely AR, Gongora E, Hoopes CW, Bellot S, McElwee SK, et al. 
Strategies and outcomes of extracorporeal membrane oxygenation use in peripartum 
patients: a single institution experience. J Matern Fetal Neonatal Med 2024;37:2355293.  
https://doi.org/10.1080/14767058.2024.2355293 
732. Hilfiker-Kleiner D, Westhoff-Bleck M, Gunter HH, von Kaisenberg CS, Bohnhorst B, 
Hoeltje M, et al. A management algorithm for acute heart failure in pregnancy. The 
Hannover experience. Eur Heart J 2015;36:769‚Äì70. https://doi.org/10.1093/ 
eurheartj/ehv039  
ESC Guidelines                                                                                                                                                                                            105


<!-- PAGE 106 -->

### Page 106

733. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task 
force for the diagnosis and treatment of acute and chronic heart failure of the 
European Society of Cardiology (ESC) developed with the special contribution of 
the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129‚Äì200.  
https://doi.org/10.1093/eurheartj/ehw128 
734. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B√∂hm M, et al. 2021 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. 
Eur Heart J 2021;42:3599‚Äì726. https://doi.org/10.1093/eurheartj/ehab368 
735. Libhaber E, Sliwa K, Bachelier K, Lamont K, B√∂hm M. Low systolic blood pressure and 
high resting heart rate as predictors of outcome in patients with peripartum cardiomyopathy. Int J Cardiol 2015;190:376‚Äì82. https://doi.org/10.1016/j.ijcard.2015.04.081 
736. Haghikia A, Tongers J, Berliner D, K√∂nig T, Sch√§fer A, Brehm M, et al. Early ivabradine 
treatment in patients with acute peripartum cardiomyopathy: subanalysis of the 
German PPCM registry. Int J Cardiol 2016;216:165‚Äì7. https://doi.org/10.1016/j.ijcard. 
2016.04.143 
737. Egidy Assenza G, Dimopoulos K, Budts W, Donti A, Economy KE, Gargiulo GD, et al. 
Management of acute cardiovascular complications in pregnancy. Eur Heart J 2021;42: 
4224‚Äì40. https://doi.org/10.1093/eurheartj/ehab546 
738. Sliwa K, Azibani F, Baard J, Osman A, Z√ºhlke L, Lachmann A, et al. Reducing late maternal death due to cardiovascular disease‚Äîa pragmatic pilot study. Int J Cardiol 2018; 
272:70‚Äì6. https://doi.org/10.1016/j.ijcard.2018.07.140 
739. Kaye AB, Bhakta A, Moseley AD, Rao AK, Arif S, Lichtenstein SJ, et al. Review of cardiovascular drugs in pregnancy. J Womens Health (Larchmt) 2019;28:686‚Äì97. https:// 
doi.org/10.1089/jwh.2018.7145 
740. Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, et al. 
Recommendations on pre-hospital & early hospital management of acute heart failure: 
a consensus paper from the Heart Failure Association of the European Society of 
Cardiology, the European Society of Emergency Medicine and the Society of 
Academic Emergency Medicine. Eur J Heart Fail 2015;17:544‚Äì58. https://doi.org/10. 
1002/ejhf.289 
741. Punnoose LR, Coscia LA, Armenti DP, Constantinescu S, Moritz MJ. Pregnancy outcomes in heart transplant recipients. J Heart Lung Transplant 2020;39:473‚Äì80.  
https://doi.org/10.1016/j.healun.2020.02.005 
742. Acuna S, Zaffar N, Dong S, Ross H, D‚ÄôSouza R. Pregnancy outcomes in women with 
cardiothoracic transplants: a systematic review and meta-analysis. J Heart Lung 
Transplant 2020;39:93‚Äì102. https://doi.org/10.1016/j.healun.2019.11.018 
743. Dagher O, Alami Laroussi N, Carrier M, Cecere R, Charbonneau E, de Denus S, et al. 
Pregnancy after heart transplantation: a well-thought-out decision? The Quebec provincial experience‚Äîa multi-centre cohort study. Transpl Int 2018;31:977‚Äì87. https:// 
doi.org/10.1111/tri.13144 
744. D‚ÄôSouza R, Soete E, Silversides CK, Zaffar N, Van Mieghem T, Van Cleemput J, et al. 
Pregnancy outcomes following cardiac transplantation. J Obstet Gynaecol Can 2018; 
40:566‚Äì71. https://doi.org/10.1016/j.jogc.2017.08.030 
745. Macera F, Occhi L, Masciocco G, Varrenti M, Frigerio M. A new life: motherhood after 
heart transplantation. A single-center experience and review of literature. 
Transplantation 2018;102:1538‚Äì44. https://doi.org/10.1097/TP.0000000000002281 
746. O‚ÄôBoyle PJ, Smith JD, Danskine AJ, Lyster HS, Burke MM, Banner NR. De novo HLA 
sensitization and antibody mediated rejection following pregnancy in a heart transplant 
recipient. Am J Transplant 2010;10:180‚Äì3. https://doi.org/10.1111/j.1600-6143.2009. 
02875.x 
747. Ginwalla M, Pando MJ, Khush KK. Pregnancy-related human leukocyte antigen sensitization leading to cardiac allograft vasculopathy and graft failure in a heart transplant 
recipient: a case report. Transplant Proc 2013;45:800‚Äì2. https://doi.org/10.1016/j. 
transproceed.2012.10.038 
748. Kuczaj A, Pawlak S, ≈öliwka J, Przyby≈Çowski P. Pregnancies after orthotopic heart transplantation: a single-center experience. Transplant Proc 2022;54:1065‚Äì9. https://doi.org/ 
10.1016/j.transproceed.2022.01.026 
749. Irani RA, Coscia LA, Chang E, Lappen JR. Society for Maternal‚ÄìFetal Medicine consult 
series #66: prepregnancy evaluation and pregnancy management of patients with solid 
organ transplants. Am J Obstet Gynecol 2023;229:B10‚Äì32. https://doi.org/10.1016/j. 
ajog.2023.04.022 
750. Bry C, Hubert D, Reynaud-Gaubert M, Dromer C, Mal H, Roux A, et al. Pregnancy 
after lung and heart‚Äìlung transplantation: a French multicentre retrospective study 
of 39 pregnancies. ERJ Open Res 2019;5:00254-2018. https://doi.org/10.1183/ 
23120541.00254-2018 
751. Durst JK, Rampersad RM. Pregnancy in women with solid-organ transplants: a review. 
Obstet Gynecol Surv 2015;70:408‚Äì18. https://doi.org/10.1097/OGX.0000000000000194 
752. Peccatori FA, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, 
pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and 
follow-up. Ann Oncol 2013;24:vi160‚Äì70. https://doi.org/10.1093/annonc/mdt199 
753. Silverstein J, Post AL, Chien AJ, Olin R, Tsai KK, Ngo Z, et al. Multidisciplinary management of cancer during pregnancy. JCO Oncol Pract 2020;16:545‚Äì57. https://doi.org/10. 
1200/OP.20.00077 
754. Cubillo A, Morales S, Go√±i E, Matute F, Mu√±oz JL, P√©rez-D√≠az D, et al. Multidisciplinary 
consensus on cancer management during pregnancy. Clin Transl Oncol 2021;23: 
1054‚Äì66. https://doi.org/10.1007/s12094-020-02491-8 
755. Narayanan M, Elkayam U, Naqvi TZ. Echocardiography in pregnancy: part 2. Curr 
Cardiol Rep 2016;18:90. https://doi.org/10.1007/s11886-016-0761-6 
756. Furen√§s E, Eriksson P, Wennerholm UB, Dellborg M. Pregnancy in a healthy population: dynamics of NTproBNP and hs-cTroponin T. Open Heart 2020;7:e001293.  
https://doi.org/10.1136/openhrt-2020-001293 
757. Lyon AR, L√≥pez-Fern√°ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 
European Hematology Association (EHA), the European Society for Therapeutic 
Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society 
(IC-OS). Eur Heart J 2022;43:4229‚Äì361. https://doi.org/10.1093/eurheartj/ehac244 
758. Chait-Rubinek L, Mariani JA, Goroncy N, Herschtal A, Wheeler GC, Dwyer MK, et al. 
A retrospective evaluation of risk of peripartum cardiac dysfunction in survivors of 
childhood, adolescent and young adult malignancies. Cancers (Basel) 2019;11:1046.  
https://doi.org/10.3390/cancers11081046 
759. Thompson KA, Hildebrandt MA, Ater JL. Cardiac outcomes with pregnancy after cardiotoxic therapy for childhood cancer. J Am Coll Cardiol 2017;69:594‚Äì5. https://doi.org/ 
10.1016/j.jacc.2016.11.040 
760. Lane-Cordova AD, Khan SS, Grobman WA, Greenland P, Shah SJ. Long-term cardiovascular risks associated with adverse pregnancy outcomes: JACC review topic of the 
week. J Am Coll Cardiol 2019;73:2106‚Äì16. https://doi.org/10.1016/j.jacc.2018.12.092 
761. Parikh NI, Gonzalez JM, Anderson CAM, Judd SE, Rexrode KM, Hlatky MA, et al. 
Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities 
for cardiovascular disease prevention in women: a scientific statement from the 
American Heart Association. Circulation 2021;143:e902‚Äì16. https://doi.org/10.1161/ 
CIR.0000000000000961 
762. Ghossein-Doha C, Thilaganathan B, Vaught AJ, Briller JE, Roos-Hesselink JW. 
Hypertensive pregnancy disorder, an under-recognized women specific risk factor 
for heart failure? Eur J Heart Fail 2025;27:459‚Äì72. https://doi.org/10.1002/ejhf.3520 
763. Hauspurg A, Jeyabalan A. Postpartum preeclampsia or eclampsia: defining its place and 
management among the hypertensive disorders of pregnancy. Am J Obstet Gynecol 
2022;226:S1211‚Äì21. https://doi.org/10.1016/j.ajog.2020.10.027 
764. Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R. Cardiovascular disease 
risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol 
2013;28:1‚Äì19. https://doi.org/10.1007/s10654-013-9762-6 
765. Lopes Perdigao J, Lewey J, Hirshberg A, Koelper N, Srinivas SK, Elovitz MA, et al. 
Furosemide for accelerated recovery of blood pressure postpartum in women with 
a hypertensive disorder of pregnancy: a randomized controlled trial. Hypertension 
2021;77:1517‚Äì24. https://doi.org/10.1161/HYPERTENSIONAHA.120.16133 
766. Jannet D, Carbonne B, Sebban E, Milliez J. Nicardipine versus metoprolol in the treatment of hypertension during pregnancy: a randomized comparative trial. Obstet 
Gynecol 1994;84:354‚Äì9. 
767. ACOG committee opinion no. 767: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Obstet Gynecol 2019;133: 
e174‚Äì80. https://doi.org/10.1097/AOG.0000000000003075 
768. Buchanan TA, Xiang AH, Page KA. Gestational diabetes mellitus: risks and management during and after pregnancy. Nat Rev Endocrinol 2012;8:639‚Äì49. https://doi.org/ 
10.1038/nrendo.2012.96 
769. Claesson R, Ignell C, Shaat N, Berntorp K. Hba1c as a predictor of diabetes after gestational diabetes mellitus. Prim Care Diabetes 2017;11:46‚Äì51. https://doi.org/10.1016/j. 
pcd.2016.09.002 
770. Burlina S, Dalfr√† MG, Chilelli NC, Lapolla A. Gestational diabetes mellitus and future 
cardiovascular risk: an update. Int J Endocrinol 2016;2016:2070926. https://doi.org/ 
10.1155/2016/2070926 
771. Grandi SM, Filion KB, Yoon S, Ayele HT, Doyle CM, Hutcheon JA, et al. Cardiovascular 
disease-related morbidity and mortality in women with a history of pregnancy complications. Circulation 2019;139:1069‚Äì79. https://doi.org/10.1161/CIRCULATIONAHA. 
118.036748 
772. Crump C, Sundquist J, McLaughlin MA, Dolan SM, Govindarajulu U, Sieh W, et al. 
Adverse pregnancy outcomes and long term risk of ischemic heart disease in mothers: 
national cohort and co-sibling study. BMJ 2023;380:e072112. https://doi.org/10.1136/ 
bmj-2022-072112 
773. Marx N, Federici M, Sch√ºtt K, M√ºller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC 
Guidelines for the management of cardiovascular disease in patients with diabetes. Eur 
Heart J 2023;44:4043‚Äì140. https://doi.org/10.1093/eurheartj/ehad192 
774. Adam S, McIntyre HD, Tsoi KY, Kapur A, Ma RC, Dias S, et al. Pregnancy as an opportunity to prevent type 2 diabetes mellitus: FIGO best practice advice. Int J Gynaecol 
Obstet 2023;160:56‚Äì67. https://doi.org/10.1002/ijgo.14537 
775. Fu J, Retnakaran R. The life course perspective of gestational diabetes: an opportunity 
for the prevention of diabetes and heart disease in women. EClinicalMedicine 2022;45: 
101294. https://doi.org/10.1016/j.eclinm.2022.101294 
776. Catov JM, Snyder GG, Fraser A, Lewis CE, Liu K, Althouse AD, et al. Blood pressure 
patterns and subsequent coronary artery calcification in women who delivered


<!-- PAGE 107 -->

### Page 107

preterm 
births. 
Hypertension 
2018;72:159‚Äì66. 
https://doi.org/10.1161/ 
HYPERTENSIONAHA.117.10693 
777. Catov JM, Snyder GG, Bullen BL, Barinas-Mitchell EJM, Holzman C. Women with preterm birth have evidence of subclinical atherosclerosis a decade after delivery. J 
Womens Health (Larchmt) 2019;28:621‚Äì7. https://doi.org/10.1089/jwh.2018.7148 
778. Hall PS, Nah G, Vittinghoff E, Parker DR, Manson JE, Howard BV, et al. Relation of 
pregnancy loss to risk of cardiovascular disease in parous postmenopausal women 
(from the Women‚Äôs Health Initiative). Am J Cardiol 2019;123:1620‚Äì5. https://doi.org/ 
10.1016/j.amjcard.2019.02.012 
779. Kyriacou H, Al-Mohammad A, Muehlschlegel C, Foster-Davies L, Bruco MEF, Legard 
C, et al. The risk of cardiovascular diseases after miscarriage, stillbirth, and induced 
abortion: a systematic review and meta-analysis. Eur Heart J Open 2022;2:oeac065.  
https://doi.org/10.1093/ehjopen/oeac065 
780. T√∏rris C, Bj√∏rnnes AK. Duration of lactation and maternal risk of metabolic syndrome: 
a systematic review and meta-analysis. Nutrients 2020;12:2718. https://doi.org/10. 
3390/nu12092718 
781. Tschiderer L, Seekircher L, Kunutsor SK, Peters SAE, O‚ÄôKeeffe LM, Willeit P. 
Breastfeeding is associated with a reduced maternal cardiovascular risk: systematic review and meta-analysis involving data from 8 studies and 1 192 700 parous women. J 
Am Heart Assoc 2022;11:e022746. https://doi.org/10.1161/JAHA.121.022746 
782. Wang YX, Arvizu M, Rich-Edwards JW, Manson JE, Wang L, Missmer SA, et al. 
Breastfeeding duration and subsequent risk of mortality among US women: a prospective cohort study. EClinicalMedicine 2022;54:101693. https://doi.org/10.1016/j. 
eclinm.2022.101693 
783. Kirkegaard H, Bliddal M, St√∏vring H, Rasmussen KM, Gunderson EP, K√∏ber L, et al. 
Breastfeeding and later maternal risk of hypertension and cardiovascular disease‚Äî 
the role of overall and abdominal obesity. Prev Med 2018;114:140‚Äì8. https://doi.org/ 
10.1016/j.ypmed.2018.06.014 
784. Qu G, Wang L, Tang X, Wu W, Sun Y. Association between duration of breastfeeding 
and maternal hypertension: a systematic review and meta-analysis. Breastfeed Med 
2018;13:318‚Äì26. https://doi.org/10.1089/bfm.2017.0180 
785. Schwarz EB, Ray RM, Stuebe AM, Allison MA, Ness RB, Freiberg MS, et al. Duration of 
lactation and risk factors for maternal cardiovascular disease. Obstet Gynecol 2009;113: 
974‚Äì82. https://doi.org/10.1097/01.AOG.0000346884.67796.ca 
786. Peters SA, van der Schouw YT, Wood AM, Sweeting MJ, Moons KG, Weiderpass E, et al. 
Parity, breastfeeding and risk of coronary heart disease: a pan-European case-cohort 
study. Eur J Prev Cardiol 2016;23:1755‚Äì65. https://doi.org/10.1177/2047487316658571 
787. Stuebe AM, Michels KB, Willett WC, Manson JE, Rexrode K, Rich-Edwards JW. 
Duration of lactation and incidence of myocardial infarction in middle to late adulthood. Am J Obstet Gynecol 2009;200:138.e1‚Äìe8. https://doi.org/10.1016/j.ajog.2008. 
10.001 
788. Chetwynd EM, Stuebe AM, Rosenberg L, Troester M, Rowley D, Palmer JR. 
Cumulative lactation and onset of hypertension in African-American women. Am J 
Epidemiol 2017;186:927‚Äì34. https://doi.org/10.1093/aje/kwx163 
789. Magnus MC, Wallace MK, Demirci JR, Catov JM, Schmella MJ, Fraser A. Breastfeeding 
and later-life cardiometabolic health in women with and without hypertensive disorders of pregnancy. J Am Heart Assoc 2023;12:e026696. https://doi.org/10.1161/JAHA. 
122.026696 
790. Peters SAE, Yang L, Guo Y, Chen Y, Bian Z, Du J, et al. Breastfeeding and the risk of 
maternal cardiovascular disease: a prospective study of 300 000 Chinese women. J 
Am Heart Assoc 2017;6:e006081. https://doi.org/10.1161/JAHA.117.006081 
791. Gunderson EP, Hurston SR, Ning X, Lo JC, Crites Y, Walton D, et al. Lactation and 
progression to type 2 diabetes mellitus after gestational diabetes mellitus: a prospective cohort study. Ann Intern Med 2015;163:889‚Äì98. https://doi.org/10.7326/M15-0807 
792. Countouris ME, Holzman C, Althouse AD, Snyder GG, Barinas-Mitchell E, Reis SE, 
et al. Lactation and maternal subclinical atherosclerosis among women with and without a history of hypertensive disorders of pregnancy. J Womens Health (Larchmt) 2020; 
29:789‚Äì98. https://doi.org/10.1089/jwh.2019.7863 
793. Matsunaga T, Kadomatsu Y, Tsukamoto M, Kubo Y, Okada R, Nagayoshi M, et al. 
Associations of breastfeeding history with metabolic syndrome and cardiovascular 
risk factors in community-dwelling parous women: the Japan multi-institutional collaborative cohort study. PLoS One 2022;17:e0262252. https://doi.org/10.1371/journal. 
pone.0262252 
794. Nguyen B, Gale J, Nassar N, Bauman A, Joshy G, Ding D. Breastfeeding and cardiovascular disease hospitalization and mortality in parous women: evidence from a large 
Australian cohort study. J Am Heart Assoc 2019;8:e011056. https://doi.org/10.1161/ 
JAHA.118.011056 
795. McKinney J, Keyser L, Clinton S, Pagliano C. ACOG committee opinion no. 736: optimizing postpartum care. Obstet Gynecol 2018;132:784‚Äì5. https://doi.org/10.1097/ 
AOG.0000000000002849 
796. Gamble DT, Brikinns B, Myint PK, Bhattacharya S. Hypertensive disorders of pregnancy and subsequent cardiovascular disease: current national and international guidelines and the need for future research. Front Cardiovasc Med 2019;6:55. https://doi.org/ 
10.3389/fcvm.2019.00055 
797. Hedeager Momsen AM, H√∏toft D, √òrtenblad L, Friis Lauszus F, Krogh RHA, Lynggaard 
V, et al. Diabetes prevention interventions for women after gestational diabetes mellitus: an overview of reviews. Endocrinol Diabetes Metab 2021;4:e00230. https://doi.org/ 
10.1002/edm2.230 
798. Kitt J, Fox R, Frost A, Shanyinde M, Tucker K, Bateman PA, et al. Long-term blood pressure control after hypertensive pregnancy following physician-optimized self- 
management: the POP-HT randomized clinical trial. JAMA 2023;330:1991‚Äì9. https:// 
doi.org/10.1001/jama.2023.21523 
799. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B√§ck M, et al. 2021 ESC 
Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 
42:3227‚Äì337. https://doi.org/10.1093/eurheartj/ehab484 
800. Balaji B, Ranjit Mohan A, Rajendra P, Mohan D, Ram U, Viswanathan M. Gestational 
diabetes mellitus postpartum follow-up testing: challenges and solutions. Can J 
Diabetes 2019;43:641‚Äì6. https://doi.org/10.1016/j.jcjd.2019.04.011  
ESC Guidelines                                                                                                                                                                                            107

<!-- 2025_Valvular_Heart_Disease.md -->

# ESC Guidelines: Valvular Heart Disease (2025)

**Source**: `2025_Valvular_Heart_Disease.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 102

---

## Table of Contents

- [2025 ESC/EACTS Guidelines for the management of valvular heart disease](#2025-esc/eacts-guidelines-for-the-management-of-va) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 6)*
  - [2. Introduction](#2-introduction) *(p. 8)*
    - [2.1. What is new](#21-what-is-new) *(p. 9)*
  - [3. The Heart Team and Heart Valve Centre](#3-the-heart-team-and-heart-valve-centre) *(p. 15)*
    - [3.1. The Heart Valve Network](#31-the-heart-valve-network) *(p. 15)*
      - [3.1.1. Composition of the Heart Team](#311-composition-of-the-heart-team) *(p. 16)*
      - [3.1.2. Procedural volume and clinical outcomes](#312-procedural-volume-and-clinical-outcomes) *(p. 17)*
  - [4. Imaging of patients with valvular heart disease](#4-imaging-of-patients-with-valvular-heart-disease) *(p. 18)*
    - [4.1. Initial valve assessment](#41-initial-valve-assessment) *(p. 18)*
    - [4.2. Associated diseases and conditions](#42-associated-diseases-and-conditions) *(p. 19)*
    - [4.3. Evaluation of valvular heart disease dynamics and variability](#43-evaluation-of-valvular-heart-disease-dynamics-a) *(p. 19)*
    - [4.4. Assessment of extravalvular cardiac consequences from valvular heart disease](#44-assessment-of-extravalvular-cardiac-consequence) *(p. 19)*
    - [4.5. Evaluation of eligibility, planning, and guiding of interventions](#45-evaluation-of-eligibility,-planning,-and-guidin) *(p. 19)*
  - [5. Clinical evaluation of patients with valvular heart disease](#5-clinical-evaluation-of-patients-with-valvular-he) *(p. 19)*
    - [5.1. Clinical examination](#51-clinical-examination) *(p. 19)*
    - [5.2. Assessment of comorbidities and risk stratification](#52-assessment-of-comorbidities-and-risk-stratifica) *(p. 19)*
    - [5.3. Biomarkers](#53-biomarkers) *(p. 20)*
    - [5.4. Exercise testing](#54-exercise-testing) *(p. 21)*
    - [5.5. Invasive investigations](#55-invasive-investigations) *(p. 21)*
      - [5.5.1. Coronary angiography](#551-coronary-angiography) *(p. 21)*
      - [5.5.2. Cardiac catheterization](#552-cardiac-catheterization) *(p. 21)*
    - [5.6. Patient-centred care and shared decision-making](#56-patient-centred-care-and-shared-decision-making) *(p. 21)*
  - [6. Management of conditions associated with valvular heart disease](#6-management-of-conditions-associated-with-valvula) *(p. 21)*
    - [6.1. Diagnosis and management of coronary artery disease](#61-diagnosis-and-management-of-coronary-artery-dis) *(p. 21)*
    - [6.2. Atrial fibrillation](#62-atrial-fibrillation) *(p. 23)*
    - [6.3. Cancer and radiation therapy](#63-cancer-and-radiation-therapy) *(p. 23)*
    - [6.4. Prophylaxis of rheumatic fever](#64-prophylaxis-of-rheumatic-fever) *(p. 24)*
    - [6.5. Cardiogenic shock and acute heart failure](#65-cardiogenic-shock-and-acute-heart-failure) *(p. 24)*
    - [6.6. Palliative care](#66-palliative-care) *(p. 24)*
  - [7. Aortic regurgitation](#7-aortic-regurgitation) *(p. 24)*
    - [7.1. Prevalence and aetiology](#71-prevalence-and-aetiology) *(p. 24)*
    - [7.2. Evaluation](#72-evaluation) *(p. 24)*
    - [7.3. Medical therapy](#73-medical-therapy) *(p. 26)*
    - [7.4. Indications for intervention](#74-indications-for-intervention) *(p. 26)*
    - [7.5. Follow-up](#75-follow-up) *(p. 26)*
    - [7.6. Special patient populations](#76-special-patient-populations) *(p. 28)*
  - [8. Aortic stenosis](#8-aortic-stenosis) *(p. 28)*
    - [8.1. Prevalence and aetiology](#81-prevalence-and-aetiology) *(p. 28)*
    - [8.2. Evaluation](#82-evaluation) *(p. 28)*
      - [8.2.1. Echocardiography and cardiac computed tomography](#821-echocardiography-and-cardiac-computed-tomograp) *(p. 28)*
      - [8.2.2. Additional diagnostic and prognostic parameters](#822-additional-diagnostic-and-prognostic-parameter) *(p. 29)*
      - [8.2.3. Procedural planning](#823-procedural-planning) *(p. 29)*
    - [8.3. Medical therapy](#83-medical-therapy) *(p. 29)*
    - [8.4. Indication for intervention](#84-indication-for-intervention) *(p. 31)*
      - [8.4.1. Symptomatic severe aortic stenosis](#841-symptomatic-severe-aortic-stenosis) *(p. 31)*
      - [8.4.2. Asymptomatic severe aortic stenosis](#842-asymptomatic-severe-aortic-stenosis) *(p. 31)*
      - [8.4.3. Moderate aortic stenosis](#843-moderate-aortic-stenosis) *(p. 31)*
    - [8.5. Treatment options](#85-treatment-options) *(p. 33)*
      - [8.5.1. The mode of intervention in candidates for a bioprosthesis](#851-the-mode-of-intervention-in-candidates-for-a-b) *(p. 33)*
        - [8.5.1.1. Age and life expectancy](#8511-age-and-life-expectancy) *(p. 34)*
        - [8.5.1.2. Anatomical features](#8512-anatomical-features) *(p. 34)*
        - [8.5.1.3. Lifetime management](#8513-lifetime-management) *(p. 34)*
    - [8.6. Follow-up](#86-follow-up) *(p. 37)*
  - [9. Mitral regurgitation](#9-mitral-regurgitation) *(p. 37)*
    - [9.1. Primary mitral regurgitation](#91-primary-mitral-regurgitation) *(p. 37)*
      - [9.1.1. Prevalence and aetiology](#911-prevalence-and-aetiology) *(p. 37)*
      - [9.1.2. Evaluation](#912-evaluation) *(p. 37)*
        - [9.1.2.1. Echocardiography and right heart catheterization](#9121-echocardiography-and-right-heart-catheterizat) *(p. 37)*
        - [9.1.2.2. Biomarkers](#9122-biomarkers) *(p. 37)*
        - [9.1.2.3. Cardiac magnetic resonance and computed tomography](#9123-cardiac-magnetic-resonance-and-computed-tomog) *(p. 38)*
        - [9.1.2.4. Genetic evaluation](#9124-genetic-evaluation) *(p. 40)*
      - [9.1.3. Medical therapy](#913-medical-therapy) *(p. 40)*
      - [9.1.4. Indications for intervention](#914-indications-for-intervention) *(p. 40)*
      - [9.1.5. Follow-up](#915-follow-up) *(p. 41)*
    - [9.2. Secondary mitral regurgitation](#92-secondary-mitral-regurgitation) *(p. 41)*
      - [9.2.1. Prevalence and aetiology](#921-prevalence-and-aetiology) *(p. 41)*
      - [9.2.2. Evaluation](#922-evaluation) *(p. 41)*
      - [9.2.3. Definition of atrial secondary mitral regurgitation](#923-definition-of-atrial-secondary-mitral-regurgit) *(p. 41)*
      - [9.2.4. Management of ventricular secondary mitral regurgitation](#924-management-of-ventricular-secondary-mitral-re) *(p. 42)*
        - [9.2.4.1. Medical and device therapy](#9241-medical-and-device-therapy) *(p. 42)*
        - [9.2.4.2. Indications for intervention](#9242-indications-for-intervention) *(p. 43)*
        - [9.2.4.3. Follow-up](#9243-follow-up) *(p. 44)*
      - [9.2.5. Management of atrial secondary mitral regurgitation](#925-management-of-atrial-secondary-mitral-regurgit) *(p. 45)*
        - [9.2.5.1. Medical therapy and rhythm management](#9251-medical-therapy-and-rhythm-management) *(p. 45)*
        - [9.2.5.2. Indications for intervention](#9252-indications-for-intervention) *(p. 45)*
        - [9.2.5.3. Follow-up](#9253-follow-up) *(p. 45)*
  - [10. Mitral stenosis](#10-mitral-stenosis) *(p. 45)*
    - [10.1. Prevalence and aetiology](#101-prevalence-and-aetiology) *(p. 45)*
    - [10.2. Rheumatic mitral stenosis](#102-rheumatic-mitral-stenosis) *(p. 45)*
      - [10.2.1. Evaluation](#1021-evaluation) *(p. 45)*
      - [10.2.2. Medical therapy](#1022-medical-therapy) *(p. 46)*
      - [10.2.3. Indications for intervention](#1023-indications-for-intervention) *(p. 46)*
      - [10.2.4. Follow-up](#1024-follow-up) *(p. 46)*
    - [10.3. Degenerative mitral stenosis with mitral annular calcification](#103-degenerative-mitral-stenosis-with-mitral-annul) *(p. 46)*
      - [10.3.1. Evaluation](#1031-evaluation) *(p. 47)*
      - [10.3.2. Indications for intervention](#1032-indications-for-intervention) *(p. 47)*
  - [11. Tricuspid regurgitation](#11-tricuspid-regurgitation) *(p. 48)*
    - [11.1. Prevalence and aetiology](#111-prevalence-and-aetiology) *(p. 48)*
    - [11.2. Evaluation](#112-evaluation) *(p. 49)*
    - [11.3. Medical therapy](#113-medical-therapy) *(p. 49)*
    - [11.4. Indications for intervention](#114-indications-for-intervention) *(p. 49)*
      - [11.4.1. Surgery](#1141-surgery) *(p. 49)*
        - [11.4.1.1. Patients without indication for left-sided valve surgery](#11411-patients-without-indication-for-left-sided-v) *(p. 51)*
        - [11.4.1.2. Patients with indication for left-sided valve surgery](#11412-patients-with-indication-for-left-sided-valv) *(p. 51)*
      - [11.4.2. Transcatheter techniques](#1142-transcatheter-techniques) *(p. 52)*
  - [12. Tricuspid stenosis](#12-tricuspid-stenosis) *(p. 53)*
    - [12.1. Prevalence and aetiology](#121-prevalence-and-aetiology) *(p. 53)*
    - [12.2. Evaluation](#122-evaluation) *(p. 53)*
    - [12.3. Medical therapy](#123-medical-therapy) *(p. 54)*
    - [12.4. Indications for intervention](#124-indications-for-intervention) *(p. 54)*
  - [13. Multiple and mixed valvular heart disease](#13-multiple-and-mixed-valvular-heart-disease) *(p. 54)*
    - [13.1. Prevalence and undertreatment](#131-prevalence-and-undertreatment) *(p. 54)*
    - [13.2. Evaluation and diagnostic pitfalls](#132-evaluation-and-diagnostic-pitfalls) *(p. 54)*
    - [13.3. Indications for intervention](#133-indications-for-intervention) *(p. 54)*
      - [13.3.1. Multiple valvular heart disease](#1331-multiple-valvular-heart-disease) *(p. 54)*
      - [13.3.2. Mixed aortic valve disease](#1332-mixed-aortic-valve-disease) *(p. 56)*
      - [13.3.3. Mixed mitral valve disease](#1333-mixed-mitral-valve-disease) *(p. 56)*
    - [13.4. Follow-up](#134-follow-up) *(p. 56)*
  - [14. Management of patients with prosthetic valves or valve repair](#14-management-of-patients-with-prosthetic-valves-o) *(p. 56)*
    - [14.1. Choice of prosthetic valve](#141-choice-of-prosthetic-valve) *(p. 56)*
    - [14.2. Follow-up of patients with prosthetic valves](#142-follow-up-of-patients-with-prosthetic-valves) *(p. 57)*
    - [14.3. Antithrombotic therapy in patients with treated valvular heart disease](#143-antithrombotic-therapy-in-patients-with-treate) *(p. 57)*
      - [14.3.1. Mechanical heart valves](#1431-mechanical-heart-valves) *(p. 57)*
        - [14.3.1.1. Post-operative anticoagulation and therapeutic targets](#14311-post-operative-anticoagulation-and-therapeut) *(p. 57)*
        - [14.3.1.2. Prevention and management of bleeding](#14312-prevention-and-management-of-bleeding) *(p. 59)*
        - [14.3.1.3. Management of anticoagulation therapy before and after non-cardiac invasive procedures](#14313-management-of-anticoagulation-therapy-before) *(p. 59)*
      - [14.3.2. Biological heart valves](#1432-biological-heart-valves) *(p. 61)*
        - [14.3.2.1. Patients with a surgical biological heart valve and no indication for oral anticoagulation](#14321-patients-with-a-surgical-biological-heart-va) *(p. 61)*
        - [14.3.2.2. Patients with a transcatheter heart valve and no indication for oral anticoagulation](#14322-patients-with-a-transcatheter-heart-valve-an) *(p. 61)*
        - [14.3.2.3. Patients with a surgical biological heart valve and an indication for oral anticoagulation](#14323-patients-with-a-surgical-biological-heart-va) *(p. 62)*
        - [14.3.2.4. Patients with a transcatheter biological heart valve and an indication for oral anticoagulation](#14324-patients-with-a-transcatheter-biological-hea) *(p. 62)*
    - [14.4. Management of prosthetic valve dysfunction and complications](#144-management-of-prosthetic-valve-dysfunction-and) *(p. 63)*
      - [14.4.1. Structural valve deterioration](#1441-structural-valve-deterioration) *(p. 63)*
      - [14.4.2. Non-structural valve dysfunction](#1442-non-structural-valve-dysfunction) *(p. 64)*
        - [14.4.2.1. Prosthesis‚Äìpatient mismatch](#14421-prosthesis‚Äìpatient-mismatch) *(p. 64)*
        - [14.4.2.2. Paravalvular leak and haemolysis](#14422-paravalvular-leak-and-haemolysis) *(p. 64)*
      - [14.4.3. Endocarditis](#1443-endocarditis) *(p. 64)*
      - [14.4.4. Valve thrombosis](#1444-valve-thrombosis) *(p. 64)*
        - [14.4.4.1. Hypo-attenuated leaflet thickening](#14441-hypo-attenuated-leaflet-thickening) *(p. 64)*
        - [14.4.4.2. Clinically significant valve thrombosis](#14442-clinically-significant-valve-thrombosis) *(p. 64)*
  - [15. Management during non-cardiac surgery](#15-management-during-non-cardiac-surgery) *(p. 66)*
    - [15.1. Pre-operative evaluation](#151-pre-operative-evaluation) *(p. 66)*
    - [15.2. Specific valve lesions](#152-specific-valve-lesions) *(p. 66)*
      - [15.2.1. Aortic stenosis](#1521-aortic-stenosis) *(p. 66)*
      - [15.2.2. Mitral stenosis](#1522-mitral-stenosis) *(p. 67)*
      - [15.2.3. Aortic and mitral regurgitation](#1523-aortic-and-mitral-regurgitation) *(p. 67)*
    - [15.3. Peri-operative monitoring](#153-peri-operative-monitoring) *(p. 68)*
  - [16. Management of valvular heart disease during pregnancy](#16-management-of-valvular-heart-disease-during-pre) *(p. 68)*
    - [16.1. Management before pregnancy](#161-management-before-pregnancy) *(p. 68)*
    - [16.2. Management during pregnancy](#162-management-during-pregnancy) *(p. 69)*
      - [16.2.1. Patients with native valve disease](#1621-patients-with-native-valve-disease) *(p. 69)*
      - [16.2.2. Patients with prosthetic valves](#1622-patients-with-prosthetic-valves) *(p. 69)*
  - [17. Sex-specific considerations in patients with valvular heart disease](#17-sex-specific-considerations-in-patients-with-va) *(p. 69)*
    - [17.1. Aortic valve disease](#171-aortic-valve-disease) *(p. 69)*
    - [17.2. Mitral valve disease](#172-mitral-valve-disease) *(p. 70)*
    - [17.3. Tricuspid valve disease](#173-tricuspid-valve-disease) *(p. 70)*
  - [18. Key messages](#18-key-messages) *(p. 70)*
  - [19. Gaps in evidence](#19-gaps-in-evidence) *(p. 71)*
  - [20. ‚ÄòWhat to do‚Äô and ‚ÄòWhat not to do‚Äô messages from the Guidelines](#20-‚Äòwhat-to-do‚Äô-and-‚Äòwhat-not-to-do‚Äô-messages-from) *(p. 73)*
  - [21. Evidence tables](#21-evidence-tables) *(p. 76)*
  - [22. Data availability statement](#22-data-availability-statement) *(p. 76)*
  - [23. Author information](#23-author-information) *(p. 76)*
  - [Appendix](#appendix) *(p. 76)*
  - [References](#references) *(p. 77)*
  - [References](#references) *(p. 77)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2025 ESC/EACTS Guidelines for the 
management of valvular heart disease 
Developed by the task force for the management of valvular heart 
disease of the European Society of Cardiology (ESC) and the 
European Association for Cardio-Thoracic Surgery (EACTS) 
Authors/Task Force Members: Fabien Praz  *‚Ä†, (ESC Chairperson) (Switzerland), 
Michael A. Borger  *‚Ä†, (EACTS Chairperson) (Germany), Jonas Lanz  
‚Ä°, (ESC Task 
Force Co-ordinator) (Switzerland), Mateo Marin-Cuartas  
‚Ä°, (EACTS Task Force 
Co-ordinator) (Germany), Ana Abreu  
(Portugal), Marianna Adamo (Italy), 
Nina Ajmone Marsan (Netherlands), Fabio Barili  
(Italy), Nikolaos Bonaros  
(Austria), Bernard Cosyns  
(Belgium), Ruggero De Paulis  
(Italy), Habib Gamra  
(Tunisia), Marjan Jahangiri (United Kingdom), Anders Jeppsson  
(Sweden),  
Robert J.M. Klautz  
(Netherlands), Benoit Mores  
(Belgium),  
Esther P√©rez-David  
(Spain), Janine P√∂ss (Germany), Bernard D. Prendergast 
(United Kingdom), Bianca Rocca  
(Italy), Xavier Rossello  
(Spain), Mikio Suzuki 
(Serbia), Holger Thiele  
(Germany), Christophe Michel Tribouilloy  
(France), 
Wojtek Wojakowski  
(Poland), and ESC/EACTS Scientific Document Group 
* Corresponding authors: Fabien Praz, Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, Tel: +41 31 632 83 50, Email: fabien.praz@insel.ch and 
Michael A. Borger, University Clinic of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany, Tel: +49 341 865 1422, Email: michael.borger@helios-gesundheit.de 
‚Ä† The two Chairpersons contributed equally to the document and are joint corresponding authors. 
‚Ä° The two Task Force Co-ordinators contributed equally to the document. 
Author/Task Force Member affiliations are listed in author information. 
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix. 
ESC subspecialty communities having participated in the development of this document: 
Associations: Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), 
European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), and Heart Failure Association (HFA) 
Working Groups: Cardiovascular Pharmacotherapy 
Patient Forum 
Disclaimer. The European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) Guidelines represent the views of the ESC and the EACTS and were produced 
after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC and the EACTS are not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC/EACTS Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation 
to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account when exercising their clinical judgement, as well as in the 
determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC/EACTS Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient‚Äôs health condition and in consultation with that patient and, where appropriate and/or 
necessary, the patient‚Äôs caregiver. Nor do the ESC/EACTS Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or 
guidelines issued by the competent public health authorities, in order to manage each patient‚Äôs case in light of the scientifically accepted data pursuant to their respective ethical and professional 
obligations. It is also the health professional‚Äôs responsibility to verify the applicable rules and regulations relating to drugs and medical devices prior to making any clinical decision and to check whether 
a more recent version of this document exists. The ESC and the EACTS warn readers that the technical language may be misinterpreted and decline any responsibility in this respect. 
Permissions. The content of these ESC/EACTS Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC/EACTS 
Guidelines may be translated or reproduced in any form without written permission from the ESC and the EACTS. Permissions can be obtained upon submission of a written request 
to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com). 
This article has been co-published with permission in the European Heart Journal and European Journal of Cardio-Thoracic Surgery. All rights reserved. ¬© The European Society of Cardiology and 
the European Association for Cardio-Thoracic Surgery 2025.  
The articles are identical except for minor stylistic and spelling differences in keeping with each journal‚Äôs style. Either citation can be used when citing this article.  
https://doi.org/10.1093/eurheartj/ehaf194 
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Alec Vahanian, (ESC Review Co-ordinator) (France), Carlos-A. Mestres, (EACTS Review 
Co-ordinator) (South Africa), Leila Abid (Tunisia), Suleman Aktaa (United Kingdom), Enoch F. Akowuah (United 
Kingdom), Elena Arbelo (Spain), Folkert W. Asselbergs (Netherlands), Emanuele Barbato (Italy), Giuseppe Boriani 
(Italy), Margarita Brida (Croatia), Sergio Buccheri (Sweden), Robert A. Byrne (Republic of Ireland), Ovidiu Chioncel 
(Romania), Lenard Conradi (Germany), Michele De Bonis (Italy), Victoria Delgado (Spain), Anna Franzone (Italy), 
Kristina Hermann Haugaa (Norway), Bettina Heidecker (Germany), Borja Ibanez (Spain), Bernard Iung (France), 
Stefan James (Sweden), Lars K√∏ber (Denmark), Konstantinos C. Koskinas (Switzerland), Ulf Landmesser (Germany), 
Gregory Y.H. Lip (United Kingdom), John William McEvoy (Ireland), Gil Meltzer (Israel), David Messika-Zeitoun 
(Canada), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Inge Moelgaard (Denmark), 
Jens Cosedis Nielsen (Denmark), Gareth Owens (United Kingdom), Agnes A. Pasquet (Belgium), Thomas Pilgrim 
(Switzerland), Eva Prescott (Denmark), Eduard Quintana (Spain), Volker Rudolph (Germany), Rafael Sadaba (Spain), 
Anna Sannino (Germany), Felix C. Tanner (Switzerland), Marina Urena (France), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Alexander Wahba (Norway), Thomas Walther (Germany), Adam Witkowski (Poland), 
and Katja Zeppenfeld (Netherlands) 
All experts involved in the development of these guidelines have submitted declarations of interest, 
which are reported in a supplementary document to the guidelines. See the European Heart Journal online or  
https://www.escardio.org/Guidelines for supplementary documents as well as evidence tables.  
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
Keywords 
Guidelines ‚Ä¢ European Society of Cardiology (ESC) ‚Ä¢ European Association for Cardio-Thoracic Surgery (EACTS) ‚Ä¢ 
Valvular heart disease ‚Ä¢ Aortic stenosis ‚Ä¢ Aortic regurgitation ‚Ä¢ Mitral stenosis ‚Ä¢ Mitral regurgitation ‚Ä¢ Tricuspid 
regurgitation ‚Ä¢ Tricuspid stenosis ‚Ä¢ Multivalvular disease ‚Ä¢ TAVI ‚Ä¢ SAVR ‚Ä¢ Heart surgery ‚Ä¢ Transcatheter edge-to- 
edge repair ‚Ä¢ Transcatheter valve replacement  
Table of contents 
1. Preamble ...................................................................................................................... 6 
2. Introduction ............................................................................................................... 8 
2.1. What is new .....................................................................................................
9 
3. The Heart Team and Heart Valve Centre ................................................. 15 
3.1. The Heart Valve Network ....................................................................... 15 
3.1.1. Composition of the Heart Team ..................................................
16 
3.1.2. Procedural volume and clinical outcomes ................................
17 
4. Imaging of patients with valvular heart disease ........................................ 18 
4.1. Initial valve assessment ............................................................................... 18 
4.2. Associated diseases and conditions ...................................................... 19 
4.3. Evaluation of valvular heart disease dynamics and variability .... 19 
4.4. Assessment of extravalvular cardiac consequences from 
valvular heart disease ........................................................................................... 19 
4.5. Evaluation of eligibility, planning, and guiding of interventions . 19 
5. Clinical evaluation of patients with valvular heart disease .................. 19 
5.1. Clinical examination .................................................................................... 19 
5.2. Assessment of comorbidities and risk stratification ...................... 19 
5.3. Biomarkers ...................................................................................................... 20 
5.4. Exercise testing ............................................................................................. 21 
5.5. Invasive investigations ................................................................................. 21 
5.5.1. Coronary angiography .......................................................................
21 
5.5.2. Cardiac catheterization .....................................................................
21 
5.6. Patient-centred care and shared decision-making ......................... 21 
6. Management of conditions associated with valvular heart disease . 21 
6.1. Diagnosis and management of coronary artery disease .............. 21 
6.2. Atrial fibrillation ............................................................................................ 23 
6.3. Cancer and radiation therapy ................................................................. 23 
6.4. Prophylaxis of rheumatic fever .............................................................. 24 
6.5. Cardiogenic shock and acute heart failure ........................................ 24 
6.6. Palliative care .................................................................................................. 24 
7. Aortic regurgitation ............................................................................................. 24 
7.1. Prevalence and aetiology ........................................................................... 24 
7.2. Evaluation ......................................................................................................... 24 
7.3. Medical therapy ............................................................................................. 26 
7.4. Indications for intervention ...................................................................... 26 
7.5. Follow-up ......................................................................................................... 26 
7.6. Special patient populations ...................................................................... 28 
8. Aortic stenosis ....................................................................................................... 28 
8.1. Prevalence and aetiology ........................................................................... 28 
8.2. Evaluation ......................................................................................................... 28 
8.2.1. Echocardiography and cardiac computed tomography ......
28 
8.2.2. Additional diagnostic and prognostic parameters .................
29 
8.2.3. Procedural planning ............................................................................
29 
8.3. Medical therapy ............................................................................................. 29 
8.4. Indication for intervention ........................................................................ 31 
8.4.1. Symptomatic severe aortic stenosis ............................................
31 
8.4.2. Asymptomatic severe aortic stenosis .........................................
31 
8.4.3. Moderate aortic stenosis ..................................................................
31 
8.5. Treatment options ....................................................................................... 33 
8.5.1. The mode of intervention in candidates for a bioprosthesis
33 
8.5.1.1. Age and life expectancy ............................................................
34 
8.5.1.2. Anatomical features ...................................................................
34 
8.5.1.3. Lifetime management ................................................................
34 
8.6. Follow-up ......................................................................................................... 37


<!-- PAGE 3 -->

### Page 3

9. Mitral regurgitation .............................................................................................. 37 
9.1. Primary mitral regurgitation .................................................................... 37 
9.1.1. Prevalence and aetiology ..................................................................
37 
9.1.2. Evaluation ................................................................................................
37 
9.1.2.1. Echocardiography and right heart catheterization .......
37 
9.1.2.2. Biomarkers .....................................................................................
37 
9.1.2.3. Cardiac magnetic resonance and computed 
tomography ...................................................................................................
38 
9.1.2.4. Genetic evaluation ......................................................................
40 
9.1.3. Medical therapy ....................................................................................
40 
9.1.4. Indications for intervention .............................................................
40 
9.1.5. Follow-up ................................................................................................
41 
9.2. Secondary mitral regurgitation ............................................................... 41 
9.2.1. Prevalence and aetiology ..................................................................
41 
9.2.2. Evaluation ................................................................................................
41 
9.2.3. Definition of atrial secondary mitral regurgitation ................
41 
9.2.4. Management of ventricular secondary mitral  
regurgitation .......................................................................................................
42 
9.2.4.1. Medical and device therapy ....................................................
42 
9.2.4.2. Indications for intervention ....................................................
43 
9.2.4.3. Follow-up ........................................................................................
44 
9.2.5. Management of atrial secondary mitral regurgitation ..........
45 
9.2.5.1. Medical therapy and rhythm management ......................
45 
9.2.5.2. Indications for intervention ....................................................
45 
9.2.5.3. Follow-up ........................................................................................
45 
10. Mitral stenosis ...................................................................................................... 45 
10.1. Prevalence and aetiology ........................................................................ 45 
10.2. Rheumatic mitral stenosis ...................................................................... 45 
10.2.1. Evaluation .............................................................................................
45 
10.2.2. Medical therapy ..................................................................................
46 
10.2.3. Indications for intervention ..........................................................
46 
10.2.4. Follow-up ..............................................................................................
46 
10.3. Degenerative mitral stenosis with mitral annular calcification
46 
10.3.1. Evaluation .............................................................................................
47 
10.3.2. Indications for intervention ..........................................................
47 
11. Tricuspid regurgitation ..................................................................................... 48 
11.1. Prevalence and aetiology ........................................................................ 48 
11.2. Evaluation ...................................................................................................... 49 
11.3. Medical therapy .......................................................................................... 49 
11.4. Indications for intervention ................................................................... 49 
11.4.1. Surgery ...................................................................................................
49 
11.4.1.1. Patients without indication for left-sided valve  
surgery .............................................................................................................
51 
11.4.1.2. Patients with indication for left-sided valve surgery ..
51 
11.4.2. Transcatheter techniques ..............................................................
52 
12. Tricuspid stenosis ............................................................................................... 53 
12.1. Prevalence and aetiology ........................................................................ 53 
12.2. Evaluation ...................................................................................................... 53 
12.3. Medical therapy .......................................................................................... 54 
12.4. Indications for intervention ................................................................... 54 
13. Multiple and mixed valvular heart disease ............................................... 54 
13.1. Prevalence and undertreatment .......................................................... 54 
13.2. Evaluation and diagnostic pitfalls ......................................................... 54 
13.3. Indications for intervention ................................................................... 54 
13.3.1. Multiple valvular heart disease .....................................................
54 
13.3.2. Mixed aortic valve disease .............................................................
56 
13.3.3. Mixed mitral valve disease .............................................................
56 
13.4. Follow-up ...................................................................................................... 56 
14. Management of patients with prosthetic valves or valve repair .... 56 
14.1. Choice of prosthetic valve ..................................................................... 56 
14.2. Follow-up of patients with prosthetic valves ................................. 57 
14.3. Antithrombotic therapy in patients with treated valvular 
heart disease ........................................................................................................... 57 
14.3.1. Mechanical heart valves ..................................................................
57 
14.3.1.1. Post-operative anticoagulation and therapeutic 
targets ..............................................................................................................
57 
14.3.1.2. Prevention and management of bleeding .......................
59 
14.3.1.3. Management of anticoagulation therapy before and 
after non-cardiac invasive procedures ...............................................
59 
14.3.2. Biological heart valves .....................................................................
61 
14.3.2.1. Patients with a surgical biological heart valve and no 
indication for oral anticoagulation .......................................................
61 
14.3.2.2. Patients with a transcatheter heart valve and no 
indication for oral anticoagulation .......................................................
61 
14.3.2.3. Patients with a surgical biological heart valve and an 
indication for oral anticoagulation .......................................................
62 
14.3.2.4. Patients with a transcatheter biological heart valve 
and an indication for oral anticoagulation ........................................
62 
14.4. Management of prosthetic valve dysfunction and 
complications .......................................................................................................... 63 
14.4.1. Structural valve deterioration ......................................................
63 
14.4.2. Non-structural valve dysfunction ...............................................
64 
14.4.2.1. Prosthesis‚Äìpatient mismatch ...............................................
64 
14.4.2.2. Paravalvular leak and haemolysis .......................................
64 
14.4.3. Endocarditis .........................................................................................
64 
14.4.4. Valve thrombosis ...............................................................................
64 
14.4.4.1. Hypo-attenuated leaflet thickening ...................................
64 
14.4.4.2. Clinically significant valve thrombosis ..............................
64 
15. Management during non-cardiac surgery ................................................. 66 
15.1. Pre-operative evaluation ......................................................................... 66 
15.2. Specific valve lesions ................................................................................. 66 
15.2.1. Aortic stenosis ....................................................................................
66 
15.2.2. Mitral stenosis .....................................................................................
67 
15.2.3. Aortic and mitral regurgitation ...................................................
67 
15.3. Peri-operative monitoring ...................................................................... 68 
16. Management of valvular heart disease during pregnancy .................. 68 
16.1. Management before pregnancy ........................................................... 68 
16.2. Management during pregnancy ............................................................ 69 
16.2.1. Patients with native valve disease ..............................................
69 
16.2.2. Patients with prosthetic valves ....................................................
69 
17. Sex-specific considerations in patients with valvular heart disease
69 
17.1. Aortic valve disease .................................................................................. 69 
17.2. Mitral valve disease .................................................................................... 70 
17.3. Tricuspid valve disease ............................................................................ 70 
18. Key messages ....................................................................................................... 70 
19. Gaps in evidence ................................................................................................. 71 
20. ‚ÄòWhat to do‚Äô and ‚ÄòWhat not to do‚Äô messages from the Guidelines
73 
21. Evidence tables .................................................................................................... 76 
22. Data availability statement .............................................................................. 76 
23. Author information ........................................................................................... 76 
24. Appendix ................................................................................................................ 76 
25. References ............................................................................................................. 77  
ESC Guidelines                                                                                                                                                                                                 3


<!-- PAGE 4 -->

### Page 4

Tables of Recommendations 
Recommendation Table 1 ‚Äî Recommendations for the 
management of chronic coronary syndrome in patients with valvular 
heart disease (see also Supplementary data online, Evidence Table 1)
22 
Recommendation Table 2 ‚Äî Recommendations for the 
management of atrial fibrillation in patients with native valvular heart 
disease (see also Supplementary data online, Evidence Tables 2 and 3)
23 
Recommendation Table 3 ‚Äî Recommendations on indications for 
intervention in severe aortic regurgitation (see also Supplementary 
data online, Evidence Tables 4‚Äì8) ........................................................................ 28 
Recommendation Table 4 ‚Äî Recommendations on indications for 
intervention in symptomatic and asymptomatic severe aortic stenosis, 
and recommended mode of intervention (see also Supplementary data 
online, Evidence Tables 9‚Äì13) ......................................................................................... 36 
Recommendation Table 5 ‚Äî Recommendations on indications for 
concomitant aortic valve replacement at the time of coronary artery 
bypass grafting or ascending aorta surgery ..................................................... 37 
Recommendation Table 6 ‚Äî Recommendations on indications for 
intervention in severe primary mitral regurgitation (see also 
Supplementary data online, Evidence Tables 14‚Äì16) ................................... 40 
Recommendation Table 7 ‚Äî Recommendations on indications for 
intervention in secondary mitral regurgitation (see also 
Supplementary data online, Evidence Tables 17‚Äì20) ................................... 45 
Recommendation Table 8 ‚Äî Recommendations on indications for 
percutaneous mitral commissurotomy, mitral valve surgery, and 
transcatheter intervention in clinically severe rheumatic and 
degenerative mitral stenosis (see also Supplementary data online, 
Evidence Table 21) ............................................................................................. 48 
Recommendation Table 9 ‚Äî Recommendations on indications for 
intervention in tricuspid regurgitation (see also Supplementary data 
online, Evidence Tables 22 and 23) ............................................................................
53 
Recommendation Table 10 ‚Äî Recommendations on indications for 
intervention in tricuspid stenosis ........................................................................ 54 
Recommendation Table 11 ‚Äî Recommendations on indications for 
surgery of concomitant left-sided valvular heart disease .......................... 56 
Recommendation Table 12 ‚Äî Recommendations on indications for 
intervention in patients with mixed moderate aortic stenosis and 
moderate aortic regurgitation (see also Supplementary data online, 
Evidence Table 24) ...................................................................................................... 56 
Recommendation Table 13 ‚Äî Recommendations for prosthetic 
valve selection .............................................................................................................. 57 
Recommendation Table 14 ‚Äî Recommendations for the 
management of antithrombotic therapy in patients with a 
mechanical heart valve ............................................................................................. 59 
Recommendation Table 15 ‚Äî Recommendations for the 
management of antithrombotic therapy in patients with a 
mechanical heart valve undergoing elective non-cardiac surgery or 
invasive procedures ................................................................................................... 60 
Recommendation Table 16 ‚Äî Recommendations for the 
management of antithrombotic therapy in patients with a biological 
heart valve or valve repair ...................................................................................... 62 
Recommendation Table 17 ‚Äî Recommendations for the 
management of prosthetic valve dysfunction (see also 
Supplementary data online, Evidence Table 25) ............................................ 66  
List of tables 
Table 1 Classes of recommendations .................................................................. 7 
Table 2 Levels of evidence ........................................................................................ 7 
Table 3 New recommendations ............................................................................ 9 
Table 4 Revised recommendations .................................................................... 11 
Table 5 Requirements for a Heart Valve Centre ........................................ 17 
Table 6 Complex procedures ideally performed in the most 
experienced Heart Valve Centres ...................................................................... 17 
Table 7 Clinical and echocardiographic criteria predicting outcome 
improvement in patients with severe ventricular secondary mitral 
regurgitation undergoing mitral transcatheter edge-to-edge repair .... 44 
Table 8 Contraindications for percutaneous mitral 
commissurotomy in rheumatic mitral stenosis ............................................. 48 
Table 9 Echocardiographic pitfalls, robust measures, and 
complementary multimodality imaging parameters in multiple or 
mixed valvular heart disease ................................................................................. 55 
Table 10 International normalized ratio targets and therapeutic 
ranges for patients with a mechanical heart valve ....................................... 59 
Table 11 Peri-operative management of antithrombotic treatment 
in patients with a mechanical heart valve undergoing non-cardiac 
surgery based on type of procedure and underlying risk ......................... 60 
Table 12 Criteria for the diagnosis of moderate or severe aortic 
and mitral haemodynamic valve deterioration .......................................... 63 
Table 13 ‚ÄòWhat to do‚Äô and ‚Äòwhat not to do‚Äô ................................................. 73   
List of figures 
Figure 1 The Heart Valve Network ................................................................... 16 
Figure 2 Integrative imaging assessment of patients with valvular 
heart disease ................................................................................................................ 18 
Figure 3 Central illustration. Patient-centred evaluation for 
treatment of valvular heart disease .................................................................... 20 
Figure 4 Imaging assessment of patients with aortic regurgitation ...... 25 
Figure 5 Management of patients with aortic regurgitation .................... 27 
Figure 6 Integrative imaging assessment of patients with aortic 
stenosis ........................................................................................................................... 30 
Figure 7 Management of patients with severe aortic stenosis ............... 32 
Figure 8 Aortic valve treatment options ......................................................... 33 
Figure 9 Factors to be considered when selecting the mode of 
intervention for aortic stenosis ............................................................................ 35 
Figure 10 Echocardiographic assessment of patients with mitral 
regurgitation ................................................................................................................. 38 
Figure 11 Management of patients with severe primary mitral 
regurgitation ................................................................................................................. 39 
Figure 12 Most frequently used criteria for the diagnosis of atrial 
secondary mitral regurgitation ............................................................................. 42 
Figure 13 Treatment of severe secondary mitral regurgitation 
without concomitant coronary artery disease .............................................. 43 
Figure 14 Management of clinically severe rheumatic mitral stenosis 
(mitral valve area ‚â§1.5 cm2) .................................................................................. 47 
Figure 15 Echocardiographic and invasive assessment of tricuspid 
regurgitation ................................................................................................................. 50 
Figure 16 Stepwise evaluation of patients with tricuspid regurgitation
51 
Figure 17 Management of patients with tricuspid regurgitation ............ 52 
Figure 18 Antithrombotic therapy following mechanical heart valve 
implantation ............................................................................................................................... 58 
Figure 19 Antithrombotic therapy following biological heart valve 
implantation or surgical valve repair .................................................................. 61 
Figure 20 Management of left-sided obstructive and non-obstructive 
mechanical heart valve thrombosis .................................................................... 65 
Figure 21 Management of non-cardiac surgery in patients with 
severe aortic stenosis ............................................................................................... 67 
Figure 22 The Pregnancy Heart Team model of care ............................... 68


<!-- PAGE 5 -->

### Page 5

Abbreviations and acronyms 
2D 
Two-dimensional 
3D 
Three-dimensional 
4D 
Four-dimensional 
ACE-I 
Angiotensin-converting enzyme-inhibitor 
ACTIVATION 
PercutAneous Coronary inTervention prIor to 
transcatheter aortic VAlve implantaTION trial 
AF 
Atrial fibrillation 
AO 
Aorta 
AP 
Anteroposterior 
AR 
Aortic regurgitation 
ARB 
Angiotensin receptor blocker 
AS 
Aortic stenosis 
ASA 
Acetylsalicylic acid 
ATLANTIS 
Anti-Thrombotic Strategy to Lower All 
Cardiovascular and Neurologic Ischemic and 
Hemorrhagic Events after Trans-Aortic Valve 
Implantation for Aortic Stenosis 
AU 
Agatston units 
AV 
Aortic valve 
AVA 
Aortic valve area 
AVAi 
Aortic valve area indexed for body surface area 
AVATAR 
Aortic Valve Replacement Versus 
Conservative Treatment in Asymptomatic 
Severe Aortic Stenosis 
AVCS 
Aortic valve calcium score 
AVr 
Aortic valve repair 
BASILICA 
Bioprosthetic or native Aortic Scallop 
Intentional Laceration to prevent Iatrogenic 
Coronary Artery obstruction 
BAV 
Bicuspid aortic valve 
BHV 
Biological heart valve 
BNP 
Brain natriuretic peptide 
BP 
Blood pressure 
BSA 
Body surface area 
CABG 
Coronary artery bypass grafting 
CAD 
Coronary artery disease 
CCT 
Cardiac computed tomography 
CCTA 
Coronary computed tomography 
angiography 
CHA2DS2-VASc 
Congestive heart failure or left ventricular 
dysfunction, hypertension, age ‚â•75 (doubled), 
diabetes, stroke (doubled), vascular disease, 
age 65‚Äì74, sex category (female) 
CI 
Confidence interval 
CIED 
Cardiac implantable electronic device 
CKD 
Chronic kidney disease 
CMR 
Cardiac magnetic resonance 
COAPT 
Cardiovascular Outcomes Assessment of the 
MitraClip Percutaneous Therapy for Heart Failure 
Patients with Functional Mitral Regurgitation 
CRT 
Cardiac resynchronization therapy 
CT 
Computed tomography 
CW 
Continuous wave 
CYP 
Cytochrome P 
DAPT 
Dual antiplatelet therapy 
DEDICATE 
Randomized, Multicenter, Event-Driven Trial 
of TAVI versus SAVR in Patients with 
Symptomatic Severe Aortic-Valve Stenosis 
DOAC 
Direct oral anticoagulant  
DSE 
Dobutamine stress echocardiography 
DVI 
Doppler velocity index 
EACTS 
European Association for Cardio-Thoracic 
Surgery 
EARLY TAVR 
Evaluation of TAVR Compared to Surveillance 
for Patients with Asymptomatic Severe Aortic 
Stenosis trial 
ECG 
Electrocardiogram 
EDV 
End-diastolic velocity 
ENVISAGE-TAVI AF 
Edoxaban vs. Standard of Care and Their 
Effects on Clinical Outcomes in Patients 
Having Undergone Transcatheter Aortic Valve 
Implantation‚ÄìAtrial Fibrillation 
EOA 
Effective orifice area 
EROA 
Effective regurgitant orifice area 
ESC 
European Society of Cardiology 
EuroSCORE 
European System for Cardiac Operative Risk 
Evaluation 
EVoLVeD 
Early Valve Replacement guided by Biomarkers 
of LV Decompensation in Asymptomatic 
Patients with Severe Aortic Stenosis 
FAC 
Fractional area change 
FFR 
Fractional flow reserve 
FWS 
Free wall strain 
GALILEO 
Global multicenter, open-label, randomized, 
event-driven, active-controlled study 
comparing a rivAroxaban-based 
antithrombotic strategy to an 
antipLatelet-based strategy after transcatheter 
aortIc vaLve rEplacement (TAVR) to Optimize 
clinical outcomes trial 
GDMT 
Guideline-directed medical therapy 
GLS 
Global longitudinal strain 
h 
Hour 
HALT 
Hypo-attenuated leaflet thickening 
HF 
Heart failure 
HFpEF 
Heart failure with preserved ejection fraction 
HFrEF 
Heart failure with reduced ejection fraction 
HR 
Hazard ratio 
HTx 
Heart transplantation 
INR 
International normalized ratio 
IU 
International unit 
KCCQ 
Kansas City Cardiomyopathy Questionnaire 
LA 
Left atrium/left atrial 
LAAO 
Left atrial appendage occlusion 
LAAOS 
Left Atrial Appendage Occlusion Study 
LAMPOON 
Laceration of the Anterior Mitral leaflet to 
Prevent Outflow ObstructioN 
LAVI 
Left atrial volume index 
LMWH 
Low-molecular-weight heparin 
LV 
Left ventricle/left ventricular 
LVAD 
Left ventricular assist device 
LVEF 
Left ventricular ejection fraction 
LVESD 
Left ventricular end-systolic diameter 
LVESDi 
Left ventricular end-systolic diameter indexed 
to BSA 
LVESVi 
Left ventricular end-systolic volume indexed to 
BSA 
LVOT 
Left ventricular outflow tract 
MA 
Mitral annulus  
ESC Guidelines                                                                                                                                                                                                 5


<!-- PAGE 6 -->

### Page 6

MAC 
Mitral annular calcification 
MATTERHORN 
Multicenter, Randomized, Controlled Study to 
Assess Mitral Valve Reconstruction for 
Advanced Insufficiency of Functional or 
Ischemic Origin trial 
MHV 
Mechanical heart valve 
MITRA-FR 
Percutaneous Repair with the MitraClip 
Device for Severe Functional/Secondary Mitral 
Regurgitation trial 
mPAP 
Mean pulmonary artery pressure 
MR 
Mitral regurgitation 
MRI 
Magnetic resonance imaging 
MS 
Mitral stenosis 
M-TEER 
Mitral transcatheter edge-to-edge repair 
MV 
Mitral valve 
MVA 
Mitral valve area 
MVHD 
Multiple valvular heart disease 
N 
No 
NCS 
Non-cardiac surgery 
NOTION 
Nordic Aortic Valve Intervention trial 
NT-proBNP 
N-terminal pro-B-type natriuretic protein 
NYHA 
New York Heart Association 
OAC 
Oral anticoagulation 
PAWP 
Pulmonary artery wedge pressure 
PCI 
Percutaneous coronary intervention 
PET 
Positron emission tomography 
PH 
Pulmonary hypertension 
PHT 
Pressure half-time 
PISA 
Proximal isovelocity surface area 
P mean 
Mean pressure gradient 
PMC 
Percutaneous mitral commissurotomy 
PMR 
Primary mitral regurgitation 
POPular TAVI 
Antiplatelet Therapy for Patients Undergoing 
Transcatheter Aortic Valve Implantation 
PPM 
Prosthesis‚Äìpatient mismatch 
PROM 
Patient-reported outcome measure 
PVL 
Paravalvular leak 
PVR 
Pulmonary vascular resistance 
RA 
Right atrium/right atrial 
RCT 
Randomized controlled trial 
RECOVERY 
Randomized Comparison of Early Surgery 
versus Conventional Treatment in Very Severe 
Aortic Stenosis 
RESHAPE-HF2 
Randomized Investigation of the MitraClip 
Device in Heart Failure: 2nd Trial in Patients 
with Clinically Significant Functional Mitral 
Regurgitation 
RF 
Regurgitant fraction 
RHC 
Right heart catheterization 
RHD 
Rheumatic heart disease 
RV 
Right ventricle/right ventricular 
RVEF 
Right ventricular ejection fraction 
RVol 
Regurgitant volume 
SAM 
Systolic anterior movement 
SAPT 
Single antiplatelet therapy 
SAV 
Surgical aortic valve 
SAVR 
Surgical aortic valve replacement 
SGLT2i 
Sodium‚Äìglucose co-transporter 2 inhibitor 
SMR 
Secondary mitral regurgitation  
SPAP 
Systolic pulmonary artery pressure 
STS 
Society of Thoracic Surgeons 
STS-PROM 
Society of Thoracic Surgeons predicted risk of 
mortality 
SVD 
Structural valve deterioration 
SVi 
Stroke volume index 
TAPSE 
Tricuspid annular plane systolic excursion 
TAV 
Transcatheter aortic valve 
TAVI 
Transcatheter aortic valve implantation 
TDI 
Tissue Doppler imaging 
TEER 
Transcatheter edge-to-edge repair 
THV 
Transcatheter heart valve 
TMVI 
Transcatheter mitral valve implantation 
TOE 
Transoesophageal echocardiography 
TR 
Tricuspid regurgitation 
TRILUMINATE 
Clinical Trial to Evaluate Cardiovascular 
Outcomes in Patients Treated With the 
Tricuspid Valve Repair System trial 
TRISCEND 
Edwards EVOQUE Transcatheter Tricuspid 
Valve Replacement: Pivotal Clinical 
Investigation of Safety and Clinical Efficacy 
using a Novel Device 
TS 
Tricuspid stenosis 
TTE 
Transthoracic echocardiography 
TTR 
Time in therapeutic range 
TV 
Tricuspid valve 
UFH 
Unfractionated heparin 
VCA 
Vena contracta area 
VHD 
Valvular heart disease 
VKA 
Vitamin K antagonist 
Vmax 
Peak transvalvular velocity 
VSARR 
Valve-sparing aortic root replacement 
VTE 
Venous thromboembolism 
VTI 
Velocity time integral 
WHO 
World Health Organisation 
WU 
Wood unit 
Y 
Yes 
1. Preamble 
Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic 
approach for an individual patient with a given condition. ESC/EACTS 
Guidelines are intended for use by health professionals but do not override 
their individual responsibility to make appropriate and accurate decisions 
in consideration of each patient‚Äôs health condition and in consultation with 
the patient or the patient‚Äôs caregiver where appropriate and/or necessary. 
It is also the health professional‚Äôs responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and to respect the ethical rules of their profession. 
ESC Guidelines represent the official position of the ESC on a given 
topic. Guideline topics are selected for updating after annual expert review of new evidence conducted by the ESC Clinical Practice 
Guidelines (CPG) Committee. ESC Policies and Procedures for formulating and issuing ESC Guidelines can be found on the ESC website 
(https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/ 
Guidelines-development/Writing-ESC-Guidelines). 
This guideline updates and replaces the previous version from 2021. This 
Task Force was selected by the ESC and the EACTS to include professionals


<!-- PAGE 7 -->

### Page 7

involved with the medical care of patients with this pathology and to include 
patient representatives and methodologists. The selection procedure included an open call for authors and aimed to include members from across 
the whole of the ESC region and from relevant ESC Subspecialty 
Communities. Consideration was given to diversity and inclusion. 
Guidelines Task Forces perform a critical review and evaluation of the 
published literature on diagnostic and therapeutic approaches including 
assessment of the risk‚Äìbenefit ratio. Recommendations are based on 
major randomized trials and relevant systematic reviews and 
meta-analyses, when available. Systematic literature searches are conducted in cases of controversy or uncertainty to ensure that all key 
studies were considered. For recommendations related to diagnosis 
and prognosis, additional types of evidence are included, such as diagnostic accuracy studies and studies focused on the development and validation of prognostic models. The strength of each recommendation and 
the level of evidence supporting it are weighed and scored according 
to pre-defined criteria as outlined in Tables 1 and 2. Patient-Reported 
Outcome Measures (PROMs) and Patient-Reported Experience 
Measures (PREMs) are also evaluated when available as the basis for recommendations and/or discussion in these guidelines. 
Evidence tables summarizing key information from relevant studies 
are generated to facilitate the formulation of recommendations, to 
Table 1 Classes of recommendations  
¬©

	

	


	


	
	¬Å
	¬ç
¬è	
					


¬ê¬ù
	


¬ç
			

¬†	

¬≠	
	

	




	


	
¬Å
		
¬ù¬ç


 
¬Ä¬ê¬ù	¬Ç

	¬ù			¬ç
¬É¬ù	


¬†	
					
¬ê¬ù¬ç
	

Table 2 Levels of evidence  







	
		
	


		
							
					
¬©¬Å¬ç¬Å¬è¬ê¬è¬ù
ESC Guidelines                                                                                                                                                                                                 7


<!-- PAGE 8 -->

### Page 8

enhance comprehension of recommendations after publication, and to 
reinforce transparency in the guidelines development process. The tables are published in their own section of the guidelines and reference 
specific recommendation tables. 
After an iterative process of deliberations, a first Task Force vote on 
all recommendations is conducted prior to the initiation of rounds of 
review. A second Task Force vote on all recommendations is conducted after the final round of review and revision. For each vote, 
the Task Force follows ESC voting procedures and all recommendations require at least 75% agreement among voting members to be approved. Voting restrictions may be applied based on declarations of 
interests. 
The writing and reviewing panels provide declaration-of-interest 
forms for all relationships that might be perceived as real or potential 
sources of conflicts of interest. Their declarations of interest are reviewed according to the ESC declaration-of-interest rules, which can 
be found on the ESC website (http://www.escardio.org/doi) and are 
compiled in a report published in a supplementary document with 
the guidelines. Funding for the development of these ESC/EACTS 
Guidelines was derived entirely from the ESC and the EACTS with 
no involvement of the healthcare industry. 
The ESC CPG Committee supervises and co-ordinates the preparation of new guidelines and approves their publication. In addition to 
review by the ESC CPG Committee, these ESC/EACTS Guidelines 
underwent multiple rounds of double-blind peer review on a dedicated 
online review platform. The review was conducted by topic experts, including members from ESC National Cardiac Societies, EACTS 
Network of National Cardiac Surgery Societies and from relevant 
ESC Subspecialty Communities. The Guideline Task Force considered 
all review comments and was required to respond to all those classified 
as major. After appropriate revisions, the Task Force, the ESC CPG 
Committee members and the EACTS Council members approved 
the final document for publication in the European Heart Journal and 
in the European Journal of Cardio-Thoracic Surgery. 
Unless otherwise stated, the guideline content refers to sex, understood as the biological condition of being male or female, defined by 
genes, hormones, and sexual organs. Off-label use of medication may 
be presented in this guideline if a sufficient level of evidence shows 
that it can be considered medically appropriate for a given condition. 
However, decisions on off-label use must be made by the responsible 
health professional giving special consideration to ethical rules concerning healthcare, the specific situation of the patient, patient consent, and 
country-specific health regulations. 
2. Introduction 
New evidence has accumulated since the publication of the 2021 
European Society of Cardiology (ESC)/European Association for 
Cardio-Thoracic Surgery (EACTS) Guidelines for the management of valvular 
heart disease, leading to the need for new recommendations (Table 3 
New recommendations) and revision of existing recommendations 
(Table 4 Revised recommendations) concerning the following topics: 
‚Ä¢ The importance of shared and patient-centred decision-making by 
multidisciplinary expert Heart Teams working within a regional network has been reinforced. Patients with complex conditions or requiring complex procedures should be referred to high-volume 
centres, where corresponding expertise is concentrated to ensure 
high-quality treatment. 
‚Ä¢ Advanced imaging modalities‚Äîsuch as three-dimensional (3D) echocardiography, cardiac computed tomography (CCT), and cardiac 
magnetic resonance (CMR) imaging‚Äîhave gained importance and 
become a central aspect in the screening and evaluation of patients 
with valvular heart disease (VHD). 
‚Ä¢ Emphasis is put on the importance of correctly assessing the cause(s) 
and mechanism(s) of all valve diseases. In particular, the distinction 
between atrial and ventricular secondary mitral regurgitation (SMR) 
has clear implications in terms of prognosis and management. 
‚Ä¢ New evidence has been published regarding the benefits of 
intervention for the treatment of severe aortic stenosis (AS) irrespective of symptoms, left ventricular ejection fraction (LVEF), and 
flow reserve. 
‚Ä¢ The criteria used for decision-making concerning the optimal modality of AS treatment [transcatheter aortic valve (AV) implantation 
(TAVI) or surgical AV replacement (SAVR)] based on a Heart Team 
approach have been refined, including the combination of key aspects 
such as age, procedural risk, and anatomical suitability, incorporating 
estimated life expectancy and lifetime management considerations. 
‚Ä¢ Further randomized evidence confirming the mid-term safety and efficacy of TAVI in low-risk patients has been published. 
‚Ä¢ The indications for TAVI in patients with bicuspid AV (BAV) stenosis 
or severe aortic regurgitation (AR) at high surgical risk, based on anatomical suitability and a comprehensive Heart Team evaluation, are 
discussed. 
‚Ä¢ Several advancements have been made regarding the treatment of 
patients with primary mitral regurgitation (PMR): refinement of the 
criteria for intervention in asymptomatic patients; demonstration 
of the value of minimally invasive mitral valve (MV) surgery to reduce 
the length of hospital stay and accelerate recovery; and large-scale 
data confirming the role of transcatheter edge-to-edge repair 
(TEER) in high-risk patients. 
‚Ä¢ Longer-term follow-up data and two new randomized controlled 
trials (RCTs) concerning the management of patients with ventricular 
SMR have been published. 
‚Ä¢ The evidence for the treatment of tricuspid valve (TV) disease is 
growing‚Äîincluding new randomized data supporting concomitant 
TV repair during left-sided valve surgery, and transcatheter options 
(repair and replacement) that reduce tricuspid regurgitation (TR), 
promote reverse right ventricular (RV) remodelling, and improve 
quality of life compared with medical treatment. 
‚Ä¢ Efforts have been made to provide improved guidance regarding the 
diagnostic steps and management of patients with multiple and mixed 
VHD. 
‚Ä¢ Definitions of structural valve deterioration (SVD) have been updated and unified. 
‚Ä¢ The recommendations concerning the use of direct oral anticoagulants (DOACs) in patients with VHD have been updated, and the importance of education and (self-)monitoring is emphasized. 
‚Ä¢ Sex-specific considerations in patients with VHD have been extended and regrouped into a new dedicated section (see Section 17).   
Because of demographic changes, patients with VHD frequently 
present with concomitant cardiovascular diseases, increasing the complexity of treatment strategies. These Guidelines focus on acquired


<!-- PAGE 9 -->

### Page 9

VHD and do not deal in detail with overlapping cardiovascular diseases 
such as infective endocarditis,5 chronic coronary syndrome,6 and atrial 
fibrillation (AF),7 as well as all scenarios of aortic or congenital disease,8,9 because these topics are covered in separate Guidelines. 
The 2025 ESC/EACTS Guidelines for the management of valvular heart 
disease aim to be concise, focused on relevant issues for clinicians and 
patients, and to provide clear and simple practical recommendations, 
assisting healthcare providers in their daily clinical decision-making. A 
compilation of the evidence considered for new recommendations, or 
those with an updated class of recommendation or level of evidence, 
can be consulted online (see Supplementary data online, Evidence 
Tables). The Task Force for these Guidelines acknowledges that 
multiple factors influence and ultimately determine the most appropriate treatment of individual patients within a given community. 
These factors include the availability of equipment and technology, 
and the expertise and volumes, in complex procedures, such as valve 
repair or transcatheter interventions. Moreover, given the lack of evidence on some topics related to VHD, several recommendations are 
the result of expert consensus opinion. Therefore, deviations from 
these Guidelines may be appropriate in certain clinical circumstances, 
and decision-making should always be based on a collaborative, multidisciplinary Heart Team approach centred on individual characteristics, needs, and prognosis, as well as the preferences of the informed 
patient. 
2.1. What is new  
Table 3 New recommendations 
Recommendations 
Classa 
Levelb  
Diagnosis of coronary artery disease‚ÄîSection 6.1 
Omission of invasive coronary angiography should be considered in TAVI candidates, if procedural planning CT angiography is of sufficient 
quality to rule out significant CAD. 
IIa 
B 
PCI should be considered in patients with a primary indication to undergo TAVI and ‚â•90% coronary artery stenosis in segments with a 
reference diameter ‚â•2.5 mm. 
IIa 
B 
Indications for intervention in severe aortic regurgitation‚ÄîSection 7.4 
TAVI may be considered for the treatment of severe AR in symptomatic patients ineligible for surgery according to the Heart Team, if the 
anatomy is suitable. 
IIb 
B 
Indications for intervention in symptomatic and asymptomatic severe aortic stenosis, and recommended mode of intervention‚ÄîSection 8.5 
Intervention should be considered in asymptomatic patients (confirmed by a normal exercise test, if feasible) with severe, high-gradient AS 
and LVEF ‚â•50%, as an alternative to close active surveillance, if the procedural risk is low. 
IIa 
A 
TAVI may be considered for the treatment of severe BAV stenosis in patients at increased surgical risk, if the anatomy is suitable. 
IIb 
B 
Indications for intervention in severe primary mitral regurgitation‚ÄîSection 9.1 
Surgical MV repair is recommended in low-risk asymptomatic patients with severe PMR without LV dysfunction (LVESD <40 mm, LVESDi  
<20 mm/m2, and LVEF >60%) when a durable result is likely, if at least three of the following criteria are fulfilled: 
‚Ä¢ AF 
‚Ä¢ SPAP at rest >50 mmHg 
‚Ä¢ LA dilatation (LAVI ‚â•60 mL/m2 or LA diameter ‚â•55 mm) 
‚Ä¢ Concomitant secondary TR ‚â• moderate. 
I 
B 
Minimally invasive MV surgery may be considered at experienced centres to reduce the length of stay and accelerate recovery. 
IIb 
B 
Indications for intervention in secondary mitral regurgitation‚ÄîSection 9.2 
MV surgery, surgical AF ablation, if indicated, and LAAO should be considered in symptomatic patients with severe atrial SMR under optimal 
medical therapy. 
IIa 
B 
TEER may be considered in symptomatic patients with severe atrial SMR not eligible for surgery after optimization of medical therapy 
including rhythm control, when appropriate. 
IIb 
B 
MV surgery may be considered in patients with moderate SMR undergoing CABG. 
IIb 
B 
Indications for mitral valve surgery and transcatheter intervention in clinically severe rheumatic and degenerative mitral stenosis‚Äî 
Section 10.3 
TMVI may be considered in symptomatic patients with extensive MAC and severe MV dysfunction at experienced Heart Valve Centres with 
expertise in complex MV surgery and transcatheter interventions. 
IIb 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                                 9


<!-- PAGE 10 -->

### Page 10

Indications for intervention in tricuspid regurgitation‚ÄîSection 11.4 
Careful evaluation of TR aetiology, stage of the disease (i.e. degree of TR severity, RV and LV dysfunction, and PH), patient operative risk, 
and likelihood of recovery by a multidisciplinary Heart Team is recommended in patients with severe TR prior to intervention. 
I 
C 
Surgery of concomitant severe mitral regurgitation‚ÄîSection 13.3 
MV surgery is recommended in patients with severe MR undergoing surgery for another valve. 
I 
C 
Indications for intervention in patients with mixed moderate aortic stenosis and moderate aortic regurgitation‚ÄîSection 13.3 
Intervention is recommended in symptomatic patients with mixed moderate AV stenosis and moderate regurgitation, and a mean 
gradient ‚â•40 mmHg or Vmax ‚â•4.0 m/s. 
I 
B 
Intervention is recommended in asymptomatic patients with mixed moderate AV stenosis and moderate regurgitation, with Vmax ‚â•4.0 m/s 
and LVEF <50% not attributable to other cardiac disease. 
I 
C 
Prosthetic valve selection‚ÄîSection 14.1 
An MHV should be considered in patients with an estimated long life expectancy, if there are no contraindications for long-term OAC. 
IIa 
B 
Management of antithrombotic therapy in patients with a mechanical heart valve‚ÄîSection 14.3 
It is recommended that INR targets are based on the type and position of MHV, patient‚Äôs risk factors, and comorbidities. 
I 
A 
Patient education is recommended to improve the quality of OAC. 
I 
A 
Management of antithrombotic therapy in patients with mechanical heart valves undergoing elective non-cardiac surgery or invasive 
procedures‚ÄîSection 14.3 
Continuing VKA treatment is recommended in patients with an MHV for minor or minimally invasive interventions associated with no or 
minimal bleeding. 
I 
A 
Interruption (3‚Äì4 days before surgery), and resumption of VKA without bridging, may be considered to reduce bleeding in patients with 
new-generation aortic MHV and no other thromboembolic risk factors undergoing major non-cardiac surgery or invasive procedures. 
IIb 
B 
Management of antithrombotic therapy in patients with a biological heart valve or valve repair‚ÄîSection 14.3 
Surgical biological heart valve without indication for oral anticoagulation 
Lifelong low-dose ASA (75‚Äì100 mg/day) may be considered 3 months after surgical implantation of an aortic or mitral BHV in patients 
without clear indication for OAC. 
IIb 
C 
Transcatheter aortic valve implantation without indication for oral anticoagulation 
DAPT is not recommended to prevent thrombosis after TAVI, unless there is a clear indication. 
III 
B 
Surgical repair without indication for oral anticoagulation 
Low-dose ASA (75‚Äì100 mg/day) may be considered after surgical MV or TV repair in preference to OAC in patients without clear 
indication for OAC and at high bleeding risk. 
IIb 
B 
Surgical biological heart valve with indication for oral anticoagulation 
OAC continuation is recommended in patients with a clear indication for OAC undergoing surgical BHV implantation. 
I 
B 
DOAC continuation may be considered after surgical BHV implantation in patients with an indication for DOAC. 
IIb 
B 
Surgical repair with indication for oral anticoagulation and/or antiplatelet therapy 
Continuation of OAC or antiplatelet therapy should be considered after surgical valve repair in patients with a clear indication for an 
antithrombotic therapy. 
IIa 
B 
Management of mechanical heart valve failure‚ÄîSection 14.4 
Reoperation is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. 
I 
C 
Management of valve thrombosis‚ÄîSection 14.4 
TOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis. 
I 
C 
¬© ESC/EACTS 2025
4D, four-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; BAV, bicuspid aortic valve; BHV, biological heart valve; CABG, 
coronary artery bypass grafting; CAD, coronary artery disease; CT, computed tomography; DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; INR, international normalized 
ratio; LA, left atrium/left atrial; LAAO, left atrial appendage occlusion; LAVI, left atrial volume index; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left 
ventricular end-systolic diameter; LVESDi, left ventricular end-systolic diameter indexed to body surface area; MAC, mitral annular calcification; MHV, mechanical heart valve; MR, mitral 
regurgitation; MV, mitral valve; OAC, oral anticoagulation; PCI, percutaneous coronary intervention; PH, pulmonary hypertension; PMR, primary mitral regurgitation; RV, right ventricle/right 
ventricular; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery pressure; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TMVI, 
transcatheter mitral valve implantation; TOE, transoesophageal echocardiography; TR, tricuspid regurgitation; TV, tricuspid valve; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 11 -->

### Page 11

Table 4 Revised recommendations 
Recommendations in 2021 version 
Classa 
Levelb 
Recommendations in 2025 version 
Classa 
Levelb  
Management of coronary artery disease in patients with valvular heart disease‚ÄîSection 6.1 
CCTA should be considered as an alternative to 
coronary angiography before valve surgery in patients 
with severe VHD and low probability of CAD. 
IIa 
C 
CCTA is recommended before valve intervention in 
patients with moderate or lower (‚â§50%) pre-test 
likelihood of obstructive CAD. 
I 
B 
Coronary angiography is recommended before valve 
surgery in patients with severe VHD and any of the 
following: 
‚Ä¢ History of cardiovascular disease 
‚Ä¢ Suspected myocardial ischaemia 
‚Ä¢ LV systolic dysfunction 
‚Ä¢ In men >40 years of age and post-menopausal women 
‚Ä¢ One or more cardiovascular risk factors. 
I 
C 
Invasive coronary angiography is recommended before 
valve intervention in patients with high and very high 
(>50%) pre-test likelihood of obstructive CAD. 
I 
C 
Coronary angiography is recommended in the 
evaluation of severe SMR. 
I 
C 
Invasive coronary angiography is recommended in the 
evaluation of CAD in patients with severe ventricular SMR. 
I 
C 
PCI should be considered in patients with a primary 
indication to undergo TAVI and coronary artery 
diameter stenosis >70% in proximal segments. 
IIa 
C 
PCI may be considered in patients with a primary 
indication to undergo transcatheter valve interventions 
and coronary artery stenosis ‚â•70% in proximal 
segments of main vessels. 
IIb 
B 
PCI should be considered in patients with a primary 
indication to undergo transcatheter MV intervention 
and coronary artery diameter stenosis >70% in 
proximal segments. 
IIa 
C 
Management of atrial fibrillation in patients with native valvular heart disease‚ÄîSection 6.2 
LAAO should be considered to reduce the 
thromboembolic risk in patients with AF and a 
CHA2DS2-VASc score ‚â•2 undergoing valve surgery. 
IIa 
B 
Surgical closure of the LA appendage is recommended 
as an adjunct to OAC in patients with AF undergoing 
valve surgery to prevent cardioembolic stroke and 
systemic thromboembolism. 
I 
B 
Concomitant AF ablation should be considered in 
patients undergoing valve surgery, balancing the benefits 
of freedom from atrial arrhythmias and the risk factors 
for recurrence (LA dilatation, years in AF, age, renal 
dysfunction, and other cardiovascular risk factors). 
IIa 
A 
Concomitant surgical ablation is recommended in 
patients undergoing MV surgery with AF suitable for a 
rhythm control strategy to prevent symptoms and 
recurrence of AF, according to an experienced team of 
electrophysiologists and arrhythmia surgeons. 
I 
A 
Concomitant surgical ablation should be considered in 
patients undergoing non-MV surgery with AF suitable 
for a rhythm control strategy to prevent symptoms and 
recurrence of AF, according to an experienced team of 
electrophysiologists and arrhythmia surgeons. 
IIa 
B 
The use of DOACs is not recommended in patients 
with AF and moderate-to-severe MS. 
III 
C 
The use of DOACs is not recommended in patients 
with AF and rheumatic MS with an MVA ‚â§2.0 cm2. 
III 
B 
Indications for surgery in severe aortic regurgitation‚ÄîSection 7.4 
AV repair may be considered in selected patients at 
experienced centres when durable results are 
expected. 
IIb 
C 
AV repair should be considered in selected patients 
with severe AR at experienced centres, when durable 
results are expected. 
IIa 
B 
Surgery may be considered in asymptomatic patients 
with LVESD >20 mm/m2 BSA (especially in patients 
with small body size) or resting LVEF ‚â§55%, if surgery is 
at low risk. 
IIb 
C 
AV surgery may be considered in asymptomatic 
patients with severe AR and LVESDi >22 mm/m2 or 
LVESVi >45 mL/m2 [especially in patients with small 
body size (BSA <1.68 m2)], or resting LVEF ‚â§55%, if 
surgical risk is low. 
IIb 
B 
Indications for intervention in symptomatic severe aortic stenosis‚ÄîSection 8.4.1 
Intervention is recommended in symptomatic patients 
with severe low-flow (SVi ‚â§35 mL/m2), low-gradient 
(<40 mmHg) AS with reduced LVEF (<50%), and 
evidence of flow (contractile) reserve. 
I 
B 
Intervention is recommended in symptomatic patients 
with low-flow (SVi ‚â§35 mL/m2), low-gradient 
(<40 mmHg) AS with reduced LVEF (<50%) after 
careful confirmation that AS is severe. 
I 
B                       
Continued  
ESC Guidelines                                                                                                                                                                                               11


<!-- PAGE 12 -->

### Page 12

Intervention should be considered in symptomatic 
patients with low-flow, low-gradient (<40 mmHg) AS 
with normal LVEF after careful confirmation that the AS 
is severe. 
IIa 
C 
Intervention should be considered in symptomatic 
patients with low-flow (SVi ‚â§35 mL/m2), low-gradient 
(<40 mmHg) AS with normal LVEF (‚â•50%) after 
careful confirmation that AS is severe. 
IIa 
B 
Indications for intervention in asymptomatic severe aortic stenosis‚ÄîSection 8.5 
Intervention should be considered in asymptomatic 
patients with severe AS and LV dysfunction (LVEF  
<55%) without another cause. 
IIa 
B 
Intervention should be considered in asymptomatic 
patients with severe AS and LVEF ‚â•50%, if the 
procedural risk is low and one of the following 
parameters is present: 
‚Ä¢ Very severe AS (mean gradient ‚â•60 mmHg or Vmax  
>5.0 m/s). 
‚Ä¢ Severe valve calcification (ideally assessed by CCT) 
and Vmax progression ‚â•0.3 m/s/year. 
‚Ä¢ Markedly elevated BNP/NT-proBNP levels (more 
than three times age- and sex-corrected normal 
range, confirmed on repeated measurement without 
other explanation). 
‚Ä¢ LVEF <55% without another cause. 
IIa 
B 
Intervention should be considered in asymptomatic 
patients with LVEF >55% and a normal exercise test if 
the procedural risk is low and one of the following 
parameters is present: 
‚Ä¢ Very severe AS (mean gradient ‚â•60 mmHg or Vmax  
>5 m/s). 
‚Ä¢ Severe valve calcification (ideally assessed by CCT) 
and Vmax progression ‚â•0.3 m/s/year. 
‚Ä¢ Markedly elevated BNP levels (more than three times 
age- and sex-corrected normal range) confirmed by 
repeated measurements and without other 
explanation. 
IIa 
B 
Mode of intervention in symptomatic severe aortic stenosis‚ÄîSection 8.5 
The choice between surgical and transcatheter 
intervention must be based upon careful evaluation of 
clinical, anatomical, and procedural factors by the Heart 
Team, weighing the risks and benefits of each approach 
for an individual patient. The Heart Team 
recommendation should be discussed with the patient 
who can then make an informed treatment choice. 
I 
C 
It is recommended that the mode of intervention is 
based on Heart Team assessment of individual clinical, 
anatomical, and procedural characteristics, 
incorporating lifetime management considerations and 
estimated life expectancy. 
I 
C 
TAVI is recommended in older patients (‚â•75 years), or 
in those who are high risk (STS-PROM/EuroSCORE II  
>8%) or unsuitable for surgery. 
I 
A 
TAVI is recommended in patients ‚â•70 years of age with 
tricuspid AV stenosis, if the anatomy is suitable. 
I 
A 
SAVR is recommended in younger patients who are low 
risk for surgery (<75 years and STS-PROM/ 
EuroSCORE II <4%), or in patients who are operable 
and unsuitable for transfemoral TAVI. 
I 
B 
SAVR is recommended in patients <70 years of age, if 
the surgical risk is low. 
I 
B 
SAVR or TAVI are recommended for remaining 
patients according to individual clinical, anatomical, and 
procedural characteristics. 
I 
B 
SAVR or TAVI are recommended for all remaining 
candidates for an aortic BHV according to Heart Team 
assessment.1‚Äì4 
I 
B 
Non-transfemoral TAVI may be considered in patients 
who are inoperable and unsuitable for transfemoral 
TAVI. 
IIb 
C 
Non-transfemoral TAVI should be considered in 
patients who are unsuitable for surgery and 
transfemoral access. 
IIa 
B 
Indications for intervention in severe primary mitral regurgitation‚ÄîSection 9.1.4 
Surgery should be considered in asymptomatic patients 
with preserved LV function (LVESD <40 mm and LVEF  
>60%) and AF secondary to MR or PH (SPAP at rest  
>50 mmHg). 
IIa 
B 
MV surgery should be considered in asymptomatic 
patients with severe PMR without LV dysfunction 
(LVESD <40 mm, LVESDi <20 mm/m2, and LVEF  
>60%) in the presence of PH (SPAP at rest  
>50 mmHg), or AF secondary to MR. 
IIa 
B 
Surgical MV repair should be considered in low-risk 
asymptomatic patients with LVEF >60%, LVESD  
<40 mm, and significant LA dilatation (volume 
index ‚â•60 mL/m2 or diameter ‚â•55 mm) when 
performed in a Heart Valve Centre and a durable repair 
is likely. 
IIa 
B 
Surgical MV repair should be considered in low-risk 
asymptomatic patients with severe PMR without LV 
dysfunction (LVESD <40 mm, LVESDi <20 mm/m2, 
and LVEF >60%) in the presence of significant LA 
dilatation (LAVI ‚â•60 mL/m2 or LA diameter ‚â•55 mm), 
when performed in a Heart Valve Centre and a durable 
repair is likely. 
IIa 
B                         
Continued


<!-- PAGE 13 -->

### Page 13

TEER may be considered in symptomatic patients who 
fulfil the echocardiographic criteria of eligibility, are judged 
inoperable or at high surgical risk by the Heart Team, and 
for whom the procedure is not considered futile. 
IIb 
B 
TEER should be considered in symptomatic patients 
with severe PMR who are anatomically suitable and at 
high surgical risk according to the Heart Team. 
IIa 
B 
Severe ventricular secondary mitral regurgitation and concomitant coronary artery disease‚ÄîSection 9.2 
In symptomatic patients who are judged not 
appropriate for surgery by the Heart Team on the basis 
of their individual characteristics, PCI (and/or TAVI) 
possibly followed by TEER (in case of persisting severe 
SMR) should be considered. 
IIa 
C 
PCI followed by TEER after re-evaluation of MR may be 
considered in symptomatic patients with chronic severe 
ventricular SMR and non-complex CAD. 
IIb 
C 
Indications for intervention in severe ventricular secondary mitral regurgitation without concomitant coronary artery disease‚ÄîSection 9.2 
TEER should be considered in selected symptomatic 
patients not eligible for surgery and fulfilling criteria 
suggesting an increased chance of responding to the 
treatment. 
IIa 
B 
TEER is recommended to reduce HF hospitalizations 
and improve quality of life in haemodynamically stable, 
symptomatic patients with impaired LVEF (<50%) and 
persistent severe ventricular SMR, despite optimized 
GDMT and CRT (if indicated), fulfilling specific clinical 
and echocardiographic criteria. 
I 
A 
In high-risk symptomatic patients not eligible for surgery 
and not fulfilling the criteria suggesting an increased 
chance of responding to TEER, the Heart Team may 
consider in selected cases a TEER procedure or other 
transcatheter valve therapy if applicable, after careful 
evaluation for ventricular assist device or heart 
transplant. 
IIb 
C 
TEER may be considered for symptom improvement in 
selected symptomatic patients with severe ventricular 
SMR not fulfilling the specific clinical and 
echocardiographic criteria, after careful evaluation of 
LVAD or HTx. 
IIb 
B 
Valve surgery may be considered in symptomatic 
patients judged appropriate for surgery by the Heart 
Team. 
IIb 
C 
MV surgery may be considered in symptomatic patients 
with severe ventricular SMR without advanced HF who 
are not suitable for TEER. 
IIb 
C 
Indications for intervention in tricuspid regurgitation in patients with left-sided valvular heart disease requiring surgery‚ÄîSection 11.4 
Surgery is recommended in patients with severe 
primary TR undergoing left- sided valve surgery. 
I 
C 
Concomitant TV surgery is recommended in patients 
with severe primary or secondary TR. 
I 
B 
Surgery is recommended in patients with severe 
secondary TR undergoing left-sided valve surgery. 
I 
B 
Surgery should be considered in patients with moderate 
primary TR undergoing left-sided valve surgery. 
IIa 
C 
Concomitant TV repair should be considered in 
patients with moderate primary or secondary TR, to 
avoid progression of TR and RV remodelling. 
IIa 
B 
Surgery should be considered in patients with mild or 
moderate secondary TR with a dilated annulus 
(‚â•40 mm or >21 mm/m2 by 2D echocardiography) 
undergoing left-sided valve surgery. 
IIa 
B 
Concomitant TV repair may be considered in selected 
patients with mild secondary TR and tricuspid annulus 
dilatation (‚â•40 mm or >21 mm/m2) to avoid 
progression of TR and RV remodelling. 
IIb 
B 
Indications for intervention in patients with severe tricuspid regurgitation without left-sided valvular heart disease requiring surgery‚Äî 
Section 11.4 
Transcatheter treatment of symptomatic secondary 
severe TR may be considered in inoperable patients at a 
Heart Valve Centre with expertise in the treatment of 
TV disease. 
IIb 
C 
Transcatheter TV treatment should be considered to 
improve quality of life and RV remodelling in high-risk 
patients, with symptomatic severe TR despite optimal 
medical therapy, in the absence of severe RV 
dysfunction or pre-capillary PH. 
IIa 
A 
Prosthetic valve selection‚ÄîSection 14.1 
A mechanical prosthesis may be considered in patients 
already on long-term anticoagulation due to the high 
risk for thromboembolism. 
IIb 
C 
An MHV may be considered in patients with a clear 
indication for long-term OAC. 
IIb 
C 
Management of antithrombotic therapy in patients with a mechanical heart valve‚ÄîSection 14.3 
OAC using a VKA is recommended lifelong for all 
patients with an MHV prosthesis. 
I 
B 
Lifelong OAC with a VKA is recommended for all 
patients with MHVs to prevent thromboembolic 
complications. 
I 
A                       
Continued  
ESC Guidelines                                                                                                                                                                                               13


<!-- PAGE 14 -->

### Page 14

For patients with a VKA, INR self-management is 
recommended provided appropriate training and 
quality control are performed. 
I 
B 
INR self-monitoring and self-management are 
recommended over standard monitoring in selected, 
trained patients to improve efficacy. 
I 
A 
In patients with MHVs, it is recommended to (re)initiate 
the VKA on the first post-operative day. 
I 
C 
Following cardiac surgery with MHV implantation, it is 
recommended to start UFH or LMWH bridging and 
VKA within 24 h, or as soon as considered safe. 
I 
B 
In patients who have undergone valve surgery with an 
indication for post-operative therapeutic bridging, it is 
recommended to start either UFH or LMWH 12‚Äì24 h 
after surgery. 
I 
C 
The addition of low-dose ASA (75‚Äì100 mg/day) to 
VKA may be considered in selected patients with MHVs 
in case of concomitant atherosclerotic disease and low 
risk of bleeding. 
IIb 
C 
The addition of low-dose ASA (75‚Äì100 mg/day) to VKA 
should be considered in selected patients with MHVs in 
case of concomitant symptomatic atherosclerotic disease, 
considering the individual bleeding risk profile. 
IIa 
B 
The addition of low-dose ASA (75‚Äì100 mg/day) to 
VKA should be considered after thromboembolism 
despite an adequate INR. 
IIa 
C 
Either an increase in INR target or the addition of 
low-dose ASA (75‚Äì100 mg/day) should be considered 
in patients with MHVs who develop a major 
thromboembolic complication despite documented 
adequate INR. 
IIa 
C 
DOACs are not recommended in patients with an 
MHV prosthesis. 
III 
B 
DOACs and/or DAPT are not recommended to 
prevent thrombosis in patients with an MHV. 
III 
A 
Management of antithrombotic therapy in patients with mechanical heart valves undergoing elective non-cardiac surgery or invasive 
procedures‚ÄîSection 14.3 
It is recommended that VKAs are timely discontinued 
prior to elective surgery to aim for an INR <1.5. 
I 
C 
It is recommended to discontinue VKA at least 4 days 
before major elective non-cardiac surgery, aiming for an 
INR <1.5, and to resume VKA treatment within 24 h 
after surgery, or as soon as considered safe. 
I 
B 
In patients with MHVs, it is recommended to (re)initiate 
the VKA on the first post-operative day. 
I 
C 
Therapeutic doses of either UFH or subcutaneous 
LMWH are recommended for bridging. 
I 
B 
VKA interruption and resumption with bridging should 
be considered in patients with an MHV and 
thromboembolic risk factors undergoing major 
non-cardiac surgery. 
IIa 
B 
Bridging of OAC, when interruption is needed, is 
recommended in patients with any of the following 
indications: 
‚Ä¢ MHV 
‚Ä¢ AF with significant MS 
‚Ä¢ AF with CHA2DS2-VASc score ‚â•3 for women or 2 
for men 
‚Ä¢ Acute thrombotic event within the previous 4 weeks 
‚Ä¢ High acute thromboembolic risk. 
I 
C 
Management of antithrombotic therapy in patients with a biological heart valve or valve repair‚ÄîSection 14.3 
Lifelong SAPT is recommended after TAVI in patients 
with no baseline indication for OAC. 
I 
A 
Low-dose ASA (75‚Äì100 mg/day) is recommended for 
12 months after TAVI in patients without indication for 
OAC. 
I 
A 
Long-term (after the first 12 months) low-dose ASA 
(75‚Äì100 mg/day) should be considered after TAVI in 
patients without clear indication for OAC. 
IIa 
C 
OAC is recommended lifelong for TAVI patients who 
have other indications for OAC. 
I 
B 
OAC is recommended for TAVI patients who have 
other indications for OAC. 
I 
B 
OAC with VKA should be considered during the first 
3 months after mitral and tricuspid repair. 
IIa 
C 
OAC, with either VKAs or DOACs, should be considered 
during the first 3 months after surgical MV or TV repair. 
IIa 
B 
Routine use of OAC is not recommended after TAVI in 
patients without baseline indication. 
III 
B 
Routine use of OAC is not recommended after TAVI in 
patients without baseline indication. 
III 
A 
Management of haemolysis and paravalvular leak‚ÄîSection 14.4 
Decision on transcatheter or surgical closure of 
clinically significant PVLs should be considered based on 
patient risk status, leak morphology, and local expertise. 
IIa 
C 
It is recommended that the decision between 
transcatheter or surgical closure of clinically significant 
PVLs is based on Heart Team evaluation, including 
patient risk, leak morphology, and local expertise. 
I 
C                         
Continued


<!-- PAGE 15 -->

### Page 15

### 3 The Heart Team and Heart Valve

Centre 
3.1. The Heart Valve Network 
Despite increasing attention within the medical community, VHD continues to be underdiagnosed and undertreated in the general population, and public awareness remains low.10‚Äì13 Beside screening using 
auscultation and imaging when appropriate, the co-ordinated implementation of Heart Teams, Heart Valve Centres, and Heart Valve 
Networks at a local level represents an essential step to timely diagnose 
and treat patients with VHD. 
An integrated regional Heart Valve Network, incorporating outpatient Heart Valve Clinics (for initial diagnosis and ongoing surveillance) and specialist Heart Valve Centres (for advanced imaging and 
surgical or transcatheter intervention), allows optimal patient care 
through timely access to specialist assessment, accurate diagnosis, improved decision-making, and matching of patients to healthcare providers with appropriate expertise, experience, and resources (Figure 1).12 
In addition, dedicated Heart Valve Clinics ensure consistent application 
of clinical guidelines, efficient use of resources, and overall high-quality 
patient care, which in turn may improve outcomes.14,15 Medical goals 
include careful clinical and echocardiographic evaluation, monitoring 
at appropriate time intervals (so-called ‚Äòwatchful waiting‚Äô), application 
Transcatheter closure should be considered for suitable 
PVLs with clinically significant regurgitation and/or 
haemolysis in patients at high or prohibitive surgical risk. 
IIa 
B 
Transcatheter closure should be considered for suitable 
PVLs with clinically significant regurgitation and/or 
haemolysis. 
IIa 
B 
Management of biological heart valve failure‚ÄîSection 14.4 
Reoperation is recommended in symptomatic patients 
with a significant increase in transprosthetic gradient 
(after exclusion of valve thrombosis) or severe 
regurgitation. 
I 
C 
Reintervention is recommended in symptomatic 
patients with significant valve dysfunction not 
attributable to valve thrombosis. 
I 
C 
Transcatheter, transfemoral valve-in-valve implantation 
in the aortic position should be considered by the Heart 
Team depending on anatomical considerations, features 
of the prosthesis, and in patients who are at high 
operative risk or inoperable. 
IIa 
B 
Transcatheter transfemoral valve-in-valve implantation 
in the aortic position should be considered in patients 
with significant valve dysfunction who are at 
intermediate or high surgical risk, and have suitable 
anatomical and prosthesis features, as assessed by the 
Heart Team. 
IIa 
B 
Transcatheter valve-in-valve implantation in the mitral 
and tricuspid position may be considered in selected 
patients at high risk for surgical reintervention. 
IIb 
B 
Transcatheter transvenous mitral or tricuspid 
valve-in-valve implantation should be considered in 
patients with significant valve dysfunction at intermediate 
or high surgical risk, if the anatomy is suitable. 
IIa 
B 
Management of mechanical heart valve thrombosis‚ÄîSection 14.4 
Urgent or emergency valve replacement is 
recommended for obstructive thrombosis in critically ill 
patients without serious comorbidity. 
I 
B 
Heart Team evaluation is recommended in patients 
with acute HF (NYHA class III or IV) due to obstructive 
MHV thrombosis to determine appropriate 
management (repeat valve replacement or low-dose 
slow infusion fibrinolysis). 
I 
B 
Fibrinolysis (using recombinant tissue plasminogen 
activator 10 mg bolus + 90 mg in 90 min with UFH or 
streptokinase 1 500 000 U in 60 min without UFH) 
should be considered when surgery is not available or is 
very high risk, or for thrombosis of right-sided 
prostheses. 
IIa 
B 
Management of biological heart valve thrombosis‚ÄîSection 14.4 
Anticoagulation using a VKA and/or UFH is 
recommended in BHV thrombosis before considering 
reintervention. 
I 
C 
OAC using VKA is recommended in BHV thrombosis 
before considering reintervention. 
I 
B 
¬© ESC/EACTS 2025
2D, two-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; BHV, biological heart valve; BNP, brain natriuretic peptide; 
BSA, body surface area; CAD, coronary artery disease; CCT, cardiac computed tomography; CCTA, coronary computed tomography angiography; CHA2DS2-VASc, congestive heart failure 
or left ventricular dysfunction, hypertension, age ‚â•75 (doubled), diabetes, stroke (doubled), vascular disease, age 65‚Äì74, sex category (female); CRT, cardiac resynchronization therapy; 
DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; EuroSCORE, European System for Cardiac Operative Risk Evaluation; GDMT, guideline-directed medical therapy; h, 
hour; HF, heart failure; HTx, heart transplantation; INR, international normalized ratio; LA, left atrium/left atrial; LAAO, left atrial appendage occlusion; LAVI, left atrial volume index; 
LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic 
diameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; LVESVi, left ventricular end-systolic volume indexed to BSA; MHV, mechanical heart valve; min, minute; MR, 
mitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVA, mitral valve area; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; OAC, 
oral anticoagulation; PCI, percutaneous coronary intervention; PH, pulmonary hypertension; PMR, primary mitral regurgitation; PVL, paravalvular leak; RV, right ventricle/right 
ventricular; SAPT, single antiplatelet therapy; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery pressure; STS-PROM, Society 
of Thoracic Surgeons predicted risk of mortality; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TR, tricuspid 
regurgitation; TV, tricuspid valve; UFH, unfractionated heparin; VHD, valvular heart disease; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               15


<!-- PAGE 16 -->

### Page 16

of guideline-directed medical therapy (GDMT), timely referral, and 
post-procedural follow-up.15,16 Broader aims include patient education, 
the training of physicians and nurse specialists, swift and efficient access 
to specialist care, and recruitment into clinical trials. 
Heart Valve Centres should ensure that their facilities match institutional and local statutory requirements (Table 5), report procedural volumes and outcomes, and monitor treatment quality. They hold 
responsibility for the training and education of surgeons, interventional 
and imaging cardiologists, dedicated nurses, and allied professionals.17,18 
Expertise in the surgical management of coronary artery disease 
(CAD), vascular diseases, and complications must be available. New 
techniques should be taught by trained mentors using simulator models, when feasible, to minimize learning-curve effects. More broadly, 
Heart Valve Centres co-ordinate the management of patients with 
VHD across the entire Heart Valve Network, supporting services at 
community level, encouraging early referral, and promoting education 
and communication with other medical departments, referring cardiologists, primary care physicians, and rehabilitation clinics. 
3.1.1. Composition of the Heart Team 
The Heart Team is now an established feature of VHD programmes that 
has been formally endorsed by previous ESC/EACTS Guidelines19,20 and 
corresponding organizations worldwide.17 
The value of the Heart Team approach has become increasingly 
apparent as options for the treatment of VHD have extended to include high-risk and inoperable patients (most of whom now undergo 
transcatheter interventions), and low-risk and asymptomatic patients (who derive prognostic benefit from increasingly safe procedures). Despite significant accumulation of data concerning the 
management of VHD over the last two decades, many patients in 
daily practice have clinical characteristics that do not match those 
of participants included in clinical trials. The Heart Team approach 
is therefore particularly helpful when there is uncertainty or a lack 
of strong evidence. 
The Heart Team meeting facilitates balanced presentation of all 
appropriate options for medical, interventional, and surgical 
treatment, using tools and techniques for shared decision-making. 








	
	








	


¬Å

¬Å


	¬ç¬è¬ê¬ù
¬†


¬≠




	



¬Ä






¬Ç





Figure 1 The Heart Valve Network. HF, heart failure; VHD, valvular heart disease.


<!-- PAGE 17 -->

### Page 17

The patient‚Äôs preference plays a central role in this process, although 
the Heart Team recommendation should be based upon key objective 
medical considerations (particularly the relative risks and benefits of any 
procedure). 
Meetings should take place on a regular basis with standardized 
minimum datasets (to ensure that all relevant information is available) and appropriate administrative support (often provided by 
specialist nurses with expertise in the care of patients with VHD). 
In-person meetings of the full Heart Team may not be feasible for 
every patient, and local standardized protocols may be implemented to facilitate swift decision-making for specific cohorts (e.g. elderly TAVI candidates or young patients with BAV disease). Equally, 
the need for Heart Team evaluation should not paralyse clinical 
decision-making, and ad hoc discussions remain appropriate in urgent situations. 
Core members of the Heart Team include the cardiologist treating 
the patient (who is best placed to present their case and act as their advocate), specialists in advanced cardiovascular imaging and peri- 
procedural guiding,21,22 surgeons, and interventional cardiologists 
with training and expertise in surgical and transcatheter valve procedures. Specialized nursing personnel play an essential role to improve 
patient information and education, as well as co-ordinate work-up 
and management steps in high-volume centres (Figure 1; Table 5). 
Cardiologists with expertise in heart failure (HF) and electrophysiology, 
as well as geriatricians, cardiovascular anaesthetists, and intensivists involved in peri-procedural care, should also be available to facilitate the 
discussion of particularly complex clinical scenarios when needed (extended Heart Team) (Figure 1; Table 5). 
3.1.2. Procedural volume and clinical outcomes 
The correlation between high institutional (and individual operator) 
volume and best procedural outcomes is intuitive, yet complex. 
Nevertheless, there is evidence of such a relationship for many cardiovascular procedures including SAVR,23,24 surgical MV repair,25,26 mitral 
and tricuspid TEER,27‚Äì30 and TAVI (particularly in centres with an associated high-volume SAVR programme).31‚Äì33 Studies have shown 
that an annualized operator volume of approximately 25 surgical mitral 
valve procedures,26 50 TAVIs (‚àº100 per centre),33 a cumulative experience of ‚àº50 M-TEER procedures per operator/centre,27 and a 
site volume of more than 20 T-TEERs/year30 are associated with improved technical and clinical outcomes. Higher institutional surgical 
volume is associated with lower complication rates,34‚Äì36 improved 
management,37 and better infrastructural support.38,39 
National procedural activity varies widely between high-, middle-, and 
low-income countries,40 and it is therefore difficult to provide 
recommendations concerning the precise number of institutional or operator procedures that is required for high-quality care, excellent facilities, 
and processes. Instead, a network approach that highlights the importance 
of centres performing a high volume of procedures (e.g. based upon quartiles in individual countries or regions) seems more suitable, with complex 
procedures concentrated in the centres with the highest volumes (Table 6). 
Table 5 Requirements for a Heart Valve Centre 
Requirements  
Centre performing heart valve procedures with on-site interventional 
cardiology and cardiac surgery departments providing 24-h/7-day services. 
Heart Team core members: Cardiologist with imaging expertise, 
interventional cardiologist, cardiac surgeon. 
Additional specialists, if required (Extended Heart Team): 
Specialized nursing personnel, HF specialist, electrophysiologist, 
cardiovascular anaesthetist, geriatrician, and other specialists 
(e.g. intensive care, vascular surgery, infectious diseases, neurology, 
radiology). 
The Heart Team must meet on a regular basis and work according to 
locally defined standard operating procedures and clinical governance 
arrangements. 
A hybrid cardiac catheterization laboratory is desirable. 
High volume for hospital and individual operators. 
Multimodality imaging (including advanced echocardiography, CCT, CMR, 
and nuclear techniques) and expertise in peri-procedural imaging guidance of 
surgical and transcatheter procedures. 
Heart Valve Clinic for outpatient assessment and follow-up. 
Data review: continuous monitoring, evaluation, and reporting of procedural 
volumes and quality indicators, including clinical outcomes, as well as PROMs 
complemented by local/external audits. 
Education programmes targeting primary care and referring physicians, 
operators, and diagnostic and interventional imaging specialists. 
¬© ESC/EACTS 2025
CCT, cardiac computed tomography; CMR, cardiac magnetic resonance; HF, heart failure; 
PROM, patient-reported outcome measure.  
Table 6 Complex procedures ideally performed in the 
most experienced Heart Valve Centres 
Transcatheter interventions 
Surgical interventions  
‚Ä¢ Transfemoral TAVI in patients 
with high-risk features: 
‚Äì Low coronary ostia 
‚Äì Difficult femoral anatomy 
‚Äì Bicuspid valve 
‚Äì Severe calcification protruding 
into the LVOT 
‚Äì Severe LV and/or RV impairment 
‚Äì Pure AV regurgitation 
‚Äì Multiple valve disease 
‚Äì Complex coronary artery disease 
‚Äì Severe extracardiac disease 
(e.g. renal failure, PH) 
‚Ä¢ Non-transfemoral TAVI 
‚Ä¢ Valve-in-valve (including 
TAV-in-TAV) 
‚Ä¢ All leaflet modification procedures 
(BASILICA, LAMPOON etc.) 
‚Ä¢ PVL closure procedures 
‚Ä¢ Complex M-TEERa 
‚Ä¢ Redo M-TEER procedures 
‚Ä¢ Tricuspid or mitral valve-in-ring or 
valve-in-valve, valve-in-MAC 
‚Ä¢ TMVI 
‚Ä¢ All tricuspid procedures 
‚Ä¢ High-risk procedures (especially 
in patients with LV and/or RV 
impairment) 
‚Ä¢ Redo procedures 
‚Ä¢ Minimally invasive and robotic 
valve surgery 
‚Ä¢ Complex MV repair 
‚Äì Barlow disease 
‚Äì Anterior or bileaflet prolapse 
‚Äì High risk of SAM 
‚Äì Severe MAC 
‚Ä¢ AV repair 
‚Ä¢ Ross procedure 
‚Ä¢ Valve surgery combined with 
complex surgery of the aorta 
‚Ä¢ Endocarditis surgery 
¬© ESC/EACTS 2025
AV, aortic valve; BASILICA, Bioprosthetic or native Aortic Scallop Intentional Laceration to 
prevent Iatrogenic Coronary Artery obstruction; LAMPOON, Laceration of the Anterior 
Mitral leaflet to Prevent Outflow ObstructioN; LV, left ventricular/left ventricle; LVOT, left 
ventricular outflow tract; MAC, mitral annular calcification; M-TEER, mitral transcatheter 
edge-to-edge repair; MV, mitral valve; PH, pulmonary hypertension; PVL: paravalvular leak; RV, 
right ventricular/right ventricle; SAM, systolic anterior movement; TAV, transcatheter aortic 
valve; TAVI, transcatheter aortic valve implantation; TMVI, transcatheter mitral valve implantation. 
aSee Supplementary Table S2.   
ESC Guidelines                                                                                                                                                                                               17


<!-- PAGE 18 -->

### Page 18

Internal quality assessment (see dedicated document concerning TAVI 
from the ESC41), systematic recording, and public availability of the volume 
and outcome data of the performed procedures are essential. Participation 
in national or international registries should be encouraged. These considerations are of particular importance regarding asymptomatic low-risk patients (where low mortality and procedural safety are paramount), those 
with multiple comorbidities (where the need for multidisciplinary collaboration is essential), and new techniques with a steep learning curve (where 
better results may be obtained at experienced centres). 
There is a pressing need to ensure higher dispersion and adoption of 
interventions for VHD, especially (but not exclusively) in middle- and 
lower-income countries where rheumatic heart disease (RHD) remains 
the principal cause of VHD.42,43 Key strategies include awareness programmes, increased public and medical education, simplified and improved diagnostic tools, and measures to reduce costs and facilitate 
access to evidence-based treatment options.44 
4. Imaging of patients with valvular 
heart disease 
Multimodality imaging is now the standard approach in VHD 
management to determine the pathophysiology, assess severity, 
plan interventions, and identify complications (Figure 2). The use 
of imaging for the assessment of each specific valve lesion is described in the corresponding sections. The role of imaging is transversal from diagnosis to follow-up and should encompass an 
integrative assessment. 
4.1. Initial valve assessment 
Comprehensive transthoracic echocardiography (TTE) is the first-line 
examination to confirm valve dysfunction, and determine the aetiology, 
mechanism, and severity of VHD, as well as cardiac chamber anatomy 
and damage.45,46 It should be performed by properly trained imagers.47‚Äì49 Quantitative imaging analysis (as opposed to visual) should 
be the goal in all patients with relevant VHD, complemented by qualitative and semi-quantitative evaluation. The severity of VHD should be 
assessed using an integrative approach of all criteria checked for consistency. When TTE is of poor quality or inconclusive, transoesophageal 
echocardiography (TOE) and/or additional diagnostic imaging modalities should be applied (e.g. calcium scoring and anatomy of the 
valve using CCT). In specific clinical scenarios [e.g. thrombosis, prosthetic valve dysfunction, endocarditis, mitral stenosis (MS), assessment 
of MV or TV anatomy], TOE has a central diagnostic role.50,51 






	





	

¬Å



¬ç¬è


¬ç¬è

¬ê
¬ù¬†
¬Å
¬è	

	¬≠¬Ä¬ç¬è
¬Ç
¬É
¬Ñ
Figure 2 Integrative imaging assessment of patients with valvular heart disease. 3D, three-dimensional; CAD, coronary artery disease; CCT, cardiac 
computed tomography; CMR: cardiac magnetic resonance; TOE; transoesophageal echocardiography; TTE, transthoracic echocardiography; VHD, 
valvular heart disease.


<!-- PAGE 19 -->

### Page 19

Moreover, in patients with regurgitant lesions, particularly AR, CMR has 
gained key value in clinical practice. 
4.2. Associated diseases and conditions 
Imaging plays a crucial role in identifying associated diseases and conditions. The presence of concomitant left ventricular (LV) systolic or diastolic dysfunction, RV systolic dysfunction, red flags indicating 
cardiomyopathies (e.g. amyloidosis, hypertrophic cardiomyopathy), 
and aortopathy should prompt further examinations to ensure optimal 
risk stratification and VHD management. In addition to TTE, advanced 
imaging modalities, like CCT, may be required to assess the aorta, 
single-photon emission computed tomography (CT) for detection of 
ischaemia/necrosis, positron emission tomography (PET) for inflammation, nuclear scintigraphy for cardiac amyloidosis, or CMR for tissue 
characterization. 
4.3. Evaluation of valvular heart disease 
dynamics and variability 
Serial imaging studies to detect changes over time, or variability due to 
haemodynamic conditions or initiation/up-titration of medical therapy, are of utmost importance to guide decisions. The dynamic pattern of VHD may convey additional prognostic information. 
Exercise echocardiography helps to identify the cause of dyspnoea, 
unveil symptoms in apparently asymptomatic patients, identifies dynamic changes of VHD severity, and can contribute to refinement 
of the indication for an intervention, especially for AS and mitral regurgitation (MR).52 
4.4. Assessment of extravalvular cardiac 
consequences from valvular heart disease 
Several studies investigating different valve lesions have established 
the relevance of extravalvular cardiac damage in terms of prognosis,53‚Äì55 recovery after intervention,56 and quality of life.57 The presence of LV hypertrophy, left atrium (LA) dilatation, LV or RV 
dysfunction and/or remodelling, myocardial fibrosis, and pulmonary 
hypertension (PH) provide important prognostic information, and 
may influence the timing and type of treatment. Although not necessarily chronological in their order of appearance, the understanding 
of cardiac damage, particularly damage involving the LV, is essential 
to guide appropriate medical therapy before and after any intervention. Transthoracic echocardiography (TTE) including global longitudinal strain (GLS) and CMR can be particularly useful in that 
regard.58‚Äì60 
4.5. Evaluation of eligibility, planning, and 
guiding of interventions 
Transoesophageal echocardiography (TOE) (preferentially 3D) is the 
preferred tool for the assessment of suitability for aortic, mitral, and 
TV repair.45,49,61‚Äì63 Risk stratification for an intervention should integrate all the points mentioned above. 
Transoesophageal echocardiography (TOE), including standard 3D 
views, is also the modality of choice to guide atrioventricular transcatheter interventions and should be performed by specially trained 
interventional echocardiographers.61,64 Cardiac computed tomography (CCT) is frequently used to evaluate the relationship of the 
valve with adjacent structures [e.g. coronary arteries and left ventricular outflow tract (LVOT)], the extension of calcification [e.g. in mitral annular calcification (MAC)], and for sizing of the prosthesis. 
CT angiography is frequently employed to evaluate the anatomy 
of surgical, arterial, or venous access routes and detect cardiac or 
extracardiac complications (e.g. bleeding or embolic events). 
Coronary CT angiography (CCTA) is increasingly utilized to assess 
the presence of CAD. 
5. Clinical evaluation of patients 
with valvular heart disease 
5.1. Clinical examination 
Patients with VHD can be either asymptomatic or present with a wide 
spectrum of symptoms, including acute or chronic HF. An initial meticulous history and a comprehensive physical examination of the patient 
with auscultation, documentation of clinical signs of HF such as dyspnoea, impaired physical capacity and fatigue, peripheral oedema, and 
pleural effusion, as well as a systematic frailty assessment, are crucial.65 
In addition, comorbidities and coexisting cardiac conditions should be 
documented (Figure 3). Particular attention should be given to recent 
changes in symptoms or physical findings indicating a potential worsening of the valve lesion or ventricular function. 
5.2. Assessment of comorbidities and risk 
stratification 
Risk stratification of patients with VHD has been mainly developed 
based on surgical populations. The European System for Cardiac 
Operative Risk Evaluation II (EuroSCORE II)66,67 (https://www. 
euroscore.org) and the Society of Thoracic Surgeons predicted risk 
of 
mortality 
(STS-PROM) 
score68 
(http://riskcalc.sts.org/ 
stswebriskcalc/calculate) are the most commonly used scoring systems 
to estimate surgical risk. Both risk scores have been calibrated to predict post-operative outcomes.69‚Äì71 The STS-PROM score is dynamic to 
account for changes in patient risk profiles, the type of procedure (aortic, mitral, and tricuspid), and outcomes over time. The outdated (logistic) EuroSCORE I model systematically overestimated surgical 
mortality.70,72 
In patients considered for TAVI, surgical risk scores have lower accuracy and tend to overestimate the risk of events.73‚Äì75 Discrepancies 
between observed and predicted peri-procedural mortality after 
TAVI using surgical risk scores point towards a need for 
TAVI-specific scores. Models predicting short- and medium-term survival specifically designed for TAVI are rarely used in daily clinical practice due to limitations of their predictive performance.76‚Äì79 Specific 
scores have also been developed for patients undergoing mitral 
TEER (M-TEER),80‚Äì82 but the high heterogeneity of the population 
with MR limits their external validity and therefore routine clinical 
use so far.83 Recently, a dedicated clinical score has been calibrated 
and validated to stratify the risk associated with first-time and repeat 
isolated TV surgery (TRI-SCORE; https://www.tri-score.com/), and its 
use should be encouraged for patients with TV disease,84,85 as an alternative to the more complex Society of Thoracic Surgeons (STS) 
score for isolated TV surgery (https://isolatedtvsurgcalc.research.sts. 
org/).  
ESC Guidelines                                                                                                                                                                                               19


<!-- PAGE 20 -->

### Page 20

Other cardiac conditions and comorbidities‚Äîsuch as CAD, concomitant multiple valve and aortic disease, and RV dysfunction, as 
well as chronic kidney disease (CKD)‚Äîare not always appropriately 
captured in risk models, even if they are known to impact outcomes.86 
Similarly, specific unfavourable characteristics like porcelain aorta, mobile aortic atheroma, and previous mediastinal radiation therapy increase the surgical risk, and therefore may favour transcatheter 
treatment options. Frailty, including nutritional state, represents another 
important determinant of outcomes after valve interventions,87‚Äì89a 
which can be evaluated using appropriate tools as summarized in a recent consensus statement.90 Several methods have been proposed, 
from the simple Fried Frailty Index to more complex scores91 such 
as the Hospital Frailty Risk Score, which has been validated in a large 
cohort of TAVI and M-TEER patients.92 
The use of PROMs that engage patients in the co-evaluation of their 
health and wellbeing is encouraged. Several scoring systems have been 
proposed and validated for reproducibility and association with clinical 
outcomes, like the Quality of Recovery 15-item PROM or the Kansas 
City Cardiomyopathy Questionnaire (KCCQ).93‚Äì95 
5.3. Biomarkers 
Biomarker levels indicating either cardiac wall stress [e.g. brain natriuretic peptide (BNP)] or myocardial damage (e.g. troponin), in asymptomatic and symptomatic patients, may help to monitor VHD 
progress and determine the most appropriate timing of intervention. 
In patients with VHD, the natriuretic peptide ratio [the ratio of 
measured BNP or N-terminal pro-B-type natriuretic protein 















	



Figure 3 Central illustration. Patient-centred evaluation for treatment of valvular heart disease.


<!-- PAGE 21 -->

### Page 21

(NT-proBNP) to upper limit of normal for age, sex, and assay] 
has been shown to be a powerful, independent, and incremental 
predictor of mortality.96‚Äì98 In patients undergoing AV replacement, 
the accumulation of several elevated biomarkers of cardiovascular 
stress was associated with higher all-cause and cardiovascular mortality, and a higher rate of repeat hospitalization.99,100 
5.4. Exercise testing 
Because of the slow progression of valve lesions, patients may gradually 
limit their activity levels over several years and deny having actual symptoms that can be unmasked by exercise testing.12 This is particularly important in cases of AS, because once symptoms occur there is a sharp 
increase in the risk of sudden cardiac death, unless a valve intervention 
is performed.101‚Äì104 Exercise testing may provide additional information about the haemodynamic severity of VHD and help determine 
the risk and optimal timing of intervention by objectively evaluating 
functional capacity.101,103 Cardiopulmonary exercise testing has a 
prognostic role and can assist decision-making in patients with VHD 
of intermediate severity, particularly those with asymptomatic 
AR.101,105,106 
Exercise echocardiography is used for the assessment of LV global 
and segmental function, pulmonary artery pressure, and aortic and mitral pressure gradients.101,107 It also documents exercise-induced increase of MR and TR severity, especially in patients with secondary 
disease.108,109 Prognostic impact has been shown mainly for AS and 
MR.110,111 Misconceptions regarding its risk and tolerability contribute 
to the overall underuse of exercise testing in patients with VHD,12 despite data confirming its safety in most asymptomatic patients.112,113 
5.5. Invasive investigations 
5.5.1. Coronary angiography 
Coronary artery assessment is recommended to evaluate the need for 
revascularization when valve surgery or an intervention is planned. The 
information regarding the existence of concomitant CAD should be 
available at the time of Heart Team discussion. CCTA is recommended 
as an alternative to coronary angiography to rule out CAD in patients 
who are at low or moderate risk of obstructive CAD. 
Coronary blood flow and fractional flow reserve (FFR) are altered in 
the setting of concomitant VHD, and functional haemodynamic assessment of CAD in these patients is not well established.114‚Äì118 
5.5.2. Cardiac catheterization 
Right heart catheterization (RHC) should be performed in patients with 
equivocal echocardiographic findings, particularly those with MV disease, as well as in all candidates for the treatment of severe TR. In exceptional cases with unclear AS severity, it can be combined with 
measurements of the transaortic gradients allowing estimation of the 
aortic valve area (AVA). Right heart catheterization contributes to assess the repercussions of any left-sided VHD or LV impairment on 
the pulmonary circulation and right side of the heart. It provides information regarding volume state, cardiac output, and vascular resistance, 
differentiating between pre- and post-capillary PH, and should be ideally 
performed in euvolaemia. 
Measurements of the pulmonary capillary wedge pressure v-wave 
can inform about MR severity, but are neither sensitive nor specific, 
and may also be increased if the compliance of the LA is reduced or 
in case of diastolic LV dysfunction, as in patients with MS or chronic 
HF.119 
Similarly, the height of the right atrium (RA) v-wave, and the pressure curve mimicking the RV pattern (‚Äòventricularization‚Äô of the RA 
pressure), are signs of relevant TR, which are frequently accompanied by increased RV end-diastolic pressure in case of associated RV 
dysfunction. In patients with severe TR, pulmonary vascular resistance (PVR) should be calculated to unmask pulmonary vascular disease, which may not be captured by echocardiography due to RV 
systolic dysfunction or underestimation of pulmonary pressures because of TR. 
5.6. Patient-centred care and shared 
decision-making 
Given that treatment of VHD typically involves several modalities and 
specialities, and may result in a complex and sometimes time- 
consuming decision-making process, patient education and information, using online material and face-to-face conversations, are essential at each step. A clearly defined point of contact for all questions 
relating to the disease or type of treatments should be communicated 
to the patient and their relatives.120 The symptomatic and prognostic 
benefits, as well as the advantages and disadvantages of any treatment 
option, should be presented in an open and evidence-based manner. 
This includes mortality and risks of reintervention and complications 
(also over the long term), as well as recovery time and the need for 
cardiac, and if necessary psychological, rehabilitation until return to 
physical activity and work. Other issues to be discussed before the 
procedure include the need for oral anticoagulation (OAC) and its 
monitoring, as well as the noise generated by mechanical heart valves 
(MHVs). Information regarding centre experience and volume for a 
specific procedure should be provided. Misconceptions (e.g. subjective overestimation of the risk of surgery) should be addressed and potential interactions with individual lifestyle factors‚Äîincluding social 
activities, family and professional life, and hobbies‚Äîshould be discussed in detail. 
The Heart Team recommendation regarding the treatment and its 
modality must be based on evidence and anatomical considerations, 
balancing the risks and benefits of available treatment options.16 The 
patient and patient‚Äôs relatives need to be well informed about the rationale leading to the Heart Team recommendation, and given ample 
time to share personal preferences.121 At the end of the process, a 
shared decision is made between the treating team and the informed 
patient and relatives (Figure 3). 
6. Management of conditions 
associated with valvular heart 
disease 
6.1. Diagnosis and management of 
coronary artery disease 
The presence of CAD plays an important role in decision-making 
regarding the timing and modality of treatment, and should be 
assessed before Heart Team discussion. In patients with a low 
or moderate pre-test likelihood of obstructive CAD (‚â§50%), 
CCTA is recommended to rule out relevant CAD with high sensitivity.122‚Äì124 
Several studies have investigated the value of CCT angiography for 
CAD screening in elderly TAVI candidates. While sensitivity for the detection of obstructive CAD is high (95%‚Äì97%), specificity (68%‚Äì73%) is  
ESC Guidelines                                                                                                                                                                                               21


<!-- PAGE 22 -->

### Page 22

modest, mainly explained by the high prevalence of coronary artery calcification and AF in patients with severe AS, which limit imaging resolution and interpretability.125,126 If CCT angiography obtained during 
standard pre-TAVI evaluation is of sufficient quality to exclude relevant 
CAD, omission of invasive coronary angiography should be considered.125‚Äì129 
The value of invasive functional haemodynamic assessment of CAD 
in patients with severe AS may be limited, because AS impacts coronary 
haemodynamics. Therefore, caution is warranted in the interpretation 
of functional measurements in the presence of severe AS until more 
data are available.115,116 
Recommendations for the management of chronic CAD associated 
with VHD are provided below (Recommendation Table 1), as well as in 
dedicated guideline documents.6 The indications for coronary artery 
bypass grafting (CABG) in patients undergoing surgery for the treatment of VHD are mainly based on observational data, which do not 
provide detailed information on the degree of stenosis and the complexity of CAD.130 It has been demonstrated that subendocardial blood 
flow in the myocardium improves early after SAVR, most likely due to 
improved cardiac output and reduction of LV wall stress.131 The presence of CAD is associated with peri-operative and late adverse events 
in patients with AS undergoing SAVR132 that likely outweigh the increased risk of peri-procedural adverse events of combined SAVR 
and CABG compared with isolated SAVR. Indeed, in a large observational study, patients with CAD demonstrated better long-term survival after combined SAVR and CABG compared with SAVR alone, 
despite longer cross-clamp times.133 In patients with a primary indication for valve surgery, CABG is recommended in patients with coronary artery stenosis of ‚â•70% and should be considered in those with 
stenosis of ‚â•50%‚Äì70%, given the opportunity of concomitant full 
revascularization. 
The impact of CAD in patients undergoing TAVI remains under investigation. The randomized Nordic Aortic Valve Intervention (NOTION)-3 
trial compared a strategy of routine percutaneous coronary intervention (PCI) versus conservative management in 455 patients with severe 
symptomatic AS undergoing TAVI, who also had stable CAD and at 
least one stenosis of ‚â•90% based on visual angiographic assessment 
or FFR of ‚â§0.80 in a segment with ‚â•2.5 mm reference diameter.134 
Percutaneous coronary intervention was associated with lower risk 
of a composite endpoint event including all-cause death, myocardial infarction or urgent revascularization at a median follow-up of 2 years. 
Exploratory analyses suggest that the increased risk in the conservative treatment arm was driven by differences in the risk of myocardial 
infarction and urgent revascularization in patients with a diameter 
stenosis of ‚â•90%, rather than those with positive FFR and stenosis 
of <90%. The risk of bleeding was higher in the PCI than in the conservative 
treatment group. Another multicentre RCT, the PercutAneous Coronary 
inTervention prIor to transcatheter aortic VAlve implantaTION 
(ACTIVATION) trial, was discontinued due to slow recruitment.135 
In this underpowered and thus inconclusive trial, a routine PCI strategy 
of ‚â•70% stenoses in main epicardial vessels (or ‚â•50% if protected left 
main or vein graft) did not meet non-inferiority compared with conservative CAD treatment with respect to the composite of all-cause death and 
rehospitalization; moreover, PCI was associated with higher bleeding 
rates. Observational data show that TAVI can be performed safely in patients with untreated CAD with low short- and long-term rates of acute 
coronary syndrome and unplanned coronary revascularization.135‚Äì139 
In two recent meta-analyses of mostly observational data, PCI was not 
associated with a mortality benefit in patients with chronic CAD 
undergoing TAVI.140,141 
Optimal timing of PCI in patients undergoing TAVI remains yet to 
be determined. In NOTION-3, PCI was performed before TAVI in 
the majority of the patients (concomitantly or shortly after in only 
26% of the patients). Decision-making concerning the timing of 
PCI should take into account the type of valve used for TAVI and 
the complexity of the coronary lesions.142,143 Valves with a high 
frame‚Äîparticularly in the context of a narrow aortic root, commissural misalignment, or valve-in-valve procedures‚Äîcan pose challenges for coronary access following TAVI.144,145 The presence 
of significant CAD should therefore be considered for optimal 
transcatheter valve selection and reinforces the importance of optimized implantation technique and commissural alignment.143,146 
Several RCTs comparing the value and timing of PCI with 
medical therapy are ongoing (NCT04634240, NCT04310046, and 
NCT05078619). 
Based on the available data, PCI should be considered in patients with 
a primary indication to undergo TAVI and high-grade (‚â•90%) coronary 
artery stenosis in large vessels of ‚â•2.5 mm. In patients with stenosis of 
‚â•70%, PCI may be considered based on symptom status.142,143 In patients with ischaemic ventricular SMR, surgical revascularization of 
CAD has been associated with MR reduction147 and favourable clinical 
outcomes in observational studies.148,149 According to very limited 
data, improvement of SMR may occur in a minority of patients (about 
one-third) after PCI, which may therefore be considered prior to MV 
intervention.150 
For patients with VHD presenting with acute coronary syndrome, 
treatment decisions should be made according to the most recent 
ESC Guidelines.151 In patients presenting with non-ST-segment elevation acute coronary syndrome, it may be particularly challenging to 
determine the leading cause of elevated troponin levels, which are 
also frequently observed in decompensated VHD. Therefore, the 
treatment strategy should be determined by the Heart Team, taking 
into account symptoms, as well as coronary, valve, and access 
anatomy.136,138,139 
Recommendation Table 1 ‚Äî Recommendations for the 
management of chronic coronary syndrome in patients 
with valvular heart disease (see also Supplementary 
data online, Evidence Table 1) 
Recommendations 
Classa 
Levelb 
Diagnosis of coronary artery disease  
CCTA is recommended before valve intervention in 
patients with moderate or lower (‚â§50%) pre-test 
likelihood of obstructive CAD.122‚Äì124 
I 
B 
Invasive coronary angiography is recommended 
before valve intervention in patients with high and 
very high (>50%) pre-test likelihood of obstructive 
CAD. 
I 
C 
Invasive coronary angiography is recommended in 
the evaluation of CAD in patients with severe 
ventricular SMR. 
I 
C 
Omission of invasive coronary angiography should be 
considered in TAVI candidates, if procedural planning 
CT angiography is of sufficient quality to rule out 
significant CAD.125‚Äì129 
IIa 
B                         
Continued


<!-- PAGE 23 -->

### Page 23

6.2. Atrial fibrillation 
The interplay between AF and VHD is complex, and has an essential 
role in the prognosis and evolution of VHD during the patient‚Äôs lifetime. 
Valvular heart disease is independently associated with AF and almost 
one-third of patients with AF have a history of VHD.152 Conversely, 
AF is the main trigger of the development of atrial secondary MR and 
TR. In a recent cohort study, 8% of individuals with AF developed moderate or severe TR within 3 years of follow-up compared with only 2% 
in those in sinus rhythm.153 While disturbed annular dynamics have 
been postulated,150,154 the exact pathophysiology leading to secondary 
atrioventricular VHD in some, but not all patients with AF remains 
largely unclear. 
Detailed recommendations on the anticoagulation management of 
patients with VHD and AF are provided below (Recommendation 
Table 2) and in Section 14, as well as in specific Guidelines.7 Patients 
with a combination of VHD and AF have a high incidence of thromboembolic or bleeding complications.155 DOACs have replaced vitamin K 
antagonists (VKAs) in most clinical scenarios and are recommended for 
patients with VHD presenting with AF, except for patients with a MHV 
or mitral stenosis with a valve area ‚â§2.0 cm2. The use of apixaban,156 
dabigatran,157 edoxaban,158 and rivaroxaban159 is supported by subgroup analyses of large RCTs. Recommendations regarding the antithrombotic treatment of patients with MHVs and biological heart valves 
(BHVs) are described in Section 14 of these Guidelines. 
In the Left Atrial Appendage Occlusion Study (LAAOS) III trial, surgical left atrial appendage occlusion (LAAO) in patients with AF and a 
CHA2DS2-VASc [congestive heart failure or left ventricular dysfunction, hypertension, age ‚â•75 (doubled), diabetes, stroke (doubled), vascular disease, age 65‚Äì74, sex category (female)] score of ‚â•2 points 
undergoing cardiac surgery was associated with a 33% reduction of 
the risk of stroke or systemic embolism at a mean follow-up of 
3.8 years.160 These findings were confirmed by a large meta-analysis including four RCTs.161 A subanalysis of LAAOS III showed that the benefit of LAAO remains consistent irrespective of the use of VKAs or 
DOACs, as well as in the absence of OAC (although representing 
only 10% of the included population).162 In an RCT including patients 
with severe AS and AF undergoing TAVI, concomitant transcatheter 
LAAO was non-inferior to medical therapy with respect to a composite 
primary endpoint including all-cause mortality, stroke, and major bleeding at 2 years. Of note, rates of major or life-threatening bleeding were 
similar in the two groups and arterial or venous thromboembolisms 
more frequent in the TAVI/LAAO arm, leaving uncertainty regarding 
the usefulness of combining both procedures.163 
6.3. Cancer and radiation therapy 
Valvular heart disease is commonly associated with cancer and represents a well-known long-term side effect of intensive radiation therapy176 for treatment of Hodgkin or non-Hodgkin lymphoma, breast 
cancer, and other thoracic malignancies.177 Clinically significant VHD 
most commonly appears decades after radiotherapy. The incidence 
of radiation-induced VHD is increasing owing to longer survival of patients with cancer. Risk factors are summarized in Supplementary data 
online, Table S1. Patients at risk should be screened for VHD using TTE 
10 years after radiation exposure and followed up every 5 years 
thereafter.178 
Indications for myocardial revascularization 
CABG is recommended in patients with a primary 
indication for valve surgery and coronary artery 
stenosis ‚â•70%.c 
I 
C 
CABG should be considered in patients with a 
primary indication for valve surgery and coronary 
artery stenosis ‚â•50%‚Äì70%. 
IIa 
C 
PCI should be considered in patients with a primary 
indication to undergo TAVI and ‚â•90% coronary 
artery stenosis in segments with a reference 
diameter ‚â•2.5 mm.134 
IIa 
B 
PCI may be considered in patients with a primary 
indication to undergo transcatheter valve 
interventions and coronary artery stenosis ‚â•70% in 
proximal segments of main vessels.135‚Äì137 
IIb 
B 
¬© ESC/EACTS 2025
CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCTA, coronary 
computed tomography angiography; CT, computed tomography; PCI, percutaneous 
coronary intervention; SMR, secondary mitral regurgitation; TAVI, transcatheter aortic 
valve implantation. 
aClass of recommendation. 
bLevel of evidence. 
cStenosis ‚â•50% can be considered for left main stenosis.  
Recommendation Table 2 ‚Äî Recommendations for the 
management of atrial fibrillation in patients with native 
valvular heart disease (see also Supplementary data 
online, Evidence Tables 2 and 3) 
Recommendations 
Classa 
Levelb 
Anticoagulation  
DOACs are recommended for stroke prevention in 
preference to VKAs in patients with AF and AS, AR, 
or MR who are eligible for OAC.156‚Äì159,164 
I 
A 
The use of DOACs is not recommended in patients 
with AF and rheumatic MS with an 
MVA ‚â§2.0 cm2.165 
III 
B 
Surgical interventions 
Concomitant surgical ablation is recommended in 
patients undergoing MV surgery with AF suitable for a 
rhythm control strategy to prevent symptoms and 
recurrence of AF, according to an experienced team of 
electrophysiologists and arrhythmia surgeons.166‚Äì173 
I 
A 
Surgical closure of the LA appendage is 
recommended as an adjunct to OAC in patients with 
AF undergoing valve surgery to prevent 
cardioembolic stroke and systemic 
thromboembolism.160‚Äì162 
I 
B 
Concomitant surgical ablation should be considered 
in patients undergoing non-MV surgery with AF 
suitable for a rhythm control strategy to prevent 
symptoms and recurrence of AF, according to an 
experienced team of electrophysiologists and 
arrhythmia surgeons.167,169,174,175 
IIa 
B 
¬© ESC/EACTS 2025
AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; DOAC, direct oral 
anticoagulant; LA, left atrium/left atrial; MR, mitral regurgitation; MS, mitral stenosis; MV, 
mitral valve; MVA, mitral valve area; OAC, oral anticoagulation; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               23


<!-- PAGE 24 -->

### Page 24

Radiotherapy may lead to aortic and/or valvular calcification, CAD of 
proximal segments, restrictive cardiomyopathy, pericardial adhesions 
and calcifications with constriction, restrictive lung disease, chest wall 
scarring, and impaired wound healing, especially in patients who underwent radiation by means of older techniques (>20 years ago). The above 
factors complicate any surgical approach and increase the operative risk, 
which is underestimated by traditional risk scores.179‚Äì181 TAVI is proposed as an alternative for patients presenting with radiation-induced 
AS in the 2022 ESC Guidelines on cardio-oncology182 based on favourable, 
but limited, observational data,183,184 because this category of patients 
has been excluded from RCTs.183,184 Furthermore, M-TEER in patients 
presenting with radiation-induced MV disease with MR is often limited 
by thickened leaflets with restricted movement and subsequent risk of 
iatrogenic stenosis. 
In patients with active or stable cancer and severe AS, both TAVI and 
SAVR can be considered based on life expectancy, age, prognosis, and 
disability following cancer treatment, with a trend towards more TAVI 
utilization.185 TAVI procedural complication rates appear similar compared with those of control subjects without cancer.186 To avoid futility, treatment decisions discussed by the Heart Team should involve the 
treating oncologists.5,182 
6.4. Prophylaxis of rheumatic fever 
Rheumatic heart disease remains the most common cause of death 
from VHD worldwide.187 Prevention should preferentially target the 
first occurrence of acute rheumatic fever. Correct diagnosis and early 
antibiotic treatment of group A Streptococcus throat or skin infection 
is key for primary prevention. Large-scale screening combined with 
prophylaxis in children or adolescents with latent RHD appears to be 
an effective strategy to reduce the risk of disease progression and 
RHD prevalence.188‚Äì190 In patients with established RHD, secondary 
long-term prophylaxis with benzathine benzyl penicillin 1.2 million 
international units (IU) every 3‚Äì4 weeks over 10 years is recommended to prevent recurrent episodes, especially in children and adolescents. Long-term prophylaxis into adulthood should be considered 
in high-risk patients according to the severity of VHD and exposure 
to group A Streptococcus.191,192 
6.5. Cardiogenic shock and acute heart 
failure 
Acute presentation or decompensation of VHD can result in cardiogenic shock due to rapid haemodynamic deterioration and altered cardiac function. Alternatively, pre-existing VHD can be a bystander of an 
acute cardiovascular condition further exacerbating circulatory impairment until the occurrence of cardiogenic shock. In this setting, assessment of the severity of VHD, as well as its contribution to acute HF, 
may be difficult. Evidence concerning acute VHD management in this 
context is scarce and only exists for the MV and AV.193,194 
Hospital admission for acute decompensated AS is a frequent problem seen in up to 25% of AS hospitalizations.195,196 However, only a minority of these patients (1.6%‚Äì3.2%) present with cardiogenic 
shock.197,198 While intensive care treatment remains the cornerstone 
of haemodynamic stabilization and support, an intervention should be 
considered early, because it represents the only way to reverse progressive organ dysfunction due to low cardiac output. Balloon aortic 
valvuloplasty has been used in this context in the past, but has been 
largely replaced by TAVI in recent years, due to the high risk of severe 
AR and mortality in the acute setting.199‚Äì201 Several large observational 
studies have established the feasibility of TAVI in patients with 
cardiogenic shock with similar device success, even if LVEF is low, although 30-day mortality remains higher (13%‚Äì19%) compared with 
routine TAVI.194,197,198 Surgery represents the preferred treatment 
in patients with acute AR, while TAVI has only been described in individual cases or patients with a failed surgical valve (valve-in-valve). Fast 
pacing over a temporary pacemaker lead shortens the diastole and may 
temporarily improve haemodynamics until the intervention.5,8 
Except for papillary muscle rupture, acute PMR rarely leads to cardiogenic shock and may be best treated by surgical valve repair or replacement. In contrast, increasing evidence supports the use of 
M-TEER in patients with acute ventricular SMR, particularly following 
acute myocardial infarction, due to lower mortality compared with surgery or medical treatment in propensity-matched analyses.194,202,203 
This strategy might also be helpful to facilitate weaning from mechanical 
circulatory support. 
6.6. Palliative care 
In some patients with advanced VHD not qualifying for surgical or 
transcatheter therapies, medical HF treatment remains the only, and 
sometimes best, available option. These patients usually present late, 
have extensive cardiac damage, develop terminal HF during the natural 
evolution of VHD, and are ineligible for mechanical circulatory support 
or heart transplantation (HTx). Early implementation of expert multidisciplinary palliative and end-of-life care, with the support of HF specialists,204‚Äì206 reduces the number of hospitalizations and improves 
quality of life and symptom burden, in particular dyspnoea, pain, and 
anxiety.207 Continuous co-ordination between all involved subspecialties, and transparent communication with the patient and their relatives, are key to ensure high quality of care. 
7. Aortic regurgitation 
7.1. Prevalence and aetiology 
Chronic AR is mainly due to intrinsic abnormalities of the AV cusps and/ 
or secondary to progressive dilatation of the aortic root and/or ascending aorta. In high-income countries, degenerative changes are the leading cause of AR, while RHD is more frequent in middle- and 
low-income countries.12 Acute presentations are usually related to infective endocarditis or extension of aortic dissection into the aortic 
root. Chronic pure severe AR is more frequent in men and is associated 
with BAV and concomitant dilatation of the aorta in more than one-half 
of cases.208 
7.2. Evaluation 
During stepwise AR evaluation, the following aspects should be addressed: the severity of AR, its mechanism, and aetiology; the haemodynamic impact on LV function and pulmonary pressure; and 
evaluation of the ascending aorta. While echocardiography is the first- 
line modality, CMR and CCT are more accurate for the measurement 
of specific parameters (Figure 4). The results of the evaluation need to 
take into consideration the haemodynamic condition of the patient, 
particularly the blood pressure (BP), since high pressures can lead to 
overestimation of the regurgitant volume (RVol). 
Assessment of AR severity with TTE follows an integrative approach 
considering qualitative, semi-quantitative, and quantitative parameters, 
but remains challenging.45 Consequences of AR on LV size and function 
must be carefully assessed. Cut-offs for intervention are mostly 
based on two-dimensional (2D) echocardiographic measurements. 
However, 3D echocardiography and CMR allow more accurate


<!-- PAGE 25 -->

### Page 25

evaluation of LV volumes and LVEF than 2D echocardiography, and are 
useful in borderline cases (Figure 4).45,209 Strain imaging can be helpful in 
identifying subclinical LV dysfunction209‚Äì211 and can therefore influence 
the optimal timing of intervention. Reduced longitudinal strain and contractile reserve at stress echocardiography,212 elevated biomarkers 
(BNP),213,214 and the presence of myocardial fibrosis detected by 
CMR need to be integrated in the decision-making process, even if 
not entirely validated yet.209 
Given its close relationship with AV function, accurate measurements of the aortic diameter are required at all levels: the annulus, 
sinuses of Valsalva, sinotubular junction, and ascending aorta.8,215,216 
The largest diameter is used to indicate the specific aortic phenotype: root phenotype, ascending phenotypes, and extended or 
mixed forms (see Supplementary data online, Figure S1).8 The mechanism of AR and aortic diameters determine suitability for AV sparing or repair.217,218 




	






¬Å
¬ç¬è¬ê¬ù
¬ç¬è¬ê¬ç
¬ç¬è

	


¬†







¬≠



¬ç	

¬ç

¬Ä
¬Ç¬É¬≠¬Ñ¬Ö

¬Ü
‚â•¬Ä¬á¬ç¬à¬≠	
¬Å
¬É	
¬â¬†		

¬è¬ù¬ç‚â•¬Ö¬ä¬Å
¬ã


¬ê¬å¬é



¬ã



¬è¬à‚â•¬ë¬Ö
¬ç‚â•¬Ä¬ä
>¬á¬Å
Figure 4 Imaging assessment of patients with aortic regurgitation. AR, aortic regurgitation; CCT, cardiac computed tomography; CMR, cardiac magnetic resonance; EDV, end-diastolic velocity; EROA, effective regurgitant orifice area; LV, left ventricle/left ventricular; LVEF, left ventricular ejection 
fraction; LVESDi, left ventricular end-systolic diameter indexed to body surface area; LVESVi, left ventricular end-systolic volume indexed to body surface area; LVOT, left ventricular outflow tract; PHT, pressure half-time; RF, regurgitant fraction; RVol; regurgitant volume. aSee Recommendation Table 3 
for specific cut-offs.   
ESC Guidelines                                                                                                                                                                                               25


<!-- PAGE 26 -->

### Page 26

The morphology of the AV represents a critical aspect in the diagnosis and treatment of AR. Pure AR in the context of BAV uncommonly 
manifests with normal aortic diameters, being more often associated 
with a dilated ascending aorta and/or root. It is important to define 
the valve phenotype to determine the repair probability and long-term 
result of AV repair or AV-sparing procedures. The degree of symmetry 
is an important predictor of BAV reparability with better long-term results in more symmetric phenotypes.219‚Äì221 
7.3. Medical therapy 
Medical therapy, especially angiotensin-converting enzyme-inhibitors 
(ACE-Is) or dihydropyridine calcium channel blockers, may provide 
symptomatic improvement in individuals with chronic severe AR for 
whom surgery is not feasible or contraindicated. The value of ACE-Is 
or dihydropyridines in delaying surgery in the presence of moderate 
or severe AR in asymptomatic patients has not been established, and 
their use is not recommended for this indication. The use of beta- 
blockers increases the length of the diastole and therefore the RVol, 
and should be used with caution if indicated for another reason. 
However, beta-blockers can be used along with ACE-Is or angiotensin 
receptor blockers (ARBs) after surgery, if indicated (systolic HF or 
heart rate control).222,223 
7.4. Indications for intervention 
Acute severe AR usually requires immediate surgery depending on the 
aetiology, such as infective endocarditis or spontaneous, traumatic, 
or iatrogenic aortic dissection.5,8 Surgery for the treatment of chronic 
severe AR is indicated depending on symptoms and/or the effects of 
the RVol on LV size and function (see Recommendation Table 3 and  
Figure 5). The presence of associated aortic dilatation dictates surgery, 
irrespective of AR severity. When the patient is symptomatic and AR 
severe, surgery is recommended unless the anticipated surgical risk is 
prohibitive.224‚Äì228 Concomitant surgical treatment of severe AR 
is also recommended, irrespective of symptoms, in patients requiring 
CABG, ascending aorta surgery, or any other cardiac surgical 
procedures.229,230 
For the asymptomatic patient with severe AR, indications for 
surgery are based on the degree of functional impairment of the 
LV [LVEF ‚â§50%, left ventricular end-systolic diameter (LVESD)  
>50 mm, or left ventricular end-systolic diameter indexed to body surface area (BSA) (LVESDi) >25 mm/m2, especially in those with small 
BSA (BSA <1.68 m2) and elderly patients with low ventricular compliance].226,228,231‚Äì234 If surgery is deemed low risk, there is observational 
evidence from echocardiographic studies that early intervention might 
be beneficial for long-term prognosis when LVEF is ‚â§55%, LVESDi is 
>22 mm/m2, and/or left ventricular end-systolic volume indexed to 
BSA (LVESVi) is >45 mL/m2.235‚Äì239 A volumetric cut-off value of 
LVESVi ‚â•43 mL/m2 using CMR was recently proposed to guide the 
management of asymptomatic patients240,241 and appears to have better predictive value than LV diameter.242 Surgery may also be discussed 
in selected low-risk asymptomatic patients with significant LV dilatation 
(left ventricular end-diastolic diameter >65 mm) and progressive increase of LV diameters and/or decrease of LVEF during follow-up. 
Exercise testing should be performed, when feasible, in patients with 
severe AR who do not report symptoms and do not meet criteria 
for surgery.212 
AV replacement is still the standard surgical approach in most AR 
cases (see Section 14.1 regarding prosthesis type considerations). 
However, owing to a better understanding of the pathophysiology of 
the aortic root (see Supplementary data online, Figure S1) paralleled 
with favourable long-term results, valve-sparing aortic root replacement (VSARR) and AV repair are increasingly performed in centres 
with appropriate expertise (Figure 5).243‚Äì255 In patients with root enlargement and good tissue quality (i.e. pliable AV cusps with normal motion), a valve-sparing procedure has been demonstrated to be superior 
to the use of a composite valve graft (Bentall procedure) in terms of 
long-term mortality and overall morbidity (thromboembolism and 
endocarditis, with similar need for reoperation),250‚Äì253,255‚Äì257 and 
should be therefore favoured by experienced centres, in particular 
in patients with an estimated long life expectancy.258 Valve preservation or valve repair should also be considered for patients with BAV 
based on age, anatomical presentation, and centre experience 
(Figure 5).220,245,246,259 
When performed by experienced surgeons in well-selected young 
individuals, pulmonary autograft implantation (Ross operation) may 
also be a good alternative to prosthetic valve replacement.260‚Äì263 
TAVI may be considered at experienced centres for selected patients 
with AR who are ineligible for surgery. The use of non-dedicated transcatheter valves for this indication is off-label and associated with an increased risk of valve malpositioning and residual AR, with consecutively 
higher rates of second valve implantation (about 10%) or surgical conversion, as compared with TAVI in AS.264‚Äì268 Dedicated devices appear 
to minimize the risk of valve migration and residual AR in selected patients, but are associated with a high new permanent pacemaker implantation rate (24%).267‚Äì269 
Aortic dilatation is closely linked to AR. Dedicated ESC Guidelines 
give guidance regarding the evaluation and management of aortic 
root and ascending aortic dilatation.8 The aortic phenotype (see  
Supplementary data online, Figure S1), degree and rate of progression 
of aortic dilatation, and the underlying aetiology all affect timing of surgery, with the main indication being maximum aortic diameter.270‚Äì272 
Dilation of the aortic root, which typically occurs in Marfan syndrome 
and other patients with connective tissue disease, has a worse prognosis compared with isolated dilatation of the ascending aorta and requires closer surveillance.270‚Äì272 Surgery is recommended in all 
patients with a maximal aortic root or ascending aneurysm diameter 
of ‚â•55 mm. In the presence of additional risk factors, a threshold of 
50 mm may be considered for selected low-risk patients treated at experienced centres.8 If the patient has an established indication for AV 
surgery (due to AR or AS), concomitant surgery of the aortic root 
or the ascending aorta should be considered at a diameter of 
‚â•45 mm. This threshold has been more clearly demonstrated in patients with BAV and should also be based on the patient‚Äôs height273 
or specific intraoperative findings, such as the shape and thickness of 
the aortic wall. 
7.5. Follow-up 
A multimodality imaging approach45,274 and biomarkers like BNP213,214 
might help identify patients at increased risk of LV damage early 
and guide the appropriate timing of intervention. Yearly follow-up is recommended in asymptomatic patients with severe AR. Closer follow- 
up (3‚Äì6 months) is recommended for those approaching thresholds 
for surgery, or showing a progressive dilatation of the LV or decrease 
of LVEF. Cardiac magnetic resonance can be especially useful in such 
a setting. Patients with moderate AR should be followed on a yearly basis, with echocardiography performed every 2 years. 
When a dilated ascending aorta is initially diagnosed by TTE, a multislice electrocardiographic-triggered CCT/CMR scan is recommended


<!-- PAGE 27 -->

### Page 27

Patient with AR 
SigniÔ¨Åcant aortic root enlargementa 
Severe AR
SigniÔ¨Åcant AR
VSARR
Bentall
VSARR
and AV repair 
Symptoms
AV surgery 
(Class IIb) 
Follow-up
AV surgery 
(Class I)
TAVI
(Class IIb)
SAVR
AV repair
(Class IIa)
Eligible for surgeryb 
LVEF ‚â§50% or
LVESD >50 mm or LVESDi >25 mm/m2
LVEF ‚â§55% or
LVESDi >22 mm/m2
or LVESVi >45 mL/m2
Good tissue quality
Team expertise
Young patient
Good tissue quality
Team expertise
Young patient
Figure 5 Management of patients with aortic regurgitation. AR, aortic regurgitation; AV, aortic valve; LVEF, left ventricular ejection fraction; LVESD, 
left ventricular end-systolic diameter; LVESDi, left ventricular end-systolic diameter indexed to body surface area; LVESVi, left ventricular end-systolic 
volume indexed to body surface area; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve replacement; VSARR, valve-sparing aortic root replacement. aIndications for surgery on the root/ascending aorta are described in the 2024 ESC Guidelines for the management of peripheral 
arterial and aortic diseases.8 bConcomitant replacement of the aortic root or ascending aorta should be considered if the maximal diameter is 
‚â•45 mm and the predicted surgical risk is low.   
ESC Guidelines                                                                                                                                                                                               27


<!-- PAGE 28 -->

### Page 28

to confirm maximal diameter, rule out isolated single sinus dilatation, 
and provide a baseline reference. When the baseline aortic diameter 
is >45 mm, a second TTE examination is recommended at 6 months 
to confirm the stability of the finding, followed by serial examinations 
on a yearly basis thereafter.275 Any increase of >3 mm should be validated by CT angiography/CMR and compared with baseline data.275 
After repair of the ascending aorta, patients with Marfan syndrome 
and other connective tissue diseases remain at risk for dissection of untreated portions of the aorta, and require lifelong regular multidisciplinary follow-up at an expert centre.8 
7.6. Special patient populations 
Patients with concomitant VHD and those with AS combined with AR 
are discussed in Section 13.3.3. In patients with moderate AR and indication for CABG or MV surgery, the decision to treat the AV should be 
discussed by the Heart Team based on the aetiology of AR and other 
clinical factors, like the estimated life expectancy and the operative risk, 
as data show that progression of moderate AR may be very slow.276 
The presence of aortic dilation and AR in asymptomatic patients 
poses the problem of limiting the level of physical activity, but consistent data are lacking. Current recommendations for participation in 
competitive sport are restrictive, especially regarding isometric exercise in patients with connective tissue disease,277 while a more liberal 
approach is likely to be appropriate in other patients. 
Given the familial risk of thoracic aortic aneurysms, screening with 
appropriate imaging studies and testing for genetic abnormalities in 
first-degree relatives is indicated in patients with connective tissue disease.278 Since aortic dilation is present in ‚àº10% of first-degree relatives 
of patients with a BAV, it is also considered appropriate to encourage 
echocardiographic screening in this specific population.275,279 
8. Aortic stenosis 
8.1. Prevalence and aetiology 
Even if AS is the most common primary valve lesion referred for intervention in Europe and North America,12 underdiagnosis and undertreatment remain relevant concerns.10 Degenerative pathogenesis 
with cusps calcification is most common in developed countries and 
prevalence is rising rapidly because of the ageing population.11,12,187 
BAVs, or more rarely unicuspid AVs, are prone to earlier degeneration, 
constitute the dominant valve morphology in younger patients requiring AV replacement, and are frequently associated with dilatation of the 
aortic root or ascending aorta.280,281 In low- and middle-income countries, rheumatic aetiology remains frequent and AS usually presents 
combined with rheumatic MV disease.282 
8.2. Evaluation 
8.2.1. Echocardiography and cardiac computed 
tomography 
Aortic stenosis is a disease slowly evolving from mild to severe valve 
obstruction as a consequence of increasing valve fibrosis and calcification, although progression accelerates as haemodynamic severity 
increases.283 
Echocardiography is key to confirm the diagnosis and allows comprehensive assessment of the anatomy and severity of stenosis. Evaluation 
of the haemodynamic consequences on cardiac function and geometry, 
and the detection of aortic pathology or concomitant valve disease, 
provide important prognostic information that may influence management.284 Staging of extravalvular damage has been proposed,53 but 
it may be difficult to attribute other cardiac abnormalities to AS itself, 
because comorbidities are frequent in patients with AS and the 
observed damage may not occur in the expected chronological sequence. However, the detection of concomitant cardiac conditions 
[e.g. HF with preserved EF (HFpEF), amyloidosis, or hypertrophic 
Recommendation Table 3 ‚Äî Recommendations on indications for intervention in severe aortic regurgitation 
(see also Supplementary data online, Evidence Tables 4‚Äì8) 
Recommendations 
Classa 
Levelb 
Severe aortic regurgitation  
AV surgery is recommended in symptomatic patients 
with severe AR regardless of LV function.224‚Äì228 
I 
B 
AV surgery is recommended in asymptomatic 
patients with severe AR and LVESD >50 mm or 
LVESDi >25 mm/m2 [especially in patients with small 
body size (BSA <1.68 m2)] or resting 
LVEF ‚â§50%.226,228,231,233,234 
I 
B 
AV surgery is recommended in symptomatic and 
asymptomatic patients with severe AR undergoing 
CABG or surgery of the ascending aorta. 
I 
C 
AV repair should be considered in selected patients 
with severe AR at experienced centres, when 
durable results are expected.220,245,246,259 
IIa 
B 
AV surgery may be considered in asymptomatic patients 
with severe AR and LVESDi  
>22 mm/m2,226,228,231‚Äì234 or LVESVic >45 mL/m2 
[especially in patients with small body size (BSA  
<1.68 m2)],235‚Äì241 or resting LVEF ‚â§55%, if the surgical 
risk is low. 
IIb 
B                                                                                                   
Continued 
TAVI may be considered for the treatment of severe 
AR in symptomatic patients ineligible for surgery 
according to the Heart Team, if the anatomy is 
suitable.264,265,268,269 
IIb 
B 
Concomitant surgery of the ascending aorta 
Valve-sparing aortic root replacement is 
recommended in young patients with aortic root 
dilatation at experienced centres, when durable 
results are expected.247,250‚Äì253,255 
I 
B 
When AV surgery is indicated and the predicted 
surgical risk is low, replacement of the aortic root or 
ascending aorta should be considered if the maximal 
diameter is ‚â•45 mm.d 
IIa 
C 
¬© ESC/EACTS 2025
AR, aortic regurgitation; AV, aortic valve; BSA, body surface area; CABG, coronary artery 
bypass grafting; CMR, cardiac magnetic resonance; LV, left ventricle/left ventricular; LVEF, 
left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVESDi, left 
ventricular end-systolic diameter indexed to BSA; LVESVi, left ventricular end-systolic 
volume indexed to BSA; TAVI, transcatheter aortic valve implantation. 
aClass of recommendation. 
bLevel of evidence. 
cUsing echocardiography or CMR. 
dConsidering age, BSA, the aetiology of the valvular disease, the presence of a bicuspid AV, 
and the intraoperative shape and thickness of the ascending aorta.


<!-- PAGE 29 -->

### Page 29

cardiomyopathy] may help to optimize medical treatment before and 
after valve intervention.285,286 
Current European recommendations for the echocardiographic 
grading of AS rely on measurement of the mean pressure gradient 
(most robust parameter), peak transvalvular velocity (Vmax), and effective AVA. Although AVA is theoretically the ideal parameter for assessing severity, there are numerous technical limitations associated with 
its calculation.284,287 
Aortic stenosis may be further categorized according to flow state 
based on stroke volume index (SVi) when there is discordance between 
echocardiographic parameters (Figure 6). A threshold of 35 mL/m2 is 
conventionally accepted to discern low from normal flow, although 
sex-specific thresholds have been proposed.292  
Concordant criteria: 
‚Ä¢ High-gradient AS [mean gradient ‚â•40 mmHg, Vmax ‚â•4.0 m/s, AVA 
‚â§1 cm2 (or ‚â§0.6 cm2/m2)] is considered severe irrespective of LV 
function and flow conditions.  
Discordant criteria: 
‚Ä¢ Low-flow, low-gradient AS with reduced LVEF  
(mean gradient <40 mmHg, AVA ‚â§1 cm2, SVi ‚â§35 mL/m2, LVEF <50%). 
‚Ä¢ Low-flow, low-gradient AS with preserved LVEF  
(mean gradient <40 mmHg, AVA ‚â§1 cm2, SVi ‚â§35 mL/m2,  
LVEF ‚â•50%). 
‚Ä¢ Normal-flow, low-gradient AS with preserved EF  
(mean gradient <40 mmHg, AVA ‚â§1 cm2, SVi >35 mL/m2,  
LVEF ‚â•50%). 
‚Ä¢ Discordant high-gradient AS (mean gradient ‚â•40 mmHg,  
AVA >1 cm2).  
Patients with discordant normal-flow, low-gradient AS usually have 
moderate stenosis.293‚Äì295 Discordant high-gradient AS is considered 
severe if not caused by a reversible high-flow status.296‚Äì298 
In patients with low-flow, low-gradient AS with reduced LVEF, dobutamine stress echocardiography (DSE) can help to discriminate between pseudo-severe and true severe AS in the presence of flow 
reserve (increase in stroke volume of ‚â•20%).289,299 
Cardiac computed tomography calcium AV scoring is readily available and provides important adjunctive information in patients with 
low-flow, low-gradient AS because it correlates with haemodynamic 
severity, progression, and clinical outcomes.300,301 Values of >2000 
Agatston units (AU) in men and >1200 AU in women indicate severe 
AS with high sensitivity and specificity (‚àº85%).302,303 While higher 
thresholds (men >3000 AU, women >1600 AU) are very specific, severe AS becomes unlikely in patients with calcium AV scoring of 
<1600 AU in men and <800 AU in women.284,302,303 Cautious interpretation is required in patients who can develop severe AS without 
pronounced AV calcification such as in BAV, concomitant amyloidosis, 
and predominantly fibrotic stenosis associated with post-rheumatic, 
radiation-induced and inflammatory disease.304‚Äì308 
In low-flow, low gradient AS with reduced LVEF, CCT AV calcium 
scoring and DSE provide complementary information. If findings are 
equivocal, an integrated assessment considering all available clinical, 
morphological, and haemodynamic factors is required. 
8.2.2. Additional diagnostic and prognostic 
parameters 
The ratio of the LVOT to the AV Doppler jet velocity time integral 
(VTI, dimensionless index or velocity ratio) does not require 
calculation of LVOT area and may assist evaluation when other parameters are equivocal (<0.25 suggests that severe AS is highly likely).309 
Assessment of GLS can be useful for risk stratification310 and evaluation of extravalvular cardiac damage.311,312 It provides additional information regarding LV function and a threshold of ‚àí15% may contribute 
to identifying patients with severe asymptomatic AS at increased risk of 
clinical deterioration or premature mortality.59 
Estimated valvuloarterial impedance has been shown to be prognostic 
of adverse clinical outcomes before and after valve replacement.313‚Äì315 
Transoesophageal echocardiography (TOE) allows morphological 
evaluation of the valve, planimetry of AVA and assessment of potential subvalvular obstruction (unless there is acoustic shadowing caused by calcification), and evaluation of concomitant valve disease, and can be of value for 
peri-procedural imaging in challenging clinical or anatomical scenarios.316 
Natriuretic peptides can be used to arbitrate the sources of symptoms in patients with multiple potential causes and help to identify 
those with high-risk asymptomatic AS who may benefit from early 
intervention.97,317 
Exercise testing can unmask symptoms and haemodynamic intolerance 
(fall in BP >20 mm Hg) and is recommended for risk stratification in 
asymptomatic patients with severe AS.102,318 Exercise echocardiography 
may provide additional prognostic information by assessing the increase in 
mean pressure gradient and change in LV function.319 Cardiopulmonary 
exercise testing, eventually complemented by echocardiography, can 
help to uncover cardiac dysfunction in asymptomatic patients, discriminate cardiac from pulmonary limitation or deconditioning in patients with 
non-specific symptoms, and inform risk stratification.105,106,320,321 
Cardiac magnetic resonance is used to identify altered global LV 
geometry due to remodelling, as well as to quantify myocardial scarring 
and diffuse fibrosis, which are associated with the occurrence of adverse events.322‚Äì324 
Transthyretin cardiac amyloidosis may coexist with AS in elderly patients and the two conditions may causally interrelate.325 When transthyretin cardiac amyloidosis is suspected, the presence of monoclonal protein 
in serum and urine should be excluded using immunofixation and quantitative determination of free light chains, and diagnosis ascertained by 
means of diphosphonate scintigraphy.326 Despite the limited long-term 
prognosis associated with cardiac transthyretin amyloidosis, patients 
with concomitant severe AS usually benefit from valve intervention.327 
LV catheterization is not recommended unless there are symptoms 
and signs of severe AS, and non-invasive investigations are inconclusive. 
8.2.3. Procedural planning 
Cardiac computed tomography is key to determining suitability for 
TAVI and planning the procedure. It is the preferred imaging tool to assess AV anatomy including annulus size, dimensions of the aortic root 
and ascending aorta, the extent and distribution of valve and LVOT calcification, the distance of coronary ostia from the annular plane, optimal 
fluoroscopic projections for transcatheter valve deployment, and the 
feasibility of vascular access.49,328,329 
Transoesophageal echocardiography (TOE), which is more operator- 
dependent and does not allow assessment of coronary and peripheral 
vascular anatomy, or CMR may be considered when CCT is difficult to interpret or relatively contraindicated (e.g. in patients with renal failure).330,331 
8.3. Medical therapy 
No medical therapies have been shown to influence the natural 
history of AS to date. Neither statins, which demonstrated 
favourable effects in pre-clinical studies,332‚Äì334 nor substances  
ESC Guidelines                                                                                                                                                                                               29


<!-- PAGE 30 -->

### Page 30

Patient with suspected AS
Vmax ‚â•4 m/s and mean PG ‚â•40 mmHg
AVA ‚â§1 cm2
(AVAi ‚â§0.6 cm2/m2)
AVA ‚â§1 cm2
(AVAi ‚â§0.6 cm2/m2)
Non-severe AS
Exclude measurement errorsa
SVi ‚â§35 mL/m2
Reversible high Ô¨Çowb
LVEF ‚â•50%
AVCS
>1200 AU (female)
>2000 AU (male)
Severe AS
Severe AS
DSE with Ô¨Çow reserved 
and AVA >1 cm2
Integrated assessmentf
Pseudo-severe AS
Normal Ô¨Çow low-gradient AS
(severe AS less likely)c
Reassess under normal Ô¨Çow
DSE with Ô¨Çow reserved and AVA ‚â§1 cm2
and/ore 
AVCS >1200 AU (female) >2000 AU (male)
Figure 6 Integrative imaging assessment of patients with aortic stenosis. AS, aortic stenosis; AU, Agatston units; AV, aortic valve; AVA, aortic valve 
area; AVAi; aortic valve area indexed for body surface area; AVCS, aortic valve calcium score; CCT, cardiac computed tomography; CT, computed 
tomography; DSE, dobutamine stress echocardiography; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; MRI, magnetic 
resonance imaging; mean PG, mean pressure gradient; SVi, stroke volume indexed for BSA; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; Vmax, peak transvalvular velocity. aIn particular, verify LVOT diameter and multiwindow Doppler interrogation. bHigh flow may 
be reversible (anaemia, hyperthyroidism, or arteriovenous fistulae). Upper limit of normal flow using pulsed Doppler: cardiac index 4.3 L/min/m2, SVi 
58 mL/m2.288 cAvailable evidence refers to patients with preserved LVEF. Check for bradycardia or uncontrolled hypertension, which may lead to prolonged ejection time and reduced flow rate. Depending on symptoms, integrated assessment complemented by CCT AV calcium scoring may be pursued. dFlow reserve: ‚â•20% increase in stroke volume in response to low-dose dobutamine or if change in stroke volume of 10%‚Äì20%, calculate 
projected AVA.289,290 eIf one test is not conclusive, complement diagnostics with the other test. fBased on clinical judgement (typical symptoms without 
other explanation), morphological valve changes, LV hypertrophy (in absence of coexistent hypertension), and consistent findings using different modes 
of assessment [TTE and TOE, invasive assessment, AV planimetry by CT or MRI (cut-off 1.2 cm2)]291.


<!-- PAGE 31 -->

### Page 31

targeting calcification pathways alter disease progression.335,336 
Coexistent hypertension should be treated to avoid additional afterload, preferably using renin-angiotensin system blockers, although 
careful titration is required to avoid symptomatic hypotension.337 
In patients with symptomatic severe AS and HF, initiation of medical 
therapy or temporary improvement in symptoms should not delay 
intervention. Medication frequently requires re-adjustment following 
valve intervention and preventive therapies should be implemented 
according to current Guidelines.338 In patients with persisting HF 
and/or reduced LVEF, medical therapy should be introduced before 
and up-titrated after valve intervention according to the current HF 
Guidelines.339,340 
8.4. Indication for intervention 
8.4.1. Symptomatic severe aortic stenosis 
Symptomatic severe AS has an unfavourable prognosis if left untreated, 
and early intervention is strongly recommended in all patients with an 
estimated life expectancy exceeding 1 year10 (Figure 7). 
Intervention is recommended in all eligible symptomatic patients 
with high-gradient severe AS. However, management of patients with 
low-gradient AS is more challenging: 
‚Ä¢ Low-flow, low-gradient AS with reduced LVEF: reduced LV function usually improves after intervention if it is predominantly 
caused by excessive afterload.341‚Äì343 However, improvement is 
unlikely if the primary cause is fibrosis due to myocardial infarction 
or cardiomyopathy. Intervention is recommended when severe AS 
is confirmed by CCT (calcium scoring) or stress echocardiography,341 while patients with pseudo-severe AS should receive 
GDMT.339,344 Although the absence of flow reserve is associated 
with increased surgical and long-term mortality, both modes of 
intervention improved LVEF and clinical outcomes in observational 
studies.341,342,345‚Äì347 
‚Ä¢ Low-flow, low-gradient AS with preserved LVEF: outcomes are improved with intervention (either TAVI or SAVR) compared with 
medical treatment alone in patients with low-flow, low-gradient AS 
and preserved LVEF.348,349 Intervention should therefore be considered in patients with symptoms after careful confirmation that AS is 
severe. 
‚Ä¢ Normal-flow, low-gradient AS with preserved LVEF: prognosis 
of these patients is similar to that of moderate AS. Unless 
multimodality diagnostic evaluation clearly suggests severe 
AS, regular clinical and echocardiographic surveillance is 
recommended.293,294,350  
8.4.2. Asymptomatic severe aortic stenosis 
Up to 40% of patients with severe AS do not report symptoms at the 
time of diagnosis.351,352 In roughly one-third of these, exercise testing 
can uncover symptoms or reduced exercise capacity attributable to 
AS,102,103,318 and such patients should be treated as symptomatic. 
However, exercise testing is not always feasible because of frailty or impaired mobility.353 Intervention is recommended in asymptomatic patients with severe AS and an LVEF of <50% without another 
cause.14,102,318,319,354‚Äì360 For patients with severe high-gradient AS 
and no adverse prognostic features, close active clinical surveillance, 
so-called ‚Äòwatchful waiting‚Äô, has previously been the default management strategy. However, four RCTs comparing early AV intervention 
with clinical surveillance suggest that early intervention should be 
considered as an alternative in patients at low procedural risk.360‚Äì363 
This approach is reinforced if additional adverse prognostic features 
(very high Vmax,14,353,364 elevated natriuretic peptides,97,317,365,366 severe valve calcification,303,364 rapid Vmax progression,353,364 or LVEF 
of <55%14,354,356‚Äì359) are present. Restricted local resources (that 
may impede close surveillance) or long waiting lists (that preclude 
prompt treatment when symptoms develop) are further arguments favouring an early intervention. 
The Evaluation of TAVR Compared to Surveillance for Patients with 
Asymptomatic Severe Aortic Stenosis (EARLY TAVR) trial360 randomized 901 patients to early TAVI or clinical surveillance and demonstrated 
a reduction of 50% in the primary composite endpoint of all-cause mortality, stroke, or unplanned hospitalization for cardiovascular causes associated with pre-emptive intervention.360 The result was driven by 26.2% 
of the patients in the clinical surveillance group who converted to TAVI 
within 6 months of randomization due to the development of symptoms 
or adverse prognostic factors. There was no significant difference in 
strokes and all-cause mortality over 5-year follow-up. 
In the Early Valve Replacement Guided by Biomarkers of LV 
Decompensation in Asymptomatic Patients with Severe AS 
(EVoLVeD) RCT, which included 224 asymptomatic patients with severe AS and myocardial fibrosis (late gadolinium enhancement on 
CMR), early valve intervention (with SAVR or TAVI) failed to reduce 
the incidence of all-cause death or unplanned AS-related hospitalization 
compared with clinical surveillance.361 However, the study was underpowered and the median time to intervention was prolonged to 
5 months in the experimental arm. 
Two previous smaller trials compared early SAVR with clinical 
surveillance. In the Randomized Comparison of Early Surgery vs 
Conventional 
Treatment 
in 
Very 
Severe 
Aortic 
Stenosis 
(RECOVERY) trial (145 patients), there was a reduction in all-cause 
mortality following early SAVR over a mean follow-up of 6.2 years.362 
In the Aortic Valve Replacement Versus Conservative Treatment 
in Asymptomatic Severe Aortic Stenosis (AVATAR) trial (157 
patients), a reduction in the composite primary endpoint was noted 
after a mean follow-up of 2.5 years with a significant reduction in 
HF hospitalizations and mortality at long-term follow-up.363,367 
Limitations of these surgical studies included their small sample sizes, 
enrolment of selected young populations at low surgical risk (mean 
ages 64 and 67 years, respectively), and inclusion of patients with mostly very severe AS. 
A meta-analysis of the four RCTs showed that early intervention is 
associated with a significant reduction in unplanned cardiovascular or 
HF hospitalization and stroke, but not all-cause or cardiovascular mortality. Limitations of this analysis include the heterogeneity of the 
pooled trials and lack of granularity with respect to specific events owing to the study-level analysis.368 
Additional RCTs (NCT04204915 and NCT03972644) will further 
inform and refine the management of patients with severe asymptomatic AS. 
8.4.3. Moderate aortic stenosis 
Surgical intervention for moderate AS should only be performed in patients undergoing CABG,369 surgery of the ascending aorta or other 
valve disease (see Section 13). There is evidence of an association between moderate AS and adverse outcomes in patients with and without HF with reduced EF (HFrEF),370‚Äì372 but it is unknown whether 
this is causal or related to comorbidities. In an early terminated trial randomizing 178 patients with moderate AS and HFrEF to TAVI or clinical 
surveillance, no differences with respect to hard clinical endpoints were  
ESC Guidelines                                                                                                                                                                                               31


<!-- PAGE 32 -->

### Page 32

TAVI
(Class I)
SAVR
(Class I)
Symptomsb
LVEF <50% without another cause
Presence of one or more of the following:
‚Ä¢ High-gradient AS
‚Ä¢ Severe valve calciÔ¨Åcationc and Vmax progression ‚â•0.3 m/s/year
‚Ä¢ Elevated BNP or NT-proBNP levels attributable to ASd
‚Ä¢ LVEF <55% attributable to AS
‚Ä¢ Exercise test with sustained fall in BP >20 mmHg 
Close active surveillancee
Heart Team evaluationf
(Class I)
Low procedural risk
Intervention
(Class IIa)
SAVR or TAVI
(Class I)
Patients <70 years if surgical risk is low
All remaining candidates for a bioprosthesis
Patients ‚â•70 years with a tricuspid aortic valve if anatomy is suitable 
Patients with severe ASa
Figure 7 Management of patients with severe aortic stenosis. AS, aortic stenosis; AVCS, aortic valve calcium score; BNP, brain natriuretic peptide; BP, 
blood pressure; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; Vmax, peak transvalvular velocity. aIntegrative imaging assessment of AS (Figure 6). bConfirmed 
by a normal exercise test, if feasible. cAVCS >2000 in men, >1200 in women. dMore than three times age- and sex-corrected normal range. 
eEducate patient and reassess at least every 6 months (or promptly if symptoms occur). fHeart Team assessment based upon individual patient factors 
(Figure 9; Recommendation Table 4). Dashed arrow only applies to asymptomatic patients.


<!-- PAGE 33 -->

### Page 33

found, while patients undergoing TAVI had improved quality of 
life (change in KCCQ of 12.8 ¬± 21.9 points vs 3.2 ¬± 22.8 points; 
P = 0.018).373 Ongoing trials are expected to provide new insights 
(NCT04889872 and NCT05149755). 
8.5. Treatment options 
The mode of AV intervention depends on the estimated life expectancy, expected prosthesis durability, patient preference, and specific 
trade-offs associated with different treatment options (Figure 8). 
Most patients with AS undergoing valve intervention in Europe and 
North America receive a BHV (by either SAVR or TAVI).374 BHVs 
do not require long-term anticoagulation but have limited durability 
that varies between devices and is inversely associated with age.375 
MHVs are durable but require long-term anticoagulation, with associated thromboembolic and bleeding risks.260,376 In general, an MHV 
should be preferred in patients aged <60 years and a BHV in patients 
aged >65 years in aortic position (see Section 14.1). 
The Ross procedure (replacement of the AV with the patient‚Äôs pulmonary autograft combined with homograft pulmonary valve 
replacement) is associated with excellent long-term survival when performed in selected patients at centres with high expertise.260,263,377,378 
Although a valuable surgical option in young patients with prolonged life 
expectancy in whom anticoagulation is undesirable or contraindicated, 
it is associated with procedural complexity and the need for reintervention in ‚àº15% of patients within 15 years (Figure 8).263,377 
Balloon aortic valvuloplasty may be rarely considered as a bridge to 
TAVI or SAVR in carefully selected patients with decompensated AS, 
and in those with severe AS who require urgent high-risk non-cardiac 
surgery (NCS) (see Section 15.2.1). The procedure carries significant 
risks of acute complications.379 
A substantial increase in the number of patients undergoing AV intervention has been observed over the past decade as a consequence of the 
introduction of TAVI, improved diagnostic techniques, and evolving indications for intervention.374,380‚Äì383 Nevertheless, there is still wide variation in worldwide access to TAVI as a result of high device costs in 
comparison with surgical prostheses and variation in healthcare resources and reimbursement systems between countries.384‚Äì386 In addition, registries suggest that late referral and undertreatment remain 
frequent.12,387 
8.5.1. The mode of intervention in candidates for a 
bioprosthesis 
The two modes of BHV replacement, TAVI and SAVR, have been compared in RCTs across the spectrum of surgical risk in predominantly 
elderly patients with tricuspid AS. 
In patients unsuitable for surgery, TAVI was superior to medical 
therapy with a number-needed-to-treat of five to prevent one death 
at 1-year follow-up.388 Subsequently, RCTs showed non-inferiority of 
TAVI compared with SAVR in patients at high,389‚Äì391 intermediate,3,392,393 and low surgical risk,1,394,395 with comparable longer-term 
outcomes demonstrated during follow-up periods ranging from 4 to 
10 years.2,4,396‚Äì398 Of note, the majority of patients included in 
RCTs were male, while patients with low-flow low-gradient AS or adverse anatomical characteristics (including BAVs or complex CAD) 
were excluded per protocol. 
Meta-analyses of RCTs show a risk reduction in all-cause death and 
disabling stroke with TAVI in low-risk patients at 1 year, but no differences to SAVR at longer-term follow-up or in patients at intermediate 
or high surgical risk.399,400 The early benefit of TAVI in low-risk patients 
has since been corroborated in the investigator-initiated Randomized, 
Multicenter, Event-Driven Trial of TAVI vs SAVR in Patients with 
Symptomatic Severe Aortic-Valve Stenosis (DEDICATE), which met 
its non-inferiority target with a composite of death and stroke rate at 
1 year of 5.4% in the TAVI group vs 10.0% in the SAVR group [hazard 
ratio (HR), 0.53; 95% confidence interval (CI), 0.35‚Äì0.79] and all- 
cause death rates of 2.6% and 6.2% (HR 0.43; 95% CI, 0.24‚Äì0.73), 
respectively.395 
Rates of vascular complications and paravalvular leak (PVL) are consistently higher after TAVI despite refined transcatheter heart valve 
(THV) designs, whereas severe bleeding, acute kidney injury, and new- 
onset AF are more frequent after SAVR.2,4,399,401 Even though PVL has 
been associated with adverse clinical outcomes,402,403 it does not seem 
to impact the comparison of clinical outcomes between TAVI and 
SAVR in RCTs.2,4,395 
New pacemaker implantations are more frequent after TAVI, particularly when using self-expanding valves.3,394,404 Conflicting data exist 
regarding the long-term impact of new pacemaker implantation or 
new-onset left bundle branch block following AV intervention.405‚Äì407 
Patients undergoing TAVI have quicker recoveries, shorter hospital 






	




¬Å¬ç¬Å¬è
¬ê¬ù
¬†¬ù
	
Figure 8 Aortic valve treatment options. OAC, oral anticoagulation; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve 
implantation.   
ESC Guidelines                                                                                                                                                                                               33


<!-- PAGE 34 -->

### Page 34

stays, and more rapid improvements in quality of life compared with 
those who undergo SAVR.1,2,408,409 
Available data do not suggest systematic differences in durability between the two treatment modalities. Randomized controlled trials and 
observational studies have reported comparable rates of BHV failure related to SVD with transcatheter and surgical valves up to 10 years.2,398,410 
However, potential selection and survival bias, the use of variable definitions of SVD, limited follow-up durations, differential attrition 
rates,2,4,396,400 competing risk of death, and the use of multiple valve 
types in the surgical arms of RCTs may limit direct comparison.411 
Although conclusive evidence is still lacking, concomitant non- 
complex CAD can be addressed either by CABG or PCI, while 
complex CAD favours CABG (see Section 6.1). In the only RCT comparing these two strategies, the transcatheter valve and vessels 
(TCW) trial, randomization of patients with severe AS and concomitant CAD to FFR-guided PCI plus TAVI resulted in fewer deaths and 
major bleeding events compared with combined SAVR plus CABG at 
12 months.412 However, inferences from trial results are limited due 
to early termination, modest sample sizes, event rates deviating from 
those observed in registries and other RCTs, and a low prevalence of 
complex CAD. 
8.5.1.1. Age and life expectancy 
The relationship between estimated life expectancy and prosthetic heart 
valve durability determines the likelihood of a future reintervention. 
Although life expectancy may be a theoretically better guide than age 
alone for treatment decisions, it is difficult to estimate for an individual patient owing to large geographical (https://ghdx.healthdata.org/record/ 
ihme-data/gbd-2019-life-tables-1950-2019) and interindividual variability.413 In combination with cardiac and extracardiac comorbidities, as 
well as anatomical factors, age contributes to risk estimation and represents a pragmatic surrogate for life expectancy. In addition, age thresholds 
characterize the populations enrolled in RCTs better than life expectancy. 
It is notable that younger patients with AS seem to have lower life expectancy than the general population despite valve replacement, whereas life 
expectancy almost normalizes after treatment in older cohorts.414,415 
While several trials compared TAVI with SAVR in study populations 
aged 70‚Äì85 years accross the surgical risk spectrum, the representation 
of patients aged <70 years in RCTs is low and therefore evidence 
limited.1,394,395,416 
8.5.1.2. Anatomical features 
The advantages of TAVI demonstrated in RCTs are largely confined to 
patients treated via the transfemoral approach.401 While SAVR remains 
the preferred treatment option when iliofemoral artery disease precludes transfemoral TAVI, TAVI via a non-transfemoral access (transaxillary, transcarotid, transcaval, transinnominate, or transapical) 
constitutes an alternative supported by observational data in patients 
unsuitable for surgery.417‚Äì423 
Other anatomical factors that favour SAVR or led to exclusion of patients from RCTs comparing TAVI with SAVR are  (Figure 9): 
‚Ä¢ Aortic annular dimensions that lie outside sizing recommendations 
for currently available transcatheter devices. 
‚Ä¢ Excessive or bulky calcifications of the annulus or LVOT, which increase the risk of PVL and annular rupture.424,425 
‚Ä¢ Increased risk of coronary obstruction with TAVI (cusp height greater 
than coronary height in combination with shallow sinuses of Valsalva, 
or high calcium burden of corresponding cusp).329 
In contrast, anatomical findings such as porcelain aorta, severe chest 
deformation, or intact grafts post-CABG favour TAVI. Right anterior 
thoracotomy or upper hemisternotomy are minimally invasive access 
alternatives to sternotomy for performing SAVR, which are being 
used with increasing frequency.426,427 
In BAV patients, severe AS usually occurs earlier compared with tricuspid AV and is frequently associated with aortopathy.219,281,428 
Prevalence of BAV anatomy sharply increases in younger AS patients.429 BAV anatomy adds complexity to TAVI because of asymmetric AV calcification and elliptical annular shape, as well as the lack of 
standardization of valve sizing. 
Patients with BAV have been excluded from almost all landmark 
RCTs comparing TAVI with SAVR to date.429,430 In the NOTION 2 
trial, the composite of all-cause death, stroke, or valve- or HF-related 
rehospitalization was numerically more frequent (seven vs two events) 
at 1 year in the underpowered subgroup of 100 patients with BAV (HR, 
3.8; 95% CI, 0.8‚Äì18.5; P = 0.07).416 Whereas some observational studies 
report favourable outcomes with TAVI in selected BAV patients,430‚Äì432 
others suggest higher stroke, annular rupture, and PVL rates as compared with TAVI in tricuspid AS.433 Heavy cusp calcification, particularly 
in conjunction with a calcified raphe, is associated with increased risk 
of aortic root injury, PVL, and mortality after TAVI.434 Data on TAVI 
in two-sinus BAV (Sievers type 0) are scarce.219,435 
For the above-mentioned reasons, SAVR remains the primary mode 
of treatment for stenotic BAV, particularly if patients are young or have 
coexistent aortopathy or unfavourable valve morphology. TAVI may be 
considered in patients at increased surgical risk, if anatomy is suitable. 
Patients with small annuli in relation to their body stature are at increased risk of prosthesis‚Äìpatient mismatch (PPM) after valve replacement. Annular enlargement allows for implantation of larger BHVs 
with SAVR. Given its technical complexity it should be performed 
in experienced centres, and the benefit must be balanced against a 
possibly higher risk of operative mortality.436 Prostheses with 
supra-annular design reduce PPM risk with TAVI, although randomized 
long-term data evaluating the impact on clinical outcomes or valve 
durability are pending.394,437,438 
8.5.1.3. Lifetime management 
Decision-making concerning the mode of intervention and type of 
prosthesis needs to integrate expected valve durability, and the potential risks of future reinterventions (Figure 9). Surgical THV explantation 
followed by SAVR is a rare (<1% of all TAVI procedures) but technically 
challenging procedure.439‚Äì441 Although its incidence among patients 
undergoing TAVI is stable, absolute numbers are increasing due to 
the total increase in TAVI procedures performed and the peri- 
operative risk remains high (early mortality rates as high as 12%‚Äì 
17%).440‚Äì445 The majority of surgical THV explantations are performed 
in patients at high surgical risk with urgent or emergent, 
non-SVD-related indication for reintervention (frequently endocarditis) within 2 years after TAVI.440,442‚Äì444 
Implanting a transcatheter aortic valve inside a surgical (TAV-in-SAV) 
or prior transcatheter valve (TAV-in-TAV) is associated with lower 
peri-procedural risk compared with redo SAVR.446‚Äì451 However, 
valve-in-valve implantation (particularly TAV-in-SAV) increases the 
risk of severe PPM,448 which has been linked to adverse outcomes in 
observational studies.452‚Äì455 In addition, valve-in-valve implantation immobilizes the leaflets of the failed prosthesis in an open position, creating a covered tube (or neo-skirt) that may cause direct coronary 
obstruction in patients with shallow sinuses of Valsalva or indirect


<!-- PAGE 35 -->

### Page 35

coronary flow obstruction as a result of sinus sequestration if the ascending aorta is narrow and the neo-skirt reaches the sinotubular 
junction.456,457 
The risk of coronary obstruction varies considerably depending on 
the index valve type, and is particularly increased if a stentless SAV or 
stented SAV with externally mounted leaflets is in place.457 The risk 
of sinus sequestration at the time of TAV-in-TAV implantation is particularly increased in supra-annular valves with a high neo-skirt.458,459 
Even if coronary flow is preserved, coronary access may be difficult 
or impossible in a relevant proportion of patients after valve-in-valve 
implantation, especially after TAV-in-TAV.460‚Äì462 
In patients who require a reintervention due to dysfunction of a surgical or transcatheter bioprosthesis, but are at increased risk of severe 
PPM or coronary obstruction, redo SAVR may be preferable despite 
the increased surgical risk. Fracture of surgical valves and leaflet modification techniques have been proposed for patients at high surgical risk 
and, if contemplated, should be performed in carefully selected patients 
at experienced centres (Table 6).463,464 
The need for a meticulous CT-based anatomical analysis is paramount in patients with an estimated life expectancy exceeding the 
assumed valve durability to anticipate future risks at the time of 
the index valve intervention. Based on individual assessment, the 
following measures should be considered with respect to lifetime 
management: 
‚Ä¢ Use of surgical and transcatheter valves with proven long-term durability to reduce the likelihood of reintervention.2,4,375,410,411,465‚Äì467 
‚Ä¢ SAVR with aortic root enlargement or implantation of a supra-annular 
transcatheter valve in patients with a small annulus at risk of severe 
PPM based on the predicted effective orifice area (EOA).436,438,468,469 
‚Ä¢ No implantation of stentless prostheses or prostheses with externally mounted leaflets in patients at risk of coronary obstruction during 
future TAV-in-SAV implantation.457 



	


		


‚â•¬Å
¬ç¬è¬ê¬ù
¬†


¬≠
¬ê
¬ç¬Ä

¬Ç¬Ä
	



	
¬É¬Å








	




¬Ñ¬Ö	
¬Ç

¬≠¬≠¬Ü	
¬≠¬Ü¬Ö¬ç¬Ç

¬á¬á¬Ü¬Ñ
¬Ñ
¬à

Figure 9 Factors to be considered when selecting the mode of intervention for aortic stenosis. CAD, coronary artery disease; LV, left ventricular; 
LVOT, left ventricular outflow tract; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; THV, transcatheter heart 
valve; VHD, valvular heart disease. aLV thrombus and infective endocarditis are relative contraindications to TAVI and are therefore not listed. 
bParticularly relevant for patients in whom the anticipated life expectancy is thought to exceed valve durability.   
ESC Guidelines                                                                                                                                                                                               35


<!-- PAGE 36 -->

### Page 36

‚Ä¢ Anticipation of the feasibility and risks of a possible future TAV-in-TAV 
procedure considering related technical aspects at the index TAVI 
(device choice, neo-skirt height, commissural alignment, and implantation depth).456,470  
Considering life-time management aspects and the scarcity of randomized data in patients younger than 70 years, SAVR remains the preferred treatment in patients <70 years of age if surgical risk is low. 
TAVI is recommended as the primary treatment modality in elderly patients ‚â•70 years of age with a tricuspid AV, if anatomy is suitable and 
transfemoral access is feasible, to reduce the risk of early adverse outcomes and accelerate recovery. 
For all other candidates for a bioprosthesis, the most appropriate 
mode of intervention should be carefully selected by the Heart 
Team, taking into account procedural risk based on anatomical characteristics and comorbidities, expected outcomes, lifetime management 
considerations, and patient preference (Figure 9; Recommendation 
Table 4). Recommendations for concomitant valve replacement at 
the time of CABG or ascending aortic surgery are listed in  
Recommendation Table 5. 
Recommendation Table 4 ‚Äî Recommendations on indications for intervention in symptomatic and asymptomatic severe 
aortic stenosis, and recommended mode of intervention (see also Supplementary data online, Evidence Tables 9‚Äì13) 
Recommendations 
Classa 
Levelb 
Symptomatic patients with severe aortic stenosis  
Intervention is recommended in symptomatic patients with severe, high-gradient AS [mean gradient ‚â•40 mmHg, Vmax ‚â•4.0 m/s, 
AVA ‚â§1.0 cm2 (or ‚â§0.6 cm2/m2 BSA)].388,471‚Äì474 
I 
B 
Intervention is recommended in symptomatic patients with low-flow (SVi ‚â§35 mL/m2), low-gradient (<40 mmHg) AS with reduced LVEF 
(<50%) after careful confirmation that AS is severe.342,345,346,348,475 
I 
B 
Intervention should be considered in symptomatic patients with low-flow (SVi ‚â§35 mL/m2), low-gradient (<40 mmHg) AS with normal 
LVEF (‚â•50%) after careful confirmation that AS is severe.c 293,348,349,476‚Äì481 
IIa 
B 
Asymptomatic patients with severe aortic stenosis 
Intervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause.14,354‚Äì359 
I 
B 
Intervention should be considered in asymptomatic patients (confirmed by a normal exercise test, if feasible) with severe, high-gradient AS 
and LVEF ‚â•50% as an alternative to close active surveillance, if the procedural risk is low.360‚Äì363,367,368 
IIa 
A 
Intervention should be considered in asymptomatic patients with severe AS and LVEF ‚â•50% if the procedural risk is low and one of the 
following parameters is present: 
‚Ä¢ Very severe AS (mean gradient ‚â•60 mmHg or Vmax >5.0 m/s).14,362,363,482‚Äì484 
‚Ä¢ Severe valve calcification (ideally assessed by CCT) and Vmax progression ‚â•0.3 m/s/year.303,353,364 
‚Ä¢ Markedly elevated BNP/NT-proBNP levels (more than three times age- and sex-corrected normal range, confirmed on repeated 
measurement without other explanation).97,365 
‚Ä¢ LVEF <55% without another cause.14,354,356‚Äì359 
IIa 
B 
Intervention should be considered in asymptomatic patients with severe AS and a sustained fall in BP (>20 mmHg) during exercise testing. 
IIa 
C 
Mode of intervention 
It is recommended that AV interventions are performed in Heart Valve Centres that report their local expertise and outcome data, have 
on-site interventional cardiology and cardiac surgical programmes, and a structured collaborative Heart Team. 
I 
C 
It is recommended that the mode of intervention is based on Heart Team assessment of individual clinical, anatomical, and procedural 
characteristics, incorporating lifetime management considerations and estimated life expectancy. 
I 
C 
TAVI is recommended in patients ‚â•70 years of age with tricuspid AV stenosis, if the anatomy is suitable.d 1‚Äì4,389‚Äì397,465,485,486 
I 
A 
SAVR is recommended in patients <70 years of age, if the surgical risk is low.e 413,429,487 
I 
B 
SAVR or TAVI are recommended for all remaining candidates for an aortic BHV according to Heart Team assessment.2,4,396,397,429,488‚Äì490 
I 
B 
Non-transfemoral TAVI should be considered in patients who are unsuitable for surgery and transfemoral access.417‚Äì423,491‚Äì498 
IIa 
B 
TAVI may be considered for the treatment of severe BAV stenosis in patients at increased surgical risk, if the anatomy is  
suitable.430‚Äì432,434,499‚Äì502 
IIb 
B 
Balloon aortic valvotomy may be considered as a bridge to SAVR or TAVI in haemodynamically unstable patients, and (if feasible) in those 
with severe AS who require urgent high-risk NCS. 
IIb 
C 
¬© ESC/EACTS 2025
AS, aortic stenosis; AV, aortic valve; AVA, aortic valve area; BAV, bicuspid aortic valve; BHV, biological heart valve; BNP, brain natriuretic peptide; BP, blood pressure; BSA, body surface area; 
CCT, cardiac computed tomography; EuroSCORE, European System for Cardiac Operative Risk Evaluation; LVEF, left ventricular ejection fraction; NCS, non-cardiac surgery; NT-proBNP, 
N-terminal pro-B-type natriuretic peptide; SAVR, surgical aortic valve replacement; STS-PROM, Society of Thoracic Surgeons predicted risk of mortality; SVi, stroke volume index; TAVI, 
transcatheter aortic valve implantation; Vmax, peak transvalvular velocity. 
aClass of recommendation. 
bLevel of evidence. 
cExplanations (such as measurement errors, uncontrolled blood pressure, and conditions lowering the stroke volume) other than severe AS for a small AVA but low gradient despite 
preserved LVEF are frequent and must be carefully excluded. 
dSuitability regarding transfemoral access, annulus dimensions, device landing zone calcification pattern, and coronary obstruction risk (Figure 9). 
eSurgical risk based on STS-PROM (http://riskcalc.sts.org/stswebriskcalc/#/calculate) and EuroSCORE II (http://www.euroscore.org/calc.html) <4% and Heart Team assessment.


<!-- PAGE 37 -->

### Page 37

8.6. Follow-up 
The rate of progression of AS varies widely and asymptomatic patients, 
their family, and medical caregivers need careful education, with particular emphasis on the importance of regular follow-up (ideally at a Heart 
Valve Centre)14 and prompt reporting of symptoms. Asymptomatic patients with severe AS should be followed up at least every 6 months to 
allow detection of early symptoms (using exercise testing if complaints 
are inconclusive) and any change in echocardiographic parameters (particularly LVEF). Serial measurements of natriuretic peptides can provide 
additional useful information regarding the timing of treatment. 
Younger patients with mild AS and no significant leaflet calcification 
may be followed up every 2‚Äì3 years. With increasing stenosis severity, 
progression accelerates and follow-up intervals should be gradually reduced.283,503 Several studies suggest that the prognosis of moderate degenerative AS is worse than previously considered,504,505 particularly if 
there is significant valve calcification, and these patients should be re- 
evaluated at least annually. 
Cardiac rehabilitation is frequently performed after AV intervention, 
especially after surgery and in elderly patients, and is associated with improved activities of daily living and 6-minute walking distance.506 After 
valve intervention, an early echocardiographic examination within the 
first weeks after valve replacement is recommended to document baseline prosthetic valve function. Cardiological evaluations and echocardiographic examinations are recommended annually in patients with a 
bioprosthesis, and whenever changes in clinical symptoms or signs suggestive of valve dysfunction are noted. 
9. Mitral regurgitation 
Chronic MR is one of the most common acquired valve pathologies,12,187 while acute MR is observed in the context of infective endocarditis, chordal rupture, or as a complication of myocardial infarction 
(papillary muscle rupture). MR either relates to anatomical changes of 
the MV apparatus (primary), or to LV or LA dilatation and dysfunction 
(secondary).193 Since natural history, prognosis, and management differ 
according to aetiologies, populations should be clearly distinguished in 
clinical practice and research.12,507 
9.1. Primary mitral regurgitation 
9.1.1. Prevalence and aetiology 
Primary mitral regurgitation relates to an anatomical lesion of one or 
more of the three main components (not including the annulus) of the 
MV apparatus (valve leaflets, chordae tendineae, and papillary muscles). 
PMR is observed in 55% of patients with MR who require treatment.507 
While degenerative disease related to fibroelastic deficiency or myxomatous alterations (in its most severe form, Barlow‚Äôs disease) are the most 
common aetiologies in higher-income countries, RHD is most frequently 
found in the rest of the world. MV endocarditis is a separate entity of PMR 
caused by acute or chronic infectious conditions and is discussed in the 
corresponding Guidelines.5 In a small subgroup of patients, PMR is associated with a higher incidence of ventricular arrhythmias, and sudden cardiac death has been reported in individual cases, especially in patients with 
Barlow‚Äôs disease.508 The arrhythmogenic burden is independent from MR 
severity and has been associated with mitral annular disjunction. Atrial displacement of the posterior MV leaflet hinge point is assumed to cause excessive mobility of the valvular apparatus and increases tension on the 
papillary muscles and the posterobasal myocardium, causing local fibrosis, 
which may lead to ventricular arrhythmias and sudden cardiac death.509 
9.1.2. Evaluation 
9.1.2.1. Echocardiography and right heart catheterization 
Echocardiography is the diagnostic method of choice for the quantification of MR, determination of its aetiology, and identification of cardiac 
consequences (Figure 10). TTE is used for initial evaluation that includes: 
(i) assessment of valve morphology (presence and location of prolapse 
or flail, calcifications, and/or mitral annular disjunction); (ii) integrative 
severity grading; and (iii) quantification of LV and LA dimensions and 
function, as well as assessment of concomitant RV dysfunction.46 
Quantitative parameters such as the effective regurgitant orifice area 
(EROA) have prognostic implications.510,511 Volumetric methods provide additional information on MR severity [RVol and regurgitant fraction (RF)].512 Accurate colour flow settings must be used to avoid 
overestimation of MR severity. 
Transoesophageal echocardiography (TOE) represents the method of 
choice to assess valve anatomy, leaflet quality, motion, and coaptation, as 
well as to confirm MR severity.513 Three-dimensional TOE provides an 
excellent morphological and functional view of the different valve segments, and should be used systematically when planning and performing 
surgical or transcatheter repair.514 
Exercise echocardiography evaluates dynamic changes in regurgitant jet 
and pulmonary pressures during peak exercise, and might be helpful in patients with discordant symptoms and regurgitation severity at rest.515,516 
In asymptomatic patients with severe PMR, increased LV or LA dimensions, as well as elevated pulmonary pressures (>50 mmHg at 
rest), moderate or more secondary TR, and AF are important markers 
of worse prognosis, and should be considered for intervention timing 
(Figure 11; Section 9.1.4).517,518 
Right heart catheterization remains important in patients with PMR 
for confirmation of pulmonary artery pressures in case of discrepancy 
between echocardiographic MR severity and clinical symptoms, as well 
as in the presence of concomitant lung disease.519 
9.1.2.2. Biomarkers 
Cardiac biomarkers are recognized indicators of disease 
severity with prognostic implications, but may also be non- 
specific. NT-proBNP levels are directly related to the 
New York Heart Association (NYHA) functional class in PMR.520 
Recommendation Table 5 ‚Äî Recommendations on indications for concomitant aortic valve replacement at 
the time of coronary artery bypass grafting or ascending 
aorta surgery 
Recommendations 
Classa 
Levelb  
SAVR is recommended in symptomatic and 
asymptomatic patients with severe AS undergoing 
CABG or surgical intervention on the ascending 
aorta. 
I 
C 
SAVR should be considered in symptomatic and 
asymptomatic patients with moderate ASc 
undergoing CABG or surgical intervention on the 
ascending aorta. 
IIa 
C 
¬© ESC/EACTS 2025
AS, aortic stenosis; AVA, aortic valve area; CABG, coronary artery bypass grafting; SAVR, 
surgical aortic valve replacement. 
aClass of recommendation. 
bLevel of evidence. 
cDefined as an AVA of 1.0‚Äì1.5 cm2 (or mean aortic gradient of 25‚Äì40 mmHg) in 
normal-flow conditions. Clinical assessment is essential to determine whether SAVR is 
appropriate for an individual patient.   
ESC Guidelines                                                                                                                                                                                               37


<!-- PAGE 38 -->

### Page 38

In a multicentre registry including more than 1300 patients with PMR, 
increased BNP level was an independent predictor of long-term mortality under medical treatment. However, pre-operative BNP activation 
did not impact long-term mortality after surgical treatment.96 
9.1.2.3. Cardiac magnetic resonance and computed tomography 
Cardiac magnetic resonance imaging is an alternative to precisely quantify RVol and RF in cases of inconclusive or discordant measurements, 
and the gold standard to determine cardiac dimensions and chamber 
volumes.521,522 The combination of planimetered volumetric methods 
and phase contrast measurement of the MV inflow are used for this 
purpose.523 In patients with Barlow‚Äôs disease and mitral annular disjunction, CMR-detected myocardial fibrosis524 has been associated with 
ventricular arrhythmias and sudden cardiac death.525 
Cardiac computed tomography provides high-resolution anatomical 
details of the entire MV apparatus523,526 and increasingly plays a role in 
MV intervention planning, particularly in the assessment of arterial access 
for extracorporeal circulation and the presence of MV calcification in minimally invasive surgery,527 as well as the feasibility of transcatheter MV implantation (TMVI) based on annulus size and risk of LVOT obstruction.528 



	
‚â•7 mm (‚â•8 mm for biplane)
		
¬Å¬ç¬è¬ê¬ù¬†
¬≠¬Ä¬ù¬≠¬Ä¬Ç¬≠¬Å¬ç¬è¬É
¬Ñ¬Ö‚â•¬É¬Ü
‚â§60%
¬Ö‚â•¬á¬á
¬à¬Ä‚â•60 mL/m2
¬à¬â¬ä
¬ã




¬Ñ¬Ö‚â§¬å¬Ü
20%‚àí50%
¬à
¬Ñ¬é¬ë
¬é¬ë

¬Ñ¬é¬ë
¬à¬é¬ë



¬é¬ë
¬é


¬ã

¬Ñ¬à>¬á¬Ü¬í
¬Ñ	¬≠¬ë
‚â• moderate
¬ë


¬ì
¬Ñ¬î
¬ì
¬ë¬Ç¬à ‚â•40 mm2 (or ‚â•30 mm2 if elliptical regurgitant orifice area)  
¬ë‚â•¬ï¬Ü‚â•¬É¬á¬†
¬ë‚â•¬á¬Ü¬ñ
Figure 10 Echocardiographic assessment of patients with mitral regurgitation. EROA, effective regurgitant orifice area; LAVI, left atrial volume index; 
LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVOT, left ventricular outflow tract; MR, mitral regurgitation; PMR, 
primary mitral regurgitation; RF, regurgitant fraction; RVol, regurgitant volume; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery 
pressure; TR, tricuspid regurgitation; VTI, velocity time integral. aSee Table 7 for criteria predicting outcome improvement.


<!-- PAGE 39 -->

### Page 39

Patient with severe primary mitral regurgitation
Symptoms
LVEF ‚â§60% or LV dilatation
(LVESD ‚â•40 mm or LVESDi ‚â•20 mm/m2)
High surgical risk according 
to the Heart Team
Anatomical suitability for TEERa
Presence of at least 3 of the following:
‚Ä¢ AF
‚Ä¢ SPAP at rest >50 mmHg
‚Ä¢ LAVI ‚â•60 mL/m2 or diameter ‚â•55 mm
‚Ä¢ Concomitant secondary TR ‚â•moderate
SigniÔ¨Åcant LA dilatation
(LAVI ‚â•60 mL/m2 or diameter ‚â•55 mm)
and high likelihood of durable repair
Watchful waiting
MV surgery
(preferably repair)
(Class IIa)
TEER
(Class IIa)
Surgical
MV repair
(Class IIa)
AF or 
SPAP at rest >50 mmHg
MV surgery
(preferably repair)
(Class I)
TMVI
if feasible
High risk surgery in 
selected 
patients
Medical treatment
Figure 11 Management of patients with severe primary mitral regurgitation. AF, atrial fibrillation; LA, left atrial; LAVI, left atrial volume index; LV, left 
ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; MV, mitral valve; SPAP, systolic pulmonary artery pressure; TEER, transcatheter edge-to-edge repair; TMVI, transcatheter mitral 
valve implantation; TR, tricuspid regurgitation. aSee Supplementary data online, Table S2.   
ESC Guidelines                                                                                                                                                                                               39


<!-- PAGE 40 -->

### Page 40

Due its high sensitivity for detection of calcifications, CCT is instrumental for procedural planning (surgical and transcatheter) in patients 
with MAC.529 
9.1.2.4. Genetic evaluation 
There is increasing evidence that specific mitral pathologies may be associated with genetic conditions. A meta-analysis of six genome-wide 
association studies identified 14 potential genetic loci associated with 
primary MR. By comprising epigenetic, transcriptional, and proteomic 
data, the following genes could be identified as potential genetic sources 
of the pathology: LMCD1, SPTBN1, LTBP2, TGFB2, NMB, and ALPK3.530 
However, genetic testing is not recommended in routine practice. 
9.1.3. Medical therapy 
Medical therapy has a limited role in patients with PMR. Afterload reduction with sodium nitroprusside has been used as a bridge to an 
intervention in patients with acute severe PMR without signs of hypotension. Inotropic agents and diuretics are usually indicated to reduce 
filling pressures and control pulmonary congestion, while the implantation of an intra-aortic balloon pump helps to further reduce afterload 
in exceptional cases of acute PMR. 
In chronic PMR without signs of LV dysfunction or criteria for an 
intervention, there is no evidence supporting prophylactic afterload reduction. Patients with PMR and impaired LV function should receive 
GDMT according to HF Guidelines.340 
9.1.4. Indications for intervention 
Urgent surgery or transcatheter treatment is indicated in patients with 
acute severe PMR because it is poorly haemodynamically tolerated. In patients with papillary muscle rupture and endocarditis, surgical valve replacement is generally required, while acute degenerative chordal rupture can be 
treated with surgical MV repair or TEER in high-risk patients. 
Indications for surgery in patients with chronic asymptomatic and 
symptomatic PMR are summarized in Recommendation Table 6 and  
Figure 11. In cases of severe PMR, restoring the anatomy by surgical 
MV repair, including annuloplasty, is the treatment of choice in operable 
patients when an optimal and durable result is expected. According 
to contemporary data, the procedure can be performed with 
a low mortality risk (1.2%) in appropriately selected patients.531 
Compared with replacement, MV repair has been associated with 
lower peri-operative mortality along with significantly better long- 
term survival and functional outcomes.532,533 Repair of more complex pathologies such as valves with annular or leaflet calcifications, 
as well as in cases of RHD, is challenging and should be attempted in 
experienced Heart Valve Centres.534‚Äì536 When MV repair is not 
feasible, valve replacement with preservation of the subvalvular apparatus should be performed.537 
High-risk and elderly patients with chronic PMR, though uncommon, 
may benefit from a less-invasive M-TEER procedure.538 Peri- 
interventional and mid-term results with regard to residual MR and 
mean transmitral gradient are closely related to patient outcomes.538 
The use of latest-generation devices along with a growing team experience have improved results, and allow for the successful treatment 
of more complex anatomical conditions (Supplementary data online,  
Table S2).539,540 The decision regarding the mode of intervention or 
conservative treatment should be made by the Heart Team, considering 
clinical and anatomical characteristics, as well as procedural risks and 
patient preference. The longer-term efficacy of TEER compared with 
surgery is still under investigation in high- (NCT03271762) and 
intermediate-risk PMR patients (NCT04198870), as well as in 
all-risk-category patients >60 years of age (NCT05051033).541 TMVI 
is very effective in abolishing MR in selected high-risk patients, particularly those with complex MV anatomy for TEER (Supplementary data 
online, Table S2).542,543 The major drawbacks of current TMVI systems 
include limited availability, high screening failure rate, as well as the risk of 
LVOT obstruction and valve thrombosis. Limited data exist for PMR patients and regarding mid-term prosthesis durability. 
In patients with asymptomatic PMR with signs of LV dysfunction 
(i.e. LVEF ‚â§60%, LVESD ‚â•40 mm, or LVESDi ‚â•20 mm/m2) the benefit of early surgery is well established.544‚Äì546 Furthermore, there is increasing evidence that the presence of LA dilatation [LA volume index 
(LAVI) ‚â•60 mL/m2 or LA diameter ‚â•55 mm], AF, systolic pulmonary 
artery pressure (SPAP) at rest of >50 mmHg, and concomitant moderate or severe secondary TR are associated with worse long-term 
prognosis irrespective of LV function after corrective surgery, and 
should therefore prompt referral in low-risk patients, particularly if 
a high probability of MV repair is expected.517,518,547 A recent study 
showed that women have a higher risk of long-term mortality after 
MV repair than men, even at lower degrees of ventricular dilatation 
and dysfunction, suggesting the potential usefulness of sex-specific indexed thresholds.548 Ventricular arrhythmias in patients with MV prolapse have been linked to impaired prognosis and possibly sudden 
cardiac death, especially in the presence of mitral annular disjunction.549‚Äì551 Ring annuloplasty stabilizes the posterior annulus, reduces 
traction on the subvalvular apparatus,552 and may lower the risk of arrhythmias.553 Minimally invasive surgery via right mini-thoracotomy is 
used with increasing frequency in experienced centres.554‚Äì556 A recent RCT demonstrated similar safety and efficacy compared with 
conventional sternotomy. Mini-thoracotomy was associated with 
shorter hospital stay and improved physical activity within the first 
6 weeks after surgery, a difference that disappeared at 12 weeks.557 
The use of minimally invasive MV surgery may therefore be considered to reduce hospital stay and accelerate recovery in experienced 
centres. However, in a national registry, these benefits were less 
clear.558 
Recommendation Table 6 ‚Äî Recommendations on 
indications for intervention in severe primary mitral 
regurgitation (see also Supplementary data online, 
Evidence Tables 14‚Äì16) 
Recommendations 
Classa 
Levelb  
MV repair is the recommended surgical technique to 
treat patients with severe PMR when the result is 
expected to be durable.26,532,533,559,560 
I 
B 
MV surgery is recommended in symptomatic 
patients with severe PMR considered operable by 
the Heart Team.26,532,533,561 
I 
B 
MV surgery is recommended in asymptomatic 
patients with severe PMR and LV dysfunction 
(LVESD ‚â•40 mm or LVESDi ‚â•20 mm/m2 or 
LVEF ‚â§60%).522,544,545 
I 
B                         
Continued


<!-- PAGE 41 -->

### Page 41

9.1.5. Follow-up 
Asymptomatic patients with severe MR not fulfilling the criteria for an 
intervention, and with documented preserved exercise capacity, should 
undergo clinical and echocardiographic follow-up twice per year (watchful waiting strategy), ideally in the setting of a Heart Valve Clinic.568 
Follow-up may also include serial measurements of BNP levels, electrocardiogram (ECG) and/or Holter monitoring, and (in selected cases) exercise echocardiography and CMR to confirm MR severity, and cardiac 
chamber function and dimensions.46 Asymptomatic patients with moderate MR and preserved LV function can be followed on a yearly basis 
with echocardiographic assessment every 1 or 2 years. 
The frequency of follow-up after an intervention depends on the type 
of procedure performed. Very good long-term durability of MV repair in 
PMR due to valve prolapse with a low recurrence rate has been reported 
at experienced centres with freedom from moderate or severe MR of 
87.5% at 20 years.533,559 Serial clinical and echocardiographic follow-up 
in patients without pre-operative LV dysfunction or rhythm abnormalities every 2‚Äì3 years thereafter is sufficient. Patients with atrial or ventricular arrhythmias possibly related to MV disease should be further 
evaluated using continuous ECG monitoring. Patients with recurrent 
MR after surgical ring annuloplasty frequently undergo repeat surgery 
(usually MV replacement), while transcatheter alternatives are reserved 
for selected high-risk patients because of the risk of increased gradients 
(M-TEER), PVL, and LVOT obstruction (mitral valve-in-ring procedures).569,570 In patients undergoing MV replacement, closer follow-up 
on a yearly basis is required due to the risk of prosthetic valve dysfunction 
or SVD (see Section 14.4). Following TEER, reported rates of residual MR 
and increased transmitral gradients are higher than after surgical repair, 
suggesting that yearly follow-up is appropriate.571 Although rare, the 
need for surgical treatment after failed TEER is associated with increased 
peri-operative mortality and low valve repair rates,541,572 while transcatheter solutions to detach TEER implants and replace the valve have 
been described in few cases.573,574 
9.2. Secondary mitral regurgitation 
9.2.1. Prevalence and aetiology 
Secondary mitral regurgitation is present when the MV structure appears 
grossly normal but the MV is nonetheless incompetent, due to alterations 
in LV and LA geometry, dyssynchrony, and imbalances between MV closing and tethering forces.575 The prevalence of severe SMR in patients with 
chronic HF is ‚àº10% and higher in patients with reduced vs preserved LVEF 
(25% vs 4%).576 Secondary mitral regurgitation can be classified as atrial or 
ventricular with different pathophysiological and morphological characteristics, as well as contrasting prognostic and therapeutic implications.577 
Ventricular SMR is more common and associated with worse long-term 
prognosis.513,578‚Äì580 Dilated or ischaemic cardiomyopathy are the most 
frequent causes of severe ventricular SMR. Acute HF exacerbation may 
occur in patients with chronic HF due to a renewed ischaemic event, arrhythmia, infection, or volume overload. Atrial SMR is due to pure mitral 
annular dilation and is observed in patients with long-standing AF and/or 
HFpEF.581 Factors predisposing to atrial SMR include age ‚â•65 years, female sex, LA dilatation, and diastolic dysfunction.582 From a morphological 
point of view, ventricular SMR is characterized by leaflet tethering and restricted motion combined with annular dilation, while annulus enlargement and flattening leading to planar coaptation are predominantly 
observed in atrial SMR. The prevalence of atrial SMR has been underestimated in the past and was occasionally misclassified as PMR due to 
pseudo-prolapse with leaflet tethering in advanced stages. 
9.2.2. Evaluation 
Echocardiographic criteria to define significant SMR according to aetiology are reported in Figure 10. Importantly, SMR assessment should 
be performed after optimization of medical therapy and in a euvolaemic 
and normotensive state. When quantifying EROA and RVol in SMR, 
lower thresholds may apply to define severe regurgitation because of 
the potential elliptical regurgitant orifice and/or the low-flow state. 
An EROA of ‚â•30 mm2 and/or an RVol of ‚â•45 mL has been identified 
as having a significant impact on outcomes,45 with prognosis improved 
after treatment.583,584 Cardiac magnetic resonance is used to confirm 
SMR severity and assess cardiac chamber function and dimensions. 
The extent of myocardial fibrosis, as assessed with CMR, has been associated with poor prognosis.585 Owing to the dynamic nature of SMR, 
exercise echocardiography may help to identify patients with severe 
SMR when values at rest are inconclusive.45 
9.2.3. Definition of atrial secondary mitral 
regurgitation 
Characteristics distinguishing between atrial and ventricular SMR are 
displayed in Figure 12. 
Surgical MV repair is recommended in low-risk 
asymptomatic patients with severe PMR without LV 
dysfunction (LVESD <40 mm, LVESDi <20 mm/m2, 
and LVEF >60%) when a durable result is likely, if at 
least three of the following criteria are 
fulfilled:517,547,562‚Äì564 
‚Ä¢ AF 
‚Ä¢ SPAP at rest >50 mmHg 
‚Ä¢ LA dilatation (LAVI ‚â•60 mL/m2 or LA 
diameter ‚â•55 mm) 
‚Ä¢ Concomitant secondary TR ‚â• moderate. 
I 
B 
MV surgery should be considered in asymptomatic 
patients with severe PMR without LV dysfunction 
(LVESD <40 mm, LVESDi <20 mm/m2, and LVEF  
>60%) in the presence of PH (SPAP at rest  
>50 mmHg), or AF secondary to MR.517,518,562,565 
Ila 
B 
Surgical MV repair should be considered in low-risk 
asymptomatic patients with severe PMR without LV 
dysfunction (LVESD <40 mm, LVESDi <20 mm/m2, 
and LVEF >60%) in the presence of significant LA 
dilatation (LAVI ‚â•60 mL/m2 or LA 
diameter ‚â•55 mm), when performed in a Heart 
Valve Centre and a durable repair is likely.517,565 
IIa 
B 
TEER should be considered in symptomatic patients 
with severe PMR who are anatomically suitable and 
at high surgical risk according to the Heart 
Team.538,540,566 
IIa 
B 
Minimally invasive MV surgery may be considered at 
experienced centres to reduce the length of stay and 
accelerate recovery.557,567 
IIb 
B 
¬© ESC/EACTS 2025
AF, atrial fibrillation; LA, left atrium/left atrial; LAVI, left atrial volume index; LV, left 
ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular 
end-systolic diameter; LVESDi, left ventricular end-systolic diameter indexed to body 
surface area; MR, mitral regurgitation; MV, mitral valve; PH, pulmonary hypertension; 
PMR, primary mitral regurgitation; SPAP, systolic pulmonary artery pressure; TEER, 
transcatheter edge-to-edge repair; TR, tricuspid regurgitation. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               41


<!-- PAGE 42 -->

### Page 42

Atrial SMR is most frequently defined by the presence of the following key criteria:513,578‚Äì580,586‚Äì590 
‚Ä¢ preserved LVEF (‚â•50%) without regional wall motion abnormalities 
or leaflet tethering; AND 
‚Ä¢ no or mildly dilated LV cavity [LV end-diastolic dimension of <56 mm 
in women and <63 mm in men; indexed LV end-diastolic volume of 
<71 mL/m2 (in women) or <79 mL/m2 (in men)]; AND 
‚Ä¢ mitral annulus (MA) dilatation [anteroposterior (AP) diameter of 
>35 mm]; AND 
‚Ä¢ enlarged LA (LAVI >34 mL/m2).  
Echocardiography frequently reveals normal leaflet motion with planar coaptation, and normal leaflet morphology with a central MR jet in 
atrial SMR. However, at advanced stages, an overlap between atrial and 
ventricular SMR criteria can be observed in the case of late LV damage 
due to continuous volume overload.591,592 Clinical criteria (i.e. history 
of AF and/or diagnosis of HFpEF) are also useful and should be taken 
into consideration. 
9.2.4. Management of ventricular secondary mitral  
regurgitation 
9.2.4.1. Medical and device therapy 
In patients with ventricular SMR, GDMT for the treatment of HF is recommended prior to any MV intervention.339,340 The combination of 
ACE-Is/ARBs or angiotensin receptor/neprilysin inhibitors, beta- 
blockers, mineralocorticoid receptor antagonists, and sodium‚Äìglucose 
co-transporter 2 inhibitors (SGLT2is) at the maximum tolerated doses 
is recommended according to the HF Guidelines.340 Initiation and up- 
titration of neurohormonal drugs need to be tailored according to 
the patient profile, mainly based on BP, heart rate, potassium levels, 
and renal function.593 Notably, GDMT up-titration must be rapid (within 6 weeks) and take place in the context of close follow-up visits, especially in the case of a recent hospitalization for acute HF.594 About 
40% of patients with ventricular SMR experience improvement of 
SMR severity after 1‚Äì3 months of optimized GDMT.595,596 Cardiac resynchronization therapy (CRT) should also be considered as part of HF 
management before an MV intervention according to HF guideline criteria (LVEF ‚â§35% and wide QRS).597,598 Although no dedicated RCTs 












‚â•
	
		
¬Å
¬ç	
			
¬è¬ê¬ù¬†¬≠
	
¬è¬Ä¬ù¬†¬Ç¬É¬Ñ¬≠
¬Ö

		
¬Å¬ç	
	
¬ç¬Ü

¬á		

¬ç	
¬à
¬ç¬Ü

¬à
¬â	
¬à		

¬ä	
¬Ä
¬ã¬Ü
¬à¬Ü



	

Figure 12 Most frequently used criteria for the diagnosis of atrial secondary mitral regurgitation. AO, aorta; AP, anteroposterior; HFpEF, heart failure 
with preserved ejection fraction; LA, left atrium/left atrial; LAVI, left atrial volume index; LV, left ventricle/left ventricular; LVEF, left ventricular ejection 
fraction; MA, mitral annulus; MR, mitral regurgitation; MV, mitral valve; SMR, secondary mitral regurgitation. aLV end-diastolic dimension of <56 mm in 
females and <63 mm in males; indexed LV end-diastolic volume <71 mL/m2 (in women) or <79 mL/m2 (in men). bAdditional echocardiographic criteria 
for atrial SMR may no longer be fulfilled in advanced stages.


<!-- PAGE 43 -->

### Page 43

exist, SMR reduction by at least one grade has been described in 40%‚Äì 
60% of patients and is associated with reverse LV remodelling and improved clinical outcomes.597,599,600 
9.2.4.2. Indications for intervention 
The management of patients with ventricular SMR should be discussed 
by a multidisciplinary Heart Team including HF specialists. The indication for intervention is based on the persistence of symptoms (i.e. 
NYHA class II‚ÄìV) despite adequate GDMT and CRT, if indicated 
(Figure 13). GDMT is the only option for very frail patients or those 
with limited life expectancy. 
In the Cardiovascular Outcomes Assessment of the MitraClip 
Percutaneous Therapy for Heart Failure Patients with Functional 
Mitral Regurgitation (COAPT) trial, M-TEER was shown to be safe 
and reduced recurrent HF hospitalization and all-cause mortality 
at 2 and 5 years of follow-up, compared with optimized GDMT 
in patients with ventricular SMR without relevant CAD.583,584 
In a second study (Percutaneous Repair with the MitraClip Device for 
Ventricular SMR
Persistence of symptoms and SMR
Atrial SMR
Patient with severe symptomatic SMR without concomitant CAD
High surgical risk according 
to the Heart Team
Clinical and echocardiographic criteria fulÔ¨Ålleda according 
to the Heart Team 
Advanced HF
LVAD
or HTx
GDMT optimization including CRT, if indicated
Persistence of symptoms and SMR
TEER 
(Class IIb)
MV surgery in patients not suitable for TEERb
(Class IIb)
TEER
in patients with contraindication(s) 
or waiting for
LVAD or HTx
(Class IIb)
Medical therapy and follow-up
Optimization of medical treatment including rate or rhythm control
TEER
(Class I)
MV
surgery
(Class IIa)
TEER
(Class IIb)
Figure 13 Treatment of severe secondary mitral regurgitation without concomitant coronary artery disease. CAD, coronary artery disease; CRT, 
cardiac resynchronization therapy; GDMT, guideline-directed medical therapy; HF, heart failure; HTx, heart transplantation; LVAD, left ventricular assist 
device; MV, mitral valve; SMR, secondary mitral regurgitation; TEER, transcatheter edge-to-edge repair. aSee Table 7. bSee Supplementary data online,  
Table S2.   
ESC Guidelines                                                                                                                                                                                               43


<!-- PAGE 44 -->

### Page 44

Severe Functional/Secondary Mitral Regurgitation, MITRA-FR), no differences were demonstrated for the combined primary endpoint of all- 
cause mortality or HF hospitalization at 1 and 2 years.601,602 These diverging results might be explained by effect sizes of the trials, differences 
in trial design, patient selection and follow-up, echocardiographic assessment of SMR severity, use of GDMT, and technical factors.603‚Äì605 A 
third RCT, the Randomized Investigation of the MitraClip Device in 
Heart Failure: 2nd Trial in Patients with Clinically Significant 
Functional Mitral Regurgitation (RESHAPE-HF-2) trial showed a 36% 
reduction in the rates of HF hospitalization or cardiovascular death 
at 2 years in the intervention arm driven by reduction of first or recurrent HF hospitalization. When considered in isolation, cardiovascular 
mortality was not significantly reduced during the observation period. 
In addition, there was a significant improvement in quality of life as 
measured by the KCCQ overall score (mean difference between study 
groups, 10.9 points; 95% CI, 6.8‚Äì15.0; P <0.001).606 A recent study-level 
meta-analysis of these three trials showed a significant reduction of HF 
rehospitalization at 24 months (HR, 0.63, 95% CI, 0.50‚Äì0.80) and the 
composite of death and all-cause hospitalizations (HR, 0.72, 95% CI, 
0.51‚Äì0.999).607 However, there was no statistically significant difference 
in death from any cause or cardiovascular death at 24 months. 
Transcatheter edge-to-edge repair is therefore recommended to reduce HF hospitalizations, and improve quality of life, in symptomatic patients with persisting severe SMR despite optimized GDMT fulfilling 
specific clinical and echocardiographic criteria (Table 7). Although less 
challenging than in PMR, anatomical suitability for TEER needs to be assessed upfront (Supplementary data online, Table S2). There is also increasing observational evidence supporting the use of TEER for the 
improvement of symptoms, functional capacity, and quality of life in patients with ventricular SMR not fulfilling the clinical and echocardiographic criteria for outcome improvement.608‚Äì612 This particularly 
applies to patients not tolerating GDMT in whom TEER may help up- 
titration, as well as those with recent myocardial infarction and persistent severe ventricular SMR.203,613 
Transcatheter implantation of an indirect annuloplasty device into 
the coronary sinus has been proposed as an alternative that preserves 
valve integrity. Despite rather modest SMR reduction (22.4% decrease 
in mitral RVol) and no significant effect on quality of life in a small sham- 
controlled RCT, symptomatic improvement and reverse remodelling 
were observed in registries at 1 year.614,615 Heart transplantation or 
left ventricular assist device (LVAD) implantation should be considered 
in selected patients with severe ventricular SMR and advanced HF. 
In patients with ventricular SMR without relevant CAD, indications 
for isolated MV surgery are restrictive owing to procedural risks and 
the absence of proven mortality benefit.616 The Multicenter, 
Randomized, Controlled Study to Assess Mitral Valve Reconstruction 
for Advanced Insufficiency of Functional or Ischemic Origin 
(MATTERHORN) trial, which included a mixed population mainly composed of patients with ventricular SMR (84%), demonstrated that TEER 
is non-inferior to surgical repair or replacement with regard to a composite endpoint of death, HF hospitalization, MV reintervention, implantation of an assist device, or stroke within 1 year after the 
procedure, and showed a better safety profile.617 In patients with severe ischaemic ventricular SMR and concomitant CAD requiring coronary revascularization, MV surgery at the time of CABG is 
recommended, unless the patient is at high surgical risk and/or the coronary anatomy is suitable for PCI. Although isolated undersized mitral 
annuloplasty is the most commonly performed MV repair procedure, 
recurrent MR rates were high with this technique in an RCT618 and reverse LV remodelling is limited, especially in patients with an increased 
tenting area (>1.35 cm2/m2 BSA),619 in whom MV replacement is usually required.620 The addition of subvalvular modification in patients 
with LV dilatation and pronounced MV leaflet tenting may improve results for MV repair,621 but durability and impact on HF symptoms with 
this technique require further investigation. 
The treatment of moderate ischaemic SMR in patients undergoing 
CABG remains controversial. Meta-analyses, including four RCTs comparing CABG with concomitant MV surgery vs CABG alone, have 
shown lower rates of recurrent MR but no benefit in terms of mortality 
and clinical outcomes.622‚Äì624 Therefore, clinical decision-making should 
weigh peri-operative risks of more complex surgery against the long- 
term risk of MR progression. 
9.2.4.3. Follow-up 
Patients with ventricular SMR need to be followed up carefully after 
intervention by an HF specialist, because they remain at increased 
risk of events despite intervention. The 5-year cumulative incidence 
of all-cause death or HF hospitalization was 73.6% in the device arm 
of the COAPT study.584 Clinical, laboratory, and echocardiographic 
evaluation every 3 or 6 months, according to the HF stage, is recommended. Durability of the procedural result, as well as congestion status 
and the need for further GDMT optimization facilitated by SMR reduction,613 need to be assessed. Patients and families should be trained in 
monitoring vital signs, body weight, and HF symptoms to avoid late hospital admissions and facilitate management of possible decompensation. 
Also, patients must be educated on the importance of not discontinuing 
medical therapies after intervention since the two treatments (devices 
and drugs) are complementary. 
Patients with ventricular SMR, who are asymptomatic and/or have 
moderate or dynamic MR, should undergo clinical and echocardiographic follow-up at least twice per year. 
Table 7 Clinical and echocardiographic criteria predicting outcome improvement in patients with severe 
ventricular secondary mitral regurgitation undergoing 
mitral transcatheter edge-to-edge repair  
Anatomy deemed suitable for M-TEER 
NYHA class ‚â•II 
LVEF 20%‚Äì50% 
LVESD ‚â§70 mm 
At least one HF hospitalization within the previous year or increased 
natriuretic peptide levels (BNP ‚â•300 pg/mL or NT-proBNP ‚â•1000 pg/mL) 
SPAP ‚â§70 mmHg 
No severe RV dysfunction 
No Stage D or advanced HF 
No CAD requiring revascularization 
No severe AV and/or TV disease 
No hypertrophic, restrictive, or infiltrative cardiomyopathies 
¬© ESC/EACTS 2025
AV, aortic valve; BNP, brain natriuretic peptide; CAD, coronary artery disease; HF, heart 
failure; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic 
diameter; M-TEER, mitral transcatheter edge-to-edge repair; NT-proBNP, N-terminal 
pro-B-type natriuretic protein; NYHA, New York Heart Association; RV, right ventricle/ 
right ventricular; SPAP, systolic pulmonary artery pressure; TV, tricuspid valve.


<!-- PAGE 45 -->

### Page 45

9.2.5. Management of atrial secondary mitral 
regurgitation 
9.2.5.1. Medical therapy and rhythm management 
In patients with atrial SMR, underlying causes need to be recognized and 
treated. Associated HFpEF and AF should be managed according to the 
relevant Guidelines.7,340 The use of SGLT2is should be encouraged in 
patients with HFpEF due to their proven efficacy in reducing cardiovascular death and HF hospitalization.625 Limited data show that rhythm 
control may contribute to reduce atrial SMR severity and reverse LA 
dilatation.626 
9.2.5.2. Indications for intervention 
Registry data demonstrate that patients with atrial SMR are typically 
elderly with associated AF. Mitral valve surgery has been recently associated with lower rates of HF hospitalizations and mortality compared 
with GDMT in a matched population, despite a higher risk profile in the 
surgical arm at baseline.627 Data from several observational studies also 
suggest that surgical annuloplasty is effective and durable in patients with 
atrial SMR, because it counteracts the main mechanism of MR progression.628‚Äì630 Its combination with surgical AF ablation (Maze procedure) 
and concomitant LAAO may have further advantages,630,631 while the frequently associated relevant TR can also be addressed during the same procedure.627 Transcatheter edge-to-edge repair may also be considered 
because observational studies have demonstrated high safety and procedural success,588‚Äì590,632,633 as well as compared with surgery in a small subgroup (n = 34) of the MATTERHORN RCT.634 However, the risk of 
increased gradient due to planar leaflet coaptation, large regurgitant jet, 
and limited MV area (MVA) needs to be taken into consideration.592,635 
Further studies are warranted to investigate the treatment modalities of 
patients with atrial SMR. 
9.2.5.3. Follow-up 
Patients with atrial SMR undergoing surgical or transcatheter intervention should be followed up on a yearly basis, including clinical and echocardiographic evaluation. In cases of HFpEF, as an underlying cause of 
atrial SMR, consultation with an HF specialist is necessary. 
Asymptomatic patients with severe atrial SMR not fulfilling the criteria for an intervention should undergo clinical and echocardiographic 
follow-up at least once per year. 
10. Mitral stenosis 
10.1. Prevalence and aetiology 
The aetiology of MS is most frequently rheumatic or degenerative, 
while rare forms can be drug-induced, inflammatory, or 
carcinoid-related. Rheumatic fever is the most common cause of 
MS and death due to VHD worldwide. Its prevalence has decreased 
in high- and middle-income countries, but remains a major healthcare problem in low-income countries, where it predominantly 
affects young patients.12,187,644 Degenerative MS related to MAC 
is 
a 
distinct 
age-dependent 
pathology 
requiring 
different 
treatment strategies.645‚Äì647 Both aetiologies are more frequent in 
females.648 
10.2. Rheumatic mitral stenosis 
10.2.1. Evaluation 
Echocardiography is the preferred method for screening in endemic regions and the assessment of the severity, extent of anatomical lesions, 
and haemodynamic consequences of MS. Involvement of other valves, 
particularly secondary TR, should be identified. Mitral valve area using 
Recommendation Table 7 ‚Äî Recommendations on indications 
for 
intervention 
in 
secondary 
mitral 
regurgitation (see also Supplementary data online, 
Evidence Tables 17‚Äì20) 
Recommendations 
Classa 
Levelb 
Severe atrial secondary mitral regurgitation  
MV surgery, surgical AF ablation, if indicated, and 
LAAO should be considered in symptomatic patients 
with severe atrial SMR under optimal medical 
therapy.627‚Äì630,636,637 
IIa 
B 
TEER may be considered in symptomatic patients 
with severe atrial SMR not eligible for surgery after 
optimization of medical therapy including rhythm 
control, when appropriate.588,590,638,639 
IIb 
B                                                                                                   
Continued 
Ventricular secondary mitral regurgitation and concomitant 
coronary artery disease 
MV surgery is recommended in patients with severe 
ventricular SMR undergoing CABG.640 
I 
B 
MV surgery may be considered in patients with 
moderate SMR undergoing CABG.622‚Äì624,641,642 
IIb 
B 
PCI followed by TEER after re-evaluation of MR may 
be considered in symptomatic patients with chronic 
severe ventricular SMR and non-complex CAD.150 
IIb 
C 
Severe ventricular secondary mitral regurgitation without 
concomitant coronary artery disease 
TEER is recommended to reduce HF hospitalizations 
and improve quality of life in haemodynamically 
stable, symptomatic patients with impaired LVEF 
(<50%) and persistent severe ventricular SMR, 
despite optimized GDMT and CRT (if indicated), 
fulfilling specific clinical and echocardiographic 
criteria.c 583,584,606,608,643 
I 
A 
TEER may be considered for symptom improvement 
in selected symptomatic patients with severe 
ventricular SMR not fulfilling the specific clinical and 
echocardiographic criteria,c after careful evaluation 
of LVAD or HTx.203,608‚Äì610 
IIb 
B 
MV surgery may be considered in symptomatic 
patients with severe ventricular SMR without 
advanced HF who are not suitable for TEER.617 
IIb 
C 
¬© ESC/EACTS 2025
AF, atrial fibrillation; CABG, coronary artery bypass grafting; CAD, coronary artery disease; 
CRT, cardiac resynchronization therapy; GDMT, guideline-directed medical therapy; HF, 
heart failure; HTx, heart transplantation; LAAO, left atrial appendage occlusion; LVAD, 
left ventricular assist device; LVEF, left ventricular ejection faction; MR, mitral 
regurgitation; MV, mitral valve; PCI, percutaneous coronary intervention; SMR, 
secondary mitral regurgitation; TEER, transcatheter edge-to-edge repair. 
aClass of recommendation. 
bLevel of evidence. 
cSee Table 7.   
ESC Guidelines                                                                                                                                                                                               45


<!-- PAGE 46 -->

### Page 46

2D planimetry is the most commonly used measurement to assess 
stenosis severity, but 3D TTE and TOE have additional diagnostic 
value.649 An MVA of ‚â§1.5 cm2 in conjunction with clinical factors 
(symptoms, high risk of thromboembolism, or haemodynamic decompensation) is indicative of clinically severe MS. Mean transvalvular gradient and pulmonary pressures reflect its consequences and have 
prognostic value.649,650 Leaflet thickening and fibrosis, along with commissural fusion and shortening of the subvalvular apparatus, are the 
most important pathomechanisms of stenosis associated with RHD. 
The presence and extent of leaflet and subvalvular calcifications influence treatment decisions. Scoring systems have been developed to assess the suitability of patients for percutaneous mitral commissurotomy 
(PMC) (see Supplementary data online, Table S3).651‚Äì653 
Exercise testing is indicated in asymptomatic patients or patients 
with symptoms that are equivocal or discordant with the severity of 
stenosis. Exercise echocardiography provides additional information 
on exercise capacity and related changes in mitral gradient and pulmonary artery pressure, and is preferred over DSE, especially when there 
are contraindications to dobutamine.654 Transoesophageal echocardiography should be systematically performed in PMC candidates to exclude LA thrombus or after an embolic episode, and may play an 
essential role for procedural guidance.52,655 
10.2.2. Medical therapy 
Diuretics, beta-blockers, digoxin, non-dihydropyridine calcium channel 
blockers, and ivabradine can improve symptoms by controlling volume 
overload and heart rate. Anticoagulation with a VKA with a target international normalized ratio (INR) between 2 and 3 is indicated in patients 
with AF, and DOACs should be avoided in patients with an MVA of 
‚â§2.0 cm2 according to current evidence.165,656,657 Interventions to restore sinus rhythm (cardioversion or catheter pulmonary vein isolation) 
are unlikely to be successful in patients with untreated severe MS. If AF 
is of recent onset and the LA moderately enlarged, cardioversion can be 
attempted soon after successful intervention or in patients with moderate MS combined with amiodarone treatment.658,659 In patients in 
sinus rhythm, OAC is indicated after systemic embolism or if a thrombus is present in the LA, and should also be considered when TOE 
shows dense spontaneous echocardiographic contrast or an enlarged 
LA (M-mode diameter >50 mm or LA volume >60 mL/m2).660 
Prophylaxis of infective endocarditis is indicated as appropriate.5 
10.2.3. Indications for intervention 
The type (PMC or surgery) and timing of treatment should be decided 
based on clinical characteristics, the anatomy of the valve and subvalvular apparatus, and local expertise.661‚Äì663 The management of clinically 
severe rheumatic MS is summarized in Figure 14 and Recommendation 
Table 8. 
In general, indication for intervention should be limited to patients 
with clinically severe rheumatic MS (MVA <1.5 cm2) in whom PMC is 
expected to have a significant impact on clinical outcome. In higher- 
income countries, where the incidence of rheumatic fever and the number of PMCs performed is low, this treatment should be restricted to 
expert operators in specialized centres to improve safety and procedural success rate.661,664 Efforts should be made to increase the availability of PMC in lower-income countries, where access to treatment is 
limited for economic reasons.665,666 Percutaneous mitral commissurotomy 
may be also considered in symptomatic patients with an MVA of 
>1.5 cm2, if symptoms cannot be explained by another cause and 
if the anatomy is favourable (see Table 8). Percutaneous mitral 
commissurotomy should be considered as a first-line treatment for patients with anatomically suitable rheumatic MS and mild-to-moderate 
calcification without severe subvalvular impairment. Selected patients 
with unfavourable anatomical and clinical characteristics can still benefit 
from PMC, particularly if they are at increased surgical risk. When 
symptomatic restenosis occurs after surgical commissurotomy or 
PMC, reintervention in most cases requires surgical valve replacement, 
but redo PMC can be proposed in selected candidates with favourable 
characteristics, if the predominant mechanism is commissural refusion. 
Long-term follow-up has shown favourable results following PMC despite a growing number of elderly patients with suboptimal clinical and 
anatomical characteristics.663‚Äì665 
For patients in whom PMC is contraindicated (Table 8), surgical MV 
repair or, more frequently, replacement are good alternatives. 
Although repair is much more challenging than for PMR, it can be attempted at experienced centres.663 
For patients with multiple VHD including MS, a comprehensive 
evaluation by the Heart Team and an individualized approach is necessary. Surgery is preferable to PMC in patients with severe MS and severe AV disease, unless the surgical risk is high. In selected cases with 
severe MS and moderate AV disease, PMC can be performed to postpone surgical treatment of both valves. 
In high-risk cases with concomitant severe TR, PMC may be considered in selected patients with sinus rhythm, moderate atrial enlargement, and secondary TR due to post-capillary PH. In non-high-risk 
cases, surgery on both valves is preferred.651,652,662,667 Treatment of 
patients with low-gradient severe MS (MVA <1.5 cm2, mean gradient  
<10 mmHg) is challenging, because these patients are often older 
and have unfavourable anatomy.668,669 
10.2.4. Follow-up 
Asymptomatic patients with clinically severe MS who have not undergone intervention should be followed up yearly by TTE, and at longer intervals (2‚Äì3 years) in cases of moderate stenosis. After PMC, the 
post-procedural MVA and mean mitral gradient are important parameters that influence long-term clinical outcomes. Follow-up of patients 
after successful PMC is necessary because asymptomatic restenosis may 
occur. Progressive rheumatic involvement of other valves should be periodically assessed, irrespective of the therapy modality. Finally, education 
and the engagement of the family is key in patients with rheumatic MS, 
since it usually affects young individuals and women of childbearing age. 
10.3. Degenerative mitral stenosis with 
mitral annular calcification 
Patients presenting with MAC are elderly and have significant comorbidities, including disease of other valves. Mitral annular calcification is also an 
indicator of cardiovascular disease severity and is associated with an increased risk of AF, stroke, and death.670,671 The incidence of MAC varies 
substantially, depending on the age of the studied population and the imaging modality used. It can be a consequence of many different pathological processes and, depending on the underlying disease, can be 
accompanied by stenosis, regurgitation, or both. However, most patients 
with MAC do not have significant valvular dysfunction.647,672 
Generally, MS occurs due to calcific extension into the MV leaflets or 
subvalvular apparatus, and in some patients it is associated with combined MR.673 Treatment options (including transcatheter and surgical 
approaches) are high-risk procedures and evidence from RCTs is 
lacking.


<!-- PAGE 47 -->

### Page 47

10.3.1. Evaluation 
Echocardiography is used for initial evaluation, but is frequently limited 
by acoustic shadowing due to severe calcification. Evaluation of MVA by 
planimetry is less reliable than in rheumatic MS, and TOE should 
therefore be used liberally. Degenerative MS can coexist with varying 
degrees of MR. Mean transmitral gradient has been shown to be associated with increased mortality irrespective of MR severity.674 
Electrocardiogram-gated CCT is necessary to assess the degree and locations of calcifications, especially if an intervention is planned.647,674‚Äì676 
Calcifications are usually more prominent at the posterior aspect of the 
annulus. 
10.3.2. Indications for intervention 
Intervention is recommended in symptomatic patients who are not responsive to medical therapy, weighing the potential benefits of the procedure against its associated risks. In elderly patients with degenerative MS 
and MAC, surgery is technically challenging and high risk. However, 
Contraindication or high risk for surgery
Favourable clinical characteristicsc
Favourable anatomical characteristicsc
Patient with rheumatic mitral stenosis and mitral valve area ‚â§1.5 cm2
Surgeryd
Symptoms
Symptoms
Exercise testing
Surgery
Surgery
PMC
Follow-up
PMC
Contraindication to PMCb
High risk of embolism or haemodynamic decompensationa
Contraindication to or unfavourable characteristics for PMC
Figure 14 Management of clinically severe rheumatic mitral stenosis (mitral valve area ‚â§1.5 cm2). AF, atrial fibrillation; LA, left atrium; MS, mitral 
stenosis; MV, mitral valve; MVA, mitral valve area; NCS, non-cardiac surgery; NYHA, New York Heart Association; PH, pulmonary hypertension; 
PMC, percutaneous mitral commissurotomy; SPAP, systolic pulmonary artery pressure; TR, tricuspid regurgitation. aHigh thromboembolic risk: history 
of systemic embolism, dense spontaneous contrast in the LA, new-onset AF. High-risk of haemodynamic decompensation: SPAP >50 mmHg at rest, 
need for major NCS, desire for pregnancy or pregnant. bSee Table 8. cFavourable = absence of unfavourable characteristics for PMC defined by unfavourable anatomical characteristics [echocardiographic score >8, Cormier score 3 (calcification of MV of any extent as assessed by fluoroscopy), 
severe TR] or unfavourable clinical characteristics (old age, history of commissurotomy, NYHA class IV, permanent AF, severe PH) (for the definition 
of scores see Supplementary data online, Table S3). dIf operative risk is low.   
ESC Guidelines                                                                                                                                                                                               47


<!-- PAGE 48 -->

### Page 48

surgical MV repair or replacement with extensive decalcification and 
patch reconstruction of the annulus can be performed in selected patients 
at experienced centres (e.g. young patients post-chest radiation), where 
mortality rates of <5% have been reported.677‚Äì679 
Degenerative MS is not amenable to PMC because commissural fusion is absent. In symptomatic high-risk patients with suitable anatomy, transcatheter implantation of a TAVI prosthesis in the mitral 
position is feasible but associated with frequent complications, including LVOT obstruction, valve embolization, stroke, and haemolysis due 
to PVL. Open surgical valve replacement via the LA with a TAVI device 
is an alternative that allows complete anterior leaflet removal;680 
however, mortality remains high. The use of dedicated TMVI devices 
is therefore encouraged because it appears to be safer.542,681 Heart 
Team evaluation should guide the choice of treatment avoiding futility, 
because mortality remains high, even after successful treatment 
(10%‚Äì30% within 1 year). 
11. Tricuspid regurgitation 
11.1. Prevalence and aetiology 
TR is a common echocardiographic finding in the general population, 
with higher prevalence in women and older patients. Trivial or mild 
TR is mostly a benign condition. Significant TR (‚â• moderate) has a reported age- and sex-adjusted prevalence of 0.55% (4% in people aged 
‚â•75 years).682 Severe TR is associated with increased risk of death 
and HF, independent of comorbidities, ventricular function, and pulmonary pressures.683‚Äì686 
Only 8%‚Äì10% of patients with TR present with clear anatomical abnormalities of the TV apparatus (primary TR), which can be due to infective endocarditis, RHD, carcinoid syndrome, congenital abnormalities (e.g. 
Ebstein‚Äôs anomaly), chest radiation, or myxomatous disease, as well as 
trauma or iatrogenic valve damage (e.g. after endomyocardial biopsy).682 
Cardiac implantable electronic device (CIED)-related TR represents a 
separate entity requiring a specific diagnostic approach and management.687 In patients with a CIED, diagnostic efforts should be made to 
clarify if the lead is the cause of TR (CIED-related TR) or incidental 
(CIED-associated TR).688 
In patients with secondary TR, TV leaflets are structurally normal and 
regurgitation is caused by annular dilatation and/or leaflet tethering due 
to RA dilatation, and/or RV dilation and dysfunction. Based on the main 
morphological and haemodynamic characteristics, two phenotypes of 
secondary TR have been proposed:689 (i) atrial secondary TR, mainly 
due to AF and characterized by the absence of significant leaflet tethering, but with marked RA and annular dilatation along with preserved RV 
size/function, pulmonary pressure, and LV function; and (ii) ventricular 
secondary TR, due to annular dilatation and leaflet tethering as a consequence of left-sided ventricular or valvular disease (post-capillary 
PH), pre-capillary PH, or primary RV cardiomyopathy/ischaemia (also 
after left-sided valve surgery).690 At an advanced disease stage, these 
two phenotypes may no longer be distinguishable, and therefore early 
characterization is key to determine outcome.691,692 Evidence of an impact on patient management is currently lacking; therefore, current 
recommendations for intervention consider mainly primary vs secondary TR. 
Recommendation Table 8 ‚Äî Recommendations on 
indications for percutaneous mitral commissurotomy, 
mitral valve surgery, and transcatheter intervention 
in clinically severe rheumatic and degenerative mitral 
stenosis 
(see 
also 
Supplementary 
data 
online, 
Evidence Table 21) 
Recommendations 
Classa 
Levelb  
PMC is recommended in symptomatic patients in the 
absence of unfavourable characteristics for PMC.c 
651‚Äì653,662,665 
I 
B 
PMC is recommended in any symptomatic patients 
with a contraindication or at high risk for surgery. 
I 
C 
MV surgery is recommended in symptomatic 
patients who are not suitable for PMC. 
I 
C 
PMC should be considered as initial treatment in 
symptomatic patients with suboptimal anatomy but 
no unfavourable clinical characteristics for PMC.c 
IIa 
C 
PMC should be considered in asymptomatic patients 
without unfavourable clinical and anatomical 
characteristics for PMC, and: 
‚Ä¢ High thromboembolic risk (history of systemic 
embolism, dense spontaneous contrast in the LA, 
new-onset or paroxysmal AF), and/or 
‚Ä¢ High risk of haemodynamic decompensation 
(SPAP >50 mmHg at rest, need for major NCS, 
pregnant or desire for pregnancy). 
IIa 
C 
TMVI may be considered in symptomatic patients 
with extensive MAC and severe MV dysfunction at 
experienced Heart Valve Centres with expertise in 
complex MV surgery and transcatheter 
interventions.542,680,681 
IIb 
C 
¬© ESC/EACTS 2025
AF, atrial fibrillation; LA, left atrium/left atrial; MAC, mitral annular calcification; MV, mitral 
valve; NCS, non-cardiac surgery; NYHA, New York Heart Association; PH, pulmonary 
hypertension; PMC, percutaneous mitral commissurotomy; SPAP, systolic pulmonary 
artery pressure; TMVI, transcatheter mitral valve implantation; TR, tricuspid regurgitation. 
aClass of recommendation. 
bLevel of evidence. 
cUnfavourable characteristics for PMC can be defined by the presence of several of the 
following characteristics: clinical characteristics (old age, history of commissurotomy, NYHA 
class IV, permanent AF, severe PH); anatomical characteristics [echocardiographic score >8, 
Cormier score group 3 (calcification of MV of any extent as assessed by fluoroscopy), 
severe TR] (for the definition of scores see Supplementary data online, Table S3).  
Table 8 Contraindications for percutaneous mitral 
commissurotomy in rheumatic mitral stenosis 
Contraindications  
MVA >1.5 cm2 a 
LA thrombusb 
More than mild MR 
Severe or bi-commissural calcification 
Absence of commissural fusion 
Severe concomitant AV disease, or severe combined tricuspid stenosis and 
regurgitation requiring surgery 
Concomitant CAD requiring bypass surgery 
¬© ESC/EACTS 2025
AV, aortic valve; CAD, coronary artery disease; LA, left atrium/left atrial; MR, mitral 
regurgitation; MVA, mitral valve area; OAC, oral anticoagulation; PMC, percutaneous 
mitral commissurotomy; TOE, transoesophageal echocardiography. 
aPMC may be considered in patients with MVA of >1.5 cm2 with symptoms that cannot be 
explained by another cause and if the anatomy is favourable. 
bWhen the thrombus is located in the LA appendage, PMC may be considered in patients 
with contraindications to surgery or those without urgent need for intervention, in whom 
OAC can be safely given for 1‚Äì3 months, provided repeat TOE confirms resolution of 
thrombus.


<!-- PAGE 49 -->

### Page 49

11.2. Evaluation 
Echocardiography is recommended to assess patients with TR45 and 
should include evaluation of severity and aetiology (including characterization of left-sided heart disease and, if applicable, CIED lead location 
and interaction with the valve apparatus), the impact of TR on the right- 
sided chambers (RV and RA size and function), and assessment of central venous (inferior vena cava) and pulmonary pressures. Transthoracic 
echocardiography provides sufficient diagnostic information in most 
patients. Transoesophageal echocardiography is necessary for when 
visualization of the TV apparatus. In candidates for an intervention, advanced techniques, such as strain analysis and 3D echocardiography, 
should also be applied when available. 
Assessment of TR severity should be ideally performed in euvolaemic status, with optimized pulmonary and systemic pressures, and 
based on an integrative approach considering multiple qualitative and 
quantitative parameters (Figure 15).45,693 A grading scheme extending 
beyond severe, including ‚Äòmassive‚Äô and ‚Äòtorrential‚Äô grades, has been proposed to refine TR reduction assessment after transcatheter interventions and has been used in several studies.694,695 Although this 
five-grade scale may be associated with a proportional increase in 
symptoms and event risk,694,695 an intervention should be considered 
without delay, as soon as TR is severe, with the aim of reducing TR 
to moderate or less.696,697 
Echocardiographic assessment of the RV is challenging due to its 
complex geometry, imaging constraints, and the high dependency on 
loading conditions. When accurate measurements of RV size and function, as well as RV volume, are necessary for decision-making, CMR 
should be used because of its high accuracy and reproducibility.698,699 
In Figure 15, upper limits of normal for different RV size parameters 
are provided to guide definition of RV dilatation and remodelling. In 
the setting of severe TR, RV function is often overestimated and therefore the most conservative/cautious thresholds are suggested for the 
currently used echocardiographic parameters to identify RV dysfunction at the earliest stage possible. Cut-off values for severe RV dysfunction are also provided to indicate high-risk or possibly futile 
interventions. Although robust validation is lacking, all these reference 
values are chosen based on large multicentre reports of normative data 
and outcomes.60,697,700‚Äì704 
Echocardiography often underestimates pulmonary pressures in 
cases of severe TR.705 Right heart catheterization is therefore recommended in all candidates for an intervention to assess the haemodynamic consequences of TR on the RA and venous circulation (e.g. 
ventricularization of the RA pressure curves), measure end-diastolic 
RV pressure, and document volume overload. The assessment of pulmonary pressures and vascular resistance are key to exclude masked 
severe pre-capillary PH.706 
RV‚Äìpulmonary artery coupling refers to the ability of the RV systolic 
performance to match a given pulmonary afterload maintaining adequate cardiac output, and can be measured invasively or approximated using echocardiography [i.e. tricuspid annular plane systolic 
excursion (TAPSE)/SPAP].707,708 RV‚Äìpulmonary artery uncoupling 
(low TAPSE/SPAP) occurs when sustained increases in afterload cannot be matched by RV contractile reserve and has been associated 
with poor prognosis in different HF conditions, including severe TR. 
Although not yet prospectively validated, this index may improve 
risk stratification. 
Electrocardiogram-gated CCT with dedicated protocols ensuring 
sufficient contrast enhancement of the right heart cavities provides detailed characterization of the RA, RV, and vena cava anatomy, the location of the right coronary artery, and is crucial to assess suitability and 
device sizing for several transcatheter interventions.689,697 
Before any intervention is considered, careful evaluation of TR aetiology, disease stage (TR severity, RV and LV dysfunction, and PH), patient operative risk, and likelihood of recovery by a dedicated 
collaborative Heart Team is recommended (Figure 16). Dedicated clinical risk scores for TR patients have been described recently. The 
TRI-SCORE709 and the STS isolated TV risk calculator710 take into consideration clinical and echocardiographic signs of RV dysfunction, and 
secondary organ (particularly hepatic and renal) impairment. They 
both allow improved estimates of peri-procedural risk in patients 
with severe TR undergoing surgery and possibly help to avoid futile interventions.84,711 The importance of risk stratification was demonstrated in a recent registry analysis (n = 2413) comparing any 
interventions with conservative management. Early TV intervention 
(transcatheter valve repair or surgery) was associated with improved 
mid-term survival in patients with a low or intermediate TRI-SCORE 
(up to 5 points), while patients with a high TRI-SCORE (‚â•6) did not derive any benefit compared with conservative management.696 
Moreover, isolated TV surgery (repair or replacement) improved survival at 10 years in patients with a low TRI-SCORE (‚â§3). The same 
benefit was observed in patients with an intermediate TRI-SCORE 
(4‚Äì5) after successful TV repair only.689,697,709 Patients with moderate 
or severe TR should be regularly followed up clinically and by echocardiography at least every 6 months. 
11.3. Medical therapy 
Patients with relevant TR should be first treated according to the assumed aetiology, including optimal HF treatment, pulmonary vasodilators for PH, and rhythm control for AF.339,693 
In the case of HF symptoms, diuretics should be initiated in a stepwise approach,339 beginning with loop diuretics eventually combined 
with aldosterone antagonists, thiazide diuretics, and/or SGLT2is.712 
However, according to current knowledge, medical therapy has very 
limited effect on the evolution of TR severity and none of these measures should delay evaluation of an intervention at an expert centre.713 
11.4. Indications for intervention 
11.4.1. Surgery 
Patients are often referred too late for surgery when significant RV and 
other organ failure have occurred. Isolated TV surgery has therefore 
been considered to be generally high risk, with in-hospital mortality 
rates of 8%‚Äì10% in several reports,714,715 but contemporary cohorts 
have demonstrated improved outcomes when patients are referred 
earlier and more effective techniques are used.716 Valve repair using 
an annuloplasty ring is preferred over replacement, whenever technically feasible, especially in low-risk patients with suitable anatomy.709 
However, TV replacement may be necessary in cases of advanced disease with marked annular dilatation and leaflet tethering.688,717 For 
CIED-related TR, preparation of any entrapped tricuspid leaflet and 
possibly lead extraction with implantation of an epicardial system has 
been associated with improved TV function.688,717  
ESC Guidelines                                                                                                                                                                                               49


<!-- PAGE 50 -->

### Page 50





	

	








¬Å¬ç¬è¬Å



¬ê¬ù¬†¬è¬Å



¬≠¬Ä¬†¬è¬Å
	



¬Å¬Ç¬è¬Å

¬Å¬Ç¬è¬Å


¬É ¬Ñ¬Ç¬ù
	¬Ö¬Ñ¬Ç¬Ü¬è
	¬á¬à ¬Ñ¬Å¬ê¬â
	¬ä¬† ¬Ñ¬Å¬Ç¬â
¬ê	¬á¬Ñ¬Ä¬Ü¬â
¬á¬É
‚â§¬ê¬Ä¬â
¬É ¬Ñ¬Ç¬Ü
	¬Ö¬Ñ¬ã¬è
	¬á¬à ¬Ñ¬Ç¬Ç¬â
	¬ä¬† ¬Ñ¬≠¬â
¬ê	¬á¬Ñ¬ê¬Ä¬â
¬á¬É
‚â§¬Å¬Å¬â



¬É
¬Å¬Ü¬å
¬É¬à
‚â§¬Ç¬Ä¬å
	
¬Å¬à¬é

¬É
¬Å¬Ü¬å
¬É¬à
>¬Ç¬Ä¬å
	
‚â§¬Å¬à¬é
	
¬Ä¬à¬é
¬É ¬ê¬Ä¬å

¬ë



¬í¬É
‚â• ¬ç¬Ü¬Å
	
‚â•¬ç¬Ä¬†¬è¬ì
¬á
‚â•¬Ä¬Ü¬â
¬ê	¬É‚â•¬ù¬Ä¬Å
¬É‚â•¬≠¬î¬ï¬ë¬Å¬Ü¬ñ¬ê¬Ü¬è¬ó
	

¬ò‚â•¬ù
¬å
¬ô¬ò
¬á¬ô¬ö
¬ö


¬†
¬õ
¬†

¬ú


¬ö
¬à¬õ¬ò¬û

¬É



¬ü

Figure 15 Echocardiographic and invasive assessment of tricuspid regurgitation. 3D, three-dimensional; CIED, cardiac implantable electronic device; 
CW, continuous-wave; EROA, effective regurgitant orifice area; FAC, fractional area change; FWS, free wall strain; GLS, global longitudinal strain; mPAP, 
mean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PH, pulmonary hypertension; PISA, proximal isovelocity surface area; PVR, 
pulmonary vascular resistance; RF, regurgitant fraction; RV, right ventricle/ventricular; RVEF, right ventricular ejection fraction; RVol, regurgitant volume; 
TAPSE, tricuspid annular plane systolic excursion; TDI, tissue Doppler imaging; TR, tricuspid regurgitation; VCA, vena contracta area; WU, wood unit. 
aRV apical focused view.


<!-- PAGE 51 -->

### Page 51

11.4.1.1. Patients without indication for left-sided valve  
surgery 
In patients with severe TR but without the need for left-sided valve surgery, surgical intervention is recommended in operable symptomatic 
patients with primary TR (Figure 17; Recommendation Table 9).718 
Furthermore, it should be considered in symptomatic patients with secondary TR, or in asymptomatic patients with primary or secondary TR 
and signs of RV dilatation or RV function deterioration.719 However, 
patients with severe LV/RV dysfunction or PH do not qualify due to 
high operative risk.84,686,720 
11.4.1.2. Patients with indication for left-sided valve surgery 
Severe primary or secondary TR is unlikely to improve after isolated 
surgical treatment of left-sided valve disease, and reoperation for 
TR treatment is associated with high peri-operative mortality.721 
Therefore, TV surgery is recommended at the time of the index 
procedure. 
Mild TR with associated significant annular dilatation or moderate 
TR, if left uncorrected at the time of left-sided valve surgery, will progress in approximately one-quarter of patients and is associated with 
worse outcome.690,722 In patients with moderate TR, TV repair annuloplasty during MV surgery should be considered, because large retrospective studies723,724 and two recent RCTs have shown beneficial 
effects on TR progression and RV remodelling over time.725,726 
However, no effects on mortality, HF events, or reoperation were observed in the repair group.725,727 Concomitant TV repair has also 
been associated with a higher risk of conduction disturbances requiring pacemaker implantation (up to 14%),725,728 with potential negative 
impacts on longer-term outcomes.729,730 In patients with mild TR and 
annular dilatation (‚â•40 mm or >21 mm/m2) undergoing left-sided 
valve surgery, previous observational studies have demonstrated a 
benefit of concomitant TV repair in terms of TR progression723,724 
and RV function,731 and a trend towards improved long-term survival.724 
However, a subanalysis of a recent RCT did not identify any difference in 
the progression of TR or other outcomes in this category of patients 






	



	






¬Å
¬ç¬è¬ê
¬Å¬è¬ù¬†¬≠
Figure 16 Stepwise evaluation of patients with tricuspid regurgitation. RV, right ventricle/right ventricular. aSee Supplementary data online, Table S4.   
ESC Guidelines                                                                                                                                                                                               51


<!-- PAGE 52 -->

### Page 52

during a 2-year follow-up period.725 In turn, the need of pacemaker implantation after surgery led to a subsequent increase in HF hospitalizations, endocarditis, and mortality.729 Annuloplasty may therefore 
be considered after careful evaluation of the risk factors for progressive annular dilatation and TR (AF, RA size, pulmonary pressures, 
etc.), balancing against the risk of possible pacemaker implantation 
(Supplementary data online, Table S5).732 
11.4.2. Transcatheter techniques 
Several transcatheter approaches for the treatment of TR have been 
developed, including TEER, direct annuloplasty, and orthotopic and heterotopic TV replacement. Data from large multicentre registries, single- 
arm clinical trials, and two recent RCTs in patients with severe TR at 
intermediate and high risk for surgery have shown the safety of transcatheter repair, as well as the ability to reduce TR to moderate or less in 
Patient with tricuspid regurgitation
Need for left-sided valve surgery
Severe primary or secondary TR
RV dilatation or
RV function deterioration
Appropriate for surgery according to the Heart Team
Moderate or severe primary or secondary TR
Severe RV/LV
dysfunction or severe pre-capillary pulmonary hypertension
Mild secondary TR
No concomitant
TV surgery
Medical therapy
Transcatheter therapya
TV surgeryb
TA dilatation
(‚â•40 mm or >21 mm/m2)
Symptomatic
Severity/aetiology of TR
Severity/aetiology of TR
Figure 17 Management of patients with tricuspid regurgitation. LV, left ventricle/left ventricular; RV, right ventricle/right ventricular; TA, tricuspid 
annulus; TR, tricuspid regurgitation; TV, tricuspid valve. aThe Heart Team with expertise in the treatment of TV disease evaluates anatomical eligibility 
for transcatheter therapy including jet location, coaptation gap, leaflet tethering, and potential interference with pacing lead. bRepair whenever possible, 
particularly in cases of moderate TR or mild TR with significant TA dilatation.


<!-- PAGE 53 -->

### Page 53

more than 80% of cases when anatomical suitability was confirmed.713,733‚Äì735 The Clinical Trial to Evaluate Cardiovascular 
Outcomes in Patients Treated With the Tricuspid Valve Repair 
System (TRILUMINATE) Pivotal Trial showed also a lower incidence 
of the composite endpoint of death from any cause or TV surgery, 
HF hospitalization, and improvement in quality of life as measured 
with the KCCQ score after tricuspid TEER compared with medical 
treatment that was exclusively driven by improved quality of life 
[11.7 points (95% CI, 6.8‚Äì16.6); P <0.001].713 At 2 years, a lower incidence of HF hospitalizations has been observed in the intervention 
group, despite a high rate of crossovers (59%).736 
Another investigator-initiated RCT (the Tri.Fr trial) demonstrated 
the benefit of tricuspid TEER in combination with GDMT over medical 
therapy alone, for a composite score driven by improved PROMs.737 
Another recent RCT (the Edwards EVOQUE Transcatheter 
Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety 
and Clinical Efficacy using a Novel Device (TRISCEND) II trial), comparing transcatheter TV replacement with optimized medical therapy in 
patients with symptomatic severe TR, showed similar results with a 
win ratio favouring TV replacement mainly explained by symptom 
and quality-of-life improvement. In these studies, reverse RV remodelling was also observed. However, the safety profile of transcatheter TV 
replacement was less favourable, including higher risk for major bleeding (15%) and post-procedural pacemaker implantation in about one- 
quarter of the pacemaker-na√Øve patients after 12 months of follow- 
up.738 Based on these data, transcatheter treatment should be considered to improve quality of life and RV remodelling in high-risk patients 
with symptomatic severe TR, despite optimal medical therapy, but 
without severe RV dysfunction or pre-capillary PH. 
Transvenous CIED lead repositioning or extraction can be considered in selected patients to improve TR or avoid lead jailing before 
any tricuspid interventions, although the efficacy of this procedure is 
uncertain and the risk of damaging the TV not negligible.688,717,739 
Recurrent TR after previous tricuspid annuloplasty usually requires cardiac reoperation for surgical TV replacement. Transcatheter valve-in-ring 
implantation is an off-label procedure to treat residual TR in high-risk patients. Challenges are the non-circular shape and the open form of the surgical annuloplasty ring.740 However, transcatheter tricuspid valve-in-valve 
procedures have been performed with satisfactory results.741 
Transcatheter TV procedures should be performed at an experienced Heart Valve Centre with expertise in the treatment of 
TV disease (Table 6). Careful evaluation of clinical and anatomical 
suitability is key for appropriate patient and device selection to 
achieve optimal TR reduction and symptomatic response to the 
therapy. 
12. Tricuspid stenosis 
12.1. Prevalence and aetiology 
Tricuspid stenosis (TS) is a relatively rare disease that is most commonly 
associated with congenital conditions or enzymatic disorders, such as 
Whipple‚Äôs or Fabry‚Äôs disease. It can also be acquired as an isolated manifestation of RHD or occur in combination with aortic and/or MV involvement. Moreover, TS can be the consequence of carcinoid disease due to 
serotonin-mediated proliferation, causing apposition of fibroblasts and 
extracellular matrix on the valve leaflets and the subvalvular apparatus. 
Rare causes include medications (e.g. fenfluramine or methysergide) or inflow obstruction due to CIED-associated thrombus formation or endocarditis with large vegetations. 
12.2. Evaluation 
Valve evaluation and diagnosis of TS is based on echocardiography, and 
consists of the anatomical assessment of the leaflet tissue and the subvalvular apparatus. Leaflet thickening with or without calcifications and 
Recommendation Table 9 ‚Äî Recommendations on indications for intervention in tricuspid regurgitation (see 
also Supplementary data online, Evidence Tables 22 and 23) 
Recommendations 
Classa 
Levelb  
Careful evaluation of TR aetiology, stage of the 
disease (i.e. degree of TR severity, RV and LV 
dysfunction, and PH), patient operative risk, and 
likelihood of recovery by a multidisciplinary Heart 
Team is recommended in patients with severe TR 
prior to intervention.691,742 
I 
C                                                                                                   
Continued 
Patients with tricuspid regurgitation and left-sided valvular 
heart disease requiring surgery 
Concomitant TV surgeryc is recommended in 
patients with severe primary or secondary 
TR.725,731,743,744 
I 
B 
Concomitant TV repair should be considered in 
patients with moderate primary or secondary TR, to 
avoid progression of TR and RV 
remodelling.723,724,726,731 
IIa 
B 
Concomitant TV repair may be considered 
in selected patients with mild secondary TR 
and tricuspid annulus dilatation (‚â•40 mm or 
>21 mm/m2), to avoid progression of TR and RV 
remodelling.723‚Äì726,731,743 
IIb 
B 
Patients with severe tricuspid regurgitation without left-sided 
valvular heart disease requiring surgery 
TV surgeryc is recommended in symptomatic 
patients with severe primary TR without severe RV 
dysfunction or severe PH. 
I 
C 
TV surgeryc should be considered in asymptomatic 
patients with severe primary TR who have RV 
dilatation/RV function deterioration, but without 
severe LV/RV dysfunction or severe PH. 
IIa 
C 
TV surgeryc should be considered in patients with 
severe secondary TR who are symptomatic or have 
RV dilatation/RV function deterioration, but without 
severe LV/RV dysfunction or PH.685,720,745‚Äì747 
IIa 
B 
Transcatheter TV treatment should be considered to 
improve quality of life and RV remodelling in high-risk 
patients with symptomatic severe TR despite optimal 
medical therapy in the absence of severe RV 
dysfunction or pre-capillary PH.713,733,735,738,748‚Äì751 
IIa 
A 
¬© ESC/EACTS 2025
LV, left ventricle/left ventricular; PH, pulmonary hypertension; RV, right ventricle/right 
ventricular; TR, tricuspid regurgitation; TV, tricuspid valve. 
aClass of recommendation. 
bLevel of evidence. 
cValve repair whenever possible.   
ESC Guidelines                                                                                                                                                                                               53


<!-- PAGE 54 -->

### Page 54

commissural fusions are pathognomonic findings of rheumatic involvement. A mean diastolic transvalvular gradient of >5 mmHg at a normal 
heart rate indicates severe TS.649 
12.3. Medical therapy 
Medical therapy is a bridge to surgical or transcatheter intervention. 
Intensive sodium restriction and concomitant diuretic therapy can 
lead to symptom improvement and diminish hepatic congestion. 
12.4. Indications for intervention 
Although valve repair is preferred in younger patients,752 valve replacement is frequently required (see Recommendation Table 10). Biological 
heart valves have demonstrated adequate mid- and long-term results, 
and are preferred over MHVs because of high thrombogenicity in the 
low-pressure system.753 In the case of BHV degeneration, transcatheter 
valve-in-valve procedures are good alternatives to re-replacement.754 
Transcatheter TV implantation is an emerging field, although limited experience is available for the treatment of TS.749,755 In patients with carcinoid disease, a stable oncological situation is a prerequisite for any 
valve intervention to maximize survival and valve durability.756 
Although data are very limited, TV balloon valvuloplasty can be an 
option in selected patients with TS (and no relevant TR), as well as in 
those with concomitant mitral and tricuspid rheumatic pathology.757 
However, in contrast to rheumatic MS, tricuspid rheumatic disease 
more frequently presents as combined stenosis and regurgitation, 
which limits the applicability of balloon valvuloplasty. 
13. Multiple and mixed valvular 
heart disease 
13.1. Prevalence and undertreatment 
Patients frequently present with disease of more than one native heart 
valve [multiple VHD (MVHD)], or coexisting stenosis and regurgitation 
of the same valve (mixed VHD).758 While the main cause of MVHD or 
mixed VHD has shifted to degeneration in high-income countries, the 
leading aetiology in low- and middle-income countries remains 
RHD.758,759 Regurgitation of atrioventricular valves secondary to cardiomyopathy or long-standing primary valve disease, and late effects of radiation therapy, are further causes of MVHD.758,760 Challenges in diagnostic 
evaluation coupled with limited data to guide clinical decisions contribute 
to late referral and undertreatment of patients with MVHD.758 
13.2. Evaluation and diagnostic pitfalls 
In view of the complex haemodynamic interplay of multiple and mixed 
valve lesions, assessment by a Heart Team at a Heart Valve Centre and 
use of an integrative multimodality approach is key to gain diagnostic 
certainty, detect cardiac damage, and evaluate therapeutic options.761,762 In the light of paucity of data on diagnostic and prognostic 
parameters in patients with MVHD, assessment largely focuses on 
pathophysiological considerations and evidence derived from isolated 
valve lesions. 
Echocardiography is the main tool to diagnose MVHD, assess mechanism, severity, and associated cardiac damage, and monitor disease 
progression.761 Haemodynamic interdependence between multiple 
valve defects alters the loading and flow conditions, thereby limiting 
the diagnostic validity of measures established to grade single valve defects (Table 9). In the presence of MVHD, low-flow states are frequent. 
The continuity equation becomes erroneous if transvalvular flows are 
unequal, and pressure half-time (PHT)-derived methods are inaccurate 
if the ventricular compliance or filling is altered.761 In this context, 
TOE can provide important detailed anatomical and mechanistic 
flow-independent information.46,761 
If symptoms or echocardiographic findings are equivocal, multimodality diagnostics should be considered on an individual basis to assess 
the cumulative repercussions of MVHD. 
Measures obtained during cardiopulmonary exercise testing reflect 
the effect of MVHD on functional capacity.52,105,654,761,779 Levels of 
natriuretic peptides such as NT-proBNP correlate with functional 
and echocardiographic parameters, and provide incremental prognostic value in patients with mixed aortic disease and MVHD.98,780 AV calcium scoring confirms the diagnosis of true severe AS under low-flow 
conditions, as described in Section 8.2.777 Cardiac magnetic resonance 
imaging enables the independent assessment of valvular regurgitation 
using volumetric methods or direct flow quantification.45,46,522,762,781 
Importantly, invasive cardiac output-derived measures based on 
thermodilution or the Fick equation using estimated oxygen uptake 
are inaccurate in low-flow conditions or severe TR, commonly present in MVHD.782 
13.3. Indications for intervention 
Given the heterogeneity of clinical scenarios and the lack of evidence on 
optimal treatment pathways, it is recommended that patients with 
MVHD are evaluated for intervention by a collaborative Heart Team 
at a Heart Valve Centre with experience in multimodality imaging 
and treatment of complex VHD.16,764 
Patients presenting with a lesion fulfilling criteria for an intervention 
based on recommendations for single VHD should be treated accordingly. In the remaining patients, assessment of symptoms and functional 
status, as well as cardiac damage (which may be masked by the consequences of concomitant lesions and occur before symptoms manifest), 
is required. The risk‚Äìbenefit ratio of intervention needs to take into 
account diagnostic (un)certainty, the mechanisms and severity of 
MVHD, and patient-specific factors, as well as procedural options and 
risks to determine the mode, timing, and sequence of valve treatment. 
13.3.1. Multiple valvular heart disease 
Multiple VHD with primary (as opposed to secondary) valvular disease 
usually requires surgical treatment of all relevant valvular lesions. 
Simultaneous treatment of concomitant severe valve defects is recommended and treatment of concomitant moderate AS, or moderate TR, 
should be considered (Recommendation Table 11). 
Recommendation Table 10 ‚Äî Recommendations on 
indications for intervention in tricuspid stenosis 
Recommendations 
Classa 
Levelb  
Surgeryc is recommended in symptomatic patients 
with severe TS.d 
I 
C 
Surgeryc is recommended in patients with severe TS 
undergoing left-sided valve intervention.e 
I 
C 
¬© ESC/EACTS 2025
MV, mitral valve; PMC, percutaneous mitral commissurotomy; TS, tricuspid stenosis; TV, 
tricuspid valve. 
aClass of recommendation. 
bLevel of evidence. 
cUsually TV replacement. 
dPercutaneous balloon valvuloplasty can be attempted as a first approach if TS is isolated. 
ePercutaneous balloon valvuloplasty can be attempted if PMC can be performed on the MV.


<!-- PAGE 55 -->

### Page 55

Transcatheter treatment options are established for severe AS 
(TAVI), rheumatic MS (PMC), and primary MR and TR (TEER or transcatheter replacement) in patients with MVHD at high surgical risk, if 
anatomy is suitable.401,783 In the context of a transcatheter strategy, 
a staged approach‚Äîtypically beginning with the downstream lesion 
(aortic, followed by mitral and tricuspid)‚Äîis generally preferred to 
avoid potential haemodynamic deterioration.784,785 
MVHD with severe secondary regurgitation of both atrioventricular 
valves is usually the consequence of either HFrEF with ventricular SMR 
and secondary TR, or atrial dilatation leading to both atrial MR and TR 
Table 9 Echocardiographic pitfalls, robust measures, and complementary multimodality imaging parameters in multiple or mixed valvular heart disease  
Valve lesion to be assessed  
AS 
AR 
MS 
MR  
Concomitant  
valve lesion 
AS 
‚Äî 
PHT unreliable 
LV volume increase less 
pronounced 
(hypertrophy, 
disproportionate diastolic LV 
pressure overload763) 
PHT unreliable 
(LV compliance ‚Üì 764) 
Low gradient due to low 
flow possible 
(low-flow state669) 
Regurgitant volume ‚Üë 
MR colour-flow jet area ‚Üë 
(increased afterload and 
transmitral systolic pressure 
gradient46) 
AR 
Simplified Bernoulli 
equation overestimates 
gradient if LVOT  
velocity ‚Üë 765 
‚Äî 
PHT unreliable 
(gradient ‚Üì, altered LV 
compliance766) 
MVA by continuity 
equation using aortic 
forward flow unreliable46 
Doppler volumetric 
method using net aortic 
forward flow invalid 
Mitral-to-aortic VTI ratio 
unreliable 
(increased transaortic 
flow46) 
MS 
Low-flow low-gradient 
possible 
(low-flow state761) 
LV volume increase less 
pronounced 
(reduced preload761) 
‚Äî 
Mitral-to-aortic VTI ratio 
unreliable 
(increased mitral VTI due to 
stenosis767) 
Calcifications may shadow 
jet area 
MR 
Low-flow low-gradient 
(MR-induced low-flow 
state768) 
AS confused with MR jet 
PHT unreliable 
(altered LV compliance763) 
Doppler volumetric 
method using net mitral 
forward flow invalid 
(increased flow46) 
PHT unreliable 
(altered LA and LV 
compliance769,770) 
Continuity equation  
unreliable 
(increased transmitral  
flow761) 
‚Äî 
TR 
Low-flow low-gradient 
possible 
(TR induced low-flow 
state771) 
‚Äî 
Low gradient possible 
(low-flow state668) 
PHT may be less reliable 
(impaired LV filling due to 
ventricular 
interdependence772,773) 
Regurgitant volume‚Üì in 
SMR possible 
(decreased preload774) 
Robust echocardiography 
measurements 
AVA (continuity equation), 
DVI761 
In mixed AR and AS: Vmax 
and mean gradient reflect 
combined burden765 
EROA (PISA), vena 
contracta46,761 
Planimetry and 3D 
MVA (TOE)529,775 
In mixed MR & MS: 
mean gradient reflects 
combined burden674,776 
EROA (PISA), vena 
contracta46,761 
Alternative imaging  
modalities 
CT: AV calcium  
scoring777 
CMR: regurgitant volume 
and fraction45,46 
‚Äî 
CMR: regurgitant volume 
and fraction45,46 
¬© ESC/EACTS 2025
Measures reported refer to assessment of the valve lesions listed in the columns. Adapted from 761. 
3D, three-dimensional; AR, aortic regurgitation; AS, aortic stenosis; AV, aortic valve; AVA, aortic valve area; CMR, cardiac magnetic resonance; CT, computed tomography; DVI, Doppler 
velocity index; EROA, effective regurgitant orifice area; LA, left atrium/left atrial; LV, left ventricle/left ventricular; LVOT, left ventricular outflow tract; MR, mitral regurgitation; MS, mitral 
stenosis; MVA, mitral valve area; PHT, pressure half-time; PISA, proximal isovelocity surface area; SMR, secondary mitral regurgitation; TOE, transoesophageal echocardiography; TR, tricuspid 
regurgitation; VHD, valvular heart disease; Vmax, peak transvalvular velocity; VTI, velocity time integral; ‚Üë, increase; ‚Üì, decrease; ‚Äî, none.   
ESC Guidelines                                                                                                                                                                                               55


<!-- PAGE 56 -->

### Page 56

(often TR > MR). While surgery aims to address all relevant valve lesions 
in a single procedure, a stepwise transcatheter strategy offers the possibility of reassessing the upstream valve(s) under altered loading conditions, usually 3 months after the initial intervention. In very selected 
cases simultaneous transcatheter valve treatment may be considered.788,789 However, evidence is limited and primarily derived from 
modestly sized observational studies.786‚Äì789 
13.3.2. Mixed aortic valve disease 
The severity of mixed AV disease is often underestimated and patients 
with balanced moderate AR and AS show adverse event rates comparable to patients with severe isolated AS.790,791 
Transvalvular gradients measured by Doppler reflect the overall 
haemodynamic burden of both regurgitation and stenosis, and are strongly associated with adverse outcomes.765,791‚Äì793 Therefore, the presence 
of high transvalvular gradients justifies valve intervention in patients 
with moderate mixed AV disease, even if regurgitation is graded as moderate and the calculated or planimetric AVA is >1 cm2 (Recommendation 
Table 12). Patients presenting with mixed AV disease, but with gradients 
below thresholds for intervention, should undergo careful multimodality 
diagnostics including assessment of cardiac damage to inform individual 
treatment strategies. Global longitudinal strain and natriuretic peptides 
have shown incremental prognostic value beyond symptom status and 
single lesion severity in patients with preserved LVEF.762,794‚Äì796 
13.3.3. Mixed mitral valve disease 
Mixed MV disease is usually present in patients with rheumatic valve disease or MAC. If MVA is ‚â§1.5 cm2, recommendations for isolated MS 
apply. However, patients with an MVA of >1.5 cm2 and moderate 
MR may be evaluated for valve replacement based on symptoms, anatomical characteristics, transmitral gradient, and signs of cardiac damage 
such as LA dilatation, AF, or PH.529,674,776,797 
13.4. Follow-up 
Due to the cumulative haemodynamic impact of MVHD or mixed 
VHD, progression of its severity and the development of cardiac damage may be faster than in single VHD.761 Therefore, follow-up intervals 
should be adjusted according to individual patient characteristics. 
14. Management of patients with 
prosthetic valves or valve repair 
14.1. Choice of prosthetic valve 
When choosing between an MHV and a BHV prosthesis for an individual 
patient, age, life expectancy, lifestyle, bleeding and thromboembolic risks, 
possibility of pregnancy, and patient preference should be considered. 
Life expectancy is estimated according to age, sex, comorbidities, ethnicity, 
and geographical area.798 An MHV is preferred in younger patients with 
longer life expectancy and in those with a pre-existing indication for long- 
term OAC (Recommendation Table 13). Generally, a BHV is implanted in 
patients with shorter life expectancy, increased bleeding risk due to frailty 
or comorbidities, in women contemplating pregnancy, and in patients in 
whom stable INRs with adequate times in therapeutic range are unlikely.799 
Importantly, the performance of different BHV prostheses can vary considerably.800 The impact of the aetiology of the native valve disease, if any, on 
the choice between an MHV and a BHV remains unexplored. 
Several large observational studies, smaller RCTs, and meta-analyses 
have compared long-term mortality with BHV and MHV prostheses in 
patients aged 50‚Äì70 years.376,801‚Äì805 Some of the studies showed 
lower mortality with an MHV in AV patients <60 years and MV patients 
<65 years old,801,804 while others failed to show any differences.376,802,803 Most of these studies were limited by their observational nature and missing information on the type of prostheses 
implanted. RCTs with sufficient statistical power comparing biological 
and mechanical prostheses are warranted. 
Replacement of the AV using an autograft (Ross procedure) is an 
alternative to an MHV in young patients that should be performed 
at experienced centres by operators with dedicated expertise (see 
also Section 8).806 General recommendations are summarized in  
Recommendation Table 13. 
Recommendation Table 11 ‚Äî Recommendations on 
indications for surgery of concomitant left-sided valvular heart diseasea 
Recommendations 
Classb 
Levelc 
Concomitant aortic stenosis  
SAVR is recommended in patients with severe AS 
undergoing surgery for another valve. 
I 
C 
SAVR should be considered in patients with 
moderate ASd undergoing surgery for another valve. 
IIa 
C 
Concomitant aortic regurgitation 
AV surgery is recommended in patients with severe 
AR undergoing surgery for another valve. 
I 
C 
Concomitant mitral regurgitation 
MV surgery is recommended in patients with severe 
MR undergoing surgery for another valve. 
I 
C 
¬© ESC/EACTS 2025
AR, aortic regurgitation; AS, aortic stenosis; AV, aortic valve; AVA, aortic valve area; MR, mitral 
regurgitation; MV, mitral valve; SAVR, surgical aortic valve replacement; TV, tricuspid valve. 
aRecommendations for surgery of concomitant TV disease are listed in Section 11 and Section 12. 
bClass of recommendation. 
cLevel of evidence. 
dDefined as an AVA of 1.0‚Äì1.5 cm2 (or mean aortic gradient of 25‚Äì40 mmHg) in normal-flow 
conditions. Clinical assessment is essential to determine whether SAVR is appropriate for an 
individual patient.  
Recommendation Table 12 ‚Äî Recommendations on 
indications for intervention in patients with mixed moderate aortic stenosis and moderate aortic regurgitation 
(see also Supplementary data online, Evidence Table 24) 
Recommendations 
Classa 
Levelb  
Intervention is recommended in symptomatic 
patients with mixed moderate AV stenosisc and 
moderate regurgitation, and a mean 
gradient ‚â•40 mmHg or Vmax ‚â•4.0 m/s.790‚Äì793 
I 
B 
Intervention is recommended in asymptomatic 
patients with mixed moderate AV stenosisc and 
moderate regurgitation with Vmax ‚â•4.0 m/s, and 
LVEF <50% not attributable to other cardiac 
disease.791 
I 
C 
¬© ESC/EACTS 2025
AV, aortic valve; AVA, aortic valve area; LVEF, left ventricular ejection fraction; Vmax, peak 
transvalvular velocity. 
aClass of recommendation. 
bLevel of evidence. 
cAVA >1 cm2.


<!-- PAGE 57 -->

### Page 57

14.2. Follow-up of patients with prosthetic 
valves 
All patients with prosthetic valves require lifelong clinical and echocardiographic follow-up to detect deterioration of prosthetic function, 
associated cardiac damage, or progressive disease of another valve. 
Serial TTE measurements of transprosthetic gradients, calculation of 
the effective valve area, and evaluation of leaflet motion and morphology should be performed in patients receiving a BHV within 
3 months after valve implantation, again at 1 year, and annually thereafter, or sooner if new cardiovascular symptoms occur.812 TOE is recommended in all cases of suspected prosthetic valve dysfunction or 
endocarditis. In the latter case, CCT and PET-CT are also recommended, if the diagnosis is unclear, and to identify primary or secondary infection foci.5 
Cinefluoroscopy for MHVs and CCT provide useful additional information, if valve thrombus or pannus is suspected.812 Imaging should be 
repeated in the case of thrombolytic and antithrombotic treatment of 
MVH thrombosis, even if gradients are normalized.813 
14.3. Antithrombotic therapy in patients 
with treated valvular heart disease 
14.3.1. Mechanical heart valves 
14.3.1.1. Post-operative anticoagulation and therapeutic targets 
Mechanical heart valves require lifelong treatment with a VKA 
guided by the INR. Bridging with either therapeutic unfractionated 
heparin (UFH) or low-molecular-weight heparin (LMWH) and 
VKA should be initiated within 24 h after MHV implantation, or as 
soon as considered safe. Heparin can be stopped when the INR is 
documented for 2 consecutive days within the therapeutic range 
(Figure 18).814 Two meta-analyses and a prospective study have suggested slightly lower bleeding rates using UFH bridging compared 
with LMWH after MHV replacement or cardiac surgery.814‚Äì816 
However, RCTs comparing the timing and dosage of each bridging 
strategy are lacking. 
For all patients with an MHV, lifelong VKA is recommended to 
avoid major thrombotic complications, since cardioembolic or valve 
thrombosis rates without anticoagulation are substantial (12% per 
year and 22% per year for first-generation aortic and mitral MHVs, 
respectively).817 The INR target and range should be chosen considering the type, position, and number of valves, the patient‚Äôs thrombotic risk, and comorbidities (see Table 10 and Recommendation 
Table 14). In patients with an MHV developing a major thromboembolic complication despite adequate INR and time in therapeutic 
range (TTR, usually defined as >60%),820 either increased VKA intensity (e.g. INR target and range increased by 0.5 units) or the addition 
of low-dose acetylsalicylic acid (ASA) (75‚Äì100 mg/day) should be considered.818 Direct oral anticoagulants or dual antiplatelet therapy 
(DAPT) are contraindicated to prevent thromboembolism in patients 
with an MHV.821‚Äì824 
Given the complexity of lifelong VKA therapy due to high intra- 
and interpatient variability, the need for monitoring, drug and food 
interactions,825,826 the narrow therapeutic window, influence of comorbidities, and non-modifiable characteristics (e.g. ageing, genetics, 
and ethnicity), RCTs have shown that patient‚Äôs education, as well 
as disease and treatment awareness, significantly improves anticoagulation quality and adherence.827‚Äì830 International normalized ratio self-monitoring and/or self-management increase efficacy, but 
not safety, as compared with a standard approach; INR self- 
monitoring can be used by motivated patients after adequate 
training.827‚Äì830 
The indication for VKA and DAPT combination in MHV patients 
presenting with acute coronary syndrome is described in the corresponding ESC Guidelines.151,831 In patients with an MHV and an indication for single antiplatelet therapy (SAPT) due to symptomatic 
major atherosclerotic diseases and low bleeding risk, low-dose 
ASA in combination with a VKA should be considered, because 
this strategy has been shown to significantly lower the incidence 
of major adverse cardiovascular events.818 However, the combination of antiplatelet agents (single or dual) and VKA increases the 
risk of bleeding,825 and therefore their use should be carefully 
weighted. In a large meta-analysis that included MHV patients, the 
combination of VKA with either ASA or clopidogrel increased clinically relevant bleeding compared with VKA alone (clopidogrel odds 
ratio, 3.55; 95% CI, 2.78‚Äì4.54; ASA odds ratio, 1.50; 95% CI, 1.29‚Äì 
1.74), which may be aggravated because of potential pharmacokinetic drug interactions on the cytochrome P (CYP)450s 2C19 and 
3A4.825 
Recommendation Table 13 ‚Äî Recommendations for 
prosthetic valve selection 
Recommendations 
Classa 
Levelb 
Mechanical heart valve  
An MHV is recommended according to the desire of 
the informed patient and if there is no 
contraindication to long-term anticoagulation. 
I 
C 
An MHV should be considered in patients with an 
estimated long life expectancy,c if there are no 
contraindications for long-term OAC.801,807‚Äì811 
IIa 
B 
An MHV should be considered in patients aged 
<60 years for prostheses in the aortic position and 
aged <65 years for prostheses in the mitral 
position.801,807‚Äì811 
IIa 
C 
An MHV should be considered in patients with a 
pre-existing MHV in another position. 
IIa 
C 
An MHV may be considered in patients with a clear 
indication for long-term OAC. 
IIb 
C 
Biological heart valve 
A BHV is recommended according to the desire of 
the informed patient. 
I 
C 
A BHV is recommended when an adequate quality of 
anticoagulation with VKA is unlikely, in patients at 
high bleeding risk, or with estimated short life 
expectancy.c 
I 
C 
A BHV should be considered in patients aged 
>65 years for prostheses in the aortic position or 
aged >70 years for prostheses in the mitral position. 
IIa 
C 
A BHV should be considered in women 
contemplating pregnancy. 
IIa 
C 
¬© ESC/EACTS 2025
BHV, biological heart valve; MHV, mechanical heart valve; OAC, oral anticoagulation; VKA, 
vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cLife expectancy should be estimated according to age, sex, comorbidities, ethnicity, and 
geographical area.   
ESC Guidelines                                                                                                                                                                                               57


<!-- PAGE 58 -->

### Page 58

Continue VKA
(Class I)
Mechanical heart valve replacement
Start UFH or LMWH bridging and VKA within 24 h or as soon as considered safe
(Class I)
Lifelong VKA with INR based on individual patient proÔ¨Åle and valve characteristics
Promote patient education and training for self-monitoring to improve TTR
(Class I) 
SpeciÔ¨Åc clinical scenarios
Elective NCS 
or invasive procedures
Minor or minimally invasive 
interventionsa
If documented adequate
INR, increase INR target,
or add low-dose ASA
(Class IIa) 
Add low-dose ASA
based on individual bleeding proÔ¨Åle 
(Class IIa)
Symptomatic atherosclerotic disease
Cardioembolic complication
Thromboembolic risk factorsb
Heparin bridgingc
(Class IIa)
VKA interruption at least
4 days before surgery and resumption within 24 h or as soon as considered safe
(Class I)
VKA interruption (3‚Äì4 days before surgery) and resumption
(within 24 h) without bridging
(Class IIb)
Figure 18 Antithrombotic therapy following mechanical heart valve implantation. AF, atrial fibrillation; ASA, acetylsalicylic acid; INR, international normalized ratio; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; MHV, mechanical heart valve; MS, 
mitral stenosis; N, no; NCS, non-cardiac surgery; TTR, time in therapeutic range; UFH: unfractionated heparin; VKA, vitamin K antagonist; Y, yes. aSkin; minor 
eye surgery including cataract; dental cleaning, treatment of caries, and dental extractions; pacemaker or device implantation; and diagnostic cardiac catheterization. bMHV in mitral or tricuspid position, older MHV generations in any position, inherited or acquired hypercoagulable state, LV dysfunction (LVEF  
<35%), AF with significant MS, recent (<12 months) major thrombotic event (i.e. cardioembolic stroke, deep vein thrombosis, pulmonary embolism). 
cBridging needs to be started as soon as INR reaches a sub-therapeutic value and on the first postoperative day or as soon as considered safe.


<!-- PAGE 59 -->

### Page 59

14.3.1.2. Prevention and management of bleeding 
Since patients with MHVs receive lifelong VKA, strategies to prevent 
bleeding need to be implemented. Proton pump inhibitors reduce 
the risk of upper gastrointestinal bleeding by approximately 40% in patients taking VKAs825,839,840 and should therefore be prescribed to patients with MHVs, particularly in those with additional bleeding risk 
factors (e.g. elderly, antiplatelet agent co-administration, chronic use 
of non-steroidal anti-inflammatory drugs, high INR, or alcohol abuse). 
Randomized controlled trials and a meta-analysis did not demonstrate 
a benefit of oral vitamin K1 supplementation in addition to temporary 
VKA cessation in non-bleeding patients with a supratherapeutic INR 
(4.5‚Äì10.0), with a trend toward reduced safety, which may be relevant 
for MHV patients.841,842 For non-bleeding patients with an INR of 
>10.0, oral vitamin K1 (2.0‚Äì3.0 mg) should be administered, avoiding 
overcorrection.841,843 
In cases of uncontrolled life-threatening or other major bleeding,844 
VKA use must be interrupted and reversal with non-activated 
four-factor prothrombin complex concentrates is preferred over fresh 
frozen plasma, because of higher safety and effectiveness.845‚Äì848 A reduced 
starting dose (12.5 rather than 25 IU/kg) in patients with more thrombogenic MHVs may be considered.849 In addition, vitamin K1 should be administered to reverse the effect of VKA. Intravenous route corrects 
INR ‚àº4 h faster than oral administration,850 with no differences at 24 h 
and an unknown clinical impact. VKA should be restarted as soon as major 
bleeding is controlled. 
14.3.1.3. Management of anticoagulation therapy before and after 
non-cardiac invasive procedures 
In patients with an MHV, VKA treatment should not be interrupted for: 
minor or minimally invasive procedures on the skin or eyes (including 
cataract with topical anaesthesia); dental cleaning, treatment of caries, 
and dental extractions; pacemaker implantation; cardiac catheterization; 
and endoscopic procedures (Recommendation Table 15; Table 11).851‚Äì856 
Topical antifibrinolytic or haemostatic agents may improve local 
haemostasis.853 
In patients with an MHV and high thromboembolic risk 
(Recommendation Table 16; Table 11) undergoing non-cardiac, elective 
major invasive procedures with high risk of bleeding (see  
Supplementary data online, Table S6), VKA treatment must be interrupted at least 4 days before the procedure, bridging with LMWH 
should be started as soon as the INR reaches a subtherapeutic value, 
and the INR should be <1.5 on the day of surgery.816,857,858 
Measuring anti-Xa activity at peak and trough may be appropriate to 
manage LMWH dosing in selected patients, such as those with severe 
obesity or underweight.859 In cases of urgent, major invasive procedures, four-factor prothrombin complex concentrate should be administrated to timely correct the INR for the intervention, if needed. For 
the management of antithrombotic drugs in patients undergoing major 
cardiac surgery, please refer to recent EACTS Guidelines.860 
Recommendation Table 14 ‚Äî Recommendations for the management of antithrombotic therapy in patients with a 
mechanical heart valve 
Recommendations 
Classa 
Levelb  
Following cardiac surgery with MHV implantation, it is recommended to start UFH or LMWH bridging and VKA within 24 h, or as soon as 
considered safe.815,816,832‚Äì834 
I 
B 
Lifelong OAC with a VKA is recommended for all patients with MHVs to prevent thromboembolic complications.821‚Äì823,835‚Äì838 
I 
A 
INR self-monitoring and self-management are recommended over standard monitoring in selected, trained patients to improve 
efficacy.827,828 
I 
A 
It is recommended that INR targets are based on the type and position of the MHV, patient risk factors, and comorbidities.c 818,819,835‚Äì838 
I 
A 
Patient education is recommended to improve the quality of OAC.827‚Äì830 
I 
A 
The addition of low-dose ASA (75‚Äì100 mg/day) to VKA should be considered in selected patients with MHVs in case of concomitant 
symptomatic atherosclerotic disease considering the individual bleeding risk profile.818 
IIa 
B 
Either an increase in INR target or the addition of low-dose ASA (75‚Äì100 mg/day) should be considered in patients with MHVs who 
develop a major thromboembolic complication despite documented adequate INR.818 
IIa 
C 
DOACs and/or DAPT are not recommended to prevent thrombosis in patients with an MHV.821‚Äì824 
III 
A 
¬© ESC/EACTS 2025
ASA, acetylsalicylic acid; DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; h, hour; INR, international normalized ratio; LMWH, low-molecular-weight heparin; MHV, 
mechanical heart valve; OAC, oral anticoagulation; UFH, unfractionated heparin; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cSee Table 10 for details.  
Table 10 International normalized ratio targets and 
therapeutic ranges for patients with a mechanical heart 
valve 
MHV type and position 
Additional 
pro-thrombotic 
factorsa 
INR target 
and (range)  
First-line treatment with VKA only 
Ball-in cage, tilting disc valve 
in any position, all MHV in 
mitral/tricuspid position 
No 
3 (2.5‚Äì3.5) 
Yes 
3.5 (3‚Äì4)b 
Bileaflet, current-generation 
single-tilting aortic MHV 
No 
2.5 (2‚Äì3)c 
Yes 
3 (2.5‚Äì3.5) 
¬© ESC/EACTS 2025
AF, atrial fibrillation; ASA, acetylsalicylic acid; INR, international normalized ratio; LV, left 
ventricle/left ventricular; LVEF, left ventricular ejection fraction; MHV, mechanical heart 
valve; MS, mitral stenosis; VKA, vitamin K antagonist. 
aInherited or acquired hypercoagulable state, LV dysfunction (LVEF <35%), AF with 
significant MS, recent (<12 months) major thrombotic event (i.e. cardioembolic stroke, 
deep vein thrombosis, pulmonary embolism). 
bIn patients at very high thrombotic risk, low-dose ASA may be added instead.818 
cIn patients at high bleeding risk, INR target could be maintained at a lower interval: 
2 (1.5‚Äì2.5).819   
ESC Guidelines                                                                                                                                                                                               59


<!-- PAGE 60 -->

### Page 60

Recommendation Table 15 ‚Äî Recommendations for the management of antithrombotic therapy in patients with a 
mechanical heart valve undergoing elective non-cardiac surgery or invasive procedures 
Recommendations 
Classa 
Levelb  
Continuing VKA treatment is recommended in patients with an MHV for minor or minimally invasive interventionsc associated with no or minimal 
bleeding.851‚Äì856 
I 
A 
It is recommended to discontinue VKA at least 4 days before major non-cardiac elective surgery, aiming for an INR <1.5, and to resume VKA 
treatment within 24 h after surgery, or as soon as considered safe.816,857,858 
I 
B 
VKA interruption and resumption with bridgingd should be considered in patients with an MHV and thromboembolic risk factorse 
undergoing major NCS.816,857,858 
IIa 
B 
Interruption (3‚Äì4 days before surgery) and resumption of VKA without bridging may be considered to reduce bleeding in patients with 
new-generation aortic MHVs and no other thromboembolic risk factorse undergoing major NCS or invasive procedures.816,857,858,861‚Äì864 
IIb 
B 
¬© ESC/EACTS 2025
AF, atrial fibrillation; h, hour; INR, international normalized ratio; LV, left ventricular; LVEF, left ventricular ejection fraction; MHV, mechanical heart valve; MS, mitral stenosis; NCS, non-cardiac 
surgery; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cSkin; minor eye surgery including cataract; dental cleaning, treatment of caries, and dental extractions; pacemaker or device implantation; diagnostic cardiac catheterization; gastroscopic, 
colonoscopic, bronchoscopic, or genitourinary diagnostic or therapeutic procedures considered at low bleeding risk. 
dBridging needs to be started as soon as INR reaches a subtherapeutic value and on the first post-operative day or as soon as considered safe. 
eMHV in mitral or tricuspid position, older MHV generations in any position, inherited or acquired hypercoagulable state, LV dysfunction (LVEF <35%), AF with significant MS, recent 
(<12 months) major thrombotic event (i.e. cardioembolic stroke, deep vein thrombosis, pulmonary embolism).  
Table 11 Peri-operative management of antithrombotic treatment in patients with a mechanical heart valve undergoing non-cardiac surgery based on type of procedure and underlying risk  
Minimally invasive proceduresa 
Major NCS or invasive proceduresa 
Pre-procedure 
Post-procedure 
Pre-procedure 
Post-procedure  
Low thromboembolic risk 
New-generation aortic 
MHV and no additional 
risk factorsb 
OAC 
No interruption 
of VKA 
Continue VKA 
Interrupt VKA at least 3‚Äì 
4 days prior to procedure 
with target INR <1.5 on 
the day of surgery 
Resume VKA as soon as 
feasible, within 24 h 
Bridging 
‚Äî 
‚Äî 
No bridging may be 
considered 
No bridging may be 
considered, unless unable 
to administer OAC 
Supporting 
measures 
‚Äî 
Topical antifibrinolytic or 
haemostatic agents may 
be considered to improve 
local haemostasis 
‚Äî 
Mechanical and 
pharmacological VTE 
prophylaxis, if indicated 
Moderate-to-high thromboembolic risk 
MHV in mitral or 
tricuspid position or 
other thromboembolic  
risk factorsb 
OAC 
No interruption 
of VKA 
Continue VKA 
Interrupt VKA at least 
4 days prior to procedure 
with target INR <1.5 the 
day of the procedure 
Resume VKA within 24 h 
Bridging 
‚Äî 
‚Äî 
Bridging with LMWH or 
UFH if CKD stage IV or V, 
starting at INR below the 
therapeutic range 
Bridging with UFH or 
LMWH post-operatively 
within 24 h 
Supporting 
measures 
‚Äî 
Topical antifibrinolytic or 
haemostatic agents may 
be considered to improve 
local haemostasis 
‚Äî 
Appropriate mechanical 
and pharmacological 
VTE prophylaxis 
¬© ESC/EACTS 2025
AF, atrial fibrillation; CKD, chronic kidney disease; h, hour; INR, international normalized ratio; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular 
ejection fraction; MHV, mechanical heart valve; MS, mitral stenosis; NCS, non-cardiac surgery; OAC, oral anticoagulation; UFH, unfractionated heparin; VKA, vitamin K antagonist; VTE, 
venous thromboembolism. 
aSee Supplementary Table S6. 
bInherited or acquired hypercoagulable state, LV dysfunction (LVEF <35%), AF with significant MS, recent (<12 months) major thrombotic event (i.e. cardioembolic stroke, deep vein 
thrombosis, pulmonary embolism).


<!-- PAGE 61 -->

### Page 61

For patients with an MHV and low cardioembolic risk (e.g. a new- 
generation MHV in the aortic position without additional risk factors) 
undergoing elective major NCS or invasive procedures, VKA interruption (3‚Äì4 days before surgery)816,857,858,861‚Äì864 and resumption861‚Äì863 
within 24 h may be performed without bridging to reduce post-surgical 
bleeding without increasing the risk of thrombosis (see Figure 18). 
14.3.2. Biological heart valves 
The management of antithrombotic treatment after BHV implantation 
or valve repair is summarized in Recommendation Table 16 and Figure 19. 
14.3.2.1. Patients with a surgical biological heart valve and no 
indication for oral anticoagulation 
The optimal antithrombotic strategy early after surgical implantation of 
an aortic BHV remains controversial due to the lack of high-quality evidence. Multiple observational studies support the short-term use of 
VKAs to reduce the risk of thromboembolism,865,866 while data on 
DOACs are missing. A small RCT and a meta-analysis found that 
VKA treatment for 3 months significantly increased major bleeding 
compared with low-dose ASA, without reducing mortality or 
thromboembolic events, but statistical power was low.867,868 
Therefore, both strategies (OAC or ASA) are reasonable within 
3 months of surgical aortic BHV implantation. In the absence of randomized evidence, patients undergoing mitral or tricuspid BHV implantation should receive OAC for at least 3 months due to the increased 
risk of AF and thromboembolisms. 
14.3.2.2. Patients with a transcatheter heart valve and no indication 
for oral anticoagulation 
Based on evidence from RCTs, lifelong low-dose ASA is the recommended antithrombotic treatment after TAVI in patients without 
OAC indication. In the Antiplatelet Therapy for Patients Undergoing 
Transcatheter Aortic Valve Implantation (POPular TAVI) trial (cohort 
A), the incidence of bleeding and the composite of bleeding or 
thromboembolic events were both reduced with ASA compared 
with DAPT at 1 year.869 One RCT [Global multicenter, open-label, randomized, 
event-driven, 
active-controlled 
study 
comparing 
a 
rivAroxaban-based antithrombotic strategy to an antipLatelet-based 
strategy after transcatheter aortIc vaLve rEplacement (TAVR) to 
Optimize clinical outcomes, GALILEO], which investigated a systematic 
OAC
for 3 months
(Class IIa) 
ASA
for 3 months
(Class IIb) 
MV/TV
surgical repair
OAC
long term
(Class I) 
OAC
long term
(Class I) 
ASA for 
12 months
(Class I)
OAC
long term
(Class I) 
OAC
long term
(Class I) 
OAC
long term
(Class I) 
OAC
for 3 months
(Class IIa) 
ASA long term after Ô¨Årst
12 months
(Class IIa)
ASA long term according to bleeding risk
(Class IIb) 
ASA or OAC
for 3 months
(Class IIa) 
ASA
for 3 months
(Class IIa) 
TAVI
SAVR
MVR/TVR
Aortic surgical repair
Indication for long-term anticoagulation
High bleeding risk
Figure 19 Antithrombotic therapy following biological heart valve implantation or surgical valve repair. ASA, acetylsalicylic acid; MV, mitral valve; 
MVR, mitral valve replacement; OAC, oral anticoagulation; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; 
TV, tricuspid valve; TVR, tricuspid valve replacement.   
ESC Guidelines                                                                                                                                                                                               61


<!-- PAGE 62 -->

### Page 62

antithrombotic strategy of rivaroxaban (10 mg/day) in combination 
with low-dose ASA compared with DAPT with clopidogrel for the first 
3 months, was halted prematurely due to an increased risk of death or 
thromboembolic complications, and an increased risk of bleeding in 
the rivaroxaban/ASA group.870 The systematic use of DOACs after 
TAVI in patients without indication for OAC is therefore not recommended. Data on antithrombotic management after implantation of 
transcatheter mitral BHVs or tricuspid BHVs are limited. Vitamin K antagonist treatment for ‚â•3 months is commonly prescribed, while 
DOACs may represent an alternative allowing for earlier discharge 
and a lower risk of short-term bleeding complications (median follow- 
up, 4.7 months).871 
For patients without baseline OAC undergoing mitral or tricuspid 
transcatheter valve implantation, OAC (either with DOAC or VKA) 
is initiated and usually pursued for at least 6 months or indefinitely 
(in particular after valve implantation in the tricuspid position), while 
patients undergoing TEER usually receive single long-term antiplatelet 
therapy with ASA. 
14.3.2.3. Patients with a surgical biological heart valve and an 
indication for oral anticoagulation 
Lifelong OAC is recommended for patients with surgical BHVs with 
other indications for OAC. The evidence supports the use of 
DOACs in preference to VKAs in patients with AF, even during the 
early post-operative period.872‚Äì877 A previously existing therapy with 
a DOAC may be continued after BHV implantation and should be restarted, as soon as considered surgically safe, usually within 2‚Äì3 days of 
surgery.860 
14.3.2.4. Patients with a transcatheter biological heart valve and an 
indication for oral anticoagulation 
In the POPular TAVI trial (cohort B), the incidence of bleeding over a period of 1 month or 1 year was lower with OAC than with OAC plus clopidogrel.878 Oral anticoagulation alone was non-inferior to OAC plus 
clopidogrel with respect to ischaemic events, but the non-inferiority margin was large. In Edoxaban vs Standard of Care and Their Effects on 
Clinical Outcomes in Patients Having Undergone Transcatheter Aortic 
Valve Implantation‚ÄìAtrial Fibrillation (ENVISAGE-TAVI-AF),879 edoxaban 
was non-inferior to VKA regarding the composite primary endpoint 
(death from any cause, myocardial infarction, ischaemic stroke, systemic 
thromboembolic event, valve thrombosis, or major bleeding), but the incidence of major bleeding was higher with edoxaban than with VKA. The 
Anti-Thrombotic Strategy to Lower All Cardiovascular and Neurologic 
Ischemic and Hemorrhagic Events after Trans-Aortic Valve Implantation 
for Aortic Stenosis (ATLANTIS) trial880 showed that apixaban was not 
superior to VKA after TAVI when there was a pre-existing indication 
for OAC, and there was a signal of higher non-cardiovascular mortality 
with apixaban. Therefore, no definitive recommendation can be made 
concerning the use of VKAs vs DOACs in patients who have undergone 
TAVI with a pre-existing indication for OAC. 
Antithrombotic therapy after transcatheter MV or TV implantation 
remains empirical because data are limited. A high proportion of patients are already under OAC because of AF (almost 50% of the population with MR and 80%‚Äì90% of the candidates for TR treatment). 
Common practice is to continue the pre-existing anticoagulation regimen. Vitamin K antagonists and DOACs have been used in this setting 
with or without combination with ASA.871 However, the high bleeding 
risk of this usually elderly population needs to be taken into 
consideration. 
Recommendation Table 16 ‚Äî Recommendations for 
the management of antithrombotic therapy in patients 
with a biological heart valve or valve repair 
Recommendations 
Classa 
Levelb  
Surgical biological heart valve without indication for oral 
anticoagulation 
Low-dose ASA (75‚Äì100 mg/day) or OAC 
using a VKA should be considered for the first 
3 months after surgical implantation of an aortic 
BHV in patients without clear indication for 
OAC.865,866 
IIa 
B 
A VKA should be considered for the first 3 months 
after surgical implantation of a mitral or tricuspid 
BHV in patients without clear indication for 
OAC.867,868 
IIa 
B 
Lifelong low-dose ASA (75‚Äì100 mg/day) may be 
considered 3 months after surgical implantation of an 
aortic or mitral BHV in patients without clear 
indication for OAC. 
IIb 
C 
Transcatheter aortic valve implantation without indication for 
oral anticoagulation 
Low-dose ASA (75‚Äì100 mg/day) is recommended 
for 12 months after TAVI in patients without 
indication for OAC.869,880‚Äì883 
I 
A 
Long-term (after the first 12 months) low-dose ASA 
(75‚Äì100 mg/day) should be considered after TAVI in 
patients without clear indication for OAC. 
IIa 
C 
DAPT is not recommended to prevent thrombosis 
after TAVI, unless there is a clear indication.881 
III 
B 
Routine use of OAC is not recommended after TAVI 
in patients without baseline indication.869,880 
III 
A 
Surgical repair without indication for oral anticoagulation 
OAC, with either VKAs or DOACs, should be 
considered during the first 3 months after surgical 
MV or TV repair.884‚Äì888 
IIa 
B 
Low-dose ASA (75‚Äì100 mg/day) should be 
considered for the first 3 months after surgical AV 
repair in patients without indication for OAC. 
IIa 
C 
Low-dose ASA (75‚Äì100 mg/day) may be considered 
after surgical MV or TV repair in preference to OAC 
in patients without clear indication for OAC and at 
high bleeding risk.884‚Äì888 
IIb 
B 
Surgical biological heart valve with indication for oral 
anticoagulation 
OAC continuation is recommended in patients with 
a clear indication for OAC undergoing surgical BHV 
implantation.877,889,890 
I 
B 
DOACs should be considered over VKAs after 
3 months following surgical implantation of a BHV in 
patients with AF.872‚Äì874,876,891 
IIa 
B 
DOAC continuation may be considered after 
surgical BHV implantation in patients with an 
indication for DOAC. 877,889,890 
IIb 
B                         
Continued


<!-- PAGE 63 -->

### Page 63

14.4. Management of prosthetic valve 
dysfunction and complications 
Prosthetic valve dysfunction can occur due to intrinsic permanent 
changes to the prosthetic valve (defined as SVD) or non-structural valve 
dysfunction resulting from any abnormality not intrinsic to the prosthetic valve itself. Valve thrombosis and endocarditis are considered 
separate entities due to their specific presentation and management, 
but may both result in SVD. 
14.4.1. Structural valve deterioration 
Structural valve deterioration has been defined by several consensus 
documents812,895,896 and includes wear and tear, leaflet disruption, 
leaflet fibrosis or calcification, and stent or strut fracture or deformation. BHV (transcatheter or surgical) SVD is more frequent than 
MHV SVD. The incidence of SVD may be underestimated by the simple 
analysis of patients with valve-related deaths or those undergoing reintervention. To ensure timely diagnosis, serial measurement should be 
performed and compared with the TTE performed at discharge, or 
within 1‚Äì3 months after valve implantation. 
The criteria for haemodynamic deterioration associated with 
aortic and mitral SVD can be found in Table 12.895,896 The diagnosis of moderate or severe haemodynamic deterioration should 
prompt referral to an experienced Heart Valve Centre for evaluation and treatment, and to exclude all causes of non-structural 
valve dysfunction, particularly PVL or PPM, as well as thrombosis 
and endocarditis. This step requires the use of advanced 
imaging techniques (TOE, CCT, and/or PET-CT) to document 
SVD-related morphological changes and elucidate its mechanism. 
Structural valve deterioration associated with corresponding clinical criteria (e.g. new onset or worsening of symptoms, LV or RV 
dilation/dysfunction, or PH) indicates BHV failure with potential 
need for reintervention. Decisions about the treatment modality 
(redo surgery or transcatheter valve-in-valve implantation) should 
be made within the interdisciplinary Heart Team, depending on reoperation risk and anatomical considerations,445,897 including the 
risk of coronary obstruction,144,442,446,461 as well as prosthesis 
type and size.898‚Äì900 When considering a valve-in-valve procedure 
for a degenerated aortic BHV, the possibility of creating a PPM in 
small valves should be anticipated and may impact intervention or 
valve selection.448 
Given the larger sizes of BHVs in mitral or tricuspid positions, transfemoral/transseptal valve-in-valve implantation represents an attractive 
alternative to redo open surgery.570,900‚Äì903 In the case of mitral 
valve-in-valve implantation the risk of LVOT obstruction, although 
Transcatheter biological heart valve with indication for oral 
anticoagulation 
OAC is recommended for TAVI patients who have 
other indications for OAC.879,892‚Äì894 
I 
B 
Surgical repair with indication for oral anticoagulation and/or 
antiplatelet therapy 
Continuation of OAC or antiplatelet therapy should 
be considered after surgical valve repair in patients 
with a clear indication for an antithrombotic 
therapy.890 
IIa 
B 
¬© ESC/EACTS 2025
AF, atrial fibrillation; ASA, acetylsalicylic acid; AV, aortic valve; BHV, biological heart valve; 
DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; MV, mitral valve; OAC, 
oral anticoagulation; TAVI, transcatheter aortic valve implantation; TV, tricuspid valve; VKA, 
vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.  
Table 12 Criteria for the diagnosis of moderate or severe aortic and mitral haemodynamic valve deterioration  
Moderate 
Severe  
Aortic BHV 
SVD or non-structural valve 
dysfunction (except PVL or PPM),a 
thrombosis, or endocarditis 
Increase in mean transvalvular gradient ‚â•10 mmHg 
resulting in mean gradient ‚â•20 mmHg 
Increase in mean transvalvular gradient ‚â•20 mmHg 
resulting in mean gradient ‚â•30 mmHg 
AND 
AND 
Decrease in EOA ‚â•0.3 cm2 or ‚â•25%, and/or decrease in 
DVI ‚â•0.1 or ‚â•20%, compared with echocardiographic 
assessment performed 1‚Äì3 months post-procedure 
Decrease in EOA ‚â•0.6 cm2 or ‚â•50%, and/or decrease in 
DVI ‚â•0.2 or ‚â•40%, compared with echocardiographic 
assessment performed 1‚Äì3 months post-procedure 
OR 
OR 
New occurrence or increase of ‚â•1 grade of 
intraprosthetic AR resulting in ‚â• moderate AR 
New occurrence or increase of ‚â•2 grades of intraprosthetic 
AR resulting in ‚â• moderate-to-severe AR 
Mitral BHV 
SVD or non-structural valve 
dysfunction (except PVL or PPM),b 
thrombosis, or endocarditis 
Increase in DVI ‚â•0.4 or ‚â•20%, resulting in DVI ‚â•2.2, or 
decrease in EOA ‚â•0.5 cm2 or ‚â•25%, resulting in EOA  
<1.5 cm2, usually associated with increase of transmitral 
gradient ‚â•5 mmHg 
Increase in DVI ‚â•0.8 or ‚â•40%, resulting in DVI ‚â•2.7, or 
decrease in EOA ‚â•1.0 cm2 or ‚â•50%, resulting in EOA  
<1 cm2, usually associated with increase of transmitral 
gradient ‚â•10 mmHg 
OR 
OR 
New occurrence or increase of ‚â•1 grade of 
intraprosthetic MR resulting in ‚â•moderate MR 
New occurrence or increase of ‚â•2 grades of intraprosthetic 
MR resulting in ‚â•moderate-to-severe MR 
¬© ESC/EACTS 2025
Adapted from 895,896. 
AR, aortic regurgitation; AV, aortic valve; BHV, biological heart valve; DVI, Doppler velocity index; EOA, effective orifice area; MR, mitral regurgitation; PPM, prosthesis‚Äìpatient mismatch; 
PVL, paravalvular leak; SVD, structural valve deterioration. 
aObstruction by pannus; dilatation of the aortic root after stentless BHV; or AV-sparing operations. 
bLeaflet entrapment by pannus, chordae, or suture.   
ESC Guidelines                                                                                                                                                                                               63


<!-- PAGE 64 -->

### Page 64

infrequent, should be carefully ruled out, especially in patients with 
small and hypertrophic ventricles.904 
14.4.2. Non-structural valve dysfunction 
14.4.2.1. Prosthesis‚Äìpatient mismatch 
Prosthesis‚Äìpatient mismatch should be prevented whenever possible after either transcatheter or surgical valve-replacement procedures (see Section 8.5.1.2). When occurring in the aortic 
position, severe PPM is associated with decreased quality of life, increased rate of rehospitalization and reintervention, and possible 
reduction in long-term survival, although findings are not consistent 
throughout all studies.454,905‚Äì909 Moderate PPM is more common, 
but seems to have a limited impact on outcomes. The projected 
indexed EOA may be predicted prior to valve implantation to 
avoid severe PPM,908 although this concept has been challenged.910 
Less is known about the prevalence and consequences of PPM in 
the mitral and tricuspid positions, and established definitions are 
lacking. 
Prosthesis‚Äìpatient mismatch is an infrequent indication for reintervention. However, reoperation should be considered in symptomatic patients with severe PPM, particularly if the patient is low 
risk.394,437,438 
14.4.2.2. Paravalvular leak and haemolysis 
The diagnosis of PVL requires systematic TOE, because TTE may be 
inconclusive. Haemolytic anaemia can often be detected in patients 
with prosthetic valves and is best assessed by measuring lactate dehydrogenase and haptoglobin serum levels, but rarely leads to symptoms. Intervention is needed if a PVL causes haemolysis requiring 
blood transfusions or symptoms, or if secondary to valve endocarditis. 
Transcatheter PVL closure is a valid alternative to surgery in the case 
of significant regurgitation or haemolysis, if feasible depending on the 
size and location of the leak, but requires specific expertise and planning. Care must be taken not to interfere with mechanical leaflet motion in MHV patients. Reported results for transcatheter PVL closure 
are inconsistent, with several patients returning with recurrent PVL 
and/or haemolysis.911 When surgery or transcatheter intervention 
are contraindicated, medical therapy aims to counteract the effect 
of haemolysis (iron supplementation and erythropoietin) or reduce 
it (beta-blockers).912 
14.4.3. Endocarditis 
Antibiotic prophylaxis is recommended in all patients with a prosthetic valve (including transcatheter valve prostheses) and after valve 
repair using prosthetic material or with previous episode(s) of infective endocarditis, and should also be considered after transcatheter 
MV or TV repair.5 It is recommended in such patients when undergoing dental extractions, oral surgery, or other procedures requiring 
manipulation of the gingival or peri-apical region of the teeth. 
Particular attention to dental and cutaneous hygiene, and strict 
aseptic measures during any invasive procedure, are also advised in 
this population. Additional details on endocarditis prophylaxis are 
mentioned in the 2023 ESC Guidelines for the management of 
endocarditis.5 
14.4.4. Valve thrombosis 
Valve thrombosis occurs mainly in MHVs,913,914 but can also be observed in BHVs.915,916 The spectrum of BHV thrombosis ranges 
from incidental CCT findings, such as hypo-attenuated leaflet thickening (HALT) with or without reduced leaflet motion but normal 
gradients, to clinically apparent presentations with elevated 
gradients, symptoms of valve obstruction, or thromboembolic 
events.917‚Äì919 
14.4.4.1. Hypo-attenuated leaflet thickening 
Hypo-attenuated leaflet thickening is detected by CCT in 10%‚Äì30% of 
aortic BHVs depending on antithrombotic management, the definition 
of HALT, the timepoint of assessment, and the type of valve.917,919‚Äì921 
The significance and clinical implications of these findings with respect 
to thromboembolic risk and valve durability remain uncertain. 
Accordingly, routine use of CCT to detect HALT is not indicated.918‚Äì920 In patients with relevant increases in gradients, in 
whom HALT and restricted leaflet motion is confirmed by CCT, 
elective use of DOACs or VKAs should be considered to resolve leaflet thrombosis.918,921,922 
14.4.4.2. Clinically significant valve thrombosis 
Obstructive valve thrombosis should be suspected in any patient 
with any type of prosthetic valve who presents with new-onset 
dyspnoea or HF symptoms, an embolic event, or an unexpected increase in transvalvular gradients. If TTE findings are uncertain, the 
diagnosis should be confirmed by TOE and/or CCT to distinguish 
between 
thrombus, 
pannus, 
and 
degeneration.923‚Äì925 
Cinefluoroscopy can detect impaired MHV leaflet motion and reduced opening angles. 
Adequate anticoagulation must be promptly restored in all patients 
with MHV thrombosis and subtherapeutic INR. Although surgery remains the first-line option in critically ill patients, emergency valve replacement is associated with increased risk, whereas bleeding and 
systemic embolism are increased with fibrinolysis.926‚Äì928 Slow, low- 
dose infusion appears to lower complication rates, while preserving 
thrombolytic success rates.928‚Äì931a It is recommended that the decision between surgery and fibrinolysis is taken within the Heart 
Team, and individualized by weighing clinical factors and local expertise (Figure 20). 
Management of non-obstructive thrombosis or obstructive 
thrombosis of an MHV without pronounced HF symptoms depends mainly on the occurrence of a thromboembolic event 
and the size of the thrombus. Surgery should be considered for 
a large (>10 mm) non-obstructive prosthetic valve thrombus 
that is complicated by embolism or persists despite optimal 
OAC.913,932,933 
Anticoagulation using a VKA is the first-line treatment for clinically 
relevant BHV thrombosis, unless urgent reintervention or fibrinolysis is required due to progressive acute HF or haemodynamic 
instability.934‚Äì938 Because clinically relevant BHV thrombosis is associated with recurrence and may contribute to prosthetic degeneration, indefinite anticoagulation may be considered after a 
confirmed episode, but this strategy must be balanced against the 
risk of bleeding.936,939


<!-- PAGE 65 -->

### Page 65

OR
Signs and symptoms of MHV thrombosis
Large thrombus (‚â•10 mm)
complicated by embolism
Acute heart failure with NYHA Class III or IV
due to obstructive thrombosis
Evidence for inadequate OAC
Fibrinolysis
(low-dose slow infusion)
Favoured if:
‚Ä¢ High surgical risk
‚Ä¢ Right-sided valve prosthesis
Surgery
Favoured if:
‚Ä¢ Recurrent event
‚Ä¢ Possible pannus
‚Ä¢ Cardiogenic shock
‚Ä¢ Large thrombus
‚Ä¢ Thromboembolic event
‚Ä¢ Contraindication to Ô¨Åbrinolysis
Surgery
(Class IIa)
Heart Team evaluation
(Class I)
Heart Team evaluation
Bridge until target INR,
identify and correct causes of inadequate OAC
Continue VKA ¬± ASA with more intense monitoring
Repeat imaging for monitoring of thrombus resolution 
or persistence
Persistent thrombus with 
clinically relevant obstruction or 
thromboembolic event
Increase VKA intensity or add low-dose ASA
(Class IIa)
TTE plus 
TOE and/or CCT or Ô¨Çuoroscopy (Class I)
Figure 20 Management of left-sided obstructive and non-obstructive mechanical heart valve thrombosis. ASA, acetylsalicylic acid; CCT, cardiac computed tomography; INR, international normalized ratio; MHV, mechanical heart valve; NYHA, New York Heart Association; OAC, oral anticoagulation; 
TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; VKA, vitamin K antagonist.   
ESC Guidelines                                                                                                                                                                                               65


<!-- PAGE 66 -->

### Page 66

### 15 Management during

non-cardiac surgery 
In patients with significant VHD who undergo NCS, the risk of peri- 
operative cardiovascular complications is increased and related to 
both the timing of the procedure (i.e. urgent vs non-urgent) and type 
of surgery (low, intermediate, or high risk), as well as patient-specific 
factors (type and severity of VHD, LV function, etc.).194,957‚Äì959 
Detailed recommendations related to NCS are available in the 2022 
ESC Guidelines on cardiovascular assessment and management of patients 
undergoing non-cardiac surgery.960 
15.1. Pre-operative evaluation 
Echocardiography should be performed in all patients with VHD requiring 
NCS. Patient- and surgery-specific factors, along with risk calculators, can 
be used to guide the treatment strategy. Determination of functional capacity is a pivotal step for pre-operative risk assessment, measured either by 
the ability to perform activities in daily life or by exercise testing. Screening 
for frailty using validated tools is advisable.90 Decisions on pre- and peri- 
operative management, surveillance, and continuation of chronic cardiovascular medical treatment should be taken after multidisciplinary discussion involving cardiologists, surgeons, and cardiac anaesthesiologists, as 
well as the team who will be in charge of the NCS. Patients receiving 
OAC treatment should be managed as described in Section 14. 
15.2. Specific valve lesions 
15.2.1. Aortic stenosis 
In patients with severe symptomatic AS, the treatment depends on the 
urgency and risk of NCS. If life-saving time-sensitive NCS is needed, it 
should be performed under careful haemodynamic monitoring avoiding 
rapid changes of volume status, with prompt treatment of arrhythmia regardless of AS severity. In cases of urgent high-risk NCS, TAVI or balloon 
aortic valvuloplasty should be considered in patients with critical AS prior 
to surgery, considering the risk of developing severe acute AR after 
Recommendation Table 17 ‚Äî Recommendations for the management of prosthetic valve dysfunction (see also  
Supplementary data online, Evidence Table 25) 
Recommendations 
Classa 
Levelb 
Haemolysis and paravalvular leak  
It is recommended that the decision between transcatheter or surgical closure of clinically significant PVLs is based on Heart Team 
evaluation, including patient risk, leak morphology, and local expertise. 
I 
C 
Reoperation is recommended if a PVL is related to endocarditis, or causes haemolysis requiring repeated blood transfusion or leading to HF 
symptoms. 
I 
C 
Transcatheter closure should be considered for suitable PVLs with clinically significant regurgitation and/or haemolysis.940 
IIa 
B 
Mechanical heart valve failure 
Reoperation is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. 
I 
C 
Biological heart valve failure 
Reintervention is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. 
I 
C 
Transcatheter, transfemoral valve-in-valve implantation in the aortic position should be considered in patients with significant valve 
dysfunction who are at intermediate or high surgical risk, and have suitable anatomical and prosthesis features, as assessed by the Heart 
Team.447,448,450,451,941 
IIa 
B 
Transcatheter transvenous mitral or tricuspid valve-in-valve implantation should be considered in patients with significant valve dysfunction 
at intermediate or high surgical risk, if the anatomy is suitable.569,570,681,942‚Äì944 
IIa 
B 
Reoperation should be considered in asymptomatic patients with significant prosthetic dysfunction, if surgical risk is low. 
IIa 
C 
Valve thrombosis 
TOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis.914,918,923,925,945‚Äì948 
I 
C 
Mechanical heart valve thrombosis 
Heart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine 
appropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis).923,926‚Äì929,931,949‚Äì954 
I 
B 
Surgery should be considered for large (>10 mm) prosthetic thrombus complicated by embolism.913,932,933 
IIa 
C 
Biological heart valve thrombosis 
OAC using VKA is recommended in BHV thrombosis before considering reintervention.867,934‚Äì937,955,956 
I 
B 
OAC should be considered in patients with leaflet thickening and reduced leaflet motion leading to elevated gradients at least until 
resolution.918,920‚Äì922 
IIa 
B 
¬© ESC/EACTS 2025
4D, four-dimensional; BHV, biological heart valve; CT, computed tomography; HF, heart failure; MHV, mechanical heart valve; NYHA, New York Heart Association; OAC, oral 
anticoagulation; PVL, paravalvular leak; TOE, transoesophageal echocardiography; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 67 -->

### Page 67

balloon aortic valvuloplasty.194,961 Urgent low- and intermediate-risk 
NCS can be performed relatively safely in patients with severe AS.962 
Patients in whom NCS can be deferred (i.e. non-urgent NCS) 
should undergo pre-operative Heart Team evaluation to determine 
whether SAVR or TAVI is preferable. TAVI may be preferred to 
SAVR if faster recovery plays a role, particularly in elderly patients 
in whom complex or high-risk NCS is planned.963 The treatment of 
asymptomatic patients with severe AS should be individualized 
(Figure 21).964 
15.2.2. Mitral stenosis 
Heart rate and fluid balance should be controlled to prevent pulmonary 
oedema during NCS and arterial vasodilators should be avoided. 
Non-cardiac surgery is safe in patients with an MVA of >1.5 cm2, and in 
asymptomatic patients with MVA ‚â§1.5 cm2 and SPAP of <50 mmHg. 
Symptomatic patients or those with SPAP of >50 mmHg should undergo 
PMC or other appropriate valve intervention before high-risk NCS, if possible.965,966 Asymptomatic patients with MVA ‚â§1.5 cm2 can undergo 
low-to-moderate-risk NCS under careful monitoring, especially if PMC 
is unsuitable. Multidisciplinary management is advised for patients with significant MS who are ineligible for valve intervention. 
15.2.3. Aortic and mitral regurgitation 
Non-cardiac surgery can usually be performed safely in asymptomatic patients with severe MR or AR and preserved LV function. If NCS is urgent, 
patients should undergo surgery under strict haemodynamic monitoring, 
regardless of symptom status. In cases of elective (non-urgent) NCS in 
patients with severe ventricular SMR, medical therapy should be optimized. If symptoms persist and NCS is intermediate or high risk, TEER 
should be considered after Heart Team discussion based on clinical 
Patient with severe AS requiring NCS
LOW-MODERATE
Urgent NCS
HIGH
HIGH
HIGH
LOW
Elective NCS
Symptoms or LV dysfunction
Consider TAVI
or balloon aortic 
valvuloplasty 
before NCS
if doable, or NCS
under strict 
monitoring
NCS
NCS under strict monitoring
Heart Team decision:
SAVR or TAVI
Risk of NCS
Risk of NCS
Patient risk for
AV procedure
(TAVI/SAVR)
Figure 21 Management of non-cardiac surgery in patients with severe aortic stenosis. AS, aortic stenosis; AV, aortic valve; LV, left ventricular; NCS, 
non-cardiac surgery; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.   
ESC Guidelines                                                                                                                                                                                               67


<!-- PAGE 68 -->

### Page 68

and anatomical selection criteria.194,584 Valve treatment should be performed for patients with AR meeting the criteria for valve intervention 
before any elective intermediate- or high-risk NCS.966,967 
15.3. Peri-operative monitoring 
Heart rate control (particularly in MS) and careful fluid management 
(particularly in AS and MR with reduced LVEF) are needed throughout 
the procedure. The involvement of specialized cardiovascular anaesthesiologists should be considered in complex situations because TOE 
monitoring may be considered. Pulmonary artery catheterization is 
not routinely used. 
16. Management of valvular heart 
disease during pregnancy 
Specific ESC Guidelines on this topic are available (the 2025 ESC 
Guidelines on cardiovascular disease during pregnancy) and should be consulted for further details.968 Pregnancies in patients with VHD should 
be considered high risk and managed under the close supervision of a 
cardiologist and a multidisciplinary Pregnancy Heart Team. The importance of midwives and other specialized nursing personnel is increasingly 
recognized for high-quality direct patient interactions. Shared decision- 
making is especially important when addressing the cardiovascular risk 
of pregnancy and the benefit‚Äìrisk ratios of therapeutic options and 
modes of delivery (Figure 22). 
16.1. Management before pregnancy 
Ideally, women should undergo a thorough physical examination by 
their general practitioner for VHD screening prior to pregnancy. A specialized evaluation including TTE should be performed by a cardiologist 
in the case of clinical suspicion.968,969 
If VHD is diagnosed, pre-pregnancy counselling is imperative. 
Unplanned pregnancies in patients with VHD should be discouraged. 
Contraception methods should be recommended after discussion 
with the patient in the presence of a significant maternal and/or foetal 
risk. In patients contemplating pregnancy, the maternal risk should be 
assessed using the modified WHO classification and other scores such 
as the CARPREG or DEVI risk score (see Supplementary data online,  
Table S7).970 




	


	


















































	







	
¬Å¬ç
¬è¬ê	¬ê¬ù¬†¬≠¬Ä¬Ä¬Å
	
¬è¬ê¬Ç¬ù¬†¬≠
¬É¬Ñ¬†¬Ö¬Ö¬Å¬ç¬è¬è¬≠¬Å¬ù¬è¬Ü
¬ê

¬ê

	
¬ù
	¬ê
¬Ö




	
¬Å	¬á
	

¬É	¬Ä¬Ä¬Å¬Ü
¬≠
	¬É
¬Ü
Figure 22 The Pregnancy Heart Team model of care. AS, aortic stenosis; ECG, electrocardiogram; MS, mitral stenosis; TTE, transthoracic echocardiography; VHD, valvular heart disease.


<!-- PAGE 69 -->

### Page 69

Before recommending pregnancy, the following conditions need to 
be corrected: 
‚Ä¢ MS with MVA <1.5 cm2, even when asymptomatic.971 
‚Ä¢ Severe AS with symptoms, or abnormal exercise test, or LV systolic 
dysfunction.972 
‚Ä¢ Heritable aortic disorders and high risk of aortic dissection: prophylactic 
aortic repair is recommended prior to pregnancy in women with 
Marfan syndrome and an aortic diameter of >45 mm, and may be considered in women with an aortic diameter between 40 and 45 mm 
when risk factors for dissection exist.973 Aneurysmal dilation in women 
with BAV should be corrected when the aortic diameter is ‚â•50 mm.974 
Close follow-up in dedicated units and beta-blocker therapy during 
pregnancy and post-partum are recommended unless contraindicated, 
although strong evidence is only available for Marfan syndrome.  
Valvular regurgitant lesions are generally well tolerated during pregnancy. Prophylactic intervention is therefore not recommended in the 
absence of class I or IIa indications. 
The first therapeutic option for MS in a woman considering pregnancy should be PMC. When implantation of a prosthetic valve is necessary, BHVs are recommended, although early SVD remains a 
serious concern.975 Mechanical heart valves must be avoided due to 
the high risk of maternal and foetal complications linked to the potential 
teratogenic effects of VKAs, as well as the increased risk of bleeding.976 
The Ross procedure may be considered for the treatment of AV disease at centres with expertise. 
16.2. Management during pregnancy 
16.2.1. Patients with native valve disease 
Pregnancy can worsen the clinical course of left-sided stenotic valvular 
lesions because increased cardiac output causes an increment of transvalvular gradient of ‚àº50%, mainly between the first and second trimesters. Regurgitant lesions are less likely to cause complications, except 
in high-risk cases (LV systolic dysfunction, PH, and cardiac events before 
pregnancy).977 
Mild MS is generally well tolerated.978 Heart failure occurs in 
one-third of pregnant women with an MVA of <1.5 cm2 and in one-half 
of those with an MVA of <1.0 cm2, most often during the second trimester.971 Percutaneous mitral commissurotomy should be considered if symptoms or SPAP of >50 mmHg persist despite optimal 
medical therapy (diuretics and beta-1-selective beta-blockers), preferably after the 20th week of pregnancy. 
Regarding AS, pregnancy is generally well tolerated if prior exercise 
tolerance was normal, even in severe AS, while HF has been reported 
to occur in up to 25% of symptomatic patients.972 In symptomatic 
patients despite medical therapy (i.e. diuretics), TAVI seems to be 
the preferred option in very selected patients, although evidence is 
lacking. Percutaneous balloon valvuloplasty may be an alternative option. Procedures should be performed in an experienced valve 
centre.972,979,980 
Surgery under cardiopulmonary bypass is associated with a high rate 
of foetal loss and should be restricted to conditions that threaten the 
mother‚Äôs life if transcatheter intervention is not possible or has failed. 
Vaginal delivery is the first choice for the majority of patients. 
Caesarean section is preferred if there is an obstetric indication, 
and in the case of severe MS or AS, ascending aortic diameter of 
>45 mm, severe PH, or if delivery starts while the patient is being 
treated with OAC. 
16.2.2. Patients with prosthetic valves 
Pregnant patients with MHVs should be followed in a centre with corresponding expertise. In a cohort of 212 women with MHVs, valve 
thrombosis occurred in 10 (4.7%) pregnancies and haemorrhagic 
events occurred in 49 (23.1%).976 Therapeutic OAC during pregnancy 
is essential to avoid thrombosis. The higher efficacy of VKAs compared 
with LMWH to prevent thrombosis must be balanced against increased 
foetal risks.981 
In patients requiring ‚â§5 mg/day of warfarin, OAC with warfarin 
throughout pregnancy, changing to UFH before delivery, is advocated, 
in order to reduce the risk of thrombosis. In patients requiring higher 
doses, switching to dose-adjusted LMWH at least twice per day with 
strict anti-Xa monitoring during the first trimester is recommended 
to avoid the teratogenic effect of VKAs (for corresponding flowcharts 
see the 2025 ESC Guidelines for the management of cardiovascular diseases during pregnancy968). 
Lifetime management of women with a BHV considering pregnancy 
is central and transcatheter valve-in-valve implantation may be considered as a bridge to MHV implantation.982 
17. Sex-specific considerations 
in patients with valvular heart 
disease 
Although men and women are equally likely to experience VHD, sex- 
specific prevalence exists according to valve type and disease pathophysiology.644,648,983 Women more frequently suffer from MV disease 
such as prolapse, RHD or TR, while men more often present with AS or 
AR, especially associated with BAV.984 Men also suffer from endocarditis of any valve more frequently.985 
Female sex is associated with higher mortality in the presence of various VHDs,986 including early post-treatment,987 and is included as a 
risk factor in surgical risk prediction tools such as the STS and 
EuroSCORE calculators. However, risk scores are often derived 
from populations including a majority of men.988 In addition, risk prediction scores are susceptible to referral bias that results in a well- 
established higher risk of undertreatment or delayed treatment of 
VHD in women.983,984,986 
17.1. Aortic valve disease 
Female patients with severe AS present more often with shortness of 
breath, whereas males more frequently have angina, presumably due to 
the higher incidence of CAD.989 The pathophysiology of AS seems to 
differ according to sex, with women having less calcium and more fibrosis.990 Concentric ventricular hypertrophy and remodelling are also 
more frequently observed in women than in men, resulting in higher 
LVEF but smaller LV cavity and stroke volume.991 Consequently, paradoxical low-flow, low-gradient constellations are frequent and may 
both contribute to the underdiagnosis of severe AS in women and delay 
an intervention.992 The use of sex-specific thresholds to define flow 
limitation (<40 mL/m2 for men and <32 mL/m2 for women) has therefore been suggested,292 and the use of CCT to quantify the calcium 
score should be performed in women with discordant echocardiographic parameters.777 
Women are less likely to be referred to a cardiologist and 
undergo investigations. Surgical aortic valve replacement is performed less frequently in women, especially if echocardiographic 
parameters are discordant.993 In patients presenting with severe  
ESC Guidelines                                                                                                                                                                                               69


<!-- PAGE 70 -->

### Page 70

AS and Class I indications for SAVR, a significantly higher proportion 
of men than women are referred for evaluation by a cardiac 
surgeon.994,995 
Male patients derive a clearer benefit from SAVR compared with women, who have higher in-hospital and long-term mortality and morbidity,987,996 possibly explained by more severe concentric hypertrophy991 
and a smaller aortic annulus predisposing to PPM.997 Conversely, in a 
randomized trial (RHEIA) that compared TAVI with SAVR in 443 women with a mean age of 73 years, TAVI was superior in reducing the 
primary endpoint composed of death, stroke, or rehospitalization at 
1 year, predominantly driven by a reduction in rehospitalization for 
valve- or procedure-related symptoms or worsening HF.998 Several observational studies suggest that elderly women have lower mortality 
after TAVI,999 even if the rates of major vascular complications and 
bleeding tend to be higher.997 
Indexed cut-offs to indicate treatment of AR are validated, but only 
partially account for sex differences. Newer studies using echocardiographic volumes1000 and CMR1001 suggest that women may experience 
higher event rates at lower cut-offs compared with men, but this requires further investigation. 
17.2. Mitral valve disease 
Patients with RHD are often young women and have a high prevalence 
of major cardiovascular complications with far-reaching impacts on reproductive health and access to care.282 Although women experience 
favourable outcomes compared with men when treated by percutaneous balloon valvuloplasty, access to these procedures is still limited 
in low-income countries.662 
Fibroelastic disease with MV prolapse is also more frequent in women, and may be accompanied by morphological abnormalities of 
the MA associated with fibrosis of the papillary muscles or the inferobasal LV that may act as the substrate for sudden cardiac death, 
even in the absence of severe MR.1002 Recent evidence has supported considering lower women-specific cut-offs for intervention 
with regard to LVESD (36 mm; indexed LVESD, 1.8 cm/m2), while 
the LVEF cut-off was similar to men (58%), albeit with higher 
mortality.548 
Ventricular SMR associated with low LVEF is more frequent in men 
with HF,1003 while atrial SMR due to chronic AF and/or HFpEF affects 
more women (58% vs 42% male).579 
Female sex is a risk factor for the development of MAC and was reported to account for 68% of the patients included in a large-scale 
transcatheter MV replacement in MAC registry.1004 Furthermore, women present with a faster disease progression.1005 
17.3. Tricuspid valve disease 
Tricuspid regurgitation is more prevalent in women,208 and female 
sex is associated with accelerated disease progression.1006‚Äì1008 
Hypotheses to explain these observations include the overall higher 
prevalence of HFpEF and AF in women.1009 Women are usually 
diagnosed at an older age and the cause of TR is most frequently 
a consequence of left valvular disease or annular dilatation attributable 
to RA dilatation.1010 No differences have been detected to date 
in terms of adverse events after surgery1011 or transcatheter TV 
interventions.1012,1013 
18. Key messages 
Heart Team and Heart Valve Centre 
‚Ä¢ An integrated regional Heart Valve Network incorporating outpatient Heart Valve Clinics and specialist Heart Valve Centres allows 
optimal patient care. 
‚Ä¢ Heart Valve Centres should fulfil institutional and local statutory requirements, and strive for high procedural volume and excellent clinical outcomes. 
‚Ä¢ Heart Team recommendations should be based upon these guideline 
recommendations, relevant updated evidence, key medical considerations, and patient preferences. 
‚Ä¢ Core members of the Heart Team include the primary clinical cardiologist, cardiologists with subspecialty expertise in VHD, specialists in 
advanced cardiovascular imaging and peri-procedural imaging guidance, and surgeons and interventional cardiologists with training 
and expertise in valve interventions. 
‚Ä¢ A network approach that distinguishes between higher- and 
lower-volume centres is appropriate, with more complex procedures focused in the most experienced (i.e. upper quartile) 
centres. Information on the network organization should be communicated to patients, as well as referring cardiologists and general 
practitioners.  
Aortic regurgitation 
‚Ä¢ Assessment of AR severity with TTE remains challenging and current 
cut-offs for intervention are mostly based on 2D measurements, although 3D echocardiography and CMR allow more accurate evaluation of LV volumes and LVEF. 
‚Ä¢ Mechanisms of AR may be closely related to the aortic diameters that 
should be measured accurately at all levels of the aortic root (annulus, 
sinuses, and sinotubular junction). 
‚Ä¢ Indication for operation is based on symptoms, LV volumes, LVEF, 
and aortic diameters. Although valve replacement remains the standard treatment, AV repair (or AV sparing when associated with root 
aneurysm) is being increasingly used to avoid prosthesis-related complications, especially in experienced centres. 
‚Ä¢ Current transcatheter options for AR are limited and applicable only 
in patients who are ineligible for surgery.  
Aortic stenosis 
‚Ä¢ Diagnosis of severe AS requires integrative evaluation of pressure 
gradients (the most robust measurements), AVA, flow conditions, 
the extent of valve calcification, and LV function. 
‚Ä¢ Selection of the most appropriate mode of intervention should take 
into account clinical characteristics (age and estimated life expectancy, concomitant conditions), access and valve anatomy (particularly 
the feasibility of transfemoral TAVI and calcification patterns), and 
surgical risk, as well as repeat procedure options and risks (lifetime 
management).  
Mitral regurgitation 
‚Ä¢ The echocardiographic diagnostic workup of patients with MR includes multiparametric assessment of MR severity, evaluation of


<!-- PAGE 71 -->

### Page 71

MV anatomy (often with 3D TOE), identification of the mechanism 
(PMR, ventricular SMR, or atrial SMR), and evaluation of cardiac 
damage. 
‚Ä¢ Surgical MV repair is the preferred method of treatment in severe 
PMR. Transcatheter edge-to-edge repair is recommended in patients 
who are inoperable or high risk according to the Heart Team. 
‚Ä¢ Surgical MV repair is the procedure of choice for asymptomatic patients with primary MR and signs of cardiac damage, including moderate or more TR. 
‚Ä¢ In patients with ventricular SMR, GDMT (including CRT if indicated) 
is the initial and essential treatment step. In symptomatic patients 
without CAD needing revascularization, M-TEER is recommended. 
In patients with concomitant complex CAD and those not suitable 
for TEER, mitral surgery may be considered. 
‚Ä¢ In patients with atrial SMR, MV surgery, AF ablation if indicated, and 
LAAO should be considered after optimization of medical therapy. 
Transcatheter edge-to-edge repair may be considered in patients at 
high surgical risk.  
Mitral stenosis 
‚Ä¢ Most patients with severe rheumatic MS and favourable valve anatomy should undergo PMC, which is the standard of care. Surgery 
is recommended for symptomatic patients with contraindications 
or unfavourable anatomical and clinical characteristics for PMC. 
‚Ä¢ Decision-making in patients with unfavourable anatomy should take 
into account local PMC experience. 
‚Ä¢ In selected patients with clinically severe degenerative MS and MAC, 
transcatheter intervention or surgery may improve symptoms.  
Tricuspid regurgitation 
‚Ä¢ Concomitant TV repair is the preferred method for patients with 
left-sided valve pathology and associated moderate or severe TR. 
‚Ä¢ The use of risk scores for the assessment of RV and secondary organ 
dysfunction should be strongly encouraged in patients with isolated 
severe TV disease. 
‚Ä¢ In isolated severe TR without severe RV dysfunction, surgery should 
be performed at an early stage in patients at low operative risk. 
‚Ä¢ In isolated severe TR patients at increased surgical risk, tricuspid 
TEER or transcatheter replacement should be considered to improve quality of life and RV remodelling, in the absence of severe 
RV dysfunction or pre-capillary PH.  
Tricuspid stenosis 
‚Ä¢ TS is a very rare manifestation of acquired VHD in high-income 
countries. 
‚Ä¢ TS is mainly associated with rheumatic valve disease, carcinoid syndrome, or enzymatic disorders such as Fabry‚Äôs or Whipple‚Äôs disease. 
‚Ä¢ Treatment of symptomatic TS mainly involves surgical TV 
replacement.  
Multiple and mixed valvular heart disease 
‚Ä¢ Transvalvular gradients and velocities reflect the combined burden of 
regurgitation and stenosis in mixed aortic and mitral disease. 
‚Ä¢ Treatment decisions should be based on the assessment of symptom 
and functional status, cardiac damage, anatomical suitability, and the 
risk‚Äìbenefit ratio of intervention and lifetime management 
considerations. 
‚Ä¢ Patients with mixed moderate AS and AR have similar detrimental 
outcomes compared with those with severe isolated AS. 
‚Ä¢ In transcatheter procedures, which allow a sequential approach, 
downstream lesions should be treated first to prevent potential 
haemodynamic deterioration and allow improvement of upstream 
lesions due to changing loading conditions and reverse 
remodelling.  
Antithrombotic treatment in patients with a mechanical 
heart valve 
‚Ä¢ International normalized ratio therapeutic range should be balanced 
to the type and anatomical site of MHV, as well to the thrombotic risk 
profile of the individual patient. 
‚Ä¢ Patient training, self-monitoring, and education can increase INR stability and TTR. 
‚Ä¢ Minor or minimally invasive NCS procedures do not require VKA 
interruption in patients with an MHV. 
‚Ä¢ In patients with an MHV undergoing elective major NCS, bridging 
may be omitted if the thromboembolic risk is low.  
Non-cardiac surgery 
‚Ä¢ The risk of peri-operative cardiovascular complications related to 
surgery and to patient-specific factors should be evaluated and communicated to the patient and surgical team. 
‚Ä¢ In patients with symptomatic severe AS requiring urgent high-risk 
NCS, BAV or TAVI should be considered prior to surgery. In patients 
planned for elective NCS, AV intervention is recommended prior to 
NCS.  
Pregnancy 
‚Ä¢ In women with VHD, decisions regarding management before and during pregnancy should be taken after discussion by the multidisciplinary 
Pregnancy Heart Team. Unplanned pregnancies should be discouraged. 
‚Ä¢ The following conditions should be corrected prior to considering 
pregnancy: 
‚Äì clinically severe MS (MVA <1.5 cm2), even when asymptomatic 
‚Äì severe symptomatic AS, or asymptomatic patients with impaired 
LV function or a pathological exercise test 
‚Äì heritable aortic disorders and high risk of aortic dissection. 
‚Ä¢ Vaginal delivery is the first choice for the majority of patients. 
Indications for Caesarean section include pre-term labour in patients 
on OAC, severe MS or AS, aggressive aortic pathology, acute intractable HF, and severe PH. 
‚Ä¢ Women with MHVs should be managed in expert centres.  
19. Gaps in evidence 
General aspects 
‚Ä¢ Patient-reported outcome measures are infrequently reported 
in VHD studies. Patient-reported outcome measure-oriented studies 
are required to improve quality of life and patient satisfaction. 
‚Ä¢ Methods to address underdiagnosis and undertreatment of VHD 
need to be identified and implemented.  
ESC Guidelines                                                                                                                                                                                               71


<!-- PAGE 72 -->

### Page 72

Heart Team and Heart Valve Centre 
‚Ä¢ Structured research is required to investigate the relationship between procedural volume and clinical outcomes, in order to define 
minimum annual thresholds for individual operators and institutions 
undertaking surgical and transcatheter valve interventions. 
‚Ä¢ There is a pressing need to ensure higher dispersion and adoption of 
interventions for VHD, especially in middle- and low-income countries.  
Conditions associated with valvular heart disease 
‚Ä¢ CAD: 
‚Äì The prognostic value of functional assessment of stable, moderate 
coronary stenosis in VHD patients remains to be determined. 
‚Äì The optimal strategy (invasive vs non-invasive) for CAD assessment in specific VHD populations remains to be elucidated. 
‚Äì The optimal timing of PCI in patients with CAD undergoing TAVI 
is yet to be determined. 
‚Äì The benefit of complete coronary revascularization with CABG in 
patients with combined VHD and CAD requires further research. 
‚Ä¢ AF: 
‚Äì It is unclear which patients with chronic persistent AF and concomitant VHD are deemed to be suitable for rhythm control 
therapy. 
‚Äì The protective effect against stroke of OAC with VKA or DOACs 
in patients after surgical or transcatheter LAAO remains to be 
determined. 
‚Ä¢ Cardiogenic shock and acute HF: 
‚Äì The optimal treatment strategy in VHD patients presenting with 
cardiogenic shock and acute HF is unknown.  
Aortic regurgitation 
‚Ä¢ Impact of early LV remodelling on prognosis in asymptomatic AR patients is unknown. 
‚Ä¢ Prognostic value of CMR-derived indices in asymptomatic patients 
needs to be determined. 
‚Ä¢ More data are required on long-term results of surgical AV repair for AR. 
‚Ä¢ More evidence is required on transcatheter treatment options for 
AR, in particular using dedicated devices.  
Aortic stenosis 
‚Ä¢ Better understanding of the pathophysiology of AS is needed to propose innovative medical therapy. 
‚Ä¢ Further research is required on: 
‚Äì Refined prognostic markers to guide timing of intervention in 
asymptomatic patients. 
‚Äì The role of revascularization in patients with severe AS and asymptomatic concomitant CAD. 
‚Äì Further data on the long-term durability of transcatheter valves in 
comparison with surgical BHVs in younger patients. 
‚Äì The role of TAVI in patients with BAV AS and patients <70 years 
of age. 
‚Äì Results of intervention (valve or coronary) after TAVI or SAVR. 
‚Äì Determining the optimal lifetime management strategy for AS 
patients.  
Mitral regurgitation 
‚Ä¢ The association between primary MR and ventricular arrhythmias requires more investigation, including the impact of intervention on 
ventricular arrhythmias. 
‚Ä¢ More data are required on the role of TEER in patients with advanced HF. 
‚Ä¢ Long-term results of TEER need to be further assessed, including the 
clinical relevance of transmitral gradients after treatment of both primary and secondary MR. 
‚Ä¢ Results of ongoing trials comparing MV surgery with TEER in non- 
high risk primary MR patients are awaited. 
‚Ä¢ Data on the mid- and long-term clinical impacts of transcatheter MV 
replacement are required. 
‚Ä¢ More data on the clinical impacts of surgical and transcatheter treatment of atrial SMR are required.  
Mitral stenosis 
‚Ä¢ The potential role of TMVI using dedicated devices in high-risk 
patients is to be determined, particularly those with severe 
MAC.  
Tricuspid regurgitation 
‚Ä¢ The long-term risks and benefits of concomitant TV surgery in patients with less than moderate TR and annular dilatation undergoing 
left-sided valve surgery need to be determined. 
‚Ä¢ Further investigations are required on the outcomes of TV intervention in asymptomatic patients with severe TR and RV dysfunction or 
significant dilation. 
‚Ä¢ The importance of addressing concomitant AF in patients with TR 
needs to be investigated. 
‚Ä¢ More data are required on the indications, timing, and long-term outcomes of TV repair and replacement for TV disease. 
‚Ä¢ Better understanding is required of the respective role of surgery vs 
transcatheter TV therapy for TR treatment.  
Tricuspid stenosis 
‚Ä¢ The role of transcatheter TV replacement remains unexplored in patients with TS. The most efficient way to achieve ventricular pacing in 
patients after TV replacement needs to be investigated.  
Multiple and mixed valvular heart disease 
‚Ä¢ Further evaluation of the impact on outcomes and indication for 
intervention, as well as timing and modalities of intervention, is 
required.  
Prosthetic valves 
‚Ä¢ Further development of current prosthetic valve devices is required 
to address their main complications (e.g. improved tissue processing 
to reduce degeneration of bioprostheses or new mechanical valve 
designs to reduce risk of thrombosis). 
‚Ä¢ Antithrombotic drugs in MHV patients: 
‚Äì Whether UFH or LMWH should be preferred as bridging therapy 
after MHV implantation, as well as their timing and dosage, remains 
to be established. 
‚Äì For patients with MHV undergoing major NCS, the optimal post- 
operative management and bridging of VKA needs further 
investigation. 
‚Äì The role of pharmacogenomics for VKORC1, CYP2C9, and 
CYP4F2 in patients with highly variable INR, and low TTR or major 
vascular complications despite good adherence, should be further 
investigated. 
‚Äì More data on the risks and benefits of slow thrombolysis for valve 
thrombosis are required.


<!-- PAGE 73 -->

### Page 73

Pregnancy 
‚Ä¢ More data are required on optimal management of anticoagulation in 
pregnant women with MHVs. Prospective studies comparing different antithrombotic regimens are lacking.  
Non-cardiac surgery 
‚Ä¢ Clinical utility of scales for peri-operative risk evaluation needs to be 
determined.  
Sex-specific considerations 
‚Ä¢ The development of sex-adjusted surgical risk prediction tools is required. 
‚Ä¢ Additional data are needed to validate sex-specific cut-offs indicating 
interventions. 
‚Ä¢ Further research is needed to investigate sex-related differences in 
the prognosis and treatment of specific valve diseases, especially 
TR.  
20. ‚ÄòWhat to do‚Äô and ‚ÄòWhat not 
to do‚Äô messages from the 
Guidelines 
Class I and Class III recommendations from throughout the guideline 
document are summarized in Table 13. 
Table 13 ‚ÄòWhat to do‚Äô and ‚Äòwhat not to do‚Äô 
Recommendations 
Classa 
Levelb  
Recommendations for the management of coronary artery disease in patients with valvular heart disease 
CCTA is recommended before valve intervention in patients with moderate or lower (‚â§50%) pre-test likelihood of obstructive CAD. 
I 
B 
Invasive coronary angiography is recommended before valve intervention in patients with high and very high (>50%) pre-test likelihood of 
obstructive CAD. 
I 
C 
Invasive coronary angiography is recommended in the evaluation of CAD in patients with severe ventricular SMR. 
I 
C 
CABG is recommended in patients with a primary indication for valve surgery and coronary artery diameter stenosis ‚â•70%. 
I 
C 
Recommendations for the management of atrial fibrillation in patients with native valvular heart disease 
DOACs are recommended for stroke prevention in preference to VKAs in patients with AF and AS, AR, or MR who are eligible for OAC. 
I 
A 
Concomitant surgical ablation is recommended in patients undergoing MV surgery with AF suitable for a rhythm control strategy to prevent 
symptoms and recurrence of AF, according to an experienced team of electrophysiologists and arrhythmia surgeons. 
I 
A 
Surgical closure of the LA appendage is recommended as an adjunct to OAC in patients with AF undergoing valve surgery to prevent 
cardioembolic stroke and systemic thromboembolism. 
I 
B 
The use of DOACs is not recommended in patients with AF and rheumatic MS with an MVA ‚â§2.0 cm2. 
III 
B 
Recommendations on indications for surgery in severe aortic regurgitation 
AV surgery is recommended in symptomatic patients with severe AR regardless of LV function. 
I 
B 
AV surgery is recommended in asymptomatic patients with severe AR and LVESD >50 mm or LVESDi >25 mm/m2 [especially in patients 
with small body size (BSA <1.68 m2)] or resting LVEF ‚â§50%. 
I 
B 
Valve-sparing aortic root replacement is recommended in young patients with aortic root dilatation at experienced centres when durable 
results are expected. 
I 
B 
AV surgery is recommended in symptomatic and asymptomatic patients with severe AR undergoing CABG or surgery of the ascending 
aorta. 
I 
C 
Recommendations for intervention and mode of intervention in severe aortic stenosis 
Symptomatic patients with severe aortic stenosis 
Intervention is recommended in symptomatic patients with severe, high-gradient AS [mean gradient ‚â•40 mmHg, Vmax ‚â•4.0 m/s, and 
AVA ‚â§1.0 cm2 (or ‚â§0.6 cm2/m2 BSA)]. 
I 
B 
Intervention is recommended in symptomatic patients with low-flow (SVi ‚â§35 mL/m2), low-gradient (<40 mmHg) AS with reduced LVEF 
(<50%) after careful confirmation that AS is severe. 
I 
B 
Asymptomatic patients with severe aortic stenosis 
Intervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause. 
I 
B 
Mode of intervention in patients with symptomatic severe aortic stenosis 
It is recommended that AV interventions are performed in Heart Valve Centres that report their local expertise and outcome data, have 
on-site interventional cardiology and cardiac surgical programmes, and a structured collaborative Heart Team. 
I 
C 
It is recommended that the mode of intervention is based on Heart Team assessment of individual clinical, anatomical, and procedural 
characteristics, incorporating lifetime management considerations and estimated life expectancy. 
I 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                               73


<!-- PAGE 74 -->

### Page 74

TAVI is recommended in patients ‚â•70 years of age with tricuspid AV stenosis, if the anatomy is suitable. 
I 
A 
SAVR is recommended in patients <70 years of age, if the surgical risk is low. 
I 
B 
SAVR or TAVI are recommended for all remaining candidates for an aortic BHV according to Heart Team assessment. 
I 
B 
Concomitant aortic valve surgery at the time of coronary artery bypass grafting or ascending aorta surgery 
SAVR is recommended in symptomatic and asymptomatic patients with severe AS undergoing CABG or surgical intervention on the 
ascending aorta. 
I 
C 
Recommendations for intervention in severe mitral regurgitation 
Primary mitral regurgitation 
MV repair is the recommended surgical technique to treat patients with severe PMR when the result is expected to be durable. 
I 
B 
MV surgery is recommended in symptomatic patients with severe PMR considered operable by the Heart Team. 
I 
B 
MV surgery is recommended in asymptomatic patients with severe PMR with LV dysfunction (LVESD ‚â•40 mm or LVESDi ‚â•20 mm/m2 or 
LVEF ‚â§60%). 
I 
B 
Surgical MV repair is recommended in low-risk asymptomatic patients with severe PMR without LV dysfunction (LVESD <40 mm, LVESDi  
<20 mm/m2, and LVEF >60%) when a durable result is likely, if at least three of the following criteria are fulfilled: 
‚Ä¢ AF 
‚Ä¢ SPAP at rest >50 mmHg 
‚Ä¢ LA dilatation (LAVI ‚â•60 mL/m2 or LA diameter ‚â•55 mm) 
‚Ä¢ concomitant TR ‚â• moderate. 
I 
B 
Ventricular secondary mitral regurgitation and concomitant coronary artery disease 
MV surgery is recommended in patients with severe ventricular SMR undergoing CABG. 
I 
B 
Ventricular secondary mitral regurgitation without concomitant coronary artery disease 
TEER is recommended to reduce HF hospitalizations and improve quality of life in haemodynamically stable, symptomatic patients with 
impaired LVEF (<50%) and persistent severe ventricular SMR, despite optimized GDMT and CRT (if indicated), fulfilling specific clinical and 
echocardiographic criteria. 
I 
A 
Recommendations for mitral stenosis 
Indications for mitral valve surgery and transcatheter intervention in clinically severe rheumatic and degenerative mitral stenosis 
PMC is recommended in symptomatic patients in the absence of unfavourable characteristics for PMC. 
I 
B 
PMC is recommended in any symptomatic patients with a contraindication or a high risk for surgery. 
I 
C 
MV surgery is recommended in symptomatic patients who are not suitable for PMC. 
I 
C 
Recommendations for tricuspid regurgitation 
Indications for intervention in tricuspid regurgitation 
Careful evaluation of TR aetiology, stage of the disease (i.e. degree of TR severity, RV and LV dysfunction, and PH), patient operative risk, 
and likelihood of recovery by a multidisciplinary Heart Team is recommended in patients with severe TR prior to intervention. 
I 
C 
Patients with left-sided valvular heart disease requiring tricuspid valve surgery 
Concomitant TV surgery is recommended in patients with severe primary or secondary TR. 
I 
B 
Patients with severe tricuspid regurgitation (without left-sided valvular heart disease requiring surgery) 
TV surgery is recommended in symptomatic patients with severe primary TR without severe RV dysfunction or severe PH. 
I 
C 
Recommendations on tricuspid stenosis 
Surgery is recommended in symptomatic patients with severe TS. 
I 
C 
Surgery is recommended in patients with severe TS undergoing left-sided valve intervention. 
I 
C 
Recommendations for surgery of concomitant left-sided valvular heart disease 
Concomitant aortic stenosis 
SAVR is recommended in patients with severe AS undergoing surgery for another valve. 
I 
C 
Concomitant aortic regurgitation 
AV surgery is recommended in patients with severe AR undergoing surgery for another valve. 
I 
C 
Concomitant mitral regurgitation 
MV surgery is recommended in patients with severe MR undergoing surgery for another valve. 
I 
C                         
Continued


<!-- PAGE 75 -->

### Page 75

Recommendations on indications for intervention in patients with mixed moderate aortic stenosis and moderate aortic regurgitation 
Intervention is recommended in symptomatic patients with mixed moderate AV stenosis and moderate regurgitation, and a mean 
gradient ‚â•40 mmHg or Vmax ‚â•4.0 m/s. 
I 
B 
Intervention is recommended in asymptomatic patients with mixed moderate AV stenosis and moderate regurgitation with Vmax ‚â•4.0 m/s, 
and LVEF <50% not attributable to other cardiac disease. 
I 
C 
Recommendations for prosthetic valve selection 
Mechanical heart valves 
An MHV is recommended according to the desire of the informed patient and if there is no contraindication to long-term anticoagulation. 
I 
C 
Biological heart valves 
A BHV is recommended according to the desire of the informed patient. 
I 
C 
A BHV is recommended when an adequate quality of anticoagulation with VKA is unlikely, in patients at high bleeding risk, or with estimated 
short life expectancy. 
I 
C 
Recommendations for the management of antithrombotic therapy in patients with a mechanical heart valve replacement 
Lifelong OAC with a VKA is recommended for all patients with MHVs to prevent thromboembolic complications. 
I 
A 
INR self-monitoring and self-management are recommended over standard monitoring in selected, trained patients to improve efficacy. 
I 
A 
It is recommended that INR targets are based on the type and position of the MHV, and the patient‚Äôs risk factors and comorbidities. 
I 
A 
Patient education is recommended to improve the quality of OAC. 
I 
A 
Following cardiac surgery with MHV implantation, it is recommended to start UFH or LMWH bridging and VKA within 24 h, or as soon as 
considered safe. 
I 
B 
DOACs and/or DAPT are not recommended to prevent thrombosis in patients with an MHV. 
III 
A 
Recommendations for the management of antithrombotic therapy in patients with mechanical heart valves undergoing elective 
non-cardiac surgery or invasive procedures 
Continuing VKA treatment is recommended in patients with an MHV for minor or minimally invasive interventions associated with no or 
minimal bleeding. 
I 
A 
It is recommended to discontinue VKA at least 4 days before major elective NCS, aiming for an INR <1.5, and to resume VKA treatment 
within 24 h after surgery, or as soon as considered safe. 
I 
B 
Recommendations for the management of antithrombotic therapy in patients with a biological heart valve or valve repair 
Transcatheter aortic valve implantation without indication for oral anticoagulation 
Low-dose ASA (75‚Äì100 mg/day) is recommended for 12 months after TAVI in patients without indication for OAC. 
I 
A 
DAPT is not recommended to prevent thrombosis after TAVI, unless there is a clear indication. 
III 
A 
Routine use of OAC is not recommended after TAVI in patients without baseline indication. 
III 
A 
Surgical biological heart valve with indication for oral anticoagulation 
OAC continuation is recommended in patients with a clear indication for OAC undergoing surgical BHV implantation. 
I 
B 
Transcatheter biological heart valve with indication for oral anticoagulation 
OAC is recommended for TAVI patients who have other indications for OAC. 
I 
B 
Recommendations on management of prosthetic valve dysfunction 
Haemolysis and paravalvular leak 
It is recommended that the decision between transcatheter or surgical closure of clinically significant PVLs is based on Heart Team 
evaluation, including patient risk, leak morphology, and local expertise. 
I 
C 
Reoperation is recommended if a PVL is related to endocarditis, or causes haemolysis requiring repeated blood transfusion or leading to HF 
symptoms. 
I 
C 
Mechanical heart valve failure 
Reoperation is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. 
I 
C 
Biological heart valve failure 
Reintervention is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. 
I 
C 
Valve thrombosis 
TOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis. 
I 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                               75


<!-- PAGE 76 -->

### Page 76

### 21 Evidence tables

Evidence tables are available at European Heart Journal online. 
22. Data availability statement 
No new data were generated or analysed in support of this research. 
23. Author information 
Jonas Lanz, Department of Cardiology, Bern University Hospital, 
Bern, 
Switzerland; 
Mateo 
Marin-Cuartas, 
University 
Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, 
Germany; Ana Abreu, Faculdade de Medicina da Universidade de 
Lisboa (FMUL), ISAMB, IMPSP, CCUL, CAML, Lisboa, Portugal; 
Servi√ßo Cardiologia, Unidade de Reabilita√ß√£o Cardiovascular, ULS 
Santa Maria/FMUL, Lisboa, Portugal; Marianna Adamo, Institute 
of Cardiology, ASST Spedali Civili, Brescia, Italy; Department of 
medical and surgical specialties, radiological sciences, and public 
health, University of Brescia, Italy; Nina Ajmone Marsan, 
Department of Cardiology, Leiden University Medical Center, 
Leiden, Netherlands; Fabio Barili, Department of Biomedical and 
Clinical Sciences, Universit√† Degli Studi Di Milano, Milan, Italy; 
University Cardiac Surgery Unit, IRCCS Ospedale Galeazzi - 
Sant‚ÄôAmbrogio, Milan, Italy; Department of Epidemiology, Harvard 
T.H. Chan School of Public Health Boston, MA, United States of 
America; Nikolaos Bonaros, Department of Cardiac Surgery, 
Medical University of Innsbruck, Innsbruck, Austria; University 
Hospital Innsbruck, Innsbruck, Austria; Bernard Cosyns, 
Cardiology department, Universitair Ziekenhuis Brussel, Brussels, 
Belgium; Ruggero De Paulis, Department of cardiac surgery, 
European Hospital, Rome, Italy; Unicamillus University, Rome, 
Italy; Habib Gamra, Cardiology University of Monastir, Monastir, 
Tunisia; Marjan Jahangiri, Cardiac Surgery, St George‚Äôs Hospital, 
London, United Kingdom; Anders Jeppsson, Cardiothoracic surgery, Sahlgrenska University Hospital, Gothenburg, Sweden; 
Molecular and clinical medicine, Institute of medicine, Sahlgrenska 
Academy, University of Gothenburg, Gothenburg, Sweden; 
Robert J.M. Klautz, Department of Cardiothoracic Surgery, 
Leiden 
University 
Medical 
Center, 
Leiden, 
Netherlands; 
Department of Cardiothoracic Surgery, Amsterdam University 
Medical Center, Amsterdam, Netherlands; Benoit Mores, 
(Belgium), ESC Patient Forum, Sophia Antipolis, France; Esther 
P√©rez-David, Cardiology Department, Hospital Universitario La 
Paz, IdiPaz (Hospital la Paz Research Institute), Facultad de 
Medicina Universidad Europea de Madrid, Madrid, Spain; Janine 
P√∂ss, Department of internal medicine/cardiology, Heart Centre 
Leipzig at University of Leipzig, Leipzig, Germany; Bernard 
D. Prendergast, Heart Vascular & Thoracic Institute, Cleveland 
Clinic London, London, United Kingdom; Department of 
Cardiology, St Thomas‚Äô Hospital, London, United Kingdom; 
Bianca Rocca, Department of Medicine and Surgery, LUM 
University Casamassima (Ba), Italy; Xavier Rossello, Cardiology 
Department, Hospital Universitari Son Espases, Palma de Mallorca, 
Spain; Health Research Institute of the Balearic Islands (IdISBa), 
Universitat de les Illes Balears (UIB), Palma de Mallorca, Spain; 
Mikio Suzuki, (Serbia), ESC Patient Forum, Sophia Antipolis, 
France; Holger Thiele, Department of Internal Medicine/ 
Cardiology, Heart Centre Leipzig at Leipzig University, Leipzig, 
Germany; Leipzig Heart Science, Leipzig, Germany; Christophe 
Michel Tribouilloy, Cardiology department, Amiens University 
Hospital, Amiens, France; and Wojtek Wojakowski, Division of 
Cardiology and Structural Heart Diseases, Medical University of 
Silesia, Katowice, Poland. 
24. Appendix 
ESC/EACTS Scientific Document Group 
Includes Document Reviewers, ESC National Cardiac Societies and 
EACTS Network of National Cardiac Surgery Societies 
Document 
Reviewers: 
Alec 
Vahanian 
(ESC 
Review 
Co-ordinator) 
(France), 
Carlos-A. 
Mestres 
(EACTS 
Review 
Co-ordinator) (South Africa), Leila Abid (Tunisia), Suleman Aktaa 
(United Kingdom), Elena Arbelo (Spain), Folkert W. Asselbergs 
(Netherlands), Emanuele Barbato (Italy), Giuseppe Boriani (Italy), 
Margarita Brida (Croatia), Sergio Buccheri (Sweden), Robert Byrne 
(Republic of Ireland), Ovidiu Chioncel (Romania), Lenard Conradi 
(Germany), Michele De Bonis (Italy), Victoria Delgado (Spain), Enoch 
F. Akowuah (United Kingdom), Anna Franzone (Italy), Kristina 
Hermann Haugaa (Norway), Bettina Heidecker (Germany), Borja 
Ibanez (Spain), Bernard Iung (France), Stefan James (Sweden), Lars 
K√∏ber (Denmark), Konstantinos C. Koskinas (Switzerland), Ulf 
Mechanical heart valve thrombosis 
Heart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine 
appropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis). 
I 
B 
Biological heart valve thrombosis 
OAC using VKA is recommended in BHV thrombosis before considering reintervention. 
I 
B 
¬© ESC/EACTS 2025
4D, four-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; AVA, aortic valve area; BHV, biological heart valve; BSA, body 
surface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCTA, coronary CT angiography; CRT, cardiac resynchronization therapy; CT, computed tomography; 
DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulation; GDMT, guideline-directed medical therapy; h, hour; HF, heart failure; INR, international normalized ratio; LA, left atrium/ 
left atrial; LAVI, left atrial volume index; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic 
diameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; MHV, mechanical heart valve; MR, mitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVA, mitral valve area; 
NCS, non-cardiac surgery; NYHA, New York Heart Association; OAC, oral anticoagulation; PH, pulmonary hypertension; PMC, percutaneous mitral commissurotomy; PMR, primary mitral 
regurgitation; PVL, paravalvular leak; RV, right ventricle/right ventricular; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery 
pressure; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TOE, transoesophageal echocardiography; TR, tricuspid 
regurgitation; TS, tricuspid stenosis; TV, tricuspid valve; UFH, unfractionated heparin; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 77 -->

### Page 77

Landmesser (Germany), Gregory Y.H. Lip (United Kingdom), John 
William McEvoy (Ireland), Gil Meltzer (Israel), David Messika-Zeitoun 
(Canada), Borislava Mihaylova (United Kingdom), Richard Mindham 
(United Kingdom), Inge Moelgaard (Denmark), Jens Cosedis Nielsen 
(Denmark), Gareth Owens (United Kingdom), Agnes A. Pasquet 
(Belgium), Thomas Pilgrim (Switzerland), Eva Prescott (Denmark), 
Eduard Quintana (Spain), Volker Rudolph (Germany), Rafael Sadaba 
(Spain), Anna Sannino (Germany), Felix C. Tanner (Switzerland), Marina 
Urena (France), Ilonca Vaartjes (Netherlands), Christiaan Vrints 
(Belgium), Alexander Wahba (Norway), Thomas Walther (Germany), 
Adam Witkowski (Poland), and Katja Zeppenfeld (Netherlands) 
Contributor either withdrew or was engaged in only a part of the review process: Davide Capodanno 
ESC National Cardiac Societies actively involved in the review 
process of the 2025 ESC/EACTS Guidelines for the management for 
valvular heart disease: 
Albania: Albanian Society of Cardiology, Naltin Shuka; Algeria: 
Algerian Society of Cardiology, Brahim Kichou; Armenia: Armenian 
Cardiologists Association, Aram L. Chilingaryan; Austria: Austrian 
Society of Cardiology, Philipp Emanuel Bartko; Azerbaijan: 
Azerbaijan Society of Cardiology, Fuad Samadov; Belgium: Belgian 
Society of Cardiology, Caroline M. Van de Heyning; Bosnia and 
Herzegovina: Association of Cardiologists of Bosnia and 
Herzegovina, Zumreta Kusljugic; Bulgaria: Bulgarian Society of 
Cardiology, Elena Kinova; Croatia: Croatian Cardiac Society, Josko 
Bulum; Cyprus: Cyprus Society of Cardiology, Christos Eftychiou; 
Czechia: Czech Society of Cardiology, Hana Linkova; Denmark: 
Danish Society of Cardiology, Emil Fosb√∏l; Egypt: Egyptian Society 
of Cardiology, Hesham Bahaa; Estonia: Estonian Society of 
Cardiology, Jaagup Truusalu; Finland: Finnish Cardiac Society, Jarkko 
Piuhola; France: French Society of Cardiology, Erwan Donal; 
Georgia: Georgian Society of Cardiology, Shalva Petriashvili; 
Germany: German Cardiac Society, Tanja Katharina Rudolph; 
Greece: Hellenic Society of Cardiology, Maria Drakopoulou; 
Hungary: Hungarian Society of Cardiology, Attila Kert√©sz; Iceland: 
Icelandic Society of Cardiology, Hjalti Gu√∞mundsson; Ireland: Irish 
Cardiac Society, Ben Cole; Israel: Israel Heart Society, Shemy 
Carasso; Italy: Italian Federation of Cardiology, Alessandro Navazio; 
Kazakhstan: Association of Cardiologists of Kazakhstan, Madina 
Sugralimova; Kosovo (Republic of): Kosovo Society of Cardiology, 
Gani Bajraktari; Kyrgyzstan: Kyrgyz Society of Cardiology, Alina 
Kerimkulova; Libya: Libyan Cardiac Society, Elham Omran Elgdhafi; 
Lithuania: Lithuanian Society of Cardiology, Sigita Glaveckaite; 
Luxembourg: Luxembourg Society of Cardiology, Frederic Lebrun; 
Malta: Maltese Cardiac Society, Daniela Cassar Demarco; Moldova 
(Republic of): Moldavian Society of Cardiology, Dorin Mihail Lisii; 
Netherlands: Netherlands Society of Cardiology, Sebastian 
Streukens; North Macedonia: National Society of Cardiology of 
North Macedonia, Emilija Antova; Norway: Norwegian Society of 
Cardiology, H√•vard Dalen; Poland: Polish Cardiac Society, Tomasz 
Kukulski; Portugal: Portuguese Society of Cardiology, Cristina 
Gavina; Romania: Romanian Society of Cardiology, Bogdan 
A. Popescu; San Marino: San Marino Society of Cardiology, 
Roberto Bini; Serbia: Cardiology Society of Serbia, Igor Ivanov; 
Slovakia: Slovak Society of Cardiology, Martin Hudec; Slovenia: 
Slovenian Society of Cardiology, Matja≈æ Bunc; Spain: Spanish Society 
of Cardiology, Thomas Javier Bermejo; Sweden: Swedish Society of 
Cardiology, Carl Johan Cronstedt Meurling; Switzerland: Swiss 
Society of Cardiology, Raban Jeger; Tunisia: Tunisian Society of 
Cardiology and Cardio-Vascular Surgery, Leila Abid; T√ºrkiye: 
Turkish Society of Cardiology, Muzaffer M. Degertekin; Ukraine: 
Ukrainian Association of Cardiology, Elena G. Nesukay; United 
Kingdom of Great Britain and Northern Ireland: British 
Cardiovascular Society, Madalina Garbi; Uzbekistan: Association of 
Cardiologists of Uzbekistan, Guzal Mullabayeva. 
EACTS Network of National Cardiac Surgery Societies actively involved in the review process of the 2025 ESC/EACTS 
Guidelines for the management for valvular heart disease: 
Austria: Austrian Society of Cardiac and Thoracic Vascular 
Surgery, Martin Grabenwoeger; Belgium: Belgian Association for 
Cardio-Thoracic Surgery, Frederic Vanden Eynden; Czechia: The 
Czech Society for Cardiovascular Surgery, Jan Vojacek; France: The 
French Society for Thoracic and Cardiovascular Surgery; Andr√© 
Vincentelli; 
Germany: 
German 
Society 
for 
Thoracic 
and 
Cardiovascular Surgery, Volkmar Falk; Greece: Hellenic Society of 
Thoracic and Cardiovascular Surgeons, Panagiotis Dedeilias; Italy: Italian 
Society for Cardiac Surgery, Alessandro Parolari; Netherlands: 
Netherlands Association for Cardio-thoracic surgery, Jerry Braun; 
North Macedonia: North Macedonian Society of Cardiac 
Surgery, Aleksandar Nikolic; Norway: Norwegian Association for 
Cardiothoracic Surgery, Vegard S. Ellensen; Portugal: Sociedade 
Portuguesa de Cirurgia Card√≠aca Tor√°cica e Vascular, Miguel Sousa-Uva; 
Serbia: Serbian Society for Cardiovascular Surgery, Slobodan Micovic; 
Spain: Sociedad Espa√±ola de Cirug√≠a Cardiovascular y Endovascular, 
Juan J. Legarra; Switzerland: Swiss Society for Thoracic and 
Cardiovascular Surgery, Enrico Ferrari; United Kingdom: The Society 
for Cardiothoracic Surgery in Great Britain and Ireland, Narain Moorjani 
ESC Clinical Practice Guidelines (CPG) Committee: 
Ulf 
Landmesser 
(Chairperson) 
(Germany), 
Stefan 
James 
(Co-Chairperson) (Sweden), Marianna Adamo (Italy), Suleman Aktaa 
(United Kingdom), Folkert W. Asselbergs (Netherlands), Colin 
Baigent (United Kingdom), Michael A. Borger (Germany), Giuseppe 
Boriani (Italy), Margarita Brida (Croatia), Robert A. Byrne (Ireland), 
Estelle Gandjbakhch (France), Bettina Heidecker (Germany), Anja 
Hennemuth (Germany), Borja Ibanez (Spain), Peter J√ºni (United 
Kingdom), Gregory Y.H. Lip (United Kingdom), John William McEvoy 
(Ireland), Borislava Mihaylova (United Kingdom), Inge Moelgaard 
(Denmark), Lis Neubeck (United Kingdom), Eva Prescott (Denmark), 
Bianca Rocca (Italy), Xavier Rossello (Spain), Anna Sannino 
(Germany), Felix C. Tanner (Switzerland), Wojtek Wojakowski 
(Poland), and Katja Zeppenfeld (Netherlands) 
EACTS Council: Volkmar Falk (President) (Germany), Patrick 
Myers (Secretary General) (Switzerland), Joseph Bavaria (United 
States of America), Korkut Bostanci (T√ºrkiye), Filip Casselman 
(Belgium), Mario Gaudino (United States of America), Jurgen Hoerer 
(Germany), Nabil Hussein (United Kingdom), Virginia Litle (United 
States of America), Franca Melfi (Italy), Rafael Sadaba (Spain), Florian 
Schoenhoff (Switzerland), Matthias Siepe (Switzerland), and Tanya 
Warburton (United Kingdom) 
25. References 
1. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter 
aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J 
Med 2019;380:1695‚Äì705. https://doi.org/10.1056/NEJMoa1814052 
2. Mack MJ, Leon MB, Thourani VH, Pibarot P, Hahn RT, Genereux P, et al. Transcatheter 
aortic-valve replacement in low-risk patients at five years. N Engl J Med 2023;389: 
1949‚Äì960. https://doi.org/10.1056/NEJMoa2307447 
3. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, et al. 
Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl 
J Med 2017;376:1321‚Äì31. https://doi.org/10.1056/NEJMoa1700456  
ESC Guidelines                                                                                                                                                                                               77


<!-- PAGE 78 -->

### Page 78

4. Forrest JK, Deeb GM, Yakubov SJ, Gada H, Mumtaz MA, Ramlawi B, et al. 4-Year outcomes of patients with aortic stenosis in the Evolut low risk trial. J Am Coll Cardiol 2023; 
82:2163‚Äì65. https://doi.org/10.1016/j.jacc.2023.09.813 
5. Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023 
ESC Guidelines for the management of endocarditis. Eur Heart J 2023;44: 
3948‚Äì4042. https://doi.org/10.1093/eurheartj/ehad193 
6. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC 
Guidelines for the management of chronic coronary syndromes: developed by the 
task force for the management of chronic coronary syndromes of the European 
Society of Cardiology (ESC) Endorsed by the European Association for 
Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024;45:3415‚Äì537. https://doi.org/ 
10.1093/eurheartj/ehae177 
7. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns H, et al. 2024 
ESC Guidelines for the management of atrial fibrillation developed in collaboration 
with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 
2024;45:3314‚Äì414. https://doi.org/10.1093/eurheartj/ehae176 
8. Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC 
Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J 
2024;45:3538‚Äì700. https://doi.org/10.1093/eurheartj/ehae179 
9. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller G-P, et al. 
Force for the management of adult congenital heart disease of the European Society of 
Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital 
Cardiology (AEPC), International Society for Adult Congenital Heart Disease 
(ISACHD). Eur Heart J 2020;42:563‚Äì645. https://doi.org/10.1093/eurheartj/ehaa554 
10. G√©n√©reux P, Sharma RP, Cubeddu RJ, Aaron L, Abdelfattah OM, Koulogiannis KP, et al. 
The mortality burden of untreated aortic stenosis. J Am Coll Cardiol 2023;82:2101‚Äì9.  
https://doi.org/10.1016/j.jacc.2023.09.796 
11. d‚ÄôArcy JL, Coffey S, Loudon MA, Kennedy A, Pearson-Stuttard J, Birks J, et al. 
Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. 
Eur Heart J 2016;37:3515‚Äì22. https://doi.org/10.1093/eurheartj/ehw229 
12. Iung B, Delgado V, Rosenhek R, Price S, Prendergast B, Wendler O, et al. 
Contemporary presentation and management of valvular heart disease: the 
EURObservational research programme valvular heart disease II survey. Circulation 
2019;140:1156‚Äì69. https://doi.org/10.1161/CIRCULATIONAHA.119.041080 
13. Gaede L, Di Bartolomeo R, van der Kley F, Els√§sser A, Iung B, M√∂llmann H. Aortic valve 
stenosis: what do people know? A heart valve disease awareness survey of over 8,800 
people aged 60 or over. EuroIntervention 2016;12:883‚Äì9. https://doi.org/10.4244/ 
eijy16m06_02 
14. Lancellotti P, Magne J, Dulgheru R, Clavel MA, Donal E, Vannan MA, et al. Outcomes of 
patients with asymptomatic aortic stenosis followed up in heart valve clinics. JAMA 
Cardiol 2018;3:1060‚Äì8. https://doi.org/10.1001/jamacardio.2018.3152 
15. Lancellotti P, Rosenhek R, Pibarot P, Iung B, Otto CM, Tornos P, et al. ESC Working 
Group on Valvular Heart Disease Position Paper‚Äîheart valve clinics: organization, 
structure, and experiences. Eur Heart J 2013;34:1597‚Äì606. https://doi.org/10.1093/ 
eurheartj/ehs443 
16. Chambers JB, Prendergast B, Iung B, Rosenhek R, Zamorano JL, Pierard LA, et al. 
Standards defining a ‚ÄòHeart Valve Centre‚Äô: ESC Working Group on Valvular Heart 
Disease and European Association for Cardiothoracic Surgery Viewpoint. Eur Heart 
J 2017;38:2177‚Äì83. https://doi.org/10.1093/eurheartj/ehx370 
17. Nishimura RA, O‚ÄôGara PT, Bavaria JE, Brindis RG, Carroll JD, Kavinsky CJ, et al. 2019 
AATS/ACC/ASE/SCAI/STS Expert Consensus Systems of Care document: a proposal 
to optimize care for patients with valvular heart disease: a joint report of the American 
Association for Thoracic Surgery, American College of Cardiology, American Society 
of Echocardiography, Society for Cardiovascular Angiography and Interventions, and 
Society of Thoracic Surgeons. J Am Coll Cardiol 2019;73:2609‚Äì35. https://doi.org/10. 
1016/j.jacc.2018.10.007 
18. Dreyfus G, Windecker S. How to shape the future of cardiology and cardiac surgery? 
Eur Heart J 2020;41:3693‚Äì701. https://doi.org/10.1093/eurheartj/ehaa707 
19. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/ 
EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43: 
561‚Äì632. https://doi.org/10.1093/eurheartj/ehab395 
20. Leonardi S, Capodanno D, Sousa-Uva M, Vrints C, Rex S, Guarracino F, et al. 
Composition, structure, and function of heart teams: a joint position paper of the 
ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with 
complex coronary artery disease requiring myocardial revascularization. Eur Heart J 
Acute Cardiovasc Care 2021;10:83‚Äì93. https://doi.org/10.1093/ehjacc/zuaa013 
21. Agricola E, Ancona F, Brochet E, Donal E, Dweck M, Faletra F, et al. The structural 
heart disease interventional imager rationale, skills and training: a position paper of 
the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 
2021;22:471‚Äì9. https://doi.org/10.1093/ehjci/jeab005 
22. Hahn RT, Mahmood F, Kodali S, Lang R, Monaghan M, Gillam LD, et al. Core competencies in echocardiography for imaging structural heart disease interventions: an expert consensus statement. JACC Cardiovasc Imaging 2019;12:2560‚Äì70. https://doi.org/ 
10.1016/j.jcmg.2019.10.008 
23. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon 
volume and operative mortality in the United States. N Engl J Med 2003;349:2117‚Äì27.  
https://doi.org/10.1056/NEJMsa035205 
24. Khera R, Pandey A, Koshy T, Ayers C, Nallamothu BK, Das SR, et al. Role of hospital 
volumes in identifying low-performing and high-performing aortic and mitral valve surgical centers in the United States. JAMA Cardiol 2017;2:1322‚Äì31. https://doi.org/10. 
1001/jamacardio.2017.4003 
25. Gammie JS, O‚ÄôBrien SM, Griffith BP, Ferguson TB, Peterson ED. Influence of hospital 
procedural volume on care process and mortality for patients undergoing elective surgery for mitral regurgitation. Circulation 2007;115:881‚Äì7. https://doi.org/10.1161/ 
CIRCULATIONAHA.106.634436 
26. Chikwe J, Toyoda N, Anyanwu AC, Itagaki S, Egorova NN, Boateng P, et al. Relation of 
mitral valve surgery volume to repair rate, durability, and survival. J Am Coll Cardiol 
2017;69:2397‚Äì406. https://doi.org/10.1016/j.jacc.2017.02.026 
27. Chhatriwalla AK, Vemulapalli S, Szerlip M, Kodali S, Hahn RT, Saxon JT, et al. Operator 
experience and outcomes of transcatheter mitral valve repair in the United States. J Am 
Coll Cardiol 2019;74:2955‚Äì65. https://doi.org/10.1016/j.jacc.2019.09.014 
28. Bonow RO, O‚ÄôGara PT, Adams DH, Badhwar V, Bavaria JE, Elmariah S, et al. 2019 
AATS/ACC/SCAI/STS Expert Consensus Systems of Care document: operator and 
institutional recommendations and requirements for transcatheter mitral valve intervention: a joint report of the American Association for Thoracic Surgery, the 
American College of Cardiology, the Society for Cardiovascular Angiography and 
Interventions, and The Society of Thoracic Surgeons. J Am Coll Cardiol 2020;76: 
96‚Äì117. https://doi.org/10.1016/j.jacc.2019.12.002 
29. Grayburn PA, Mack MJ, Manandhar P, Kosinski AS, Sannino A, Smith RL 2nd, et al. 
Comparison of transcatheter edge-to-edge mitral valve repair for primary mitral regurgitation outcomes to hospital volumes of surgical mitral valve repair. Circ Cardiovasc Interv 
2024;17:e013581. https://doi.org/10.1161/circinterventions.123.013581 
30. Wild MG, Stolz L, Rosch S, Rudolph F, Goebel B, K√∂ll B, et al. Transcatheter valve repair for tricuspid regurgitation: 1-year results from a large European real-world registry. J Am Coll Cardiol 2025;85:220‚Äì31. https://doi.org/10.1016/j.jacc.2024.10.068 
31. Carroll JD, Vemulapalli S, Dai D, Matsouaka R, Blackstone E, Edwards F, et al. 
Procedural experience for transcatheter aortic valve replacement and relation to outcomes: the STS/ACC TVT registry. J Am Coll Cardiol 2017;70:29‚Äì41. https://doi.org/10. 
1016/j.jacc.2017.04.056 
32. Mao J, Redberg RF, Carroll JD, Marinac-Dabic D, Laschinger J, Thourani V, et al. 
Association between hospital surgical aortic valve replacement volume and transcatheter aortic valve replacement outcomes. JAMA Cardiol 2018;3:1070‚Äì8. https://doi.org/ 
10.1001/jamacardio.2018.3562 
33. Vemulapalli S, Carroll JD, Mack MJ, Li Z, Dai D, Kosinski AS, et al. Procedural volume 
and outcomes for transcatheter aortic-valve replacement. N Engl J Med 2019;380: 
2541‚Äì50. https://doi.org/10.1056/NEJMsa1901109 
34. Edwards FH, Ferraris VA, Kurlansky PA, Lobdell KW, He X, O‚ÄôBrien SM, et al. Failure 
to rescue rates after coronary artery bypass grafting: an analysis from the Society of 
Thoracic Surgeons adult cardiac surgery database. Ann Thorac Surg 2016;102: 
458‚Äì64. https://doi.org/10.1016/j.athoracsur.2016.04.051 
35. Wallen T, Habertheuer A, Bavaria JE, Hughes GC, Badhwar V, Jacobs JP, et al. Elective 
aortic root replacement in North America: analysis of STS adult cardiac surgery database. Ann Thorac Surg 2019;107:1307‚Äì12. https://doi.org/10.1016/j.athoracsur.2018. 
12.039 
36. Geirsson A, Ahlsson A, Franco-Cereceda A, Fuglsang S, Gunn J, Hansson EC, et al. 
Hospital volumes and later year of operation correlates with better outcomes in acute 
Type A aortic dissection. Eur J Cardiothorac Surg 2018;53:276‚Äì81. https://doi.org/10. 
1093/ejcts/ezx231 
37. Gonzalez AA, Dimick JB, Birkmeyer JD, Ghaferi AA. Understanding the 
volume-outcome effect in cardiovascular surgery: the role of failure to rescue. JAMA 
Surg 2014;149:119‚Äì23. https://doi.org/10.1001/jamasurg.2013.3649 
38. Wakeam E, Asafu-Adjei D, Ashley SW, Cooper Z, Weissman JS. The association of 
intensivists with failure-to-rescue rates in outlier hospitals: results of a national survey 
of intensive care unit organizational characteristics. J Crit Care 2014;29:930‚Äì5. https:// 
doi.org/10.1016/j.jcrc.2014.06.010 
39. Ward ST, Dimick JB, Zhang W, Campbell DA, Ghaferi AA. Association between hospital staffing models and failure to rescue. Ann Surg 2019;270:91‚Äì4. https://doi.org/10. 
1097/sla.0000000000002744 
40. Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, et al. European 
Society of Cardiology: cardiovascular disease statistics 2019. Eur Heart J 2020;41: 
12‚Äì85. https://doi.org/10.1093/eurheartj/ehz859 
41. Ali N, Aktaa S, Younsi T, Beska B, Batra G, Blackman DJ, et al. European Society of 
Cardiology quality indicators for the care and outcomes of adults undergoing transcatheter aortic valve implantation. Eur Heart J Qual Care Clin Outcomes 2024;10: 
723‚Äì36. https://doi.org/10.1093/ehjqcco/qcae006 
42. Messika-Zeitoun D, Baumgartner H, Burwash IG, Vahanian A, Bax J, Pibarot P, et al. 
Unmet needs in valvular heart disease. Eur Heart J 2023;44:1862‚Äì73. https://doi.org/ 
10.1093/eurheartj/ehad121


<!-- PAGE 79 -->

### Page 79

43. van Dijk WB, Schuit E, van der Graaf R, Groenwold RHH, Laurijssen S, Casadei B, et al. 
Applicability of European Society of Cardiology guidelines according to gross national 
income. Eur Heart J 2022;44:598‚Äì607. https://doi.org/10.1093/eurheartj/ehac606 
44. Sengupta PP, Kluin J, Lee SP, Oh JK, Smits A. The future of valvular heart disease assessment and therapy. Lancet 2024;403:1590‚Äì602. https://doi.org/10.1016/s0140- 
6736(23)02754-x 
45. Lancellotti P, Pibarot P, Chambers J, La Canna G, Pepi M, Dulgheru R, et al. 
Multi-modality imaging assessment of native valvular regurgitation: an EACVI and 
ESC council of valvular heart disease position paper. Eur Heart J Cardiovasc Imaging 
2022;23:e171‚Äì232. https://doi.org/10.1093/ehjci/jeab253 
46. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. 
Recommendations for noninvasive evaluation of native valvular regurgitation: a report 
from the American Society of Echocardiography developed in collaboration with the 
Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017;30: 
303‚Äì71. https://doi.org/10.1016/j.echo.2017.01.007 
47. Popescu BA, Andrade MJ, Badano LP, Fox KF, Flachskampf FA, Lancellotti P, et al. 
European Association of Echocardiography recommendations for training, competence, and quality improvement in echocardiography. Eur J Echocardiogr 2009;10: 
893‚Äì905. https://doi.org/10.1093/ejechocard/jep151 
48. Chambers JB, Garbi M, Nieman K, Myerson S, Pierard LA, Habib G, et al. 
Appropriateness criteria for the use of cardiovascular imaging in heart valve disease 
in adults: a European Association of Cardiovascular Imaging report of literature review 
and current practice. Eur Heart J Cardiovasc Imaging 2017;18:489‚Äì98. https://doi.org/ 
10.1093/ehjci/jew309 
49. Agricola E, Ancona F, Bartel T, Brochet E, Dweck M, Faletra F, et al. Multimodality imaging for patient selection, procedural guidance, and follow-up of transcatheter interventions for structural heart disease: a consensus document of the EACVI Task Force 
on Interventional Cardiovascular Imaging: part 1: access routes, transcatheter aortic 
valve implantation, and transcatheter mitral valve interventions. Eur Heart J 
Cardiovasc Imaging 2023;24:e209‚Äì68. https://doi.org/10.1093/ehjci/jead096 
50. Zoghbi WA, Jone PN, Chamsi-Pasha MA, Chen T, Collins KA, Desai MY, et al. 
Guidelines for the evaluation of prosthetic valve function with cardiovascular imaging: 
a report from the American Society of Echocardiography developed in collaboration 
with the Society for Cardiovascular Magnetic Resonance and the Society of 
Cardiovascular Computed Tomography. J Am Soc Echocardiogr 2024;37:2‚Äì63.  
https://doi.org/10.1016/j.echo.2023.10.004 
51. Faletra FF, Agricola E, Flachskampf FA, Hahn R, Pepi M, Ajmone Marsan N, et al. 
Three-dimensional transoesophageal echocardiography: how to use and when to 
use‚Äîa clinical consensus statement from the European Association of 
Cardiovascular Imaging of the European Society of Cardiology. Eur Heart J 
Cardiovasc Imaging 2023;24:e119‚Äì97. https://doi.org/10.1093/ehjci/jead090 
52. Picano E, Pibarot P, Lancellotti P, Monin JL, Bonow RO. The emerging role of exercise 
testing and stress echocardiography in valvular heart disease. J Am Coll Cardiol 2009;54: 
2251‚Äì60. https://doi.org/10.1016/j.jacc.2009.07.046 
53. Genereux P, Pibarot P, Redfors B, Mack MJ, Makkar RR, Jaber WA, et al. Staging classification of aortic stenosis based on the extent of cardiac damage. Eur Heart J 2017;38: 
3351‚Äì8. https://doi.org/10.1093/eurheartj/ehx381 
54. Stolz L, Doldi PM, Orban M, Karam N, Puscas T, Wild MG, et al. Staging heart failure 
patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge 
repair. JACC Cardiovasc Interv 2023;16:140‚Äì51. https://doi.org/10.1016/j.jcin.2022.10. 
032 
55. Dietz MF, Prihadi EA, van der Bijl P, Ajmone Marsan N, Delgado V, Bax JJ. Prognostic 
implications of staging right heart failure in patients with significant secondary tricuspid 
regurgitation. JACC Heart Fail 2020;8:627‚Äì36. https://doi.org/10.1016/j.jchf.2020.02. 
008 
56. G√©n√©reux P, Pibarot P, Redfors B, Bax JJ, Zhao Y, Makkar RR, et al. Evolution and prognostic impact of cardiac damage after aortic valve replacement. J Am Coll Cardiol 2022; 
80:783‚Äì800. https://doi.org/10.1016/j.jacc.2022.05.006 
57. Genereux P, Cohen DJ, Pibarot P, Redfors B, Bax JJ, Zhao Y, et al. Cardiac damage and 
quality of life after aortic valve replacement in the PARTNER trials. J Am Coll Cardiol 
2023;81:743‚Äì52. https://doi.org/10.1016/j.jacc.2022.11.059 
58. Kwak S, Everett RJ, Treibel TA, Yang S, Hwang D, Ko T, et al. Markers of myocardial 
damage predict mortality in patients with aortic stenosis. J Am Coll Cardiol 2021;78: 
545‚Äì58. https://doi.org/10.1016/j.jacc.2021.05.047 
59. Magne J, Cosyns B, Popescu BA, Carstensen HG, Dahl J, Desai MY, et al. Distribution 
and prognostic significance of left ventricular global longitudinal strain in asymptomatic 
significant aortic stenosis: an individual participant data meta-analysis. JACC Cardiovasc 
Imaging 2019;12:84‚Äì92. https://doi.org/10.1016/j.jcmg.2018.11.005 
60. Prihadi EA, van der Bijl P, Dietz M, Abou R, Vollema EM, Marsan NA, et al. Prognostic 
implications of right ventricular free wall longitudinal strain in patients with significant 
functional tricuspid regurgitation. Circ Cardiovasc Imaging 2019;12:e008666. https://doi. 
org/10.1161/CIRCIMAGING.118.008666 
61. Little SH, Rigolin VH, Garcia-Sayan E, Hahn RT, Hung J, Mackensen GB, et al. 
Recommendations for special competency in echocardiographic guidance of structural 
heart disease interventions: from the American Society of Echocardiography. J Am Soc 
Echocardiogr 2023;36:350‚Äì65. https://doi.org/10.1016/j.echo.2023.01.014 
62. Hahn RT, Saric M, Faletra FF, Garg R, Gillam LD, Horton K, et al. Recommended standards for the performance of transesophageal echocardiographic screening for structural heart intervention: from the American Society of Echocardiography. J Am Soc 
Echocardiogr 2022;35:1‚Äì76. https://doi.org/10.1016/j.echo.2021.07.006 
63. Nicoara A, Skubas N, Ad N, Finley A, Hahn RT, Mahmood F, et al. Guidelines for the 
use of transesophageal echocardiography to assist with surgical decision-making in the 
operating room: a surgery-based approach: from the American Society of 
Echocardiography 
in 
collaboration 
with 
the 
Society 
of 
Cardiovascular 
Anesthesiologists and the Society of Thoracic Surgeons. J Am Soc Echocardiogr 2020; 
33:692‚Äì734. https://doi.org/10.1016/j.echo.2020.03.002 
64. Popescu BA, Stefanidis A, Fox KF, Cosyns B, Delgado V, Di Salvo GD, et al. Training, 
competence, and quality improvement in echocardiography: the European Association 
of Cardiovascular Imaging Recommendations: update 2020. Eur Heart J Cardiovasc 
Imaging 2020;21:1305‚Äì19. https://doi.org/10.1093/ehjci/jeaa266 
65. Iung B, Delgado V, Lazure P, Murray S, Sirnes PA, Rosenhek R, et al. Educational needs 
and application of guidelines in the management of patients with mitral regurgitation. A 
European mixed-methods study. Eur Heart J 2018;39:1295‚Äì303. https://doi.org/10. 
1093/eurheartj/ehx763 
66. Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. 
EuroSCORE II. Eur J Cardiothorac Surg 2012;41:734‚Äì44; discussion 744‚Äì735. https:// 
doi.org/10.1093/ejcts/ezs043 
67. Ad N, Holmes SD, Patel J, Pritchard G, Shuman DJ, Halpin L. Comparison of 
EuroSCORE II, original EuroSCORE, and the Society of Thoracic Surgeons Risk 
Score in Cardiac Surgery Patients. Ann Thorac Surg 2016;102:573‚Äì9. https://doi.org/ 
10.1016/j.athoracsur.2016.01.105 
68. O‚ÄôBrien SM, Shahian DM, Filardo G, Ferraris VA, Haan CK, Rich JB, et al. The Society of 
Thoracic Surgeons 2008 cardiac surgery risk models: part 2‚Äîisolated valve surgery. 
Ann Thorac Surg 2009;88:S23‚Äì42. https://doi.org/10.1016/j.athoracsur.2009.05.056 
69. Duchnowski P, Hryniewiecki T, Ku≈õmierczyk M, Szymanski P. Performance of the 
EuroSCORE II and the Society of Thoracic Surgeons score in patients undergoing aortic valve replacement for aortic stenosis. J Thorac Dis 2019;11:2076‚Äì81. https://doi.org/ 
10.21037/jtd.2019.04.48 
70. Provenchere S, Chevalier A, Ghodbane W, Bouleti C, Montravers P, Longrois D, et al. 
Is the EuroSCORE II reliable to estimate operative mortality among octogenarians? 
PLoS One 2017;12:e0187056. https://doi.org/10.1371/journal.pone.0187056 
71. Taleb Bendiab T, Brusset A, Estagnasi√© P, Squara P, Nguyen LS. Performance of 
EuroSCORE II and Society of Thoracic Surgeons risk scores in elderly patients undergoing aortic valve replacement surgery. Arch Cardiovasc Dis 2021;114:474‚Äì81. https:// 
doi.org/10.1016/j.acvd.2020.12.004 
72. Roques F, Michel P, Goldstone AR, Nashef SAM. The logistic EuroSCORE. Eur Heart J 
2003;24:882‚Äì3. https://doi.org/10.1016/S0195-668X(02)00799-6 
73. Al-Azizi K, Shih E, DiMaio JM, Squiers JJ, Moubarak G, Kluis A, et al. Assessment of TVT 
and STS risk score performances in patients undergoing transcatheter aortic valve replacement. JSCAI 2023;2:100600. https://doi.org/10.1016/j.jscai.2023.100600 
74. Compagnone M, Moretti C, Marcelli C, Taglieri N, Ghetti G, Corsini A, et al. Surgical 
risk scores applied to transcatheter aortic valve implantation: friends or foes? 
Short-term and long-term outcomes from a single-center registry. J Invasive Cardiol 
2019;31:E282‚Äì88. 
75. Tarantini G, Lef√®vre T, Terkelsen CJ, Frerker C, Ohlmann P, Mojoli M, et al. One-year 
outcomes of a European transcatheter aortic valve implantation cohort according to 
surgical risk. Circ Cardiovasc Interv 2019;12:e006724. https://doi.org/10.1161/ 
CIRCINTERVENTIONS.118.006724 
76. Arnold SV, Reynolds MR, Lei Y, Magnuson EA, Kirtane AJ, Kodali SK, et al. Predictors of 
poor outcomes after transcatheter aortic valve replacement: results from the 
PARTNER (Placement of Aortic Transcatheter Valve) trial. Circulation 2014;129: 
2682‚Äì90. https://doi.org/10.1161/circulationaha.113.007477 
77. Edwards FH, Cohen DJ, O‚ÄôBrien SM, Peterson ED, Mack MJ, Shahian DM, et al. 
Development and validation of a risk prediction model for in-hospital mortality after 
transcatheter aortic valve replacement. JAMA Cardiol 2016;1:46‚Äì52. https://doi.org/10. 
1001/jamacardio.2015.0326 
78. Iung B, Laou√©nan C, Himbert D, Eltchaninoff H, Chevreul K, Donzeau-Gouge P, et al. 
Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score. Heart 2014;100:1016‚Äì23. https://doi.org/ 
10.1136/heartjnl-2013-305314 
79. Arnold SV, Afilalo J, Spertus JA, Tang Y, Baron SJ, Jones PG, et al. Prediction of poor 
outcome after transcatheter aortic valve replacement. J Am Coll Cardiol 2016;68: 
1868‚Äì77. https://doi.org/10.1016/j.jacc.2016.07.762 
80. Raposeiras-Roubin S, Adamo M, Freixa X, Arzamendi D, Benito-Gonz√°lez T, 
Montefusco A, et al. A score to assess mortality after percutaneous mitral valve repair. 
J Am Coll Cardiol 2022;79:562‚Äì73. https://doi.org/10.1016/j.jacc.2021.11.041 
81. Shah N, Madhavan MV, Gray WA, Brener SJ, Ahmad Y, Lindenfeld J, et al. Prediction of 
death or HF hospitalization in patients with severe FMR: the COAPT risk score. JACC 
Cardiovasc Interv 2022;15:1893‚Äì905. https://doi.org/10.1016/j.jcin.2022.08.005 
82. Hausleiter J, Lachmann M, Stolz L, Bedogni F, Rubbio AP, Est√©vez-Loureiro R, et al. 
Artificial intelligence-derived risk score for mortality in secondary mitral regurgitation  
ESC Guidelines                                                                                                                                                                                               79


<!-- PAGE 80 -->

### Page 80

treated by transcatheter edge-to-edge repair: the EuroSMR risk score. Eur Heart J 
2024;45:922‚Äì36. https://doi.org/10.1093/eurheartj/ehad871 
83. Adamo M, Rubbio AP, Zaccone G, Pighi M, Massussi M, Tomasoni D, et al. Prediction 
of mortality and heart failure hospitalisations in patients undergoing M-TEER: external 
validation of the COAPT risk score. EuroIntervention 2023;18:1408‚Äì17. https://doi.org/ 
10.4244/EIJ-D-22-00992 
84. Dreyfus J, Audureau E, Bohbot Y, Coisne A, Lavie-Badie Y, Bouchery M, et al. 
TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery. Eur Heart J 2022;43:654‚Äì62. https://doi.org/10.1093/eurheartj/ 
ehab679 
85. Dreyfus J, Bohbot Y, Coisne A, Lavie-Badie Y, Flagiello M, Bazire B, et al. Predictive value of the TRI-SCORE for in-hospital mortality after redo isolated tricuspid valve surgery. Heart 2023;109:951‚Äì8. https://doi.org/10.1136/heartjnl-2022-322167 
86. Lantelme P, Aubry M, Peng JC, Riche B, Souteyrand G, Jaafar P, et al. Comorbidities 
may offset expected improved survival after transcatheter aortic valve replacement. 
Eur Heart J Open 2022;2:oeac029. https://doi.org/10.1093/ehjopen/oeac029 
87. Piankova P, Afilalo J. Prevalence and prognostic implications of frailty in transcatheter aortic 
valve replacement. Cardiol Clin 2020;38:75‚Äì87. https://doi.org/10.1016/j.ccl.2019.09.011 
88. Kim DH, Afilalo J, Shi SM, Popma JJ, Khabbaz KR, Laham RJ, et al. Evaluation of changes 
in functional status in the year after aortic valve replacement. JAMA Intern Med 2019; 
179:383‚Äì91. https://doi.org/10.1001/jamainternmed.2018.6738 
89. Scotti A, Coisne A, Granada JF, Driggin E, Madhavan MV, Zhou Z, et al. Impact of malnutrition in patients with heart failure and secondary mitral regurgitation: the COAPT 
Trial. J Am Coll Cardiol 2023;82:128‚Äì38. https://doi.org/10.1016/j.jacc.2023.04.047 
89a. Pagnesi M, Adamo M, Stolz L, Pancaldi E, Kresoja KP, von Stein J, et al. Malnutrition 
and outcomes in patients with tricuspid regurgitation undergoing transcatheter 
tricuspid valve repair. Eur J Heart Fail 2025. https://doi.org/10.1002/ejhf.3623. Epub 
ahead of print. PMID: 39980251. 
90. S√ºndermann SH, B√§ck C, Bischoff-Ferrari HA, Dehbi HM, Szekely A, V√∂ller H, et al. 
Preinterventional frailty assessment in patients scheduled for cardiac surgery or transcatheter aortic valve implantation: a consensus statement of the European Association 
for Cardio-Thoracic Surgery (EACTS) and the European Association of Preventive 
Cardiology (EAPC) of the European Society of Cardiology (ESC). Eur J Cardiothorac 
Surg 2023;64:ezad181. https://doi.org/10.1093/ejcts/ezad181 
91. Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, et al. Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute 
Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied 
Professions (ACNAP), European Association of Preventive Cardiology (EAPC), 
European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases 
(VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), 
Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, 
WG Thrombosis, of the European Society of Cardiology, European Primary Care 
Cardiology Society (EPCCS). Eur J Prev Cardiol 2022;29:216‚Äì27. https://doi.org/10. 
1093/eurjpc/zwaa167 
92. Kundi H, Popma JJ, Reynolds MR, Strom JB, Pinto DS, Valsdottir LR, et al. Frailty and 
related outcomes in patients undergoing transcatheter valve therapies in a nationwide 
cohort. Eur Heart J 2019;40:2231‚Äì9. https://doi.org/10.1093/eurheartj/ehz187 
93. Brusco NK, Atkinson V, Woods J, Myles PS, Hodge A, Jones C, et al. Implementing 
PROMS for elective surgery patients: feasibility, response rate, degree of recovery 
and patient acceptability. J Patient Rep Outcomes 2022;6:73. https://doi.org/10.1186/ 
s41687-022-00483-6 
94. Arnold SV, Spertus JA, Lei Y, Allen KB, Chhatriwalla AK, Leon MB, et al. Use of the Kansas 
City Cardiomyopathy Questionnaire for monitoring health status in patients with aortic 
stenosis. Circ Heart Fail 2013;6:61‚Äì7. https://doi.org/10.1161/circheartfailure.112.970053 
95. Arnold SV, Spertus JA, Gosch K, Dunlay SM, Olds DM, Jones PG, et al. Validation of the 
Kansas City Cardiomyopathy Questionnaire in patients with tricuspid regurgitation. 
JAMA Cardiol 2025;10:117‚Äì25 https://doi.org/10.1001/jamacardio.2024.4266 
96. Clavel MA, Tribouilloy C, Vanoverschelde JL, Pizarro R, Suri RM, Szymanski C, et al. 
Association of B-type natriuretic peptide with survival in patients with degenerative 
mitral regurgitation. J Am Coll Cardiol 2016;68:1297‚Äì307. https://doi.org/10.1016/j. 
jacc.2016.06.047 
97. Clavel MA, Malouf J, Michelena HI, Suri RM, Jaffe AS, Mahoney DW, et al. B-type natriuretic peptide clinical activation in aortic stenosis: impact on long-term survival. J Am 
Coll Cardiol 2014;63:2016‚Äì25. https://doi.org/10.1016/j.jacc.2014.02.581 
98. Zhang B, Xu H, Zhang H, Liu Q, Ye Y, Hao J, et al. Prognostic value of N-terminal pro‚Äì 
B-type natriuretic peptide in elderly patients with valvular heart disease. J Am Coll 
Cardiol 2020;75:1659‚Äì72. https://doi.org/10.1016/j.jacc.2020.02.031 
99. Lindman BR, Breyley JG, Schilling JD, Vatterott AM, Zajarias A, Maniar HS, et al. 
Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic 
stenosis undergoing valve replacement. Heart 2015;101:1382‚Äì8. https://doi.org/10. 
1136/heartjnl-2015-307742 
100. Lindman BR, Clavel MA, Abu-Alhayja‚Äôa R, Cote N, Dagenais F, Novak E, et al. 
Multimarker approach to identify patients with higher mortality and rehospitalization 
rate after surgical aortic valve replacement for aortic stenosis. JACC Cardiovasc Interv 
2018;11:2172‚Äì81. https://doi.org/10.1016/j.jcin.2018.07.039 
101. Henri C, Pi√©rard LA, Lancellotti P, Mongeon F-P, Pibarot P, Basmadjian AJ. Exercise 
testing and stress imaging in valvular heart disease. Can J Cardiol 2014;30:1012‚Äì26.  
https://doi.org/10.1016/j.cjca.2014.03.013 
102. Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur 
Heart J 2005;26:1309‚Äì13. https://doi.org/10.1093/eurheartj/ehi250 
103. Redfors B, Pibarot P, Gillam LD, Burkhoff D, Bax JJ, Lindman BR, et al. Stress testing in 
asymptomatic aortic stenosis. Circulation 2017;135:1956‚Äì76. https://doi.org/10.1161/ 
CIRCULATIONAHA.116.025457 
104. Lund O, Nielsen TT, Emmertsen K, Fl√∏ C, Rasmussen B, Jensen FT, et al. Mortality and 
worsening of prognostic profile during waiting time for valve replacement in aortic 
stenosis. Thorac Cardiovasc Surg 1996;44:289‚Äì95. https://doi.org/10.1055/s-2007- 
1012039 
105. Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 focused update: clinical 
recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Eur Heart J 2018;39:1144‚Äì61. https://doi.org/10.1093/eurheartj/ 
ehw180 
106. Hoedemakers S, Pugliese NR, Stassen J, Vanoppen A, Claessens J, Gojevic T, et al. 
mPAP/CO slope and oxygen uptake add prognostic value in aortic stenosis. 
Circulation 
2024;149:1172‚Äì82. 
https://doi.org/10.1161/CIRCULATIONAHA.123. 
067130 
107. Lancellotti P, Dulgheru R, Go YY, Sugimoto T, Marchetta S, Oury C, et al. Stress echocardiography in patients with native valvular heart disease. Heart 2018;104:807‚Äì13.  
https://doi.org/10.1136/heartjnl-2017-311682 
108. Gentry JL III, Phelan D, Desai MY, Griffin BP. The role of stress echocardiography in 
valvular heart disease: a current appraisal. Cardiology 2017;137:137‚Äì50. https://doi. 
org/10.1159/000460274 
109. Lancellotti P, Magne J. Stress echocardiography in regurgitant valve disease. Circ 
Cardiovasc Imaging 2013;6:840‚Äì9. https://doi.org/10.1161/CIRCIMAGING.113.000474 
110. Lancellotti P, Magne J, Donal E, O‚ÄôConnor K, Dulgheru R, Rosca M, et al. Determinants 
and prognostic significance of exercise pulmonary hypertension in asymptomatic severe 
aortic 
stenosis. 
Circulation 
2012;126:851‚Äì9. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.111.088427 
111. Coisne A, Aghezzaf S, Galli E, Mouton S, Richardson M, Dubois D, et al. Prognostic values of exercise echocardiography and cardiopulmonary exercise testing in patients 
with primary mitral regurgitation. Eur Heart J Cardiovasc Imaging 2022;23:1552‚Äì61.  
https://doi.org/10.1093/ehjci/jeab231 
112. Saeed S, Rajani R, Seifert R, Parkin D, Chambers JB. Exercise testing in patients with 
asymptomatic moderate or severe aortic stenosis. Heart 2018;104:1836‚Äì42. https:// 
doi.org/10.1136/heartjnl-2018-312939 
113. Saeed S, Chambers JB. Exercise testing in aortic stenosis: safety, tolerability, clinical 
benefits and prognostic value. J Clin Med 2022;11:4983. https://doi.org/10.3390/ 
jcm11174983 
114. Scarsini R, Pesarini G, Zivelonghi C, Piccoli A, Ferrero V, Lunardi M, et al. Physiologic 
evaluation of coronary lesions using instantaneous wave-free ratio (iFR) in patients 
with severe aortic stenosis undergoing transcatheter aortic valve implantation. 
EuroIntervention 2018;13:1512‚Äì9. https://doi.org/10.4244/EIJ-D-17-00542 
115. Pesarini G, Scarsini R, Zivelonghi C, Piccoli A, Gambaro A, Gottin L, et al. Functional 
assessment of coronary artery disease in patients undergoing transcatheter aortic 
valve implantation: influence of pressure overload on the evaluation of lesions severity. 
Circ Cardiovasc Interv 2016;9:e004088. https://doi.org/10.1161/circinterventions.116. 
004088 
116. Ahmad Y, G√∂tberg M, Cook C, Howard JP, Malik I, Mikhail G, et al. Coronary hemodynamics in patients with severe aortic stenosis and coronary artery disease undergoing transcatheter aortic valve replacement: implications for clinical indices of coronary 
stenosis severity. JACC Cardiovasc Interv 2018;11:2019‚Äì31. https://doi.org/10.1016/j. 
jcin.2018.07.019 
117. Ardehali A, Segal J, Cheitlin MD. Coronary blood flow reserve in acute aortic regurgitation. 
J 
Am 
Coll 
Cardiol 
1995;25:1387‚Äì92. 
https://doi.org/10.1016/0735- 
1097(95)00018-Y 
118. Akasaka T, Yoshida K, Hozumi T, Takagi T, Kaji S, Kawamoto T, et al. Restricted coronary flow reserve in patients with mitral regurgitation improves after mitral reconstructive surgery. J Am Coll Cardiol 1998;32:1923‚Äì30. https://doi.org/10.1016/S0735- 
1097(98)00490-2 
119. D‚ÄôAlto M, Dimopoulos K, Coghlan JG, Kovacs G, Rosenkranz S, Naeije R. Right heart 
catheterization for the diagnosis of pulmonary hypertension: controversies and practical issues. Heart Fail Clin 2018;14:467‚Äì77. https://doi.org/10.1016/j.hfc.2018.03.011 
120. Lindman BR, Arnold SV, Bagur R, Clarke L, Coylewright M, Evans F, et al. Priorities for 
patient-centered research in valvular heart disease: a report from the National Heart, 
Lung, and Blood Institute Working Group. J Am Heart Assoc 2020;9:e015975. https:// 
doi.org/10.1161/JAHA.119.015975 
121. Dharmarajan K, Foster J, Coylewright M, Green P, Vavalle JP, Faheem O, et al. The 
medically managed patient with severe symptomatic aortic stenosis in the TAVR 
era: patient characteristics, reasons for medical management, and quality of shared decision making at heart valve treatment centers. PLoS One 2017;12:e0175926. https:// 
doi.org/10.1371/journal.pone.0175926


<!-- PAGE 81 -->

### Page 81

122. Ren X, Liu K, Zhang H, Meng Y, Li H, Sun X, et al. Coronary evaluation before heart 
valvular surgery by using coronary computed tomographic angiography versus invasive 
coronary angiography. J Am Heart Assoc 2021;10:e019531. https://doi.org/10.1161/ 
jaha.120.019531 
123. Opolski MP, Staruch AD, Jakubczyk M, Min James K, Gransar H, Staruch M, et al. CT 
angiography for the detection of coronary artery stenoses in patients referred for cardiac valve surgery. JACC Cardiovasc Imaging 2016;9:1059‚Äì70. https://doi.org/10.1016/j. 
jcmg.2015.09.028 
124. Meijboom Willem B, Mollet Nico R, Van Mieghem Carlos AG, Kluin J, Weustink Annick 
C, Pugliese F, et al. Pre-operative computed tomography coronary angiography to detect significant coronary artery disease in patients referred for cardiac valve surgery. J 
Am Coll Cardiol 2006;48:1658‚Äì65. https://doi.org/10.1016/j.jacc.2006.06.054 
125. Gatti M, Gallone G, Poggi V, Bruno F, Serafini A, Depaoli A, et al. Diagnostic accuracy of 
coronary computed tomography angiography for the evaluation of obstructive coronary artery disease in patients referred for transcatheter aortic valve implantation: a systematic review and meta-analysis. Eur Radiol 2022;32:5189‚Äì200. https://doi.org/10. 
1007/s00330-022-08603-y 
126. Diller GP, Gerwing M, Boroni Grazioli S, De-Torres-Alba F, Radke RM, Vormbrock J, 
et al. Utility of coronary computed tomography angiography in patients undergoing 
transcatheter aortic valve implantation: a meta-analysis and meta-regression based 
on published data from 7458 patients. J Clin Med 2024;13:631. https://doi.org/10. 
3390/jcm13020631 
127. Kondoleon NP, Layoun H, Spilias N, Sipko J, Kanaan C, Harb S, et al. Effectiveness of 
pre-TAVR CTA as a screening tool for significant CAD before TAVR. JACC Cardiovasc 
Interv 2023;16:1990‚Äì2000. https://doi.org/10.1016/j.jcin.2023.05.030 
128. Malebranche D, Hoffner MKM, Huber AT, Cicovic A, Spano G, Bernhard B, et al. 
Diagnostic performance of quantitative coronary artery disease assessment using 
computed tomography in patients with aortic stenosis undergoing transcatheter 
aortic-valve implantation. BMC Cardiovasc Disord 2022;22:178. https://doi.org/10. 
1186/s12872-022-02623-8 
129. Chieffo A, Giustino G, Spagnolo P, Panoulas VF, Montorfano M, Latib A, et al. Routine 
screening of coronary artery disease with computed tomographic coronary angiography in place of invasive coronary angiography in patients undergoing transcatheter 
aortic valve replacement. Circ Cardiovasc Interv 2015;8:e002025. https://doi.org/10. 
1161/circinterventions.114.002025 
130. Patel KP, Michail M, Treibel TA, Rathod K, Jones DA, Ozkor M, et al. Coronary revascularization in patients undergoing aortic valve replacement for severe aortic stenosis. 
JACC Cardiovasc Interv 2021;14:2083‚Äì96. https://doi.org/10.1016/j.jcin.2021.07.058 
131. Miyagawa S, Masai T, Fukuda H, Yamauchi T, Iwakura K, Itoh H, et al. Coronary microcirculatory dysfunction in aortic stenosis: myocardial contrast echocardiography study. 
Ann Thorac Surg 2009;87:715‚Äì9. https://doi.org/10.1016/j.athoracsur.2008.11.078 
132. Beach JM, Mihaljevic T, Svensson LG, Rajeswaran J, Marwick T, Griffin B, et al. Coronary 
artery disease and outcomes of aortic valve replacement for severe aortic stenosis. J 
Am Coll Cardiol 2013;61:837‚Äì48. https://doi.org/10.1016/j.jacc.2012.10.049 
133. Thalji NM, Suri RM, Daly RC, Greason KL, Dearani JA, Stulak JM, et al. The prognostic 
impact of concomitant coronary artery bypass grafting during aortic valve surgery: implications for revascularization in the transcatheter era. J Thorac Cardiovasc Surg 2015; 
149:451‚Äì60. https://doi.org/10.1016/j.jtcvs.2014.08.073 
134. L√∏nborg J, Jabbari R, Sabbah M, Veien KT, Niemel√§ M, Freeman P, et al. PCI in patients 
undergoing transcatheter aortic-valve implantation. N Engl J Med 2024;391:2189‚Äì200.  
https://doi.org/10.1056/NEJMoa2401513 
135. Patterson T, Clayton T, Dodd M, Khawaja Z, Morice MC, Wilson K, et al. 
ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic 
VAlve implantaTION): a randomized clinical trial. JACC Cardiovasc Interv 2021;14: 
1965‚Äì74. https://doi.org/10.1016/j.jcin.2021.06.041 
136. Okuno T, Demirel C, Tomii D, Heg D, H√§ner J, Siontis GCM, et al. Long-term risk of 
unplanned percutaneous coronary intervention after transcatheter aortic valve replacement. EuroIntervention 2022;18:797‚Äì803. https://doi.org/10.4244/eij-d-22-00342 
137. Persits I, Layoun H, Kondoleon NP, Spilias N, Badwan O, Sipko J, et al. Impact of untreated chronic obstructive coronary artery disease on outcomes after transcatheter 
aortic valve replacement. Eur Heart J 2024;45:1890‚Äì900. https://doi.org/10.1093/ 
eurheartj/ehae019 
138. Ogami T, Kliner DE, Toma C, Sanon S, Smith AJC, Serna-Gallegos D, et al. Acute coronary syndrome after transcatheter aortic valve implantation (results from over 
40,000 patients). Am J Cardiol 2023;193:126‚Äì32. https://doi.org/10.1016/j.amjcard. 
2023.02.003 
139. Mentias A, Desai MY, Saad M, Horwitz PA, Rossen JD, Panaich S, et al. Incidence and 
outcomes of acute coronary syndrome after transcatheter aortic valve replacement. 
JACC Cardiovasc Interv 2020;13:938‚Äì50. https://doi.org/10.1016/j.jcin.2019.11.027 
140. Yassen M, Moustafa A, Venkataramany B, Schodowski E, Royfman R, Eltahawy E. 
Clinical outcomes of transcatheter aortic valve replacement with and without percutaneous coronary intervention‚Äîan updated meta-analysis and systematic review. Curr 
Probl Cardiol 2023;48:101980. https://doi.org/10.1016/j.cpcardiol.2023.101980 
141. Altibi AM, Ghanem F, Hammad F, Patel J, Song HK, Golwala H, et al. Clinical outcomes 
of revascularization with percutaneous coronary intervention prior to transcatheter 
aortic valve replacement: a comprehensive meta-analysis. Curr Probl Cardiol 2022;47: 
101339. https://doi.org/10.1016/j.cpcardiol.2022.101339 
142. Tomii D, Pilgrim T, Borger MA, De Backer O, Lanz J, Reineke D, et al. Aortic stenosis 
and coronary artery disease: decision-making between surgical and transcatheter management. Circulation 2024;150:2046‚Äì69. https://doi.org/10.1161/circulationaha.124. 
070502 
143. Tarantini G, Tang G, Nai Fovino L, Blackman D, Van Mieghem NM, Kim WK, et al. 
Management of coronary artery disease in patients undergoing transcatheter aortic 
valve implantation. A clinical consensus statement from the European Association of 
Percutaneous Cardiovascular Interventions in collaboration with the ESC Working 
Group on Cardiovascular Surgery. EuroIntervention 2023;19:37‚Äì52. https://doi.org/ 
10.4244/eij-d-22-00958 
144. Barbanti M, Costa G, Picci A, Criscione E, Reddavid C, Valvo R, et al. Coronary cannulation after transcatheter aortic valve replacement: the RE-ACCESS study. JACC 
Cardiovasc Interv 2020;13:2542‚Äì55. https://doi.org/10.1016/j.jcin.2020.07.006 
145. Costa G, Sammartino S, Strazzieri O, Motta S, Frittitta V, Dipietro E, et al. Coronary 
cannulation following TAVR using self-expanding devices with commissural alignment: 
the RE-ACCESS 2 study. JACC Cardiovasc Interv 2024;17:727‚Äì37. https://doi.org/10. 
1016/j.jcin.2023.12.015 
146. Tang GHL, Amat-Santos IJ, Backer OD, Avvedimento M, Redondo A, Barbanti M, et al. 
Rationale, definitions, techniques, and outcomes of commissural alignment in TAVR. 
JACC Cardiovasc Interv 2022;15:1497‚Äì518. https://doi.org/10.1016/j.jcin.2022.06.001 
147. Campwala SZ, Bansal RC, Wang N, Razzouk A, Pai RG. Factors affecting regression of 
mitral regurgitation following isolated coronary artery bypass surgery. Eur J 
Cardiothorac Surg 2005;28:783‚Äì7. https://doi.org/10.1016/j.ejcts.2005.10.010 
148. Castleberry AW, Williams JB, Daneshmand MA, Honeycutt E, Shaw LK, Samad Z, et al. 
Surgical revascularization is associated with maximal survival in patients with ischemic 
mitral regurgitation: a 20-year experience. Circulation 2014;129:2547‚Äì56. https://doi. 
org/10.1161/CIRCULATIONAHA.113.005223 
149. Samad Z, Shaw LK, Phelan M, Ersboll M, Risum N, Al-Khalidi HR, et al. Management and 
outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction. Eur Heart J 2015;36:2733‚Äì41. https://doi.org/10.1093/ 
eurheartj/ehv343 
150. Yousefzai R, Bajaj N, Krishnaswamy A, Goel SS, Agarwal S, Aksoy O, et al. Outcomes of 
patients with ischemic mitral regurgitation undergoing percutaneous coronary intervention. Am J Cardiol 2014;114:1011‚Äì7. https://doi.org/10.1016/j.amjcard.2014.07.012 
151. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC 
Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44: 
3720‚Äì826. https://doi.org/10.1093/eurheartj/ehad191 
152. Thomas KL, Jackson LR 2nd, Shrader P, Ansell J, Fonarow GC, Gersh B, et al. 
Prevalence, characteristics, and outcomes of valvular heart disease in patients with atrial fibrillation: insights from the ORBIT-AF (outcomes registry for better informed 
treatment for atrial fibrillation). J Am Heart Assoc 2017;6:e006475. https://doi.org/10. 
1161/jaha.117.006475 
153. Naser JA, Castrichini M, Ibrahim HH, Scott CG, Lin G, Lee E, et al. Secondary tricuspid 
regurgitation: incidence, types, and outcomes in atrial fibrillation vs. sinus rhythm. Eur 
Heart J 2024;45:2878‚Äì90. https://doi.org/10.1093/eurheartj/ehae346 
154. Naser JA, Pislaru C, Roslan A, Ciobanu AO, Jouni H, Nkomo VT, et al. Unfavorable 
tricuspid annulus dynamics: a novel concept to explain development of tricuspid regurgitation in atrial fibrillation. J Am Soc Echocardiogr 2022;35:664‚Äì6. https://doi.org/10. 
1016/j.echo.2022.02.009 
155. Vinereanu D, Wang A, Mulder H, Lopes RD, Jansky P, Lewis BS, et al. Outcomes in 
anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. 
Heart 2018;104:1292‚Äì9. https://doi.org/10.1136/heartjnl-2017-312272 
156. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in 
Atrial Fibrillation (ARISTOTLE) trial. Circulation 2015;132:624‚Äì32. https://doi.org/10. 
1161/CIRCULATIONAHA.114.014807 
157. Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, et al. 
Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular 
heart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant therapy). Circulation 2016;134:589‚Äì98. https://doi.org/10.1161/CIRCULATIONAHA.115. 
020950 
158. De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, et al. 
Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 
48 trial. J Am Coll Cardiol 2017;69:1372‚Äì82. https://doi.org/10.1016/j.jacc.2016.12.031 
159. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, et al. 
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with 
non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 2014;35:3377‚Äì85. https://doi.org/10. 
1093/eurheartj/ehu305 
160. Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M, et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med 2021; 
384:2081‚Äì91. https://doi.org/10.1056/NEJMoa2101897  
ESC Guidelines                                                                                                                                                                                               81


<!-- PAGE 82 -->

### Page 82

### 161 Mart√≠n Guti√©rrez E, Casta√±o M, Gualis J, Martinez-Comendador JM, Maiorano P,

Castillo L, et al. Beneficial effect of left atrial appendage closure during cardiac surgery: 
a meta-analysis of 280 585 patients. Eur J Cardiothorac Surg 2020;57:252‚Äì62. https://doi. 
org/10.1093/ejcts/ezz289 
162. Connolly SJ, Healey JS, Belley-Cote EP, Balasubramanian K, Paparella D, Brady K, et al. 
Oral anticoagulation use and left atrial appendage occlusion in LAAOS III. Circulation 
2023;148:1298‚Äì304. https://doi.org/10.1161/CIRCULATIONAHA.122.060315 
163. Kapadia SR, Krishnaswamy A, Whisenant B, Potluri S, Iyer V, Aragon J, et al. 
Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation. Circulation 2024;149:734‚Äì43. https://doi. 
org/10.1161/circulationaha.123.067312 
164. Dawwas GK, Dietrich E, Cuker A, Barnes GD, Leonard CE, Lewis JD. Effectiveness and 
safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation: a population-based cohort study. Ann Intern Med 2021;174:910‚Äì9. https://doi. 
org/10.7326/m20-6194 
165. Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, 
et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J 
Med 2022;387:978‚Äì88. https://doi.org/10.1056/NEJMoa2209051 
166. Rankin JS, Grau-Sepulveda MV, Ad N, Damiano RJ Jr, Gillinov AM, Brennan JM, et al. 
Associations between surgical ablation and operative mortality after mitral valve procedures. Ann Thorac Surg 2018;105:1790‚Äì6. https://doi.org/10.1016/j.athoracsur.2017. 
12.035 
167. Badhwar V, Rankin JS, Ad N, Grau-Sepulveda M, Damiano RJ, Gillinov AM, et al. 
Surgical ablation of atrial fibrillation in the United States: trends and propensity 
matched outcomes. Ann Thorac Surg 2017;104:493‚Äì500. https://doi.org/10.1016/j. 
athoracsur.2017.05.016 
168. Gillinov AM, Gelijns AC, Parides MK, DeRose JJ Jr, Moskowitz AJ, Voisine P, et al. 
Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med 2015; 
372:1399‚Äì409. https://doi.org/10.1056/NEJMoa1500528 
169. Huffman MD, Karmali KN, Berendsen MA, Andrei AC, Kruse J, McCarthy PM, et al. 
Concomitant atrial fibrillation surgery for people undergoing cardiac surgery. 
Cochrane Database Syst Rev 2016;2016:CD011814. https://doi.org/10.1002/ 
14651858.CD011814.pub2 
170. Wang H, Han J, Wang Z, Yin Z, Liu Z, Jin Y, et al. A prospective randomized trial of the 
cut-and-sew Maze procedure in patients undergoing surgery for rheumatic mitral valve 
disease. J Thorac Cardiovasc Surg 2018;155:608‚Äì17. https://doi.org/10.1016/j.jtcvs.2017. 
07.084 
171. Lawrance CP, Henn MC, Miller JR, Sinn LA, Schuessler RB, Maniar HS, et al. A minimally 
invasive Cox maze IV procedure is as effective as sternotomy while decreasing major 
morbidity and hospital stay. J Thorac Cardiovasc Surg 2014;148:955‚Äì61; discussion 
962‚Äì952. https://doi.org/10.1016/j.jtcvs.2014.05.064 
172. Cheng DC, Ad N, Martin J, Berglin EE, Chang BC, Doukas G, et al. Surgical ablation for 
atrial fibrillation in cardiac surgery: a meta-analysis and systematic review. Innovations 
(Phila) 2010;5:84‚Äì96. https://doi.org/10.1097/IMI.0b013e3181d9199b 
173. McClure GR, Belley-Cote EP, Jaffer IH, Dvirnik N, An KR, Fortin G, et al. Surgical ablation of atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Europace 2018;20:1442‚Äì50. https://doi.org/10.1093/europace/eux336 
174. Yoo JS, Kim JB, Ro SK, Jung Y, Jung SH, Choo SJ, et al. Impact of concomitant surgical 
atrial fibrillation ablation in patients undergoing aortic valve replacement. Circ J 2014; 
78:1364‚Äì71. https://doi.org/10.1253/circj.cj-13-1533 
175. Malaisrie SC, Lee R, Kruse J, Lapin B, Wang EC, Bonow RO, et al. Atrial fibrillation ablation in patients undergoing aortic valve replacement. J Heart Valve Dis 2012;21: 
350‚Äì7. 
176. Gujral DM, Lloyd G, Bhattacharyya S. Radiation-induced valvular heart disease. Heart 
2016;102:269‚Äì76. https://doi.org/10.1136/heartjnl-2015-308765 
177. Lee C, Hahn RT. Valvular heart disease associated with radiation therapy: a contemporary review. Struct Heart 2023;7:100104. https://doi.org/10.1016/j.shj.2022.100104 
178. Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, et al. Expert 
consensus for multi-modality imaging evaluation of cardiovascular complications of 
radiotherapy in adults: a report from the European Association of Cardiovascular 
Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 2013; 
26:1013‚Äì32. https://doi.org/10.1016/j.echo.2013.07.005 
179. Wu W, Masri A, Popovic ZB, Smedira NG, Lytle BW, Marwick TH, et al. Long-term 
survival of patients with radiation heart disease undergoing cardiac surgery: a cohort 
study. Circulation 2013;127:1476‚Äì85. https://doi.org/10.1161/CIRCULATIONAHA. 
113.001435 
180. Donnellan E, Masri A, Johnston DR, Pettersson GB, Rodriguez LL, Popovic ZB, et al. 
Long-term outcomes of patients with mediastinal radiation-associated severe aortic 
stenosis and subsequent surgical aortic valve replacement: a matched cohort study. J 
Am Heart Assoc 2017;6:e005396. https://doi.org/10.1161/JAHA.116.005396 
181. Donnellan E, Alashi A, Johnston DR, Gillinov AM, Pettersson GB, Svensson LG, et al. 
Outcomes of patients with mediastinal radiation-associated mitral valve disease undergoing cardiac surgery. Circulation 2019;140:1288‚Äì90. https://doi.org/10.1161/ 
CIRCULATIONAHA.119.040546 
182. Lyon AR, L√≥pez-Fern√°ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 
European Hematology Association (EHA), the European Society for Therapeutic 
Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society 
(IC-OS). Eur Heart J 2022;43:4229‚Äì361. https://doi.org/10.1093/eurheartj/ehac244 
183. Yazdchi F, Hirji SA, Nohria A, Percy E, Harloff M, Malarczyk A, et al. Transcatheter 
compared with surgical aortic valve replacement in patients with previous chest- 
directed radiation therapy. JACC CardioOncol 2021;3:397‚Äì407. https://doi.org/10. 
1016/j.jaccao.2021.07.005 
184. Zafar MR, Mustafa SF, Miller TW, Alkhawlani T, Sharma UC. Outcomes after transcatheter aortic valve replacement in cancer survivors with prior chest radiation therapy: a systematic review and meta-analysis. Cardiooncology 2020;6:8. https://doi.org/10. 
1186/s40959-020-00062-y 
185. Ullah W, Thalambedu N, Zahid S, Muhammadzai Hamza Zahid U, Sandhyavenu H, 
Kumar A, et al. Trends and outcomes of TAVI and SAVR in cancer and noncancer patients. JACC Adv 2023;2:100167. https://doi.org/10.1016/j.jacadv.2022.100167 
186. Lind A, Totzeck M, Mahabadi AA, Janosi RA, El Gabry M, Ruhparwar A, et al. Impact of 
cancer in patients undergoing transcatheter aortic valve replacement: a single-center 
study. JACC CardioOncol 2020;2:735‚Äì43. https://doi.org/10.1016/j.jaccao.2020.11.008 
187. Yadgir S, Johnson CO, Aboyans V, Adebayo OM, Adedoyin RA, Afarideh M, et al. 
Global, regional, and national burden of calcific aortic valve and degenerative mitral 
valve diseases, 1990‚Äì2017. Circulation 2020;141:1670‚Äì80. https://doi.org/10.1161/ 
CIRCULATIONAHA.119.043391 
188. Rwebembera J, Marangou J, Mwita JC, Mocumbi AO, Mota C, Okello E, et al. 2023 
World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic 
heart disease. Nat Rev Cardiol 2023;21:250‚Äì63. https://doi.org/10.1038/s41569-023- 
00940-9 
189. Karki P, Uranw S, Bastola S, Mahato R, Shrestha NR, Sherpa K, et al. Effectiveness of 
systematic echocardiographic screening for rheumatic heart disease in Nepalese 
schoolchildren: a cluster randomized clinical trial. JAMA Cardiol 2021;6:420‚Äì26.  
https://doi.org/10.1001/jamacardio.2020.7050 
190. Beaton A, Okello E, Rwebembera J, Grobler A, Engelman D, Alepere J, et al. Secondary 
antibiotic prophylaxis for latent rheumatic heart disease. N Engl J Med 2022;386: 
230‚Äì40. https://doi.org/10.1056/NEJMoa2102074 
191. Kumar RK, Antunes MJ, Beaton A, Mirabel M, Nkomo VT, Okello E, et al. 
Contemporary diagnosis and management of rheumatic heart disease: implications 
for closing the gap: a scientific statement from the American Heart Association. 
Circulation 2020;142:e337‚Äì57. https://doi.org/10.1161/cir.0000000000000921 
192. World Health Organization. WHO Guideline on the Prevention and Diagnosis of 
Rheumatic Fever and Rheumatic Heart Disease. https://www.who.int/publications/i/ 
item/9789240100077 (28 March 2025, date last accessed). 
193. Chioncel O, Adamo M, Nikolaou M, Parissis J, Mebazaa A, Yilmaz MB, et al. Acute heart 
failure and valvular heart disease: a scientific statement of the Heart Failure 
Association, the Association for Acute CardioVascular Care and the European 
Association of Percutaneous Cardiovascular Interventions of the European Society 
of Cardiology. Eur J Heart Fail 2023;25:1025‚Äì48. https://doi.org/10.1002/ejhf.2918 
194. L√ºsebrink E, Lanz H, Kellnar A, Karam N, Kapadia S, Makkar R, et al. (December 11, 
2024) Management of acute decompensated valvular heart disease. Eur J Heart Fail,  
https://doi.org/10.1002/ejhf.3549 
195. Kolte D, Khera S, Vemulapalli S, Dai D, Heo S, Goldsweig AM, et al. Outcomes following urgent/emergent transcatheter aortic valve replacement: insights from the STS/ 
ACC TVT registry. JACC Cardiovasc Interv 2018;11:1175‚Äì85. https://doi.org/10.1016/ 
j.jcin.2018.03.002 
196. Elbadawi A, Elgendy IY, Mentias A, Saad M, Mohamed AH, Choudhry MW, et al. 
Outcomes of urgent versus nonurgent transcatheter aortic valve replacement. 
Catheter Cardiovasc Interv 2020;96:189‚Äì95. https://doi.org/10.1002/ccd.28563 
197. Masha L, Vemulapalli S, Manandhar P, Balan P, Shah P, Kosinski AS, et al. Demographics, 
procedural characteristics, and clinical outcomes when cardiogenic shock precedes 
TAVR in the United States. JACC Cardiovasc Interv 2020;13:1314‚Äì25. https://doi.org/ 
10.1016/j.jcin.2020.02.033 
198. Goel K, Shah P, Jones BM, Korngold E, Bhardwaj A, Kar B, et al. Outcomes of transcatheter aortic valve replacement in patients with cardiogenic shock. Eur Heart J 
2023;44:3181‚Äì95. https://doi.org/10.1093/eurheartj/ehad387 
199. Buchwald AB, Meyer T, Scholz K, Schorn B, Unterberg C. Efficacy of balloon valvuloplasty in patients with critical aortic stenosis and cardiogenic shock‚Äîthe role of shock 
duration. Clin Cardiol 2001;24:214‚Äì8. https://doi.org/10.1002/clc.4960240308 
200. Moreno PR, Jang IK, Newell JB, Block PC, Palacios IF. The role of percutaneous aortic 
balloon valvuloplasty in patients with cardiogenic shock and critical aortic stenosis. J Am 
Coll Cardiol 1994;23:1071‚Äì5. https://doi.org/10.1016/0735-1097(94)90592-4 
201. Llah ST, Sharif S, Ullah S, Sheikh SA, Shah MA, Shafi OM, et al. TAVR vs balloon aortic 
valvotomy for severe aortic stenosis and cardiogenic shock: an insight from the national inpatient sample database. Cardiovasc Revasc Med 2023;55:1‚Äì7. https://doi.org/10. 
1016/j.carrev.2023.05.006 
202. Tang GHL, Estevez-Loureiro R, Yu Y, Prillinger JB, Zaid S, Psotka MA. Survival following 
edge-to-edge transcatheter mitral valve repair in patients with cardiogenic shock: a nationwide analysis. J Am Heart Assoc 2021;10:e019882. https://doi.org/10.1161/jaha.120. 
019882


<!-- PAGE 83 -->

### Page 83

### 203 Haberman D, Estevez-Loureiro R, Benito-Gonzalez T, Denti P, Arzamendi D, Adamo

M, et al. Conservative, surgical, and percutaneous treatment for mitral regurgitation 
shortly after acute myocardial infarction. Eur Heart J 2021;43:641‚Äì50. https://doi. 
org/10.1093/eurheartj/ehab496 
204. Hill L, Prager Geller T, Baruah R, Beattie JM, Boyne J, de Stoutz N, et al. Integration of a 
palliative approach into heart failure care: a European Society of Cardiology Heart 
Failure Association position paper. Eur J Heart Fail 2020;22:2327‚Äì39. https://doi.org/ 
10.1002/ejhf.1994 
205. Kyriakou M, Middleton N, Ktisti S, Philippou K, Lambrinou E. Supportive care interventions to promote health-related quality of life in patients living with heart failure: a systematic review and meta-analysis. Heart Lung Circ 2020;29:1633‚Äì47. https://doi.org/10. 
1016/j.hlc.2020.04.019 
206. Fendler TJ, Swetz KM, Allen LA. Team-based palliative and end-of-life care for heart 
failure. Heart Fail Clin 2015;11:479‚Äì98. https://doi.org/10.1016/j.hfc.2015.03.010 
207. Br√§nnstr√∂m M, Boman K. Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER: a randomized controlled study. Eur J Heart Fail 
2014;16:1142‚Äì51. https://doi.org/10.1002/ejhf.151 
208. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, et al. Prevalence and clinical 
determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart 
Study). Am J Cardiol 1999;83:897‚Äì902. https://doi.org/10.1016/s0002-9149(98) 
01064-9 
209. Lee JKT, Franzone A, Lanz J, Siontis GCM, Stortecky S, Gr√§ni C, et al. Early detection of 
subclinical myocardial damage in chronic aortic regurgitation and strategies for timely 
treatment of asymptomatic patients. Circulation 2018;137:184‚Äì96. https://doi.org/10. 
1161/circulationaha.117.029858 
210. Alashi A, Khullar T, Mentias A, Gillinov AM, Roselli EE, Svensson LG, et al. Long-term 
outcomes after aortic valve surgery in patients with asymptomatic chronic aortic regurgitation and preserved LVEF: impact of baseline and follow-up global longitudinal 
strain. JACC Cardiovasc Imaging 2020;13:12‚Äì21. https://doi.org/10.1016/j.jcmg.2018. 
12.021 
211. deCampos D, Teixeira R, Saleiro C, Botelho A, Gon√ßalve L. Global longitudinal strain in 
chronic asymptomatic aortic regurgitation: systematic review. Echo Res Pract 2020;7: 
39‚Äì48. https://doi.org/10.1530/erp-20-0024 
212. Lee SY, Park SJ, Kim EK, Chang SA, Lee SC, Ahn JH, et al. Predictive value of exercise 
stress echocardiography in asymptomatic patients with severe aortic regurgitation and 
preserved left ventricular systolic function without LV dilatation. Int J Cardiovasc 
Imaging 2019;35:1241‚Äì7. https://doi.org/10.1007/s10554-019-01565-1 
213. Pizarro R, Bazzino OO, Oberti PF, Falconi ML, Arias AM, Krauss JG, et al. Prospective 
validation of the prognostic usefulness of B-type natriuretic peptide in asymptomatic 
patients with chronic severe aortic regurgitation. J Am Coll Cardiol 2011;58:1705‚Äì14.  
https://doi.org/10.1016/j.jacc.2011.07.016 
214. Koƒçkov√° R, L√≠nkov√° H, Hlubock√° Z, Mƒõd√≠lek K, Tuna M, Voj√°ƒçek J, et al. Multiparametric 
strategy to predict early disease decompensation in asymptomatic severe aortic regurgitation. Circ Cardiovasc Imaging 2022;15:e014901. https://doi.org/10.1161/circimaging. 
122.014901 
215. Goldstein SA, Evangelista A, Abbara S, Arai A, Asch FM, Badano LP, et al. Multimodality 
imaging of diseases of the thoracic aorta in adults: from the American Society of 
Echocardiography and the European Association of Cardiovascular Imaging: endorsed 
by the Society of Cardiovascular Computed Tomography and Society for 
Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2015;28:119‚Äì82. https:// 
doi.org/10.1016/j.echo.2014.11.015 
216. Czerny M, Grabenw√∂ger M, Berger T, Aboyans V, Della Corte A, Chen EP, et al. 
EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of 
the aortic organ. Eur J Cardiothorac Surg 2024;65:ezad426. https://doi.org/10.1093/ 
ejcts/ezad426 
217. le Polain de Waroux JB, Pouleur AC, Goffinet C, Vancraeynest D, Van Dyck M, Robert 
A, et al. Functional anatomy of aortic regurgitation: accuracy, prediction of surgical repairability, and outcome implications of transesophageal echocardiography. Circulation 
2007;116:I264‚Äì9. https://doi.org/10.1161/CIRCULATIONAHA.106.680074 
218. Lansac E, Di Centa I, Raoux F, Al Attar N, Acar C, Joudinaud T, et al. A lesional classification to standardize surgical management of aortic insufficiency towards valve repair. Eur J Cardiothorac Surg 2008;33:872‚Äì8; discussion 878‚Äì880. https://doi.org/10. 
1016/j.ejcts.2007.12.033 
219. Michelena HI, Della Corte A, Evangelista A, Maleszewski JJ, Edwards WD, Roman MJ, 
et al. International consensus statement on nomenclature and classification of the congenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional and 
research purposes. Eur J Cardiothorac Surg 2021;60:448‚Äì76. https://doi.org/10.1093/ 
ejcts/ezab038 
220. Ehrlich T, de Kerchove L, Vojacek J, Boodhwani M, El-Hamamsy I, De Paulis R, et al. 
State-of-the art bicuspid aortic valve repair in 2020. Prog Cardiovasc Dis 2020;63: 
457‚Äì64. https://doi.org/10.1016/j.pcad.2020.04.010 
221. Evangelista Masip A, Galian-Gay L, Guala A, Lopez-Sainz A, Teixido-Tur√† G, Ruiz 
Mu√±oz A, et al. Unraveling bicuspid aortic valve enigmas by multimodality imaging: clinical implications. J Clin Med 2022;11:456. https://doi.org/10.3390/jcm11020456 
222. Elder DHJ, Wei L, Szwejkowski BR, Libianto R, Nadir A, Pauriah M, et al. The impact of 
renin-angiotensin-aldosterone system blockade on heart failure outcomes and 
mortality in patients identified to have aortic regurgitation: a large population cohort 
study. J Am Coll Cardiol 2011;58:2084‚Äì91. https://doi.org/10.1016/j.jacc.2011.07.043 
223. Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, et al. 
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices 
and patient management. An expert consensus meeting report of the Heart Failure 
Association of the European Society of Cardiology. Eur J Heart Fail 2019;21: 
1169‚Äì86. https://doi.org/10.1002/ejhf.1531 
224. Chaliki HP, Mohty D, Avierinos JF, Scott CG, Schaff HV, Tajik AJ, et al. Outcomes after 
aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. Circulation 2002;106:2687‚Äì93. https://doi.org/10.1161/ 
01.cir.0000038498.59829.38 
225. Kaneko T, Ejiofor JI, Neely RC, McGurk S, Ivkovic V, Stevenson LW, et al. Aortic regurgitation with markedly reduced left ventricular function is not a contraindication 
for aortic valve replacement. Ann Thorac Surg 2016;102:41‚Äì7. https://doi.org/10. 
1016/j.athoracsur.2015.12.068 
226. Tornos P, Sambola A, Permanyer-Miralda G, Evangelista A, Gomez Z, Soler-Soler J. 
Long-term outcome of surgically treated aortic regurgitation: influence of guideline adherence toward early surgery. J Am Coll Cardiol 2006;47:1012‚Äì7. https://doi.org/10. 
1016/j.jacc.2005.10.049 
227. Klodas E, Enriquez-Sarano M, Tajik AJ, Mullany CJ, Bailey KR, Seward JB. Optimizing 
timing of surgical correction in patients with severe aortic regurgitation: role of symptoms. J Am Coll Cardiol 1997;30:746‚Äì52. https://doi.org/10.1016/s0735-1097(97) 
00205-2 
228. Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward JB, Tajik AJ. Mortality 
and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. 
Circulation 1999;99:1851‚Äì7. https://doi.org/10.1161/01.cir.99.14.1851 
229. Fiedler AG, Bhambhani V, Laikhter E, Picard MH, Wasfy MM, Tolis G, et al. Aortic valve 
replacement associated with survival in severe regurgitation and low ejection fraction. 
Heart 2018;104:835‚Äì40. https://doi.org/10.1136/heartjnl-2017-312024 
230. Tribouilloy CM, Enriquez-Sarano M, Schaff HV, Orszulak TA, Fett SL, Bailey KR, et al. 
Excess mortality due to coronary artery disease after valve surgery. Secular trends in 
valvular regurgitation and effect of internal mammary artery bypass. Circulation 1998; 
98:II108‚Äì15. 
231. Forman R, Firth BG, Barnard MS. Prognostic significance of preoperative left ventricular ejection fraction and valve lesion in patients with aortic valve replacement. Am J 
Cardiol 1980;45:1120‚Äì5. https://doi.org/10.1016/0002-9149(80)90468-3 
232. Bonow RO, Lakatos E, Maron BJ, Epstein SE. Serial long-term assessment of the natural 
history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function. Circulation 1991;84:1625‚Äì35. https://doi.org/10.1161/01.cir. 
84.4.1625 
233. Bhudia SK, McCarthy PM, Kumpati GS, Helou J, Hoercher KJ, Rajeswaran J, et al. 
Improved outcomes after aortic valve surgery for chronic aortic regurgitation with severe left ventricular dysfunction. J Am Coll Cardiol 2007;49:1465‚Äì71. https://doi.org/10. 
1016/j.jacc.2007.01.026 
234. Sambola A, Tornos P, Ferreira-Gonzalez I, Evangelista A. Prognostic value of preoperative indexed end-systolic left ventricle diameter in the outcome after surgery in patients with chronic aortic regurgitation. Am Heart J 2008;155:1114‚Äì20. https://doi. 
org/10.1016/j.ahj.2007.12.025 
235. Yang LT, Michelena HI, Scott CG, Enriquez-Sarano M, Pislaru SV, Schaff HV, et al. 
Outcomes in chronic hemodynamically significant aortic regurgitation and limitations 
of current guidelines. J Am Coll Cardiol 2019;73:1741‚Äì52. https://doi.org/10.1016/j.jacc. 
2019.01.024 
236. Mentias A, Feng K, Alashi A, Rodriguez LL, Gillinov AM, Johnston DR, et al. Long-term 
outcomes in patients with aortic regurgitation and preserved left ventricular ejection 
fraction. J Am Coll Cardiol 2016;68:2144‚Äì53. https://doi.org/10.1016/j.jacc.2016.08.045 
237. de Meester C, Gerber BL, Vancraeynest D, Pouleur AC, Noirhomme P, Pasquet A, 
et al. Do guideline-based indications result in an outcome penalty for patients with severe aortic regurgitation? JACC Cardiovasc Imaging 2019;12:2126‚Äì38. https://doi.org/ 
10.1016/j.jcmg.2018.11.022 
238. Yang LT, Anand V, Zambito EI, Pellikka PA, Scott CG, Thapa P, et al. Association of 
echocardiographic left ventricular end-systolic volume and volume-derived ejection 
fraction with outcome in asymptomatic chronic aortic regurgitation. JAMA Cardiol 
2021;6:189‚Äì98. https://doi.org/10.1001/jamacardio.2020.5268 
239. Yang LT, Lee CC, Su CH, Amano M, Nabeshima Y, Kitano T, et al. Analysis of left ventricular indexes and mortality among Asian adults with hemodynamically significant 
chronic aortic regurgitation. JAMA Netw Open 2023;6:e234632. https://doi.org/10. 
1001/jamanetworkopen.2023.4632 
240. Hashimoto G, Enriquez-Sarano M, Stanberry LI, Oh F, Wang M, Acosta K, et al. 
Association of left ventricular remodeling assessment by cardiac magnetic resonance 
with outcomes in patients with chronic aortic regurgitation. JAMA Cardiol 2022;7: 
924‚Äì33. https://doi.org/10.1001/jamacardio.2022.2108 
241. Malahfji M, Crudo V, Kaolawanich Y, Nguyen DT, Telmesani A, Saeed M, et al. Influence 
of cardiac remodeling on clinical outcomes in patients with aortic regurgitation. J Am 
Coll Cardiol 2023;81:1885‚Äì98. https://doi.org/10.1016/j.jacc.2023.03.001 
242. Vermes E, Iacuzio L, Levy F, Bohbot Y, Renard C, Gerber B, et al. Role of cardiovascular 
magnetic resonance in native valvular regurgitation: a comprehensive review of  
ESC Guidelines                                                                                                                                                                                               83


<!-- PAGE 84 -->

### Page 84

protocols, grading of severity, and prediction of valve surgery. Front Cardiovasc Med 
2022;9:881141. https://doi.org/10.3389/fcvm.2022.881141 
243. Flynn CD, Tian DH, Wilson-Smith A, David T, Matalanis G, Misfeld M, et al. Systematic 
review and meta-analysis of surgical outcomes in Marfan patients undergoing aortic 
root surgery by composite-valve graft or valve sparing root replacement. Ann 
Cardiothorac Surg 2017;6:570‚Äì81. https://doi.org/10.21037/acs.2017.11.06 
244. Chauvette V, Kluin J, de Kerchove L, El Khoury G, Sch√§fers HJ, Lansac E, et al. 
Outcomes of valve-sparing surgery in heritable aortic disorders: results from the 
AVIATOR registry. Eur J Cardiothorac Surg 2022;62:ezac366. https://doi.org/10.1093/ 
ejcts/ezac366 
245. Wilson-Smith AR, Wilson-Smith CJ, Strode Smith J, Ng D, Muston BT, Eranki A, et al. 
The outcomes of three decades of the David and Yacoub procedures in bicuspid aortic 
valve patients‚Äîa systematic review and meta-analysis. Ann Cardiothorac Surg 2023;12: 
286‚Äì94. https://doi.org/10.21037/acs-2023-avs2-19 
246. Zuo Y, Tan R, Qin C. Outcomes of valve-sparing aortic root replacement in patients 
with bicuspid aortic valve and tricuspid aortic valve: a systematic review and 
meta-analysis. J Cardiothorac Surg 2023;18:206. https://doi.org/10.1186/s13019-023- 
02329-8 
247. Mastrobuoni S, Govers PJ, Veen KM, Jahanyar J, van Saane S, Segreto A, et al. 
Valve-sparing aortic root replacement using the reimplantation (David) technique: a 
systematic review and meta-analysis on survival and clinical outcome. Ann 
Cardiothorac Surg 2023;12:149‚Äì58. https://doi.org/10.21037/acs-2023-avs1-0038 
248. Aicher D, Fries R, Rodionycheva S, Schmidt K, Langer F, Schafers HJ. Aortic valve repair 
leads to a low incidence of valve-related complications. Eur J Cardiothorac Surg 2010;37: 
127‚Äì32. https://doi.org/10.1016/j.ejcts.2009.06.021 
249. de Meester C, Pasquet A, Gerber BL, Vancraeynest D, Noirhomme P, El Khoury G, 
et al. Valve repair improves the outcome of surgery for chronic severe aortic regurgitation: a propensity score analysis. J Thorac Cardiovasc Surg 2014;148:1913‚Äì20. https:// 
doi.org/10.1016/j.jtcvs.2014.02.010 
250. Klotz S, Stock S, Sievers HH, Diwoky M, Petersen M, Stierle U, et al. Survival and reoperation pattern after 20 years of experience with aortic valve-sparing root replacement in patients with tricuspid and bicuspid valves. J Thorac Cardiovasc Surg 2018;155: 
1403‚Äì11.e1401. https://doi.org/10.1016/j.jtcvs.2017.12.039 
251. Elbatarny M, Tam DY, Edelman JJ, Rocha RV, Chu MWA, Peterson MD, et al. 
Valve-sparing root replacement versus composite valve grafting in aortic root dilation: 
a meta-analysis. Ann Thorac Surg 2020;110:296‚Äì306. https://doi.org/10.1016/j. 
athoracsur.2019.11.054 
252. Leontyev S, Schamberger L, Davierwala PM, Von Aspern K, Etz C, Lehmann S, et al. 
Early and late results after David vs Bentall procedure: a propensity matched analysis. 
Ann Thorac Surg 2019;110:120‚Äì6. https://doi.org/10.1016/j.athoracsur.2019.10.020 
253. Mastrobuoni S, de Kerchove L, Navarra E, Watremez C, Vancraeynest D, Rubay J, et al. 
Long-term experience with valve-sparing reimplantation technique for the treatment 
of aortic aneurysm and aortic regurgitation. J Thorac Cardiovasc Surg 2019;158:14‚Äì23.  
https://doi.org/10.1016/j.jtcvs.2018.10.155 
254. Lansac E, Di Centa I, Sleilaty G, Lejeune S, Khelil N, Berrebi A, et al. Long-term results 
of external aortic ring annuloplasty for aortic valve repair. Eur J Cardiothorac Surg 2016; 
50:350‚Äì60. https://doi.org/10.1093/ejcts/ezw070 
255. Lee H, Cho YH, Sung K, Kim WS, Park KH, Jeong DS, et al. Clinical outcomes of root 
reimplantation and Bentall procedure: propensity score matching analysis. Ann Thorac 
Surg 2018;106:539‚Äì47. https://doi.org/10.1016/j.athoracsur.2018.02.057 
256. Norton EL, Patel PM, Levine D, Wei JW, Binongo JN, Leshnower BG, et al. Bentall versus valve-sparing aortic root replacement for root pathology with moderate-to-severe 
aortic insufficiency: a propensity-matched analysis. Eur J Cardiothorac Surg 2023;64: 
ezad231. https://doi.org/10.1093/ejcts/ezad231 
257. Arabkhani B, Klautz RJM, de Heer F, De Kerchove L, El Khoury G, Lansac E, et al. A 
multicentre, propensity score matched analysis comparing a valve-sparing approach 
to valve replacement in aortic root aneurysm: insight from the AVIATOR database. 
Eur J Cardiothorac Surg 2023;63:ezac514. https://doi.org/10.1093/ejcts/ezac514 
258. Levine D, Patel P, Zhao Y, Chung M, Singh S, Childress P, et al. Valve-sparing aortic root 
replacement versus composite valve graft with bioprosthesis in patients under age 50. J 
Thorac Cardiovasc Surg 2023;168:992‚Äì1002.e1. https://doi.org/10.1016/j.jtcvs.2023.07. 
016 
259. Schneider U, Hofmann C, Sch√∂pe J, Niewald AK, Giebels C, Karliova I, et al. Long-term 
results of differentiated anatomic reconstruction of bicuspid aortic valves. JAMA Cardiol 
2020;5:1366‚Äì73. https://doi.org/10.1001/jamacardio.2020.3749 
260. Mazine A, Rocha RV, El-Hamamsy I, Ouzounian M, Yanagawa B, Bhatt DL, et al. Ross 
procedure vs mechanical aortic valve replacement in adults: a systematic review and 
meta-analysis. JAMA Cardiol 2018;3:978‚Äì87. https://doi.org/10.1001/jamacardio.2018. 
2946 
261. Takkenberg JJM, Klieverik LMA, Schoof PH, van Suylen RJ, van Herwerden LA, 
Zondervan PE, et al. The Ross procedure: a systematic review and meta-analysis. 
Circulation 
2009;119:222‚Äì8. 
https://doi.org/10.1161/CIRCULATIONAHA.107. 
726349 
262. Yokoyama Y, Kuno T, Toyoda N, Fujisaki T, Takagi H, Itagaki S, et al. Ross procedure 
versus mechanical versus bioprosthetic aortic valve replacement: a network 
meta-analysis. J Am Heart Assoc 2023;12:e8066. https://doi.org/10.1161/jaha.122. 
027715 
263. El-Hamamsy I, Toyoda N, Itagaki S, Stelzer P, Varghese R, Williams EE, et al. 
Propensity-matched comparison of the Ross procedure and prosthetic aortic valve replacement in adults. J Am Coll Cardiol 2022;79:805‚Äì15. https://doi.org/10.1016/j.jacc. 
2021.11.057 
264. Sawaya FJ, Deutsch MA, Seiffert M, Yoon SH, Codner P, Wickramarachchi U, et al. 
Safety and efficacy of transcatheter aortic valve replacement in the treatment of 
pure aortic regurgitation in native valves and failing surgical bioprostheses: results 
from an international registry study. JACC Cardiovasc Interv 2017;10:1048‚Äì56. https:// 
doi.org/10.1016/j.jcin.2017.03.004 
265. Yoon SH, Schmidt T, Bleiziffer S, Schofer N, Fiorina C, Munoz-Garcia AJ, et al. 
Transcatheter aortic valve replacement in pure native aortic valve regurgitation. J 
Am Coll Cardiol 2017;70:2752‚Äì63. https://doi.org/10.1016/j.jacc.2017.10.006 
266. Poletti E, De Backer O, Scotti A, Costa G, Bruno F, Fiorina C, et al. Transcatheter aortic valve replacement for pure native aortic valve regurgitation: the PANTHEON international project. JACC Cardiovasc Interv 2023;16:1974‚Äì85. https://doi.org/10.1016/j.jcin. 
2023.07.026 
267. Garcia S, Ye J, Webb J, Reardon M, Kleiman N, Goel S, et al. Transcatheter treatment 
of native aortic valve regurgitation: the North American experience with a novel device. JACC Cardiovasc Interv 2023;16:1953‚Äì60. https://doi.org/10.1016/j.jcin.2023.05. 
018 
268. Adam M, Tamm AR, Wienemann H, Unbehaun A, Klein C, Arnold M, et al. 
Transcatheter aortic valve replacement for isolated aortic regurgitation using a new 
self-expanding TAVR system. JACC Cardiovasc Interv 2023;16:1965‚Äì73. https://doi. 
org/10.1016/j.jcin.2023.07.038 
269. Vahl TP, Thourani VH, Makkar RR, Hamid N, Khalique OK, Daniels D, et al. 
Transcatheter aortic valve implantation in patients with high-risk symptomatic native 
aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study. Lancet 
2024;403:1451‚Äì9. https://doi.org/10.1016/s0140-6736(23)02806-4 
270. Borger MA, Preston M, Ivanov J, Fedak PW, Davierwala P, Armstrong S, et al. Should 
the ascending aorta be replaced more frequently in patients with bicuspid aortic valve 
disease? J Thorac Cardiovasc Surg 2004;128:677‚Äì83. https://doi.org/10.1016/j.jtcvs. 
2004.07.009 
271. Coady MA, Rizzo JA, Hammond GL, Mandapati D, Darr U, Kopf GS, et al. What is the 
appropriate size criterion for resection of thoracic aortic aneurysms? J Thorac 
Cardiovasc Surg 1997;113:476‚Äì91; discussion 489‚Äì491. https://doi.org/10.1016/ 
S0022-5223(97)70360-X 
272. Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, et al. Yearly rupture 
or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann 
Thorac Surg 2002;73:17‚Äì27; discussion 27‚Äì18. https://doi.org/10.1016/s0003- 
4975(01)03236-2 
273. Zafar MA, Li Y, Rizzo JA, Charilaou P, Saeyeldin A, Velasquez CA, et al. Height alone, 
rather than body surface area, suffices for risk estimation in ascending aortic aneurysm. 
J Thorac Cardiovasc Surg 2018;155:1938‚Äì50. https://doi.org/10.1016/j.jtcvs.2017.10.140 
274. Popoviƒá ZB, Desai MY, Griffin BP. Decision making with imaging in asymptomatic aortic regurgitation. JACC Cardiovasc Imaging 2018;11:1499‚Äì513. https://doi.org/10.1016/j. 
jcmg.2018.05.027 
275. Evangelista A, Sitges M, Jondeau G, Nijveldt R, Pepi M, Cuellar H, et al. Multimodality 
imaging in thoracic aortic diseases: a clinical consensus statement from the European 
Association of Cardiovascular Imaging and the European Society of Cardiology working group on aorta and peripheral vascular diseases. Eur Heart J Cardiovasc Imaging 
2023;24:e65‚Äì85. https://doi.org/10.1093/ehjci/jead024 
276. Weisenberg D, Omelchenko A, Shapira Y, Vaturi M, Monakier D, Bental T, et al. 
Mid-term echocardiographic progression of patients with moderate aortic regurgitation: implications for aortic valve surgery. J Heart Valve Dis 2013;22:192‚Äì4. 
277. Budts W, Pieles GE, Roos-Hesselink JW, Sanz de la Garza M, D‚ÄôAscenzi F, 
Giannakoulas G, et al. Recommendations for participation in competitive sport in adolescent and adult athletes with Congenital Heart Disease (CHD): position statement of 
the Sports Cardiology & Exercise Section of the European Association of Preventive 
Cardiology (EAPC), the European Society of Cardiology (ESC) Working Group on 
Adult Congenital Heart Disease and the Sports Cardiology, Physical Activity and 
Prevention Working Group of the Association for European Paediatric and 
Congenital Cardiology (AEPC). Eur Heart J 2020;41:4191‚Äì9. https://doi.org/10.1093/ 
eurheartj/ehaa501 
278. Robertson EN, van der Linde D, Sherrah AG, Vallely MP, Wilson M, Bannon PG, et al. 
Familial non-syndromal thoracic aortic aneurysms and dissections‚Äîincidence and 
family screening outcomes. Int J Cardiol 2016;220:43‚Äì51. https://doi.org/10.1016/j. 
ijcard.2016.06.086 
279. Bray JJH, Freer R, Pitcher A, Kharbanda R. Family screening for bicuspid aortic valve and 
aortic dilatation: a meta-analysis. Eur Heart J 2023;44:3152‚Äì64. https://doi.org/10.1093/ 
eurheartj/ehad320 
280. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic 
valves in adults having isolated aortic valve replacement for aortic stenosis, with or 
without associated aortic regurgitation. Circulation 2005;111:920‚Äì5. https://doi.org/ 
10.1161/01.Cir.0000155623.48408.C5


<!-- PAGE 85 -->

### Page 85

281. Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J Med 
2014;370:1920‚Äì9. https://doi.org/10.1056/NEJMra1207059 
282. Z√ºhlke L, Engel ME, Karthikeyan G, Rangarajan S, Mackie P, Cupido B, et al. 
Characteristics, complications, and gaps in evidence-based interventions in rheumatic 
heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur 
Heart J 2015;36:1115‚Äì22a. https://doi.org/10.1093/eurheartj/ehu449 
283. Willner N, Prosperi-Porta G, Lau L, Nam Fu AY, Boczar K, Poulin A, et al. Aortic stenosis progression: a systematic review and meta-analysis. JACC Cardiovasc Imaging 2023; 
16:314‚Äì28. https://doi.org/10.1016/j.jcmg.2022.10.009 
284. Dweck MR, Loganath K, Bing R, Treibel TA, McCann GP, Newby DE, et al. 
Multi-modality imaging in aortic stenosis: an EACVI clinical consensus document. Eur 
Heart J Cardiovasc Imaging 2023;24:1430‚Äì43. https://doi.org/10.1093/ehjci/jead153 
285. Jaiswal V, Agrawal V, Khulbe Y, Hanif M, Huang H, Hameed M, et al. Cardiac amyloidosis and aortic stenosis: a state-of-the-art review. Eur Heart J Open 2023;3:oead106.  
https://doi.org/10.1093/ehjopen/oead106 
286. Desai MY, Alashi A, Popovic ZB, Wierup P, Griffin BP, Thamilarasan M, et al. 
Outcomes in patients with obstructive hypertrophic cardiomyopathy and concomitant aortic stenosis undergoing surgical myectomy and aortic valve replacement. J 
Am Heart Assoc 2021;10:e018435. https://doi.org/10.1161/JAHA.120.018435 
287. Baumgartner H, Hung J, Bermejo J, Chambers JB, Edvardsen T, Goldstein S, et al. 
Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the 
American Society of Echocardiography. J Am Soc Echocardiogr 2017;30:372‚Äì92.  
https://doi.org/10.1016/j.echo.2017.02.009 
288. Rusinaru D, Bohbot Y, Djelaili F, Delpierre Q, Altes A, Serbout S, et al. Normative reference values of cardiac output by pulsed-wave Doppler echocardiography in adults. 
Am J Cardiol 2021;140:128‚Äì33. https://doi.org/10.1016/j.amjcard.2020.10.046 
289. Annabi MS, Touboul E, Dahou A, Burwash IG, Bergler-Klein J, Enriquez-Sarano M, et al. 
Dobutamine stress echocardiography for management of low-flow, low-gradient aortic stenosis. J Am Coll Cardiol 2018;71:475‚Äì85. https://doi.org/10.1016/j.jacc.2017.11. 
052 
290. Clavel MA, Burwash IG, Mundigler G, Dumesnil JG, Baumgartner H, Bergler-Klein J, 
et al. Validation of conventional and simplified methods to calculate projected valve 
area at normal flow rate in patients with low flow, low gradient aortic stenosis: the 
multicenter TOPAS (True or Pseudo Severe Aortic Stenosis) study. J Am Soc 
Echocardiogr 2010;23:380‚Äì6. https://doi.org/10.1016/j.echo.2010.02.002 
291. Ash J, Sandhu GS, Arriola-Montenegro J, Agakishiev D, Clavel MA, Pibarot P, et al. 
Performance of computed tomographic angiography-based aortic valve area for assessment of aortic stenosis. J Am Heart Assoc 2023;12:e029973. https://doi.org/10. 
1161/jaha.123.029973 
292. Guzzetti E, Poulin A, Annabi MS, Zhang B, Kalavrouziotis D, Couture C, et al. 
Transvalvular flow, sex, and survival after valve replacement surgery in patients with 
severe aortic stenosis. J Am Coll Cardiol 2020;75:1897‚Äì909. https://doi.org/10.1016/j. 
jacc.2020.02.065 
293. Mehrotra P, Jansen K, Flynn AW, Tan TC, Elmariah S, Picard MH, et al. Differential left 
ventricular remodelling and longitudinal function distinguishes low flow from normal- 
flow preserved ejection fraction low-gradient severe aortic stenosis. Eur Heart J 2013; 
34:1906‚Äì14. https://doi.org/10.1093/eurheartj/eht094 
294. Tribouilloy C, Rusinaru D, Marechaux S, Castel AL, Debry N, Maizel J, et al. 
Low-gradient, low-flow severe aortic stenosis with preserved left ventricular ejection 
fraction: characteristics, outcome, and implications for surgery. J Am Coll Cardiol 2015; 
65:55‚Äì66. https://doi.org/10.1016/j.jacc.2014.09.080 
295. Jander N, Minners J, Holme I, Gerdts E, Boman K, Brudi P, et al. Outcome of patients 
with low-gradient ‚Äúsevere‚Äù aortic stenosis and preserved ejection fraction. Circulation 
2011;123:887‚Äì95. https://doi.org/10.1161/CIRCULATIONAHA.110.983510 
296. Bohbot Y, Kubala M, Rusinaru D, Mar√©chaux S, Vanoverschelde JL, Tribouilloy C. 
Survival and management of patients with discordant high-gradient aortic stenosis: a 
propensity-matched study. JACC Cardiovasc Imaging 2021;14:1672‚Äì4. https://doi.org/ 
10.1016/j.jcmg.2021.02.010 
297. Unger P, Powers A, Le Nezet E, Lacasse-Rioux E, Galloo X, Clavel MA. Prevalence and 
outcomes of patients with discordant high-gradient aortic stenosis. J Am Coll Cardiol 
2024;83:1109‚Äì19. https://doi.org/10.1016/j.jacc.2024.01.025 
298. Ito S, Oh JK, Michelena HI, Egbe AC, Connolly HM, Pellikka PA, et al. High-gradient 
aortic stenosis with valve area >1.0 cm2: the ‚Äúforgotten‚Äù discordant hemodynamic 
phenotype. JACC Cardiovasc Imaging 2025;18:166‚Äì76. https://doi.org/10.1016/j.jcmg. 
2024.07.025 
299. Ribeiro HB, Lerakis S, Gilard M, Cavalcante JL, Makkar R, Herrmann HC, et al. 
Transcatheter aortic valve replacement in patients with low-flow, low-gradient aortic 
stenosis: the TOPAS-TAVI registry. J Am Coll Cardiol 2018;71:1297‚Äì308. https://doi. 
org/10.1016/j.jacc.2018.01.054 
300. Clavel MA, Pibarot P, Messika-Zeitoun D, Capoulade R, Malouf J, Aggarval S, et al. 
Impact of aortic valve calcification, as measured by MDCT, on survival in patients 
with aortic stenosis: results of an international registry study. J Am Coll Cardiol 2014; 
64:1202‚Äì13. https://doi.org/10.1016/j.jacc.2014.05.066 
301. Tastet L, Enriquez-Sarano M, Capoulade R, Malouf J, Araoz PA, Shen M, et al. Impact of 
aortic valve calcification and sex on hemodynamic progression and clinical outcomes in 
AS. J Am Coll Cardiol 2017;69:2096‚Äì8. https://doi.org/10.1016/j.jacc.2017.02.037 
302. Clavel MA, Messika-Zeitoun D, Pibarot P, Aggarwal SR, Malouf J, Araoz PA, et al. The 
complex nature of discordant severe calcified aortic valve disease grading: new insights 
from combined Doppler echocardiographic and computed tomographic study. J Am 
Coll Cardiol 2013;62:2329‚Äì38. https://doi.org/10.1016/j.jacc.2013.08.1621 
303. Pawade T, Clavel MA, Tribouilloy C, Dreyfus J, Mathieu T, Tastet L, et al. Computed 
tomography aortic valve calcium scoring in patients with aortic stenosis. Circ Cardiovasc 
Imaging 2018;11:e007146. https://doi.org/10.1161/CIRCIMAGING.117.007146 
304. Shen M, Oh JK, Guzzetti E, Singh GK, Pawade T, Tastet L, et al. Computed tomography 
aortic valve calcium scoring in patients with bicuspid aortic valve stenosis. Struct Heart 
2022;6:100027. https://doi.org/10.1016/j.shj.2022.100027 
305. Shen M, Tastet L, Capoulade R, Larose √â, B√©dard √â, Arsenault M, et al. Effect of age and 
aortic valve anatomy on calcification and haemodynamic severity of aortic stenosis. 
Heart 2017;103:32‚Äì9. https://doi.org/10.1136/heartjnl-2016-309665 
306. Wanchaitanawong W, Kanjanavanit R, Srisuwan T, Wongcharoen W, Phrommintikul 
A. Diagnostic role of aortic valve calcium scoring in various etiologies of aortic stenosis. 
Sci Rep 2023;13:8019. https://doi.org/10.1038/s41598-023-34118-7 
307. Ye Z, Clavel MA, Foley TA, Pibarot P, Enriquez-Sarano M, Michelena HI. Computed 
tomography calcium scoring in aortic stenosis: bicuspid versus tricuspid morphology. 
Heart 2024;110:594‚Äì602. https://doi.org/10.1136/heartjnl-2023-323281 
308. Maznyczka A, Tomii D, Angellotti D, Baekke PS, Nakase M, Samim D, et al. Fibrotic vs 
calcific aortic stenosis: characteristics and outcomes in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv 2024;17:2969‚Äì71. https://doi.org/ 
10.1016/j.jcin.2024.09.041 
309. Rusinaru D, Malaquin D, Marechaux S, Debry N, Tribouilloy C. Relation of dimensionless index to long-term outcome in aortic stenosis with preserved LVEF. JACC 
Cardiovasc Imaging 2015;8:766‚Äì75. https://doi.org/10.1016/j.jcmg.2015.01.023 
310. Thellier N, Altes A, Rietz M, Menet A, Layec J, Outteryck F, et al. Additive prognostic 
value of left ventricular dispersion and deformation in patients with severe aortic stenosis. JACC Cardiovasc Imaging 2023;17:235‚Äì45. https://doi.org/10.1016/j.jcmg.2023.09. 
010 
311. Vollema EM, Amanullah MR, Prihadi EA, Ng ACT, van der Bijl P, Sin YK, et al. 
Incremental value of left ventricular global longitudinal strain in a newly proposed staging classification based on cardiac damage in patients with severe aortic stenosis. Eur 
Heart J Cardiovasc Imaging 2020;21:1248‚Äì58. https://doi.org/10.1093/ehjci/jeaa220 
312. Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, et al. Causes and 
consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography 
in cardiac amyloidosis. JACC Cardiovasc Imaging 2016;9:126‚Äì38. https://doi.org/10. 
1016/j.jcmg.2015.05.014 
313. Harada K, Saitoh T, Tanaka J, Shibayama K, Berdejo J, Shiota T. Valvuloarterial impedance, but not aortic stenosis severity, predicts syncope in patients with aortic stenosis. 
Circ Cardiovasc Imaging 2013;6:1024‚Äì31. https://doi.org/10.1161/circimaging.113. 
000584 
314. Hachicha Z, Dumesnil JG, Pibarot P. Usefulness of the valvuloarterial impedance to 
predict adverse outcome in asymptomatic aortic stenosis. J Am Coll Cardiol 2009;54: 
1003‚Äì11. https://doi.org/10.1016/j.jacc.2009.04.079 
315. Pibarot P, Salaun E, Dahou A, Avenatti E, Guzzetti E, Annabi MS, et al. 
Echocardiographic results of transcatheter versus surgical aortic valve replacement 
in low-risk patients: the PARTNER 3 trial. Circulation 2020;141:1527‚Äì37. https://doi. 
org/10.1161/circulationaha.119.044574 
316. Zamorano JL, Badano LP, Bruce C, Chan KL, Goncalves A, Hahn RT, et al. EAE/ASE 
recommendations for the use of echocardiography in new transcatheter interventions 
for valvular heart disease. Eur Heart J 2011;32:2189‚Äì214. https://doi.org/10.1093/ 
eurheartj/ehr259 
317. Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, et al. 
Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004;109:2302‚Äì8. https://doi.org/10.1161/01.CIR. 
0000126825.50903.18 
318. Rafique AM, Biner S, Ray I, Forrester JS, Tolstrup K, Siegel RJ. Meta-analysis of prognostic value of stress testing in patients with asymptomatic severe aortic stenosis. Am J 
Cardiol 2009;104:972‚Äì7. https://doi.org/10.1016/j.amjcard.2009.05.044 
319. Lancellotti P, Lebois F, Simon M, Tombeux C, Chauvel C, Pierard LA. Prognostic importance of quantitative exercise Doppler echocardiography in asymptomatic valvular 
aortic stenosis. Circulation 2005;112:I377‚Äì82. https://doi.org/10.1161/circulationaha. 
104.523274 
320. Le VD, Jensen GV, Kj√∏ller-Hansen L. Prognostic usefulness of cardiopulmonary exercise testing for managing patients with severe aortic stenosis. Am J Cardiol 2017;120: 
844‚Äì9. https://doi.org/10.1016/j.amjcard.2017.05.047 
321. Hoedemakers S, Verwerft J, Reddy YNV, Delvaux R, Stroobants S, Jogani S, et al. 
Cardiac dysfunction rather than aortic valve stenosis severity drives exercise intolerance and adverse hemodynamics. Eur Heart J Cardiovasc Imaging 2023;25:302‚Äì12.  
https://doi.org/10.1093/ehjci/jead276  
ESC Guidelines                                                                                                                                                                                               85


<!-- PAGE 86 -->

### Page 86

322. Bing R, Cavalcante JL, Everett RJ, Clavel MA, Newby DE, Dweck MR. Imaging and impact of myocardial fibrosis in aortic stenosis. JACC Cardiovasc Imaging 2019;12:283‚Äì96.  
https://doi.org/10.1016/j.jcmg.2018.11.026 
323. Everett RJ, Treibel TA, Fukui M, Lee H, Rigolli M, Singh A, et al. Extracellular myocardial 
volume in patients with aortic stenosis. J Am Coll Cardiol 2020;75:304‚Äì16. https://doi. 
org/10.1016/j.jacc.2019.11.032 
324. Thornton GD, Vassiliou VS, Musa TA, Aziminia N, Craig N, Dattani A, et al. Myocardial 
scar and remodelling predict long-term mortality in severe aortic stenosis beyond 10 
years. Eur Heart J 2024;45:2019‚Äì22. https://doi.org/10.1093/eurheartj/ehae067 
325. Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, et al. 
Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J 
Am Coll Cardiol 2021;77:128‚Äì39. https://doi.org/10.1016/j.jacc.2020.11.006 
326. Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert 
consensus recommendations for the suspicion and diagnosis of transthyretin cardiac 
amyloidosis. Circ Heart Fail 2019;12:e006075. https://doi.org/10.1161/circheartfailure. 
119.006075 
327. Cannata F, Chiarito M, Pinto G, Villaschi A, Sanz-S√°nchez J, Fazzari F, et al. 
Transcatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a 
systematic review and meta-analysis. ESC Heart Fail 2022;9:3188‚Äì97. https://doi.org/ 
10.1002/ehf2.13876 
328. Blanke P, Weir-McCall JR, Achenbach S, Delgado V, Hausleiter J, Jilaihawi H, et al. 
Computed tomography imaging in the context of Transcatheter Aortic Valve 
Implantation (TAVI)/Transcatheter Aortic Valve Replacement (TAVR). JACC 
Cardiovasc Imaging 2019;12:1‚Äì24. https://doi.org/10.1016/j.jcmg.2018.12.003 
329. Khan JM, Kamioka N, Lisko JC, Perdoncin E, Zhang C, Maini A, et al. Coronary obstruction from TAVR in native aortic stenosis: development and validation of multivariate 
prediction model. JACC Cardiovasc Interv 2023;16:415‚Äì25. https://doi.org/10.1016/j. 
jcin.2022.11.018 
330. Reindl M, Lechner I, Holzknecht M, Tiller C, Fink P, Oberhollenzer F, et al. Cardiac magnetic resonance imaging versus computed tomography to guide transcatheter aortic 
valve replacement: a randomized, open-label, noninferiority trial. Circulation 2023; 
148:1220‚Äì30. https://doi.org/10.1161/CIRCULATIONAHA.123.066498 
331. Gleitman S, Elbaz-Greener G, Ghanim D, Kusniec F, Rabin A, Sudarsky D, et al. Similar 
procedural success of transcutaneous aortic valve replacement with prosthesis valve 
sizing by either three-dimensional transesophageal echocardiography modeling or 
computed tomography. J Am Soc Echocardiogr 2020;33:1149‚Äì51. https://doi.org/10. 
1016/j.echo.2020.05.026 
332. Rosseb√∏ AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive 
lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359: 
1343‚Äì56. https://doi.org/10.1056/NEJMoa0804602 
333. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 
2005;352:2389‚Äì97. https://doi.org/10.1056/NEJMoa043876 
334. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid lowering with rosuvastatin on 
progression of aortic stenosis: results of the aortic stenosis progression observation: 
measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010;121: 
306‚Äì14. https://doi.org/10.1161/CIRCULATIONAHA.109.900027 
335. Pawade TA, Doris MK, Bing R, White AC, Forsyth L, Evans E, et al. Effect of denosumab 
or alendronic acid on the progression of aortic stenosis: a double-blind randomized 
controlled trial. Circulation 2021;143:2418‚Äì27. https://doi.org/10.1161/CIRCU 
LATIONAHA.121.053708 
336. Diederichsen ACP, Lindholt JS, M√∂ller S, √òvrehus KA, Auscher S, Lambrechtsen J, et al. 
Vitamin K2 and D in patients with aortic valve calcification: a randomized double- 
blinded 
clinical 
trial. 
Circulation 
2022;145:1387‚Äì97. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.121.057008 
337. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 
ESC Guidelines for the management of elevated blood pressure and hypertension. Eur 
Heart J 2024;45:3912‚Äì4018. https://doi.org/10.1093/eurheartj/ehae178 
338. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B√§ck M, et al. 2021 ESC 
Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 
42:3227‚Äì337. https://doi.org/10.1093/eurheartj/ehab484 
339. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B√∂hm M, et al. 2021 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart 
failure of the European Society of Cardiology (ESC) with the special contribution of 
the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599‚Äì726.  
https://doi.org/10.1093/eurheartj/ehab368 
340. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B√∂hm M, et al. 2023 
Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute 
and chronic heart failure: developed by the Task Force for the diagnosis and treatment 
of acute and chronic heart failure of the European Society of Cardiology (ESC) with 
the special contribution of the Heart Failure Association (HFA) of the ESC. Eur 
Heart J 2023;44:3627‚Äì39. https://doi.org/10.1093/eurheartj/ehad195 
341. Monin JL, Qu√©r√© JP, Monchi M, Petit H, Baleynaud S, Chauvel C, et al. Low-gradient 
aortic stenosis: operative risk stratification and predictors for long-term outcome: a 
multicenter study using dobutamine stress hemodynamics. Circulation 2003;108: 
319‚Äì24. https://doi.org/10.1161/01.CIR.0000079171.43055.46 
342. Tribouilloy C, Levy F, Rusinaru D, Gueret P, Petit-Eisenmann H, Baleynaud S, et al. 
Outcome after aortic valve replacement for low-flow/low-gradient aortic stenosis 
without contractile reserve on dobutamine stress echocardiography. J Am Coll 
Cardiol 2009;53:1865‚Äì73. https://doi.org/10.1016/j.jacc.2009.02.026 
343. Quere JP, Monin JL, Levy F, Petit H, Baleynaud S, Chauvel C, et al. Influence of preoperative left ventricular contractile reserve on postoperative ejection fraction in low- 
gradient aortic stenosis. Circulation 2006;113:1738‚Äì44. https://doi.org/10.1161/ 
circulationaha.105.568824 
344. Fougeres E, Tribouilloy C, Monchi M, Petit-Eisenmann H, Baleynaud S, Pasquet A, et al. 
Outcomes of pseudo-severe aortic stenosis under conservative treatment. Eur Heart J 
2012;33:2426‚Äì33. https://doi.org/10.1093/eurheartj/ehs176 
345. Levy F, Laurent M, Monin JL, Maillet JM, Pasquet A, Le Tourneau T, et al. Aortic valve 
replacement for low-flow/low-gradient aortic stenosis operative risk stratification and 
long-term outcome: a European multicenter study. J Am Coll Cardiol 2008;51:1466‚Äì72.  
https://doi.org/10.1016/j.jacc.2007.10.067 
346. Maes F, Lerakis S, Barbosa Ribeiro H, Gilard M, Cavalcante JL, Makkar R, et al. 
Outcomes from transcatheter aortic valve replacement in patients with low-flow, low- 
gradient aortic stenosis and left ventricular ejection fraction less than 30%: a substudy 
from the TOPAS-TAVI registry. JAMA Cardiol 2019;4:64‚Äì70. https://doi.org/10.1001/ 
jamacardio.2018.4320 
347. Sato K, Sankaramangalam K, Kandregula K, Bullen JA, Kapadia SR, Krishnaswamy A, 
et al. Contemporary outcomes in low-gradient aortic stenosis patients who underwent dobutamine stress echocardiography. J Am Heart Assoc 2019;8:e011168.  
https://doi.org/10.1161/JAHA.118.011168 
348. Ueyama H, Kuno T, Harrington M, Takagi H, Krishnamoorthy P, Sharma SK, et al. 
Impact of surgical and transcatheter aortic valve replacement in low-gradient aortic 
stenosis: a meta-analysis. JACC Cardiovasc Interv 2021;14:1481‚Äì92. https://doi.org/10. 
1016/j.jcin.2021.04.038 
349. Clavel MA, Dumesnil JG, Capoulade R, Mathieu P, Senechal M, Pibarot P. Outcome of 
patients with aortic stenosis, small valve area, and low-flow, low-gradient despite preserved left ventricular ejection fraction. J Am Coll Cardiol 2012;60:1259‚Äì67. https://doi. 
org/10.1016/j.jacc.2011.12.054 
350. Chadha G, Bohbot Y, Rusinaru D, Marechaux S, Tribouilloy C. Outcome of normal- 
flow low-gradient severe aortic stenosis with preserved left ventricular ejection fraction: a propensity-matched study. J Am Heart Assoc 2019;8:e012301. https://doi.org/10. 
1161/JAHA.119.012301 
351. Pellikka PA, Sarano ME, Nishimura RA, Malouf JF, Bailey KR, Scott CG, et al. Outcome 
of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during 
prolonged 
follow-up. 
Circulation 
2005;111:3290‚Äì5. 
https://doi.org/10.1161/ 
circulationaha.104.495903 
352. Heuvelman HJ, van Geldorp MW, Kappetein AP, Geleijnse ML, Galema TW, Bogers AJ, 
et al. Clinical course of patients diagnosed with severe aortic stenosis in the Rotterdam 
area: insights from the AVARIJN study. Neth Heart J 2012;20:487‚Äì93. https://doi.org/ 
10.1007/s12471-012-0309-3 
353. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, et al. Prospective 
study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997;95:2262‚Äì70. https://doi.org/10.1161/01. 
cir.95.9.2262 
354. Bohbot Y, de Meester de Ravenstein C, Chadha G, Rusinaru D, Belkhir K, Trouillet C, 
et al. Relationship between left ventricular ejection fraction and mortality in asymptomatic and minimally symptomatic patients with severe aortic stenosis. JACC 
Cardiovasc Imaging 2019;12:38‚Äì48. https://doi.org/10.1016/j.jcmg.2018.07.029 
355. Capoulade R, Le Ven F, Clavel MA, Dumesnil JG, Dahou A, Thebault C, et al. 
Echocardiographic predictors of outcomes in adults with aortic stenosis. Heart 
2016;102:934‚Äì42. https://doi.org/10.1136/heartjnl-2015-308742 
356. Dahl JS, Eleid MF, Michelena HI, Scott CG, Suri RM, Schaff HV, et al. Effect of left ventricular ejection fraction on postoperative outcome in patients with severe aortic stenosis undergoing aortic valve replacement. Circ Cardiovasc Imaging 2015;8:e002917.  
https://doi.org/10.1161/CIRCIMAGING.114.002917 
357. Taniguchi T, Morimoto T, Shiomi H, Ando K, Kanamori N, Murata K, et al. Prognostic 
impact of left ventricular ejection fraction in patients with severe aortic stenosis. JACC 
Cardiovasc Interv 2018;11:145‚Äì57. https://doi.org/10.1016/j.jcin.2017.08.036 
358. Ito S, Miranda WR, Nkomo VT, Connolly HM, Pislaru SV, Greason KL, et al. Reduced 
left ventricular ejection fraction in patients with aortic stenosis. J Am Coll Cardiol 2018; 
71:1313‚Äì21. https://doi.org/10.1016/j.jacc.2018.01.045 
359. De Azevedo D, Boute M, Tribouilloy C, Mar√©chaux S, Pouleur AC, Bohbot Y, et al. 
Quantifying the survival loss linked to late therapeutic indication in high-gradient severe aortic stenosis. JACC Adv 2024;3:100830. https://doi.org/10.1016/j.jacadv.2024. 
100830 
360. G√©n√©reux P, Schwartz A, Oldemeyer JB, Pibarot P, Cohen DJ, Blanke P, et al. 
Transcatheter aortic-valve replacement for asymptomatic severe aortic stenosis. N 
Engl J Med 2024;392:217‚Äì27. https://doi.org/10.1056/NEJMoa2405880 
361. Loganath K, Craig NJ, Everett RJ, Bing R, Tsampasian V, Molek P, et al. Early intervention in patients with asymptomatic severe aortic stenosis and myocardial fibrosis: the


<!-- PAGE 87 -->

### Page 87

EVOLVED randomized clinical trial. JAMA 2024;333:213‚Äì21. https://doi.org/10.1001/ 
jama.2024.22730 
362. Kang DH, Park SJ, Lee SA, Lee S, Kim DH, Kim HK, et al. Early surgery or conservative 
care for asymptomatic aortic stenosis. N Engl J Med 2020;382:111‚Äì9. https://doi.org/ 
10.1056/NEJMoa1912846 
363. Banovic M, Putnik S, Penicka M, Doros G, Deja MA, Kockova R, et al. Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis: the 
AVATAR 
Trial. 
Circulation 
2022;145:648‚Äì58. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.121.057639 
364. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, et al. Predictors of 
outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611‚Äì7.  
https://doi.org/10.1056/NEJM200008313430903 
365. Nakatsuma K, Taniguchi T, Morimoto T, Shiomi H, Ando K, Kanamori N, et al. B-type 
natriuretic peptide in patients with asymptomatic severe aortic stenosis. Heart 2019; 
105:384‚Äì90. https://doi.org/10.1136/heartjnl-2018-313746 
366. Parikh V, Kim C, Siegel RJ, Arsanjani R, Rader F. Natriuretic peptides for risk stratification of patients with valvular aortic stenosis. Circ Heart Fail 2015;8:373‚Äì80. https://doi. 
org/10.1161/CIRCHEARTFAILURE.114.001649 
367. Banovic M, Putnik S, Da Costa BR, Penicka M, Deja MA, Kotrc M, et al. Aortic valve 
replacement versus conservative treatment in asymptomatic severe aortic stenosis: 
long-term follow-up of the AVATAR trial. Eur Heart J 2024;45:4526‚Äì35. https://doi. 
org/10.1093/eurheartj/ehae585 
368. G√©n√©reux P, Banovic M, Kang DH, Giustino G, Prendergast BD, Lindman BR, et al. 
Aortic valve replacement vs clinical surveillance in asymptomatic severe aortic stenosis: 
a systematic review and meta-analysis. J Am Coll Cardiol 2024;85:912‚Äì22. https://doi. 
org/10.1016/j.jacc.2024.11.006 
369. Smith WTI, Ferguson TBJ, Ryan T, Landolfo CK, Peterson ED. Should coronary artery 
bypass graft surgery patients with mild or moderate aortic stenosis undergo concomitant aortic valve replacement? A decision analysis approach to the surgical dilemma. J 
Am Coll Cardiol 2004;44:1241‚Äì7. https://doi.org/10.1016/j.jacc.2004.06.031 
370. Jean G, Van Mieghem NM, Gegenava T, van Gils L, Bernard J, Geleijnse ML, et al. 
Moderate aortic stenosis in patients with heart failure and reduced ejection fraction. 
J Am Coll Cardiol 2021;77:2796‚Äì803. https://doi.org/10.1016/j.jacc.2021.04.014 
371. Jacquemyn X, Strom JB, Strange G, Playford D, Stewart S, Kutty S, et al. Moderate aortic valve stenosis is associated with increased mortality rate and lifetime loss: systematic review and meta-analysis of reconstructed time-to-event data of 409 680 patients. 
J Am Heart Assoc 2024;13:e033872. https://doi.org/10.1161/jaha.123.033872 
372. Amanullah MR, Pio SM, Ng ACT, Sin KYK, Marsan NA, Ding ZP, et al. Prognostic implications of associated cardiac abnormalities detected on echocardiography in patients with moderate aortic stenosis. JACC Cardiovasc Imaging 2021;14:1724‚Äì37.  
https://doi.org/10.1016/j.jcmg.2021.04.009 
373. Van Mieghem NM, Elmariah S, Spitzer E, Pibarot P, Nazif TM, Bax JJ, et al. 
Transcatheter aortic valve replacement in patients with systolic heart failure and moderate aortic stenosis: TAVR UNLOAD. J Am Coll Cardiol 2024;85:878‚Äì90. https://doi. 
org/10.1016/j.jacc.2024.10.070 
374. Graversen PL, Butt JH, √òstergaard L, Jensen AD, Warming PE, Strange JE, et al. 
Changes in aortic valve replacement procedures in Denmark from 2008 to 2020. 
Heart 2023;109:557‚Äì63. https://doi.org/10.1136/heartjnl-2022-321594 
375. Johnston DR, Soltesz EG, Vakil N, Rajeswaran J, Roselli EE, Sabik JF 3rd, et al. Long-term 
durability of bioprosthetic aortic valves: implications from 12,569 implants. Ann Thorac 
Surg 2015;99:1239‚Äì47. https://doi.org/10.1016/j.athoracsur.2014.10.070 
376. Goldstone AB, Chiu P, Baiocchi M, Lingala B, Patrick WL, Fischbein MP, et al. 
Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement. N 
Engl J Med 2017;377:1847‚Äì57. https://doi.org/10.1056/NEJMoa1613792 
377. Mazine A, David TE, Stoklosa K, Chung J, Lafreniere-Roula M, Ouzounian M. Improved 
outcomes following the Ross procedure compared with bioprosthetic aortic valve replacement. J Am Coll Cardiol 2022;79:993‚Äì1005. https://doi.org/10.1016/j.jacc.2021.12. 
026 
378. Notenboom ML, Melina G, Veen KM, De Robertis F, Coppola G, De Siena P, et al. 
Long-term clinical and echocardiographic outcomes following the Ross procedure: a 
post hoc analysis of a randomized clinical trial. JAMA Cardiology 2023;9:6‚Äì14. https:// 
doi.org/10.1001/jamacardio.2023.4090 
379. Alkhouli M, Zack CJ, Sarraf M, Bashir R, Nishimura RA, Eleid MF, et al. Morbidity and 
mortality associated with balloon aortic valvuloplasty: a national perspective. Circ 
Cardiovasc Interv 2017;10:e004481. https://doi.org/10.1161/CIRCINTERVENTIONS. 
116.004481 
380. Sharma T, Krishnan AM, Lahoud R, Polomsky M, Dauerman HL. National trends in 
TAVR and SAVR for patients with severe isolated aortic stenosis. J Am Coll Cardiol 
2022;80:2054‚Äì6. https://doi.org/10.1016/j.jacc.2022.08.787 
381. Gaede L, Blumenstein J, Eckel C, Grothusen C, Tiyerili V, S√∂temann D, et al. 
Transcatheter-based aortic valve replacement vs. isolated surgical aortic valve replacement in 2020. Clin Res Cardiol 2022;111:924‚Äì33. https://doi.org/10.1007/s00392-022- 
02006-1 
382. Nguyen V, Willner N, Eltchaninoff H, Burwash IG, Michel M, Durand E, et al. Trends in 
aortic valve replacement for aortic stenosis: a French nationwide study. Eur Heart J 
2022;43:666‚Äì79. https://doi.org/10.1093/eurheartj/ehab773 
383. Mori M, Gupta A, Wang Y, Vahl T, Nazif T, Kirtane AJ, et al. Trends in transcatheter 
and surgical aortic valve replacement among older adults in the United States. J Am Coll 
Cardiol 2021;78:2161‚Äì72. https://doi.org/10.1016/j.jacc.2021.09.855 
384. Pilgrim T, Windecker S. Expansion of transcatheter aortic valve implantation: new indications and socio-economic considerations. Eur Heart J 2018;39:2643‚Äì45. https:// 
doi.org/10.1093/eurheartj/ehy228 
385. Durko AP, Osnabrugge RL, Van Mieghem NM, Milojevic M, Mylotte D, Nkomo VT, 
et al. Annual number of candidates for transcatheter aortic valve implantation per 
country: current estimates and future projections. Eur Heart J 2018;39:2635‚Äì42.  
https://doi.org/10.1093/eurheartj/ehy107 
386. Barbato E, Noc M, Baumbach A, Dudek D, Bunc M, Skalidis E, et al. Mapping interventional cardiology in Europe: the European Association of Percutaneous Cardiovascular 
Interventions (EAPCI) Atlas project. Eur Heart J 2020;41:2579‚Äì88. https://doi.org/10. 
1093/eurheartj/ehaa475 
387. Benfari G, Essayagh B, Michelena HI, Ye Z, Inojosa JM, Ribichini FL, et al. Severe aortic 
stenosis: secular trends of incidence and outcomes. Eur Heart J 2024;45:1877‚Äì86.  
https://doi.org/10.1093/eurheartj/ehad887 
388. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter 
aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N 
Engl J Med 2010;363:1597‚Äì607. https://doi.org/10.1056/NEJMoa1008232 
389. Gleason TG, Reardon MJ, Popma JJ, Deeb GM, Yakubov SJ, Lee JS, et al. 5-Year outcomes of self-expanding transcatheter versus surgical aortic valve replacement in high- 
risk patients. J Am Coll Cardiol 2018;72:2687‚Äì96. https://doi.org/10.1016/j.jacc.2018.08. 
2146 
390. Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, et al. 5-Year outcomes 
of transcatheter aortic valve replacement or surgical aortic valve replacement for high 
surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. 
Lancet 2015;385:2477‚Äì84. https://doi.org/10.1016/S0140-6736(15)60308-7 
391. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter 
versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364: 
2187‚Äì98. https://doi.org/10.1056/NEJMoa1103510 
392. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter 
or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016; 
374:1609‚Äì20. https://doi.org/10.1056/NEJMoa1514616 
393. Toff WD, Hildick-Smith D, Kovac J, Mullen MJ, Wendler O, Mansouri A, et al. Effect of 
transcatheter aortic valve implantation vs surgical aortic valve replacement on all-cause 
mortality in patients with aortic stenosis: a randomized clinical trial. JAMA 2022;327: 
1875‚Äì87. https://doi.org/10.1001/jama.2022.5776 
394. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O‚ÄôHair D, et al. Transcatheter 
aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J 
Med 2019;380:1706‚Äì15. https://doi.org/10.1056/NEJMoa1816885 
395. Blankenberg S, Seiffert M, Vonthein R, Baumgartner H, Bleiziffer S, Borger MA, et al. 
Transcatheter or surgical treatment of aortic-valve stenosis. N Engl J Med 2024;390: 
1572‚Äì83. https://doi.org/10.1056/NEJMoa2400685 
396. Makkar RR, Thourani VH, Mack MJ, Kodali SK, Kapadia S, Webb JG, et al. Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med 2020;382: 
799‚Äì809. https://doi.org/10.1056/NEJMoa1910555 
397. Van Mieghem NM, Deeb GM, S√∏ndergaard L, Grube E, Windecker S, Gada H, et al. 
Self-expanding transcatheter vs surgical aortic valve replacement in intermediate-risk 
patients: 5-year outcomes of the SURTAVI randomized clinical trial. JAMA Cardiol 
2022;7:1000‚Äì8. https://doi.org/10.1001/jamacardio.2022.2695 
398. Thyregod HGH, J√∏rgensen TH, Ihlemann N, Steinbr√ºchel DA, Nissen H, Kjeldsen BJ, 
et al. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the 
NOTION trial. Eur Heart J 2024;45:1116‚Äì24. https://doi.org/10.1093/eurheartj/ 
ehae043 
399. Ahmad Y, Howard JP, Arnold AD, Madhavan MV, Cook CM, Alu M, et al. 
Transcatheter versus surgical aortic valve replacement in lower-risk and higher-risk patients: a meta-analysis of randomized trials. Eur Heart J 2023;44:836‚Äì52. https://doi. 
org/10.1093/eurheartj/ehac642 
400. Barili F, Brophy JM, Ronco D, Myers PO, Uva MS, Almeida RMS, et al. Risk of bias in 
randomized clinical trials comparing transcatheter and surgical aortic valve replacement: a systematic review and meta-analysis. JAMA Netw Open 2023;6:e2249321.  
https://doi.org/10.1001/jamanetworkopen.2022.49321 
401. Siontis GCM, Overtchouk P, Cahill TJ, Modine T, Prendergast B, Praz F, et al. 
Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J 
2019;40:3143‚Äì53. https://doi.org/10.1093/eurheartj/ehz275 
402. Pibarot P, Hahn RT, Weissman NJ, Arsenault M, Beaudoin J, Bernier M, et al. 
Association of paravalvular regurgitation with 1-year outcomes after transcatheter 
aortic valve replacement with the SAPIEN 3 valve. JAMA Cardiol 2017;2:1208‚Äì16.  
https://doi.org/10.1001/jamacardio.2017.3425 
403. Kodali S, Pibarot P, Douglas PS, Williams M, Xu K, Thourani V, et al. Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve 
in the PARTNER trial: characterizing patients and impact on outcomes. Eur Heart J 
2015;36:449‚Äì56. https://doi.org/10.1093/eurheartj/ehu384  
ESC Guidelines                                                                                                                                                                                               87


<!-- PAGE 88 -->

### Page 88

404. Lerman TT, Levi A, Kornowski R. Meta-analysis of short- and long-term clinical outcomes of the self-expanding Evolut R/pro valve versus the balloon-expandable 
Sapien 3 valve for transcatheter aortic valve implantation. Int J Cardiol 2023;371: 
100‚Äì8. https://doi.org/10.1016/j.ijcard.2022.09.035 
405. Faroux L, Chen S, Muntan√©-Carol G, Regueiro A, Philippon F, Sondergaard L, et al. 
Clinical impact of conduction disturbances in transcatheter aortic valve replacement 
recipients: a systematic review and meta-analysis. Eur Heart J 2020;41:2771‚Äì81.  
https://doi.org/10.1093/eurheartj/ehz924 
406. Greason KL, Lahr BD, Stulak JM, Cha YM, Rea RF, Schaff HV, et al. Long-term mortality 
effect of early pacemaker implantation after surgical aortic valve replacement. Ann 
Thorac Surg 2017;104:1259‚Äì64. https://doi.org/10.1016/j.athoracsur.2017.01.083 
407. R√ºck A, Saleh N, Glaser N. Outcomes following permanent pacemaker implantation 
after transcatheter aortic valve replacement: SWEDEHEART observational study. 
JACC Cardiovasc Interv 2021;14:2173‚Äì81. https://doi.org/10.1016/j.jcin.2021.07.043 
408. Baron SJ, Wang K, House JA, Magnuson EA, Reynolds MR, Makkar R, et al. 
Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients 
with severe aortic stenosis at intermediate risk. Circulation 2019;139:877‚Äì88. https:// 
doi.org/10.1161/CIRCULATIONAHA.118.035236 
409. Tam DY, Azizi PM, Fremes SE, Chikwe J, Gaudino M, Wijeysundera HC. The cost- 
effectiveness of transcatheter aortic valve replacement in low surgical risk patients 
with severe aortic stenosis. Eur Heart J Qual Care Clin Outcomes 2021;7:556‚Äì63.  
https://doi.org/10.1093/ehjqcco/qcaa058 
410. Pibarot P, Ternacle J, Jaber WA, Salaun E, Dahou A, Asch FM, et al. Structural deterioration of transcatheter versus surgical aortic valve bioprostheses in the PARTNER-2 
trial. J Am Coll Cardiol 2020;76:1830‚Äì43. https://doi.org/10.1016/j.jacc.2020.08.049 
411. Fatima B, Mohananey D, Khan FW, Jobanputra Y, Tummala R, Banerjee K, et al. 
Durability data for bioprosthetic surgical aortic valve: a systematic review. JAMA 
Cardiol 2019;4:71‚Äì80. https://doi.org/10.1001/jamacardio.2018.4045 
412. Kedhi E, Hermanides RS, Dambrink JE, Singh SK, Ten Berg JM, van Ginkel D, et al. 
TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and 
coronary bypass grafting for treatment of patients with aortic valve stenosis and complex or multivessel coronary disease (TCW): an international, multicentre, prospective, open-label, non-inferiority, randomised controlled trial. Lancet 2025;404: 
2593‚Äì602. https://doi.org/10.1016/s0140-6736(24)02100-7 
413. Martinsson A, Nielsen SJ, Milojevic M, Redfors B, Omerovic E, Tonnessen T, et al. Life 
expectancy after surgical aortic valve replacement. J Am Coll Cardiol 2021;78:2147‚Äì57.  
https://doi.org/10.1016/j.jacc.2021.09.861 
414. Glaser N, Persson M, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. Loss in 
life expectancy after surgical aortic valve replacement: SWEDEHEART study. J Am Coll 
Cardiol 2019;74:26‚Äì33. https://doi.org/10.1016/j.jacc.2019.04.053 
415. Attinger-Toller A, Ferrari E, Tueller D, Templin C, Muller O, Nietlispach F, et al. 
Age-related outcomes after transcatheter aortic valve replacement: insights from 
the SwissTAVI registry. JACC Cardiovasc Interv 2021;14:952‚Äì60. https://doi.org/10. 
1016/j.jcin.2021.01.042 
416. J√∏rgensen TH, Thyregod HGH, Savontaus M, Willemen Y, Bleie √ò, Tang M, et al. 
Transcatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic stenosis: the NOTION-2 trial. Eur Heart J 2024;45:3804‚Äì14. https://doi.org/10.1093/ 
eurheartj/ehae331 
417. Dahle TG, Kaneko T, McCabe JM. Outcomes following subclavian and axillary artery 
access for transcatheter aortic valve replacement: Society of the Thoracic Surgeons/ 
American College of Cardiology TVT registry report. JACC Cardiovasc Interv 2019; 
12:662‚Äì9. https://doi.org/10.1016/j.jcin.2019.01.219 
418. Gleason TG, Schindler JT, Hagberg RC, Deeb GM, Adams DH, Conte JV, et al. 
Subclavian/axillary access for self-expanding transcatheter aortic valve replacement 
renders equivalent outcomes as transfemoral. Ann Thorac Surg 2018;105:477‚Äì83.  
https://doi.org/10.1016/j.athoracsur.2017.07.017 
419. Kirker E, Korngold E, Hodson RW, Jones BM, McKay R, Cheema M, et al. Transcarotid 
versus subclavian/axillary access for transcatheter aortic valve replacement with 
SAPIEN 3. Ann Thorac Surg 2020;110:1892‚Äì7. https://doi.org/10.1016/j.athoracsur. 
2020.05.141 
420. Debry N, Trimech TR, Gandet T, Vincent F, Hysi I, Delhaye C, et al. Transaxillary compared with transcarotid access for TAVR: a propensity-matched comparison from a 
French multicentre registry. EuroIntervention 2020;16:842‚Äì9. https://doi.org/10.4244/ 
eij-d-20-00117 
421. Beurtheret S, Karam N, Resseguier N, Houel R, Modine T, Folliguet T, et al. Femoral 
versus nonfemoral peripheral access for transcatheter aortic valve replacement. J Am 
Coll Cardiol 2019;74:2728‚Äì39. https://doi.org/10.1016/j.jacc.2019.09.054 
422. Greenbaum AB, Babaliaros VC, Chen MY, Stine AM, Rogers T, O‚ÄôNeill WW, et al. 
Transcaval access and closure for transcatheter aortic valve replacement: a prospective investigation. J Am Coll Cardiol 2017;69:511‚Äì21. https://doi.org/10.1016/j.jacc.2016. 
10.024 
423. Lederman RJ, Babaliaros VC, Lisko JC, Rogers T, Mahoney P, Foerst JR, et al. Transcaval 
versus transaxillary TAVR in contemporary practice: a propensity-weighted analysis. 
JACC Cardiovasc Interv 2022;15:965‚Äì75. https://doi.org/10.1016/j.jcin.2022.03.014 
424. Okuno T, Asami M, Heg D, Lanz J, Praz F, Hagemeyer D, et al. Impact of left ventricular 
outflow tract calcification on procedural outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Interv 2020;13:1789‚Äì99. https://doi.org/10.1016/j.jcin. 
2020.04.015 
425. Barbanti M, Yang TH, Rod√®s Cabau J, Tamburino C, Wood DA, Jilaihawi H, et al. 
Anatomical and procedural features associated with aortic root rupture during 
balloon-expandable transcatheter aortic valve replacement. Circulation 2013;128: 
244‚Äì53. https://doi.org/10.1161/circulationaha.113.002947 
426. Kirmani BH, Jones SG, Muir A, Malaisrie SC, Chung DA, Williams RJ, et al. Limited versus full sternotomy for aortic valve replacement. Cochrane Database Syst Rev 2023;12: 
CD011793. https://doi.org/10.1002/14651858.CD011793.pub3 
427. Paparella D, Malvindi PG, Santarpino G, Moscarelli M, Guida P, Fattouch K, et al. Full 
sternotomy and minimal access approaches for surgical aortic valve replacement: a 
multicentre propensity-matched study. Eur J Cardiothorac Surg 2020;57:709‚Äì16.  
https://doi.org/10.1093/ejcts/ezz286 
428. Vincent F, Ternacle J, Denimal T, Shen M, Redfors B, Delhaye C, et al. Transcatheter 
aortic valve replacement in bicuspid aortic valve stenosis. Circulation 2021;143: 
1043‚Äì61. https://doi.org/10.1161/CIRCULATIONAHA.120.048048 
429. Alperi A, Voisine P, Kalavrouziotis D, Dumont E, Dagenais F, Perron J, et al. Aortic 
valve replacement in low-risk patients with severe aortic stenosis outside randomized 
trials. J Am Coll Cardiol 2021;77:111‚Äì23. https://doi.org/10.1016/j.jacc.2020.10.056 
430. Makkar RR, Yoon SH, Leon MB, Chakravarty T, Rinaldi M, Shah PB, et al. Association 
between transcatheter aortic valve replacement for bicuspid vs tricuspid aortic stenosis and mortality or stroke. JAMA 2019;321:2193‚Äì202. https://doi.org/10.1001/jama. 
2019.7108 
431. Halim SA, Edwards FH, Dai D, Li Z, Mack MJ, Holmes DR, et al. Outcomes of transcatheter aortic valve replacement in patients with bicuspid aortic valve disease: a report from the Society of Thoracic Surgeons/American College of Cardiology 
Transcatheter Valve Therapy Registry. Circulation 2020;141:1071‚Äì9. https://doi.org/ 
10.1161/CIRCULATIONAHA.119.040333 
432. Forrest JK, Kaple RK, Ramlawi B, Gleason TG, Meduri CU, Yakubov SJ, et al. 
Transcatheter aortic valve replacement in bicuspid versus tricuspid aortic valves 
from the STS/ACC TVT registry. JACC Cardiovasc Interv 2020;13:1749‚Äì59. https:// 
doi.org/10.1016/j.jcin.2020.03.022 
433. Montalto C, Sticchi A, Crimi G, Laricchia A, Khokhar AA, Giannini F, et al. Outcomes 
after transcatheter aortic valve replacement in bicuspid versus tricuspid anatomy: a 
systematic review and meta-analysis. JACC Cardiovasc Interv 2021;14:2144‚Äì55.  
https://doi.org/10.1016/j.jcin.2021.07.052 
434. Yoon SH, Bleiziffer S, De Backer O, Delgado V, Arai T, Ziegelmueller J, et al. Outcomes 
in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve 
stenosis. J Am Coll Cardiol 2017;69:2579‚Äì89. https://doi.org/10.1016/j.jacc.2017.03.017 
435. Jilaihawi H, Chen M, Webb J, Himbert D, Ruiz CE, Rod√©s-Cabau J, et al. A bicuspid aortic valve imaging classification for the TAVR era. JACC Cardiovasc Imaging 2016;9: 
1145‚Äì58. https://doi.org/10.1016/j.jcmg.2015.12.022 
436. S√° MPBO, Zhigalov K, Cavalcanti LRP, Escorel Neto AC, Rayol SC, Weymann A, et al. 
Impact of aortic annulus enlargement on the outcomes of aortic valve replacement: a 
meta-analysis. Semin Thorac Cardiovasc Surg 2021;33:316‚Äì25. https://doi.org/10.1053/j. 
semtcvs.2020.06.046 
437. Head SJ, Reardon MJ, Deeb GM, Van Mieghem NM, Popma JJ, Gleason TG, et al. 
Computed tomography-based indexed aortic annulus size to predict prosthesis- 
patient mismatch. Circ Cardiovasc Interv 2019;12:e007396. https://doi.org/10.1161/ 
circinterventions.118.007396 
438. Herrmann HC, Mehran R, Blackman DJ, Bailey S, M√∂llmann H, Abdel-Wahab M, et al. 
Self-expanding or balloon-expandable TAVR in patients with a small aortic annulus. N 
Engl J Med 2024;390:1959‚Äì71. https://doi.org/10.1056/NEJMoa2312573 
439. Yokoyama Y, Kuno T, Zaid S, Kaneko T, Takagi H, Tang GHL, et al. Surgical explantation of transcatheter aortic bioprosthesis: a systematic review and meta-analysis. 
JTCVS Open 2021;8:207‚Äì27. https://doi.org/10.1016/j.xjon.2021.09.023 
440. Marin-Cuartas M, Tang GHL, Kiefer P, Fukuhara S, Lange R, Harrington KB, et al. 
Transcatheter heart valve explant with infective endocarditis-associated prosthesis 
failure and outcomes: the EXPLANT-TAVR international registry. Eur Heart J 2024; 
45:2519‚Äì32. https://doi.org/10.1093/eurheartj/ehae292 
441. Hirji SA, Percy ED, McGurk S, Malarczyk A, Harloff MT, Yazdchi F, et al. Incidence, 
characteristics, predictors, and outcomes of surgical explantation after transcatheter 
aortic valve replacement. J Am Coll Cardiol 2020;76:1848‚Äì59. https://doi.org/10.1016/ 
j.jacc.2020.08.048 
442. Jawitz OK, Gulack BC, Grau-Sepulveda MV, Matsouaka RA, Mack MJ, Holmes DR Jr, 
et al. Reoperation after transcatheter aortic valve replacement: an analysis of the 
Society of Thoracic Surgeons database. JACC Cardiovasc Interv 2020;13:1515‚Äì25.  
https://doi.org/10.1016/j.jcin.2020.04.029 
443. Hawkins RB, Deeb GM, Sukul D, Patel HJ, Gualano SK, Chetcuti SJ, et al. Redo surgical 
aortic valve replacement after prior transcatheter versus surgical aortic valve replacement. JACC Cardiovasc Interv 2023;16:942‚Äì53. https://doi.org/10.1016/j.jcin.2023.03. 
015 
444. Bapat VN, Zaid S, Fukuhara S, Saha S, Vitanova K, Kiefer P, et al. Surgical explantation 
after TAVR failure: mid-term outcomes from the EXPLANT-TAVR international


<!-- PAGE 89 -->

### Page 89

registry. JACC Cardiovasc Interv 2021;14:1978‚Äì91. https://doi.org/10.1016/j.jcin.2021. 
07.015 
445. Bowdish ME, Habib RH, Kaneko T, Thourani VH, Badhwar V. Cardiac surgery after 
transcatheter aortic valve replacement: trends and outcomes. Ann Thorac Surg 2024; 
118:155‚Äì62. https://doi.org/10.1016/j.athoracsur.2024.03.024 
446. Landes U, Webb JG, De Backer O, Sondergaard L, Abdel-Wahab M, Crusius L, et al. 
Repeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunction. J Am Coll Cardiol 2020;75:1882‚Äì93. https://doi.org/10.1016/j.jacc.2020.02.051 
447. Tam DY, Dharma C, Rocha RV, Ouzounian M, Wijeysundera HC, Austin PC, et al. 
Transcatheter ViV versus redo surgical AVR for the management of failed biological 
prosthesis: early and late outcomes in a propensity-matched cohort. JACC Cardiovasc 
Interv 2020;13:765‚Äì74. https://doi.org/10.1016/j.jcin.2019.10.030 
448. S√° MBPO, Van den Eynde J, Simonato M, Cavalcanti LRP, Doulamis IP, Weixler V, et al. 
Valve-in-valve transcatheter aortic valve replacement versus redo surgical aortic valve 
replacement: an updated meta-analysis. JACC Cardiovasc Interv 2021;14:211‚Äì20. https:// 
doi.org/10.1016/j.jcin.2020.10.020 
449. Percy ED, Harloff MT, Hirji S, McGurk S, Yazdchi F, Newell P, et al. Nationally representative repeat transcatheter aortic valve replacement outcomes: report from the 
centers for Medicare and Medicaid services. JACC Cardiovasc Interv 2021;14: 
1717‚Äì26. https://doi.org/10.1016/j.jcin.2021.06.011 
450. Makkar RR, Kapadia S, Chakravarty T, Cubeddu RJ, Kaneko T, Mahoney P, et al. 
Outcomes of repeat transcatheter aortic valve replacement with balloon-expandable 
valves: a registry study. Lancet 2023;402:1529‚Äì40. https://doi.org/10.1016/s0140- 
6736(23)01636-7 
451. Deharo P, Bisson A, Herbert J, Lacour T, Etienne CS, Porto A, et al. Transcatheter 
valve-in-valve aortic valve replacement as an alternative to surgical re-replacement. J 
Am Coll Cardiol 2020;76:489‚Äì99. https://doi.org/10.1016/j.jacc.2020.06.010 
452. Dismorr M, Glaser N, Franco-Cereceda A, Sartipy U. Effect of prosthesis-patient mismatch on long-term clinical outcomes after bioprosthetic aortic valve replacement. J 
Am Coll Cardiol 2023;81:964‚Äì75. https://doi.org/10.1016/j.jacc.2022.12.023 
453. Head SJ, Mokhles MM, Osnabrugge RL, Pibarot P, Mack MJ, Takkenberg JJ, et al. The 
impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement: a systematic review and meta-analysis of 34 observational studies comprising 27 
186 patients with 133 141 patient-years. Eur Heart J 2012;33:1518‚Äì29. https://doi.org/ 
10.1093/eurheartj/ehs003 
454. Herrmann HC, Daneshvar SA, Fonarow GC, Stebbins A, Vemulapalli S, Desai ND, 
et al. Prosthesis‚Äìpatient mismatch in patients undergoing transcatheter aortic valve replacement: from the STS/ACC TVT registry. J Am Coll Cardiol 2018;72:2701‚Äì11.  
https://doi.org/10.1016/j.jacc.2018.09.001 
455. Ternacle J, Pibarot P, Herrmann HC, Kodali S, Leipsic J, Blanke P, et al. 
Prosthesis-patient mismatch after aortic valve replacement in the PARTNER 2 trial 
and registry. JACC Cardiovasc Interv 2021;14:1466‚Äì77. https://doi.org/10.1016/j.jcin. 
2021.03.069 
456. Akodad M, Sellers S, Landes U, Meier D, Tang Gilbert HL, Gada H, et al. 
Balloon-expandable valve for treatment of Evolut valve failure. JACC Cardiovasc Interv 
2022;15:368‚Äì77. https://doi.org/10.1016/j.jcin.2021.12.021 
457. Ribeiro HB, Rod√©s-Cabau J, Blanke P, Leipsic J, Kwan Park J, Bapat V, et al. Incidence, 
predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the 
VIVID registry. Eur Heart J 2018;39:687‚Äì95. https://doi.org/10.1093/eurheartj/ehx455 
458. Ochiai T, Oakley L, Sekhon N, Komatsu I, Flint N, Kaewkes D, et al. Risk of coronary 
obstruction due to sinus sequestration in redo transcatheter aortic valve replacement. 
JACC Cardiovasc Interv 2020;13:2617‚Äì27. https://doi.org/10.1016/j.jcin.2020.09.022 
459. Akodad M, Sellers S, Gulsin GS, Tzimas G, Landes U, Chatfield Andrew G, et al. Leaflet 
and neoskirt height in transcatheter heart valves. JACC Cardiovasc Interv 2021;14: 
2298‚Äì300. https://doi.org/10.1016/j.jcin.2021.07.034 
460. Tang GH, Spencer J, Rogers T, Grubb KJ, Gleason P, Gada H, et al. Feasibility of coronary access following redo-TAVR for Evolut failure: a computed tomography simulation study. Circ Cardiovasc Interv 2023;16:e013238. https://doi.org/10.1161/ 
CIRCINTERVENTIONS.123.013238 
461. De Backer O, Landes U, Fuchs A, Yoon SH, Mathiassen ON, Sedaghat A, et al. 
Coronary access after TAVR-in-TAVR as evaluated by multidetector computed tomography. JACC Cardiovasc Interv 2020;13:2528‚Äì38. https://doi.org/10.1016/j.jcin.2020. 
06.016 
462. Fukui M, Okada A, Thao KR, Burns MR, Koike H, Wang C, et al. Feasibility of redo- 
transcatheter aortic valve replacement in Sapien valves based on in vivo computed 
tomography assessment. Circ Cardiovasc Interv 2023;16:e013497. https://doi.org/10. 
1161/CIRCINTERVENTIONS.123.013497 
463. Chhatriwalla AK, Allen KB, Depta JP, Rodriguez E, Thourani VH, Whisenant BK, et al. 
Outcomes of bioprosthetic valve fracture in patients undergoing valve-in-valve TAVR. 
JACC Cardiovasc Interv 2023;16:530‚Äì9. https://doi.org/10.1016/j.jcin.2022.12.019 
464. Khan JM, Babaliaros VC, Greenbaum AB, Spies C, Daniels D, Depta JP, et al. Preventing 
coronary obstruction during transcatheter aortic valve replacement: results from the 
multicenter international BASILICA registry. JACC Cardiovasc Interv 2021;14:941‚Äì8.  
https://doi.org/10.1016/j.jcin.2021.02.035 
465. J√∏rgensen TH, Thyregod HGH, Ihlemann N, Nissen H, Petursson P, Kjeldsen BJ, et al. 
Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement. Eur Heart J 2021;42: 
2912‚Äì9. https://doi.org/10.1093/eurheartj/ehab375 
466. O‚ÄôHair D, Yakubov SJ, Grubb KJ, Oh JK, Ito S, Deeb GM, et al. Structural valve deterioration after self-expanding transcatheter or surgical aortic valve implantation in patients at intermediate or high risk. JAMA Cardiol 2023;8:111‚Äì9. https://doi.org/10. 
1001/jamacardio.2022.4627 
467. Rodriguez-Gabella T, Voisine P, Puri R, Pibarot P, Rod√©s-Cabau J. Aortic bioprosthetic 
valve durability: incidence, mechanisms, predictors, and management of surgical and 
transcatheter valve degeneration. J Am Coll Cardiol 2017;70:1013‚Äì28. https://doi.org/ 
10.1016/j.jacc.2017.07.715 
468. Pibarot P, Magne J, Leipsic J, Cote N, Blanke P, Thourani VH, et al. Imaging for predicting and assessing prosthesis-patient mismatch after aortic valve replacement. JACC 
Cardiovasc Imaging 2019;12:149‚Äì62. https://doi.org/10.1016/j.jcmg.2018.10.020 
469. Freitas-Ferraz Afonso B, Tirado-Conte G, Dagenais F, Ruel M, Al-Atassi T, Dumont E, 
et al. Aortic stenosis and small aortic annulus. Circulation 2019;139:2685‚Äì702. https:// 
doi.org/10.1161/CIRCULATIONAHA.118.038408 
470. Tang GHL, Zaid S, Fuchs A, Yamabe T, Yazdchi F, Gupta E, et al. Alignment of transcatheter aortic-valve neo-commissures (ALIGN TAVR): impact on final valve orientation and coronary artery overlap. JACC Cardiovasc Interv 2020;13:1030‚Äì42. https://doi. 
org/10.1016/j.jcin.2020.02.005 
471. Kapadia SR, Leon MB, Makkar RR, Tuzcu EM, Svensson LG, Kodali S, et al. 5-Year outcomes of transcatheter aortic valve replacement compared with standard treatment 
for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled 
trial. Lancet 2015;385:2485‚Äì91. https://doi.org/10.1016/S0140-6736(15)60290-2 
472. Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, et al. 
Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl 
J Med 2012;366:1696‚Äì704. https://doi.org/10.1056/NEJMoa1202277 
473. Turina J, Hess O, Sepulcri F, Krayenbuehl HP. Spontaneous course of aortic valve disease. Eur Heart J 1987;8:471‚Äì83. https://doi.org/10.1093/oxfordjournals.eurheartj. 
a062307 
474. Pellikka PA, Nishimura RA, Bailey KR, Tajik AJ. The natural history of adults with 
asymptomatic, hemodynamically significant aortic stenosis. J Am Coll Cardiol 1990;15: 
1012‚Äì7. https://doi.org/10.1016/0735-1097(90)90234-g 
475. Mangner N, Stachel G, Woitek F, Haussig S, Schlotter F, Hollriegel R, et al. Predictors of 
mortality and symptomatic outcome of patients with low-flow severe aortic stenosis 
undergoing transcatheter aortic valve replacement. J Am Heart Assoc 2018;7:e007977.  
https://doi.org/10.1161/JAHA.117.007977 
476. Eleid MF, Padang R, Al-Hijji M, Pislaru SV, Greason KL, Maltais S, et al. Hemodynamic 
response in low-flow low-gradient aortic stenosis with preserved ejection fraction 
after TAVR. J Am Coll Cardiol 2019;73:1731‚Äì2. https://doi.org/10.1016/j.jacc.2019.01. 
034 
477. Rusinaru D, Bohbot Y, Ringle A, Marechaux S, Diouf M, Tribouilloy C. Impact of low 
stroke volume on mortality in patients with severe aortic stenosis and preserved left 
ventricular ejection fraction. Eur Heart J 2018;39:1992‚Äì9. https://doi.org/10.1093/ 
eurheartj/ehy123 
478. Zheng Q, Djohan AH, Lim E, Ding ZP, Ling LH, Shi L, et al. Effects of aortic valve replacement on severe aortic stenosis and preserved systolic function: systematic review 
and network meta-analysis. Sci Rep 2017;7:5092. https://doi.org/10.1038/s41598-017- 
05021-9 
479. Salaun E, Clavel MA, Hahn RT, Jaber WA, Asch FM, Rodriguez L, et al. Outcome of 
flow-gradient patterns of aortic stenosis after aortic valve replacement: an analysis 
of the PARTNER 2 trial and registry. Circ Cardiovasc Interv 2020;13:e008792. https:// 
doi.org/10.1161/CIRCINTERVENTIONS.119.008792 
480. Annabi MS, C√¥t√© N, Dahou A, Bartko PE, Bergler-Klein J, Burwash IG, et al. 
Comparison of early surgical or transcatheter aortic valve replacement versus conservative management in low-flow, low-gradient aortic stenosis using inverse probability 
of treatment weighting: results from the TOPAS prospective observational cohort 
study. J Am Heart Assoc 2020;9:e017870. https://doi.org/10.1161/jaha.120.017870 
481. Mosleh W, Amer MR, Ding Y, Megaly M, Mather JF, McMahon S, et al. Benefit of transcatheter aortic valve replacement in patients with paradoxical low-flow low-gradient 
versus high-gradient aortic stenosis and preserved left ventricular function. Circ 
Cardiovasc Interv 2021;14:e010042. https://doi.org/10.1161/circinterventions.120. 
010042 
482. Bohbot Y, Kowalski C, Rusinaru D, Ringle A, Marechaux S, Tribouilloy C. Impact of 
mean transaortic pressure gradient on long-term outcome in patients with severe aortic stenosis and preserved left ventricular ejection fraction. J Am Heart Assoc 2017;6: 
e005850. https://doi.org/10.1161/JAHA.117.005850 
483. Costa GNF, Cardoso JFL, Oliveiros B, Gon√ßalves L, Teixeira R. Early surgical intervention versus conservative management of asymptomatic severe aortic stenosis: a systematic review and meta-analysis. Heart 2023;109:314‚Äì21. https://doi.org/10.1136/ 
heartjnl-2022-321411 
484. Bohbot Y, Rusinaru D, Delpierre Q, Marechaux S, Tribouilloy C. Risk stratification of 
severe aortic stenosis with preserved left ventricular ejection fraction using peak aortic  
ESC Guidelines                                                                                                                                                                                               89


<!-- PAGE 90 -->

### Page 90

jet velocity: an outcome study. Circ Cardiovasc Imaging 2017;10:e006760. https://doi. 
org/10.1161/CIRCIMAGING.117.006760 
485. Adams DH, Popma JJ, Reardon MJ. Transcatheter aortic-valve replacement with a self- 
expanding prosthesis. N Engl J Med 2014;371:967‚Äì8. https://doi.org/10.1056/ 
NEJMc1408396 
486. Thyregod HGH, Steinbr√ºchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, 
et al. Transcatheter versus surgical aortic valve replacement in patients with severe 
aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical 
trial. J Am Coll Cardiol 2015;65:2184‚Äì94. https://doi.org/10.1016/j.jacc.2015.03.014 
487. Thourani VH, Suri RM, Gunter RL, Sheng S, O‚ÄôBrien SM, Ailawadi G, et al. 
Contemporary real-world outcomes of surgical aortic valve replacement in 141,905 
low-risk, intermediate-risk, and high-risk patients. Ann Thorac Surg 2015;99:55‚Äì61.  
https://doi.org/10.1016/j.athoracsur.2014.06.050 
488. Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V, et al. 
Transcatheter aortic valve replacement versus surgical valve replacement in 
intermediate-risk patients: a propensity score analysis. Lancet 2016;387:2218‚Äì25.  
https://doi.org/10.1016/s0140-6736(16)30073-3 
489. Coylewright M, Grubb KJ, Arnold SV, Batchelor W, Dhoble A, Horne A Jr, et al. 
Outcomes of balloon-expandable transcatheter aortic valve replacement in younger 
patients in the low-risk era. JAMA Cardiol 2025;10:127‚Äì35. https://doi.org/10.1001/ 
jamacardio.2024.4237 
490. Ullah W, DiMeglio M, Sana MK, Muhammadzai HZU, Kochar K, Zahid S, et al. 
Outcomes after transcatheter aortic valve implantation in patients excluded from clinical trials. JACC Adv 2023;2:100271. https://doi.org/10.1016/j.jacadv.2023.100271 
491. Reents W, Barth S, Griese DP, Winkler S, Babin-Ebell J, Kerber S, et al. Transfemoral 
versus transapical transcatheter aortic valve implantation: a single-centre experience. 
Eur J Cardiothorac Surg 2019;55:744‚Äì50. https://doi.org/10.1093/ejcts/ezy363 
492. Allen KB, Chhatriwalla AK, Cohen D, Saxon J, Hawa Z, Kennedy KF, et al. Transcarotid 
versus transapical and transaortic access for transcatheter aortic valve replacement. 
Ann Thorac Surg 2019;108:715‚Äì22. https://doi.org/10.1016/j.athoracsur.2019.02.007 
493. Overtchouk P, Folliguet T, Pinaud F, Fouquet O, Pernot M, Bonnet G, et al. 
Transcarotid approach for transcatheter aortic valve replacement with the Sapien 3 
prosthesis. JACC Cardiovasc Interv 2019;12:413‚Äì9. https://doi.org/10.1016/j.jcin.2018. 
11.014 
494. Kumar N, Khera R, Fonarow GC, Bhatt DL. Comparison of outcomes of transfemoral 
versus transapical approach for transcatheter aortic valve implantation. Am J Cardiol 
2018;122:1520‚Äì6. https://doi.org/10.1016/j.amjcard.2018.07.025 
495. van Wely M, van Nieuwkerk AC, Rooijakkers M, van der Wulp K, Gehlmann H, 
Verkroost M, et al. Transaxillary versus transfemoral access as default access in 
TAVI: a propensity matched analysis. Int J Cardiol 2024;394:131353. https://doi.org/ 
10.1016/j.ijcard.2023.131353 
496. Allen KB, Watson D, Vora AN, Mahoney P, Chhatriwalla AK, Schwartz JG, et al. 
Transcarotid versus transaxillary access for transcatheter aortic valve replacement 
with a self-expanding valve: a propensity-matched analysis. JTCVS Tech 2023;21: 
45‚Äì55. https://doi.org/10.1016/j.xjtc.2023.07.019 
497. Salihu A, Ferlay C, Kirsch M, Shah PB, Skali H, Fournier S, et al. Outcomes and safety of 
transcaval transcatheter aortic valve replacement: a systematic review and 
meta-analysis. Can J Cardiol 2024;40:2054‚Äì62. https://doi.org/10.1016/j.cjca.2024.05. 
016 
498. Abraham B, Sous M, Sedhom R, Megaly M, Roman S, Sweeney J, et al. Meta-analysis on 
transcarotid versus transfemoral and other alternate accesses for transcatheter aortic 
valve implantation. Am J Cardiol 2023;192:196‚Äì205. https://doi.org/10.1016/j.amjcard. 
2023.01.023 
499. Williams MR, Jilaihawi H, Makkar R, O‚ÄôNeill WW, Guyton R, Malaisrie SC, et al. The 
PARTNER 3 bicuspid registry for transcatheter aortic valve replacement in 
low-surgical-risk patients. JACC Cardiovasc Interv 2022;15:523‚Äì32. https://doi.org/10. 
1016/j.jcin.2022.01.279 
500. Waksman R, Craig PE, Torguson R, Asch FM, Weissman G, Ruiz D, et al. Transcatheter 
aortic valve replacement in low-risk patients with symptomatic severe bicuspid aortic 
valve stenosis. JACC Cardiovasc Interv 2020;13:1019‚Äì27. https://doi.org/10.1016/j.jcin. 
2020.02.008 
501. Elbadawi A, Saad M, Elgendy IY, Barssoum K, Omer MA, Soliman A, et al. Temporal 
trends and outcomes of transcatheter versus surgical aortic valve replacement for bicuspid aortic valve stenosis. JACC Cardiovasc Interv 2019;12:1811‚Äì22. https://doi.org/ 
10.1016/j.jcin.2019.06.037 
502. Tch√©tch√© D, Ziviello F, De Biase C, De Backer O, Hovasse T, Leroux L, et al. 
Transcatheter aortic valve implantation with the Evolut platform for bicuspid aortic 
valve stenosis: the international, multicentre, prospective BIVOLUTX registry. 
EuroIntervention 2023;19:502‚Äì11. https://doi.org/10.4244/eij-d-23-00021 
503. Yang L-T, Boler A, Medina-Inojosa Jose R, Scott Christopher G, Maurer Matthew J, 
Eleid Mackram F, et al. Aortic stenosis progression, cardiac damage, and survival. 
JACC Cardiovasc Imaging 2021;14:1113‚Äì26. https://doi.org/10.1016/j.jcmg.2021.01.017 
504. Strange G, Stewart S, Celermajer D, Prior D, Scalia GM, Marwick T, et al. Poor long- 
term survival in patients with moderate aortic stenosis. J Am Coll Cardiol 2019;74: 
1851‚Äì63. https://doi.org/10.1016/j.jacc.2019.08.004 
505. Samad Z, Vora AN, Dunning A, Schulte PJ, Shaw LK, Al-Enezi F, et al. Aortic valve surgery and survival in patients with moderate or severe aortic stenosis and left ventricular dysfunction. Eur Heart J 2016;37:2276‚Äì86. https://doi.org/10.1093/eurheartj/ 
ehv701 
506. Oz A, Tsoumas I, Lampropoulos K, Xanthos T, Karpettas N, Papadopoulos D. Cardiac 
rehabilitation after TAVI‚Äîa systematic review and meta-analysis. Curr Probl Cardiol 
2023;48:101531. https://doi.org/10.1016/j.cpcardiol.2022.101531 
507. Monteagudo Ruiz JM, Galderisi M, Buonauro A, Badano L, Aruta P, Swaans MJ, et al. 
Overview of mitral regurgitation in Europe: results from the European Registry of mitral regurgitation (EuMiClip). Eur Heart J Cardiovasc Imaging 2018;19:503‚Äì7. https://doi. 
org/10.1093/ehjci/jey011 
508. Nalliah CJ, Mahajan R, Elliott AD, Haqqani H, Lau DH, Vohra JK, et al. Mitral valve prolapse and sudden cardiac death: a systematic review and meta-analysis. Heart 2019; 
105:144‚Äì51. https://doi.org/10.1136/heartjnl-2017-312932 
509. Van der Bijl P, Stassen J, Haugaa KH, Essayagh B, Basso C, Thiene G, et al. Mitral annular 
disjunction in the context of mitral valve prolapse: identifying the at-risk patient. JACC 
Cardiovasc Imaging 2024;17:1229‚Äì45. https://doi.org/10.1016/j.jcmg.2024.03.006 
510. Antoine C, Benfari G, Michelena HI, Maalouf JF, Nkomo VT, Thapa P, et al. Clinical outcome of degenerative mitral regurgitation. Circulation 2018;138:1317‚Äì26. https://doi. 
org/10.1161/CIRCULATIONAHA.117.033173 
511. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V, 
et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. 
N Engl J Med 2005;352:875‚Äì83. https://doi.org/10.1056/NEJMoa041451 
512. O‚ÄôGara PT, Grayburn PA, Badhwar V, Afonso LC, Carroll JD, Elmariah S, et al. 2017 
ACC Expert Consensus Decision Pathway on the management of mitral regurgitation: 
a report of the American College of Cardiology Task Force on Expert Consensus 
Decision Pathways. J Am Coll Cardiol 2017;70:2421‚Äì49. https://doi.org/10.1016/j.jacc. 
2017.09.019 
513. Dziadzko V, Dziadzko M, Medina-Inojosa JR, Benfari G, Michelena HI, Crestanello JA, 
et al. Causes and mechanisms of isolated mitral regurgitation in the community: clinical 
context and outcome. Eur Heart J 2019;40:2194‚Äì202. https://doi.org/10.1093/ 
eurheartj/ehz314 
514. Samad Z, Shaw LK, Phelan M, Glower DD, Ersboll M, Toptine JH, et al. Long-term outcomes of mitral regurgitation by type and severity. Am Heart J 2018;203:39‚Äì48. https:// 
doi.org/10.1016/j.ahj.2018.05.001 
515. Bakkestrom R, Banke A, Christensen NL, Pecini R, Irmukhamedov A, Andersen M, 
et al. Hemodynamic characteristics in significant symptomatic and asymptomatic primary mitral valve regurgitation at rest and during exercise. Circ Cardiovasc Imaging 
2018;11:e007171. https://doi.org/10.1161/CIRCIMAGING.117.007171 
516. Utsunomiya H, Hidaka T, Susawa H, Izumi K, Harada Y, Kinoshita M, et al. 
Exercise-stress echocardiography and effort intolerance in asymptomatic/minimally 
symptomatic patients with degenerative mitral regurgitation combined invasive- 
noninvasive hemodynamic monitoring. Circ Cardiovasc Imaging 2018;11:e007282.  
https://doi.org/10.1161/CIRCIMAGING.117.007282 
517. Butcher SC, Essayagh B, Steyerberg EW, Benfari G, Antoine C, Grigioni F, et al. Factors 
influencing post-surgical survival in degenerative mitral regurgitation. Eur Heart J 2023; 
44:871‚Äì81. https://doi.org/10.1093/eurheartj/ehad004 
518. Grigioni F, Clavel MA, Vanoverschelde JL, Tribouilloy C, Pizarro R, Huebner M, et al. 
The MIDA mortality risk score: development and external validation of a prognostic 
model for early and late death in degenerative mitral regurgitation. Eur Heart J 2018; 
39:1281‚Äì91. https://doi.org/10.1093/eurheartj/ehx465 
519. Del Rio-Pertuz G, Nugent K, Argueta-Sosa E. Right heart catheterization in clinical 
practice: a review of basic physiology and important issues relevant to interpretation. 
Am J Cardiovasc Dis 2023;13:122‚Äì37. 
520. Mentias A, Patel K, Patel H, Gillinov AM, Rodriguez LL, Svensson LG, et al. Prognostic 
utility of brain natriuretic peptide in asymptomatic patients with significant mitral regurgitation and preserved left ventricular ejection fraction. Am J Cardiol 2016;117: 
258‚Äì63. https://doi.org/10.1016/j.amjcard.2015.10.040 
521. Cawley PJ, Hamilton-Craig C, Owens DS, Krieger EV, Strugnell WE, Mitsumori L, et al. 
Prospective comparison of valve regurgitation quantitation by cardiac magnetic resonance imaging and transthoracic echocardiography. Circ Cardiovasc Imaging 2013;6: 
48‚Äì57. https://doi.org/10.1161/CIRCIMAGING.112.975623 
522. Penicka M, Vecera J, Mirica DC, Kotrc M, Kockova R, Van Camp G. Prognostic implications of magnetic resonance-derived quantification in asymptomatic patients with organic mitral regurgitation: comparison with Doppler echocardiography-derived 
integrative 
approach. 
Circulation 
2018;137:1349‚Äì60. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.117.029332 
523. Naoum C, Blanke P, Cavalcante JL, Leipsic J. Cardiac computed tomography and magnetic resonance imaging in the evaluation of mitral and tricuspid valve disease. Circ 
Cardiovasc Imaging 2017;10:e005331. https://doi.org/10.1161/CIRCIMAGING.116. 
005331 
524. Kitkungvan D, Nabi F, Kim RJ, Bonow RO, Khan MA, Xu J, et al. Myocardial fibrosis in 
patients with primary mitral regurgitation with and without prolapse. J Am Coll Cardiol 
2018;72:823‚Äì34. https://doi.org/10.1016/j.jacc.2018.06.048


<!-- PAGE 91 -->

### Page 91

525. Garg P, Swift AJ, Zhong L, Carlhall CJ, Ebbers T, Westenberg J, et al. Assessment of 
mitral valve regurgitation by cardiovascular magnetic resonance imaging. Nat Rev 
Cardiol 2020;17:298‚Äì312. https://doi.org/10.1038/s41569-019-0305-z 
526. Feuchtner GM, Alkadhi H, Karlo C, Sarwar A, Meier A, Dichtl W, et al. Cardiac CT 
angiography for the diagnosis of mitral valve prolapse: comparison with echocardiography. Radiology 2010;254:374‚Äì83. https://doi.org/10.1148/radiol.2541090393 
527. Gollmann-Tepek√∂yl√º C, N√§gele F, H√∂fer D, Holfeld J, Hirsch J, Oezpeker CU, et al. A 
qualitative improvement program for minimally invasive mitral surgery: technical advancements ameliorate outcome and operative times. Interdiscip Cardiovasc Thorac 
Surg 2023;36:ivad030. https://doi.org/10.1093/icvts/ivad030 
528. Tarzia P, Ciampi P, Lanza O, Canali E, Canestrelli S, Cal√≤ L. Multi-modality imaging for 
pre-procedural planning of transcatheter mitral valve interventions. Eur Heart J Suppl 
2023;25:C205‚Äì11. https://doi.org/10.1093/eurheartjsupp/suad021 
529. Eleid MF, Foley TA, Said SM, Pislaru SV, Rihal CS. Severe mitral annular calcification: 
multimodality imaging for therapeutic strategies and interventions. JACC Cardiovasc 
Imaging 2016;9:1318‚Äì37. https://doi.org/10.1016/j.jcmg.2016.09.001 
530. Roselli C, Yu M, Nauffal V, Georges A, Yang Q, Love K, et al. Genome-wide association 
study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse. Eur 
Heart J 2022;43:1668‚Äì80. https://doi.org/10.1093/eurheartj/ehac049 
531. Badhwar V, Chikwe J, Gillinov AM, Vemulapalli S, O‚ÄôGara PT, Mehaffey JH, et al. Risk of 
surgical mitral valve repair for primary mitral regurgitation. J Am Coll Cardiol 2023;81: 
636‚Äì48. https://doi.org/10.1016/j.jacc.2022.11.017 
532. Lazam S, Vanoverschelde JL, Tribouilloy C, Grigioni F, Suri RM, Avierinos JF, et al. 
Twenty-year outcome after mitral repair versus replacement for severe degenerative 
mitral regurgitation: analysis of a large, prospective, multicenter, international registry. 
Circulation 
2017;135:410‚Äì22. 
https://doi.org/10.1161/CIRCULATIONAHA.116. 
023340 
533. David TE, David CM, Tsang W, Lafreniere-Roula M, Manlhiot C. Long-term results of 
mitral valve repair for regurgitation due to leaflet prolapse. J Am Coll Cardiol 2019;74: 
1044‚Äì53. https://doi.org/10.1016/j.jacc.2019.06.052 
534. Deja MA, Malinowski M, Widenka K, Stozynski N, Bartus K, Kapelak B, et al. 
Comparison of repair vs replacement in calcific and rheumatic mitral disease. Ann 
Thorac Surg 2023;116:954‚Äì61. https://doi.org/10.1016/j.athoracsur.2023.04.048 
535. Brescia AA, Watt TMF, Murray SL, Rosenbloom LM, Kleeman KC, Allgeyer H, et al. 
Rheumatic mitral valve repair or replacement in the valve-in-valve era. J Thorac 
Cardiovasc Surg 2022;163:591‚Äì602.e1. https://doi.org/10.1016/j.jtcvs.2020.04.118 
536. Chen SW, Chen CY, Chien-Chia Wu V, Chou AH, Cheng YT, Chang SH, et al. Mitral 
valve repair versus replacement in patients with rheumatic heart disease. J Thorac 
Cardiovasc Surg 2022;164:57‚Äì67.e11. https://doi.org/10.1016/j.jtcvs.2020.07.117 
537. Yun KL, Sintek CF, Miller DC, Pfeffer TA, Kochamba GS, Khonsari S, et al. Randomized 
trial comparing partial versus complete chordal-sparing mitral valve replacement: effects on left ventricular volume and function. J Thorac Cardiovasc Surg 2002;123: 
707‚Äì14. https://doi.org/10.1067/mtc.2002.121048 
538. Makkar RR, Chikwe J, Chakravarty T, Chen Q, O‚ÄôGara PT, Gillinov M, et al. 
Transcatheter mitral valve repair for degenerative mitral regurgitation. JAMA 2023; 
329:1778‚Äì88. https://doi.org/10.1001/jama.2023.7089 
539. von Bardeleben RS, Mahoney P, Morse MA, Price MJ, Denti P, Maisano F, et al. 1-Year 
outcomes with fourth-generation mitral valve transcatheter edge-to-edge repair from 
the EXPAND G4 study. JACC Cardiovasc Interv 2023;16:2600‚Äì10. https://doi.org/10. 
1016/j.jcin.2023.09.029 
540. Zahr F, Smith RL, Gillam LD, Chadderdon S, Makkar R, von Bardeleben RS, et al. 
One-year outcomes from the CLASP IID randomized trial for degenerative mitral regurgitation. JACC Cardiovasc Interv 2023;15:2803‚Äì16. https://doi.org/10.1016/j.jcin. 
2023.10.002 
541. Kaneko T, Hirji S, Zaid S, Lange R, Kempfert J, Conradi L, et al. Mitral valve surgery after 
transcatheter edge-to-edge repair: mid-term outcomes from the CUTTING-EDGE 
international registry. JACC Cardiovasc Interv 2021;14:2010‚Äì21. https://doi.org/10. 
1016/j.jcin.2021.07.029 
542. Wild MG, Kreidel F, Hell MM, Praz F, Mach M, Adam M, et al. Transapical mitral valve 
implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience. Eur J Heart Fail 2022;24:899‚Äì907. https://doi.org/10.1002/ejhf.2434 
543. Ludwig S, Perrin N, Coisne A, Ben Ali W, Weimann J, Duncan A, et al. Clinical outcomes of transcatheter mitral valve replacement: two-year results of the 
CHOICE-MI Registry. EuroIntervention 2023;19:512‚Äì25. https://doi.org/10.4244/EIJ- 
D-22-01037 
544. Suri RM, Vanoverschelde JL, Grigioni F, Schaff HV, Tribouilloy C, Avierinos J-F, et al. 
Association between early surgical intervention vs watchful waiting and outcomes 
for mitral regurgitation due to flail mitral valve leaflets. JAMA 2013;310:609‚Äì16.  
https://doi.org/10.1001/jama.2013.8643 
545. Tribouilloy C, Grigioni F, Avierinos JF, Barbieri A, Rusinaru D, Szymanski C, et al. 
Survival implication of left ventricular end-systolic diameter in mitral regurgitation 
due to flail leaflets a long-term follow-up multicenter study. J Am Coll Cardiol 2009; 
54:1961‚Äì68. https://doi.org/10.1016/j.jacc.2009.06.047 
546. Tribouilloy C, Rusinaru D, Grigioni F, Avierinos JF, Vanoverschelde JL, Benfari G, et al. 
Indexing left ventricular end-systolic dimension to body size: association with mortality 
in patients with degenerative mitral regurgitation. Eur J Heart Fail 2024;26:2563‚Äì9.  
https://doi.org/10.1002/ejhf.3393 
547. Essayagh B, Antoine C, Benfari G, Messika-Zeitoun D, Michelena H, Le Tourneau T, 
et al. Prognostic implications of left atrial enlargement in degenerative mitral regurgitation. J Am Coll Cardiol 2019;74:858‚Äì70. https://doi.org/10.1016/j.jacc.2019.06.032 
548. Abadie BQ, Cremer PC, Vakamudi S, Gillinov AM, Svensson LG, Cho L. Sex-specific 
prognosis of left ventricular size and function following repair of degenerative mitral 
regurgitation. J Am Coll Cardiol 2024;83:303‚Äì12. https://doi.org/10.1016/j.jacc.2023. 
10.033 
549. Dejgaard LA, Skjolsvik ET, Lie OH, Ribe M, Stokke MK, Hegbom F, et al. The mitral 
annulus disjunction arrhythmic syndrome. J Am Coll Cardiol 2018;72:1600‚Äì9. https:// 
doi.org/10.1016/j.jacc.2018.07.070 
550. Essayagh B, Sabbag A, Antoine C, Benfari G, Batista R, Yang LT, et al. The mitral annular 
disjunction of mitral valve prolapse: presentation and outcome. JACC Cardiovasc 
Imaging 2021;14:2073‚Äì87. https://doi.org/10.1016/j.jcmg.2021.04.029 
551. Essayagh B, Sabbag A, Antoine C, Benfari G, Yang LT, Maalouf J, et al. Presentation and 
outcome of arrhythmic mitral valve prolapse. J Am Coll Cardiol 2020;76:637‚Äì49. https:// 
doi.org/10.1016/j.jacc.2020.06.029 
552. Weiner MM, Boateng P, Pandis D, Miller MA, Adams DH. Impact of mitral valve repair 
on the Pickelhaube sign. Eur Heart J 2019;40:2267. https://doi.org/10.1093/eurheartj/ 
ehy458 
553. Pandis D, David N, Ei-Eshmawi A, Miller MA, Boateng P, Costa AC, et al. Noncomplex 
ventricular arrhythmia associated with greater freedom from recurrent ectopy at 1 
year after mitral repair surgery. JTCVS Open 2024;19:94‚Äì113. https://doi.org/10. 
1016/j.xjon.2024.04.005 
554. Bonaros N, Hoefer D, Oezpeker C, Gollmann-Tepekoylu C, Holfeld J, Dumfarth J, 
et al. Predictors of safety and success in minimally invasive surgery for degenerative mitral disease. Eur J Cardiothorac Surg 2022;61:637‚Äì44. https://doi.org/10.1093/ejcts/ 
ezab438 
555. Berretta P, Kempfert J, Van Praet F, Salvador L, Lamelas J, Nguyen TC, et al. 
Risk-related clinical outcomes after minimally invasive mitral valve surgery: insights 
from the Mini-Mitral International Registry. Eur J Cardiothorac Surg 2023;63:ezad090.  
https://doi.org/10.1093/ejcts/ezad090 
556. Pfannmueller B, Misfeld M, Verevkin A, Garbade J, Holzhey DM, Davierwala P, et al. 
Loop neochord versus leaflet resection techniques for minimally invasive mitral valve 
repair: long-term results. Eur J Cardiothorac Surg 2021;59:180‚Äì6. https://doi.org/10. 
1093/ejcts/ezaa255 
557. Akowuah EF, Maier RH, Hancock HC, Kharatikoopaei E, Vale L, Fernandez-Garcia C, 
et al. Minithoracotomy vs conventional sternotomy for mitral valve repair: a randomized clinical trial. JAMA 2023;329:1957‚Äì66. https://doi.org/10.1001/jama.2023.7800 
558. Olsthoorn JR, Heuts S, Houterman S, Maessen JG, Sardari Nia P. Effect of minimally 
invasive mitral valve surgery compared to sternotomy on short- and long-term outcomes: a retrospective multicentre interventional cohort study based on 
Netherlands Heart Registration. Eur J Cardiothorac Surg 2022;61:1099‚Äì106. https:// 
doi.org/10.1093/ejcts/ezab507 
559. Lang M, Vitanova K, Voss B, Feirer N, Rheude T, Krane M, et al. Beyond the 10-year 
horizon: mitral valve repair solely with chordal replacement and annuloplasty. Ann 
Thorac Surg 2023;115:96‚Äì103. https://doi.org/10.1016/j.athoracsur.2022.05.036 
560. Newell P, Percy E, Hirji S, Harloff M, McGurk S, Malarczyk A, et al. Outcomes of mitral 
valve repair among high- and low-volume surgeons within a high-volume institution. 
Ann Thorac Surg 2023;115:412‚Äì19. https://doi.org/10.1016/j.athoracsur.2022.05.057 
561. Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation 2006;113:2238‚Äì44.  
https://doi.org/10.1161/CIRCULATIONAHA.105.599175 
562. Grigioni F, Benfari G, Vanoverschelde JL, Tribouilloy C, Avierinos JF, Bursi F, et al. 
Long-term implications of atrial fibrillation in patients with degenerative mitral regurgitation. J Am Coll Cardiol 2019;73:264‚Äì74. https://doi.org/10.1016/j.jacc.2018.10.067 
563. Ratwatte S, Strange G, Playford D, Stewart S, Celermajer DS. Prevalence of pulmonary 
hypertension in mitral regurgitation and its influence on outcomes. Open Heart 2023; 
10:e002268. https://doi.org/10.1136/openhrt-2023-002268 
564. Essayagh B, Antoine C, Benfari G, Maalouf J, Michelena HI, Crestanello JA, et al. 
Functional tricuspid regurgitation of degenerative mitral valve disease: a crucial determinant of survival. Eur Heart J 2020;41:1918‚Äì29. https://doi.org/10.1093/eurheartj/ 
ehaa192 
565. Essayagh B, Benfari G, Antoine C, Grigioni F, Le Tourneau T, Roussel JC, et al. The 
MIDA-Q mortality risk score: a quantitative prognostic tool for the mitral valve prolapse spectrum. Circulation 2023;147:798‚Äì811. https://doi.org/10.1161/CIRCULA 
TIONAHA.122.062612 
566. Benfari G, Sorajja P, Pedrazzini G, Taramasso M, Gavazzoni M, Biasco L, et al. 
Association of transcatheter edge-to-edge repair with improved survival in older patients with severe, symptomatic degenerative mitral regurgitation. Eur Heart J 2022; 
43:1626‚Äì35. https://doi.org/10.1093/eurheartj/ehab910 
567. Speziale G, Nasso G, Esposito G, Conte M, Greco E, Fattouch K, et al. Results of mitral 
valve repair for Barlow disease (bileaflet prolapse) via right minithoracotomy versus 
conventional median sternotomy: a randomized trial. J Thorac Cardiovasc Surg 2011; 
142:77‚Äì83. https://doi.org/10.1016/j.jtcvs.2010.08.033  
ESC Guidelines                                                                                                                                                                                               91


<!-- PAGE 92 -->

### Page 92

568. Zilberszac R, Heinze G, Binder T, Laufer G, Gabriel H, Rosenhek R. Long-term outcome of active surveillance in severe but asymptomatic primary mitral regurgitation. 
JACC Cardiovasc Imaging 2018;11:1213‚Äì21. https://doi.org/10.1016/j.jcmg.2018.05.014 
569. Sengupta A, Yazdchi F, Alexis SL, Percy E, Premkumar A, Hirji S, et al. Reoperative mitral surgery versus transcatheter mitral valve replacement: a systematic review. J Am 
Heart Assoc 2021;10:e019854. https://doi.org/10.1161/JAHA.120.019854 
570. Simonato M, Whisenant B, Ribeiro HB, Webb JG, Kornowski R, Guerrero M, et al. 
Transcatheter mitral valve replacement after surgical repair or replacement: comprehensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the 
VIVID 
registry. 
Circulation 
2021;143:104‚Äì16. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.120.049088 
571. Sugiura A, Kavsur R, Spieker M, Iliadis C, Goto T, √ñzt√ºrk C, et al. Recurrent mitral regurgitation after MitraClip: predictive factors, morphology, and clinical implication. Circ 
Cardiovasc Interv 2022;15:e010895. https://doi.org/10.1161/CIRCINTERVENTIONS. 
121.010895 
572. Zaid S, Avvedimento M, Vitanova K, Akansel S, Bhadra OD, Ascione G, et al. Impact of 
mitral regurgitation etiology on mitral surgery after transcatheter edge-to-edge repair: 
from the CUTTING-EDGE registry. JACC Cardiovasc Interv 2023;16:1176‚Äì88. https:// 
doi.org/10.1016/j.jcin.2023.02.029 
573. Bartkowiak J, Reineke D, Tomii D, Brugger N, Pilgrim T, Terbeck S, et al. Electrosurgical 
laceration and stabilization of MitraClip followed by valve implantation for iatrogenic 
mitral stenosis. JACC Cardiovasc Interv 2022;15:110‚Äì12. https://doi.org/10.1016/j.jcin. 
2021.10.011 
574. Lisko JC, Greenbaum AB, Guyton RA, Kamioka N, Grubb KJ, Gleason PT, et al. 
Electrosurgical detachment of MitraClips from the anterior mitral leaflet prior to 
transcatheter mitral valve implantation. JACC Cardiovasc Interv 2020;13:2361‚Äì70.  
https://doi.org/10.1016/j.jcin.2020.06.047 
575. Huang AL, Dal-Bianco JP, Levine RA, Hung JW. Secondary mitral regurgitation: cardiac 
remodeling, diagnosis, and management. Struct Heart 2022;7:100129. https://doi.org/ 
10.1016/j.shj.2022.100129 
576. Bartko PE, Heitzinger G, Pavo N, Heitzinger M, Spinka G, Prausm√ºller S, et al. Burden, 
treatment use, and outcome of secondary mitral regurgitation across the spectrum of 
heart failure: observational cohort study. BMJ 2021;373:n1421. https://doi.org/10. 
1136/bmj.n1421 
577. Deferm S, Bertrand PB, Verbrugge FH, Verhaert D, Rega F, Thomas JD, et al. Atrial 
functional mitral regurgitation: JACC review topic of the week. J Am Coll Cardiol 
2019;73:2465‚Äì76. https://doi.org/10.1016/j.jacc.2019.02.061 
578. Mori M, Zogg CK, Amabile A, Fereydooni S, Agarwal R, Weininger G, et al. Impact of 
secondary mitral regurgitation on survival in atrial and ventricular dysfunction. PLoS 
One 2022;17:e0277385. https://doi.org/10.1371/journal.pone.0277385 
579. Moonen A, Ng MKC, Playford D, Strange G, Scalia GM, Celermajer DS. Atrial functional mitral regurgitation: prevalence, characteristics and outcomes from the National 
Echo Database of Australia. Open Heart 2023;10:e002180. https://doi.org/10.1136/ 
openhrt-2022-002180 
580. Okamoto C, Okada A, Nishimura K, Moriuchi K, Amano M, Takahama H, et al. 
Prognostic comparison of atrial and ventricular functional mitral regurgitation. Open 
Heart 2021;8:e001574. https://doi.org/10.1136/openhrt-2021-001574 
581. Farhan S, Silbiger JJ, Halperin JL, Zhang L, Dukkipati SR, Vogel B, et al. Pathophysiology, 
echocardiographic diagnosis, and treatment of atrial functional mitral regurgitation: 
JACC state-of-the-art review. J Am Coll Cardiol 2022;80:2314‚Äì30. https://doi.org/10. 
1016/j.jacc.2022.09.046 
582. Naser JA, Michelena HI, Lin G, Scott CG, Lee E, Kennedy AM, et al. Incidence, risk factors, and outcomes of atrial functional mitral regurgitation in patients with atrial fibrillation or sinus rhythm. Eur Heart J Cardiovasc Imaging 2023;24:1450‚Äì7. https://doi.org/ 
10.1093/ehjci/jead199 
583. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter 
mitral-valve repair in patients with heart failure. N Engl J Med 2018;379:2307‚Äì18.  
https://doi.org/10.1056/NEJMoa1806640 
584. Stone GW, Abraham WT, Lindenfeld J, Kar S, Grayburn PA, Lim DS, et al. Five-year 
follow-up after transcatheter repair of secondary mitral regurgitation. N Engl J Med 
2023;388:2037‚Äì48. https://doi.org/10.1056/NEJMoa2300213 
585. Cavalcante JL, Kusunose K, Obuchowski NA, Jellis C, Griffin BP, Flamm SD, et al. 
Prognostic impact of ischemic mitral regurgitation severity and myocardial infarct 
quantification by cardiovascular magnetic resonance. JACC Cardiovasc Imaging 2020; 
13:1489‚Äì501. https://doi.org/10.1016/j.jcmg.2019.11.008 
586. Kim K, Kitai T, Kaji S, Pak M, Toyota T, Sasaki Y, et al. Outcomes and predictors of 
cardiac events in medically treated patients with atrial functional mitral regurgitation. 
Int J Cardiol 2020;316:195‚Äì202. https://doi.org/10.1016/j.ijcard.2020.06.042 
587. Mesi O, Gad MM, Crane AD, Ramchand J, Puri R, Layoun H, et al. Severe atrial functional mitral regurgitation: clinical and echocardiographic characteristics, management 
and outcomes. JACC Cardiovasc Imaging 2021;14:797‚Äì808. https://doi.org/10.1016/j. 
jcmg.2021.02.008 
588. Doldi P, Stolz L, Orban M, Karam N, Praz F, Kalbacher D, et al. Transcatheter mitral 
valve repair in patients with atrial functional mitral regurgitation. JACC Cardiovasc 
Imaging 2022;15:1843‚Äì51. https://doi.org/10.1016/j.jcmg.2022.05.009 
589. Masiero G, Montonati C, Rubbio AP, Adamo M, Grasso C, Denti P, et al. Impact of 
transcatheter edge-to-edge mitral valve repair on atrial functional mitral regurgitation 
from the GIOTTO registry. Am J Cardiol 2024;211:219‚Äì27. https://doi.org/10.1016/j. 
amjcard.2023.11.007 
590. Yoon SH, Makar M, Kar S, Chakravarty T, Oakley L, Sekhon N, et al. Outcomes after 
transcatheter edge-to-edge mitral valve repair according to mitral regurgitation etiology and cardiac remodeling. JACC Cardiovasc Interv 2022;15:1711‚Äì22. https://doi. 
org/10.1016/j.jcin.2022.07.004 
591. Chen QF, Zhou X, Katsouras CS, Ni C, Zhu H, Liu C, et al. Atrial and ventricular functional mitral regurgitation: prevalence, characteristics, outcomes, and disease progression. Eur Heart J Cardiovasc Imaging 2024;26:545‚Äì56. https://doi.org/10.1093/ehjci/ 
jeae309 
592. von Stein P, von Stein J, Hohmann C, Wienemann H, Guthoff H, K√∂rber MI, et al. Atrial 
functional mitral regurgitation subtypes undergoing transcatheter edge-to-edge repair: 
suboptimal outcomes in atriogenic hamstringing. JACC Cardiovasc Imaging 2025;18: 
16‚Äì29. https://doi.org/10.1016/j.jcmg.2024.06.019 
593. Rosano GMC, Moura B, Metra M, B√∂hm M, Bauersachs J, Ben Gal T, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart 
Failure Association of the European Society of Cardiology. Eur J Heart Fail 2021;23: 
872‚Äì81. https://doi.org/10.1002/ejhf.2206 
594. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, 
tolerability and efficacy of up-titration of guideline-directed medical therapies for acute 
heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 
2022;400:1938‚Äì52. https://doi.org/10.1016/s0140-6736(22)02076-1 
595. Spinka G, Bartko PE, Heitzinger G, Prausmuller S, Winter MP, Arfsten H, et al. 
Guideline directed medical therapy and reduction of secondary mitral regurgitation. 
Eur Heart J Cardiovasc Imaging 2022;23:755‚Äì64. https://doi.org/10.1093/ehjci/jeac068 
596. Pagnesi M, Adamo M, Sama IE, Anker SD, Cleland JG, Dickstein K, et al. Clinical impact 
of changes in mitral regurgitation severity after medical therapy optimization in heart 
failure. Clin Res Cardiol 2022;111:912‚Äì23. https://doi.org/10.1007/s00392-022-01991- 
7 
597. Di Biase L, Auricchio A, Mohanty P, Bai R, Kautzner J, Pieragnoli P, et al. Impact of cardiac resynchronization therapy on the severity of mitral regurgitation. Europace 2011; 
13:829‚Äì38. https://doi.org/10.1093/europace/eur047 
598. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 
ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 
2021;42:3427‚Äì520. https://doi.org/10.1093/eurheartj/ehab364 
599. Michalski B, Stankovic I, Pagourelias E, Ciarka A, Aarones M, Winter S, et al. 
Relationship of mechanical dyssynchrony and LV remodeling with improvement of mitral regurgitation after CRT. JACC Cardiovasc Imaging 2022;15:212‚Äì20. https://doi.org/ 
10.1016/j.jcmg.2021.08.010 
600. Ypenburg C, Lancellotti P, Tops LF, Bleeker GB, Holman ER, Pierard LA, et al. Acute 
effects of initiation and withdrawal of cardiac resynchronization therapy on papillary 
muscle dyssynchrony and mitral regurgitation. J Am Coll Cardiol 2007;50:2071‚Äì7.  
https://doi.org/10.1016/j.jacc.2007.08.019 
601. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al. 
Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl 
J Med 2018;379:2297‚Äì306. https://doi.org/10.1056/NEJMoa1805374 
602. Iung B, Armoiry X, Vahanian A, Boutitie F, Mewton N, Trochu JN, et al. Percutaneous 
repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. 
Eur J Heart Fail 2019;21:1619‚Äì27. https://doi.org/10.1002/EJHF.1616 
603. Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional 
mitral regurgitation: a new conceptual framework that reconciles the results of the 
MITRA-FR and COAPT trials. JACC Cardiovasc Imaging 2019;12:353‚Äì62. https://doi. 
org/10.1016/j.jcmg.2018.11.006 
604. Senni M, Adamo M, Metra M, Alfieri O, Vahanian A. Treatment of functional mitral regurgitation in chronic heart failure: can we get a ‚Äòproof of concept‚Äô from the MITRA-FR 
and COAPT trials? Eur J Heart Fail 2019;21:852‚Äì61. https://doi.org/10.1002/EJHF.1491 
605. Pibarot P, Delgado V, Bax JJ. MITRA-FR vs. COAPT: lessons from two trials with diametrically opposed results. Eur Heart J Cardiovasc Imaging 2019;20:620‚Äì24. https://doi. 
org/10.1093/ehjci/jez073 
606. Anker SD, Friede T, von Bardeleben RS, Butler J, Khan MS, Diek M, et al. Transcatheter 
valve repair in heart failure with moderate to severe mitral regurgitation. N Engl J Med 
2024;391:1799‚Äì809. https://doi.org/10.1056/NEJMoa2314328 
607. Anker MS, Porthun J, Bonnet G, Schulze PC, Rassaf T, Landmesser U. Percutaneous 
transcatheter edge-to-edge repair for functional mitral regurgitation in heart failure: 
a meta-analysis of 3 randomized controlled trials. J Am Coll Cardiol 2024;84: 
2364‚Äì68. https://doi.org/10.1016/j.jacc.2024.08.026 
608. Koell B, Orban M, Weimann J, Kassar M, Karam N, Neuss M, et al. Outcomes stratified 
by adapted inclusion criteria after mitral edge-to-edge repair. J Am Coll Cardiol 2021;78: 
2408‚Äì21. https://doi.org/10.1016/j.jacc.2021.10.011 
609. Scotti A, Latib A, Rubbio AP, Testa L, Adamo M, Denti P, et al. Derivation and validation of a clinical risk score for COAPT-ineligible patients who underwent transcatheter edge-to-edge repair. Am J Cardiol 2023;186:100‚Äì8. https://doi.org/10.1016/j. 
amjcard.2022.10.024


<!-- PAGE 93 -->

### Page 93

### 610 Godino C, Munaf√≤ A, Scotti A, Estevez-Loureiro R, Portoles Hernandez A, Arzamendi

D, et al. MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 
1-year outcomes from the International MitraBridge registry. J Heart Lung Transplant 
2020;39:1353‚Äì62. https://doi.org/10.1016/j.healun.2020.09.005 
611. Ailawadi G, Lim DS, Mack MJ, Trento A, Kar S, Grayburn PA, et al. One-year outcomes 
after MitraClip for functional mitral regurgitation. Circulation 2019;139:37‚Äì47. https:// 
doi.org/10.1161/CIRCULATIONAHA.117.031733 
612. Goel K, Lindenfeld J, Makkar R, Naik H, Atmakuri S, Mahoney P, et al. Transcatheter 
edge-to-edge repair in 5,000 patients with secondary mitral regurgitation: COAPT 
post-approval study. J Am Coll Cardiol 2023;82:1281‚Äì97. https://doi.org/10.1016/j. 
jacc.2023.07.015 
613. Adamo M, Tomasoni D, Stolz L, Stocker TJ, Pancaldi E, Koell B, et al. Impact of transcatheter edge-to-edge mitral valve repair on guideline-directed medical therapy uptitration. JACC Cardiovasc Interv 2023;16:896‚Äì905. https://doi.org/10.1016/j.jcin.2023.01. 
362 
614. Witte KK, Lipiecki J, Siminiak T, Meredith IT, Malkin CJ, Goldberg SL, et al. The 
REDUCE FMR trial: a randomized sham-controlled study of percutaneous mitral annuloplasty in functional mitral regurgitation. JACC Heart Fail 2019;7:945‚Äì55. https:// 
doi.org/10.1016/j.jchf.2019.06.011 
615. Anker SD, Starling RC, Khan MS, Friede T, Filippatos G, Lindenfeld J, et al. 
Percutaneous mitral valve annuloplasty in patients with secondary mitral regurgitation 
and severe left ventricular enlargement. JACC Heart Fail 2021;9:453‚Äì62. https://doi.org/ 
10.1016/j.jchf.2021.03.002 
616. Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral 
valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 2005;45:381‚Äì7. https://doi.org/10.1016/j. 
jacc.2004.09.073 
617. Baldus S, Doenst T, Pfister R, Gummert J, Kessler M, Boekstegers P, et al. 
Transcatheter repair versus mitral-valve surgery for secondary mitral regurgitation. 
N Engl J Med 2024;391:1787‚Äì98. https://doi.org/10.1056/NEJMoa2408739 
618. Acker MA, Parides MK, Perrault LP, Moskowitz AJ, Gelijns AC, Voisine P, et al. 
Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N 
Engl J Med 2014;370:23‚Äì32. https://doi.org/10.1056/NEJMoa1312808 
619. von Stumm M, Dudde F, Holst T, Sequeira-Gross T, Pausch J, Muller L, et al. Predicting 
clinical outcome by indexed mitral valve tenting in functional mitral valve regurgitation. 
Open Heart 2021;8:e001483. https://doi.org/10.1136/openhrt-2020-001483 
620. Girdauskas E, Pausch J, Reichenspurner H, Kempfert J, Kuntze T, Owais T, et al. 
Subannular repair for functional mitral regurgitation with reduced systolic ventricle 
function: rationale and design of REFORM-MR registry. J Cardiothorac Surg 2022;17: 
343. https://doi.org/10.1186/s13019-022-02045-9 
621. Pausch J, Sequeira Gross T, M√ºller L, von Stumm M, Kloth B, Reichenspurner H, et al. 
Subannular repair for functional mitral regurgitation type IIIb in patients with ischaemic 
versus dilated cardiomyopathy. Eur J Cardiothorac Surg 2021;60:122‚Äì30. https://doi.org/ 
10.1093/ejcts/ezab048 
622. Kopjar T, Gasparovic H, Mestres CA, Milicic D, Biocina B. Meta-analysis of concomitant mitral valve repair and coronary artery bypass surgery versus isolated coronary 
artery bypass surgery in patients with moderate ischaemic mitral regurgitation. Eur J 
Cardiothorac Surg 2016;50:212‚Äì22. https://doi.org/10.1093/ejcts/ezw022 
623. Altarabsheh SE, Deo SV, Dunlay SM, Erwin PJ, Obeidat YM, Navale S, et al. 
Meta-analysis of usefulness of concomitant mitral valve repair or replacement for 
moderate ischemic mitral regurgitation with coronary artery bypass grafting. Am J 
Cardiol 2017;119:734‚Äì41. https://doi.org/10.1016/j.amjcard.2016.11.024 
624. Michler RE, Smith PK, Parides MK, Ailawadi G, Thourani V, Moskowitz AJ, et al. 
Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. 
N Engl J Med 2016;374:1932‚Äì41. https://doi.org/10.1056/NEJMoa1602003 
625. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, 
et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis 
of five randomised controlled trials. Lancet 2022;400:757‚Äì67. https://doi.org/10. 
1016/S0140-6736(22)01429-5 
626. Soulat-Dufour L, Lang S, Addetia K, Ederhy S, Adavane-Scheuble S, Chauvet-Droit M, 
et al. Restoring sinus rhythm reverses cardiac remodeling and reduces valvular regurgitation in patients with atrial fibrillation. J Am Coll Cardiol 2022;79:951‚Äì61. https://doi. 
org/10.1016/j.jacc.2021.12.029 
627. Kagiyama N, Kaneko T, Amano M, Sato Y, Ohno Y, Obokata M, et al. Clinical outcomes 
of mitral valve surgery in atrial functional mitral regurgitation in the REVEAL-AFMR 
registry. 
JAMA 
Netw 
Open 
2024;7:e2428032. 
https://doi.org/10.1001/ 
jamanetworkopen.2024.28032 
628. Wagner CM, Brescia AA, Watt TMF, Bergquist C, Rosenbloom LM, Ceniza NN, et al. 
Surgical strategy and outcomes for atrial functional mitral regurgitation: all functional 
mitral regurgitation is not the same! J Thorac Cardiovasc Surg 2024;167:647‚Äì55. https:// 
doi.org/10.1016/j.jtcvs.2022.02.056 
629. Balogh Z, Mizukami T, Bartunek J, Collet C, Beles M, Albano M, et al. Mitral valve repair 
of atrial functional mitral regurgitation in heart failure with preserved ejection fraction. 
J Clin Med 2020;9:3432. https://doi.org/10.3390/jcm9113432 
630. Ye Q, Li Y, Zhang W, Zhao Y, Zhao C, Li Z, et al. Catheter ablation or surgical therapy 
in severe atrial functional mitral regurgitation caused by long-standing persistent atrial 
fibrillation-propensity score analysis. J Am Heart Assoc 2024;13:e035695. https://doi. 
org/10.1161/jaha.124.035695 
631. Chen J, Wang Y, Lv M, Yang Z, Zhu S, Wei L, et al. Mitral valve repair and surgical ablation for atrial functional mitral regurgitation. Ann Transl Med 2020;8:1420. https://doi. 
org/10.21037/atm-20-2958 
632. Benito-Gonz√°lez T, Carrasco-Chinchilla F, Est√©vez-Loureiro R, Pascual I, Arzamendi D, 
Garrote-Coloma C, et al. Clinical and echocardiographic outcomes of transcatheter 
mitral valve repair in atrial functional mitral regurgitation. Int J Cardiol 2021;345: 
29‚Äì35. https://doi.org/10.1016/j.ijcard.2021.09.056 
633. Popolo Rubbio A, Testa L, Grasso C, Sisinni A, Tusa M, Agricola E, et al. Transcatheter 
edge-to-edge mitral valve repair in atrial functional mitral regurgitation: insights from 
the multi-center MITRA-TUNE registry. Int J Cardiol 2022;349:39‚Äì45. https://doi. 
org/10.1016/j.ijcard.2021.11.027 
634. Rudolph F, Geyer M, Baldus S, De Luca VM, Doenst T, Pfister R, et al. Transcatheter 
repair versus surgery for atrial versus ventricular functional mitral regurgitation: a post 
hoc analysis of the MATTERHORN trial. Circulation 2024;151:418‚Äì20. https://doi.org/ 
10.1161/circulationaha.124.072648 
635. Tanaka T, Sugiura A, Vogelhuber J, √ñzt√ºrk C, B√∂hm L, Wilde N, et al. Outcomes of 
transcatheter edge-to-edge repair for atrial functional mitral regurgitation. 
EuroIntervention 2024;20:e250‚Äì60. https://doi.org/10.4244/eij-d-23-00819 
636. Gemelli M, Gallo M, Addonizio M, Van den Eynde J, Pradegan N, Danesi TH, et al. 
Surgical ablation for atrial fibrillation during mitral valve surgery: a systematic review 
and meta-analysis of randomized controlled trials. Am J Cardiol 2023;209:104‚Äì13.  
https://doi.org/10.1016/j.amjcard.2023.09.088 
637. Suwalski P, Kowalewski M, Jasi≈Ñski M, Staromlynski J, Zembala M, Widenka K, et al. 
Survival after surgical ablation for atrial fibrillation in mitral valve surgery: analysis 
from the Polish National Registry of Cardiac Surgery Procedures (KROK). J 
Thorac Cardiovasc Surg 2019;157:1007‚Äì18.e1004. https://doi.org/10.1016/j.jtcvs. 
2018.07.099 
638. Hamada S, Ueyama H, Aikawa T, Kampaktsis PN, Misumida N, Takagi H, et al. 
Outcomes of transcatheter edge-to-edge repair for atrial functional mitral regurgitation: a meta-analysis of observational studies. Catheter Cardiovasc Interv 2023;102: 
751‚Äì60. https://doi.org/10.1002/ccd.30806 
639. Sodhi N, Asch FM, Ruf T, Petrescu A, von Bardeleben S, Lim DS, et al. Clinical outcomes with transcatheter edge-to-edge repair in atrial functional MR from the 
EXPAND study. JACC Cardiovasc Interv 2022;15:1723‚Äì30. https://doi.org/10.1016/j. 
jcin.2022.07.023 
640. Deja MA, Grayburn PA, Sun B, Rao V, She L, Krejca M, et al. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. 
Circulation 
2012;125:2639‚Äì48. 
https://doi.org/10.1161/CIRCULATIONAHA.111. 
072256 
641. Chan KM, Punjabi PP, Flather M, Wage R, Symmonds K, Roussin I, et al. Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional 
ischemic mitral regurgitation: final results of the Randomized Ischemic Mitral 
Evaluation (RIME) trial. Circulation 2012;126:2502‚Äì10. https://doi.org/10.1161/ 
circulationaha.112.143818 
642. Virk SA, Tian DH, Sriravindrarajah A, Dunn D, Wolfenden HD, Suri RM, et al. 
Mitral valve surgery and coronary artery bypass grafting for moderate-to-severe 
ischemic mitral regurgitation: meta-analysis of clinical and echocardiographic outcomes. J Thorac Cardiovasc Surg 2017;154:127‚Äì36. https://doi.org/10.1016/j.jtcvs. 
2017.03.039 
643. Adamo M, Fiorelli F, Melica B, D‚ÄôOrtona R, Lupi L, Giannini C, et al. COAPT-like profile 
predicts long-term outcomes in patients with secondary mitral regurgitation undergoing MitraClip implantation. JACC Cardiovasc Interv 2021;14:15‚Äì25. https://doi.org/10. 
1016/J.JCIN.2020.09.050 
644. Coffey S, Roberts-Thomson R, Brown A, Carapetis J, Chen M, Enriquez-Sarano M, 
et al. Global epidemiology of valvular heart disease. Nat Rev Cardiol 2021;18:853‚Äì64.  
https://doi.org/10.1038/s41569-021-00570-z 
645. Kingue S, Ba SA, Balde D, Diarra MB, Anzouan-Kacou JB, Anisubia B, et al. The 
VALVAFRIC study: a registry of rheumatic heart disease in Western and Central 
Africa. Arch Cardiovasc Dis 2016;109:321‚Äì9. https://doi.org/10.1016/j.acvd.2015. 
12.004 
646. Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, et al. European 
Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J 2022;43: 
716‚Äì99. https://doi.org/10.1093/eurheartj/ehab892 
647. Churchill TW, Yucel E, Deferm S, Levine RA, Hung J, Bertrand PB. Mitral valve dysfunction in patients with annular calcification: JACC review topic of the week. J Am Coll 
Cardiol 2022;80:739‚Äì51. https://doi.org/10.1016/j.jacc.2022.05.032 
648. Andell P, Li X, Martinsson A, Andersson C, Stagmo M, Zoller B, et al. Epidemiology of 
valvular heart disease in a Swedish nationwide hospital-based register study. Heart 
2017;103:1696‚Äì703. https://doi.org/10.1136/heartjnl-2016-310894 
649. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. 
Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009;22:1‚Äì23; quiz 101‚Äì102. https://doi.org/10. 
1016/j.echo.2008.11.029  
ESC Guidelines                                                                                                                                                                                               93


<!-- PAGE 94 -->

### Page 94

650. Otto CM, Davis KB, Reid CL, Slater JN, Kronzon I, Kisslo KB, et al. Relation between 
pulmonary artery pressure and mitral stenosis severity in patients undergoing balloon 
mitral commissurotomy. Am J Cardiol 1993;71:874‚Äì8. https://doi.org/10.1016/0002- 
9149(93)90844-3 
651. Bouleti C, Iung B, Laouenan C, Himbert D, Brochet E, Messika-Zeitoun D, et al. Late 
results of percutaneous mitral commissurotomy up to 20 years: development and validation of a risk score predicting late functional results from a series of 912 patients. 
Circulation 
2012;125:2119‚Äì27. 
https://doi.org/10.1161/CIRCULATIONAHA.111. 
055905 
652. Nunes MC, Tan TC, Elmariah S, do Lago R, Margey R, Cruz-Gonzalez I, et al. The echo 
score revisited: impact of incorporating commissural morphology and leaflet displacement to the prediction of outcome for patients undergoing percutaneous mitral valvuloplasty. Circulation 2014;129:886‚Äì95. https://doi.org/10.1161/CIRCULATION 
AHA.113.001252 
653. Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon 
dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 1988;60:299‚Äì308. https://doi.org/10. 
1136/hrt.60.4.299 
654. Lancellotti P, Pellikka PA, Budts W, Chaudhry FA, Donal E, Dulgheru R, et al. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations 
from the European Association of Cardiovascular Imaging and the American Society of 
Echocardiography. Eur Heart J Cardiovasc Imaging 2016;17:1191‚Äì229. https://doi.org/ 
10.1093/ehjci/jew190 
655. Brochet E, D√©taint D, Fondard O, Tazi-Mezalek A, Messika-Zeitoun D, Iung B, et al. 
Early hemodynamic changes versus peak values: what is more useful to predict occurrence of dyspnea during stress echocardiography in patients with asymptomatic mitral 
stenosis? J Am Soc Echocardiogr 2011;24:392‚Äì8. https://doi.org/10.1016/j.echo.2011.01. 
006 
656. Al Rawahi MN, Al-Maqbali JS, Al Noumani J, Al Alawi AM, Essebag V. Novel oral anticoagulants in patients with atrial fibrillation and moderate to severe mitral stenosis: a 
systematic review. Cureus 2023;15:e33222. https://doi.org/10.7759/cureus.33222 
657. Kim JY, Kim SH, Myong JP, Kim YR, Kim TS, Kim JH, et al. Outcomes of direct oral anticoagulants in patients with mitral stenosis. J Am Coll Cardiol 2019;73:1123‚Äì31. https:// 
doi.org/10.1016/j.jacc.2018.12.047 
658. Vilvanathan VK, Srinivas Prabhavathi Bhat BC, Nanjappa MC, Pandian B, Bagi V, Kasturi 
S, et al. A randomized placebo-controlled trial with amiodarone for persistent atrial 
fibrillation in rheumatic mitral stenosis after successful balloon mitral valvuloplasty. 
Indian Heart J 2016;68:671‚Äì7. https://doi.org/10.1016/j.ihj.2016.02.013 
659. Sharma G, Anantha Krishnan R, Bohra V, Ramakrishnan S, Naik N, Seth S, et al. 
Evaluation of early direct current cardioversion for maintenance of sinus rhythm in 
rheumatic atrial fibrillation following successful balloon mitral valvotomy. Indian 
Heart J 2016;68:486‚Äì92. https://doi.org/10.1016/j.ihj.2015.11.013 
660. Keenan NG, Cueff C, Cimadevilla C, Brochet E, Lepage L, Detaint D, et al. Usefulness 
of left atrial volume versus diameter to assess thromboembolic risk in mitral stenosis. 
Am J Cardiol 2010;106:1152‚Äì6. https://doi.org/10.1016/j.amjcard.2010.06.024 
661. Badheka AO, Shah N, Ghatak A, Patel NJ, Chothani A, Mehta K, et al. Balloon mitral 
valvuloplasty in the United States: a 13-year perspective. Am J Med 2014;127: 
1126.e1121‚Äì1126.e1112. https://doi.org/10.1016/j.amjmed.2014.05.015 
662. Tomai F, Gaspardone A, Versaci F, Ghini AS, Altamura L, De Luca L, et al. Twenty year 
follow-up after successful percutaneous balloon mitral valvuloplasty in a large contemporary series of patients with mitral stenosis. Int J Cardiol 2014;177:881‚Äì5. https://doi. 
org/10.1016/j.ijcard.2014.10.040 
663. Bouleti C, Iung B, Himbert D, Messika-Zeitoun D, Brochet E, Garbarz E, et al. 
Relationship between valve calcification and long-term results of percutaneous mitral 
commissurotomy for rheumatic mitral stenosis. Circ Cardiovasc Interv 2014;7:381‚Äì9.  
https://doi.org/10.1161/CIRCINTERVENTIONS.113.000858 
664. Bouleti C, Iung B, Himbert D, Brochet E, Messika-Zeitoun D, Detaint D, et al. 
Reinterventions after percutaneous mitral commissurotomy during long-term follow- 
up, up to 20 years: the role of repeat percutaneous mitral commissurotomy. Eur Heart 
J 2013;34:1923‚Äì30. https://doi.org/10.1093/eurheartj/eht097 
665. Desnos C, Iung B, Himbert D, Ducrocq G, Urena M, Cormier B, et al. Temporal trends 
on percutaneous mitral commissurotomy: 30 years of experience. J Am Heart Assoc 
2019;8:e012031. https://doi.org/10.1161/JAHA.119.012031 
666. Ambari AM, Setianto B, Santoso A, Dwiputra B, Radi B, Alkatiri AA, et al. Survival analysis of patients with rheumatic MS after PBMV compared with MVS in a 
low-to-middle-income country. Neth Heart J 2019;27:559‚Äì64. https://doi.org/10. 
1007/s12471-019-01315-x 
667. Song H, Kang DH, Kim JH, Park KM, Song JM, Choi KJ, et al. Percutaneous mitral valvuloplasty versus surgical treatment in mitral stenosis with severe tricuspid regurgitation. Circulation 2007;116:I246‚Äì50. https://doi.org/10.1161/CIRCULATIONAHA.107. 
678151 
668. Soesanto AM, Roeswita D, Atmosudigdo IS, Adiarto S, Sahara E. Clinical and hemodynamic factors associated with low gradient severe rheumatic mitral stenosis. Int J 
Angiol 2022;32:43‚Äì7. https://doi.org/10.1055/s-0042-1751231 
669. El Sabbagh A, Reddy YNV, Barros-Gomes S, Borlaug BA, Miranda WR, Pislaru SV, et al. 
Low-gradient severe mitral stenosis: hemodynamic profiles, clinical characteristics, and 
outcomes. J Am Heart Assoc 2019;8:e010736. https://doi.org/10.1161/JAHA.118. 
010736 
670. Okura H, Nakada Y, Nogi M, Ishihara S, Okamura A, Okayama S, et al. Prevalence of 
mitral annular calcification and its association with mitral valvular disease. 
Echocardiography 2021;38:1907‚Äì12. https://doi.org/10.1111/echo.15236 
671. Kato N, Padang R, Scott CG, Guerrero M, Pislaru SV, Pellikka PA. The natural history 
of severe calcific mitral stenosis. J Am Coll Cardiol 2020;75:3048‚Äì57. https://doi.org/10. 
1016/j.jacc.2020.04.049 
672. Chehab O, Roberts-Thomson R, Bivona A, Gill H, Patterson T, Pursnani A, et al. 
Management of patients with severe mitral annular calcification: JACC state-of-the-art 
review. J Am Coll Cardiol 2022;80:722‚Äì38. https://doi.org/10.1016/j.jacc.2022.06.009 
673. Okuno T, Brugger N, Asami M, Heg D, Siontis GCM, Winkel MG, et al. Clinical impact 
of mitral calcium volume in patients undergoing transcatheter aortic valve implantation. J Cardiovasc Comput Tomogr 2021;15:356‚Äì65. https://doi.org/10.1016/j.jcct. 
2020.10.003 
674. Bertrand PB, Churchill TW, Yucel E, Namasivayam M, Bernard S, Nagata Y, et al. 
Prognostic importance of the transmitral pressure gradient in mitral annular calcification with associated mitral valve dysfunction. Eur Heart J 2020;41:4321‚Äì8. https://doi. 
org/10.1093/eurheartj/ehaa819 
675. Urena M, Himbert D, Brochet E, Carrasco JL, Iung B, Nataf P, et al. Transseptal transcatheter mitral valve replacement using balloon-expandable transcatheter heart valves: 
a step-by-step approach. JACC Cardiovasc Interv 2017;10:1905‚Äì19. https://doi.org/10. 
1016/j.jcin.2017.06.069 
676. Guerrero ME, Grayburn P, Smith RLI, Sorajja P, Wang DD, Ahmad Y, et al. Diagnosis, 
classification, and management strategies for mitral annular calcification. JACC 
Cardiovasc Interv 2023;16:2195‚Äì210. https://doi.org/10.1016/j.jcin.2023.06.044 
677. Uchimuro T, Fukui T, Shimizu A, Takanashi S. Mitral valve surgery in patients with severe mitral annular calcification. Ann Thorac Surg 2016;101:889‚Äì95. https://doi.org/10. 
1016/j.athoracsur.2015.08.071 
678. Fukui M, Cavalcante JL, Ahmed A, Bae R, Bapat VN, G√∂ssl M, et al. Clinical outcomes of 
mitral valve disease with mitral annular calcification. Am J Cardiol 2022;174:107‚Äì13.  
https://doi.org/10.1016/j.amjcard.2022.03.041 
679. Kato N, Pellikka PA, Scott CG, Lee AT, Jain V, Eleid MF, et al. Impact of mitral intervention on outcomes of patients with mitral valve dysfunction and annulus calcification. 
Catheter Cardiovasc Interv 2022;99:1807‚Äì16. https://doi.org/10.1002/ccd.30093 
680. Brener MI, Hamandi M, Hong E, Pizano A, Harloff MT, Garner EF, et al. Early outcomes 
following transatrial transcatheter mitral valve replacement in patients with severe mitral annular calcification. J Thorac Cardiovasc Surg 2024;167:1263‚Äì1275.e3. https://doi. 
org/10.1016/j.jtcvs.2022.07.038 
681. Guerrero ME, Eleid MF, Wang DD, Pursnani A, Kodali SK, George I, et al. 5-Year prospective evaluation of mitral valve-in-valve, valve-in-ring, and valve-in-MAC outcomes: 
MITRAL trial final results. JACC Cardiovasc Interv 2023;16:2211‚Äì27. https://doi.org/10. 
1016/j.jcin.2023.06.041 
682. Topilsky Y, Maltais S, Medina Inojosa J, Oguz D, Michelena H, Maalouf J, et al. Burden of 
tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc 
Imaging 2019;12:433‚Äì42. https://doi.org/10.1016/j.jcmg.2018.06.014 
683. Chorin E, Rozenbaum Z, Topilsky Y, Konigstein M, Ziv-Baran T, Richert E, et al. 
Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc 
Imaging 2020;21:157‚Äì65. https://doi.org/10.1093/ehjci/jez216 
684. Topilsky Y, Inojosa JM, Benfari G, Vaturi O, Maltais S, Michelena H, et al. Clinical presentation and outcome of tricuspid regurgitation in patients with systolic dysfunction. 
Eur Heart J 2018;39:3584‚Äì92. https://doi.org/10.1093/eurheartj/ehy434 
685. Kadri AN, Menon V, Sammour YM, Gajulapalli RD, Meenakshisundaram C, Nusairat L, 
et al. Outcomes of patients with severe tricuspid regurgitation and congestive heart 
failure. Heart 2019;105:1813‚Äì7. https://doi.org/10.1136/heartjnl-2019-315004 
686. Dreyfus J, Ghalem N, Garbarz E, Cimadevilla C, Nataf P, Vahanian A, et al. Timing of 
referral of patients with severe isolated tricuspid valve regurgitation to surgeons 
(from a French nationwide database). Am J Cardiol 2018;122:323‚Äì6. https://doi.org/ 
10.1016/j.amjcard.2018.04.003 
687. Hoke U, Auger D, Thijssen J, Wolterbeek R, van der Velde ET, Holman ER, et al. 
Significant lead-induced tricuspid regurgitation is associated with poor prognosis at 
long-term follow-up. Heart 2014;100:960‚Äì8. https://doi.org/10.1136/heartjnl-2013- 
304673 
688. Andreas M, Burri H, Praz F, Soliman O, Badano L, Barreiro M, et al. Tricuspid valve disease and cardiac implantable electronic devices. Eur Heart J 2024;45:346‚Äì65. https:// 
doi.org/10.1093/eurheartj/ehad783 
689. Praz F, Muraru D, Kreidel F, Lurz P, Hahn RT, Delgado V, et al. Transcatheter treatment for tricuspid valve disease. EuroIntervention 2021;17:791‚Äì808. https://doi.org/ 
10.4244/EIJ-D-21-00695 
690. Song H, Kim MJ, Chung CH, Choo SJ, Song MG, Song JM, et al. Factors associated with 
development of late significant tricuspid regurgitation after successful left-sided valve 
surgery. Heart 2009;95:931‚Äì6. https://doi.org/10.1136/hrt.2008.152793 
691. Galloo X, Dietz MF, Fortuni F, Prihadi EA, Cosyns B, Delgado V, et al. Prognostic implications of atrial vs. ventricular functional tricuspid regurgitation. Eur Heart J 
Cardiovasc Imaging 2023;24:733‚Äì41. https://doi.org/10.1093/ehjci/jead016


<!-- PAGE 95 -->

### Page 95

692. Schlotter F, Dietz MF, Stolz L, Kresoja KP, Besler C, Sannino A, et al. Atrial functional 
tricuspid regurgitation: novel definition and impact on prognosis. Circ Cardiovasc Interv 
2022;15:e011958. https://doi.org/10.1161/CIRCINTERVENTIONS.122.011958 
693. Adamo M, Chioncel O, Pagnesi M, Bayes-Genis A, Abdelhamid M, Anker SD, et al. 
Epidemiology, pathophysiology, diagnosis and management of chronic right-sided 
heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart 
Failure Association (HFA) and the European Association of Percutaneous 
Cardiovascular Interventions (EAPCI) of the ESC. Eur J Heart Fail 2024;26:18‚Äì33.  
https://doi.org/10.1002/ejhf.3106 
694. Fortuni F, Dietz MF, Prihadi EA, van der Bijl P, De Ferrari GM, Knuuti J, et al. Prognostic 
implications of a novel algorithm to grade secondary tricuspid regurgitation. JACC 
Cardiovasc Imaging 2021;14:1085‚Äì95. https://doi.org/10.1016/j.jcmg.2020.12.011 
695. Peri Y, Sadeh B, Sherez C, Hochstadt A, Biner S, Aviram G, et al. Quantitative assessment of effective regurgitant orifice: impact on risk stratification, and cut-off for severe 
and torrential tricuspid regurgitation grade. Eur Heart J Cardiovasc Imaging 2020;21: 
768‚Äì76. https://doi.org/10.1093/ehjci/jez267 
696. Dreyfus J, Galloo X, Taramasso M, Heitzinger G, Benfari G, Kresoja KP, et al. 
TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation. 
Eur Heart J 2024;45:586‚Äì97. https://doi.org/10.1093/eurheartj/ehad585 
697. Hahn RT, Lawlor MK, Davidson CJ, Badhwar V, Sannino A, Spitzer E, et al. Tricuspid 
Valve Academic Research Consortium definitions for tricuspid regurgitation and trial 
endpoints. Eur Heart J 2023;44:4508‚Äì32. https://doi.org/10.1093/eurheartj/ehad653 
698. Petersen SE, Khanji MY, Plein S, Lancellotti P, Bucciarelli-Ducci C. European 
Association of Cardiovascular Imaging expert consensus paper: a comprehensive review of cardiovascular magnetic resonance normal values of cardiac chamber size 
and aortic root in adults and recommendations for grading severity. Eur Heart J 
Cardiovasc Imaging 2019;20:1321‚Äì31. https://doi.org/10.1093/ehjci/jez232 
699. Kawel-Boehm N, Hetzel SJ, Ambale-Venkatesh B, Captur G, Francois CJ, 
Jerosch-Herold M, et al. Reference ranges (‚Äúnormal values‚Äù) for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update. J Cardiovasc Magn Reson 
2020;22:87. https://doi.org/10.1186/s12968-020-00683-3 
700. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. 
Recommendations for cardiac chamber quantification by echocardiography in adults: 
an update from the American Society of Echocardiography and the European 
Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16: 
233‚Äì70. https://doi.org/10.1093/ehjci/jev014 
701. Addetia K, Miyoshi T, Citro R, Daimon M, Gutierrez Fajardo P, Kasliwal RR, et al. 
Two-dimensional echocardiographic right ventricular size and systolic function measurements stratified by sex, age, and ethnicity: results of the World Alliance of 
Societies of Echocardiography study. J Am Soc Echocardiogr 2021;34:1148‚Äì1157.e1.  
https://doi.org/10.1016/j.echo.2021.06.013 
702. Addetia K, Miyoshi T, Amuthan V, Citro R, Daimon M, Gutierrez Fajardo P, et al. 
Normal values of three-dimensional right ventricular size and function measurements: 
results of the World Alliance Societies of Echocardiography study. J Am Soc 
Echocardiogr 2023;36:858‚Äì866.e1. https://doi.org/10.1016/j.echo.2023.04.011 
703. Dietz MF, Prihadi EA, van der Bijl P, Goedemans L, Mertens BJA, Gursoy E, et al. 
Prognostic implications of right ventricular remodeling and function in patients with 
significant secondary tricuspid regurgitation. Circulation 2019;140:836‚Äì45. https:// 
doi.org/10.1161/CIRCULATIONAHA.119.039630 
704. Eriksen-Volnes T, Grue JF, Hellum Olaisen S, Letnes JM, Nes B, L√∏vstakken L, et al. 
Normalized echocardiographic values from guideline-directed dedicated views for cardiac dimensions and left ventricular function. JACC Cardiovasc Imaging 2023;16: 
1501‚Äì15. https://doi.org/10.1016/j.jcmg.2022.12.020 
705. Lurz P, Orban M, Besler C, Braun D, Schlotter F, Noack T, et al. Clinical characteristics, 
diagnosis, and risk stratification of pulmonary hypertension in severe tricuspid regurgitation and implications for transcatheter tricuspid valve repair. Eur Heart J 2020;41: 
2785‚Äì95. https://doi.org/10.1093/eurheartj/ehaa138 
706. Stocker TJ, Hertell H, Orban M, Braun D, Rommel KP, Ruf T, et al. Cardiopulmonary 
hemodynamic profile predicts mortality after transcatheter tricuspid valve repair in 
chronic heart failure. JACC Cardiovasc Interv 2021;14:29‚Äì38. https://doi.org/10.1016/j. 
jcin.2020.09.033 
707. Brener MI, Lurz P, Hausleiter J, Rod√©s-Cabau J, Fam N, Kodali SK, et al. Right 
ventricular-pulmonary arterial coupling and afterload reserve in patients undergoing 
transcatheter tricuspid valve repair. J Am Coll Cardiol 2022;79:448‚Äì61. https://doi. 
org/10.1016/j.jacc.2021.11.031 
708. Stolz L, Weckbach LT, Karam N, Kalbacher D, Praz F, Lurz P, et al. Invasive right ventricular to pulmonary artery coupling in patients undergoing transcatheter 
edge-to-edge tricuspid valve repair. JACC Cardiovasc Imaging 2023;16:564‚Äì6. https:// 
doi.org/10.1016/j.jcmg.2022.10.004 
709. Dreyfus J, Juarez-Casso F, Sala A, Carnero-Alcazar M, Eixer√©s-Esteve A, Bohbot Y, et al. 
Benefit of isolated surgical valve repair or replacement for functional tricuspid regurgitation and long-term outcomes stratified by the TRI-SCORE. Eur Heart J 2024;45: 
4512‚Äì22. https://doi.org/10.1093/eurheartj/ehae578 
710. Thourani VH, Bonnell L, Wyler von Ballmoos MC, Mehaffey JH, Bowdish M, Kurlansky 
P, et al. Outcomes of isolated tricuspid valve surgery: a Society of Thoracic Surgeons 
analysis and risk model. Ann Thorac Surg 2024;118:873‚Äì81. https://doi.org/10.1016/j. 
athoracsur.2024.04.014 
711. Anguita-G√°mez M, Giraldo MA, Nombela-Franco L, Eixeres Esteve A, Cuerpo G, 
Lopez-Menendez J, et al. Validation of the TRI-SCORE in patients undergoing surgery 
for isolated tricuspid regurgitation. Heart 2023;109:1401‚Äì6. https://doi.org/10.1136/ 
heartjnl-2022-322067 
712. Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, et al. Empagliflozin 
effects on pulmonary artery pressure in patients with heart failure: results from the 
EMBRACE-HF 
trial. 
Circulation 
2021;143:1673‚Äì86. 
https://doi.org/10.1161/ 
circulationaha.120.052503 
713. Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med 2023;388:1833‚Äì42. https:// 
doi.org/10.1056/NEJMoa2300525 
714. Dreyfus J, Flagiello M, Bazire B, Eggenspieler F, Viau F, Riant E, et al. Isolated tricuspid 
valve surgery: impact of aetiology and clinical presentation on outcomes. Eur Heart J 
2020;41:4304‚Äì17. https://doi.org/10.1093/eurheartj/ehaa643 
715. Scotti A, Sturla M, Granada JF, Kodali SK, Coisne A, Mangieri A, et al. Outcomes of isolated tricuspid valve replacement: a systematic review and meta-analysis of 5,316 patients from 35 studies. EuroIntervention 2022;18:840‚Äì51. https://doi.org/10.4244/EIJ-D- 
22-00442 
716. Chen Q, Bowdish ME, Malas J, Roach A, Gill G, Rowe G, et al. Isolated tricuspid operations: the Society of Thoracic Surgeons adult cardiac surgery database analysis. Ann 
Thorac Surg 2023;115:1162‚Äì70. https://doi.org/10.1016/j.athoracsur.2022.12.041 
717. Hahn RT, Wilkoff BL, Kodali S, Birgersdotter-Green UM, Ailawadi G, Addetia K, et al. 
Managing implanted cardiac electronic devices in patients with severe tricuspid regurgitation: JACC state-of-the-art review. J Am Coll Cardiol 2024;83:2002‚Äì14. https://doi. 
org/10.1016/j.jacc.2024.02.045 
718. Taramasso M, Gavazzoni M, Pozzoli A, Dreyfus GD, Bolling SF, George I, et al. 
Tricuspid regurgitation: predicting the need for intervention, procedural success, 
and recurrence of disease. JACC Cardiovasc Imaging 2019;12:605‚Äì21. https://doi.org/ 
10.1016/j.jcmg.2018.11.034 
719. Bannehr M, Edlinger CR, Kahn U, Liebchen J, Okamoto M, H√§hnel V, et al. Natural 
course of tricuspid regurgitation and prognostic implications. Open Heart 2021;8: 
e001529. https://doi.org/10.1136/openhrt-2020-001529 
720. Park SJ, Oh JK, Kim SO, Lee SA, Kim HJ, Lee S, et al. Determinants of clinical outcomes 
of surgery for isolated severe tricuspid regurgitation. Heart 2021;107:403‚Äì10. https:// 
doi.org/10.1136/heartjnl-2020-317715 
721. McCarthy PM, Bhudia SK, Rajeswaran J, Hoercher KJ, Lytle BW, Cosgrove DM, et al. 
Tricuspid valve repair: durability and risk factors for failure. J Thorac Cardiovasc Surg 
2004;127:674‚Äì85. https://doi.org/10.1016/j.jtcvs.2003.11.019 
722. Kwak JJ, Kim YJ, Kim MK, Kim HK, Park JS, Kim KH, et al. Development of tricuspid 
regurgitation late after left-sided valve surgery: a single-center experience with long- 
term echocardiographic examinations. Am Heart J 2008;155:732‚Äì7. https://doi.org/ 
10.1016/j.ahj.2007.11.010 
723. Dreyfus GD, Corbi PJ, Chan KM, Bahrami T. Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair? Ann Thorac Surg 2005;79: 
127‚Äì32. https://doi.org/10.1016/j.athoracsur.2004.06.057 
724. Dreyfus GD, Essayagh B, Benfari G, Dulguerov F, Haley SR, Dommerc C, et al. 
Outcome of consistent guideline-based tricuspid management in patients undergoing 
degenerative mitral regurgitation correction. JTCVS Open 2021;7:125‚Äì38. https://doi. 
org/10.1016/j.xjon.2021.07.010 
725. Gammie JS, Chu MWA, Falk V, Overbey JR, Moskowitz AJ, Gillinov M, et al. 
Concomitant tricuspid repair in patients with degenerative mitral regurgitation. N 
Engl J Med 2022;386:327‚Äì39. https://doi.org/10.1056/NEJMoa2115961 
726. Pettinari M, De Kerchove L, Lazam S, Pasquet A, Gerber B, Vanoverschelde JL, et al. 
Mid-term results of a randomized trial of tricuspid annuloplasty for less-than-severe 
functional tricuspid regurgitation at the time of mitral valve surgery. Eur J 
Cardiothorac Surg 2019;55:851‚Äì8. https://doi.org/10.1093/ejcts/ezy378 
727. Ailawadi G, Voisine P, Raymond S, Gelijns AC, Moskowitz AJ, Falk V, et al. Pacemaker 
implantation associated with tricuspid repair in the setting of mitral valve surgery: insights from a Cardiothoracic Surgical Trials Network randomized trial. J Thorac 
Cardiovasc Surg 2022;167:2104‚Äì16.e5. https://doi.org/10.1016/j.jtcvs.2022.11.031 
728. Ragnarsson S, Taha A, Nielsen SJ, Amabile A, Geirsson A, Krane M, et al. Pacemaker 
implantation following tricuspid valve annuloplasty. JTCVS Open 2023;16:276‚Äì89.  
https://doi.org/10.1016/j.xjon.2023.08.017 
729. Iribarne A, Alabbadi SH, Moskowitz AJ, Ailawadi G, Badhwar V, Gillinov M, et al. 
Permanent pacemaker implantation and long-term outcomes of patients undergoing 
concomitant mitral and tricuspid valve surgery. J Am Coll Cardiol 2024;83:1656‚Äì68.  
https://doi.org/10.1016/j.jacc.2024.02.042 
730. Kassab J, Harb SC, Desai MY, Gillinov AM, Layoun H, El Dahdah J, et al. Incidence, risk 
factors, and outcomes associated with permanent pacemaker implantation following 
tricuspid valve surgery. J Am Heart Assoc 2024;13:e032760. https://doi.org/10.1161/ 
jaha.123.032760 
731. Chikwe J, Itagaki S, Anyanwu A, Adams DH. Impact of concomitant tricuspid annuloplasty on tricuspid regurgitation, right ventricular function, and pulmonary artery  
ESC Guidelines                                                                                                                                                                                               95


<!-- PAGE 96 -->

### Page 96

hypertension after repair of mitral valve prolapse. J Am Coll Cardiol 2015;65:1931‚Äì8.  
https://doi.org/10.1016/j.jacc.2015.01.059 
732. Chang JD, Manning WJ, Ebrille E, Zimetbaum PJ. Tricuspid valve dysfunction following 
pacemaker or cardioverter-defibrillator implantation. J Am Coll Cardiol 2017;69: 
2331‚Äì41. https://doi.org/10.1016/j.jacc.2017.02.055 
733. von Bardeleben RS, Lurz P, Sorajja P, Ruf T, Hausleiter J, Sitges M, et al. Two-year outcomes for tricuspid repair with a transcatheter edge-to-edge valve repair from the 
transatlantic TRILUMINATE trial. Circ Cardiovasc Interv 2023;16:e012888. https://doi. 
org/10.1161/CIRCINTERVENTIONS.122.012888 
734. Lurz P, Besler C, Schmitz T, Bekeredjian R, Nickenig G, M√∂llmann H, et al. Short-term 
outcomes of tricuspid edge-to-edge repair in clinical practice. J Am Coll Cardiol 2023;82: 
281‚Äì91. https://doi.org/10.1016/j.jacc.2023.05.008 
735. Kodali SK, Hahn RT, Davidson CJ, Narang A, Greenbaum A, Gleason P, et al. 1-Year 
outcomes of transcatheter tricuspid valve repair. J Am Coll Cardiol 2023;81:1766‚Äì76.  
https://doi.org/10.1016/j.jacc.2023.02.049 
736. Kar S, Makkar RR, Whisenant BK, Hamid N, Naik H, Tadros P, et al. (March 30, 2025) 
Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: the TRILUMINATE pivotal randomized trial. Circulation, https://doi.org/10. 
1161/CIRCULATIONAHA.125.074536 
737. Donal E, Dreyfus J, Leurent G, Coisne A, Leroux PY, Ganivet A, et al. Transcatheter 
edge-to-edge repair for severe isolated tricuspid regurgitation: the Tri.Fr randomized 
clinical trial. JAMA 2025;333:124‚Äì32. https://doi.org/10.1001/jama.2024.21189 
738. Hahn RT, Makkar R, Thourani VH, Makar M, Sharma RP, Haeffele C, et al. 
Transcatheter valve replacement in severe tricuspid regurgitation. N Engl J Med 
2024;392:115‚Äì26. https://doi.org/10.1056/NEJMoa2401918 
739. Park SJ, Gentry JLI, Varma N, Wazni O, Tarakji KG, Mehta A, et al. Transvenous extraction of pacemaker and defibrillator leads and the risk of tricuspid valve regurgitation. 
JACC Clin Electrophysiol 2018;4:1421‚Äì8. https://doi.org/10.1016/j.jacep.2018.07.011 
740. Aboulhosn J, Cabalka AK, Levi DS, Himbert D, Testa L, Latib A, et al. Transcatheter 
valve-in-ring implantation for the treatment of residual or recurrent tricuspid valve 
dysfunction after prior surgical repair. JACC Cardiovasc Interv 2017;10:53‚Äì63. https:// 
doi.org/10.1016/j.jcin.2016.10.036 
741. Chen S, Dershowitz L, George I. Transcatheter valve implantation for degenerated tricuspid bioprosthesis and failed tricuspid ring. Ann Cardiothorac Surg 2021;10:651‚Äì7.  
https://doi.org/10.21037/acs-2021-tviv-11 
742. Rao VN, Giczewska A, Chiswell K, Felker GM, Wang A, Glower DD, et al. Long-term 
outcomes of phenoclusters in severe tricuspid regurgitation. Eur Heart J 2023;44: 
1910‚Äì23. https://doi.org/10.1093/eurheartj/ehad133 
743. Van de Veire NR, Braun J, Delgado V, Versteegh MI, Dion RA, Klautz RJ, et al. Tricuspid 
annuloplasty prevents right ventricular dilatation and progression of tricuspid regurgitation in patients with tricuspid annular dilatation undergoing mitral valve repair. J 
Thorac Cardiovasc Surg 2011;141:1431‚Äì9. https://doi.org/10.1016/j.jtcvs.2010.05.050 
744. Brescia AA, Ward ST, Watt TMF, Rosenbloom LM, Baker M, Khan S, et al. Outcomes 
of guideline-directed concomitant annuloplasty for functional tricuspid regurgitation. 
Ann Thorac Surg 2020;109:1227‚Äì32. https://doi.org/10.1016/j.athoracsur.2019.07.035 
745. Hamandi M, Smith RL, Ryan WH, Grayburn PA, Vasudevan A, George TJ, et al. 
Outcomes of isolated tricuspid valve surgery have improved in the modern era. Ann 
Thorac Surg 2019;108:11‚Äì5. https://doi.org/10.1016/j.athoracsur.2019.03.004 
746. Russo M, Di Mauro M, Saitto G, Lio A, Berretta P, Taramasso M, et al. Outcome of 
patients undergoing isolated tricuspid repair or replacement surgery. Eur J 
Cardiothorac Surg 2022;62:ezac230. https://doi.org/10.1093/ejcts/ezac230 
747. Abdelbar A, Kenawy A, Zacharias J. Minimally invasive tricuspid valve surgery. J Thorac 
Dis 2021;13:1982‚Äì92. https://doi.org/10.21037/jtd-20-1331 
748. Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L, et al. 
Transcatheter versus medical treatment of patients with symptomatic severe tricuspid 
regurgitation. J Am Coll Cardiol 2019;74:2998‚Äì3008. https://doi.org/10.1016/j.jacc.2019. 
09.028 
749. Kodali S, Hahn RT, Makkar R, Makar M, Davidson CJ, Puthumana JJ, et al. Transfemoral 
tricuspid valve replacement and one-year outcomes: the TRISCEND study. Eur Heart J 
2023;44:4862‚Äì73. https://doi.org/10.1093/eurheartj/ehad667 
750. Donal E, Sitges M, Panis V, Schueler R, Lapp H, Moellmann H, et al. Characterization of 
tricuspid valve anatomy and coaptation gap in subjects receiving tricuspid transcatheter edge-to-edge repair: observations from the bRIGHT TriClip study. J Am Soc 
Echocardiogr 2024;37:397‚Äì404. https://doi.org/10.1016/j.echo.2023.12.002 
751. Wild MG, L√∂w K, Rosch S, Gercek M, Higuchi S, Massberg S, et al. Multicenter experience with the transcatheter leaflet repair system for symptomatic tricuspid regurgitation. JACC Cardiovasc Interv 2022;15:1352‚Äì63. https://doi.org/10.1016/j.jcin.2022.05. 
041 
752. Sarralde JA, Bernal JM, Llorca J, Pont√≥n A, Diez-Solorzano L, Gim√©nez-Rico JR, et al. 
Repair of rheumatic tricuspid valve disease: predictors of very long-term mortality 
and reoperation. Ann Thorac Surg 2010;90:503‚Äì8. https://doi.org/10.1016/j. 
athoracsur.2010.03.105 
753. Saran N, Dearani JA, Said SM, Greason KL, Pochettino A, Stulak JM, et al. Long-term 
outcomes of patients undergoing tricuspid valve surgery. Eur J Cardiothorac Surg 
2019;56:950‚Äì8. https://doi.org/10.1093/ejcts/ezz081 
754. McElhinney DB, Cabalka AK, Aboulhosn JA, Eicken A, Boudjemline Y, Schubert S, et al. 
Transcatheter tricuspid valve-in-valve implantation for the treatment of dysfunctional 
surgical bioprosthetic valves: an international, multicenter registry study. Circulation 
2016;133:1582‚Äì93. https://doi.org/10.1161/CIRCULATIONAHA.115.019353 
755. Pereyra M, Farina JM, Chao CJ, Ayoub C, Arsanjani R. Percutaneous transcatheter pulmonary and tricuspid valve replacements in a patient with carcinoid heart disease. Eur 
Heart J Case Rep 2023;7:ytad511. https://doi.org/10.1093/ehjcr/ytad511 
756. Connolly HM, Schaff HV, Abel MD, Rubin J, Askew JW, Li Z, et al. Early and late outcomes of surgical treatment in carcinoid heart disease. J Am Coll Cardiol 2015;66: 
2189‚Äì96. https://doi.org/10.1016/j.jacc.2015.09.014 
757. Yunoki K, Naruko T, Itoh A, Ohashi J, Fujimoto K, Shirai N, et al. Percutaneous transcatheter balloon valvuloplasty for bioprosthetic tricuspid valve stenosis. Circulation 
2006;114:e558‚Äì9. https://doi.org/10.1161/CIRCULATIONAHA.106.618611 
758. Tribouilloy C, Bohbot Y, Kubala M, Ruschitzka F, Popescu B, Wendler O, et al. 
Characteristics, management, and outcomes of patients with multiple native valvular 
heart disease: a substudy of the EURObservational Research Programme Valvular 
Heart Disease II Survey. Eur Heart J 2022;43:2756‚Äì66. https://doi.org/10.1093/ 
eurheartj/ehac209 
759. Iung B, Baron G, Tornos P, Gohlke-B√§rwolf C, Butchart EG, Vahanian A. Valvular heart 
disease in the community: a European experience. Curr Probl Cardiol 2007;32:609‚Äì61.  
https://doi.org/10.1016/j.cpcardiol.2007.07.002 
760. Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol AD, et al. 
Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst 
2015;107:djv008. https://doi.org/10.1093/jnci/djv008 
761. Unger P, Pibarot P, Tribouilloy C, Lancellotti P, Maisano F, Iung B, et al. Multiple and 
mixed valvular heart diseases. Circ Cardiovasc Imaging 2018;11:e007862. https://doi. 
org/10.1161/CIRCIMAGING.118.007862 
762. Ajmone Marsan N, Delgado V, Shah DJ, Pellikka P, Bax JJ, Treibel T, et al. Valvular heart 
disease: shifting the focus to the myocardium. Eur Heart J 2023;44:28‚Äì40. https://doi. 
org/10.1093/eurheartj/ehac504 
763. de Marchi SF, Windecker S, Aeschbacher BC, Seiler C. Influence of left ventricular relaxation on the pressure half time of aortic regurgitation. Heart 1999;82:607‚Äì13.  
https://doi.org/10.1136/hrt.82.5.607 
764. Unger P, Tribouilloy C. Aortic stenosis with other concomitant valvular disease: aortic 
regurgitation, mitral regurgitation, mitral stenosis, or tricuspid regurgitation. Cardiol 
Clin 2020;38:33‚Äì46. https://doi.org/10.1016/j.ccl.2019.09.002 
765. Unger P, Clavel M-A. Mixed aortic valve disease: a diagnostic challenge, a prognostic 
threat. Structural Heart 2020;4:468‚Äì74. https://doi.org/10.1080/24748706.2020. 
1817643 
766. Flachskampf FA, Weyman AE, Gillam L, Liu CM, Abascal VM, Thomas JD. Aortic regurgitation shortens Doppler pressure half-time in mitral stenosis: clinical evidence, in vitro simulation and theoretic analysis. J Am Coll Cardiol 1990;16:396‚Äì404. https://doi. 
org/10.1016/0735-1097(90)90592-d 
767. Tribouilloy C, Shen WF, Rey JL, Adam MC, Lesbre JP. Mitral to aortic velocity-time integral ratio: a non-geometric pulsed-Doppler regurgitant index in isolated pure mitral 
regurgitation. Eur Heart J 1994;15:1335‚Äì9. https://doi.org/10.1093/oxfordjournals. 
eurheartj.a060390 
768. Benfari G, Clavel M-A, Nistri S, Maffeis C, Vassanelli C, Enriquez-Sarano M, et al. 
Concomitant mitral regurgitation and aortic stenosis: one step further to low-flow 
preserved ejection fraction aortic stenosis. Eur Heart J Cardiovasc Imaging 2018;19: 
569‚Äì73. https://doi.org/10.1093/ehjci/jex172 
769. Mohan JC, Mukherjee S, Kumar A, Arora R, Patel AR, Pandian NG. Does chronic mitral 
regurgitation influence Doppler pressure half-time‚Äìderived calculation of the mitral 
valve area in patients with mitral stenosis? Am Heart J 2004;148:703‚Äì9. https://doi. 
org/10.1016/j.ahj.2003.12.043 
770. Hauge SW, Estensen ME, Persson R, Abebe S, Mekonnen D, Nega B, et al. The importance of concomitant mitral regurgitation for estimates of mitral valve area by pressure 
half time in patients with chronic rheumatic heart disease. Int J Cardiol 2024;398: 
131600. https://doi.org/10.1016/j.ijcard.2023.131600 
771. Dahou A, Magne J, Clavel MA, Capoulade R, Bartko PE, Bergler-Klein J, et al. Tricuspid 
regurgitation is associated with increased risk of mortality in patients with low-flow 
low-gradient aortic stenosis and reduced ejection fraction: results of the multicenter 
TOPAS study (True or Pseudo-Severe Aortic Stenosis). JACC Cardiovasc Interv 2015; 
8:588‚Äì96. https://doi.org/10.1016/j.jcin.2014.08.019 
772. Shiran A, Sagie A. Tricuspid regurgitation in mitral valve disease: incidence, prognostic 
implications, mechanism, and management. J Am Coll Cardiol 2009;53:401‚Äì8. https:// 
doi.org/10.1016/j.jacc.2008.09.048 
773. Naeije R, Badagliacca R. The overloaded right heart and ventricular interdependence. 
Cardiovasc Res 2017;113:1474‚Äì85. https://doi.org/10.1093/cvr/cvx160 
774. Furukawa A, Abe Y, Ito K, Hosogi S, Yamamoto K, Ito H. Mechanisms of changes in 
functional mitral regurgitation by preload alterations. J Cardiol 2018;71:570‚Äì6.  
https://doi.org/10.1016/j.jjcc.2017.12.005 
775. Wunderlich NC, Beigel R, Siegel RJ. Management of mitral stenosis using 2D and 3D 
echo-Doppler imaging. JACC Cardiovasc Imaging 2013;6:1191‚Äì205. https://doi.org/10. 
1016/j.jcmg.2013.07.008


<!-- PAGE 97 -->

### Page 97

776. Cho IJ, Lee SE, Jeong H, Chang HJ. Determinants of clinical outcomes in patients with 
mixed mitral valve disease. Echocardiography 2020;37:1164‚Äì70. https://doi.org/10. 
1111/echo.14673 
777. Pawade T, Sheth T, Guzzetti E, Dweck Marc R, Clavel M-A. Why and how to measure 
aortic valve calcification in patients with aortic stenosis. JACC Cardiovasc Imaging 2019; 
12:1835‚Äì48. https://doi.org/10.1016/j.jcmg.2019.01.045 
779. Bandera F, Generati G, Pellegrino M, Garatti A, Labate V, Alfonzetti E, et al. Mitral regurgitation in heart failure: insights from CPET combined with exercise echocardiography. Eur Heart J Cardiovasc Imaging 2017;18:296‚Äì303. https://doi.org/10.1093/ehjci/ 
jew096 
780. Bissessor N, Shanahan L, Wee YS, Stewart R, Lowe B, Kerr A, et al. The role of natriuretic peptides in patients with chronic complex (mixed or multiple) heart valve disease. Congest Heart Fail 2010;16:50‚Äì4. https://doi.org/10.1111/j.1751-7133.2009. 
00132.x 
781. Myerson SG. CMR in evaluating valvular heart disease: diagnosis, severity, and outcomes. JACC Cardiovasc Imaging 2021;14:2020‚Äì32. https://doi.org/10.1016/j.jcmg. 
2020.09.029 
782. Grafton G, Cascino TM, Perry D, Ashur C, Koelling TM. Resting oxygen consumption 
and heart failure: importance of measurement for determination of cardiac output 
with the use of the Fick principle. J Card Fail 2020;26:664‚Äì72. https://doi.org/10. 
1016/j.cardfail.2019.02.004 
783. Singh AD, Mian A, Devasenapathy N, Guyatt G, Karthikeyan G. Percutaneous mitral 
commissurotomy versus surgical commissurotomy for rheumatic mitral stenosis: a 
systematic review and meta-analysis of randomised controlled trials. Heart 2020; 
106:1094‚Äì101. https://doi.org/10.1136/heartjnl-2019-315906 
784. Winter MP, Bartko PE, Krickl A, Gatterer C, Don√† C, Nitsche C, et al. Adaptive development of concomitant secondary mitral and tricuspid regurgitation after transcatheter aortic valve replacement. Eur Heart J Cardiovasc Imaging 2021;22:1045‚Äì53.  
https://doi.org/10.1093/ehjci/jeaa106 
785. Khan F, Okuno T, Malebranche D, Lanz J, Praz F, Stortecky S, et al. Transcatheter aortic 
valve replacement in patients with multivalvular heart disease. JACC Cardiovasc Interv 
2020;13:1503‚Äì14. https://doi.org/10.1016/j.jcin.2020.03.052 
786. Adamo M, Pagnesi M, Ghizzoni G, Est√©vez-Loureiro R, Raposeiras-Roubin S, Tomasoni 
D, et al. Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral 
valve repair for secondary mitral regurgitation and its impact on mortality. Eur J 
Heart Fail 2022;24:2175‚Äì84. https://doi.org/10.1002/ejhf.2637 
787. Kavsur R, Iliadis C, Spieker M, Brachtendorf BM, Tiyerili V, Metze C, et al. Predictors 
and prognostic relevance of tricuspid alterations in patients undergoing transcatheter 
edge-to-edge mitral valve repair. EuroIntervention 2021;17:827‚Äì34. https://doi.org/10. 
4244/eij-d-20-01094 
788. Mehr M, Karam N, Taramasso M, Ouarrak T, Schneider S, Lurz P, et al. Combined tricuspid and mitral versus isolated mitral valve repair for severe MR and TR: an analysis 
from the TriValve and TRAMI registries. JACC Cardiovasc Interv 2020;13:543‚Äì50.  
https://doi.org/10.1016/j.jcin.2019.10.023 
789. Besler C, Blazek S, Rommel KP, Noack T, von Roeder M, Luecke C, et al. Combined 
mitral and tricuspid versus isolated mitral valve transcatheter edge-to-edge repair in 
patients with symptomatic valve regurgitation at high surgical risk. JACC Cardiovasc 
Interv 2018;11:1142‚Äì51. https://doi.org/10.1016/j.jcin.2018.04.010 
790. Egbe AC, Luis SA, Padang R, Warnes CA. Outcomes in moderate mixed aortic valve 
disease: is it time for a paradigm shift? J Am Coll Cardiol 2016;67:2321‚Äì9. https://doi.org/ 
10.1016/j.jacc.2016.03.509 
791. Egbe AC, Poterucha JT, Warnes CA. Mixed aortic valve disease: midterm outcome and 
predictors of adverse events. Eur Heart J 2016;37:2671‚Äì8. https://doi.org/10.1093/ 
eurheartj/ehw079 
792. Zilberszac R, Gabriel H, Schemper M, Zahler D, Czerny M, Maurer G, et al. Outcome 
of combined stenotic and regurgitant aortic valve disease. J Am Coll Cardiol 2013;61: 
1489‚Äì95. https://doi.org/10.1016/j.jacc.2012.11.070 
793. Isaza N, Desai MY, Kapadia SR, Krishnaswamy A, Rodriguez LL, Grimm RA, et al. 
Long-term outcomes in patients with mixed aortic valve disease and preserved left 
ventricular ejection fraction. J Am Heart Assoc 2020;9:e014591. https://doi.org/10. 
1161/jaha.119.014591 
794. Saijo Y, Isaza N, Conic JZ, Desai MY, Johnston D, Roselli EE, et al. Left ventricular longitudinal strain in characterization and outcome assessment of mixed aortic valve disease phenotypes. JACC Cardiovasc Imaging 2021;14:1324‚Äì34. https://doi.org/10.1016/j. 
jcmg.2021.01.020 
795. Bernard J, Jean G, Bienjonetti-Boudreau D, Jacques F, Tastet L, Salaun E, et al. 
Prognostic utility of N-terminal pro B-type natriuretic peptide ratio in mixed aortic 
valve disease. Open Heart 2023;10:e002361. https://doi.org/10.1136/openhrt-2023- 
002361 
796. Onishi H, Naganuma T, Izumo M, Ouchi T, Yuki H, Mitomo S, et al. Prognostic relevance of B-type natriuretic peptide in patients with moderate mixed aortic valve disease. ESC Heart Fail 2022;9:2474‚Äì83. https://doi.org/10.1002/ehf2.13946 
797. Carpentier AF, Pellerin M, Fuzellier JF, Relland JY. Extensive calcification of the 
mitral valve anulus: pathology and surgical management. J Thorac Cardiovasc Surg 
1996;111:718‚Äì29; discussion 729‚Äì730. https://doi.org/10.1016/s0022-5223(96) 
70332-x 
798. World Health Organization. Life Expectancy at Birth. https://www.who.int/ 
data/gho/indicator-metadata-registry/imr-details/3131 (28 March 2025, date 
last accessed). 
799. Johansson I, Benz AP, Kovalova T, Balasubramanian K, Fukakusa B, Lynn MJ, et al. 
Outcomes of patients with a mechanical heart valve and poor anticoagulation control 
on warfarin. Thromb Haemost 2024;124:613‚Äì24. https://doi.org/10.1055/s-0043- 
1777827 
800. Persson M, Glaser N, Nilsson J, Friberg O, Franco-Cereceda A, Sartipy U. Comparison 
of long-term performance of bioprosthetic aortic valves in Sweden from 2003 to 2018. 
JAMA Netw Open 2022;5:e220962. https://doi.org/10.1001/jamanetworkopen.2022. 
0962 
801. Jiang Y, Wang S, Bian J, Chen S, Shao Y. Mechanical versus bioprosthetic aortic valve 
replacement in middle-aged adults: a systematic review and meta-analysis. J 
Cardiovasc Dev Dis 2023;10:90. https://doi.org/10.3390/jcdd10020090 
802. Kim MS, Kim HR, Lee SH, Lee S, Joo HC. Aortic valve replacement in patients aged 50 
to 69 years: analysis using Korean National Big Data. J Card Surg 2022;37:3623‚Äì30.  
https://doi.org/10.1111/jocs.16908 
803. Vogt F, Santarpino G, Fujita B, Frerker C, Bauer T, Beckmann A, et al. Surgical aortic 
valve replacement in patients aged 50‚Äì69 years‚Äîinsights from the German Aortic 
Valve Registry (GARY). Eur J Cardiothorac Surg 2022;62:ezac286. https://doi.org/10. 
1093/ejcts/ezac286 
804. Glaser N, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. Aortic valve replacement with mechanical vs. biological prostheses in patients aged 50‚Äì69 years. 
Eur Heart J 2016;37:2658‚Äì67. https://doi.org/10.1093/eurheartj/ehv580 
805. Kiyose AT, Suzumura EA, Laranjeira L, Buehler AM, Santo JAE, Berwanger O, et al. 
Comparison of biological and mechanical prostheses for heart valve surgery: a systematic review of randomized controlled trials. Arq Bras Cardiol 2019;112:292‚Äì301. https:// 
doi.org/10.5935/abc.20180272 
806. Bouhout I, Ghoneim A, Poirier N, Cartier R, Demers P, Perrault LP, et al. Impact of the 
learning curve on early outcomes following the Ross procedure. Can J Cardiol 2017;33: 
493‚Äì500. https://doi.org/10.1016/j.cjca.2016.11.014 
807. Tasoudis PT, Varvoglis DN, Vitkos E, Mylonas KS, S√° MP, Ikonomidis JS, et al. 
Mechanical versus bioprosthetic valve for aortic valve replacement: systematic review 
and meta-analysis of reconstructed individual participant data. Eur J Cardiothorac Surg 
2022;62:ezac268. https://doi.org/10.1093/ejcts/ezac268 
808. Leviner DB, Witberg G, Levi A, Landes U, Schwartz N, Shiran A, et al. Mechanical vs 
bioprosthetic aortic valve replacement in patients younger than 70 years of age: a hazard ratio meta-analysis. Can J Cardiol 2022;38:355‚Äì64. https://doi.org/10.1016/j.cjca. 
2021.12.008 
809. Yu J, Qiao E, Wang W. Mechanical or biologic prostheses for mitral valve replacement: 
a systematic review and meta-analysis. Clin Cardiol 2022;45:701‚Äì16. https://doi.org/10. 
1002/clc.23854 
810. Yanagawa B, Lee J, Ouzounian M, Bagai A, Cheema A, Verma S, et al. Mitral valve prosthesis choice in patients <70 years: a systematic review and meta-analysis of 20 219 
patients. J Card Surg 2020;35:818‚Äì25. https://doi.org/10.1111/jocs.14478 
811. Ahmed A, Awad AK, Varghese KS, Sehgal VS, Hisham K, George J, et al. Bioprosthetic 
versus mechanical valves for mitral valve replacement in patients <70 years: an updated pairwise meta-analysis. Gen Thorac Cardiovasc Surg 2024;72:95‚Äì103. https:// 
doi.org/10.1007/s11748-023-01956-1 
812. Capodanno D, Petronio AS, Prendergast B, Eltchaninoff H, Vahanian A, 
Modine T, et al. Standardized definitions of structural deterioration and valve 
failure in assessing long-term durability of transcatheter and surgical aortic 
bioprosthetic valves: a consensus statement from the European Association 
of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the 
European Society of Cardiology (ESC) and the European Association for 
Cardio-Thoracic Surgery (EACTS). Eur Heart J 2017;38:3382‚Äì90. https://doi. 
org/10.1093/eurheartj/ehx303 
813. Meskin M, Dimasi A, Votta E, Jaworek M, Fusini L, Muratori M, et al. A novel multiparametric score for the detection and grading of prosthetic mitral valve obstruction in 
cases with different disc motion abnormalities. Ultrasound Med Biol 2019;45: 
1708‚Äì20. https://doi.org/10.1016/j.ultrasmedbio.2019.03.011 
814. Passaglia LG, de Barros GM, de Sousa MR. Early postoperative bridging anticoagulation after mechanical heart valve replacement: a systematic review and 
meta-analysis. J Thromb Haemost 2015;13:1557‚Äì67. https://doi.org/10.1111/jth. 
13047 
815. Li BX, Liu SD, Qi L, Sun S, Sun W, Li YM, et al. Comparison of different bridging anticoagulation therapies used after mechanical heart valve replacement in Chinese patients 
‚Äîa prospective cohort study. J Cardiothorac Surg 2020;15:40. https://doi.org/10.1186/ 
s13019-020-1084-7 
816. Tao E, Luo YL, Tao Z, Wan L. A meta-analysis of bridging anticoagulation between low 
molecular weight heparin and heparin. Medicine (Baltimore) 2020;99:e18729. https:// 
doi.org/10.1097/MD.0000000000018729 
817. Baudet EM, Puel V, McBride JT, Grimaud JP, Roques F, Clerc F, et al. Long-term results 
of valve replacement with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 1995; 
109:858‚Äì70. https://doi.org/10.1016/s0022-5223(95)70309-8  
ESC Guidelines                                                                                                                                                                                               97


<!-- PAGE 98 -->

### Page 98

818. Massel DR, Little SH. Antiplatelet and anticoagulation for patients with prosthetic 
heart valves. Cochrane Database Syst Rev 2013;2013:CD003464. https://doi.org/10. 
1002/14651858.CD003464.pub2 
819. Torella M, Torella D, Chiodini P, Franciulli M, Romano G, De Santo L, et al. LOWERing 
the INtensity of oral anticoaGulant therapy in patients with bileaflet mechanical aortic 
valve replacement: results from the ‚ÄúLOWERING-IT‚Äù Trial. Am Heart J 2010;160: 
171‚Äì8. https://doi.org/10.1016/j.ahj.2010.05.005 
820. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit 
of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029‚Äì37. https://doi.org/10. 
1161/CIRCULATIONAHA.107.750000 
821. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. 
Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 
369:1206‚Äì14. https://doi.org/10.1056/NEJMoa1300615 
822. Puskas JD, Gerdisch M, Nichols D, Fermin L, Rhenman B, Kapoor D, et al. 
Anticoagulation and antiplatelet strategies after On-X mechanical aortic valve replacement. J Am Coll Cardiol 2018;71:2717‚Äì26. https://doi.org/10.1016/j.jacc.2018.03.535 
823. Schlitt A, von Bardeleben RS, Ehrlich A, Eimermacher A, Peetz D, Dahm M, et al. 
Clopidogrel and aspirin in the prevention of thromboembolic complications after 
mechanical aortic valve replacement (CAPTA). Thromb Res 2003;109:131‚Äì35.  
https://doi.org/10.1016/s0049-3848(03)00143-9 
824. Wang TY, Svensson LG, Wen J, Vekstein A, Gerdisch M, Rao VU, et al. Apixaban or 
warfarin in patients with an On-X mechanical aortic valve. NEJM Evid 2023;2: 
EVIDoa2300067. https://doi.org/10.1056/EVIDoa2300067 
825. Wang M, Zeraatkar D, Obeda M, Lee M, Garcia C, Nguyen L, et al. Drug‚Äìdrug interactions with warfarin: a systematic review and meta-analysis. Br J Clin Pharmacol 2021; 
87:4051‚Äì100. https://doi.org/10.1111/bcp.14833 
826. Tan CSS, Lee SWH. Warfarin and food, herbal or dietary supplement interactions: a 
systematic review. Br J Clin Pharmacol 2021;87:352‚Äì74. https://doi.org/10.1111/bcp. 
14404 
827. Heneghan CJ, Garcia-Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead C, et al. 
Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst 
Rev 2016;7:CD003839. https://doi.org/10.1002/14651858.CD003839.pub3 
828. Khouja C, Brunton G, Richardson M, Stokes G, Blanchard L, Burchett H, et al. Oral 
anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, 
self-monitoring, and stakeholder experiences. Syst Rev 2022;11:232. https://doi.org/ 
10.1186/s13643-022-02098-w 
829. Park YK, Lee MJ, Kim JH, Lee JS, Park RW, Kim GM, et al. Genetic and non-genetic factors affecting the quality of anticoagulation control and vascular events in atrial fibrillation. J Stroke Cerebrovasc Dis 2017;26:1383‚Äì90. https://doi.org/10.1016/j. 
jstrokecerebrovasdis.2017.02.022 
830. Praxedes MFDS, Silva JLPD, Cruz AJAD, Viana CC, Barbosa HC, Guimaraes NS, et al. 
Assessment of the relationship between the level of patient knowledge on warfarin 
therapy and the quality of oral anticoagulation: a systematic review and meta-analysis. 
PLoS One 2023;18:e0289836. https://doi.org/10.1371/journal.pone.0289836 
831. Marx N, Federici M, Sch√ºtt K, Muller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC 
Guidelines for the management of cardiovascular disease in patients with diabetes. Eur 
Heart J 2023;44:4043‚Äì140. https://doi.org/10.1093/eurheartj/ehad192 
832. Meurin P, Tabet JY, Weber H, Renaud N, Ben Driss A. Low-molecular-weight heparin 
as a bridging anticoagulant early after mechanical heart valve replacement. Circulation 
2006;113:564‚Äì9. https://doi.org/10.1161/circulationaha.105.575571 
833. Ferreira I, Dos L, Tornos P, Nicolau I, Permanyer-Miralda G, Soler-Soler J. Experience 
with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart 2003;89:527‚Äì30. https://doi.org/10.1136/heart.89.5.527 
834. Caldeira D, David C, Santos AT, Costa J, Pinto FJ, Ferreira JJ. Efficacy and safety of low 
molecular weight heparin in patients with mechanical heart valves: systematic review 
and meta-analysis. J Thromb Haemost 2014;12:650‚Äì9. https://doi.org/10.1111/jth. 
12544 
835. Pengo V, Palareti G, Cucchini U, Molinatti M, Del Bono R, Baudo F, et al. Low-intensity 
oral anticoagulant plus low-dose aspirin during the first six months versus 
standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses 
(LIWACAP). Clin Appl Thromb Hemost 2007;13:241‚Äì8. https://doi.org/10.1177/ 
1076029607302544 
836. Meschengieser SS, Fondevila CG, Frontroth J, Santarelli MT, Lazzari MA. Low-intensity 
oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation 
alone: a randomized trial in patients with mechanical prosthetic heart valves. J 
Thorac 
Cardiovasc 
Surg 
1997;113:910‚Äì6. 
https://doi.org/10.1016/s0022- 
5223(97)70264-2 
837. Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, et al. Reduced 
anticoagulation after mechanical aortic valve replacement: interim results from the 
prospective randomized On-X valve anticoagulation clinical trial randomized Food 
and Drug Administration investigational device exemption trial. J Thorac Cardiovasc 
Surg 2014;147:1202‚Äì10; discussion 1210‚Äì1201. https://doi.org/10.1016/j.jtcvs.2014. 
01.004 
838. Hanigan S, Kong X, Haymart B, Kline-Rogers E, Kaatz S, Krol G, et al. Standard versus 
higher intensity anticoagulation for patients with mechanical aortic valve replacement 
and additional risk factors for thromboembolism. Am J Cardiol 2021;159:100‚Äì6. https:// 
doi.org/10.1016/j.amjcard.2021.08.023 
839. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, et al. 
Association of proton pump inhibitors with reduced risk of warfarin-related serious 
upper gastrointestinal bleeding. Gastroenterology 2016;151:1105‚Äì12.e1110. https:// 
doi.org/10.1053/j.gastro.2016.08.054 
840. Kurlander JE, Barnes GD, Fisher A, Gonzalez JJ, Helminski D, Saini SD, et al. Association 
of antisecretory drugs with upper gastrointestinal bleeding in patients using oral anticoagulants: a systematic review and meta-analysis. Am J Med 2022;135:1231‚Äì43.e1238.  
https://doi.org/10.1016/j.amjmed.2022.05.031 
841. Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP, et al. Oral vitamin K 
versus placebo to correct excessive anticoagulation in patients receiving warfarin: a 
randomized trial. Ann Intern Med 2009;150:293‚Äì300. https://doi.org/10.7326/0003- 
4819-150-5-200903030-00005 
842. Khatib R, Ludwikowska M, Witt DM, Ansell J, Clark NP, Holbrook A, et al. Vitamin K 
for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and 
meta-analysis. Blood Adv 2019;3:789‚Äì96. https://doi.org/10.1182/bloodadvances. 
2018025163 
843. Gunther KE, Conway G, Leibach L, Crowther MA. Low-dose oral vitamin K is safe and 
effective for outpatient management of patients with an INR>10. Thromb Res 2004; 
113:205‚Äì9. https://doi.org/10.1016/j.thromres.2004.03.004 
844. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific 
and Standardization Committee of the International Society on Thrombosis and 
Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic 
medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692‚Äì4. https:// 
doi.org/10.1111/j.1538-7836.2005.01204.x 
845. Brekelmans MPA, van Ginkel K, Daams JG, Hutten BA, Middeldorp S, Coppens M. 
Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis. J Thromb 
Thrombolysis 2017;44:118‚Äì29. https://doi.org/10.1007/s11239-017-1506-0 
846. Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, et al. 
Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. 
A systematic review and meta-analysis. Thromb Haemost 2016;116:879‚Äì90. https://doi. 
org/10.1160/TH16-04-0266 
847. Hood C, Goldstein JN, Milling TJ, Refaai MA, Bajcic P, Goldstein B, et al. INR and vitamin K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma. Blood Adv 2023;7:2206‚Äì13. https://doi.org/10.1182/bloodadvances.2022009015 
848. Sarode R, Milling TJJ, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and 
safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb 
study. Circulation 2013;128:1234‚Äì43. https://doi.org/10.1161/CIRCULATIONAHA. 
113.002283 
849. Erdoes G, Koster A, Ortmann E, Meesters MI, Bolliger D, Baryshnikova E, et al. A 
European consensus statement on the use of four-factor prothrombin complex concentrate for cardiac and non-cardiac surgical patients. Anaesthesia 2021;76:381‚Äì92.  
https://doi.org/10.1111/anae.15181 
850. Eichinger S. Reversing vitamin K antagonists: making the old new again. Hematology Am 
Soc Hematol Educ Program 2016;2016:605‚Äì11. https://doi.org/10.1182/asheducation- 
2016.1.605 
851. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al. Pacemaker or 
defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013;368: 
2084‚Äì93. https://doi.org/10.1056/NEJMoa1302946 
852. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, et al. 
Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the 
Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients 
Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014;129: 
2638‚Äì44. https://doi.org/10.1161/CIRCULATIONAHA.113.006426 
853. Engelen ET, Schutgens RE, Mauser-Bunschoten EP, van Es RJJ, van Galen KPM. 
Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions. Cochrane Database Syst Rev 2018;7: 
CD012293. https://doi.org/10.1002/14651858.CD012293.pub2 
854. Ghanbari H, Phard WS, Al-Ameri H, Latchamsetty R, Jongnarngsin K, Crawford T, 
et al. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to 
heparin-based bridging therapy during implantation of cardiac rhythm devices. Am J 
Cardiol 2012;110:1482‚Äì8. https://doi.org/10.1016/j.amjcard.2012.06.057 
855. Makuloluwa AK, Tiew S, Briggs M. Peri-operative management of ophthalmic patients 
on anti-thrombotic agents: a literature review. Eye (Lond) 2019;33:1044‚Äì59. https:// 
doi.org/10.1038/s41433-019-0382-6 
856. Nagata N, Yasunaga H, Matsui H, Fushimi K, Watanabe K, Akiyama J, et al. Therapeutic 
endoscopy-related GI bleeding and thromboembolic events in patients using warfarin 
or direct oral anticoagulants: results from a large nationwide database analysis. Gut 
2018;67:1805‚Äì12. https://doi.org/10.1136/gutjnl-2017-313999


<!-- PAGE 99 -->

### Page 99

857. Dohler I, Roder D, Schlesinger T, Nassen CA, Germer CT, Wiegering A, et al. 
Risk-adjusted perioperative bridging anticoagulation reduces bleeding complications 
without increasing thromboembolic events in general and visceral surgery. BMC 
Anesthesiol 2023;23:56. https://doi.org/10.1186/s12871-023-02017-z 
858. Shah S, Nayfeh T, Hasan B, Urtecho M, Firwana M, Saadi S, et al. Perioperative management of vitamin K antagonists and direct oral anticoagulants: a systematic review 
and meta-analysis. Chest 2023;163:1245‚Äì57. https://doi.org/10.1016/j.chest.2022.11. 
032 
859. Gigante B, Tamargo J, Agewall S, Atar D, Ten Berg J, Campo G, et al. Update on antithrombotic therapy and body mass: a clinical consensus statement of the 
European 
Society 
of 
Cardiology 
Working 
Group 
on 
Cardiovascular 
Pharmacotherapy and the European Society of Cardiology Working Group on 
Thrombosis. Eur Heart J Cardiovasc Pharmacother 2024;10:614‚Äì45. https://doi.org/10. 
1093/ehjcvp/pvae064 
860. Jeppsson A, Rocca B, Hansson EC, Gudbjartsson T, James S, Kaski JK, et al. 2024 
EACTS Guidelines on perioperative medication in adult cardiac surgery. Eur J 
Cardiothorac Surg 2024;67:ezae355. https://doi.org/10.1093/ejcts/ezae355 
861. Kovacs MJ, Wells PS, Anderson DR, Lazo-Langner A, Kearon C, Bates SM, et al. 
Postoperative low molecular weight heparin bridging treatment for patients at high 
risk of arterial thromboembolism (PERIOP2): double blind randomised controlled 
trial. BMJ 2021;373:n1205. https://doi.org/10.1136/bmj.n1205 
862. Kuo HC, Liu FL, Chen JT, Cherng YG, Tam KW, Tai YH. Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: a systematic review and 
meta-analysis. Clin Cardiol 2020;43:441‚Äì9. https://doi.org/10.1002/clc.23336 
863. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and 
meta-analysis of bleeding and thromboembolic rates. Circulation 2012;126:1630‚Äì9.  
https://doi.org/10.1161/CIRCULATIONAHA.112.105221 
864. Yong JW, Yang LX, Ohene BE, Zhou YJ, Wang ZJ. Periprocedural heparin bridging in 
patients receiving oral anticoagulation: a systematic review and meta-analysis. BMC 
Cardiovasc Disord 2017;17:295. https://doi.org/10.1186/s12872-017-0719-7 
865. Brennan JM, Edwards FH, Zhao Y, O‚ÄôBrien S, Booth ME, Dokholyan RS, et al. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of 
Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 2012; 
60:971‚Äì7. https://doi.org/10.1016/j.jacc.2012.05.029 
866. Rafiq S, Steinbr√ºchel DA, Lille√∏r NB, Moller CH, Lund JT, Thiis JJ, et al. Antithrombotic 
therapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a randomized controlled trial. Thromb Res 2017;150:104‚Äì10. https://doi.org/10.1016/j. 
thromres.2016.11.021 
867. Butnaru A, Shaheen J, Tzivoni D, Tauber R, Bitran D, Silberman S. Diagnosis and treatment of early bioprosthetic malfunction in the mitral valve position due to thrombus 
formation. Am J Cardiol 2013;112:1439‚Äì44. https://doi.org/10.1016/j.amjcard.2013.06. 
014 
868. Russo A, Grigioni F, Avierinos JF, Freeman WK, Suri R, Michelena H, et al. 
Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol 2008;51:1203‚Äì11.  
https://doi.org/10.1016/j.jacc.2007.10.058 
869. Dangas GD, Tijssen JGP, W√∂hrle J, Sondergaard L, Gilard M, Mollmann H, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 
2020;382:120‚Äì9. https://doi.org/10.1056/NEJMoa1911425 
870. Alkhalil M, Edwards R, Puri R, Kalra A, Zaman A, Das R. Aspirin versus dual antiplatelet 
therapy in patients undergoing trans-catheter aortic valve implantation, updated 
meta-analysis. Cardiovasc Drugs Ther 2022;36:279‚Äì83. https://doi.org/10.1007/ 
s10557-021-07146-6 
871. El B√®ze N, Himbert D, Suc G, Brochet E, Ajzenberg N, Cailliau A, et al. Comparison of 
direct oral anticoagulants vs vitamin K antagonists after transcatheter mitral valve replacement. J Am Coll Cardiol 2024;83:334‚Äì46. https://doi.org/10.1016/j.jacc.2023.10. 
031 
872. Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M, et al. 
Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation 
and bioprosthetic valves. Circulation 2017;135:1273‚Äì5. https://doi.org/10.1161/ 
CIRCULATIONAHA.116.026714 
873. Guimar√£es HP, Lopes RD, de Barros E Silva PGM, Liporace IL, Sampaio RO, 
Tarasoutchi F, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic 
mitral valve. N Engl J Med 2020;383:2117‚Äì26. https://doi.org/10.1056/NEJM 
oa2029603 
874. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Angoulvant D, 
et al. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thromb 
Haemost 2016;115:1056‚Äì63. https://doi.org/10.1160/TH16-01-0007 
875. Shim CY, Seo J, Kim YJ, Lee SH, De Caterina R, Lee S, et al. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a 
randomized clinical trial. J Thorac Cardiovasc Surg 2023;165:58‚Äì67.e54. https://doi.org/ 
10.1016/j.jtcvs.2021.01.127 
876. Siontis KC, Yao X, Gersh BJ, Noseworthy PA. Direct oral anticoagulants in patients 
with atrial fibrillation and valvular heart disease other than significant mitral stenosis 
and mechanical valves: a meta-analysis. Circulation 2017;135:714‚Äì6. https://doi.org/ 
10.1161/CIRCULATIONAHA.116.026793 
877. Suppah M, Kamal A, Saadoun R, Baradeiya AMA, Abraham B, Alsidawi S, et al. An 
evidence-based approach to anticoagulation therapy comparing direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation and bioprosthetic 
valves: a systematic review, meta-analysis, and network meta-analysis. Am J Cardiol 
2023;206:132‚Äì50. https://doi.org/10.1016/j.amjcard.2023.07.141 
878. Nijenhuis VJ, Brouwer J, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al. 
Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 2020;382:1696‚Äì707. https://doi.org/10.1056/NEJMoa1915152 
879. Van Mieghem NM, Unverdorben M, Hengstenberg C, Mollmann H, Mehran R, 
Lopez-Otero D, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after 
TAVR. N Engl J Med 2021;385:2150‚Äì60. https://doi.org/10.1056/NEJMoa2111016 
880. Collet JP, Van Belle E, Thiele H, Berti S, Lhermusier T, Manigold T, et al. Apixaban vs. 
standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur 
Heart J 2022;43:2783‚Äì97. https://doi.org/10.1093/eurheartj/ehac242 
881. Brouwer J, Nijenhuis VJ, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al. 
Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N 
Engl J Med 2020;383:1447‚Äì57. https://doi.org/10.1056/NEJMoa2017815 
882. Maes F, Stabile E, Ussia GP, Tamburino C, Pucciarelli A, Masson JB, et al. Meta-analysis 
comparing single versus dual antiplatelet therapy following transcatheter aortic valve 
implantation. Am J Cardiol 2018;122:310‚Äì5. https://doi.org/10.1016/j.amjcard.2018. 
04.006 
883. Rod√©s-Cabau J, Masson JB, Welsh RC, Garcia Del Blanco B, Pelletier M, Webb JG, et al. 
Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE 
(Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve 
Implantation) randomized clinical trial. JACC Cardiovasc Interv 2017;10:1357‚Äì65.  
https://doi.org/10.1016/j.jcin.2017.04.014 
884. Meurin P, Tabet JY, Iliou MC, Pierre B, Corone S, Cristofini P, et al. Thromboembolic 
events early after mitral valve repair: incidence and predictive factors. Int J Cardiol 2008; 
126:45‚Äì52. https://doi.org/10.1016/j.ijcard.2007.03.115 
885. van der Wall SJ, Olsthoorn JR, Heuts S, Klautz RJM, Tomsic A, Jansen EK, et al. 
Antithrombotic therapy after mitral valve repair: VKA or aspirin? J Thromb 
Thrombolysis 2018;46:473‚Äì81. https://doi.org/10.1007/s11239-018-1724-0 
886. Mazur PK, Arghami A, Macielak SA, Nei SD, Viehman JK, King KS, et al. Apixaban for 
anticoagulation after robotic mitral valve repair. Ann Thorac Surg 2023;115:966‚Äì73.  
https://doi.org/10.1016/j.athoracsur.2022.07.045 
887. Paparella D, Di Mauro M, Bitton Worms K, Bolotin G, Russo C, Trunfio S, et al. 
Antiplatelet versus oral anticoagulant therapy as antithrombotic prophylaxis after mitral valve repair. J Thorac Cardiovasc Surg 2016;151:1302‚Äì8.e1301. https://doi.org/10. 
1016/j.jtcvs.2015.12.036 
888. Trevis J, Akowuah E. Which antithrombotic strategy provides the best outcomes after 
mitral valve repair in patients who remain in sinus rhythm? Interact Cardiovasc Thorac 
Surg 2022;35:ivac085. https://doi.org/10.1093/icvts/ivac085 
889. Moser N, Omar MA, Koshman SL, Lin M, Youngson E, Kent W, et al. Direct oral anticoagulants for atrial fibrillation in early postoperative valve repair or bioprosthetic replacement. J Thorac Cardiovasc Surg 2023;168:523‚Äì32.e3. https://doi.org/10.1016/j. 
jtcvs.2023.03.004 
890. Mentias A, Saad M, Michael M, Nakhla S, Menon V, Harb S, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation and valve replacement or repair. J Am Heart Assoc 2022;11:e026666. https://doi.org/10.1161/jaha.122.026666 
891. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Babuty D, et al. 
Prognostic value of CHA2DS2-VASc score in patients with ‚Äònon-valvular atrial fibrillation‚Äô and valvular heart disease: the Loire Valley Atrial Fibrillation Project. Eur Heart J 
2015;36:1822‚Äì30. https://doi.org/10.1093/eurheartj/ehv163 
892. Jochheim D, Barbanti M, Capretti G, Stefanini GG, Hapfelmeier A, Zadrozny M, et al. 
Oral anticoagulant type and outcomes after transcatheter aortic valve replacement. 
JACC Cardiovasc Interv 2019;12:1566‚Äì76. https://doi.org/10.1016/j.jcin.2019.03.003 
893. Didier R, Lhermusier T, Auffret V, Eltchaninoff H, Le Breton H, Cayla G, et al. TAVR 
patients requiring anticoagulation: direct oral anticoagulant or vitamin K antagonist? 
JACC Cardiovasc Interv 2021;14:1704‚Äì13. https://doi.org/10.1016/j.jcin.2021.05.025 
894. Tanawuttiwat T, Stebbins A, Marquis-Gravel G, Vemulapalli S, Kosinski AS, Cheng A. 
Use of direct oral anticoagulant and outcomes in patients with atrial fibrillation after 
transcatheter aortic valve replacement: insights from the STS/ACC TVT registry. J 
Am Heart Assoc 2022;11:e023561. https://doi.org/10.1161/jaha.121.023561 
895. VARC-3 Writing Committee; G√©n√©reux P, Piazza N, Alu MC, Nazif T, Hahn RT, et al. 
Valve academic research consortium 3: updated endpoint definitions for aortic valve 
clinical research. J Am Coll Cardiol 2021;77:2717‚Äì46. https://doi.org/10.1016/j.jacc. 
2021.02.038 
896. Pibarot P, Herrmann HC, Wu C, Hahn RT, Otto CM, Abbas AE, et al. Standardized 
definitions for bioprosthetic valve dysfunction following aortic or mitral valve replacement: JACC state-of-the-art review. J Am Coll Cardiol 2022;80:545‚Äì61. https://doi.org/ 
10.1016/j.jacc.2022.06.002 
897. Kaneko T, Bapat VN, Alakhtar AM, Zaid S, George I, Grubb KJ, et al. Transcatheter 
heart valve explantation for transcatheter aortic valve replacement failure: a Heart  
ESC Guidelines                                                                                                                                                                                               99


<!-- PAGE 100 -->

### Page 100

Valve Collaboratory expert consensus document on operative techniques. J Thorac 
Cardiovasc Surg 2024;169:878‚Äì89. https://doi.org/10.1016/j.jtcvs.2024.04.025 
898. Bleiziffer S, Rudolph TK. Patient prosthesis mismatch after SAVR and TAVR. Front 
Cardiovasc Med 2022;9:761917. https://doi.org/10.3389/fcvm.2022.761917 
899. Hirji SA, Percy ED, Zogg CK, Malarczyk A, Harloff MT, Yazdchi F, et al. Comparison of 
in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real-world outcomes. Eur Heart J 2020;41:2747‚Äì55. https://doi.org/10.1093/ 
eurheartj/ehaa252 
900. Tam DY, Vo TX, Wijeysundera HC, Dvir D, Friedrich JO, Fremes SE. Transcatheter 
valve-in-valve versus redo surgical aortic valve replacement for the treatment of degenerated bioprosthetic aortic valve: a systematic review and meta-analysis. Catheter 
Cardiovasc Interv 2018;92:1404‚Äì11. https://doi.org/10.1002/ccd.27686 
901. Bleiziffer S, Simonato M, Webb JG, Rodes-Cabau J, Pibarot P, Kornowski R, et al. 
Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves. Eur Heart J 2020;41:2731‚Äì42. https://doi.org/10.1093/eurheartj/ehaa544 
902. Guerrero M, Vemulapalli S, Xiang Q, Wang DD, Eleid M, Cabalka AK, et al. Thirty-day 
outcomes of transcatheter mitral valve replacement for degenerated mitral bioprostheses (valve-in-valve), failed surgical rings (valve-in-ring), and native valve with severe mitral annular calcification (valve-in-mitral annular calcification) in the United States: data 
from the Society of Thoracic Surgeons/American College of Cardiology/Transcatheter 
Valve Therapy Registry. Circ Cardiovasc Interv 2020;13:e008425. https://doi.org/10. 
1161/CIRCINTERVENTIONS.119.008425 
903. Eleid MF, Whisenant BK, Cabalka AK, Williams MR, Nejjari M, Attias D, et al. Early outcomes of percutaneous transvenous transseptal transcatheter valve implantation in 
failed bioprosthetic mitral valves, ring annuloplasty, and severe mitral annular calcification. JACC Cardiovasc Interv 2017;10:1932‚Äì42. https://doi.org/10.1016/j.jcin.2017.08. 
014 
904. Little SH, Bapat V, Blanke P, Guerrero M, Rajagopal V, Siegel R. Imaging guidance for 
transcatheter mitral valve intervention on prosthetic valves, rings, and annular calcification. JACC Cardiovasc Imaging 2021;14:22‚Äì40. https://doi.org/10.1016/j.jcmg.2019.10. 
027 
905. Fallon JM, DeSimone JP, Brennan JM, O‚ÄôBrien S, Thibault DP, DiScipio AW, et al. The 
incidence and consequence of prosthesis-patient mismatch after surgical aortic valve 
replacement. Ann Thorac Surg 2018;106:14‚Äì22. https://doi.org/10.1016/j.athoracsur. 
2018.01.090 
906. Flameng W, Herregods MC, Vercalsteren M, Herijgers P, Bogaerts K, Meuris B. 
Prosthesis-patient mismatch predicts structural valve degeneration in bioprosthetic 
heart 
valves. 
Circulation 
2010;121:2123‚Äì9. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.109.901272 
907. Zorn GLI, Little SH, Tadros P, Deeb GM, Gleason TG, Heiser J, et al. Prosthesis‚Äìpatient mismatch in high-risk patients with severe aortic stenosis: a randomized trial of 
a self-expanding prosthesis. J Thorac Cardiovasc Surg 2016;151:1014‚Äì23.e3, 
1023.e1011‚Äì1013. https://doi.org/10.1016/j.jtcvs.2015.10.070 
908. Thourani VH, Abbas AE, Ternacle J, Hahn RT, Makkar R, Kodali SK, et al. 
Patient-prosthesis mismatch after surgical aortic valve replacement: analysis of the 
PARTNER trials. Ann Thorac Surg 2024;117:1164‚Äì71. https://doi.org/10.1016/j. 
athoracsur.2024.01.023 
909. Tomii D, Okuno T, Heg D, Nakase M, Lanz J, Praz F, et al. Long-term outcomes of measured and predicted prosthesis-patient mismatch following transcatheter aortic valve 
replacement. EuroIntervention 2023;19:746‚Äì56. https://doi.org/10.4244/eij-d-23- 
00456 
910. Vriesendorp MD, De Lind Van Wijngaarden RAF, Head SJ, Kappetein AP, Hickey GL, 
Rao V, et al. The fallacy of indexed effective orifice area charts to predict prosthesis‚Äì 
patient mismatch after prosthesis implantation. Eur Heart J Cardiovasc Imaging 2020;21: 
1116‚Äì22. https://doi.org/10.1093/ehjci/jeaa044 
911. Sorajja P, Bae R, Lesser JA, Pedersen WA. Percutaneous repair of paravalvular prosthetic regurgitation: patient selection, techniques and outcomes. Heart 2015;101: 
665‚Äì73. https://doi.org/10.1136/heartjnl-2014-306270 
912. Ruiz CE, Hahn RT, Berrebi A, Borer JS, Cutlip DE, Fontana G, et al. Clinical trial principles and endpoint definitions for paravalvular leaks in surgical prosthesis. Eur Heart J 
2018;39:1224‚Äì45. https://doi.org/10.1093/eurheartj/ehx211 
913. Laplace G, Lafitte S, Lab√®que JN, Perron JM, Baudet E, Deville C, et al. Clinical significance of early thrombosis after prosthetic mitral valve replacement: a postoperative 
monocentric study of 680 patients. J Am Coll Cardiol 2004;43:1283‚Äì90. https://doi. 
org/10.1016/j.jacc.2003.09.064 
914. Symersky P, Budde RPJ, de Mol BAJM, Prokop M. Comparison of multidetector-row 
computed tomography to echocardiography and fluoroscopy for evaluation of patients with mechanical prosthetic valve obstruction. Am J Cardiol 2009;104:1128‚Äì34.  
https://doi.org/10.1016/j.amjcard.2009.05.061 
915. Egbe AC, Pislaru SV, Pellikka PA, Poterucha JT, Schaff HV, Maleszewski JJ, et al. 
Bioprosthetic valve thrombosis versus structural failure: clinical and echocardiographic 
predictors. J Am Coll Cardiol 2015;66:2285‚Äì94. https://doi.org/10.1016/j.jacc.2015.09. 
022 
916. Rheude T, Pellegrini C, Stortecky S, Marwan M, Xhepa E, Ammon F, et al. Meta-analysis 
of bioprosthetic valve thrombosis after transcatheter aortic valve implantation. Am J 
Cardiol 2021;138:92‚Äì9. https://doi.org/10.1016/j.amjcard.2020.10.018 
917. Blanke P, Leipsic JA, Popma JJ, Yakubov SJ, Deeb GM, Gada H, et al. Bioprosthetic aortic valve leaflet thickening in the Evolut Low Risk sub-study. J Am Coll Cardiol 2020;75: 
2430‚Äì42. https://doi.org/10.1016/j.jacc.2020.03.022 
918. Chakravarty T, Sondergaard L, Friedman J, De Backer O, Berman D, Kofoed KF, et al. 
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: 
an observational study. Lancet 2017;389:2383‚Äì92. https://doi.org/10.1016/S0140- 
6736(17)30757-2 
919. Makkar RR, Blanke P, Leipsic J, Thourani V, Chakravarty T, Brown D, et al. Subclinical 
leaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3 cardiac computed tomography substudy. J Am Coll Cardiol 2020;75:3003‚Äì15. https://doi. 
org/10.1016/j.jacc.2020.04.043 
920. De Backer O, Dangas GD, Jilaihawi H, Leipsic JA, Terkelsen CJ, Makkar R, et al. 
Reduced leaflet motion after transcatheter aortic-valve replacement. N Engl J Med 
2020;382:130‚Äì9. https://doi.org/10.1056/NEJMoa1911426 
921. Montalescot G, Redheuil A, Vincent F, Desch S, De Benedictis M, Eltchaninoff H, et al. 
Apixaban and valve thrombosis after transcatheter aortic valve replacement: the 
ATLANTIS-4D-CT randomized clinical trial substudy. JACC Cardiovasc Interv 2022; 
15:1794‚Äì804. https://doi.org/10.1016/j.jcin.2022.07.014 
922. Ruile P, Jander N, Blanke P, Schoechlin S, Rein√∂hl J, Gick M, et al. Course of early subclinical leaflet thrombosis after transcatheter aortic valve implantation with or without 
oral anticoagulation. Clin Res Cardiol 2017;106:85‚Äì95. https://doi.org/10.1007/s00392- 
016-1052-3 
923. G√ºnduz S, √ñzkan M, Kal√ßik M, G√ºrsoy OM, Astarcioglu MA, Karakoyun S, et al. 
Sixty-four-section cardiac computed tomography in mechanical prosthetic heart valve 
dysfunction: thrombus or pannus. Circ Cardiovasc Imaging 2015;8:e003246. https://doi. 
org/10.1161/CIRCIMAGING.115.003246 
924. Lancellotti P, Pibarot P, Chambers J, Edvardsen T, Delgado V, Dulgheru R, et al. 
Recommendations for the imaging assessment of prosthetic heart valves: a report 
from the European Association of Cardiovascular Imaging endorsed by the Chinese 
Society of Echocardiography, the Inter-American Society of Echocardiography, and 
the Brazilian Department of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 
2016;17:589‚Äì90. https://doi.org/10.1093/ehjci/jew025 
925. Tanis W, Habets J, van den Brink RBA, Symersky P, Budde RP, Chamuleau SA. 
Differentiation of thrombus from pannus as the cause of acquired mechanical prosthetic heart valve obstruction by non-invasive imaging: a review of the literature. Eur 
Heart J Cardiovasc Imaging 2014;15:119‚Äì29. https://doi.org/10.1093/ehjci/jet127 
926. Karthikeyan G, Senguttuvan NB, Joseph J, Devasenapathy N, Bahl VK, Airan B. Urgent 
surgery compared with fibrinolytic therapy for the treatment of left-sided prosthetic 
heart valve thrombosis: a systematic review and meta-analysis of observational studies. 
Eur Heart J 2013;34:1557‚Äì66. https://doi.org/10.1093/eurheartj/ehs486 
927. Castilho FM, De Sousa MR, Mendonca AL, Ribeiro AL, Caceres-Loriga FM. 
Thrombolytic therapy or surgery for valve prosthesis thrombosis: systematic review 
and meta-analysis. J Thromb Haemost 2014;12:1218‚Äì28. https://doi.org/10.1111/jth. 
12577 
928. Chopard R, Vidoni C, Besutti M, Ismail M, Ecarnot F, Favoulet B, et al. Surgery versus 
thrombolytic therapy for the management of left-sided prosthetic valve thrombosis 
without hemodynamic compromise: a systematic review and meta-analysis. J Am 
Heart Assoc 2024;13:e035143. https://doi.org/10.1161/jaha.124.035143 
929. √ñzkan M, G√ºnduz S, G√ºner A, Kalcik M, Gursoy MO, Uygur B, et al. Thrombolysis or 
surgery in patients with obstructive mechanical valve thrombosis: the multicenter 
HATTUSHA study. J Am Coll Cardiol 2022;79:977‚Äì89. https://doi.org/10.1016/j.jacc. 
2021.12.027 
930. √ñzkan M, G√ºnduz S, G√ºrsoy OM, Karakoyun S, Astarcioglu MA, Kalcik M, et al. 
Ultraslow thrombolytic therapy: a novel strategy in the management of PROsthetic 
MEchanical valve thrombosis and the prEdictors of outcomE: the ultra-slow 
PROMETEE trial. Am Heart J 2015;170:409‚Äì18. https://doi.org/10.1016/j.ahj.2015.04. 
025 
931. Sadeghipour P, Saedi S, Saneei L, Rafiee F, Yoosefi S, Parsaee M, et al. Fast vs. ultraslow 
thrombolytic infusion regimens in patients with obstructive mechanical prosthetic 
valve thrombosis: a pilot randomized clinical trial. Eur Heart J Cardiovasc 
Pharmacother 2022;8:668‚Äì76. https://doi.org/10.1093/ehjcvp/pvab083 
931a. Karthikeyan G, Rajashekar P, Devasenapathy N, Biswas S, Kidambi B, Singal A, et al. 
Urgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis: a 
randomized trial. Eur Heart J 2025:ehaf391. https://doi.org/10.1093/eurheartj/ehaf391 
932. Bemurat LR, Laffort PR, Deville CJ, Roques XG, Baudet EM, Roudaut RP. Management 
of nonobstructive thrombosis of prosthetic mitral valve in asymptomatic patients in 
the early postoperative period: a study in 20 patients. Echocardiography 1999;16: 
339‚Äì46. https://doi.org/10.1111/j.1540-8175.1999.tb00823.x 
933. Mutuberr√≠a-Urdaniz M, Rodr√≠guez-Palomares JF, Ferreira I, Ba√±eras J, Teixid√≥ G, 
Guti√©rrez L, et al. Non-obstructive prosthetic heart valve thrombosis (NOPVT): really 
a benign entity? Int J Cardiol 2015;197:16‚Äì22. https://doi.org/10.1016/j.ijcard.2015.06. 
021


<!-- PAGE 101 -->

### Page 101

934. Egbe AC, Connolly HM, Pellikka PA, Schaff HV, Hanna R, Maleszewski JJ, et al. 
Outcomes of warfarin therapy for bioprosthetic valve thrombosis of surgically implanted valves: a prospective study. JACC Cardiovasc Interv 2017;10:379‚Äì87. https:// 
doi.org/10.1016/j.jcin.2016.11.027 
935. Jose J, Sulimov DS, El-Mawardy M, Sato T, Allali A, Holy EW, et al. Clinical bioprosthetic 
heart valve thrombosis after transcatheter aortic valve replacement: incidence, characteristics, and treatment outcomes. JACC Cardiovasc Interv 2017;10:686‚Äì97. https:// 
doi.org/10.1016/j.jcin.2017.01.045 
936. Petrescu I, Egbe AC, Ionescu F, Nkomo VT, Greason KL, Pislaru C, et al. Long-term 
outcomes of anticoagulation for bioprosthetic valve thrombosis. J Am Coll Cardiol 
2020;75:857‚Äì66. https://doi.org/10.1016/j.jacc.2019.12.037 
937. Pislaru SV, Hussain I, Pellikka PA, Maleszewski JJ, Hanna RD, Schaff HV, et al. 
Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic 
valve thrombosis: lessons from a case series. Eur J Cardiothorac Surg 2015;47: 
725‚Äì32. https://doi.org/10.1093/ejcts/ezu201 
938. Puri R, Auffret V, Rod√©s-Cabau J. Bioprosthetic valve thrombosis. J Am Coll Cardiol 
2017;69:2193‚Äì211. https://doi.org/10.1016/j.jacc.2017.02.051 
939. Sellers SL, Turner CT, Sathananthan J, Cartlidge TRG, Sin F, Bouchareb R, et al. 
Transcatheter aortic heart valves: histological analysis providing insight to leaflet thickening and structural valve degeneration. JACC Cardiovasc Imaging 2019;12:135‚Äì45.  
https://doi.org/10.1016/j.jcmg.2018.06.028 
940. Alkhouli M, Rihal CS, Zack CJ, Eleid MF, Maor E, Sarraf M, et al. Transcatheter and surgical management of mitral paravalvular leak: long-term outcomes. JACC Cardiovasc 
Interv 2017;10:1946‚Äì56. https://doi.org/10.1016/j.jcin.2017.07.046 
941. Dvir D, Webb JG, Bleiziffer S, Pasic M, Waksman R, Kodali S, et al. Transcatheter aortic 
valve implantation in failed bioprosthetic surgical valves. JAMA 2014;312:162‚Äì70.  
https://doi.org/10.1001/jama.2014.7246 
942. Yoon SH, Whisenant BK, Bleiziffer S, Delgado V, Dhoble A, Schofer N, et al. Outcomes 
of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification. Eur Heart J 2019;40:441‚Äì51. https://doi. 
org/10.1093/eurheartj/ehy590 
943. Whisenant B, Kapadia SR, Eleid MF, Kodali SK, McCabe JM, Krishnaswamy A, et al. 
One-year outcomes of mitral valve-in-valve using the SAPIEN 3 transcatheter heart 
valve. JAMA Cardiol 2020;5:1245‚Äì52. https://doi.org/10.1001/jamacardio.2020.2974 
944. McElhinney DB, Aboulhosn JA, Dvir D, Whisenant B, Zhang Y, Eicken A, et al. 
Mid-term valve-related outcomes after transcatheter tricuspid valve-in-valve or 
valve-in-ring replacement. J Am Coll Cardiol 2019;73:148‚Äì57. https://doi.org/10.1016/ 
j.jacc.2018.10.051 
945. Muratori M, Montorsi P, Teruzzi G, Celeste F, Doria E, Alamanni F, et al. Feasibility and 
diagnostic accuracy of quantitative assessment of mechanical prostheses leaflet motion 
by transthoracic and transesophageal echocardiography in suspected prosthetic valve 
dysfunction. Am J Cardiol 2006;97:94‚Äì100. https://doi.org/10.1016/j.amjcard.2005.07. 
112 
946. Barbetseas J, Nagueh SF, Pitsavos C, Toutouzas PK, Qui√±ones MA, Zoghbi WA. 
Differentiating thrombus from pannus formation in obstructed mechanical prosthetic 
valves: an evaluation of clinical, transthoracic and transesophageal echocardiographic 
parameters. J Am Coll Cardiol 1998;32:1410‚Äì7. https://doi.org/10.1016/s0735- 
1097(98)00385-4 
947. Such√° D, Symersky P, Vonken EJPA, Provoost E, Chamuleau SA, Budde RP. 
Multidetector-row computed tomography allows accurate measurement of mechanical prosthetic heart valve leaflet closing angles compared with fluoroscopy. J Comput 
Assist Tomogr 2014;38:451‚Äì6. https://doi.org/10.1097/RCT.0b013e3182ab5f15 
948. Daniel WG, M√ºgge A, Grote J, Hausmann D, Nikutta P, Laas J, et al. Comparison of 
transthoracic and transesophageal echocardiography for detection of abnormalities 
of prosthetic and bioprosthetic valves in the mitral and aortic positions. Am J Cardiol 
1993;71:210‚Äì5. https://doi.org/10.1016/0002-9149(93)90740-4 
949. √ñzkan M, √áakal B, Karakoyun S, G√ºrsoy OM, √áevik C, Kal√ßƒ±k M, et al. Thrombolytic 
therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low- 
dose, slow infusion of tissue-type plasminogen activator. Circulation 2013;128:532‚Äì40.  
https://doi.org/10.1161/circulationaha.113.001145 
950. Taherkhani M, Hashemi SR, Hekmat M, Safi M, Taherkhani A, Movahed MR. 
Thrombolytic therapy for right-sided mechanical pulmonic and tricuspid valves: the largest survival analysis to date. Tex Heart Inst J 2015;42:543‚Äì7. https://doi.org/10.14503/ 
THIJ-14-4659 
951. Roudaut R, Roques X, Lafitte S, Choukroun E, Laborde N, Madona F, et al. Surgery for 
prosthetic valve obstruction. A single center study of 136 patients. Eur J Cardiothorac 
Surg 2003;24:868‚Äì72. https://doi.org/10.1016/s1010-7940(03)00568-2 
952. Nishanth KR, Shankar M, Srinivasa KH, Manjunath CN, Ravindranath KS. Fibrinolysis in 
left-sided mechanical prosthetic valve thrombosis with high INR. Eur Heart J Acute 
Cardiovasc Care 2020;9:S58‚Äì62. https://doi.org/10.1177/2048872619846329 
953. Separham A, Ghaffari S, Aslanabadi N, Sohrabi B, Ghojazadeh M, Anamzadeh E, et al. 
Prosthetic valve thrombosis. J Card Surg 2015;30:246‚Äì50. https://doi.org/10.1111/jocs. 
12510 
954. Farzaneh K, Mortazavi SH, Oraii A, Abbasi K, Salehi Omran A, Ahmadi Tafti SH, et al. 
Safety of thrombolytic therapy in patients with prosthetic heart valve thrombosis who 
have high international normalized ratio levels. J Card Surg 2020;35:2522‚Äì8. https://doi. 
org/10.1111/jocs.14777 
955. Jander N, Kienzle RP, Kayser G, Neumann FJ, Gohlke-Baerwolf C, Minners J. 
Usefulness of phenprocoumon for the treatment of obstructing thrombus in bioprostheses in the aortic valve position. Am J Cardiol 2012;109:257‚Äì62. https://doi. 
org/10.1016/j.amjcard.2011.08.038 
956. Oliver JM, Gallego P, Gonzalez A, Dominguez FJ, Gamallo C, Mesa JM. Bioprosthetic 
mitral valve thrombosis: clinical profile, transesophageal echocardiographic features, 
and follow-up after anticoagulant therapy. J Am Soc Echocardiogr 1996;9:691‚Äì9.  
https://doi.org/10.1016/s0894-7317(96)90066-8 
957. Agarwal S, Rajamanickam A, Bajaj NS, Griffin BP, Catacutan T, Svensson LG, et al. 
Impact of aortic stenosis on postoperative outcomes after noncardiac surgeries. Circ 
Cardiovasc 
Qual 
Outcomes 
2013;6:193‚Äì200. 
https://doi.org/10.1161/CIRC 
OUTCOMES.111.000091 
958. Taniguchi T, Morimoto T, Shiomi H, Ando K, Shirai S, Kanamori N, et al. Elective non- 
cardiac surgery in patients with severe aortic stenosis ‚Äî observations from the 
CURRENT AS registry. Circ J 2020;84:1173‚Äì82. https://doi.org/10.1253/circj.CJ-20- 
0026 
959. Luis SA, Dohaei A, Chandrashekar P, Scott CG, Padang R, Lokineni S, et al. Impact of 
aortic valve replacement for severe aortic stenosis on perioperative outcomes following major noncardiac surgery. Mayo Clin Proc 2020;95:727‚Äì37. https://doi.org/10.1016/ 
j.mayocp.2019.10.038 
960. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC 
Guidelines on cardiovascular assessment and management of patients undergoing non- 
cardiac surgery. Eur Heart J 2022;43:3826‚Äì924. https://doi.org/10.1093/eurheartj/ 
ehac270 
961. Okuno T, Demirel C, Tomii D, Erdoes G, Heg D, Lanz J, et al. Risk and timing of noncardiac surgery after transcatheter aortic valve implantation. JAMA Netw Open 2022;5: 
e2220689. https://doi.org/10.1001/jamanetworkopen.2022.20689 
962. Tashiro T, Pislaru SV, Blustin JM, Nkomo VT, Abel MD, Scott CG, et al. Perioperative 
risk of major non-cardiac surgery in patients with severe aortic stenosis: a reappraisal 
in contemporary practice. Eur Heart J 2014;35:2372‚Äì81. https://doi.org/10.1093/ 
eurheartj/ehu044 
963. Okuno T, Yahagi K, Horiuchi Y, Sato Y, Tanaka T, Koseki K, et al. The role of transcatheter aortic valve replacement in the patients with severe aortic stenosis requiring major non-cardiac surgery. Cardiovasc Interv Ther 2019;34:345‚Äì51. https://doi.org/10. 
1007/s12928-019-00575-z 
964. Calleja AM, Dommaraju S, Gaddam R, Cha S, Khandheria BK, Chaliki HP. Cardiac risk 
in patients aged >75 years with asymptomatic, severe aortic stenosis undergoing noncardiac surgery. Am J Cardiol 2010;105:1159‚Äì63. https://doi.org/10.1016/j.amjcard. 
2009.12.019 
965. Sohrabi B, Kazemi B, Mehryar A, Teimouri-Dereshki A, Toufan M, Aslanabadi N. 
Correlation between pulmonary artery pressure measured by echocardiography 
and right heart catheterization in patients with rheumatic mitral valve stenosis (a prospective study). Echocardiography 2016;33:7‚Äì13. https://doi.org/10.1111/echo.13000 
966. Smilowitz NR, Armanious A, Bangalore S, Ramakrishna H, Berger JS. Cardiovascular 
outcomes of patients with pulmonary hypertension undergoing noncardiac surgery. 
Am J Cardiol 2019;123:1532‚Äì7. https://doi.org/10.1016/j.amjcard.2019.02.006 
967. Bajaj NS, Agarwal S, Rajamanickam A, Parashar A, Poddar KL, Griffin BP, et al. Impact of 
severe mitral regurgitation on postoperative outcomes after noncardiac surgery. Am J 
Med 2013;126:529‚Äì35. https://doi.org/10.1016/j.amjmed.2012.12.005 
968. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C, Cifkova 
R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165‚Äì241. https://doi.org/10.1093/ 
eurheartj/ehy340 
969. Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, et al. Pregnancy 
outcomes in women with cardiovascular disease: evolving trends over 10 years in the 
ESC Registry Of Pregnancy And Cardiac disease (ROPAC). Eur Heart J 2019;40: 
3848‚Äì55. https://doi.org/10.1093/eurheartj/ehz136 
970. Pande SN, Yavana Suriya J, Ganapathy S, Pillai AA, Satheesh S, Mondal N, et al. 
Validation of risk stratification for cardiac events in pregnant women with valvular 
heart disease. J Am Coll Cardiol 2023;82:1395‚Äì406. https://doi.org/10.1016/j.jacc. 
2023.07.023 
971. van Hagen IM, Thorne SA, Taha N, Youssef G, Elnagar A, Gabriel H, et al. Pregnancy 
outcomes in women with rheumatic mitral valve disease: results from the Registry of 
Pregnancy and Cardiac Disease. Circulation 2018;137:806‚Äì16. https://doi.org/10.1161/ 
CIRCULATIONAHA.117.032561 
972. Orwat S, Diller GP, van Hagen IM, Schmidt R, Tobler D, Greutmann M, et al. Risk of 
pregnancy in moderate and severe aortic stenosis: from the multinational ROPAC 
registry. J Am Coll Cardiol 2016;68:1727‚Äì37. https://doi.org/10.1016/j.jacc.2016.07.750 
973. Meijboom LJ, Vos FE, Timmermans J, Boers GH, Zwinderman AH, Mulder BJ. 
Pregnancy and aortic root growth in the Marfan syndrome: a prospective study. Eur 
Heart J 2005;26:914‚Äì20. https://doi.org/10.1093/eurheartj/ehi103 
974. McKellar SH, MacDonald RJ, Michelena HI, Connolly HM, Sundt TMI. Frequency of cardiovascular events in women with a congenitally bicuspid aortic valve in a single  
ESC Guidelines                                                                                                                                                                                            101


<!-- PAGE 102 -->

### Page 102

community and effect of pregnancy on events. Am J Cardiol 2011;107:96‚Äì9. https://doi. 
org/10.1016/j.amjcard.2010.08.061 
975. Wichert-Schmitt B, Grewal J, Malinowski AK, Pfaller B, Losenno KL, Kiess MC, et al. 
Outcomes of pregnancy in women with bioprosthetic heart valves with or without 
valve dysfunction. J Am Coll Cardiol 2022;80:2014‚Äì24. https://doi.org/10.1016/j.jacc. 
2022.09.019 
976. van Hagen IM, Roos-Hesselink JW, Ruys TPE, Merz WM, Goland S, Gabriel H, et al. 
Pregnancy in women with a mechanical heart valve: data of the European Society of 
Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation 2015; 
132:132‚Äì42. https://doi.org/10.1161/CIRCULATIONAHA.115.015242 
977. Pfaller B, Dave Javier A, Grewal J, Gabarin N, Colman J, Kiess M, et al. Risk associated 
with valvular regurgitation during pregnancy. J Am Coll Cardiol 2021;77:2656‚Äì64.  
https://doi.org/10.1016/j.jacc.2021.03.327 
978. Hameed A, Karaalp IS, Tummala PP, Wani OR, Canetti M, Akhter MW, et al. The effect 
of valvular heart disease on maternal and fetal outcome of pregnancy. J Am Coll Cardiol 
2001;37:893‚Äì9. https://doi.org/10.1016/s0735-1097(00)01198-0 
979. Hoover E, Corlin T, Lohr J, Sabol B, Yamamura Y, Jacobs K, et al. TAVR beyond fetal 
viability: an alternative to preterm delivery in symptomatic severe aortic stenosis. JACC 
Case Rep 2023;27:102104. https://doi.org/10.1016/j.jaccas.2023.102104 
980. Sajja A, Dassanayake M, Morales IA, Wenger NK, Smith C, Xie J, et al. Valve-in-valve 
transcatheter aortic valve replacement during second trimester of pregnancy. JACC 
Case Rep 2023;27:102074. https://doi.org/10.1016/j.jaccas.2023.102074 
981. D‚ÄôSouza R, Ostro J, Shah PS, Silversides CK, Malinowski A, Murphy KE, et al. 
Anticoagulation for pregnant women with mechanical heart valves: a systematic review 
and meta-analysis. Eur Heart J 2017;38:1509‚Äì16. https://doi.org/10.1093/eurheartj/ 
ehx032 
982. Fuchs A, Urena M, Chong-Nguyen C, Kikoine J, Brochet E, Abtan J, et al. Valve-in-valve 
and valve-in-ring transcatheter mitral valve implantation in young women contemplating pregnancy. Circ Cardiovasc Interv 2020;13:e009579. https://doi.org/10.1161/ 
CIRCINTERVENTIONS.120.009579 
983. Mascherbauer J, Kammerlander A, Nitsche C, Bax J, Delgado V, Evangelista A, et al. 
Sex-related differences in severe native valvular heart disease: the ESC-EORP 
Valvular Heart Disease II survey. Eur Heart J 2024;45:3818‚Äì33. https://doi.org/10. 
1093/eurheartj/ehae523 
984. Cote N, Clavel MA. Sex differences in the pathophysiology, diagnosis, and management of aortic stenosis. Cardiol Clin 2020;38:129‚Äì38. https://doi.org/10.1016/j.ccl. 
2019.09.008 
985. Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, et al. Clinical presentation, 
aetiology and outcome of infective endocarditis. Results of the ESC-EORP 
EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. 
Eur Heart J 2019;40:3222‚Äì32. https://doi.org/10.1093/eurheartj/ehz620 
986. Avierinos JF, Inamo J, Grigioni F, Gersh B, Shub C, Enriquez-Sarano M. Sex differences 
in morphology and outcomes of mitral valve prolapse. Ann Intern Med 2008;149: 
787‚Äì95. https://doi.org/10.7326/0003-4819-149-11-200812020-00003 
987. Brown JM, O‚ÄôBrien SM, Wu C, Sikora JA, Griffith BP, Gammie JS. Isolated aortic valve 
replacement in North America comprising 108,687 patients in 10 years: changes in 
risks, valve types, and outcomes in the Society of Thoracic Surgeons National 
Database. J Thorac Cardiovasc Surg 2009;137:82‚Äì90. https://doi.org/10.1016/j.jtcvs. 
2008.08.015 
988. O‚ÄôBrien SM, Feng L, He X, Xian Y, Jacobs JP, Badhwar V, et al. The Society of Thoracic 
Surgeons 2018 adult cardiac surgery risk models: part 2‚Äîstatistical methods and results. Ann Thorac Surg 2018;105:1419‚Äì28. https://doi.org/10.1016/j.athoracsur.2018. 
03.003 
989. Shan Y, Pellikka PA. Aortic stenosis in women. Heart 2020;106:970‚Äì6. https://doi.org/ 
10.1136/heartjnl-2019-315407 
990. Voisine M, Hervault M, Shen M, Boilard AJ, Filion B, Rosa M, et al. Age, sex, and valve 
phenotype differences in fibro-calcific remodeling of calcified aortic valve. J Am Heart 
Assoc 2020;9:e015610. https://doi.org/10.1161/JAHA.119.015610 
991. Capoulade R, Clavel MA, Le Ven F, Dahou A, Thebault C, Tastet L, et al. Impact of left 
ventricular remodelling patterns on outcomes in patients with aortic stenosis. Eur 
Heart J Cardiovasc Imaging 2017;18:1378‚Äì87. https://doi.org/10.1093/ehjci/jew288 
992. Simard L, C√¥t√© N, Dagenais F, Mathieu P, Couture C, Trahan S, et al. Sex-related discordance between aortic valve calcification and hemodynamic severity of aortic stenosis: is valvular fibrosis the explanation? Circ Res 2017;120:681‚Äì91. https://doi.org/10. 
1161/CIRCRESAHA.116.309306 
993. Bienjonetti-Boudreau D, Fleury MA, Voisine M, Paquin A, Chouinard I, Tailleur M, et al. 
Impact of sex on the management and outcome of aortic stenosis patients. Eur Heart J 
2021;42:2683‚Äì91. https://doi.org/10.1093/eurheartj/ehab242 
994. Tribouilloy C, Bohbot Y, Rusinaru D, Belkhir K, Diouf M, Altes A, et al. Excess mortality 
and undertreatment of women with severe aortic stenosis. J Am Heart Assoc 2021;10: 
e018816. https://doi.org/10.1161/JAHA.120.018816 
995. Hartzell M, Malhotra R, Yared K, Rosenfield HR, Walker JD, Wood MJ. Effect of gender 
on treatment and outcomes in severe aortic stenosis. Am J Cardiol 2011;107:1681‚Äì6.  
https://doi.org/10.1016/j.amjcard.2011.01.059 
996. Lowenstern A, Sheridan P, Wang TY, Boero I, Vemulapalli S, Thourani VH, et al. Sex 
disparities in patients with symptomatic severe aortic stenosis. Am Heart J 2021;237: 
116‚Äì26. https://doi.org/10.1016/j.ahj.2021.01.021 
997. Onorati F, D‚ÄôErrigo P, Barbanti M, Rosato S, Covello RD, Maraschini A, et al. Different 
impact of sex on baseline characteristics and major periprocedural outcomes of transcatheter and surgical aortic valve interventions: results of the multicenter Italian 
OBSERVANT registry. J Thorac Cardiovasc Surg 2014;147:1529‚Äì39. https://doi.org/ 
10.1016/j.jtcvs.2013.05.039 
998. Tchetche D, Pibarot P, Bax JJ, Bonaros N, Windecker S, Dumonteil N, et al. 
Transcatheter vs. surgical aortic valve replacement in women: the RHEIA trial. Eur 
Heart J 2025:ehaf133. https://doi.org/10.1093/eurheartj/ehaf133 
999. Saad M, Nairooz R, Pothineni NVK, Almomani A, Kovelamudi S, Sardar P, et al. 
Long-term outcomes with transcatheter aortic valve replacement in women compared with men: evidence from a meta-analysis. JACC Cardiovasc Interv 2018;11: 
24‚Äì35. https://doi.org/10.1016/j.jcin.2017.08.015 
1000. Akintoye E, Saijo Y, Braghieri L, Badwan O, Patel H, Dabbagh MM, et al. Impact of age 
and sex on left ventricular remodeling in patients with aortic regurgitation. J Am Coll 
Cardiol 2023;81:1474‚Äì87. https://doi.org/10.1016/j.jacc.2023.02.037 
1001. Kammerlander AA, Don√† C, Nitsche C, Koschutnik M, Zafar A, Eslami P, et al. Sex 
differences in left ventricular remodeling and outcomes in chronic aortic regurgitation. J Clin Med 2020;9:4100. https://doi.org/10.3390/jcm9124100 
1002. Basso C, Iliceto S, Thiene G, Perazzolo Marra M. Mitral valve prolapse, ventricular arrhythmias, and sudden death. Circulation 2019;140:952‚Äì64. https://doi.org/10.1161/ 
CIRCULATIONAHA.118.034075 
1003. Stolfo D, Uijl A, Vedin O, Stromberg A, Faxen UL, Rosano GMC, et al. Sex-based differences in heart failure across the ejection fraction spectrum: phenotyping, and 
prognostic and therapeutic implications. JACC Heart Fail 2019;7:505‚Äì15. https://doi. 
org/10.1016/j.jchf.2019.03.011 
1004. El Sabbagh A, Al-Hijji M, Wang DD, Eleid M, Urena M, Himbert D, et al. Predictors of 
left ventricular outflow tract obstruction after transcatheter mitral valve replacement 
in severe mitral annular calcification: an analysis of the Transcatheter Mitral Valve 
Replacement in Mitral Annular Calcification Global Registry. Circ Cardiovasc Interv 
2021;14:e010854. https://doi.org/10.1161/CIRCINTERVENTIONS.121.010854 
1005. Willner N, Burwash IG, Beauchesne L, Chan V, Vulesevic B, Ascah K, et al. Natural 
history of mitral annular calcification and calcific mitral valve disease. J Am Soc 
Echocardiogr 2022;35:925‚Äì32. https://doi.org/10.1016/j.echo.2022.05.007 
1006. Offen S, Playford D, Strange G, Stewart S, Celermajer DS. Adverse prognostic impact 
of even mild or moderate tricuspid regurgitation: insights from the National 
Echocardiography Database of Australia. J Am Soc Echocardiogr 2022;35:810‚Äì17.  
https://doi.org/10.1016/j.echo.2022.04.003 
1007. Mutlak D, Khalil J, Lessick J, Kehat I, Agmon Y, Aronson D. Risk factors for the development of functional tricuspid regurgitation and their population-attributable fractions. JACC Cardiovasc Imaging 2020;13:1643‚Äì51. https://doi.org/10.1016/j.jcmg. 
2020.01.015 
1008. Prihadi EA, van der Bijl P, Gursoy E, Abou R, Mara Vollema E, Hahn RT, et al. 
Development of significant tricuspid regurgitation over time and prognostic implications: new insights into natural history. Eur Heart J 2018;39:3574‚Äì81. https://doi.org/ 
10.1093/eurheartj/ehy352 
1009. Beale AL, Nanayakkara S, Segan L, Mariani JA, Maeder MT, van Empel V, et al. Sex differences in heart failure with preserved ejection fraction pathophysiology: a detailed 
invasive hemodynamic and echocardiographic analysis. JACC Heart Fail 2019;7: 
239‚Äì49. https://doi.org/10.1016/j.jchf.2019.01.004 
1010. Dietz MF, Prihadi EA, van der Bijl P, Fortuni F, Marques AI, Ajmone Marsan N, et al. 
Sex-specific differences in etiology and prognosis in patients with significant tricuspid 
regurgitation. Am J Cardiol 2021;147:109‚Äì15. https://doi.org/10.1016/j.amjcard.2021. 
02.016 
1011. Pfannmueller B, Eifert S, Seeburger J, Misfeld M, Borger M, Mende M, et al. 
Gender-dependent differences in patients undergoing tricuspid valve surgery. 
Thorac Cardiovasc Surg 2013;61:37‚Äì41. https://doi.org/10.1055/s-0032-1324406 
1012. Fortmeier V, Lachmann M, K√∂rber MI, Unterhuber M, Schober AR, Stolz L, et al. 
Sex-related differences in clinical characteristics and outcome prediction among patients undergoing transcatheter tricuspid valve intervention. JACC Cardiovasc Interv 
2023;16:909‚Äì23. https://doi.org/10.1016/j.jcin.2023.01.378 
1013. Scotti A, Coisne A, Taramasso M, Granada JF, Ludwig S, Rodes-Cabau J, et al. 
Sex-related characteristics and short-term outcomes of patients undergoing transcatheter tricuspid valve intervention for tricuspid regurgitation. Eur Heart J 2023; 
44:822‚Äì32. https://doi.org/10.1093/eurheartj/ehac735
